PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Satz, P; Alfano, MS; Light, R; Morgenstern, H; Zaucha, K; Asarnow, RF; Newton, S				Satz, P; Alfano, MS; Light, R; Morgenstern, H; Zaucha, K; Asarnow, RF; Newton, S			Persistent post-concussive syndrome: A proposed methodology and literature review to determine the effects, if any, of mild head and other bodily injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; CHRONIC PAIN; BASE RATES; SYMPTOMS; CHILDREN; ATTENTION; SEQUELAE; SEVERITY	Following mild head injury, a subgroup of individuals exhibit a constellation of chronic symptoms, a condition Alexander(1995) labeled Persistent Post-Concussive Syndrome (PPCS). He implicated neurological factors in the initial phase of the syndrome but psychological factors in the maintenance of symptoms. However, it is unclear as to whether an initial mild head injury is necessary or sufficient to cause the symptoms of PPCS. We first outline a study design comparing a mild closed-head injury group to both a normal and an other injury control group to answer this question. Next, we review the literature since 1960 to determine the findings of any studies using this design. The results of the literature review indicate that few such studies exist. To date, those that have been done suggest that there is no strong evidence for a specific effect for mild head injury on cognitive functioning. We discuss directions for future research given these findings.	Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, Los Angeles, CA 90024 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Daniel Freeman Mem Hosp, Inglewood, CA USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Dept Child Psychiat, Los Angeles, CA 90024 USA; Fuller Theol Seminary, Grad Sch Psychol, Pasadena, CA 91101 USA		Satz, P (corresponding author), Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Neuropsychol Div, NPI Room C8-747,760 Westwood Plaza, Los Angeles, CA 90024 USA.	psatz@med.net.ucla.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alexander MP, 1996, NEUROLOGY, V46, P1488, DOI 10.1212/WNL.46.5.1488-a; Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BARRY C, 1997, P INT NEUR SOC C ORL; BIJUR PE, 1990, PEDIATRICS, V86, P337; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KEWMAN DG, 1991, INT J PSYCHIAT MED, V21, P253, DOI 10.2190/FRYK-TMGA-AULW-BM5G; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KURTZKE JF, 1997, CLIN NEUROLOGY, V66, P1; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; WEISSMAN HN, 1991, FORENSIC REPORTS, V4, P417; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	36	69	70	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1999	21	5					620	628		10.1076/jcen.21.5.620.870			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	264XG	WOS:000084207900003	10572282				2022-02-06	
J	Gleckman, AM; Bell, MD; Evans, RJ; Smith, TW				Gleckman, AM; Bell, MD; Evans, RJ; Smith, TW			Diffuse axonal injury in infants with nonaccidental craniocerebral trauma - Enhanced detection by beta-amyloid precursor protein immunohistochemical staining	ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE			English	Article							PERMANENT BRAIN-DAMAGE; HEAD-INJURY; MENTAL-RETARDATION; SHAKING; MARKER; APP	Objective.-Accurate identification of diffuse axonal injury is important in the forensic investigation of infants who have died from traumatic brain injury. beta-Amyloid precursor protein (beta-APP) immunohistochemical staining is highly sensitive in identifying diffuse axonal injury. However the effectiveness of this method in brain-injured infants has not been well established. The present study was undertaken to assess the utility of beta-APP immunohistochemistry in detecting diffuse axonal injury in infants with either shaken baby syndrome or blunt head trauma. Materials and Methods.-Archival formalin-fixed, paraffin-embedded blocks from infants (<1 year old) with shaken baby syndrome (7 cases) and blunt head trauma (3) and blocks from 7 control cases that included nontraumatic cerebral edema (1), acute hypoxic-ischemic encephalopathy (1), and normal brain (5) were immunostained for beta-APP. A semiquantitative assessment of the severity of axonal staining was made. Corresponding hematoxylin-eosin-stained sections were examined for the presence of axonal swellings. Results.-Immunostaining for beta-APP identified diffuse axonal injury in 5 of 7 infants with shaken baby syndrome and 2 of 3 infants with blunt head trauma. Immunoreactive axons were easily identified and were present in the majority of the sections examined. By contrast, hematoxylineosin staining revealed axonal swellings in only 3 of 7 infants with shaken baby syndrome and 1 of 3 infants with blunt head trauma. Most of these sections had few if any visible axonal swellings, which were often overlooked on initial review of the slides. No beta-APP immunoreactivity was observed in any of the 7 control cases. Conclusions.-Immunostaining for beta-APP can easily and reliably identify diffuse axonal injury in infants younger than 1 year and is considerably more sensitive than routine hematoxylin-eosin staining. We recommend its use in the forensic evaluation of infants with fatal craniocerebral trauma.	Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA; Med Examiner Dept, Miami, FL USA; Off Chief Med Examiner, Boston, MA USA		Smith, TW (corresponding author), Univ Massachusetts, Med Ctr, Dept Pathol Neuropathol, 55 Lake Ave N, Worcester, MA 01655 USA.						BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DIMAIO DJ, 1993, FORENSIC PATHOLOGY; Duckett S., 1995, PEDIAT NEUROPATHOLOG, P243; FERREIRA A, 1993, J NEUROSCI, V13, P3112; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kreutzberg GW, 1997, GREENFIELDS NEUROPAT, P85; MAXWELL WI, 1997, J NEUROTRAUM, V15, P419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MERTEN DF, 1983, PEDIATR ANN, V12, P882, DOI 10.3928/0090-4481-19831201-06; NAOUMENKO J, 1967, J NEUROPATH EXP NEUR, V26, P669, DOI 10.1097/00005072-196710000-00012; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHERRIFF FE, 1993, ACTA NEUROPATHOL, V87, P57; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4	24	69	70	0	3	COLLEGE AMER PATHOLOGISTS	NORTHFIELD	C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA	0003-9985			ARCH PATHOL LAB MED	Arch. Pathol. Lab. Med.	FEB	1999	123	2					146	151					6	Medical Laboratory Technology; Medicine, Research & Experimental; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology; Research & Experimental Medicine; Pathology	166PM	WOS:000078586000013	10050789				2022-02-06	
J	Muthuswamy, J; Sherman, DL; Thakor, NV				Muthuswamy, J; Sherman, DL; Thakor, NV			Higher-order spectral analysis of burst patterns in EEG	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						burst-suppression; EEG; nonlinearity and self-coupling; polyspectrum	NEONATAL ELECTROENCEPHALOGRAPHY; BISPECTRAL ANALYSIS; PROGNOSTIC VALUE	Burst suppression patterns in electroencephalograms (EEG's) have been observed in a variety of situations including recovery of a subject from a traumatic brain injury. They are associated with grave prognostic outcomes in neonates, We study power spectral parameters and bispectral parameters of the EEG at baseline, during early recovery from an asphyxic arrest (EEG burst patterns) and during late recovery after EEG evolves into a more continuous activity, The bicoherence indexes, which indicate the degree of phase coupling between two frequency components of a signal, are significantly higher within the delta-theta band of the EEG bursts than in the baseline of late recovery waveforms, The bispectral parameters show a more detectable trend than the power spectral parameters. In the second part of the study, we looked into the possibility of higher (>2) -order nonlinearities in the EEG bursts using the diagonal slices of the polyspectrum. The diagonal elements of the polyspectrum reveal the presence of self-frequency and self-phase coupling of orders higher than two in majority of the EEG bursts studied. The bicoherence indexes and the diagonal elements of the polyspectrum strongly indicate the presence of nonlinearities of order two and in many cases higher, in the EEG generator during episodes of bursting. This indication of nonlinearity in EEG signals provides a novel quantitative measure of brain's response to injury.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA		Thakor, NV (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, 720 Rutland Ave, Baltimore, MD 21205 USA.		Thakor, Nitish/G-9110-2015; Thakor, Nitish V/A-5878-2008	Thakor, Nitish/0000-0002-9981-9395; Muthuswamy, Jit/0000-0003-3924-9869	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS24282] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS024282] Funding Source: NIH RePORTER		ASO K, 1989, J CLIN NEUROPHYSIOL, V6, P103, DOI 10.1097/00004691-198904000-00001; BARNETT TP, 1971, SCIENCE, V172, P401, DOI 10.1126/science.172.3981.401; Brillinger D. R., 1980, Journal of Time Series Analysis, V1, P95, DOI 10.1111/j.1467-9892.1980.tb00303.x; DUMERMUTH G, 1971, ELECTROEN CLIN NEURO, V31, P137, DOI 10.1016/0013-4694(71)90183-0; DUMERMUTH G, 1970, IEEE T ACOUST SPEECH, VAU18, P404, DOI 10.1109/TAU.1970.1162144; Goel V, 1996, IEEE T BIO-MED ENG, V43, P1083, DOI 10.1109/10.541250; GRIGGDAMBERGER MM, 1989, PEDIATR NEUROL, V5, P84, DOI 10.1016/0887-8994(89)90032-5; Hinich M. J., 1982, J TIME A, V3, P169, DOI DOI 10.1111/J.1467-9892.1982.TB00339.X; HOLMES G, 1982, ELECTROEN CLIN NEURO, V53, P60, DOI 10.1016/0013-4694(82)90106-7; HOLMES GL, 1993, J CLIN NEUROPHYSIOL, V10, P323, DOI 10.1097/00004691-199307000-00008; HUBER PJ, 1971, IEEE T ACOUST SPEECH, VAU19, P78, DOI 10.1109/TAU.1971.1162163; LANGMOEN IA, 1983, J NEUROPHYSIOL, V50, P1320, DOI 10.1152/jn.1983.50.6.1320; MUTHUSWAMY J, 1995, THESIS RENSSELAER PO; NING T, 1993, IEEE T BIO-MED ENG, V40, P870, DOI 10.1109/10.245607; NING TK, 1989, IEEE T BIO-MED ENG, V36, P497, DOI 10.1109/10.18759; Patel J.K., 1982, HDB NORMAL DISTRIBUT, V2nd; PEZZANI C, 1986, NEUROPEDIATRICS, V17, P11, DOI 10.1055/s-2008-1052492; RAGHUVEER MR, 1990, IEEE T AUTOMAT CONTR, V35, P48, DOI 10.1109/9.45142; SEBERT G, 1989, P WORKSH HIGHER ORDE, P223; SHERMAN DL, 1994, IEEE T SIGNAL PROCES, V42, P332, DOI 10.1109/78.275606; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; ZHOU GT, 1995, IEEE T SIGNAL PROCES, V43, P1173, DOI 10.1109/78.382402	22	69	70	0	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	NEW YORK	345 E 47TH ST, NEW YORK, NY 10017-2394 USA	0018-9294			IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	JAN	1999	46	1					92	99		10.1109/10.736762			8	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	152NA	WOS:000077782600011	9919830				2022-02-06	
J	Roberts, WO; Brust, JD; Leonard, B				Roberts, WO; Brust, JD; Leonard, B			Youth ice hockey tournament injuries: rates and patterns compared to season play	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						concussion; injury severity; injury mechanism	SPINAL-INJURIES; FACE MASKS; HEAD; NECK	Objective: To prospectively document the incidence of game injury rates in youth ice hockey tournaments to compare with season-long game injury rates and to analyze the injuries occurring at tournaments by mechanism, type, body location, severity, player position, and period of play. Design: A prospective injury report form completed for injured players by the tournament athletic trainer. Setting: Four boys' tournaments and one girls' tournament during the 1993-94 season. Participants: 807 boys and girls, ages 9-19. Measurements/Main Results: 60 injuries occurred in boys and 4 occurred in girls. There were 26 boys with significant injuries and no girls with significant injuries. The significant game injury rates per 1000 player hours were 50.9 for boys combined, 57.9 for boys' Peewee A, 42.7 for boys' Bantam A, 64.8 for boys' varsity high school, 44.8 for boys' Junior Gold, and 0 for girls' Peewee A and B. Cerebral concussion comprised 15% of boys' injuries. Conclusions: The significant injury rate for boys' tournament game play was 4-6 times higher than the season game injury rates in two previous season-long studies. in boys' games, 65% of "all" injuries and 77% of "significant" injuries were related to collisions. The girls' rules of play do not allow body checking, and there were no significant injuries in girls' games. The boys had high rates of cerebral concussion injury at all age levels. Minimizing the frequency and intensity of collisions in the boys' game may decrease the injury rates, especially in the tournament setting.	MinnHealth SportsCare, White Bear Lake, MN 55110 USA; Univ Minnesota, Sch Med, Dept Family Practice & Community Hlth, Minneapolis, MN 55455 USA; Allina Fdn, Minnetonka, MN USA; Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA		Roberts, WO (corresponding author), MinnHealth SportsCare, 4786 Banning Ave, White Bear Lake, MN 55110 USA.	rober037@maroon.tc.umn.edu		Roberts, William O/0000-0003-4517-4330			BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; CASTALDI C R, 1991, Dental Clinics of North America, V35, P647; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; Kelly JP, 1997, NEUROLOGY, V48, P581; LAPRADE RF, 1995, AM J SPORT MED, V23, P773, DOI 10.1177/036354659502300624; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; MURRAY TM, 1995, PEDIATRICS, V95, P419; PARAYRE R, 1989, ASTM STP, V1050, P37; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; REYNEN PD, 1994, AM J SPORT MED, V22, P167, DOI 10.1177/036354659402200203; RISSER WL, 1994, PEDIATRICS, V94, P757; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Sutherland G W, 1976, Am J Sports Med, V4, P264, DOI 10.1177/036354657600400605; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; TATOR CH, 1991, CAN J SURG, V34, P63; Tegner Y, 1991, Br J Sports Med, V25, P87; *US HOCK ANN GUID, 1997, PUBL US, P75; Watson RC, 1997, CLIN J SPORT MED, V7, P192, DOI 10.1097/00042752-199707000-00007	26	69	70	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JAN	1999	31	1					46	51		10.1097/00005768-199901000-00009			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	155ZF	WOS:000077976400008	9927009				2022-02-06	
J	Prigatano, GP; Bruna, O; Mataro, M; Munoz, JM; Fernandez, S; Junque, C				Prigatano, GP; Bruna, O; Mataro, M; Munoz, JM; Fernandez, S; Junque, C			Initial disturbances of consciousness and resultant impaired awareness in Spanish patients with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness; consciousness; Glasgow Coma Scale; neuropsychology; posttraumatic amnesia; traumatic brain injury	BEHAVIORAL LIMITATIONS; HEAD-INJURY; ANOSOGNOSIA; DYSFUNCTION; 1-YEAR; COMA	The purpose of this prospective, between-subjects study was to took at impaired awareness cross-culturally in patients with traumatic brain injury (TBI) and to relate impaired awareness after injury to the initial estimates of disturbed consciousness at time of injury. The study was conducted in community and inpatient and outpatient rehabilitation centers in Barcelona and;Madrid. Participants were 30 persons with primarily moderate to severe TBI who could complete a written questionnaire concerning their functioning and 28 age- and gender-matched controls. A Spanish translation of the Patient Competency Rating Scale (PCRS) was administered to each participant. Relatives or significant others also completed this scale on each participant using the relative's version (PCRS-R). Difference scores, Obtained by subtracting PCRS-R from PCRS-P (PCRS-P minus PCRS-R), were used as a marker of impaired awareness. Individuals with TBI were rated (by self and significant others) as being less competent than controls. Forty percent of Spanish patients with TBI who suffered severe injuries tended to overestimate their behavioral competencies. The PCRS-P minus the PCRS-R difference scores tended to correlate with admitting Glasgow Coma Scale (GCS) scores and retrospective estimates of posttraumatic amnesia (PTA). Initial disturbances of consciousness, one measure of severity of brain injury, appeared to relate to later measures of impaired self-awareness in Spanish patients with TBI. Non-brain-injured controls did not tend to report levels of competency that differed from their relatives' reports.	St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Phoenix, AZ 85013 USA; Univ Ramon Llull, Fac Psicol Blanquerna, Barcelona, Spain; Univ Barcelona, Fac Psicol, Barcelona, Spain; Univ Complutense Madrid, Fac Psicol, Madrid, Spain; Univ Jaen, Dept Psicol, Jaen, Spain		Prigatano, GP (corresponding author), St Josephs Hosp & Med Ctr, Barrow Neurol Inst, 350 W Thomas Rd, Phoenix, AZ 85013 USA.		Mataro, Maria/B-4524-2011; Bruna, Olga/ABG-7936-2020; Junque, Carme/B-4400-2011	Mataro, Maria/0000-0002-9946-2656; Bruna, Olga/0000-0002-7851-2909; Junque, Carme/0000-0002-6381-3063			CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fleming J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI [https://doi.org/10.1177/030802269505800204, DOI 10.1177/030802269505800204]; GIANOTTI G, 1975, PSYCHIAT CLIN BASEL, V8, P99; Jennett B, 1981, MANAGEMENT HEAD INJU; KERTESZ A, 1993, CLIN NEUROPSYCHOLOGY; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; PRIGATANO GP, 1988, BNI Q, V4, P40; PRIGATANO GP, 1995, MANUAL BNI SCREEN HI; PRIGATANO GP, 1987, BNI Q, V3, P10; PRIGATANO GP, 1991, AWRENESS DEFICIT BRA; SHERER M, 1998, IN PRESS J INT NEURO; SQUIRE LR, 1988, J CLIN EXPT NEUROPSC, V10, P737; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; TEASDALE G, 1974, LANCET, V2, P81; [No title captured]; [No title captured]	26	69	70	0	7	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					29	38		10.1097/00001199-199810000-00005			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600005	9753533				2022-02-06	
J	Hillier, SL; Hiller, JE; Metzer, J				Hillier, SL; Hiller, JE; Metzer, J			Epidemiology of traumatic brain injury in south Australia	BRAIN INJURY			English	Article							HEAD TRAUMA; SEVERITY	Reviews of statewide hospital separations' summaries and medical record data from a major teaching hospital, were conducted to describe the epidemiology of traumatic brain injury (TBI) in South Australia (SA), and to document the demographics of the population affected and the nature of their injuries. The groups most at risk were defined for targeting preventive programmes, and predictions were made regarding their ongoing service needs, for more appropriate provision of care. The results indicate that SA experiences a high incidence of TBI. At 322 per 100 000 head of population annually, it exceeds studies (with comparable methodologies) in communities in the United States and Europe. The causes, nature and severity of the injuries were similar to those found in the international literature, as were the profiles of the population most at risk. Specifically, young males living in the country and working in manual trades showed the highest incidence, and were most likely to have sustained their TBI whilst driving a motor vehicle. When a formula to predict service needs was adapted using the SA data, it was apparent that hospitals in this state care for more than 4000 new cases of TBI each year and that, on discharge, over 1000 of these will have some degree of residual impairment and will therefore require some form of post-injury services.	UNIV ADELAIDE,DEPT COMMUNITY MED,ADELAIDE,SA,AUSTRALIA; UNIV S AUSTRALIA,SCH PSYCHOL,ADELAIDE,SA 5001,AUSTRALIA				Hillier, Susan/D-4590-2009; Hiller, Janet E./A-5633-2008	Hillier, Susan/0000-0002-6071-6137; Hiller, Janet E./0000-0002-8532-4033			*AD TRAUM REG, 1991, AD TRAUM REG REP; *AUSTR BUR STAT, 1992, 43084 AUSTR BUR STAT; *AUSTR BUR STAT, 1993, 27304 AUSTR BUR STAT; *AUSTR BUR STAT, 1993, 27224 AUSTR BUR STAT; BADCOCK KM, 1987, HEAD INJURY STUDY FL; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BRENNAN MA, 1981, IRISH MED J, V74, P5; CARLSSON GS, 1986, ACTA NEUROCHIR, V36, P13; Caveness W F, 1979, Adv Neurol, V22, P1; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; *INP SEP INF SYST, 1991, UNPUB; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; LYLE DM, 1990, COMMUNITY HEALTH ST, V14, P118; MacKenzie E J, 1989, Md Med J, V38, P725; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; SELECKI BR, 1981, INJURIES HEAD SPINE; Servadei F, 1985, J Neurosurg Sci, V29, P297; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x; World Health Organization, 1978, INT CLASS DIS; [No title captured]	25	69	69	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1997	11	9					649	659					11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	XT726	WOS:A1997XT72600004	9376833				2022-02-06	
J	Allison, SC; Abraham, LD; Petersen, CL				Allison, SC; Abraham, LD; Petersen, CL			Reliability of the Modified Ashworth Scale in the assessment of plantar flexor muscle spasticity in patients with traumatic brain injury	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						spasticity measurement; ankle; reliability	STROKE PATIENTS; HEMIPARESIS; VARIABLES; GAIT	Although the Modified Ashworth Scale (MAS) is commonly used to assess the severity of muscle spasticity for ankle plantarflexors, its reliability has only been established for elbow muscles. Interrater reliability, intrarater reliability and temporal (between-days) reliability were examined in this study. Also, interrater reliability for use of the scale with plantarflexors was compared with reported results from the measurement of elbow flexors. Thirty adult volunteers with traumatic brain injuries participated. There were 20 men and 10 women; the mean age was 28.3 years (SD = 10.8). Two physical therapists used the MAS to score the subjects independently Measurements were repeated to yield multiple scores for intrarater reliability assessment. Twenty-one of the subjects returned individually on separate days to be measured again, so that temporal reliability could be assessed. Spearman's correlation coefficients were 0.73 for interrater reliability 0.74 and 0.55 for intrarater reliability, and 0.82 for temporal reliability. Overall, reliability of the MAS for assessing plantarflexor spasticity in patients with traumatic brain injury was found to be minimally adequate to support its continued use. However, interrater reliability was less than that which has been reported for elbow flexors, and intrarater reliability findings were mixed.	UNIV TEXAS,DEPT KINESIOL & HLTH EDUC,AUSTIN,TX 78712; HEALTHCARE REHABIL CTR,AUSTIN,TX		Allison, SC (corresponding author), AMEDD CTR & SCH,PHYS THERAPY BRANCH,FT SAM HOUSTON,TX 78234, USA.						ASHWORTH B, 1964, PRACTITIONER, V192, P540; Bobath, 1978, ADULT HEMIPLEGIA EVA; BOHANNON RW, 1987, ARCH PHYS MED REHAB, V68, P777; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BOHANNON RW, 1987, PHYS THER, V67, P1218, DOI 10.1093/ptj/67.8.1218; BOHANNON RW, 1991, ARCH PHYS MED REHAB, V72, P682; GONELLA C, 1982, PHYS THER, V62, P436; HUGENHOLTZ H, 1992, CAN J NEUROL SCI, V19, P188, DOI 10.1017/S0317167100042244; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; LEVIN MF, 1993, J NEUROL, V240, P63, DOI 10.1007/BF00858718; Patterson, 1989, J NEUROL REHABIL, V3, P205, DOI DOI 10.1177/136140968900300406; PEACOCK WJ, 1991, J NEUROSURG, V74, P380, DOI 10.3171/jns.1991.74.3.0380; POTTER NA, 1985, PHYS THER, V65, P1671, DOI 10.1093/ptj/65.11.1671; ROSE SA, 1991, PHYS THER, V71, P961, DOI 10.1093/ptj/71.12.961; ROTHSTEIN JM, 1993, PRIMER MEASUREMENT I; Sloan R L, 1992, Int J Rehabil Res, V15, P158, DOI 10.1097/00004356-199206000-00009; [No title captured]	18	69	74	0	5	CHAPMAN HALL LTD	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN	0342-5282			INT J REHABIL RES	Int. J. Rehabil. Res.	MAR	1996	19	1					67	78		10.1097/00004356-199603000-00007			12	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	UE742	WOS:A1996UE74200007	8730545				2022-02-06	
J	Baldwin, SA; Scheff, SW				Baldwin, SA; Scheff, SW			Intermediate filament change in astrocytes following mild cortical contusion	GLIA			English	Article						glial fibrillary acidic protein; vimentin; proliferation	FIBRILLARY ACIDIC PROTEIN; REACTIVE ASTROCYTES; MESSENGER-RNA; DENTATE GYRUS; BRAIN INJURY; ADULT-RATS; CEREBRAL-CORTEX; GLIAL REACTION; VISUAL-CORTEX; EXPRESSION	Astrocytes are known to become reactive as a result of various types of lesions. They upregulate astrocytic-specific intermediate filament glial fibrillary acidic protein (GFAP) and show a positive signal for the intermediate filament vimentin, a protein primarily found in developing astrocytes. An animal model for cortical contusions has been developed that manifests many of the neuropathologies seen in human closed head injury. The model involves an electronic controlled pneumatic impact device (ECPI), which can deliver precise and controlled cortical contusions to an animal. This model can be used to study astrocyte response to injury, leading to a better understanding of glial reaction to head trauma in humans. Young adult male Fisher 344 rats were subjected to a mild dorsal lateral cortical impact. The astrocytic intermediate filaments GFAP and vimentin were upregulated in a time-dependent manner 2 days after injury. By 30 days following contusion these intermediate filaments returned to near preinjury levels. Using the same injury model bromodeoxyuridine (BrdU) was injected in additional animals on the day of sacrifice, 1, 2, 4, and 10 days after injury, to label cells synthesizing new DNA. Double labeling utilizing fluorescence immunocytochemistry indicated that on postinjury day 2 very few GFAP-positive cells were double labeled with BrdU. No double-labeled cells were seen at the other time points. These data suggest that astrocyte proliferation may not be a major response to mild cortical contusion and that vimentin expression may not necessarily be associated with astrocytic proliferation in response to injury. (C) 1996 Wiley-Liss, Inc.	UNIV KENTUCKY, SANDERS BROWN CTR AGING 311, LEXINGTON, KY 40536 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline		AGHAJANIAN G. K., 1967, BRAIN RES, V6, P716, DOI 10.1016/0006-8993(67)90128-X; BARRES BA, 1991, J NEUROSCI, V11, P3685; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BRAND S, 1984, ANAT EMBRYOL, V169, P21, DOI 10.1007/BF00300583; CALEY DW, 1968, J COMP NEUROL, V133, P45, DOI 10.1002/cne.901330104; CIESIELSKITRESKA J, 1982, NEUROSCIENCE, V7, P509, DOI 10.1016/0306-4522(82)90284-6; CIESIELSKITRESKA J, 1982, NEUROCHEM RES, V7, P275, DOI 10.1007/BF00965640; CORTEZ S, 1982, BRAIN RES, V482, P271; Cotman C.W., 1978, NEURONAL PLASTICITY, P227; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUFFY PE, 1983, ASTROCYTES NORMAL RE; DYSON SE, 1976, BRAIN RES, V114, P365, DOI 10.1016/0006-8993(76)90960-4; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.biochem.54.1.135; FAGAN AM, 1990, EXP NEUROL, V110, P105, DOI 10.1016/0014-4886(90)90055-W; FEDOROFF S, 1985, MOL BASES NEURAL DEV, P91; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; GILMORE SA, 1990, GLIA, V3, P342, DOI 10.1002/glia.440030505; GLEZER II, 1990, BRAIN RES BULL, V24, P401, DOI 10.1016/0361-9230(90)90096-I; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; LANGAN TJ, 1992, BRAIN RES, V577, P200, DOI 10.1016/0006-8993(92)90275-E; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; MALHOTRA SK, 1990, CYTOBIOS, V61, P133; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MIKUCKI SA, 1991, METAB BRAIN DIS, V6, P33, DOI 10.1007/BF01000383; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; OBLINGER MM, 1993, INT J DEV NEUROSCI, V11, P149, DOI 10.1016/0736-5748(93)90075-O; OPPENHEIM RW, 1975, J COMP NEUROL, V161, P383, DOI 10.1002/cne.901610308; PALAY SL, 1962, J CELL BIOL, V12, P385, DOI 10.1083/jcb.12.2.385; PETITO CK, 1992, PROG BRAIN RES, V94, P381; PIXLEY SKR, 1984, DEV BRAIN RES, V15, P201, DOI 10.1016/0165-3806(84)90097-X; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; PRIVAT A, 1988, ASTROCYTES CELL BIOL, P105; RAISMAN G, 1985, SYNAPTIC PLASTICITY, P13; SCHEFF SW, 1989, NEURAL REGENERATION, P137; SCHIFFER D, 1986, BRAIN RES, V374, P110, DOI 10.1016/0006-8993(86)90399-9; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SHAO YP, 1994, GLIA, V11, P1, DOI 10.1002/glia.440110103; SINGH DNP, 1989, ACTA ANAT, V134, P156; STEWARD O, 1990, J NEUROSCI, V10, P2373; STEWARD O, 1974, EXP BRAIN RES, V20, P45; STICHEL CC, 1994, GLIA, V10, P89, DOI 10.1002/glia.440100203; SUZUKI M, 1991, ACTA NEUROPATHOL, V82, P93, DOI 10.1007/BF00293950; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TETZLAFF W, 1988, GLIA, V1, P90, DOI 10.1002/glia.440010110; WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205; WENZEL J, 1991, BRAIN RES, V560, P122, DOI 10.1016/0006-8993(91)91222-M; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	53	69	70	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAR	1996	16	3					266	275					10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TY427	WOS:A1996TY42700009	8833197				2022-02-06	
J	Tavalin, SJ; Ellis, EF; Satin, LS				Tavalin, SJ; Ellis, EF; Satin, LS			Mechanical perturbation of cultured cortical neurons reveals a stretch-induced delayed depolarization	JOURNAL OF NEUROPHYSIOLOGY			English	Article							CONCUSSIVE BRAIN INJURY; GLUTAMATE NEUROTOXICITY; CELL-CULTURE; EXTRACELLULAR POTASSIUM; RAT; NMDA; ELECTROPHYSIOLOGY; ANTAGONISTS; RECEPTOR; CALCIUM	1. An in vitro cellular model of injury was used to elucidate mechanisms contributing to traumatic brain injury (TBI). Neonatal rat cortical neurons cultured on a flexible silastic membrane were stretched rapidly and reversibly by a 50-ms pulse of pressurized air. 2. Sublethal cell stretch depolarized neuronal resting membrane potential by similar to 10 mV but only if cells were incubated for 1 h after injury. Stretch-induced delayed depolarization (or SIDD) returned to baseline values within 24 h. 3. SIDD was dependent on the degree of cell stretch and required neuronal firing, calcium entry, and N-methyl-D-aspartate receptor activation for its induction but not its maintainance. 4. Similarities between SIDD and TBI suggest that SIDD may play a role in brain injury.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYSIOL, RICHMOND, VA 23298 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-07027] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline		BIRCH PJ, 1988, EUR J PHARMACOL, V156, P177, DOI 10.1016/0014-2999(88)90163-X; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COULTER DA, 1992, J NEUROPHYSIOL, V68, P362, DOI 10.1152/jn.1992.68.2.362; DICHTER MA, 1978, BRAIN RES, V149, P279, DOI 10.1016/0006-8993(78)90476-6; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Nilsson P, 1990, J CEREB BLOOD FLOW M, V10, P331; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1	27	69	70	0	6	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	DEC	1995	74	6					2767	2773		10.1152/jn.1995.74.6.2767			7	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Physiology	TM559	WOS:A1995TM55900051	8747234				2022-02-06	
J	VILKKI, J; AHOLA, K; HOLST, P; OHMAN, J; SERVO, A; HEISKANEN, O				VILKKI, J; AHOLA, K; HOLST, P; OHMAN, J; SERVO, A; HEISKANEN, O			PREDICTION OF PSYCHOSOCIAL RECOVERY AFTER HEAD-INJURY WITH COGNITIVE TESTS AND NEUROBEHAVIORAL RATINGS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE DAMAGE; NEUROPSYCHOLOGICAL DEFICITS; BRAIN INJURY; PERSEVERATION; QUALITY; SCALE; LIFE; COMA	A series of 53 patients was studied using a battery of tests and a neurobehavioral rating scale on average 4 months after closed-head injury (CHI). Social outcome was assessed 1 year after injury by interviewing a family member. The results supported the hypothesis that tests of flexibility and programming rather than tests of cognitive skills predict psychosocial recovery after CHI. Spatial Learning with Self-Set Coals and Sorting were measures of flexibility and programming. Contrary to expectation, word fluency performance was unrelated to these measures, but was associated with conventional intelligence tests, which did not predict psychosocial recovery. Cognition/energy deficit on the Neurobehavioral Rating Scale and increased age were useful predictors of poor psychosocial outcome, whereas computed tomography findings or the Glasgow Coma Score were weakly related to the outcome indices. Evidently, cognitive flexibility and mental programming are very important psychological prerequisites of social recovery after CHI.			VILKKI, J (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT NEUROSURG,TOPELIUKSENKATU 5,SF-00260 HELSINKI,FINLAND.			Ohman, Juha/0000-0002-6592-1367			Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Baddeley A.D., 1986, WORKING MEMORY; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Benson D.F., 1986, FRONTAL LOBES; Benton AL, 1963, REVISED VISUAL RETEN; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; Goldman-Rakic P.S., 2011, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDSTEIN FC, 1987, NEUROBEHAVIORAL RECO, P217; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; GROSS Y, 1989, CLIN NEUROPSYCHOLOGY, P179; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KREUZER JS, 1990, VOCATIONAL REHABILIT, P35; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Luria A.R., 1973, WORKING BRAIN; Mayes A., 1988, HUMAN ORGANIC MEMORY; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Milner B., 1964, FRONTAL GRANULAR COR, P313; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; ODDY M, 1984, CLOSED HEAD INJURY P, P108; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; SANDSON J, 1984, NEUROPSYCHOLOGIA, V22, P715, DOI 10.1016/0028-3932(84)90098-8; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1990, J CLIN EXP NEUROPSYC, V12, P34; STUSS DT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P157; TEASDALE G, 1974, LANCET, V2, P81; VILKKI J, 1989, NEUROPSYCHOLOGIA, V27, P1101, DOI 10.1016/0028-3932(89)90189-9; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; VILKKI J, 1989, NEUROPSYCHOLOGIA, V27, P971, DOI 10.1016/0028-3932(89)90072-9; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; [No title captured]	49	69	71	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1994	16	3					325	338		10.1080/01688639408402643			14	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	NR764	WOS:A1994NR76400001	7929700				2022-02-06	
J	KOFLER, M; KRONENBERG, MF; RIFICI, C; SALTUARI, L; BAUER, G				KOFLER, M; KRONENBERG, MF; RIFICI, C; SALTUARI, L; BAUER, G			EPILEPTIC SEIZURES ASSOCIATED WITH INTRATHECAL BACLOFEN APPLICATION	NEUROLOGY			English	Article							SPASTICITY; OVERDOSE; EVENTS	We report the clinical and EEG findings in three patients presenting with seizures associated with intrathecal baclofen application for treatment of spasticity. All patients had a history of traumatic brain injury, while one patient also suffered a spinal cord injury. Two patients experienced their first seizure following intrathecal baclofen test bolus injection. Another patient had convulsions on two occasions: following postoperative baclofen dose adjustment, and after sleep deprivation. Structural brain disease seems prerequisite for baclofen to exert epileptogenic activity, since seizures have not occurred in patients receiving intrathecal baclofen for spasticity of solely spinal origin. Antiepileptic medication permitted the continuation of intrathecal baclofen treatment in the three patients.	BAYLOR COLL MED, DIV RESTORAT NEUROL & HUMAN NEUROBIOL, HOUSTON, TX USA; UNIV MESSINA, CTR NEUROLESI, MESSINA, ITALY		KOFLER, M (corresponding author), UNIV INNSBRUCK, DEPT NEUROL, ANICHSTR 35, A-6020 INNSBRUCK, AUSTRIA.		Kofler, Markus/P-5585-2019; Rifici, Carmela/ABH-4398-2020	Kofler, Markus/0000-0002-2962-0903			ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418; DELHAAS EM, 1991, INT J CLIN PHARM TH, V29, P274; DRALLE D, 1989, LANCET, V2, P916; FAIGLE JW, 1972, POSTGRAD MED J, V48, P9; JONES RSG, 1989, EXP NEUROL, V104, P155, DOI 10.1016/S0014-4886(89)80009-3; MOTT DD, 1989, J PHARMACOL EXP THER, V249, P721; MULLER H, 1987, J NEUROL, V234, P348, DOI 10.1007/BF00314294; MULLERSCHWEFE G, 1989, J NEUROSURG, V71, P273, DOI 10.3171/jns.1989.71.2.0273; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; ROMIJN JA, 1986, LANCET, V2, P696; Saltuari L, 1992, Acta Neurol (Napoli), V14, P195; SALTUARI L, 1992, LANCET, V339, P373, DOI 10.1016/0140-6736(92)91697-7; Takahashi T., 1987, ELECTROENCEPHALOGRAP, P209	13	69	70	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JAN	1994	44	1					25	27		10.1212/WNL.44.1.25			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MR371	WOS:A1994MR37100007	8290085				2022-02-06	
J	SCHWAB, K; GRAFMAN, J; SALAZAR, AM; KRAFT, J				SCHWAB, K; GRAFMAN, J; SALAZAR, AM; KRAFT, J			RESIDUAL IMPAIRMENTS AND WORK STATUS 15 YEARS AFTER PENETRATING HEAD-INJURY - REPORT FROM THE VIETNAM HEAD-INJURY STUDY	NEUROLOGY			English	Article							FOLLOW-UP; NEUROLOGY; EPILEPSY; LESIONS	We investigated the relationship of neurologic, neuropsychological, and social interaction impairments to the work status of a large sample of penetrating head-injured patients wounded some 15 years earlier during combat in Vietnam. Extensive standardized testing of neurologic, neuropsychological, and social functioning was done at follow-up on each head-injured patient (N = 520), as well as on a sample of uninjured controls (N = 85). Fifty-six percent of the head-injured patients were working at follow-up compared with 82% of the uninjured controls. Seven systematically defined impairments proved to be most correlated with work status. These were post-traumatic epilepsy, paresis, visual field loss, verbal memory loss, visual memory loss, psychological problems, and violent behavior. These disabilities had a cumulative and nearly equipotent effect upon the likelihood of work. We suggest that a simple summed score of the number of these seven disabilities can yield a residual ''disability score'' which may prove to be a practical tool for assessing the likelihood of return to work for patients in this population and perhaps in other brain-injured populations. These findings may also help to focus rehabilitation efforts on those disabilities most likely to affect return to work.	UNIFORMED SERV UNIV HLTH SCI, DEPT NEUROL, HEAD INJURY UNIT, BETHESDA, MD 20814 USA; NINCDS, COGNIT NEUROSCI SECT, BETHESDA, MD 20892 USA					Grafman, Jordan H./0000-0001-8645-4457			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BECK SJ, 1960, RORSCHACHS TEST BASI, V2, P75; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; COHANY SR, 1990, MONTHLY LABOR RE APR, P22; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DRESSER AC, 1973, ARCH NEUROL-CHICAGO, V29, P111, DOI 10.1001/archneur.1973.00490260055011; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Eysenck HJ, 1975, MANUAL EYSENCK PERSO; FREEDMAN PE, 1987, J NEUROL NEUROSUR PS, V50, P398, DOI 10.1136/jnnp.50.4.398; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; GRAFMAN J, 1990, CORTEX, V26, P361, DOI 10.1016/S0010-9452(13)80086-X; GRAFMAN J, 1985, ARCH NEUROL-CHICAGO, V42, P1162, DOI 10.1001/archneur.1985.04060110044014; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Grafman J., 1987, NEUROBEHAVIORAL RECO, P43; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1988, HEAD TRAUMA RES PROJ; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P264, DOI 10.1001/archneur.1963.00460030048004; KJONAS B, 1987, P SECTION SURVEY RES; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KRAFT J, IN PRESS ARCH PHYS M; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LUDLOW CL, 1986, BRAIN, V109, P55, DOI 10.1093/brain/109.1.55; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; OVERALL JE, 1962, PSYCHOL REP, V10, P799; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1986, NEUROLOGY, V36, P459, DOI 10.1212/WNL.36.4.459; SALAZAR AM, 1987, DV  EPILEPTOLOGY, V16, P753; SALAZAR AM, 1987, ADV EPILEPTOL, V16, P627; SMUTOK M A, 1985, Neurology, V35, P83; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vogenthaler D R, 1987, Brain Inj, V1, P113; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; 1982, B US DEP LABOR, V2096	45	69	70	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN	1993	43	1					95	103		10.1212/WNL.43.1_Part_1.95			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KJ189	WOS:A1993KJ18900017	8423917				2022-02-06	
J	ANDREWS, BT; PITTS, LH				ANDREWS, BT; PITTS, LH			FUNCTIONAL RECOVERY AFTER TRAUMATIC TRANSTENTORIAL HERNIATION	NEUROSURGERY			English	Article						BURR HOLE; HEAD INJURY; SUBDURAL HEMATOMA; TRANSTENTORIAL HERNIATION	ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; TENTORIAL HERNIATION; MANAGEMENT; PROGNOSIS; CHILDREN	To elucidate the factors associated with functional recovery after traumatic transtentorial herniation, we reviewed the records of 153 consecutive patients admitted with clinical signs of transtentorial herniation (altered level of consciousness, anisocoria or pupillary unresponsiveness, and abnormal motor findings). Overall, 28 patients (18%) had a functional outcome: 14 patients (9%) made a good recovery and 14 were moderately disabled. Sixteen patients (10.5%) were severly disabled or vegetative, and 104 (60%) died. Compared with patients who died or were left severely disabled or vegetative, patients who had a good recovery were younger (21 versus 38 years), were significantly more likely to be children (less-than-or-equal-to 17 years old) and have anisocoria and a deteriorating Glasgow Coma Score (GCS), and were significantly less likely to be flaccid or have bilaterally fixed pupils; moderately disabled patients also had a lower median age and a higher frequency of anisocoria. There was no difference in the incidence of significant intracranial hematomas between patients with a functional outcome and those with a nonfunctional outcome. Twenty-seven percent of the 95 patients with anisocoria had a good outcome or moderate disability, whereas only 3.5% of the 58 patients with bilaterally fixed and dilated pupils at admission had a functional recovery (P < 0.05). Age, level of consciousness, and the degree of residual upper brain stem function at admission appear to be the most important determinants of functional outcome after traumatic transtentorial herniation.	SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94110		ANDREWS, BT (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,EDITORIAL OFF,DEPT NEUROL SURG,1360 9TH AVE,SUITE 210,SAN FRANCISCO,CA 94122, USA.						AMACHER AL, 1987, NEUROSURGERY, V20, P954; Andrews B T, 1988, Neurosurgery, V22, P614, DOI 10.1097/00006123-198803000-00035; ANDREWS BT, 1989, NEUROSURGERY, V24, P345, DOI 10.1227/00006123-198903000-00006; ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; ANDREWS BT, 1987, SURG NEUROL, V28, P699; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRENDLER SJ, 1970, BRAIN, V93, P381, DOI 10.1093/brain/93.2.381; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; GROSSMAN RG, 1981, NEW ENGL J MED, V304, P1540, DOI 10.1056/NEJM198106183042510; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; HOFF JT, 1978, WESTERN J MED, V128, P112; HOWELL DA, 1959, BRAIN, V82, P525, DOI 10.1093/brain/82.4.525; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; JAMIESON KG, 1972, J NEUROSURG, V37, P528, DOI 10.3171/jns.1972.37.5.0528; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETTB, 1981, MANAGEMENT HEAD INJU; KERNOHAN JW, 1929, LARCH NEUROOL PSYCHI, V21, P274; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; MAHONEY DB, 1981, NEUROSURGERY, V8, P2551; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1983, J NEUROSURG, V58, P566, DOI 10.3171/jns.1983.58.4.0566; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NEWFIELD P, 1980, NEUROSURGERY, V6, P596; OVERGAARD J, 1973, LANCET, V2, P631; PITTS LH, 1981, CLIN NEUROSURG, V29, P203; RICHARDS T, 1974, SURGERY, V75, P253; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; ROCKSWOLD GL, 1988, NEUROSURGERY, V22, P614; SACHS E, 1978, NEUROSURGERY, V3, P66, DOI 10.1227/00006123-197807000-00011; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SEELIG JM, 1981, J NEUROSURG, V55, P516, DOI 10.3171/jns.1981.55.4.0516; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140	39	69	70	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	AUG	1991	29	2					227	231		10.1227/00006123-199108000-00010			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	FX980	WOS:A1991FX98000010	1886660				2022-02-06	
J	Vink, R; Head, VA; Rogers, PJ; McIntosh, TK; Faden, AI				Vink, Robert; Head, Valerie A.; Rogers, Peter J.; McIntosh, Tracy K.; Faden, Alan I.			Mitochondrial Metabolism Following Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL-BLOOD-FLOW; OXIDATIVE-PHOSPHORYLATION; MG-2+	Although a number of studies of traumatic brain injury have implicated mitochondrial dysfunction as a cause of altered posttraumatic energy metabolism, no studies to date have isolated mitochondria and measured their respiratory capacity following trauma. The present study sought to determine whether mitochondrial capacity for oxidative phosphorylation is adversely affected by fluid-percussion-induced traumatic brain injury in rats. Prior to brain injury, the mitochondrial respiratory control ratio was 4.3 +/- 0.2 and the ratio of nmoles of ADP phosphorylated per natom oxygen consumed (ADP/O ratio) was 2.66 +/- 0.09. After injury (2.8 atm; t = 4 h), there were slight but not significant alterations in ADP/O ratio (2.41 +/- 0.07) and state 3 respiratory rate (ADP stimulated); however, there were no changes in the respiratory control ratio. These data suggest that traumatic brain injury, unlike ischemia, does not cause uncoupling of ATP synthesis from respiration, and that brain mitochondria are quite resistant to trauma-induced injury.	[Vink, Robert] James Cook Univ, Dept Chem & Biochem, Townsville, Qld 4811, Australia; [Head, Valerie A.; Faden, Alan I.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Head, Valerie A.; Faden, Alan I.] Vet Adm Med Ctr, Ctr Neural Injury, San Francisco, CA 94121 USA; [Rogers, Peter J.] Griffith Univ, Sch Sci, Brisbane, Qld 4111, Australia; [McIntosh, Tracy K.] Univ Connecticut, Ctr Hlth, Dept Surg, Farmington, CT USA		Vink, R (corresponding author), James Cook Univ N Queensland, Dept Chem & Biochem, Townsville, Qld 4811, Australia.		Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [902269]; Veterans Administration Merit ReviewUS Department of Veterans Affairs; Queen Elizabeth II Fellowship; Australian National Research Fellowships Advisory Committee	This work was supported in part by Centers for Disease Control Grant 902269 to A.I.F., and a Veterans Administration Merit Review Grant to T.K.M.R. Vink is a recipient of a Queen Elizabeth II Fellowship and is supported by the Australian National Research Fellowships Advisory Committee.	ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; Estabrook RW, 1967, METHOD ENZYMOL, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FAGIAN MM, 1986, BIOCHIM BIOPHYS ACTA, V852, P262, DOI 10.1016/0005-2728(86)90231-8; GINSBERG MD, 1977, ANN NEUROL, V1, P519, DOI 10.1002/ana.410010603; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P438, DOI 10.1038/jcbfm.1984.63; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; KLINGENBERG M, 1977, STRUCTURE FUNCTION E, P275; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KRAMER R, 1986, BIOCHIM BIOPHYS ACTA, V855, P201, DOI 10.1016/0005-2736(86)90166-5; Lai J C, 1979, Methods Enzymol, V55, P51; LEE NM, 1970, BIOCHEM BIOPH RES CO, V40, P1058, DOI 10.1016/0006-291X(70)90901-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASINI A, 1983, J BIOENERG BIOMEMBR, V15, P217, DOI 10.1007/BF00743942; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORENOSANCHEZ R, 1985, J BIOL CHEM, V260, P2554; OZAWA K, 1967, J BIOCHEM-TOKYO, V61, P512, DOI 10.1093/oxfordjournals.jbchem.a128576; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; SAKS VA, 1975, EUR J BIOCHEM, V57, P273, DOI 10.1111/j.1432-1033.1975.tb02299.x; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; WILSON EJ, 1987, NEUROCHEM RES, V12, P831; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	31	69	69	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SPR	1990	7	1					21	27		10.1089/neu.1990.7.21			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	V21VN	WOS:000208235200003	2342116				2022-02-06	
J	FADEN, AI				FADEN, AI			TRH ANALOG YM-14673 IMPROVES OUTCOME FOLLOWING TRAUMATIC BRAIN AND SPINAL-CORD INJURY IN RATS - DOSE-RESPONSE STUDIES	BRAIN RESEARCH			English	Article									UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143		FADEN, AI (corresponding author), VET ADM MED CTR,NEUROL SERV 127,CTR NEURAL INJURY 127,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, P50NS014543] Funding Source: NIH RePORTER		BASSIRI RM, 1973, J CLIN INVEST, V52, P1616, DOI 10.1172/JCI107339; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; DEMEDIUK P, IN PRESS J NEUROTRAU; FADEN AI, 1985, NEUROLOGY, V35, P1331, DOI 10.1212/WNL.35.9.1331; FADEN AI, 1987, CLIN NEUROPHARMACOL, V10, P193, DOI 10.1097/00002826-198706000-00001; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1983, PEPTIDES, V4, P631, DOI 10.1016/0196-9781(83)90009-8; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1982, NEUROLOGY, V32, P1083, DOI 10.1212/WNL.32.10.1083; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; FADEN AI, 1987, PHYSL BASIS FUNCTION, V47, P531; FEUERSTEIN G, 1984, NEUROPEPTIDES, V4, P303, DOI 10.1016/0143-4179(84)90004-0; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; HANNAN CJ, 1982, NEUROSCI LETT, V33, P299, DOI 10.1016/0304-3940(82)90389-5; HOLADAY JW, 1982, LIFE SCI, V31, P385, DOI 10.1016/0024-3205(82)90419-2; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; KOSKINEN LOD, IN PRESS ANN NY ACAD; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; LUX WE, 1983, CIRC SHOCK, V10, P262; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785, DOI 10.1152/ajpregu.1988.254.5.R785; MCINTOSH TK, IN PRESS NEUROSCIENC; METCALF G, 1982, BRAIN RES REV, V4, P389, DOI 10.1016/0165-0173(82)90012-1; OSHAUGHNESSY CT, IN PRESS J PHYSL LON; PRANGE A J JR, 1979, P75; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; YAMAKAMI I, IN PRESS J CEREB BLO; YAMAMOTO M, IN PRESS ANN NY ACAD; YARBROUGH GG, 1979, PROG NEUROBIOL, V12, P291, DOI 10.1016/0301-0082(79)90012-1; Young W, 1985, Cent Nerv Syst Trauma, V2, P109	36	69	72	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 8	1989	486	2					228	235		10.1016/0006-8993(89)90509-X			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	U6056	WOS:A1989U605600004	2499400				2022-02-06	
J	LINDGREN, S; RINDER, L				LINDGREN, S; RINDER, L			EXPERIMENTAL STUDIES IN HEAD INJURY .2. PRESSURE PROPAGATION IN PERCUSSION CONCUSSION	BIOPHYSIK			English	Article																	Clark S. L., 1943, SURG GYNECOL OBSTET, V77, P403; CLEMEDSON C, 1961, ACTA PHYSIOL SCAND, V51, P47, DOI 10.1111/j.1748-1716.1961.tb02112.x; CLEMEDSON CJ, 1956, AM J PHYSIOL, V184, P119, DOI 10.1152/ajplegacy.1955.184.1.119; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296, DOI 10.1152/physrev.1945.25.2.296; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; HAMBERGER A, 1966, J NEUROPATH EXP NEUR, V25, P68, DOI 10.1097/00005072-196601000-00004; LINDGREN SO, 1964, LANCET, V1, P1251; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; LUNDBECK H, 1963, BIOTECHNOL BIOENG, V5, P167, DOI 10.1002/bit.260050302; TREVENA DH, 1964, NATURE, V203, P1158, DOI 10.1038/2031158c0; [No title captured]	11	69	69	0	0				0006-3517			BIOPHYSIK			1966	3	2					174	&		10.1007/BF01191611			0	Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics	82478	WOS:A19668247800009	5982794				2022-02-06	
J	OMMAYA, AK; HIRSCH, AE; FLAMM, ES; MAHONE, RH				OMMAYA, AK; HIRSCH, AE; FLAMM, ES; MAHONE, RH			CEREBRAL CONCUSSION IN MONKEY - AN EXPERIMENTAL MODEL	SCIENCE			English	Article																	Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GURDJIAN ES, 1965, 7 STAPP CRASH C P; HOLBOURN AHS, 1943, LANCET, P438; OMMAYA AK, 1964, J NEUROSURG, V31, P249; OMMAYA AK, IN PRESS; SELLIER K, 1963, HEFTE UNFALLHEILKUND	6	69	72	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science		1966	153	3732					211	&		10.1126/science.153.3732.211			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	79346	WOS:A19667934600051	4957321				2022-02-06	
J	Xie, BS; Wang, YQ; Lin, Y; Mao, Q; Feng, JF; Gao, GY; Jiang, JY				Xie, Bao-Shu; Wang, Yi-Qin; Lin, Yong; Mao, Qing; Feng, Jun-Feng; Gao, Guo-Yi; Jiang, Ji-Yao			Inhibition of ferroptosis attenuates tissue damage and improves long-term outcomes after traumatic brain injury in mice	CNS NEUROSCIENCE & THERAPEUTICS			English	Article						ferroptosis; iron accumulation; lipid ROS accumulation; traumatic brain injury (TBI)	HIPPOCAMPAL CELL-DEATH; NECROPTOSIS; HYPOTHERMIA; APOPTOSIS; STRESS	Aims Ferroptosis, a new form of iron-dependent programmed cell death, has been shown to be involved in a range of diseases. However, the role of ferroptosis in traumatic brain injury (TBI) has yet to be elucidated. We aimed to investigate whether ferroptosis is induced after TBI and whether the inhibition of ferroptosis would protect against traumatic brain injury in a controlled cortical impact injury (CCI) mouse model. Methods After establishing the TBI model in mice, we determined the biochemical and morphological changes associated with ferroptosis, including iron accumulation with Perl's staining, neuronal cell death with Fluoro-Jade B (FJB) staining, iron metabolism dysfunction with Western blotting, reactive oxygen species (ROS) accumulation with malondialdehyde (MDA) assays, and shrunken mitochondria with transmission electron microscopy. Furthermore, a specific inhibitor of ferroptosis, ferrostatin-1(fer-1), was administrated by cerebral ventricular injection after CCI. We used cresyl violet (CV) staining to assess lesion volume, along with the Morris water maze and beam walk test to evaluate long-term outcomes. Results TBI was followed by iron accumulation, dysfunctional iron metabolism, the upregulation of ferroptosis-related genes, reduced glutathione peroxidase (GPx) activity, and the accumulation of lipid-reactive oxygen species (ROS). Three days (d) after TBI, transmission electron microscopy (TEM) confirmed that the mitochondria had shrunk a typical characteristic of ferroptosis. Importantly, the administration of Fer-1 by cerebral ventricular injection significantly reduced iron deposition and neuronal degeneration while attenuating injury lesions and improving long-term motor and cognitive function. Conclusion This study demonstrated an effective method with which to treat TBI by targeting ferroptosis.	[Xie, Bao-Shu; Lin, Yong; Mao, Qing; Feng, Jun-Feng; Gao, Guo-Yi; Jiang, Ji-Yao] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Xie, Bao-Shu; Lin, Yong; Feng, Jun-Feng; Gao, Guo-Yi; Jiang, Ji-Yao] Shanghai Inst Head Trauma, Shanghai, Peoples R China; [Wang, Yi-Qin] Shanghai Jiao Tong Univ, Sch Med, Sino French Res Ctr Life Sci & Genom, State Key Lab Med Genom,Rui Jin Hosp, Shanghai, Peoples R China		Gao, GY; Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai, Peoples R China.	gao3@sina.com; jiyaojiang@126.com			Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine [BXJ201824]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81772058, 81471856, 81471244, 81771317]	Doctoral Innovation Fund Projects from Shanghai Jiao Tong University School of Medicine, Grant/Award Number: BXJ201824; National Natural Science Foundation of China, Grant/Award Number: No.81772058, 81471856 and 81471244 and 81771317	Abou-Abbass H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005342; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Al Nimer F, 2011, BRAIN BEHAV IMMUN, V25, P981, DOI 10.1016/j.bbi.2010.10.017; Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Cao Y, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0251-1; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Do Van B, 2016, NEUROBIOL DIS, V94, P169, DOI 10.1016/j.nbd.2016.05.011; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Guiney SJ, 2017, NEUROCHEM INT, V104, P34, DOI 10.1016/j.neuint.2017.01.004; Hattori K, 2017, EMBO REP, V18, P2067, DOI 10.15252/embr.201744228; Imai H, 2017, CURR TOP MICROBIOL, V403, P143, DOI 10.1007/82_2016_508; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Jin YC, 2015, J NEUROTRAUM, V32, P1090, DOI 10.1089/neu.2014.3649; Lachaier E, 2014, ANTICANCER RES, V34, P6417; Lee S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0544-4; Li Q, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90777; Lin Y, 2015, BIOMATERIALS, V69, P148, DOI 10.1016/j.biomaterials.2015.08.010; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24547; Lu L., 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/470676; Ma S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.208; Maiorino M, 2018, ANTIOXID REDOX SIGN, V29, P61, DOI 10.1089/ars.2017.7115; Majdan M, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002331; Martin-Sanchez D, 2017, J AM SOC NEPHROL, V28, P218, DOI 10.1681/ASN.2015121376; McGinn MJ, 2016, NEUROSURG CLIN N AM, V27, P397, DOI 10.1016/j.nec.2016.06.002; Muller T, 2017, CELL MOL LIFE SCI, V74, P3631, DOI 10.1007/s00018-017-2547-4; Potts Mathew B, 2006, NeuroRx, V3, P143; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Sheng XH, 2017, PHYS CHEM CHEM PHYS, V19, P13153, DOI 10.1039/c7cp00804j; Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a; Speer RE, 2013, FREE RADICAL BIO MED, V62, P26, DOI 10.1016/j.freeradbiomed.2013.01.026; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Tuo QZ, 2017, MOL PSYCHIATR, V22, P1520, DOI 10.1038/mp.2017.171; Wang CF, 2016, SCI REP-UK, V6, DOI 10.1038/srep37063; Wenzel SE, 2017, CELL, V171, P628, DOI 10.1016/j.cell.2017.09.044; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Zhu S, 2017, CANCER RES, V77, P2064, DOI 10.1158/0008-5472.CAN-16-1979; Zille M, 2017, STROKE, V48, P1033, DOI 10.1161/STROKEAHA.116.015609	43	68	73	11	53	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-5930	1755-5949		CNS NEUROSCI THER	CNS Neurosci. Ther.	APR	2019	25	4					465	475		10.1111/cns.13069			11	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	HP7WS	WOS:000461901900006	30264934	Bronze, Green Published	Y	N	2022-02-06	
J	Horti, AG; Naik, R; Foss, CA; Minn, I; Misheneva, V; Du, Y; Wang, YC; Mathews, WB; Wu, YK; Hall, A; LaCourse, C; Ahn, HH; Nam, H; Lesniak, WG; Valentine, H; Pletnikova, O; Troncoso, JC; Smith, MD; Calabresi, PA; Savonenko, AV; Dannals, RF; Pletnikov, MV; Pomper, MG				Horti, Andrew G.; Naik, Ravi; Foss, Catherine A.; Minn, Il; Misheneva, Varia; Du, Yong; Wang, Yuchuan; Mathews, William B.; Wu, Yunkou; Hall, Andrew; LaCourse, Catherine; Ahn, Hye-Hyun; Nam, Hwanhee; Lesniak, Wojciech G.; Valentine, Heather; Pletnikova, Olga; Troncoso, Juan C.; Smith, Matthew D.; Calabresi, Peter A.; Savonenko, Alena V.; Dannals, Robert F.; Pletnikov, Mikhail V.; Pomper, Martin G.			PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R)	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						neuroinflammation; positron-emission tomography; CSF1R; DAM; [C-11]CPPC	ALZHEIMERS-DISEASE; PROGENITOR-CELL; CSF-1 RECEPTOR; MOUSE MODEL; NEUROINFLAMMATION; EXPRESSION; INFLAMMATION; INHIBITOR; LIGANDS; GLIA	While neuroinflammation is an evolving concept and the cells involved and their functions are being defined, microglia are understood to be a key cellular mediator of brain injury and repair. The ability to measure microglial activity specifically and non-invasively would be a boon to the study of neuroinflammation, which is involved in a wide variety of neuropsychiatric disorders including traumatic brain injury, demyelinating disease, Alzheimer's disease (AD), and Parkinson's disease, among others. We have developed [C-11]CPPC [5-cyano-N-(4-(4-[C-11]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl)furan-2-carboxamide], a positron-emitting, high-affinity ligand that is specific for the macrophage colony-stimulating factor 1 receptor (CSF1R), the expression of which is essentially restricted to microglia within brain. [C-11] CPPC demonstrates high and specific brain uptake in a murine and nonhuman primate lipopolysaccharide model of neuroinflammation. It also shows specific and elevated uptake in a murine model of AD, experimental allergic encephalomyelitis murine model of demyelination and in postmortem brain tissue of patients with AD. Radiation dosimetry in mice indicated [C-11] CPPC to be safe for future human studies. [C-11] CPPC can be synthesized in sufficient radiochemical yield, purity, and specific radioactivity and possesses binding specificity in relevant models that indicate potential for human PET imaging of CSF1R and the microglial component of neuroinflammation.	[Horti, Andrew G.; Naik, Ravi; Foss, Catherine A.; Minn, Il; Du, Yong; Mathews, William B.; Wu, Yunkou; Hall, Andrew; Ahn, Hye-Hyun; Nam, Hwanhee; Lesniak, Wojciech G.; Valentine, Heather; Dannals, Robert F.; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA; [Misheneva, Varia; LaCourse, Catherine; Pletnikov, Mikhail V.; Pomper, Martin G.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21287 USA; [Wang, Yuchuan] Merck & Co Inc, West Point, PA 19486 USA; [Pletnikova, Olga; Troncoso, Juan C.; Savonenko, Alena V.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Troncoso, Juan C.; Smith, Matthew D.; Calabresi, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA		Horti, AG; Pomper, MG (corresponding author), Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA.; Pomper, MG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21287 USA.	ahorti1@jhmi.edu; mpomper@jhmi.edu	Calabresi, Peter A./AAF-2288-2019; LaCourse, Catherine M/L-8604-2019; Pletnikov, Mikhail V/G-8709-2012; Savonenko, Alena/AAT-2274-2021	LaCourse, Catherine M/0000-0002-9477-6920; Pletnikov, Mikhail V/0000-0002-8819-6559; Du, Yong/0000-0002-0237-6154; Smith, Matthew/0000-0001-6614-569X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG054802, EB024495, NS041435]; Johns Hopkins University Alzheimer's Disease Research CenterJohns Hopkins University [AG05146]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB024495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS041435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG054802, R33AG054802, P50AG005146] Funding Source: NIH RePORTER	We acknowledge Dr. Xiaolei Song for providing an EAE mouse and Dr. Hiroto Kuwabara for fruitful discussions. We are grateful to Dr. Polina Sysa Shah; Paige Finley, MS; and James Engles, MS, for assistance with animal experiments. This research was supported by NIH Grants AG054802, EB024495, and NS041435 and by the Johns Hopkins University Alzheimer's Disease Research Center (Grant AG05146).	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Aid S, 2010, NEUROSCI LETT, V478, P113, DOI 10.1016/j.neulet.2010.04.076; AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; ALTERMAN RL, 1994, MOL CHEM NEUROPATHOL, V21, P177, DOI 10.1007/BF02815350; Bernard-Gauthier V, 2014, BIOORG MED CHEM LETT, V24, P4784, DOI 10.1016/j.bmcl.2014.09.014; Boissonneault V, 2009, BRAIN, V132, P1078, DOI 10.1093/brain/awn331; Chitu V, 2016, TRENDS NEUROSCI, V39, P378, DOI 10.1016/j.tins.2016.03.005; Deczkowska A, 2018, CELL, V173, P1073, DOI 10.1016/j.cell.2018.05.003; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dickens AM, 2014, J NUCL MED, V55, P466, DOI 10.2967/jnumed.113.125625; Dobos N, 2012, J ALZHEIMERS DIS, V28, P905, DOI 10.3233/JAD-2011-111097; El-Gamal MI, 2018, J MED CHEM, V61, P5450, DOI 10.1021/acs.jmedchem.7b00873; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Hannestad J, 2012, NEUROIMAGE, V63, P232, DOI 10.1016/j.neuroimage.2012.06.055; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hickman SE, 2014, BIOCHEM PHARMACOL, V88, P495, DOI 10.1016/j.bcp.2013.11.021; Illig CR, 2008, BIOORG MED CHEM LETT, V18, P1642, DOI 10.1016/j.bmcl.2008.01.059; Janssen B, 2018, MOLECULES, V23, DOI 10.3390/molecules23030607; Jones MV, 2008, J NEUROIMMUNOL, V199, P83, DOI 10.1016/j.jneuroim.2008.05.013; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Krauser JA, 2015, XENOBIOTICA, V45, P107, DOI 10.3109/00498254.2014.945988; LEE SC, 1993, J IMMUNOL, V150, P594; Lentz MR, 2010, J NEUROVIROL, V16, P368, DOI 10.3109/13550284.2010.513029; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; Masgrau R, 2017, TRENDS MOL MED, V23, P486, DOI 10.1016/j.molmed.2017.04.005; Melnikova T, 2013, J NEUROSCI, V33, P3765, DOI 10.1523/JNEUROSCI.4251-12.2013; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Nandi S, 2012, DEV BIOL, V367, P100, DOI 10.1016/j.ydbio.2012.03.026; Catorce MN, 2016, CURR NEUROPHARMACOL, V14, P155, DOI 10.2174/1570159X14666151204122017; Palle Pushpalatha, 2017, Med Sci (Basel), V5, DOI 10.3390/medsci5040023; Peyraud F, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0634-1; Prieto-Morin C, 2016, J NEUROL, V263, P1864, DOI 10.1007/s00415-016-8197-x; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; Smith AM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-85; Tronel C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040802; Walker DG, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00244; Yan SD, 1997, NATURE, V389, P689; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]	41	68	68	0	28	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 29	2019	116	5					1686	1691		10.1073/pnas.1812155116			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HJ1SN	WOS:000456944600038	30635412	Green Published, Bronze			2022-02-06	
J	Mason, S				Mason, Shayne			Lactate Shuttles in Neuroenergetics - Homeostasis, Allostasis and Beyond	FRONTIERS IN NEUROSCIENCE			English	Article						neuroenergetics; lactate; astrocyte-neuron lactate shuttle (ANLS); astrocyte-microglia lactate shuttle (AMLS); neuropathology; traumatic brain injury (TBI); neurodegenerative disease; infectious neuroinflammatory disease	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; HUMAN VISUAL-CORTEX; CEREBROSPINAL-FLUID; ENERGY-METABOLISM; IN-VIVO; AXONAL DEGENERATION; SYNAPTIC ACTIVITY; OXIDATIVE STRESS; LACTIC-ACID	Understanding brain energy metabolism neuroenergetics is becoming increasingly important as it can be identified repeatedly as the source of neurological perturbations. Within the scientific community we are seeing a shift in paradigms from the traditional neurocentric view to that of a more dynamic, integrated one where astrocytes are no longer considered as being just supportive, and activated microglia have a profound influence. Lactate is emerging as the "good guy," contrasting its classical "bad guy" position in the now superseded medical literature. This review begins with the evolution of the concept of "lactate shuttles"; goes on to the recent shift in ideas regarding normal neuroenergetics (homeostasis) specifically, the astrocytc-neuron lactate shuttle; and progresses to covering the metabolic implications whereby homeostasis is lost a state of allostasis, and the function of microglia. The role of lactate, as a substrate and shuttle, is reviewed in light of allostatic stress, and beyond in an acute state of allostatic stress in terms of physical brain trauma, and reflected upon with respect to persistent stress as allostatic overload-neurodegenerative diseases. Finally, the recently proposed astrocyte-microglia lactate shuttle is discussed in terms of chronic neuroinflammatory infectious diseases, using tuberculous meningitis as an example. The novelty extended by this review is that the directionality of lactate, as shuttles in the brain, in neuropathophysiological states is emerging as crucial in neuroenergetics.	[Mason, Shayne] North West Univ, Ctr Human Metab, Potchefstroom, South Africa		Mason, S (corresponding author), North West Univ, Ctr Human Metab, Potchefstroom, South Africa.	nmr.nwu@gmail.com		Mason, Shayne/0000-0002-2945-5768	Technological Innovation Agency (TIA) of the Department of Science and Technology of South Africa	Research funding was provided by the Technological Innovation Agency (TIA) of the Department of Science and Technology of South Africa. Opinions expressed and conclusions arrived at, are those of the author and are not necessarily to be attributed to the funding body TIA.	Albanese M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0502-1; Angamo EA, 2016, J NEUROPHYSIOL, V116, P2420, DOI 10.1152/jn.00327.2016; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Aubert A, 2005, P NATL ACAD SCI USA, V102, P16448, DOI 10.1073/pnas.0505427102; Aubert A, 2005, J CEREBR BLOOD F MET, V25, P1476, DOI 10.1038/sj.jcbfm.9600144; Aubert A, 2007, P NATL ACAD SCI USA, V104, P4188, DOI 10.1073/pnas.0605864104; Bak LK, 2006, J CEREBR BLOOD F MET, V26, P1285, DOI 10.1038/sj.jcbfm.9600281; Baltan S, 2015, METAB BRAIN DIS, V30, P25, DOI 10.1007/s11011-014-9595-3; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bender AS, 1997, BRAIN RES, V750, P59, DOI 10.1016/S0006-8993(96)01331-5; Bergersen LH, 2007, NEUROSCIENCE, V145, P11, DOI 10.1016/j.neuroscience.2006.11.062; Berthet C, 2012, CEREBROVASC DIS, V34, P329, DOI 10.1159/000343657; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; Blair C, 2011, DEV PSYCHOPATHOL, V23, P845, DOI 10.1017/S0954579411000344; Bliss TM, 2004, J NEUROSCI, V24, P6202, DOI 10.1523/JNEUROSCI.0805-04.2004; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bourgeois NMA, 2016, ENDOCRINOLOGY, V157, P2560, DOI 10.1210/en.2015-2025; Bouzat P, 2014, CURR OPIN CRIT CARE, V20, P133, DOI 10.1097/MCC.0000000000000072; Bouzier-Sore AK, 2003, BIOCHIMIE, V85, P841, DOI 10.1016/j.biochi.2003.08.003; Bouzier-Sore AK, 2002, J PHYSIOL-PARIS, V96, P273, DOI 10.1016/S0928-4257(02)00016-5; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; Brooks G.A., 1985, CIRCULATION RESP MET, P208; BROOKS GA, 1986, MED SCI SPORT EXER, V18, P360, DOI 10.1249/00005768-198606000-00019; BROOKS GA, 1986, FASEB J, V45, P2924; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/BST0300258; Brooks GA, 2000, MED SCI SPORT EXER, V32, P790, DOI 10.1097/00005768-200004000-00011; Brooks GA, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00408; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Cambron M, 2012, J CEREBR BLOOD F MET, V32, P413, DOI 10.1038/jcbfm.2011.193; Campbell GR, 2014, MULT SCLER J, V20, P1806, DOI 10.1177/1352458514544537; Capuani F, 2015, SCI REP-UK, V5, DOI 10.1038/srep11880; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; Carpenter KLH, 2014, EUR J PHARM SCI, V57, P87, DOI 10.1016/j.ejps.2013.12.012; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; Chaumeil MM, 2016, NEUROIMAGE-CLIN, V12, P180, DOI 10.1016/j.nicl.2016.06.018; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chih CP, 2003, J CEREBR BLOOD F MET, V23, P1263, DOI 10.1097/01.WCB.0000081369.51727.6F; Chih CP, 2001, TRENDS NEUROSCI, V24, P573, DOI 10.1016/S0166-2236(00)01920-2; Chiry O, 2008, BRAIN RES, V1226, P61, DOI 10.1016/j.brainres.2008.06.025; Covarrubias-Pinto A, 2015, FREE RADICAL BIO MED, V89, P1085, DOI 10.1016/j.freeradbiomed.2015.09.024; Danese A, 2012, PHYSIOL BEHAV, V106, P29, DOI 10.1016/j.physbeh.2011.08.019; Cruz RSD, 2012, SCI WORLD J, DOI 10.1100/2012/420984; Debernardi R, 1999, BRAIN RES, V850, P39, DOI 10.1016/S0006-8993(99)02022-3; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Dienel GA, 2004, NEUROCHEM INT, V45, P321, DOI 10.1016/j.neuint.2003.10.011; Dienel GA, 2003, NEUROCHEM INT, V43, P339, DOI 10.1016/S0197-0186(03)00021-4; Dienel GA, 2001, J NEUROSCI RES, V66, P824, DOI 10.1002/jnr.10079; Dienel GA, 2015, METAB BRAIN DIS, V30, P281, DOI 10.1007/s11011-014-9493-8; Dienel GA, 2014, J CEREBR BLOOD F MET, V34, P1736, DOI 10.1038/jcbfm.2014.153; DiNuzzo M, 2010, J CEREBR BLOOD F MET, V30, P1895, DOI 10.1038/jcbfm.2010.151; DiNuzzo M, 2010, J CEREBR BLOOD F MET, V30, P586, DOI 10.1038/jcbfm.2009.232; Draoui N, 2011, DIS MODEL MECH, V4, P727, DOI 10.1242/dmm.007724; Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736; Eder C, 1998, AM J PHYSIOL-CELL PH, V275, pC327, DOI 10.1152/ajpcell.1998.275.2.C327; Erlichman JS, 2008, J NEUROSCI, V28, P4888, DOI 10.1523/JNEUROSCI.5430-07.2008; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Finsterwald C, 2015, CURR PHARM DESIGN, V21, P3570, DOI 10.2174/1381612821666150710144502; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Garseth M, 2000, J NEUROSCI RES, V60, P779, DOI 10.1002/1097-4547(20000615)60:6<779::AID-JNR10>3.0.CO;2-M; Genc S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-162; Giaume C, 2007, CELL DEATH DIFFER, V14, P1324, DOI 10.1038/sj.cdd.4402144; Giaume C, 2010, NAT REV NEUROSCI, V11, P87, DOI 10.1038/nrn2757; Gjedde A, 2002, J CEREBR BLOOD F MET, V22, P1, DOI 10.1097/00004647-200201000-00001; Gjedde A, 2001, J CEREBR BLOOD F MET, V21, P1384, DOI 10.1097/00004647-200112000-00002; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; Glenn TC, 2015, J NEUROTRAUM, V32, P820, DOI 10.1089/neu.2014.3483; Glenn TC, 2015, J NEUROTRAUM, V32, P811, DOI 10.1089/neu.2014.3482; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; Gouarne C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081528; Guzman M, 2001, TRENDS ENDOCRIN MET, V12, P169, DOI 10.1016/S1043-2760(00)00370-2; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Hashimoto T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002915; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.0.CO;2-N; Itoh Y, 2003, P NATL ACAD SCI USA, V100, P4879, DOI 10.1073/pnas.0831078100; Jolivet R, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004036; Jolivet R, 2010, J CEREBR BLOOD F MET, V30, P1982, DOI 10.1038/jcbfm.2010.132; JUEPTNER M, 1995, NEUROIMAGE, V2, P148, DOI 10.1006/nimg.1995.1017; Karagiannis A, 2016, J CEREBR BLOOD F MET, V36, P1202, DOI 10.1177/0271678X15611912; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; Kolko M, 2016, NEUROCHEM RES, V41, P1229, DOI 10.1007/s11064-015-1792-x; Korogod N, 2015, ELIFE, V4, DOI 10.7554/eLife.05793; Kuchiiwa T, 2011, HISTOCHEM CELL BIOL, V135, P351, DOI 10.1007/s00418-011-0794-2; KUHR WG, 1988, J CEREBR BLOOD F MET, V8, P130, DOI 10.1038/jcbfm.1988.17; Laskas J. M., 2009, GAME BRAIN GENTLEMEN; Laskas J.M., 2015, CONCUSSION; Laughton JD, 2000, NEUROSCIENCE, V96, P619, DOI 10.1016/S0306-4522(99)00580-1; Laureys G, 2014, NEUROSCIENCE, V277, P367, DOI 10.1016/j.neuroscience.2014.07.022; Lee NY, 2016, PHARM RES-DORDR, V33, P1711, DOI 10.1007/s11095-016-1912-6; Leen WG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042745; Li CY, 2011, CURR ALZHEIMER RES, V8, P67; Logan JG, 2008, J CLIN NURS, V17, P201, DOI 10.1111/j.1365-2702.2008.02347.x; Lutz NW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000595; Magistretti PJ, 2009, AM J CLIN NUTR, V90, p875S, DOI 10.3945/ajcn.2009.27462CC; Magistretti PJ, 2006, J EXP BIOL, V209, P2304, DOI 10.1242/jeb.02208; Magistretti PJ, 1996, CEREB CORTEX, V6, P50, DOI 10.1093/cercor/6.1.50; Magistretti PJ, 2000, BRAIN RES, V886, P108, DOI 10.1016/S0006-8993(00)02945-0; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; Mangia S, 2003, NEUROSCIENCE, V118, P7, DOI 10.1016/S0306-4522(02)00792-3; Mangia S, 2003, J NEUROSCI RES, V71, P463, DOI 10.1002/jnr.10531; Mangia S, 2009, J NEUROCHEM, V109, P55, DOI 10.1111/j.1471-4159.2009.06003.x; Mason S, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1053-2; Mason S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1597-9; Mason S, 2015, METABOLOMICS, V11, P822, DOI 10.1007/s11306-014-0741-z; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; McEwen BS, 2006, METABOLISM, V55, pS20, DOI 10.1016/j.metabol.2006.07.008; McEwen BS, 2011, ANNU REV MED, V62, P431, DOI 10.1146/annurev-med-052209-100430; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; Moffett John R, 2013, Front Neuroenergetics, V5, P11, DOI 10.3389/fnene.2013.00011; Moro N, 2013, BRAIN RES, V1535, P124, DOI 10.1016/j.brainres.2013.08.044; Newington Jordan T, 2013, J Neurodegener Dis, V2013, P234572, DOI 10.1155/2013/234572; Nijland PG, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0261-8; NORENBERG MD, 1987, J NEUROPATH EXP NEUR, V46, P154, DOI 10.1097/00005072-198703000-00004; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Olson JK, 2001, J VIROL, V75, P9780, DOI 10.1128/JVI.75.20.9780-9789.2001; Oresic M, 2008, TRENDS BIOTECHNOL, V26, P647, DOI 10.1016/j.tibtech.2008.09.001; Ovanesov MV, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-50; Patet C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0638-5; Pavlides S, 2010, AGING-US, V2, P185, DOI 10.18632/aging.100134; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Pellerin L, 2004, NEUROSCIENTIST, V10, P53, DOI 10.1177/1073858403260159; Pellerin L, 2010, DIABETES METAB, V36, pS59, DOI 10.1016/S1262-3636(10)70469-9; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; Pellerin L, 2002, INT CONGR SER, V1235, P189, DOI 10.1016/S0531-5131(02)00186-3; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Perez-Escuredo J, 2016, BBA-MOL CELL RES, V1863, P2481, DOI 10.1016/j.bbamcr.2016.03.013; Pertega-Gomes N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-352; Peters A, 2015, NEUROSCI BIOBEHAV R, V56, P139, DOI 10.1016/j.neubiorev.2015.07.001; Pierre K, 2000, NEUROSCIENCE, V100, P617, DOI 10.1016/S0306-4522(00)00294-3; Pizzuto R, 2012, BBA-BIOENERGETICS, V1817, P1679, DOI 10.1016/j.bbabio.2012.05.010; Porras OH, 2004, J NEUROSCI, V24, P9669, DOI 10.1523/JNEUROSCI.1882-04.2004; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407; Rake AJ, 2010, PEDIATR CRIT CARE ME, V11, P707, DOI 10.1097/PCC.0b013e3181e88b1f; Rakus D, 2016, J PROTEOME RES, V15, P2479, DOI 10.1021/acs.jproteome.5b01149; Ramautar R, 2013, CURR OPIN CHEM BIOL, V17, P841, DOI 10.1016/j.cbpa.2013.06.015; Ranjbar M, 2017, NEURAL COMPUT APPL, V28, P1109, DOI 10.1007/s00521-015-2112-8; Regenold WT, 2008, J NEUROL SCI, V275, P106, DOI 10.1016/j.jns.2008.07.032; Robinet C, 2011, NEUROSCIENCE, V192, P155, DOI 10.1016/j.neuroscience.2011.06.059; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Rosafio K, 2016, NEUROSCIENCE, V317, P108, DOI 10.1016/j.neuroscience.2015.12.052; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Rothman DL, 2003, ANNU REV PHYSIOL, V65, P401, DOI 10.1146/annurev.physiol.65.092101.142131; Rouach N, 2008, SCIENCE, V322, P1551, DOI 10.1126/science.1164022; Sack GH, 2010, J BIOENERG BIOMEMBR, V42, P189, DOI 10.1007/s10863-010-9291-x; Sahlin K, 2002, J PHYSIOL-LONDON, V541, P569, DOI 10.1113/jphysiol.2002.016683; Sampol Denys, 2013, Front Neuroenergetics, V5, P5, DOI 10.3389/fnene.2013.00005; Sanita P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-154; SAPPEYMARINIER D, 1992, J CEREBR BLOOD F MET, V12, P584, DOI 10.1038/jcbfm.1992.82; Sawada Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep27758; Schurr A, 1997, BRAIN RES, V774, P221, DOI 10.1016/S0006-8993(97)81708-8; Schurr A, 1999, ANN NY ACAD SCI, V893, P386, DOI 10.1111/j.1749-6632.1999.tb07862.x; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; Schurr A, 1997, J NEUROCHEM, V69, P423; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Shannon M, 2007, JOGNN-J OBST GYN NEO, V36, P125, DOI 10.1111/J.1552-6909.2007.00126.x; Shulman RG, 2004, TRENDS NEUROSCI, V27, P489, DOI 10.1016/j.tins.2004.06.005; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Sokoloff L, 1989, BASIC NEUROCHEMISTRY, V2, P338; Somashekar BS, 2011, J PROTEOME RES, V10, P4186, DOI 10.1021/pr2003352; Sone JY, 2017, J NEUROSURG, V126, P768, DOI 10.3171/2016.2.JNS151972; Steele ML, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.09.018; Sterling P., 1988, HDB LIFE STRESS COGN, P629; Stewart James A, 2006, J Physiol Anthropol, V25, P133, DOI 10.2114/jpa2.25.133; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Stumvoll M, 2004, REV ENDOCR METAB DIS, V5, P99, DOI 10.1023/B:REMD.0000021430.56457.2c; Stumvoll M, 2003, DIABETES, V52, P903, DOI 10.2337/diabetes.52.4.903; Sussman ES, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15610; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Tabernero A, 1996, NEUROSCI RES, V26, P369, DOI 10.1016/S0168-0102(96)01121-2; Taher M, 2016, EUR J PAEDIATR NEURO, V20, P3, DOI 10.1016/j.ejpn.2015.09.008; Tannenbaum B, 2002, BRAIN RES, V953, P82, DOI 10.1016/S0006-8993(02)03273-0; Tomiyama AJ, 2012, PHYSIOL BEHAV, V106, P40, DOI 10.1016/j.physbeh.2011.11.016; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; Verwaest KA, 2011, BBA-MOL BASIS DIS, V1812, P1371, DOI 10.1016/j.bbadis.2011.08.001; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; Wender R, 2000, J NEUROSCI, V20, P6804, DOI 10.1523/JNEUROSCI.20-18-06804.2000; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Wishart DS, 2008, J CHROMATOGR B, V871, P164, DOI 10.1016/j.jchromb.2008.05.001; Wyss MT, 2011, J NEUROSCI, V31, P7477, DOI 10.1523/JNEUROSCI.0415-11.2011; Yamanishi S, 2006, AM J PHYSIOL-HEART C, V290, pH925, DOI 10.1152/ajpheart.01012.2005; Zeis T, 2015, BRAIN BEHAV IMMUN, V48, P313, DOI 10.1016/j.bbi.2015.04.013; Zhou AP, 2015, TUBERCULOSIS, V95, P294, DOI 10.1016/j.tube.2015.02.038; Zuo RJ, 2015, J BIOL CHEM, V290, P21280, DOI 10.1074/jbc.M115.656629; Zwingmann C, 2000, GLIA, V32, P286, DOI 10.1002/1098-1136(200012)32:3<286::AID-GLIA80>3.0.CO;2-P	199	68	71	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	FEB 2	2017	11								43	10.3389/fnins.2017.00043			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EJ5CH	WOS:000393233600001	28210209	gold, Green Published			2022-02-06	
J	Koerte, IK; Mayinger, M; Muehlmann, M; Kaufmann, D; Lin, AP; Steffinger, D; Fisch, B; Rauchmann, BS; Immler, S; Karch, S; Heinen, FR; Ertl-Wagner, B; Reiser, M; Stern, RA; Zafonte, R; Shenton, ME				Koerte, Inga K.; Mayinger, Michael; Muehlmann, Marc; Kaufmann, David; Lin, Alexander P.; Steffinger, Denise; Fisch, Barbara; Rauchmann, Boris-Stephan; Immler, Stefanie; Karch, Susanne; Heinen, Florian R.; Ertl-Wagner, Birgit; Reiser, Maximilian; Stern, Robert A.; Zafonte, Ross; Shenton, Martha E.			Cortical thinning in former professional soccer players	BRAIN IMAGING AND BEHAVIOR			English	Article						Repetitive subconcussive head impact; Soccer; Cortical thickness; Aging; Traumatic brain injury	CONCUSSION; THICKNESS	Soccer is the most popular sport in the world. Soccer players are at high risk for repetitive subconcussive head impact when heading the ball. Whether this leads to long-term alterations of the brain's structure associated with cognitive decline remains unknown. The aim of this study was to evaluate cortical thickness in former professional soccer players using high-resolution structural MR imaging. Fifteen former male professional soccer players (mean age 49.3 [SD 5.1] years) underwent high-resolution structural 3 T MR imaging, as well as cognitive testing. Fifteen male, age-matched former professional non-contact sport athletes (mean age 49.6 [SD 6.4] years) served as controls. Group analyses of cortical thickness were performed using voxel-based statistics. Soccer players demonstrated greater cortical thinning with increasing age compared to controls in the right inferolateral-parietal, temporal, and occipital cortex. Cortical thinning was associated with lower cognitive performance as well as with estimated exposure to repetitive subconcussive head impact. Neurocognitive evaluation revealed decreased memory performance in the soccer players compared to controls. The association of cortical thinning and decreased cognitive performance, as well as exposure to repetitive subconcussive head impact, further supports the hypothesis that repetitive subconcussive head impact may play a role in early cognitive decline in soccer players. Future studies are needed to elucidate the time course of changes in cortical thickness as well as their association with impaired cognitive function and possible underlying neurodegenerative process.	[Koerte, Inga K.; Mayinger, Michael; Muehlmann, Marc; Lin, Alexander P.; Rauchmann, Boris-Stephan; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Koerte, Inga K.; Mayinger, Michael; Muehlmann, Marc; Kaufmann, David; Steffinger, Denise; Fisch, Barbara; Rauchmann, Boris-Stephan; Ertl-Wagner, Birgit; Reiser, Maximilian] Univ Munich, Inst Clin Radiol, Munich, Germany; [Koerte, Inga K.; Muehlmann, Marc] Univ Munich, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Kaufmann, David] Charite, Dept Radiol, Berlin, Germany; [Lin, Alexander P.; Shenton, Martha E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA; [Immler, Stefanie; Heinen, Florian R.] Univ Munich, Dept Pediat Neurol & Dev Med, Dr von Hauner Childrens Hosp, Munich, Germany; [Karch, Susanne] Univ Munich, Dept Psychiat, Munich, Germany; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Zafonte, Ross] Harvard Med Sch, Brigham & Womens Hosp, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp,Massachusetts Gen Hosp, Boston, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Boston, MA USA		Koerte, IK (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02115 USA.; Koerte, IK (corresponding author), Univ Munich, Inst Clin Radiol, Munich, Germany.; Koerte, IK (corresponding author), Univ Munich, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany.	ikoerte@bwh.harvard.edu	Ertl-Wagner, Birgit/AAD-5708-2020; Shenton, Martha/V-8780-2019; Koerte, Inga Katharina/AAW-3031-2021; , Bob/ABA-8507-2020; Heinen, Florian/B-6594-2015	Heinen, Florian/0000-0002-3872-6136; Ertl-Wagner, Birgit/0000-0002-7896-7049	Else Kroner-Fresenius Stiftung, Germany; Department of DefenseUnited States Department of Defense [X81XWH-07-CC-CSDoD]; VA Merit AwardUS Department of Veterans Affairs; Petraeic Legate foundation, Germany	This study was supported by the Else Kroner-Fresenius Stiftung, Germany (IK). This work was also partially funded by grants from The Department of Defense (X81XWH-07-CC-CSDoD; RZ, MES) and a VA Merit Award (MES). Michael Mayinger was supported by the Petraeic Legate foundation, Germany.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; EKBLOM B, 1986, SPORTS MED, V3, P50, DOI 10.2165/00007256-198603010-00005; Fjell AM, 2009, CEREB CORTEX, V19, P2001, DOI 10.1093/cercor/bhn232; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Koerte IK, 2015, J NEUROTRAUM, V32, P1287, DOI 10.1089/neu.2014.3715; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Shin MS, 2006, NAT PROTOC, V1, P892, DOI 10.1038/nprot.2006.115; Sowell ER, 2007, CEREB CORTEX, V17, P1550, DOI 10.1093/cercor/bhl066; Storsve AB, 2014, J NEUROSCI, V34, P8488, DOI 10.1523/JNEUROSCI.0391-14.2014; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tysvaer A, 1981, Br J Sports Med, V15, P163; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364	22	68	68	0	25	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2016	10	3					792	798		10.1007/s11682-015-9442-0			7	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DU7IL	WOS:000382387300018	26286826				2022-02-06	
J	Lambert, C; Cisternas, P; Inestrosa, NC				Lambert, Catherine; Cisternas, Pedro; Inestrosa, Nibaldo C.			Role of Wnt Signaling in Central Nervous System Injury	MOLECULAR NEUROBIOLOGY			English	Article						Wnt signaling; Stroke; Spinal cord injury; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; SPINAL-CORD-INJURY; BETA-CATENIN; SYNAPTIC DIFFERENTIATION; ISCHEMIC-STROKE; GENE-EXPRESSION; NEURONAL DEATH; IMPACT INJURY; IN-VITRO	The central nervous system (CNS) is highly sensitive to external mechanical damage, presenting a limited capacity for regeneration explained in part by its inability to restore either damaged neurons or the synaptic network. The CNS may suffer different types of external injuries affecting its function and/or structure, including stroke, spinal cord injury, and traumatic brain injury. These pathologies critically affect the quality of life of a large number of patients worldwide and are often fatal because available therapeutics are ineffective and produce limited results. Common effects of the mentioned pathologies involves the triggering of several cellular and metabolic responses against injury, including infiltration of blood cells, inflammation, glial activation, and neuronal death. Although some of the underlying molecular mechanisms of those responses have been elucidated, the mechanisms driving these processes are poorly understood in the context of CNS injury. In the last few years, it has been suggested that the activation of the Wnt signaling pathway could be important in the regenerative response after CNS injury, activating diverse protective mechanisms including the stimulation of neurogenesis, blood brain structure consolidation and the recovery of cognitive brain functions. Because Wnt signaling is involved in several physiological processes, the putative positive role of its activation after injury could be the basis for novel therapeutic approaches to CNS injury.	[Lambert, Catherine; Cisternas, Pedro; Inestrosa, Nibaldo C.] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Ctr Envejecimiento & Regenerac CARE, Alameda 340,POB 114-D, Santiago, Chile; [Inestrosa, Nibaldo C.] Univ New S Wales, Fac Med, Sch Psychiat, Ctr Hlth Brain Ageing, Sydney, NSW, Australia; [Inestrosa, Nibaldo C.] Pontificia Univ Catolica Chile, Ctr UC, Sindrome Down, Santiago, Chile; [Inestrosa, Nibaldo C.] Univ Magallanes, Ctr Excelencia Biomed Magallanes CEBIMA, Punta Arenas, Chile		Inestrosa, NC (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Ctr Envejecimiento & Regenerac CARE, Alameda 340,POB 114-D, Santiago, Chile.	ninestrosa@bio.puc.cl			Basal Center for Excellence in Science and Technology (Conicyt-PFB); FondecytComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT [1120156, 3150291, 3150475]; Sociedad Quimica y Minera de Chile (SQM)	This work was supported by grants from the Basal Center for Excellence in Science and Technology (Conicyt-PFB 12/2007) and from Fondecyt: to NCI (No 1120156) to CL (postdoctoral fellowships No 3150291) and PC (postdoctoral fellowships No 3150475). We also thank the Sociedad Quimica y Minera de Chile (SQM) for special grants to study "The role of potassium in hypertension and cognition" and "The role of lithium in human health". We also thank Felipe G. Serrano for artwork (www.illustrative-science.com).	Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Arrazola MS, 2009, J CELL PHYSIOL, V221, P658, DOI 10.1002/jcp.21902; BelAiba RS, 2006, CIRC RES, V98, P828, DOI 10.1161/01.RES.0000210539.54861.27; Ben Borgens R, 2012, Q REV BIOL, V87, P89, DOI 10.1086/665457; Benbrook DM, 2011, CURR CANCER DRUG TAR, V11, P586; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Cao HQ, 2013, NEUROSCI BULL, V29, P94, DOI 10.1007/s12264-012-1277-8; Cerpa W, 2008, J BIOL CHEM, V283, P5918, DOI 10.1074/jbc.M705943200; Chen YC, 2012, NEUROL RES, V34, P390, DOI 10.1179/1743132812Y.0000000027; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Cisternas P, 2014, MOL NEUROBIOL, V49, P574, DOI 10.1007/s12035-013-8540-5; Clark CEJ, 2014, SCI CHINA LIFE SCI, V57, P366, DOI 10.1007/s11427-014-4640-3; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; David MD, 2010, J NEUROSCI RES, V88, P3011, DOI 10.1002/jnr.22464; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; DeVivo MJ, 2012, SPINAL CORD, V50, P365, DOI 10.1038/sc.2011.178; Dobkin BH, 1997, CURR OPIN NEUROL, V10, P493, DOI 10.1097/00019052-199712000-00010; Dupont P, 2012, NEUROBIOL DIS, V47, P237, DOI 10.1016/j.nbd.2012.04.007; Edvinsson LIH, 2011, J CEREBR BLOOD F MET, V31, P1554, DOI 10.1038/jcbfm.2011.70; Fancy SPJ, 2011, NAT NEUROSCI, V14, P1009, DOI 10.1038/nn.2855; Farias GG, 2007, J NEUROSCI, V27, P5313, DOI 10.1523/JNEUROSCI.3934-06.2007; Farias GG, 2009, J BIOL CHEM, V284, P15857, DOI 10.1074/jbc.M808986200; Feigenson K, 2011, ASN NEURO, V3, DOI 10.1042/AN20110004; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Gonzalez P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050793; Gonzalez-Fernandez C, 2014, J NEUROTRAUM, V31, P565, DOI 10.1089/neu.2013.3067; Guo SZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052665; Habib SJ, 2013, SCIENCE, V339, P1445, DOI 10.1126/science.1231077; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hall EC, 2014, J TRAUMA ACUTE CARE, V76, P859, DOI 10.1097/TA.0000000000000148; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hodar C, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-348; Inestrosa NC, 2012, J NEUROIMMUNE PHARM, V7, P788, DOI 10.1007/s11481-012-9417-5; Inestrosa NC, 2010, NAT REV NEUROSCI, V11, P77, DOI 10.1038/nrn2755; Jansen O, 2013, NAT REV NEUROL, V9, P645, DOI 10.1038/nrneurol.2013.204; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kalani MYS, 2008, P NATL ACAD SCI USA, V105, P16970, DOI 10.1073/pnas.0808616105; Kang WH, 2015, J NEUROTRAUM, V32, P1011, DOI 10.1089/neu.2014.3667; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Leeds PR, 2014, ACS CHEM NEUROSCI, V5, P422, DOI 10.1021/cn500040g; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Li XJ, 2013, INT J CLIN EXP PATHO, V6, P1245; Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024; Liu B, 2013, INVEST OPHTH VIS SCI, V54, P444, DOI 10.1167/iovs.12-10774; Liu FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066393; Liu YB, 2008, J NEUROSCI, V28, P8376, DOI 10.1523/JNEUROSCI.1939-08.2008; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marchetti B, 2013, TRENDS MOL MED, V19, P144, DOI 10.1016/j.molmed.2012.12.001; Fernandez-Martos CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027000; Mastroiacovo F, 2009, J CEREBR BLOOD F MET, V29, P264, DOI 10.1038/jcbfm.2008.111; Miyashita T, 2009, J NEUROTRAUM, V26, P955, DOI 10.1089/neu.2008.0776; Mufti RE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103530; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Niu LJ, 2012, NEUROSCIENCE, V213, P19, DOI 10.1016/j.neuroscience.2012.03.057; Nusse R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011163; Nusse R, 2012, EMBO J, V31, P2670, DOI 10.1038/emboj.2012.146; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281; Pi XC, 2009, P NATL ACAD SCI USA, V106, P5675, DOI 10.1073/pnas.0809568106; Piccin D, 2011, STEM CELLS, V29, P528, DOI 10.1002/stem.589; Pinto C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00239; Planutiene M, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-28; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Reeves MJ, 2008, LANCET NEUROL, V7, P915, DOI 10.1016/S1474-4422(08)70193-5; Rios JA, 2014, PROG NEUROBIOL, V121, P125, DOI 10.1016/j.pneurobio.2014.07.004; Rosso SB, 2005, NAT NEUROSCI, V8, P34, DOI 10.1038/nn1374; Rosso SB, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00103; Salinas PC, 2008, ANNU REV NEUROSCI, V31, P339, DOI 10.1146/annurev.neuro.31.060407.125649; Scott EL, 2013, BRAIN RES, V1514, P63, DOI 10.1016/j.brainres.2012.12.015; Seifert-Held T, 2011, ATHEROSCLEROSIS, V218, P233, DOI 10.1016/j.atherosclerosis.2011.05.015; Serrano FG, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-61; Silva-Alvarez C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00097; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; Tapia-Rojas C, 2015, BIOCHEM J, V466, P415, DOI 10.1042/BJ20140207; Tian YF, 2012, J CEREBR BLOOD F MET, V32, P780, DOI 10.1038/jcbfm.2011.179; Toledo EM, 2010, MOL PSYCHIATR, V15, P272, DOI 10.1038/mp.2009.72; Tourette C, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001895; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Umschweif G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076129; Varela-Nallar L, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00100; Varela-Nallar L, 2010, P NATL ACAD SCI USA, V107, P21164, DOI 10.1073/pnas.1010011107; Wang HY, 2006, CELL SIGNAL, V18, P934, DOI 10.1016/j.cellsig.2005.12.008; Wang SS, 2013, BIOTECHNOL LETT, V35, P1199, DOI 10.1007/s10529-013-1199-1; Warlow C, 2003, J THROMB HAEMOST, V1, P1422, DOI 10.1046/j.1538-7836.2003.00328.x; Warlow C, 2003, LANCET, V362, P1211, DOI 10.1016/S0140-6736(03)14544-8; Weinsheimer SM, 2011, TRANSL STROKE RES, V2, P575, DOI 10.1007/s12975-011-0103-3; White BD, 2010, STEM CELLS, V28, P297, DOI 10.1002/stem.268; Whiting M.D., 2006, COGNITIVE IMPAIRMENT; Wu XM, 2013, INT J CLIN EXP PATHO, V6, P1282; Xie R, 2014, STROKE, V45, P2769, DOI 10.1161/STROKEAHA.114.005406; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang XT, 2014, J NEUROSCI RES, V92, P148, DOI 10.1002/jnr.23314; Yin Y, 2013, NEUROBIOL DIS, V59, P165, DOI 10.1016/j.nbd.2013.07.013; Young W, 2009, CELL TRANSPLANT, V18, P951, DOI 10.3727/096368909X471251; Yu FS, 2013, J NEUROSURG, V119, P766, DOI 10.3171/2013.6.JNS13135; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang JC, 2014, NEUROSCIENCE, V274, P419, DOI 10.1016/j.neuroscience.2014.06.001; Zhang L, 2013, INT J MOL MED, V32, P867, DOI 10.3892/ijmm.2013.1456; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang YK, 2013, J CLIN INVEST, V123, P2268, DOI 10.1172/JCI65364; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zimmerman ZF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008086; Zou FH, 2013, J MOL NEUROSCI, V49, P395, DOI 10.1007/s12031-012-9906-2	115	68	72	1	27	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAY	2016	53	4					2297	2311		10.1007/s12035-015-9138-x			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI6WS	WOS:000373641500021	25976365				2022-02-06	
J	Yuan, F; Xu, ZM; Lu, LY; Nie, H; Ding, J; Ying, WH; Tian, HL				Yuan, Fang; Xu, Zhi-Ming; Lu, Li-Yan; Nie, Hui; Ding, Jun; Ying, Wei-Hai; Tian, Heng-Li			SIRT2 inhibition exacerbates neuroinflammation and blood-brain barrier disruption in experimental traumatic brain injury by enhancing NF-kappa B p65 acetylation and activation	JOURNAL OF NEUROCHEMISTRY			English	Article						blood-brain barrier; cerebral edema; inflammation; SIRT2; traumatic brain injury	OXIDATIVE STRESS; MICROGLIAL ACTIVATION; PARKINSONS-DISEASE; GENE-EXPRESSION; CELL-DEATH; IN-VITRO; DEACETYLASE; LIPOPOLYSACCHARIDE; RESPONSES; MODELS	Sirtuin 2 (SIRT2) is a member of the sirtuin family of NAD(+)-dependent protein deacetylases. In recent years, SIRT2 inhibition has emerged as a promising treatment for neurodegenerative diseases. However, to date, there is no evidence of a specific role for SIRT2 in traumatic brain injury (TBI). We investigated the effects of SIRT2 inhibition on experimental TBI using the controlled cortical impact (CCI) injury model. Adult male mice underwent CCI or sham surgery. A selective brain-permeable SIRT2 inhibitor, AK-7, was administrated 30 min before injury. The volume of the brain edema lesion and the water content of the brain were significantly increased in mice treated with AK-7 (20 mg/kg), compared with the vehicle group, following TBI (p < 0.05 at 1 day and p < 0.05 at 3 days, respectively). Concomitantly, AK-7 administration greatly worsened neurobehavioral deficits on days 3 and 7 after CCI. Furthermore, blood-brain barrier disruption and matrix metalloproteinases (MMP)-9 activity increased following SIRT2 inhibition. AK-7 treatment increased TBI-induced microglial activation both in vivo and in vitro, accompanied by a large increase in the expression and release of inflammatory cytokines. Mechanistically, SIRT2 inhibition increased both K310 acetylation and nuclear translocation of NF-kappa B p65, leading to enhanced NF-kappa B activation and up-regulation of its target genes, including aquaporin 4 (AQP4), MMP-9, and pro-inflammatory cytokines. Together, these data demonstrate that SIRT2 inhibition exacerbates TBI by increasing NF-kappa B p65 acetylation and activation. Our findings provide additional evidence of an anti-inflammatory effect of SIRT2.	[Yuan, Fang; Xu, Zhi-Ming; Ding, Jun; Tian, Heng-Li] Shanghai Jiao Tong Univ, Dept Neurosurg, Affiliated Peoples Hosp 6, Sch Med, Shanghai 200030, Peoples R China; [Lu, Li-Yan] Shanghai Jiao Tong Univ, Dept Radiol, Affiliated Peoples Hosp 6, Sch Med, Shanghai 200030, Peoples R China; [Nie, Hui; Ying, Wei-Hai] Shanghai Jiao Tong Univ, Med X Res Inst, Neurosci & Neuroengn Res Ctr, Shanghai 200030, Peoples R China		Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Affiliated Peoples Hosp 6, Sch Med, Shanghai 200030, Peoples R China.; Ying, WH (corresponding author), Shanghai Jiao Tong Univ, Med X Res Inst, Neurosci & Neuroengn Res Ctr, Shanghai 200030, Peoples R China.	415523055@qq.com; tianhlsh@126.com		Yuan, Fang/0000-0002-4060-7830	National Nature and Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271383, 81471245]; Shanghai Science and Technique Committee [13411951400]	This research was supported by funds from National Nature and Science Foundation of China (81271383,81471245) and the Shanghai Science and Technique Committee (13411951400). Lei-Lei Chen is gratefully acknowledged for her assistance with the flow cytometry analyses. The authors declare that they have no conflicts of interest.	Bobrowska A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034805; Chen HY, 2015, NEUROREPORT, V26, P88, DOI 10.1097/WNR.0000000000000305; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen XQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116919; Choi YH, 2013, BIOCHEM BIOPH RES CO, V437, P245, DOI 10.1016/j.bbrc.2013.06.053; Chopra V, 2012, CELL REP, V2, P1492, DOI 10.1016/j.celrep.2012.11.001; de Oliveira RM, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00082; Di Fruscia P, 2015, CHEMMEDCHEM, V10, P69, DOI 10.1002/cmdc.201402431; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donmez G, 2012, J NEUROSCI, V32, P124, DOI 10.1523/JNEUROSCI.3442-11.2012; Eskandarian HA, 2013, SCIENCE, V341, P525, DOI 10.1126/science.1238858; Grall F, 2003, ARTHRITIS RHEUM, V48, P1249, DOI 10.1002/art.10942; Hoffmann G, 2014, J BIOL CHEM, V289, P5208, DOI 10.1074/jbc.M113.487736; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kim MJ, 2013, FREE RADICAL BIO MED, V63, P432, DOI 10.1016/j.freeradbiomed.2013.06.005; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lee AS, 2014, BIOCHEM BIOPH RES CO, V450, P1363, DOI 10.1016/j.bbrc.2014.06.135; Li YX, 2013, NEUROSCI LETT, V544, P36, DOI 10.1016/j.neulet.2013.03.032; Lin JT, 2013, BIOCHEM BIOPH RES CO, V441, P897, DOI 10.1016/j.bbrc.2013.10.153; Lo Sasso G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103573; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Luthi-Carter R, 2010, P NATL ACAD SCI USA, V107, P7927, DOI 10.1073/pnas.1002924107; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Maxwell MM, 2011, HUM MOL GENET, V20, P3986, DOI 10.1093/hmg/ddr326; Nie H, 2014, NEUROREPORT, V25, P838, DOI 10.1097/WNR.0000000000000192; Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780; Pais TF, 2013, EMBO J, V32, P2603, DOI 10.1038/emboj.2013.200; Pallos J, 2008, HUM MOL GENET, V17, P3767, DOI 10.1093/hmg/ddn273; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Qiu XL, 2010, BBA-PROTEINS PROTEOM, V1804, P1576, DOI 10.1016/j.bbapap.2009.09.015; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Rhee JW, 2007, J BIOCHEM MOL BIOL, V40, P88; Rothgiesser KM, 2010, J CELL SCI, V123, P4251, DOI 10.1242/jcs.073783; Taylor DM, 2011, ACS CHEM BIOL, V6, P540, DOI 10.1021/cb100376q; Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang YP, 2014, EMBO J, V33, P1304, DOI 10.1002/embj.201387224; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004	40	68	71	0	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2016	136	3					581	593		10.1111/jnc.13423			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	DC3UQ	WOS:000369144800014	26546505	Bronze			2022-02-06	
J	Junge, A; Dvorak, J				Junge, Astrid; Dvorak, Jiri			Football injuries during the 2014 FIFA World Cup	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PRECOMPETITION MEDICAL ASSESSMENT; DATA-COLLECTION PROCEDURES; SPORTS INJURIES; CONSENSUS STATEMENT; ATHLETICS CHAMPIONSHIPS; ELITE FOOTBALL; SURVEILLANCE; ILLNESSES; DEFINITIONS; PLAYERS	Background FIFA has surveyed match injuries in its tournaments since 1998. Aim To analyse the incidence and characteristics of match injuries incurred during the 2014 FIFA World Cup in comparison to previous FIFA World Cups. Methods The chief physicians of the participating teams reported all newly incurred injuries of their players after the match on a standardised report form. 124 (97%) forms were returned. Results A total of 104 injuries were reported, equivalent to an incidence of 1.68 injuries per match (95% CI 1.36 to 2.00). 64 (63.4%) injuries were caused by contact with another player. Thigh (26; 25%) and head (19; 18%) were the most frequently injured body parts. The most frequent diagnosis was thigh strain (n=18). Five concussions and three fractures to the head were reported. While most thigh strains (15/17; 88.2%) occurred without contact, almost all head injuries (18/19; 94.7%) were caused by contact. 0.97 injuries per match (95% CI 0.72 to 1.22) were expected to result in absence from training or match. Eight injuries were classified as severe. The incidence of match injuries in the 2014 FIFA World Cup was significantly lower than the average of the four preceding FIFA World Cups, both for all injuries (2.34; 95% CI 2.15 to 2.53) and time-loss injuries (1.51; 95% CI 1.37 to 1.65). Conclusions The overall incidence of injury during the FIFA World Cups decreased from 2002 to 2014 by 37%. A detailed analysis of the injury mechanism is recommended to further improve prevention strategies.	[Junge, Astrid; Dvorak, Jiri] FIFA Med Assessment & Res Ctr F MARC, Zurich, Switzerland; [Junge, Astrid; Dvorak, Jiri] Schulthess Klin, Zurich, Switzerland; [Junge, Astrid] MSH, Hamburg, Germany; [Dvorak, Jiri] FIFA, Zurich, Switzerland		Dvorak, J (corresponding author), F MARC, Schulthess Klin, Lengghalde 2, CH-8008 Zurich, Switzerland.	Medical@FIFA.org		Junge, Astrid/0000-0002-6815-9793	FIFA	This study was funded by FIFA.	Arnason A, 2008, SCAND J MED SCI SPOR, V18, P40, DOI 10.1111/j.1600-0838.2006.00634.x; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.034579; Dvorak J, 2013, BRIT J SPORT MED, V47, P1199, DOI 10.1136/bjsports-2013-092767; Dvorak J, 2012, BRIT J SPORT MED, V46, P1132, DOI 10.1136/bjsports-2011-090374; Dvorak J, 2011, BRIT J SPORT MED, V45, P626, DOI 10.1136/bjsm.2010.079905; Dvorak J, 2009, CLIN J SPORT MED, V19, P316, DOI 10.1097/JSM.0b013e3181b21b6e; Eirale C, 2013, J SCI MED SPORT, V16, P113, DOI 10.1016/j.jsams.2012.07.001; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Engebretsen L, 2013, BRIT J SPORT MED, V47, P407, DOI 10.1136/bjsports-2013-092380; Engebretsen L, 2010, BRIT J SPORT MED, V44, P772, DOI 10.1136/bjsm.2010.076992; Feddermann-Demont N, 2014, BRIT J SPORT MED, V48, P513, DOI 10.1136/bjsports-2013-093087; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; Fuller CW, 2004, AM J SPORT MED, V32, p28S, DOI 10.1177/0363546503261247; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2012, BRIT J SPORT MED, V46, P11, DOI 10.1136/bjsports-2011-090634; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Goldman EF, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006782.pub2; Junge A, 2008, BRIT J SPORT MED, V42, P413, DOI 10.1136/bjsm.2008.046631; Junge A, 2004, AM J SPORT MED, V32, p80S, DOI 10.1177/0363546503261245; Junge A, 2004, AM J SPORT MED, V32, p23S, DOI 10.1177/0363546503261246; Junge A, 2013, BRIT J SPORT MED, V47, P782, DOI 10.1136/bjsports-2013-092205; Junge A, 2009, AM J SPORT MED, V37, P2165, DOI 10.1177/0363546509339357; Langevoort G, 2007, SCAND J MED SCI SPOR, V17, P400, DOI 10.1111/j.1600-0838.2006.00587.x; Alonso JM, 2009, CLIN J SPORT MED, V19, P26, DOI 10.1097/JSM.0b013e318191c8e7; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mountjoy M, 2010, BRIT J SPORT MED, V44, P522, DOI 10.1136/bjsm.2010.071720; Nichols Andrew W, 2013, Clin J Sport Med, V23, P85, DOI 10.1097/JSM.0b013e31827e9f40; Petersen J, 2011, AM J SPORT MED, V39, P2296, DOI 10.1177/0363546511419277; Timpka T, 2014, BRIT J SPORT MED, V48, P483, DOI 10.1136/bjsports-2013-093241; Tscholl P, 2007, BRIT J SPORT MED, V41, pI8, DOI 10.1136/bjsm.2007.036871; Tscholl P, 2007, BRIT J SPORT MED, V41, pI15, DOI 10.1136/bjsm.2007.036889; Walden M, 2005, SCAND J MED SCI SPOR, V15, P118, DOI 10.1111/j.1600-0838.2004.00393.x; Walden M, 2007, KNEE SURG SPORT TR A, V15, P1155, DOI 10.1007/s00167-007-0290-3; Yeung SS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001256, 10.1002/14651858.CD001256.pub2]	36	68	72	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2015	49	9					599	U58		10.1136/bjsports-2014-094469			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CG0TZ	WOS:000352985700010	25878077	Green Published, hybrid			2022-02-06	
J	Patel, TP; Gullotti, DM; Hernandez, P; O'Brien, WT; Capehart, BP; Morrison, B; Bass, C; Eberwine, JE; Abel, T; Meaney, DF				Patel, Tapan P.; Gullotti, David M.; Hernandez, Pepe; O'Brien, W. Timothy; Capehart, Bruce P.; Morrison, Barclay, III; Bass, Cameron; Eberwine, James E.; Abel, Ted; Meaney, David F.			An open-source toolbox for automated phenotyping of mice in behavioral tasks	FRONTIERS IN BEHAVIORAL NEUROSCIENCE			English	Article						automated behavior; blast-induced traumatic brain injury; Elk-1 knockout; spatial object recognition; social interaction; Barnes maze	TRAUMATIC BRAIN-INJURY; LONG-TERM-MEMORY; HOME CAGE ACTIVITY; RECOGNITION MEMORY; TRANSCRIPTION FACTOR; C57BL/6J MICE; OPEN-FIELD; ELK-1; HIPPOCAMPUS; ANXIETY	Classifying behavior patterns in mouse models of neurological, psychiatric and neurodevelopmental disorders is critical for understanding disease causality and treatment. However, complete characterization of behavior is time-intensive, prone to subjective scoring, and often requires specialized equipment. Although several reports describe automated home-cage monitoring and individual task scoring methods, we report the first open source, comprehensive toolbox for automating the scoring of several common behavior tasks used by the neuroscience community. We show this new toolbox is robust and achieves equal or better consistency when compared to manual scoring methods. We use this toolbox to study the alterations in behavior that occur following blast-induced traumatic brain injury (bTBI), and study if these behavior patterns are altered following genetic deletion of the transcription factor Ets-like kinase 1 (Elk-1). Due to the role of Elk-1 in neuronal survival and proposed role in synaptic plasticity, we hypothesized that Elk-1 deletion would improve some neurobehavioral deficits, while impairing others, following blast exposure. In Elk-1 knockout (KO) animals, deficits in open field, spatial object recognition (SOR) and elevated zero maze performance after blast exposure disappeared, while new significant deficits appeared in spatial and associative memory. These are the first data suggesting a molecular mediator of anxiety deficits following bTBI, and represent the utility of the broad screening tool we developed. More broadly, we envision this open-source toolbox will provide a more consistent and rapid analysis of behavior across many neurological diseases, promoting the rapid discovery of novel pathways mediating disease progression and treatment.	[Patel, Tapan P.; Gullotti, David M.; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Hernandez, Pepe; Abel, Ted] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [O'Brien, W. Timothy] Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; [Capehart, Bruce P.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA; [Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY USA; [Bass, Cameron] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA; [Eberwine, James E.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Meaney, David F.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	Morrison, Barclay/B-7132-2008; Abel, Ted/AAX-2825-2021	Morrison, Barclay/0000-0001-7676-0864; Abel, Ted/0000-0003-2423-4592; Patel, Tapan/0000-0001-8959-6645; Meaney, David/0000-0002-0954-4122	Department of Army [W911F-10-1-0526]; Simon Foundation Autism Research Initiative [248429, R21MH099648-02]	Funding for this project was provided by the Department of Army grant W911F-10-1-0526, the Simon Foundation Autism Research Initiative 248429, and R21MH099648-02. We thank the Neurobehavior Testing Core of the Penn Medicine Neuroscience Center for providing some of the videos for software development.	Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Balderas I, 2008, LEARN MEMORY, V15, P618, DOI 10.1101/lm.1028008; Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011; Barrett LE, 2006, NAT METHODS, V3, P455, DOI 10.1038/NMETH885; Besnard A, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00035; Bonasera SJ, 2008, PSYCHOPHARMACOLOGY, V196, P591, DOI 10.1007/s00213-007-0994-6; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Casadesus G, 2001, MECH AGEING DEV, V122, P1887, DOI 10.1016/S0047-6374(01)00324-4; Cesari F, 2004, GENESIS, V38, P87, DOI 10.1002/gene.20003; Chen SA, 2006, NEUROPSYCHOPHARMACOL, V31, P2692, DOI 10.1038/sj.npp.1301008; Choleris E, 2001, NEUROSCI BIOBEHAV R, V25, P235, DOI 10.1016/S0149-7634(01)00011-2; Clifford S, 2007, J AUTISM DEV DISORD, V37, P301, DOI 10.1007/s10803-006-0160-8; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Defensor EB, 2011, BEHAV BRAIN RES, V217, P302, DOI 10.1016/j.bbr.2010.10.033; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goulding EH, 2008, P NATL ACAD SCI USA, V105, P20575, DOI 10.1073/pnas.0809053106; Gullotti DM, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4027873; Jacobson LH, 2007, PSYCHOPHARMACOLOGY, V190, P541, DOI 10.1007/s00213-006-0631-9; Jhuang H, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1064; Joachims T, 1999, ADVANCES IN KERNEL METHODS, P169; Kabra M, 2013, NAT METHODS, V10, P64, DOI [10.1038/NMETH.2281, 10.1038/nmeth.2281]; Karlsson RM, 2005, PHARMACOL BIOCHEM BE, V80, P427, DOI 10.1016/j.pbb.2004.12.009; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; MARKOW TA, 1981, P NATL ACAD SCI-BIOL, V78, P430, DOI 10.1073/pnas.78.1.430; Millecamps M, 2005, ARTHRITIS RHEUM-US, V52, P3470, DOI 10.1002/art.21403; Morris JF, 2013, HUM PATHOL, V44, P766, DOI 10.1016/j.humpath.2012.08.001; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rutten K, 2008, J NEUROSCI METH, V171, P72, DOI 10.1016/j.jneumeth.2008.02.006; Sananbenesi F, 2002, MOL CELL NEUROSCI, V21, P463, DOI 10.1006/mcne.2002.1188; Sharma A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009002; SIMON P, 1994, BEHAV BRAIN RES, V61, P59, DOI 10.1016/0166-4328(94)90008-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Steele AD, 2007, P NATL ACAD SCI USA, V104, P1983, DOI 10.1073/pnas.0610779104; TAMBORINI P, 1989, ARCH TOXICOL, V63, P85, DOI 10.1007/BF00316429; Tang XD, 2005, PHYSIOL BEHAV, V84, P105, DOI 10.1016/j.physbeh.2004.10.017; Tang XD, 2002, BEHAV BRAIN RES, V136, P555, DOI 10.1016/S0166-4328(02)00228-0; Vekovischeva OY, 2007, BEHAV PROCESS, V75, P23, DOI 10.1016/j.beproc.2007.01.006; Vianna MRM, 2000, LEARN MEMORY, V7, P333, DOI 10.1101/lm.34600; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002	47	68	68	0	7	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5153			FRONT BEHAV NEUROSCI	Front. Behav. Neurosci.	OCT 8	2014	8								349	10.3389/fnbeh.2014.00349			16	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	AW0LQ	WOS:000345984200001	25339878	Green Published, gold			2022-02-06	
J	Okuma, Y; Liu, KY; Wake, H; Liu, R; Nishimura, Y; Hui, Z; Teshigawara, K; Haruma, J; Yamamoto, Y; Yamamoto, H; Date, I; Takahashi, HK; Mori, S; Nishibori, M				Okuma, Yu; Liu, Keyue; Wake, Hidenori; Liu, Rui; Nishimura, Yoshito; Hui, Zhong; Teshigawara, Kiyoshi; Haruma, Jun; Yamamoto, Yasuhiko; Yamamoto, Hiroshi; Date, Isao; Takahashi, Hideo K.; Mori, Shuji; Nishibori, Masahiro			Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1-RAGE interaction	NEUROPHARMACOLOGY			English	Article						Traumatic brain injury; Glycyrrhizin; HMGB1; RAGE; Brain edema	MOBILITY GROUP BOX-1; CHRONIC HEPATITIS-C; FACTOR-KAPPA-B; THERAPEUTIC TARGET; ACTIVATION; ISCHEMIA; RECEPTOR; PROTEIN; DISRUPTION; LICORICE	Glycyrrhizin (GL) is a major constituent of licorice root and has been suggested to inhibit the release of high mobility group box-1 (HMGB1), a protein considered representative of damage-associated molecular patterns. We found that GL bound HMGB1 but not RAGE with a moderate equilibrium dissociation constant value based on surface plasmon resonance analysis. This complex formation prevented HMGB1 from binding to RAGE in vitro. The effects of glycyrrhizin on traumatic brain injury (TBI) induced by fluid percussion were examined in rats or mice in the present study. GL was administered intravenously after TBI. Treatment of rats with GL dose-dependently suppressed the increase in BBB permeability and impairment of motor functions, in association with the inhibition of HMGB1 translocation in neurons in injured sites. The beneficial effects of GL on motor and cognitive functions persisted for 7 days after injury. The expression of TNF-alpha, IL-1 beta and IL-6 in injured sites was completely inhibited by GL treatment. In RAGE-/- mice, the effects of GL were not observed. These results suggested that GL may be a novel therapeutic agent for TBI through its interference with HMGB1 and RAGE interaction. (C) 2014 Elsevier Ltd. All rights reserved.	[Okuma, Yu; Liu, Keyue; Wake, Hidenori; Liu, Rui; Nishimura, Yoshito; Hui, Zhong; Teshigawara, Kiyoshi; Haruma, Jun; Nishibori, Masahiro] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Kita Ku, Okayama 7008558, Japan; [Okuma, Yu; Haruma, Jun; Date, Isao] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurosurg, Kita Ku, Okayama 7008558, Japan; [Yamamoto, Yasuhiko; Yamamoto, Hiroshi] Kanazawa Univ, Grad Sch Med Sci, Dept Biochem & Mol Vasc Biol, Kanazawa, Ishikawa 9208640, Japan; [Takahashi, Hideo K.] Kinki Univ, Dept Pharmacol, Osakasayama 5898511, Japan; [Mori, Shuji] Shujitsu Univ, Sch Pharm, Dept Pharmacol, Okayama 7038516, Japan		Nishibori, M (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmacol, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	yakuri@md.okayama-u.ac.jp	Nishimura, Yoshito/ABF-6713-2020	Nishimura, Yoshito/0000-0003-0224-7501; Okuma, Yu/0000-0003-4769-8111; Takahashi, Hideo/0000-0001-9444-9746	Scientific Research from the Ministry of Health, Labor and Welfare of JapanMinistry of Health, Labour and Welfare, Japan; Japan Society for the Promotion of Science (JSPS)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [23659687, 24390061]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [25461335] Funding Source: KAKEN	This work was supported by grants from the Scientific Research from the Ministry of Health, Labor and Welfare of Japan, from the Japan Society for the Promotion of Science (JSPS No. 23659687, 24390061).	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Arase Y, 1997, CANCER, V79, P1494, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B; Cherng JM, 2006, EUR J PHARMACOL, V547, P10, DOI 10.1016/j.ejphar.2006.06.080; Gong G, 2012, ACTA PHARMACOL SIN, V33, P11, DOI 10.1038/aps.2011.151; He M, 2011, EMBO REP, V12, P358, DOI 10.1038/embor.2011.28; Hidaka I, 2007, LIVER INT, V27, P845, DOI 10.1111/j.1478-3231.2007.01492.x; Hwang IK, 2006, ACTA PHARMACOL SIN, V27, P959, DOI 10.1111/j.1745-7254.2006.00346.x; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Kumada H, 2002, ONCOLOGY-BASEL, V62, P94, DOI 10.1159/000048283; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Liu R, 2009, ACTA MED OKAYAMA, V63, P203; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mabuchi A, 2009, MICROCIRCULATION, V16, P364, DOI 10.1080/10739680902796917; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Miyaji C, 2002, INT IMMUNOPHARMACOL, V2, P1079, DOI 10.1016/S1567-5769(02)00033-4; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Myint KM, 2006, DIABETES, V55, P2510, DOI 10.2337/db06-0221; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ohnishi M, 2011, NEUROPHARMACOLOGY, V61, P975, DOI 10.1016/j.neuropharm.2011.06.026; Ohshima T, 2005, J NEUROCHEM, V94, P917, DOI 10.1111/j.1471-4159.2005.03233.x; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Pascual O, 2012, P NATL ACAD SCI USA, V109, pE197, DOI 10.1073/pnas.1111098109; Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739; Shamsa F., 2010, Journal of Medicinal Plants, V9, P1; Sharifzadeh M, 2008, PLANTA MED, V74, P485, DOI 10.1055/s-2008-1074494; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Takei H, 2008, J PHARMACOL SCI, V106, P460, DOI 10.1254/jphs.FP0072378; van Rossum TGJ, 1999, CLIN THER, V21, P2080, DOI 10.1016/S0149-2918(00)87239-2; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zurolo E, 2011, BRAIN, V134, P1015, DOI 10.1093/brain/awr032	33	68	74	1	25	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	OCT	2014	85						18	26		10.1016/j.neuropharm.2014.05.007			9	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	AN8KR	WOS:000340853600003	24859607				2022-02-06	
J	Plumb, TR; Peachey, JT; Zelman, DC				Plumb, Taylor R.; Peachey, John T.; Zelman, Diane C.			Sleep Disturbance Is Common Among Servicemembers and Veterans of Operations Enduring Freedom and Iraqi Freedom	PSYCHOLOGICAL SERVICES			English	Article						veterans; military service; sleep; insomnia; nightmares; PTSD	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; COGNITIVE-BEHAVIOR THERAPY; TRAUMATIC BRAIN-INJURY; QUALITY INDEX ADDENDUM; PSYCHIATRIC-DISORDERS; CHRONIC INSOMNIA; COMBAT VETERANS; AFGHANISTAN; WAR	Sleep routines that develop as an adaptation or reaction to deployment can persist upon return stateside. Sleep problems intensify and are intensified by psychiatric distress. This research presents the findings of a comprehensive survey of sleep impairment in relation to demographic data, military history, combat exposure, and mental illness symptoms among a general sample of 375 servicemembers and veterans of Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) at a wide range of times postdeployment. Sleep impairment was assessed with the Pittsburgh Sleep Quality Index (PSQI) and the Addendum for PTSD. Posttraumatic stress disorder (PTSD), depression, and anxiety symptoms were evaluated, with the PTSD Checklist-Military, the Patient Health Questionnaire-9 and the Generalized Anxiety Disorder-7. Sleep problems were common across the sample, with 45.4% of participants reporting sleep onset greater than 30 minutes, 21.4% typically achieving less than 4.5 hours of total sleep time, and 56% reporting being awake in bed more than 15% of the night. Global PSQI scores classified 89% of the sample as "poor sleepers." Sleep problems were more severe among servicemembers with less education, from lower ranks (E1-E3), with greater combat exposure, and greater depression, anxiety, and PTSD symptoms. These findings suggest the need for routine screening of sleep problems among veterans and increased professional training in interventions for insomnia and nightmares. For individuals experiencing sleep problems with concurrent psychiatric symptoms, addressing sleep concerns may be one less-stigmatizing way to transition servicemembers and veterans into needed mental health services.	[Plumb, Taylor R.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA; [Peachey, John T.; Zelman, Diane C.] Alliant Int Univ, Calif Sch Profess Psychol, Clin Psychol Program, San Francisco, CA 94133 USA		Zelman, DC (corresponding author), Alliant Int Univ, Calif Sch Profess Psychol, One Beach St, San Francisco, CA 94133 USA.	dzelman@alliant.edu		Zelman, Diane/0000-0003-3061-5228			Babor T.F., 2001, AUDIT THE ALCOHOL US; Baker DG, 2009, MIL MED, V174, P773; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Caldwell Barbara A, 2005, Issues Ment Health Nurs, V26, P721, DOI 10.1080/01612840591008294; Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4; Collier E, 2003, J Psychiatr Ment Health Nurs, V10, P697, DOI 10.1046/j.1365-2850.2003.00654.x; Cukrowicz KC, 2006, DREAMING, V16, P1, DOI DOI 10.1037/1053-0797.16.1.1; ESPIE CA, 1989, J BEHAV THER EXP PSY, V20, P143, DOI 10.1016/0005-7916(89)90047-5; Espie CA, 2001, J CONSULT CLIN PSYCH, V69, P58, DOI 10.1037//0022-006X.69.1.58; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Friedman MJ, 2006, AM J PSYCHIAT, V163, P586, DOI 10.1176/appi.ajp.163.4.586; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gelis LA, 2010, MIL MED, V175, P567, DOI 10.7205/MILMED-D-09-00123; Germain A, 2005, J ANXIETY DISORD, V19, P233, DOI 10.1016/j.janxdis.2004.02.001; Gorman LA, 2011, PSYCHIAT SERV, V62, P28, DOI 10.1176/ps.62.1.pss6201_0028; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Haimov I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061390; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2003, CLIN PSYCHOL REV, V23, P377, DOI 10.1016/S0272-7358(03)00032-1; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Insana SP, 2013, J TRAUMA STRESS, V26, P192, DOI 10.1002/jts.21793; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Manber R., 2012, OXFORD HDB SLEEP SLE, P471, DOI DOI 10.1093/OXFORDHB/9780195376203.013.0024; Manber R, 2012, J CLIN SLEEP MED, V8, P209, DOI 10.5664/jcsm.1786; Margolies SO, 2013, J CLIN PSYCHOL, V69, P1026, DOI 10.1002/jclp.21970; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Neylan T. C., 2013, COGNITIVE BEHA UNPUB; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Peachey JT, 2012, TRAIN EDUC PROF PSYC, V6, P18, DOI 10.1037/a0026793; Perlis ML, 2010, J SLEEP RES, V19, P31, DOI 10.1111/j.1365-2869.2009.00768.x; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Pietrzak RH, 2010, J PSYCHOSOM RES, V69, P441, DOI 10.1016/j.jpsychores.2010.07.002; Plumb T., 2008, INT SOC TRAUM STRESS; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Reeves RR, 2005, J PSYCHOSOC NURS MEN, V43, P18, DOI 10.3928/02793695-20050701-06; Reite M., 2009, CLIN MANUAL EVALUATI, P1; ROSZELL DK, 1991, HOSP COMMUNITY PSYCH, V42, P293; Rudd MD, 2011, PROF PSYCHOL-RES PR, V42, P354, DOI 10.1037/a0025164; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sharafkhaneh A, 2004, SLEEP MED, V5, P345, DOI 10.1016/j.sleep.2004.01.019; Sher L, 2011, MIL MED, V176, P601, DOI 10.7205/MILMED-D-11-00026; Skinner KM, 2000, J INTERPERS VIOLENCE, V15, P291, DOI 10.1177/088626000015003005; Smith MT, 2005, CLIN PSYCHOL REV, V25, P559, DOI 10.1016/j.cpr.2005.04.004; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tan M., 2013, ARMY TIMES      0201; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; U. S. Department of Veterans Affairs, 2012, COMB EXP SCAL CES; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Weathers F.W., 1993, ANN CONV INT SOC TRA; WEBB WB, 1974, PSYCHOPHYSIOLOGY, V11, P265, DOI 10.1111/j.1469-8986.1974.tb00543.x; Woodward SH, 1996, J TRAUMA STRESS, V9, P137, DOI 10.1007/BF02116839	56	68	68	0	17	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1541-1559	1939-148X		PSYCHOL SERV	Psychol. Serv.	MAY	2014	11	2					209	219		10.1037/a0034958			11	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	AI3TC	WOS:000336784900011	24274111				2022-02-06	
J	Verfaellie, M; Lafleche, G; Spiro, A; Bousquet, K				Verfaellie, Mieke; Lafleche, Ginette; Spiro, Avron, III; Bousquet, Kathryn			Neuropsychological Outcomes in OEF/OIF Veterans With Self-Report of Blast Exposure: Associations With Mental Health, but not mTBI	NEUROPSYCHOLOGY			English	Article						TBI; blast injuries; PTSD; depression; neuropsychological outcome	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; IRAQ-WAR; POSTCONCUSSIVE SYMPTOMS; PROCESSING SPEED; COMBAT VETERANS; PERFORMANCE; SOLDIERS; PTSD	Objective: To examine neuropsychological outcomes in veterans of Operations Enduring and Iraqi Freedom (OEF/OIF) with self-reported histories of blast exposure and determine the contribution of deployment-related mild traumatic brain injury (mTBI), and posttraumatic stress disorder (PTSD) and depression to performance. The effect of number of blast exposures and distance from the blast was also assessed. Method: OEF/OIF veterans who reported exposure to blast underwent structured interviews and were assigned to no-TBI (n = 39), mTBI without loss of consciousness (LOC; n = 53), or mTBI with LOC (n = 35) groups. They were administered tests of executive function, memory, and motor function at least 6 months after the index event. Results: Neuropsychological outcomes did not differ as a function of mTBI group. Blast load and distance from the blast also did not affect neuropsychological performance. Both PTSD and depression symptoms were significantly associated with neuropsychological outcomes. Conclusions: A history of mTBI with or without LOC during deployment does not contribute to objective cognitive impairment in the chronic phase post injury. In contrast, PTSD and depression symptoms are associated with cognitive performance decrements. This finding is thought to reflect at least in part the impact of psychiatric distress on neuropsychological performance.	[Verfaellie, Mieke; Lafleche, Ginette; Bousquet, Kathryn] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA 02130 USA; [Verfaellie, Mieke; Lafleche, Ginette; Spiro, Avron, III; Bousquet, Kathryn] Boston Univ, Sch Med, Boston, MA 02118 USA; [Spiro, Avron, III] VA Boston Healthcare Syst, Boston, MA 02130 USA; [Spiro, Avron, III] Boston Univ, Sch Publ Hlth, Boston, MA USA		Verfaellie, M (corresponding author), VA Boston Healthcare Syst, Memory Disorders Res Ctr 151A, 150 South Huntington Ave, Boston, MA 02130 USA.	verf@bu.edu		Verfaellie, Mieke/0000-0001-5535-4584; Spiro III, Avron/0000-0003-4080-8621	Clinical Science Research and Development; Rehabilitation Research and Development Services of the Department of Veterans AffairsUS Department of Veterans Affairs	This research was supported by the Clinical Science Research and Development and the Rehabilitation Research and Development Services of the Department of Veterans Affairs. The authors have no conflict of interest affecting this article.	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Benedict R., 1997, BRIEF VISUOSPATIAL M; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chattarji, 2009, POSTTRAUMATIC STRESS, P151, DOI DOI 10.1007/978-1-60327-329-9_7; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Cooper DB, 2010, NEUROREHABILITATION, V26, P233, DOI 10.3233/NRE-2010-0559; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Halstead W.C., 1947, BRAIN INTELLIGENCE; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrae M., 2008, MILD TRAUMATIC BRAIN; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; Paniak C, 2000, BRAIN INJURY, V14, P219; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Porter RJ, 2007, AUST NZ J PSYCHIAT, V41, P115, DOI 10.1080/00048670601109881; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Southwick S. M., 2007, HDB PTSD SCI PRACTIC, P166; Tanielian T. L., 2008, INVISIBLE WOUNDS WAR, V1, DOI [10.1037/e527612010-001, DOI 10.1037/E527612010-001]; Tiffin, 1968, PURDUE PEGBOARD EXAM; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P441, DOI 10.1023/A:1007781107513; Verfaellie M, 2012, PTSD MILD TRAUMATIC, P83; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Walter KH, 2010, J TRAUMA STRESS, V23, P292, DOI 10.1002/jts.20506; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; WechslerD, 2001, WECHSLER TEST ADULT; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3	65	68	68	1	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2014	28	3					337	346		10.1037/neu0000027			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AG3QH	WOS:000335334000002	24245929				2022-02-06	
J	Joseph, B; Friese, RS; Sadoun, M; Aziz, H; Kulvatunyou, N; Pandit, V; Wynne, J; Tang, A; O'Keeffe, T; Rhee, P				Joseph, Bellal; Friese, Randall S.; Sadoun, Moutamn; Aziz, Hassan; Kulvatunyou, Narong; Pandit, Viraj; Wynne, Julie; Tang, Andrew; O'Keeffe, Terence; Rhee, Peter			The BIG (brain injury guidelines) project: Defining the management of traumatic brain injury by acute care surgeons	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; guidelines for management of traumatic brain injury; neurosurgical consultation; acute care surgeons; repeat head computed tomography	COMPUTED-TOMOGRAPHY; HEAD-INJURY; PREDICTION; UTILITY; CT	BACKGROUND It is becoming a standard practice that any positive identification of a radiographic intracranial injury requires transfer of the patient to a trauma center for observation and repeat head computed tomography (RHCT). The purpose of this study was to define guidelinesbased on each patient's history, physical examination, and initial head CT findingsregarding which patients require a period of observation, RHCT, or neurosurgical consultation. METHODS In our retrospective cohort analysis, we reviewed the records of 3,803 blunt traumatic brain injury patients during a 4-year period. We classified patients according to neurologic examination results, use of intoxicants, anticoagulation status, and initial head CT findings. We then developed brain injury guidelines (BIG) based on the individual patient's need for observation or hospitalization, RHCT, or neurosurgical consultation. RESULTS A total of 1,232 patients had an abnormal head CT finding. In the BIG 1 category, no patients worsened clinically or radiographically or required any intervention. BIG 2 category had radiographic worsening in 2.6% of the patients. All patients who required neurosurgical intervention (13%) were in BIG 3. There was excellent agreement between assigned BIG and verified BIG. statistic is equal to 0.98. CONCLUSION We have proposed BIG based on patient's history, neurologic examination, and findings of initial head CT scan. These guidelines must be used as supplement to good clinical examination while managing patients with traumatic brain injury. Prospective validation of the BIG is warranted before its widespread implementation. LEVEL OF EVIDENCE Epidemiologic study, level III.	[Joseph, Bellal; Friese, Randall S.; Sadoun, Moutamn; Aziz, Hassan; Kulvatunyou, Narong; Pandit, Viraj; Wynne, Julie; Tang, Andrew; O'Keeffe, Terence; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021	Aziz, Hassan/0000-0003-0406-1946			Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Huynh T, 2006, AM SURGEON, V72, P1162; Joseph B, 2014, REPEAT HEAD COMPUTED; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kaups KL, 1998, J TRAUMA, V45, P884, DOI 10.1097/00005373-199811000-00007; Langlois J, TRAUMATIC BRAIN INJU; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; RHODES M, 1993, J TRAUMA, V35, P384, DOI 10.1097/00005373-199309000-00009; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Sugerman DE, 2012, J TRAUMA ACUTE CARE, V73, P1491, DOI 10.1097/TA.0b013e3182782675; Tang AL, 2010, SCAND J SURG, V99, P61, DOI 10.1177/145749691009900202; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237	22	68	68	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2014	76	4					965	969		10.1097/TA.0000000000000161			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AE7FF	WOS:000334161500016	24662858				2022-02-06	
J	Merrifield, C; Danckert, J				Merrifield, Colleen; Danckert, James			Characterizing the psychophysiological signature of boredom	EXPERIMENTAL BRAIN RESEARCH			English	Article						Boredom; Depression; Heart rate; Skin conductance levels; Attention	TRAUMATIC BRAIN-INJURY; AUTONOMIC AROUSAL; PRONENESS; CORTISOL; DISTINCT; ADULTS; LAPSES	Research on the experience and expression of boredom is underdeveloped. The purpose of the present study was to explore the psychophysiological signature of the subjective experience of boredom. Healthy undergraduates (n = 72) viewed previously validated and standardized video clips to induce boredom, sadness, and a neutral affective state, while their heart rate (HR), skin conductance levels (SCL), and cortisol levels were measured. Boredom yielded dynamic psychophysiological responses that differed from the other emotional states. Of particular interest, the physiological signature of boredom relative to sadness was characterized by rising HR, decreased SCL, and increased cortisol levels. This pattern of results suggests that boredom may be associated with both increased arousal and difficulties with sustained attention. These findings may help to resolve divergent conceptualizations of boredom in the extant literature and, ultimately, to enhance our understanding and treatment of clinical syndromes in which self-reported boredom is a prominent symptom.	[Merrifield, Colleen; Danckert, James] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada		Danckert, J (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.	jdancker@uwaterloo.ca			Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); NSERC Canada Graduate Scholarship (CGS)Natural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) Canada Research Chair and Discovery Grants to J. D. and NSERC Canada Graduate Scholarship (CGS)-Masters and Vanier CGS awards to C. M. We would like to thank Dr. David Moscovitch for his assistance with data collection, design and analysis, and comments on earlier drafts of this work.	Barmack JE, 1939, AM J PSYCHOL, V52, P467; Berlyne D. E., 1960, CONFLICT AROUSAL CUR; Black, 1970, PHYSL CORRELATES EMO, P205, DOI [10.1016/B978-0-12-102850-3.50016-5., DOI 10.1016/B978-0-12-102850-3.50016-5]; BLASZCZYNSKI A, 1990, PSYCHOL REP, V67, P35, DOI 10.2466/PR0.67.5.35-42; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; COLES MGH, 1972, J EXP PSYCHOL, V96, P371, DOI 10.1037/h0033603; de Weerth C, 2003, CLIN CHEM, V49, P658, DOI 10.1373/49.4.658; Eastwood, 2010, INT GAMBL STUD, V10, P91, DOI [10.1080/14459791003754414, DOI 10.1080/14459791003754414, 10.1080/1445979100 3754414]; Eastwood JD, 2012, PERSPECT PSYCHOL SCI, V7, P482, DOI 10.1177/1745691612456044; EKMAN P, 1980, J PERS SOC PSYCHOL, V38, P270, DOI 10.1037/0022-3514.38.2.270; Fahlman SA, 2013, ASSESSMENT, V20, P68, DOI 10.1177/1073191111421303; Fahlman SA, 2009, J SOC CLIN PSYCHOL, V28, P307, DOI 10.1521/jscp.2009.28.3.307; FARMER R, 1986, J PERS ASSESS, V50, P4, DOI 10.1207/s15327752jpa5001_2; Fothergill A, 2007, PLANET EARTH; FRITH CD, 1983, BIOL PSYCHOL, V17, P27, DOI 10.1016/0301-0511(83)90064-9; GEIWITZ PJ, 1966, J PERS SOC PSYCHOL, V3, P592, DOI 10.1037/h0023202; Goldberg Y, 2013, BEHAV SCI-BASEL, V3, P434, DOI 10.3390/bs3030434; Goldberg YK, 2011, J SOC CLIN PSYCHOL, V30, P647, DOI 10.1521/jscp.2011.30.6.647; GROSS JJ, 1995, COGNITION EMOTION, V9, P87, DOI 10.1080/02699939508408966; HEBB DO, 1955, PSYCHOL REV, V62, P243, DOI 10.1037/h0041823; Hermens DF, 2004, BIOL PSYCHOL, V66, P221, DOI 10.1016/j.biopsycho.2003.10.006; Hofmann SG, 2006, INT J PSYCHOPHYSIOL, V61, P134, DOI 10.1016/j.ijpsycho.2005.09.003; KIRSCHBAUM C, 1989, NEUROPSYCHOBIOLOGY, V22, P150, DOI 10.1159/000118611; Lacey JI, 1959, RES PSYCHOTHERAPY; Lackschewitz H, 2008, PSYCHONEUROENDOCRINO, V33, P612, DOI 10.1016/j.psyneuen.2008.01.016; LEDOUX I, 1996, EMOTIONAL BRAIN MYST; Lee CM, 2007, ADDICT BEHAV, V32, P1384, DOI 10.1016/j.addbeh.2006.09.010; LePera N., 2011, NEW SCH PSYCHOL B, V8, P15, DOI DOI 10.1037/E741452011-003; LONDON H, 1972, J ABNORM PSYCHOL, V80, P29, DOI 10.1037/h0033311; Lovell D. P., 1979, CHAMP; LUNDBERG U, 1993, ERGONOMICS, V36, P601, DOI 10.1080/00140139308967923; Malkovsky E, 2012, EXP BRAIN RES, V221, P59, DOI 10.1007/s00221-012-3147-z; Martin M., 2006, QUAL RES PSYCHOL, V3, P193, DOI [10.1191/1478088706qrp066oa, DOI 10.1191/1478088706QRP0660A, DOI 10.1191/1478088706QRP066OA]; MIKULAS WL, 1993, PSYCHOL REC, V43, P3; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; OBRIST PA, 1970, PSYCHOPHYSIOLOGY, V6, P695, DOI 10.1111/j.1469-8986.1970.tb02257.x; OHMAN A, 2000, HDB PSYCHOPHYSIOLOGY; Ohsuga M, 2001, INT J PSYCHOPHYSIOL, V40, P211, DOI 10.1016/S0167-8760(00)00189-6; Papillo JF., 1990, PRINCIPLES PSYCHOPHY, P456; Passik SD, 2003, PSYCHO-ONCOL, V12, pS227; Passik Steven D, 2003, Palliat Support Care, V1, P41; Pattyn N, 2008, PHYSIOL BEHAV, V93, P369, DOI 10.1016/j.physbeh.2007.09.016; PHILIPPOT P, 1993, COGNITION EMOTION, V7, P171, DOI 10.1080/02699939308409183; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Sommers J, 2000, J CLIN PSYCHOL, V56, P149, DOI 10.1002/(SICI)1097-4679(200001)56:1<149::AID-JCLP14>3.0.CO;2-Y; Strahler J, 2010, PSYCHOPHYSIOLOGY, V47, P587, DOI 10.1111/j.1469-8986.2009.00957.x; Theobald Dale E, 2003, Palliat Support Care, V1, P71; van Tilburg WAP, 2012, MOTIV EMOTION, V36, P181, DOI 10.1007/s11031-011-9234-9; Vodanovich SJ, 2003, J PSYCHOL, V137, P569, DOI 10.1080/00223980309600636; VODANOVICH SJ, 1991, PSYCHOL REP, V69, P1139, DOI 10.2466/PR0.69.8.1139-1146; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WATT JD, 1992, PSYCHOL REP, V70, P688, DOI 10.2466/PR0.70.3.688-690	54	68	70	4	38	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	FEB	2014	232	2					481	491		10.1007/s00221-013-3755-2			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AA0GG	WOS:000330773000012	24202238	Green Submitted			2022-02-06	
J	Prathep, S; Sharma, D; Hallman, M; Joffe, A; Krishnamoorthy, V; Mackensen, GB; Vavilala, MS				Prathep, Sumidtra; Sharma, Deepak; Hallman, Matthew; Joffe, Aaron; Krishnamoorthy, Vijay; Mackensen, G. Burkhard; Vavilala, Monica S.			Preliminary Report on Cardiac Dysfunction After Isolated Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						cardiac function; echocardiography; traumatic brain injury	LEFT-VENTRICULAR DYSFUNCTION; WALL-MOTION ABNORMALITIES; TROPONIN-I; ECHOCARDIOGRAPHIC EVALUATION; INTRACRANIAL-PRESSURE; MYOCARDIAL DAMAGE; INFARCTION; STRESS; STROKE	Objective: The aim of this study was to examine cardiac dysfunction during the first 2 weeks after isolated traumatic brain injury and its association with in-hospital mortality. Design Retrospective. Setting Level 1 regional trauma center. Patients Adult patients with severe traumatic brain injury. Methods: After institutional review board approval, data from adult patients with isolated traumatic brain injury who underwent echocardiography during the first 2 weeks after traumatic brain injury between 2003 and 2010 were examined. Patients with preexisting cardiac disease were excluded. Clinical characteristics and echocardiogram reports were abstracted. Cardiac dysfunction was defined as left ventricular ejection fraction less than 50% or presence of regional wall motion abnormality. Interventions: None. Measurement and Main Results: We examined data from 139 patients with isolated traumatic brain injury who underwent echocardiographic evaluation. Patients were 5820 years old, 66% were male patients, and 62.6% had subdural hematoma; admission Glasgow Coma Scale score was 3 +/- 1 (3-15) and head Abbreviated Injury Scale was 4 +/- 1 (2-5). Of this cohort, 22.3% had abnormal echocardiogram: reduced left ventricular ejection fraction was documented in 12% (left ventricular ejection fraction, 43% +/- 8%) and 17.5% of patients had a regional wall motion abnormality. Hospital day 1 was the most common day of echocardiographic exam. Abnormal echocardiogram was independently associated with all cause in-hospital mortality (9.6 [2.3-40.2]; p = 0.002). Conclusions: Cardiac dysfunction in the setting of isolated traumatic brain injury occurs and is associated with increased in-hospital mortality. This finding raises the question as to whether there are uncharted opportunities for a more timely recognition of cardiac dysfunction and subsequent optimization of the hemodynamic management of these patients.	[Prathep, Sumidtra; Sharma, Deepak; Hallman, Matthew; Joffe, Aaron; Krishnamoorthy, Vijay; Mackensen, G. Burkhard; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Prathep, Sumidtra; Sharma, Deepak; Hallman, Matthew; Joffe, Aaron; Krishnamoorthy, Vijay; Mackensen, G. Burkhard; Vavilala, Monica S.] Univ Washington, Dept Pain Med, Seattle, WA 98195 USA; [Sharma, Deepak; Vavilala, Monica S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA		Vavilala, MS (corresponding author), Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA.	vavilala@uw.edu	Mackensen, G. Burkhard/AAJ-3951-2021		National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [3R01NS072308-03]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER	Supported, in part, by grant 3R01NS072308-03 from National Institute of Neurological Diseases and Stroke.; Drs. Krishnamoorthy and Vavilala received funding support from the National Institutes of Health. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Ako J, 2006, AM J MED, V119, P10, DOI 10.1016/j.amjmed.2005.08.022; Bahloul M, 2006, AM J CRIT CARE, V15, P462; Berman M, 2010, J HEART LUNG TRANSPL, V29, P957, DOI 10.1016/j.healun.2010.04.008; Brain Trauma Foundation, 2007, J NEUROTRAUMA S, V24, pS1; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Bulsara KR, 2003, J NEUROSURG, V98, P524, DOI 10.3171/jns.2003.98.3.0524; Davison DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11226; Di Angelantonio E, 2005, J NEUROL NEUROSUR PS, V76, P76, DOI 10.1136/jnnp.2004.041491; Dupuis M, 2012, SEIZURE-EUR J EPILEP, V21, P51, DOI 10.1016/j.seizure.2011.09.006; Flynn M, 2009, J THORAC CARDIOV SUR, V137, P1063, DOI 10.1016/j.jtcvs.2008.12.023; GILBERT EM, 1988, J THORAC CARDIOV SUR, V95, P1003; Hinson HE, 2012, CURR OPIN CRIT CARE, V18, P139, DOI 10.1097/MCC.0b013e3283513290; Horowitz MB, 1998, ACTA NEUROCHIR, V140, P87, DOI 10.1007/s007010050063; James P, 2000, BRIT MED J, V320, P1502, DOI 10.1136/bmj.320.7248.1502; KOLIN A, 1984, STROKE, V15, P990, DOI 10.1161/01.STR.15.6.990; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; Mashaly Hazem Antar, 2008, Cleve Clin J Med, V75 Suppl 2, pS26; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; Moussouttas M, 2012, NEUROCRIT CARE, V16, P381, DOI 10.1007/s12028-012-9673-5; MYERS MG, 1982, STROKE, V13, P838, DOI 10.1161/01.STR.13.6.838; Parekh N, 2000, J AM COLL CARDIOL, V36, P1328, DOI 10.1016/S0735-1097(00)00857-3; Parr MJA, 1996, BRIT MED J, V313, P681; Richard C, 2011, ANN INTENSIVE CARE, V1, DOI 10.1186/2110-5820-1-39; Riera Maria, 2010, J Trauma, V68, pE13, DOI 10.1097/TA.0b013e3181469d5b; Samuels MA, 2007, CIRCULATION, V116, P77, DOI 10.1161/CIRCULATIONAHA.106.678995; SCHRADER H, 1985, ACTA NEUROL SCAND, V72, P283; SEILER C, 1992, J HEART LUNG TRANSPL, V11, P867; SHANLIN RJ, 1988, J AM COLL CARDIOL, V12, P727, DOI 10.1016/S0735-1097(88)80065-2; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Song HS, 2008, J CLIN NEUROL, V4, P75, DOI 10.3988/jcn.2008.4.2.75; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Sosin DM, 1995, JAMA-J AM MED ASSOC, V273, P1778; Temes RE, 2010, NEUROCRIT CARE, V13, P359, DOI 10.1007/s12028-010-9447-x; Tung P, 2004, STROKE, V35, P548, DOI 10.1161/01.STR.0000114874.96688.54; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046	35	68	71	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2014	42	1					142	147		10.1097/CCM.0b013e318298a890			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	274OK	WOS:000328615600036	23963125	Green Accepted			2022-02-06	
J	Honeybul, S; Janzen, C; Kruger, K; Ho, KM				Honeybul, Stephen; Janzen, Courtney; Kruger, Kate; Ho, Kwok M.			The impact of cranioplasty on neurological function	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; decompressive craniectomy; syndrome of trephined; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DEATH FOLLOWING CRANIOPLASTY; COGNITIVE STATUS EXAMINATION; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; BLOOD-FLOW; HEMICRANIECTOMY; COMPLICATION; IMPROVEMENT	Objectives. To assess changes in neurological function after cranioplasty. Methods. Functional and neurocognitive assessments including activities of daily living assessment, functional independence measure (FIM) and the Cognitive assessment report (COGNISTAT) were conducted on all patients within 72 h before and 7 days after cranioplasty. A change in the total FIM score of 2 points was taken to be clinically significant. Results. Assessments were performed on 25 patients. The functional status was unchanged in eighteen patients (72%), four patients (16%) demonstrated a significant improvement and three patients (12%) deteriorated significantly. Those with deterioration after cranioplasty had some forms of complications including pneumocephalus or seizure. After excluding the three patients who had immediate medical or surgical complications after surgery, there was a mild overall improvement in the mean FIM score (2.1, 95% confidence interval 0.1-4.3, p = 0.049), mainly due to an improvement in their motor function. Conclusions. A small but significant number of patients appear to improve clinically following cranioplasty. The so-called syndrome of the trephined may be more common than had been previously appreciated.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6000, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA, Australia; [Janzen, Courtney; Kruger, Kate] Sir Charles Gairdner Hosp, Dept Occupat Therapy, Perth, WA 6000, Australia; [Ho, Kwok M.] Univ Western Australia, Royal Perth Hosp, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6000, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Agrawal D, 2005, EUR J CLIN MICROBIOL, V24, P772, DOI 10.1007/s10096-005-0017-7; Ahmed AI, 2010, NEUROCRIT CARE, V13, P393, DOI 10.1007/s12028-010-9420-8; Baussart B, 2006, ACTA ANAESTH SCAND, V50, P762, DOI 10.1111/j.1399-6576.2006.01038.x; Bijlenga P, 2007, J NEUROL NEUROSUR PS, V78, P430, DOI 10.1136/jnnp.2006.099242; Chalouhi N, 2012, NEUROLOGIST, V18, P423, DOI 10.1097/NRL.0b013e318272f7be; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; Dickson HG, 1995, SCAND J REHABIL MED, V27, P253; Doninger NA, 2000, J HEAD TRAUMA REHAB, V15, P683, DOI 10.1097/00001199-200002000-00007; Doninger NA, 2006, REHABIL PSYCHOL, V51, P281, DOI 10.1037/0090-5550.51.4.281; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393; Gottlob Irene, 2002, Strabismus, V10, P271, DOI 10.1076/stra.10.4.271.13830; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Lanterna LA, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0910; Mokri B, 2010, HEADACHE, V50, P1206, DOI 10.1111/j.1526-4610.2010.01715.x; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Voss HU, 2011, CLIN IMAG, V35, P253, DOI 10.1016/j.clinimag.2010.07.008; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166; Zebian B, 2011, BRIT J NEUROSURG, V25, P785, DOI 10.3109/02688697.2011.623801	36	68	69	0	10	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2013	27	5					636	641		10.3109/02688697.2013.817532			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	216FG	WOS:000324266800015	23883370				2022-02-06	
J	Kozlowski, KF; Graham, J; Leddy, JJ; Devinney-Boymel, L; Willer, BS				Kozlowski, Karl F.; Graham, James; Leddy, John J.; Devinney-Boymel, Lee; Willer, Barry S.			Exercise Intolerance in Individuals With Postconcussion Syndrome	JOURNAL OF ATHLETIC TRAINING			English	Article						brain injuries; concussions; treadmill test	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYNDROME; UP-REGULATION; SYMPTOMS; RECOVERY; CHALLENGE; CAPACITY; STRESS	Context: Little is known about exercise intolerance or the utility of an exercise evaluation in patients with postconcussion syndrome (PCS). Objective: To assess exercise intolerance in male and female patients with PCS. Design: Cross-sectional study. Setting: Laboratory setting. Patients or Other Participants: Participants included a convenience sample of 34 patients with PCS (17 males, 17 females; age = 25.9 +/- 10.9 years) and 22 uninjured individuals on whom we gathered historical deidentified laboratory data (control group; 11 males, 11 females; age = 23.3 +/- 6.2 years). Main Outcome Measure(s): Self-reported symptoms, heart rate, systolic and diastolic blood pressures (BPs), and the Borg rating of perceived exertion were measured before, during each minute of, and immediately after a graded treadmill exercise test (Balke protocol). Exercise was stopped when participants could no longer maintain the effort or reported the onset of or increase in PCS symptoms. Results: Exercise test duration (8.5 +/- 4.4 minutes versus 17.9 +/- 3.6 minutes; t(51) = 1.8, P < .001), heart rate (142.8 +/- 24.1 versus 175.2 +/- 17.4; t(54) - -5.5, P < .001), and systolic BP (142.1 +/- 18.3 mm Hg versus 155.5 +/- 24.5 mm Hg; t(53) = 2.3, P = .02) were lower, and diastolic BP (78.4 +/- 10.2 mm Hg versus 73.5 +/- 11.7 mm Hg; t(53) = 2.2, P = .03) was higher at test cessation in the PCS than control group. Cox regression showed the odds of a shorter exercise duration were nearly 8 times greater in the PCS than control group (hazard ratio = 7.93; 95% confidence interval = 3.39, 18.56). In the general linear models that adjusted for differences in test duration, rating of perceived exertion was the only physiologic measure to show an overall difference between groups, with the control group reporting higher ratings than the PCS group (t(53) = -6.0, P < .001). Within the PCS group, systolic BP was the only measure to show a sex effect, with males showing higher pressure readings than females throughout the exercise tests (t(31) = 2.8, P = .009). Conclusions: Patients with PCS had a symptom-limited response to exercise, and the treadmill test was a potentially useful tool to monitor the recovery from PCS.	[Kozlowski, Karl F.] Canisius Coll, Dept Kinesiol, Buffalo, NY 14208 USA; [Graham, James] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Leddy, John J.] SUNY Buffalo, Dept Orthopaed, Buffalo, NY 14260 USA; [Leddy, John J.] SUNY Buffalo, Sports Med Inst, Buffalo, NY 14260 USA; [Devinney-Boymel, Lee] SUNY Buffalo, Dept Exercise & Nutr Sci, Buffalo, NY 14260 USA; [Willer, Barry S.] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14260 USA		Kozlowski, KF (corresponding author), Canisius Coll, Koessler Ctr 173, 2001 Main St, Buffalo, NY 14208 USA.	karl.kozlowski@canisius.edu	Kozlowski, Karl/H-5253-2019				*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P704; American College of Sports Medicine, 2006, ACSMS GUID EX TEST P, P18; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Brys M, 2003, AM J PHYSIOL-HEART C, V285, pH1048, DOI 10.1152/ajpheart.00062.2003; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Dawes H, 2006, DISABIL REHABIL, V28, P1243, DOI 10.1080/09638280600554595; Dawes HN, 2005, ARCH PHYS MED REHAB, V86, P912, DOI 10.1016/j.apmr.2004.10.043; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Faul M, 2010, TRAUMATIC BRAIN INJU; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Merritta C, 2010, INT J REHABIL RES, V33, P109, DOI 10.1097/MRR.0b013e32832e6b37; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; World Health Organization, 1993, ICD 10 CLASS MENT BE, P63	36	68	69	0	16	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2013	48	5					627	635		10.4085/1062-6050-48.5.02			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	268AR	WOS:000328140600006	23952041	Bronze, Green Published			2022-02-06	
J	Dennis, M; Simic, N; Bigler, ED; Abildskov, T; Agostino, A; Taylor, HG; Rubin, K; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Dennis, Maureen; Simic, Nevena; Bigler, Erin D.; Abildskov, Tracy; Agostino, Alba; Taylor, H. Gerry; Rubin, Kenneth; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Cognitive, affective, and conative theory of mind (ToM) in children with traumatic brain injury	DEVELOPMENTAL COGNITIVE NEUROSCIENCE			English	Article						Childhood traumatic brain injury; Social cognition; Theory of mind; Emotion; Empathy; MRI	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CHILDHOOD HEAD-INJURY; MIRROR-NEURON SYSTEM; 1ST 6 MONTHS; SOCIAL COGNITION; INHIBITORY CONTROL; DEFAULT-MODE; BEHAVIORAL-REGULATION; SPECTRUM DISORDERS; SPEECH ACTS	We studied three forms of dyadic communication involving theory of mind (ToM) in 82 children with traumatic brain injury (TBI) and 61 children with orthopedic injury (OI): Cognitive (concerned with false belief), Affective (concerned with expressing socially deceptive facial expressions), and Conative (concerned with influencing another's thoughts or feelings). We analyzed the pattern of brain lesions in the TBI group and conducted voxel-based morphometry for all participants in five large-scale functional brain networks, and related lesion and volumetric data to ToM outcomes. Children with TBI exhibited difficulty with Cognitive, Affective, and Conative ToM. The perturbation threshold for Cognitive ToM is higher than that for Affective and Conative ToM, in that Severe TBI disturbs Cognitive ToM but even Mild Moderate TBI disrupt Affective and Conative ToM. Childhood TBI was associated with damage to all five large-scale brain networks. Lesions in the Mirror Neuron Empathy network predicted lower Conative ToM involving ironic criticism and empathic praise. Conative ToM was significantly and positively related to the package of Default Mode, Central Executive, and Mirror Neuron Empathy networks and, more specifically, to two hubs of the Default Mode Network, the posterior cingulate/retrosplenial cortex and the hippocampal formation, including entorhinal cortex and parahippocampal cortex. (C) 2012 Elsevier Ltd. All rights reserved.	[Dennis, Maureen; Simic, Nevena] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Bigler, Erin D.; Abildskov, Tracy] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Agostino, Alba] Ryerson Univ, Dept Psychol, Toronto, ON, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Stancin, Terry] Univ Hosp Cleveland, Case Med Ctr, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Rubin, Kenneth] Univ Maryland, Dept Human Dev & Quantitat Methodol, College Pk, MD 20742 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA		Dennis, M (corresponding author), Hosp Sick Children, Dept Psychol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	maureen.dennis@sickkids.ca	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020; Gerhardt, Cynthia/E-3109-2011; Vannatta, Kathryn/E-4237-2011; Rubin, Kenneth H/M-5276-2018	Rubin, Kenneth H/0000-0002-2608-2484; Agostino, Alexandra/0000-0001-8739-0061; Yeates, Keith/0000-0001-7680-2892	National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 RO1 HD 04946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	Preparation of this paper was supported by National Institute of Neurological Diseases and Stroke Grant 1 RO1 HD 04946, "Social Outcomes in Pediatric Traumatic Brain Injury."	Adams RB, 2006, MOTIV EMOTION, V30, P179, DOI 10.1007/s11031-006-9020-2; Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x; Baron-Cohen S., 2000, UNDERSTANDING OTHER, pUN; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bickart KC, 2011, NAT NEUROSCI, V14, P163, DOI 10.1038/nn.2724; Bigler E.D., HETEROGENEITY BRAIN; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Dawes CT, 2012, P NATL ACAD SCI USA, V109, P6479, DOI 10.1073/pnas.1118653109; Delgado MR, 2000, J NEUROPHYSIOL, V84, P3072, DOI 10.1152/jn.2000.84.6.3072; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2001, BRAIN COGNITION, V47, P197; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; DENNIS M, 1993, J PEDIATR PSYCHOL, V18, P639, DOI 10.1093/jpepsy/18.5.639; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dunbar RIM, 2012, TRENDS COGN SCI, V16, P101, DOI 10.1016/j.tics.2011.11.013; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Green MJ, 2003, COGNITION EMOTION, V17, P779, DOI 10.1080/02699930302282; Greenbaum RL, 2009, ALCOHOL CLIN EXP RES, V33, P1656, DOI 10.1111/j.1530-0277.2009.01003.x; Gu XS, 2013, CEREB CORTEX, V23, P20, DOI 10.1093/cercor/bhr367; Hadjikhani N, 2006, CEREB CORTEX, V16, P1276, DOI 10.1093/cercor/bh069; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; HILGARD ER, 1980, J HIST BEHAV SCI, V16, P107, DOI 10.1002/1520-6696(198004)16:2<107::AID-JHBS2300160202>3.0.CO;2-Y; Hill EL, 2003, PHILOS T R SOC B, V358, P281, DOI 10.1098/rstb.2002.1209; Howard I, 2005, ETHNIC DIS, V15, pS51; Huang L, 2011, SOC PSYCHOL PERS SCI, V2, P351, DOI 10.1177/1948550610391677; Jakobson R., 1960, STYLE LANGUAGE, P350; Kalbe E, 2010, CORTEX, V46, P769, DOI 10.1016/j.cortex.2009.07.010; Kamawar D, 2011, J EXP CHILD PSYCHOL, V108, P734, DOI 10.1016/j.jecp.2010.10.005; Kamawar D, 2009, J COGN DEV, V10, P285, DOI 10.1080/15248370903389499; Kober H, 2008, NEUROIMAGE, V42, P998, DOI 10.1016/j.neuroimage.2008.03.059; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leblanc N, 2005, DEV NEUROPSYCHOL, V28, P829, DOI 10.1207/s15326942dn2803_5; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Lieberman MD, 2007, ANNU REV PSYCHOL, V58, P259, DOI 10.1146/annurev.psych.58.110405.085654; MACLEAN PD, 1949, PSYCHOSOM MED, V11, P338, DOI 10.1097/00006842-194911000-00003; Max J. E., 2005, J AM ACAD CHILD ADOL, V44, P435; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; Menon V, 2011, TRENDS COGN SCI, V15, P483, DOI 10.1016/j.tics.2011.08.003; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Militello L.G., 2006, COLL TECHN SYST CTS; Molenberghs P, 2012, NEUROSCI BIOBEHAV R, V36, P341, DOI 10.1016/j.neubiorev.2011.07.004; Newsome MR, 2012, INT J DEV NEUROSCI, V30, P255, DOI 10.1016/j.ijdevneu.2011.10.008; Nummenmaa L, 2012, P NATL ACAD SCI USA, V109, P9599, DOI 10.1073/pnas.1206095109; O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Perner J, 1998, LANGUAGE THOUGHT INT, P270; Qin SZ, 2012, P NATL ACAD SCI USA, V109, P7941, DOI 10.1073/pnas.1120408109; Rameson LT, 2012, J COGNITIVE NEUROSCI, V24, P235, DOI 10.1162/jocn_a_00130; Rameson LT, 2009, SOC PERSONAL PSYCHOL, V3, P94, DOI 10.1111/j.1751-9004.2008.00154.x; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G, 2010, NAT REV NEUROSCI, V11, P264, DOI 10.1038/nrn2805; Russell J., 1997, AUTISM EXECUTIVE DIS, P256; Schilbach L, 2008, CONSCIOUS COGN, V17, P457, DOI 10.1016/j.concog.2008.03.013; Schulte-Ruther M, 2007, J COGNITIVE NEUROSCI, V19, P1354, DOI 10.1162/jocn.2007.19.8.1354; Senju A, 2012, NEUROSCIENTIST, V18, P108, DOI 10.1177/1073858410397208; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Singer T, 2006, NATURE, V439, P466, DOI 10.1038/nature04271; Sinopoli KJ, 2012, INT J DEV NEUROSCI, V30, P207, DOI 10.1016/j.ijdevneu.2011.08.006; Sinopoli KJ, 2011, J CLIN EXP NEUROPSYC, V33, P805, DOI 10.1080/13803395.2011.562864; Sommer M, 2010, BRAIN RES, V1354, P123, DOI 10.1016/j.brainres.2010.07.057; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Stano J, 1999, WECHSLER ABBREVIATED; Stiller J, 2007, SOC NETWORKS, V29, P93, DOI 10.1016/j.socnet.2006.04.001; TEASDALE G, 1974, LANCET, V2, P81; Uddin LQ, 2011, J NEUROSCI, V31, P18578, DOI 10.1523/JNEUROSCI.4465-11.2011; Uekermann J, 2010, NEUROSCI BIOBEHAV R, V34, P734, DOI 10.1016/j.neubiorev.2009.10.009; Vogel AC, 2010, NEUROPSYCHOL REV, V20, P362, DOI 10.1007/s11065-010-9145-7; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901; Ybarra O, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00075; Yeates K.O., J INT NEURO IN PRESS; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Zaitchik D, 2010, NEUROPSYCHOLOGIA, V48, P2528, DOI 10.1016/j.neuropsychologia.2010.04.031	100	68	70	1	43	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1878-9293	1878-9307		DEV COGN NEUROS-NETH	Dev. Cogn. Neurosci.	JUL	2013	5						25	39		10.1016/j.dcn.2012.11.006			15	Psychology, Developmental; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	168WZ	WOS:000320739900003	23291312	Green Accepted, Bronze, Green Published			2022-02-06	
J	McCrory, P; Meeuwisse, W; Aubry, M; Cantu, B; Dvorak, J; Echemendia, R; Engebretsen, L; Johnston, K; Kutcher, J; Raftery, M; Sills, A; Benson, B; Davis, G; Ellenbogen, R; Guskiewicz, K; Herring, SA; Iverson, G; Jordan, B; Kissick, J; McCrea, M; McIntosh, A; Maddocks, D; Makdissi, M; Purcell, L; Putukian, M; Schneider, K; Tator, C; Turner, M				McCrory, Paul; Meeuwisse, Willem; Aubry, Mark; Cantu, Bob; Dvorak, Jiri; Echemendia, Ruben; Engebretsen, Lars; Johnston, Karen; Kutcher, Jeff; Raftery, Martin; Sills, Allen; Benson, Brian; Davis, Gavin; Ellenbogen, Richard; Guskiewicz, Kevin; Herring, Stanley A.; Iverson, Grant; Jordan, Barry; Kissick, James; McCrea, Michael; McIntosh, Andrew; Maddocks, David; Makdissi, Michael; Purcell, Laura; Putukian, Margot; Schneider, Kathryn; Tator, Charles; Turner, Michael			Consensus statement on Concussion in Sport-The 4th International Conference on Concussion in Sport held in Zurich, November 2012	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article; Proceedings Paper	4th International Conference on Concussion in Sport	NOV, 2012	Zurich, SWITZERLAND				CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; POSTURAL CONTROL; HEAD-INJURIES; LONG-TERM; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; AUSTRALIAN RULES; BRAIN-INJURY		[McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Meeuwisse, Willem] Univ Calgary, Fac Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Meeuwisse, Willem] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Cantu, Bob] Boston Univ, Med Ctr, Ctr Study Traumat Encephalopathy, Boston, MA USA; [Dvorak, Jiri] Univ Zurich, CH-8006 Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin Zurich, Zurich, Switzerland; [Dvorak, Jiri] F MARC FIFA Med Assessment & Res Ctr, Zurich, Switzerland; [Echemendia, Ruben] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Echemendia, Ruben] Univ Missouri, Kansas City, MO USA; [Engebretsen, Lars] Univ Oslo, Oslo Univ Hosp, Dept Orthopaed Surg, N-0316 Oslo, Norway; [Engebretsen, Lars] Univ Oslo, Fac Med, N-0316 Oslo, Norway; [Engebretsen, Lars] Oslo Sports Trauma Res Ctr, Oslo, Norway; [Engebretsen, Lars] IOC, Lausanne, Switzerland; [Johnston, Karen] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Johnston, Karen] Concuss Management Program Athlet Edge Sports Med, Toronto, ON, Canada; [Kutcher, Jeff] Univ Michigan, Dept Neurol, Michigan NeuroSport, Ann Arbor, MI USA; [Raftery, Martin] Int Rugby Board, Dublin, Ireland; [Sills, Allen] Vanderbilt Univ, Med Ctr, Vanderbilt Sports Concuss Ctr, Nashville, TN USA; [Benson, Brian] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Benson, Brian] Univ Calgary, Dept Family Med, Fac Kinesiol, Calgary, AB, Canada; [Benson, Brian] Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB, Canada; [Davis, Gavin] Austin Hosp, Dept Neurosurg, Melbourne, Vic 3084, Australia; [Davis, Gavin] Cabrini Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Davis, Gavin] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Ellenbogen, Richard] Univ Washington Seattle, Dept Neurol Surg, Seattle, WA USA; [Guskiewicz, Kevin] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Herring, Stanley A.] Seattle Seahawks, Seattle Sports Concuss Program, Seattle, WA USA; [Herring, Stanley A.] Seattle Mariners, Seattle, WA USA; [Iverson, Grant] Univ British Columbia, Neuropsychol Outcome Assessment Lab, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Jordan, Barry] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Jordan, Barry] Burke Rehabil Hosp, White Plains, NY USA; [Jordan, Barry] New York State Athlet Commiss, New York, NY USA; [Kissick, James] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Kissick, James] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI USA; [McIntosh, Andrew] Monash Univ, Monash Injury Res Inst, Australian Ctr Res Injury Sports & Its Prevent, Clayton, Vic 3800, Australia; [McIntosh, Andrew] Univ New S Wales, Fac Sci, Sydney, NSW 2052, Australia; [McIntosh, Andrew] McIntosh Consultancy & Res Pty Ltd, Sydney, NSW, Australia; [Maddocks, David] Perry Maddocks Trollope Lawyers, Melbourne, Vic, Australia; [Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Makdissi, Michael] Univ Melbourne, Melbourne Physiotherapy Dept, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Purcell, Laura] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Purcell, Laura] McMaster Univ, David Braley Sport Med & Rehabil Ctr, Hamilton, ON, Canada; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Putukian, Margot] Univ Med & Dent New Jersey, Newark, NJ 07103 USA; [Turner, Michael] British Horseracing Author, London, England; [Schneider, Kathryn] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Tator, Charles] Toronto Western Hosp, Toronto, ON, Canada; [Tator, Charles] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Tator, Charles] Krembil Neurosci Ctr, Toronto, ON, Canada		McCrory, P (corresponding author), Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia.	paulmccr@bigpond.net.au		McCrory, Paul/0000-0003-4850-0568; Guskiewicz, Kevin/0000-0002-8682-2130			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Broshek DK, 2005, CLIN SPORTS MED, V24, px; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10, DOI 10.1071/HE08010; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney JS, 2008, BRIT J SPORT MED, V42, P51; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Eckner JT, 2012, PSYCHOL ASSESSMENT, V24, P249, DOI 10.1037/a0025042; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 2000, SPORT HLTH, V18, P35; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P4; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M, 2004, CLIN SPORTS MED, V23, pix; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2000, STANDARDIZED ASSESSM, P22; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P., 2011, CLIN SPORTS MED, V30, pxi; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Peng Rui-yun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Shaw NH, 2004, CMAJ, V170, P8; Shaw NH, 2004, CMAJ, V170, P6; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; VAGNOZZI R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	162	68	68	0	44	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	MAY	2013	16	3					178	189		10.1016/j.jsams.2013.02.009			12	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	142WH	WOS:000318827800002	23541595	hybrid, Green Submitted, Green Accepted			2022-02-06	
J	Zhang, PY; Yu, HX; Zhou, NY; Zhang, J; Wu, Y; Zhang, YL; Bai, YL; Jia, J; Zhang, Q; Tian, S; Wu, JF; Hu, YS				Zhang, Pengyue; Yu, Huixian; Zhou, Naiyun; Zhang, Jie; Wu, Yi; Zhang, Yuling; Bai, Yulong; Jia, Jie; Zhang, Qi; Tian, Shan; Wu, Junfa; Hu, Yongshan			Early exercise improves cerebral blood flow through increased angiogenesis in experimental stroke rat model	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						Early exercise; Cerebral blood flow; Angiogenesis; Laser speckle flowmetry; Cerebral ischemia and reperfusion	LASER SPECKLE FLOWMETRY; TRAUMATIC BRAIN-INJURY; ARTERY OCCLUSION; PROGENITOR CELLS; STEM-CELLS; EXPRESSION; ISCHEMIA; NEOVASCULARIZATION; NEUROGENESIS; RECOVERY	Background: Early exercise after stroke promoted angiogenesis and increased microvessles density. However, whether these newly formatted vessels indeed give rise to functional vascular and improve the cerebral blood flow (CBF) in impaired brain region is still unclear. The present study aimed to determine the effect of early exercise on angiogenesis and CBF in ischemic region. Methods: Adult male Sprague Dawley rats were subjected to 90 min middle cerebral artery occlusion(MCAO) and randomly divided into early exercise and non-exercised control group 24 h later. Two weeks later, CBF in ischemic region was determined by laser speckle flowmetry(LSF). Meantime, micro vessels density, the expression of tie-2, total Akt and phosphorylated Akt (p-Akt), and infarct volume were detected with immunohistochemistry, 2,3,5 triphenyltetrazolium chloride (TTC) staining and western blotting respectively. The function was evaluated by seven point's method. Results: Our results showed that CBF, vessel density and expression of Tie-2, p-Akt in ischemic region were higher in early exercise group compared with those in non-exercise group. Consistent with these results, rats in early exercise group had a significantly reduced infarct volume and better functional outcomes than those in non-exercise group. Conclusions: Our results indicated that early exercise after MCAO improved the CBF in ischemic region, reduced infarct volume and promoted the functional outcomes, the underlying mechanism was correlated with angiogenesis in the ischemic cortex.	[Zhang, Pengyue; Yu, Huixian; Wu, Yi; Zhang, Yuling; Bai, Yulong; Jia, Jie; Zhang, Qi; Tian, Shan; Wu, Junfa; Hu, Yongshan] Fudan Univ, Huashan Hosp, Dept Rehabil, Shanghai 200433, Peoples R China; [Zhou, Naiyun] Shanghai Jiao Tong Univ, Dept Biomed Engn, Shanghai 200030, Peoples R China; [Zhou, Naiyun] SUNY Stony Brook, Dept Biomed Engn, New York, NY USA; [Zhang, Jie] First Peoples Hosp Yunnan Prov, Genet Diag Ctr, Yunnan Prov Key Lab Birth Defects & Genet Dis, Kunming, Peoples R China; [Wu, Yi] Fudan Univ, Huashan Hosp, Yonghe Branch, Shanghai 200032, Peoples R China		Hu, YS (corresponding author), Fudan Univ, Huashan Hosp, Dept Rehabil, Shanghai 200433, Peoples R China.	dr_huys@yahoo.com.cn		pengyue, zhang/0000-0002-7381-9303	Chinese National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81272169, 81201502, 81171856, 81171855]	The present study is supported by Chinese National Natural Science Foundation (81272169, 81201502, 81171856, and 81171855).	Arai K, 2009, FEBS J, V276, P4644, DOI 10.1111/j.1742-4658.2009.07176.x; Ayata C, 2004, J CEREBR BLOOD F MET, V24, P744, DOI 10.1097/01.WCB.0000122745.72175.D5; Bajetto A, 2001, FRONT NEUROENDOCRIN, V22, P147, DOI 10.1006/frne.2001.0214; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Beck H, 2009, ACTA NEUROPATHOL, V117, P481, DOI 10.1007/s00401-009-0483-6; Boas DA, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3285504; BONNER R, 1981, APPL OPTICS, V20, P2097, DOI 10.1364/AO.20.002097; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Bullitt E, 2009, AM J NEURORADIOL, V30, P1857, DOI 10.3174/ajnr.A1695; Chae CH, 2009, NEUROSCIENCE, V164, P1665, DOI 10.1016/j.neuroscience.2009.09.075; Chae CH, 2009, NEUROCHEM INT, V55, P208, DOI 10.1016/j.neuint.2009.02.024; Chen MD, 2011, STROKE, V42, P832, DOI 10.1161/STROKEAHA.110.607747; Cheng XW, 2010, CIRCULATION, V122, P707, DOI 10.1161/CIRCULATIONAHA.109.909218; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Croll SD, 2001, MOL NEUROBIOL, V23, P121, DOI 10.1385/MN:23:2-3:121; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Ding YH, 2006, NEUROL RES, V28, P184, DOI 10.1179/016164106X98053; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Favier J, 2001, THERAPIE, V56, P455; Galvin R, 2011, STROKE, V42, P681, DOI 10.1161/STROKEAHA.110.594689; Gao XW, 2008, J NEUROCHEM, V105, P943, DOI 10.1111/j.1471-4159.2008.05218.x; Gao XW, 2010, TRANSL STROKE RES, V1, P202, DOI 10.1007/s12975-010-0017-5; GARCIA JH, 1971, ACTA NEUROPATHOL, V18, P273, DOI 10.1007/BF00688441; Gavin TP, 2007, ACTA PHYSIOL, V191, P139, DOI 10.1111/j.1748-1716.2007.01723.x; Gertz K, 2006, CIRC RES, V99, P1132, DOI 10.1161/01.RES.0000250175.14861.77; Ginsberg MD, 1997, AM J NEURORADIOL, V18, P1435; Green AR, 2008, BRIT J PHARMACOL, V153, pS325, DOI 10.1038/sj.bjp.0707594; Green DJ, 2011, EXP PHYSIOL, V96, P57, DOI 10.1113/expphysiol.2009.048694; Guo XB, 2009, J NEUROTRAUM, V26, P1337, DOI [10.1089/neu.2008.0733, 10.1089/neu.2008-0733]; Guyot LL, 2001, NEUROSCI LETT, V299, P37, DOI 10.1016/S0304-3940(01)01510-5; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Hayashi T, 2006, CURR NEUROVASC RES, V3, P119, DOI 10.2174/156720206776875902; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jiang Q, 2005, NEUROIMAGE, V28, P698, DOI 10.1016/j.neuroimage.2005.06.063; JW G, 1965, SOME EFFECTS TARGET, P1688; Krupinski J, 2003, NEUROREPORT, V14, P1171, DOI 10.1097/00001756-200306110-00014; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Laughlin MH, 2008, J PHYSIOL PHARMACOL, V59, P71; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647-200002000-00021; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; Michelini LC, 2009, EXP PHYSIOL, V94, P947, DOI 10.1113/expphysiol.2009.047449; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Patan S, 2004, CANC TREAT, V117, P3; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Rhyu IJ, 2010, NEUROSCIENCE, V167, P1239, DOI 10.1016/j.neuroscience.2010.03.003; Robin AM, 2006, J CEREBR BLOOD F MET, V26, P125, DOI 10.1038/sj.jcbfm.9600172; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Saxena SK, 2007, ACTA NEUROL SCAND, V115, P339, DOI 10.1111/j.1600-0404.2006.00751.x; Shin HK, 2008, STROKE, V39, P1548, DOI 10.1161/STROKEAHA.107.499483; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Slevin M, 2006, CLIN SCI, V111, P171, DOI 10.1042/CS20060049; Strong AJ, 2006, J CEREBR BLOOD F MET, V26, P645, DOI 10.1038/sj.jcbfm.9600240; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Teng H, 2008, J CEREBR BLOOD F MET, V28, P764, DOI 10.1038/sj.jcbfm.9600573; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Timmons JA, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-19; Wan YQ, 2007, J NEUROSCI RES, V85, P73, DOI 10.1002/jnr.21091; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; Wei L, 2001, STROKE, V32, P2179, DOI 10.1161/hs0901.094282; Weintraub MI, 2006, STROKE, V37, P1917, DOI 10.1161/01.STR.0000226651.04862.da; Woulfe DS, 2010, EXPERT REV HEMATOL, V3, P81, DOI 10.1586/EHM.09.75; Xu XS, 2008, BRAIN RES, V1227, P12, DOI 10.1016/j.brainres.2008.06.018; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Zhang PY, 2013, INT J MOL SCI, V14, P6074, DOI 10.3390/ijms14036074; Zhang Pengyue, 2012, Front Biosci (Elite Ed), V4, P2476; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zheng QP, 2011, TOHOKU J EXP MED, V224, P221, DOI 10.1620/tjem.224.221; Zinn S, 2007, ARCH PHYS MED REHAB, V88, P173, DOI 10.1016/j.apmr.2006.11.015	75	68	74	3	46	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	APR 26	2013	10								43	10.1186/1743-0003-10-43			10	Engineering, Biomedical; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology; Rehabilitation	141NY	WOS:000318733100001	23622352	Green Published, gold			2022-02-06	
J	Simpson, G; Jones, K				Simpson, Grahame; Jones, Kate			How important is resilience among family members supporting relatives with traumatic brain injury or spinal cord injury?	CLINICAL REHABILITATION			English	Article						Traumatic brain injury; spinal cord injury; family adaptation; caregiver; resilience	PSYCHOLOGICAL DISTRESS; LIFE SATISFACTION; HEAD-INJURY; REHABILITATION; SPOUSES; PEOPLE; IMPACT; ADJUSTMENT; ADAPTATION; STRESS	Objective: To investigate the relationship between resilience and affective state, caregiver burden and caregiving strategies among family members of people with traumatic brain or spinal cord injury. Design: An observational prospective cross-sectional study. Setting: Inpatient and community rehabilitation services. Subjects: Convenience sample of 61 family respondents aged 18 years or older at the time of the study and supporting a relative with severe traumatic brain injury (n = 30) or spinal cord injury (n = 31). Main measures: Resilience Scale, Positive And Negative Affect Schedule, Caregiver Burden Scale, Functional Independence Measure, Carer's Assessment of Managing Index. Results: Correlational analyses found a significant positive association between family resilience scores and positive affect (r(s) = 0.67), and a significant negative association with negative affect (r(s) = -0.47) and caregiver burden scores (r(s) = -0.47). No association was found between family resilience scores and their relative's severity of functional impairment. Family members with high resilience scores rated four carer strategies as significantly more helpful than family members with low resilience scores. Between-groups analyses (families supporting relative with traumatic brain injury vs. spinal cord injury) found no significant differences in ratings of the perceived helpfulness of carer strategies once Bonferroni correction for multiple tests was applied. Conclusions: Self-rated resilience correlated positively with positive affect, and negatively with negative affect and caregiver burden. These results are consistent with resilience theories which propose that people with high resilience are more likely to display positive adaptation when faced by significant adversity.	[Simpson, Grahame; Jones, Kate] Liverpool Hosp, Sydney, NSW, Australia		Simpson, G (corresponding author), Liverpool Hlth Serv, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool Bc, NSW 1871, Australia.	grahame.simpson@sswahs.nsw.gov.au	Simpson, Grahame K/W-1074-2019; Jones, Kate/AAV-7641-2021	Simpson, Grahame K/0000-0001-8156-9060; Jones, Kate/0000-0002-5964-3479	NSW Life Time Care and Support Authority [08/210]	This work was supported by the NSW Life Time Care and Support Authority (08/210).	Alfano D P, 1994, Appl Neuropsychol, V1, P57, DOI 10.1207/s15324826an0101&2_10; Anderson MI, 2009, BRAIN INJURY, V23, P931, DOI 10.3109/02699050903302336; Campbell-Sills L, 2006, BEHAV RES THER, V44, P585, DOI 10.1016/j.brat.2005.05.001; Chan RCK, 2000, CLIN REHABIL, V14, P137, DOI 10.1191/026921500675826560; Earvolino-Ramirez M, 2007, NURS FORUM, V42, P73, DOI 10.1111/j.1744-6198.2007.00070.x; Elmstahl S, 1996, ARCH PHYS MED REHAB, V77, P177, DOI 10.1016/S0003-9993(96)90164-1; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Friborg O, 2003, INT J METH PSYCH RES, V12, P65, DOI 10.1002/mpr.143; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Kolakowsky-Hayner SA, 1999, NEUROREHABILITATION, V13, P27; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/h0080325; KOSCIULEK JF, 1993, J REHABIL, V59, P40; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; Lopez J, 2005, ARCH GERONTOL GERIAT, V41, P81, DOI 10.1016/j.archger.2004.12.001; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Mancini AD, 2006, J CLIN PSYCHOL, V62, P971, DOI 10.1002/jclp.20283; Mckee K, 2009, AGING MENT HEALTH, V13, P255, DOI 10.1080/13607860802342219; Meade MA, 2004, REHABIL PSYCHOL, V49, P150, DOI 10.1037/0090-5550.49.2.150; Newman R, 2005, PROF PSYCHOL-RES PR, V36, P227, DOI 10.1037/0735-7028.36.3.227; Nolan M, 1996, UNDERSTANDING FAMILY; Nolan M., 1998, ASSESSING NEEDS FAMI; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; Ponsford J, 2002, TRAUMATIC BRAIN INJU; Post MWM, 2005, SPINAL CORD, V43, P311, DOI 10.1038/sj.sc.3101704; Richardson GE, 2002, J CLIN PSYCHOL, V58, P307, DOI 10.1002/jclp.10020; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SPINA S, 2005, BRAIN IMPAIR, V6, P33, DOI DOI 10.1375/BRIM.6.1.33.65478; *UN DAT SYST MED R, 1997, GUID UN DAT SET MED; Wagnild G M, 1993, J Nurs Meas, V1, P165; Watson D., 1994, PANAS 10 MAN POS NEG; Weitzenkamp DA, 1997, ARCH PHYS MED REHAB, V78, P822, DOI 10.1016/S0003-9993(97)90194-5; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001	36	68	68	2	49	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	APR	2013	27	4					367	377		10.1177/0269215512457961			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	140FN	WOS:000318639900010	23012693				2022-02-06	
J	Quintana, A; Erta, M; Ferrer, B; Comes, G; Giralt, M; Hidalgo, J				Quintana, Albert; Erta, Maria; Ferrer, Beatriz; Comes, Gemma; Giralt, Mercedes; Hidalgo, Juan			Astrocyte-specific deficiency of interleukin-6 and its receptor reveal specific roles in survival, body weight and behavior	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Interleukin-6; Astrocyte; Intrauterine survival; Body weight; Normal behavior	TUMOR-NECROSIS-FACTOR; ELEVATED PLUS-MAZE; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; TRANSGENIC MICE; CYTOKINE RECEPTORS; GENE-EXPRESSION; KNOCKOUT MICE; RAT BEHAVIOR; IL-6	Interleukin-6 (IL-6) is a major cytokine which controls not only the immune system but also exhibits many other functions including effects in the central nervous system (CNS). IL-6 is known to be produced by different cells in the CNS, and all the major CNS do respond to IL-6, which makes it difficult to dissect the specific roles of each cell type when assessing the role of IL-6 in the brain. We have produced for the first time foxed mice for IL-6 and have crossed them with GFAP-Cre mice to delete IL-6 in astrocytes (Ast-IL-6 KO mice), and have compared their phenotype with that of mice with deletion of IL-6 receptor in astrocytes (Ast-IL6R KO mice). Our results indicate a major prosurvival role of the astrocyte IL-6 system at early ages (intrauterine life), which was also involved to various degrees in the control of adult body weight, locomotor activity, anxiety and exploratory behaviors. In some occasions deleting IL-6R in astrocytes mimicked the phenotype of Ast-IL-6 KO mice (i.e. activity), while in others the opposite was observed (i.e. exploration), suggesting autocrine and paracrine (presumably on neurons) roles of astrocyte IL-6. Our results suggest important roles of the astrocyte IL-6 system on normal brain physiology, in some cases totally unexpected from previous results with total IL-6 KO mice. (C) 2012 Elsevier Inc. All rights reserved.	[Quintana, Albert; Erta, Maria; Ferrer, Beatriz; Comes, Gemma; Giralt, Mercedes; Hidalgo, Juan] Univ Autonoma Barcelona, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Fac Biociencias, E-08193 Barcelona, Spain; [Quintana, Albert; Erta, Maria; Ferrer, Beatriz; Comes, Gemma; Giralt, Mercedes; Hidalgo, Juan] Univ Autonoma Barcelona, Inst Neurosci, E-08193 Barcelona, Spain		Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Fac Biociencias, Edificio C, E-08193 Barcelona, Spain.	juan.hidalgo@uab.es	Quintana, Albert/N-5544-2015; Giralt, Mercedes/K-1626-2014; Hidalgo, Juan/C-9082-2011	Quintana, Albert/0000-0003-1674-7160; Giralt, Mercedes/0000-0002-1806-1528; Hidalgo, Juan/0000-0003-0921-1122; COMES, GEMMA/0000-0002-4074-7665	FP6 Integrated Project Exgenesis [LSHM-CT-2004-005272]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission; Ministerio de Ciencia e InnovacionInstituto de Salud Carlos IIISpanish GovernmentEuropean Commission [RETICS (REEM, RD07/0060/0002)]; UAB;  [SAF2008-00435];  [SAF2011-23272]	The authors acknowledge the collaboration of the Unit of Transgenic Animals, CBATEG, from the Universitat Autonoma de Barcelona, for generating the IL-6 floxed mice, and especially the collaboration of Richard Palmiter for the generation of the IL-6 construct. The help of Jordi Mann with the HB and EPM programs is gratefully acknowledged. This work was supported by SAF2008-00435, SAF2011-23272, FP6 Integrated Project Exgenesis (LSHM-CT-2004-005272), and by Instituto de Salud Carlos III and Ministerio de Ciencia e Innovacion-Fondo Europeo de Desarrollo Regional (FEDER), ref. RETICS (REEM, RD07/0060/0002) to JH. Maria Erta gratefully acknowledges a PhD fellowship from UAB.	Alleva E, 1998, EUR J NEUROSCI, V10, P3664, DOI 10.1046/j.1460-9568.1998.00377.x; ARCHER J, 1973, ANIM BEHAV, V21, P205, DOI 10.1016/S0003-3472(73)80065-X; Armario A, 1998, J NEUROIMMUNOL, V92, P160, DOI 10.1016/S0165-5728(98)00199-4; Baier PC, 2009, BEHAV BRAIN RES, V200, P192, DOI 10.1016/j.bbr.2009.01.013; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bauer S, 2007, NAT REV NEUROSCI, V8, P221, DOI 10.1038/nrn2054; Benrick A, 2009, J NEUROENDOCRINOL, V21, P620, DOI 10.1111/j.1365-2826.2009.01879.x; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; BOISSIER J R, 1962, Therapie, V17, P1225; Braida D, 2004, BEHAV BRAIN RES, V153, P423, DOI 10.1016/j.bbr.2003.12.018; Burton MD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-54; Butterweck V, 2003, BEHAV BRAIN RES, V144, P49, DOI 10.1016/S0166-4328(03)00059-7; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chai Z, 1996, J EXP MED, V183, P311, DOI 10.1084/jem.183.1.311; Chesnokova V, 2002, ENDOCRINOLOGY, V143, P1571, DOI 10.1210/en.143.5.1571; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Chourbaji S, 2006, NEUROBIOL DIS, V23, P587, DOI 10.1016/j.nbd.2006.05.001; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; DALRYMPLE SA, 1995, INFECT IMMUN, V63, P2262, DOI 10.1128/IAI.63.6.2262-2268.1995; Deverman BE, 2009, NEURON, V64, P61, DOI 10.1016/j.neuron.2009.09.002; Di Gregorio GB, 2004, AM J PHYSIOL-ENDOC M, V287, pE182, DOI 10.1152/ajpendo.00189.2003; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Ellingsgaard H, 2008, P NATL ACAD SCI USA, V105, P13163, DOI 10.1073/pnas.0801059105; Faldt J, 2004, ENDOCRINOLOGY, V145, P2680, DOI 10.1210/en.2003-1319; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Fernandes C, 1999, PHARMACOL BIOCHEM BE, V64, P731, DOI 10.1016/S0091-3057(99)00139-2; FILE SE, 1975, PSYCHOPHARMACOLOGIA, V44, P53, DOI 10.1007/BF00421184; Garcia-Oscos F, 2012, BIOL PSYCHIAT, V71, P574, DOI 10.1016/j.biopsych.2011.11.018; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Hidalgo J, 2010, BRAIN BEHAV IMMUN, V24, P119, DOI 10.1016/j.bbi.2009.09.002; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; Kasckow JW, 1997, ENDOCRINOLOGY, V138, P4774, DOI 10.1210/en.138.11.4774; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Marz P, 1999, EUR J NEUROSCI, V11, P2995, DOI 10.1046/j.1460-9568.1999.00755.x; McFarland-Mancini MM, 2010, J IMMUNOL, V184, P7219, DOI 10.4049/jimmunol.0901929; Murphy PG, 1999, EUR J NEUROSCI, V11, P2243, DOI 10.1046/j.1460-9568.1999.00641.x; Nadal R., 2006, TASKS TECHNIQUES SAM, P25; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Quintana A, 2008, DEV NEUROBIOL, V68, P195, DOI 10.1002/dneu.20584; Quintana A, 2010, P NATL ACAD SCI USA, V107, P10996, DOI 10.1073/pnas.1006214107; RODGERS RJ, 1995, PHARMACOL BIOCHEM BE, V52, P297, DOI 10.1016/0091-3057(95)00138-M; Rose-John S, 2007, EXPERT OPIN THER TAR, V11, P613, DOI 10.1517/14728222.11.5.613; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; Schele E, 2012, J NEUROENDOCRINOL, V24, P930, DOI 10.1111/j.1365-2826.2012.02286.x; SCHINDLER R, 1990, BLOOD, V75, P40; Senaris RM, 2011, J NEUROENDOCRINOL, V23, P675, DOI 10.1111/j.1365-2826.2011.02158.x; SHELLARD SA, 1993, ANTI-CANCER DRUG, V4, P491, DOI 10.1097/00001813-199308000-00011; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Stalder AK, 1998, AM J PATHOL, V153, P767, DOI 10.1016/S0002-9440(10)65620-9; Swiergiel AH, 2006, BEHAV BRAIN RES, V171, P94, DOI 10.1016/j.bbr.2006.03.024; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Vereyken EJF, 2007, EUR J NEUROSCI, V25, P3605, DOI 10.1111/j.1460-9568.2007.05615.x; Vgontzas AN, 1999, J CLIN ENDOCR METAB, V84, P2603, DOI 10.1210/jc.84.8.2603; Wallenius K, 2002, BIOCHEM BIOPH RES CO, V293, P560, DOI 10.1016/S0006-291X(02)00230-9; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; Wang XQ, 2009, ANNU REV IMMUNOL, V27, P29, DOI 10.1146/annurev.immunol.24.021605.090616; Wernstedt I, 2006, AM J PHYSIOL-REG I, V291, pR551, DOI 10.1152/ajpregu.00514.2005	67	68	70	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591			BRAIN BEHAV IMMUN	Brain Behav. Immun.	JAN	2013	27						162	173		10.1016/j.bbi.2012.10.011			12	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	058JE	WOS:000312629100020	23085146				2022-02-06	
J	Mahley, RW; Huang, YD				Mahley, Robert W.; Huang, Yadong			Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4-Associated Neuropathology	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							INCREASED TAU PHOSPHORYLATION; TRAUMATIC BRAIN-INJURY; E4 DOMAIN INTERACTION; E EPSILON 4; ALZHEIMERS-DISEASE; MUTANT P53; APOE GENOTYPE; PHARMACOLOGICAL CHAPERONE; IN-VITRO; DEPENDENT IMPAIRMENT	An attractive strategy to treat proteinopathies (diseases caused by malformed or misfolded proteins) is to restore protein function by inducing proper three-dimensional structure. We hypothesized that this approach would be effective in reversing the detrimental effects of apolipoprotein (apo) E4, the major allele that significantly increases the risk of developing Alzheimer's disease and other neurodegenerative disorders. ApoE4's detrimental effects result from its altered protein conformation ("domain interaction"), making it highly susceptible to proteolytic cleavage and the generation of neurotoxic fragments. Here, we review apoE structure and function and how apoE4 causes neurotoxicity, and describe the identification of potent;mall-molecule-based "structure correctors" that induce proper apoE4 folding. SAP. studies identified a series of small molecules that significantly reduced apoE4's neurotoxic effects in cultured neurons and a series that reduced apoE4 fragment levels in vivo, providing proof-of-concept for our approach. Structure-corrector-based therapies could prove to be highly effective for the treatment of many protein-misfolding diseases.	[Mahley, Robert W.; Huang, Yadong] Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; [Mahley, Robert W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Huang, Yadong] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Mahley, Robert W.; Huang, Yadong] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA		Mahley, RW (corresponding author), Gladstone Inst Neurol Dis, 1650 Owens St, San Francisco, CA 94158 USA.	rmahley@gladstone.ucsf.edu	Du, Yan-Jun/K-1522-2019; Graaff, Reindert/G-8941-2011	Du, Yan-Jun/0000-0001-9533-8976; 	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 AG022074]; Alzheimer's Drug Discovery Foundation [20110501]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG022074] Funding Source: NIH RePORTER	We thank Sylvia Richmond for manuscript preparation, Anna Lisa Lucido and Gary Howard for editorial assistance, and John C. W. Carroll for graphics. We are indebted to the staff of the Merck Research Laboratories (Boston, MA) for providing compounds from the Merck library and preparing specific chemical analogues. This work was supported, in part, by National Institutes of Health Grant P01 AG022074, Alzheimer's Drug Discovery Foundation Grant 20110501, a gift from the Stephen D. Bechtel, Jr. Foundation, and Merck Research Laboratories.	Accurso FJ, 2010, NEW ENGL J MED, V363, P1991, DOI 10.1056/NEJMoa0909825; Agosta F, 2009, P NATL ACAD SCI USA, V106, P2018, DOI 10.1073/pnas.0812697106; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; [Anonymous], 2009, MOL THER, V17, P1309; BALCH WE, 2011, COLD SPRING HARB PER, V3, DOI DOI 10.1101/CSHPERSPECT.A004499; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Benjamin ER, 2009, J INHERIT METAB DIS, V32, P424, DOI 10.1007/s10545-009-1077-0; Bien-Ly N, 2011, P NATL ACAD SCI USA, V108, P4236, DOI 10.1073/pnas.1018381108; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brodbeck J, 2008, P NATL ACAD SCI USA, V105, P1343, DOI 10.1073/pnas.0709906104; Brodbeck J, 2011, J BIOL CHEM, V286, P17217, DOI 10.1074/jbc.M110.217380; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Burt TD, 2008, P NATL ACAD SCI USA, V105, P8718, DOI 10.1073/pnas.0803526105; Buttini M, 1999, J NEUROSCI, V19, P4867; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Castellano JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002156; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Chen HK, 2012, J BIOL CHEM, V287, P5253, DOI 10.1074/jbc.M111.276162; Chen HK, 2011, J BIOL CHEM, V286, P5215, DOI 10.1074/jbc.M110.151084; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Enzinger C, 2003, ARCH NEUROL-CHICAGO, V60, P65, DOI 10.1001/archneur.60.1.65; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Fan JQ, 2003, METHOD ENZYMOL, V363, P412; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fazekas F, 2000, J NEUROL NEUROSUR PS, V69, P25, DOI 10.1136/jnnp.69.1.25; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Grainger DJ, 2004, J IMMUNOL, V173, P6366, DOI 10.4049/jimmunol.173.10.6366; Hagemans MLC, 2005, BRAIN, V128, P671, DOI 10.1093/brain/awh384; Harhangi BS, 2000, NEUROLOGY, V54, P1272, DOI 10.1212/WNL.54.6.1272; Harris FM, 2004, J BIOL CHEM, V279, P44795, DOI 10.1074/jbc.M408127200; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Hatters DM, 2005, J BIOL CHEM, V280, P34288, DOI 10.1074/jbc.M506044200; Hirshhorn R., 2001, METABOLIC MOL BASES, P3389; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Huang YD, 2010, TRENDS MOL MED, V16, P287, DOI 10.1016/j.molmed.2010.04.004; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Hughes D, 2010, J INHERIT METAB DIS, V33, pS148; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kalid O, 2010, J COMPUT AID MOL DES, V24, P971, DOI 10.1007/s10822-010-9390-0; Khanna R, 2010, MOL THER, V18, P23, DOI 10.1038/mt.2009.220; Kim J, 2011, J NEUROSCI, V31, P18007, DOI 10.1523/JNEUROSCI.3773-11.2011; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kornhaber GJ, 2008, CHEMBIOCHEM, V9, P2643, DOI 10.1002/cbic.200800249; Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Li YJ, 2004, NEUROLOGY, V62, P2005, DOI 10.1212/01.WNL.0000128089.53030.AC; Lieberman RL, 2007, NAT CHEM BIOL, V3, P101, DOI 10.1038/nchembio850; Lieberman RL, 2009, BIOCHEMISTRY-US, V48, P4816, DOI 10.1021/bi9002265; Lindquist SL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004507; Liou B, 2006, J BIOL CHEM, V281, P4242, DOI 10.1074/jbc.M511110200; Lir H., 2004, BIOCHIM BIOPHYS ACTA, V1689, P219; Maegawa GHB, 2007, J BIOL CHEM, V282, P9150, DOI 10.1074/jbc.M609304200; Mahley RW, 2009, J LIPID RES, V50, pS183, DOI 10.1194/jlr.R800069-JLR200; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Martinez M, 2005, AM J MED GENET B, V136B, P72, DOI 10.1002/ajmg.b.30196; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nichols WC, 2009, NEUROLOGY, V72, P310, DOI 10.1212/01.wnl.0000327823.81237.d1; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Okumiya T, 2007, MOL GENET METAB, V90, P49, DOI 10.1016/j.ymgme.2006.09.010; Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583; Parenti G, 2007, MOL THER, V15, P508, DOI 10.1038/sj.mt.6300074; Parsian A, 2002, GENOMICS, V79, P458, DOI 10.1006/geno.2002.6707; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Pedemonte N, 2010, AM J PHYSIOL-CELL PH, V298, pC866, DOI 10.1152/ajpcell.00404.2009; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Riordan JR, 2008, ANNU REV BIOCHEM, V77, P701, DOI 10.1146/annurev.biochem.75.103004.142532; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sawkar AR, 2006, CELL MOL LIFE SCI, V63, P1179, DOI 10.1007/s00018-005-5437-0; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Serohijos AWR, 2008, P NATL ACAD SCI USA, V105, P3256, DOI 10.1073/pnas.0800254105; Sidransky E, 2009, NEW ENGL J MED, V361, P1651, DOI 10.1056/NEJMoa0901281; Sloane PA, 2010, CURR OPIN PULM MED, V16, P591, DOI 10.1097/MCP.0b013e32833f1d00; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Steet RA, 2006, P NATL ACAD SCI USA, V103, P13813, DOI 10.1073/pnas.0605928103; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Van Goor F, 2006, AM J PHYSIOL-LUNG C, V290, pL1117, DOI 10.1152/ajplung.00169.2005; Van Goor F, 2011, P NATL ACAD SCI USA, V108, P18843, DOI 10.1073/pnas.1105787108; VANGOOR F, 2009, WINE, V106, P18825, DOI DOI 10.1073/PNAS.0904709106; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wang W, 2008, CURR OPIN ONCOL, V20, P90, DOI 10.1097/CCO.0b013e3282f31d6f; Wang Z, 2010, TRANSL ONCOL, V3, P1, DOI 10.1593/tlo.09250; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188; Xu Q, 2004, J BIOL CHEM, V279, P25511, DOI 10.1074/jbc.M311256200; Yam GHF, 2005, FASEB J, V19, P12, DOI 10.1096/fj.04-2375com; Ye SM, 2005, P NATL ACAD SCI USA, V102, P18700, DOI 10.1073/pnas.0508693102; Zarate YA, 2008, LANCET, V372, P1427, DOI 10.1016/S0140-6736(08)61589-5; Zhong N, 2008, ALZHEIMERS DEMENT, V4, P179, DOI 10.1016/j.jalz.2008.01.006; Zhong N, 2009, J BIOL CHEM, V284, P6027, DOI 10.1074/jbc.R800009200	114	68	70	0	24	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	NOV 8	2012	55	21					8997	9008		10.1021/jm3008618			12	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	033CE	WOS:000310769500003	23013167	Green Accepted			2022-02-06	
J	Zhao, W; Varghese, M; Vempati, P; Dzhun, A; Cheng, A; Wang, J; Lange, D; Bilski, A; Faravelli, I; Pasinetti, GM				Zhao, Wei; Varghese, Merina; Vempati, Prashant; Dzhun, Anastasiya; Cheng, Alice; Wang, Jun; Lange, Dale; Bilski, Amanda; Faravelli, Irene; Pasinetti, Giulio Maria			Caprylic Triglyceride as a Novel Therapeutic Approach to Effectively Improve the Performance and Attenuate the Symptoms Due to the Motor Neuron Loss in ALS Disease	PLOS ONE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MEDIUM-CHAIN TRIGLYCERIDES; SUPEROXIDE-DISMUTASE GENE; TRAUMATIC BRAIN-INJURY; KETOGENIC DIET; MOUSE MODEL; MITOCHONDRIAL DYSFUNCTION; SKELETAL-MUSCLE; TRANSGENIC MICE; SPINAL-CORD	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of motor neurons causing progressive muscle weakness, paralysis, and finally death. ALS patients suffer from asthenia and their progressive weakness negatively impacts quality of life, limiting their daily activities. They have impaired energy balance linked to lower activity of mitochondrial electron transport chain enzymes in ALS spinal cord, suggesting that improving mitochondrial function may present a therapeutic approach for ALS. When fed a ketogenic diet, the G93A ALS mouse shows a significant increase in serum ketones as well as a significantly slower progression of weakness and lower mortality rate. In this study, we treated SOD1-G93A mice with caprylic triglyceride, a medium chain triglyceride that is metabolized into ketone bodies and can serve as an alternate energy substrate for neuronal metabolism. Treatment with caprylic triglyceride attenuated progression of weakness and protected spinal cord motor neuron loss in SOD1-G93A transgenic animals, significantly improving their performance even though there was no significant benefit regarding the survival of the ALS transgenic animals. We found that caprylic triglyceride significantly promoted the mitochondrial oxygen consumption rate in vivo. Our results demonstrated that caprylic triglyceride alleviates ALS-type motor impairment through restoration of energy metabolism in SOD1-G93A ALS mice, especially during the overt stage of the disease. These data indicate the feasibility of using caprylic acid as an easily administered treatment with a high impact on the quality of life of ALS patients.	[Zhao, Wei; Varghese, Merina; Vempati, Prashant; Dzhun, Anastasiya; Cheng, Alice; Wang, Jun; Bilski, Amanda; Faravelli, Irene; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Zhao, Wei; Wang, Jun; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, New York, NY USA; [Lange, Dale] Hosp Special Surg, New York, NY 10021 USA		Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.	Giulio.Pasinetti@mssm.edu	Faravelli, Irene/AAP-6300-2020; Varghese, Merina/H-5472-2019; Zhao, Wei/A-2206-2010	Faravelli, Irene/0000-0001-8126-7353; Varghese, Merina/0000-0002-1517-3903; Pasinetti, Giulio/0000-0002-1524-5196; Zhao, Wei/0000-0002-3449-2395	NIH-NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5R24 CA095823-04]; NSF Major Research InstrumentationNational Science Foundation (NSF) [DBI-9724504]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 S10 RR0 9145-01]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24CA095823] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR009145] Funding Source: NIH RePORTER	This work was supported by funding from: NIH-NCI shared resources grant (5R24 CA095823-04), http://www.nih.gov/; NSF Major Research Instrumentation grant (DBI-9724504), http://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5260; and NIH shared instrumentation grant (1 S10 RR0 9145-01); http://www.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alavian KN, 2012, BRAIN RES, V1446, P1, DOI 10.1016/j.brainres.2012.01.046; Andreassen OA, 2001, J NEUROCHEM, V77, P383, DOI 10.1046/j.1471-4159.2001.00188.x; BACH AC, 1982, AM J CLIN NUTR, V36, P950, DOI 10.1093/ajcn/36.5.950; Beal MF, 2002, FREE RADICAL RES, V36, P455, DOI 10.1080/10715760290021315; BJUGN R, 1993, BRAIN RES, V627, P25, DOI 10.1016/0006-8993(93)90744-8; Browne SE, 1998, J NEUROCHEM, V71, P281; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cheng BH, 2009, BRAIN RES, V1286, P25, DOI 10.1016/j.brainres.2009.06.060; CHIU AY, 1995, MOL CELL NEUROSCI, V6, P349, DOI 10.1006/mcne.1995.1027; Ciavarro GL, 2003, J NEUROSCI METH, V129, P61, DOI 10.1016/S0165-0270(03)00201-2; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crugnola V, 2010, ARCH NEUROL-CHICAGO, V67, P849, DOI 10.1001/archneurol.2010.128; Cudkowicz M, 2011, NAT MED, V17, P1652, DOI 10.1038/nm.2579; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Dorst J, 2011, J NEUROL, V258, P613, DOI 10.1007/s00415-010-5805-z; Douglas RM, 2010, AM J PHYSIOL-CELL PH, V298, pC1594, DOI 10.1152/ajpcell.00298.2009; Fidler JA, 2011, FASEB J, V25, P4369, DOI 10.1096/fj.11-190819; Fujita K, 1996, J NEUROSCI RES, V45, P276, DOI 10.1002/(SICI)1097-4547(19960801)45:3<276::AID-JNR9>3.0.CO;2-A; Genton L, 2011, CLIN NUTR, V30, P553, DOI 10.1016/j.clnu.2011.06.004; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Henderson ST, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-31; Ho L, 2012, NUTR NEUROSCI, V15, P37, DOI 10.1179/1476830511Y.0000000027; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; HUTTENLOCHER PR, 1971, NEUROLOGY, V21, P1097, DOI 10.1212/WNL.21.11.1097; Jung CW, 2002, J NEUROSCI METH, V114, P165, DOI 10.1016/S0165-0270(01)00524-6; Kaal ECA, 2000, J NEUROCHEM, V74, P1158; Kong JM, 1998, J NEUROSCI, V18, P3241; Laffel L, 1999, DIABETES-METAB RES, V15, P412, DOI 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; PERLMAN BJ, 1984, MOL PHARMACOL, V26, P83; Pradat PF, 2010, AMYOTROPH LATERAL SC, V11, P166, DOI 10.3109/17482960902822960; PRAMATAROVA A, 1995, AM J HUM GENET, V56, P592; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI 10.1089/neu.2008-0769; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Roman Marian W, 2010, Issues Ment Health Nurs, V31, P435, DOI 10.3109/01612841003768231; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Rothstein JD, 2003, ANN NEUROL, V53, P423, DOI 10.1002/ana.10561; Ruskin DN, 2011, PHYSIOL BEHAV, V103, P501, DOI 10.1016/j.physbeh.2011.04.001; Ruskin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008349; Sasaki S, 1996, NEUROSCI LETT, V204, P53, DOI 10.1016/0304-3940(96)12314-4; SILLS MA, 1986, ARCH DIS CHILD, V61, P1168, DOI 10.1136/adc.61.12.1168; SPECTOR R, 1988, J NEUROCHEM, V50, P639, DOI 10.1111/j.1471-4159.1988.tb02958.x; Stafstrom CE, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00059; Strong M, 2003, AMYOTROPH LATERAL SC, V4, P136, DOI 10.1080/14660820310011250; Tu PH, 1997, LAB INVEST, V76, P441; Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339; Vining EPG, 1998, ARCH NEUROL-CHICAGO, V55, P1433, DOI 10.1001/archneur.55.11.1433; Wiedemann FR, 1998, J NEUROL SCI, V156, P65, DOI 10.1016/S0022-510X(98)00008-2; Wlaz P, 2012, NEUROPHARMACOLOGY, V62, P1882, DOI 10.1016/j.neuropharm.2011.12.015; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhao W, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-51; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	53	68	70	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2012	7	11							e49191	10.1371/journal.pone.0049191			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	048TK	WOS:000311935800228	23145119	Green Published, gold, Green Submitted			2022-02-06	
J	Fukuda, AM; Pop, V; Spagnoli, D; Ashwal, S; Obenaus, A; Badaut, J				Fukuda, A. M.; Pop, V.; Spagnoli, D.; Ashwal, S.; Obenaus, A.; Badaut, J.			DELAYED INCREASE OF ASTROCYTIC AQUAPORIN 4 AFTER JUVENILE TRAUMATIC BRAIN INJURY: POSSIBLE ROLE IN EDEMA RESOLUTION?	NEUROSCIENCE			English	Article						edema; astrocyte; aquaporin; juvenile traumatic brain injury	ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; AQP4 EXPRESSION; WATER CHANNELS; HEAD-INJURY; RAT-BRAIN; MICE; MODEL; PAIN; CHILDREN	Traumatic brain injury (TBI) is one of the leading causes of death and disability in children and adolescents. The neuropathological sequelae that result from TBI are a complex cascade of events including edema formation, which occurs more frequently in the pediatric than the adult population. This developmental difference in the response to injury may be related to higher water content in the young brain and also to molecular mechanisms regulating water homeostasis. Aquaporins (AQPs) provide a unique opportunity to examine the mechanisms underlying water mobility, which remain poorly understood in the juvenile post-traumatic edema process. We examined the spatiotemporal expression pattern of principal brain AQPs (AQP1, AQP4, and AQP9) after juvenile TBI (jTBI) related to edema formation and resolution observed using magnetic resonance imaging (MRI). Using a controlled cortical impact in postnatal 17 day-old rats as a model of jTBI, neuroimaging analysis showed a global decrease in water mobility (apparent diffusion coefficient, ADC) and an increase in edema (T2-values) at 1 day post-injury, which normalized by 3 days. Immunohistochemical analysis of AQP4 in perivascular astrocyte endfeet was increased in the lesion at 3 and 7 days postinjury as edema resolved. In contrast, AQP1 levels distant from the injury site were increased at 7, 30, and 60 days within septal neurons but did not correlate with changes in edema formation. Group differences were not observed AQP9. Overall, our observations confirm that astrocyticAQP4 plays a more central role than AQP1 or AQP9 during the edema process in the young brain. (C) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Badaut, J.] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; [Fukuda, A. M.; Badaut, J.] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Spagnoli, D.; Obenaus, A.] Loma Linda Univ, Dept Radiat Med, Loma Linda, CA 92354 USA; [Spagnoli, D.; Obenaus, A.] Loma Linda Univ, Dept Biophys & Engn, Loma Linda, CA 92354 USA; [Obenaus, A.] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA		Badaut, J (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Coleman Pavil,Room A1120,11175 Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu		Fukuda, Andrew/0000-0002-7927-6602	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01HD061946]; Loma Linda University Dept. of Pediatrics Research Fund; Swiss Science FoundationSwiss National Science Foundation (SNSF) [FN 31003A-122166, IZKOZ3-128973]; National Medical Test Bed; NASANational Aeronautics & Space Administration (NASA) [NCC9-149]; Department of Radiation Medicine at Loma Linda University; National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure [0923559]; Loma Linda University School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	The authors thank Beatrice Ternon for her help for part of the histology and tissue analysis and Arash Adami and David Ajao for TBI induction. This work was supported in part by NINDS Grant R01HD061946 (J.B.), the Loma Linda University Dept. of Pediatrics Research Fund, the Swiss Science Foundation (FN 31003A-122166 and IZKOZ3-128973, J.B.), National Medical Test Bed (A.O.) and a NASA Cooperative Agreement NCC9-149 to the Radiobiology Program, Department of Radiation Medicine at Loma Linda University. A portion of this material was performed in the Loma Linda University School of Medicine Advanced Imaging and Microscopy Core that is supported by the National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure Grant No. 0923559 (Sean M. Wilson) and the Loma Linda University School of Medicine.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Adelson PD, 1998, ACT NEUR S, V71, P250; Ajao D, 2012, J NEUROTRAUMA; Auguste KI, 2007, FASEB J, V21, P108, DOI 10.1096/fj.06-6848com; Badaut J, 2004, NEUROSCIENCE, V128, P27, DOI 10.1016/j.neuroscience.2004.05.042; Badaut J, 2011, CEREBROVASC DIS, V31, P521, DOI 10.1159/000324328; Badaut J, 2010, NEUROSCIENCE, V168, P1047, DOI 10.1016/j.neuroscience.2009.10.030; Badaut J, 2007, PEDIATR RES, V62, P248, DOI 10.1203/PDR.0b013e3180db291b; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bertolizio G, 2011, PEDIATR ANESTH, V21, P1198, DOI 10.1111/j.1460-9592.2011.03695.x; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Borsani E, 2010, CURR NEUROPHARMACOL, V8, P122, DOI 10.2174/157015910791233187; Borsook D, 2012, BRAIN, V135, P320, DOI 10.1093/brain/awr271; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Dibaj P, 2007, J NEUROCHEM, V103, P2620, DOI 10.1111/j.1471-4159.2007.04979.x; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; DOBBING J, 1981, EARLY HUM DEV, V5, P227, DOI 10.1016/0378-3782(81)90030-X; Faul M, 2010, TRAUMATIC BRAIN INJU; Fenton RA, 2010, CELL MOL LIFE SCI, V67, P829, DOI 10.1007/s00018-009-0218-9; GALLAGHER JP, 1995, PROG NEUROBIOL, V45, P373, DOI 10.1016/0301-0082(95)98600-A; Gomori E, 2006, INT J DEV NEUROSCI, V24, P295, DOI 10.1016/j.ijdevneu.2006.05.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Hsu MS, 2011, NEUROSCIENCE, V178, P21, DOI 10.1016/j.neuroscience.2011.01.020; Igarashi H, 2011, NEUROL SCI, V32, P113, DOI 10.1007/s10072-010-0431-1; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lee DJ, 2012, EPILEPSY RES, V98, P264, DOI 10.1016/j.eplepsyres.2011.09.016; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Meng SZ, 2004, EUR J NEUROSCI, V19, P2261, DOI 10.1111/j.0953-816X.2004.03315.x; Moftakhar P, 2010, J NEUROPATH EXP NEUR, V69, P1201, DOI 10.1097/NEN.0b013e3181fd252c; Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nesic O, 2008, J NEUROCHEM, V105, P628, DOI 10.1111/j.1471-4159.2007.05177.x; Nesic O, 2010, NEUROSCIENCE, V168, P1019, DOI 10.1016/j.neuroscience.2010.01.037; Nicchia GP, 2005, FASEB J, V19, P1674, DOI 10.1096/fj.04-3281fje; Obenaus A, 2008, NEUROPHARMACOLOGY, V55, P271, DOI 10.1016/j.neuropharm.2008.06.010; Oliva AA, 2011, NEUROSCIENCE, V180, P272, DOI 10.1016/j.neuroscience.2011.02.020; Oshio K, 2006, BIOCHEM BIOPH RES CO, V341, P1022, DOI 10.1016/j.bbrc.2006.01.062; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Singewald GM, 2011, NEUROPSYCHOPHARMACOL, V36, P793, DOI 10.1038/npp.2010.213; Skucas VA, 2011, J NEUROSCI, V31, P6392, DOI 10.1523/JNEUROSCI.6249-10.2011; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tait MJ, 2010, NEUROSCIENCE, V167, P60, DOI 10.1016/j.neuroscience.2010.01.053; Tomura S, 2011, J NEUROTRAUM, V28, P237, DOI 10.1089/neu.2010.1443; Tourdias T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-143; Tourdias T, 2009, NEUROIMAGE, V47, P659, DOI 10.1016/j.neuroimage.2009.04.070; Tran ND, 2010, J NEUROSURG, V112, P1095, DOI 10.3171/2009.8.JNS081704; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Wilcock DM, 2009, NEUROSCIENCE, V159, P1055, DOI 10.1016/j.neuroscience.2009.01.023; Yang J, 2011, J ALZHEIMERS DIS, V27, P711, DOI 10.3233/JAD-2011-110725; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zheng GQ, 2010, NEUROCHEM INT, V56, P651, DOI 10.1016/j.neuint.2010.01.014	64	68	72	1	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	OCT 11	2012	222						366	378		10.1016/j.neuroscience.2012.06.033			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	010HM	WOS:000309085500033	22728101	Green Accepted			2022-02-06	
J	Hayashida, K; Sano, M; Kamimura, N; Yokota, T; Suzuki, M; Maekawa, Y; Kawamura, A; Abe, T; Ohta, S; Fukuda, K; Hori, S				Hayashida, Kei; Sano, Motoaki; Kamimura, Naomi; Yokota, Takashi; Suzuki, Masaru; Maekawa, Yuichiro; Kawamura, Akio; Abe, Takayuki; Ohta, Shigeo; Fukuda, Keiichi; Hori, Shingo			H-2 Gas Improves Functional Outcome After Cardiac Arrest to an Extent Comparable to Therapeutic Hypothermia in a Rat Model	JOURNAL OF THE AMERICAN HEART ASSOCIATION			English	Article						cardiac arrest; cardiopulmonary resuscitation; hydrogen gas; therapeutic hypothermia; ventricular fibrillation	HYDROGEN-RICH WATER; AMERICAN-HEART-ASSOCIATION; TRAUMATIC BRAIN-INJURY; MOLECULAR-HYDROGEN; CARDIOPULMONARY-RESUSCITATION; OXIDATIVE STRESS; MODERATE HYPOTHERMIA; ANTIOXIDANT; MITOCHONDRIAL; METABOLISM	Background-All clinical and biological manifestations related to postcardiac arrest (CA) syndrome are attributed to ischemia-reperfusion injury in various organs including brain and heart. Molecular hydrogen (H-2) has potential as a novel antioxidant. This study tested the hypothesis that inhalation of H-2 gas starting at the beginning of cardiopulmonary resuscitation (CPR) could improve the outcome of CA. Methods and Results-Ventricular fibrillation was induced by transcutaneous electrical epicardial stimulation in rats. After 5 minutes of the subsequent CA, rats were randomly assigned to 1 of 4 experimental groups at the beginning of CPR: mechanical ventilation (MV) with 2% N-2 and 98% O-2 under normothermia (37 degrees C), the control group; MV with 2% H-2 and 98% O-2 under normothermia; MV with 2% N-2 and 98% O-2 under therapeutic hypothermia (TH), 33 degrees C; and MV with 2% H-2 and 98% O-2 under TH. Mixed gas inhalation and TH continued until 2 hours after the return of spontaneous circulation (ROSC). H-2 gas inhalation yielded better improvement in survival and neurological deficit score (NDS) after ROSC to an extent comparable to TH. H-2 gas inhalation, but not TH, prevented a rise in left ventricular end-diastolic pressure and increase in serum IL-6 level after ROSC. The salutary impact of H-2 gas was at least partially attributed to the radical-scavenging effects of H-2 gas, because both 8-OHdG- and 4-HNE-positive cardiomyocytes were markedly suppressed by H-2 gas inhalation after ROSC. Conclusions-Inhalation of H-2 gas is a favorable strategy to mitigate mortality and functional outcome of post-CA syndrome in a rat model, either alone or in combination with TH.	[Hayashida, Kei; Suzuki, Masaru; Hori, Shingo] Keio Univ, Sch Med, Dept Emergency & Crit Care Med, Tokyo, Japan; [Sano, Motoaki; Maekawa, Yuichiro; Kawamura, Akio; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan; [Abe, Takayuki] Keio Univ, Sch Med, Clin Res Ctr, Tokyo, Japan; [Kamimura, Naomi; Yokota, Takashi; Ohta, Shigeo] Nippon Med Sch, Grad Sch Med, Inst Dev & Aging Sci, Dept Biochem & Cell Biol, Kanagawa, Japan		Sano, M (corresponding author), 35 Shinanomachi, Tokyo 1608582, Japan.	msano@a8.keio.jp	Fukuda, Keiichi/L-3777-2013; Sano, Motoaki/L-3405-2013		KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI); Marumo Research Foundation of the Japanese Society of Acute Medicine; Research Foundation of the General Insurance Association of Japan; Graduate School Doctoral Student Aid Program, Keio University	This work was supported by a Grant-in-Aid for Scientific Research (KAKENHI; to S. H.), the Marumo Research Foundation of the Japanese Society of Acute Medicine (to K. H.), the Research Foundation of the General Insurance Association of Japan (to K. H.), and Graduate School Doctoral Student Aid Program, Keio University (to K.H.).	Abella BS, 2004, CIRCULATION, V109, P2786, DOI 10.1161/01.CIR.0000131940.19833.85; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Aoki K, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-12; Buchholz BM, 2008, AM J TRANSPLANT, V8, P2015, DOI 10.1111/j.1600-6143.2008.02359.x; Callaway CW, 2008, CRIT CARE MED, V36, P2607, DOI 10.1097/CCM.0b013e318184443b; CARDEN DL, 1987, ANN EMERG MED, V16, P1317, DOI 10.1016/S0196-0644(87)80408-0; Che DF, 2011, CRIT CARE MED, V39, P1423, DOI 10.1097/CCM.0b013e318212020a; Chen CW, 2010, NEUROCHEM RES, V35, P1111, DOI 10.1007/s11064-010-0162-y; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Fujita K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007247; Hayashida K, 2008, BIOCHEM BIOPH RES CO, V373, P30, DOI 10.1016/j.bbrc.2008.05.165; Hickey RW, 2000, CRIT CARE MED, V28, P3511, DOI 10.1097/00003246-200010000-00027; Ito M, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-24; Kajiyama S, 2008, NUTR RES, V28, P137, DOI 10.1016/j.nutres.2008.01.008; Kamimura N, 2011, OBESITY, V19, P1396, DOI 10.1038/oby.2011.6; Kang KM, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-11; Kimura A, 2002, CRIT CARE MED, V30, P1499, DOI 10.1097/00003246-200207000-00017; Li J, 2010, BRAIN RES, V1328, P152, DOI 10.1016/j.brainres.2010.02.046; Lin JY, 2010, RESUSCITATION, V81, P1197, DOI 10.1016/j.resuscitation.2010.05.019; Liu Q, 2010, LIVER INT, V30, P958, DOI 10.1111/j.1478-3231.2010.02254.x; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Merchant RM, 2006, CRIT CARE MED, V34, P1935, DOI 10.1097/01.CCM.0000220494.90290.92; Nakao A, 2010, J CLIN BIOCHEM NUTR, V46, P140, DOI 10.3164/jcbn.09-100; Nakayama M, 2010, NEPHROL DIAL TRANSPL, V25, P3026, DOI 10.1093/ndt/gfq196; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; NEUMAR RW, 1995, RESUSCITATION, V29, P249, DOI 10.1016/0300-9572(94)00827-3; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Ohta S, 2012, BBA-GEN SUBJECTS, V1820, P586, DOI 10.1016/j.bbagen.2011.05.006; Ohta S, 2011, CURR PHARM DESIGN, V17, P2241, DOI 10.2174/138161211797052664; Ono H, 2012, MED GAS RES, V2, DOI 10.1186/2045-9912-2-14; Ono H, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-12; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Schneider A, 2012, RESUSCITATION, V83, P232, DOI 10.1016/j.resuscitation.2011.07.023; Shimouchi A, 2012, ADV EXP MED BIOL, V737, P245, DOI 10.1007/978-1-4614-1566-4_36; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; VONPLANTA I, 1988, J APPL PHYSIOL, V65, P2641, DOI 10.1152/jappl.1988.65.6.2641; Walters JH, 2011, RESUSCITATION, V82, P508, DOI 10.1016/j.resuscitation.2011.01.021; Xie KL, 2010, SHOCK, V34, P495, DOI 10.1097/SHK.0b013e3181def9aa; Xie KL, 2010, SHOCK, V34, P90, DOI 10.1097/SHK.0b013e3181cdc4ae; Ye S, 2012, CIRCULATION, V125, P123, DOI 10.1161/CIRCULATIONAHA.111.062257	41	68	74	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2047-9980			J AM HEART ASSOC	J. Am. Heart Assoc.	OCT	2012	1	5							e003459	10.1161/JAHA.112.003459			13	Cardiac & Cardiovascular Systems	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	243RU	WOS:000326335500012	23316300	gold, Green Published			2022-02-06	
J	Zhao, ZR; Loane, DJ; Murray, MG; Stoica, BA; Faden, AI				Zhao, Zaorui; Loane, David J.; Murray, Michael G., II; Stoica, Bogdan A.; Faden, Alan I.			Comparing the Predictive Value of Multiple Cognitive, Affective, and Motor Tasks after Rodent Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; composite score; controlled cortical impact; correlation; traumatic brain injury	CONTROLLED CORTICAL IMPACT; RECOGNITION MEMORY; SEARCH STRATEGIES; SPATIAL MEMORY; HEAD-INJURY; RATS; RECOVERY; DEFICITS; MODEL; IMPAIRMENT	Controlled cortical impact injury (CCI) is a widely-used, clinically-relevant model of traumatic brain injury (TBI). Although functional outcomes have been used for years in this model, little work has been done to compare the predictive value of various cognitive and sensorimotor assessment tests, singly or in combination. Such information would be particularly useful for assessing mechanisms of injury or therapeutic interventions. Following isoflurane anesthesia, C57BL/6 mice were subjected to sham, mild (5.0 m/sec), moderate (6.0 m/sec), or severe (7.5 m/sec) CCI. A battery of behavioral tests were evaluated and compared, including the standard Morris water maze (sMWM), reversal Morris water maze (rMWM), novel object recognition (NOR), passive avoidance (PA), tail-suspension (TS), beam walk (BW), and open-field locomotor activity. The BW task, performed at post-injury days (PID) 0, 1, 3, 7, 14, 21, and 28, showed good discrimination as a function of injury severity. The sMWM and rMWM tests (PID 14-23), as well as NOR (PID 24 and 25), effectively discriminated spatial and novel object learning and memory across injury severity levels. Notably, the rMWM showed the greatest separation between mild and moderate/severe injury. PA (PID 27 and 28) and TS (PID 24) also reflected differences across injury levels, but to a lesser degree. We also compared individual functional measures with histological outcomes such as lesion volume and neuronal cell loss across anatomical regions. In addition, we created a novel composite behavioral score index from individual complementary behavioral scores, and it provided superior discrimination across injury severities compared to individual tests. In summary, this study demonstrates the feasibility of using a larger number of complementary functional outcome behavioral tests than those traditionally employed to follow post-traumatic recovery after TBI, and suggests that the composite score may be a helpful tool for screening new neuroprotective agents or for addressing injury mechanisms.	[Zhao, Zaorui] Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Hlth Sci Facil HSFI 1, Baltimore, MD 21201 USA; Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA		Zhao, ZR (corresponding author), Univ Maryland, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Hlth Sci Facil HSFI 1, 685 W Baltimore St,Room 263, Baltimore, MD 21201 USA.	zzhao@anes.umm.edu	Loane, David/ABD-5177-2021; STOICA, BOGDAN/H-9782-2013	Loane, David/0000-0003-0393-3503; STOICA, BOGDAN/0000-0002-2501-6434	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 (NS052568), R01 (NS061839)]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839, R01NS052568] Funding Source: NIH RePORTER	We thank Rainier Cabatbat for expert technical support and Dr. Shruti Kabadi and Dr. Ming Tan for helpful discussion. This work was supported by NIH grants R01 (NS052568) and R01 (NS061839) to A.I.F.	BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Best P. J., 1979, PHYSIOL BEHAV, V10, P193; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; BOUTON ME, 1993, PSYCHOL BULL, V114, P80, DOI 10.1037/0033-2909.114.1.80; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Clark RE, 2000, J NEUROSCI, V20, P8853; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; Duffy S, 2008, NEUROPSYCHOPHARMACOL, V33, P1004, DOI 10.1038/sj.npp.1301486; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; Gresack JE, 2007, NEUROBIOL LEARN MEM, V88, P393, DOI 10.1016/j.nlm.2007.07.015; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Janus C, 2004, LEARN MEMORY, V11, P337, DOI 10.1101/lm.70104; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Labrie V, 2009, LEARN MEMORY, V16, P28, DOI 10.1101/lm.1112209; Lattal KM, 2001, J NEUROSCI, V21, P5773, DOI 10.1523/JNEUROSCI.21-15-05773.2001; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MOSER E, 1993, J NEUROSCI, V13, P3916; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; O'Leary TP, 2011, BEHAV BRAIN RES, V216, P531, DOI 10.1016/j.bbr.2010.08.030; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; Pajoohesh-Ganji A, 2010, NEUROSCI RES, V67, P117, DOI 10.1016/j.neures.2010.02.009; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Rossato JI, 2006, LEARN MEMORY, V13, P431, DOI 10.1101/lm.315206; RUSSO NJ, 1976, PHYSIOL BEHAV, V16, P191, DOI 10.1016/0031-9384(76)90304-8; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; Varvel SA, 2005, PSYCHOPHARMACOLOGY, V179, P863, DOI 10.1007/s00213-004-2121-2; Wan HM, 1999, J NEUROSCI, V19, P1142; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whiting M. D., 2006, ANIMAL MODELS COGNIT; Xu J, 2009, J NEUROSCI, V29, P3676, DOI 10.1523/JNEUROSCI.5716-08.2009; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang HT, 2008, NEUROPSYCHOPHARMACOL, V33, P1611, DOI 10.1038/sj.npp.1301537; Zhao ZR, 2010, P NATL ACAD SCI USA, V107, P5605, DOI 10.1073/pnas.0910578107	74	68	70	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2012	29	15					2475	2489		10.1089/neu.2012.2511			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	022NY	WOS:000309967300005	22924665	Green Published			2022-02-06	
J	Bagley, AF; Daneshvar, DH; Schanker, BD; Zurakowski, D; d'Hemecourt, CA; Nowinski, CJ; Cantu, RC; Goulet, K				Bagley, Alexander F.; Daneshvar, Daniel H.; Schanker, Benjamin D.; Zurakowski, David; d'Hemecourt, Charles A.; Nowinski, Christopher J.; Cantu, Robert C.; Goulet, Kristian			Effectiveness of the SLICE Program for Youth Concussion Education	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion education; student-athletes; SLICE; concussion; injury prevention	CHRONIC TRAUMATIC ENCEPHALOPATHY; FOOTBALL-LEAGUE; HIGH-SCHOOL; ICE HOCKEY; INJURY; EPIDEMIOLOGY; ACHIEVEMENT; SPORTS; BRAIN	Objective: To analyze the effectiveness of the Sports Legacy Institute Community Educators (SLICE) curriculum for student-athletes on recognition and appropriate responses to concussions. Design: Prospective cohort study, level II. Setting: The SLICE concussion workshop. Participants: All students ranging from 9 to 18 years (n = 636) taking the SLICE concussion education program. Intervention: The SLICE concussion education program featuring interactive demonstrations, discussion, and case studies of athletes delivered by medical students and others in health-related fields. Main Outcome Measures: Evaluations assessing knowledge of concussion recognition and appropriate response were administered before and after participating in the SLICE concussion education program. Results: Students displayed significant improvements in absolute mean score on the concussion knowledge quiz between prepresentation and postpresentation (P < 0.0001). Significant improvements in mean score were observed among both male and female students within each age group. The proportion of students who passed the quiz increased from 34% prepresentation to 80% postpresentation (P < 0.0001). However, the percentage who passed the quiz postpresentation was significantly higher among female students compared with male students (P < 0.0001) and among students 13 years of age or older compared with students less than 13 years (P < 0.0001). Using multivariable logistic regression, we identified age group and gender as the most significant factors associated with passing the quiz postpresentation. Conclusion: The SLICE program promotes effective learning and knowledge about concussion recognition and response among students ranging from 9 to 18 years. Lessons from the SLICE program may be broadly applicable to youth concussion education.	[Bagley, Alexander F.] Harvard Univ, Sch Med, MD PhD Program, Cambridge, MA 02138 USA; [Bagley, Alexander F.; Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Boston, MA USA; [Daneshvar, Daniel H.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Daneshvar, Daniel H.; Nowinski, Christopher J.; Cantu, Robert C.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Schanker, Benjamin D.; Zurakowski, David] Harvard Univ, Biophys Program, Boston, MA 02115 USA; [Zurakowski, David; d'Hemecourt, Charles A.; Goulet, Kristian] Boston Childrens Hosp, Dept Orthoped Surg, Div Sports Med, Boston, MA USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Goulet, Kristian] ActiveCare Med Ctr, Eastern Ontario Concuss Clin, Kanata, ON, Canada		Bagley, AF (corresponding author), Harvard Univ, Sch Med, MD PhD Program, 550 Winthrop Mail Ctr, Cambridge, MA 02138 USA.	abagley@mit.edu		Daneshvar, Daniel/0000-0003-3691-9513	Boston Bruins Foundation	The Boston Bruins Foundation provided a grant to Sports Legacy Institute to support and expand SLICE chapters.	Anderson AJ, 2000, PEDIATRICS, V105, P657, DOI 10.1542/peds.105.3.640; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Centers for Disease Control, CDC FACT SHEET ATHL; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Dale E., 1946, AUDIO VISUAL METHODS, V1; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; KIMBALL MM, 1989, PSYCHOL BULL, V105, P198, DOI 10.1037/0033-2909.105.2.198; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Council of Youth Sports, NCYS REP TRENDS PART; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Stumpf H, 1998, CURR DIR PSYCHOL SCI, V7, P192, DOI 10.1111/1467-8721.ep10836927; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Zazryn T, 2007, SPORTS MED, V37, P467, DOI 10.2165/00007256-200737060-00001	24	68	68	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2012	22	5					385	389		10.1097/JSM.0b013e3182639bb4			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	004PU	WOS:000308694400002	22929042				2022-02-06	
J	Jin, G; deMoya, MA; Duggan, M; Knightly, T; Mejaddam, AY; Hwabejire, J; Lu, J; Smith, WM; Kasotakis, G; Velmahos, GC; Socrate, S; Alam, HB				Jin, Guang; deMoya, Marc A.; Duggan, Michael; Knightly, Thomas; Mejaddam, Ali Y.; Hwabejire, John; Lu, Jennifer; Smith, William Michael; Kasotakis, Georgios; Velmahos, George C.; Socrate, Simona; Alam, Hasan B.			TRAUMATIC BRAIN INJURY AND HEMORRHAGIC SHOCK: EVALUATION OF DIFFERENT RESUSCITATION STRATEGIES IN A LARGE ANIMAL MODEL OF COMBINED INSULTS	SHOCK			English	Article						Traumatic brain injury; hemorrhage; edema; swine; shock	FOCAL CEREBRAL-ISCHEMIA; FRESH-FROZEN PLASMA; HEAD-INJURY; FLUID RESUSCITATION; POLYTRAUMA; HEMODILUTION; COAGULATION; IMPACT; TISSUE; SWINE	Traumatic brain injury (TBI) and hemorrhagic shock (HS) are the leading causes of trauma-related mortality and morbidity. Combination of TBI and HS (TBI + HS) is highly lethal, and the optimal resuscitation strategy for this combined insult remains unclear. A critical limitation is the lack of suitable large animal models to test different treatment strategies. We have developed a clinically relevant large animal model of TBI + HS, which was used to evaluate the impact of different treatments on brain lesion size and associated edema. Yorkshire swine (42-50 kg) were instrumented to measure hemodynamic parameters and intracranial pressure. A computer-controlled cortical impact device was used to create a TBI through a 20-mm craniotomy: 15-mm cylindrical tip impactor at 4 m/s velocity, 100-ms dwell time, and 12-mm penetration depth. Volume-controlled hemorrhage was started (40% blood volume) concurrent with the TBI. After 2 h of shock, animals were randomized to one of three resuscitation groups (n = 5/group): (a) normal saline (NS); (b) 6% hetastarch, Hextend (Hex); and (c) fresh frozen plasma (FFP). Volumes of Hex and FFP matched the shed blood, whereas NS was three times the volume. After 6 h of postresuscitation monitoring, brains were sectioned into 5-mm slices and stained with TIC (2,3,5-triphenyltetrazolium chloride) to quantify the lesion size and brain swelling. Combination of 40% blood loss with cortical impact and a period of shock (2 h) resulted in a highly reproducible brain injury. Total fluid requirements were lower in the Hex and FFP groups. Lesion size and brain swelling in the FFP group (2,160 +/- 202.6 mm(3) and 22% +/- 1.0%, respectively) were significantly smaller than those in the NS group (3,285 +/- 130.8 mm(3) and 37% +/- 1.6%, respectively) (P < 0.05). Hex treatment decreased the swelling (29% +/- 1.6%) without reducing the lesion size. Early administration of FFP reduces the size of brain lesion and associated swelling in a large animal model of TBI + HS. In contrast, artificial colloid (Hex) decreases swelling without reducing the actual size of the brain lesion.	[Jin, Guang; deMoya, Marc A.; Duggan, Michael; Knightly, Thomas; Mejaddam, Ali Y.; Hwabejire, John; Lu, Jennifer; Smith, William Michael; Kasotakis, Georgios; Velmahos, George C.; Alam, Hasan B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA; [Socrate, Simona] MIT, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA		Alam, HB (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.	hbalam@partners.org		Kasotakis, George/0000-0002-7630-0742	US Army Medical Research Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; U.S. Army Research Office [W911NF-07-D-0004]	This study was funded by a pant from the US Army Medical Research Material Command GRANTT00521959 (to H.B.A.) and by the U.S. Army Research Office under contract number W911NF-07-D-0004 (to SS).	Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; Alam HB, 2009, J TRAUMA, V67, P856, DOI 10.1097/TA.0b013e3181b5ae75; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Baker AJ, 2008, J TRAUMA, V64, P348, DOI 10.1097/01.ta.0000245973.71929.db; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bilotta F, 2007, NEW ENGL J MED, V357, P2635; Bourguignon PR, 1998, ARCH SURG-CHICAGO, V133, P390, DOI 10.1001/archsurg.133.4.390; Brown LM, 2011, J TRAUMA, V71, pS358, DOI 10.1097/TA.0b013e318227f152; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Crookes BA, 2004, J TRAUMA, V57, P547, DOI 10.1097/01.TA.0000135162.85859.4C; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Earle SA, 2007, J AM COLL SURGEONS, V204, P261, DOI 10.1016/j.jamcollsurg.2006.11.014; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jin G, 2010, TRANSL STROKE RES, V1, P65, DOI 10.1007/s12975-009-0009-5; Jin G, 2009, EXP NEUROL, V217, P165, DOI 10.1016/j.expneurol.2009.02.004; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Myburgh J, 2007, NEW ENGL J MED, V357, P874; OHTAKI M, 1993, SURG NEUROL, V40, P196, DOI 10.1016/0090-3019(93)90068-C; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peiniger S, 2011, CRIT CARE, V15, DOI 10.1186/cc10048; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Sambasivan CN, 2009, AM J SURG, V197, P576, DOI 10.1016/j.amjsurg.2008.12.011; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Shuja F, 2008, J TRAUMA, V65, P975, DOI 10.1097/TA.0b013e3181801cd9; Takano K, 1997, STROKE, V28, P1255, DOI 10.1161/01.STR.28.6.1255; TU YK, 1988, J NEUROSURG, V69, P72, DOI 10.3171/jns.1988.69.1.0072; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	34	68	69	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUL	2012	38	1					49	56		10.1097/SHK.0b013e3182574778			8	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	961WV	WOS:000305501100009	22575994				2022-02-06	
J	Slobounov, S; Gay, M; Johnson, B; Zhang, K				Slobounov, Semyon; Gay, Michael; Johnson, Brian; Zhang, Kai			Concussion in athletics: ongoing clinical and brain imaging research controversies	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild TBI; Neuroimaging; Clinical outcome	MAGNETIC-RESONANCE-SPECTROSCOPY; COMPENSATORY CORTICAL ACTIVATION; WORKING-MEMORY DYSFUNCTION; SELF-REPORTED CONCUSSIONS; RESTING-STATE NETWORKS; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; WHITE-MATTER; FUNCTIONAL CONNECTIVITY; DEFAULT-MODE	Concussion, the most common form of traumatic brain injury, proves to be increasingly complex and not mild in nature as its synonymous term mild traumatic brain injury (mTBI) would imply. Despite the increasing occurrence and prevalence of mTBI there is no universally accepted definition and conventional brain imaging techniques lack the sensitivity to detect subtle changes it causes. Moreover, clinical management of sports induced mild traumatic brain injury has not changed much over the past decade. Advances in neuroimaging that include electroencephalography (EEG), functional magnetic resonance imaging (fMRI), resting-state functional connectivity, diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS) offer promise in aiding research into understanding the complexities and nuances of mTBI which may ultimately influence clinical management of the condition. In this paper the authors review the major findings from these advanced neuroimaging methods along with current controversy within this field of research. As mTBI is frequently associated with youth and sports injury this review focuses on sportsaEurorelated mTBI in the younger population.	[Slobounov, Semyon; Gay, Michael; Johnson, Brian; Zhang, Kai] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Slobounov, Semyon] NINDS, NIH, Bethesda, MD USA; [Slobounov, Semyon] Penn State Univ, Dept Orthopaed & Med Rehabil, HMC, University Pk, PA 16802 USA; [Johnson, Brian] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreation Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Zhang, Kai/F-3261-2015	Zhang, Kai/0000-0002-5460-6150			Alves W., 1989, MILD HEAD INJURY; ALVES WM, 1987, CLIN SPORT MED, V6, P211; Anderson T, 2006, PRACTICAL NEUROLOGY, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Arciniegas DB, 2011, INT J PSYCHOPHYSIOL, V82, P41, DOI 10.1016/j.ijpsycho.2011.03.004; Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Barwick F, 2012, CLIN NEUROPHYSIOL, V123, P278, DOI 10.1016/j.clinph.2011.06.027; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bigler E. D, 2012, BRAIN IMAGING BEHAV; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cao C, 2011, CLIN NEUROPHYSIOL, V122, P1314, DOI 10.1016/j.clinph.2010.12.042; CAoSMC C, 2000, CLIN J SPORT MED, V10, P209; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chang L, 2004, ANN NEUROL, V56, P259, DOI 10.1002/ana.20190; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chiaravalloti ND, 2005, J CLIN EXP NEUROPSYC, V27, P33, DOI 10.1080/138033990513609; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Courtney Susan M., 2004, Cognitive Affective & Behavioral Neuroscience, V4, P501, DOI 10.3758/CABN.4.4.501; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; FAAS FH, 1968, J NEUROSURG, V28, P137, DOI 10.3171/jns.1968.28.2.0137; Flamm E S, 1966, Surg Forum, V17, P414; Forn C, 2006, NEUROIMAGE, V31, P686, DOI 10.1016/j.neuroimage.2005.12.030; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Gardner A, 2010, ARCH CLIN NEUROPSYCH, V25, P174, DOI 10.1093/arclin/acq007; Gasparovic C., 2009, J NEUROTRAUM; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geets W, 1985, Rev Electroencephalogr Neurophysiol Clin, V14, P333; Giza CC, 2001, J ATHL TRAINING, V36, P228; Glaser MA, 1940, W SURG, V48, P6989; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Helgeson S. R, 2011, BRAIN INJURY PROFESS, V7; Henry L. C., 2011, J NEUROTRAUM; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P49, DOI 10.1076/jcen.25.1.49.13631; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horowitz AL, 1995, MRI PHYS RADIOLOGIST; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; Jaeggi SM, 2003, NEUROIMAGE, V19, P210, DOI 10.1016/S1053-8119(03)00098-3; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Jasper HH, 1940, ARCH NEURO PSYCHIATR, V44, P328, DOI 10.1001/archneurpsyc.1940.02280080088005; Johnson B, 2012, NEUROSCI LETT, V509, P5, DOI 10.1016/j.neulet.2011.11.013; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; JUEPTNER M, 1995, NEUROIMAGE, V2, P148, DOI 10.1006/nimg.1995.1017; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Landau SM, 2004, NEUROIMAGE, V22, P211, DOI 10.1016/j.neuroimage.2004.01.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; LOPESDASILVA F, 1991, ELECTROEN CLIN NEURO, V79, P81, DOI DOI 10.1016/0013-4694(91)90044-5; LUTZENBERGER W, 1987, J PSYCHOPHYSIOL, V1, P81; Mainero C, 2006, J NEUROL SCI, V245, P93, DOI 10.1016/j.jns.2005.08.024; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; Olejniczak P, 2006, J CLIN NEUROPHYSIOL, V23, P186, DOI 10.1097/01.wnp.0000220079.61973.6c; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pantano P, 2006, J NEUROIMAGING, V16, P104, DOI 10.1111/j.1552-6569.2006.00029.x; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Rypma B, 1999, P NATL ACAD SCI USA, V96, P6558, DOI 10.1073/pnas.96.11.6558; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Schwarz A, 2010, NY TIMES; Shah S, 2012, BRAIN INJURY, V26, P201, DOI 10.3109/02699052.2012.654591; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shekdar K, 2011, SEMIN ULTRASOUND CT, V32, P510, DOI 10.1053/j.sult.2011.08.001; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S., 2012, CLIN NEUROPHYSIOLOGY; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Slobounov S, 2011, IEEE ENG MED BIO, P1383, DOI 10.1109/IEMBS.2011.6090325; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Sporns O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001049; Stulemeijer M, 2010, J NEUROTRAUM, V27, P1585, DOI 10.1089/neu.2010.1298; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhu T, 2011, NEUROIMAGE, V56, P1398, DOI 10.1016/j.neuroimage.2011.02.010	170	68	68	1	50	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		224	243		10.1007/s11682-012-9167-2			20	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967LI	WOS:000305908900006	22669496				2022-02-06	
J	Griesbach, GS; Tio, DL; Vincelli, J; McArthur, DL; Taylor, AN				Griesbach, Grace S.; Tio, Delia L.; Vincelli, Jennifer; McArthur, David L.; Taylor, Anna N.			Differential Effects of Voluntary and Forced Exercise on Stress Responses after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adrenocorticotropic hormone; corticosterone; brain-derived neurotrophic factor; exercise; glucocorticoid receptors	LATERAL FLUID PERCUSSION; ADRENOCORTICAL AXIS; TEMPORAL WINDOW; MESSENGER-RNA; UP-REGULATION; MILD; CORTICOSTERONE; HIPPOCAMPUS; DYSFUNCTION; SEVERITY	Voluntary exercise increases levels of brain-derived neurotrophic factor (BDNF) after traumatic brain injury (TBI) when it occurs during a delayed time window. In contrast, acute post-TBI exercise does not increase BDNF. It is well known that increases in glucocorticoids suppress levels of BDNF. Moreover, recent work from our laboratory showed that there is a heightened stress response after fluid percussion injury (FPI). In order to determine if a heightened stress response is also observed with acute exercise, at post-injury days 0-4 and 7-11, corticosterone (CORT) and adrenocorticotropic hormone (ACTH) release were measured in rats running voluntarily or exposed to two daily 20-min periods of forced running wheel exercise. Forced, but not voluntary exercise, continuously elevated CORT. ACTH levels were initially elevated with forced exercise, but decreased by post-injury day 7 in the control, but not the FPI animals. As previously reported, voluntary exercise did not increase BDNF in the FPI group as it did in the control animals. Forced exercise did not increase levels of BDNF in any group. It did, however, decrease hippocampal glucocorticoid receptors in the control group. The results suggest that exercise regimens with strong stress responses may not be beneficial during the early post-injury period.	[Griesbach, Grace S.; Vincelli, Jennifer; McArthur, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Tio, Delia L.; Taylor, Anna N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA		Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957030, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS06190]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061960] Funding Source: NIH RePORTER	We thank David Garfinkel and Shyama Nair for their excellent technical assistance. This research was supported by NIH grant NS06190 to G. S. G., and the UCLA Brain Injury Research Center.	Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Dallman MF, 2004, ANN NY ACAD SCI, V1018, P141, DOI 10.1196/annals.1296.017; Droste SK, 2007, NEUROENDOCRINOLOGY, V86, P26, DOI 10.1159/000104770; ENGELAND WC, 1977, ENDOCRINOLOGY, V100, P138, DOI 10.1210/endo-100-1-138; Furay AR, 2008, ENDOCRINOLOGY, V149, P5482, DOI 10.1210/en.2008-0642; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Johnson KL, 2006, AACN ADV CRIT CARE, V17, P39, DOI 10.1097/00044067-200601000-00006; Kwon MS, 2006, NEUROSCIENCE, V142, P1281, DOI 10.1016/j.neuroscience.2006.07.027; Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Neigh GN, 2009, J CEREBR BLOOD F MET, V29, P1673, DOI 10.1038/jcbfm.2009.85; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; O'Callaghan RM, 2009, HIPPOCAMPUS, V19, P1019, DOI 10.1002/hipo.20591; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pinheiro J. C., 2000, MIXED EFFECTS MODELS; R Development Core Team, 2011, R LANG ENV STAT COMP; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x	40	68	70	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1426	1433		10.1089/neu.2011.2229			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600016	22233388	Green Published			2022-02-06	
J	Yeates, KO; Taylor, HG; Rusin, J; Bangert, B; Dietrich, A; Nuss, K; Wright, M				Yeates, Keith Owen; Taylor, H. Gerry; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn; Wright, Martha			Premorbid child and family functioning as predictors of post-concussive symptoms in children with mild traumatic brain injuries	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Post-concussive; Mild head injury; Children; Premorbid; Moderator	HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RELIABILITY; ADOLESCENTS; BEHAVIOR	Study aim: This study sought to determine whether premorbid child and family functioning accounts for or moderates group differences in post-concussive symptoms following mild traumatic brain injury (TBI) in childhood. Methods: This prospective, longitudinal cohort study recruited 8- to 15-year-old children, 186 with mild TBI and 99 with orthopedic injuries (OI), from consecutive emergency department admissions. Parents and children rated post-concussive symptoms within 3 weeks of injury and at 1, 3, and 12 months post injury. Parents also provided retrospective ratings of pre-injury symptoms, as well as of premorbid child behavioral adjustment, overall family functioning, and other stressors and resources in the family environment. Results: Children with mild TBI reported more post-concussive symptoms than those with OI, as did their parents, although premorbid child behavioral adjustment and symptoms also were significant predictors of post-concussive symptoms. Group differences in somatic symptoms as reported by parents were more pronounced among children from families that were higher functioning and had more environmental resources. Discussion: Mild TBI during childhood results in more post-concussive symptoms than OI, even after children's premorbid adjustment is taken into account. Counter to expectations, post-concussive symptoms following mild TBI may actually be more apparent among children from higher-functioning families with greater resources. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	[Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; [Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Wright, Martha] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH 43205 USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH 43205 USA		Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Yeates, Keith/AAJ-4223-2020	Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD44099, HD39834]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099, R01HD039834] Funding Source: NIH RePORTER	This work was supported by grants HD44099 and HD39834 from the National Institutes of Health to the first author.	ACHENBACH TM, 2001, MANUAL ASEBA SCHOOL; Alexander, 1997, Semin Clin Neuropsychiatry, V2, P177; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; Ashwal S., 2010, PEDIAT TRAUMATIC BRA, P68; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Faul M, 2010, TRAUMATIC BRAIN INJU; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Giza CC, 2001, J ATHL TRAINING, V36, P228; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; McKinlay A, 2010, INJURY PREV, V16, P31, DOI 10.1136/ip.2009.022483; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P3, DOI 10.1111/j.1365-2214.2009.01006.x; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moos RH, 1994, LIFE STRESSORS SOCIA; Moos RH, 1988, J SUBSTANCE ABUSE, V1, P135, DOI DOI 10.1016/S0899-3289(88)80017-8; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	48	68	68	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		231	237		10.1016/j.ijdevneu.2011.05.008			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800009	21651973	Green Accepted			2022-02-06	
J	Hinzman, JM; Thomas, TC; Quintero, JE; Gerhardt, GA; Lifshitz, J				Hinzman, Jason M.; Thomas, Theresa Currier; Quintero, Jorge E.; Gerhardt, Greg A.; Lifshitz, Jonathan			Disruptions in the Regulation of Extracellular Glutamate by Neurons and Glia in the Rat Striatum Two Days after Diffuse Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						LY 379268; DL-threo-beta-benzyloxyaspartate; omega-conotoxin; (S)-4-carboxyphenylglycine	EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION INJURY; CENTRAL-NERVOUS-SYSTEM; HUMAN HEAD-INJURY; RECEPTOR AGONIST; TRANSPORTER GLT-1; IN-VIVO; PREFRONTAL CORTEX; NEUROLOGICAL DISORDERS; MICRODIALYSIS PROBES	Disrupted regulation of extracellular glutamate in the central nervous system contributes to and can exacerbate the acute pathophysiology of traumatic brain injury (TBI). Previously, we reported increased extracellular glutamate in the striatum of anesthetized rats 2 days after diffuse brain injury. To determine the mechanism(s) responsible for increased extracellular glutamate, we used enzyme-based microelectrode arrays (MEAs) coupled with specific pharmacological agents targeted at in vivo neuronal and glial regulation of extracellular glutamate. After TBI, extracellular glutamate was significantly increased in the striatum by (similar to 90%) averaging 4.1 +/- 0.6 mu M compared with sham 2.2 +/- 0.4 mu M. Calcium-dependent neuronal glutamate release, investigated by local application of an N-type calcium channel blocker, was no longer a significant source of extracellular glutamate after TBI, compared with sham. In brain-injured animals, inhibition of glutamate uptake with local application of an excitatory amino acid transporter inhibitor produced significantly greater increase in glutamate spillover (similar to 65%) from the synapses compared with sham. Furthermore, glutamate clearance measured by locally applying glutamate into the extracellular space revealed significant reductions in glutamate clearance parameters in brain-injured animals compared with sham. Taken together, these data indicate that disruptions in calcium-mediated glutamate release and glial regulation of extracellular glutamate contribute to increased extracellular glutamate in the striatum 2 days after diffuse brain injury. Overall, these data suggest that therapeutic strategies used to regulate glutamate release and uptake may improve excitatory circuit function and, possibly, outcomes following TBI.	[Hinzman, Jason M.; Thomas, Theresa Currier; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Gerhardt, Greg A.] Univ Kentucky, Chandler Med Ctr, Morris K Udall Parkinsons Dis Res Ctr Excellence, Lexington, KY 40536 USA; [Hinzman, Jason M.; Quintero, Jorge E.; Gerhardt, Greg A.] Univ Kentucky, Chandler Med Ctr, Ctr Microelectrode Technol, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Dept Phys Med & Rehabil, Lexington, KY 40536 USA		Lifshitz, J (corresponding author), Univ Kentucky, Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, B463 Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	JLifshitz@uky.edu	Thomas, Theresa Currier/K-1979-2019	Thomas, Theresa Currier/0000-0002-9619-7666	USPHSUnited States Department of Health & Human ServicesUnited States Public Health Service [DA017186, NS3978, AG013494]; NSF (ERC)European Research Council (ERC)National Science Foundation (NSF) [EEC-0310723]; DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N6601-09-2080]; Kentucky Spinal Cord and Head Injury Research Trust [7-11];  [F31NS067899]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS067899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG013494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA017186] Funding Source: NIH RePORTER	The authors thank Francois Pomerleau and Peter Huettl for technical assistance on the glutamate recordings, and Amanda Bolton for assistance on the rtPCR. Support provided by F31NS067899, USPHS DA017186, USPHS NS3978, AG013494, NSF (ERC) EEC-0310723 DARPA N6601-09-2080, and Kentucky Spinal Cord and Head Injury Research Trust Grant 7-11.	Albrecht P, 2010, CNS NEUROL DISORD-DR, V9, P373, DOI 10.2174/187152710791292567; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Baker DA, 2002, J NEUROSCI, V22, P9134; Battaglia G, 1997, NEUROSCI LETT, V229, P161, DOI 10.1016/S0304-3940(97)00442-4; Bond A, 1999, NEUROSCI LETT, V273, P191, DOI 10.1016/S0304-3940(99)00663-1; Bond A, 2000, J PHARMACOL EXP THER, V294, P800; Borland LM, 2005, J NEUROSCI METH, V146, P149, DOI 10.1016/j.jneumeth.2005.02.002; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Burmeister JJ, 2002, J NEUROSCI METH, V119, P163, DOI 10.1016/S0165-0270(02)00172-3; Burmeister JJ, 2001, ANAL CHEM, V73, P1037, DOI 10.1021/ac0010429; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Carbonell WS, 1999, ANN NY ACAD SCI, V890, P287, DOI 10.1111/j.1749-6632.1999.tb08005.x; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Day BK, 2006, J NEUROCHEM, V96, P1626, DOI 10.1111/j.1471-4159.2006.03673.x; Diamond JS, 2005, J NEUROSCI, V25, P2906, DOI 10.1523/JNEUROSCI.5125-04.2005; DiIorio P, 1996, J NEUROCHEM, V67, P302; Domercq M, 2007, J IMMUNOL, V178, P6549, DOI 10.4049/jimmunol.178.10.6549; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRIEDEMANN MN, 1992, NEUROBIOL AGING, V13, P325, DOI 10.1016/0197-4580(92)90046-Z; GEMBA T, 1994, NEUROSCIENCE, V63, P789, DOI 10.1016/0306-4522(94)90523-1; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hamann M, 2002, EUR J NEUROSCI, V15, P308, DOI 10.1046/j.0953-816x.2001.01861.x; Harvey BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022135; Hascup ER, 2010, J NEUROCHEM, V115, P1608, DOI 10.1111/j.1471-4159.2010.07066.x; Hascup ER, 2009, BRAIN RES, V1291, P12, DOI 10.1016/j.brainres.2009.06.084; Hascup KN, 2007, ELECTROCHEMICAL METH; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; Jabaudon D, 1999, P NATL ACAD SCI USA, V96, P8733, DOI 10.1073/pnas.96.15.8733; Jaquins-Gerstl A, 2009, J NEUROSCI METH, V183, P127, DOI 10.1016/j.jneumeth.2009.06.023; Jensen JB, 2000, INT J DEV NEUROSCI, V18, P309, DOI 10.1016/S0736-5748(99)00099-4; Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Koura SS, 1998, ACT NEUR S, V71, P244; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lupinsky D, 2010, J NEUROSCI, V30, P7624, DOI 10.1523/JNEUROSCI.1187-10.2010; Matsushita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P207; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McIntosh TK, 1996, LAB INVEST, V74, P315; Melendez RI, 2005, J PHARMACOL EXP THER, V314, P139, DOI 10.1124/jpet.104.081521; Montiel T, 2005, NEUROSCIENCE, V133, P667, DOI 10.1016/j.neuroscience.2004.11.020; Movsesyan VA, 2006, J NEUROTRAUM, V23, P117, DOI 10.1089/neu.2006.23.117; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Neher E, 2008, NEURON, V59, P861, DOI 10.1016/j.neuron.2008.08.019; Nicholson C, 2000, PROG BRAIN RES, V125, P129; Nickell J, 2007, NEUROBIOL AGING, V28, P1737, DOI 10.1016/j.neurobiolaging.2006.07.015; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1999, ANN NY ACAD SCI, V890, P273, DOI 10.1111/j.1749-6632.1999.tb08004.x; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Phillis JW, 2000, BRAIN RES, V880, P224, DOI 10.1016/S0006-8993(00)02755-4; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Reinert M, 2000, Neurosurg Focus, V8, pe10; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Rutherford EC, 2007, J NEUROCHEM, V102, P712, DOI 10.1111/j.1471-4159.2007.04596.x; Ryglewski S, 2007, PLOS BIOL, V5, P818, DOI 10.1371/journal.pbio.0050066; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schoepp DD, 2001, J PHARMACOL EXP THER, V299, P12; Stephens ML, 2011, NEUROBIOL AGING, V32, P811, DOI 10.1016/j.neurobiolaging.2009.05.009; Stoffel M, 1997, ACT NEUR S, V70, P91; Stoffel M, 2002, J NEUROTRAUM, V19, P467, DOI 10.1089/08977150252932415; Stover JF, 2003, J NEUROTRAUM, V20, P315, DOI 10.1089/089771503765172273; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Thomas TC, 2012, J NEUROTRAUM, V29, P187, DOI 10.1089/neu.2011.2091; Thomas TC, 2009, NEUROPSYCHOPHARMACOL, V34, P436, DOI 10.1038/npp.2008.74; Timmerman W, 1997, SYNAPSE, V27, P242, DOI 10.1002/(SICI)1098-2396(199711)27:3<242::AID-SYN9>3.0.CO;2-D; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tovar Y.R. L.B., 2009, NEUROCHEM INT, V54, P186; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099	88	68	71	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1197	1208		10.1089/neu.2011.2261			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100020	22233432	Green Published			2022-02-06	
J	Masliah, E; Diez-Tejedor, E				Masliah, E.; Diez-Tejedor, E.			THE PHARMACOLOGY OF NEUROTROPHIC TREATMENT WITH CEREBROLYSIN: BRAIN PROTECTION AND REPAIR TO COUNTERACT PATHOLOGIES OF ACUTE AND CHRONIC NEUROLOGICAL DISORDERS	DRUGS OF TODAY			English	Article							PEPTIDERGIC DRUG CEREBROLYSIN; MODERATE FOREBRAIN ISCHEMIA; FIBROBLAST-GROWTH-FACTOR; TRANSGENIC MODEL; ALZHEIMERS-DISEASE; CELL-DEATH; FIMBRIA-FORNIX; SPATIAL MEMORY; SHORT-TERM; NEUROGENESIS	Neurotrophic factors are considered as part of the therapeutic strategy for neurological disorders like dementia, stroke and traumatic brain injury. Cerebrolysin is a neuropeptide preparation which mimics the action of endogenous neurotrophic factors on brain protection and repair In dementia models, Cerebrolysin decreases beta-amyloid deposition and microtubule-associated protein tau phosphorylation by regulating glycogen synthase kinase-3 beta thus supporting the brain's self-repair after stroke. Both, traumatic brain and spinal cord injury conditions stimulate the expression of natural neurotrophic factors to promote repair and regeneration processes-axonal regeneration, neuronal plasticity and neurogenesis-that is considered to be crucial for the future recovery. Neuroprotective effects of Cerebrolysin on experimentally induced traumatic spinal cord injury have shown that Cerebrolysin prevents apoptosis of lesioned motoneurons and promotes functional recovery. This section summarizes the most relevant data on the pharmacology of Cerebrolysin obtained from in vitro assays (biochemical and cell cultures) and in vivo animal models of acute and chronic neurological disorders.	[Masliah, E.] Univ Calif La Jolla, Dept Neurosci, La Jolla, CA 92093 USA; [Diez-Tejedor, E.] Univ Autonoma Madrid, La Paz Univ Hosp, Dept Neurol, Health Res Inst,IdiPAZ,Neurosci Res Lab, Madrid, Spain; [Diez-Tejedor, E.] Univ Autonoma Madrid, La Paz Univ Hosp, Stroke Ctr, Health Res Inst,IdiPAZ,Neurosci Res Lab, Madrid, Spain		Masliah, E (corresponding author), Univ Calif La Jolla, Neurosci & Pathol Dept, 9500 Gilman Dr, La Jolla, CA 92093 USA.	emasliah@ucsd.edu			EVER Neuro Pharma	The production of this supplement of Drugs of Today was sponsored by EVER Neuro Pharma, the manufacturer of Cerebrolysin. The authors have not received any payments for the writing of this article.	Abdelaziz O., 2007, PAN ARAB J NEUROSURG, V11, P51; AKAI F, 1992, HISTOL HISTOPATHOL, V7, P213; Allegri RF, 2012, DRUG TODAY, V48, P25, DOI 10.1358/dot.2012.48(Suppl.A).1739721; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P281; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; Bornstein N, 2012, DRUG TODAY, V48, P43, DOI 10.1358/dot.2012.48(Suppl.A).1739723; Bowes M., 2000, NEUROLOGYREVIEWS, V8; Chen HH, 2007, NEUROBIOL AGING, V28, P1148, DOI 10.1016/j.neurobiolaging.2006.05.036; Conte V., 2003, EUR J TRAUMA, V7, P335; CUMMINGS BJ, 1993, EXP NEUROL, V124, P315, DOI 10.1006/exnr.1993.1202; Dong H, 2004, NEUROSCIENCE, V127, P601, DOI 10.1016/j.neuroscience.2004.05.040; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; EVER Neuro Pharma GmbH, 2009, SUMM PROD CHAR; FrancisTurner L, 1996, NEUROSCI LETT, V202, P193, DOI 10.1016/0304-3940(95)12240-0; GOLD PE, 1986, BEHAV NEURAL BIOL, V46, P87, DOI 10.1016/S0163-1047(86)90927-1; Gonzalez ME, 1998, J NEURAL TRANSM-SUPP, P333; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gschanes A, 1998, J NEURAL TRANSM-SUPP, P313; Gschanes A, 1999, BEHAV BRAIN RES, V100, P161, DOI 10.1016/S0166-4328(98)00127-2; Gutmann B, 2002, NEUROTOX RES, V4, P59, DOI 10.1080/10298420290007637; Haninec P, 2004, EXP BRAIN RES, V159, P425, DOI 10.1007/s00221-004-1969-z; Haninec P, 2003, ANN ANAT, V185, P233, DOI 10.1016/S0940-9602(03)80030-4; Hanson LR, 2009, AM J NEUROPROTEC NEU, V1, P60, DOI DOI 10.1166/AJNN.2009.1010; Hartbauer M, 2001, J NEURAL TRANSM, V108, P459, DOI 10.1007/s007020170067; Hutter-Paier B, 1998, J NEURAL TRANSM-SUPP, P363; Hutter-Paier B, 1998, J NEURAL TRANSM-SUPP, P351; HutterPaier B, 1996, ARZNEIMITTELFORSCH, V46, P237; Lombardi VRM, 1999, METHOD FIND EXP CLIN, V21, P331, DOI 10.1358/mf.1999.21.5.541910; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mallory M, 1999, ACTA NEUROPATHOL, V97, P437, DOI 10.1007/s004010051012; Mamounas LA, 2000, J NEUROSCI, V20, P771, DOI 10.1523/JNEUROSCI.20-02-00771.2000; Masliah E, 2000, J NEURAL TRANSM-SUPP, P175; Masliah E, 1999, PHARMACOL BIOCHEM BE, V62, P239, DOI 10.1016/S0091-3057(98)00144-0; Masliah E., 1997, CONNECTIONS COGNITIO, P121; Mattson MP, 2000, BRAIN PATHOL, V10, P300, DOI 10.1111/j.1750-3639.2000.tb00264.x; Merino J.J., 2009, CEPHALALGIA S, V29, P60; Reinprecht I, 1999, HISTOCHEM J, V31, P394; Ren J, 2007, RESTOR NEUROL NEUROS, V25, P25; Revesz T, 2002, BRAIN PATHOL, V12, P343; Riley C, 2006, J NEURAL TRANSM, V113, P103, DOI 10.1007/s00702-005-0302-8; Rockenstein E, 2005, J NEURAL TRANSM, V112, P269, DOI 10.1007/s00702-004-0181-4; Rockenstein E, 2003, J NEURAL TRANSM, V110, P1313, DOI 10.1007/s00702-003-0025-7; Rockenstein E, 2002, J NEURAL TRANSM-SUPP, P327; Rockenstein E, 2007, ACTA NEUROPATHOL, V113, P265, DOI 10.1007/s00401-006-0166-5; Rockenstein E, 2006, J NEUROSCI RES, V83, P1252, DOI 10.1002/jnr.20818; Rockenstein E, 2011, J NEUROSCI RES, V89, P1812, DOI 10.1002/jnr.22712; Sacchetti B, 2001, NEUROBIOL LEARN MEM, V76, P1, DOI 10.1006/nlme.2001.4014; Satou T, 2000, J NEURAL TRANSM, V107, P1253, DOI 10.1007/s007020070015; Schauer E, 2006, J NEURAL TRANSM, V113, P855, DOI 10.1007/s00702-005-0384-3; Schwab M, 1996, J NEURAL TRANSM-SUPP, P279; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; Schwab M, 1997, EXP TOXICOL PATHOL, V49, P29; Schwab M, 1997, EXP TOXICOL PATHOL, V49, P105; STOPA EG, 1990, BIOCHEM BIOPH RES CO, V171, P690, DOI 10.1016/0006-291X(90)91201-3; Sugita Y, 1993, No To Shinkei, V45, P325; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Thome J, 2012, DRUG TODAY, V48, P63, DOI 10.1358/dot.2012.48(Suppl.A).1739724; Ubhi K, 2009, ACTA NEUROPATHOL, V117, P699, DOI 10.1007/s00401-009-0505-4; Valouskova V, 1999, NEUROBIOL LEARN MEM, V71, P132, DOI 10.1006/nlme.1998.3877; Valouskova V, 1998, J NEURAL TRANSM-SUPP, P343; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; VANTINI G, 1992, PSYCHONEUROENDOCRINO, V17, P401, DOI 10.1016/0306-4530(92)90045-9; Veinbergs I, 2000, J NEURAL TRANSM-SUPP, P273; WALLACE JE, 1980, J GERONTOL, V35, P355, DOI 10.1093/geronj/35.3.355; Wen Y, 2007, BBA-MOL BASIS DIS, V1772, P473, DOI 10.1016/j.bbadis.2006.10.011; Windholz E, 2000, HISTOCHEM J, V32, P79, DOI 10.1023/A:1004053809591; Wolf H.J., 2001, 5 INT C PROG ALZH PA; Wronski R, 2000, J NEURAL TRANSM, V107, P145, DOI 10.1007/s007020050013; Yuen EC, 1996, BRAIN DEV-JPN, V18, P362, DOI 10.1016/0387-7604(96)00051-4; Zhang CL, 2010, J NEUROSCI RES, V88, P3275, DOI 10.1002/jnr.22495	70	68	78	0	23	PROUS SCIENCE, SAU-THOMSON REUTERS	BARCELONA	398 PROVENCA, 08025 BARCELONA, SPAIN	1699-3993	1699-4019		DRUG TODAY	Drugs Today	APR	2012	48			A			3	24		10.1358/dot.2012.48(Suppl.A).1739716			22	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	959GW	WOS:000305301900002	22514792				2022-02-06	
J	Blume, HK; Vavilala, MS; Jaffe, KM; Koepsell, TD; Wang, J; Temkin, N; Durbin, D; Dorsch, A; Rivara, FP				Blume, Heidi K.; Vavilala, Monica S.; Jaffe, Kenneth M.; Koepsell, Thomas D.; Wang, Jin; Temkin, Nancy; Durbin, Dennis; Dorsch, Andrea; Rivara, Frederick P.			Headache After Pediatric Traumatic Brain Injury: A Cohort Study	PEDIATRICS			English	Article						traumatic brain injury; headache; child; epidemiology; posttraumatic headache; adolescents	SEX-DIFFERENCES; POSTTRAUMATIC HEADACHE; HIGH-SCHOOL; POSTCONCUSSIVE SYMPTOMS; UNITED-STATES; CONCUSSION; PREVALENCE; RECOVERY; MIGRAINE; CHILDREN	OBJECTIVE: To determine the prevalence of headache 3 and 12 months after pediatric traumatic brain injury (TBI). METHODS: This is a prospective cohort study of children ages 5 to 17 years in which we analyzed the prevalence of headache 3 and 12 months after mild TBI (mTBI; n = 402) and moderate/severe TBI (n = 60) compared with controls with arm injury (AI; n = 122). RESULTS: The prevalence of headache 3 months after injury was significantly higher after mTBI than after AI overall (43% vs 26%, relative risk [RR]: 1.7 [95% confidence interval (CI): 1.2-2.3]), in adolescents (13-17 years; 46% vs 25%, RR: 1.8 [95% CI: 1.1-3.1]), and in girls (59% vs 24%, RR: 2.4 [95% CI: 1.4-4.2]). The prevalence of headache at 3 months was also higher after moderate/severe TBI than AI in younger children (5-12 years; 60% vs 27%; RR: 2.0 [95% CI: 1.2-3.4]). Twelve months after injury, TBI was not associated with a significantly increased frequency of headache. However, girls with mTBI reported serious headache (>= 5 of 10 pain scale rating) more often than controls (27% vs 10%, RR: 2.2 [95% CI: 0.9-5.6]). CONCLUSIONS: Pediatric TBI is associated with headache. A substantial number of children suffer from headaches months after their head injury. The prevalence of headache during the year after injury is related to injury severity, time after injury, age, and gender. Girls and adolescents appear to be at highest risk of headache in the months after TBI. Pediatrics 2012; 129: e31-e39	[Blume, Heidi K.] Univ Washington, Div Pediat Neurol, Seattle, WA 98105 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98105 USA; [Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98105 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98105 USA; [Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98105 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98105 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98105 USA; [Vavilala, Monica S.; Jaffe, Kenneth M.; Koepsell, Thomas D.; Wang, Jin; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98105 USA; [Blume, Heidi K.] Seattle Childrens Res Inst, Seattle, WA USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Dorsch, Andrea] Mary Bridge Childrens Hosp, Div Pediat Psychol, Tacoma, WA USA		Blume, HK (corresponding author), Univ Washington, Seattle Childrens Hosp & Res Inst, Div Pediat Neurol, 4800 Sandpoint Way,Mailstop B-5552, Seattle, WA 98105 USA.	heidi.blume@seattlechildrens.org	Durbin, Dennis/AAD-7829-2022				Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Hershey Andrew D, 2005, Curr Pain Headache Rep, V9, P341, DOI 10.1007/s11916-005-0010-y; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; Kirk C, 2008, DEV MED CHILD NEUROL, V50, P422, DOI 10.1111/j.1469-8749.2008.02063.x; LANZI G, 1985, CEPHALALGIA, V5, P211, DOI 10.1046/j.1468-2982.1985.0504211.x; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lucas S, 2011, NATURAL HIST HEADACH; Marr A., 2004, CENTRAL NERVOUS SYST; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Powers SW, 2003, PEDIATRICS, V112, pE1, DOI 10.1542/peds.112.1.e1; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Rivara FP, 2011, HEALTH SERV RES, V46, P964, DOI 10.1111/j.1475-6773.2010.01236.x; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Wong DL, 2001, WONGS ESSENTIALS PED, P1301; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	32	68	69	0	11	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2012	129	1					E31	E39		10.1542/peds.2011-1742			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	870BT	WOS:000298644800005	22144708				2022-02-06	
J	Mayes, SD; Calhoun, SL; Aggarwal, R; Baker, C; Mathapati, S; Anderson, R; Petersen, C				Mayes, Susan Dickerson; Calhoun, Susan L.; Aggarwal, Richa; Baker, Courtney; Mathapati, Santoshkumar; Anderson, Robert; Petersen, Christopher			Explosive, oppositional, and aggressive behavior in children with autism compared to other clinical disorders and typical children	RESEARCH IN AUTISM SPECTRUM DISORDERS			English	Article						Explosive; Oppositional; Aggressive; Autism; ADHD	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; DEFIANT DISORDER; PSYCHIATRIC-DISORDERS; ASPERGER-SYNDROME; PROCESSING SPEED; GENDER-DIFFERENCES; SPECTRUM DISORDER	Maternal ratings of explosiveness, opposition, and aggression were analyzed in 1609 children 6-16 years of age. Behavior problems were common in autism, ADHD-Combined type, and depression, whereas children with ADHD-Inattentive type, anxiety disorder, and acquired brain injury did not differ from typical controls. More than 40% of children with autism, ADHD-Combined type, and depression met criteria for oppositional-defiant disorder (ODD), and less than 15% did in the other groups. Male gender and low SES increased the risk of behavior problems, but correlations were small between behavior problems and age and IQ. Our findings have implications for new DSM-V diagnostic categories and criteria. The DSM-V needs to clarify whether or not an additional diagnosis of ODD should be made in children with autism who meet ODD criteria. The proposed DSM-V states that ADHD and temper dysregulation disorder with dysphoria not be diagnosed in autism, but does not mention ODD. Our study also suggests that diagnoses of temper dysregulation disorder with dysphoria and prepubertal bipolar disorder may be redundant to a diagnosis of ODD. (C) 2011 Elsevier Ltd. All rights reserved.	[Mayes, Susan Dickerson; Calhoun, Susan L.; Aggarwal, Richa; Baker, Courtney; Mathapati, Santoshkumar; Anderson, Robert; Petersen, Christopher] Penn State Coll Med, Dept Psychiat, Hershey, PA USA		Mayes, SD (corresponding author), Hershey Med Ctr, Dept Psychiat H073, 500 Univ Dr, Hershey, PA 17033 USA.	smayes@psu.edu					Abikoff H, 2004, J AM ACAD CHILD PSY, V43, P802, DOI 10.1097/01.chi.0000128791.10014.ac; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; BARKLEY RA, 1990, J CONSULT CLIN PSYCH, V58, P775, DOI 10.1037/0022-006X.58.6.775; Barkley RA, 2006, ATTENTION DEFICIT HY, P184; Bellini S., 2004, FOCUS AUTISM DEV DIS, V19, P78, DOI DOI 10.1177/10883576040190020201; Biederman J, 2001, J AM ACAD CHILD PSY, V40, P871, DOI 10.1097/00004583-200108000-00007; Bimbrauer J. S., 1993, BEHAV CHANGE, V10, P63, DOI DOI 10.1017/S0813483900005556; Bixler EO, 2009, SLEEP, V32, P731, DOI 10.1093/sleep/32.6.731; Bodfish JW, 2000, J AUTISM DEV DISORD, V30, P237, DOI 10.1023/A:1005596502855; Boylan K, 2010, J AM ACAD CHILD PSY, V49, P152, DOI 10.1016/j.jaac.2009.09.007; Brereton AV, 2006, J AUTISM DEV DISORD, V36, P863, DOI 10.1007/s10803-006-0125-y; Brosnan J, 2011, RES DEV DISABIL, V32, P437, DOI 10.1016/j.ridd.2010.12.023; Calhoun SL, 2005, PSYCHOL SCHOOLS, V42, P333, DOI 10.1002/pits.20067; Card NA, 2008, CHILD DEV, V79, P1185, DOI 10.1111/j.1467-8624.2008.01184.x; Carlson CL, 1997, J AM ACAD CHILD PSY, V36, P1706, DOI 10.1097/00004583-199712000-00019; Chacko A, 2005, J AM ACAD CHILD PSY, V44, P249, DOI 10.1097/00004583-200503000-00009; Clark T, 1999, EUR CHILD ADOLES PSY, V8, P50, DOI 10.1007/s007870050083; Connor DF, 2010, J DEV BEHAV PEDIATR, V31, P427, DOI 10.1097/DBP.0b013e3181e121bd; Dawson G, 2010, PEDIATRICS, V125, pE17, DOI 10.1542/peds.2009-0958; Efron D, 2010, J PAEDIATR CHILD H, V46, P392, DOI 10.1111/j.1440-1754.2010.01750.x; Eikeseth S, 2002, BEHAV MODIF, V26, P49, DOI 10.1177/0145445502026001004; Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022; Fabiano GA, 2007, SCHOOL PSYCHOL REV, V36, P195; Fabiano GA, 2009, CLIN PSYCHOL REV, V29, P129, DOI 10.1016/j.cpr.2008.11.001; Faraone SV, 1998, J AM ACAD CHILD PSY, V37, P185, DOI 10.1097/00004583-199802000-00011; FENSKE EC, 1985, ANAL INTERVEN DEVEL, V5, P49, DOI 10.1016/S0270-4684(85)80005-7; Frazier TW, 2010, J CHILD ADOL PSYCHOP, V20, P167, DOI 10.1089/cap.2009.0048; Gadow KD, 2005, AUTISM, V9, P392, DOI 10.1177/1362361305056079; Gadow KD, 2008, J AUTISM DEV DISORD, V38, P1710, DOI 10.1007/s10803-008-0556-8; Green J, 2000, J AUTISM DEV DISORD, V30, P279, DOI 10.1023/A:1005523232106; Greene RW, 2002, J EMOT BEHAV DISORD, V10, P79, DOI 10.1177/10634266020100020201; Gross-Tsur V, 2006, DEV MED CHILD NEUROL, V48, P901, DOI 10.1017/S0012162206001976; Guttmann-Steinmetz S, 2009, J AUTISM DEV DISORD, V39, P976, DOI 10.1007/s10803-009-0706-7; Harris SL, 2000, J AUTISM DEV DISORD, V30, P137, DOI 10.1023/A:1005459606120; Howard JS, 2005, RES DEV DISABIL, V26, P359, DOI 10.1016/j.ridd.2004.09.005; Howlin P, 2003, J AUTISM DEV DISORD, V33, P3, DOI 10.1023/A:1022270118899; Hurtig T, 2009, AUTISM, V13, P583, DOI 10.1177/1362361309335719; Jacobson J, 1998, BEHAV INTERVENT, V13, P201, DOI [DOI 10.1002/(SICI)1099-078X, DOI 10.1002/(SICI)1099-078X(199811)13:4]; Jensen PS, 1997, J AM ACAD CHILD PSY, V36, P1065, DOI 10.1097/00004583-199708000-00014; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1088, DOI 10.1001/archpsyc.56.12.1088; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P926, DOI 10.1007/s10803-010-1118-4; Kanne SM, 2009, J AUTISM DEV DISORD, V39, P827, DOI 10.1007/s10803-008-0688-x; Kaplan SL, 2011, YOUR CHILD DOES NOT; Kim JA., 2000, AUTISM, V4, P117, DOI [DOI 10.1177/1362361300004002002, 10.1177/1362361300004002002]; King S, 2010, EXPERT REV NEUROTHER, V10, P1581, DOI [10.1586/ern.10.146, 10.1586/ERN.10.146]; Krug D, 1993, AUTISM BEHAV CHECKLI; Lalonde J, 1998, CAN J PSYCHIAT, V43, P623, DOI 10.1177/070674379804300612; Leyfer OT, 2006, J AUTISM DEV DISORD, V36, P849, DOI 10.1007/s10803-006-0123-0; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; MANJIVIONA J, 1995, J AUTISM DEV DISORD, V25, P23, DOI 10.1007/BF02178165; Matson JL, 1996, RES DEV DISABIL, V17, P433, DOI 10.1016/S0891-4222(96)00030-3; Matson JL, 2007, RES DEV DISABIL, V28, P341, DOI 10.1016/j.ridd.2005.12.004; Maughan B, 2004, J CHILD PSYCHOL PSYC, V45, P609, DOI 10.1111/j.1469-7610.2004.00250.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Mayes SD, 2004, CLIN NEUROPSYCHOL, V18, P559, DOI 10.1080/13854040490888530; Mayes SD, 2004, J DEV PHYS DISABIL, V16, P257, DOI 10.1023/B:JODD.0000032301.07550.0e; Mayes SD, 2001, J ABNORM CHILD PSYCH, V29, P263, DOI 10.1023/A:1010337916636; Mayes SD, 1999, INFANT YOUNG CHILD, V12, P90, DOI 10.1097/00001163-199910000-00011; Mayes SD, 2003, J AUTISM DEV DISORD, V33, P329, DOI 10.1023/A:1024462719081; Mayes SD, 2008, J AUTISM DEV DISORD, V38, P428, DOI 10.1007/s10803-007-0410-4; Mayes SD, 2007, CHILD NEUROPSYCHOL, V13, P469, DOI 10.1080/09297040601112773; Mayes SD, 2006, LEARN INDIVID DIFFER, V16, P145, DOI 10.1016/j.lindif.2005.07.004; Mayes SD, 2012, RES AUTISM SPECT DIS, V6, P277, DOI 10.1016/j.rasd.2011.05.009; Mayes SD, 2011, J DEV PHYS DISABIL, V23, P325, DOI 10.1007/s10882-011-9231-7; Mayes SD, 2011, RES AUTISM SPECT DIS, V5, P749, DOI 10.1016/j.rasd.2010.09.002; Mayes SD, 2011, RES AUTISM SPECT DIS, V5, P474, DOI 10.1016/j.rasd.2010.06.012; Mayes SD, 2009, J ATTEN DISORD, V12, P540, DOI 10.1177/1087054708320402; Mayes SD, 2009, J AUTISM DEV DISORD, V39, P1682, DOI 10.1007/s10803-009-0812-6; Mayes SD, 2009, SLEEP MED CLIN, V4, P19, DOI 10.1016/j.jsmc.2008.12.004; Mayes SD, 2009, RES AUTISM SPECT DIS, V3, P931, DOI 10.1016/j.rasd.2009.04.002; Mayes SD, 2009, J PEDIATR PSYCHOL, V34, P328, DOI 10.1093/jpepsy/jsn083; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2005, AM J PSYCHIAT, V162, P1142, DOI 10.1176/appi.ajp.162.6.1142; MCEACHIN JJ, 1993, AM J MENT RETARD, V97, P359; Milich R, 2001, CLIN PSYCHOL-SCI PR, V8, P463, DOI 10.1093/clipsy/8.4.463; Miller JN, 2000, J ABNORM PSYCHOL, V109, P227, DOI 10.1037/0021-843X.109.2.227; Miller JN, 1997, J CHILD PSYCHOL PSYC, V38, P247; Miller JN., 2000, AUTISM, V4, P29, DOI DOI 10.1177/1362361300041003; Murphy O, 2009, RES AUTISM SPECT DIS, V3, P474, DOI 10.1016/j.rasd.2008.09.008; Murray MJ, 2011, J AUTISM DEV DISORD, V41, P1586, DOI 10.1007/s10803-011-1178-0; Nagaraj R, 2006, J CHILD NEUROL, V21, P450, DOI 10.1177/08830738060210060801; Nichols S, 2000, J PEDIATR PSYCHOL, V25, P545, DOI 10.1093/jpepsy/25.8.545; Pandina GJ, 2007, J AUTISM DEV DISORD, V37, P367, DOI 10.1007/s10803-006-0234-7; Posner K, 2007, J CHILD ADOL PSYCHOP, V17, P547, DOI 10.1089/cap.2007.0075; Prinz R., 1987, ADV BEHAV ASSESSMENT, P57; Psychological Corporation, 1999, WECHSL ABBR SCAL INT; Russell E, 2005, AUST NZ J PSYCHIAT, V39, P633, DOI 10.1111/j.1440-1614.2005.01637.x; Schopler E., 1986, CHILDHOOD AUTISM RAT; Sheinkopf SJ, 1998, J AUTISM DEV DISORD, V28, P15, DOI 10.1023/A:1026054701472; Smith T, 2000, AM J MENT RETARD, V105, P269, DOI 10.1352/0895-8017(2000)105<0269:RTOIEI>2.0.CO;2; So CYC, 2008, BEHAV RES THER, V46, P983, DOI 10.1016/j.brat.2008.06.007; Sukhodolsky DG, 2008, J ABNORM CHILD PSYCH, V36, P117, DOI 10.1007/s10802-007-9165-9; SZATMARI P, 1995, J AM ACAD CHILD PSY, V34, P1662, DOI 10.1097/00004583-199512000-00017; Tryon P. A., 2006, FOCUS AUTISM OTHER D, V21, P2, DOI [10.1177/10883576060210010101, DOI 10.1177/10883576060210010101]; van der Oord S, 2007, EUR CHILD ADOLES PSY, V16, P48, DOI 10.1007/s00787-006-0574-z; Waxmonsky J, 2008, J CHILD ADOL PSYCHOP, V18, P573, DOI 10.1089/cap.2008.065; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501	102	68	68	3	44	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1750-9467	1878-0237		RES AUTISM SPECT DIS	Res. Autism Spectr. Disord.	JAN-MAR	2012	6	1					1	10		10.1016/j.rasd.2011.08.001			10	Education, Special; Psychology, Developmental; Psychiatry; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Psychology; Psychiatry; Rehabilitation	858TU	WOS:000297826400001					2022-02-06	
J	van Heugten, C; Gregorio, GW; Wade, D				van Heugten, Caroline; Gregorio, Gisela Wolters; Wade, Derick			Evidence-based cognitive rehabilitation after acquired brain injury: A systematic review of content of treatment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain injuries; Stroke; Cognition disorders; Rehabilitation; Randomised controlled trial	RANDOMIZED CONTROLLED-TRIAL; TIME PRESSURE MANAGEMENT; CLOSED-HEAD INJURY; HEMISPHERE STROKE PATIENTS; OF-THE-LITERATURE; SPEECH-THERAPY; UNILATERAL NEGLECT; CHRONIC APHASIA; VISUAL NEGLECT; LANGUAGE REHABILITATION	We reviewed all randomised trials on cognitive rehabilitation in order to determine the effective elements in terms of patients' and treatment characteristics, treatment goals and outcome. A total of 95 random controlled trials were included from January 1980 until August 2010 studying 4068 patients in total. Most studies had been conducted on language (n = 25), visuospatial functioning (n = 24), and memory (n = 14). Stroke patients were the commonest subjects (57%; overall mean age 52.2, SD = 15.0 years). Of the interventions 39% were offered more than 12 months after onset and 23% were offered within two months of onset. The mean (SD) number of hours of treatment actually delivered was 4.1 (3.6) per week; treatment was mostly offered individually. No papers gave specific information on the expertise or competences of the staff involved. With 95 RCTs there is a large body of evidence to support the efficacy of cognitive rehabilitation, and the current study can serve as a database for clinicians and researchers. But most studies have given little information about the actual content of the treatment which makes it difficult to use the studies when making treatment decisions in daily clinical practice. We suggest developing an international checklist to make standardised description of non-pharmacological complex interventions possible.	[van Heugten, Caroline] Maastricht Univ, Dept Psychiat & Neuropsychol, Sch Mental Hlth & Neurosci, NL-6200 MD Maastricht, Netherlands; [van Heugten, Caroline] Maastricht Univ, Dept Neuropsychol & Psychopharmacol, NL-6200 MD Maastricht, Netherlands; [Wade, Derick] Maastricht Univ, Care & Publ Hlth Res Inst, NL-6200 MD Maastricht, Netherlands; [Wade, Derick] Oxford Ctr Enablement, Oxford, England		van Heugten, C (corresponding author), Maastricht Univ, Dept Psychiat & Neuropsychol, Sch Mental Hlth & Neurosci, POB 616, NL-6200 MD Maastricht, Netherlands.	c.vanheugten@maastrichtuniversity.nl		Wade, Derick/0000-0002-1188-8442			[Anonymous], 2005, CLIN REHABIL, V19, P811, DOI 10.1191/0269215505cr923ed; ANTONUCCI G, 1995, J CLIN EXP NEUROPSYC, V17, P383, DOI 10.1080/01688639508405131; Bakheit AMO, 2007, CLIN REHABIL, V21, P885, DOI 10.1177/0269215507078486; Barker-Collo SL, 2009, STROKE, V40, P3293, DOI 10.1161/STROKEAHA.109.558239; Berg IJ, 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI DOI 10.1080/09602019108401384; Boutron I, 2005, J CLIN EPIDEMIOL, V58, P1233, DOI 10.1016/j.jclinepi.2005.05.004; CARTER LT, 1983, AM J OCCUP THER, V37, P320, DOI 10.5014/ajot.37.5.320; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; Cherney Leora R, 2003, Top Stroke Rehabil, V9, P22; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Couillet J, 2010, NEUROPSYCHOL REHABIL, V20, P321, DOI 10.1080/09602010903467746; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DAVID R, 1982, J NEUROL NEUROSUR PS, V45, P957, DOI 10.1136/jnnp.45.11.957; Denes G, 1996, APHASIOLOGY, V10, P385, DOI 10.1080/02687039608248418; DICARLO LM, 1980, ARCH PHYS MED REHAB, V61, P41; Dirette DK, 1999, OCCUP THER J RES, V19, P223, DOI 10.1177/153944929901900401; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; Doesborgh S, 2004, APHASIOLOGY, V18, P213, DOI 10.1080/02687030344000580; Doesborgh SJC, 2004, STROKE, V35, P141, DOI 10.1161/01.STR.0000105460.52928.A6; Donkervoort M, 2001, NEUROPSYCHOL REHABIL, V11, P549, DOI 10.1080/09602010143000093; Doornhein K, 1998, NEUROPSYCHOL REHABIL, V8, P393, DOI 10.1080/713755579; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; DRUMMOND SS, 1981, J COMMUN DISORD, V14, P287, DOI 10.1016/0021-9924(81)90013-7; Edmans JA, 2000, CLIN REHABIL, V14, P230, DOI 10.1191/026921500673333145; Elman RJ, 1999, J SPEECH LANG HEAR R, V42, P411, DOI 10.1044/jslhr.4202.411; FANTHOME Y, 1995, DISABIL REHABIL, V17, P413, DOI 10.3109/09638289509166654; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; Geurtsen GJ, 2010, J REHABIL MED, V42, P97, DOI 10.2340/16501977-0508; Glasziou P, 2008, BMJ-BRIT MED J, V336, P1472, DOI 10.1136/bmj.39590.732037.47; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; Hildebrandt H, 2006, J NEUROL, V253, P512, DOI 10.1007/s00415-006-0013-6; Hinckley JJ, 2001, APHASIOLOGY, V15, P463, DOI 10.1080/02687040042000340; Jacquin-Courtois S, 2010, BRAIN, V133, P895, DOI 10.1093/brain/awp327; Kalra L, 1997, STROKE, V28, P1386, DOI 10.1161/01.STR.28.7.1386; Kang SH, 2009, CLIN REHABIL, V23, P434, DOI 10.1177/0269215508101732; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kasten E, 1998, NAT MED, V4, P1083, DOI 10.1038/2079; Katz N, 2005, DISABIL REHABIL, V27, P1235, DOI 10.1080/09638280500076079; Katz RC, 1997, J SPEECH LANG HEAR R, V40, P493, DOI 10.1044/jslhr.4003.493; Kerner MJ, 1985, COGNITIVE REHABILITA, V1, P26; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lincoln N B, 1985, Int Rehabil Med, V7, P99; LINCOLN NB, 1984, LANCET, V1, P1197; LINCOLN NB, 1984, BEHAV PSYCHOTHER, V12, P237, DOI 10.1017/S0141347300010806; LINCOLN NB, 1982, BEHAV PSYCHOTHER, V10, P162, DOI 10.1017/S0141347300007023; Luukkainen-Markkula R, 2009, RESTOR NEUROL NEUROS, V27, P663, DOI 10.3233/RNN-2009-0520; Lyon JG, 1997, APHASIOLOGY, V11, P693, DOI 10.1080/02687039708249416; MacKay S, 1988, Geriatr Nurs, V9, P177; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; Man DWK, 2006, NEUROREHABILITATION, V21, P205; Mazer BL, 2003, ARCH PHYS MED REHAB, V84, P541, DOI 10.1053/apmr.2003.50085; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; MEIKLE M, 1979, BRIT MED J, V2, P87, DOI 10.1136/bmj.2.6182.87; Meinzer M, 2007, J INT NEUROPSYCH SOC, V13, P846, DOI 10.1017/S1355617707071111; NEISTADT ME, 1992, AM J OCCUP THER, V46, P141, DOI 10.5014/ajot.46.2.141; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Perera R, 2007, BRIT MED J, V334, P127, DOI 10.1136/bmj.39045.396817.68; Poggel DA, 2004, NEUROLOGY, V63, P2069, DOI 10.1212/01.WNL.0000145773.26378.E5; PRINS RS, 1989, APPL PSYCHOLINGUIST, V10, P85, DOI 10.1017/S0142716400008432; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Robertson IH, 2002, NEUROPSYCHOL REHABIL, V12, P439, DOI 10.1080/09602010244000228; Rochon E, 2005, NEUROPSYCHOL REHABIL, V15, P1, DOI 10.1080/09602010343000327; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rose FD, 1999, DISABIL REHABIL, V21, P548; ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Rusconi ML, 2002, EURA MEDICOPHYS, V38, P159; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sarkamo T, 2008, BRAIN, V131, P866, DOI 10.1093/brain/awn013; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SHEWAN CM, 1984, BRAIN LANG, V23, P272, DOI 10.1016/0093-934X(84)90068-3; Smania N, 2000, ARCH PHYS MED REHAB, V81, P379, DOI 10.1053/mr.2000.6921; Smania N, 2006, NEUROLOGY, V67, P2050, DOI 10.1212/01.wnl.0000247279.63483.1f; SODERBACK I, 1988, SCAND J REHABIL MED, V20, P47; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Soong W, 2005, INT J REHABIL RES, V28, P341, DOI 10.1097/00004356-200512000-00006; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Sturm W, 1991, NEUROPSYCHOL REHABIL, V1, P259, DOI DOI 10.1080/09602019108402258; TAYLOR M M, 1971, Archives of Physical Medicine and Rehabilitation, V52, P163; Thickpenny-Davis KL, 2007, J HEAD TRAUMA REHAB, V22, P303, DOI 10.1097/01.HTR.0000290975.09496.93; Thomas-Stonell N, 1994, J HEAD TRAUMA REHAB, V9, P25, DOI DOI 10.1097/00001199-199412000-00005; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Tsang MHM, 2009, DISABIL REHABIL, V31, P630, DOI 10.1080/09638280802240621; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; van Hout MSE, 2008, PSYCHOTHER PSYCHOSOM, V77, P289, DOI 10.1159/000140088; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Watanabe TK, 1998, BRAIN INJURY, V12, P81; WEINBERG J, 1979, ARCH PHYS MED REHAB, V60, P491; WEINBERG J, 1977, ARCH PHYS MED REHAB, V58, P479; WEINBERG J, 1982, Journal of Clinical Neuropsychology, V4, P59, DOI 10.1080/01688638208401117; WERTZ RT, 1981, J SPEECH HEAR RES, V24, P580, DOI 10.1044/jshr.2404.580; WERTZ RT, 1986, ARCH NEUROL-CHICAGO, V43, P653, DOI 10.1001/archneur.1986.00520070011008; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Wiart L, 1997, ARCH PHYS MED REHAB, V78, P424, DOI 10.1016/S0003-9993(97)90236-7; Winkens I, 2009, CLIN REHABIL, V23, P79, DOI 10.1177/0269215508097855; Winkens I, 2009, ARCH PHYS MED REHAB, V90, P1672, DOI 10.1016/j.apmr.2009.04.016; Worrall L, 2000, APHASIOLOGY, V14, P911, DOI 10.1080/02687030050127711; Zeloni G, 2002, J NEUROL NEUROSUR PS, V73, P195, DOI 10.1136/jnnp.73.2.195	107	68	68	2	61	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	5					653	673		10.1080/09602011.2012.680891			21	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	010UZ	WOS:000309121200001	22537117	Green Submitted			2022-02-06	
J	Hirschberg, R; Giacino, JT				Hirschberg, Ron; Giacino, Joseph T.			The Vegetative and Minimally Conscious States: Diagnosis, Prognosis and Treatment	NEUROLOGIC CLINICS			English	Article						Consciousness; Vegetative state; Traumatic brain injury; Neuroimaging; Outcomes	ANOXIC BRAIN-INJURY; DISORDERS; RECOVERY; ZOLPIDEM; COMA; SCALE; RECOMMENDATIONS; AMANTADINE; ACCURACY; INSIGHTS	Severe acquired brain injury has profound impact on alertness, cognition, and behavior. Among those who survive the initial injury, a significant minority fail to fully recover self and environmental awareness, and go on to experience prolonged disorders of consciousness (DOC) that can last a lifetime. Although there are no standards of care to guide clinical management, a growing body of empirical evidence is beginning to accrue to inform clinical decision making. In this article, we review the state of the science as it pertains to diagnosis, prognosis, and treatment of patients with DOC.	[Hirschberg, Ron; Giacino, Joseph T.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Hirschberg, Ron; Giacino, Joseph T.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Hirschberg, Ron] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Giacino, Joseph T.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA		Giacino, JT (corresponding author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.	jgiacino@partners.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			American Congress of Rehabilitation Medicine, 2005, ARCH PHYS MED REHAB, V76, P205; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Clauss RP, 2000, S AFR MED J, V90, P68; Cohen SI, 2008, AM J PHYS MED REHAB, V87, P229, DOI 10.1097/PHM.0b013e318161971b; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Giacino J, 2008, HDB CLIN NEUROLOGY, V90, P99; Giacino JT, 2007, CURR OPIN NEUROL, V20, P614, DOI 10.1097/WCO.0b013e3282f189ef; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Giacino JT, 2005, REHABILITATION TRAUM, P305; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; James W, 1999, NEW AGE NEW THOUGHT, P51; JENNETT B, 1972, LANCET, V1, P734; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; Lombardi F, 2007, COCHRANE DB SYST REV, V2, P1; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; Monti MM, 2009, PROG BRAIN RES, V177, P249, DOI 10.1016/S0079-6123(09)17717-8; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Moreno DR, 2010, NEUROLOGY, V75, P1871, DOI 10.1212/WNL.0b013e3181feb259; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff Nicholas D, 2010, Cleve Clin J Med, V77 Suppl 3, pS27, DOI 10.3949/ccjm.77.s3.05; Schiff Nicholas D., 2002, Thalamus & Related Systems, V2, P55, DOI 10.1016/S1472-9288(02)00028-6; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Shames JL, 2008, ARCH PHYS MED REHAB, V89, P386, DOI 10.1016/j.apmr.2007.08.137; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Smart CM, 2008, NAT CLIN PRACT NEURO, V4, P448, DOI 10.1038/ncpneuro0823; SPUDIS EV, 1991, J NEUROL SCI, V102, P128, DOI 10.1016/0022-510X(91)90060-K; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; TEASDALE G, 1974, LANCET, V2, P81; Vanhaudenhuyes A, 2008, NEUROLOGY, V71, P1; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Whyte J, 2007, AM J PHYS MED REHAB, V86, P86, DOI 10.1097/PHM.0b013e31802f0434; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	51	68	82	1	23	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	NOV	2011	29	4					773	+		10.1016/j.ncl.2011.07.009			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	853BN	WOS:000297401300006	22032660				2022-02-06	
J	Luchetti, S; Bossers, K; Van de Bilt, S; Agrapart, V; Morales, RR; Frajese, GV; Swaab, DF				Luchetti, Sabina; Bossers, Koen; Van de Bilt, Saskia; Agrapart, Vincent; Morales, Rafael Ramirez; Frajese, Giovanni Vanni; Swaab, Dick F.			Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease	NEUROBIOLOGY OF AGING			English	Article						Neurosteroids; GABA-A receptors; Alzheimer's disease; Postmortem; Prefrontal cortex; Aromatase; Gene expression	TRAUMATIC BRAIN-INJURY; DIAZEPAM-BINDING INHIBITOR; RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; OF-THE-ART; GABA(A) RECEPTORS; PROGESTERONE METABOLITES; NEUROACTIVE STEROIDS; NERVOUS-SYSTEM; SPINAL-CORD	Expression of the genes for enzymes involved in neurosteroid biosynthesis was studied in human prefrontal cortex (PFC) in the course of Alzheimer's disease (AD) (n = 49). Quantitative RT-PCR (qPCR) revealed that mRNA levels of diazepam binding inhibitor (DBI), which is involved in the first step of steroidogenesis and in GABAergic transmission, were increased, as were mRNA levels for several neurosteroid biosynthetic enzymes. Aromatase, 17 beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) and aldo-keto reductase 1C2 (AKR1C2), were all increased in the late stages of AD. Several GABA-A subunits were significantly reduced in AD. Increased expression of aromatase in the PFC was confirmed by immunohistochemistry and was found to be localized predominantly in astrocytes. These data suggest a role for estrogens and allopregnanolone produced by astrocytes in the PFC in AD, possibly as part of a rescue program. The reduced gene expression of some synaptic and extra-synaptic GABA-A subunits may indicate a deficit of modulation of GABA-A receptors by neuro active steroids, which may contribute to the neuropsychiatric characteristics of this disease. (C) 2009 Elsevier Inc. All rights reserved.	[Luchetti, Sabina; Bossers, Koen; Van de Bilt, Saskia; Swaab, Dick F.] NIN, NL-1105 BA Amsterdam, Netherlands; [Luchetti, Sabina] Santa Lucia Fdn Sci Inst, Ist Dermopat Immacolata IDI IRCCS, Rome, Italy; [Agrapart, Vincent; Morales, Rafael Ramirez; Frajese, Giovanni Vanni] Univ Roma Tor Vergata, Endocrinol Lab, Dept Internal Med, Rome, Italy; [Frajese, Giovanni Vanni] Univ Cassino, Fac Motor Sci, I-03043 Cassino, Italy		Luchetti, S (corresponding author), Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.	s.luchetti@nin.knaw.nl	Kruisbrink, Jenneke/D-8060-2013; Bossers, Koen/I-4002-2013; Ramirez Morales, Rafael/C-9444-2013	Ramirez Morales, Rafael/0000-0001-8261-8450; Bossers, Koen/0000-0002-0272-4518; Swaab, Dick/0000-0002-9665-7845	Istituto Der-mopatico Immacolata (IDI-IRCCS); Santa Lucia Foundation (Santa Lucia-IRCCS), Rome, Italy; Netherlands Institute for Neuroscience	Authors would like to thank, R. Balesar, B. Fisser, A. Sluiter, U. Unmehopa, J.J. Van Heerikhuize for technical assistance, Dr. M. Hofman for statistical advises, Dr. M.R.J. Mason and Dr. W. Kamphuis for critical comments of the paper. S.L. was supported by funds from the Istituto Der-mopatico Immacolata (IDI-IRCCS to Prof. G. Frajese) and the Santa Lucia Foundation (Santa Lucia-IRCCS to Prof G. Bernardi), Rome, Italy. Experimental materials were funded by the Netherlands Institute for Neuroscience to D.F.S. We thank the Netherlands Brain Bank for providing the human material.	Bancher C, 1996, EUR ARCH PSY CLIN N, V246, P137, DOI 10.1007/BF02189115; BARBACCIA ML, 1986, ARCH GEN PSYCHIAT, V43, P1143; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Belelli D, 2002, NEUROPHARMACOLOGY, V43, P651, DOI 10.1016/S0028-3908(02)00172-7; Bialek M, 2004, POL J PHARMACOL, V56, P509; Biggio F, 2006, PHARMACOL BIOCHEM BE, V84, P545, DOI 10.1016/j.pbb.2006.07.002; Biggio G, 2001, INT REV NEUROBIOL, V46, P207; Birzniece V, 2006, BRAIN RES REV, V51, P212, DOI 10.1016/j.brainresrev.2005.11.001; Bossers K, 2009, BRAIN PATHOL, V19, P91, DOI 10.1111/j.1750-3639.2008.00171.x; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Busche MA, 2008, SCIENCE, V321, P1686, DOI 10.1126/science.1162844; Carroll JC, 2007, J NEUROSCI, V27, P13357, DOI 10.1523/JNEUROSCI.2718-07.2007; Cherrier MM, 2005, NEUROLOGY, V64, P2063, DOI 10.1212/01.WNL.0000165995.98986.F1; Cholerton B, 2002, DRUG AGING, V19, P405, DOI 10.2165/00002512-200219060-00002; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Concas A, 1999, EUR J PHARMACOL, V375, P225, DOI 10.1016/S0014-2999(99)00232-0; COSTA E, 1994, ANN NY ACAD SCI, V746, P223; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DOREGO JL, 2009, FRONT NEUROENDOCRINO; Dubrovsky BO, 2005, PROG NEURO-PSYCHOPH, V29, P169, DOI 10.1016/j.pnpbp.2004.11.001; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; FERRARESE C, 1990, NEUROLOGY, V40, P632, DOI 10.1212/WNL.40.4.632; FERRERO P, 1988, J NEUROL SCI, V87, P327, DOI 10.1016/0022-510X(88)90257-2; Follesa P, 2005, J NEUROCHEM, V94, P659, DOI 10.1111/j.1471-4159.2005.03303.x; Francis PT, 2003, INT J GERIATR PSYCH, V18, pS15, DOI 10.1002/gps.934; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Garcia-Ovejero D, 2005, BRAIN RES REV, V48, P273, DOI 10.1016/j.brainresrev.2004.12.018; Garcia-Segura LM, 2008, J NEUROENDOCRINOL, V20, P705, DOI 10.1111/j.1365-2826.2008.01713.x; Genazzani AR, 2007, HUM REPROD UPDATE, V13, P175, DOI 10.1093/humupd/dml042; Deniselle MCG, 2007, EXP NEUROL, V203, P406, DOI 10.1016/j.expneurol.2006.08.019; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; He XY, 2005, MOL CELL ENDOCRINOL, V229, P111, DOI 10.1016/j.mce.2004.08.011; Herd MB, 2007, PHARMACOL THERAPEUT, V116, P20, DOI 10.1016/j.pharmthera.2007.03.007; Hogervorst Eef, 2008, Evid Based Med, V13, P71, DOI 10.1136/ebm.13.3.71; Kask K, 2008, PSYCHOPHARMACOLOGY, V199, P161, DOI 10.1007/s00213-008-1150-7; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Lanctot KL, 2007, INT PSYCHOGERIATR, V19, P151, DOI 10.1017/S1041610206003899; Leichtnam ML, 2006, PHARM RES-DORDR, V23, P1117, DOI 10.1007/s11095-006-0072-5; Lethaby A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003122.pub2; Li R, 2000, J NEUROCHEM, V75, P1447, DOI 10.1046/j.1471-4159.2000.0751447.x; Lin HK, 2004, STEROIDS, V69, P795, DOI 10.1016/j.steroids.2004.09.014; Liu XA, 2008, NEUROCHEM RES, V33, P1811, DOI 10.1007/s11064-008-9638-4; LOWE SL, 1988, BRAIN, V111, P785, DOI 10.1093/brain/111.4.785; Lu PH, 2006, ARCH NEUROL-CHICAGO, V63, P177, DOI 10.1001/archneur.63.2.nct50002; Manly JJ, 2000, NEUROLOGY, V54, P833, DOI 10.1212/WNL.54.4.833; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Mellon SH, 2001, INT REV NEUROBIOL, V46, P33; Mohler H, 2006, CELL TISSUE RES, V326, P505, DOI 10.1007/s00441-006-0284-3; MOUNTJOY CQ, 1984, BRAIN, V107, P507, DOI 10.1093/brain/107.2.507; Mulnard RA, 2005, ANN NY ACAD SCI, V1052, P173, DOI 10.1196/annals.1347.014; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Penning TM, 2003, J STEROID BIOCHEM, V85, P247, DOI 10.1016/S0960-0760(03)00236-X; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pike CJ, 2006, ENDOCRINE, V29, P233, DOI 10.1385/ENDO:29:2:233; Pluchino N, 2006, J STEROID BIOCHEM, V102, P205, DOI 10.1016/j.jsbmb.2006.09.023; REINIKAINEN KJ, 1988, J NEUROL SCI, V84, P101, DOI 10.1016/0022-510X(88)90179-7; Rosario ER, 2006, J NEUROSCI, V26, P13384, DOI 10.1523/JNEUROSCI.2514-06.2006; Rosario ER, 2004, JAMA-J AM MED ASSOC, V292, P1431, DOI 10.1001/jama.292.12.1431-b; ROSARIO ER, 2009, NEUROBIOL AGING; ROSSOR MN, 1982, BRAIN, V105, P313, DOI 10.1093/brain/105.2.313; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stell BM, 2003, P NATL ACAD SCI USA, V100, P14439, DOI 10.1073/pnas.2435457100; Stoffel-Wagner B, 2001, EUR J ENDOCRINOL, V145, P669, DOI 10.1530/eje.0.1450669; THIGPEN AE, 1993, J CLIN INVEST, V92, P903, DOI 10.1172/JCI116665; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; van Wingen G, 2007, J NEUROSCI, V27, P11416, DOI 10.1523/JNEUROSCI.1715-07.2007; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vongher JM, 1999, PHARMACOL BIOCHEM BE, V64, P777, DOI 10.1016/S0091-3057(99)00140-9; Wang JM, 2007, CURR ALZHEIMER RES, V4, P510, DOI 10.2174/156720507783018262; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yague JG, 2006, NEUROSCIENCE, V138, P389, DOI 10.1016/j.neuroscience.2005.11.054	85	68	70	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	NOV	2011	32	11					1964	1976		10.1016/j.neurobiolaging.2009.12.014			13	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	824RV	WOS:000295220700005	20045216				2022-02-06	
J	Carlozzi, NE; Tulsky, DS; Kisala, PA				Carlozzi, Noelle E.; Tulsky, David S.; Kisala, Pamela A.			Traumatic Brain Injury Patient-Reported Outcome Measure: Identification of Health-Related Quality-of-Life Issues Relevant to Individuals With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Health-related quality of life; Outcome assessment (health care); Patient-reported outcomes; Quality of life; Rehabilitation; Traumatic brain injury	REHABILITATION STAKEHOLDERS; PARTICIPATION; SEVERITY; IMPACT	Carlozzi NE, Tulsky DS, Kisala PA. Traumatic brain injury patient-reported outcome measure: identification of health-related quality-of-life issues relevant to individuals with traumatic brain injury. Arch Phys Med Rehabil 2011;92 (10 Suppl 1):S52-60. This 2-part qualitative study explored health-related quality of life (HRQOL) in individuals with traumatic brain injury (TBI). A community-based participatory action research design was used, which emphasizes collaboration between researchers and individuals with disabilities to ensure that results are relevant for individuals with TBI. In study 1, community members (N=20) with TBI served as "experts" during 1-on-1 semistructured interviews, reviewing current HRQOL items and identifying HRQOL issues commonly experienced by individuals with TBI. Each participant identified at least 31 issues, with most generating more than 90 responses, highlighting the multifaceted nature of HRQOL in TBI. Study 2 consisted of 7 patient/consumer groups (33 individuals with TBI), 4 caregiver groups (17 caregivers), and 2 provider groups (15 providers). Qualitative analysis of patient focus groups indicated that 48% of focus group comments were related to emotional issues; 23%, to social functioning; 14%, to physical functioning; 11%, to cognition; and 7%, to personality changes (caregiver and provider focus group analysis indicated identical patterns of findings). In addition, both studies evaluated the applicability in TBI of generic items developed by the Patient-Reported Outcomes Measurement Information System and the Neurology Quality of Life Measurement initiative. Findings suggest that although there is some overlap between current generic measures of HRQOL and concepts reported by individuals with TBI, these generic measures do not capture the full complexity of HRQOL in TBI. TBI-targeted item banks are needed to ensure sensitive assessment of HRQOL in TBI.	[Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ctr Rehabil Outcomes & Assessment Res, Ann Arbor, MI 48109 USA		Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, Ctr Rehabil Outcomes & Assessment Res, N Campus Res Complex,Bldg 520,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu		Tulsky, David/0000-0002-4335-4509	National Institute on Disability and Rehabilitation Research [H133G070138]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133G070138).	Amtmann D, 2011, ARCH PHYS MED REHAB, V92, pS12, DOI 10.1016/j.apmr.2011.04.025; Bottari C, 2007, J HEAD TRAUMA REHAB, V22, P26, DOI 10.1097/00001199-200701000-00003; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cella D F, 1992, J Palliat Care, V8, P8; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Cella D, 2011, ARCH PHYS MED REHAB, V92, pS28, DOI 10.1016/j.apmr.2011.01.025; Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011; CELLA DF, 1995, SEMIN ONCOL, V22, P73; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Faul M, 2010, TRAUMATIC BRAIN INJU; Golden Z, 2003, INT J NEUROSCI, V113, P733, DOI 10.1080/00207450390200044; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Heinemann AW, 2011, ARCH PHYS MED REHAB, V92, P564, DOI 10.1016/j.apmr.2010.07.220; *I MED, 2006, EV HRSA TRAUM BRAIN; KISALA P, 2010, APPL PSYCHO IN PRESS; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; MESSICK S, 1984, J EDUC MEAS, V21, P215, DOI 10.1111/j.1745-3984.1984.tb01030.x; Messick S, 1988, TEST VALIDITY, P33, DOI 10.4324/9780203056905-11; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Quatrano LA, 2011, ARCH PHYS MED REHAB, V92, pS7, DOI 10.1016/j.apmr.2010.08.032; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosenthal M, 2007, HDB REHABILITATION P, P49; Sherer M., 2005, FORENSIC NEUROPSYCHO, P237; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; Soo C, 2007, COCHRANE DB SYST REV, V3; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Strauss A., 1998, BASICS QUALITATIVE R, V2nd Edition; VANDERLINDEN WJ, 1997, HDB MODERN IRT; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; Whyte J, 2005, PHYS MED REHABILITAT, P1677; Whyte J, 2005, PHYS MED REHABILITAT	38	68	69	2	20	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2011	92	10		1			S52	S60		10.1016/j.apmr.2010.12.046			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	833DG	WOS:000295861400008	21958923				2022-02-06	
J	Tran, HT; Sanchez, L; Esparza, TJ; Brody, DL				Tran, Hien T.; Sanchez, Laura; Esparza, Thomas J.; Brody, David L.			Distinct Temporal and Anatomical Distributions of Amyloid-beta and Tau Abnormalities following Controlled Cortical Impact in Transgenic Mice	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; INTRANEURONAL A-BETA-42 ACCUMULATION; ALZHEIMERS-DISEASE; A-BETA; PRECURSOR-PROTEIN; HEAD-INJURY; PLAQUE-FORMATION; GAMMA-SECRETASE; DOWN-SYNDROME; MOUSE MODEL	Traumatic brain injury TBI is a major environmental risk factor for Alzheimer's disease. Intracellular accumulations of amyloid-beta and tau proteins have been observed within hours following severe TBI in humans. Similar abnormalities have been recapitulated in young 3xTg-AD mice subjected to the controlled cortical impact model (CCI) of TBI and sacrificed at 24 h and 7 days post injury. This study investigated the temporal and anatomical distributions of amyloid-beta and tau abnormalities from 1 h to 24 h post injury in the same model. Intra-axonal amyloid-beta accumulation in the fimbria was detected as early as 1 hour and increased monotonically over 24 hours following injury. Tau immunoreactivity in the fimbria and amygdala had a biphasic time course with peaks at 1 hour and 24 hours, while tau immunoreactivity in the contralateral CA1 rose in a delayed fashion starting at 12 hours after Injury Furthermore, rapid intra-axonal amyloid-beta accumulation was similarly observed post controlled cortical injury in APP/PS1 mice, another transgenic Alzheimer's disease mouse model. Acute increases in total and phospho-tau imunoreactivity were also evident in single transgenic Tau(p301L) mice subjected to controlled cortical injury. These data provide further evidence for the causal effects of moderately severe contusional TBI on acceleration of acute Alzheimer-related abnormalities and the independent la on hip between a amyloid-beta and tau in this setting.	[Tran, Hien T.; Sanchez, Laura; Esparza, Thomas J.; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO 63130 USA; [Brody, David L.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO USA		Tran, HT (corresponding author), Washington Univ, Dept Neurol, St Louis, MO 63130 USA.	brodyd@neuro.wustl.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS065069 (Brody), K08 NS049237 (Brody)]; Burroughs Wellcome Career AwardBurroughs Wellcome Fund; Biomedical Sciences (Brody); Thrasher Research Fund (Brody); Washington University Office of Undergraduate Research Award (Sanchez); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237, R01NS065069] Funding Source: NIH RePORTER	This work was supported by NIH R01 NS065069 (Brody), NIH K08 NS049237 (Brody), a Burroughs Wellcome Career Award in the Biomedical Sciences (Brody), the Thrasher Research Fund (Brody), and a Washington University Office of Undergraduate Research Award (Sanchez). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Blanchard V, 2003, EXP NEUROL, V184, P247, DOI 10.1016/S0014-4886(03)00252-8; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Casas C, 2004, AM J PATHOL, V165, P1289, DOI 10.1016/S0002-9440(10)63388-3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Gyure KA, 2001, ARCH PATHOL LAB MED, V125, P489; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mastrangelo MA, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-81; Mori C, 2002, AMYLOID, V9, P88, DOI 10.3109/13506120208995241; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Osawa S, 2008, J BIOL CHEM, V283, P19283, DOI 10.1074/jbc.M705954200; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Schwetye KE, 2010, NEUROBIOL DIS, V40, P555, DOI 10.1016/j.nbd.2010.06.018; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Winton MJ, 2011, J NEUROSCI, V31, P7691, DOI 10.1523/JNEUROSCI.6637-10.2011; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wirths O, 2006, ACTA NEUROPATHOL, V111, P312, DOI 10.1007/s00401-006-0041-4; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119	46	68	70	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2011	6	9							e25475	10.1371/journal.pone.0025475			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834DM	WOS:000295939600028	21980472	Green Published, Green Submitted, gold			2022-02-06	
J	Cuthbert, JP; Corrigan, JD; Harrison-Felix, C; Coronado, V; Dijkers, MP; Heinemann, AW; Whiteneck, GG				Cuthbert, Jeffrey P.; Corrigan, John D.; Harrison-Felix, Cynthia; Coronado, Victor; Dijkers, Marcel P.; Heinemann, Allen W.; Whiteneck, Gale G.			Factors That Predict Acute Hospitalization Discharge Disposition for Adults With Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Healthcare disparities; Hospitalization; Nursing homes, Patient discharge; Rehabilitation; Rehabilitation centers	MODEL SYSTEMS; ACUTE-CARE; OUTCOMES; MORTALITY; OLDER; INSURANCE; ACCESS; HEALTH; AGE; DISABILITY	Objective: To identify factors predicting acute hospital discharge disposition after moderate to severe traumatic brain injury (TBI). Design: Secondary analysis of existing datasets. Setting: Acute care hospitals. Participants: Adults hospitalized with moderate to severe TBI included in 3 large sets of archival data: (1) Centers for Disease Control and Prevention Central Nervous System Injury Surveillance database (n=15,646); (2) the National Trauma Data Bank (n=52,012); and (3) the National Study on the Costs and Outcomes of Trauma (n=1286). Interventions: None. Main Outcome Measure: Discharge disposition from acute hospitalization to 1 of 3 postacute settings: (1) home, (2) inpatient rehabilitation, or (3) subacute settings, including nursing homes and similar facilities. Results: The Glasgow Coma Scale (GCS) score and length of acute hospital length of stay (LOS) accounted for 35% to 44% of the variance in discharges to home versus not home, while age and sex added from 5% to 8%, and race/ethnicity and hospitalization payment source added another 2% to 5%. When predicting discharge to rehabilitation versus subacute care for those not going home, GCS and LOS accounted for 2% to 4% of the variance, while age and sex added 7% to 31%, and race/ethnicity and payment source added 4% to 5%. Across the datasets, longer LOS, older age, and white race increased the likelihood of not being discharged home; the most consistent predictor of discharge to rehabilitation was younger age. Conclusions: The decision to discharge to home a person with moderate to severe TBI appears to be based primarily on severity-related factors. In contrast, the decision to discharge to rehabilitation rather than to subacute care appears to reflect sociobiologic and socioeconomic factors; however, generalizability of these results is limited by the restricted range of potentially important variables available for analysis.	[Cuthbert, Jeffrey P.; Harrison-Felix, Cynthia; Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Coronado, Victor] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Heinemann, Allen W.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA		Cuthbert, JP (corresponding author), 3425 S Clarkson St, Englewood, CO 80113 USA.	JCuthbert@Craighospital.org	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021; Corrigan, John D./E-2921-2011	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, U.S. Department of EducationUS Department of Education [H133A060038]; Traumatic Brain Injury Model System Centers [H133A070022]; Ohio State UniversityOhio State University [H133A070029]; Mount Sinai Medical Center [H133A070033]; Rehabilitation Institute of Chicago [H133A080045]	Supported by a supplemental grant to the Traumatic Brain Injury Model Systems National Data and Statistical Center from the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, U.S. Department of Education (grant no. H133A060038): and Traumatic Brain Injury Model System Centers grants to Craig Hospital (grant no. H133A070022), Ohio State University (grant no. H133A070029), Mount Sinai Medical Center (grant no. H133A070033), and the Rehabilitation Institute of Chicago (grant no. H133A080045).	Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BODOFSKY E, 2010, INT BRAIN INJ ASS 8; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Chang PFJ, 2008, ARCH PHYS MED REHAB, V89, P231, DOI 10.1016/j.apmr.2007.08.143; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; CROSS J, 2003, MMWR-MORBID MORTAL W, V52, P276; Faul M, 2010, TRAUMATIC BRAIN INJU; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Goleburn CR, 2001, J CLIN GEROPSYCHOL, V7, P161; Hadley J, 2006, HEALTH AFFAIR, V25, P1679, DOI 10.1377/hlthaff.25.6.1679; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Labi MLC, 2003, BRAIN INJURY, V17, P265, DOI 10.1080/0269905021000038410; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; Malec JF, 2009, BRAIN INJURY, V23, P22, DOI 10.1080/02699050802590320; Marr A., 2004, CENTRAL NERVOUS SYST; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Okoro CA, 2005, J HEALTH CARE POOR U, V16, P453, DOI 10.1353/hpu.2005.0058; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Richardson LD, 2010, MT SINAI J MED, V77, P166, DOI 10.1002/msj.20174; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2003, ACAD EMERG MED, V10, P1260, DOI 10.1197/S1069-6563(03)00497-4; Sentell T, 2007, J GEN INTERN MED, V22, P289, DOI 10.1007/s11606-007-0345-7; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shahian DM, 2007, CIRCULATION, V115, P1518, DOI 10.1161/CIRCULATIONAHA.106.633008; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; *US DEP HHS, 2004, INT CLASS DIS 9 REV; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	40	68	70	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2011	92	5					721	730		10.1016/j.apmr.2010.12.023			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	759YO	WOS:000290288000005	21530719				2022-02-06	
J	Kilbaugh, TJ; Bhandare, S; Lorom, DH; Saraswati, M; Robertson, CL; Margulies, SS				Kilbaugh, Todd J.; Bhandare, Sunita; Lorom, David H.; Saraswati, Manda; Robertson, Courtney L.; Margulies, Susan S.			Cyclosporin A Preserves Mitochondrial Function after Traumatic Brain Injury in the Immature Rat and Piglet	JOURNAL OF NEUROTRAUMA			English	Article						cerebral microdialysis; cyclosporin A; mitochondrial bioenergetics; neuroprotection; pediatric brain injury	MATURATION-DEPENDENT RESPONSE; DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; OXIDATIVE STRESS; PERMEABILITY TRANSITION; CYTOCHROME-C; CEREBRAL METABOLISM; DAMAGE; DYSFUNCTION; CALCIUM	Cyclosporin A (CsA) has been shown to be neuroprotective in mature animal models of traumatic brain injury (TBI), but its effects on immature animal models of TBI are unknown. In mature animal models, CsA inhibits the opening of the mitochondrial permeability transition pore (MPTP), thereby maintaining mitochondrial homeostasis following injury by inhibiting calcium influx and preserving mitochondrial membrane potential. The aim of the present study was to evaluate CsA's ability to preserve mitochondrial bioenergetic function following TBI (as measured by mitochondrial respiration and cerebral microdialysis), in two immature models (focal and diffuse), and in two different species (rat and piglet). Three groups were studied: injured + CsA, injured + saline vehicle, and uninjured shams. In addition, we evaluated CsA's effects on cerebral hemodynamics as measured by a novel thermal diffusion probe. The results demonstrate that post-injury administration of CsA ameliorates mitochondrial dysfunction, preserves cerebral blood flow (CBF), and limits neuropathology in immature animals 24 h post-TBI. Mitochondria were isolated 24 h after controlled cortical impact (CCI) in rats and rapid non-impact rotational injury (RNR) in piglets, and CsA ameliorated cerebral bioenergetic crisis with preservation of the respiratory control ratio (RCR) to sham levels. Results were more dramatic in RNR piglets than in CCI rats. In piglets, CsA also preserved lactate pyruvate ratios (LPR), as measured by cerebral microdialysis and CBF at sham levels 24 h after injury, in contrast to the significant alterations seen in injured piglets compared to shams (p<0.01). The administration of CsA to piglets following RNR promoted a 42% decrease in injured brain volume (p<0.01). We conclude that CsA exhibits significant neuroprotective activity in immature models of focal and diffuse TBI, and has exciting translational potential as a therapeutic agent for neuroprotection in children.	[Lorom, David H.; Margulies, Susan S.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [Kilbaugh, Todd J.] Univ Penn, Sch Med Anesthesiol & Crit Care Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Bhandare, Sunita] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Saraswati, Manda; Robertson, Courtney L.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA		Margulies, SS (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulies@seas.upenn.edu		Kilbaugh, Todd/0000-0002-4959-3092	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679]; Endowed Chair of Anesthesiology and Critical Care Medicine at the Children's Hospital of Philadelphia; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS069545, R01NS039679] Funding Source: NIH RePORTER	These studies were supported by NIH/NINDS grant R01NS039679 and the Endowed Chair of Anesthesiology and Critical Care Medicine at the Children's Hospital of Philadelphia. We are thankful for the technical and scientific assistance of Trupti Akella, Stuart Friess, Jill Ralston, and Gary Fiskum.	Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BATES TE, 1994, DEV NEUROSCI-BASEL, V16, P321, DOI 10.1159/000112126; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; de Gatta MDF, 2002, CLIN PHARMACOKINET, V41, P115; DELMAESTRO R, 1987, MECH AGEING DEV, V41, P29, DOI 10.1016/0047-6374(87)90051-0; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2007, J NEUROTRAUM, V24, P5, DOI 10.1089/neu.2006.0054; Eliseev RA, 2007, NEUROBIOL AGING, V28, P1532, DOI 10.1016/j.neurobiolaging.2006.06.022; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Fukui S, 2003, ACT NEUR S, V86, P301; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Ghafari A, 2007, TRANSPL P, V39, P1219, DOI 10.1016/j.transproceed.2007.03.014; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hoyert Donna L, 2006, Natl Vital Stat Rep, V54, P1; Hutchinson PJ, 2005, ACTA NEUROCHIR SUPPL, V95, P441; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Hwang JH, 2010, BRAIN RES, V1359, P208, DOI 10.1016/j.brainres.2010.08.047; Ibrahim NG, 2010, J NEUROTRAUM, V27, P1021, DOI 10.1089/neu.2009.1212; Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0; Leger PL, 2010, EXP NEUROL; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Lie RH, 2010, ACTA ANAESTH SCAND, V54, P804, DOI 10.1111/j.1399-6576.2010.02241.x; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Mazzeo AT, 2008, ACTA NEUROCHIR, V150, P1019, DOI 10.1007/s00701-008-0021-7; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Nakai A, 2004, PEDIATR NEUROL, V30, P247, DOI 10.1016/j.pediatrneurol.2003.09.006; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nishiyama A, 2003, HYPERTENSION, V42, P754, DOI 10.1161/01.HYP.0000085195.38870.44; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Patrick PD, 2006, J CHILD NEUROL, V21, P879, DOI 10.1177/08830738060210100901; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saito A, 2005, MOL NEUROBIOL, V31, P105, DOI 10.1385/MN:31:1-3:105; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; Setkowicz Z, 2004, EPILEPSY RES, V61, P63, DOI 10.1016/j.eplepsyres.2004.06.001; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Turner MS, 2003, ACT NEUR S, V87, P81; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3	94	68	69	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					763	774		10.1089/neu.2010.1635			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100277	21250918	Green Published			2022-02-06	
J	Griesbach, GS; Hovda, DA; Tio, DL; Taylor, AN				Griesbach, G. S.; Hovda, D. A.; Tio, D. L.; Taylor, A. N.			HEIGHTENING OF THE STRESS RESPONSE DURING THE FIRST WEEKS AFTER A MILD TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						corticosterone; fluid percussion injury; dexamethasone; adrenocorticotropic hormone; traumatic brain injury and stress	CORTICOTROPIN-RELEASING HORMONE; LATERAL FLUID PERCUSSION; PITUITARY-ADRENAL AXIS; NEUROTROPHIC FACTOR EXPRESSION; MAJOR DEPRESSIVE DISORDER; ADRENOCORTICAL-RESPONSE; GENE-EXPRESSION; DEVELOPING RAT; UP-REGULATION; ACUTE-PHASE	The effects of a mild traumatic brain injury range from white matter disruption to affective disorders. We set out to determine the response to restraint-induced stress after a mild fluid-percussion injury (FPI), an experimental model for brain injury. Hypothalamic-pituitary-adrenal (HPA) axis regulation of corticosterone (CORT) and adrenocorticotropic hormone (ACTH) was determined during the first post-injury weeks, which corresponds to the same time period when rehabilitative exercise has been shown to be ineffective after a mild FPI. Adult male rats underwent either an FPI or sham injury. Additional rats were only exposed to anesthesia. HPA regulation was evaluated by measuring the effects of dexamethasone (DEX) treatment on CORT and ACTH. Tail vein blood was collected following 30-min restraint stress, at post-injury days (PID) 1, 7 and 14, prior to (0 min) and at 30, 60, 90 and 120 min after stress onset. Results from these studies indicate that the stress response was significantly more pronounced after FPI in that CORT and ACTH restraint-induced increases were more pronounced and longer lasting compared to controls. DEX suppression of CORT and ACTH was observed in all groups, suggesting that stress hyper-responsiveness after mild FPI is not attributable to reduced sensitivity of CORT feedback regulation. The increased sensitivity to stressful events in the first two post-injury weeks after a mild FPI may have a negative impact on early rehabilitative therapies. (c) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Griesbach, G. S.; Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Tio, D. L.; Taylor, A. N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA		Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957030, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			NINDS awardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS6190]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061960] Funding Source: NIH RePORTER	This study was supported by NINDS award NS6190 (GSG) and the UCLA Brain Injury Research Center. We would also wish to thank David L. McArthur, PhD. for his statistical advice and David Garfinkel for his excellent technical help.	Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Ashman TA, 2006, MT SINAI J MED, V73, P999; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bornstein SR, 2008, TRENDS ENDOCRIN MET, V19, P175, DOI 10.1016/j.tem.2008.01.009; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; de Kloet ER, 2000, EUR J PHARMACOL, V405, P187, DOI 10.1016/S0014-2999(00)00552-5; DeKeyser FG, 2000, NEUROIMMUNOMODULAT, V7, P182, DOI 10.1159/000026437; Faul M, 2010, EMERGENCY DEP VISITS; Gold PW, 2002, MOL PSYCHIATR, V7, P254, DOI 10.1038/sj.mp.4001032; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hansson AC, 2000, EUR J NEUROSCI, V12, P2918, DOI 10.1046/j.1460-9568.2000.00185.x; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hirasawa K, 2000, J NEUROSURG, V93, P581, DOI 10.3171/jns.2000.93.4.0581; Houshyar H, 2001, J NEUROENDOCRINOL, V13, P875, DOI 10.1046/j.1365-2826.2001.00714.x; Ising M, 2005, PROG NEURO-PSYCHOPH, V29, P1085, DOI 10.1016/j.pnpbp.2005.03.014; Johnson KL, 2006, AACN ADV CRIT CARE, V17, P39, DOI 10.1097/00044067-200601000-00006; Juruena Mario F., 2004, Revista Brasileira de Psiquiatria, V26; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Neigh GN, 2009, J CEREBR BLOOD F MET, V29, P1673, DOI 10.1038/jcbfm.2009.85; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Posener JA, 2000, ARCH GEN PSYCHIAT, V57, P755, DOI 10.1001/archpsyc.57.8.755; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; REIMOLD M, PSYCHOPHARM IN PRESS; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; Santibanez M, 2006, J NEUROSCI RES, V84, P1270, DOI 10.1002/jnr.21023; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; SHENKIN HA, 1971, J NEUROSURG, V34, P657, DOI 10.3171/jns.1971.34.5.0657; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; Strohle A, 2003, PHARMACOPSYCHIATRY, V36, pS207; SWANSON LW, 1983, ANNU REV NEUROSCI, V6, P269, DOI 10.1146/annurev.ne.06.030183.001413; Szmydynger-Chodobska J, 2011, J CEREBR BLOOD F MET, V31, P47, DOI 10.1038/jcbfm.2010.188; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Taylor AN, 2010, J NEUROTRAUM, V27, P1081, DOI 10.1089/neu.2009.1252; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Vreeburg SA, 2009, ARCH GEN PSYCHIAT, V66, P617, DOI 10.1001/archgenpsychiatry.2009.50; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Xu Miao, 2007, Chin J Traumatol, V10, P90; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Yuan ZH, 2010, CHIN J TRAUMATOL, V13, P42, DOI 10.3760/cma.j.issn.1008-1275.2010.01.008	70	68	71	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 31	2011	178						147	158		10.1016/j.neuroscience.2011.01.028			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	736WK	WOS:000288525500015	21277947	Green Accepted			2022-02-06	
J	Caeyenberghs, K; Leemans, A; Geurts, M; Taymans, T; Vander Linden, C; Smits-Engelsman, BCM; Sunaert, S; Swinnen, SP				Caeyenberghs, Karen; Leemans, Alexander; Geurts, Monique; Taymans, Tom; Vander Linden, Catharine; Smits-Engelsman, Bouwien C. M.; Sunaert, Stefan; Swinnen, Stephan P.			Brain-Behavior Relationships in Young Traumatic Brain Injury Patients: DTI Metrics are Highly Correlated with Postural Control	HUMAN BRAIN MAPPING			English	Article						traumatic brain injury; DTI; balance; children; neuroplasticity	DIFFUSION TENSOR IMAGES; WHITE-MATTER; HEAD-INJURY; CEREBELLAR ATROPHY; CORPUS-CALLOSUM; MILD; CHILDREN; BALANCE; MODERATE; ATLAS	Traumatic brain injury (TBI) is a major cause of impairment and functional disability in children and adolescents, including deterioration in fine as well as gross motor skills. The aim of this study was to assess deficits in sensory organization and postural ability in a young group of TBI patients versus controls by using quantitative force-platform recordings, and to test whether balance deficits are related to variation in structural properties of the motor and sensory white matter pathways. Twelve patients with TBI and 14 controls (aged 8-20 years) performed the Sensory Organisation Test (SOT) protocol of the EquiTest(R) (Neurocom). All participants were scanned using Diffusion Tensor Imaging (DTI) along with standard anatomical scans. Quantitative comparisons of DTI parameters (fractional anisotropy, axial and radial diffusivity) between TBI patients and controls were performed. Correlations between DTI parameters and SOT balance scores were determined. Findings revealed that the TBI group scored generally lower than the control group on the SOT, indicative of deficits in postural control. In the TBI group, reductions in fractional anisotropy were noted in the cerebellum, posterior thalamic radiation, and corticospinal tract. Degree of white matter deterioration was highly correlated with balance deficits. This study supports the view that DTI is a valuable tool for assessing the integrity of white matter structures and for selectively predicting functional motor deficits in TBI patients. Hum Brain Mapp 31:992-1002, 2010. (C) 2009 Wiley-Liss, Inc.	[Swinnen, Stephan P.] Katholieke Univ Leuven, Grp Biomed Sci, Res Ctr Motor Control & Neuroplast, Lab Motor Control, B-3001 Heverlee, Belgium; [Leemans, Alexander] Cardiff Univ, Sch Psychol, CUBRIC, Cardiff, S Glam, Wales; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, Dept Radiol, Utrecht, Netherlands; [Vander Linden, Catharine] Ghent Univ Hosp, Dept Phys Med & Rehabil, Child Rehabil Ctr, Ghent, Belgium; [Smits-Engelsman, Bouwien C. M.] Univ Profess, Breda, Netherlands; [Sunaert, Stefan] Katholieke Univ Leuven, Univ Hosp, Dept Radiol, B-3001 Heverlee, Belgium		Swinnen, SP (corresponding author), Katholieke Univ Leuven, Grp Biomed Sci, Res Ctr Motor Control & Neuroplast, Lab Motor Control, Tervuursevest 101, B-3001 Heverlee, Belgium.	stephan.swinnen@faber.kuleuven.be	Leemans, Alexander/A-1784-2011; Sunaert, Stefan/E-8031-2011	Leemans, Alexander/0000-0002-9306-6126; Sunaert, Stefan/0000-0002-1177-4680; Caeyenberghs, Karen/0000-0001-7009-6843	Research Foundation - Flanders (FWO)FWO [7.0004.05]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P6/29]	Support for this study was provided through a grant from the Research Programme of the Research Foundation - Flanders (FWO) (Levenslijn # 7.0004.05), as well as Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a PhD fellowship of the Research Foundation - Flanders (FWO).	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Arfanakis K, 2002, MAGNET RESON MED, V47, P354, DOI 10.1002/mrm.10046; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bleyenheuft Y, 2007, PEDIATRICS, V120, pE1502, DOI 10.1542/peds.2007-0394; Boska MD, 2007, NEUROBIOL DIS, V26, P590, DOI 10.1016/j.nbd.2007.02.010; Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; Ge YL, 2005, ANN NY ACAD SCI, V1064, P202, DOI 10.1196/annals.1340.039; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hong JH, 2009, BRAIN RES BULL, V80, P30, DOI 10.1016/j.brainresbull.2009.05.021; Hoon AH, 2002, NEUROLOGY, V59, P752, DOI 10.1212/WNL.59.5.752; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Kamali A, 2009, EUR RADIOL, V19, P1480, DOI 10.1007/s00330-009-1305-x; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lancaster JL, 2007, HUM BRAIN MAPP, V28, P1194, DOI 10.1002/hbm.20345; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Leemans A, 2005, LECT NOTES COMPUT SC, V3708, P523; Leemans A., 2009, 17 ANN M INT SOC MAG, DOI DOI 10.1093/OCCMED/KQR069; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2005, MRI ATLAS HUMAN WHIT; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; SCHAECHTER JD, 2009, MICROSTRUCT IN PRESS; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits-Engelsman BC, 1998, MOVEMENT ASSESSMENT; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sosin DM, 1996, BRAIN INJURY, V10, P47; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Sugden, 1992, MOVEMENT ASSESSMENT; Thomas B, 2005, BRAIN, V128, P2562, DOI 10.1093/brain/awh600; Van Hecke W, 2008, NEUROIMAGE, V43, P69, DOI 10.1016/j.neuroimage.2008.07.006; Van Hecke W, 2007, IEEE T MED IMAGING, V26, P1598, DOI 10.1109/TMI.2007.906786; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412	65	68	68	0	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUL	2010	31	7					992	1002		10.1002/hbm.20911			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	622TT	WOS:000279689400005	19998364	Green Published			2022-02-06	
J	Emery, CA; Hagel, B; Decloe, M; Carly, M				Emery, Carolyn A.; Hagel, Brent; Decloe, Melissa; Carly, McKay			Risk factors for injury and severe injury in youth ice hockey: a systematic review of the literature	INJURY PREVENTION			English	Article							DATA-COLLECTION PROCEDURES; CONSENSUS STATEMENT; BODY CHECKING; RATES; SPORT; BODYCHECKING; DEFINITIONS; PLAYERS	Objective To identify risk factors for injury in youth ice hockey (ie, body checking, age, player position, player experience and level of play). Study design Systematic review and meta-analysis. Methods A systematic review of the literature, including a meta-analysis component was completed. Ten electronic databases and the American Society for Testing and Materials Safety in Ice Hockey series (volumes 1-4) were systematically searched with strict inclusion and exclusion criteria to identify articles examining risk factors for injury in youth ice hockey. Results Participation in games, compared with practices, was associated with an increased risk of injury in all studies examined. Age, level of play and player position produced inconsistent findings. Body checking was identified as a significant risk factor for all injuries (summary rate ratio: 2.45; 95% CI 1.7 to 3.6) and concussion (summary odds ratio: 1.71; 95% CI 1.2 to 2.44). Conclusions Findings regarding most risk factors for injury remain inconclusive; however, body checking was found to be associated with an increased risk of injury. Policy implications regarding delaying body checking to older age groups and to only the most elite levels requires further rigorous investigation.	[Emery, Carolyn A.] Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Carly, McKay] Univ Western Ontario, London, ON N6A 3K7, Canada		Emery, CA (corresponding author), Univ Calgary, Sport Med Ctr, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	caemery@ucalgary.ca	Hagel, Brent/AAK-3319-2020; Emery, Carolyn/AAI-2761-2020	McKay, Carly/0000-0001-7664-3211	Alberta Heritage Foundation for Medical ResearchAlberta Heritage Foundation for Medical ResearchGeneral Electric; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Paediatric Rehabilitation through the Alberta Children's Hospital Foundation; Canadian National Railway Company; Social Sciences and Humanities Research Council of Canada (SSHRCC)Social Sciences and Humanities Research Council of Canada (SSHRC); Department of Paediatrics Child Health Research Group Scholarship; Alberta Centre for Injury Control	Dr Emery and Dr Hagel are supported by a Population Health Investigator Award from the Alberta Heritage Foundation for Medical Research. Dr Emery also holds and a New Investigator Award from the Canadian Institutes of Health Research and a Professorship in Paediatric Rehabilitation funded through the Alberta Children's Hospital Foundation. Dr Hagel holds a Professorship in Child Health and Wellness funded by the Alberta Children's Hospital Foundation, through the support of an anonymous donor and Canadian National Railway Company. Melissa Decloe's MSc was supported by the Social Sciences and Humanities Research Council of Canada (SSHRCC), a Department of Paediatrics Child Health Research Group Scholarship and the Joanne A. Vincenten Scholarship from the Alberta Centre for Injury Control. Carly McKay is supported by SSHRCC.	Benson Brian W, 2005, Med Sport Sci, V49, P86, DOI 10.1159/000085393; BERNARD D, 1993, AM SOC TESTING MAT S, P44; BJORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Caine D, 2006, CLIN J SPORT MED, V16, P500, DOI 10.1097/01.jsm.0000251181.36582.a0; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; Egger M., 2001, SYSTEMATIC REV HLTH; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; EMERY CA, 2008, BRIT J SPORT MED, V42, P491; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; FINKE R C, 1988, Journal of Orthopaedic and Sports Physical Therapy, V10, P54; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Fuller CW, 2006, SCAND J MED SCI SPOR, V16, P83, DOI 10.1111/j.1600-0838.2006.00528.x; Hagel BE, 2006, CAN MED ASSOC J, V175, P155, DOI 10.1503/cmaj.051531; *HOCKEYCANADA, HOCK CAN ANN REP 200; *INT HOCKEYFEDERAT, 2009, INT IC HOCK FED SURV; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MCKAY C, 2008, BRIT J SPORT MED, V42, P533; MCKAY C, 2008, BRIT J SPORT MED, V42, P532; Molsa J, 2003, AM J SPORT MED, V31, P751; MONTELPARE WJ, 2004, J ASTM INT, V1, P70; REGNIER G, 1989, SAF ICE HOCKEY; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Smith AM, 1997, AM J SPORT MED, V25, P500, DOI 10.1177/036354659702500413; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; *USAHOCKEY, 2009, US HOCK ANN C REG RE; Warsh JM, 2009, CLIN J SPORT MED, V19, P134, DOI 10.1097/JSM.0b013e3181987783; Wattie N, 2007, PEDIATRICS, V120, P142, DOI 10.1542/peds.2006-2672; WIGGINS W, 1999, IMPLICATION INTRO BO; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06; WILLIAMSON IJS, 2006, EPIDEMIOLOGICAL INVE	37	68	69	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	APR	2010	16	2					113	118		10.1136/ip.2009.022764			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	577FW	WOS:000276208800009	20363818				2022-02-06	
J	DeMatteo, CA; Hanna, SE; Mahoney, WJ; Hollenberg, RD; Scott, LA; Law, MC; Newman, A; Lin, CYA; Xu, LQ				DeMatteo, Carol A.; Hanna, Steven E.; Mahoney, William J.; Hollenberg, Robert D.; Scott, Louise A.; Law, Mary C.; Newman, Anne; Lin, Chia-Yu A.; Xu, Liqin			"My Child Doesn't Have a Brain Injury, He Only Has a Concussion"	PEDIATRICS			English	Article						adolescent; brain concussion; brain injuries; child; pediatric hospitals	SPORT-RELATED CONCUSSION; DECISION-TREE ANALYSIS; GLASGOW COMA SCALE; IMPAIRED CONSCIOUSNESS; MANAGEMENT; CLASSIFICATION; ADOLESCENTS; POPULATION; PREDICTION; STATEMENT	OBJECTIVE: The term "concussion" is frequently used in clinical records to describe a traumatic head injury; however, there are no standard definitions of this term, particularly in how it is used with children. The goals of this study were to examine the clinical correlates of the concussion diagnosis and to identify the factors that lead to the use of this term in a regional pediatric center. METHODS: Medical data were prospectively collected from 434 children with traumatic brain injury who were admitted to a Canadian children's hospital. A proportional hazards regression was used to examine the association of the concussion diagnosis and the times until discharge and school return. A classification-tree analysis modeled the clinical correlates of patients who received a concussion diagnosis. RESULTS: The concussion label was significantly more likely to be applied to children with mild Glasgow Coma Scale scores of 13 to 15 (P = .03). The concussion label was strongly predictive of earlier hospital discharge (odds ratio [OR]: 1.5; 95% confidence interval [CI]: 1.2-1.9; P = .003) and earlier return to school (OR: 2.4 [95% CI: 1.6-3.7]; P < .001). A diagnosis of a concussion was significantly more likely when the computed-tomography results were normal and the child had lost consciousness. CONCLUSIONS: Children with mild traumatic brain injuries have an increased frequency of receiving the concussion label, although the label may also be applied to children with more-severe injuries. The concussion diagnosis is associated with important clinical outcomes. Its typical use in hospital settings likely refers to an impact-related mild brain injury, in the absence of indicators other than a loss of consciousness. Clinicians may use the concussion label because it is less alarming to parents than the term mild brain injury, with the intent of implying that the injury is transient with no significant long-term health consequences. Pediatrics 2010; 125: 327-334	[DeMatteo, Carol A.] McMaster Univ, Sch Rehabil Sci, Inst Appl Hlth Sci, Hamilton, ON L8S 1C7, Canada; [Hanna, Steven E.] McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada; [Mahoney, William J.; Hollenberg, Robert D.] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Hollenberg, Robert D.] McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada; [DeMatteo, Carol A.; Hollenberg, Robert D.; Newman, Anne] McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada; [DeMatteo, Carol A.; Hanna, Steven E.; Law, Mary C.; Lin, Chia-Yu A.] McMaster Univ, CanChild Ctr Childhood Disabil Res, Hamilton, ON L8S 1C7, Canada; [DeMatteo, Carol A.; Hollenberg, Robert D.; Newman, Anne] McMaster Childrens Hosp, Hamilton, ON, Canada		DeMatteo, CA (corresponding author), McMaster Univ, Sch Rehabil Sci, Inst Appl Hlth Sci, Room 433,1400 Main St W, Hamilton, ON L8S 1C7, Canada.	dematteo@mcmaster.ca		Hanna, Steven/0000-0003-3120-9600	Ontario Neurotrauma Foundation, Canada [2004-ABI-MTBI-305]; Ontario Ministry of Health and Long-term CareMinistry of Health and Long-Term Care, Ontario	This research was funded by a research grant from the Ontario Neurotrauma Foundation, Canada (2004-ABI-MTBI-305). The CanChild Centre for Childhood Disability Research is supported by the Ontario Ministry of Health and Long-term Care.	Anderson T, 2006, PRACTICAL NEUROLOGY, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Breiman L., 1984, CLASSIFICATION REGRE; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; *CAN PED SOC, 2006, PEDIAT CHILD HLTH, V11, P420; Cantu RC, 2007, NEW ENGL J MED, V356, P1787; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CHAPMAN SB, 1999, ADV SPEECH LANGUAGE, V1, P19; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Falk AC, 2005, CHILD NERV SYST, V21, P430, DOI 10.1007/s00381-005-1142-4; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hall KM, 1997, ARCH PHYS MED REHAB, V78, pS5, DOI 10.1016/S0003-9993(97)90149-0; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563, DOI 10.1089/neu.2000.17.563; Thompson Matthew D, 2003, Semin Pediatr Neurol, V10, P130, DOI 10.1016/S1071-9091(03)00021-4; Wade D, 1992, MEASUREMENT NEUROLOG; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; World Health Organization, 2004, ICD 10 INT STAT CLAS; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	39	68	70	0	25	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2010	125	2					327	334		10.1542/peds.2008-2720			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	573VH	WOS:000275942900018	20083526				2022-02-06	
J	McHugh, GS; Butcher, I; Steyerberg, EW; Marmarou, A; Lu, J; Lingsma, HF; Weir, J; Maas, AIR; Murray, GD				McHugh, Gillian S.; Butcher, Isabella; Steyerberg, Ewout W.; Marmarou, Anthony; Lu, Juan; Lingsma, Hester F.; Weir, James; Maas, Andrew I. R.; Murray, Gordon D.			A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project	CLINICAL TRIALS			English	Article							ACUTE STROKE; NEUROPROTECTIVE AGENTS; PROGNOSTIC ANALYSIS; CLINICAL-TRIALS; DESIGN; EFFICACY; SCALES	Background Clinical trials in traumatic brain injury have a disappointing track record, with a long history of 'negative' Phase III trials. One contributor to this lack of success is almost certainly the low efficiency of the conventional approach to the analysis, which discards information by dichotomizing an ordinal outcome scale. Purpose Our goal was to evaluate the potential efficiency gains, which can be achieved by using techniques, which extract additional information from ordinal outcome data - the proportional odds model and the sliding dichotomy. In addition, we evaluated the additional efficiency gains, which can be achieved through covariate adjustment. Methods The study was based on simulations, which were built around a database of patient-level data extracted from eight Phase III trials and three observational studies in traumatic brain injury. Two different putative treatment effects were explored, one which followed the proportional odds model, and the other which assumed that the effect of the intervention was to reduce the risk of death without changing the distribution of outcomes within survivors. The results are expressed as efficiency gains, reported as the percentage reduction in sample size that can be used with the ordinal analyses without loss of statistical power relative to the conventional binary analysis. Results The simulation results show substantial efficiency gains. Use of the sliding dichotomy allows sample sizes to be reduced by up to 40% without loss of statistical power. The proportional odds model gives modest additional gains over and above the gains achieved by use of the sliding dichotomy. Limitations As with any simulation study, it is difficult to know how far the findings may be extrapolated beyond the actual situations that were modeled. Conclusions Both ordinal techniques offer substantial efficiency gains relative to the conventional binary analysis. The choice between the two techniques involves subtle value judgments. In the situations examined, the proportional odds model gave efficiency gains over and above the sliding dichotomy, but arguably, the sliding dichotomy is more intuitive and clinically appealing. Clinical Trials 2010; 7: 44-57. http://ctj.sagepub.com.	[McHugh, Gillian S.; Butcher, Isabella; Weir, James; Murray, Gordon D.] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Marmarou, Anthony; Lu, Juan] Virginia Commonwealth Univ, Dept Neurosurg, Med Ctr, Richmond, VA USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium		Murray, GD (corresponding author), Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	gordon.murray@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS-042691]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803] Funding Source: UKRI; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	This work was supported by the US National Institutes of Health (Clinical Trial Design and Analysis in TBI Project: R01 NS-042691).	Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Bolland K, 1998, STAT MED, V17, P2835, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.3.CO;2-#; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; JENNETT B, 1975, LANCET, V1, P480; Lees KR, 2000, LANCET, V355, P1949, DOI 10.1016/S0140-6736(00)02326-6; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Mendelow AD, 2005, LANCET, V365, P387; Miller SW, 2008, STROKE, V39, pE14, DOI 10.1161/STROKEAHA.107.500355; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Optimising Anal Stroke Trials OAST, 2008, INT J STROKE, V3, P78, DOI 10.1111/j.1747-4949.2008.00184.x; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Saver JL, 2009, NEUROLOGY, V72, P1310, DOI 10.1212/01.wnl.0000341308.73506.b7; Steyerberg, 2019, CLIN PREDICTION MODE; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young FB, 2005, STROKE, V36, P597, DOI 10.1161/01.STR.0000154856.42135.85	23	68	68	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1740-7745	1740-7753		CLIN TRIALS	Clin. Trials	FEB	2010	7	1					44	57		10.1177/1740774509356580			14	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	561VU	WOS:000275008800004	20156956				2022-02-06	
J	Norrie, J; Heitger, M; Leathem, J; Anderson, T; Jones, R; Flett, R				Norrie, Joan; Heitger, Marcus; Leathem, Janet; Anderson, Tim; Jones, Richard; Flett, Ross			Mild traumatic brain injury and fatigue: A prospective longitudinal study	BRAIN INJURY			English	Article						Fatigue; mild traumatic brain injury; concussion; depression; anxiety; FSS; FAS; RPSQ; HADS; SF-36v2	POST-CONCUSSION SYMPTOMS; FORM HEALTH SURVEY; DEPRESSION SCALE; HOSPITAL ANXIETY; HEAD-INJURY; POSTCONCUSSION SYMPTOMS; MISERABLE MINORITY; SEVERITY SCALE; SURVEY SF-36; FOLLOW-UP	Primary objective: To examine fatigue prevalence, severity, predictors and co-variates over 6 months post-mild traumatic brain injury (MTBI). Research design: Longitudinal prospective study including 263 adults with MTBI. Procedures: Participants completed the Fatigue Severity Scale (FSS), Rivermead Post-concussion Symptoms Questionnaire (RPSQ), Hospital Anxiety and Depression Scale (HADS) and the Short Form 36 Health Survey-Version 2 (SF-36v2). Complete data were available for 159 participants. Key measures; prevalence-RPSQ Item 6: severity-FSS. The effect of time on fatigue prevalence and severity was examined using ANOVA. Multiple regression analysis identified statistically significant covariates. Main outcomes and results: Post-MTBI fatigue prevalence was 68%, 38% and 34% at 1 week, 3 and 6 months, respectively. There was a strong effect for time over the first 3 months and moderate-to-high correlations between fatigue prevalence and severity. Early fatigue strongly predicted later fatigue; depression, but not anxiety was a predictor. Fatigue was seen as laziness by family or friends in 30% of cases. Conclusions: Post-MTBI fatigue is a persistent post-concussion symptom, exacerbated by depression but not anxiety. It diminishes in the first 3 months and then becomes relatively stable, suggesting the optimum intervention placement is at 3 months or more post-MTBI.	[Norrie, Joan; Flett, Ross] Massey Univ, Dept Psychol, Palmerston North 4442, New Zealand; [Heitger, Marcus; Anderson, Tim; Jones, Richard] Univ Otago, Dept Med, Christchurch, New Zealand; [Heitger, Marcus; Anderson, Tim; Jones, Richard] Van der Veer Inst Parkinsons & Brain Res, Christchurch, New Zealand; [Leathem, Janet] Massey Univ, Dept Psychol, Wellington, New Zealand		Norrie, J (corresponding author), Massey Univ, Dept Psychol, PB 11222, Palmerston North 4442, New Zealand.	j.m.norrie@massey.ac.nz		Flett, Ross/0000-0002-3638-710X; Jones, Richard/0000-0003-2287-3358	Canterbury Medical Research Foundation (CMRF) [05/02]	The study was hosted by the Canterbury District Health Board and the University of Otago-Christchurch, New Zealand. Funding for participants' travel costs was provided by the Canterbury Medical Research Foundation (CMRF project number 05/02). We wish to thank these institutions for their support of this research.	Addington AM, 2001, PSYCHOL MED, V31, P1037, DOI 10.1017/S0033291701004214; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CAVALLO MM, 2005, TXB TRAUMATIC BRAIN, P533; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; de Leon MB, 2009, ARCH PHYS MED REHAB, V90, P956, DOI 10.1016/j.apmr.2008.12.016; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; FUHRER R, 1995, PSYCHOL MED, V25, P895, DOI 10.1017/S0033291700037387; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; HEITGER MH, 2005, MILD HEAD INJURY USE; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hillier SL, 1997, BRAIN INJURY, V11, P661; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jason L A, 1999, J Health Psychol, V4, P9, DOI 10.1177/135910539900400103; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinnear P., 2008, SPSS 15 MADE SIMPLE; Kleinman L, 2000, QUAL LIFE RES, V9, P499, DOI 10.1023/A:1008960710415; Krupp, 2003, FATIGUE; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Martin CR, 2005, CURR PSYCHIATRY REV, V1, P69, DOI 10.2174/1573400052953510; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; *NZ GUID GROUP, 2006, ACC2404 NZ GUID GROU; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2000, BRAIN INJURY, V14, P219; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; RAO V, 2005, TXB TRAUMATIC BRAIN, P369; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Russo J, 1998, MED CARE, V36, P752, DOI 10.1097/00005650-199805000-00015; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; SCHONBERGER M, 2010, PSYCHIAT RE IN PRESS; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Stewart AL, 1992, MEASURING FUNCTIONIN; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wang WR, 2006, QUAL LIFE RES, V15, P1525, DOI 10.1007/s11136-006-0012-1; Ware J., 2000, SCORE VERSION 2 SF 3; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 2004, ICD 10 INT STAT CLAS; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Yang CM, 2005, QUAL LIFE RES, V14, P1357, DOI 10.1007/s11136-004-5680-0; ZASLER ND, 2005, BRAIN INJURY MED PRI; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	73	68	69	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	13-14					1528	1538		10.3109/02699052.2010.531687			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	691QV	WOS:000285096800002	21058899				2022-02-06	
J	Benge, JF; Pastorek, NJ; Thornton, GM				Benge, Jared F.; Pastorek, Nicholas J.; Thornton, G. Matthew			Postconcussive Symptoms in OEF-OIF Veterans: Factor Structure and Impact of Posttraumatic Stress	REHABILITATION PSYCHOLOGY			English	Article; Proceedings Paper	37th Annual Meeting of the International-Neuropsychological-Society	FEB, 2009	Atlanta, GA	Int Neuropsychol Soc		factor analysis; measurement; mild traumatic brain injury; postconcussive symptoms; posttraumatic stress; veterans	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYNDROME; CONSTRUCT-VALIDITY; CHRONIC PAIN; HEAD-INJURY; QUESTIONNAIRE; IRAQ; RELIABILITY; COMPLAINTS	Purpose: Veterans with a history of mild traumatic brain injury (mTBI) are reporting postconcussive symptoms (PCSx) in addition to experiencing postdeployment physical and emotional comorbidities. The Veterans Health Administration has mandated specialized evaluation and treatment for veterans with a history of mTBI and has suggested widespread use of the Neurobehavioral Symptom Inventory (NSI) as a measure of PCSx. This study evaluated the NSI's factor structure and assessed the impact of posttraumatic stress (PTS) on the scale at the item and factor levels. Research Method. Five hundred twenty-nine charts of returning veterans who screened positive for traumatic brain injury were reviewed, and 345 who met criteria for mTBI were included in the study. Results: Results of factor analysis on the NSI revealed a difficult-to-interpret factor structure that was inconsistent with the results of civilian studies. PTS explained 5%-38% of the variance in individual PCSx, and after controlling for this variance, the factor structure more closely paralleled findings from the civilian literature. Conclusion: PTS is an important variable to account for when evaluating PCSx in veterans. Research and clinical implications for the measurement and interpretation of self-reported PCSx are discussed.	[Benge, Jared F.; Pastorek, Nicholas J.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Benge, Jared F.] Baylor Coll Med, Menninger Dept Psychiat, Houston, TX 77030 USA; [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Thornton, G. Matthew] Univ Houston, Dept Psychol, Houston, TX 77004 USA		Benge, JF (corresponding author), Michael E DeBakey VA Med Ctr, 116 MHCL,2002 Holcombe Blvd, Houston, TX 77030 USA.	Jared.Benge@va.gov		Benge, Jared/0000-0001-6201-3278; Pastorek, Nicholas/0000-0002-9290-380X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Centers for Disease Control and Prevention, 2008, BLAST INJ EAR BLAST; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; *DEF VET BRAIN INJ, 2006, CLIN PRACT GUID REC; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Mendes T, 2008, AGING MENT HEALTH, V12, P177, DOI 10.1080/13607860701797281; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Piland SG, 2003, J ATHL TRAINING, V38, P104; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; SPSS Inc, 2007, SPSS 16 0 COMP SOFTW; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thompson B., 2004, EXPLORATORY CONFIRMA; US Government Accountability Office, 2008, VA HLTH CAR MILD TRA; Weathers F.W., 1993, 9 ANN C ISTSS; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	33	68	68	0	1	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2009	54	3					270	278		10.1037/a0016736			9	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology; Rehabilitation	488SW	WOS:000269371100004	19702425				2022-02-06	
J	Bjork, JM; Grant, SJ				Bjork, James M.; Grant, Steven J.			Does Traumatic Brain Injury Increase Risk for Substance Abuse?	JOURNAL OF NEUROTRAUMA			English	Article						addiction; closed-head injury; cognition; drug abuse; drug dependence; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; DECISION-MAKING; DRUG-USE; EMERGENCY-ROOM; IMPULSE CONTROL; COCAINE USERS; PRIMARY-CARE; ALCOHOL; DEFICITS	Wars in Afghanistan and Iraq have resulted in thousands of military personnel suffering traumatic brain injury (TBI), including closed-head injuries. Of interest is whether these individuals and other TBI survivors are at increased risk for substance use disorder (SUD). While it has been well established that drug or alcohol intoxication itself increases probability of suffering a TBI in accidents or acts of violence, little is known about whether the brain insult itself increases the likelihood that a previously non-drug-abusing individual would develop SUD. Might TBI survivors be unusually vulnerable to addiction to opiate analgesics compared to other pain patients? Similarly, it is not known if TBI increases the likelihood of relapse among persons with SUD in remission. We highlight challenges in answering these questions, and review neurochemical and behavioral evidence that supports a causal relationship between TBI and SUD. In this review, we conclude that little is known regarding the directionality of TBI increasing drug abuse, and that collaborative research in this area is critically needed.	[Bjork, James M.; Grant, Steven J.] Natl Inst Drug Abuse, Div Clin Neurosci & Behav Res, NIH, Bethesda, MD 20892 USA		Bjork, JM (corresponding author), Natl Inst Drug Abuse, Div Clin Neurosci & Behav Res, NIH, 6001 Execut Blvd,Room 3151, Bethesda, MD 20892 USA.	jbjork@mail.nih.gov	Bjork, James/Q-5108-2019	Bjork, James/0000-0003-0593-3291			Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584; Bechara A, 2005, CURR OPIN NEUROL, V18, P734, DOI 10.1097/01.wco.0000194141.56429.3c; Beer JS, 2006, J COGNITIVE NEUROSCI, V18, P871, DOI 10.1162/jocn.2006.18.6.871; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Cherpitel CJ, 2008, DRUG ALCOHOL DEPEN, V97, P226, DOI 10.1016/j.drugalcdep.2008.03.033; Cherpitel CJ, 2008, AM J DRUG ALCOHOL AB, V34, P576, DOI 10.1080/00952990802308189; Cherpitel CJ, 2007, DRUG ALCOHOL REV, V26, P201, DOI 10.1080/09595230601146686; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Di Chiara G, 2007, CURR OPIN PHARMACOL, V7, P69, DOI 10.1016/j.coph.2006.11.003; Dixon MR, 2005, BEHAV INTERVENT, V20, P101, DOI 10.1002/bin.173; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Franken IHA, 2007, BIOL PSYCHOL, V75, P45, DOI 10.1016/j.biopsycho.2006.11.003; Franulic A, 2000, BRAIN INJURY, V14, P431; Hester R, 2007, NEUROPSYCHOPHARMACOL, V32, P1974, DOI 10.1038/sj.npp.1301326; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kaufman JN, 2003, J NEUROSCI, V23, P7839; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P615, DOI 10.1017/S1355617707070762; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McHugh L, 2008, BRAIN INJURY, V22, P715, DOI 10.1080/02699050802263027; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Reynolds B, 2006, BEHAV PHARMACOL, V17, P651, DOI 10.1097/FBP.0b013e3280115f99; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Schlund MW, 2002, BRAIN INJURY, V16, P527, DOI 10.1080/02699050110113679; Schultz W, 2007, TRENDS NEUROSCI, V30, P203, DOI 10.1016/j.tins.2007.03.007; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tate DG, 2004, ARCH PHYS MED REHAB, V85, P1837, DOI 10.1016/j.apmr.2004.02.022; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Taylor SF, 2007, NEUROSCIENTIST, V13, P160, DOI 10.1177/1073858406298184; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Vitale S, 2006, DRUG ALCOHOL DEPEN, V82, P1, DOI 10.1016/j.drugalcdep.2005.08.017; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087	50	68	68	0	18	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2009	26	7					1077	1082		10.1089/neu.2008.0849			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	470HJ	WOS:000267965500013	19203230	Green Published			2022-02-06	
J	Fadyl, JK; McPherson, KM				Fadyl, Joanna Kristin; McPherson, Kathryn M.			Approaches to Vocational Rehabilitation After Traumatic Brain Injury: A Review of the Evidence	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						review; traumatic brain injury; vocational rehabilitation; work reentry	MILIEU-BASED NEUROREHABILITATION; QUALITY-OF-LIFE; SUPPORTED EMPLOYMENT; WORK; RETURN; OUTCOMES; MODEL; INDIVIDUALS; PROGRAM; INTEGRATION	Background: Return to work after traumatic brain injury (TBI) is an important outcome but frequently problematic to achieve. Vocational rehabilitation is commonly recommended as a means of facilitating return to work after TBI. However, there are several different approaches to vocational rehabilitation after TBI and little guidance regarding how to identify the best option for a particular context. Objectives: To (1) identify approaches most commonly underpinning vocational Interventions in TBI and (2) evaluate the evidence for effectiveness, strengths and weaknesses, and application of each approach for the TBI population. Methods: Principles of systematic review were used for searching and critiquing articles. Findings are expressed as descriptive synthesis owing to heterogeneity of designs and outcome measures. Results: Three broad categories of vocational rehabilitation for people with TBI were identified on the basis of models that underpin them-program-based vocational rehabilitation, supported employment, and case coordinated. The characteristics, similarities, differences, and applications of each approach are described, as are their strengths and limitations. Conclusions: There is little clear evidence to suggest what should be considered the "best practice" approach to vocational rehabilitation,	[Fadyl, Joanna Kristin; McPherson, Kathryn M.] AUT Univ, Sch Rehabil & Occupat Studies, Auckland 1142, New Zealand		Fadyl, JK (corresponding author), AUT Univ, Sch Rehabil & Occupat Studies, Private Bag 92006, Auckland 1142, New Zealand.	jfadyl@aut.ac.nz		McPherson, Kath/0000-0003-0487-8497; McPherson, Kathryn/0000-0003-1240-8882			*ACC COMP CORP, 2007, ACC INJ STAT 2006; Babineau J L, 1998, Work, V10, P137, DOI 10.3233/WOR-1998-10205; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BREIL L, 1996, J VOCAT REHABIL, V7, P151; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Catalano D, 2006, NEUROREHABILITATION, V21, P279; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; CRISP R, 1992, J REHABIL, V58, P27; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; ELLERD DA, 1992, J APPL REHABILITATIO, V23, P48; EVANS RW, 1990, COMMUNITY INTEGRATIO, P125; Fineout-Overholt E, 2005, NURSE LEAD, V3, P26, DOI 10.1016/j.mnl.2005.09.007; Gamble D, 2003, J REHABIL, V69, P31; Gamble D, 2003, J VOCATIONAL REHABIL, V19, P47; GOLDEN TP, 1993, J REHABIL, V59, P55; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HOARE R, 2004, NZ STAT ASS 2004 C J; Johansson U, 2006, AM J OCCUP THER, V60, P60, DOI 10.5014/ajot.60.1.60; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Johnstone B, 2006, NEUROREHABILITATION, V21, P335; Kendall E, 2006, J VOCAT REHABIL, V25, P149; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; LAMARCHE JA, 1995, J HEAD TRAUMA REHAB, V10, P81, DOI 10.1097/00001199-199508000-00008; Lawthers AG, 2003, INT J QUAL HEALTH C, V15, P287, DOI 10.1093/intqhc/mzg048; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; MALEC J, 1995, PRACTICAL SOLUTIONS, P89; Malec JF, 2006, BRAIN INJURY, V20, P227, DOI 10.1080/02699050500488124; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Murphy L, 2006, BRAIN INJURY, V20, P1119, DOI 10.1080/02699050600664335; Murrey GJ, 2004, BRAIN INJURY, V18, P519, DOI 10.1080/02699050310001646125; O'Brien L, 2007, BRAIN INJURY, V21, P465, DOI 10.1080/02699050701315134; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; O'Neill JH, 2004, ARCH PHYS MED REHAB, V85, pS68, DOI 10.1016/j.apmr.2003.08.114; Oppermann JD, 2004, BRAIN INJURY, V18, P941, DOI 10.1080/02699050410001671919; PARENTE R, 1996, J VOCATIONAL REHABIL, V7, P181; PARENTE R, 1991, J HEAD TRAUMA REHAB, V6, P35; Petticrew M, 2006, SYSTEMATIC REVIEWS IN THE SOCIAL SCIENCES: A PRACTICAL GUIDE, P1, DOI 10.1002/9780470754887; PRESTON B, 1992, REHABIL COUNS BULL, V35, P230; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; Schonbrun SL, 2007, J REHABIL, V73, P26; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; THOMAS DF, 1993, COMMUNITY BASED EMPL; Turner-Stokes L, 2006, CLIN MED, V6, P91, DOI 10.7861/clinmedicine.6-1-91; Vandiver VL, 2003, J HEAD TRAUMA REHAB, V18, P457, DOI 10.1097/00001199-200309000-00007; Wall JR, 1998, NEUROREHABILITATION, V10, P39, DOI 10.3233/NRE-1998-10105; Wall JR, 1998, BRAIN INJURY, V12, P215; Wehman P, 2000, NEUROREHABILITATION, V15, P71; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN P, 2000, TRAUMATIC BRAIN INJU, P201; Wehman P, 1996, J VOCATIONAL REHABIL, V7, P205; Wehman P, 2007, J HEAD TRAUMA REHAB, V22, P95, DOI 10.1097/01.HTR.0000265097.44683.22; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; World Health Organization, 2007, INT CLASS FUNCT DIS; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	69	68	69	1	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2009	24	3					195	212		10.1097/HTR.0b013e3181a0d458			18	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	448HD	WOS:000266252800006	19461367				2022-02-06	
J	Longhi, L; Perego, C; Ortolano, F; Zanier, ER; Bianchi, P; Stocchetti, N; McIntosh, TK; De Simoni, MG				Longhi, Luca; Perego, Carlo; Ortolano, Fabrizio; Zanier, Elisa R.; Bianchi, Paolo; Stocchetti, Nino; McIntosh, Tracy K.; De Simoni, Maria Grazia			C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; inflammation; complement; neuroprotection	ISCHEMIA-REPERFUSION INJURY; MEMBRANE ATTACK COMPLEX; HEAD-INJURY; C1 INHIBITOR; C1-ESTERASE INHIBITOR; LEUKOCYTE ADHESION; GENE-EXPRESSION; NERVOUS-SYSTEM; MOTOR FUNCTION; FACTOR-B	Objective. The aim of the study was to evaluate the effects of C1-inhibitor (C1-INH), an endogenous inhibitor of complement and kinin systems, on neurobehavioral and histological outcome following controlled cortical impact brain injury. Design: Experimental prospective randomized study in mice. Setting. Experimental laboratory. Subjects: Male C5781/6 mice (n = 81). Interventions: Mice were subjected to controlled cortical impact brain injury followed by an intravenous bolus of either C1-INH (15 U either at 10 minutes or 1 hour postinjury) or saline (equal volume, 150 mu l at 10 minutes postinjury). Sham-operated mice received identical surgery and saline injection without brain injury. Neurological motor function was evaluated weekly for 4 weeks using the Composite Neuroscore. Cognitive function was evaluated at 4 weeks postinjury using the Morris Water Maze. Histological outcome was performed by measuring the contusion volume at 1 week and 4 weeks postinjury. Measurements and Main Results., Brain-injured mice receiving C1-INH at 10 minutes postinjury showed attenuated motor deficits, cognitive dysfunction and reduced contusion volume compared to brain-injured mice receiving saline. Mice receiving C1-INH at 1 hour postinjury showed reduced motor deficits compared to brain-injured mice receiving saline, but no significantly different cognitive and histological outcome. Immunohistochemical analysis showed that 20 minutes after infusion, C1-INH was localised on endothelial cells and in brain tissue surrounding brain capillaries of the injured hemisphere. Conclusion: Our results show that post-traumatic administration of C1-INH attenuates neuro-behavioral deficits and histological damage associated with traumatic brain injury. (Crit Care Med 2009; 37:659-665)	[Longhi, Luca; Perego, Carlo; Ortolano, Fabrizio; Zanier, Elisa R.; De Simoni, Maria Grazia] Mario Negri Inst Pharmacol Res, Lab Inflammat & Nervous Syst Dis, Dept Neurosci, I-20157 Milan, Italy; [Longhi, Luca; Ortolano, Fabrizio; Zanier, Elisa R.; Bianchi, Paolo; Stocchetti, Nino] Univ Milan, Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, Dept Anesthesia & Crit Care Med,Neurosurg Intens, Milan, Italy		De Simoni, MG (corresponding author), Mario Negri Inst Pharmacol Res, Lab Inflammat & Nervous Syst Dis, Dept Neurosci, Via Eritrea 62, I-20157 Milan, Italy.	desimoni@marionegri.it	Stocchetti, Nino/O-7444-2017; Perego, Carlo/AAA-6513-2020; Longhi, Luca/AAF-9903-2021; De Simoni, Maria Grazia/I-6021-2012; Zanier, Elisa/AAA-8095-2020	Stocchetti, Nino/0000-0003-3250-6834; Perego, Carlo/0000-0002-0259-0003; Longhi, Luca/0000-0001-9894-8788; De Simoni, Maria Grazia/0000-0001-6695-5297; Zanier, Elisa/0000-0002-3011-8718; Ortolano, Fabrizio/0000-0003-1996-948X			Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Cai SH, 2005, J IMMUNOL, V174, P6462, DOI 10.4049/jimmunol.174.10.6462; Cai SH, 2003, J IMMUNOL, V171, P4786, DOI 10.4049/jimmunol.171.9.4786; Caliezi C, 2000, PHARMACOL REV, V52, P91; Davis AE, 2007, IMMUNOBIOLOGY, V212, P313, DOI 10.1016/j.imbio.2006.10.003; De Simoni MG, 2004, AM J PATHOL, V164, P1857, DOI 10.1016/S0002-9440(10)63744-3; De Simoni MG, 2003, J CEREBR BLOOD F MET, V23, P232, DOI 10.1097/01.WCB.0000046146.31247.A1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hartman RE, 2002, J NEUROSCI, V22, P10083; Horstick G, 2002, IMMUNOBIOLOGY, V205, P552, DOI 10.1078/0171-2985-00154; Jiang HX, 2001, J EXP MED, V194, P1609, DOI 10.1084/jem.194.11.1609; Kerr FK, 2008, MOL IMMUNOL, V45, P670, DOI 10.1016/j.molimm.2007.07.008; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Storini C, 2005, NEUROBIOL DIS, V19, P10, DOI 10.1016/j.nbd.2004.11.001; STORINI C, 2007, SOC NEUR ANN M; Storini C, 2006, J PHARMACOL EXP THER, V318, P849, DOI 10.1124/jpet.106.105064; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tornqvist E, 1996, NEUROBIOL AGING, V17, P695; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Wagenaar-Bos IGA, 2006, IMMUNOL ALLERGY CLIN, V26, P615, DOI 10.1016/j.iac.2006.08.004; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Whalen MJ, 1998, ACT NEUR S, V71, P212; Xiong ZQ, 2003, J NEUROSCI, V23, P955; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497	53	68	68	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2009	37	2					659	665		10.1097/CCM.0b013e318195998a			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402LI	WOS:000263014800037	19114897				2022-02-06	
J	McLean, SA; Kirsch, NL; Tan-Schriner, CU; Sen, A; Frederiksen, S; Harris, RE; Maixner, W; Maio, RF				McLean, Samuel A.; Kirsch, Ned L.; Tan-Schriner, Cheribeth U.; Sen, Ananda; Frederiksen, Shirley; Harris, Richard E.; Maixner, William; Maio, Ronald F.			Health status, not head injury, predicts concussion symptoms after minor injury	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SICKNESS IMPACT PROFILE; BLOOD-PRESSURE; PAIN SENSITIVITY; SCALE; CARE; POLYMORPHISMS; QUESTIONNAIRE; INTENSITY	Objective: Postconcussion (PC) syndrome etiology remains poorly understood. We sought to examine predictors of persistent PC symptoms after minor injury. Methods: Health status, symptom, and injury information were obtained on a sample of patients presenting to the emergency department after minor injury. Postconcussion and cognitive symptoms were assessed at I, 3, and 12 months. Results: Among 507 patients enrolled, 339 had head injury. Repeated-measures logistic regression modeling of PC and cognitive symptom presence across time indicated that baseline mental health status and physical health status were most predictive of persistent symptoms. In contrast, head injury presence did not predict persistent PC syndrome. Discussion: Baseline mental health status and physical health status were associated with persistent PC syndrome after minor injury, but head injury status was not. Further studies of PC syndrome pathogenesis are needed. (C) 2009 Elsevier Inc. All rights reserved.	[McLean, Samuel A.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC 27599 USA; [McLean, Samuel A.] Univ N Carolina, TRYUMPH Res Program, Chapel Hill, NC 27599 USA; [Sen, Ananda] Univ Michigan, Med Ctr, Ctr Stat Consulting & Res, Ann Arbor, MI 48109 USA; [Maio, Ronald F.] Univ Michigan, Med Ctr, Injury Res Ctr, Ann Arbor, MI 48109 USA; [Tan-Schriner, Cheribeth U.] Michigan Publ Hlth Inst, Okemos, MI 48864 USA; [Maixner, William] Univ N Carolina, Ctr Neurosensory Disorders, Chapel Hill, NC 27599 USA		McLean, SA (corresponding author), Univ N Carolina, Dept Emergency Med, Chapel Hill, NC 27599 USA.	samclean@email.unc.edu		McLean, Samuel/0000-0001-9482-3582	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CCR523223-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23 RR017607-01]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K12RR017607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K23AR050410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [P01DE007509] Funding Source: NIH RePORTER	This study was funded by the Centers for Disease Control (R49/CCR523223-01). Doctor McLean is supported by NIH K23 RR017607-01.	Al-Windi A, 2004, J PSYCHOSOM RES, V57, P307, DOI 10.1016/S0022-3999(03)00612-3; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bragdon EE, 1997, INT J BEHAV MED, V4, P17, DOI 10.1207/s15327558ijbm0401_2; Bruehl S, 2004, NEUROSCI BIOBEHAV R, V28, P395, DOI 10.1016/j.neubiorev.2004.06.004; *CDC, 2001, M SUMM NAT CTR UNPUB; *CDCP AG, 2001, MILD TRAUM INJ TOOL; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; DIATCHENKO L, 2006, AM J MOL GE IN PRESS; Diatchenko L, 2006, PAIN, V125, P216, DOI 10.1016/j.pain.2006.05.024; Diatchenko L, 2006, PAIN, V123, P226, DOI 10.1016/j.pain.2006.04.015; Fillingim RB, 1998, INT J PSYCHOPHYSIOL, V30, P313, DOI 10.1016/S0167-8760(98)00024-5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILSON BS, 1975, AM J PUBLIC HEALTH, V65, P1304, DOI 10.2105/AJPH.65.12.1304; Girdler SS, 1998, PSYCHOSOM MED, V60, P736, DOI 10.1097/00006842-199811000-00016; KAY DWK, 1971, LANCET, V2, P1052; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KROENKE K, 1993, ARCH INTERN MED, V153, P2474, DOI 10.1001/archinte.153.21.2474; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Li C, 2005, MATURITAS, V52, P306, DOI 10.1016/j.maturitas.2005.05.005; Maixner W, 1997, PSYCHOSOM MED, V59, P503, DOI 10.1097/00006842-199709000-00007; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McBeth J, 2001, ARTHRITIS RHEUM, V44, P940, DOI 10.1002/1529-0131(200104)44:4<940::AID-ANR151>3.0.CO;2-S; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; *ORG WH, 1978, ICD 9 CLASS MENT BEH; Pfleeger M, 1997, INT J PSYCHOPHYSIOL, V27, P161, DOI 10.1016/S0167-8760(97)00058-5; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RUTHERFORD WH, 1977, LANCET, V1, P1; Stein MB, 2005, NEUROPSYCHOPHARMACOL, V30, P2092, DOI 10.1038/sj.npp.1300787; SYMONDS C, 1962, LANCET, V1, P1; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wolfe F, 2003, J RHEUMATOL, V30, P369; Wolfe F, 2006, J RHEUMATOL, V33, P2291; Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941	39	68	68	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	FEB	2009	27	2					182	190		10.1016/j.ajem.2008.01.054			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	416DN	WOS:000263985600009	19371526				2022-02-06	
J	Kline, AE; Hoffman, AN; Cheng, JP; Zafonte, RD; Massucci, JL				Kline, Anthony E.; Hoffman, Ann N.; Cheng, Jeffrey P.; Zafonte, Ross D.; Massucci, Jaime L.			Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Antipsychotics; Beam-walk; Controlled cortical impact; Functional recovery; Haloperidol; Learning and memory; Morris water maze; Neurobehavior; Risperidone; Traumatic brain injury	5-HT1A RECEPTOR AGONIST; CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; ATYPICAL ANTIPSYCHOTICS; CORTEX INJURY; RATS; HALOPERIDOL; SENSORIMOTOR; HYPOTHERMIA; EXPERIENCE	Antipsychotics are often administered to traumatic brain injured (TBI) patients as a means of controlling agitation, albeit the rehabilitative consequences of this intervention are not well known. Hence. the goal of this study was to evaluate the effects of risperidone (RISP) and haloperidol (HAL) on behavioral outcome after experimental TBI. Anesthetized rats received either a cortical impact or sham injury and then were randomly assigned to five TBI (RISP 0.045 mg/kg, RISP 0.45 mg/kg, RISP 4.5 mg/kg, HAL 0.5 mg/kg and VEHicle 1 ml/kg) and three Sham (RISP 4.5 mg/kg, HAL 0.5 mg/kg and VEH 1 mL/kg) groups. Treatments began 24 h after surgery and were provided once daily for 19 days. Behavior was assessed with established motor (beam-balance/walk) and cognitive (spatial learning/memory in a water maze) tasks on post-operative days 1-5 and 14-19, respectively. RISP and HAL delayed motor recovery, impaired the acquisition of spatial learning, and slowed swim speed relative to VEH in both TBI and sham groups. These data indicate that chronic administration of RISP and HAL impede behavioral recovery after TBI and impair performance in uninjured controls. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Massucci, Jaime L.] Christiana Care Hlth Syst, Emergency Med, Newark, DE 19718 USA; [Kline, Anthony E.; Hoffman, Ann N.; Cheng, Jeffrey P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basic Cognit, Pittsburgh, PA 15213 USA; [Zafonte, Ross D.] Harvard Univ, Sch Med, Boston, MA 02114 USA; [Zafonte, Ross D.] Spaulding Rehabil Hosp, Boston, MA 02114 USA; [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA		Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700, R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	This work was supported by NIH grants HD043851 and HD046700 (AEK).	Bayir H, 2005, CRIT CARE MED, V33, pS498, DOI 10.1097/01.CCM.0000186787.64500.12; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Levine A M, 1988, Brain Inj, V2, P165, DOI 10.3109/02699058809150940; Levy M, 2005, NEUROREHABILITATION, V20, P279; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Olsen AS, 2007, J NEUROTRAUM, V24, P1245; Rosengarten H, 2002, PROG NEURO-PSYCHOPH, V26, P1047, DOI 10.1016/S0278-5846(02)00221-X; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	25	68	68	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	DEC 31	2008	448	3					263	267		10.1016/j.neulet.2008.10.076			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	385CM	WOS:000261790700008	18983891	Green Accepted			2022-02-06	
J	Dietz, RM; Weiss, JH; Shuttleworth, CW				Dietz, Robert M.; Weiss, John H.; Shuttleworth, Claude W.			Zn2+ influx is critical for some forms of spreading depression in brain slices	JOURNAL OF NEUROSCIENCE			English	Article						hippocampal slice; mitochondria; spreading depression; calcium channels; zinc; ouabain	HIPPOCAMPAL CA1 NEURONS; PERIINFARCT DEPOLARIZATIONS; CEREBRAL-ISCHEMIA; NEUROTRANSMITTER RELEASE; CORTICAL-NEURONS; IN-VITRO; ZINC; CALCIUM; MITOCHONDRIAL; MECHANISMS	Spreading depression ( SD) is wave of profound depolarization that propagates throughout brain tissue and can contribute to the spread of injury after stroke or traumatic insults. The contribution of Ca2+ influx to SD differs depending on the stimulus, and we show here that Zn2+ can play a critical complementary role in murine hippocampal slices. In initial studies, we used the Na+/K+ ATPase inhibitor ouabain and found conditions in which SD was always prevented by L- type Ca2+ channel blockers; however, Ca2+ influx was not responsible for L- type effects. Cytosolic Ca2+ increases were not detectable in CA1 neurons before SD, and removal of extracellular Ca2+ did not prevent ouabain- SD. In contrast, cytosolic Zn2+ increases were observed in CA1 neurons before ouabain- SD, and L- type channel block prevented the intracellular Zn2+ rises. A slow mitochondrial depolarization observed before ouabain- SD was abolished by L- type channel block, and Zn2+ accumulation contributed substantially to initial mitochondrial depolarizations. Selective chelation of Zn2+ with N, N, N', N'- tetrakis(2-pyridylmethyl) ethylenediamine ( TPEN) abolished SD, implying that Zn2+ entry can play a critical role in the generation of ouabain- SD. TPEN was most effective when synaptic activity was reduced by adenosine A1 receptor activation, and a combination of Ca2+ and Zn2+ removal was required to prevent ouabain- SD when A1 receptors were blocked. Similarly, Zn2+ chelation could prevent SD triggered by oxygen/ glucose deprivation but Zn2+ accumulation did not contribute to SD triggered by localized high K+ exposures. These results identify Zn2+ as a new target for the block of spreading depolarizations after brain injury.	[Dietz, Robert M.; Shuttleworth, Claude W.] Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA; [Weiss, John H.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92697 USA; [Weiss, John H.] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA		Shuttleworth, CW (corresponding author), Univ New Mexico, Sch Med, Dept Neurosci, MSC08 4740,1 Univ New Mexico, Albuquerque, NM 87131 USA.	bshuttleworth@salud.unm.edu	weiss, john/B-4283-2008	weiss, john/0000-0001-9323-7813	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS051288-03, NS36548, NS051288, R01 NS051288, R01 NS036548] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051288, R01NS036548] Funding Source: NIH RePORTER		ADLER EM, 1991, J NEUROSCI, V11, P1496; Aitken PG, 1998, J NEUROPHYSIOL, V80, P1514, DOI 10.1152/jn.1998.80.3.1514; Ayata C, 2000, NEUROSCIENCE, V95, P639; Bahar S, 2000, J NEUROPHYSIOL, V84, P311; BALESTRINO M, 1986, BRAIN RES, V385, P219, DOI 10.1016/0006-8993(86)91067-X; Balestrino M, 1999, BRAIN RES, V838, P37, DOI 10.1016/S0006-8993(99)01674-1; Basarsky TA, 1998, J NEUROSCI, V18, P7189; Basarsky TA, 1999, J NEUROSCI, V19, P6439; Bonanni L, 2006, J NEUROSCI, V26, P6851, DOI 10.1523/JNEUROSCI.5444-05.2006; BURESOVA O, 1969, Journal of Neurobiology, V1, P135, DOI 10.1002/neu.480010202; Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Devinney MJ, 2005, CELL CALCIUM, V37, P225, DOI 10.1016/j.ceca.2004.10.003; DIETZ RM, 2007, SOC NEUR ABSTR, V33; Dietz RM, 2007, HIPPOCAMPUS, V17, P1049, DOI 10.1002/hipo.20336; Dineley KE, 2005, MITOCHONDRION, V5, P55, DOI 10.1016/j.mito.2004.11.001; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Dineley KE, 2002, MOL PHARMACOL, V62, P618, DOI 10.1124/mol.62.3.618; Duchen MR, 2003, METHOD ENZYMOL, V361, P353; Footitt DR, 1998, BRAIN RES, V781, P339, DOI 10.1016/S0006-8993(97)01359-0; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; Gerich FJ, 2006, J NEUROPHYSIOL, V96, P492, DOI 10.1152/jn.01015.2005; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hashimoto M, 2000, BRAIN RES, V872, P294, DOI 10.1016/S0006-8993(00)02509-9; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; Jarvis CR, 2001, CEREB CORTEX, V11, P249, DOI 10.1093/cercor/11.3.249; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kay AR, 2003, J NEUROSCI, V23, P6847; Kerchner GA, 2000, J PHYSIOL-LONDON, V528, P39, DOI 10.1111/j.1469-7793.2000.00039.x; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kunkler PE, 2004, HIPPOCAMPUS, V14, P356, DOI 10.1002/hipo.10181; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Malaiyandi LM, 2005, J NEUROCHEM, V93, P1242, DOI 10.1111/j.1471-4159.2005.03116.x; Marchi B, 2000, CELL CALCIUM, V28, P225, DOI 10.1054/ceca.2000.0155; Masino SA, 1999, J NEUROSCI, V19, P1932; Menna G, 2000, J NEUROPHYSIOL, V83, P1338, DOI 10.1152/jn.2000.83.3.1338; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Peters O, 2003, J NEUROSCI, V23, P9888; Qian J, 2005, J PHYSIOL-LONDON, V566, P747, DOI 10.1113/jphysiol.2005.089276; RADER RK, 1989, NEUROSCI LETT, V99, P125, DOI 10.1016/0304-3940(89)90276-0; RAMOS JG, 1975, ACTA PHYSIOL LAT AM, V25, P112; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; Sensi SL, 2000, EUR J NEUROSCI, V12, P3813, DOI 10.1046/j.1460-9568.2000.00277.x; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Shuttleworth CW, 2003, J NEUROSCI, V23, P3196; Shuttleworth CWR, 2001, J NEUROSCI, V21, P4225, DOI 10.1523/JNEUROSCI.21-12-04225.2001; SMITH PD, 1984, ANAL BIOCHEM, V143, P188, DOI 10.1016/0003-2697(84)90575-X; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Tanaka E, 1997, J NEUROPHYSIOL, V78, P891, DOI 10.1152/jn.1997.78.2.891; Umegaki M, 2005, J NEUROSCI, V25, P1387, DOI 10.1523/JNEUROSCI.4182-04.2005; van den Maagdenberg AMJM, 2004, NEURON, V41, P701, DOI 10.1016/S0896-6273(04)00085-6; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; YOUNG JN, 1992, BRAIN RES, V573, P70, DOI 10.1016/0006-8993(92)90114-O	59	68	72	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	AUG 6	2008	28	32					8014	8024		10.1523/JNEUROSCI.0765-08.2008			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	334RE	WOS:000258238100010	18685026	Green Accepted, Bronze, Green Published			2022-02-06	
J	Vilalta, A; Sahuquillo, J; Rosell, A; Poca, MA; Riveiro, M; Montaner, J				Vilalta, Anna; Sahuquillo, Juan; Rosell, Anna; Poca, Maria A.; Riveiro, Marilyn; Montaner, Joan			Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases	INTENSIVE CARE MEDICINE			English	Article; Proceedings Paper	8th International Neurotrauma Symposium	MAY 21-25, 2006	Rotterdam, NETHERLANDS			blood-brain barrier; brain extracellular fluid; matrix metalloproteinases; gelatinases; microdialysis; neuroinflammation; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; MESSENGER-RNA; HEAD-INJURY; MATRIX-METALLOPROTEINASE-9; EXPRESSION; BLOOD; BARRIER; EDEMA	Objective: Recent experimental evidence suggests that matrix metalloproteinases (MMPs) are implicated in the pathophysiology of traumatic brain injury (TBI) by increasing blood-brain barrier permeability and exacerbating posttraumatic edema. We examined the acute profile ofMMP- 2 and MMP-9 in the plasma of patients with moderate or severe TBI and in the brain extracellular fluid (ECF). Design: Prospective observational study. Setting: Neurotraumatology intensive care unit of a tertiary university hospital. Patients: Twenty patients with moderate or severe TBI were included and three groups were used as controls: 20 patients with a mild head injury and normal CT scan, 15 moderate polytrauma patients without TBI, and 20 healthy volunteers. Interventions: Plasma samples were collected within the first 12 h and at 24 h post-injury. Simultaneous brain microdialysate and plasma samples were obtained in four moderate-severe TBI patients at additional timepoints: 48, 72, and 96 h post-TBI. Measurements and main results: Gelatinases (MMP-2 and MMP-9) were measured by gelatin zymography. A significant increase in plasma gelatinases was observed at baseline when compared with healthy volunteers in the study group. This early increase was followed by a significant decrease at 24 h post-injury. Brain microdialysis samples presented a similar time profile as plasma samples for both gelatinases. Conclusions: High levels of gelatinases were found in plasma and brain ECF in the early phase of TBI, indicating that both local and systemic trauma-induced upregulation of gelatinases in the acute phase might play an important role in the pathophysiology of TBI and could be a future therapeutic target.	[Sahuquillo, Juan; Poca, Maria A.] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Neurosurg, Barcelona 08035, Spain; [Vilalta, Anna] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, UNINN, Barcelona 08035, Spain; [Rosell, Anna; Montaner, Joan] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurovasc Res Lab, Barcelona 08035, Spain; [Rosell, Anna; Montaner, Joan] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurovasc Unit, Barcelona 08035, Spain; [Riveiro, Marilyn] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Neurotraumatol Intens Care Unit, Barcelona 08035, Spain		Sahuquillo, J (corresponding author), Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Neurosurg, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	sahuquillo@neurotrauma.net	Poca, Maria A./B-8475-2008; Montaner, Joan/D-3063-2015; Sahuquillo, Juan/B-3577-2008; Riveiro, Marilyn/S-5242-2016	Poca, Maria A./0000-0002-3831-0536; Montaner, Joan/0000-0003-4845-2279; Sahuquillo, Juan/0000-0003-0713-5875; Riveiro, Marilyn/0000-0002-1645-3720; Vilalta, Anna/0000-0002-2183-072X; Rosell Novel, Anna/0000-0003-1082-3599			Agrawal SM, 2008, SEMIN CELL DEV BIOL, V19, P42, DOI 10.1016/j.semcdb.2007.06.003; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Fatar M, 2005, CEREBROVASC DIS, V20, P141, DOI 10.1159/000087197; Gasche Y, 2006, FRONT BIOSCI-LANDMRK, V11, P1289, DOI 10.2741/1883; Horstmann S, 2003, STROKE, V34, P2165, DOI 10.1161/01.STR.0000088062.86084.F2; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Mun-Bryce S, 1998, AM J PHYSIOL-REG I, V274, pR1203, DOI 10.1152/ajpregu.1998.274.5.R1203; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Ning M, 2006, NEUROLOGY, V66, P1550, DOI 10.1212/01.wnl.0000216133.98416.b4; Parks WC, 1998, BIOL EXTRAC, P263; Pfefferkorn T, 2003, STROKE, V34, P2025, DOI 10.1161/01.STR.0000083051.93319.28; Poca MA, 2006, J NEUROTRAUM, V23, P1510, DOI 10.1089/neu.2006.23.1510; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Sahuquillo J, 2002, NEUROCIRUGIA, V13, P78; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sellebjerg F, 2003, BRAIN RES BULL, V61, P347, DOI 10.1016/S0361-9230(03)00097-2; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; TEASDALE G, 1974, LANCET, V2, P81; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vilalta A, 2006, J NEUROTRAUM, V23, P772; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375	38	68	70	0	8	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	AUG	2008	34	8					1384	1392		10.1007/s00134-008-1056-1			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	330IH	WOS:000257933700006	18350273				2022-02-06	
J	DePompei, R; Gillette, Y; Goetz, E; Xenopoulos-Oddsson, A; Bryen, D; Dowds, M				DePompei, Roberta; Gillette, Yvonne; Goetz, Elaine; Xenopoulos-Oddsson, Annette; Bryen, Diane; Dowds, Murdo			Practical applications for use of PDAs and smartphones with children and adolescents who have traumatic brain injury	NEUROREHABILITATION			English	Article						Pediatric traumatic brain injury; PDAs; smartphones; memory and organizational; intervention plan	PORTABLE ELECTRONIC DEVICES; MEMORY AID; REHABILITATION; ADULTS	It is often recommended that individuals with memory and organizational problems after a traumatic brain injury (TBI) use some type of memory device such as a paper calendar. Recently the use of electronic devices has been suggested. This article outlines data obtained from in vivo trials using personal data assistants (PDAs) and follow up in depth studies with PDAs and smartphones. These trials were conduced with individuals who had memory and organizational problems as a result of cognitive disorders of traumatic brain injury (TBI) or intellectual disability (ID) Results indicate that the use of electronic devices can enhance independent behavior. Factors influencing success include: student motivation, audible beep of the device; support for programming and troubleshooting, alterations of functions; and selection of features to motivate. Based on the result of the studies, an intervention plan for use of PDAs was developed for use by clinicians.	[DePompei, Roberta; Gillette, Yvonne; Goetz, Elaine; Xenopoulos-Oddsson, Annette; Bryen, Diane; Dowds, Murdo] Univ Akron, Sch Speech Language Pathol & Audiol, Akron, OH 44325 USA		DePompei, R (corresponding author), Univ Akron, Sch Speech Language Pathol & Audiol, Polsky 188K, Akron, OH 44325 USA.	rdepom1@uakron.edu					Carey AC, 2005, MENT RETARD, V43, P322; Cihak D., 2006, FOCUS AUTISM DEV DIS, V21, P89, DOI 10.1177/10883576060210020601; Constantinidou F., 2004, TRAUMATIC BRAIN INJU, P337; DePompei R, 2004, LEARNING COGNITIVE C; EHLHARDT L, 2008, NEUROPSYCHOL REHABIL, V1, P1; Epstein J. N., 2001, Journal of Special Education Technology, V16, P19; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Friedman J, 2007, CRIT REV, V19, P1, DOI 10.1080/08913810701497506; FRIEDMAN M, 2005, WEB ACCESSIBILITY GU; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; Gillette Y, 2004, NEUROREHABILITATION, V19, P233; GILLETTE Y, 2003, ACHIEVING COMMUNICAT; GILLETTE Y, 2008, PSYCHOL SCH IN PRESS; Hagiwara T., 2007, FOCUS AUTISM OTHER D, V22, P96, DOI [10.1177/10883576070220021001, DOI 10.1177/10883576070220021001]; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Hart T, 2003, BRAIN INJURY, V17, P401, DOI 10.1080/0269905021000038438; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Inglis EA, 2004, NEUROPSYCHOL REHABIL, V14, P77, DOI 10.1080/09602010343000129; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Bryen DN, 2007, INTELLECT DEV DISAB, V45, P1, DOI 10.1352/1934-9556(2007)45[1:CPUBAW]2.0.CO;2; PARENTE R, 1991, COGNITIVE REHABILITA, P147; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; Taber T. A., 1999, FOCUS AUTISM OTHER D, V14, P159, DOI DOI 10.1177/108835769901400305; Taber-Doughty T, 2005, RES DEV DISABIL, V26, P411, DOI 10.1016/j.ridd.2004.07.006; THONEOTTO AIT, 2003, INT J PSYCHOL, V38, P1, DOI DOI 10.1080/00207590344000169; van den Broek MD, 2000, BRAIN INJURY, V14, P455; WADE TK, 2001, BRAIN INJURY, V14, P455; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161	33	68	68	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2008	23	6					487	499					13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	391CI	WOS:000262210200005	19127002				2022-02-06	
J	Muenchberger, H; Kendall, E; Neal, R				Muenchberger, Heidi; Kendall, Elizabeth; Neal, Ronita			Identity transition following traumatic brain injury: A dynamic process of contraction, expansion and tentative balance	BRAIN INJURY			English	Article						Traumatic brain injury; rehabilitation; identity; lived experience; disability	QUALITY-OF-LIFE; CHRONIC ILLNESS; SELF-CONCEPT; HEAD-INJURY; MULTIPLE-SCLEROSIS; PERSONAL IDENTITY; BIOGRAPHICAL WORK; CRITICAL INCIDENT; HEALTH-CARE; NARRATIVES	Primary objective: The study aimed to understand turning points and processes that define the experience of identity change for individuals with brain injury. Research design: The current study applied an interpretive qualitative research design using a phenomenological approach. Qualitative 'life-story' interviewing was undertaken to explore the natural course of identity following TBI and a critical incident technique was applied to systematically examine key milestones. Methods and procedures: A purposive sample of six individuals with brain injury who represented a successive range of post-injury time frames (1-2 years, 2-5 years, 5-10 years, 10-15 years, 15-20 years and 25+ years) participated in the interviews. Main outcomes and results: Qualitative analysis indicated that identity transition was characterized by a dynamic and convoluted process of contraction, expansion and tentative balance. Conclusions: The influence of subjective processes on the development of identity highlights the inadequacy of fragmented approaches when exploring the individual experience. Findings from this study have important implications for the delivery of person-focused rehabilitation and remind one to consider with caution the usual indicators of adjustment that are often applied to brain injury rehabilitation.	[Muenchberger, Heidi; Kendall, Elizabeth; Neal, Ronita] Griffith Univ, Res Ctr Clin & Community Practice Innovat, Brisbane, Qld 4111, Australia		Muenchberger, H (corresponding author), Res Ctr Clin & Community Practice Innovat, Univ Dr, Meadowbrook, Qld 4131, Australia.	h.muenchberger@griffith.edu.au	Muenchberger, Heidi/C-8425-2009; kendall, elizabeth/F-5065-2013	Kendall, Elizabeth/0000-0003-2399-1460			Atkinson M, 1997, AM J PSYCHIAT, V154, P99; Boeije HR, 2002, SOC SCI MED, V55, P881, DOI 10.1016/S0277-9536(01)00238-6; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939; Care W D, 1996, J Nurs Staff Dev, V12, P27; Charmaz K., 1987, RES SOCIOLOGY HLTH C, V6, P283, DOI DOI 10.1111/1467-9566.EP10491512; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Clapton J, 2002, DISABIL REHABIL, V24, P987, DOI 10.1080/09638280210152058; Cloute K, 2008, NEUROPSYCHOL REHABIL, V18, P651, DOI 10.1080/09602010701306989; Conneeley AL., 2002, BRIT J OCCUP THER, V65, P356; Cook-Sather A, 2006, INT J LEADERSH EDUC, V9, P345, DOI 10.1080/13603120600895437; CORBIN J, 1987, RES SOCIOLOGY HLTH C, V6, P249, DOI DOI 10.1046/J.1365-2648.2001.01767.X; Coyle J, 1999, SOCIOL HEALTH ILL, V21, P95, DOI 10.1111/1467-9566.00144; Crisp R., 1993, DISABIL HANDICAP SOC, V8, P393, DOI DOI 10.1080/02674649366780371; Cutcliffe JR, 1999, J ADV NURS, V30, P374, DOI 10.1046/j.1365-2648.1999.01090.x; DEMO DH, 1992, ANNU REV SOCIOL, V18, P303; Dempsey OP, 2002, FAM PRACT, V19, P611, DOI 10.1093/fampra/19.6.611; Dowswell G, 2000, J CLIN NURS, V9, P507, DOI 10.1046/j.1365-2702.2000.00411.x; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Faircloth CA, 2004, SOCIOL HEALTH ILL, V26, P242, DOI 10.1111/j.1467-9566.2004.00388.x; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; Forss A, 2004, SOCIOL HEALTH ILL, V26, P306, DOI 10.1111/j.1467-9566.2004.00392.x; Galvin RD, 2005, SOCIOL HEALTH ILL, V27, P393, DOI 10.1111/j.1467-9566.2005.00448.x; Gilbert N., 1993, ANAL TABULAR DATA LO; Grbich C., 1999, QUALITATIVE RES HLTH; Heidegger Martin, 1962, BEING TIME, P437; Hitlin S, 2003, SOC PSYCHOL QUART, V66, P118, DOI 10.2307/1519843; Hoofinen D., 2003, BRAIN INJURY, V15, P189; JOHNSON CN, 1990, CHILD DEV, V61, P962, DOI 10.2307/1130868; Johnson M, 2000, NURS PHILOS, V1, P134, DOI DOI 10.1046/J.1466-769X.2000.00027.X; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kirkevold M, 2002, DISABIL REHABIL, V24, P887, DOI 10.1080/09638280210142239; Klinger L, 2005, J OCCUP SCI, V12, P9, DOI 10.1080/14427591.2005.9686543; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kralik D, 2002, J ADV NURS, V39, P146, DOI 10.1046/j.1365-2648.2000.02254.x; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LEWINGTON P, 1996, WHAT IS MEANING RECO; Little M, 1998, SOC SCI MED, V47, P1485, DOI 10.1016/S0277-9536(98)00248-2; MATHIESON CM, 1995, SOCIOL HEALTH ILL, V17, P283, DOI 10.1111/1467-9566.ep10933316; MAYS N, 1995, BRIT MED J, V320, P50; MELIA KM, 1982, J ADV NURS, V7, P327, DOI 10.1111/j.1365-2648.1982.tb00248.x; MORSE JM, 1995, J ADV NURS, V21, P886, DOI 10.1046/j.1365-2648.1995.21050886.x; Newsome R, 1996, AUSTR J REHABILITATI, V2, P71; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; NORMAN IJ, 1992, J ADV NURS, V17, P590, DOI 10.1111/j.1365-2648.1992.tb02837.x; Paterson B, 2001, J ADV NURS, V34, P574, DOI 10.1046/j.1365-2648.2001.01786.x; Paterson J., 2002, REHABIL NURS, V27, P13, DOI DOI 10.1002/J.2048-7940.2002.TB01973.X; Patton M.Q., 1990, QUALITATIVE EVALUATI; Petrella L, 2005, BRAIN INJURY, V19, P643, DOI 10.1080/02699050410001671874; Price B, 1996, J ADV NURS, V24, P275, DOI 10.1046/j.1365-2648.1996.02047.x; Purves Barbara, 2004, Can J Occup Ther, V71, P173; ROBINSON I, 1990, SOC SCI MED, V30, P1173, DOI 10.1016/0277-9536(90)90257-S; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Van Gennep A., 1960, RITES PASSAGE; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Ville I, 2005, SOCIOL HEALTH ILL, V27, P324, DOI 10.1111/j.1467-9566.2005.00445.x; Woolsey L. K., 1986, CANADIAN J COUNSELLI, V20, P242, DOI DOI 10.1037/H0061470; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x	62	68	68	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	12					979	992	PII 905451178	10.1080/02699050802530532			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	371RV	WOS:000260849900009	19005890				2022-02-06	
J	Gregory, NG; Lee, CJ; Widdicombe, JP				Gregory, Neville G.; Lee, Claire J.; Widdicombe, Joanne P.			Depth of concussion in cattle shot by penetrating captive bolt	MEAT SCIENCE			English	Article						captive bolt; gun; stunning; cattle; slaughter; concussion; abattoir; nystagmus; corneal reflex; tongue	SLAUGHTER; SUICIDE	The prevalence of shallow depth of concussion following captive bolt shooting was assessed in 1608 cattle at an abattoir. Depth of concussion was determined in each animal from physical collapse, presence or absence of corneal reflex, normal rhythmic breathing, eyeball rotation, and whether the animal was re-shot. The presence of nystagmus and the absence of tongue protrusion were also monitored as potential indicators of a shallow depth of concussion, and simultaneous noise measurements assessed whether loudness of gun discharge was linked to concussion depth. The prevalence of a shallow depth of concussion was 8% for all cattle and 15%, for young bulls. Nystagmus was associated with other indicators of a shallow depth of concussion. Absence of tongue protrusion was not associated with depth of concussion, but could serve as a useful indicator of jaw relaxation and insensibility following exsanguination. Soft-sounding shots (<= 111 dB) when using 4.5 gr cartridges were associated with shallow depth of concussion, (C) 2007 Elsevier Ltd. All rights reserved.	[Gregory, Neville G.; Lee, Claire J.; Widdicombe, Joanne P.] BBSRC, Hatfield AL9 7TA, Herts, England; [Gregory, Neville G.; Lee, Claire J.; Widdicombe, Joanne P.] Univ London Royal Vet Coll, Hatfield AL9 7TA, Herts, England		Gregory, NG (corresponding author), BBSRC, Hawkshead Lane, Hatfield AL9 7TA, Herts, England.	ngregory@rve.ac.uk					BLACKMORE DK, 1988, VET CONTINUING ED PU, V118; Gnjidic Z, 2002, ACTA NEUROCHIR, V144, P1271, DOI 10.1007/s00701-002-1018-2; Grandin T, 2002, J AM VET MED ASSOC, V221, P1258, DOI 10.2460/javma.2002.221.1258; Gregory N., 2000, Journal of Applied Animal Welfare Science, V3, P215, DOI 10.1207/S15327604JAWS0303_3; Gregory NG, 2006, MEAT SCI, V74, P655, DOI 10.1016/j.meatsci.2006.05.021; Gregory NG, 1998, ANIMAL WELFARE MEAT, P298; Gregory NG, 2007, ANIMAL WELFARE MEAT, P299; MENDELOW AD, 1990, HDB CLIN NEUROLOGY, V57, P123; TOGLIA JU, 1976, HDB CLIN NEUROLOGY, V24, P119; Viola L, 2004, J FORENSIC SCI, V49, P595	10	68	71	0	41	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0309-1740			MEAT SCI	Meat Sci.	DEC	2007	77	4					499	503		10.1016/j.meatsci.2007.04.026			5	Food Science & Technology	Science Citation Index Expanded (SCI-EXPANDED)	Food Science & Technology	241DO	WOS:000251637300008	22061934				2022-02-06	
J	Simonsen, LL; Sonne-Holm, S; Krasheninnikoff, M; Engberg, AW				Simonsen, Louise Lau; Sonne-Holm, Stig; Krasheninnikoff, Michael; Engberg, Aase W.			Symptomatic heterotopic ossification after very severe traumatic brain injury in 114 patients: Incidence and risk factors	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						symptomatic heterotopic ossification; severe traumatic brain injuries; risk factors	ECTOPIC-BONE-FORMATION; SPINAL-CORD INJURY; HEAD-INJURIES; REHABILITATION; ADOLESCENTS; MANAGEMENT; HEMIPLEGIA; ANTIGENS; CHILDREN	The incidence of heterotopic ossification (HO) among patients with traumatic brain injury (TBI) varies in the literature from 11 to 73.3%. The aim of this study was to determine the incidence of HO among patients with very severe TBI treated in a new established intensive rehabilitation Brain Injury Unit and to list some of the risk-predicting features. The study comprised an approximately complete, consecutive series of 114 adult patients from a well-defined geographical area, and with a posttraurnatic amnesia period of at least 28 days, i.e. very severe TBI. Demographic and functional data as well as data about trauma severity and hospital stay of these patients have been registered prospectively in a database (Danish National Head Injury database) at the Brain Injury Unit where the sub acute rehabititation took place. The present study was based retrospectively on this database, combined with X-rays obtained for symptoms of HO and/or as fracture control. Clinically significant HO was found in 7.9% of the patients. Logistic regression showed an independent significant positive correlation between HO, the female gender and a high Injury Severity Score. The low incidence of HO might be explained by the application of early mobitisation and physiotherapy of the patients. The higher incidence of HO among women speaks for humoural and hormone factors initiating bone formation outside the bones. (c) 2007 Elsevier Ltd. All rights reserved.	Copenhagen Univ Hosp, Dept Orthopaed Surg, Hvidovre, Denmark; Copenhagen Univ Hosp, Dept Neurol Rehabil, Brain Injury Unit, Hvidovre, Denmark		Simonsen, LL (corresponding author), Valby Langgade 88 C,2 Tv, DK-2500 Valby, Denmark.	touiselau@dadtnet.dk					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; FURMAN R, 1970, J BONE JOINT SURG AM, VA 52, P1131, DOI 10.2106/00004623-197052060-00005; GARLAND DE, 1983, PHYS THER, V63, P2004, DOI 10.1093/ptj/63.12.2004; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P531; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Garland DE., 1995, TRAUMATIC BRAIN INJU, P119; Gebuhr P, 1996, ACTA ORTHOP SCAND, V67, P29, DOI 10.3109/17453679608995604; GOLDBERG MA, 1977, ARCH INTERN MED, V137, P619, DOI 10.1001/archinte.137.5.619; Greenwood R, 1993, NEUROLOGICAL REHABIL, P206; HAJEK VE, 1987, ARCH PHYS MED REHAB, V68, P313; HARDY AG, 1963, J BONE JOINT SURG BR, V45, P76, DOI 10.1302/0301-620X.45B1.76; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; Jacobsen S, 1995, Ugeskr Laeger, V157, P5385; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; Kushwaha V P, 1998, J Am Acad Orthop Surg, V6, P298; LAL S, 1989, ARCH PHYS MED REHAB, V70, P387; LARSON JM, 1981, RHEUMATOL REHABIL, V20, P193, DOI 10.1093/rheumatology/20.4.193; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIBERSON M, 1953, JAMA-J AM MED ASSOC, V152, P1010, DOI 10.1001/jama.1953.03690110024008; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; MINAIRE P, 1980, ARCH PHYS MED REHAB, V61, P214; MITAL MA, 1987, J PEDIATR ORTHOPED, V7, P83, DOI 10.1097/01241398-198701000-00017; NICHOLAS JJ, 1973, ARCH PHYS MED REHAB, V54, P354; ORZEL JA, 1985, J NUCL MED, V26, P125; PUZAS JE, 1989, CLIN ORTHOP RELAT R, P269; ROSENTHAL M, 1999, REHABILITATION ADULT, P63; ROSIN AJ, 1975, ANN RHEUM DIS, V34, P499, DOI 10.1136/ard.34.6.499; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120, DOI 10.1302/0301-620X.63B1.7204466; Stover SL, 1986, MANAGEMENT SPINAL CO, P284; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; VARGHESE G, 1991, ARCH PHYS MED REHAB, V72, P1009; VENIER L H, 1971, Archives of Physical Medicine and Rehabilitation, V52, P475	34	68	79	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	OCT	2007	38	10					1146	1150		10.1016/j.injury.2007.03.019			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	229GS	WOS:000250791900005	17572418				2022-02-06	
J	Magnus, T; Coksaygan, T; Korn, T; Xue, HP; Arumugam, TV; Mughal, MR; Eckley, DM; Tang, SC; DeTolla, L; Rao, MS; Cassiani-Ingoni, R; Mattson, MP				Magnus, Tim; Coksaygan, Turhan; Korn, Thomas; Xue, Haipeng; Arumugam, Thiruma V.; Mughal, Mohamed R.; Eckley, D. Mark; Tang, Sung-Chun; DeTolla, Louis; Rao, Mahendra S.; Cassiani-Ingoni, Riccardo; Mattson, Mark P.			Evidence that nucleocytoplasmic Olig2 translocation mediates brain-injury-induced differentiation of glial precursors to astrocytes	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						glial progenitors; Olig2; astrocytes; NG2; stabwound	NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; ADULT SPINAL-CORD; SUBVENTRICULAR ZONE; PROGENITOR-CELL; RESTRICTED PRECURSORS; GENE-FUNCTION; RAT-BRAIN; EXPRESSION; NEUROGENESIS	The mechanisms by which neural and glial progenitor cells in the adult brain respond to tissue injury are unknown. We studied the responses of these cells to stab wound injury in rats and in two transgenic mouse models in which Y/GFP is driven either by Sox2 (a neural stem cell marker) or by T alpha-1 (which marks newly born neurons). The response of neural progenitors was low in all nonneurogenic regions, and no neurogenesis occurred at the injury site. Glial progenitors expressing Olig2 and NG2 showed the greatest response. The appearance of these progenitors preceded the appearance of reactive astrocytes. Surprisingly, we found evidence of the translocation of the transcription factor Olig2 into cytoplasm in the first week after injury, a mechanism that is known to mediate the differentiation of astrocytes during brain development. Translocation of Olig2, down-regulation of NG2, and increased glial fibrillary acidic protein expression were recapitulated in vitro after exposure of glial progenitors to serum components or bone morphogentic protein by up-regulation of Notch-1. The glial differentiation and Olig2 translocation could be blocked by inhibition of Notch-1 with the gamma-secretase inhibitor DAPT. Together, these data indicate that the prompt maturation of numerous Olig2(+) glial progenitors to astrocytes underlies the repair process after a traumatic injury. In contrast, neural stem cells and neuronal progenitor cells appear to play only a minor role in the injured adult CNS. (c) 2007 Wiley-Liss, Inc.	NIA, GRC, Lab Neurosci, Intramural Res Program,NIH, Baltimore, MD 21224 USA; Univ Maryland, Sch Med, Comparat Med Program, Baltimore, MD 21201 USA; Harvard Univ, Inst Med, Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; NIA, Lab Genet, NIH, Baltimore, MD 21224 USA; Natl Taiwan Univ Hosp, Dept Neuol, Stroke Ctr, Taipei, Taiwan; Natl Inst Neurol Disorders & Stroke, Neuroimmunol Branch, NIH, Bethesda, MD USA		Magnus, T (corresponding author), NIA, GRC, Lab Neurosci, Intramural Res Program,NIH, 5600 Nathan Shock Dr,Room 406A, Baltimore, MD 21224 USA.	magnust@mail.nih.gov	Arumugam, Thiruma Valavan/B-4898-2011; Arumugam, Thiruma/AAG-6958-2019; Eckley, Mark/M-3526-2014; Eckley, David Mark/I-9245-2019; Arumugam, Thiruma/C-7969-2009; Korn, Thomas/AAE-6960-2019; Mattson, Mark P/F-6038-2012	Eckley, Mark/0000-0003-2296-5164; Korn, Thomas/0000-0002-3633-0955; Tang, Sung-Chun/0000-0003-3731-5973; Arumugam, Thiruma/0000-0002-3377-0939			Aguirre A, 2004, J NEUROSCI, V24, P10530, DOI 10.1523/JNEUROSCI.3572-04.2004; Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; ARUMUGAM TV, 2006, IN PRESS NAT MED; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Brazel CY, 2005, AGING CELL, V4, P197, DOI 10.1111/j.1474-9726.2005.00158.x; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Cai JL, 2004, J NEUROCHEM, V88, P212, DOI 10.1046/j.1471-4159.2003.02184.x; Coksaygan T, 2006, EXP NEUROL, V197, P475, DOI 10.1016/j.expneurol.2005.10.030; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fukuda S, 2004, CELL DEATH DIFFER, V11, P196, DOI 10.1038/sj.cdd.4401332; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374; Hall AK, 2004, J NEUROSCI RES, V76, P1, DOI 10.1002/jnr.20019; Han SSW, 2002, EXP NEUROL, V177, P360, DOI 10.1006/exnr.2002.7995; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LEVINE JM, 1993, GLIA, V7, P307, DOI 10.1002/glia.440070406; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Ligon KL, 2006, P NATL ACAD SCI USA, V103, P7853, DOI 10.1073/pnas.0511001103; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Marshall CAG, 2005, J NEUROSCI, V25, P7289, DOI 10.1523/JNEUROSCI.1924-05.2005; Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004; Mekki-Dauriac S, 2002, DEVELOPMENT, V129, P5117; Muroyama Y, 2005, NATURE, V438, P360, DOI 10.1038/nature04139; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Parent JM, 1998, NEUROSCI LETT, V247, P9, DOI 10.1016/S0304-3940(98)00269-9; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rao M, 2004, J NEUROTRAUM, V21, P415, DOI 10.1089/089771504323004566; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; Rao MS, 1997, DEV BIOL, V188, P48, DOI 10.1006/dbio.1997.8597; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sakakibara S, 1997, J NEUROSCI, V17, P8300; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Setoguchi T, 2004, J CELL BIOL, V166, P963, DOI 10.1083/jcb.200404104; Takebayashi H, 2002, CURR BIOL, V12, P1157, DOI 10.1016/S0960-9822(02)00926-0; Talbott JF, 2005, EXP NEUROL, V192, P11, DOI 10.1016/j.expneurol.2004.05.038; Wang S, 1998, NAT BIOTECHNOL, V16, P196, DOI 10.1038/nbt0298-196; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; WOLSWIJK G, 1991, ANN NY ACAD SCI, V633, P502; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; Wu YY, 2002, GLIA, V38, P65, DOI 10.1002/glia.10049; Yamamoto S, 2001, J NEUROSCI, V21, P9814, DOI 10.1523/JNEUROSCI.21-24-09814.2001; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	55	68	69	0	6	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	AUG 1	2007	85	10					2126	2137		10.1002/jnr.21368			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	196XO	WOS:000248516700007	17510983				2022-02-06	
J	Dick, R; Lincoln, AE; Agel, J; Carter, EA; Marshall, SW; Hinton, RY				Dick, Randall; Lincoln, Andrew E.; Agel, Julie; Carter, Elizabeth A.; Marshall, Stephen W.; Hinton, Richard Y.			Descriptive epidemiology of collegiate women's lacrosse injuries: National Collegiate Athletic Association injury surveillance system, 1988-1989 through 2003-2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; concussions; lower extremity injuries; knee injuries; facial injuries	ANKLE SPRAINS; PROSPECTIVE INTERVENTION; PROFESSIONAL FOOTBALL; PREVENTION PROGRAM; TEAM HANDBALL; NECK INJURIES; EYE INJURIES; ICE HOCKEY; PLAYERS; HEAD	Objective: To review 16 years of National Collegiate Athletic Association injury surveillance data for women's lacrosse and identify potential areas for injury prevention initiatives. Background: Women's lacrosse is a fast-paced, primarily noncontact sport. Participation in collegiate women's lacrosse almost doubled between the 1688-1989 and 2003-2004 seasons. Lacrosse equipment consists of sticks made of wood or a synthetic material and a hard rubber ball. Until recently, mouth guards were the only required protective equipment. Main Results: Collegiate women's lacrosse game injury rates increased over the 16-year study period. More than 60% of all severe game injuries were lower extremity sprains and strains and knee internal derangements, most frequently the result of noncontact incidents. The most common injury scenarios by injury mechanism and player activity were no contact while ball handling (16.4%) and contact from a stick while ball handling (10.5%). Contact from a stick or a ball accounted for 5.6% and 5.2% of injuries sustained during shooting activities, respectively. Approximately 22% of all game and 12% of all practice injuries involved the head and neck. Contact from a stick accounted for the majority (56.0%) of above-the-neck injuries in games; contact from the ball accounted for 20.0% of these injuries. Participants had 5 times the risk of sustaining a concussion in a game as in a practice (0.70 versus 0.15 injuries per 1000 athletic-exposures, rate ratio = 4.7, 95% confidence interval = 3.8, 6.5). Recommendations: To reduce the lower extremity injuries that comprise the greatest injury burden in women's lacrosse, future researchers should evaluate proprioceptive, plyometric, and balance training interventions designed specifically for female players. Other research areas of great interest involve determining whether protective eyewear (mandated in 2004) reduces injuries to the eye, orbit, and nasal area and identifying any unintended consequences of the mandate, such as increased risk of injuries to other areas of the face or more aggressive play.	MedStar Res Inst, Hyattsville, MD 20783 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA; Univ Minnesota, Minneapolis, MN 55455 USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Union Mem Hosp, Baltimore, MD USA		Lincoln, AE (corresponding author), MedStar Res Inst, 6495 New Hampshire Ave,Suite 201, Hyattsville, MD 20783 USA.	andrew.e.lincoln@medstar.net		Marshall, Stephen/0000-0002-2664-9233			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2004, BRIT J SPORT MED, V38, P626, DOI 10.1136/bjsm.2003.007955; Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Bahr R, 1997, SCAND J MED SCI SPOR, V7, P172, DOI 10.1111/j.1600-0838.1997.tb00135.x; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; Caraffa A, 1996, Knee Surg Sports Traumatol Arthrosc, V4, P19, DOI 10.1007/BF01565992; Dick R, 2007, J ATHL TRAINING, V42, P255; Dick R, 2007, J ATHL TRAINING, V42, P173; Goldenberg Michael S., 1995, Journal of Athletic Training, V30, P37; Grandstrand SL, 2006, J STRENGTH COND RES, V20, P331; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Livingston LA, 2006, J SCI MED SPORT, V9, P299, DOI 10.1016/j.jsams.2006.05.022; Matz SO, 2004, AM J SPORT MED, V32, P608, DOI 10.1177/0363546503262172; Myklebust G, 2003, CLIN J SPORT MED, V13, P71, DOI 10.1097/00042752-200303000-00002; *NAT COLL ASS, 2006, 1981 82 2004 05 NCAA; Pfeiffer RP, 2006, J BONE JOINT SURG AM, V88A, P1769, DOI 10.2106/JBJS.E.00616; Stoner LJ, 1993, SAFETY ICE HOCKEY, V2, P183; Thacker SB, 1999, AM J SPORT MED, V27, P753, DOI 10.1177/03635465990270061201; Verhagen E, 2004, AM J SPORT MED, V32, P1385, DOI 10.1177/0363546503262177; Waicus KM, 2002, CLIN J SPORT MED, V12, P24, DOI 10.1097/00042752-200201000-00008; Wedderkopp N, 1999, SCAND J MED SCI SPOR, V9, P41; Wester JU, 1996, J ORTHOP SPORT PHYS, V23, P332, DOI 10.2519/jospt.1996.23.5.332	24	68	68	0	7	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					262	269					8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	180RC	WOS:000247382300013	17710175				2022-02-06	
J	Bushnik, T; Englander, J; Katznelson, L				Bushnik, Tamara; Englander, Jeffrey; Katznelson, Laurence			Fatigue after TBI: Association with neuroendocrine abnormalities	BRAIN INJURY			English	Article						traumatic brain injury; hypopituitarism; fatigue; growth hormone; rehabilitation	TRAUMATIC BRAIN-INJURY; GROWTH-HORMONE DEFICIENCY; MINOR HEAD-INJURY; LONG-TERM; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; SLEEP DISTURBANCE; SEVERITY SCALE; HYPOPITUITARISM; DEPRESSION	Objective: Evaluate the association between neuroendocrine findings and fatigue after traumatic brain injury (TBI) Research design: Prospective, observational. Methods and procedures: Sixty- four individuals at least 1 year post-TBI underwent neuroendocrine testing including thyroid, adrenal, gonadal axes and growth hormone (GH) after glucagon stimulation with assessment of fatigue using the Global Fatigue Index ( GFI) and the Fatigue Severity Scale (FSS). Main outcomes and results: GFI and FSS scores were significantly higher within this sample compared to published control data. At least one pituitary axis was abnormal in 90% of participants. Higher GH levels were significantly associated with higher FSS scores. There was a noted trend between lower basal cortisol and higher scores on both the FSS and GFI. Conclusions: The association between higher GH levels and greater fatigue contradicted the prevailing hypothesis that postacute TBI fatigue is associated with GH deficiency. The association between lower basal cortisol and greater fatigue was in the expected direction. While no other trends were noted, the fatigue derived from neuroendocrine abnormalities alone may be masked by fatigue induced by other factors commonly experienced following TBI. Given the high prevalence of pituitary abnormalities, screening for hypopituitarism after TBI is a reasonable recommendation. The contribution of GH deficiency to diminished quality of life post- TBI remains unclear.	Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, PM&R, San Jose, CA 95128 USA; Stanford Univ, Med Ctr, Dept Neurosurg, Pituitary Ctr, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA		Bushnik, T (corresponding author), Santa Clara Valley Med Ctr, Rehabil Res Ctr, 751 S Bascom Ave, San Jose, CA 95128 USA.	tamara@tbi-sci.org		Katznelson, Laurence/0000-0001-8115-5714; Bushnik, Tamara/0000-0003-3328-257X			Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Baum HBA, 1996, J CLIN ENDOCR METAB, V81, P84, DOI 10.1210/jc.81.1.84; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BELZA BL, 1995, J RHEUMATOL, V22, P639; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; de Rijk AE, 1999, J PSYCHOSOM RES, V47, P509, DOI 10.1016/S0022-3999(99)00049-5; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FINKELMAN JM, 1994, HUM FACTORS, V36, P232, DOI 10.1177/001872089403600205; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Grady C, 1998, NURS RES, V47, P227, DOI 10.1097/00006199-199807000-00008; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hillier SL, 1997, BRAIN INJURY, V11, P661; JONES SL, 1994, CLIN ENDOCRINOL, V41, P123, DOI 10.1111/j.1365-2265.1994.tb03793.x; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kleinman L, 2000, QUAL LIFE RES, V9, P499, DOI 10.1023/A:1008960710415; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 1996, J PEDIATR-US, V128, pS58, DOI 10.1016/S0022-3476(96)70013-6; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MCGAULEY GA, 1990, HORM RES, V33, P52, DOI 10.1159/000181584; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; Michael Kathleen, 2002, Rehabil Nurs, V27, P89; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PACKER TL, 1994, ARCH PHYS MED REHAB, V75, P1122, DOI 10.1016/0003-9993(94)90088-4; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Ravdin LD, 1996, J CLIN PSYCHIAT, V57, P282; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P165, DOI 10.1016/S0003-9993(96)90162-8; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHARAR E, 1990, J FAM PRACTICE, V31, P257; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Taylor RR, 2002, PSYCHOSOM MED, V64, P319, DOI 10.1097/00006842-200203000-00016; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Wambach K A, 1998, J Hum Lact, V14, P219, DOI 10.1177/089033449801400311; Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003-032006; Widmer IE, 2005, J CLIN ENDOCR METAB, V90, P4579, DOI 10.1210/jc.2005-0354; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	65	68	70	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	6					559	566		10.1080/02699050701426915			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	192LU	WOS:000248204100002	17577706				2022-02-06	
J	Flaro, L; Green, P; Robertson, E				Flaro, Lloyd; Green, Paul; Robertson, Ellen			Word Memory Test failure 23 times higher in mild brain injury than in parents seeking custody: The power of external incentives	BRAIN INJURY			English	Article						brain injury; motivation; effort; symptom validity test; incentive	PERFORMANCE; ISSUES	Primary objective: Motivation has an important influence on neuropsychological test performances. This study examined effort on the Word Memory Test ( WMT) in groups with differing external incentives. Research design: 774 adults with Traumatic Brain Injury ( TBI), tested as part of a Workers' Compensation, disability or personal injury claim stood to gain financially by appearing impaired on testing. In contrast, parents ordered by the Court to undergo a parenting assessment were highly motivated to do their best on cognitive tests because their goal was to regain custody of their children. Outcomes and results: Consistent with these assumptions, 98.3% of 118 parents seeking child custody passed the WMT effort subtests but in cases of mild TBI the pass rate on the WMT was only 60%. The WMT failure rate in the mild TBI sample was 23 times higher than in the group of parents seeking custody. WMT failure was twice as frequent in the mild TBI group than in those with more severe TBI. WMT failure was also much higher in adults with mild TBI than in children with significant impairment from various clinical conditions. Conclusions: Such differences in failure rates on the WMT effort subtests cannot be explained by differences in cognitive skills but they are explainable by differences in external incentives. The findings support the recommendation that objective tests of effort should be used when evaluating cognitive impairment.			Flaro, L (corresponding author), Ed D Suite 210,17010 103 Ave, Edmonton, AB T5S 1K7, Canada.	drflaro@telus.net					ARDOLF BR, IN PRESS CLIN NEUROP; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; DEFILIPPIS N, 2005, PAR STAFF CATEGORY T; Garcia, 1999, WECHSLER ABBREVIATED; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GREEN P, 2003, DETECTION RESPONSE B; Green P., 2003, MANUAL WORD MEMORY T; Green P, 1995, MANUAL ORAL WORD MEM; Harrison A.G., 2006, ADHD REPORT, V14, P1, DOI [DOI 10.1521/ADHD.2006.14.4.1, 10.1521/adhd.2006.14.4.1]; Iverson G., 1999, J COGNITIVE REHABILI, V17, P4; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, APPL NEUROPSYCHOL, V13, P77, DOI 10.1207/s15324826an1302_3; Kuehnle K., 2000, FAMILY CONCILIATION, V38, P368, DOI DOI 10.1111/J. 174-1617. 2000. TB00580. X; Reitan R, 1969, MANUAL ADM NEUROPSYC; SULLIVAN B, IN PRESS APPL NEUROP; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; [No title captured]	23	68	68	0	11	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	4					373	383		10.1080/02699050701311133			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	168IY	WOS:000246518600003	17487635				2022-02-06	
J	Nott, MT; Chapparo, C; Baguley, IJ				Nott, Melissa T.; Chapparo, Christine; Baguley, Ian J.			Agitation following traumatic brain injury: An Australian sample	BRAIN INJURY			English	Article						traumatic brain injury; agitation; cognition; post-traumatic amnesia; outcomes	CLOSED HEAD-INJURY; SCALE; REHABILITATION; AGGRESSION; RESTLESSNESS; BEHAVIOR	Purpose: Agitation following traumatic brain injury (TBI) is perceived to limit the achievement of rehabilitation goals. The aims of this study were: (1) To examine the nature and incidence of agitation during TBI rehabilitation in an Australian sample; and (2) To explore the relationship between agitation and functional outcomes after TBI. Method: Retrospective medical record review of 80 participants admitted for rehabilitation following TBI. Outcome data collected at discharge, 6 and 24 months post-discharge, included length of stay, duration of post- traumatic amnesia ( PTA), community integration, functional independence and life satisfaction. Results: Seventy per cent of patients demonstrated agitation during rehabilitation for an average of 32 days. Agitated patients experienced longer PTA duration, increased length of stay and reduced functional independence, specifically cognitive function, at discharge. These differences between agitated and non- agitated participants did not appear to persist and were not evident at follow- up 6 and 24 months post- discharge. Longer duration of agitation was associated with delayed PTA emergence, longer rehabilitation stay and reduced functional independence at discharge and follow- up. Conclusions: A large proportion of patients with TBI experience agitation. Presence of agitation seems to limit rehabilitation gains at discharge. Longer duration of agitation is associated with persisting limitations to functional independence.	Univ Sydney, Fac Hlth Sci, Lidcombe, NSW 1825, Australia; Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia		Nott, MT (corresponding author), Univ Sydney, Fac Hlth Sci, Room J126, Lidcombe, NSW 1825, Australia.	mnot2529@mail.usyd.edu.au	Nott, Melissa T/M-6778-2018; Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Nott, Melissa T/0000-0001-7088-5826; Baguley, Ian J/0000-0001-5650-3705			Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleminger S, 2003, BMJ-BRIT MED J, V327, P4, DOI 10.1136/bmj.327.7405.4; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P917, DOI 10.1016/S0003-9993(97)90050-2; GALSKI T, 1994, ARCH PHYS MED REHAB, V75, P380, DOI 10.1016/0003-9993(94)90158-9; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Maryniak O, 2001, BRAIN INJURY, V15, P167, DOI 10.1080/026990501458399; Plylar P A, 1989, J Neurosci Nurs, V21, P353; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; van der Naalt J, 2000, BRAIN INJURY, V14, P781; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; [No title captured]	26	68	68	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2006	20	11					1175	1182		10.1080/02699050601049114			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DD	WOS:000242357600008	17123934				2022-02-06	
J	Ronne-Engstrom, E; Winkler, T				Ronne-Engstrom, E.; Winkler, T.			Continuous EEG monitoring in patients with traumatic brain injury reveals a high incidence of epileptiform activity	ACTA NEUROLOGICA SCANDINAVICA			English	Article						EEG; neurointensive care; seizures; traumatic brain injury	SEIZURES	Background - EEG is the only available method for real time monitoring of the brain and is therefore of great interest in the neurointensive care. The present study describes our experiences from implying continuous EEG monitoring as a routine method. We also present EEG patterns observed on patients with traumatic brain injury (TBI). Methods - Seventy TBI patients requiring neurointensive care were included. Digital EEG was recorded continuously. Five minutes every hour were analysed off-line. Results - Twenty-three patients (33%) developed seizures, 74 +/- 47 h after trauma. The seizures were brief, responding to phenytoin, or persistent, requiring propofol or barbiturate sedation. Six out of eight patients with persistent seizures had intracerebral contusions. Eighteen patients (26%) displayed focal high frequency activity that proceeded to seizures in eight cases. Twelve patients (17%) developed recurrent paroxysmal delta activity. The patients in the seizure group were significantly older (62 +/- 12 vs. 28 +/- 17 years) and more often exposed to low energy trauma (87% vs 22%) compared to the paroxysmal delta pattern group. Conclusion - TBI implies high risk for development of epileptiform activity, with a time lag between trauma and seizure onset. TBI patients also displayed other EEG pattern that should be investigated further in order to obtain a better understanding of posttraumatic mechanisms.	Univ Uppsala Hosp, Dept Neurosurg, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Clin Neurophysiol, Div Neurosci, S-75185 Uppsala, Sweden		Ronne-Engstrom, E (corresponding author), Univ Uppsala Hosp, Dept Neurosurg & Neurosci, S-75185 Uppsala, Sweden.	elisabeth.ronne.engstrom@akademiska.se					Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Beaumanoir A, 1996, ELECTROEN CLIN NEURO, V99, P287; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; GLOOR P, 1977, NEUROLOGY, V27, P326, DOI 10.1212/WNL.27.4.326; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TRIGGS WJ, 1990, NEUROSCI LETT, V180, P84; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Westmoreland BF, 2001, J CLIN NEUROPHYSIOL, V18, P20, DOI 10.1097/00004691-200101000-00005; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408	12	68	72	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	JUL	2006	114	1					47	53		10.1111/j.1600-0404.2006.00652.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	050DC	WOS:000238066700009	16774627				2022-02-06	
J	Giza, CC; Maria, NS; Hovda, DA				Giza, Christopher C.; Santa Maria, Naomi S.; Hovda, David A.			N-methyl-D-aspartate receptor subunit changes after traumatic injury to the developing brain	JOURNAL OF NEUROTRAUMA			English	Article						glutamate; immature; pediatric; plasticity; synapse; synaptoneurosomes; traumatic brain injury	FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; DEVELOPMENTAL LEAD-EXPOSURE; RAT HIPPOCAMPAL SLICES; MORRIS WATER MAZE; NMDA RECEPTORS; ADULT-RAT; GLUCOSE-UTILIZATION; SYNAPTIC CURRENTS; VISUAL-CORTEX	Traumatic brain injury (TBI) is a major cause of disability in the pediatric population and can result in abnormal development. Experimental studies conducted in animals have revealed impaired plasticity following developmental TBI, even in the absence of significant anatomical damage. The N-methyl-D-aspartate receptor (NMDAR) is clearly involved in both normal development and in the pathophysiology of TBI. Following lateral fluid percussion injury in postnatal day (PND) 19 rats, we tested the hypothesis that TBI sustained at an early age would result in impaired NMDAR expression. Using immunoblotting and reverse transcriptase-polymerase chain reaction (RT-PCR), protein and RNA levels of NMDAR subunits were measured in the cerebral cortex and hippocampus on post-injury days (PID) 1, 2, 4, and 7 (though the PID7 analysis was only for protein) and compared with age-matched shams. Significant effects of hemisphere (analysis of variance [ANOVA], p < 0.01), and interactions between hemisphere and injury (ANOVA,p < 0.05) and hemisphere and PID (ANOVA, p < 0.05) were found for synaptic protein levels of the NR2A subunit in hippocampus. Specifically, within the ipsilateral hippocampus, NR2A was reduced by 9.9%, 47.9%, 40.8%, and 6.3% on PID1, PID2, PID4, and PID7, respectively. Within the cortex, there was a significant effect of injury (ANOVA,p < 0.05) without any hemispheric differences. These bilateral cortical reductions measured 30.5%, 3.2%, 5.7%, and 13.4% at the same timepoints after injury. Injury had no significant main effect on NR1 or NR2B protein levels. RT-PCR analysis showed no significant changes in NR1, NR2A, or NR2B gene expression; however, as a positive control, hsp70 was induced more than twofold in ipsilateral cortex and hippocampus on PID1. It is known that NR2A expression levels increase during normal development, and in response to environmental stimuli. Our data suggest that injury-induced reduction in the expression of NR2A is one likely mechanism for the impaired experience-dependent neuroplasticity seen following traumatic injury to the immature brain.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr,Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Neurol, Dept Pediat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA		Giza, CC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr,Dept Surg, Room 18-218B NPI,Mail Code 703919, Los Angeles, CA 90095 USA.	cgiza@mednet.ucla.edu		Sta Maria, Naomi/0000-0001-9710-2908	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS002197-05, K08 NS002197-04, K08 NS002197-01A1, K08 NS002197-03, NS27544, K08 NS002197, K08 NS002197-02, R01 NS027544, NS02197] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, K08NS002197] Funding Source: NIH RePORTER		Bellinger FP, 2002, SYNAPSE, V43, P95, DOI 10.1002/syn.10020; Berggren KN, 2002, PROTEOMICS, V2, P486, DOI 10.1002/1615-9861(200205)2:5<486::AID-PROT486>3.0.CO;2-X; *BIORAD, 2005, INSTR MAN DISC SER Q; *BIORAD, INSTR MAN SYPR RUB P; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chen NS, 1999, J NEUROSCI, V19, P6844, DOI 10.1523/JNEUROSCI.19-16-06844.1999; Conti AC, 1998, J NEUROSCI, V18, P5663; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Flint AC, 1997, J NEUROSCI, V17, P2469; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; GORTER JA, 1992, BRAIN RES, V572, P176, DOI 10.1016/0006-8993(92)90467-N; Gottmann K, 1997, J NEUROSCI, V17, P2766; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hughes PD, 1998, ALCOHOL CLIN EXP RES, V22, P1255, DOI 10.1097/00000374-199809000-00010; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; JABLONSKA B, 1995, BEHAV BRAIN RES, V66, P207, DOI 10.1016/0166-4328(94)00141-2; Jett DA, 1997, PHARMACOL BIOCHEM BE, V57, P271, DOI 10.1016/S0091-3057(96)00350-4; Johnson MW, 1997, J NEUROSCI METH, V77, P151, DOI 10.1016/S0165-0270(97)00120-9; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kew JNC, 1998, J NEUROSCI, V18, P1935; Kind PC, 2001, TRENDS NEUROSCI, V24, P553, DOI 10.1016/S0166-2236(00)01921-4; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; Kuhlmann AC, 1997, NEUROSCI LETT, V233, P101, DOI 10.1016/S0304-3940(97)00633-2; Lavezzari G, 2004, J NEUROSCI, V24, P6383, DOI 10.1523/JNEUROSCI.1890-04.2004; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Max JE, 1997, BRAIN INJURY, V11, P699; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Nihei MK, 1999, MOL BRAIN RES, V66, P42, DOI 10.1016/S0169-328X(99)00005-4; Perez-Otano I, 2005, TRENDS NEUROSCI, V28, P229, DOI 10.1016/j.tins.2005.03.004; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Quinlan EM, 1999, P NATL ACAD SCI USA, V96, P12876, DOI 10.1073/pnas.96.22.12876; Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Roberts EB, 1999, J NEUROPHYSIOL, V81, P2587, DOI 10.1152/jn.1999.81.5.2587; Scheetz AJ, 2000, NAT NEUROSCI, V3, P211, DOI 10.1038/72915; SCHEETZ AJ, 1994, FASEB J, V8, P745, DOI 10.1096/fasebj.8.10.8050674; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Small DL, 1997, NEUROSCI LETT, V232, P87, DOI 10.1016/S0304-3940(97)00592-2; Takahashi T, 1996, J NEUROSCI, V16, P4376; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Weiner H. L., 2000, HEAD INJURY, P419; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	60	68	75	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2006	23	6					950	961		10.1089/neu.2006.23.950			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	056TW	WOS:000238549000011	16774479	Green Accepted			2022-02-06	
J	Devitt, R; Colantonio, A; Dawson, D; Teare, G; Ratcliff, G; Chase, S				Devitt, R.; Colantonio, A.; Dawson, D.; Teare, G.; Ratcliff, G.; Chase, S.			Prediction of long-term occupational performance outcomes for adults after moderate to severe traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						traumatic brain injury; ageing; occupational performance; long-term outcomes; prediction	COMMUNITY INTEGRATION QUESTIONNAIRE; SPINAL-CORD-INJURY; HEALTH SURVEY QUESTIONNAIRE; BLUNT HEAD-INJURY; DISABILITY; REHABILITATION; RELIABILITY; SF-36; IMPAIRMENT; EMPLOYMENT	Purpose. To examine predictors of long-term occupational performance outcomes for adults after moderate to severe traumatic brain injury (TBI). Method. This study involved analysis of data from a retrospective cohort of adults (N = 306) with moderate to severe TBI discharged from a Pennsylvania rehabilitation treatment facility. Extensive pre-injury sociodemographic, injury-severity, post-injury personal (cognitive, physical, affective), post-injury environmental (social, institutional, physical), and post-injury occupational performance (participation in self-care, productivity, leisure activities) data were gathered from hospital records and using in-person interviews. Interviews occurred at a mean time of 14 (range, 7-24) years post-injury. Hierarchical multiple regression analysis was used to investigate determinants of long-term occupational performance outcomes. Results. Pre-injury behavioural problems, male gender, post-injury cognitive and physical deficits, and lack of access to transportation were significant independent predictors of worse occupational performance outcomes. Conclusions. The study supports the use of a comprehensive model for long-term outcomes after TBI where pre-injury characteristics and post-injury cognitive and physical characteristics account for the greatest proportion of explained variance.	Univ Toronto, Fac Med, Grad Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada; Arthritis Community Res & Evaluat Unit, Toronto, ON, Canada; Toronto Rehabil Inst, Toronto, ON, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; HeathSouth Harmarville Rehabil Ctr, Pittsburgh, PA USA; Working Order, Pittsburgh, PA USA		Colantonio, A (corresponding author), Univ Toronto, Fac Med, Grad Dept Rehabil Sci, 500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121; Colantonio, Angela/0000-0003-2094-4765			Ashley M. J., 1997, J REHABILITATION OUT, V1, P40; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; *CAN ASS OCC THER, 1997, EN OCC OCC THER PERS; Charlifue SW, 1999, ARCH PHYS MED REHAB, V80, P1429, DOI 10.1016/S0003-9993(99)90254-X; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; COOPER B, 2001, MEASURING OCCUPATION, P229; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; *COUNC CLIN CLASS, 1980, INT CLASS DIS, P11; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Doninger NA, 2003, REHABIL PSYCHOL, V48, P67, DOI 10.1037/0090-5550.48.2.67; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fleming J, 1999, BRAIN INJURY, V13, P417; Fougeyrollas P., 1997, ICIDH ENV FACTORS IN, V9, P6; GARRATT AM, 1993, BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Greenspan A I, 1989, Md Med J, V38, P239; Harwood RH, 1995, MANUAL LONDON HANDIC; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KIM JA, 1997, OCCUPATIONAL THERAPY, V4, P178; KLUSMAN LE, 1989, PERCEPT MOTOR SKILL, V68, P1199, DOI 10.2466/pms.1989.68.3c.1199; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Law M., 2001, MEASURING OCCUPATION; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MENTER RR, 1995, SPINAL CORD INJURY C; MOSQUEDA L, 2004, AGING DISABILITY WHA, P35; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ocampo S, 1997, OCCUP THER INT, V4, P161; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Possl O, 2001, BRAIN INJURY, V15, P15; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Reitan R, 1985, HALSTEAD REITAN NEUR; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Spreen O., 1988, COMPENDIUM NEUROPSYC; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stewart AL, 1992, MEASURING FUNCTIONIN; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; TRIESCHMANN RB, 1990, J HEAD TRAUMA REHAB, V5, P57; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Weitzenkamp DA, 2001, SPINAL CORD, V39, P301, DOI 10.1038/sj.sc.3101146; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	69	68	68	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	MAY	2006	28	9					547	559		10.1080/00222930500219258			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	041QN	WOS:000237470900002	16690584				2022-02-06	
J	Drysdale, AJ; Ryan, D; Pertwee, RG; Platt, B				Drysdale, AJ; Ryan, D; Pertwee, RG; Platt, B			Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells	NEUROPHARMACOLOGY			English	Article						cannabidiol; calcium; CB1; vanilloid; voltage-gated calcium channels; intracellular calcium stores; IP3 receptors; ryanodine receptor	CANNABINOID RECEPTOR AGONISTS; CLOSED-HEAD INJURY; CALCIUM-CHANNELS; SYNAPTIC-TRANSMISSION; RAT; MECHANISMS; ANANDAMIDE; INHIBITION; ENDOCANNABINOIDS; SYNAPSES	The phytocannabinoid cannabidiol (CBD) is at the forefront of therapeutic cannabinoid research due to its non-psychotropic properties. Research supports its use in a variety of disorders, yet the cellular mechanisms of its action remain unclear. In this study, the effect of CBD upon Ca2+ homeostasis in hippocampal cells was characterised. CBD (1 mu M) elevated intracellular Ca2+ ([Ca2+](i)) by similar to +45% of basal Ca2+ levels in both glia (77% responders) and neurones (51% responders). Responses to CBD were reduced in high excitability HEPES buffered solution (HBS), but not affected in low excitability/low Ca2+ HBS. CBD responses were also significantly reduced (by 50%) by the universal Ca2+ channel blocker cadmium (50 mu M) and the L-type specific Ca2+ channel blocker nifedipine (20 mu M). Interestingly, intracellular store depletion with thapsigargin (2 mu M) had the most dramatic effect on CBD responses, leading on average to a full block of the response. Elevated CBD-induced [Ca2+](i) responses (> + 100%) were observed in the presence of the CB1 receptor antagonist, AM281 (1 mu M), and the vanilloid receptor antagonist, capsazepine (CPZ, 1 mu M). Overall, our data suggest that CBD modulates hippocampal [Ca2+](i) homeostasis via intracellular Ca2+ stores and L-type VGCC-mediated Ca2+ entry, with tonic cannabinoid and vanilloid receptor signalling being negatively coupled to this pathway. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland		Platt, B (corresponding author), Univ Aberdeen, Sch Med Sci, Foresterhill, Aberdeen AB25 2ZD, Scotland.	b.platt@abdn.ac.uk	Pertwee, Roger Guy/E-1312-2011	Platt, Bettina/0000-0002-7852-0749; Pertwee, Roger/0000-0003-3227-2783			Begg M, 2003, J BIOL CHEM, V278, P46188, DOI 10.1074/jbc.M307258200; Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327; Breivogel CS, 2001, MOL PHARMACOL, V60, P155, DOI 10.1124/mol.60.1.155; Brenowitz SD, 2003, J NEUROSCI, V23, P6373; Brown SP, 2004, J NEUROSCI, V24, P5623, DOI 10.1523/JNEUROSCI.0918-04.2004; CAULFIELD MP, 1992, BRIT J PHARMACOL, V106, P231, DOI 10.1111/j.1476-5381.1992.tb14321.x; Chou KJ, 2001, LIFE SCI, V69, P1541, DOI 10.1016/S0024-3205(01)01242-5; Clodfelter GV, 2002, EUR J PHARMACOL, V447, P189, DOI 10.1016/S0014-2999(02)01843-5; CONSROE P, 1981, J CLIN PHARMACOL, V21, pS428, DOI 10.1002/j.1552-4604.1981.tb02623.x; Costa B, 2004, BRIT J PHARMACOL, V143, P247, DOI 10.1038/sj.bjp.0705920; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Dib B, 1996, INT J TISSUE REACT, V18, P27; Docherty RJ, 1997, BRIT J PHARMACOL, V121, P1461, DOI 10.1038/sj.bjp.0701272; Drysdale AJ, 2003, CURR MED CHEM, V10, P2719, DOI 10.2174/0929867033456387; DRYSDALE AJ, 2005, SOC NEUR ABSTR; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; Hampson RE, 2000, J NEUROPHYSIOL, V84, P2356, DOI 10.1152/jn.2000.84.5.2356; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Huang CC, 2001, J PHYSIOL-LONDON, V532, P731, DOI 10.1111/j.1469-7793.2001.0731e.x; Kaplan BLF, 2003, J PHARMACOL EXP THER, V306, P1077, DOI 10.1124/jpet.103.051961; Lorton D, 2000, NEUROIMMUNOMODULAT, V7, P115, DOI 10.1159/000026429; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Mukhopadhyay S, 2002, CHEM PHYS LIPIDS, V121, P91, DOI 10.1016/S0009-3084(02)00153-6; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; Netzeband JG, 1999, J NEUROSCI, V19, P8765, DOI 10.1523/JNEUROSCI.19-20-08765.1999; Nogueron MI, 2001, J NEUROCHEM, V79, P371, DOI 10.1046/j.1471-4159.2001.00567.x; Nunez E, 2004, SYNAPSE, V53, P208, DOI 10.1002/syn.20050; Offertaler L, 2003, MOL PHARMACOL, V63, P699, DOI 10.1124/mol.63.3.699; Pertwee RG, 2005, NEUROPHARMACOLOGY, V48, P1139, DOI 10.1016/j.neuropharm.2005.01.010; Pertwee RG, 2004, NEUROSCI INTELL UNIT, P32; Pertwee RG, 2002, EUR J PHARMACOL, V456, P99, DOI 10.1016/S0014-2999(02)02624-9; Pertwee RG, 1996, EUR J PHARMACOL, V315, P195, DOI 10.1016/S0014-2999(96)00631-0; Platt B., 2004, Current Neuropharmacology, V2, P103, DOI 10.2174/1570159043476972; Power JM, 2005, J PHYSIOL-LONDON, V562, P439, DOI 10.1113/jphysiol.2004.076711; Robbe D, 2001, J NEUROSCI, V21, P109, DOI 10.1523/JNEUROSCI.21-01-00109.2001; Rubovitch V, 2004, MOL BRAIN RES, V120, P138, DOI 10.1016/j.molbrainres.2003.10.012; Rubovitch V, 2002, MOL BRAIN RES, V101, P93, DOI 10.1016/S0169-328X(02)00174-2; Shen MX, 1998, MOL PHARMACOL, V54, P459, DOI 10.1124/mol.54.3.459; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Showalter VM, 1996, J PHARMACOL EXP THER, V278, P989; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Sullivan JM, 1999, J NEUROPHYSIOL, V82, P1286, DOI 10.1152/jn.1999.82.3.1286; Twitchell W, 1997, J NEUROPHYSIOL, V78, P43, DOI 10.1152/jn.1997.78.1.43; van der Stelt M, 2005, EMBO J, V24, P3026, DOI 10.1038/sj.emboj.7600784; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; Verkhratsky A, 2003, J CELL MOL MED, V7, P351, DOI 10.1111/j.1582-4934.2003.tb00238.x; Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa; Waksman Y, 1999, J PHARMACOL EXP THER, V288, P1357; Walter L, 2003, J NEUROSCI, V23, P1398, DOI 10.1523/JNEUROSCI.23-04-01398.2003; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Whittle B. A., 2001, Journal of Cannabis Therapeutics, V1, P183, DOI 10.1300/J175v01n03_12; Xiong H, 2004, NEUROBIOL AGING, V25, P349, DOI 10.1016/S0197-4580(03)00123-4; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	56	68	68	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2006	50	5					621	631		10.1016/j.neuropharm.2005.11.008			11	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	034FL	WOS:000236914300012	16386766				2022-02-06	
J	Hicdonmez, T; Kanter, M; Tiryaki, M; Parsak, T; Cobanoglu, S				Hicdonmez, Tufan; Kanter, Mehmet; Tiryaki, Mehmet; Parsak, Turgay; Cobanoglu, Sebahattin			Neuroprotective effects of N-acetylcysteine on experimental closed head trauma in rats	NEUROCHEMICAL RESEARCH			English	Article						trauma; brain tissue; MDA; antioxidant enzyme activity; N-acetylcysteine; caspase-3; rat	CONTROLLED CORTICAL IMPACT; BRAIN-INJURY; LIPID-PEROXIDATION; ACETYL-CYSTEINE; OXIDATIVE STRESS; APOPTOSIS; ISCHEMIA; ANTIOXIDANTS; SUPEROXIDE; ACTIVATION	N-acetylcysteine (NAC) is a precursor of glutathione, a potent antioxidant, and a free radical scavenger. The beneficial effect of NAC on nervous system ischemia and ischemia/reperfusion models has been well documented. However, the effect of NAC on nervous system trauma remains less understood. Therefore, we aimed to investigate the therapeutic efficacy of NAC with an experimental closed head trauma model in rats. Thirty-six adult male Sprague-Dawley rats were randomly divided into three groups of 12 rats each: Group I (control), Group II (trauma-alone), and Group III (trauma+NAC treatment). In Groups II and III, a cranial impact was delivered to the skull from a height of 7 cm at a point just in front of the coronal suture and over the right hemisphere. Rats were sacrificed at 2 h (Subgroups I-A, II-A, and III-A) and 12 h (Subgroups I-B, II-B, and III-B) after the onset of injury. Brain tissues were removed for biochemical and histopathological investigation. The closed head trauma significantly increased tissue malondialdehyde (MDA) levels (P < 0.05), and significantly decreased tissue superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities (P < 0.05), but not tissue catalase (CAT) activity, when compared with controls. The administration of a single dose of NAC (150 mg/kg) 15 min after the trauma has shown protective effect via decreasing significantly the elevated MDA levels (P < 0.05) and also significantly (P < 0.05) increasing the reduced antioxidant enzyme (SOD and GPx) activities, except CAT activity. In the trauma-alone group, the neurons became extensively dark and degenerated into picnotic nuclei. The morphology of neurons in the NAC treatment group was well protected. The number of neurons in the trauma-alone group was significantly less than that of both the control and trauma+NAC treatment groups. In conclusion, the NAC treatment might be beneficial in preventing trauma-induced oxidative brain tissue damage, thus showing potential for clinical implications.	Trakya Univ, Dept Histol & Embryol, Fac Med, Edirne, Turkey; Trakya Univ, Dept Neurosurg, Fac Med, Edirne, Turkey		Kanter, M (corresponding author), Trakya Univ, Dept Histol & Embryol, Fac Med, Edirne, Turkey.	mkanter65@yahoo.com					AEBI H, 1984, METHOD ENZYMOL, V105, P121; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Cakir O, 2003, CARDIOVASC SURG, V11, P375, DOI 10.1016/S0967-2109(03)00077-2; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Charriaut-Marlangue C., 1999, Annales Pharmaceutiques Francaises, V57, P309; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Conti AC, 1998, J NEUROSCI, V18, P5663; Cuzzocrea S, 2000, CARDIOVASC RES, V47, P537, DOI 10.1016/S0008-6363(00)00018-3; Demir S, 1998, CLIN CHIM ACTA, V275, P127, DOI 10.1016/S0009-8981(98)00078-3; Dickey DT, 2004, HEARING RES, V193, P25, DOI 10.1016/j.heares.2004.02.007; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; FERRARI G, 1995, J NEUROSCI, V15, P2857; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hart AM, 2004, NEUROSCIENCE, V125, P91, DOI 10.1016/j.neuroscience.2003.12.040; Hashimoto K, 2004, NEUROPSYCHOPHARMACOL, V29, P2018, DOI 10.1038/sj.npp.1300512; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Jayalakshmi K, 2005, BRAIN RES, V1046, P97, DOI 10.1016/j.brainres.2005.03.054; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kaynar MY, 1998, NEUROSURG REV, V21, P260, DOI 10.1007/BF01105782; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Krasowska A, 2004, BRAIN RES, V997, P176, DOI 10.1016/j.brainres.2003.09.080; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; Michel PP, 1999, CLIN NEUROPHARMACOL, V22, P137; Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93; Nehru B, 2004, BIOL TRACE ELEM RES, V101, P257, DOI 10.1385/BTER:101:3:257; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicoletti VG, 2005, NEUROCHEM RES, V30, P737, DOI 10.1007/s11064-005-6867-7; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OZBEN T, 1989, FREE RADICALS OXIDAT, P163; Ozsuer H, 2005, NEUROSURG REV, V28, P143, DOI 10.1007/s10143-004-0374-1; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Paintlia MK, 2004, J NEUROSCI RES, V78, P347, DOI 10.1002/jnr.20261; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; RINK A, 1995, AM J PATHOL, V147, P1575; Santangelo F, 2003, CURR MED CHEM, V10, P2599, DOI 10.2174/0929867033456567; Sastry PS, 2000, J NEUROCHEM, V74, P1, DOI 10.1046/j.1471-4159.2000.0740001.x; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shen WH, 2003, ACTA PHARMACOL SIN, V24, P1125; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sochman J, 2002, J AM COLL CARDIOL, V39, P1422, DOI 10.1016/S0735-1097(02)01797-7; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P381, DOI 10.1016/S0025-6196(12)64861-7; SUN Y, 1988, CLIN CHEM, V34, P497; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Tian H, 2003, NEUROSCI RES, V46, P191, DOI 10.1016/S0168-0102(03)00057-9; Tripathi Y, 1999, Indian J Physiol Pharmacol, V43, P518; Unterberg AW, 1997, ACT NEUR S, V70, P106; Ustun ME, 2001, J TRAUMA, V51, P22, DOI 10.1097/00005373-200107000-00004; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang Xinyu, 2002, Chin J Traumatol, V5, P250; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055	64	68	71	0	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	APR	2006	31	4					473	481		10.1007/s11064-006-9040-z			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	051CS	WOS:000238138800004	16758355				2022-02-06	
J	Tomberg, T; Toomela, A; Pulver, A; Tikk, A				Tomberg, T; Toomela, A; Pulver, A; Tikk, A			Coping strategies, social support, life orientation and health-related quality of life following traumatic brain injury	BRAIN INJURY			English	Article						coping strategies; social support; optimism; health-related quality of life; traumatic brain injury	BREAST-CANCER; HEAD-INJURY; DEPRESSION; OPTIMISM; QUESTIONNAIRE; ADJUSTMENT; PSORIASIS; ARTHRITIS; SYMPTOMS; DISTRESS	Objective: To study coping strategies, social support and life orientation in patients following moderate and severe traumatic brain injury (TBI) in relation to health-related quality of life. Subjects: Eighty-five patients with moderate or severe TBI and 68 control persons. Methods: Estonian versions of the COPE-D test, the Brief Social Support Questionnaire, the Life Orientation Test and the RAND-36 questionnaire. Results: Persons with TBI reported using task-oriented and social/emotional support strategies less often and avoidance-oriented strategies more often than control persons (p < 0.05). The social support network, satisfaction with it and optimism as life orientation were lower in the patient group (p < 0.05). Task-oriented coping styles, satisfaction with social support and optimistic life orientation were associated with the majority of the domains of health-related quality of life and resuming work after TBI. Conclusions: To achieve effective rehabilitation and to enhance patients' well-being, it is important to improve the quality and amount of social support network, as well as to support patients' adequate coping efforts for promoting an active lifestyle.	Univ Tartu, Dept Neurol & Neurosurg, EE-51014 Tartu, Estonia; Univ Tartu, Dept Special Educ, Tartu, Estonia; Tallinn Pedag Univ, Dept Psychol, Tallinn, Estonia		Tomberg, T (corresponding author), Univ Tartu, Dept Neurol & Neurosurg, L Puusepa 2, EE-51014 Tartu, Estonia.	tiiu.tomberg@kliinikum.ee	Toomela, Aaro/H-6033-2018; Pulver, Aleksander/AAQ-6304-2020	Toomela, Aaro/0000-0002-8520-9676; Pulver, Aleksander/0000-0001-7642-4430			Andersen S, 1999, NEUROLOGY, V52, pS26; BARRERA M, 1990, J SOC PERS RELAT, V7, P541, DOI 10.1177/0265407590074010; CARVER CS, 1992, HOSTILITY, COPING & HEALTH, P167, DOI 10.1037/10105-012; CARVER CS, 1993, J PERS SOC PSYCHOL, V65, P375, DOI 10.1037/0022-3514.65.2.375; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cook SW, 1997, EDUC PSYCHOL MEAS, V57, P906, DOI 10.1177/0013164497057006002; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Downe-Wamboldt BL, 1998, J ADV NURS, V27, P1109, DOI 10.1046/j.1365-2648.1998.00621.x; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Finset A, 2000, BRAIN INJURY, V14, P887; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; HAYS RB, 1992, J CONSULT CLIN PSYCH, V60, P463, DOI 10.1037/0022-006X.60.3.463; Herodes M, 2001, EPILEPSIA, V42, P1061, DOI 10.1046/j.1528-1157.2001.0420081061.x; HOLAHAN CJ, 1995, HEALTH PSYCHOL, V14, P152, DOI 10.1037/0278-6133.14.2.152; JENNETT B, 1975, LANCET, V1, P480; Kallasmaa T, 2000, PERS INDIV DIFFER, V29, P881, DOI 10.1016/S0191-8869(99)00240-8; KAPLAN RM, 1997, SOURCEBOOK SOCIAL SU, P279; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAND Health Sciences Program, 1992, RAND 36 IT HLTH SURV; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; SARASON IG, 1994, J SOC PERS RELAT, V11, P295, DOI 10.1177/0265407594112008; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; Scharloo M, 1998, J PSYCHOSOM RES, V44, P573, DOI 10.1016/S0022-3999(97)00254-7; SCHEIER MF, 1986, J PERS SOC PSYCHOL, V51, P1257, DOI 10.1037/0022-3514.51.6.1257; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024; Schnoll RA, 1998, PSYCHO-ONCOLOGY, V7, P69, DOI 10.1002/(SICI)1099-1611(199803/04)7:2<69::AID-PON286>3.0.CO;2-8; SVELNIKAS K, 1998, THESIS U TARTU TARTU; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; TINA A, 1998, THESIS U TARTU TARTU; Toomela A, 2004, J REHABIL MED, V36, P63, DOI 10.1080/16501970310017414; Wahl A, 1999, QUAL LIFE RES, V8, P427, DOI 10.1023/A:1008944108101; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Welin C, 2000, J INTERN MED, V247, P629, DOI 10.1046/j.1365-2796.2000.00694.x; WETHINGTON E, 1986, J HEALTH SOC BEHAV, V27, P78, DOI 10.2307/2136504; WORTMAN CB, 1984, CANCER-AM CANCER SOC, V53, P2339; [No title captured], DOI DOI 10.2307/2626957	44	68	68	0	17	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2005	19	14					1181	1190		10.1080/02699050500150153			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	983ZF	WOS:000233270200001	16286333				2022-02-06	
J	Ucar, T; Akyuz, M; Kazan, S; Tuncer, R				Ucar, T; Akyuz, M; Kazan, S; Tuncer, R			Role of decompressive surgery in the management of severe head injuries: Prognostic factors and patient selection	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; intracranial hypertension; severe head injury	TRAUMATIC BRAIN-INJURY; CEREBRAL HEMISPHERIC STROKE; INTRACRANIAL HYPERTENSION; SUBARACHNOID HEMORRHAGE; CRANIECTOMY; CHILDREN; SUPPORT; EDEMA	Decompress(ve surgery or craniectomy (DC) is a treatment option, which should be considered when the intracranial pressure (ICP) cannot be treated by conservative methods. The purpose of this study was to evaluate the benefits of decompressive craniectomy in patients with intractable posttraumatic intracranial. hypertension and to evaluate the patient selection criteria for this management protocol. In this study, 100 patients with severe head injuries were involved. All patients were treated according to the European Brain Injury Consortium (EBIC) guidelines for severe head injuries and were assessed based on individual initial Glasgow Coma Scores (GCS), age, Glasgow Outcome Score (GOS), presence of systemic injury, changes in ICP, presence of mass lesion and the right timing for DC. All patients presented with a GCS of 8 or below. Based on their initial GCS, the patients were divided in two groups of 60 (group I with GCS 4-5) and 40 (group II with GCS 6-8) in each, respectively. Prognosis was evaluated according to the (GOS). After treatment with DC, 84 of the patients (84%) showed unfavorable and 16 (16%) showed favorable outcomes. In group 1, 58 patients (96.6%) showed unfavorable and two (3.4%) showed favorable outcomes. In group 11, 26 (65%) patients showed unfavorable and 14 (25%) showed favorable outcomes. The importance of initial GCS and age in patient outcomes were statistically significant. The presence of systemic injuries or mass lesions in outcomes were not statistically significant. Based on our findings, we conclude that patients with Glasgow Coma Scores of 6-8 are the best candidates for DC treatment.	Univ Akdeniz, Sch Med, Dept Neurosurg, TR-07070 Antalya, Turkey		Ucar, T (corresponding author), Univ Akdeniz, Sch Med, Dept Neurosurg, TR-07070 Antalya, Turkey.	tucar@akdeniz.edu.tr	tuncer, mehmet recai/C-6969-2016; Kazan, Saim/G-1782-2016				Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; Engelhorn T, 1999, STROKE, V30, P1456, DOI 10.1161/01.STR.30.7.1456; FISHER CM, 1994, SURG NEUROL, V41, P65, DOI 10.1016/0090-3019(94)90210-0; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HATASHITA S, 1987, J NEUROSURG, V67, P573, DOI 10.3171/jns.1987.67.4.0573; Hieu PD, 1996, CHILD NERV SYST, V12, P270; JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304; Koh MS, 2000, SURG NEUROL, V53, P225, DOI 10.1016/S0090-3019(00)00163-4; Kunze E, 1998, ACT NEUR S, V71, P16; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MCKINLEY BA, 1995, J TRAUMA, V43, P583; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Nievas MNCY, 1999, NEUROL RES, V21, P649, DOI 10.1080/01616412.1999.11740991; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RINALDI A, 1990, ACT NEUR S, V51, P394; Schneider GH, 2002, ACT NEUR S, V81, P77; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wick J, 1999, AORN J, V69, P517, DOI 10.1016/S0001-2092(06)62463-0; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	25	68	76	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2005	22	11					1311	1318		10.1089/neu.2005.22.1311			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	989OI	WOS:000233683000005	16305319				2022-02-06	
J	Farkas, O; Polgar, B; Szekeres-Bartho, J; Doczi, T; Povlishock, JT; Buki, A				Farkas, O; Polgar, B; Szekeres-Bartho, J; Doczi, T; Povlishock, JT; Buki, A			Spectrin breakdown products in the cerebrospinal fluid in severe head injury - preliminary observations	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; calpain; caspase; spectrin; human; cerebrospinal fluid	TRAUMATIC BRAIN-INJURY; CALPAIN ACTIVATION; ALPHA-SPECTRIN; AXONAL INJURY; II-SPECTRIN; PROTEOLYSIS; CASPASE; RAT; DEGRADATION; CULTURES	Background. Calcium-induced proteolytic processes are considered key players in the progressive pathobiology of traumatic brain injury (TBI). Activation of calpain and caspases after TBI leads to the cleavage of cytoskeletal proteins such as non-erythroid alpha II-spectrin. Recent reports demonstrate that the levels of spectrin and spectrin breakdown products (SBDPs) are elevated in vitro after mechanical injury, in the cerebrospinal fluid (CSF) and brain tissue following experimental TBI, and in human brain tissue after TBI. Methods. This study was initiated to detect spectrin and SBDP accumulation in the ventricular CSF of 12 severe TBI-patients with raised intracranial pressure (ICP). Nine patients with non-traumatically elevated ICP and 5 undergoing diagnostic lumbar puncture (LP) served as controls. Intact spectrin and calpain and caspase specific SBDPs in CSF collected once a day over a several day period were assessed via Western blot analysis. Parameters of severity and outcome such as ICP, Glasgow Coma Scale and Glasgow Outcome Scale were also monitored in order to reveal a potential correlation between these CSF markers and clinical parameters. Results. In control patients undergone LP no immunoreactivity was detected. Non-erythroid alpha-II-spectrin and SBDP occurred more frequently and their level was significantly higher in the CSF of TBI patients than in other pathological conditions associated with raised ICP. Those TBI patients followed for several days post-injury revealed a consistent temporal pattern for protein accumulation with the highest level achieved on the 2(nd)-3(rd) days after TBI. Conclusion. Elevation of calpain and caspase specific SBDPs is a significant finding in TBI patients indicating that intact brain spectrin- and SBDP-levels are closely associated with the specific neurochemical processes evoked by TBI. The results strongly support the potential utility of these surrogate markers in the clinical monitoring of patients with severe TBI and provide further evidence of the role of calcium-induced, calpain- and caspase-mediated structural proteolysis in TBI.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Univ Pecs, Ctr Med & Hlth Sci, Dept Neurosurg, Pecs, Hungary		Farkas, O (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat & Neurobiol, Richmond, VA 23298 USA.	ofarkas@vcu.edu	Doczi, Tamas/C-5750-2009; Buki, Andras/B-1960-2010				Banik NL, 2000, METH MOL B, V144, P195; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Brana C, 1999, EUR J NEUROSCI, V11, P2375, DOI 10.1046/j.1460-9568.1999.00653.x; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Del Bigio MR, 2000, J NEUROPATH EXP NEUR, V59, P946, DOI 10.1093/jnen/59.11.946; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LEWIN ICF, 1992, HEAD INJURIES COST C; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; PIKE BR, 1978, J NEUROCHEM, V78, P1297; RINGGER MC, 2002, J NEUROTRAUM, V19, P1302; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4	21	68	70	0	0	SPRINGER WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	AUG	2005	147	8					855	861		10.1007/s00701-005-0559-6			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	950FY	WOS:000230844200014	15924207				2022-02-06	
J	Keren, O; Yupatov, S; Radai, MM; Elad-Yarum, R; Faraggi, D; Abboud, S; Ring, H; Groswasser, Z				Keren, O; Yupatov, S; Radai, MM; Elad-Yarum, R; Faraggi, D; Abboud, S; Ring, H; Groswasser, Z			Heart rate variability (HRV) of patients with traumatic brain injury (TBI) during the post-insult sub-acute period	BRAIN INJURY			English	Article						autonomic nervous system; heart rate variability (HRV); traumatic brain injury (TBI)	AUTONOMIC DYSFUNCTION; REHABILITATION	Objective: To evaluate heart rate variability (HRV) of patients with traumatic brain injury (TBI). Methods: By a prospective study, the HRV was assessed in 20 patients with TBI during the sub-acute period post-injury (the first test was performed at a mean time post-insult of 38 days) and a matched control. The patients were examined twice, 1 month apart. The assessment included HRV (both in time and frequency domains), GCS, length of coma, brain CT, FIM and FAM. Results: A significant difference was found between patients and controls concerning HRV total power, i.e. frequencies between 0.01-0.6 Hz ( high frequency p = 0.003, low frequency p = 0.013, total power p = 0.034) and for standard deviation of RR interval p = 0.011. HRV changes were related more to the timing of the evaluation than to the severity of the brain damage. Conclusion: HRV differed of patients with TBI and in the control group. Tendency to HRV normalization changes was detected during the first 3 months after the injury, which suggests recovery of the autonomic nervous system.	Loewenstein Hosp & Rehabil Ctr, Dept Brain Injury Rehabil, IL-43100 Raanana, Israel; Tel Aviv Univ, Fac Engn, Dept Biomed Engn, IL-69978 Tel Aviv, Israel; Univ Haifa, Dept Stat, IL-31999 Haifa, Israel		Keren, O (corresponding author), Loewenstein Hosp & Rehabil Ctr, Dept Brain Injury Rehabil, 278 Achuza St,POB 3, IL-43100 Raanana, Israel.	ofkeren@internet-zahav.net					Andersson S, 1998, J PSYCHOSOM RES, V44, P645, DOI 10.1016/S0022-3999(97)00305-X; Ansakorpi H, 2000, EPILEPSIA, V41, P42, DOI 10.1111/j.1528-1157.2000.tb01503.x; Arad M, 2002, AM J PHYS MED REHAB, V81, P590, DOI 10.1097/00002060-200208000-00006; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Camm AJ, 1996, CIRCULATION, V93, P1043; Druschky A, 2001, BRAIN, V124, P2372, DOI 10.1093/brain/124.12.2372; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; GOLDSTEIN B, 1998, AM J PHYSIOL, V275, P1287; Grimby G, 1996, SCAND J REHABIL MED, V28, P51; Groswasser Z, 1998, J HEAD TRAUMA REHAB, V13, P69, DOI 10.1097/00001199-199802000-00009; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; King ML, 1997, BRAIN INJURY, V11, P445; Korpelainen JT, 1996, ACTA NEUROL SCAND, V94, P337, DOI 10.1111/j.1600-0404.1996.tb07076.x; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; LOWENSOHN RI, 1977, LANCET, V1, P626; Maschke M, 2002, J NEUROL NEUROSUR PS, V72, P116, DOI 10.1136/jnnp.72.1.116; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sinson G, 2001, AM J NEURORADIOL, V22, P143; TEASDALE G, 1974, LANCET, V2, P81; Tsuji H, 1996, CIRCULATION, V94, P2850, DOI 10.1161/01.CIR.94.11.2850; YAMOUR BJ, 1980, AM HEART J, V99, P294, DOI 10.1016/0002-8703(80)90343-9	30	68	69	1	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2005	19	8					605	611		10.1080/02699050400024946			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	933IS	WOS:000229622700005	16175814				2022-02-06	
J	Rodriguez-Paez, AC; Brunschwig, JP; Bramlett, HM				Rodriguez-Paez, AC; Brunschwig, JP; Bramlett, HM			Light and electron microscopic assessment of progressive atrophy following moderate traumatic brain injury in the rat	ACTA NEUROPATHOLOGICA			English	Article						progressive atrophy; inflammation; macrophages/microglia; traumatic brain injury; white matter	AMYLOID PRECURSOR PROTEIN; ENDOTHELIAL GROWTH-FACTOR; NONDISRUPTIVE AXONAL INJURY; NITRIC-OXIDE SYNTHASE; CLOSED-HEAD-INJURY; OPTIC-NERVE FIBERS; INFLAMMATORY RESPONSE; STRETCH-INJURY; WHITE-MATTER; POSTTRAUMATIC HYPOTHERMIA	The presence of progressive white matter atrophy following traumatic brain injury (TBI) has been reported in humans as well as in animal models. However, a quantitative analysis of progressive alterations in myelinated axons and other cellular responses to trauma has not been conducted. This study examined quantitative differences in myelinated axons from several white and gray matter structures between non-traumatized and traumatized areas at several time points up to 1 year. We hypothesize that axonal numbers decrease over time within the structures analyzed, based on our previous work demonstrating shrinkage of tissue in these vulnerable areas. Intubated, anesthetized male Sprague-Dawley rats were subjected to moderate (1.8-2.2 atm) parasagittal fluid-percussion brain injury, and perfused at various intervals after surgery. Sections from the fimbria, external capsule, thalamus and cerebral cortex from the ipsilateral hemisphere of traumatized and sham-operated animals were prepared and. estimated total numbers of myelinated axons were determined by systematic random sampling. Electron micrographs were obtained for ultrastructural analysis. A significant (P < 0.05) reduction in the number of myelinated axons in the traumatized hemisphere compared to control in all structures was observed. In addition, thalamic and cortical axonal counts decreased significantly (P < 0.05) over time. Swollen axons and macrophage/microglia infiltration were present as late as 6 months post-TBI in various structures. This study is the first to describe quantitatively chronic axonal changes in vulnerable brains regions after injury. Based on these data, a time-dependent decrease in the number of myelinated axons is seen to occur in vulnerable gray matter regions including the cerebral cortex and thalamus along with distinct morphological changes within white matter tracts after TBI. Although this progressive axonal response to TBI may include Wallerian degeneration, other potential mechanisms underlying this progressive pathological response within the white matter are discussed.	Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Neurosurg, Miami Project Cure Paralysis,Neurotrauma Res Ctr, Miami, FL 33152 USA		Bramlett, HM (corresponding author), Univ Miami, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	hbramlett@miami.edu					ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; CRUTCHER KA, 1990, ACTA NEUROBIOL EXP, V50, P115; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Grad S, 1998, CLIN CHEM LAB MED, V36, P379, DOI 10.1515/CCLM.1998.064; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HUGHES CCW, 1987, J NEUROL SCI, V79, P101, DOI 10.1016/0022-510X(87)90264-4; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; KIMBELBERG HK, 1994, NEUROBIOLOGY CENTRAL, P193; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Leclercq PD, 2002, J NEUROTRAUM, V19, P1183, DOI 10.1089/08977150260337985; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; Lu J, 2003, NEUROSCI LETT, V339, P147, DOI 10.1016/S0304-3940(03)00003-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MURPHY S, 1987, NEUROSCIENCE, V22, P381, DOI 10.1016/0306-4522(87)90342-3; Nag S, 2002, J NEUROPATH EXP NEUR, V61, P778, DOI 10.1093/jnen/61.9.778; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Peters A, 1976, FINE STRUCTURE NERVO, V3rd; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rosenberg LJ, 1997, J NEUROTRAUM, V14, P823, DOI 10.1089/neu.1997.14.823; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VEGA JA, 1994, MECH AGEING DEV, V73, P9, DOI 10.1016/0047-6374(94)90033-7; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WEST RW, 1993, CARCINOGENESIS, V14, P285, DOI 10.1093/carcin/14.2.285	86	68	69	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	2005	109	6					603	616		10.1007/s00401-005-1010-z			14	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	940KE	WOS:000230142600007	15877231				2022-02-06	
J	Soustiel, JF; Palzur, E; Nevo, O; Thaler, I; Vlodavsky, E				Soustiel, JF; Palzur, E; Nevo, O; Thaler, I; Vlodavsky, E			Neuroprotective anti-apoptosis effect of estrogens in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; estrogens; head injury; neuroprotection	MICE OVEREXPRESSING BCL-2; HEAD-INJURY; MESSENGER-RNA; EXPERIMENTAL STROKE; ESTRADIOL PROTECTS; FOREBRAIN ISCHEMIA; COGNITIVE RECOVERY; NEURONAL DAMAGE; CLINICAL-TRIALS; FOCAL ISCHEMIA	Traumatic brain injury (TBI) is a leading cause of death and functional disability in western countries, affecting mostly young patients. Despite intense and sustained efforts deployed for the development of new therapeutic strategies, no clinical benefit has been shown by any of the investigated compounds. Increasing attention has been drawn during the past two decades to the neuroprotective effects of estrogens, although most of the available data relate to ischemic brain injury. The purpose of the present study was to investigate the potential neuroprotective value of estrogens in TBI as a therapeutic modality. For this purpose, a contusion was created in the parietal cortex by dynamic cortical deformation in two groups of 10 Sprague-Dawley male rats. Following the injury, treated animals received conjugated estrogens for 3 days, using a subcutaneously implanted osmotic pump. Animals were then sacrificed, and TUNEL, anti-active Caspase 3, bcl-2, and bax labeling were performed in paraffin-embedded brain sections, allowing for comparative and quantitative analysis. In estrogen-treated animals, there was a marked and significant reduction of apoptosis in comparison with non-treated animals. The reduction in TUNEL and active Caspase 3 staining was similar and close to 50%. Optical analysis of histological slides prepared by bcl-2 labeling showed a significant increase in bcl-2 expression in estrogen-treated animals compared to non-treated animals. On the contrary, bax expression was not influenced by hormonal treatment, and no difference could be noticed between the two groups. These results support the potential therapeutic value of estrogens in TBI and further clarify their mode of action.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Phys, Acute Brain Injury Res Lab, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Neurosurg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Obstet, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Pathol, IL-31096 Haifa, Israel		Soustiel, JF (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Phys, Acute Brain Injury Res Lab, POB 9602, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il		Palzur, Eilam/0000-0003-2032-2974			Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 1998, FASEB J, V12, pA954; Belcredito S, 2001, BRAIN RES REV, V37, P335, DOI 10.1016/S0165-0173(01)00138-2; Bogdanov MB, 1999, NEUROSCI LETT, V262, P33, DOI 10.1016/S0304-3940(99)00047-6; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; Geary GG, 2000, AM J PHYSIOL-HEART C, V279, pH511, DOI 10.1152/ajpheart.2000.279.2.H511; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Holm KH, 2001, NEUROSCIENCE, V104, P397, DOI 10.1016/S0306-4522(01)00098-7; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kauser K, 1997, J VASC RES, V34, P229, DOI 10.1159/000159227; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Li KW, 1996, STROKE, V27, P498, DOI 10.1161/01.STR.27.3.498; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Patrone C, 1999, P NATL ACAD SCI USA, V96, P10905, DOI 10.1073/pnas.96.19.10905; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SABOURIN JC, 1994, INT J CANCER, V59, P1, DOI 10.1002/ijc.2910590102; Sato S, 1998, BRAIN RES, V808, P56, DOI 10.1016/S0006-8993(98)00784-7; Shi J, 1998, BRAIN RES, V810, P87, DOI 10.1016/S0006-8993(98)00888-9; Shi J, 1997, EXP BRAIN RES, V117, P200, DOI 10.1007/s002210050216; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Tang MY, 1996, BBA-LIPID LIPID MET, V1299, P155, DOI 10.1016/0005-2760(95)00227-8; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wise PM, 2000, J NEUROCYTOL, V29, P401, DOI 10.1023/A:1007169408561; Yang LC, 1998, J NEUROSCI, V18, P8145; Zaulyanov LL, 1999, CELL MOL NEUROBIOL, V19, P705, DOI 10.1023/A:1006948921855	51	68	71	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2005	22	3					345	352		10.1089/neu.2005.22.345			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	911QM	WOS:000228019500002	15785230				2022-02-06	
J	Baguley, IJ; Cameron, ID; Green, AM; Slewa-Younan, S; Marosszeky, JE; Gurka, JA				Baguley, IJ; Cameron, ID; Green, AM; Slewa-Younan, S; Marosszeky, JE; Gurka, JA			Pharmacological management of Dysautonomia following traumatic brain injury	BRAIN INJURY			English	Article							NEUROLEPTIC MALIGNANT SYNDROME; HEAD-INJURY; INTRATHECAL BACLOFEN; AUTONOMIC DYSFUNCTION; DIENCEPHALIC SEIZURES; ACUTE HYDROCEPHALUS; BROMOCRIPTINE; HYPERTENSION; HYPERTHERMIA; WITHDRAWAL	Primary objective : To document and critically evaluate the likely effectiveness of pharmacological treatments used in a sample of patients with Dysautonomia and to link these findings to previously published literature. Research design : Retrospective case control chart review. Methods and procedures : Data were collected on age, sex and GCS matched subjects with and without Dysautonomia (35 cases and 35 controls). Data included demographic and injury details, physiological parameters, medication usage, clinical progress and rehabilitation outcome. Descriptive analyses were undertaken to characterize the timing and frequency of CNS active medications. Main outcomes and results : Dysautonomic patients were significantly more likely to receive neurologically active medications. A wide variety of drugs were utilised with the most frequent being morphine/midazolam and chlorpromazine. Cessation of morphine/midazolam produced significant increases in heart rate and respiratory rate but not temperature. Chlorpromazine may have modified respiratory rate responses, but not temperature or heart rate. Conclusions : The features of Dysautonomia are similar to a number of conditions treated as medical emergencies. Despite this, no definitive treatment paradigm exists. The best available evidence is for morphine (especially intravenously), benzodiazepines, propanolol, bromocriptine and possibly intrathecal baclofen. Barriers to improving management include the lack of a standardized nomenclature, formal definition or accepted diagnostic test. Future research needs to be conducted to improve understanding of Dysautonomia with a view to minimizing disability.	Westmead Hosp, Brain Injury Rehabil Serv, Wentwothville, NSW 2145, Australia; Univ Sydney, Dept Rehabil Med, Sydney, NSW, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Westmead Hosp, Dept Rehabil Med, Wentwothville, NSW 2145, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentwothville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; Coffey RJ, 2002, ARCH PHYS MED REHAB, V83, P735, DOI 10.1053/apmr.2002.32820; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; FIGATALAMANCA L, 1985, NEUROLOGY, V35, P258, DOI 10.1212/WNL.35.2.258; Goldstein LB, 1998, ARCH NEUROL-CHICAGO, V55, P454, DOI 10.1001/archneur.55.4.454; Green LB, 1999, ARCH PHYS MED REHAB, V80, P1600, DOI 10.1016/S0003-9993(99)90337-4; Gurrera RJ, 1999, AM J PSYCHIAT, V156, P169; LU CS, 1991, MOVEMENT DISORD, V6, P381, DOI 10.1002/mds.870060424; MANDAC BR, 1993, ARCH PHYS MED REHAB, V74, P96; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; PerezVela JL, 1996, INTENS CARE MED, V22, P593, DOI 10.1007/s001340050138; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROPPER AH, 1992, CLIN DISORDERS AUTON, P747; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; SANDEL ME, 1993, BRAIN INJURY, V7, P77, DOI 10.3109/02699059309008159; Scott JS, 1997, AM J PHYS MED REHAB, V76, P200, DOI 10.1097/00002060-199705000-00007; SILVER JK, 1994, ARCH PHYS MED REHAB, V75, P885, DOI 10.1016/0003-9993(94)90113-9; SNEED RC, 1995, ARCH PHYS MED REHAB, V76, P101, DOI 10.1016/S0003-9993(95)80051-4; SOLOMON GE, 1973, J PEDIATR-US, V83, P277, DOI 10.1016/S0022-3476(73)80492-5; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Trasmonte J, 1999, CLIN PEDIATR, V38, P611, DOI 10.1177/000992289903801008; VINCENT FM, 1986, NEUROSURGERY, V18, P190, DOI 10.1227/00006123-198602000-00013; Wilkinson R, 1999, BRAIN INJURY, V13, P1025	33	68	71	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2004	18	5					409	417		10.1080/02699050310001645775			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	800SS	WOS:000220048600001	15195790				2022-02-06	
J	Pizzi, M; Sarnico, I; Boroni, F; Benarese, M; Dreano, M; Garotta, G; Valerio, A; Spano, PF				Pizzi, M; Sarnico, I; Boroni, F; Benarese, M; Dreano, M; Garotta, G; Valerio, A; Spano, PF			Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article							SOLUBLE CYTOKINE RECEPTORS; FOCAL CEREBRAL-ISCHEMIA; MYELIN GENE-EXPRESSION; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; NORMAL HUMAN-URINE; MULTIPLE-SCLEROSIS; CHOLINERGIC NEURONS; NEUROTROPHIC FACTOR; TRANSGENIC MICE	We investigated the effects of IL-6 and a chimeric derivative of IL-6 and soluble IL-6 receptor (IL6RIL6 chimera) on excitotoxic injury in rat organotypic hippocampal slices. Brief application of N-methyl-D-aspartate (NMDA) induced astrocyte reactivity, neuron cell death, and oligodendrocyte degeneration, the latter caused by secondary activation of AMPA/kainate receptors. Both these cytokines rescued neurons and oligodendrocytes, albeit the chimeric compound was much more potent and efficient than IL-6. No change was produced on reactive astrocytosis. The cytokines preserved myelin basic protein (MBP) production in slices exposed to excitotoxic insult, and when applied singularly for a week, they also enhanced both MBP and proteolipid protein expression. These effects occurred through activating the signal transducer gp130 and were associated with stimulation of transcription factors STAT1 and STAT3. Our results suggest that IL-6 and IL6RIL6 may prove to be valuable in treating neurodegenerative and demyelinating diseases. (C) 2003 Elsevier Inc. All rights reserved.	Univ Brescia, Dept Biomed Sci & Biotechnol, Div Pharmacol, I-25123 Brescia, Italy; Serono Int SA, CH-1228 Geneva, Switzerland		Pizzi, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Div Pharmacol, Viale Europa 11, I-25123 Brescia, Italy.	pizzi@med.unibs.it	Valerio, Alessandra/B-3413-2009; Spano, Pier Franco F/J-9944-2016; Pizzi, Marina/C-1452-2011; Spano, Pier Franco A/E-7621-2010; Pizzi, Marina/K-2064-2016	Valerio, Alessandra/0000-0001-5844-2256; Spano, Pier Franco F/0000-0002-9906-0964; Pizzi, Marina/0000-0002-4857-5204			Aberg MAI, 2001, MOL CELL NEUROSCI, V17, P426, DOI 10.1006/mcne.2000.0947; Agresti C, 1996, EUR J NEUROSCI, V8, P1106, DOI 10.1111/j.1460-9568.1996.tb01278.x; AKANEYA Y, 1995, EXP NEUROL, V136, P44, DOI 10.1006/exnr.1995.1082; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; BAHR BA, 1995, J NEUROSCI RES, V42, P294, DOI 10.1002/jnr.490420303; BARRES BA, 1993, DEVELOPMENT, V118, P283; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; Bensadoun JC, 2001, EUR J NEUROSCI, V14, P1753, DOI 10.1046/j.0953-816x.2001.01802.x; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Brooks PJ, 1996, J NEUROSCI, V16, P939; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Chebath J, 1997, EUR CYTOKINE NETW, V8, P359; De-Fraja C, 2000, INT J DEV NEUROSCI, V18, P439, DOI 10.1016/S0736-5748(00)00007-1; Dell'Albani P, 1998, J NEUROSCI RES, V54, P191, DOI 10.1002/(SICI)1097-4547(19981015)54:2<191::AID-JNR7>3.0.CO;2-9; Dolcet X, 2001, MOL CELL NEUROSCI, V18, P619, DOI 10.1006/mcne.2001.1058; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Eskes C, 2002, GLIA, V37, P43, DOI 10.1002/glia.10019; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; FREI K, 1991, J NEUROIMMUNOL, V31, P147; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Haggiag S, 2001, J NEUROSCI RES, V64, P564, DOI 10.1002/jnr.1108; Haggiag S, 1999, FEBS LETT, V457, P200, DOI 10.1016/S0014-5793(99)01040-6; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; Hautecoeur P, 1997, ACTA NEUROL BELG, V97, P240; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Inomata Y, 2003, BIOCHEM BIOPH RES CO, V302, P226, DOI 10.1016/S0006-291X(03)00127-X; Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x; Kahn MA, 1997, J NEUROCHEM, V68, P1413; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; KELLER ET, 1996, FRONT BIOSCI, V1, P340, DOI DOI 10.2741/A136; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kristensen BW, 2001, BRAIN RES, V896, P1, DOI 10.1016/S0006-8993(00)03304-7; KUSHIMA Y, 1992, NEUROSCI LETT, V143, P110, DOI 10.1016/0304-3940(92)90244-2; Legendre F, 2003, J BIOL CHEM, V278, P2903, DOI 10.1074/jbc.M110773200; Li S, 1999, J Neurosci, V19, pRC16; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Maimone D, 1997, J NEUROL SCI, V146, P59, DOI 10.1016/S0022-510X(96)00283-3; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; Marz P, 1999, EUR J NEUROSCI, V11, P2995, DOI 10.1046/j.1460-9568.1999.00755.x; Marz P, 1999, GLIA, V26, P191, DOI 10.1002/(SICI)1098-1136(199905)26:3<191::AID-GLIA1>3.0.CO;2-#; Matute C, 2001, TRENDS NEUROSCI, V24, P224, DOI 10.1016/S0166-2236(00)01746-X; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; NOVICK D, 1990, J CHROMATOGR, V510, P331, DOI 10.1016/S0021-9673(01)93767-7; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; Pavelko KD, 2003, J NEUROSCI, V23, P481, DOI 10.1523/JNEUROSCI.23-02-00481.2003; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2001, NEUROSCIENCE, V102, P805, DOI 10.1016/S0306-4522(00)00515-7; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Richter-Landsberg C, 1998, EXP CELL RES, V244, P218, DOI 10.1006/excr.1998.4188; SAWADA M, 1993, NEUROSCI LETT, V160, P131, DOI 10.1016/0304-3940(93)90396-3; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; Smith T, 2000, NAT MED, V6, P62, DOI 10.1038/71548; Stankoff B, 2002, J NEUROSCI, V22, P9221; Starkey GD, 2001, NEUROREPORT, V12, P4081, DOI 10.1097/00001756-200112210-00044; Sun Y, 2002, BIOCHEM BIOPH RES CO, V295, P532, DOI 10.1016/S0006-291X(02)00706-4; Taga T, 1997, ANN MED, V29, P63, DOI 10.3109/07853899708998744; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Tsigos C, 1999, J INTERF CYTOK RES, V19, P1271, DOI 10.1089/107999099312948; Valerio A, 2002, MOL CELL NEUROSCI, V21, P602, DOI 10.1006/mcne.2002.1208; VALERIO A, 1994, NEUROBIOL AGING, V15, P713, DOI 10.1016/0197-4580(94)90053-1; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Werner P, 2001, ANN NEUROL, V50, P169, DOI 10.1002/ana.1077; YAMADA M, 1994, BRAIN RES, V643, P173, DOI 10.1016/0006-8993(94)90023-X	76	68	77	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431			MOL CELL NEUROSCI	Mol. Cell. Neurosci.	FEB	2004	25	2					301	311		10.1016/j.mcn.2003.10.022			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	804YF	WOS:000220333300010	15019946				2022-02-06	
J	Espy, KA				Espy, KA			Using developmental, cognitive, and neuroscience approaches to understand executive control in young children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							PREFRONTAL CORTEX; PRESCHOOL-CHILDREN; WORKING-MEMORY; FUNCTIONAL MRI; TASK; PERFORMANCE; BRAIN	The 7 articles in this special issue address the nature of executive control in young children. Executive control is framed in a developmental context, where the unique aspects of cognition in this age range are considered. The set of articles demonstrates the multidisciplinary approaches to study cognition in young children that includes application of cognitive, neuroscience, and developmental paradigms in typically developing youngsters, as well as those affected by clinical conditions, such as traumatic brain injury, exposure to low levels of lead in the environment, and prematurity. Although much work remains to be done, these study results are illustrative of the dynamic work in this exciting developmental period.	So Illinois Univ, Sch Med, Dept Family & Community Med, Carbondale, IL 62901 USA		Espy, KA (corresponding author), So Illinois Univ, Sch Med, Dept Family & Community Med, MC 6503,600 Agr Dr, Carbondale, IL 62901 USA.	kespy@siumed.edu					Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Canfield RL, 2004, DEV NEUROPSYCHOL, V26, P513, DOI 10.1207/s15326942dn2601_8; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Casey BJ, 2001, HUM BRAIN MAPP, V13, P26, DOI 10.1002/hbm.1022; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P723, DOI 10.1080/01688638708405213; DIAMOND A, 1985, CHILD DEV, V56, P868, DOI 10.2307/1130099; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 2004, DEV NEUROPSYCHOL, V26, P465, DOI 10.1207/s15326942dn2601_6; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Flavell JH, 1999, ANNU REV PSYCHOL, V50, P21, DOI 10.1146/annurev.psych.50.1.21; Fletcher JM, 1996, DEV NEUROPSYCHOL, V12, P1, DOI 10.1080/87565649609540636; FLETCHER JM, 1984, J CLIN NEUROPSYCHOL, V6, P39, DOI 10.1080/01688638408401195; Goldman PS, 1974, PLASTICITY RECOVERY; Goldman-Rakic P.S., 2011, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Isquith PK, 2004, DEV NEUROPSYCHOL, V26, P403, DOI 10.1207/s15326942dn2601_3; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; Rennie DAC, 2004, DEV NEUROPSYCHOL, V26, P423, DOI 10.1207/s15326942dn2601_4; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Senn TE, 2004, DEV NEUROPSYCHOL, V26, P445, DOI 10.1207/s15326942dn2601_5; Smidts DP, 2004, DEV NEUROPSYCHOL, V26, P385, DOI 10.1207/s15326942dn2601_2; ZELAZO PD, 1995, DEV PSYCHOL, V31, P508, DOI 10.1037/0012-1649.31.3.508	25	68	70	2	30	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	26	1					379	384		10.1207/s15326942dn2601_1			6	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	844BO	WOS:000223132300001	15276900	Green Submitted			2022-02-06	
J	Gianinazzi, C; Grandgirard, D; Imboden, H; Egger, L; Meli, DN; Bifrare, YD; Joss, PC; Tauber, MG; Borner, C; Leib, SL				Gianinazzi, C; Grandgirard, D; Imboden, H; Egger, L; Meli, DN; Bifrare, YD; Joss, PC; Tauber, MG; Borner, C; Leib, SL			Caspase-3 mediates hippocampal apoptosis in pneumococcal meningitis	ACTA NEUROPATHOLOGICA			English	Article						apoptosis; caspase-3; dentate gyrus; bacterial meningitis	TRAUMATIC BRAIN INJURY; DELAYED NEURONAL DEATH; BACTERIAL-MENINGITIS; CELL-DEATH; NERVOUS-SYSTEM; MATRIX METALLOPROTEINASES; DNA FRAGMENTATION; PRECURSOR PROTEIN; LEARNING-DEFICITS; INHIBITION	Bacterial meningitis causes neuronal apoptosis in the hippocampal dentate gyrus, which is associated with learning and memory impairments after cured disease. The execution of the apoptotic program involves pathways that converge on activation of caspase-3, which is required for morphological changes associated with apoptosis. Here, the time course and the role of caspase-3 in neuronal apoptosis was assessed in an infant rat model of pneumococcal meningitis. During clinically asymptotic meningitis (0-12 h after infection), only minor apoptotic damage to the dentate gyrus was observed, while the acute phase (18-24 h) was characterized by a massive increase of apoptotic cells, which peaked at 36 h. In the subacute phase of the disease (36-72 h), the number of apoptotic cells decreased to control levels. Enzymatic caspase-3 activity was significantly increased in hippocampal tissue of infected animals compared to controls at 22 h. The activated enzyme was localized to immature cells of the dentate gyrus, and in vivo activity was evidenced by cleavage of the amyloid-beta precursor protein. Intracisternal administration of the caspase-3-specific inhibitor Ac-DEVDCHO significantly reduced apoptosis in the hippocampal dentate gyrus. In contrast to a study where the decrease of hippocampal apoptosis after administration of a pan-caspase inhibitor was due to downmodulation of the inflammatory response, our data demonstrate that specific inhibition of caspase-3 did not affect inflammation assessed by TNF-alpha and IL-1beta concentrations in the cerebrospinal fluid space. Taken together, the present results identify caspase-3 as a key effector of neuronal apoptosis in pneumococcal meningitis.	Univ Bern, Inst Infect Dis, CH-3010 Bern, Switzerland; Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany; Univ Bern, Dept Neurobiol, Bern, Switzerland		Leib, SL (corresponding author), Univ Bern, Inst Infect Dis, Friedbuhlstr 51, CH-3010 Bern, Switzerland.	stephen.leib@ifik.unibe.ch	Leib, Stephen/M-3786-2019; Leib, Stephen L/A-7866-2011; Grandgirard, Denis/AAB-8786-2020	Leib, Stephen/0000-0002-1106-6123; Leib, Stephen L/0000-0002-1106-6123; Grandgirard, Denis/0000-0002-4151-5196; Egger, Charlotte/0000-0001-6501-5703	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS035902] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-35902] Funding Source: Medline		Becker AJ, 1999, MOL BRAIN RES, V67, P172, DOI 10.1016/S0169-328X(99)00060-1; BIFRARE YD, 2002, SWISS MED WEEKL S130, V132, P9; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Braun JS, 2002, J CLIN INVEST, V109, P19; Braun JS, 2001, J INFECT DIS, V184, P1300, DOI 10.1086/324013; Chen J, 1998, J NEUROSCI, V18, P4914; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Daigle I, 2001, INT ARCH ALLERGY IMM, V126, P147, DOI 10.1159/000049506; De Bilbao F, 1999, J COMP NEUROL, V409, P339, DOI 10.1002/(SICI)1096-9861(19990705)409:3<339::AID-CNE1>3.0.CO;2-Q; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gerber J, 2001, BRAIN PATHOL, V11, P422, DOI 10.1111/j.1750-3639.2001.tb00410.x; Gerber J, 2001, ACTA NEUROPATHOL, V101, P499; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Gould E, 1993, Curr Opin Neurobiol, V3, P676, DOI 10.1016/0959-4388(93)90138-O; Han BH, 2000, NEUROBIOL DIS, V7, P38; IMBODEN H, 1995, IMMUNOCYTOCHEMISTRY, P236; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Koedel U, 2002, ANN NEUROL, V51, P319, DOI 10.1002/ana.10103; Leib SL, 2000, INFECT IMMUN, V68, P615, DOI 10.1128/IAI.68.2.615-620.2000; Leib SL, 2001, BRAIN, V124, P1734, DOI 10.1093/brain/124.9.1734; Leib SL, 1996, J INFECT DIS, V173, P166, DOI 10.1093/infdis/173.1.166; Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084; LEIB SL, 2001, 41 INT C ANT AG CHEM; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Loeffler JM, 2001, J INFECT DIS, V183, P247, DOI 10.1086/317921; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Nau R, 1999, J NEUROPATH EXP NEUR, V58, P265, DOI 10.1097/00005072-199903000-00006; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NITATORI T, 1995, J NEUROSCI, V15, P1001; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Pfister LA, 2000, ANN NEUROL, V47, P329, DOI 10.1002/1531-8249(200003)47:3<329::AID-ANA8>3.0.CO;2-R; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schluter D, 1996, J NEUROPATH EXP NEUR, V55, P14, DOI 10.1097/00005072-199601000-00002; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; von Mering M, 2001, BRAIN PATHOL, V11, P282; Wellmer A, 2000, NEUROSCI LETT, V296, P137, DOI 10.1016/S0304-3940(00)01645-1; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	53	68	69	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAY	2003	105	5					499	507		10.1007/s00401-003-0672-7			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	675NX	WOS:000182702400012	12677451				2022-02-06	
J	Krassioukov, AV; Ackery, A; Schwartz, G; Adamchik, Y; Liu, Y; Fehlings, MG				Krassioukov, AV; Ackery, A; Schwartz, G; Adamchik, Y; Liu, Y; Fehlings, MG			An in vitro model of neurotrauma in organotypic spinal cord cultures from adult mice	BRAIN RESEARCH PROTOCOLS			English	Article						trauma; spinal cord cultures; cell death; immunohistochemistry; neuroprotection	INJURY; NEURONS; TRAUMA; RAT	Cellular degeneration after spinal cord injury (SCI) involves numerous pathways. It is essential to use appropriate experimental models in order to understand the complex processes, which evolve after the initial trauma. The purpose of this study was to develop and assess an in vitro model of neurotrauma using organotypic slice culture of adult mice spinal cord. This model will facilitate the investigation of primary and secondary mechanisms of cell death that occurs after SCI We modified previously described methods for generating organotypic cultures of murine spinal cord. The viability of organotypic cultures was assessed by observing the outgrowth of neurites and by using a mitochondria dependent dye for live cells (tetrazolium dye; MTT). The morphological integrity of cultures was examined histologically by hematoxylin and eosin (H&E) staining for general morphology and with luxol fast blue (LFB) for myelin. Neuronal and glial (GFAP; CNPase) markers were used to identify neurons, astrocytes and oligodendroglia, respectively. Primary injury was achieved by using a weight drop (0.2 g) model of injury. Cell death after primary injury was attenuated by pre-treatment with two known neuroprotective agents: the AMPA/KA blocker CNQX and methylprednisolone. The nuclear markers Propidium iodide and Sytox-green, as well as the TUNEL (in situ terminal deoxytransferase-mediated dUTP nick end labeling) technique, were used as a quantitative indicators of cell death at 24, 48 and 72 h post-injury using a confocal microscope and image analysis software. This novel in vitro model of SCI is easy to reproduce, will facilitate the examination of post-trauma cell death mechanisms and the neuroprotective effects of pharmacological agents and aid in the study of transgenic murine models. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; Univ Toronto, Toronto Western Hosp, Hlth Network, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada		Fehlings, MG (corresponding author), Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.		Krassioukov, Andrei V/K-3131-2017; Ackery, Alun/B-6634-2016	Fehlings, Michael/0000-0002-5722-6364			Abe K, 2000, NEUROSCI RES, V38, P325, DOI 10.1016/S0168-0102(00)00188-7; Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; BALENTINE JD, 1988, LAB INVEST, V58, P93; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BUNGE RP, 1993, ADV NEUROL, V59, P75; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; DELFS J, 1989, BRAIN RES, V488, P31, DOI 10.1016/0006-8993(89)90690-2; Kakulas B A, 1999, J Spinal Cord Med, V22, P119; KERKUT GA, 1995, PROG NEUROBIOL, V46, P1, DOI 10.1016/0301-0082(94)00055-M; KERKUT GA, 1965, COMP BIOCHEM PHYSIOL, V14, P167, DOI 10.1016/0010-406X(65)90017-4; Krassioukov AV, 1996, NEUROSCIENCE, V70, P211, DOI 10.1016/0306-4522(95)00294-S; Marsh DR, 2000, MOL THER, V1, P464, DOI 10.1006/mthe.2000.0061; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Van Westerlaak MGH, 2001, EXP NEUROL, V167, P393, DOI 10.1006/exnr.2000.7570; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219	15	68	69	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1385-299X			BRAIN RES PROTOC	Brain Res. Protoc.	OCT	2002	10	2					60	68	PII S1385-299X(02)00180-0	10.1016/S1385-299X(02)00180-0			9	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	625LW	WOS:000179818800002	12431704				2022-02-06	
J	Whyte, J; Vaccaro, M; Grieb-Neff, P; Hail, T				Whyte, J; Vaccaro, M; Grieb-Neff, P; Hail, T			Psychostimulant use in the rehabilitation of individuals with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						amphetamine; attention; brain injury; dextroamphetamine; memory; methylphenidate	DEFICIT HYPERACTIVITY DISORDER; SUSTAINED-RELEASE METHYLPHENIDATE; CLOSED-HEAD-INJURY; DOUBLE-BLIND; CHILDREN; RECOVERY; AMPHETAMINE; TRIALS	Background: Psychostimulants are used commonly in the rehabilitation of individuals with traumatic brain injury (TBI), despite the dearth of well-controlled studies of their effects. The available literature suggests that these drugs predominantly affect the speed of cognitive processing and certain observational ratings of mood and behavior. Effects on sustained attention, distractibility, and memory are less clear. Objective: This article reviews the controlled research literature on the use of these drugs in TBI and presents preliminary data from the authors' laboratory that extends these findings. Some of the common research pitfalls that have limited progress in research on these drugs are discussed.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA		Whyte, J (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd,Korman Bldg,Suite 211, Philadelphia, PA 19141 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R24 HD 39621-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS 39163] Funding Source: Medline		BIRMAHER B, 1989, J AM ACAD CHILD PSY, V28, P768, DOI 10.1097/00004583-198909000-00020; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Braha RED, 1999, NEUROREHABILITATION, V12, P201; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Dhillon HS, 1998, BRAIN RES, V804, P231, DOI 10.1016/S0006-8993(98)00639-8; Dougherty DD, 1999, LANCET, V354, P2132, DOI 10.1016/S0140-6736(99)04030-1; Efron D, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.6.e6; Efron D, 1997, PEDIATRICS, V100, P662, DOI 10.1542/peds.100.4.662; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Hinkin CH, 2001, J NEUROPSYCH CLIN N, V13, P248, DOI 10.1176/appi.neuropsych.13.2.248; HOFFMAN BB, 2001, PHARM BASIS THERAPEU; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Jansen IHM, 2001, J AM GERIATR SOC, V49, P474, DOI 10.1046/j.1532-5415.2001.49092.x; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Laborde A, 1997, J HEAD TRAUMA REHAB, V12, P90, DOI 10.1097/00001199-199708000-00009; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; Mehta MA, 2000, J NEUROSCI, V20; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PELHAM WE, 1990, PEDIATRICS, V86, P226; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Pliszka SR, 1998, PEDIATR CLIN N AM, V45, P1085, DOI 10.1016/S0031-3955(05)70063-8; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Thompson SJ, 2001, J CLIN ONCOL, V19, P1802, DOI 10.1200/JCO.2001.19.6.1802; Tiberti C, 1998, EUR J NEUROL, V5, P297, DOI 10.1046/j.1468-1331.1998.530297.x; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VASTAG V, 2001, JAMA-J AM MED ASSOC, V285, P905; Volkow ND, 1998, AM J PSYCHIAT, V155, P1325, DOI 10.1176/ajp.155.10.1325; Wax PM, 1997, J TOXICOL-CLIN TOXIC, V35, P203, DOI 10.3109/15563659709001195; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P59; Whyte J., 1997, PROMISE OUTCOMES RES, P43; WHYTE J, 1998, INT PERSPECTIVES TRA, P154; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Worzniak M, 1997, J FAM PRACTICE, V44, P495	44	68	70	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2002	17	4					284	299		10.1097/00001199-200208000-00003			16	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	578UY	WOS:000177140200003	12105998				2022-02-06	
J	Griesbach, GS; Hovda, DA; Molteni, R; Gomez-Pinilla, F				Griesbach, GS; Hovda, DA; Molteni, R; Gomez-Pinilla, F			Alterations in BDNF and synapsin I within the occipital cortex and hippocampus after mild traumatic brain injury in the developing rat: Reflections of injury-induced neuroplasticity	JOURNAL OF NEUROTRAUMA			English	Article						development; fluid-percussion injury; neurotrophins; plasticity; trkB	FACTOR MESSENGER-RNA; NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; ADULT-RAT; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; FLUID PERCUSSION; HEAD-INJURY; ANTEROGRADE TRANSPORT; RETROGRADE TRANSPORT	Brain-derived neurotrophic factor (BDNF), its signal transduction receptor trkB, and its downstream effector, synapsin I, were measured in the hippocampus and occipital cortex of young animals after fluid-percussion brain injury (FPI). Isofluorane anaesthetized postnatal day 19 rats were subjected to a mild lateral FPI or sham injury. Rats were sacrificed at 24 h, 7 days, or 14 days after injury in order to determine mRNA expression. Additional animals were sacrificed at 7 and 14 days after injury for protein analysis. Only FPI animals exhibited hemispheric differences in BDNF levels. These animals exhibited a contralateral increase, ranging from 40% to 75%, in BDNF mRNA within both the hippocampus and occipital cortex at 24 h and 7 days after injury. The increase in message within the occipital cortex was accompanied by an increase in BDNF protein at 7 and 14 days after injury. However, hippocampal BDNF protein increased in both hemispheres at postinjury day 7 and was restricted to the ipsilateral hippocampus at postinjury day 14. At postinjury day 7, both trkB and synapsin I mRNA expression increased ipsilaterally and decreased contralaterally in the occipital cortex. In addition, synapsin I phosphorylation was increased by 20% in the ipsilateral cortex and by 30% in the hippocampus on this day. These results indicate that the developing brain responds to a mild injury by modifying factors related to synaptic plasticity and suggest that regions remote from the site of injury express neurotrophic signals potentially needed for compensatory responses.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Brain Injury Res Ctr, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol Sci, Los Angeles, CA 90024 USA		Griesbach, GS (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA.		Molteni, Raffaella/Q-5011-2017	Molteni, Raffaella/0000-0002-5481-7572	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544, R01NS038978] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38978, NS27544, NS30308] Funding Source: Medline		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Bareyre FM, 2001, J NEUROCHEM, V77, P173, DOI 10.1046/j.1471-4159.2001.t01-1-00215.x; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; Cabelli RJ, 1996, J NEUROSCI, V16, P7965; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CATSICAS S, 1987, P NATL ACAD SCI USA, V84, P8165, DOI 10.1073/pnas.84.22.8165; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Climent E, 2000, NEUROSCI LETT, V288, P53, DOI 10.1016/S0304-3940(00)01207-6; Conner JM, 1998, REV NEUROSCIENCE, V9, P91; Conner JM, 1997, J NEUROSCI, V17, P2295; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; GIZA CC, 2001, J NEUROTRAUMA, V18; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; Gottschalk WA, 1999, LEARN MEMORY, V6, P243; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hicks A, 1997, NEUROSCIENCE, V79, P329, DOI 10.1016/S0306-4522(96)00700-2; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOLLOWAY RALPH L., 1966, BRAIN RES, V2, P393, DOI 10.1016/0006-8993(66)90009-6; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; Lein ES, 2000, J NEUROSCI, V20, P1470; Lein ES, 2000, J COMP NEUROL, V420, P1, DOI 10.1002/(SICI)1096-9861(20000424)420:1<1::AID-CNE1>3.0.CO;2-H; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; LI L, 1995, P NATL ACAD SCI USA, V92, P9235, DOI 10.1073/pnas.92.20.9235; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; McKeon RJ, 1997, EXP NEUROL, V148, P558, DOI 10.1006/exnr.1997.6698; MELLONI RH, 1994, NEUROSCIENCE, V58, P683, DOI 10.1016/0306-4522(94)90448-0; MILLER MW, 1988, J COMP NEUROL, V274, P387, DOI 10.1002/cne.902740308; Mufson EJ, 1996, NEUROSCIENCE, V71, P179, DOI 10.1016/0306-4522(95)00431-9; NAWA H, 1995, EUR J NEUROSCI, V7, P1527, DOI 10.1111/j.1460-9568.1995.tb01148.x; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PIERIBONE VA, 1995, NATURE, V375, P493, DOI 10.1038/375493a0; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; ROZENWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429; SCHOUPS AA, 1995, DEV BRAIN RES, V86, P326, DOI 10.1016/0165-3806(95)00043-D; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SMITH A, 1984, EARLY BRAIN DAMAGE, P299; Sobreviela T, 1996, J COMP NEUROL, V375, P417; Takei N, 1997, J NEUROCHEM, V68, P370; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; VOLKMAR FR, 1972, SCIENCE, V176, P1447; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; Zhou JW, 1996, DEV BRAIN RES, V97, P297, DOI 10.1016/S0165-3806(96)00159-9	67	68	73	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2002	19	7					803	814		10.1089/08977150260190401			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	577JL	WOS:000177057700001	12184851				2022-02-06	
J	Callahan, CD; Hinkebein, JH				Callahan, CD; Hinkebein, JH			Assessment of anosmia after traumatic brain injury: Performance characteristics of the university of Pennsylvania Smell Identification Test	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Annual Convention of the American-Psychological-Association	AUG, 2000	WASHINGTON, D.C.	Amer Psychol Assoc		anosmia; performance characteristics; traumatic brain injury; University of Pennsylvania Smell Identification; Test	HEAD TRAUMA	Objective: To examine the performance characteristics of two forms of the University of Pennsylvania Smell Identification Test (UPSIT) in a sample of persons with traumatic brain injury (TBI). Design: Analysis of consecutive admissions into a brain injury rehabilitation program. Setting: Midwestern medical center. Participants: One hundred twenty-two adults diagnosed with TBI (49% severe TBI, 16% moderate TBI, 35% mild TBI). Main Outcome Measures: University of Pennsylvania Smell Identification Test (UPSIT; Sand 40-item versions). Results: Fifty-six percent of sample exhibited impaired olfaction on the full UPSIT; 40% of these patients were unaware of their deficits. Contrary to expectation, TBI patients detected dangerous odors (natural gas, gasoline, smoke) with high accuracy. Usefulness of a 3-item screening measure was examined: Missing even one item related to a 2:1 likelihood of being anosmic. Conclusions: These findings support past investigations indicating that anosmia, and unawareness of olfactory dysfunction, are common in persons with TBI and related to injury severity. The use of the 3-item screening measure as a gross indicator was supported, although caution is advised, because nearly 20% of patients performing perfectly on the 3-item screen scored in the anosmic range on the full UPSIT.	Mem Med Ctr, ABPP, Ctr Neuromuscular Sci, Springfield, IL 62781 USA; Univ Missouri, Sch Med, Dept Hlth Psychol, Columbia, MO USA		Callahan, CD (corresponding author), Mem Med Ctr, ABPP, Ctr Neuromuscular Sci, 701 N 1st St, Springfield, IL 62781 USA.						Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; CONSTANZO RM, 1992, J HEAD TRAUMA REHAB, V7, P15; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 1995, SMELL IDENTIFICATION, Vthird; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; ZASLER ND, 1992, J HEAD TRAUMA REHAB, V7, P66	10	68	71	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2002	17	3					251	256		10.1097/00001199-200206000-00006			6	Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	552WE	WOS:000175642400006	12086578				2022-02-06	
J	Chatzipanteli, K; Garcia, R; Marcillo, AE; Loor, KE; Kraydieh, S; Dietrich, WD				Chatzipanteli, K; Garcia, R; Marcillo, AE; Loor, KE; Kraydieh, S; Dietrich, WD			Temporal and segmental distribution of constitutive and inducible nitric oxide synthases after traumatic spinal cord injury: Effect of aminoguanidine treatment	JOURNAL OF NEUROTRAUMA			English	Article						immunohistochemistry; nitric oxide; nitric oxide synthase; 3-nitrotyrosine	FOCAL CEREBRAL-ISCHEMIA; ACUTE INFLAMMATORY RESPONSE; BRAIN INJURY; NADPH DIAPHORASE; L-ARGININE; POSTTRAUMATIC HYPOTHERMIA; NERVOUS-SYSTEM; NEURONAL DEATH; MESSENGER-RNA; SMOOTH-MUSCLE	Nitric oxide (NO) has been shown to play an important role in the pathophysiology of traumatic brain injury (TBI) and cerebral ischemia. However, its contribution to the pathogenesis of traumatic spinal cord injury (SCI) remains to be clarified. This study determined the time course of constitutive and inducible nitric oxide synthases (cNOS and iNOS, respectively) after SCI. Rats underwent moderate SCI at T10 using the NYU impactor device and were allowed to survive for 3, 6, or 24 h and 3 days after SCI (n = 5 in each group). For the determination of enzymatic activities, spinal cords were dissected into five segments, including levels rostral and caudal (remote) to the injury site. Other rats were perfusion fixed for the immunohistochemical localization of iNOS protein levels. cNOS activity was significantly decreased at 3 and 6 h within the traumatized T10 segment and at 3, 6, and 24 h at the rostral. (T9) level (p < 0.05). Rostral (T8) and caudal (T11, T12) to the injury site cNOS activity was also decreased at 3 h after injury (p < 0.05). However, cNOS activity returned to control levels within 6 h at T8, T11 and T12 and at one day at T10 and T9 segments. iNOS enzymatic activity was elevated at all time points tested (p < 0.05), with the most robust increase observed at 24 h. Immunostaining for iNOS at 24 h revealed that a significant cellular source of iNOS protein appeared to be invading polymorphonuclear leukocytes (PMNLs). To assess the functional consequences of iNOS inhibition, aminoguanidine treatment was initiated 5 min after SCI and rats tested using the BBB open field locomotor score. Treated rats demonstrated significantly improved hindlimb function up to 7 weeks after SCI. Histopathological analysis of contusion volume showed that aminoguanidine treatment decreased lesion volume by 37% (P < 0.05). In conclusion, these results indicate that (1) cNOS and iNOS activities are regionally and temporally affected after moderate SCI, (2) the early accumulation of PMNLs are a potentially significant source of NO-induced cytotoxic products, and (3) acute aminoguanidine treatment significantly improves functional and histopathological outcome after SCI.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33101 USA		Chatzipanteli, K (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, POB 016960, Miami, FL 33101 USA.	kchatzip@miamiproject.med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1P01 NS38665-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038665] Funding Source: NIH RePORTER		ANDERSON R, 1995, S AFR MED J, V85, P1024; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Baumgartner WA, 1999, ANN THORAC SURG, V67, P1871, DOI 10.1016/S0003-4975(99)00445-2; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BECKMAN JS, 1996, CELL PHYSL, V40, pC1424; Bethea JR, 1998, J NEUROSCI, V18, P3251; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BLOT S, 1994, STROKE, V25, P1666, DOI 10.1161/01.STR.25.8.1666; Bolanos JP, 1999, BBA-BIOENERGETICS, V1411, P415, DOI 10.1016/S0005-2728(99)00030-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRITIGAN BE, 1988, NEW ENGL J MED, V318, P858; BRUHWYLER J, 1993, NEUROSCI BIOBEHAV R, V17, P373, DOI 10.1016/S0149-7634(05)80114-9; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Callsen-Cencic P, 1999, CELL TISSUE RES, V295, P183, DOI 10.1007/s004410051224; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; Dalkara T, 1997, INT REV NEUROBIOL, V40, P319; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; FLEMING I, 1991, EUR J PHARMACOL, V200, P375, DOI 10.1016/0014-2999(91)90602-M; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Guizar-Sahagun G, 1998, NEUROREPORT, V9, P2899, DOI 10.1097/00001756-199808240-00040; HALL ED, 1986, J NEUROTRAUM, V3, P626; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hara H, 1997, J CEREBR BLOOD F MET, V17, P515, DOI 10.1097/00004647-199705000-00005; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; Hirabayashi H, 2000, BRAIN RES, V852, P319, DOI 10.1016/S0006-8993(99)02117-4; HOYT KR, 1992, BRAIN RES, V592, P310, DOI 10.1016/0006-8993(92)91690-G; HSU CY, 1994, NEUROBIOLOGY CENTRAL, P145; Hu WH, 1998, EUR J PHARMACOL, V342, P325, DOI 10.1016/S0014-2999(97)01492-1; Hu WH, 2000, J CHEM NEUROANAT, V17, P183, DOI 10.1016/S0891-0618(99)00039-3; Hu WH, 1999, J NEUROTRAUM, V16, P85, DOI 10.1089/neu.1999.16.85; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Ishida A, 2001, EXP NEUROL, V168, P323, DOI 10.1006/exnr.2000.7606; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; Kaur C, 1999, HISTOL HISTOPATHOL, V14, P417, DOI 10.14670/HH-14.417; Kelly DJ, 2001, J AM SOC NEPHROL, V12, P2098, DOI 10.1681/ASN.V12102098; KIM N, 1993, J CLIN INVEST, V91, P437, DOI 10.1172/JCI116220; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; LAMAS S, 1992, J CLIN INVEST, V90, P879, DOI 10.1172/JCI115963; Lin SZ, 1996, STROKE, V27, P747, DOI 10.1161/01.STR.27.4.747; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; MANZONI O, 1993, J NEUROCHEM, V61, P368, DOI 10.1111/j.1471-4159.1993.tb03580.x; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NAVAGOMI S, 1999, EUR J NEUROSCI, V11, P2160; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; PALMER RMJ, 1992, BRIT J PHARMACOL, V105, P11, DOI 10.1111/j.1476-5381.1992.tb14202.x; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Parkinson JF, 1997, J MOL MED, V75, P174, DOI 10.1007/s001090050102; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RAVICHANDRAN LV, 1995, AM J PHYSIOL-HEART C, V268, pH2216, DOI 10.1152/ajpheart.1995.268.6.H2216; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; SHAPPELL SB, 1994, HDB IMMUNOPHARMACOLO, P29; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131, DOI 10.1152/ajpcell.1991.260.6.C1131; Vizzard MA, 1997, J AUTONOM NERV SYST, V64, P128, DOI 10.1016/S0165-1838(97)00025-8; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Xu M, 1998, BRAIN RES, V808, P23, DOI 10.1016/S0006-8993(98)00787-2; Xu M, 2000, EXP NEUROL, V161, P472, DOI 10.1006/exnr.1999.7278; ZHANG FY, 1994, J CEREBR BLOOD F MET, V14, P217, DOI 10.1038/jcbfm.1994.28; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213; Zhao WG, 1996, J NEUROIMMUNOL, V64, P123, DOI 10.1016/0165-5728(95)00158-1	98	68	72	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					639	651		10.1089/089771502753754109			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900008	12042098				2022-02-06	
J	Exner, GU				Exner, GU			Missed chronic anterior Monteggia lesion - Closed reduction by gradual lengthening and angulation of the ulna	JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME			English	Article							RADIAL HEAD; CHILDREN; DISLOCATION; MANAGEMENT	Two consecutive cases of chronic dislocation of the head of the radius after missed Bado type-I Monteggia lesions are presented. Reduction was successfully achieved in both patients after ulnar corticotomy, gradual lengthening and angulation of the ulna using an external fixator. Open reduction or reconstruction of the radio-ulnar capitellar joint was not undertaken. The age at injury was seven years in the older and two years in the younger patient, The time from injury to treatment was five years in the older and three months in the younger child. At follow-up, nine years after completion of treatment in the older and eight months in the younger patient, both show satisfactory movement, function of the forearm and reduction of the head of the radius. This technique may be considered in missed Monteggia lesions before open procedures on the radio-ulnar capitellar joint are undertaken.	Univ Zurich, Orthopad Klin, Zurich, Switzerland		Exner, GU (corresponding author), Univ Klin Zurich, Sect Paediat & Tumour Orthopaed, Forchstr 340, CH-3008 Zurich, Switzerland.						Bado J L, 1967, Clin Orthop Relat Res, V50, P71; Bell Tawse AJ, 1965, J BONE JOINT SURG BR, V47, P718; HIRAYAMA T, 1987, J BONE JOINT SURG BR, V69, P639, DOI 10.1302/0301-620X.69B4.3611173; Inoue G, 1998, ACTA ORTHOP SCAND, V69, P73, DOI 10.3109/17453679809002361; JUDET R, 1962, PRESSE MED, V70, P689; KALAMCHI A, 1986, J BONE JOINT SURG AM, V68A, P615, DOI 10.2106/00004623-198668040-00022; LAMMENS J, 1991, J BONE JOINT SURG BR, V73, P412, DOI 10.1302/0301-620X.73B3.1670440; LLOYDROBERTS GC, 1977, J BONE JOINT SURG BR, V59, P402, DOI 10.1302/0301-620X.59B4.925049; Rodgers WB, 1996, J BONE JOINT SURG AM, V78A, P1322, DOI 10.2106/00004623-199609000-00005; Seel MJ, 1999, J PEDIATR ORTHOPED, V19, P306, DOI 10.1097/00004694-199905000-00006	10	68	73	0	2	BRITISH EDITORIAL SOC BONE JOINT SURGERY	LONDON	22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND	0301-620X	2044-5377		J BONE JOINT SURG BR	J. Bone Joint Surg.-Br. Vol.	MAY	2001	83B	4					547	550		10.1302/0301-620X.83B4.11103			4	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	434WW	WOS:000168839700018	11380129				2022-02-06	
J	Statler, KD; Kochanek, PM; Dixon, CE; Alexander, HL; Warner, DS; Clark, RSB; Wisniewski, SR; Graham, SH; Jenkins, LW; Marion, DW; Safar, PJ				Statler, KD; Kochanek, PM; Dixon, CE; Alexander, HL; Warner, DS; Clark, RSB; Wisniewski, SR; Graham, SH; Jenkins, LW; Marion, DW; Safar, PJ			Isoflurane improves long-term neurologic outcome versus fentanyl after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						analgesia; anesthesia; head injury; narcotics; opioids; sedation	CEREBRAL BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; VOLATILE ANESTHETICS; FOREBRAIN ISCHEMIA; POTASSIUM CHANNELS; XENOPUS OOCYTES; RECEPTORS; AUTOREGULATION; CALCIUM; OPIATE	Despite routine nse of fentanyl in patients after traumatic brain injury (TBI), it is unclear if it is the optimal sedative/analgesic agent. Isoflurane is commonly used in experimental TBI. We hypothesized that isoflurane would be neuroprotective versus fentanyl after TBI. Rats underwent controlled cortical impact (CCI) and received 4 h of N2O/O-2 (2:1) and either fentanyl (10 mug/kg i.v. bolus, 50 mug/kg/h infusion) or isoflurane (1% by inhalation) with controlled ventilation. Shams underwent identical preparation, without CCI. Functional outcome (beam balance, beam walking, Morris water maze [MWM] tasks) was assessed over 20 days. Lesion volume and hippocampal neuron survival were quantified on day 21. Additional rats underwent identical CCI and anesthesia with intracranial pressure (ICP) monitoring, and brain water content was assessed. Motor and MWM performances were better in injured rats treated with isoflurane versus fentanyl (p < 0.05). CA1 hippocampal damage was attenuated in isoflurane-treated rats (p < 0.05). Fentanyl-treated rats had higher mean arterial blood pressure after injury (p < 0.05); however, ICP and brain water were similar between groups. Isoflurane improved functional outcome and attenuated damage to CA1 versus fentanyl in rats subjected to CCI. Isoflurane may be neuroprotective by augmenting cerebral blood flow and/or reducing excitotoxicity, not by reducing ICP or brain water content. Alternatively, fentanyl may be detrimental. Isoflurane may mask beneficial effects of novel agents tested in TBI models. Additionally, fentanyl may not be optimal early after TBI in humans.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol & Publ Hlth, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Vet Adm Pittsburgh Hlth Ctr, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA; Duke Univ, Dept Anesthesia, Durham, NC USA		Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	kochanekpm@anes.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40686] Funding Source: Medline		ANTHONY BL, 1989, NEUROSCI LETT, V99, P191, DOI 10.1016/0304-3940(89)90288-7; BEAUMONT A, 1999, 11 INT S BRAIN OED M, P42; Bedell EA, 1998, J NEUROTRAUM, V15, P985, DOI 10.1089/neu.1998.15.985; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRADLEY PB, 1984, BRIT J PHARMACOL, V83, P763, DOI 10.1111/j.1476-5381.1984.tb16231.x; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DildyMayfield JE, 1996, J PHARMACOL EXP THER, V276, P1058; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1985, PEPTIDES, V6, P15, DOI 10.1016/0196-9781(85)90006-3; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HERNANDEZ MJ, 1978, STROKE, V9, P150, DOI 10.1161/01.STR.9.2.150; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; HOSSAIN MD, 1994, ANESTHESIOLOGY, V80, P1379, DOI 10.1097/00000542-199406000-00026; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Kamatchi GL, 1999, BRAIN RES, V831, P85, DOI 10.1016/S0006-8993(99)01401-8; KEARSE LA, 1993, ELECTROEN CLIN NEURO, V87, P374, DOI 10.1016/0013-4694(93)90150-T; KISSIN I, 1983, CAN ANAESTH SOC J, V30, P623, DOI 10.1007/BF03015233; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; LYETH BG, 1995, NEUROPEPTIDES, V29, P11, DOI 10.1016/0143-4179(95)90051-9; Mackensen GB, 1999, ANESTHESIOLOGY, V90, P873, DOI 10.1097/00000542-199903000-00031; Magyar J, 1996, MOL PHARMACOL, V50, P1520; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; McIntosh T K, 1986, NIDA Res Monogr, V75, P527; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Minami K, 1997, EUR J PHARMACOL, V339, P237, DOI 10.1016/S0014-2999(97)01354-X; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; MURR R, 1993, ANESTH ANALG, V77, P898; MURR R, 1995, ANESTH ANALG, V80, P1108, DOI 10.1097/00000539-199506000-00007; Neumaier J F, 1986, NIDA Res Monogr, V75, P101; NEUMAIER JF, 1988, J PHARMACOL EXP THER, V244, P564; Nietgen GW, 1998, BRIT J ANAESTH, V81, P569, DOI 10.1093/bja/81.4.569; Ohta S, 1995, Masui, V44, P1228; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; Patel PM, 1998, ANESTH ANALG, V86, P773, DOI 10.1097/00000539-199804000-00018; Rengasamy A, 1997, ANESTHESIOLOGY, V86, P689, DOI 10.1097/00000542-199703000-00022; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; STOVER J, 1999, 11 INT S BRAIN OEDEM, P141; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Tipps LB, 2000, NEUROSURGERY, V46, P596, DOI 10.1097/00006123-200003000-00015; VINK R, 1990, J NEUROSCI, V10, P3524; Winegar BD, 1996, ANESTHESIOLOGY, V85, P889, DOI 10.1097/00000542-199610000-00026; Zaharchuk G, 1999, STROKE, V30, P2197, DOI 10.1161/01.STR.30.10.2197; ZORN L, 1993, NEUROSCI LETT, V161, P81, DOI 10.1016/0304-3940(93)90145-B	57	68	69	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2000	17	12					1179	1189		10.1089/neu.2000.17.1179			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	379MB	WOS:000165644900006	11186231				2022-02-06	
J	Novack, TA; Alderson, AL; Bush, BA; Meythaler, JM; Canupp, K				Novack, TA; Alderson, AL; Bush, BA; Meythaler, JM; Canupp, K			Cognitive and functional recovery at 6 and 12 months post-TBI	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; COMA-DATA-BANK; PREDICTORS; 1-YEAR	Outcome studies examining recovery from traumatic brain injury (TBI) often fail to provide a clear understanding of the time course of cognitive, emotional, and behavioural recovery. The present study represents an effort to prospectively study individuals with TBI at fixed intervals, specifically 6 and 12 months post-injury with a window of +/-1 month. Seventy-two individuals with new-onset TBI underwent neuropsychological evaluation and clinical interview at 6 and 12 months post-injury. Results revealed significant improvements in cognitive abilities, including memory, processing speed, language abilities, and constructional skills. There were significant gains in community integration and involvement in productive activities, but limitations in driving activities remained. Although individuals with mild-moderate TBI performed better than individuals with severe TBI, both groups demonstrated equivalent rates of recovery across domains. The results of this study provide important information regarding the time course of TBI recovery.	Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA		Novack, TA (corresponding author), Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, 619-19th St S,SRC 530, Birmingham, AL 35249 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [403641] Funding Source: Medline		CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; GORDON WA, 1984, EVOLUTION DEFICITS A; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOU JS, 1995, ARCH NEUROL-CHICAGO, V52, P982, DOI 10.1001/archneur.1995.00540340074015; MASS AIR, 1983, J NEUROSURG, V58, P321; MATTHEWS CG, 1964, INSTRUCTION MANUAL A; MEYALER JM, 1999, ARCH PHYSICAL MED RE, V80, P1132; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan RM, 1985, HALSTEADREITAN NEURO; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Venton AL., 1983, MULTILINGUAL APHASIA; Wechsler, 1997, WECHSLER ADULT INTEL; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	24	68	71	0	5	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2000	14	11					987	996					10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	373UC	WOS:000165306800004	11104138				2022-02-06	
J	O'Dell, DM; Raghupathi, R; Crino, PB; Eberwine, JH; McIntosh, TK				O'Dell, DM; Raghupathi, R; Crino, PB; Eberwine, JH; McIntosh, TK			Traumatic brain injury alters the molecular fingerprint of TUNEL-positive cortical neurons in vivo: A single-cell analysis	JOURNAL OF NEUROSCIENCE			English	Article						TUNEL; brain injury; gene expression; cell death; caspase; aRNA amplification	SPATIAL MEMORY DEFICITS; BINDING PROTEIN CREB; MESSENGER-RNA; NEUROTROPHIC FACTOR; DNA FRAGMENTATION; GENE-EXPRESSION; GLOBAL-ISCHEMIA; IMPACT INJURY; RAT-BRAIN; APOPTOTIC NEURONS	The cerebral cortex is selectively vulnerable to cell death after traumatic brain injury (TBI). We hypothesized that the ratio of mRNAs encoding proteins important for cell survival and/or cell death is altered in individual damaged neurons after injury that may contribute to the cell's fate. To investigate this possibility, we used amplified antisense mRNA (aRNA) amplification to examine the relative abundance of 31 selected candidate mRNAs in individual cortical neurons with fragmented DNA at 12 or 24 hr after lateral fluid percussion brain injury in anesthetized rats. Only pyramidal neurons characterized by nuclear terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick end labeling (TUNEL) reactivity with little cytoplasmic staining were analyzed. For controls, non-TUNEL-positive neurons from the cortex of sham-injured animals were obtained and subjected to aRNA amplification. At 12 hr after injury, injured neurons exhibited a decrease in the relative abundance of specific mRNAs including those encoding for endogenous neuroprotective proteins. By 24 hr after injury, many of the mRNAs altered at 12 hr after injury had returned to baseline (sham-injured) levels except for increases in caspase-2 and bax mRNAs. These data suggest that TBI induces a temporal and selective alteration in the gene expression profiles or "molecular fingerprints" of TUNEL-positive neurons in the cerebral cortex. These patterns of gene expression may provide information about the molecular basis of cell death in this region after TBI and may suggest multiple avenues for therapeutic intervention.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3320 Smith Walk,Room 105-C,Hayden Hall, Philadelphia, PA 19104 USA.		Eberwine, James/B-2247-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG009900] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG009900, R01-AG9900] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, P50 NS008803] Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; BLAHA GR, 2000, IN PRESS NEUROSCIENC; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brandoli C, 1998, J NEUROSCI, V18, P7953; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Courtney MJ, 1997, J NEUROSCI, V17, P4201; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dichter M., 1995, NEUROSCIENTIST, V1, P200, DOI 10.1177/107385849500100404; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Ferrand-Drake M, 1999, NEUROSCIENCE, V93, P537, DOI 10.1016/S0306-4522(99)00181-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gorter JA, 1997, J NEUROSCI, V17, P6179; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Kinoshita M, 1997, J CEREBR BLOOD F MET, V17, P507, DOI 10.1097/00004647-199705000-00004; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kume T, 1997, BRAIN RES, V756, P200, DOI 10.1016/S0006-8993(97)00195-9; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELCHER T, 1996, NATURE, V379, P464; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Morikawa E, 1998, J NEUROSCI, V18, P9727; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Nibuya M, 1996, J NEUROSCI, V16, P2365; O'Dell DM, 1998, BIOTECHNIQUES, V25, P566, DOI 10.2144/98254bm04; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; PELLEGRINIGIAMPIETRO DE, 1992, P NATL ACAD SCI USA, V89, P10499, DOI 10.1073/pnas.89.21.10499; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, pS494; RINK A, 1995, AM J PATHOL, V147, P1575; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Rump A, 1996, J CEREBR BLOOD F MET, V16, P1362, DOI 10.1097/00004647-199611000-00034; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tuunanen J, 1999, NEUROSCIENCE, V94, P473, DOI 10.1016/S0306-4522(99)00251-1; Walton M, 1997, MOL BRAIN RES, V44, P167, DOI 10.1016/S0169-328X(96)00291-4; Walton M, 1999, J NEUROCHEM, V73, P1836; Walton M, 1996, MOL BRAIN RES, V43, P21, DOI 10.1016/S0169-328X(96)00144-1; WHITTEMORE SR, 1991, J NEUROSCI RES, V28, P156, DOI 10.1002/jnr.490280203; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415	65	68	71	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 1	2000	20	13					4821	4828					8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	327WC	WOS:000087816300008	10864939				2022-02-06	
J	Novack, TA; Dowler, RN; Bush, BA; Glen, T; Schneider, JJ				Novack, TA; Dowler, RN; Bush, BA; Glen, T; Schneider, JJ			Validity of the Orientation Log, relative to the Galveston Orientation and Amnesia Test	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article								Objective: To establish the validity of the Orientation Log (O-Log) by comparison with the Galveston Orientation and Amnesia Test (GOAT). Design: Correlation of daily measures of orientation. Setting: Acute rehabilitation hospital. Subjects: Sixty-eight inpatients receiving rehabilitation following traumatic brain injury (TBI). Primary measures: The O-Log and GOAT. Results: There was a significant correlation between the GOAT and O-Log (r = .901, P < .001). A cutoff of 25 on the O-Log was found to be comparable with the 75 cutoff on the GOAT. The scales were equivalent in measuring duration of posttraumatic amnesia. Conclusions: The O-Log is a valid measure of orientation for people with TBI and offers some advantages in administration over the GOAT.	Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL 35233 USA		Novack, TA (corresponding author), Univ Alabama, Spain Rehabil Ctr, Dept Phys Med & Rehabil, 1717 6th Ave S, Birmingham, AL 35233 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07420] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR40364] Funding Source: Medline		Hamilton BB, 1987, REHABILITATION OUTCO, P137; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004	3	68	69	0	2	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2000	15	3					957	961		10.1097/00001199-200006000-00008			5	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	321FL	WOS:000087445400008	10785625				2022-02-06	
J	Kolakowsky-Hayner, SA; Gourley, EV; Kreutzer, JS; Marwitz, JH; Cifu, DX; McKinley, WO				Kolakowsky-Hayner, SA; Gourley, EV; Kreutzer, JS; Marwitz, JH; Cifu, DX; McKinley, WO			Pre-injury substance abuse among persons with brain injury and persons with spinal cord injury	BRAIN INJURY			English	Article							ALCOHOL-USE; HEAD-INJURY; TRAUMA PATIENTS; MARIJUANA; PATTERNS	Alcohol and drug use at the time of injury have been strongly implicated as causal factors of spinal cord injury (SCI) and traumatic brain injury (TBI). Researchers have only begun their efforts to investigate the pre-injury incidence of substance abuse in an effort to identify persons at risk for traumatic injury. No studies have compared brain and spinal cord injury populations. This investigation was based in an urban, level one trauma center federally designated as a model system of comprehensive rehabilitative services for persons with TBI and persons with SCI. Pre-injury patterns of alcohol and illicit drug use were compared among patients with SCI and patients with TBI, matched for age, gender, race, and mechanism of injury (n = 52). In accordance with previous research, participants were primarily young, unmarried, males with at least a high school education. Eighty-one percent of patients with TBI and 96% of patients with SCI reported pre-injury alcohol use. The rate of pre-injury heavy drinking for both groups was alarmingly high. Fifty-seven percent of persons with SCI and 42% of persons with TBI were heavy drinkers. Implications for risk identification, treatment, and future research are discussed.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA		Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, POB 980542, Richmond, VA 23298 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Cifu, David/0000-0003-1600-9387	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133N50015, H133A980026] Funding Source: Medline		Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Drubach D A, 1993, Md Med J, V42, P989; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EDNA T, 1984, ACTA CHIR SCAND, V148, P209; FISHBURNE PM, 1979, NATL SURVEY DRUG ABU; Frisbie J H, 1984, J Am Paraplegia Soc, V7, P71; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GO BK, 1995, SPINAL CORD INJURY C; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hawkins DA, 1998, REHABIL PSYCHOL, V43, P219, DOI 10.1037/0090-5550.43.3.219; HEINEMANN A, 1991, ARCH PHYSICAL MED RE, V73, P482; Heinemann A. W., 1989, ALCOHOL HEALTH RES W, V13, P110; HEINEMANN AW, 1990, REHABIL PSYCHOL, V35, P217, DOI 10.1037/h0079065; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1989, REHABIL PSYCHOL, V34, P191, DOI 10.1037//0090-5550.34.3.191; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; ODONNELL JP, 1981, ALCOHOL HEALTH RES W, V148, P209; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1983, REHABILITATION HEAD; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; SMITH J, 1990, SPINAL NETWORK; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; TATE DG, 1993, AM J PHYS MED REHAB, V72, P192, DOI 10.1097/00002060-199308000-00004; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0	40	68	69	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1999	13	8					571	581					11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200002	10901686				2022-02-06	
J	Czosnyka, M; Smielewski, P; Piechnik, S; Al-Rawi, PG; Kirkpatrick, PJ; Matta, BF; Pickard, JD				Czosnyka, M; Smielewski, P; Piechnik, S; Al-Rawi, PG; Kirkpatrick, PJ; Matta, BF; Pickard, JD			Critical closing pressure in cerebrovascular circulation	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						critical closing pressure; cerebral autoregulation; head injury; transcranial Doppler	CEREBRAL BLOOD-FLOW; VELOCITY-MEASUREMENTS; TRANSCRANIAL DOPPLER; HEAD-INJURY; MODEL; VASOREACTIVITY; AUTOREGULATION; IMPEDANCE	Objective-Cerebral critical closing pressure (CCP) has been defined as an arterial pressure threshold below which arterial vessels collapse. Hypothetically this is equal to intracranial pressure (ICP) plus the contribution from the active tone of cerebral arterial smooth muscle. The correlation of CCP with ICP, cerebral autoregulation, and other clinical and haemodynamic modalities in patients with head injury was evaluated. Method-intracranial pressure, arterial blood pressure (ABP) and middle cerebral artery blood flow velocity were recorded daily in ventilated patients. Waveforms were processed to calculate CCP, the transcranial Doppler-derived cerebral autoregulation index (Mx), mean arterial pressure (ABP), intracranial pressure (ICP), and cerebral perfusion pressure (CPP). Results-Critical closing pressure reflected the time related changes in ICP during plateau and B waves. Overall correlation between CCP and ICP was mild but significant (R=0.41; p<0.0002). The mean difference between ABP and CCP correlated with CPP (R=0.57, 95% confidence interval (95% CI) for prediction 25 mm Hg). The difference between CCP and ICP, described previously as proportional to arterial wall tension, correlated with the index of cerebral autoregulation Mx (p<0.0002) and CPP (p<0.0001). However, by contrast with the Mx index, CCP-ICP was not significantly correlated with outcome after head injury. Conclusion-Critical closing pressure, although sensitive to variations in ICP and CPP, cannot be used as an accurate estimator of these modalities with acceptable confidence intervals. The difference CCP-ICP significantly correlates with cerebral autoregulation, but it lacks the power to predict outcome after head injury.	Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, MRC, Cambridge Ctr Brain Repair, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Anaesthesia, Cambridge CB2 2QQ, England		Czosnyka, M (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, POB 167, Cambridge CB2 2QQ, England.			Smielewski, Peter/0000-0001-5096-3938; Piechnik, Stefan K./0000-0002-0268-5221	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Aaslid R, 1992, TRANSCRANIAL DOPPLER, P49; BURTON AC, 1951, AM J PHYSIOL, V164, P319, DOI 10.1152/ajplegacy.1951.164.2.319; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CZOSNYKA M, 1994, ULTRASOUND MED BIOL, V20, P391, DOI 10.1016/0301-5629(94)90008-6; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; CZOSNYKA M, 1996, STROKE, V27, P829; DAHL A, 1992, J CEREBR BLOOD F MET, V12, P1049, DOI 10.1038/jcbfm.1992.142; DAHL A, 1992, STROKE, V23, P15, DOI 10.1161/01.STR.23.1.15; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Giller CA, 1996, ULTRASOUND MED BIOL, V22, P373, DOI 10.1016/0301-5629(96)00024-5; KONTOS HA, 1989, STROKE, V20, P1; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; MICHEL E, 1995, NEUROL RES, V17, P149, DOI 10.1080/01616412.1995.11740304; Michel E, 1997, J CEREBR BLOOD F MET, V17, P1127, DOI 10.1097/00004647-199710000-00015; PANERAI RB, 1995, NEUROPEDIATRICS, V26, P168, DOI 10.1055/s-2007-979748; PANERAI RB, 1993, PHYSIOL MEAS, V14, P411, DOI 10.1088/0967-3334/14/4/002; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236	21	68	68	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1999	66	5					606	611		10.1136/jnnp.66.5.606			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	189QD	WOS:000079915300010	10209171	Green Published, Bronze			2022-02-06	
S	Lee, SM; Wong, MD; Samii, A; Hovda, DA		Blass, JP; McDowell, FH		Lee, SM; Wong, MD; Samii, A; Hovda, DA			Evidence for energy failure following irreversible traumatic brain injury	OXIDATIVE/ENERGY METABOLISM IN NEURODEGENERATIVE DISORDERS	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Oxidative/Energy Metabolism in Neuridegenerative Disorders	MAR 19-22, 1999	NEW YORK, NEW YORK	New York Acad Sci, Winifred Masterson Burke Med Res Inst Inc, NIA, NIH, MitoKor, Amer Fed Aging Res, Warner Lambert Co, Parke Davis Pharmaceut Res			CEREBRAL GLUCOSE-UTILIZATION; RATS		Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Lee, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, 18-228 NPI, Los Angeles, CA 90095 USA.		Wong, Monica D/D-9016-2017	Wong, Monica D/0000-0001-7041-9518	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, NS37363, NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308, R01NS037363] Funding Source: NIH RePORTER		BERGSNEIDER M, 1997, J NEUROSURG, V86, P247; Delaney SM, 1996, J NEUROSCI METH, V64, P151, DOI 10.1016/0165-0270(95)00119-0; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; REIGER D, 1997, ANAL BIOCHEM, V246, P67; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	7	68	68	0	1	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-209-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	893						337	340		10.1111/j.1749-6632.1999.tb07849.x			4	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Multidisciplinary Sciences; Neurosciences; Ornithology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Science & Technology - Other Topics; Neurosciences & Neurology; Zoology	BP50E	WOS:000085330600038	10672261				2022-02-06	
J	Inman, TH; Vickery, CD; Berry, DTR; Lamb, DG; Edwards, CL; Smith, GT				Inman, TH; Vickery, CD; Berry, DTR; Lamb, DG; Edwards, CL; Smith, GT			Development and initial validation of a new procedure for evaluating adequacy of effort given during neuropsychological testing: The letter memory test	PSYCHOLOGICAL ASSESSMENT			English	Article							FORCED-CHOICE METHOD; TRAUMATIC BRAIN-INJURY; DIGIT RECOGNITION TEST; MILD HEAD TRAUMA; REY 15-ITEM TEST; IMPAIRMENT; DEFICITS; VALIDITY; PERFORMANCE; INCENTIVES	The authors report on results from a new procedure for evaluating adequacy of effort given during neuropsychological testing. The letter memory test (LMT) is a computer-administered, 45-item, forced-choice recognition task that uses consonant letters as stimuli and manipulates face difficulty level along 2 dimensions: number of letters to be remembered and number of choices amongst which the target stimulus must be identified. In 3 studies that included either analogue or known groups designs, the LMT discriminated poorly motivated from well-motivated groups at a moderately high level of accuracy, which was comparable to that of the Digit Memory Test and superior to that of the 21-Item Test. The internal consistency reliability of the LMT was also high.	Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; Duke Univ, Med Ctr, Dept Endocrinol & Psychiat, Durham, NC 27706 USA		Berry, DTR (corresponding author), Univ Kentucky, Dept Psychol, 125 Kastle Hall, Lexington, KY 40506 USA.						ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; Beck A. T., 1993, BECK DEPRESSION INVE; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERRY D, 1996, 104 ANN CONV AM PSYC; BIGLER ED, 1990, J CONSULT CLIN PSYCH, V58, P244, DOI 10.1037/0022-006X.58.2.244; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1994, PERCEPT MOTOR SKILL, V78, P1179, DOI 10.2466/pms.1994.78.3c.1179; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HEATON R, 1978, AM J PSYCHIAT, V153, P7; HISCOCK CK, 1994, J PSYCHOPATHOL BEHAV, V16, P95, DOI 10.1007/BF02232721; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; IVERSON GL, 1994, ARCH CLIN NEUROPSYCH, V9, P437, DOI 10.1016/0887-6177(94)90006-X; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; LARRABEE GJ, 1992, FORENSIC REPORTS, V5, P257; Lee G. P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI DOI 10.1037/1040-3590.4.1.43; LeesHaley PR, 1997, ASSESSMENT, V4, P321, DOI 10.1177/107319119700400402; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MENSCH AJ, 1986, INT J CLIN NEUROPSYC, V8, P59; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; Prigatano GP, 1997, ARCH CLIN NEUROPSYCH, V12, P609, DOI 10.1016/S0887-6177(97)00020-6; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; PRITCHARD D, 1992, FORENSIC REPORTS, V5, P287; Rey A., 1964, EXAMEN CLIN PSYCHOL; ROGERS R, 1988, CLIN ASSESSMENT MALI; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; Rosenthal R., 1991, METAANALYTIC PROCEDU, DOI 10.4135/9781412984997; SCHMIDT JP, 1989, PROF PSYCHOL-RES PR, V20, P140, DOI 10.1037/h0092792; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Trueblood W, 1997, ARCH CLIN NEUROPSYCH, V12, P13, DOI 10.1016/S0887-6177(96)00027-3; Wechsler, 1997, WECHSLER ADULT INTEL; WETTER MW, 1995, PROF PSYCHOL-RES PR, V26, P474, DOI 10.1037/0735-7028.26.5.474; WIDIGER TA, 1984, ARCH GEN PSYCHIAT, V41, P1005, DOI 10.1001/archpsyc.1984.01790210087011; Youngjohn, 1995, ASSESSMENT, V2, DOI [https://doi.org/10.1177/1073191195002003007, DOI 10.1177/1073191195002003007]; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	52	68	68	0	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590			PSYCHOL ASSESSMENT	Psychol. Assess.	JUN	1998	10	2					128	139		10.1037/1040-3590.10.2.128			12	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	ZW310	WOS:000074397400006					2022-02-06	
J	Kelly, JP; Rosenberg, JH				Kelly, JP; Rosenberg, JH			The development of guidelines for the management of concussion in sports	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; evidence-based guidelines; sports; traumatic brain injury	CEREBRAL CONCUSSION; HEAD-INJURIES; CONTACT-SPORTS; IMPACT; TRAUMA; MILD	Concussion in sports has caught the attention of the news media in recent years, primarily due to the high profile of certain athletes who have sustained traumatic brain injuries. Even though the management of concussion remains somewhat controversial, certain principles of neuroscience regarding mental status alterations and other symptoms resulting from concussion are well accepted by medical experts. Several authors have previously published management strategies for sports-related concussion based on their own experiences, but this article will describe the formal process of developing guidelines for the diagnosis and management of concussion in sports. The processes of literature review, evidence-based analysis, and consensus building are described. This article includes the grading scale, sideline evaluation, and management strategy adopted as a practice parameter by the American Academy of Neurology. Emphasis is placed on the need to detect mild forms of concussion through detailed observation and examination of athletes.	Rehabil Inst Chicago, Brain Injury Program, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Chicago, IL 60611 USA; So Calif Kaiser Permanente, San Diego, CA USA; Amer Acad Neurol, Disseminat Implementat & Outcomes Comm, Minneapolis, MN 55414 USA		Kelly, JP (corresponding author), Rehabil Inst Chicago, Brain Injury Program, 345 E Super St, Chicago, IL 60611 USA.						[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Barth JT, 1989, MILD HEAD INJURY; Bream H., 1996, ATHLETIC THERAPY TOD, V1, P7; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; *CO MED SOC, 1991, REP SPORTS MED COMM; Cooper PR, 1993, HEAD INJURY; DICK RW, 1994, HEAD NECK INJURIES S; Farber M, 1994, SPORTS ILLUSTRATED, p[38, 39, 46]; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JENKINS A, 1986, LANCET, V2, P445; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JUGER EC, 1997, J NEUROSURG, V86, P425; KELLY J, 1995, CURRENT THERAPY SPOR; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KELLY JP, 1995, BRAIN INJURY ASS TBI, V3, P3; KELLY JP, 1996, S SAFETY AM FOOTBALL; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1987, J NEUROSURG, V66, P707; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1971, P 11  STAP CAR CRASH; PLUM F, 1986, DIAGNOSIS STUPOR COM; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SKULTETY F, 1981, SEMIN NEUROL, V1, P275; STONE JL, 1993, HEAD INJURY ITS COMP; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; TORG JS, 1995, CURRENT THERAPY SPOR; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; YARNELL PR, 1970, LANCET, V1, P863; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; 1997, MMWR, V46, P224; 1966, CLIN NEUROSURG, V12, P386	48	68	68	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1998	13	2					53	65		10.1097/00001199-199804000-00008			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZF451	WOS:000072898800008	9575257				2022-02-06	
J	Faden, AI; Ivanova, SA; Yakovlev, AG; Mukhin, AG				Faden, AI; Ivanova, SA; Yakovlev, AG; Mukhin, AG			Neuroprotective effects of group III mGluR in traumatic neuronal injury	JOURNAL OF NEUROTRAUMA			English	Article						adenylyl cyclase; mRNA; neurons; NMDA receptor; RT-PCR; tissue culture	METABOTROPIC GLUTAMATE-RECEPTOR; SPINAL-CORD INJURY; AMINO-ACIDS; BRAIN INJURY; ACTIVATION; ANTAGONISTS; NMDA; NEUROTOXICITY; SELECTIVITY; DERIVATIVES	We have used an in vitro trauma model to examine the effects of modulation of group III metabotropic glutamate receptors (mGluR) on post-traumatic neuronal cell death, Rat cortical neuronal/glial cultures were subjected to standardized mechanical injury using a punch that delivers 28 parallel cuts to 96-well culture plates, resulting in approximately 50% neuronal cell loss in untreated cultures, RT-PCR demonstrated expression of mRNA for mGluR4, mGluR6, mGluR7, and mGluR8 in uninjured cultures as well as in adult rat brain, Treatment with the group III agonists L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) or L-serine-O-phosphate (L-SOP) resulted in dose-dependent neuroprotection, In contrast, treatment with the group III antagonists alpha-methyl-AP4 (MAP4) or (RS)-alpha-methylserine-O-phosphate (MSOP) caused dose-dependent exacerbation of injury, which was significantly attenuated by L-AP4 or L-SOP, The neuroprotective actions of L-AP4 or L-SOP were markedly reduced by the cyclic AMP analog 8-CPT-cAMP (500 mu m), which by itself had no effects at this concentration, Moreover, treatment with L-AP4 or L-SOP reduced basal cyclic AMP levels, Treatment with the NMDA antagonist MK 801 decreased post-traumatic cell death by 45% at optimal concentrations; combined treatment with MK 801 and group III agonists showed a significant enhancement of neuroprotection as compared to treatment with the NMDA antagonist alone, Our findings indicate a clear neuroprotective action for group III agonists in this model and suggest that group III mGluR are endogenously activated in response to trauma. The neuroprotective effects of group III agonists appear to result in part from modulation of adenylyl cyclase activity and are additive to those of an NMDA receptor antagonist.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Room EP-04, Washington, DC 20007 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634-07] Funding Source: Medline		AMADOR E, 1963, CLIN CHEM, V9, P391; Bruno V, 1996, EUR J PHARMACOL, V310, P61, DOI 10.1016/0014-2999(96)00358-5; Bruno V, 1997, J NEUROSCI, V17, P1891; Buisson A, 1996, EUR J NEUROSCI, V8, P138, DOI 10.1111/j.1460-9568.1996.tb01174.x; BUISSON A, 1995, EUR J PHARMACOL, V256, P109; BUSHELL TJ, 1995, NEUROPHARMACOLOGY, V34, P239, DOI 10.1016/0028-3908(95)00012-U; CHIAMULERA C, 1992, EUR J PHARMACOL, V216, P335, DOI 10.1016/0014-2999(92)90382-E; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONNOLLY BJ, 1992, BIOCHEM PHARMACOL, V44, P2303, DOI 10.1016/0006-2952(92)90673-7; COPANI A, 1995, MOL PHARMACOL, V47, P890; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P98; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GONG QZ, 1995, NEUROSCI LETT, V203, P211; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IVERSEN L, 1994, J NEUROCHEM, V63, P625; JANE DE, 1994, BRIT J PHARMACOL, V112, P809; Johansen P.A., 1995, UER J PHARM-MOLEC PH, pR1; KNOPFEL T, 1995, NEUROPHARMACOLOGY, V34, P1099, DOI 10.1016/0028-3908(95)00111-I; KRISTENSEN P, 1993, NEUROSCI LETT, V155, P159, DOI 10.1016/0304-3940(93)90697-J; LEVESQUE A, 1995, J IMMUNOL METHODS, V178, P71, DOI 10.1016/0022-1759(94)00243-P; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Maiese K, 1996, J NEUROCHEM, V66, P2419; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PANTER SS, 1994, PRINCIPLES PRACTICE, P32; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; REGAN RF, 1994, NEUROBIOLOGY CENTRAL, P173; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; SHEILLS RA, 1990, P ROYAL SOC B, V242, P91; Thomas NK, 1996, NEUROPHARMACOLOGY, V35, P637; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; Wroblewski J. T., 1996, Society for Neuroscience Abstracts, V22, P808; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	44	68	70	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1997	14	12					885	895		10.1089/neu.1997.14.885			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	YU127	WOS:000071685000001	9475370				2022-02-06	
J	Kelly, MP; Johnson, CT; Knoller, N; Drubach, DA; Winslow, MM				Kelly, MP; Johnson, CT; Knoller, N; Drubach, DA; Winslow, MM			Substance abuse, traumatic brain injury and neuropsychological outcome	BRAIN INJURY			English	Article							ACUTE ALCOHOL-INTOXICATION; CHRONIC COCAINE ABUSERS; SEVERE HEAD-INJURY; NERVOUS-SYSTEM; PREVALENCE; IMPAIRMENT; DEFICITS	The neuropsychological performance of 119 patients with severe closed traumatic brain injury (TBI) who had received toxicology screens at the time of trauma centre admission was examined. Three groups were created: normal screen, positive alcohol screen, or positive abused drugs screen (with or without the presence of alcohol). The admitting Glasgow Coma Scale (GCS) score was significantly lower in the positive alcohol screen group than the normal screen group, while the three groups did not differ in length of post-traumatic amnesia (PTA) or years of education. Neuropsychological assessment was conducted during inpatient rehabilitation: following resolution of PTA. Normal screen patients obtained significantly better scores than the abused-drugs patients on the Full Scale IQ (FIQ) and Verbal IQ (VIQ) indices of the Wechsler Adult Intelligence Scale--Revised and the Verbal Memory, General Memory, Attention-Concentration, and Delayed Recall indices of the Wechsler Memory Scale--Revised. Normal screen patients also scored significantly higher than positive alcohol screen patients on FIQ and VIQ indices and all five indices from the Wechsler Memory Scale-Revised. These data suggest the existence of an additive effect of substance abuse on neuropsychological outcome in TBI. Findings have potential implications for both acute management and rehabilitation of TBI.	TOWSON STATE UNIV, BALTIMORE, MD 21204 USA; TEL HASHOMER HOSP, KIRYAT ONO, ISRAEL		Kelly, MP (corresponding author), UNIV MARYLAND, MED SYST, SCH MED, R ADAMS COWLEY SHOCK TRAUMA CTR, 22 S GREENE ST, BALTIMORE, MD 21201 USA.						ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ARDILA A, 1991, INT J NEUROSCI, V57, P73, DOI 10.3109/00207459109150348; BENOWITZ NL, 1992, CIBA F SYMP, V166, P125; BERRY J, 1993, DRUG ALCOHOL DEPEN, V32, P231, DOI 10.1016/0376-8716(93)90087-7; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BROOKS N, 1984, CLOSED HEAD INJURY, P41; BROWN E, 1992, AM J ROENTGENOL, V159, P137, DOI 10.2214/ajr.159.1.1609688; Carroll KM, 1995, PSYCHOL ASSESSMENT, V7, P349, DOI 10.1037/1040-3590.7.3.349; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DICRESCITO V, 1974, SURG FORUM, V25, P438; Drubach D A, 1993, Md Med J, V42, P989; DRUBACH DA, 1994, CRIT CARE CLIN, V10, P635, DOI 10.1016/S0749-0704(18)30123-4; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; ELMER O, 1984, HAEMOSTASIS, V14, P223; ELMER O, 1985, ACTA CHIR SCAND, V151, P305; ELMER O, 1983, EUR SURG RES, V15, P268, DOI 10.1159/000128367; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Heaton RK, 1991, COMPREHENSIVE NORMS; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JOHNSON WD, 1969, YALE J BIOL MED, V42, P71; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; LOBERG T, 1986, NEUROPSYCHOLOGICAL A, P415; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MARR JJ, 1975, J LAB CLIN MED, V86, P253; McQueen J D, 1975, Surg Neurol, V4, P375; MILNER G, 1977, MED J AUSTRALIA, V1, P208, DOI 10.5694/j.1326-5377.1977.tb130632.x; MITTENBERG W, 1993, ARCH CLIN NEUROPSYCH, V8, P477, DOI 10.1016/0887-6177(93)90048-6; MUIR JK, 1995, J NEUROTRAUM, V12, P87, DOI 10.1089/neu.1995.12.87; MUIR JK, 1995, AM J PHYSIOL-HEART C, V268, pH68, DOI 10.1152/ajpheart.1995.268.1.H68; OMALLEY S, 1992, AM J DRUG ALCOHOL AB, V18, P131, DOI 10.3109/00952999208992826; PFENNINGER E, 1987, RESUSCITATION, V15, P125, DOI 10.1016/0300-9572(87)90023-2; PRAKASH A, 1993, INT J CLIN PHARM TH, V31, P575; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Rosselli M, 1996, J CLIN EXP NEUROPSYC, V18, P122, DOI 10.1080/01688639608408268; ROUNSAVILLE BJ, 1982, J NERV MENT DIS, V170, P209, DOI 10.1097/00005053-198204000-00005; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; SPRADEO FR, 1989, J HEAD TRAUMA REHAB, V4, P75; STRATTON R, 1981, ALCOHOL CLIN EXP RES, V5, P56; TURNETH SS, 1990, RADIOLOGY, V176, P821; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; WOOLF PD, ALCOHOLISM CLIN EXPT, V14, P205; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	54	68	69	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	1997	11	6					391	402		10.1080/026990597123386			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	WZ726	WOS:A1997WZ72600001	9171925				2022-02-06	
J	Sander, AM; Seel, RT; Kreutzer, JS; Hall, KM; High, WM; Rosenthal, M				Sander, AM; Seel, RT; Kreutzer, JS; Hall, KM; High, WM; Rosenthal, M			Agreement between persons with traumatic brain injury and their relatives regarding psychosocial outcome using the community integration questionnaire	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; FOLLOW-UP; SOCIAL-ADJUSTMENT; RECOVERY	Objective: To extend psychometric research on the Community Integration Questionnaire (CIQ) by comparing patients' reports with those of family members. Design: Reports on community integration were obtained from family members and patients 1 year after brain injury. Kappa reliability coefficients were used to examine agreement for individual items on the questionnaire. Total scores for the three CIQ scales were compared between groups using independent samples t tests. Setting: Outpatient clinics affiliated with the four NIDRR traumatic brain injury Model System rehabilitation centers. Participants: CIQ data were obtained for 259 adult patients with traumatic brain injury. For 122 cases, patients and family members provided corresponding data. In 101 cases, only self-reported data were available. In 36 cases, information was provided solely by family members. All patients received inpatient rehabilitation and were at least 16 years of age. The full range of brain injury severity was represented. Main Outcome Measure: The 15-item CIQ, comprised of three scales, Home Integration, Productive Activity, and Social Integration. Results: Analysis of kappa values found ''moderate'' to ''almost perfect'' agreement levels for all 15 items. Almost-perfect ratings were found for three of the four items on the Productive Activity Scale. Comparisons were made between scale scores derived from patients and families. The Home Integration scale showed differences, with patient scores higher than those reported by family members (t=3.51, p<.01). However, the difference in scores was attributable to small discrepancies on two items and was not considered clinically meaningful. The Total CIQ score also showed a difference, with patients reporting significantly higher levels of integration relative to family members (t=2.30, p<.05). This difference was also attributable to discrepancies on two items of the Home Integration Scale. Conclusions: The results have important implications for researchers who may be limited to one source of data. The hypothesis that patients and family members have very different perspectives of patients' community activities was not supported. Rather, similar ratings of individual activities were given with two exceptions, meal preparation and housekeeping. More research is needed to delineate relationships between agreement ratings and outcome categories. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, RICHMOND, VA 23298 USA; SANTA CLARA VALLEY MED CTR, DEPT PHYS MED & REHABIL, SAN JOSE, CA 95128 USA; BAYLOR COLL MED, INST REHABIL & RES, DEPT PHYS MED & REHABIL, HOUSTON, TX USA; WAYNE STATE UNIV, REHABIL INST MICHIGAN, DEPT PHYS MED & REHABIL, DETROIT, MI 48202 USA								BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; *COMM ACCR REH FAC, 1996, 1996 STAND MED REH; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; SHEIKH K, 1986, ARCH PHYS MED REHAB, V67, P245; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	20	68	68	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1997	78	4					353	357		10.1016/S0003-9993(97)90225-2			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	WT595	WOS:A1997WT59500005	9111453				2022-02-06	
J	Marion, DW; White, MJ				Marion, DW; White, MJ			Treatment of experimental brain injury with moderate hypothermia and 21-aminosteroids	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia; 21-aminosteroids; traumatic brain injury; secondary brain injury; axonal injury	EXPERIMENTAL HEAD-INJURY; RADICAL FORMATION; RAT-BRAIN; U74006F; DAMAGE; EDEMA; INHIBITION; MODEL	Studies of experimental traumatic brain injury have found that histologic injury is significantly reduced and behavioral outcome improved in animals treated with moderate hypothermia (32-33 degrees C) or a 21-aminosteroid. Because these treatments are thought to work through different neurochemical mechanisms, their combined use might be expected to be more efficacious than either treatment alone. To test this hypothesis, we studied each treatment separately and in combination in a rodent model of controlled cortical contusion. Treatment with moderate hypothermia (32 degrees C for 4 h), a 21-aminosteroid (U-74389G, Upjohn, 10 mg/kg intravenously, repeated 3 h after the first dose), or both, was initiated 10, 25, or 40 min after injury. The brains were perfused 24 h after injury, and sagittal sections were stained for the 68-kDa ''core'' neurofilament subunit, a marker of axonal injury. The total number of positively stained axons in the ipsilateral internal capsule were counted under light microscopy. Compared with the control group (injury but no treatment), treatment with each therapy alone or combined, initiated 10 min after injury, caused significant reductions in the number of stained axons (21-aminosteroid alone-35% reduction; hypothermia alone-55% reduction; combination-48% reduction). The number of positively stained axons was significantly reduced in the aminosteroid and combination therapy groups at all three postinjury times (p = 0.01) and in the hypothermia groups treated at 10 or 25 min (p = 0.01) but not at 40 min after injury. We concluded that combination therapy with hypothermia and 21-aminosteroids was no more efficacious than either therapy alone, and that 21-aminosteroid therapy was more efficacious than hypothermia when treatment was initiated 40 min after injury.			Marion, DW (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT NEUROL SURG,SUITE B400,200 LOTHROP ST,PITTSBURGH,PA 15213, USA.		Marion, Donald/AAR-5749-2021				ARAKI N, 1991, J CEREB BLOOD FLO S2, V11, pS843; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; Dietrich W, 1991, J CEREB BLOOD FLO S2, V11, pS846; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GINSBERG MD, 1989, J CEREB BLOOD FLO S1, V9, P380; HALL ED, 1988, BRAIN RES, V451, P350, DOI 10.1016/0006-8993(88)90782-2; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Jennett W B, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P172; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1993, MOL CHEM NEUROPATHOL, V18, P247; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; LEWIS DA, 1970, J PHARM PHARMACOL, V22, P902, DOI 10.1111/j.2042-7158.1970.tb08471.x; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; SANADA T, 1993, J NEUROTRAUM, V10, P65, DOI 10.1089/neu.1993.10.65; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	36	68	71	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1996	13	3					139	147		10.1089/neu.1996.13.139			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	UD469	WOS:A1996UD46900003	8965323				2022-02-06	
J	Dowd, MD; Krug, S				Dowd, MD; Krug, S			Pediatric blunt cardiac injury: Epidemiology, clinical features, and diagnosis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							MYOCARDIAL CONTUSION; CHEST TRAUMA; THORACIC TRAUMA; CHILDREN	Aim: The goal of this study was to describe the epidemiology, clinical presentation, diagnostic methods, and outcome in a large series of children with blunt cardiac injury (BCI). Methods: A multicenter retrospective review of all individuals less than 18 years of age diagnosed with a BCI from 1983 to 1993 was conducted. Cases included all those with a discharge diagnosis of myocardial contusion, concussion, ventricular disruption, or unspecified BCI. Results: A total of 184 cases of BCI were identified in 16 participating centers. The median age was 7.4 years, and 73% were male. Myocardial contusions accounted for 95% of the diagnoses. The leading mechanisms were motor vehicle crashes involving a pedestrian (39.7%) or passenger (31.0%). The majority (87%) had multiple system trauma, with a mean Injury Severity Score of 27.2 (SD +/- 14.4). Pulmonary contusions were present in 50.5% and rib fractures in 23.0%. The most common diagnostic test performed was a 12-lead electrocardiogram (EKG) (82%), followed by a MB band of creatine phosphokinase (CPK-MB) (69%) and echocardiogram (65%). All three tests were performed in 50%. In these patients, agreement among various diagnostic test pairs was fair (echocardiogram vs. EKG, kappa = 0.27) to poor (echocardiogram vs, CPK-MB, kappa = -0.07 and EKG vs. CPK-MB, kappa = 0.08). No hemodynamically stable patient who presented with a normal sinus rhythm subsequently developed a cardiac arrhythmia or cardiac failure. There were 25 deaths (13.6%), 3 of which were caused by acute pump failure secondary to massive cardiac injury. The remainder died of head or abdominal injuries. Of the 159 (86.4%) patients surviving, 8 (5% of survivors) had significant cardiac sequela, most commonly mitral or tricuspid insufficiency or ventricular septal defect. Conclusions: Pediatric BCI is usually diagnosed in the context of severe multiple system trauma and is less commonly an isolated event. Because of the lack of a standard, various diagnostic tests are used in the diagnosis of BCI, and these tests rarely agree. In hospitalized pediatric patients with BCI, unanticipated complications are rare. Significant sequela, although uncommon, do occur and follow-up of children with BCI should be ensured.	CHILDRENS MEM HOSP,DIV GEN & EMERGENCY MED,CHICAGO,IL 60614		Dowd, MD (corresponding author), CHILDRENS HOSP,MED CTR,DIV EMERGENCY MED,3333 BURNET AVE,CINCINNATI,OH 45229, USA.				BHP HRSA HHS [T32 PE10002] Funding Source: Medline		[Anonymous], 1990, ABBREVIATED INJURY S; BAXER BT, 1989, AM J SURG, V158, P557; BODIN L, 1988, CHEST, V94, P72, DOI 10.1378/chest.94.1.72; COOPER A, 1992, PEDIAT EMERGENCY MED, P261; DEMUTH WE, 1967, J TRAUM, V7, P443, DOI 10.1097/00005373-196705000-00009; EICHELBERGER MR, 1988, J TRAUMA, V28, P1109, DOI 10.1097/00005373-198808000-00002; FABIAN TC, 1988, J TRAUMA, V28, P50, DOI 10.1097/00005373-198801000-00007; GOLLADAY ES, 1979, J TRAUMA, V19, P526, DOI 10.1097/00005373-197919070-00008; HEALEY MA, 1990, J TRAUMA, V30, P137, DOI 10.1097/00005373-199002000-00002; HELLING TS, 1989, J TRAUMA, V29, P961, DOI 10.1097/00005373-198907000-00009; HOSSACK KF, 1988, AM J CARDIOL, V6, P1391; ILDSTAD ST, 1990, J PEDIATR SURG, V25, P287, DOI 10.1016/0022-3468(90)90066-I; KISSANE RW, 1952, CIRCULATION, V6, P421, DOI 10.1161/01.CIR.6.3.421; Krasna M J, 1992, Semin Thorac Cardiovasc Surg, V4, P195; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LANGER JC, 1989, J PEDIATR SURG, V24, P1091, DOI 10.1016/S0022-3468(89)80225-8; LAU VK, 1981, J TRAUMA, V21, P39, DOI 10.1097/00005373-198101000-00007; LIEDTKE AJ, 1974, AM J PHYSIOL, V226, P377, DOI 10.1152/ajplegacy.1974.226.2.377; LIEDTKE AJ, 1973, AM HEART J, V86, P687, DOI 10.1016/0002-8703(73)90349-9; MACDONALD RC, 1981, INTENS CARE MED, V7, P265, DOI 10.1007/BF01709720; MARVIN RF, 1973, AM J CARDIOL, V32, P723, DOI 10.1016/S0002-9149(73)80069-4; MCLEAN RF, 1992, J TRAUMA, V33, P240, DOI 10.1097/00005373-199208000-00013; NAKAYAMA DK, 1989, ANN SURG, V210, P770, DOI 10.1097/00000658-198912000-00013; NORTON MJ, 1990, AM J SURG, V160, P577, DOI 10.1016/S0002-9610(05)80749-4; PECLET MH, 1990, J PEDIATR SURG, V25, P961, DOI 10.1016/0022-3468(90)90238-5; RHEUBAN KS, 1981, J TRAUMA, V21, P170, DOI 10.1097/00005373-198102000-00015; ROUX P, 1992, J PEDIATR SURG, V27, P551, DOI 10.1016/0022-3468(92)90443-B; SABBAH HN, 1989, J TRAUMA, V29, P175, DOI 10.1097/00005373-198902000-00005; SCHROEDER JS, 1972, BRIT HEART J, V34, P645; SMYTH ST, 1979, J PEDIATR SURG, V14, P1441; TELLEZ DW, 1987, J PEDIATR SURG, V22, P1123, DOI 10.1016/S0022-3468(87)80721-2; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; WAXMAN K, 1986, ARCH SURG-CHICAGO, V121, P689; WISNER DH, 1990, ANN SURG, V212, P82, DOI 10.1097/00000658-199007000-00011; 1990, TXB PEDIATRIC ADV LI; 1994, INT CLASSIFICATION D	36	68	70	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1996	40	1					61	67		10.1097/00005373-199601000-00012			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	TU074	WOS:A1996TU07400013	8577001				2022-02-06	
J	FOX, DD; LEESHALEY, PR; EARNEST, K; DOLEZALWOOD, S				FOX, DD; LEESHALEY, PR; EARNEST, K; DOLEZALWOOD, S			BASE RATES OF POSTCONCUSSIVE SYMPTOMS IN HEALTH MAINTENANCE ORGANIZATION PATIENTS AND CONTROLS	NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; IMPAIRMENT	This study was intended to provide a normative comparison for determining the base rates of postconcussive syndrome (PCS) symptoms in patients from 4 medical departments of a health maintenance organization (HMO) and in people without acute medical or psychological complaints (controls). Recent research suggests that both neurologic and psychosocial factors influence these symptoms. Participants were 1,116 individuals who were surveyed regarding various symptoms, including those reported to be common in the PCS. Endorsement rates are presented for each PCS symptom for controls, each medical sample, and those people with a recent history of being knocked unconscious (2.3%), bumping their heads without losing consciousness (7.4%), and lawsuit involvement (6.8%), which were independently related to most PCS symptoms. The data indicate that neurologic, psychological, and environmental variables are related to having PCS complaints, and such factors should be considered before PCS complaints are used as evidence for brain damage.	LEES HALEY PSYCHOL CORP,ENCINO,CA; SO CALIF KAISER PERMANENTE,PANORAMA CITY,CA								American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOLLA KI, 1991, ARCH NEUROL-CHICAGO, V48, P61, DOI 10.1001/archneur.1991.00530130069022; DAVIDOFF DA, 1988, COGNITIVE REHABI MAR, P8; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; GFELLER JD, 1993, 13TH ANN M NAT AC NE; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MACKAY R P, 1960, Ind Med Surg, V29, P200; MELENDEZ F, 1994, ADULT NEUROPSYCHOLOG; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; NEWMAN B, 1992, NEW YORK U MED CTR R, V4, P3; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODONNELL WE, 1993, J CLIN PSYCHOL, V49, P372, DOI 10.1002/1097-4679(199305)49:3<372::AID-JCLP2270490311>3.0.CO;2-K; OHARA C, 1994, COGNITIVE SYMPTOMS C; *PSYCH ASS RES, 1994, SPRING 1994 CATALOG; Rattan G, 1987, Arch Clin Neuropsychol, V2, P257, DOI 10.1016/0887-6177(87)90013-8; REITAN R, 1992, AUG ANN M AM PSYCH A; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1977, LANCET, V1, P1; SCHINKA JA, 1994, NEUROPSYCHOLOGICAL S; SEIDENBERG M, 1994, ARCH CLIN NEUROPSYCH, V9, P353, DOI 10.1016/0887-6177(94)90023-X; WONG JM, 1993, 13TH ANN M NAT AC NE; [No title captured]	29	68	69	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	OCT	1995	9	4					606	611		10.1037/0894-4105.9.4.606			6	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	TA644	WOS:A1995TA64400019					2022-02-06	
J	HAYES, RL; YANG, K; RAGHUPATHI, R; MCINTOSH, TK				HAYES, RL; YANG, K; RAGHUPATHI, R; MCINTOSH, TK			CHANGES IN GENE-EXPRESSION FOLLOWING TRAUMATIC BRAIN INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article						BRAIN INJURY; GENE EXPRESSION; IMMEDIATE EARLY GENES; CYTOKINES	NERVE GROWTH-FACTOR; HEAT-SHOCK PROTEIN; C-FOS PROTEIN(S); CEREBELLAR GRANULE CELLS; FACTOR MESSENGER-RNA; CEREBRAL-ISCHEMIA; DIFFERENTIAL REGULATION; NEUROTROPHIC FACTOR; TRANSIENT ISCHEMIA; PRIMARY CULTURES	This paper reviews changes in gene expression produced by two rodent models of traumatic brain injury: cortical impact injury and fluid-percussion injury. Cortical impact injury produces transient increases in c-fos mRNA expression, which begin as early as 5 min after injury and subsides by 1 day after injury in the cerebral cortex ipsilateral to injury. In addition, AP-1 transcription factor binding is greatly increased in the injured cerebral cortex at 1, 3, and 5 h post-injury. AP-1 binding remains increased for at least I day after injury, while SP-1 transcription factor binding activity does not increase. Additional studies have confirmed increases in c-fos mRNA expression in the hippocampus at 30 min, 1 h, and 3 h after injury. These increases in c-fos mRNA in the hippocampus preceded increased levels of NGF mRNA that were detected at 1 and 3 h but not at 30 min following injury. Following fluid-percussion injury, increases in c-fos mRNA can be detected as early as 2 h following injury in the cortex ipsilateral to the site of injury as well as in the hippocampus. Heat-shock protein (hsp72) mRNA is also increased in the ipsilateral cortex and hippocampus following fluid percussion injury. By 24 h post-injury, both c-fos and hsp72 gene expression return to control levels. Severe but not moderate fluid percussion injury produces increased gene expression for glucose-regulated proteins (grp78, grp94) 12 h following injury. Fluid-percussion injury also produces significant increases in expression of both interleukin-1 beta and tumor necrosis factor-alpha in the injured cortex and ipsilateral hippocampus as early as 1 h post-injury, that remains elevated up to 6 h in the injured cortex and hippocampus.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV PENN,MED CTR,DEPT BIOCHEM,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19104		HAYES, RL (corresponding author), UNIV PENN,MED CTR,DEPT NEUROSURG,105 HAYDEN HALL,3220 SMITH WALK,PHILADELPHIA,PA 19104, USA.		Raghupathi, Ramesh/AAX-5538-2021				AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BAIMBRIDGE KG, 1982, BRAIN RES, V239, P519, DOI 10.1016/0006-8993(82)90526-1; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHAN RKW, 1993, J NEUROSCI, V13, P5126, DOI 10.1523/JNEUROSCI.13-12-05126.1993; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dekosky S. T., 1994, Society for Neuroscience Abstracts, V20, P193; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRAGUNOW M, 1987, NEUROSCI LETT, V82, P157, DOI 10.1016/0304-3940(87)90121-2; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAN L, 1994, J NEUROTRAUM, V11, P108; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GALL C, 1991, MOL BRAIN RES, V9, P113, DOI 10.1016/0169-328X(91)90136-L; GALL C, 1991, EPILEPSY RES S, V4, P225; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HASHIMOTO Y, 1992, NEUROSCI LETT, V139, P45, DOI 10.1016/0304-3940(92)90853-Y; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HUGHES P, 1993, NEUROSCI LETT, V150, P122, DOI 10.1016/0304-3940(93)90122-2; JEHAN F, 1993, J NEUROCHEM, V60, P1843, DOI 10.1111/j.1471-4159.1993.tb13411.x; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KAMINSKA B, 1993, NEUROSCI LETT, V153, P189, DOI 10.1016/0304-3940(93)90319-G; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KRUUER W, 1985, P NATL ACAD SCI USA, V82, P7330; LADENHEIM RG, 1993, J NEUROCHEM, V60, P260, DOI 10.1111/j.1471-4159.1993.tb05846.x; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH B G, 1991, Society for Neuroscience Abstracts, V17, P165; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1989, NEUR ABSTR, V15, P132; MOCCHETTI I, 1989, P NATL ACAD SCI USA, V86, P3891, DOI 10.1073/pnas.86.10.3891; MORGAN JI, 1991, TRENDS PHARMACOL SCI, V12, P343, DOI 10.1016/0165-6147(91)90594-I; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORGAN PF, 1991, NEUROREPORT, V2, P251, DOI 10.1097/00001756-199105000-00009; NOWAK TS, 1990, STROKE, V21, P107; NOWAK TS, 1990, CEREBROVAS BRAIN MET, V2, P345; PENG ZC, 1993, BRAIN RES, V632, P57, DOI 10.1016/0006-8993(93)91138-I; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PIERCE JES, 1995, IN PRESS J NEUROSCI; PRASAD MR, 1994, IN PRESS J NEUROCHEM; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAGHUPATHI R, 1995, IN PRESS MOL BRAIN R; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROCAMORA N, 1992, MOL BRAIN RES, V13, P27, DOI 10.1016/0169-328X(92)90041-9; RUZDIJIC S, 1993, BRAIN RES, V69, P230; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SHARP FR, 1989, NEUROSCI LETT, V100, P117, DOI 10.1016/0304-3940(89)90670-8; SHOZUHARA H, 1992, J NEUROCHEM, V59, P175, DOI 10.1111/j.1471-4159.1992.tb08888.x; SMEAL T, 1986, GENE DEV, V3, P2091; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOARES HD, 1995, IN PRESS J NEUROSCI; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1987, NEUROPHARMACOLOGY, V26, P1779, DOI 10.1016/0028-3908(87)90132-8; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TURNER R, 1989, SCIENCE, V243, P1659; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG K, UNPUB BRAIN RES; YANG K, 1993, P SOC NEUROSCI, V767, P1880; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; ZHENG M, 1988, MOL BRAIN RES, V3, P133, DOI 10.1016/0169-328X(88)90058-7	88	68	73	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					779	790		10.1089/neu.1995.12.779			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600003	8594207				2022-02-06	
J	RAGHUPATHI, R; WELSH, FA; LOWENSTEIN, DH; GENNARELLI, TA; MCINTOSH, TK				RAGHUPATHI, R; WELSH, FA; LOWENSTEIN, DH; GENNARELLI, TA; MCINTOSH, TK			REGIONAL INDUCTION OF C-FOS AND HEAT-SHOCK PROTEIN-72 MESSENGER-RNA FOLLOWING FLUID-PERCUSSION BRAIN INJURY IN THE RAT	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						BRAIN INJURY; HEAT SHOCK PROTEINS; IMMEDIATE EARLY GENES; IN SITU HYBRIDIZATION	NERVE GROWTH-FACTOR; GLIAL-LIKE CELLS; TRANSCRIPTION FACTOR; ISCHEMIA; SIGNALS; GENE; IMMUNOREACTIVITY; ACTIVATION; EXPRESSION; BREAKDOWN	To evaluate the cellular response to traumatic brain injury, the expression of mRNA for c-fos and the 72-kDa heat shock protein (hsp72) was determined using in situ hybridization following lateral fluid-percussion in jury (2.2-2.4 atm) in rat brain. At 2 h after injury, induction of c-fos mRNA was observed throughout the cortex ipsilateral to the site of injury, while increased expression of hsp72 mRNA was restricted to regions of the cortex surrounding the contusion area. An increase in c-fos mRNA, but not hsp72 mRNA, was observed bilaterally in the CA, subfield of the hippocampus and the granule cells of the dentate gyrus and in the thalamus ipsilateral to the impact site. By 6 h, increased expression of c-fos mRNA was observed only in the corpus callosum on the impact side; hsp72 mRNA persisted in the deep cortical layers and upper layers of the subcortical white matter below the site of maximal injury. By 24 h, both c-fos and hsp72 mRNA had returned to control levels in all regions of the brain. These results demonstrate that lateral fluid-percussion brain injury triggers regionally and temporally specific expression of c-fos and hsp72 mRNA, which may be suggestive of differential neurochemical alterations in neurons and glia following experimental brain injury.	UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,EPILEPSY RES LAB,SAN FRANCISCO,CA 94143		RAGHUPATHI, R (corresponding author), UNIV PENN,DEPT SURG,DIV NEUROSURG,RM 105,HAYDEN HALL,240 S 33 ST,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R55NS026818, R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS26818] Funding Source: Medline		ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ARENANDER A, 1992, PROG BRAIN RES, V94, P177; BENJAMIN IJ, 1992, J CLIN INVEST, V89, P1685, DOI 10.1172/JCI115768; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CURRAN T, 1987, ONCOGENE, V2, P79; DRAGUNOW M, 1989, BRAIN RES, V501, P382, DOI 10.1016/0006-8993(89)90655-0; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; MCINTOSH T, 1989, Society for Neuroscience Abstracts, V15, P132; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MONSTEIN HJ, 1993, NEUROREPORT, V4, P195, DOI 10.1097/00001756-199302000-00020; MORGAN JI, 1991, TRENDS PHARMACOL SCI, V12, P343, DOI 10.1016/0165-6147(91)90594-I; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NOWAK TS, 1990, STROKE, V21, P107; NOWAK TS, 1990, CEREBROVAS BRAIN MET, V2, P345; PHILIPS LL, 1993, J NEUROTRAUM, V9, P323; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	33	68	74	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	1995	15	3					467	473		10.1038/jcbfm.1995.58			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	QT257	WOS:A1995QT25700015	7714005	Bronze			2022-02-06	
J	BUDENZ, DL; FARBER, MG; MIRCHANDANI, HG; PARK, H; RORKE, LB				BUDENZ, DL; FARBER, MG; MIRCHANDANI, HG; PARK, H; RORKE, LB			OCULAR AND OPTIC-NERVE HEMORRHAGES IN ABUSED INFANTS WITH INTRACRANIAL INJURIES	OPHTHALMOLOGY			English	Article							SHAKEN BABY SYNDROME; PERMANENT BRAIN-DAMAGE; RETINAL HEMORRHAGE; CHILD-ABUSE; CARDIOPULMONARY RESUSCITATION; COMPUTED-TOMOGRAPHY; MENTAL-RETARDATION; AUTOPSY FINDINGS; YOUNG-CHILDREN; HEAD-INJURY	Purpose: To ascertain whether the pathology of the eye and optic nerve might be useful in determining the manner of death in infants who died after sustaining apparent nonaccidental intracranial injury. Methods: Complete autopsies were performed on 13 infants who died of acute intracranial injuries after nonaccidental trauma. The infants were divided into two groups: nine with physical evidence of blunt trauma to the head, and four without detectable scalp or skull injury whose intracranial injuries were attributed to violent shaking (shaken baby syndrome). Six infants with no intracranial injuries who died suddenly from unidentifiable causes (the so-called sudden infant death syndrome) served as controls. Results: Optic nerve sheath hemorrhage, most prominent in the subdural space, was present in all 13 infants with nonaccidental intracranial injury. Multilayered retinal hemorrhage was present in at least one eye of 11 of these 13 infants. The location and quantity of the intraocular and optic nerve sheath hemorrhages did not differ in those with external head trauma and those without scalp or skull lesions. A single control infant had a few erythrocytes in the nerve fiber layer of the anterior optic nerve of one eye. The remainder of the control infants did not have evidence of hemorrhage in the eye or optic nerve sheath. Conclusion: Histopathologic analysis of optic nerve sheath and intraocular hemorrhages may be helpful in distinguishing traumatic from non-traumatic causes of death in infants.	CHILDRENS HOSP PHILADELPHIA,DEPT PATHOL,PHILADELPHIA,PA 19104; OFF MED EXAMINER,PHILADELPHIA,PA		BUDENZ, DL (corresponding author), UNIV PENN,SCHEIE EYE INST,WILLIAM C FRAYER LAB EYE PATHOL,51 N 39TH ST,PHILADELPHIA,PA 19104, USA.						AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BUYS YM, 1992, OPHTHALMOLOGY, V99, P1718; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CARR RE, 1963, AM J OPHTHALMOL, V56, P23, DOI 10.1016/0002-9394(63)91296-0; CRISOSTOMO EA, 1986, DEV MED CHILD NEUROL, V28, P68; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EISENBREY AB, 1979, CHILD BRAIN, V5, P40; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; FRANK Y, 1985, DEV MED CHILD NEUROL, V27, P312; FRIENDLY D S, 1971, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V75, P318; GIANGIACOMO J, 1988, OPHTHALMOLOGY, V95, P295; GILES CL, 1960, AM J OPHTHALMOL, V49, P1005, DOI 10.1016/0002-9394(60)91824-9; GILKES MJ, 1967, LANCET, V2, P468; GILLILAND MGF, 1991, ARCH OPHTHALMOL-CHIC, V109, P321; GOETTING MG, 1990, PEDIATRICS, V85, P585; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; GUYER DR, 1989, OPHTHALMOLOGY, V96, P860; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HARCOURT B, 1971, BMJ-BRIT MED J, V3, P398, DOI 10.1136/bmj.3.5771.398; HARLEY RD, 1980, J PEDIAT OPHTH STRAB, V17, P5; HOLT JM, 1969, BRIT J OPHTHALMOL, V53, P145, DOI 10.1136/bjo.53.3.145; JAIN IS, 1980, J PEDIAT OPHTH STRAB, V17, P14; Jensen AD, 1971, J PEDIATR OPHTHALMOL, V8, P270; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; KIFFNEY GT, 1964, ARCH OPHTHALMOL-CHIC, V72, P231; KINCAID MC, 1983, SURV OPHTHALMOL, V27, P211, DOI 10.1016/0039-6257(83)90123-6; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; MCCURTY K, 1993, 1992 ANN 50 STAT SUR; MCLELLAN NJ, 1986, ARCH DIS CHILD, V61, P1130, DOI 10.1136/adc.61.11.1130; MERIN S, 1968, AM J OPHTHALMOL, V66, P1102, DOI 10.1016/0002-9394(68)90818-0; MITCHEL L, 1987, CHILD ABUSE NEGLECT; MULLER PJ, 1974, J NEUROSURG, V41, P160, DOI 10.3171/jns.1974.41.2.0160; MUSHIN A, 1971, BRIT J OPHTHALMOL, V55, P343, DOI 10.1136/bjo.55.5.343; MUSHIN AS, 1971, BRIT MED J, V3, P402, DOI 10.1136/bmj.3.5771.402; NISHIO A, 1991, SURG NEUROL, V35, P224, DOI 10.1016/0090-3019(91)90075-K; OBER RR, 1980, J PEDIAT OPHTH STRAB, V17, P17; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; RIFFENBURGH RS, 1991, J FORENSIC SCI, V36, P741; RIFFENBURGH RS, 1991, OPHTHALMOLOGY, V98, P1519; RIVARA FP, 1988, PEDIATRICS, V81, P93; Robb R M, 1978, Trans Am Ophthalmol Soc, V76, P90; RUBENSTE.RA, 1968, AM J OPHTHALMOL, V65, P435, DOI 10.1016/0002-9394(68)93098-5; SEZEN F, 1970, BR J OPHTHALMOL, V55, P248; TILL K, 1968, BRIT MED J, V3, P400, DOI 10.1136/bmj.3.5615.400; VAPALAHT.PM, 1969, J NEUROSURG, V30, P169, DOI 10.3171/jns.1969.30.2.0169; WALSH FB, 1951, AM J OPHTHALMOL, V34, P509, DOI 10.1016/0002-9394(51)90294-2; WILKINSON WS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1472, DOI 10.1001/archopht.1989.01070020546037; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; 1988, CALIFORNIAS RECORDS	53	68	69	0	3	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0161-6420			OPHTHALMOLOGY	Ophthalmology	MAR	1994	101	3					559	565					7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	NB220	WOS:A1994NB22000031	8127577				2022-02-06	
J	SCHALEN, W; MESSETER, K; NORDSTROM, CH				SCHALEN, W; MESSETER, K; NORDSTROM, CH			CEREBRAL VASOREACTIVITY AND THE PREDICTION OF OUTCOME IN SEVERE TRAUMATIC BRAIN-LESIONS	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						CEREBRAL BLOOD FLOW; CEREBRAL METABOLISM; HEAD INJURY; OUTCOME; VASOREACTIVITY	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; MULTIMODALITY EVOKED-POTENTIALS; LEVEL SCALE RLS85; BLOOD-FLOW; INTRAVENTRICULAR PRESSURE; XENON-133 INHALATION; COMATOSE PATIENTS; ACUTE PHASE; METABOLISM	Mean hemispheric blood flow (CBF) was studied in 38 comatose, severely brain-injured patients following intravenous administration of xenon-133. Repeated measurements were performed in order to evaluate cerebral vasoreactivity following a decrease in Paco2. Simultaneously, arterial-venous oxygen differences (AVDo2) and intracranial pressure (ICP) were measured. An impaired CBF response to hyperventilation (DELTA-CBF/DELTA-Paco2 < 1.0) was obtained in 22 patients. Three of 16 patients with preserved CO2-reactivity died because of their brain injuries and 12 patients reached good recovery/moderate disability. In the group of patients with impaired vasoreactivity 11 of 22 patients died and only three patients reached good recovery/moderate disability. The study documents that in patients with severe traumatic brain lesions measurements of cerebral vasoreactivity to hyperventilation give prognostic information that is not obtained by clinical observations or CT-scanning.	UNIV LUND HOSP, DEPT NEUROSURG, S-22185 LUND, SWEDEN; UNIV LUND HOSP, DEPT ANESTHESIOL, S-22185 LUND, SWEDEN								ALEXANDER SC, 1965, ANESTHESIOLOGY, V26, P624, DOI 10.1097/00000542-196509000-00007; ALEXANDER SC, 1968, J APPL PHYSIOL, V24, P66, DOI 10.1152/jappl.1968.24.1.66; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183, DOI 10.1152/jappl.1967.23.2.183; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P249, DOI 10.1111/j.1399-6576.1978.tb01299.x; ENEVOLDSEN EM, 1977, J NEUROSURG, V47, P699, DOI 10.3171/jns.1977.47.5.0699; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GOTTSTEIN U, 1963, KLIN WOCHENSCHR, V41, P943, DOI 10.1007/BF01478536; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1980, J NEUROL NEUROSUR PS, V43, P289, DOI 10.1136/jnnp.43.4.289; JENNETT B, 1976, LANCET, V1, P1031; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nordstrom C H, 1989, Brain Inj, V3, P267, DOI 10.3109/02699058909029640; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1975, STROKE, V6, P245, DOI 10.1161/01.STR.6.3.245; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OBRIST WD, 1985, CEREBRAL BLOOD FLOW, P30; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; RISBERG J, 1975, STROKE, V6, P142, DOI 10.1161/01.STR.6.2.142; STALHAMMAR D, 1988, ACTA NEUROCHIR, V90, P73, DOI 10.1007/BF01560558; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; SUNDBARG G, 1987, J NEUROSURG, V67, P841, DOI 10.3171/jns.1987.67.6.0841; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603; TEASDALE G, 1974, LANCET, V2, P81	45	68	68	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	1991	35	2					113	122		10.1111/j.1399-6576.1991.tb03258.x			10	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	EY354	WOS:A1991EY35400005	1902616				2022-02-06	
J	ISHIGE, N; PITTS, LH; POGLIANI, L; HASHIMOTO, T; NISHIMURA, MC; BARTKOWSKI, HM; JAMES, TL				ISHIGE, N; PITTS, LH; POGLIANI, L; HASHIMOTO, T; NISHIMURA, MC; BARTKOWSKI, HM; JAMES, TL			EFFECT OF HYPOXIA ON TRAUMATIC BRAIN INJURY IN RATS .2. CHANGES IN HIGH-ENERGY PHOSPHATE-METABOLISM	NEUROSURGERY			English	Article									UNIV CALIF SAN FRANCISCO,SCH MED,DEPT NEUROL SURG,EDITORIAL OFF,1360 9TH AVE,SUITE 210,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143								ACKERMAN JJH, 1984, J MAGN RESON, V56, P318, DOI 10.1016/0022-2364(84)90109-4; BOTTOMLEY P A, 1982, Magnetic Resonance Imaging, V1, P81, DOI 10.1016/0730-725X(82)90223-5; BROWN WJ, 1972, AM J PATHOL, V67, P41; CHASON JL, 1966, J TRAUM, V6, P767, DOI 10.1097/00005373-196611000-00008; DELPY DT, 1982, PEDIATRICS, V70, P310; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; GERMAN WJ, 1974, T AM NEUROL ASS, V72, P86; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; GORDON E, 1971, ACTA ANAESTH SCAND, V15, P209, DOI 10.1111/j.1399-6576.1971.tb05462.x; HASS WK, 1977, ACTA NEUROL SCAND, V56, P240; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; JAMES TL, 1984, NMR CT INTERVENTIONA, P235; Lewis H P, 1968, Surg Forum, V19, P433; LINDQUIST JL, 1942, SURG GYNECOL OBSTET, V75, P28; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Naruse S, 1984, Neurol Res, V6, P169; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; Nelson S, 1966, HEAD INJURY, P444; NG TC, 1982, ANESTHESIOLOGY, V57, pA126; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; PRICHARD JW, 1983, P NATL ACAD SCI-BIOL, V80, P2748, DOI 10.1073/pnas.80.9.2748; ROSENTHAL M, 1982, HEAD INJURY BASIC CL, P69; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SEITZ HD, 1977, ACTA NEUROCHIR, V38, P211, DOI 10.1007/BF01401092; THULBORN KR, 1982, J CEREBR BLOOD F MET, V2, P299, DOI 10.1038/jcbfm.1982.31; WAGNER KR, 1985, J NEUROSURG, V63, P88, DOI 10.3171/jns.1985.63.1.0088; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	34	68	68	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUN	1987	20	6					854	858		10.1227/00006123-198706000-00006			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	H8835	WOS:A1987H883500005	3614564				2022-02-06	
J	VANZOMEREN, AH; DEELMAN, BG				VANZOMEREN, AH; DEELMAN, BG			DIFFERENTIAL EFFECTS OF SIMPLE AND CHOICE REACTION AFTER CLOSED HEAD-INJURY	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article									STATE UNIV GRONINGEN,DEPT NEUROL,GRONINGEN,NETHERLANDS								BENTON AL, 1957, J ABNORM SOC PSYCH, V54, P109, DOI 10.1037/h0047176; BLACKBURN H L, 1955, Confin Neurol, V15, P327; Bruhn P, 1971, Cortex, V7, P278; Carson DH, 1968, CORTEX, V4, P92; COSTA LD, 1962, PERCEPT MOTOR SKILL, V14, P391; DEE HL, 1972, T AM NEUROLOGICAL AS, V97; Donders F. C., 1868, ONDERZOEKINGEN GEDAA, VII, P92; KARP E, 1971, CORTEX, V7, P419; KLENSCH H, 1973, FORTSCHR NEUROL PSYC, V41, P575; Miller E, 1970, Cortex, V6, P121; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; Russell W Ritchie, 1934, Edinb Med J, V41, P129; Siegel S., 1956, NONPARAMETRIC STAT B; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; STRICH SJ, 1961, LANCET, V2, P443; VECHT CJ, 1975, LIFE SCI, V16, P1179, DOI 10.1016/0024-3205(75)90201-5; WELFORD AT, 1962, LANCET, V1, P335; [No title captured]	18	68	68	1	4	VAN GORCUM CO BV	ASSEN	PO BOX 43, 9400 AA ASSEN, NETHERLANDS	0303-8467			CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.		1976	79	2					81	90		10.1016/0303-8467(76)90001-9			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	DH716	WOS:A1976DH71600001	1029638				2022-02-06	
J	Henry, RJ; Ritzel, RM; Barrett, JP; Doran, SJ; Jiao, Y; Leach, JB; Szeto, GL; Wu, JF; Stoica, BA; Faden, AI; Loane, DJ				Henry, Rebecca J.; Ritzel, Rodney M.; Barrett, James P.; Doran, Sarah J.; Jiao, Yun; Leach, Jennie B.; Szeto, Gregory L.; Wu, Junfang; Stoica, Bogdan A.; Faden, Alan, I; Loane, David J.			Microglial Depletion with CSF1R Inhibitor During Chronic Phase of Experimental Traumatic Brain Injury Reduces Neurodegeneration and Neurological Deficits	JOURNAL OF NEUROSCIENCE			English	Article						CSF1R; functional recovery; microglia; neurodegeneration; neuroinflammation; traumatic brain injury	NADPH OXIDASE; NLRP3 INFLAMMASOME; PROGENITOR-CELL; NEURONAL LOSS; NEUROINFLAMMATION; ACTIVATION; EXPRESSION; DEMENTIA; PREVENTS; RISK	Chronic neuroinflammation with sustained microglial activation occurs following severe traumatic brain injury (TBI) and is believed to contribute to subsequent neurodegeneration and neurological deficits. Microglia, the primary innate immune cells in brain, are dependent on colony stimulating factor 1 receptor (CSF1R) signaling for their survival. In this preclinical study, we examined the effects of delayed depletion of chronically activated microglia on functional recovery and neurodegeneration up to 3 months postinjury. A CSF1R inhibitor, Plexxikon (PLX) 5622, was administered to adult male C57BL/6J mice at 1 month after controlled cortical impact to remove chronically activated microglia, and the inhibitor was withdrawn 1-week later to allow for microglial repopulation. Following TBI, the repopulated microglia displayed a ramified morphology similar to that of Sham uninjured mice, whereas microglia in vehicle-treated TBI mice showed the typical chronic posttraumatic hypertrophic morphology. PLX5622 treatment limited TBI-associated neuropathological changes at 3 months postinjury; these included a smaller cortical lesion, reduced hippocampal neuron cell death, and decreased NOX2-and NLRP3 inflammasome-associated neuroinflammation. Furthermore, delayed depletion of chronically activated microglia after TBI led to widespread changes in the cortical transcriptome and altered gene pathways involved in neuroinflammation, oxidative stress, and neuroplasticity. Using a variety of complementary neurobehavioral tests, PLX5622-treated TBI mice also had improved long-term motor and cognitive function recovery through 3 months postinjury. Together, these studies demonstrate that chronic phase removal of neurotoxic microglia after TBI using CSF1R inhibitors markedly reduce chronic neuroinflammation and associated neurodegeneration, as well as related motor and cognitive deficits.	[Henry, Rebecca J.; Ritzel, Rodney M.; Barrett, James P.; Doran, Sarah J.; Wu, Junfang; Stoica, Bogdan A.; Faden, Alan, I; Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Henry, Rebecca J.; Ritzel, Rodney M.; Barrett, James P.; Doran, Sarah J.; Wu, Junfang; Stoica, Bogdan A.; Faden, Alan, I; Loane, David J.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Jiao, Yun; Leach, Jennie B.; Szeto, Gregory L.] Univ Maryland, Dept Chem Biochem & Environm Engn, Baltimore, MD 21250 USA; [Szeto, Gregory L.] Univ Maryland, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA; [Szeto, Gregory L.] Univ Maryland, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA; [Stoica, Bogdan A.] Univ Maryland, Dept Radiat Oncol, DTRS, Sch Med, Baltimore, MD 21201 USA; [Stoica, Bogdan A.] Baltimore VA Med Ctr, VA Maryland Hlth Care Syst, Baltimore, MD 21201 USA; [Loane, David J.] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin, Ireland		Henry, RJ; Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.; Henry, RJ; Loane, DJ (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA.; Loane, DJ (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin, Ireland.	rhenry@som.umaryland.edu; loanedj@tcd.ie	Loane, David/ABD-5177-2021; Stoica, Bogdan/H-9782-2013	Loane, David/0000-0003-0393-3503; Henry, Rebecca/0000-0001-8548-1170; Szeto, Gregory/0000-0001-7604-1333; Stoica, Bogdan/0000-0002-2501-6434; Barrett, James/0000-0002-0924-9449; Ritzel, Rodney/0000-0002-0160-2930	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308, R01NS037313, R01NS096002, R01NS110756, R21EY029451]; U.S. Department of Veterans AffairsUS Department of Veterans Affairs [1I01 RX001993]; Science Foundation IrelandScience Foundation IrelandEuropean Commission [17/FRL/4860]	This work was supported by the National Institutes of Health (Grant R01NS082308 to D.J.L., Grant R01NS037313 to A.I.F., Grant R01NS096002 to B.A.S., Grant R01NS110756 to D.J.L., A.I.F., and B.A.S., and Grant R21EY029451 to J.B.L.), the U.S. Department of Veterans Affairs (Grant 1I01 RX001993 to B.A.S.), and Science Foundation Ireland (Grant 17/FRL/4860 to D.J.L.). We thank Victoria Meadows and Wesley Shoap for help with neurobehavioral assessment and histology and Plexxikon Inc. for the use of PLX5622.	Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Asai H, 2015, NAT NEUROSCI, V18, P1584, DOI 10.1038/nn.4132; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barrett JP, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0843-4; Beckmann N, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0510-8; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Dagher NN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0366-9; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Doran SJ, 2019, J NEUROTRAUM, V36, P1040, DOI 10.1089/neu.2018.6019; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Elmore MRP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122912; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Erblich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026317; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Faden AI, 2015, NEUROTHERAPEUTICS, V12, P143, DOI 10.1007/s13311-014-0319-5; Ferguson S, 2017, J NEUROTRAUM, V34, P1676, DOI 10.1089/neu.2016.4636; Foucher Y, 2012, STAT APPL GENET MOL, V11, DOI 10.1515/1544-6115.1815; Garcia-Cabezas MA, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00107; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Han JM, 2019, GLIA, V67, P217, DOI 10.1002/glia.23529; Heneka MT, 2018, NAT REV NEUROSCI, V19, P610, DOI 10.1038/s41583-018-0055-7; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Henry RJ, 2019, NEUROTHERAPEUTICS, V16, P216, DOI 10.1007/s13311-018-0665-9; Hume DA, 2019, TRENDS IMMUNOL, V40, P98, DOI 10.1016/j.it.2018.11.007; Jin WN, 2017, J CEREBR BLOOD F MET, V37, P2224, DOI 10.1177/0271678X17694185; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kerr N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210128; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar RG, 2018, BRAIN INJURY, V32, P383, DOI 10.1080/02699052.2018.1427888; Kuwar R, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1471-y; Lage SL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01284; Li MS, 2017, J CEREBR BLOOD F MET, V37, P2383, DOI 10.1177/0271678X16666551; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Ma MW, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6057609; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; Nandi S, 2012, DEV BIOL, V367, P100, DOI 10.1016/j.ydbio.2012.03.026; Nissen JC, 2018, EXP NEUROL, V307, P24, DOI 10.1016/j.expneurol.2018.05.021; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Olmos-Alonso A, 2016, BRAIN, V139, P891, DOI 10.1093/brain/awv379; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Pischiutta F, 2018, EXP NEUROL, V300, P167, DOI 10.1016/j.expneurol.2017.11.003; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rice RA, 2017, GLIA, V65, P931, DOI 10.1002/glia.23135; Rice RA, 2015, J NEUROSCI, V35, P9977, DOI 10.1523/JNEUROSCI.0336-15.2015; Ritzel RM, 2018, J NEUROTRAUM, V35, P1419, DOI 10.1089/neu.2017.5399; Ritzel RM, 2019, NEUROBIOL AGING, V77, P194, DOI 10.1016/j.neurobiolaging.2019.02.010; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Spangenberg E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11674-z; Spangenberg EE, 2016, BRAIN, V139, P1265, DOI 10.1093/brain/aww016; Szalay G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11499; Villacampa N, 2015, GLIA, V63, P1166, DOI 10.1002/glia.22807; Wang H, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw677; Wheeler DL, 2018, J CLIN INVEST, V128, P931, DOI 10.1172/JCI97229; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X; Witcher KG, 2018, GLIA, V66, P2719, DOI 10.1002/glia.23523; Xu X, 2018, NEUROBIOL DIS, V117, P15, DOI 10.1016/j.nbd.2018.05.016; Yang XX, 2018, FASEB J, V32, P3336, DOI 10.1096/fj.201700833RR; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	81	67	69	10	20	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	APR 1	2020	40	14					2960	2974		10.1523/JNEUROSCI.2402-19.2020			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KY7ZL	WOS:000522791300016	32094203	Green Published, Bronze, Green Submitted	Y	N	2022-02-06	
J	Li, CY; Li, WF; Liu, HH; Zhang, YJ; Chen, GC; Li, ZJ; Wang, QB				Li, Chunyan; Li, Wanfei; Liu, Huanhuan; Zhang, Yejun; Chen, Guangcun; Li, Zijing; Wang, Qiangbin			An Activatable NIR-II Nanoprobe for In Vivo Early Real-Time Diagnosis of Traumatic Brain Injury	ANGEWANDTE CHEMIE-INTERNATIONAL EDITION			English	Article						bioimaging; fluorescent probes; peroxynitrite; second near-infrared window; traumatic brain injury	QUANTUM DOTS; DISEASE; DYE; PEROXYNITRITE; NANOPARTICLES; NANOCRYSTALS; WINDOW; CELLS	Traumatic brain injury (TBI) is one of the most dangerous acute diseases resulting in high morbidity and mortality. Current methods remain limited with respect to early diagnosis and real-time feedback on the pathological process. Herein, a targeted activatable fluorescent nanoprobe (V&A@Ag2S) in the second near-infrared window (NIR-II) is presented for in vivo optical imaging of TBI. Initially, the fluorescence of V&A@Ag2S is turned off owing to energy transfer from Ag2S to the A1094 chromophore. Upon intravenous injection, V&A@Ag2S quickly accumulates in the inflamed vascular endothelium of TBI based on VCAM1-mediated endocytosis, after which the nanoprobe achieves rapid recovery of the NIR-II fluorescence of Ag2S quantum dots (QDs) owing to the bleaching of A1094 by the prodromal biomarker of TBI, peroxynitrite (ONOO-). The nanoprobe offers high specificity, rapid response, and high sensitivity toward ONOO-, providing a convenient approach for in vivo early real-time assessment of TBI.	[Li, Chunyan; Zhang, Yejun; Chen, Guangcun; Wang, Qiangbin] Chinese Acad Sci, Suzhou Key Lab Funct Mol Imaging Technol, CAS Key Lab Nanobio Interface, Div Nanobiomed, Suzhou 215123, Peoples R China; [Li, Chunyan; Zhang, Yejun; Chen, Guangcun; Wang, Qiangbin] Chinese Acad Sci, Suzhou Inst Nanotech & Nanobion, I Lab, Suzhou 215123, Peoples R China; [Li, Chunyan; Zhang, Yejun; Chen, Guangcun; Wang, Qiangbin] Univ Sci & Technol China, Hefei 230036, Anhui, Peoples R China; [Li, Chunyan; Zhang, Yejun; Chen, Guangcun; Wang, Qiangbin] Univ Chinese Acad Sci, Coll Mat Sci & Optoelect Technol, Beijing 100049, Peoples R China; [Li, Wanfei] Suzhou Univ Sci & Technol, Sch Chem Biol & Mat Engn, Res Ctr Nanophoton & Nanoelect Mat, Suzhou 215009, Peoples R China; [Liu, Huanhuan; Li, Zijing] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Lab Mol Vaccinol & Mol Diagnost,State Key, Xiamen 361102, Fujian, Peoples R China		Li, CY; Wang, QB (corresponding author), Chinese Acad Sci, Suzhou Key Lab Funct Mol Imaging Technol, CAS Key Lab Nanobio Interface, Div Nanobiomed, Suzhou 215123, Peoples R China.; Li, CY; Wang, QB (corresponding author), Chinese Acad Sci, Suzhou Inst Nanotech & Nanobion, I Lab, Suzhou 215123, Peoples R China.; Li, CY; Wang, QB (corresponding author), Univ Sci & Technol China, Hefei 230036, Anhui, Peoples R China.; Li, CY; Wang, QB (corresponding author), Univ Chinese Acad Sci, Coll Mat Sci & Optoelect Technol, Beijing 100049, Peoples R China.; Li, ZJ (corresponding author), Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Lab Mol Vaccinol & Mol Diagnost,State Key, Xiamen 361102, Fujian, Peoples R China.	cyli2012@sinano.ac.cn; zijing.li@xmu.edu.cn; qbwang2008@sinano.ac.cn		li, wanfei/0000-0002-6776-1416	National Key Research and Development Program of China [2016YFA0101503, 2017YFA0205503]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21671198, 21425103, 21501192, 21934007]; Chinese Academy of SciencesChinese Academy of Sciences [XDB32030200, 121E32KYSB20180021, ZDBS-LY-SLH021]; Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK20170066, BE2016682]; Youth Innovation Promotion Association of Chinese Academy of Sciences; CAS Key Laboratory of Nano-Bio Interface [18NBI01]	This work was financially supported by the National Key Research and Development Program of China (Grant Nos. 2016YFA0101503, 2017YFA0205503), National Natural Science Foundation of China (Grant Nos. 21671198, 21425103, 21501192, 21934007), Chinese Academy of Sciences (Grant Nos. XDB32030200, 121E32KYSB20180021, ZDBS-LY-SLH021), Natural Science Foundation of Jiangsu Province (Grant Nos. BK20170066, BE2016682), the Youth Innovation Promotion Association of Chinese Academy of Sciences, and CAS Key Laboratory of Nano-Bio Interface (No. 18NBI01). The authors thank Suzhou NIR-Optics Technologies Co., Ltd. for its instrumental and technical support on the NIR-II imaging.	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Antaris AL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15269; Antaris AL, 2016, NAT MATER, V15, P235, DOI [10.1038/NMAT4476, 10.1038/nmat4476]; Arakawa Y., 2008, ANGEW CHEM, V120, P8356; Arakawa Y, 2008, ANGEW CHEM INT EDIT, V47, P8232, DOI 10.1002/anie.200802800; Dong BH, 2013, CHEM MATER, V25, P2503, DOI 10.1021/cm400812v; Drummond GR, 2011, NAT REV DRUG DISCOV, V10, P453, DOI 10.1038/nrd3403; Ghosh D, 2014, P NATL ACAD SCI USA, V111, P13948, DOI 10.1073/pnas.1400821111; Hong GS, 2014, NAT PHOTONICS, V8, P723, DOI [10.1038/nphoton.2014.166, 10.1038/NPHOTON.2014.166]; Hong Guosong, 2012, Angew Chem Int Ed Engl, V51, P9818, DOI 10.1002/anie.201206059; Hong GS, 2012, NAT MED, V18, P1841, DOI 10.1038/nm.2995; Hong GS, 2012, ANGEW CHEM INT EDIT, V51, P9818, DOI 10.1002/anie.201206059; Kheirolomoom A, 2015, ACS NANO, V9, P8885, DOI 10.1021/acsnano.5b02611; Li B., 2018, ANGEW CHEM-GER EDIT, V130, P7605, DOI [10.1002/ange.201801226, DOI 10.1002/ANGE.201801226]; Li BH, 2018, ANGEW CHEM INT EDIT, V57, P7483, DOI 10.1002/anie.201801226; Li X, 2015, J AM CHEM SOC, V137, P12296, DOI 10.1021/jacs.5b06865; Naczynski DJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3199; Nahrendorf M, 2006, CIRCULATION, V114, P1504, DOI 10.1161/CIRCULATIONAHA.106.646380; O'Connell KM, 2013, BIOL RES NURS, V15, P253, DOI 10.1177/1099800411431823; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shao W, 2016, J AM CHEM SOC, V138, P16192, DOI 10.1021/jacs.6b08973; Smith AM, 2009, NAT NANOTECHNOL, V4, P710, DOI 10.1038/nnano.2009.326; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; Tian M, 2003, J AM CHEM SOC, V125, P348, DOI 10.1021/ja0209666; Uteshev VV, 2016, CURR PHARM DESIGN, V22, P1986, DOI 10.2174/1381612822666160201115341; Villa I, 2015, NANO RES, V8, P649, DOI 10.1007/s12274-014-0549-1; Wang R., 2014, ANGEW CHEM, V126, P12282, DOI 10.1002/ange.201407420; Wang R, 2014, ANGEW CHEM INT EDIT, V53, P12086, DOI 10.1002/anie.201407420; Yang YM, 2013, CHEM REV, V113, P192, DOI 10.1021/cr2004103; Zhang JJ, 2019, CHEM SOC REV, V48, P683, DOI 10.1039/c7cs00907k; Zhu SJ, 2017, P NATL ACAD SCI USA, V114, P962, DOI 10.1073/pnas.1617990114	32	67	68	32	219	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1433-7851	1521-3773		ANGEW CHEM INT EDIT	Angew. Chem.-Int. Edit.	JAN 2	2020	59	1					247	252		10.1002/anie.201911803		NOV 2019	6	Chemistry, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry	LE8OR	WOS:000497116800001	31626380				2022-02-06	
J	Stein, MB; Jain, S; Giacino, JT; Levin, H; Dikmen, S; Nelson, LD; Vassar, MJ; Okonkwo, DO; Diaz-Arrastia, R; Robertson, CS; Mukherjee, P; McCrea, M; MacDonald, CL; Yue, JK; Yuh, E; Sun, XY; Campbell-Sills, L; Temkin, N; Manley, GT; Adeoye, O; Badjatia, N; Boase, K; Bodien, Y; Bullock, MR; Chesnut, R; Corrigan, JD; Crawford, K; Diaz-Arrastia, R; Dikmen, S; Duhaime, AC; Ellenbogen, R; Feeser, VR; Ferguson, A; Foreman, B; Gardner, R; Gaudette, E; Giacino, JT; Gonzalez, L; Gopinath, S; Gullapalli, R; Hemphill, JC; Hotz, G; Jain, S; Korley, F; Kramer, J; Kreitzer, N; Levin, H; Lindsell, C; Machamer, J; Madden, C; Martin, A; McAllister, T; McCrea, M; Merchant, R; Mukherjee, P; Nelson, LD; Noel, F; Okonkwo, DO; Palacios, E; Perl, D; Puccio, A; Rabinowitz, M; Robertson, CS; Rosand, J; Sander, A; Satris, G; Schnyer, D; Seabury, S; Sherer, M; Stein, MB; Taylor, S; Toga, A; Temkin, N; Valadka, A; Vassar, MJ; Vespa, P; Wang, K; Yue, JK; Yuh, E; Zafonte, R				Stein, Murray B.; Jain, Sonia; Giacino, Joseph T.; Levin, Harvey; Dikmen, Sureyya; Nelson, Lindsay D.; Vassar, Mary J.; Okonkwo, David O.; Diaz-Arrastia, Ramon; Robertson, Claudia S.; Mukherjee, Pratik; McCrea, Michael; MacDonald, Christine L.; Yue, John K.; Yuh, Esther; Sun, Xiaoying; Campbell-Sills, Laura; Temkin, Nancy; Manley, Geoffrey T.; Adeoye, Opeolu; Badjatia, Neeraj; Boase, Kim; Bodien, Yelena; Bullock, M. Ross; Chesnut, Randall; Corrigan, John D.; Crawford, Karen; Diaz-Arrastia, Ramon; Dikmen, Sureyya; Duhaime, Ann-Christine; Ellenbogen, Richard; Feeser, V. Ramana; Ferguson, Adam; Foreman, Brandon; Gardner, Raquel; Gaudette, Etienne; Giacino, Joseph T.; Gonzalez, Luis; Gopinath, Shankar; Gullapalli, Rao; Hemphill, J. Claude; Hotz, Gillian; Jain, Sonia; Korley, Frederick; Kramer, Joel; Kreitzer, Natalie; Levin, Harvey; Lindsell, Chris; Machamer, Joan; Madden, Christopher; Martin, Alastair; McAllister, Thomas; McCrea, Michael; Merchant, Randall; Mukherjee, Pratik; Nelson, Lindsay D.; Noel, Florence; Okonkwo, David O.; Palacios, Eva; Perl, Daniel; Puccio, Ava; Rabinowitz, Miri; Robertson, Claudia S.; Rosand, Jonathan; Sander, Angelle; Satris, Gabriela; Schnyer, David; Seabury, Seth; Sherer, Mark; Stein, Murray B.; Taylor, Sabrina; Toga, Arthur; Temkin, Nancy; Valadka, Alex; Vassar, Mary J.; Vespa, Paul; Wang, Kevin; Yue, John K.; Yuh, Esther; Zafonte, Ross		TRACK-TBI Investigators	Risk of Posttraumatic Stress Disorder and Major Depression in Civilian Patients After Mild Traumatic Brain Injury A TRACK-TBI Study	JAMA PSYCHIATRY			English	Article							QUALITY-OF-LIFE; POSTCONCUSSIVE SYMPTOMS; PREDICTORS; ASSOCIATION; PROGNOSIS; VETERANS; CONCUSSION; MANAGEMENT; DIAGNOSIS; MILITARY	IMPORTANCE Traumatic brain injury (TBI) has been associated with adverse mental health outcomes, such as posttraumatic stress disorder (PTSD) and major depressive disorder (MDD), but little is known about factors that modify risk for these psychiatric sequelae, particularly in the civilian sector. OBJECTIVE To ascertain prevalence of and risk factors for PTSD and MDD among patients evaluated in the emergency department for mild TBI (mTBI). DESIGN. SETTING. AND PARTICIPANTS Prospective longitudinal cohort study (February 2014 to May 2018). Posttraumatic stress disorder and MDD symptoms were assessed using the PTSD Checklist for DSM-5 and the Patient Health Questionnaire-9 Item. Risk factors evaluated included preinjury and injury characteristics. Propensity score weights-adjusted multivariable logistic regression models were performed to assess associations with PTSD and MDD. A total of 1155 patients with mTBI (Glasgow Coma Scale score, 13-15) and 230 patients with nonhead orthopedic trauma injuries 17 years and older seen in 11 US hospitals with level 1 trauma centers were included in this study. MAIN OUTCOMES AND MEASURES Probable PTSD (PTSD Checklist for DSM-5 score, >= 33) and MDD (Patient Health Questionnaire -9 Item score, >= 15) at 3, 6, and 12 months postinjury. RESULTS Participants were 1155 patients (752 men [65.1%]; mean [SD] age, 40.5 [17.2] years) with mTBI and 230 patients (155 men [67.4%]; mean [SD] age, 40.4 [15.6] years) with nonhead orthopedic trauma injuries. Weights-adjusted prevalence of PTSD and/or MDD in the mTBI vs orthopedic trauma comparison groups at 3 months was 20.0% (SE, 1.4%) vs 8.7% (SE, 2.2%) (P<.001) and at 6 months was 21.2% (SE, 1.5%) vs 12.1% (SE, 3.2%) (P = .03). Risk factors for probable PTSD at 6 months after mTBI included less education (adjusted odds ratio, 0.89; 95% Cl, 0.82-0.97 per year), being black (adjusted odds ratio, 5.11; 95% Cl, 2.89-9.05), self-reported psychiatric history (adjusted odds ratio, 3.57; 95% Cl, 2.09-6.09), and injury resulting from assault or other violence (adjusted odds ratio, 3.43; 95% Cl, 1.56-7.54). Risk factors for probable MDD after mTBI were similar with the exception that cause of injury was not associated with increased risk. CONCLUSIONS AND RELEVANCE After mTBI, some individuals, on the basis of education, race/ethnicity, history of mental health problems, and cause of injury were at substantially increased risk of PTSD and/or MDD. These findings should influence recognition of at-risk individuals and inform efforts at surveillance, follow-up, and intervention.	[Stein, Murray B.; Campbell-Sills, Laura] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.; Jain, Sonia; Sun, Xiaoying] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; [Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA USA; [Giacino, Joseph T.; Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Giacino, Joseph T.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Levin, Harvey; Robertson, Claudia S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Dikmen, Sureyya; Boase, Kim; Machamer, Joan] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Nelson, Lindsay D.; McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Vassar, Mary J.; Mukherjee, Pratik; Yue, John K.; Yuh, Esther; Manley, Geoffrey T.; Satris, Gabriela] Zuckerberg San Francisco Gen Hosp & Trauma Ctr, Brain & Spinal Cord Injury Ctr, San Francisco, CA USA; [Vassar, Mary J.; Manley, Geoffrey T.; Ferguson, Adam; Taylor, Sabrina] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Okonkwo, David O.; Puccio, Ava] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Diaz-Arrastia, Ramon; Rabinowitz, Miri] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Mukherjee, Pratik; Yuh, Esther; Martin, Alastair; Palacios, Eva] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Mukherjee, Pratik; Yuh, Esther] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [MacDonald, Christine L.; Temkin, Nancy; Chesnut, Randall; Ellenbogen, Richard] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Adeoye, Opeolu; Foreman, Brandon; Kreitzer, Natalie] Univ Cincinnati, Cincinnati, OH USA; [Badjatia, Neeraj; Gullapalli, Rao] Univ Maryland, College Pk, MD 20742 USA; [Bodien, Yelena; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Bullock, M. Ross; Hotz, Gillian] Univ Miami, Coral Gables, FL 33124 USA; [Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Crawford, Karen; Gaudette, Etienne; Seabury, Seth; Toga, Arthur] Univ Southern Calif, Los Angeles, CA USA; [Duhaime, Ann-Christine] MassGen Hosp Children, Boston, MA USA; [Feeser, V. Ramana] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA USA; [Gardner, Raquel; Hemphill, J. Claude; Kramer, Joel] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Gonzalez, Luis; Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Gopinath, Shankar] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Korley, Frederick] Univ Michigan, Med Sch, Dept Emergency Med, Ann Arbor, MI USA; [Lindsell, Chris] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Madden, Christopher] UT Southwestern Med Ctr, Dept Neurol Surg, Dallas, TX USA; [McAllister, Thomas] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Merchant, Randall] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Noel, Florence] Baylor Coll Med, Dan L Duncan Inst Clin & Translat Res, Houston, TX 77030 USA; [Perl, Daniel] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD USA; [Schnyer, David] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Valadka, Alex] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Vespa, Paul] Univ Calif Los Angeles, Dept Neurol, Los Angeles Sch Med, Los Angeles, CA 90024 USA; [Wang, Kevin] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA		Stein, MB (corresponding author), Univ Calif San Diego, Dept Psychiat, Altman Clin & Translat Res Inst, 9500 Gilman Dr,MC 0855, La Jolla, CA 92093 USA.	mstein@ucsd.edu	Schnyer, David/ABD-6372-2021; Hemphill, Claude/AAY-5630-2021; Giacino, Joseph/AAF-1952-2021; Badjatia, Neeraj/AAS-4855-2021; Yue, John K/P-1348-2015	Schnyer, David/0000-0002-7472-2853; Hemphill, Claude/0000-0003-4019-7525; Giacino, Joseph/0000-0002-7916-9698; Yue, John K/0000-0001-9694-7722; Wang, Kevin/0000-0002-9343-6473; Bodien, Yelena/0000-0003-4858-2903; Badjatia, Neeraj/0000-0003-1509-9034; Ferguson, Adam/0000-0001-7102-1608	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01 NS086090]; US Department of DefenseUnited States Department of Defense [W81XWH-14-2-0176]; Abbott LaboratoriesAbbott Laboratories; One Mind; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS047996] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (grant U01 NS086090) and US Department of Defense (grant W81XWH-14-2-0176). Abbott Laboratories provided funding for add-in TRACK-TBI clinical studies. One Mind provided funding for TRACK-TBI patients stipends and support to clinical sites.	Armistead-Jehle P, 2017, PHYS MED REH CLIN N, V28, P323, DOI 10.1016/j.pmr.2016.12.008; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bell KR, 2017, J NEUROTRAUM, V34, P313, DOI 10.1089/neu.2016.4444; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bovin MJ, 2016, PSYCHOL ASSESSMENT, V28, P1379, DOI 10.1037/pas0000254; Bryant RA, 2015, BRIT J PSYCHIAT, V206, P417, DOI 10.1192/bjp.bp.114.145516; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cnossen MC, 2018, J NEUROTRAUM, V35, P2691, DOI 10.1089/neu.2017.5486; Cnossen MC, 2017, J NEUROPSYCH CLIN N, V29, P206, DOI 10.1176/appi.neuropsych.16090165; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dyer JR, 2016, J HEAD TRAUMA REHAB, V31, P225, DOI 10.1097/HTR.0000000000000177; Fann JR, 2018, LANCET PSYCHIAT, V5, P424, DOI 10.1016/S2215-0366(18)30065-8; Fann JR, 2017, J HEAD TRAUMA REHAB, V32, P332, DOI 10.1097/HTR.0000000000000322; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Foks KA, 2017, J NEUROTRAUM, V34, P2529, DOI 10.1089/neu.2016.4919; Gardner RC, 2018, NEUROLOGY, V90, pE1771, DOI 10.1212/WNL.0000000000005522; Gordon EM, 2018, J NEUROTRAUM, V35, P767, DOI 10.1089/neu.2017.5428; Grant G., 2016, TRANSLATIONAL RES TR; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Holster JL, 2017, J HEAD TRAUMA REHAB, V32, P25, DOI 10.1097/HTR.0000000000000237; Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V319, P1429, DOI 10.1001/jama.2018.1536; Kaplan GB, 2018, J NEUROTRAUM, V35, P210, DOI 10.1089/neu.2016.4953; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Madsen T, 2018, JAMA-J AM MED ASSOC, V320, P580, DOI 10.1001/jama.2018.10211; Manners JL, 2016, J NEUROTRAUM, V33, P1796, DOI 10.1089/neu.2015.4245; McCaffrey DF, 2004, PSYCHOL METHODS, V9, P403, DOI 10.1037/1082-989X.9.4.403; McCrea MA, 2017, PHYS MED REH CLIN N, V28, P271, DOI 10.1016/j.pmr.2016.12.005; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Nordstrom A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002496; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Porter KE, 2018, J PSYCHIATR RES, V102, P8, DOI 10.1016/j.jpsychires.2018.03.004; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Radhakrishnan R, 2016, LANCET PSYCHIAT, V3, P1166, DOI 10.1016/S2215-0366(16)30266-8; Ritterband LM, 2017, JAMA PSYCHIAT, V74, P68, DOI 10.1001/jamapsychiatry.2016.3249; Roden-Foreman K, 2017, J ORTHOP TRAUMA, V31, pE275, DOI 10.1097/BOT.0000000000000884; Schiehser DM, 2015, J HEAD TRAUMA REHAB, V30, pE21, DOI 10.1097/HTR.0000000000000065; Schwab K, 2017, NEUROLOGY, V88, P1571, DOI 10.1212/WNL.0000000000003839; Seabury SA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0210; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Stein MB, 2016, J NEUROTRAUM, V33, P2125, DOI 10.1089/neu.2015.4320; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Vuletic S, 2016, J HEAD TRAUMA REHAB, V31, P147, DOI 10.1097/HTR.0000000000000221; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	55	67	68	5	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	MAR	2019	76	3					249	258		10.1001/jamapsychiatry.2018.4288			10	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	HN9GA	WOS:000460506700008	30698636	Green Published, Bronze	Y	N	2022-02-06	
J	Chandran, R; Mehta, SL; Vemuganti, R				Chandran, Raghavendar; Mehta, Suresh L.; Vemuganti, Raghu			Non-coding RNAs and neuroprotection after acute CNS injuries	NEUROCHEMISTRY INTERNATIONAL			English	Article						Non-coding RNA; microRNA; lncRNA; piRNA; Ischemic stroke; Hemorrhagic stroke; Traumatic brain injury; Spinal cord injury	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; IMPROVES FUNCTIONAL RECOVERY; NEURONAL CELL-DEATH; MAGUK PROTEIN CASK; MICRORNA EXPRESSION; DOWN-REGULATION; CIRCULATING MICRORNAS; MIRNA EXPRESSION	Accumulating evidence indicates that various classes of non-coding RNAs (ncRNAs) including microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs) and long non-coding RNAs (lncRNAs) play important roles in normal state as well as the diseases of the CNS. Interestingly, ncRNAs have been shown to interact with messenger RNA, DNA and proteins, and these interactions could induce epigenetic modifications and control transcription and translation, thereby adding a new layer of genomic regulation. The ncRNA expression profiles are known to be altered after acute CNS injuries including stroke, traumatic brain injury and spinal cord injury that are major contributors of morbidity and mortality worldwide. Hence, a better understanding of the functional significance of ncRNAs following CNS injuries could help in developing potential therapeutic strategies to minimize the neuronal damage in those conditions. The potential of ncRNAs in blood and CSF as biomarkers for diagnosis and/or prognosis of acute CNS injuries has also gained importance in the recent years. This review highlighted the current progress in the understanding of the role of ncRNAs in initiation and progression of secondary neuronal damage and their application as biomarkers after acute CNS injuries. (C) 2017 Elsevier Ltd. All rights reserved.	[Vemuganti, Raghu] Univ Wisconsin, Dept Neurol Surg, Mail Code CSC 8660,600 Highland Ave, Madison, WI 53792 USA; William S Middleton Vet Hosp, Madison, WI USA		Vemuganti, R (corresponding author), Univ Wisconsin, Dept Neurol Surg, Mail Code CSC 8660,600 Highland Ave, Madison, WI 53792 USA.	vemuganti@neurosurgery.wisc.edu	Chandran, Raghavendar/AAB-9402-2019	Chandran, Raghavendar/0000-0002-7915-2810	American Heart AssociationAmerican Heart Association [15IRG23050015]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS095192]; Veterans AdministrationUS Department of Veterans Affairs [BX001638]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS095192, R21NS082957, R03NS083007] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002985] Funding Source: NIH RePORTER	The authors are supported by grants from American Heart Association (15IRG23050015), National Institute of Health (NS095192) and Veterans Administration (BX001638).	Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Barker RA, 2016, NEUROPATH APPL NEURO, V42, P6, DOI 10.1111/nan.12303; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Bracko O, 2014, J CEREBR BLOOD F MET, V34, P1522, DOI 10.1038/jcbfm.2014.112; Broughton BRS, 2009, STROKE, V40, pE331, DOI 10.1161/STROKEAHA.108.531632; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Busch DJ, 2012, J COMP NEUROL, V520, P1751, DOI 10.1002/cne.23011; Caballero-Garrido E, 2015, J NEUROSCI, V35, P12446, DOI 10.1523/JNEUROSCI.1641-15.2015; Cabin DE, 2002, J NEUROSCI, V22, P8797; Calkins MJ, 2009, ANTIOXID REDOX SIGN, V11, P497, DOI [10.1089/ars.2008.2242, 10.1089/ARS.2008.2242]; Cao L, 2012, BRAIN RES BULL, V88, P525, DOI 10.1016/j.brainresbull.2012.05.009; Chao HW, 2008, J CELL BIOL, V182, P141, DOI 10.1083/jcb.200712094; Chen F, 2015, TRANSL STROKE RES, V6, P478, DOI 10.1007/s12975-015-0429-3; Chen GQ, 2015, MOL MED REP, V12, P2465, DOI 10.3892/mmr.2015.3670; Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92; Choi S, 2006, J NEUROSCI, V26, P4811, DOI 10.1523/JNEUROSCI.4182-05.2006; Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157; Dharap A, 2013, ASN NEURO, V5, P283, DOI 10.1042/AN20130029; Dharap A, 2012, STROKE, V43, P2800, DOI 10.1161/STROKEAHA.112.669465; Dharap A, 2011, STROKE, V42, P1105, DOI 10.1161/STROKEAHA.110.598391; Dharap A, 2010, J NEUROCHEM, V113, P1685, DOI 10.1111/j.1471-4159.2010.06735.x; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Duan XM, 2014, J DIABETES COMPLICAT, V28, P705, DOI 10.1016/j.jdiacomp.2014.04.012; Feng NP, 2015, NEUROSCI LETT, V591, P1, DOI 10.1016/j.neulet.2015.02.002; Feng Y, 2015, CELL MOL BIOL, V61, P24; Funk K, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-32; Gan CS, 2012, GENET MOL RES, V11, P147, DOI 10.4238/2012.January.27.1; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Gilbert O, 2014, ATHEROSCLEROSIS, V232, P305, DOI 10.1016/j.atherosclerosis.2013.11.028; Gubern C, 2013, FEBS J, V280, P6233, DOI 10.1111/febs.12546; Guo D, 2013, STROKE, V44, P1739, DOI 10.1161/STROKEAHA.111.000835; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hachisuka S, 2014, SPINAL CORD, V52, P596, DOI 10.1038/sc.2014.86; Halic M, 2009, CELL, V138, P1058, DOI 10.1016/j.cell.2009.08.030; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hsueh YP, 2006, CURR MED CHEM, V13, P1915, DOI 10.2174/092986706777585040; Hu JZ, 2015, BRAIN RES, V1608, P191, DOI 10.1016/j.brainres.2015.02.036; Hu T, 2015, J MOL NEUROSCI, V57, P114, DOI 10.1007/s12031-015-0584-8; Huang S, 2016, NEUROSCI LETT, V615, P102, DOI 10.1016/j.neulet.2016.01.028; Hunsberger JG, 2012, AM J TRANSL RES, V4, P316; Hwang JY, 2014, J MOL BIOL, V426, P3454, DOI 10.1016/j.jmb.2014.07.032; Iwasaki YW, 2015, ANNU REV BIOCHEM, V84, P405, DOI 10.1146/annurev-biochem-060614-034258; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Jadhav SP, 2014, J NEUROCHEM, V130, P388, DOI 10.1111/jnc.12731; Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Jiang Y, 2015, J NEUROCHEM, V134, P173, DOI 10.1111/jnc.13097; Jickling GC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099283; Jin HW, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-296; Keasey MP, 2016, J MOL NEUROSCI, V59, P404, DOI 10.1007/s12031-016-0740-9; Kim JH, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/634289; Koronowski KB, 2015, STROKE, V46, P2293, DOI 10.1161/STROKEAHA.115.009876; Kostandy BB, 2012, NEUROL SCI, V33, P223, DOI 10.1007/s10072-011-0828-5; Krings T, 2011, NAT REV NEUROL, V7, P547, DOI 10.1038/nrneurol.2011.136; Kumar A, 2016, BRAIN RES BULL, V122, P35, DOI 10.1016/j.brainresbull.2016.02.016; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Lee ST, 2010, STROKE, V41, P1646, DOI 10.1161/STROKEAHA.110.579649; Lee YP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045836; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Leung LY, 2014, CLIN CHIM ACTA, V433, P139, DOI 10.1016/j.cca.2014.03.007; Li LJ, 2014, MOL MED REP, V10, P527, DOI 10.3892/mmr.2014.2172; Li PX, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.000972; Li YA, 2015, SCI REP-UK, V5, DOI 10.1038/srep13316; Liu CY, 2015, INT J MOL SCI, V16, P24302, DOI 10.3390/ijms161024302; Liu CY, 2012, J NEUROCHEM, V120, P830, DOI 10.1111/j.1471-4159.2011.07624.x; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; Liu D, 2015, CELL MOL NEUROBIOL, V35, P483, DOI 10.1007/s10571-014-0142-x; Liu DZ, 2016, J CEREBR BLOOD F MET, V36, P1374, DOI 10.1177/0271678X15610786; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu DH, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0188-x; Liu L, 2014, ADV DIFFER EQU, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0103948; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Liu P., 2015, J CEREBRAL CIRCULATI, V46, P513, DOI DOI 10.1161/STR0KEAHA.114.007482; Liu XJ, 2015, INT J CLIN EXP PATHO, V8, P3811; Liu YZ, 2016, SPINE, V41, P97, DOI 10.1097/BRS.0000000000001323; Liu ZH, 2015, J NEUROSCI, V35, P12733, DOI 10.1523/JNEUROSCI.0605-15.2015; Long GW, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-178; Lopez MS, 2016, J CEREBR BLOOD F MET, V36, P1644, DOI 10.1177/0271678X16656202; Lou YL, 2012, MOL CELL BIOCHEM, V370, P45, DOI 10.1007/s11010-012-1396-6; Louw AM, 2016, NANOMED-NANOTECHNOL, V12, P643, DOI 10.1016/j.nano.2015.10.011; Lu XCM, 2004, J NEUROSCI RES, V77, P843, DOI 10.1002/jnr.20218; Lusardi TA, 2014, FRONT MOL NEUROSCI, V7, DOI [10.3389/fnmo1.2014.00011, 10.3389/fnmol.2014.00011]; Lusardi TA, 2010, J CEREBR BLOOD F MET, V30, P744, DOI 10.1038/jcbfm.2009.253; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Madathil SK, 2011, BIOESSAYS, V33, P21, DOI 10.1002/bies.201000069; Matsuura I, 2008, J NEUROCHEM, V105, P1471, DOI 10.1111/j.1471-4159.2008.05251.x; Mehta SL, 2015, J NEUROSCI, V35, P16443, DOI 10.1523/JNEUROSCI.2943-15.2015; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Meng FJ, 2016, J NEUROSURG ANESTH, V28, P195, DOI 10.1097/ANA.0000000000000204; Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Miao W, 2015, BRAZ J MED BIOL RES, V48, P433, DOI [10.1590/1414-431X20144012, 10.1590/1414-431x20144012]; Moon JM, 2013, J CEREBR BLOOD F MET, V33, P1976, DOI 10.1038/jcbfm.2013.157; Muller AH, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1341-7; Myers J, 2007, AM J PHYS MED REHAB, V86, P142, DOI 10.1097/PHM.0b013e31802f0247; Nelson PT, 2010, J ALZHEIMERS DIS, V21, P75, DOI 10.3233/JAD-2010-091603; Neo WH, 2014, J BIOL CHEM, V289, P20788, DOI 10.1074/jbc.M113.525493; Ni JS, 2015, BRAIN BEHAV IMMUN, V49, P75, DOI 10.1016/j.bbi.2015.04.014; Noh KM, 2012, P NATL ACAD SCI USA, V109, pE962, DOI 10.1073/pnas.1121568109; O'Donnell KA, 2007, CELL, V129, P37, DOI 10.1016/j.cell.2007.03.028; Ohri SS, 2011, GLIA, V59, P1489, DOI 10.1002/glia.21191; Pandi G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058039; Peng ZF, 2013, J NEUROSCI RES, V91, P1349, DOI 10.1002/jnr.23255; Peschansky VJ, 2014, EPIGENETICS-US, V9, P3, DOI 10.4161/epi.27473; Qu Y, 2014, NEUROBIOL DIS, V63, P184, DOI 10.1016/j.nbd.2013.11.023; Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234; Raval AP, 2006, NEUROSCIENCE, V141, P1721, DOI 10.1016/j.neuroscience.2006.05.016; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Reid G, 2011, CRIT REV ONCOL HEMAT, V80, P193, DOI 10.1016/j.critrevonc.2010.11.004; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Schmidt-Kastner R, 2002, MOL BRAIN RES, V108, P81, DOI 10.1016/S0169-328X(02)00516-8; Schmitz SU, 2016, CELL MOL LIFE SCI, V73, P2491, DOI 10.1007/s00018-016-2174-5; Schober K, 2015, INT J LEGAL MED, V129, P701, DOI 10.1007/s00414-014-1129-3; Selvamani A, 2014, CLIN SCI, V127, P77, DOI 10.1042/CS20130565; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Sepramaniam S, 2014, INT J MOL SCI, V15, P1418, DOI 10.3390/ijms15011418; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Sharp FR, 2011, J CEREBR BLOOD F MET, V31, P1513, DOI 10.1038/jcbfm.2011.45; Shi Hong, 2010, Front Biosci (Elite Ed), V2, P1304; Shi H, 2013, CNS NEUROL DISORD-DR, V12, P381, DOI 10.2174/1871527311312030011; Shin JH, 2014, BBA-GENE REGUL MECH, V1839, P826, DOI 10.1016/j.bbagrm.2014.06.019; Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002; Sisalli MJ, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00115; Smith SD, 2011, RADIOL CLIN N AM, V49, P27, DOI 10.1016/j.rcl.2010.07.011; Sorensen SS, 2014, TRANSL STROKE RES, V5, P711, DOI 10.1007/s12975-014-0364-8; Stetler RA, 2014, PROG NEUROBIOL, V114, P58, DOI 10.1016/j.pneurobio.2013.11.005; Sun M, 2015, CELL TRANSPLANT, V24, P367, DOI 10.3727/096368915X686869; Sun YY, 2015, CELL MOL NEUROBIOL, V35, P1117, DOI 10.1007/s10571-015-0205-7; Taheri S, 2016, J NEUROTRAUM, V33, P1818, DOI 10.1089/neu.2015.4281; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tan JR, 2011, CURR MOL MED, V11, P76; Tan KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007689; Tao J, 2015, NEUROSCIENCE, V305, P1, DOI 10.1016/j.neuroscience.2015.07.064; Tao Z, 2015, J NEUROL SCI, V355, P113, DOI 10.1016/j.jns.2015.05.036; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016; Thompson JW, 2013, NEUROTHERAPEUTICS, V10, P789, DOI 10.1007/s13311-013-0202-9; Tripathi AK, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-39; Tsai PC, 2013, J VASC RES, V50, P346, DOI 10.1159/000351767; Varga ZV, 2013, J MOL CELL CARDIOL, V62, P111, DOI 10.1016/j.yjmcc.2013.05.009; Vartanian KB, 2015, J CEREBR BLOOD F MET, V35, P257, DOI 10.1038/jcbfm.2014.193; Vartanian KB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-140; Wade JT, 2014, NAT REV MICROBIOL, V12, P647, DOI 10.1038/nrmicro3316; Wang Hailian, 2011, Front Biosci (Elite Ed), V3, P604; Wang J, 2015, BRAIN RES, V1624, P314, DOI 10.1016/j.brainres.2015.07.052; Wang MD, 2016, MOL NEUROBIOL, V53, P1310, DOI 10.1007/s12035-015-9099-0; Wang P, 2014, NEUROCHEM RES, V39, P1279, DOI 10.1007/s11064-014-1310-6; Wang WX, 2011, ACTA NEUROPATHOL, V121, P193, DOI 10.1007/s00401-010-0756-0; Wang Y, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-77; Wang Y, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/276540; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Wei N., 2015, MOL NEUROBIOL, V11, P11; Weng HC, 2011, BIOMED RES-TOKYO, V32, P135, DOI 10.2220/biomedres.32.135; Whyte EM, 2002, BIOL PSYCHIAT, V52, P253, DOI 10.1016/S0006-3223(02)01424-5; Woodruff TM, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-11; Xu Q., 2016, CELL DEATH DIS, V7, P1; Yan W, 2016, CELL MOL BIOL, V62, P38; Yang SS, 2016, CARDIOVASC TOXICOL, V16, P213, DOI 10.1007/s12012-015-9329-8; Yang Z, 2015, MOL IMMUNOL, V65, P267, DOI 10.1016/j.molimm.2014.12.018; Yang ZB, 2016, INTERNAL MED, V55, P1279, DOI 10.2169/internalmedicine.55.5925; Yang ZB, 2014, CLIN SCI, V127, P679, DOI 10.1042/CS20140084; Yin KJ, 2010, J NEUROSCI, V30, P6398, DOI 10.1523/JNEUROSCI.0780-10.2010; Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021; Yin ZS, 2008, NEUROL RES, V30, P480, DOI 10.1179/174313208X284133; Yuan LY, 2015, STROKE, V46; Zeng L, 2014, GENE THER, V21, P37, DOI 10.1038/gt.2013.55; Zeng L, 2011, FRONT BIOSCI ELITE E, V3, P1265, DOI DOI 10.2741/330; Zeng LL, 2013, EUR NEUROL, V69, P68, DOI 10.1159/000342896; Zeng X, 2014, EUR J PAIN, V18, P1323, DOI 10.1002/j.1532-2149.2014.493.x; Zhang J, 2016, EXP NEUROL, V277, P162, DOI 10.1016/j.expneurol.2015.12.014; Zhang L, 2012, ARTERIOSCL THROM VAS, V32, P1856, DOI 10.1161/ATVBAHA.112.252619; Zhang N, 2012, INDIAN J MED RES, V135, P287; Zhang Y, 2016, J AFFECT DISORDERS, V193, P51, DOI 10.1016/j.jad.2015.12.061; Zhao CN, 2013, SCI REP-UK, V3, DOI 10.1038/srep01329; Zhao HP, 2013, STROKE, V44, P1706, DOI 10.1161/STROKEAHA.111.000504; Zhao Y, 2015, NEURAL REGEN RES, V10, P1147, DOI 10.4103/1673-5374.156983; Zheng BJ, 2015, MOL MED REP, V12, P967, DOI 10.3892/mmr.2015.3474; Zheng HW, 2012, CNS NEUROSCI THER, V18, P1003, DOI 10.1111/cns.12019; Zhong JJ, 2016, BRAIN RES, V1646, P589, DOI 10.1016/j.brainres.2016.07.002; Zhou JS, 2014, MOL MED REP, V10, P971, DOI 10.3892/mmr.2014.2245; Zhu F, 2014, J MOL NEUROSCI, V52, P148, DOI 10.1007/s12031-013-0155-9; Zhu YP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121608	191	67	70	1	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		12	22		10.1016/j.neuint.2017.01.015			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600003	28131900	Green Accepted			2022-02-06	
J	Sundman, MH; Chen, NK; Subbian, V; Chou, YH				Sundman, Mark H.; Chen, Nan-kuei; Subbian, Vignesh; Chou, Ying-hui			The bidirectional gut-brain-microbiota axis as a potential nexus between traumatic brain injury, inflammation, and disease	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Gut-brain axis; Traumatic Brain Injury; Concussion; Gut; Microbiota; Chronic Traumatic Encephalopathy; Neurodegenerative disease; Neuroinflammation; Microglia; Intestinal dysfunction	CAUSES CHRONIC NEUROINFLAMMATION; VAGUS NERVE-STIMULATION; C-REACTIVE PROTEIN; BACTERIAL TRANSLOCATION; MICROGLIAL ACTIVATION; SYSTEMIC INFLAMMATION; DOCOSAHEXAENOIC ACID; ALZHEIMERS-DISEASE; SICKNESS BEHAVIOR; IMMUNE ACTIVATION	As head injuries and their sequelae have become an increasingly salient matter of public health, experts in the field have made great progress elucidating the biological processes occurring within the brain at the moment of injury and throughout the recovery thereafter. Given the extraordinary rate at which our collective knowledge of neurotrauma has grown, new insights may be revealed by examining the existing literature across disciplines with a new perspective. This article will aim to expand the scope of this rapidly evolving field of research beyond the confines of the central nervous system (CNS). Specifically, we will examine the extent to which the bidirectional influence of the gut-brain axis modulates the complex biological processes occurring at the time of traumatic brain injury (TBI) and over the days, months, and years that follow. In addition to local enteric signals originating in the gut, it is well accepted that gastrointestinal (GI) physiology is highly regulated by innervation from the CNS. Conversely, emerging data suggests that the function and health of the CNS is modulated by the interaction between 1) neurotransmitters, immune signaling, hormones, and neuropeptides produced in the gut, 2) the composition of the gut microbiota, and 3) integrity of the intestinal wall serving as a barrier to the external environment. Specific to TBI, existing pre-clinical data indicates that head injuries can cause structural and functional damage to the GI tract, but research directly investigating the neuronal consequences of this intestinal damage is lacking. Despite this void, the proposed mechanisms emanating from a damaged gut are closely implicated in the inflammatory processes known to promote neuropathology in the brain following TBI, which suggests the gut-brain axis may be a therapeutic target to reduce the risk of Chronic Traumatic Encephalopathy and other neurodegenerative diseases following TBI. To better appreciate how various peripheral influences are implicated in the health of the CNS following TBI, this paper will also review the secondary biological injury mechanisms and the dynamic pathophysiological response to neurotrauma. Together, this review article will attempt to connect the dots to reveal novel insights into the bidirectional influence of the gut-brain axis and propose a conceptual model relevant to the recovery from TBI and subsequent risk for future neurological conditions. (C) 2017 Elsevier Inc. All rights reserved.	[Sundman, Mark H.; Chou, Ying-hui] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA; [Chen, Nan-kuei; Subbian, Vignesh] Univ Arizona, Dept Biomed Engn, Tucson, AZ USA; [Subbian, Vignesh] Univ Arizona, Dept Syst & Ind Engn, Tucson, AZ 85721 USA; [Chou, Ying-hui] Univ Arizona, Cognit Sci Program, Tucson, AZ USA; [Chou, Ying-hui] Univ Arizona, Arizona Ctr Aging, Tucson, AZ USA		Sundman, MH (corresponding author), 1503 East Univ Blvd,POB 210068, Tucson, AZ 85719 USA.	marksundman@email.arizona.edu	; Chen, Nan-kuei/E-7791-2016	Subbian, Vignesh/0000-0001-9974-8382; Chen, Nan-kuei/0000-0001-6564-4219	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER		Aamodt S, 2007, NAT NEUROSCI, V10, P1349, DOI 10.1038/nn1107-1349; Anrather J, 2016, NEUROTHERAPEUTICS, V13, P661, DOI 10.1007/s13311-016-0483-x; Anthony DC, 2012, BRAIN BEHAV IMMUN, V26, P534, DOI 10.1016/j.bbi.2011.10.011; Arrieta MC, 2006, GUT, V55, DOI 10.1136/gut.2005.085373; Asti A, 2014, J ALZHEIMERS DIS, V39, P169, DOI 10.3233/JAD-131394; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Badala F., 2008, COMPUTER LONG BEACH, V144, P724, DOI DOI 10.1038/JID.2014.371; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Balzan S, 2007, J GASTROEN HEPATOL, V22, P464, DOI 10.1111/j.1440-1746.2007.04933.x; Bansal V., 2009, J NEUROTRAUM, V26; Bansal V, 2010, J NEUROTRAUM, V27, P2255, DOI 10.1089/neu.2010.1372; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bengmark S, 2013, PHARMACOL RES, V69, P87, DOI 10.1016/j.phrs.2012.09.002; Bested AC, 2013, GUT PATHOG, V5, DOI 10.1186/1757-4749-5-3; Bickford PC, 2017, EXP GERONTOL, V94, P4, DOI 10.1016/j.exger.2017.01.027; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7; Blaser M, 2013, NAT REV MICROBIOL, V11, P213, DOI 10.1038/nrmicro2973; Blaser M, 2011, NATURE, V476, P393, DOI 10.1038/476393a; BLUTHE RM, 1994, CR ACAD SCI III-VIE, V317, P499; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Bramlett H., 2014, J NEUROTRAUM, P1; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Carr J, 2007, TRAUMA, V9, P21, DOI 10.1177/1460408607082845; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cheng YM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091530; Cheng ZQ, 2016, JOURNAL PRACT, V10, P744, DOI [10.1111/jnc.13062, 10.1080/17512786.2015.1063079]; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Cook AM, 2008, NUTR CLIN PRACT, V23, P608, DOI 10.1177/0884533608326060; Costantini TW, 2010, J TRAUMA, V68, P1349, DOI 10.1097/TA.0b013e3181dccea0; Coughlin J.M., 2016, JAMA NEUROL, V6, P193; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Crapser J, 2016, AGING-US, V8, P1049, DOI 10.18632/aging.100952; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Croisier E, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-14; Cryan JF, 2012, NAT REV NEUROSCI, V13, P701, DOI 10.1038/nrn3346; Cunningham C, 2013, GLIA, V61, P71, DOI 10.1002/glia.22350; D'Mello C, 2015, J NEUROSCI, V35, P10821, DOI 10.1523/JNEUROSCI.0575-15.2015; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davenport E.M, 2016, CONCUSSION; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; de Punder K, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00223; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Desai MS, 2016, CELL, V167, P1339, DOI 10.1016/j.cell.2016.10.043; Dinan T. G., 2017, NAT REV GASTROENTERO; Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc; DiSabato DJ, 2016, J NEUROCHEM, V139, P136, DOI 10.1111/jnc.13607; Distrutti E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106503; Divyashri G, 2015, J MED MICROBIOL, V64, P1527, DOI 10.1099/jmm.0.000184; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Ehrhart J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0350-4; El-Tawil A.M, 2012, INFLAMM BOWEL DIS, V18; Elali A, 2016, BRAIN BEHAV IMMUN, V55, P138, DOI 10.1016/j.bbi.2015.07.021; Engelhart MJ, 2004, ARCH NEUROL-CHICAGO, V61, P668, DOI 10.1001/archneur.61.5.668; Erny D, 2017, IMMUNOLOGY, V150, P7, DOI 10.1111/imm.12645; Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030; Farhadi A, 2003, J GASTROEN HEPATOL, V18, P479, DOI 10.1046/j.1440-1746.2003.03032.x; Faul M, 2010, TRAUMATIC BRAIN INJU; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Felger JC, 2013, NEUROSCIENCE, V246, P199, DOI 10.1016/j.neuroscience.2013.04.060; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Forsyth CB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028032; Gallo RL, 2012, NAT REV IMMUNOL, V12, P503, DOI 10.1038/nri3228; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Ghaisas S, 2016, PHARMACOL THERAPEUT, V158, P52, DOI 10.1016/j.pharmthera.2015.11.012; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Gimeno D, 2009, PSYCHOL MED, V39, P413, DOI 10.1017/S0033291708003723; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Haar CV, 2016, BRAIN RES, V1640, P114, DOI 10.1016/j.brainres.2015.12.030; Hall E.E., 2014, J ALZHEIMERS DIS PAR, V4, P1, DOI [10.4172/2161-0460.1000137, DOI 10.4172/2161-0460.1000137]; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Hannestad J, 2012, NEUROIMAGE, V63, P232, DOI 10.1016/j.neuroimage.2012.06.055; Hill JM, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00009; Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hornig M, 2013, CURR OPIN RHEUMATOL, V25, P488, DOI 10.1097/BOR.0b013e32836208de; Houlden A, 2016, BRAIN BEHAV IMMUN, V57, P10, DOI 10.1016/j.bbi.2016.04.003; Hsieh CY, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12327; Hu X, 2016, SCI CHINA LIFE SCI, V59, P1006, DOI 10.1007/s11427-016-5083-9; Hu YC, 2013, J SURG RES, V184, P1022, DOI 10.1016/j.jss.2013.04.005; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Iverson GL, 2015, NEUROSCI BIOBEHAV R, V56, P276, DOI 10.1016/j.neubiorev.2015.05.008; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Katzenberger RJ, 2015, FLY, V9, P68, DOI 10.1080/19336934.2015.1085623; Kekkonen RA, 2008, WORLD J GASTROENTERO, V14, P2029, DOI 10.3748/wjg.14.2029; Kelly JR, 2016, J PSYCHIATR RES, V82, P109, DOI 10.1016/j.jpsychires.2016.07.019; Kelly JR, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00392; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Kharrazian D, 2015, ALTERN THER HEALTH M, V21, P28; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Kitazawa M, 2004, ANN NY ACAD SCI, V1035, P85, DOI 10.1196/annals.1332.006; Klingelhoefer L, 2015, NAT REV NEUROL, V11, P625, DOI 10.1038/nrneurol.2015.197; Koerte I.K., 2013, JAMA-J AM MED ASSOC, V308, P1; Koerte I.K., 2015, J NEUROTRAUMA, V1293; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lamprecht M, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-45; Lasselin J, 2016, BRAIN BEHAV IMMUN, V57, P30, DOI 10.1016/j.bbi.2016.01.003; Layer A.M., 2016, NAT MED, V13, P720; Lee JW, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-37; Leonard B, 2012, NEUROSCI BIOBEHAV R, V36, P764, DOI 10.1016/j.neubiorev.2011.12.005; Levy G, 2012, J TRAUMA ACUTE CARE, V73, P338, DOI 10.1097/TA.0b013e31825debd3; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Lopez NE, 2012, J TRAUMA ACUTE CARE, V72, P1562, DOI 10.1097/TA.0b013e3182569875; Lukiw WJ, 2008, J NUTR, V138, P2510, DOI 10.3945/jn.108.096016; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Maes M, 2013, ACTA PSYCHIAT SCAND, V127, P344, DOI 10.1111/j.1600-0447.2012.01908.x; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P117; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mayer EA, 2015, J CLIN INVEST, V125, P926, DOI 10.1172/JCI76304; Mayer EA, 2014, J NEUROSCI, V34, P15490, DOI 10.1523/JNEUROSCI.3299-14.2014; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Michielan A, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/628157; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mobley AR, 2014, NUTRIENTS, V6, P2540, DOI 10.3390/nu6072540; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mohamadshahi M, 2014, BIOIMPACTS, V4, P83, DOI 10.5681/bi.2014.007; Montiel-Castro AJ, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00070; Morley Wendy A, 2014, Surg Neurol Int, V5, P97, DOI 10.4103/2152-7806.134731; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Mulak A, 2015, WORLD J GASTROENTERO, V21, P10609, DOI 10.3748/wjg.v21.i37.10609; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Neren D, 2016, NEUROCRIT CARE, V24, P308, DOI 10.1007/s12028-015-0203-0; Nevin KG, 2004, CLIN BIOCHEM, V37, P830, DOI 10.1016/j.clinbiochem.2004.04.010; Noble EE, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00009; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Ohland CL, 2010, AM J PHYSIOL-GASTR L, V298, pG807, DOI 10.1152/ajpgi.00243.2009; Oliver JM, 2016, MED SCI SPORT EXER, V48, P974, DOI 10.1249/MSS.0000000000000875; Olsen AB, 2013, NEUROGASTROENT MOTIL, V25, DOI 10.1111/nmo.12121; Ostman EM, 2001, AM J CLIN NUTR, V74, P96; Palin K, 2008, NEUROBIOL DIS, V30, P19, DOI 10.1016/j.nbd.2007.11.012; Parachikova A, 2007, NEUROBIOL AGING, V28, P1821, DOI 10.1016/j.neurobiolaging.2006.08.014; PERLMUTTER LS, 1992, J NEUROSCI RES, V33, P549, DOI 10.1002/jnr.490330407; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Perry VH, 2010, ACTA NEUROPATHOL, V120, P277, DOI 10.1007/s00401-010-0722-x; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Raftery T, 2015, UNITED EUR GASTROENT, V3, P294, DOI 10.1177/2050640615572176; Rajkumar H, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/348959; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Reddy BL, 2015, J MOL MICROB BIOTECH, V25, P51, DOI 10.1159/000375303; Redelmeier D.A., 2016, CMAJ, V188, P1; Rodes L, 2013, J MICROBIOL BIOTECHN, V23, P518, DOI 10.4014/jmb.1205.05018; Rogers GB, 2016, MOL PSYCHIATR, V21, P738, DOI 10.1038/mp.2016.50; Romijn JA, 2008, CURR OPIN CLIN NUTR, V11, P518, DOI 10.1097/MCO.0b013e328302c9b0; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Rusnak M, 2013, NAT REV NEUROL, V9, P186, DOI 10.1038/nrneurol.2013.38; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Sampson TR, 2015, CELL HOST MICROBE, V17, P565, DOI 10.1016/j.chom.2015.04.011; Sandiego CM, 2015, P NATL ACAD SCI USA, V112, P12468, DOI 10.1073/pnas.1511003112; Santos A, 2008, BASIC CLIN PHARMACOL, V103, P247, DOI 10.1111/j.1742-7843.2008.00272.x; Savignac HM, 2016, BRAIN BEHAV IMMUN, V52, P120, DOI 10.1016/j.bbi.2015.10.007; Schaller BJ, 2006, AM J GASTROENTEROL, V101, P1655, DOI 10.1111/j.1572-0241.2006.00540.x; Schedlowski M, 2014, BRAIN BEHAV IMMUN, V35, P1, DOI 10.1016/j.bbi.2013.09.015; Schmidt R, 2002, ANN NEUROL, V52, P168, DOI 10.1002/ana.10265; Scrimgeour AG, 2014, J NEUROTRAUM, V31, P989, DOI 10.1089/neu.2013.3234; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Setiawan E, 2015, JAMA PSYCHIAT, V72, P268, DOI 10.1001/jamapsychiatry.2014.2427; Sherry CL, 2010, BRAIN BEHAV IMMUN, V24, P631, DOI 10.1016/j.bbi.2010.01.015; Sherwin E, 2016, CURR OPIN GASTROEN, V32, P96, DOI 10.1097/MOG.0000000000000244; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Singh V, 2016, J NEUROSCI, V36, P7428, DOI 10.1523/JNEUROSCI.1114-16.2016; Slyepchenko A, 2017, PSYCHOTHER PSYCHOSOM, V86, P31, DOI 10.1159/000448957; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Song IU, 2009, EUR NEUROL, V62, P99, DOI 10.1159/000222780; Sonnenburg ED, 2014, CELL METAB, V20, P779, DOI 10.1016/j.cmet.2014.07.003; Sonnenburg JL, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001626; Stanley D, 2016, NAT MED, V22, P1277, DOI 10.1038/nm.4194; Steenbergen L, 2015, BRAIN BEHAV IMMUN, V48, P258, DOI 10.1016/j.bbi.2015.04.003; Su SH, 2014, BRAIN BEHAV IMMUN, V38, P111, DOI 10.1016/j.bbi.2014.01.009; Sun B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128214; Sun J, 2016, BRAIN RES, V1642, P180, DOI 10.1016/j.brainres.2016.03.042; Swidsinski A, 2012, INTEST RES, V10, P332, DOI 10.5217/ir.2012.10.4.332; Tabbaa M, 2013, NUTRIENTS, V5, P3299, DOI 10.3390/nu5083299; Tan ZS, 2007, NEUROLOGY, V68, P1902, DOI 10.1212/01.wnl.0000263217.36439.da; Tascilar N, 2010, BRATISL MED J, V111, P194; Thayer JF, 2009, NEUROIMAGE, V47, P908, DOI 10.1016/j.neuroimage.2009.05.058; Tillisch K, 2013, GASTROENTEROLOGY, V144, P1394, DOI 10.1053/j.gastro.2013.02.043; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Ulluwishewa D, 2011, J NUTR, V141, P769, DOI 10.3945/jn.110.135657; von Bernhardi R, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00124; Vuong H.E., 2017, MICROBIOME HOST BEHA, P21; Wachholz S, 2016, BRAIN BEHAV IMMUN, V55, P105, DOI 10.1016/j.bbi.2015.09.016; Wall R, 2010, LIPIDS, V45, P429, DOI 10.1007/s11745-010-3410-7; Wang W., 2015, ANN TRANSL MED, V3, P1; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Winek K., 2016, J CEREB BLOOD FLOW M; Winek K, 2016, STROKE, V47, P1354, DOI 10.1161/STROKEAHA.115.011800; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Worthmann H, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0231-2; Wu RQ, 2007, ANN SURG, V245, P480, DOI 10.1097/01.sla.0000251614.42290.ed; Wu RQ, 2009, CRIT CARE MED, V37, P2421, DOI 10.1097/CCM.0b013e3181a557a2; Xu MQ, 2015, WORLD J GASTROENTERO, V21, P102, DOI 10.3748/wjg.v21.i1.102; Yamashiro K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171521; Yin J, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002699; Zhang R, 2009, J NEUROIMMUNOL, V206, P121, DOI 10.1016/j.jneuroim.2008.09.017; Zhang X, 2015, JPEN-PARENTER ENTER, V39, P114, DOI 10.1177/0148607113501881; Zhou LH, 2015, NEUROPSYCH DIS TREAT, V11, P715, DOI 10.2147/NDT.S61997	214	67	71	2	54	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2017	66						31	44		10.1016/j.bbi.2017.05.009			14	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	FL4YE	WOS:000414236600005	28526435	Green Published			2022-02-06	
J	Sun, W; Incitti, T; Migliaresi, C; Quattrone, A; Casarosa, S; Motta, A				Sun, Wei; Incitti, Tania; Migliaresi, Claudio; Quattrone, Alessandro; Casarosa, Simona; Motta, Antonella			Viability and neuronal differentiation of neural stem cells encapsulated in silk fibroin hydrogel functionalized with an IKVAV peptide	JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE			English	Article						silk fibroin; hydrogel; sonication; encapsulation; neural stem cells; differentiation	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NEURITE OUTGROWTH; GROWTH-FACTOR; SCAFFOLDS; ADHESION; LAMININ; MATRIX; REGENERATION; CHALLENGES	Three-dimensional (3D) porous scaffolds combined with therapeutic stem cells play vital roles in tissue engineering. The adult brain has very limited regeneration ability after injuries such as trauma and stroke. In this study, injectable 3D silk fibroin-based hydrogel scaffolds with encapsulated neural stem cells were developed, aiming at supporting brain regeneration. To improve the function of the hydrogel towards neural stem cells, silk fibroin was modified by an IKVAV peptide through covalent binding. Both unmodified and modified silk fibroin hydrogels were obtained, through sonication, with mechanical stiffness comparable to that of brain tissue. Human neural stem cells were encapsulated in both hydrogels and the effects of IKVAV peptide conjugation on cell viability and neural differentiation were assessed. The silk fibroin hydrogel modified by IKVAV peptide showed increased cell viability and an enhanced neuronal differentiation capability, which contributed to understanding the effects of IKVAV peptide on the behaviour of neural stem cells. For these reasons, IKVAV-modified silk fibroin is a promising material for brain tissue engineering. Copyright (C) 2015 John Wiley & Sons, Ltd.	[Sun, Wei; Migliaresi, Claudio; Motta, Antonella] Univ Trento, Dept Ind Engn, Via Regole 101, I-38123 Mattarello, Trento, Italy; [Sun, Wei; Migliaresi, Claudio; Motta, Antonella] Univ Trento, Biotech Res Ctr, Via Regole 101, I-38123 Mattarello, Trento, Italy; [Sun, Wei; Migliaresi, Claudio; Motta, Antonella] European Inst Excellence Tissue Engn & Regenerat, Trento, Italy; [Sun, Wei; Incitti, Tania; Quattrone, Alessandro; Casarosa, Simona] Univ Trento, Ctr Integrat Biol, Trento, Italy; [Casarosa, Simona] CNR Neurosci Inst, Pisa, Italy		Motta, A (corresponding author), Univ Trento, Dept Ind Engn, Via Regole 101, I-38123 Mattarello, Trento, Italy.; Motta, A (corresponding author), Univ Trento, Biotech Res Ctr, Via Regole 101, I-38123 Mattarello, Trento, Italy.	antonella.motta@ing.unitn.it	; Motta, Antonella/E-2554-2014	Incitti, Tania/0000-0002-5573-1914; Motta, Antonella/0000-0003-4893-6863	Bridging the Gap Erasmus Mundus Project	We thank Professor Riccardo Ceccato for help in rheological testing. We also thank Valentina Adami and Pamela Gatto for their help with Columbus software. Partial financial support from the Bridging the Gap Erasmus Mundus Project is gratefully acknowledged.	Aurand ER, 2012, J FUNCT BIOMATER, V3, P839, DOI 10.3390/jfb3040839; Banerjee A, 2009, BIOMATERIALS, V30, P4695, DOI 10.1016/j.biomaterials.2009.05.050; Barinaga M, 1998, SCIENCE, V281, P1302, DOI 10.1126/science.281.5381.1302; Chen JP, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556-276X-7-170; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Fico A, 2008, STEM CELLS DEV, V17, P573, DOI 10.1089/scd.2007.0130; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Flanagan LA, 2002, NEUROREPORT, V13, P2411, DOI 10.1097/00001756-200212200-00007; Foss C, 2013, BIOMACROMOLECULES, V14, P38, DOI 10.1021/bm301174x; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Goldman S, 2005, NAT BIOTECHNOL, V23, P862, DOI 10.1038/nbt1119; Hall PE, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-71; Hopkins AM, 2013, ADV FUNCT MATER, V23, P5140, DOI 10.1002/adfm.201300435; Hosseinkhani H, 2013, ACS CHEM NEUROSCI, V4, P1229, DOI 10.1021/cn400075h; Hu Y., 2012, ADV MATER SCI ENG, V2012, P5; Jiang FX, 2008, ANN BIOMED ENG, V36, P1565, DOI 10.1007/s10439-008-9530-z; Jin HJ, 2005, ADV FUNCT MATER, V15, P1241, DOI 10.1002/adfm.200400405; Jin K, 2007, J NEUROIMMUNE PHARM, V2, P236, DOI 10.1007/s11481-007-9076-0; Kikuchi K, 2012, INT J MOL SCI, V13, P7739, DOI 10.3390/ijms13067739; Koh HS, 2008, BIOMATERIALS, V29, P3574, DOI 10.1016/j.biomaterials.2008.05.014; Kubinova S, 2010, BIOMATERIALS, V31, P5966, DOI 10.1016/j.biomaterials.2010.04.040; Li J, 2013, BIOMED RES INT, V2013, P32; Li QQ, 2014, J BIOMED MATER RES A, V102, P1991, DOI 10.1002/jbm.a.34876; Li XW, 2012, PROG POLYM SCI, V37, P1105, DOI 10.1016/j.progpolymsci.2012.02.004; Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012; Meinel L, 2004, J BIOMED MATER RES A, V71A, P25, DOI 10.1002/jbm.a.30117; MILLARUELO AI, 1988, DEV BRAIN RES, V38, P219, DOI 10.1016/0165-3806(88)90047-8; Motta A, 2004, J BIOMAT SCI-POLYM E, V15, P851, DOI 10.1163/1568562041271075; NOMIZU M, 1995, FEBS LETT, V365, P227, DOI 10.1016/0014-5793(95)00475-O; Pakulska MM, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/2/024101; Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253; RUTKA JT, 1988, J NEUROSURG, V69, P155, DOI 10.3171/jns.1988.69.2.0155; Santin M, 1999, J BIOMED MATER RES, V46, P382, DOI 10.1002/(SICI)1097-4636(19990905)46:3<382::AID-JBM11>3.0.CO;2-R; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Silva SS, 2008, BIOMACROMOLECULES, V9, P2764, DOI 10.1021/bm800874q; Srikanth M, 2013, NEURO-ONCOLOGY, V15, P319, DOI 10.1093/neuonc/nos316; Sun W, 2016, J TISSUE ENG REGEN M, V10, P876, DOI 10.1002/term.1868; Sun Y, 2008, MOL CELL NEUROSCI, V38, P245, DOI 10.1016/j.mcn.2008.02.014; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Uludag H, 2000, ADV DRUG DELIVER REV, V42, P29, DOI 10.1016/S0169-409X(00)00053-3; Vepari C, 2007, PROG POLYM SCI, V32, P991, DOI 10.1016/j.progpolymsci.2007.05.013; Vidal G, 2013, ACTA BIOMATER, V9, P4935, DOI 10.1016/j.actbio.2012.09.003; Villard V, 2006, J PEPT SCI, V12, P206, DOI 10.1002/psc.707; Vink R, 2010, NEUROTHERAPEUTICS, V7, P1, DOI 10.1016/j.nurt.2009.12.001; Wang XQ, 2008, BIOMATERIALS, V29, P1054, DOI 10.1016/j.biomaterials.2007.11.003; Zhu HL, 2012, MAT SCI ENG C-MATER, V32, P822, DOI 10.1016/j.msec.2012.01.033	47	67	68	8	71	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-6254	1932-7005		J TISSUE ENG REGEN M	J. Tissue Eng. Regen. Med.	MAY	2017	11	5					1532	1541		10.1002/term.2053			10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Engineering	EX1MJ	WOS:000402987500020	26053955				2022-02-06	
J	Liu, SF; Buch, S; Chen, YS; Choi, HS; Dai, YM; Habib, C; Hub, J; Jung, JY; Luo, Y; Utriainen, D; Wang, MY; Wu, DM; Xia, S; Haacke, EM				Liu, Saifeng; Buch, Sagar; Chen, Yongsheng; Choi, Hyun-Seok; Dai, Yongming; Habib, Charbel; Hub, Jiani; Jung, Joon-Yong; Luo, Yu; Utriainen, David; Wang, Meiyun; Wu, Dongmei; Xia, Shuang; Haacke, E. Mark			Susceptibility-weighted imaging: current status and future directions	NMR IN BIOMEDICINE			English	Article; Proceedings Paper	4th International Workshop on MRI Phase Contrast and Quantitative Susceptibility Mapping (QSM)	SEP 26-28, 2016	Univ Graz, Graz, AUSTRIA		Univ Graz	susceptibility-weighted imaging; quantitative susceptibility mapping; phase imaging; multi-channel phase data combination; stroke; cerebral microbleeds	TRAUMATIC BRAIN-INJURY; INTERVERTEBRAL DISC DEGENERATION; CAROTID ATHEROSCLEROTIC PLAQUE; PROMINENT CORTICAL VEINS; ACUTE ISCHEMIC-STROKE; SPINAL-CORD-INJURY; MAGNETIC-RESONANCE; CEREBRAL MICROBLEEDS; MR VENOGRAPHY; HIGH-RESOLUTION	Susceptibility-weighted imaging (SWI) is a method that uses the intrinsic nature of local magnetic fields to enhance image contrast in order to improve the visibility of various susceptibility sources and to facilitate diagnostic interpretation. It is also the precursor to the concept of the use of phase for quantitative susceptibility mapping (QSM). Nowadays, SWI has become a widely used clinical tool to image deoxyhemoglobin in veins, iron deposition in the brain, hemorrhages, microbleeds and calcification. In this article, we review the basics of SWI, including data acquisition, data reconstruction and post-processing. In particular, the source of cusp artifacts in phase images is investigated in detail and an improved multi-channel phase data combination algorithm is provided. In addition, we show a few clinical applications of SWI for the imaging of stroke, traumatic brain injury, carotid vessel wall, siderotic nodules in cirrhotic liver, prostate cancer, prostatic calcification, spinal cord injury and intervertebral disc degeneration. As the clinical applications of SWI continue to expand both in and outside the brain, the improvement of SWI in conjunction with QSM is an important future direction of this technology. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Liu, Saifeng; Buch, Sagar; Haacke, E. Mark] MRI Inst Biomed Res, Waterloo, ON, Canada; [Chen, Yongsheng; Habib, Charbel; Hub, Jiani; Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI USA; [Choi, Hyun-Seok; Jung, Joon-Yong] Catholic Univ Korea, St Marys Hosp, Dept Radiol, Seoul, South Korea; [Dai, Yongming; Utriainen, David; Haacke, E. Mark] MRI Inst Biomed Res, Detroit, MI USA; [Luo, Yu] Branch Shanghai First Hosp, Dept Radiol, Shanghai, Peoples R China; [Wang, Meiyun] Henan Prov Peoples Hosp, Dept Radiol, Zhengzhou, Henan, Peoples R China; [Wu, Dongmei; Haacke, E. Mark] East China Normal Univ, Shanghai Key Lab Magnet Resonance, Shanghai, Peoples R China; [Xia, Shuang] Tianjin First Cent Hosp, Dept Radiol, Tianjin, Peoples R China		Haacke, EM (corresponding author), MRI Concourse, 3990 John R St, Detroit, MI 48201 USA.	nmrimaging@aol.com	Chen, Yongsheng/U-9800-2019; Buch, Sagar/H-3746-2017; Liu, Saifeng/I-1242-2019; Jovicich, Jorge/D-2293-2010	Chen, Yongsheng/0000-0001-7114-5731; Buch, Sagar/0000-0001-9483-269X; Liu, Saifeng/0000-0002-3642-8282; Xia, Shuang/0000-0003-1626-6383; Choi, Hyun Seok/0000-0003-4999-8513; Luo, Yu/0000-0003-4620-3869	Canadian Institutes of Health Research/Heart and Stroke Foundation of Canada Synchrotron Medical Imaging Team [CIF 99472]; Telemedicine and Advanced Technology Research Center (TATRC) at the US Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-10522]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI); National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21CA184682]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA184682] Funding Source: NIH RePORTER	This work was supported in part by the Canadian Institutes of Health Research/Heart and Stroke Foundation of Canada Synchrotron Medical Imaging Team Grant under award number CIF 99472, the Telemedicine and Advanced Technology Research Center (TATRC) at the US Army Medical Research and Materiel Command (USAMRMC) under award number W81XWH-12-10522, and the National Cancer Institute, National Institutes of Health (NIH), through Grant Number R21CA184682. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The views, opinions and/or findings contained in this report are those of the author (s) and should not be construed as an official government position, policy or decision unless so designated by other documentation.	Abdul-Rahman HS, 2007, APPL OPTICS, V46, P6623, DOI 10.1364/AO.46.006623; ADAMS MA, 1986, J BONE JOINT SURG BR, V68, P36, DOI 10.1302/0301-620X.68B1.3941139; Adams MA, 2006, SPINE, V31, P2151, DOI 10.1097/01.brs.0000231761.73859.2c; Akter M, 2007, ACAD RADIOL, V14, P1011, DOI 10.1016/j.acra.2007.05.013; An H, 2003, MAGN RESON MED, V50, P708, DOI 10.1002/mrm.10576; An HY, 2015, STROKE, V46, P982, DOI 10.1161/STROKEAHA.114.008154; An HY, 2012, TRANSL STROKE RES, V3, P65, DOI 10.1007/s12975-011-0141-x; Antoniou J, 1996, J CLIN INVEST, V98, P996, DOI 10.1172/JCI118884; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; AVRAHAMI E, 1994, J NEUROL, V241, P381, DOI 10.1007/BF02033355; Ayaz M, 2010, J MAGN RESON IMAGING, V31, P142, DOI 10.1002/jmri.22001; Bai Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053237; Baik SK, 2012, CEREBROVASC DIS, V34, P206, DOI 10.1159/000342148; Balassy C, 2014, RADIOLOGY, V270, P149, DOI 10.1148/radiol.13122440; Balla DZ, 2014, NEUROIMAGE, V100, P112, DOI 10.1016/j.neuroimage.2014.06.011; Barnes S, 2009, J MAGN RESON IMAGING, V29, P1465, DOI 10.1002/jmri.21791; Barnes SRS, 2011, MAGN RESON IMAGING, V29, P844, DOI 10.1016/j.mri.2011.02.028; Barnes SRS, 2009, MAGN RESON IMAGING C, V17, P47, DOI 10.1016/j.mric.2008.12.002; Bilgic B, 2016, NEUROIMAGE, V125, P1131, DOI 10.1016/j.neuroimage.2015.08.015; Bilgic B, 2015, MAGN RESON MED, V73, P2152, DOI 10.1002/mrm.25347; Bloch LO, 2014, J CARDIOVASC MAGN R, V16, DOI 10.1186/1532-429X-16-22; Buch S, 2015, MAGN RESON MED, V73, P2185, DOI 10.1002/mrm.25350; Butcher KS, 2005, STROKE, V36, P1153, DOI 10.1161/01.STR.0000166181.86928.8b; Bydder M, 2002, MAGNET RESON MED, V47, P539, DOI 10.1002/mrm.10092; Cai JM, 2002, CIRCULATION, V106, P1368, DOI 10.1161/01.CIR.0000028591.44554.F9; Cappendijk VC, 2005, RADIOLOGY, V234, P487, DOI 10.1148/radiol.2342032101; Chalian M, 2011, J NEURORADIOLOGY, V38, P187, DOI 10.1016/j.neurad.2010.12.006; Chang K, 2014, AM J NEURORADIOL, V35, P1091, DOI 10.3174/ajnr.A3818; Charidimou A, 2012, J NEUROL SCI, V322, P50, DOI 10.1016/j.jns.2012.05.052; Chen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065866; Chen WHC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039039; Cheng AL, 2013, STROKE, V44, P2782, DOI 10.1161/STROKEAHA.113.002267; Dai Y, 2014, CLIN RADIOL, V69, pE392, DOI 10.1016/j.crad.2014.06.010; Dai YM, 2011, J MAGN RESON IMAGING, V34, P318, DOI 10.1002/jmri.22607; Dawber TR, 1951, AM J PUBLIC HEALTH N, V41, P279, DOI 10.2105/ajph.41.3.279; Deistung A, 2009, J MAGN RESON IMAGING, V29, P1478, DOI 10.1002/jmri.21673; Denk C, 2010, J MAGN RESON IMAGING, V31, P185, DOI 10.1002/jmri.21995; Dong JW, 2015, IEEE T MED IMAGING, V34, P531, DOI 10.1109/TMI.2014.2361764; Du YP, 2008, MAGN RESON MED, V59, P954, DOI 10.1002/mrm.21581; Du YPP, 2009, J MAGN RESON IMAGING, V30, P449, DOI 10.1002/jmri.21833; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Fatemi-Ardekani A, 2009, MED PHYS, V36, P5429, DOI 10.1118/1.3250860; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Feng W, 2013, MAGN RESON MED, V70, P117, DOI 10.1002/mrm.24457; Freilinger TM, 2012, JACC-CARDIOVASC IMAG, V5, P397, DOI 10.1016/j.jcmg.2012.01.012; Fujioka M, 2013, J STROKE CEREBROVASC, V22, P1428, DOI 10.1016/j.jstrokecerebrovasdis.2012.12.009; Gaens ME, 2013, RADIOLOGY, V266, P271, DOI 10.1148/radiol.12120499; Ge YL, 2009, J MAGN RESON IMAGING, V29, P1190, DOI 10.1002/jmri.21758; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Gho SM, 2014, MAGN RESON MED, V72, P337, DOI 10.1002/mrm.24920; Gilbert G, 2012, MAGN RESON IMAGING, V30, P722, DOI 10.1016/j.mri.2012.02.008; Goos JDC, 2011, STROKE, V42, P1894, DOI 10.1161/STROKEAHA.110.599837; Grandin CB, 2002, RADIOLOGY, V223, P361, DOI 10.1148/radiol.2232010673; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Gregg NM, 2015, JAMA NEUROL, V72, P1021, DOI 10.1001/jamaneurol.2015.1359; Griffith JF, 2007, SPINE, V32, pE708, DOI 10.1097/BRS.0b013e31815a59a0; Griswold MA, 2002, MAGN RESON MED, V47, P1202, DOI 10.1002/mrm.10171; Guadagno JV, 2004, J CEREBR BLOOD F MET, V24, P1249, DOI 10.1097/01.WCB.0000141557.32867.6B; Guo LF, 2013, CLIN NEURORADIOL, V23, P121, DOI 10.1007/s00062-012-0185-7; Haacke EM, 2007, AM J NEURORADIOL, V28, P316; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke E.M., 2011, SUSCEPTIBILITY WEIGH; Haacke EM, 2007, J MAGN RESON IMAGING, V26, P256, DOI 10.1002/jmri.22987; Haacke EM, 2015, MAGN RESON IMAGING, V33, P1, DOI 10.1016/j.mri.2014.09.004; Haacke EM, 2009, J MAGN RESON IMAGING, V29, P537, DOI 10.1002/jmri.21676; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HAACKE EM, 1991, PHYS MED BIOL, V36, P723, DOI 10.1088/0031-9155/36/6/002; HAACKE EM, 1995, INT J IMAG SYST TECH, V6, P153, DOI 10.1002/ima.1850060204; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; Hammond KE, 2008, NEUROIMAGE, V39, P1682, DOI 10.1016/j.neuroimage.2007.10.037; Heiss WD, 2000, J CEREBR BLOOD F MET, V20, P1276, DOI 10.1097/00004647-200009000-00002; Heiss WD, 2011, CEREBROVASC DIS, V32, P307, DOI 10.1159/000330462; Hermier M, 2004, STROKE, V35, P1989, DOI 10.1161/01.STR.0000133341.74387.96; Hernando D, 2013, MAGN RESON MED, V70, P648, DOI 10.1002/mrm.24848; Hsu EW, 1999, MAGNET RESON MED, V41, P992, DOI 10.1002/(SICI)1522-2594(199905)41:5<992::AID-MRM19>3.3.CO;2-P; Ingall Timothy, 2004, J Insur Med, V36, P143; Ishizaka K, 2010, J MAGN RESON IMAGING, V31, P32, DOI 10.1002/jmri.21989; Jin ZY, 2008, J MAGN RESON IMAGING, V28, P327, DOI 10.1002/jmri.21447; Kao HW, 2012, EUR RADIOL, V22, P1397, DOI 10.1007/s00330-012-2387-4; Kerwin WS, 2006, RADIOLOGY, V241, P459, DOI 10.1148/radiol.2412051336; Kerwin William S, 2009, Top Magn Reson Imaging, V20, P217, DOI 10.1097/RMR.0b013e3181ea2853; Kesavadas C, 2011, J NEUROL, V258, P932, DOI 10.1007/s00415-010-5843-6; Kim DH, 2014, MAGN RESON MED, V71, P1144, DOI 10.1002/mrm.24759; Kim WB, 2011, UROLOGY, V78, P447, DOI 10.1016/j.urology.2010.12.056; Krueger EC, 2007, AM J NEURORADIOL, V28, P1237, DOI 10.3174/ajnr.A0546; KULKARNI MV, 1987, RADIOLOGY, V164, P837, DOI 10.1148/radiology.164.3.3615885; Langkammer C, 2015, NEUROIMAGE, V111, P622, DOI 10.1016/j.neuroimage.2015.02.041; Li NZ, 2015, J MAGN RESON IMAGING, V41, P1695, DOI 10.1002/jmri.24728; Li RK, 2012, J MAGN RESON IMAGING, V36, P900, DOI 10.1002/jmri.23734; Li W, 2014, NMR BIOMED, V27, P219, DOI 10.1002/nbm.3056; Lingegowda D, 2012, NEUROL INDIA, V60, P160, DOI 10.4103/0028-3886.96389; Linn J, 2015, CLIN NEURORADIOL, V25, P167, DOI 10.1007/s00062-015-0458-z; Liu CL, 2015, J MAGN RESON IMAGING, V42, P23, DOI [10.3969/j.issn.1001-2400.2015.01.004, 10.1002/jmri.24768]; Liu J, 2016, J NEUROTRAUM, V33, P10, DOI 10.1089/neu.2014.3856; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu S, 2015, P 23 ANN M ISMRM TOR, P3309; Liu SF, 2014, J MAGN RESON IMAGING, V40, P698, DOI 10.1002/jmri.24413; Liu T, 2013, MAGN RESON MED, V69, P467, DOI 10.1002/mrm.24272; Liu T, 2011, NMR BIOMED, V24, P1129, DOI 10.1002/nbm.1670; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Lou M, 2014, AM J NEURORADIOL, V35, P2061, DOI 10.3174/ajnr.A4017; Luo S, 2015, J NEURORADIOLOGY, V42, P255, DOI DOI 10.1016/J.NEURAD.2014.07.002; Ma YJ, 2015, MED PHYS, V42, P637, DOI 10.1118/1.4905163; Majumdar S, 2006, NMR BIOMED, V19, P894, DOI 10.1002/nbm.1106; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; Mathiesen EB, 2001, CIRCULATION, V103, P2171; Meoded A, 2014, J NEURORADIOLOGY, V41, P108, DOI 10.1016/j.neurad.2013.04.002; Mie MB, 2010, Z MED PHYS, V20, P143, DOI 10.1016/j.zemedi.2010.02.004; Miwa K, 2014, NEUROLOGY, V83, P646, DOI 10.1212/WNL.0000000000000692; Miyanji F, 2007, RADIOLOGY, V243, P820, DOI 10.1148/radiol.2433060583; Moenninghoff C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122329; Nakarmi U, 2015, P 23 ANN M ISMRM TOR, P3329; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Neelavalli J, 2014, J MAGN RESON IMAGING, V40, P949, DOI 10.1002/jmri.24476; Neelavalli J, 2014, J MAGN RESON IMAGING, V39, P998, DOI 10.1002/jmri.24245; Neelavalli J, 2009, J MAGN RESON IMAGING, V29, P937, DOI 10.1002/jmri.21693; Nerlich AG, 1997, SPINE, V22, P2781, DOI 10.1097/00007632-199712150-00001; Noguchi T, 2011, J AM COLL CARDIOL, V58, P416, DOI 10.1016/j.jacc.2011.01.056; Park MG, 2015, J STROKE CEREBROVASC, V24, P1229, DOI 10.1016/j.jstrokecerebrovasdis.2015.01.021; Parker DL, 2014, MAGN RESON MED, V72, P563, DOI 10.1002/mrm.24932; Peterson CK, 2000, SPINE, V25, P218, DOI 10.1097/00007632-200001150-00013; Polak JF, 2011, NEW ENGL J MED, V365, P213, DOI 10.1056/NEJMoa1012592; Poser BA, 2010, NEUROIMAGE, V51, P261, DOI 10.1016/j.neuroimage.2010.01.108; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.3.CO;2-J; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Reichenbach JR, 2001, NMR BIOMED, V14, P453, DOI 10.1002/nbm.722; Reichenbach JR, 2001, NEURORADIOLOGY, V43, P364, DOI 10.1007/s002340000503; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Reichenbach JR, 2000, J COMPUT ASSIST TOMO, V24, P949, DOI 10.1097/00004728-200011000-00023; Reichenbach JR, 1998, MAGN RESON MATER PHY, V6, P62, DOI 10.1016/S1352-8661(98)00011-8; Robertson CA, 2011, J CEREBR BLOOD F MET, V31, P1788, DOI 10.1038/jcbfm.2011.67; Robinson S, 2011, MAGN RESON MED, V65, P1638, DOI 10.1002/mrm.22753; ROEMER PB, 1990, MAGNET RESON MED, V16, P192, DOI 10.1002/mrm.1910160203; Ros C, 2009, IFMBE PROC, V22, P803; Santhosh K, 2009, CLIN RADIOL, V64, P74, DOI 10.1016/j.crad.2008.04.022; Santosh C, 2008, J CEREBR BLOOD F MET, V28, P1742, DOI 10.1038/jcbfm.2008.56; Sati P, 2014, MULT SCLER J, V20, P1464, DOI 10.1177/1352458514525868; SCHNEIDERMAN G, 1987, SPINE, V12, P276, DOI 10.1097/00007632-198704000-00016; Schrag M, 2010, ACTA NEUROPATHOL, V119, P291, DOI 10.1007/s00401-009-0615-z; Schweser F, 2013, MAGN RESON MED, V69, P1581, DOI 10.1002/mrm.24405; Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Shams S, 2015, AM J NEURORADIOL, V36, P1089, DOI 10.3174/ajnr.A4248; Sharma SD, 2015, MAGN RESON MED, V74, P673, DOI 10.1002/mrm.25448; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Staub D, 2011, RADIOLOGY, V258, P618, DOI 10.1148/radiol.10101008; Sun HF, 2015, MAGN RESON MED, V73, P1932, DOI 10.1002/mrm.25316; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Tempany C, 2008, J MAGN RESON IMAGING, V27, P356, DOI 10.1002/jmri.21259; Theysohn JM, 2011, J MAGN RESON IMAGING, V33, P782, DOI 10.1002/jmri.22513; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; TSUCHIYA K, 1993, NEURORADIOLOGY, V35, P341, DOI 10.1007/BF00588364; Tsui YK, 2009, J NEUROL SCI, V287, P7, DOI 10.1016/j.jns.2009.08.064; Uetani H, 2013, AM J NEURORADIOL, V34, P984, DOI 10.3174/ajnr.A3332; Venkatesan, 1999, MAGNETIC RESONANCE I; Verma RK, 2014, EUR J RADIOL, V83, P1448, DOI 10.1016/j.ejrad.2014.05.001; Walsh DO, 2000, MAGNET RESON MED, V43, P682, DOI 10.1002/(SICI)1522-2594(200005)43:5<682::AID-MRM10>3.0.CO;2-G; Wang DN, 2015, J STROKE CEREBROVASC, V24, P2728, DOI 10.1016/j.jstrokecerebrovasdis.2015.08.003; Wang MY, 2011, MAGN RESON IMAGING, V29, P365, DOI 10.1016/j.mri.2010.10.016; Wang Y, 2015, MAGN RESON MED, V73, P82, DOI 10.1002/mrm.25358; Wei Chen, 2012, 2012 5th International Conference on BioMedical Engineering and Informatics (BMEI), P447, DOI 10.1109/BMEI.2012.6513159; Wu DM, 2016, MAGN RESON MED, V76, P478, DOI 10.1002/mrm.25878; Wu JL, 2011, J MAGN RESON IMAGING, V34, P791, DOI 10.1002/jmri.22687; Wu Z, 2009, J MAGN RESON IMAGING, V29, P177, DOI 10.1002/jmri.21617; Xia S, 2014, MAGN RESON IMAGING, V32, P1272, DOI 10.1016/j.mri.2014.08.012; Xing W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057691; Xu B, 2014, MAGN RESON MED, V72, P438, DOI 10.1002/mrm.24937; Xu YB, 2008, MAGN RESON IMAGING, V26, P1406, DOI 10.1016/j.mri.2008.04.008; Yan L, 2014, RADIOL MED, V119, P175, DOI 10.1007/s11547-013-0328-1; Yang Q, 2009, J MAGN RESON IMAGING, V30, P357, DOI 10.1002/jmri.21859; Ye YQ, 2013, J MAGN RESON IMAGING, V38, P1539, DOI 10.1002/jmri.24128; YU S, 1989, RADIOLOGY, V170, P523, DOI 10.1148/radiology.170.2.2911680; Zhang JB, 2004, NMR BIOMED, V17, P459, DOI 10.1002/nbm.926; Zhaoyang Jin, 2012, 2012 5th International Conference on BioMedical Engineering and Informatics (BMEI), P22, DOI 10.1109/BMEI.2012.6512887; Zhou D, 2014, NMR BIOMED, V27, P312, DOI 10.1002/nbm.3064; Zhou ZY, 2013, RADIOLOGY, V268, P492, DOI 10.1148/radiol.13120874; Zwanenburg JJM, 2011, NEUROIMAGE, V56, P1902, DOI 10.1016/j.neuroimage.2011.03.046	181	67	70	1	42	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	APR	2017	30	4			SI				e3552	10.1002/nbm.3552			22	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	EQ5CY	WOS:000398100400003	27192086	Green Accepted			2022-02-06	
J	Ellis, MJ; Leddy, J; Willer, B				Ellis, Michael J.; Leddy, John; Willer, Barry			Multi-Disciplinary Management of Athletes with Post-Concussion Syndrome: An Evolving Pathophysiological Approach	FRONTIERS IN NEUROLOGY			English	Article						sports-related concussion; post-concussion syndrome; athlete; multi-disciplinary; management; treatment	SPORTS-RELATED CONCUSSION; CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; POSTCONCUSSION SYNDROME; RECOVERY-TIME; VESTIBULAR REHABILITATION; SENSORIMOTOR FUNCTION; PERSISTENT SYMPTOMS	Historically, patients with sports-related concussion (SRC) have been managed in a uniform fashion consisting mostly of prescribed physical and cognitive rest with the expectation that all symptoms will spontaneously resolve with time. Although this approach will result in successful return to school and sports activities in the majority of athletes, an important proportion will develop persistent concussion symptoms characteristic of post-concussion syndrome (PCS). Recent advances in exercise science, neuroimaging, and clinical research suggest that the clinical manifestations of PCS are mediated by unique pathophysiological processes that can be identified by features of the clinical history and physical examination as well as the use of graded aerobic treadmill testing. Athletes who develop PCS represent a unique population whose care must be individualized and must incorporate a rehabilitative strategy that promotes enhanced recovery of concussion-related symptoms while preventing physical deconditioning. In this review, we present our evolving evidence-based approach to evaluation and management of athletes with PCS that aims to identify the pathophysiological mechanisms mediating persistent concussion symptoms and guides the initiation of individually tailored rehabilitation programs that target these processes. In addition, we outline the important qualified roles that multi-disciplinary healthcare professionals can play in the management of this patient population, and discuss where future research efforts must be focused to further evaluate this evolving pathophysiological approach.	[Ellis, Michael J.] Univ Manitoba, Childrens Hosp Res Inst Manitoba, Canada North Concuss Network, Dept Surg Pediat & Child Hlth,Sect Neurosurg,Pan, Winnipeg, MB, Canada; [Leddy, John] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, UBMD Dept Orthopaed & Sports Med, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Jacobs Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY 14260 USA		Ellis, MJ (corresponding author), Univ Manitoba, Childrens Hosp Res Inst Manitoba, Canada North Concuss Network, Dept Surg Pediat & Child Hlth,Sect Neurosurg,Pan, Winnipeg, MB, Canada.	mellis3@panamclinic.com			University of Manitoba Department of Surgery Thorlakson Fund	Financial support of this manuscript was provided by the University of Manitoba Department of Surgery Thorlakson Fund.	Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Arunagiri Guruswami, 2003, Curr Opin Ophthalmol, V14, P344, DOI 10.1097/00055735-200312000-00005; Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Balaban CD, 2012, BRAIN RES, V1482, P101, DOI 10.1016/j.brainres.2012.08.040; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bhattacharyya N, 2008, OTOLARYNG HEAD NECK, V139, pS47, DOI 10.1016/j.otohns.2008.08.022; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; Chung S, 2011, J TRAUMA, V70, P873, DOI 10.1097/TA.0b013e3182108823; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Connery AK, 2016, PHYS MED REH CLIN N, V27, P475, DOI 10.1016/j.pmr.2015.12.001; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2014, J ATHL TRAINING, V49, P462, DOI 10.4085/1062-6059-49.2.03; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Echemendia RJ, 2012, ARCH CLIN NEUROPSYCH, V27, P119, DOI 10.1093/arclin/acr077; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Ellis M.J., 2014, CURR RES CONCUSSION, V1, P33; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00061; Ellis MJ, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15600; Ellis MJ, 2016, CURR SPORT MED REP, V15, P27, DOI 10.1249/JSR.0000000000000223; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, CURR SPORT MED REP, V14, P20, DOI 10.1249/JSR.0000000000000108; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Garcia JD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00040; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Giza CC, 2001, J ATHL TRAINING, V36, P228; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Hall CD, 2016, J NEUROL PHYS THER, V40, P124, DOI 10.1097/NPT.0000000000000120; Hamon M, 2013, PROG NEURO-PSYCHOPH, V45, P54, DOI 10.1016/j.pnpbp.2013.04.009; Hecht JS, 2004, J HEAD TRAUMA REHAB, V19, P58, DOI 10.1097/00001199-200401000-00006; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132090, 10.3171/2013.12.JNS132093]; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry M, 2013, J NEUROSURG-PEDIATR, V12, P30, DOI 10.3171/2013.4.PEDS12477; Hershey Andrew D, 2007, Curr Pain Headache Rep, V11, P390, DOI 10.1007/s11916-007-0222-4; HILLIER SL, 2011, COCHRANE DB SYST REV, V1; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Jull G, 2002, SPINE, V27, P1835, DOI 10.1097/00007632-200209010-00004; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Khan S, 2013, NEUROREHABILITATION, V32, P437, DOI 10.3233/NRE-130866; King ML, 1997, BRAIN INJURY, V11, P445; Koenigs M, 2009, BEHAV BRAIN RES, V201, P239, DOI 10.1016/j.bbr.2009.03.004; Kontos AP, 2016, BRIT J SPORT MED, V50, P139, DOI 10.1136/bjsports-2015-095564; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Losoi H, 2015, J NEUROTRAUM, V32, P942, DOI 10.1089/neu.2014.3799; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; Matuszak JM, 2016, SPORTS HEALTH, V8, P260, DOI 10.1177/1941738116641394; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Murdin L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010696.pub2; Mutch WAC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00107; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Ota M, 2014, J AFFECT DISORDERS, V165, P59, DOI 10.1016/j.jad.2014.04.032; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Passatore M, 2006, EUR J APPL PHYSIOL, V98, P423, DOI 10.1007/s00421-006-0312-8; Richer L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005220.pub2; Scheiman M, 2011, COCHRANE DB SYST REV, V3; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Scopaz KA, 2013, SPORTS HEALTH, V5, P537, DOI 10.1177/1941738112473059; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Starling AJ, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0521-0; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2010, CAN MED ASSOC J, V182, P1173, DOI 10.1503/cmaj.091430; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Treleaven J, 2010, MANUAL THER, V15, P206, DOI 10.1016/j.math.2009.05.001; Ventura RE, 2015, SEMIN NEUROL, V35, P599, DOI 10.1055/s-0035-1563567; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Wang Y., 2014, INT J DISTRIBUTED SE, V2014, P1, DOI DOI 10.1371/J0URNAL.P0NE.0110024; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	124	67	67	0	45	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	AUG 24	2016	7								136	10.3389/fneur.2016.00136			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT9BN	WOS:000381790300001	27605923	Green Published, gold			2022-02-06	
J	Ojo, JO; Mouzon, B; Algamal, M; Leary, P; Lynch, C; Abdullah, L; Evans, J; Mullan, M; Bachmeier, C; Stewart, W; Crawford, F				Ojo, Joseph O.; Mouzon, Benoit; Algamal, Moustafa; Leary, Paige; Lynch, Cillian; Abdullah, Laila; Evans, James; Mullan, Michael; Bachmeier, Corbin; Stewart, William; Crawford, Fiona			Chronic Repetitive Mild Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and Increased T-Tau and Tau Oligomers	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axonal injury; Behavior; Cerebral blood flow; Concussion; Glial activation; hTau mice; Tau	ALZHEIMERS-DISEASE; MOUSE MODEL; HEAD-INJURY; NEUROFIBRILLARY TANGLES; PROFESSIONAL FOOTBALL; DEMENTIA-PUGILISTICA; PHOSPHORYLATED-TAU; RISK-FACTOR; ENCEPHALOPATHY; NEURODEGENERATION	Exposure to repetitive mild traumatic brain injury (mTBI) is a risk factor for chronic traumatic encephalopathy, which is characterized by patchy deposition of hyperphosphorvlated tau aggregates in neurons and astrocytes at the depths of cortical sulci. We developed an mTBI paradigm to explore effects of repetitive concussive-type injury over several months in mice with a human tau genetic background (hTau). Two injuries were induced in the hTau mice weekly over a period of 3 or 4 months and the effects were compared with those in noninjured sham animals. Behavioral and in vivo measures and detailed neuropathological assessments were conducted 6 months after the first injury. Our data confirm impairment in cerebral blood flow and white matter damage. This was accompanied by a 2-fold increase in total tau levels and mild increases in tau oligomers/conformers and pTau (Thr231) species in brain gray matter. There was no evidence of neurofibrillary/astroglial tangles, neuropil threads, or perivascular foci of tau immunoreactivity. There were neurobehavioral deficits (ie, disinhibition and impaired cognitive performance) in the mTBI animals. These data support the relevance of this new mTBI injury model for studying the consequences of chronic repetitive mTBI in humans, and the role of tau in TBI.	[Ojo, Joseph O.; Mouzon, Benoit; Algamal, Moustafa; Leary, Paige; Lynch, Cillian; Abdullah, Laila; Evans, James; Mullan, Michael; Bachmeier, Corbin; Crawford, Fiona] Roskamp Inst, Sarasota, FL USA; [Mouzon, Benoit; Abdullah, Laila; Bachmeier, Corbin; Crawford, Fiona] James A Haley Vet Hosp, Tampa, FL USA; [Mouzon, Benoit; Algamal, Moustafa; Lynch, Cillian; Bachmeier, Corbin; Crawford, Fiona] Open Univ, Milton Keynes, Bucks, England; [Bachmeier, Corbin] Bay Pines VA Healthcare Syst, Bay Pines, FL USA; [Stewart, William] Queen Elizabeth Univ Hosp, Glasgow, Lanark, Scotland; [Stewart, William] Univ Glasgow, Glasgow, Lanark, Scotland; [Stewart, William] Univ Penn, Philadelphia, PA 19104 USA		Ojo, JO (corresponding author), Roskamp Inst, Neuropathol Core Unit, 2040 Whitfield Ave, Sarasota, FL 34324 USA.	bojo@roskampinstitute.net		Algamal, Moustafa/0000-0002-6215-0122; Stewart, William/0000-0003-2199-2582	Roskamp Foundation	This study was funded by the Roskamp Foundation.	Abdullah L, 2008, NEUROMOL MED, V14, P349; Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Bazan NG, 2006, CELL MOL NEUROBIOL, V26, P901, DOI 10.1007/s10571-006-9064-6; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Braak H, 2012, CURR OPIN NEUROL, V25, P708, DOI 10.1097/WCO.0b013e32835a3432; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRAHMANN H, 1957, Psychiatr Neurol (Basel), V134, P261; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Harbuz M, 2002, EXP PHYSIOL, V87, P519, DOI 10.1113/eph8702411; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kim HY, 2007, J BIOL CHEM, V282, P18661, DOI 10.1074/jbc.R700015200; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Kovacech B, 2010, NEURODEGENER DIS, V7, P24, DOI 10.1159/000283478; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Liu YT, 2001, EUR J PHARMACOL, V428, P193, DOI 10.1016/S0014-2999(01)01255-9; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mannix R, 2014, ANN NEUROL, V74, P65; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; McKee A, 2011, J NEUROPATH EXP NEUR, V70, P517; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Millspaugh JA, 2013, US NAVAL MED B, V35, P297; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nakamura K, 2013, PRION, V7, P117, DOI 10.4161/pri.22849; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Ojo JO, 2015, J NEUROPATH EXP NEUR, V74, P1012, DOI 10.1097/NEN.0000000000000247; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Paris D, 2003, NEUROL RES, V25, P642, DOI 10.1179/016164103101201940; Patterson KR, 2011, J BIOL CHEM, V286, P23063, DOI 10.1074/jbc.M111.237974; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Phillips M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019567; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; ROBERTS GW, 1988, LANCET, V2, P1456; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shahim P, 2016, J NEUROTRAUMA; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stewart W, 2015, QJM, V109, P11; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Uchihara T, 2001, ACTA NEUROPATHOL, V101, P535; Wohleb ES, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00447; Wu JW, 2013, J BIOL CHEM, V288, P1856, DOI 10.1074/jbc.M112.394528; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhang J, 2015, J CEREBR BLOOD F MET, V35, P443, DOI 10.1038/jcbfm.2014.216	91	67	67	0	39	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2016	75	7					636	655		10.1093/jnen/nlw035			20	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	DR3BG	WOS:000379777000003	27251042	Bronze, Green Published			2022-02-06	
J	Zhao, H; Garton, T; Keep, RF; Hua, Y; Xi, GH				Zhao, Hao; Garton, Thomas; Keep, Richard F.; Hua, Ya; Xi, Guohua			Microglia/Macrophage Polarization After Experimental Intracerebral Hemorrhage	TRANSLATIONAL STROKE RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; NADPH OXIDASE; IN-VIVO; MICROGLIA; ACTIVATION; MECHANISMS; ROLES; INFLAMMATION; PLASTICITY; PATHOLOGY		[Zhao, Hao; Garton, Thomas; Keep, Richard F.; Hua, Ya; Xi, Guohua] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA		Xi, GH (corresponding author), Univ Michigan, Dept Neurosurg, R5018 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	guohuaxi@umich.edu		Garton, Thomas/0000-0001-9352-8530; Keep, Richard/0000-0001-6441-5334	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS091545, NS-079157, NS-073595, R21 NS084049, R01 NS073595, NS-091545, NS-084049, R01 NS090925, NS-090925, R01 NS079157] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS090925, R01NS073595, R21NS091545, R21NS084049, R01NS079157] Funding Source: NIH RePORTER		Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Benton RL, 2011, TRANSL STROKE RES, V2, P556, DOI 10.1007/s12975-011-0128-7; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Boscia F, 2013, ADV EXP MED BIOL, V961, P307, DOI 10.1007/978-1-4614-4756-6_26; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; del Zoppo GJ, 2010, ANN NY ACAD SCI, V1207, P46, DOI 10.1111/j.1749-6632.2010.05760.x; Fetler L, 2005, SCIENCE, V309, P392, DOI 10.1126/science.1114852; Gao HM, 2003, J NEUROSCI, V23, P6181; Girard S, 2013, GLIA, V61, P813, DOI 10.1002/glia.22478; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jin H, 2013, TRANSL STROKE RES, V4, P130, DOI 10.1007/s12975-012-0232-3; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Lee DC, 2013, NEUROBIOL AGING, V34, P1610, DOI 10.1016/j.neurobiolaging.2012.12.014; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Pennypacker KR, 2014, TRANSL STROKE RES, V5, P635, DOI 10.1007/s12975-014-0372-8; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Seifert HA, 2014, TRANSL STROKE RES, V5, P543, DOI 10.1007/s12975-014-0349-7; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 2014, PROG NEUROBIOL, V115, P45, DOI 10.1016/j.pneurobio.2013.09.007; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zhao JB, 2014, TRANSL STROKE RES, V5, P586, DOI 10.1007/s12975-014-0353-y; Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003	34	67	68	1	23	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2015	6	6					407	409		10.1007/s12975-015-0428-4			3	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CV3JE	WOS:000364154700001	26446073	Green Accepted			2022-02-06	
J	Veeramuthu, V; Narayanan, V; Kuo, TL; Delano-Wood, L; Chinna, K; Bondi, MW; Waran, V; Ganesan, D; Ramli, N				Veeramuthu, Vigneswaran; Narayanan, Vairavan; Kuo, Tan Li; Delano-Wood, Lisa; Chinna, Karuthan; Bondi, Mark William; Waran, Vicknes; Ganesan, Dharmendra; Ramli, Norlisah			Diffusion Tensor Imaging Parameters in Mild Traumatic Brain Injury and Its Correlation with Early Neuropsychological Impairment: A Longitudinal Study	JOURNAL OF NEUROTRAUMA			English	Article						DTI; imaging biomarker; mTBI; neuropsychology; ROI; TBSS	WHITE-MATTER INTEGRITY; AXONAL INJURY; CORPUS-CALLOSUM; COGNITIVE DYSFUNCTION; SPATIAL STATISTICS; ASTROCYTE ACTIVATION; SPINAL-CORD; NEUROPATHOLOGY; ANISOTROPY; MEMORY	We explored the prognostic value of diffusion tensor imaging (DTI) parameters of selected white matter (WM) tracts in predicting neuropsychological outcome, both at baseline and 6 months later, among well-characterized patients diagnosed with mild traumatic brain injury (mTBI). Sixty-one patients with mTBI (mean age=27.08; standard deviation [SD], 8.55) underwent scanning at an average of 10h (SD, 4.26) post-trauma along with assessment of their neuropsychological performance at an average of 4.35h (SD, 7.08) upon full Glasgow Coma Scale recovery. Results were then compared to 19 healthy control participants (mean age=29.05; SD, 5.84), both in the acute stage and 6 months post-trauma. DTI and neuropsychological measures between acute and chronic phases were compared, and significant differences emerged. Specifically, chronic-phase fractional anisotropy and radial diffusivity values showed significant group differences in the corona radiata, anterior limb of internal capsule, cingulum, superior longitudinal fasciculus, optic radiation, and genu of corpus callosum. Findings also demonstrated associations between DTI indices and neuropsychological outcome across two time points. Our results provide new evidence for the use of DTI as an imaging biomarker and indicator of WM damage occurring in the context of mTBI, and they underscore the dynamic nature of brain injury and possible biological basis of chronic neurocognitive alterations.	[Veeramuthu, Vigneswaran; Narayanan, Vairavan; Waran, Vicknes; Ganesan, Dharmendra] Univ Malaya, Dept Surg, Div Neurosurg, Kuala Lumpur 50603, Wilayah Perseku, Malaysia; [Kuo, Tan Li; Ramli, Norlisah] Univ Malaya, Res Imaging Ctr, Kuala Lumpur 50603, Wilayah Perseku, Malaysia; [Delano-Wood, Lisa; Bondi, Mark William] VA San Diego Healthcare Syst, San Diego, CA USA; [Delano-Wood, Lisa; Bondi, Mark William] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Chinna, Karuthan] Univ Malaya, Dept Social & Prevent Med, Julius Ctr, Kuala Lumpur 50603, Wilayah Perseku, Malaysia		Veeramuthu, V (corresponding author), Univ Malaya, Dept Surg, Div Neurosurg, Kuala Lumpur 50603, Wilayah Perseku, Malaysia.	vicveera@gmail.com	Mathaneswaran, Vickneswaran/E-5180-2010; GANESAN, DHARMENDRA/B-8437-2010; NARAYANAN, VAIRAVAN/B-9191-2010; Veeramuthu, Vigneswaran/F-2220-2015; Tan, Li Kuo/B-5494-2010; chinna, karuthan/E-4495-2014; RAMLI, NORLISAH MOHD/G-5209-2010	NARAYANAN, VAIRAVAN/0000-0002-1118-5042; Veeramuthu, Vigneswaran/0000-0003-2052-0858; Tan, Li Kuo/0000-0002-6912-172X; chinna, karuthan/0000-0002-5449-2341; RAMLI, NORLISAH MOHD/0000-0001-7497-8093	University Malaya Research Grant (UMRG) [RG008C-13HTM]; High Impact Research Grant of University of Malaya [HIR-UM.C/625/1/HIR-MOHE/12]	This research is partially funded by a University Malaya Research Grant (UMRG; RG008C-13HTM) and a High Impact Research Grant of University of Malaya (HIR-UM.C/625/1/HIR-MOHE/12).	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Alexander AL, 2011, BRAIN CONNECT, V1, P423, DOI 10.1089/brain.2011.0071; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bach M, 2014, NEUROIMAGE, V100, P358, DOI 10.1016/j.neuroimage.2014.06.021; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bonnier Christine, 2004, Pediatr Rehabil, V7, P165, DOI 10.1080/13638490410001703325; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041; Chan YL, 2003, PEDIATR RADIOL, V33, P574, DOI 10.1007/s00247-003-0949-y; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Croall ID, 2014, NEUROLOGY, V83, P494, DOI 10.1212/WNL.0000000000000666; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Faul M., 2010, TBI US EMERGENCY DEP; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Ghonemi MO, 2013, EGYPT J CRIT CARE ME, V1, P139, DOI 10.1016/j.ejccm.2013.03.002; Gold BT, 2010, NEUROIMAGE, V52, P1487, DOI 10.1016/j.neuroimage.2010.05.036; Green Robin, 2010, Neuropsychol Rehabil, V20, P471, DOI 10.1080/09602011003693298; Grossman Elan J, 2010, Top Magn Reson Imaging, V21, P379, DOI 10.1097/RMR.0b013e31823e65b8; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Iffland PH, 2014, VASCULAR MECH CNS TR, P29, DOI DOI 10.1007/978-1-4614-8690-9_2; Imperati D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023437; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubicki M, 2007, J PSYCHIATR RES, V41, P15, DOI 10.1016/j.jpsychires.2005.05.005; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mukherjee P, 2002, AM J NEURORADIOL, V23, P1445; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Rovaris M, 2005, NEUROLOGY, V65, P1526, DOI 10.1212/01.wnl.0000184471.83948.e0; Saatman K. E., 2012, TRAUMATIC BRAIN SPIN; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Sen PN, 2005, BIOPHYS J, V89, P2927, DOI 10.1529/biophysj.105.063016; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shiramizu H, 2008, NEUROL MED-CHIR, V48, P1, DOI 10.2176/nmc.48.1; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Strangman GE, 2012, NEUROREHABILITATION, V31, P295, DOI 10.3233/NRE-2012-0797; Strong MJ, 2001, J NEUROCHEM, V76, P1315, DOI 10.1046/j.1471-4159.2001.00094.x; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Voets NL, 2006, BRAIN, V129, P754, DOI 10.1093/brain/awh679; Wada T, 2012, AM J NEURORADIOL, V33, P2117, DOI 10.3174/ajnr.A3141; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	81	67	70	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2015	32	19					1497	1509		10.1089/neu.2014.3750			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CR8NC	WOS:000361609500008	25952562	Green Published, Green Accepted, Bronze, Green Submitted			2022-02-06	
J	Jonas, JB; Wang, NL; Yang, DY; Ritch, R; Panda-Jonas, S				Jonas, Jost B.; Wang, Ningli; Yang, Diya; Ritch, Robert; Panda-Jonas, Songhomitra			Facts and myths of cerebrospinal fluid pressure for the physiology of the eye	PROGRESS IN RETINAL AND EYE RESEARCH			English	Article						Cerebrospinal fluid pressure; Glaucoma; Open-angle glaucoma; Normal-pressure glaucoma; Diabetic retinopathy; Retinal vein occlusion; Brain pressure	OPTIC-NERVE SHEATH; OPEN-ANGLE GLAUCOMA; CENTRAL RETINAL VEIN; NORMAL-TENSION GLAUCOMA; IDIOPATHIC INTRACRANIAL HYPERTENSION; INCREASED INTRAOCULAR-PRESSURE; ZONE PARAPAPILLARY ATROPHY; DOPPLER PULSATILITY INDEX; VISUAL-FIELD PROGRESSION; TRAUMATIC BRAIN-INJURY	The orbital cerebrospinal fluid pressure (CSFP) represents the true counter-pressure against the intraocular pressure (lOP) across the lamina cribrosa and is, therefore, one of the two determinants of the trans-lamina cribrosa pressure difference (TLPD). From this anatomic point of view, an elevated TLPD could be due to elevated lOP or abnormally low orbital CSFP. Both experimental and clinical studies have suggested that a low CSFP could be associated with glaucomatous optic neuropathy in normal-pressure glaucoma. These included monkey studies with an experimental long-term reduction in CSFP, and clinical retrospective and prospective studies on patients with normal-pressure glaucoma. Since the choroidal blood drains via the vortex veins through the superior ophthalmic vein into the intracranial cavernous sinus, anatomy suggests that the CSFP could influence choroidal thickness. A population-based study revealed that thicker subfoveal choroidal thickness was associated with higher CSFP. Since the central retinal vein passes through the orbital CSF space, anatomy suggests that the retinal venous pressure should be at least as high as the orbital CSFP. Other experimental, clinical or population-based studies suggested an association between higher CSFP and higher retinal venous pressure and wider retinal veins. Consequently, a higher estimated CSFP was associated with arterial hypertensive retinopathy (with respect to the dilated retinal vein diameter and higher arterial-to-venous diameter) and with the prevalence, severity and incidence of diabetic retinopathy. Physiologically, CSFP was related with higher !OP. The influence of the CSFP on the episcleral venous pressure and/or a regulation of both CSFP and lOP by a center in the dorsomedial/perifornical hypothalamus may be responsible for this. In summary, the CSFP may be an overlooked parameter in ocular physiology and pathology. Abnormal changes in the CSFP, in particular in relationship to the RP, may have pathophysiologic importance. (C) 2015 Elsevier Ltd. All rights reserved.	[Jonas, Jost B.; Panda-Jonas, Songhomitra] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Seegartenklin, Heidelberg, Germany; [Jonas, Jost B.; Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol,Beijing Ophthalmol & Visu, Beijing 100730, Peoples R China; [Wang, Ningli; Yang, Diya] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China; [Ritch, Robert] New York Ear Eye & Ear Infirm Mt Sinai, Einhorn Clin Res Ctr, New York, NY USA		Wang, NL (corresponding author), Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, 1 Dongjiaominxiang St, Beijing 100730, Peoples R China.	wningli@vip.163.com		Jonas, Jost/0000-0003-2972-5227; Ritch, Robert/0000-0002-9368-7547			ALBECK MJ, 1991, J NEUROSURG, V74, P597, DOI 10.3171/jns.1991.74.4.0597; ANDERSON DR, 1973, INVEST OPHTH VISUAL, V12, P204; Bauerle J, 2011, J NEUROL, V258, P2014, DOI 10.1007/s00415-011-6059-0; Balaratnasingam C, 2007, BRIT J OPHTHALMOL, V91, P441, DOI 10.1136/bjo.2006.105338; Balaratnasingam C, 2009, EXP EYE RES, V89, P618, DOI 10.1016/j.exer.2009.06.002; Baskaran M, 2006, OPHTHALMOLOGY, V113, P1327, DOI 10.1016/j.ophtha.2006.02.063; Behrens A, 2010, NEUROSURGERY, V66, P1050, DOI 10.1227/01.NEU.0000369519.35932.F2; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; Berdahl JP, 2008, OPHTHALMOLOGY, V115, P763, DOI 10.1016/j.ophtha.2008.01.013; Berdahl John P, 2013, J Glaucoma, V22 Suppl 5, pS17, DOI 10.1097/IJG.0b013e31829349fc; Berdahl JP, 2012, INVEST OPHTH VIS SCI, V53, P1422, DOI 10.1167/iovs.11-8220; Berdahl JP, 2008, INVEST OPHTH VIS SCI, V49, P5412, DOI 10.1167/iovs.08-2228; Brandi G, 2010, ACTA NEUROCHIR, V152, P965, DOI 10.1007/s00701-010-0643-4; Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001; Burgoyne CF, 2001, J GLAUCOMA, V10, pS16, DOI 10.1097/00061198-200110001-00007; CARLSON KH, 1987, INVEST OPHTH VIS SCI, V28, P1346; Chacon M, 2010, IEEE ENG MED BIO, P996, DOI 10.1109/IEMBS.2010.5627816; COX SN, 1988, ARCH OPHTHALMOL-CHIC, V106, P1190; CULLEN LK, 1990, AM J VET RES, V51, P300; Czarnik T, 2007, J TRAUMA, V62, P207, DOI 10.1097/01.ta.0000219128.29515.d5; Dai Y, 2013, INVEST OPHTH VIS SCI, V54, P2013, DOI 10.1167/iovs.12-11255; De Moraes CG, 2011, DOC OPHTHALMOL, V123, P43, DOI 10.1007/s10633-011-9280-3; De Moraes CGV, 2011, ARCH OPHTHALMOL-CHIC, V129, P562, DOI 10.1001/archophthalmol.2011.72; Dickerman RD, 1999, NEUROL RES, V21, P243, DOI 10.1080/01616412.1999.11740925; Dubourg J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-62; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Firsching R, 2000, J NEUROSURG, V93, P33, DOI 10.3171/jns.2000.93.1.0033; Firsching R, 2011, J NEUROSURG, V115, P371, DOI 10.3171/2011.3.JNS101275; Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3; Fleischman D., 2014, ACTA OPHTHALMOL; FRISEN L, 1984, OPHTHALMOLOGY, V91, P1342; Gallardo MJ, 2006, ADV THER, V23, P921, DOI 10.1007/BF02850214; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; GILLAND O, 1969, NEW ENGL J MED, V280, P904; Greenfield DS, 1997, ARCH OPHTHALMOL-CHIC, V115, P423, DOI 10.1001/archopht.1997.01100150425022; Gupta A, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-47; Gupta Aditi, 2013, Oman J Ophthalmol, V6, P183, DOI 10.4103/0974-620X.122275; Gupta P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096661; Han Y, 2008, ANN NEUROL, V64, P221, DOI 10.1002/ana.21416; Harder B, 2007, BRIT J OPHTHALMOL, V91, P401, DOI 10.1136/bjo.2006.103341; Hawthorne C, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00121; Hayreh SS, 2009, GRAEF ARCH CLIN EXP, V247, P721, DOI 10.1007/s00417-008-0984-3; Hayreh SS, 2000, AM J OPHTHALMOL, V130, P91, DOI 10.1016/S0002-9394(00)00387-1; HAYREH SS, 1971, BRIT J OPHTHALMOL, V55, P649, DOI 10.1136/bjo.55.10.649; Hayreh SS, 1998, INVEST OPHTH VIS SCI, V39, P2296; HAYREH SS, 1978, SURV OPHTHALMOL, V23, P1, DOI 10.1016/0039-6257(78)90194-7; Hayreh SS, 2001, OPHTHALMOLOGY, V108, P1586, DOI 10.1016/S0161-6420(01)00649-2; HAYREH SS, 1977, ARCH OPHTHALMOL-CHIC, V95, P1553, DOI 10.1001/archopht.1977.04450090075006; Hayreh SS, 2000, AM J OPHTHALMOL, V129, P786, DOI 10.1016/S0002-9394(00)00384-6; HEDGES TR, 1973, AM J OPHTHALMOL, V75, P90, DOI 10.1016/0002-9394(73)90657-0; Hirooka K, 2003, J GLAUCOMA, V12, P379, DOI 10.1097/00061198-200308000-00015; Iwase A, 2004, OPHTHALMOLOGY, V111, P1641, DOI 10.1016/j.ophtha.2004.03.029; Jaggi GP, 2007, EUR J OPHTHALMOL, V17, P454, DOI 10.1177/112067210701700334; Jaggi GP, 2010, BRIT J OPHTHALMOL, V94, P1088, DOI 10.1136/bjo.2009.171660; Jaggi GP, 2012, BRIT J OPHTHALMOL, V96, P53, DOI 10.1136/bjo.2010.199224; JAMES CB, 1991, GRAEF ARCH CLIN EXP, V229, P341, DOI 10.1007/BF00170692; Jonas J. B., 2014, ACTA OPHTHALMOL; JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P1599; JONAS JB, 1993, INVEST OPHTH VIS SCI, V34, P2260; JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P1604; Jonas JB, 1999, AM J OPHTHALMOL, V127, P523, DOI 10.1016/S0002-9394(99)00030-6; JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P2942; JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P401; Jonas JB, 2006, GRAEF ARCH CLIN EXP, V244, P129, DOI 10.1007/s00417-004-1042-4; Jonas JB, 2000, PROG RETIN EYE RES, V19, P1, DOI 10.1016/S1350-9462(99)00002-6; Jonas JB, 2004, INVEST OPHTH VIS SCI, V45, P2660, DOI 10.1167/iovs.03-1363; Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P501, DOI 10.1136/bjo.2003.030650; Jonas JB, 2003, INVEST OPHTH VIS SCI, V44, P5189, DOI 10.1167/iovs.03-0174; Jonas JB, 2003, ACTA OPHTHALMOL SCAN, V81, P419, DOI 10.1034/j.1600-0420.2003.00110.x; Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P949, DOI 10.1136/bjo.87.8.949; Jonas JB, 2003, GRAEF ARCH CLIN EXP, V241, P367, DOI 10.1007/s00417-003-0643-7; Jonas JB, 2003, J GLAUCOMA, V12, P285, DOI 10.1097/00061198-200306000-00019; Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P577, DOI 10.1136/bjo.87.5.577; Jonas JB, 1999, J GLAUCOMA, V8, P227; Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P361, DOI 10.1136/bjo.87.3.361-a; JONAS JB, 1989, ACTA OPHTHALMOL, V67, P199; Jonas JB, 1999, BRIT J OPHTHALMOL, V83, P1291, DOI 10.1136/bjo.83.11.1291; JONAS JB, 1994, GRAEF ARCH CLIN EXP, V232, P759, DOI 10.1007/BF00184280; Jonas JB, 2008, GRAEF ARCH CLIN EXP, V246, P1059, DOI 10.1007/s00417-008-0780-0; Jonas JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P287, DOI 10.1001/archopht.126.2.287-b; Jonas JB, 2007, OPHTHALMOLOGY, V114, P1791, DOI 10.1016/j.ophtha.2007.04.045; Jonas JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100533; Jonas JB, 2014, AM J HYPERTENS, V27, P1170, DOI 10.1093/ajh/hpu037; Jonas JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096273; Jonas JB, 2014, ACTA OPHTHALMOL, V92, pe273, DOI 10.1111/aos.12324; Jonas JB, 2014, INVEST OPHTH VIS SCI, V55, P1292, DOI 10.1167/iovs.13-13351; Jonas JB, 2014, ACTA OPHTHALMOL, V92, pE194, DOI 10.1111/aos.12297; Jonas JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086678; Jonas JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082284; Jonas JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047237; Jonas JB, 2012, INVEST OPHTH VIS SCI, V53, P6045, DOI 10.1167/iovs.12-10623; Jonas JB, 2011, AM J OPHTHALMOL, V152, P1021, DOI 10.1016/j.ajo.2011.05.006; Jonas JB, 2011, J GLAUCOMA, V20, P405, DOI 10.1097/IJG.0b013e3181f7af9b; Jonas JB, 2011, ACTA OPHTHALMOL, V89, P505, DOI 10.1111/j.1755-3768.2010.01915.x; Kain S, 2010, BRIT J OPHTHALMOL, V94, P854, DOI 10.1136/bjo.2009.169813; Kaufmann C, 2006, ARCH OPHTHALMOL-CHIC, V124, P1104, DOI 10.1001/archopht.124.8.1104; Kawasaki R, 2013, OPHTHALMOLOGY, V120, P84, DOI 10.1016/j.ophtha.2012.07.007; Killer HE, 2007, BRAIN, V130, P514, DOI 10.1093/brain/awl324; Killer HE, 2008, J HISTOCHEM CYTOCHEM, V56, P1087, DOI 10.1369/jhc.2008.950840; Killer HE, 2008, CLIN EXP OPHTHALMOL, V36, P308, DOI 10.1111/j.1442-9071.2008.01735.x; Killer Hanspeter E, 2013, J Glaucoma, V22 Suppl 5, pS8, DOI 10.1097/IJG.0b013e318293498b; Killer HE, 2012, BRIT J OPHTHALMOL, V96, P544, DOI 10.1136/bjophthalmol-2011-300663; Killer Hanspeter Esriel, 2013, J Glaucoma, V22 Suppl 5, pS19, DOI 10.1097/IJG.0b013e3182934a0f; Killer HE, 2011, BRIT J OPHTHALMOL, V95, P822, DOI 10.1136/bjo.2010.189324; Killer HE, 2006, BRAIN, V129, P1027, DOI 10.1093/brain/awl045; Killer HE, 1999, J NEURO-OPHTHALMOL, V19, P222; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Kirk T, 2011, ANN NEUROL, V70, P323, DOI 10.1002/ana.22414; Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P76, DOI 10.1001/archopht.122.1.76; Klein R, 2007, OPHTHALMOLOGY, V114, P1884, DOI 10.1016/j.ophtha.2007.02.023; Klein R, 2006, OPHTHALMOLOGY, V113, P1488, DOI 10.1016/j.ophtha.2006.03.028; KLINGELHOFER J, 1987, KLIN WOCHENSCHR, V65, P542, DOI 10.1007/BF01727619; Kramer LA, 2012, RADIOLOGY, V263, P819, DOI 10.1148/radiol.12111986; Lang EW, 2003, J NEUROSURG, V98, P214, DOI 10.3171/jns.2003.98.1.0214; Lashutka MK, 2004, ANN EMERG MED, V43, P585, DOI 10.1016/j.annemergmed.2003.12.006; Le A, 2009, ANN EMERG MED, V53, P785, DOI 10.1016/j.annemergmed.2008.11.025; Lenfeldt N, 2007, NEUROLOGY, V68, P155, DOI 10.1212/01.wnl.0000250270.54587.71; Li J, 2013, BIOL CELL, V105, P304, DOI 10.1111/boc.201300013; Li Z, 2013, CHINESE MED J-PEKING, V126, P1588, DOI 10.3760/cma.j.issn.0366-6999.20123186; Li Z, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-66; Mader TH, 2013, J NEURO-OPHTHALMOL, V33, P249, DOI 10.1097/WNO.0b013e31829b41a6; Mader TH, 2011, OPHTHALMOLOGY, V118, P2058, DOI 10.1016/j.ophtha.2011.06.021; MAGNAES B, 1976, J NEUROSURG, V44, P687, DOI 10.3171/jns.1976.44.6.0687; Mansouri K, 2012, INVEST OPHTH VIS SCI, V53, P8050, DOI 10.1167/iovs.12-10569; Maurel D, 1996, BRAIN RES, V736, P165, DOI 10.1016/0006-8993(96)00676-2; MINCKLER DS, 1976, AM J OPHTHALMOL, V82, P741, DOI 10.1016/0002-9394(76)90012-X; Mitchell P, 2005, AM J OPHTHALMOL, V140, P131, DOI 10.1016/j.ajo.2004.12.088; MOLLER P M, 1955, Acta Ophthalmol Suppl, P1; MOLLER P M, 1954, Acta Ophthalmol (Copenh), V32, P597; Moretti R, 2009, NEUROCRIT CARE, V11, P406, DOI 10.1007/s12028-009-9250-8; Moretti R, 2009, J NEUROSURG ANESTH, V21, P16, DOI 10.1097/ANA.0b013e318185996a; Morgan WH, 2009, BRIT J OPHTHALMOL, V93, P594, DOI 10.1136/bjo.2008.149963; MORGAN WH, 1995, INVEST OPHTH VIS SCI, V36, P1163; Morgan WH, 1998, INVEST OPHTH VIS SCI, V39, P1419; Morgan WH, 2004, OPHTHALMOLOGY, V111, P1489, DOI 10.1016/j.ophtha.2003.12.053; Morgan WH, 2002, INVEST OPHTH VIS SCI, V43, P3236; Morgan WH, 1997, MICROVASC RES, V53, P211, DOI 10.1006/mvre.1997.2010; Morgan W, 2012, INVEST OPHTH VIS SCI, V53, P6880, DOI 10.1167/iovs.12-10943; Morgan WH, 2008, J GLAUCOMA, V17, P408, DOI 10.1097/IJG.0b013e31815c5f7c; Morgan WH, 2012, INVEST OPHTH VIS SCI, V53, P4676, DOI 10.1167/iovs.12-9837; Morgan WH, 2008, CLIN EXP OPHTHALMOL, V36, P802, DOI 10.1111/j.1442-9071.2008.01881.x; Motschmann M, 2001, Strabismus, V9, P13, DOI 10.1076/stra.9.1.13.711; Paques M, 2005, INVEST OPHTH VIS SCI, V46, P4707, DOI 10.1167/iovs.05-0638; PEYMAN GA, 1972, ARCH OPHTHALMOL-CHIC, V88, P650; Pillunat KR, 2014, BRIT J OPHTHALMOL, V98, P1374, DOI 10.1136/bjophthalmol-2014-305126; Pinto LA, 2012, GRAEF ARCH CLIN EXP, V250, P1075, DOI 10.1007/s00417-011-1878-3; Potgieter DW, 2011, ANAESTH INTENS CARE, V39, P95, DOI 10.1177/0310057X1103900116; Qu YZ, 2011, ACTA OPHTHALMOL, V89, pE428, DOI 10.1111/j.1755-3768.2011.02118.x; Querfurth HW, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-106; QUIGLEY HA, 1976, INVEST OPHTH VISUAL, V15, P606; Ragauskas A, 2005, ACT NEUR S, V95, P357; Ragauskas A, 2012, NEUROLOGY, V78, P1684, DOI 10.1212/WNL.0b013e3182574f50; Ragauskas A, 2014, NEUROL RES, V36, P607, DOI 10.1179/1743132813Y.0000000308; REID A, 1990, British Journal of Audiology, V24, P123, DOI 10.3109/03005369009077853; Ren RJ, 2012, GRAEF ARCH CLIN EXP, V250, P445, DOI 10.1007/s00417-011-1746-1; Ren RJ, 2011, GRAEF ARCH CLIN EXP, V249, P1057, DOI 10.1007/s00417-011-1657-1; Ren RJ, 2011, ACTA OPHTHALMOL, V89, pE142, DOI 10.1111/j.1755-3768.2010.02015.x; Ren RJ, 2010, OPHTHALMOLOGY, V117, P259, DOI 10.1016/j.ophtha.2009.06.058; Ren RJ, 2009, INVEST OPHTH VIS SCI, V50, P2175, DOI 10.1167/iovs.07-1429; RIOSMONTENEGRO EN, 1973, ARCH OPHTHALMOL-CHIC, V89, P52; RODRIGUE.LA, 1966, J COMP NEUROL, V126, P109, DOI 10.1002/cne.901260109; ROSENBLOOM AL, 1990, DIABETES CARE, V13, P22, DOI 10.2337/diacare.13.1.22; Sajjadi SA, 2006, ANN NEUROL, V59, P867, DOI 10.1002/ana.20856; Salman MS, 1997, LANCET, V350, P1367, DOI 10.1016/S0140-6736(05)65138-0; Samuels BC, 2012, INVEST OPHTH VIS SCI, V53, P7328, DOI 10.1167/iovs.12-10632; Schuman JS, 2000, OPHTHALMOLOGY, V107, P127, DOI 10.1016/S0161-6420(99)00015-9; Sheeran P, 2000, LANCET, V355, P899, DOI 10.1016/S0140-6736(99)02768-3; Shimbles S, 2005, ACTA NEUROCHIR SUPPL, V95, P197; SHIN DH, 1995, INVEST OPHTH VIS SCI, V36, P2163; SHIOSE Y, 1991, JPN J OPHTHALMOL, V35, P133; Siaudvytyte L., 2014, ACTA OPHTHALMOL; Silver DM, 2000, CURR EYE RES, V20, P115, DOI 10.1076/0271-3683(200002)20:2;1-D;FT115; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Spentzas T, 2010, PEDIATR CRIT CARE ME, V11, P593, DOI 10.1097/PCC.0b013e3181ce755c; Srinivasan S, 2012, PEDIATR EMERG CARE, V28, P696, DOI 10.1097/PEC.0b013e31825d2198; Stodtmeister R, 2008, KLIN MONATSBL AUGENH, V225, P632, DOI 10.1055/s-2008-1027233; Stodtmeister R, 2013, INVEST OPHTH VIS SCI, V54, P4698, DOI 10.1167/iovs.12-10607; Stodtmeister R, 2010, INVEST OPHTH VIS SCI, V51, P6620, DOI 10.1167/iovs.09-4594; Strumwasser A, 2011, J SURG RES, V170, P265, DOI 10.1016/j.jss.2011.03.009; Tain RW, 2009, IEEE T BIO-MED ENG, V56, P544, DOI 10.1109/TBME.2008.2006010; Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782; TARKKANEN A, 1967, ACTA OPHTHALMOL, V45, P569; Teng CC, 2011, OPHTHALMOLOGY, V118, P2409, DOI 10.1016/j.ophtha.2011.06.014; Teng CC, 2010, OPHTHALMOLOGY, V117, P909, DOI 10.1016/j.ophtha.2009.10.016; Toyokawa N, 2012, OPHTHAL SURG LAS IM, V43, P109, DOI 10.3928/15428877-20120102-06; TSUKAHARA I, 1975, A GRAEF ARCH KLIN EX, V196, P239, DOI 10.1007/BF00410035; VANDERMEULEN JA, 1987, LANCET, V2, P306; Volkov V V, 1976, Oftalmol Zh, V31, P500; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Wang NL, 2012, OPHTHALMOLOGY, V119, P2065, DOI 10.1016/j.ophtha.2012.03.054; Wang YX, 2013, ACTA OPHTHALMOL, V91, P521, DOI 10.1111/j.1755-3768.2012.02454.x; Wang YX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104267; Wegner W, 1930, ARCH AUGENHEILKD, V102, P1; WEINREB RN, 1984, AM J OPHTHALMOL, V98, P784, DOI 10.1016/0002-9394(84)90698-6; WOOD E G, 1990, Pediatric Emergency Care, V6, P285, DOI 10.1097/00006565-199012000-00009; Wostyn P, 2015, ACTA OPHTHALMOL, V93, pE83, DOI 10.1111/aos.12331; Wostyn P, 2014, PROG RETIN EYE RES, V39, P107, DOI 10.1016/j.preteyeres.2013.12.002; Wostyn P, 2013, AM J OPHTHALMOL, V156, P5, DOI 10.1016/j.ajo.2013.03.003; Wostyn P, 2010, J GLAUCOMA, V19, P225, DOI 10.1097/IJG.0b013e3181c29af4; Xie XB, 2013, CRIT CARE, V17, DOI 10.1186/cc12841; Xin XR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020142; Xu L, 2007, AM J OPHTHALMOL, V144, P541, DOI 10.1016/j.ajo.2007.05.038; Xu L, 2007, AM J OPHTHALMOL, V144, P461, DOI 10.1016/j.ajo.2007.05.013; Xu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030104; Xu P, 2010, IEEE T INF TECHNOL B, V14, P971, DOI 10.1109/TITB.2009.2027317; Yablonski M, 1979, INVEST OPHTHALMOL  S, V18, P165; Yang DY, 2014, INVEST OPHTH VIS SCI, V55, P3067, DOI 10.1167/iovs.13-13657; Yang HL, 2007, INVEST OPHTH VIS SCI, V48, P5068, DOI 10.1167/iovs.07-0790; Zeng T, 2010, CHIN J TRAUMATOL, V13, P146, DOI 10.3760/cma.j.issn.1008-1275.2010.03.003; Zhang Z, 2014, ACTA OPHTHALMOL, V92, pE475, DOI 10.1111/aos.12263	211	67	72	0	32	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1350-9462	1873-1635		PROG RETIN EYE RES	Prog. Retin. Eye Res.	MAY	2015	46						67	83		10.1016/j.preteyeres.2015.01.002			17	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	CI2PZ	WOS:000354590800003	25619727				2022-02-06	
J	Cifu, DX; Wares, JR; Hoke, KW; Wetzel, PA; Gitchel, G; Carne, W				Cifu, David X.; Wares, Joanna R.; Hoke, Kathy W.; Wetzel, Paul A.; Gitchel, George; Carne, William			Differential Eye Movements in Mild Traumatic Brain Injury Versus Normal Controls	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						eye tracking; fixations; mild traumatic brain injury; postconcussion syndrome; saccades; smooth pursuit	DEFICITS; CONCUSSION; ACTIVATION; SYMPTOMS; SOLDIERS; TBI; MRI; US	Objectives: Objective measures to diagnose and to monitor improvement of symptoms following mild traumatic brain injury (mTBI) are lacking. Computerized eye tracking has been advocated as a rapid, user friendly, and field-ready technique to meet this need. Design: Eye-tracking data collected via a head-mounted, video-based binocular eye tracker was used to examine saccades, fixations, and smooth pursuit movement in military Service Members with postconcussive syndrome (PCS) and asymptomatic control subjects in an effort to determine if eye movement differences could be found and quantified. Participants: Sixty Military Service Members with PCS and 26 asymptomatic controls. Outcome Measures: The diagnosis of mTBI was confirmed by the study physiatrist's history, physical examination, and a review of any medical records. Various features of saccades, fixation and smooth pursuit eye movements were analyzed. Results: Subjects with symptomatic mTBI had statistically larger position errors, smaller saccadic amplitudes, smaller predicted peak velocities, smaller peak accelerations, and longer durations. Subjects with symptomatic mTBI were also less likely to follow a target movement (less primary saccades). In general, symptomatic mTBI tracked the stepwise moving targets less accurately, revealing possible brain dysfunction. Conclusions: A reliable, standardized protocol that appears to differentiate mTBI from normals was developed for use in future research. This investigation represents a step toward objective identification of those with PCS. Future studies focused on increasing the specificity of eye movement differences in those with PCS are needed.	[Cifu, David X.; Carne, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Wetzel, Paul A.; Gitchel, George] Virginia Commonwealth Univ, Dept Biomed Engn, Richmond, VA 23298 USA; [Cifu, David X.] Dept Vet Affairs, Phys Med & Rehabil Program Off, Richmond, VA USA; [Wares, Joanna R.; Hoke, Kathy W.] Univ Richmond, Dept Math & Comp Sci, Richmond, VA 23173 USA		Carne, W (corresponding author), Virginia Commonwealth Univ, Dept PM&R, 1223 East Marshall St, Richmond, VA 23298 USA.	lasile@aol.com		Cifu, David/0000-0003-1600-9387	Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-09-2-206]; US Navy Bureau of Medicine and Surgery; US Army Medical Materiel Development Activity	Funding was provided for the primary study by a Defense Advanced Research Projects Agency grant (N66001-09-2-206), US Navy Bureau of Medicine and Surgery for contract funding temporary duty requirements, and the US Army Medical Materiel Development Activity for end-of-study contract funding. The funding sources had no role in the study design, analysis, interpretation of the data, the writing of the paper, or the decision to submit the paper for publication.	Arciniegas David B, 2004, Phys Med Rehabil Clin N Am, V15, P177, DOI 10.1016/S1047-9651(03)00104-9; Bast A., VETERANS HEAD INJURI; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Buxton RB, 2004, NEUROIMAGE, V23, pS220, DOI 10.1016/j.neuroimage.2004.07.013; Ceranic BJ, 1998, J NEUROL NEUROSUR PS, V65, P523, DOI 10.1136/jnnp.65.4.523; Cifu DX, 2014, J HEAD TRAUMA REHAB, V29, P11, DOI 10.1097/HTR.0b013e3182a6aaf0; Ciuffreda KJ, 2011, OPTOMETRY, V82, P61, DOI 10.1016/j.optm.2010.11.011; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Deppe M, 2004, NEUROIMAGE, V21, P1124, DOI 10.1016/j.neuroimage.2003.10.016; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Leigh RJ, 2006, NEUROLOGY EYE MOVEME; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Pickett TC, 2007, J REHABIL RES DEV, V44, P983, DOI 10.1682/JRRD.2007.01.0001; Ramat S, 2007, BRAIN, V130, P10, DOI 10.1093/brain/awl309; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; US Department of Veterans Affairs, MAN CONC MILD TRAUM; WHO, ICD 10 INT STAT CLAS; Yang M., HEAD TRAUMA SENSORS; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	26	67	67	1	36	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					21	28		10.1097/HTR.0000000000000036			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400011	24695263				2022-02-06	
J	Raj, R; Siironen, J; Skrifvars, MB; Hernesniemi, J; Kivisaari, R				Raj, Rahul; Siironen, Jari; Skrifvars, Markus B.; Hernesniemi, Juha; Kivisaari, Riku			Predicting Outcome in Traumatic Brain Injury: Development of a Novel Computerized Tomography Classification System (Helsinki Computerized Tomography Score)	NEUROSURGERY			English	Article						Computerized tomography; Helsinki CT; Marshall CT; Prediction model; Prognosis; Rotterdam CT; Sensitivity and specificity; Traumatic brain injury	GLASGOW COMA SCALE; HEAD-INJURY; ADMISSION CHARACTERISTICS; EXTERNAL VALIDATION; PROGNOSTIC VALUE; PRACTICAL SCALE; IMPACT MODELS; MORTALITY; MODERATE; CUSTOMIZATION	BACKGROUND: Early computerized tomography (CT) abnormalities are important predictors of outcome after traumatic brain injury (TBI). OBJECTIVE: To develop a novel CT scoring system (Helsinki CT score) and to compare it with the Marshall CT classification and the Rotterdam CT score in predicting long-term outcome of patients with TBI. METHODS: Eight hundred sixty-nine consecutive TBI patients were included in this open-cohort, retrospective, single-center study. Logistic regression was used to develop the Helsinki CT score. The scores from the Marshall, Rotterdam, and Helsinki CT scoring methods were added to a clinical model based on age, motor score, and pupils to evaluate their value in predicting outcome. Internal validity was assessed by a bootstrap technique and expressed as area under the curve (AUC). Outcome was 6-month unfavorable neurological outcome and mortality. RESULTS: Variables included in the Helsinki CT score were bleeding type and size, intraventricular hemorrhage, and suprasellar cisterns. In the present data set, the performance of the Helsinki CT score was superior to that of the Marshall CT and Rotterdam CT scores (AUC, 0.74-0.75 vs 0.63-0.70; P < .001). Addition of the Helsinki CT score modestly increased prognostic performance of the clinical model (AUC neurological outcome 10.02 [P =.002]; AUC mortality, 10.01 [P = .21]). In contrast, the Marshall and Rotterdam CT scores were of no additional predictive value to the clinical model (P > .05). CONCLUSION: Use of the novel Helsinki CT score improved outcome prediction accuracy, and the Helsinki CT score is a feasible alternative to the Rotterdam and Marshall CT systems. External validation of the Helsinki CT score is advocated to show generalizability.	[Raj, Rahul; Siironen, Jari; Hernesniemi, Juha; Kivisaari, Riku] Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland; [Skrifvars, Markus B.] Helsinki Univ Hosp, Dept Intens Care, Helsinki, Finland		Raj, R (corresponding author), Helsinki Univ Hosp, Dept Neurosurg, Topeliuksenkatu 5,PB 266, Helsinki 00029, Finland.	rahul.raj@hus.fi	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591	Finska Lakaresallskapet; Maire Taponen Foundation; Helsinki University Hospital EVO [TYH2012142]	This study was funded by grants from Finska Lakaresallskapet, the Maire Taponen Foundation, and a Helsinki University Hospital EVO grant (TYH2012142). The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Bakhshi-Raiez F, 2007, CRIT CARE MED, V35, P2553, DOI 10.1097/01.CCM.0000288123.29559.5A; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; Huang YH, 2012, NEUROSURGERY, V71, P80, DOI 10.1227/NEU.0b013e3182517aa1; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Jacobs B, 2013, NEUROCRIT CARE, V19, P79, DOI 10.1007/s12028-012-9795-9; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; JENNETT B, 1975, LANCET, V1, P480; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; LEE JP, 1991, ACTA NEUROL SCAND, V84, P85, DOI 10.1111/j.1600-0404.1991.tb04913.x; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; Moons KGM, 2002, J CLIN EPIDEMIOL, V55, P1054, DOI 10.1016/S0895-4356(02)00453-5; Moreno R, 1997, CRIT CARE MED, V25, P2001, DOI 10.1097/00003246-199712000-00017; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Raj R, 2014, CRIT CARE, V18, DOI 10.1186/cc13814; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Seshan VE, 2013, STAT MED, V32, P1483, DOI 10.1002/sim.5648; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Steyerberg E., 2010, CLIN PREDICTION MODE; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1974, LANCET, V2, P81; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Zhu BP, 1996, CRIT CARE MED, V24, P57, DOI 10.1097/00003246-199601000-00011	37	67	71	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2014	75	6					632	646		10.1227/NEU.0000000000000533			15	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AU2FK	WOS:000345431600022	25181434				2022-02-06	
J	Asehnoune, K; Seguin, P; Allary, J; Feuillet, F; Lasocki, S; Cook, F; Floch, H; Chabanne, R; Geeraerts, T; Roger, C; Perrigault, PF; Hanouz, JL; Lukaszewicz, AC; Biais, M; Boucheix, P; Dahyot-Fizelier, C; Capdevila, X; Mahe, PJ; Le Maguet, P; Paugam-Burtz, C; Gergaud, S; Plaud, B; Constantin, JM; Malledant, Y; Flet, L; Sebille, V; Roquilly, A				Asehnoune, Karim; Seguin, Philippe; Allary, Jeremy; Feuillet, Fanny; Lasocki, Sigismond; Cook, Fabrice; Floch, Herve; Chabanne, Russell; Geeraerts, Thomas; Roger, Claire; Perrigault, Pierre F.; Hanouz, Jean L.; Lukaszewicz, Anne C.; Biais, Matthieu; Boucheix, Perrine; Dahyot-Fizelier, Claire; Capdevila, Xavier; Mahe, Pierre J.; Le Maguet, Pascale; Paugam-Burtz, Catherine; Gergaud, Soizic; Plaud, Benoit; Constantin, Jean M.; Malledant, Yannick; Flet, Laurent; Sebille, Veronique; Roquilly, Antoine		Corti-TC Study Grp	Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial	LANCET RESPIRATORY MEDICINE			English	Article							LOW-DOSE HYDROCORTISONE; SEPTIC SHOCK; MORTALITY; THERAPY; INSUFFICIENCY; MANAGEMENT; CYTOKINES; GROWTH	Background Hospital-acquired pneumonia is common after traumatic brain injury, and might be partly a result of traumatic brain injury-induced adrenal insufficiency. We tested the efficacy of low-dose hydrocortisone with fludrocortisone for the prevention of hospital-acquired pneumonia. Methods We did this double-blind, phase 3, placebo-controlled trial in 19 intensive care units in France. We enrolled patients aged 15-65 years in the first 24 h after severe traumatic brain injury (Glasgow coma scale score 158 and trauma-associated lesion on brain CT scan). Patients were randomly assigned (1:1; fixed blocks of 12, stratified by centre and mechanism, Glasgow coma scale, age, and arterial pressure [MGAP] score) to receive either hydrocortisone (200 mg per day tapered) and fludrocortisone (50 mu g tablet once per day) or matching placebo for 10 days. Before receiving study drug, adrenal function was assessed with a short corticotropin test. Treatment was stopped if patients had no adrenal insufficiency. The primary outcome was the occurrence of hospital-acquired pneumonia within 28 days after randomisation. We did an intention-to-treat analysis and a modified intention-to-treat analysis including only patients with adrenal insufficiency (adjusted for etomidate use). This study is registered with ClinicalTrials.gov, number NCT01093261. Findings From Sept 1,2010, to Nov 29,2012, we enrolled 336 patients (168 assigned to each group). Eight patients withdrew consent. At day 28,74 of 165 patients (45%) in the steroid group and 87 of 163 (53%) in the placebo group had developed one or more episodes of hospital-acquired pneumonia (hazard ratio [Hit] 0.75; 95% CI 0.55-1-03, p=0-07). In intention-to-treat analysis, we recorded 86 episodes of hospital-acquired pneumonia in the steroid group versus 110 in the placebo group (median 0, IQR 0-1 vs median 1, IQR 0-1 cases per patient, p=0.07). In modified intention-to-treat analyses, the HR for hospital-acquired pneumonia with steroids versus placebo was 0-80 (95% CI 0.56-1-14, p=0.22) in patients with adrenal insufficiency, and, in an exploratory preplanned analysis, 0.48 (0.23-1.01; p=0.05) in patients with normal adrenal function. We recorded no adverse events related to treatment. Interpretation Low-dose hydrocortisone with fludrocortisone did not improve the outcome of patients with traumatic brain injury. However, the study was underpowered because the proportion of patients with hospital-acquired pneumonia in the placebo group was lower than expected. The results were close to statistical significance for efficacy, meaning that further studies are therefore needed.	[Asehnoune, Karim; Mahe, Pierre J.; Roquilly, Antoine] CHU Nantes, Serv Anesthesie Reanimat Chirurg, Pole Anesthesie Reanimat, F-44093 Nantes 1, France; [Seguin, Philippe; Le Maguet, Pascale; Malledant, Yannick] Univ Rennes 1, CHU Rennes, Serv Anesthesie Reanimat 1, Rennes, France; [Allary, Jeremy; Paugam-Burtz, Catherine] Hop Beaujon, AP HP, Serv Anesthesie Reanimat Chirurg, Beaujon, France; [Feuillet, Fanny; Sebille, Veronique] CHU Nantes, Plateforme Biometrie Cellule Promot Rech Clin, F-44093 Nantes 1, France; [Feuillet, Fanny; Sebille, Veronique] Univ Nantes, EA SPHERE Biostat Pharmacoepidemiol & Human Sci 4, UFR Pharm, Nantes, France; [Lasocki, Sigismond; Gergaud, Soizic] CHU Angers, Serv Anesthesie Reanimat, Angers, France; [Cook, Fabrice; Plaud, Benoit] Hop Henri Mondor, AP HP, Serv Anesthesie Reanimat Chirurg, F-94010 Creteil, France; [Floch, Herve] CHU Brest, Serv Anesthesie Reanimat, F-29285 Brest, France; [Chabanne, Russell; Constantin, Jean M.] CHU Clermont Ferrand, Serv Anesthesie Reanimat, Clermont Ferrand, France; [Geeraerts, Thomas] Univ Toulouse 3, Dept Anesthesiol & Intens Care, Univ Hosp Toulouse, Equipe Accueil Modelisat Agress Tissulaire & Noci, F-31062 Toulouse, France; [Roger, Claire] CHU Nimes, Serv Reanimat, Div Anesthesie Reanimat Douleur Urgence, Nimes, France; [Perrigault, Pierre F.] CHU Montpellier, Hop Gui de Chauliac, Serv Anesthesie Reanimat, Montpellier, France; [Hanouz, Jean L.] CHU Caen, Serv Anesthesie Reanimat, F-14000 Caen, France; [Lukaszewicz, Anne C.] Hop Lariboisiere, AP HP, Serv Anesthesie Reanimat chirurg, F-75475 Paris, France; [Biais, Matthieu] CHU Bordeaux, Serv Anesthesie Reanimat, Bordeaux, France; [Boucheix, Perrine] CHU Grenoble, Hop Michallon, Serv Anesthesie Reanimat, F-38043 Grenoble, France; [Dahyot-Fizelier, Claire] CHU Poitiers, Serv Anesthesie Reanimat, Poitiers, France; [Capdevila, Xavier] CHU Montpellier, Hop Lapeyronie, Serv Anesthesie Reanimat, Montpellier, France; [Flet, Laurent] CHU Nantes, Pole Biol Pharm, Serv Pharm, F-44093 Nantes 1, France		Asehnoune, K (corresponding author), CHU Nantes, Serv Anesthesie Reanimat, 1 Pl Alexis Ricordeau, F-44093 Nantes 1, France.	karim.asehnoune@chu-nantes.fr	Sebille, Veronique/I-3309-2015; Seguin, Philippe/P-9487-2019; FLET, Laurent/X-1192-2019; Sebille, Veronique/L-8761-2015; Roquilly, Antoine/P-9826-2017; Feuillet, Fanny/L-9041-2015; lasocki, sigismond/G-9443-2016; Didier, Journois/J-3074-2019	Seguin, Philippe/0000-0002-7774-4257; FLET, Laurent/0000-0001-8305-7085; Didier, Journois/0000-0003-1096-7373; Roquilly, Antoine/0000-0002-1029-6242; capdevila, xavier/0000-0002-9791-8779; Sebille, Veronique/0000-0002-0780-7742; hanouz, jean-luc/0000-0003-1845-8610; mimoz, olivier/0000-0003-1737-7915; Paugam-Burtz, Catherine/0000-0002-8168-7152; Malledant, yannick/0000-0001-6680-5184	Societe Francaise d'Anesthesie Reanimation	Funding Societe Francaise d'Anesthesie Reanimation.	Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Asehnoune K, 2012, INTENS CARE MED, V38, P1673, DOI 10.1007/s00134-012-2619-8; Asehnoune K, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-228; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Boonen E, 2013, NEW ENGL J MED, V368, P1477, DOI 10.1056/NEJMoa1214969; Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons, 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2007.9991; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI [10.1007/s00134-004-2210-z, 10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; HASAN D, 1989, STROKE, V20, P1156, DOI 10.1161/01.STR.20.9.1156; Huh JW, 2011, RESPIROLOGY, V16, P1088, DOI 10.1111/j.1440-1843.2011.02018.x; Kanangat S, 1999, INFECT IMMUN, V67, P2834, DOI 10.1128/IAI.67.6.2834-2840.1999; Kaufmann I, 2008, INTENS CARE MED, V34, P344, DOI 10.1007/s00134-007-0868-8; Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC; Klompas M, 2010, AM J INFECT CONTROL, V38, P237, DOI 10.1016/j.ajic.2009.10.003; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Marik PE, 2008, CRIT CARE MED, V36, P1937, DOI 10.1097/CCM.0b013e31817603ba; Meduri GU, 1999, AM J RESP CRIT CARE, V160, P961, DOI 10.1164/ajrccm.160.3.9807080; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Reynolds SF, 2005, CHEST, V127, P1397, DOI 10.1378/chest.127.4.1397; Roquilly A, 2013, AM J RESP CRIT CARE, V188, P958, DOI 10.1164/rccm.201301-0116OC; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; Roquilly A, 2011, JAMA-J AM MED ASSOC, V305, P1201, DOI 10.1001/jama.2011.360; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Sartorius D, 2010, CRIT CARE MED, V38, P831, DOI 10.1097/CCM.0b013e3181cc4a67; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004	33	67	71	2	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-2600			LANCET RESP MED	Lancet Resp. Med.	SEP	2014	2	9					706	716		10.1016/S2213-2600(14)70144-4			11	Critical Care Medicine; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Respiratory System	AO1IE	WOS:000341065000018	25066331				2022-02-06	
J	Casson, IR; Viano, DC; Haacke, EM; Kou, ZF; LeStrange, DG				Casson, Ira R.; Viano, David C.; Haacke, E. Mark; Kou, Zhifeng; LeStrange, Danielle G.			Is There Chronic Brain Damage in Retired NFL Players? Neuroradiology, Neuropsychology, and Neurology Examinations of 45 Retired Players	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						concussion; brain injury; neuroradiology; neuropsychology; clinical neurology; chronic traumatic encephalopathy (CTE)	CHRONIC TRAUMATIC ENCEPHALOPATHY; APOLIPOPROTEIN-E POLYMORPHISM; NATIONAL-FOOTBALL-LEAGUE; DIFFUSE AXONAL INJURY; PROFESSIONAL FOOTBALL; HIGH-SCHOOL; RECURRENT CONCUSSION; DISEASE; ASSOCIATION; RECOVERY	Background: Neuropathology and surveys of retired National Football League (NFL) players suggest that chronic brain damage is a frequent result of a career in football. There is limited information on the neurological statuses of living retired players. This study aimed to fill the gap in knowledge by conducting in-depth neurological examinations of 30-to 60-year-old retired NFL players. Hypothesis: In-depth neurological examinations of 30- to 60-year-old retired players are unlikely to detect objective clinical abnormalities in the majority of subjects. Study Design: A day-long medical examination was conducted on 45 retired NFL players, including state-of-the- art magnetic resonance imaging (MRI; susceptibility weighted imaging [SWI], diffusion tensor imaging [DTI]), comprehensive neuropsychological and neurological examinations, interviews, blood tests, and APOE (apolipoprotein E) genotyping. Methods: Participants' histories focused on neurological and depression symptoms, exposure to football, and other factors that could affect brain function. The neurological examination included Mini-Mental State Examination (MMSE) evaluation of cognitive function and a comprehensive search for signs of dysarthria, pyramidal system dysfunction, extrapyramidal system dysfunction, and cerebellar dysfunction. The Beck Depression Inventory (BDI) and Patient Health Questionnaire (PHQ) measured depression. Neuropsychological tests included pen-and-paper and ImPACT evaluation of cognitive function. Anatomical examination SWI and DTI MRI searched for brain injuries. The results were statistically analyzed for associations with markers of exposure to football and related factors, such as body mass index (BMI), ethanol use, and APOE4 status. Results: The retired players' ages averaged 45.6 +/- 8.9 years (range, 30-60 years), and they had 6.8 +/- 3.2 years (maximum, 14 years) of NFL play. They reported 6.9 +/- 6.2 concussions (maximum, 25) in the NFL. The majority of retired players had normal clinical mental status and central nervous system (CNS) neurological examinations. Four players (9%) had microbleeds in brain parenchyma identified in SWI, and 3 (7%) had a large cavum septum pellucidum with brain atrophy. The number of concussions/dings was associated with abnormal results in SWI and DTI. Neuropsychological testing revealed isolated impairments in 11 players (24%), but none had dementia. Nine players (20%) endorsed symptoms of moderate or severe depression on the BDI and/or met criteria for depression on PHQ; however, none had dementia, dysarthria, parkinsonism, or cerebellar dysfunction. The number of football-related concussions was associated with isolated abnormalities on the clinical neurological examination, suggesting CNS dysfunction. The APOE4 allele was present in 38% of the players, a larger number than would be expected in the general male population (23%-26%). Conclusion: MRI lesions and neuropsychological impairments were found in some players; however, the majority of retired NFL players had no clinical signs of chronic brain damage.	[Casson, Ira R.] Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; [Casson, Ira R.] Hofstra North Shore LIJ Sch Med, Dept Neurol, Hempstead, NY USA; [Viano, David C.] ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA; [Viano, David C.] Wayne State Univ, Bioengn Ctr, Dept Biomed Engn, Detroit, MI USA; [Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI USA; [Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Sch Med, Dept Biomed Engn, Detroit, MI USA; [LeStrange, Danielle G.] Lawrence Hosp Ctr, Emergency Nursing & Clin Outreach, Bronxville, NY USA		Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net			National Football League	The authors were involved with the NFL's MTBI (Mild Traumatic Brain Injury) Committee during the clinical examinations conducted in this research. The examinations were sponsored by the National Football League and were coordinated with the NFL Players Association. The study was suspended and not brought to its original conclusion. The existing convenience sample was available for analysis and represents an initial view of brain injury and neuropsychological affects in a sample of retired NFL players. We appreciate the neuroradiological assistance of Thomas Naidich, MD (Professor of Radiology, Mt Sinai School of Medicine, New York, NY); Victor Haughton, MD (Professor and Chief Neuroradiology, University of Wisconsin, Madison, WI); and Chi-Sing Zee, MD (Director of Neuroradiology, USC School of Medicine, Professor of Radiology, Los Angeles, CA). We appreciate the radiology staff at ProHEALTH (Kathleen Finzel, MD, and Patricia Roche, DO) and MR Research Center of Wayne State University (Yang Xuan, BS; Ramtilak Gattu, MS; and Randall R. Benson, MD) and the neuropsychological expertise and assistance of Mark R. Lovell, PhD; Paul Mattis, PhD; Kenneth Perrine, PhD; Reuben Echemendia, PhD; and Jennifer Manly, PhD, is appreciated. The APOE sample analysis was conducted at Duke University Medical Center. The statistical analysis of the data was performed under the direction of Dr Daniel R. Jeske, Director of Statistical Consulting Collaboratory, University of California, Riverside. Carl St Martin, MD, reviewed the article. The various sources of data were collated, organized, and archived by Chantal Parenteau, PhD, whose assistance is appreciated. Additional acknowledgments can be found in Supplement S12 (see Appendix, available at http://sph.sagepub.com/content/suppl).	Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ayaz M, 2010, J MAGN RESON IMAGING, V31, P142, DOI 10.1002/jmri.22001; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bray MS, 2009, MED SCI SPORT EXER, V41, P34, DOI 10.1249/MSS.0b013e3181844179; Brust JCM, 2010, INT J ENV RES PUB HE, V7, P1540, DOI 10.3390/ijerph7041540; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Canessa N, 2012, CHEST, V141, P1601; Casson I, 2010, NEUROLOGY TODAY, V10, P6, DOI DOI 10.1097/01.NT.0000380917.17552.b7; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Casson IR, 2008, NEUROL CLIN, V26, P217, DOI 10.1016/j.ncl.2007.11.005; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Eichner JE, 2002, AM J EPIDEMIOL, V155, P487, DOI 10.1093/aje/155.6.487; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fitzpatrick AL, 2009, ARCH NEUROL-CHICAGO, V66, P336, DOI 10.1001/archneurol.2008.582; Flashman LA, 2007, PSYCHIAT RES-NEUROIM, V154, P147, DOI 10.1016/j.pscychresns.2006.09.001; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Haacke EM, 2007, AM J NEURORADIOL, V28, P316; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Haacke EM, 2006, Z MED PHYS, V16, P237, DOI 10.1078/0939-3889-00321; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1993, MED ASPECTS BOXING, V1, P177; Katzman R, 1996, NEUROLOGY, V46, P889; Kirsch W, 2009, J ALZHEIMERS DIS, V17, P599, DOI 10.3233/JAD-2009-1073; Kou Z., 2008, CLIN MR NEUROIMAGING; Kou ZF, 2008, J HEAD TRAUMA REHAB, V23, P351, DOI 10.1097/01.HTR.0000336878.45714.4b; Kou ZF, 2012, RSC DRUG DISCOV, V24, P19, DOI 10.1039/9781849734745-00019; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Leon AS, 2004, METABOLISM, V53, P108, DOI 10.1016/j.metabol.2003.08.013; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P157, DOI 10.1136/bjsm.36.3.157; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; Morri S., 2007, INTRO DIFFUSION TENS; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Obisesan TO, 2008, METABOLISM, V57, P1669, DOI 10.1016/j.metabol.2008.07.022; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; VICTOR M, 1994, CAN J NEUROL SCI, V21, P88, DOI 10.1017/S031716710004899X; VICTOR M, 1993, NEUROL CLIN, V11, P639, DOI 10.1016/S0733-8619(18)30144-0; Westlye LT, 2012, NEUROLOGY, V79, P1961, DOI 10.1212/WNL.0b013e3182735c9c; Whitmer RA, 2007, CURR ALZHEIMER RES, V4, P103, DOI 10.2174/156720507780362047; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	85	67	67	2	23	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	SEP-OCT	2014	6	5					384	395		10.1177/1941738114540270			12	Sport Sciences	Emerging Sources Citation Index (ESCI)	Sport Sciences	V20FU	WOS:000214873300002	25177413	Green Published			2022-02-06	
J	Wang, J; Pang, T; Hafko, R; Benicky, J; Sanchez-Lemus, E; Saavedra, JM				Wang, Juan; Pang, Tao; Hafko, Roman; Benicky, Julius; Sanchez-Lemus, Enrique; Saavedra, Juan M.			Telmisartan ameliorates glutamate-induced neurotoxicity: Roles of AT(1) receptor blockade and PPAR gamma activation	NEUROPHARMACOLOGY			English	Article						Angiotensin II AT(1) Receptor Blockers; Telmisartan; PPAR gamma; Neuroprotection; Glutamate neurotoxicity; Apoptosis	II TYPE-1 RECEPTOR; TRAUMATIC BRAIN-INJURY; INNATE IMMUNE-RESPONSE; FACTOR-KAPPA-B; ANGIOTENSIN-II; VASCULAR INFLAMMATION; HYPERTENSIVE-RATS; DOWN-REGULATION; BLOOD-PRESSURE; VALPROIC ACID	Sartans (Angiotensin II AT(1) Receptor Blockers, ARBs) are powerful neuroprotective agents in vivo and protect against IL-1 beta neurotoxicity in vitro. The purpose of this research was to determine the extent of sartan neuroprotection against glutamate excitotoxicity, a common cause of neuronal injury and apoptosis. The results show that sartans are neuroprotective, significantly reducing glutamate-induced neuronal injury and apoptosis in cultured rat primary cerebellar granule cells (CGCs). Telmisartan was the most potent sartan studied, with an order of potency telmisartan > candesartan > losartan > valsartan. Mechanisms involved reduction of pro-apoptotic caspase-3 activation, protection of the survival PI3K/Akt/GSK-3 beta pathway and prevention of glutamate-induced ERK1/2 activation. NMDA receptor stimulation was essential for glutamate-induced cell injury and apoptosis. Participation of AT(1A) receptor was supported by glutamate-induced upregulation of AT(1A) gene expression and AT(1) receptor binding. Conversely, AT(1B) or AT(2) receptors played no role. Glutamate-induced neuronal injury and the neuroprotective effect of telmisartan were decreased, but not abolished, in CGCs obtained from AT(1A), knock-out mice. This indicates that although AT(1) receptors are necessary for glutamate to exert its full neurotoxic potential, part of the neuroprotective effect of telmisartan is independent of AT(1) receptor blockade. PPAR gamma activation was also involved in the neuroprotective effects of telmisartan, as telmisartan enhanced PPAR gamma nuclear translocation and the PPAR gamma antagonist GW9662 partially reversed the neuroprotective effects of telmisartan. The present results substantiate the therapeutic use of sartans, in particular telmisartan, in neurodegenerative diseases and traumatic brain disorders where glutamate neurotoxicity plays a significant role. Published by Elsevier Ltd.	[Wang, Juan; Pang, Tao; Hafko, Roman; Benicky, Julius; Sanchez-Lemus, Enrique; Saavedra, Juan M.] NIMH, Sect Pharmacol, Div Intramural Res Programs, NIH,US Dept HHS, Bethesda, MD 20892 USA; [Pang, Tao] China Pharmaceut Univ, New Drug Screening Ctr, Nanjing 210009, Jiangsu, Peoples R China; [Saavedra, Juan M.] Georgetown Univ, Dept Physiol & Pharmacol, Med Ctr, Washington, DC 20057 USA		Saavedra, JM (corresponding author), Georgetown Univ, Dept Physiol & Pharmacol, Med Ctr, Bldg D,Room 287,3970 Reservoir Rd NW, Washington, DC 20057 USA.	jw543@georgetown.edu; jb2304@georgetown.edu; scientificsupport@mesoscale.com; jms522@georgetown.edu	Saavedra, Juan/AAO-7149-2020	Saavedra, Juan/0000-0002-7238-9647	Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department Of Health and Human Services, USAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 002762-16]; Natural Science Foundation of Jiangsu Province, P.R.ChinaNatural Science Foundation of Jiangsu Province [BK 20130653]; Fundamental Research Funds for the Central Universities, P.R.ChinaFundamental Research Funds for the Central Universities [JKZD 2013006]; China Pharmaceutical University; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH002762] Funding Source: NIH RePORTER	This study was supported by the Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department Of Health and Human Services, USA (MH 002762-16), the Natural Science Foundation of Jiangsu Province, P.R.China (BK 20130653), the Fundamental Research Funds for the Central Universities, P.R.China (JKZD 2013006), and the Initial Fund of China Pharmaceutical University.	Anderson C, 2011, LANCET NEUROL, V10, P43, DOI 10.1016/S1474-4422(10)70250-7; Anderson C, 2010, J HYPERTENS, V28, P429, DOI 10.1097/HJH.0b013e3283371355; Ando H, 2004, STROKE, V35, P1726, DOI 10.1161/01.STR.0000129788.26346.18; Armando I, 2001, ENDOCRINOLOGY, V142, P3880, DOI 10.1210/en.142.9.3880; BAKRIS G, 2010, AM J CARDIOL, V105, p21A; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; CHIU AT, 1993, BIOCHEM BIOPH RES CO, V197, P440, DOI 10.1006/bbrc.1993.2499; Chrysant SG, 2010, CURR CLIN PHARMACOL, V5, P89, DOI 10.2174/157488410791110742; Cisneros IE, 2012, CURR HIV RES, V10, P392, DOI 10.2174/157016212802138832; Contestabile Antonio, 2002, Cerebellum, V1, P41, DOI 10.1080/147342202753203087; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dandona P, 2003, J CLIN ENDOCR METAB, V88, P4496, DOI 10.1210/jc.2002-021836; Danielyan L, 2010, REJUV RES, V13, P195, DOI 10.1089/rej.2009.0944; Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005; Davies NM, 2011, J ALZHEIMERS DIS, V26, P699, DOI 10.3233/JAD-2011-110347; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Duan SZ, 2009, CURR OPIN NEPHROL HY, V18, P128, DOI 10.1097/MNH.0b013e328325803b; Erbe DV, 2006, VASC PHARMACOL, V45, P154, DOI 10.1016/j.vph.2006.05.002; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; Fogari R, 2004, EUR J CLIN PHARMACOL, V59, P863, DOI 10.1007/s00228-003-0717-9; Fujino M, 2010, HYPERTENS RES, V33, P1044, DOI 10.1038/hr.2010.135; Gao XM, 1995, BRAIN RES, V703, P63, DOI 10.1016/0006-8993(95)01066-1; Heemskerk FMJ, 1999, CELL MOL NEUROBIOL, V19, P277, DOI 10.1023/A:1006985329240; Hodgkinson CP, 2003, BIOCHEM BIOPH RES CO, V308, P505, DOI 10.1016/S0006-291X(03)01416-5; Hu SQ, 2013, NEUROCHEM INT, V62, P468, DOI 10.1016/j.neuint.2013.01.022; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Jezova D, 1998, J NEUROENDOCRINOL, V10, P67, DOI 10.1046/j.1365-2826.1998.00182.x; Ji YY, 2009, LAB INVEST, V89, P887, DOI 10.1038/labinvest.2009.45; KAISER FC, 1992, NEUROREPORT, V3, P922, DOI 10.1097/00001756-199210000-00026; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Koh EJ, 2013, BRIT J PHARMACOL, V169, P1404, DOI 10.1111/bph.12229; Konstam MA, 2009, LANCET, V374, P1840, DOI 10.1016/S0140-6736(09)61913-9; Kramer D, 2010, METHODS MOL BIOL, V633, P233, DOI 10.1007/978-1-59745-019-5_17; Kung J, 2012, EXPERT OPIN DRUG SAF, V11, P565, DOI 10.1517/14740338.2012.691963; Larrayoz IM, 2009, J HYPERTENS, V27, P2365, DOI 10.1097/HJH.0b013e3283314bc7; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Lee Hae Young, 2009, J Vis Exp, DOI 10.3791/990; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Leng Y, 2006, J NEUROSCI, V26, P7502, DOI 10.1523/JNEUROSCI.0096-06.2006; Li NC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5465; Liu Z, 2012, CELL MOL NEUROBIOL, V32, P191, DOI 10.1007/s10571-011-9746-6; Min LJ, 2012, HYPERTENSION, V59, P1079, DOI 10.1161/HYPERTENSIONAHA.112.192401; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Miura S, 2011, J RENIN-ANGIO-ALDO S, V12, P1, DOI 10.1177/1470320310370852; Miyoshi M, 2008, EUR J NEUROSCI, V27, P343, DOI 10.1111/j.1460-9568.2007.06014.x; Mogi M, 2006, HYPERTENSION, V48, P141, DOI 10.1161/01.HYP.0000229648.67883.f9; Nakajima T., 2010, HYPERTENS RES, V33, P831; Nishimoto T, 2008, J NEUROSCI RES, V86, P1096, DOI 10.1002/jnr.21567; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Pang T, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-102; Pang T, 2012, J HYPERTENS, V30, P87, DOI 10.1097/HJH.0b013e32834dde5f; Phillips MI, 2008, J MOL MED, V86, P715, DOI 10.1007/s00109-008-0331-5; Qi L, 2010, INT J CLIN EXP MED, V3, P283; Rotman N, 2010, PHYSIOLOGY, V25, P176, DOI 10.1152/physiol.00018.2010; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; Saavedra JM, 2011, PSYCHONEUROENDOCRINO, V36, P1, DOI 10.1016/j.psyneuen.2010.10.001; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Savoia C, 2007, CLIN SCI, V112, P375, DOI 10.1042/CS20060247; Stangier J, 2000, J INT MED RES, V28, P149, DOI 10.1177/147323000002800401; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Suksomboon N, 2012, J CLIN PHARM THER, V37, P319, DOI 10.1111/j.1365-2710.2011.01295.x; Takaki J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-275; Tham DM, 2002, PHYSIOL GENOMICS, V11, P21, DOI 10.1152/physiolgenomics.00062.2002; Tian CH, 2008, J NEUROCHEM, V105, P994, DOI 10.1111/j.1471-4159.2007.05197.x; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Tsukuda K, 2009, HYPERTENSION, V54, P782, DOI 10.1161/HYPERTENSIONAHA.109.136879; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Viviani B, 2003, J NEUROSCI, V23, P8692; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Yamakawa H, 2003, J CEREBR BLOOD F MET, V23, P371, DOI 10.1097/01.WCB.0000047369.05600.03; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhao SM, 2008, CHINESE J PHYSIOL, V51, P357; Zhao Y, 2005, J NEUROCHEM, V94, P1395, DOI 10.1111/j.1471-4159.2005.03275.x; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082; Zhu D., 2011, PLOS ONE, V6; Zorad S, 2006, EUR J PHARMACOL, V552, P112, DOI 10.1016/j.ejphar.2006.08.062	83	67	71	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2014	79						249	261		10.1016/j.neuropharm.2013.11.022			13	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	AE1ZX	WOS:000333774200026	24316465	Green Accepted			2022-02-06	
J	Grieb, P				Grieb, Pawel			Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues	CNS DRUGS			English	Article							ACUTE ISCHEMIC-STROKE; CYTIDINE DIPHOSPHATE CHOLINE; TRAUMATIC BRAIN-INJURY; VASCULAR COGNITIVE IMPAIRMENT; CDP-CHOLINE; ORAL CITICOLINE; OLDER SUBJECTS; METABOLISM; NEURONS; CANCER	Citicoline is the generic name of the pharmaceutical substance that chemically is cytidine-5 '-diphosphocholine (CDP-choline), which is identical to the natural intracellular precursor of phospholipid phosphatidylcholine. Following injection or ingestion, citicoline is believed to undergo quick hydrolysis and dephosphorylation to yield cytidine and choline, which then enter the brain separately and are used to resynthesize CDP-choline inside brain cells. Neuroprotective activity of citicoline has been repeatedly shown in preclinical models of brain ischaemia and trauma, but two recent, large, pivotal clinical trials have revealed no benefits in ischaemic stroke and traumatic brain injury. However, the substance seems to be beneficial in some slowly advancing neurodegenerative disorders such as glaucoma and mild vascular cognitive impairment. This paper critically discusses issues related to the clinical pharmacology of citicoline, including its pharmacokinetics/biotransformation and pharmacodynamics/mode of action. It is concluded that at present, there is no adequate description of the mechanism(s) of the pharmacological actions of this substance. The possibility should be considered and tested that, in spite of apparently fast catabolism, the intact citicoline molecule or the phosphorylated intermediate products of its hydrolysis, cytidine monophosphate and phosphocholine, are pharmacologically active.	Polish Acad Sci, Mossakowski Med Res Ctr, Dept Expt Pharmacol, PL-02106 Warsaw, Poland		Grieb, P (corresponding author), Polish Acad Sci, Mossakowski Med Res Ctr, Dept Expt Pharmacol, 5 Pawinskiego Str, PL-02106 Warsaw, Poland.	pgrieb@imdik.pan.pl	Grieb, Pawel/AAT-8173-2021	Grieb, Pawel/0000-0002-6983-7947			Adamczyk M, 2006, CLIN CHEM, V52, P2123, DOI 10.1373/clinchem.2006.074369; Adibhatla R, 2005, NEUROCHEM RES, V30, P15, DOI 10.1007/s11064-004-9681-8; Adibhatla RM, 2005, BRAIN RES, V1058, P193, DOI 10.1016/j.brainres.2005.07.067; Adibhatla RM, 2003, J NEUROSCI RES, V73, P308, DOI 10.1002/jnr.10672; AGUT J, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1016; Alvarez XA, 1999, METHOD FIND EXP CLIN, V21, P535, DOI 10.1358/mf.1999.21.8.794835; Alvarez-Sabin J, 2011, STROKE, V42, pS40, DOI 10.1161/STROKEAHA.110.606509; ANSELL GB, 1961, BIOCHEM J, V78, P209, DOI 10.1042/bj0780209; Aquilina G, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2353; Arenth PM, 2011, PM&R, V3, pS123, DOI 10.1016/j.pmrj.2011.03.012; Babb SM, 2002, PSYCHOPHARMACOLOGY, V161, P248, DOI 10.1007/s00213-002-1045-y; Babb SM, 1996, PSYCHOPHARMACOLOGY, V127, P88, DOI 10.1007/BF02805979; Bligh J., 1951, J PHYSL, V117, P234; Bustamante A, 2012, J NEUROCHEM, V123, P217, DOI 10.1111/j.1471-4159.2012.07891.x; Cho HJ, 2009, METHOD FIND EXP CLIN, V31, P171, DOI 10.1358/mf.2009.31.3.1364241; Clark WM, 2012, NAT REV NEUROL, V8, P484, DOI 10.1038/nrneurol.2012.166; Cotroneo AM, 2013, CLIN INTERV AGING, V8, P131, DOI 10.2147/CIA.S38420; Cui FL, 2007, BIOPOLYMERS, V87, P174, DOI 10.1002/bip.20815; Danne O, 2010, EXPERT REV MOL DIAGN, V10, P159, DOI [10.1586/erm.10.2, 10.1586/ERM.10.2]; Davalos A, 2002, STROKE, V33, P2850, DOI 10.1161/01.STR.0000038691.03334.71; Davalos A, 2012, LANCET, V380, P349, DOI 10.1016/S0140-6736(12)60813-7; DORLANDO KJ, 1995, NEUROL RES, V17, P281, DOI 10.1080/01616412.1995.11740327; Eyigor O, 2012, BRAIN RES BULL, V87, P286, DOI 10.1016/j.brainresbull.2011.11.013; Food Safety Authority of Ireland, 2012, SAF ASS CIT; Fresta M, 1997, LIFE SCI, V61, P1227, DOI 10.1016/S0024-3205(97)00667-X; GALLETTI P, 1991, J NEUROL SCI, V103, pS19; GALLETTI P, 1985, BIOCHEM PHARMACOL, V34, P4121, DOI 10.1016/0006-2952(85)90204-7; Garcia-Cobos R, 2010, J NEUROL SCI, V299, P188, DOI 10.1016/j.jns.2010.08.027; Gibellini F, 2010, IUBMB LIFE, V62, P414, DOI 10.1002/iub.337; Gimenez R, 1998, EUR J PHARMACOL, V344, P149, DOI 10.1016/S0014-2999(98)00035-1; Glunde K, 2006, PHARMACOGENOMICS, V7, P1109, DOI 10.2217/14622416.7.7.1109; Gutierrez-Fernandez M, 2012, NEUROL RES, V34, P649, DOI 10.1179/1743132812Y.0000000058; Han M, 2007, PROSTAG OTH LIPID M, V84, P174, DOI 10.1016/j.prostaglandins.2007.08.003; Hankey GJ, 2012, LANCET, V380, P318, DOI 10.1016/S0140-6736(12)60912-X; HORROCKS L A, 1981, Progress in Lipid Research, V20, P531; Horrocks LA, 1981, United States Patent, Patent No. [4,386,078, 4386078]; Hunt AN, 2001, J BIOL CHEM, V276, P8492, DOI 10.1074/jbc.M009878200; Hurtado O, 2013, J NEUROCHEM, V126, P819, DOI 10.1111/jnc.12269; Hurtado O, 2011, STROKE, V42, pS33, DOI 10.1161/STROKEAHA.110.597435; Jochem J, 2010, J PHYSIOL PHARMACOL, V61, P37; Johansson M, 2009, CANCER EPIDEM BIOMAR, V18, P1538, DOI 10.1158/1055-9965.EPI-08-1193; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Krupinski J, 2005, NEUROCHEM RES, V30, P1067, DOI 10.1007/s11064-005-7201-0; Krupinski J, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-20; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; Lee JE, 2010, CANCER EPIDEM BIOMAR, V19, P884, DOI 10.1158/1055-9965.EPI-09-1295; LIEBERMAN I, 1956, SCIENCE, V124, P81, DOI 10.1126/science.124.3211.81; LOPEZCOVIELLA I, 1995, J NEUROCHEM, V65, P889; MANAKA S, 1974, EXPERIENTIA, V30, P179, DOI 10.1007/BF01927720; Matyja E, 2008, FOLIA NEUROPATHOL, V46, P139; Mir C, 2003, J MOL NEUROSCI, V20, P53, DOI 10.1385/JMN:20:1:53; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; MYKITA S, 1986, J NEUROCHEM, V47, P223; Oshitari T, 2002, NEUROREPORT, V13, P2109, DOI 10.1097/00001756-200211150-00023; Ottobelli L, 2013, OPHTHALMOLOGICA, V229, P219, DOI 10.1159/000350496; Parisi V, 2008, PROG BRAIN RES, V173, P541, DOI 10.1016/S0079-6123(08)01137-0; Park CH, 2006, BRAIN RES, V1081, P203, DOI 10.1016/j.brainres.2005.12.128; Putignano S, 2012, CLIN INTERV AGING, V7, P113, DOI 10.2147/CIA.S29366; Ramos-Cabrer P, 2011, INT J PHARMACEUT, V405, P228, DOI 10.1016/j.ijpharm.2010.12.014; Rejdak R, 2002, OPHTHALMIC RES, V34, P146, DOI 10.1159/000063658; Ruff RL, 2012, JAMA-J AM MED ASSOC, V308, P2032, DOI 10.1001/jama.2012.14008; Sarkar AK, 2012, J PHARMACEUT BIOMED, V71, P144, DOI 10.1016/j.jpba.2012.07.003; Savci V, 2003, EUR J PHARMACOL, V468, P129, DOI 10.1016/S0014-2999(03)01602-9; Schauss AG, 2009, INT J TOXICOL, V28, P479, DOI 10.1177/1091581809349452; SECADES JJ, 1995, METHOD FIND EXP CLIN, V17, P1; Secades JJ, 2012, REV NEUROLOGIA, V54, P173, DOI 10.33588/rn.5403.2011490; Tolvanen T, 2010, EUR J NUCL MED MOL I, V37, P874, DOI 10.1007/s00259-009-1346-z; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7; WEISS GB, 1995, LIFE SCI, V56, P637, DOI 10.1016/0024-3205(94)00427-T; WEISS SB, 1958, J BIOL CHEM, V231, P53; Wurtman RJ, 2000, BIOCHEM PHARMACOL, V60, P989, DOI 10.1016/S0006-2952(00)00436-6; Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279; YASHIMA K, 1975, J NUTR SCI VITAMINOL, V21, P49, DOI 10.3177/jnsv.21.49; Yucel N, 2006, NEUROCHEM RES, V31, P767, DOI 10.1007/s11064-006-9075-1; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	75	67	71	0	19	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs	MAR	2014	28	3					185	193		10.1007/s40263-014-0144-8			9	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	AD6EP	WOS:000333348300001	24504829	hybrid, Green Published			2022-02-06	
J	Gutierrez, GM; Conte, C; Lightbourne, K				Gutierrez, Gregory M.; Conte, Catherine; Lightbourne, Kristian			The Relationship Between Impact Force, Neck Strength, and Neurocognitive Performance in Soccer Heading in Adolescent Females	PEDIATRIC EXERCISE SCIENCE			English	Article						adolescent; strength; exercise training; gender; sport medicine; biomechanics	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; SEGMENT DYNAMIC STABILIZATION; RISK COMPENSATION; CONCUSSION; PLAYERS; SPORT; ACCELERATION; BIOMECHANICS; PREVENTION	Head impacts are common in contact sports, but only recently has there been a rising awareness of the effects of subconcussive impacts in adolescent athletes. A better understanding of how to attenuate head impacts is needed and therefore, this study investigated the relationship between neck strength, impact, and neurocognitive function in an acute bout of soccer heading in a sample of female high school varsity soccer players. Seventeen participants completed the ImPACT neurocognitive test and had their isometric neck strength tested (flexion, extension, and bilateral flexion) before heading drills. Each participant was outfitted with custom headgear with timing switches and a three-dimensional accelerometer affixed to the back of the head, which allowed for measurement of impact during heading. Participants performed a series of 15 directional headers, including 5 forward, 5 left and 5 right headers in a random order, then completed the ImPACT test again. Neurocognitive tests revealed no significant changes following heading. However, there were statistically significant, moderate, negative correlations (r = -0.500:-0.757, p < .05) between neck strength and resultant header acceleration, indicating that those with weaker necks sustained greater impacts. This suggests neck strengthening may be an important component of any head injury prevention/reduction program.	[Gutierrez, Gregory M.] NYU, Dept Phys Therapy, New York, NY 10003 USA; [Conte, Catherine] Ossining High Sch, Sci Res Program, Ossining, NY USA; [Lightbourne, Kristian] NYU, Polytech Inst, Dept Technol Management & Innovat, Brooklyn, NY USA		Gutierrez, GM (corresponding author), NYU, Dept Phys Therapy, New York, NY 10003 USA.			Gutierrez, Gregory/0000-0002-4261-8066			Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; Dezman ZDW, 2013, SPORTS HEALTH, V5, P320, DOI 10.1177/1941738113480935; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mansell J, 2005, J ATHL TRAINING, V40, P310; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mehnert Michael J, 2005, Pain Physician, V8, P391; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Phillips RO, 2011, RISK ANAL, V31, P1187, DOI 10.1111/j.1539-6924.2011.01589.x; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Reilly TT, 1976, J HUM MOV STUD, V2, P87; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0	32	67	67	3	60	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	0899-8493	1543-2920		PEDIATR EXERC SCI	Pediatr. Exerc. Sci.	FEB	2014	26	1					33	40		10.1123/pes.2013-0102			8	Pediatrics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Physiology; Sport Sciences	AE7BK	WOS:000334151500005	24091298				2022-02-06	
J	Powers, KC; Kalmar, JM; Cinelli, ME				Powers, Kaley C.; Kalmar, Jayne M.; Cinelli, Michael E.			Recovery of static stability following a concussion	GAIT & POSTURE			English	Article						Concussion; Static balance; Return-to-play; Centre of pressure	ADAPTATION; BALANCE; STANCE; SPORT	The purpose of this study was to use centre of pressure (COP) measurements to determine if static balance deficits had recovered when concussed athletes were cleared to return to play. Nine concussed varsity football players were matched with nine teammates who served as controls. Static balance in the anterior-posterior (A/P) and medial-lateral (M/L) directions was assessed during quiet stance with eyes open and eyes closed. Results showed that concussed football players displayed greater A/P COP displacements in the acute phase, which recovered by RTP; however, COP velocity remained elevated compared to controls even at RTP, particularly in the A/P direction. This balance control deficit in the A/P direction may suggest vestibular impairment, likely due to poor sensorimotor integration of the lateral vestibulospinal tract. The observed persistence of balance control deficits in concussed football players at RTP are usually undetected by traditional assessments because the current study used higher-order COP analysis. Future RTP balance measures may want to incorporate higher-order measures of balance. (C) 2013 Elsevier B. V. All rights reserved.	[Powers, Kaley C.; Kalmar, Jayne M.; Cinelli, Michael E.] Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, Waterloo, ON N2L 3C5, Canada		Cinelli, ME (corresponding author), Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, 75 Univ Ave,W Rm 501, Waterloo, ON N2L 3C5, Canada.	mcinelli@wlu.ca	Cinelli, Michael/ABE-7625-2020	Cinelli, Michael/0000-0002-5802-2590	NSERC DiscoveryNatural Sciences and Engineering Research Council of Canada (NSERC) [386601]	This project was funded through an NSERC Discovery Grant (386601).	[Anonymous], 1995, GAIT POSTURE; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Highstein SM, 2012, ANAT REC, V295, P2000, DOI 10.1002/ar.22582; Masani K, 2003, J NEUROPHYSIOL, V90, P3774, DOI 10.1152/jn.00730.2002; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; Mulligan IJ, 2013, SPORTS HEALTH, V5, P22, DOI 10.1177/1941738112467755; NASHNER LM, 1982, J NEUROSCI, V2, P536; NASHNER LM, 1982, TRENDS NEUROSCI, V5, P358, DOI 10.1016/0166-2236(82)90204-1; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; WINTER DA, 1990, MED PROG TECHNOL, V16, P31	14	67	67	1	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	JAN	2014	39	1					611	614		10.1016/j.gaitpost.2013.05.026			4	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics; Sport Sciences	259QS	WOS:000327542000104	23810088				2022-02-06	
J	Brooks, JC; Strauss, DJ; Shavelle, RM; Paculdo, DR; Hammond, FM; Harrison-Felix, CL				Brooks, Jordan C.; Strauss, David J.; Shavelle, Robert M.; Paculdo, David R.; Hammond, Flora M.; Harrison-Felix, Cynthia L.			Long-Term Disability and Survival in Traumatic Brain Injury: Results From the National Institute on Disability and Rehabilitation Research Model Systems	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Mortality; Rehabilitation; Survival	MORTALITY TRENDS; LIFE EXPECTANCY	Objectives: To document long-term survival in 1-year survivors of traumatic brain injury (TBI); to compare the use of the Disability Rating Scale (DRS) and FIM as factors in the estimation of survival probabilities; and to investigate the effect of time since injury and secular trends in mortality. Design: Cohort study of 1-year survivors of TBI followed up to 20 years postinjury. Statistical methods include standardized mortality ratio, Kaplan-Meier survival curve, proportional hazards regression, and person-year logistic regression. Setting: Postdischarge from rehabilitation units. Participants: Population-based sample of persons (N=7228) who were admitted to a TBI Model Systems facility and survived at least 1 year postinjury. These persons contributed 32,505 person-years, with 537 deaths, over the 1989 to 2011 study period. Interventions: Not applicable. Main Outcome Measure: Survival. Results: Survival was poorer than that of the general population (standardized mortality ratio = 2.1; 95% confidence interval, 1.9-2.3). Age, sex, and functional disability were significant risk factors for mortality (P<.001). FIM- and DRS-based proportional hazards survival models had comparable predictive performance (C index: .80 vs .80; Akaike information criterion: 11,005 vs 11,015). Time since injury and current calendar year were not significant predictors of long-term survival (both P>.05). Conclusions: Long-term survival prognosis in TBI depends on age, sex, and disability. FIM and DRS are useful prognostic measures with comparable statistical performance. Age- and disability-specific mortality rates in TBI have not declined over the last 20 years. A survival prognosis calculator is available online (http://www.LifeExpectancy.org/tbims.shtml). (C) 2013 by the American Congress of Rehabilitation Medicine	[Brooks, Jordan C.; Strauss, David J.; Shavelle, Robert M.; Paculdo, David R.] Life Expectancy Project, San Francisco, CA 94122 USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Harrison-Felix, Cynthia L.] Craig Hosp, Englewood, CO USA; [Harrison-Felix, Cynthia L.] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA		Brooks, JC (corresponding author), Life Expectancy Project, 1439 17th Ave, San Francisco, CA 94122 USA.	Brooks@LifeExpectancy.org		Paculdo, David/0000-0002-2184-4603	U.S. Department of Education, National Institute on Disability and Rehabilitation ResearchUS Department of Education; Traumatic Brain Injury Model Systems Centers	The Traumatic Brain Injury Model Systems National Database is supported by the U.S. Department of Education, National Institute on Disability and Rehabilitation Research in collaboration with the Traumatic Brain Injury Model Systems Centers. However, these contents do not necessarily reflect the opinions or views of the Traumatic Brain Injury Model Systems Centers, the National Institute on Disability and Rehabilitation Research, or the U.S. Department of Education.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Arias E, 2002, NATL VITAL STAT REPO; Baguley I, 2000, BRAIN INJURY, V14, P505; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Baguley IJ, 2008, BRAIN INJURY, V22, P919, DOI 10.1080/02699050802448578; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Cox DR, 1984, ANAL SURVIVAL DATA; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Harrison-Felix CL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P319; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; National Data and Statistical Center, TRAUM BRAIN INJ MOD; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shavelle RM, 2007, BRAIN INJURY MED PRI, P247; Shavelle RM, 2000, J INSUR MED, V32; Strauss D, 2004, NEUROREHABILITATION, V19, P257; Strauss D, 2000, J Insur Med, V32, P217; Strauss D, 1999, J INSUR MED, V31, P104; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; *UN DAT SYST MED R, 1997, GUID UN DAT SET MED; Zasler ND, 2009, PROG BRAIN RES, V177, P111, DOI 10.1016/S0079-6123(09)17709-9	29	67	67	1	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2013	94	11					2203	2209		10.1016/j.apmr.2013.07.005			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	250KV	WOS:000326852600023	23872079				2022-02-06	
J	Anstey, KJ; Cherbuin, N; Herath, PM				Anstey, Kaarin J.; Cherbuin, Nicolas; Herath, Pushpani M.			Development of a New Method for Assessing Global Risk of Alzheimer's Disease for Use in Population Health Approaches to Prevention	PREVENTION SCIENCE			English	Article						Risk assessment; Alzheimer's disease; Systematic review; Risk index	MILD COGNITIVE IMPAIRMENT; BODY-MASS INDEX; PHYSICAL-ACTIVITY; DEPRESSIVE SYMPTOMS; DEMENTIA RISK; HEAD-INJURY; INCIDENT DEMENTIA; MOUSE MODEL; LATE-LIFE; METAANALYSIS	Alzheimer's disease (AD) affects approximately 35 million people worldwide. Increasing evidence suggests that many risk factors for AD are modifiable. AD pathology develops over decades. Hence risk reduction interventions require very long follow-ups to show effects on AD incidence. Focussing on AD risk, instead of diagnosis, provides a more realistic target for prevention strategies. We developed a novel methodology that yields a global approach to risk assessment for AD for use in population-based settings and interventions. The methodology was used to develop a risk assessment tool that can be updated as more evidence becomes available. First, a systematic search strategy identified risk and protective factors for AD. Eleven risk factors and four protective factors for AD were identified for which odds ratios were published or could be calculated (age, sex, education, body mass index, diabetes, depression, serum cholesterol, traumatic brain injury, smoking, alcohol intake, social engagement, physical activity, cognitive activity, fish intake, and pesticide exposure). An algorithm was developed to combine the odds ratios into an AD risk score. The approach allows for interactions among risk factors which provides for their varying impact over the life-course as current evidence suggests midlife is a critical period for some risk factors. Finally, a questionnaire was developed to assess the risk and protective factors by self-report. Compared with developing risk indices on single cohort studies, this approach allows for more risk factors to be included, greater generalizeability of results, and incorporation of interactions based on findings from different stages of the lifecourse.	[Anstey, Kaarin J.; Cherbuin, Nicolas; Herath, Pushpani M.] Australian Natl Univ, Ctr Res Ageing Hlth & Wellbeing, Canberra, ACT 0200, Australia		Anstey, KJ (corresponding author), Australian Natl Univ, Ctr Res Ageing Hlth & Wellbeing, Bldg 63, Canberra, ACT 0200, Australia.	kaarin.anstey@anu.edu.au	Cherbuin, Nicolas/A-8515-2008; Anstey, Kaarin/A-3852-2008	Cherbuin, Nicolas/0000-0001-6481-0748; Anstey, Kaarin/0000-0002-9706-9316			Access Economics, 2009, KEEP DEM FRONT MIND; Akbaraly TN, 2009, NEUROLOGY, V73, P854, DOI 10.1212/WNL.0b013e3181b7849b; Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Anstey KJ, 2008, AM J GERIAT PSYCHIAT, V16, P343, DOI 10.1097/JGP.0b013e31816b72d4; Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116; Anstey KJ, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-62; Anstey KJ, 2009, AM J GERIAT PSYCHIAT, V17, P542, DOI 10.1097/JGP.0b013e3181a2fd07; Baldi I, 2003, AM J EPIDEMIOL, V157, P409, DOI 10.1093/aje/kwf216; Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52; Barnes DE, 2009, NEUROLOGY, V73, P173, DOI 10.1212/WNL.0b013e3181a81636; Barnes DE, 2010, ALZHEIMERS DEMENT, V6, P138, DOI 10.1016/j.jalz.2010.01.005; Bassuk SS, 1999, ANN INTERN MED, V131, P165, DOI 10.7326/0003-4819-131-3-199908030-00002; Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2; Caamano-Isorna F, 2006, NEUROEPIDEMIOLOGY, V26, P226, DOI 10.1159/000093378; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dal Forno G, 2005, ANN NEUROL, V57, P381, DOI 10.1002/ana.20405; DAVIDOFF F, 1995, BRIT MED J, V310, P1085, DOI 10.1136/bmj.310.6987.1085; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Fotuhi M, 2009, NAT CLIN PRACT NEURO, V5, P140, DOI 10.1038/ncpneuro1044; Fratiglioni L, 2000, LANCET, V355, P1315, DOI 10.1016/S0140-6736(00)02113-9; Gatz JL, 2005, J GERONTOL A-BIOL, V60, P744, DOI 10.1093/gerona/60.6.744; Geerlings MI, 2008, NEUROLOGY, V70, P1258, DOI 10.1212/01.wnl.0000308937.30473.d1; Hamer M, 2009, PSYCHOL MED, V39, P3, DOI 10.1017/S0033291708003681; Hayden KM, 2010, NEUROLOGY, V74, P1524, DOI 10.1212/WNL.0b013e3181dd4423; Helmer C, 1999, NEUROLOGY, V53, P1953, DOI 10.1212/WNL.53.9.1953; Huang TL, 2005, NEUROLOGY, V65, P1409, DOI 10.1212/01.wnl.0000183148.34197.2e; Jessen F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016852; Jorm AF, 2005, AUST NZ J PSYCHIAT, V39, P959, DOI 10.1111/j.1440-1614.2005.01713.x; Karp A, 2004, AM J EPIDEMIOL, V159, P175, DOI 10.1093/aje/kwh018; Kidd PM, 2008, ALTERN MED REV, V13, P85; Kivipelto M, 2006, LANCET NEUROL, V5, P735, DOI 10.1016/S1474-4422(06)70537-3; Knopman DS, 2007, NEUROLOGY, V69, P739, DOI 10.1212/01.wnl.0000267661.65586.33; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lenoir H, 2011, J ALZHEIMERS DIS, V26, P27, DOI 10.3233/JAD-2011-101614; Li YS, 2001, INT J GERIATR PSYCH, V16, P718, DOI 10.1002/gps.423; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lobo A, 2000, NEUROLOGY, V54, pS4; Lopez OL, 2007, ARCH NEUROL-CHICAGO, V64, P416, DOI 10.1001/archneur.64.3.416; Lu FP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004144; Lyman Gary H, 2005, BMC Med Res Methodol, V5, P14, DOI 10.1186/1471-2288-5-14; Mielke MM, 2010, NEUROLOGY, V75, P1888, DOI 10.1212/WNL.0b013e3181feb2bf; National Institutes of Health, 2002, NAT CHOL ED PROGR EX; Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Power MC, 2011, EPIDEMIOLOGY, V22, P646, DOI 10.1097/EDE.0b013e31822708b5; Presecki P, 2011, COLLEGIUM ANTROPOL, V35, P115; Redolat Rosa, 2012, Curr Top Behav Neurosci, V10, P293, DOI 10.1007/7854_2011_134; Reitz C, 2010, ARCH NEUROL-CHICAGO, V67, P835, DOI 10.1001/archneurol.2010.136; RITCHIE K, 1995, LANCET, V346, P931, DOI 10.1016/S0140-6736(95)91556-7; Rodriguez JJ, 2011, CURR ALZHEIMER RES, V8, P707; Sabia S, 2009, AM J CLIN NUTR, V89, P601, DOI 10.3945/ajcn.2008.26482; Saczynski JS, 2010, NEUROLOGY, V75, P35, DOI 10.1212/WNL.0b013e3181e62138; Saczynski JS, 2006, AM J EPIDEMIOL, V163, P433, DOI 10.1093/aje/kwj061; Sandroff BM, 2012, ACTA NEUROL SCAND, V126, P256, DOI 10.1111/j.1600-0404.2011.01634.x; Scarmeas N, 2009, JAMA-J AM MED ASSOC, V302, P627, DOI 10.1001/jama.2009.1144; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980; Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; Wang J, 2006, FASEB J, V20, P2313, DOI 10.1096/fj.06-6281com; Weikert M, 2012, MED ENG PHYS, V34, P590, DOI 10.1016/j.medengphy.2011.09.005; Williams John W, 2010, Evid Rep Technol Assess (Full Rep), P1; Wilson RS, 2007, NEUROLOGY, V69, P1911, DOI 10.1212/01.wnl.0000271087.67782.cb; Zammit S, 2010, BRIT J PSYCHIAT, V197, P207, DOI 10.1192/bjp.bp.109.070904	65	67	75	2	29	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1389-4986	1573-6695		PREV SCI	Prev. Sci.	AUG	2013	14	4					411	421		10.1007/s11121-012-0313-2			11	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	173GB	WOS:000321065300007	23319292	Green Published, hybrid			2022-02-06	
J	Schatz, P; Glatts, C				Schatz, Philip; Glatts, Colette			Sandbagging Baseline Test Performance on ImPACT, Without Detection, Is More Difficult than It Appears	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; Coached versus nave malingering; ImPACT	SPORTS-RELATED CONCUSSION; HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; BRAIN-INJURY; HIGH-SCHOOL; VALIDITY; DIAGNOSIS; SPECIFICITY; RELIABILITY; SYMPTOMS	Participants coached to display poor effort on neuropsychological tests have successfully evaded detection. Recent research has documented that 89 college athletes instructed to perform poorly on a follow-up baseline ImPACT (Immediate Post-concussion Assessment and Cognitive Testing) test were unable to bypass detection, but otherwise, sandbagging on baseline testing has not been directly studied. In an analog study intended to measure participants ability to successfully sandbag, we compared baseline test performance in three groups of individuals, instructed: (a) to perform their best, (b) to malinger without guidance (e.g., nave), and (c) how to malinger (e.g., coached), using ImPACT, the Medical Symptom Validity Test (MSVT), and the Balance Error Scoring System. The MSVT identified more participants in the nave (80) and coached (90) groups than those automatically flagged by ImPACT (60 and 75, respectively). Inclusion of additional indicators within ImPACT increased identification to 95 of nave and 100 of coached malingerers. These results suggest that intentional sandbagging on baseline neurocognitive testing can be readily detected.	[Schatz, Philip; Glatts, Colette] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu			International Brain Research Foundation; Sports Concussion Center of New Jersey	Dr. Schatz has received funding to study the effects of concussion in high school and collegiate athletes from the International Brain Research Foundation and the Sports Concussion Center of New Jersey. He has also served as a consultant to ImPACT Applications, Inc., in the context of analyzing normative data and establishing age-and gender-based norms. However, ImPACT Applications, Inc. had no role in the conceptualization of the study, the collection or analysis of data, the writing of the article, or the decision to submit it for publication. Ms. Glatts has no Conflict of Interest to declare.	ALVES WM, 1987, CLIN SPORT MED, V6, P211; [Anonymous], 2012, SPORTING NEWS; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT, 1989, MILD HEAD INJURY; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Elbin R. J., 2011, AMERICAN JOURNAL OF; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P, 2004, MEDICAL SYMPTOM VALI; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jelicic M, 2011, J CLIN PSYCHOL, V67, P850, DOI 10.1002/jclp.20805; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2007, IMPACT VERSION 6 0 C; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Marvez A., 2012, PLAYERS MAY TRY TO B; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moss A, 2003, BRAIN INJURY, V17, P377, DOI 10.1080/0269905031000070125; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Reilly R., 2011, TALKING FOOTBALL WIT; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P., 2012, AMERICAN JOURNAL OF; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Sollman MJ, 2010, PSYCHOL ASSESSMENT, V22, P325, DOI 10.1037/a0018857; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Weinborn M, 2012, CLIN NEUROPSYCHOL, V26, P832, DOI 10.1080/13854046.2012.686630	39	67	67	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2013	28	3					236	244		10.1093/arclin/act009			9	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	138YK	WOS:000318547600004	23403552	Bronze			2022-02-06	
J	Beckwith, JG; Greenwald, RM; Chu, JJ; Crisco, JJ; Rowson, S; Duma, SM; Broglio, SP; Mcallister, TW; Guskiewicz, KM; Mihalik, JP; Anderson, S; Schnebel, B; Brolinson, PG; Collins, MW				Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.; Crisco, Joseph J.; Rowson, Steven; Duma, Stefan M.; Broglio, Steven P.; Mcallister, Thomas W.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Anderson, Scott; Schnebel, Brock; Brolinson, P. Gunnar; Collins, Michael W.			Timing of Concussion Diagnosis Is Related to Head Impact Exposure Prior to Injury	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						HIT SYSTEM; IMPACT BIOMECHANICS; MILD TRAUMATIC BRAIN INJURY (mTBI); TRAUMATIC BRAIN INJURY (TBI); INJURY THRESHOLD; SYMPTOMATOLOGY	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL FOOTBALL; ACCELERATION; BIOMECHANICS; KINEMATICS; MAGNITUDE; LOCATION	BECKWITH, J. G., R. M. GREENWALD, J. J. CHU, J. J. CRISCO, S. ROWSON, S. M. DUMA, S. P. BROGLIO, T. W. MCALLISTER, K. M. GUSKIEWICZ, J. P. MIHALIK, S. ANDERSON, B. SCHNEBEL, P. G. BROLINSON, and M. W. COLLINS. Timing of Concussion Diagnosis Is Related to Head Impact Exposure Prior to Injury. Med. Sci. Sports Exerc., Vol. 45, No. 4, pp. 747-754, 2013. Purpose: Concussions are commonly undiagnosed in an athletic environment because the postinjury signs and symptoms may be mild, masked by the subject, or unrecognized. This study compares measures of head impact frequency, location, and kinematic response before cases of immediate and delayed concussion diagnosis. Methods: Football players from eight collegiate and six high school teams wore instrumented helmets during play (n = 1208), of which 95 were diagnosed with concussion (105 total cases). Acceleration data recorded by the instrumented helmets were reduced to five kinematic metrics: peak linear and rotational acceleration, Gadd severity index, head injury criterion, and change in head velocity (Delta v). In addition, each impact was assigned to one of four general location regions (front, back, side, and top), and the number of impacts sustained before injury was calculated over two periods (1 and 7 days). Results: All head kinematic measures associated with injury, except peak rotational acceleration (P = 0.284), were significantly higher for cases of immediate diagnosis than delayed diagnosis (P < 0.05). Players with delayed diagnosis sustained a significantly higher number of head impacts on the day of injury (32.9 +/- 24.9, P < 0.001) and within 7 d of injury (69.7 +/- 43.3, P = 0.006) than players with immediate diagnosis (16.5 +/- 15.1 and 50.2 +/- 43.6). Impacts associated with concussion occurred most frequently to the front of the head (46%) followed by the top (25%), side (16%), and back (13%) with the number of impacts by location independent of temporal diagnosis (chi(2)(3) = 4.72, P = 0.19). Conclusions: Concussions diagnosed immediately after an impact event are associated with the highest kinematic measures, whereas those characterized by delayed diagnosis are preceded by a higher number of impacts.	[Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.] Simbex, Lebanon, NH 03766 USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Crisco, Joseph J.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Broglio, Steven P.] Michigan NeuroSport, Ann Arbor, MI USA; [Mcallister, Thomas W.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA; [Guskiewicz, Kevin M.; Mihalik, Jason P.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Anderson, Scott] Univ Oklahoma, Dept Intercollegiate Athlet, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Orthoped, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Athlet, Norman, OK 73019 USA; [Brolinson, P. Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Pittsburgh, PA USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA		Beckwith, JG (corresponding author), Simbex, 10 Water St,Suite 410, Lebanon, NH 03766 USA.	jbeckwith@simbex.com	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Rowson, Steven/0000-0002-3227-0596; Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322; Crisco, Joseph/0000-0002-8786-0905	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, R01NS055020]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254, 5R49CE000196]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254, R49CE000196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported in part by award R01HD048638 and R01NS055020 from the National Institute of Health, R01CE001254 and 5R49CE000196 from the Centers for Disease Control and Prevention, and NOCSAE (07-04, 14-19). HIT System technology was developed in part under NIH R44HD40473 and research and development support from Riddell, Inc. (Chicago, IL).	Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hodgson VR, 1976, MEASUREMENT PREDICTI, V31, P121; Hodgson VR, 1970, 700901 SAE, DOI [10.4271/700901, DOI 10.4271/700901]; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	32	67	67	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	APR	2013	45	4					747	754		10.1249/MSS.0b013e3182793067			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	109ZK	WOS:000316410600018	23135364	Green Accepted, Green Submitted			2022-02-06	
J	Sarkaki, AR; Haddad, MK; Soltani, Z; Shahrokhi, N; Mahmoodi, M				Sarkaki, Ali Reza; Haddad, Mohammad Khaksari; Soltani, Zahra; Shahrokhi, Nader; Mahmoodi, Mehdi			Time- and Dose-Dependent Neuroprotective Effects of Sex Steroid Hormones on Inflammatory Cytokines after a Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; IL-1 beta; IL-6; TNF-alpha; TGF-beta	TUMOR-NECROSIS-FACTOR; RAT-BRAIN; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; MESSENGER-RNA; PROGESTERONE; EXPRESSION; RECEPTOR; INTERLEUKIN-1; ESTROGEN	Following a traumatic brain injury (TBI), excessive release of proinflammatory cytokines is the major cause of cerebral edema and neuronal loss. This study was designed to examine changes in concentrations of some proinflammatory cytokines-including interleukin-1 beta (IL-1 beta), interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor-beta (TGF-beta)-in a rat model of TBI in which the animals were treated with different doses of estrogen or progesterone 6 and 24 h after the TBI. Adult female rats were divided into 14 groups. Hormones or vehicle were given intraperitoneally 30 min after a moderate TBI was induced by the Marmarou method. The levels of proinflammatory cytokines in brain were measured at 6 and 24 h after the TBI. A high dose of estrogen (E2) or a low dose of progesterone (P1) increased brain levels of IL-1 beta 52.7% and 79.2% respectively at 6 h after the TBI. By 24h, IL-1 beta levels in the brain were 27.5% and 27% lower following administration of estrogen low dose (E1) or E2, respectively. High-dose administration of progesterone reduced brain levels of IL-6 to 45.9% at 6 h after the TBI, and P1 and E1 treatment significantly decreased IL-6 levels at 24 h. Brain levels of TNF-alpha were 72.5% lower at 6 h after the TBI following P2 treatment and 48.5% higher at 24 hrs following treatment with E2. The levels of TGF-beta were also 3.37 times higher 24 h after the TBI following treatment with E1. Both doses of the hormones tested increases TGF-beta levels 6 h after the TBI. Based on our findings, we conclude that progesterone and estrogen influence the levels of proinflammatory cytokines either at the primary or secondary stages after a TBI. Accordingly, this study suggests a mechanism by which hormones reduce cerebral edema.	[Sarkaki, Ali Reza] Ahwaz Univ Med Sci, Physiol Res Ctr, Ahvaz, Iran; [Haddad, Mohammad Khaksari; Shahrokhi, Nader] Kerman Univ Med Sci, Neurosci Res Ctr, Kerman, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Bam Int Unit, Kerman, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Physiol Res Ctr, Sch Med, Kerman, Iran; [Mahmoodi, Mehdi] Rafsanjan Univ Med Sci, Dept Biochem, Rafsanjan, Iran		Haddad, MK (corresponding author), Kerman Univ Med Sci, Physiol Res Ctr, Sch Med, Kerman, Iran.	khaksar38@yahoo.co.uk	Sarkaki, Alireza/Q-8363-2017; Shahrokhi, Nader/AAV-3747-2020; Haddad, Mohammad Khaksari/AAB-9025-2019; Soltani, Zahra/AAC-1350-2019; Mahmoodi, Mehdi/H-2754-2017	Sarkaki, Alireza/0000-0001-9272-6228; Shahrokhi, Nader/0000-0002-0149-7819; Haddad, Mohammad Khaksari/0000-0003-0770-4281; Soltani, Zahra/0000-0002-8423-6189; Mahmoodi, Mehdi/0000-0002-8463-8364	Kerman Neuroscience Center; Ahwaz Physiology Research Center	The present study was financially supported by the Kerman Neuroscience and Ahwaz Physiology Research Centers.	Bartfai T, 2007, ANN NY ACAD SCI, V1113, P173, DOI 10.1196/annals.1391.022; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Crandall C, 2006, J WOMENS HEALTH, V15, P14, DOI 10.1089/jwh.2006.15.14; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutolo M, 2006, ANN NY ACAD SCI, V1089, P538, DOI 10.1196/annals.1386.043; Das C, 2002, J REPROD IMMUNOL, V53, P257, DOI 10.1016/S0165-0378(01)00099-7; DOREDUFFY P, 1994, MOL CHEM NEUROPATHOL, V22, P161, DOI 10.1007/BF03160103; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fee DB, 2004, BRAIN RES, V1012, P52, DOI 10.1016/j.brainres.2004.03.028; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hatthachote P, 1999, ENDOCRINOLOGY, V140, P2533, DOI 10.1210/en.140.6.2533; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hoffman GE, 2006, ENDOCRINE, V29, P217, DOI 10.1385/ENDO:29:2:217; Hoffman S. W, 2001, ACAD EMERG MED, V8, P496; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Houdeau E, 2007, GASTROENTEROLOGY, V132, P982, DOI 10.1053/j.gastro.2006.12.028; Hrekova S P, 2002, Fiziol Zh, V48, P63; Hussein Mohamed Z, 2004, Egypt J Immunol, V11, P165; Jain SK, 2004, CYTOKINE, V26, P102, DOI 10.1016/j.cyto.2004.01.002; Jones NC, 2005, EUR J NEUROSCI, V22, P72, DOI 10.1111/j.1460-9568.2005.04221.x; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Jonsson Daniel, 2007, Swed Dent J Suppl, P11; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Lacut K, 2003, THROMB HAEMOSTASIS, V90, P124; LaMarca BD, 2007, AM J HYPERTENS, V20, P1216, DOI 10.1016/j.amjhyper.2007.07.002; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; molaie L Ahmad, 2007, J KERMAN U MED SCI, V15, P47; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; OLSSON T, 1995, IMMUNOL REV, V144, P245, DOI 10.1111/j.1600-065X.1995.tb00072.x; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rostworowski M, 1997, J NEUROSCI, V17, P3664; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Schaefer TM, 2005, J IMMUNOL, V175, P6509, DOI 10.4049/jimmunol.175.10.6509; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shifren JL, 2008, J CLIN ENDOCR METAB, V93, P1702, DOI 10.1210/jc.2007-2193; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Soltani Z., 2009, Iranian Journal of Endocrinology and Metabolism, V10, P629; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Won CK, 2006, J VET MED SCI, V68, P277, DOI 10.1292/jvms.68.277; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Yuan K, 2002, J PERIODONTOL, V73, P701, DOI 10.1902/jop.2002.73.7.701	58	67	72	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	1					47	54		10.1089/neu.2010.1686			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	061GU	WOS:000312837300008	21851230	Green Accepted			2022-02-06	
J	Wood, JN; Medina, SP; Feudtner, C; Luan, XQ; Localio, R; Fieldston, ES; Rubin, DM				Wood, Joanne N.; Medina, Sheyla P.; Feudtner, Chris; Luan, Xianqun; Localio, Russell; Fieldston, Evan S.; Rubin, David M.			Local Macroeconomic Trends and Hospital Admissions for Child Abuse, 2000-2009	PEDIATRICS			English	Article						child safety; maltreatment; abuse; head trauma; head injuries	TRAUMATIC BRAIN-INJURY; UNITED-STATES; COMPUTED-TOMOGRAPHY; PHYSICAL ABUSE; HEAD TRAUMA; EMERGENCY-DEPARTMENTS; MALTREATMENT; UNEMPLOYMENT; RECESSION; INFANTS	OBJECTIVE: To examine the relationship between local macroeconomic indicators and physical abuse admission rates to pediatric hospitals over time. METHODS: Retrospective study of children admitted to 38 hospitals in the Pediatric Hospital Information System database. Hospital data were linked to unemployment, mortgage delinquency, and foreclosure data for the associated metropolitan statistical areas. Primary outcomes were admission rates for (1) physical abuse in children <6 years old, (2) non-birth, non-motor vehicle crash-related traumatic brain injury (TBI) in infants <1 year old (which carry high risk for abuse), and (3) all-cause injuries. Poisson fixed-effects regression estimated trends in admission rates and associations between those rates and trends in unemployment, mortgage delinquency, and foreclosure. RESULTS: Between 2000 and 2009, rates of physical abuse and high-risk TBI admissions increased by 0.79% and 3.1% per year, respectively (P <= .02), whereas all-cause injury rates declined by 0.80% per year (P < .001). Abuse and high-risk TBI admission rates were associated with the current mortgage delinquency rate and with the change in delinquency and foreclosure rates from the previous year (P <= .03). Neither abuse nor high-risk TBI rates were associated with the current unemployment rate. The all-cause injury rate was negatively associated with unemployment, delinquency, and foreclosure rates (P <= .007). CONCLUSIONS: Multicenter hospital data show an increase in pediatric admissions for physical abuse and high-risk TBI during a time of declining all-cause injury rate. Abuse and high-risk TBI admission rates increased in relationship to local mortgage delinquency and foreclosure trends. Pediatrics 2012;130:e358-e364	[Wood, Joanne N.; Medina, Sheyla P.; Feudtner, Chris; Luan, Xianqun; Fieldston, Evan S.; Rubin, David M.] Childrens Hosp Philadelphia, PolicyLab, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris; Fieldston, Evan S.; Rubin, David M.] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Feudtner, Chris; Fieldston, Evan S.; Rubin, David M.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Localio, Russell] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA		Wood, JN (corresponding author), Childrens Hosp Philadelphia, PolicyLab, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA.	woodjo@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434; Wood, Joanne/0000-0001-6431-8024			[Anonymous], 2011, STAT NAT HOUS; [Anonymous], 2010, GROW CRIS CHILD PROT; Baum K., 2005, JUVENILE VICTIMIZATI; Berger LM, 2004, CHILD YOUTH SERV REV, V26, P725, DOI 10.1016/j.childyouth.2004.02.017; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; CATALANO R, 1991, AM J PUBLIC HEALTH, V81, P1148, DOI 10.2105/AJPH.81.9.1148; Child Welfare Information Gateway, 2008, DIFF RESP REP CHILD; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cohen Rebecca, 2011, SHOULD I STAY SHOULD; Currie J, 2011, NATL BUREAU EC RES W, P17310; Differential Response in Child Protective Services, 2011, LIT REV VERS 2; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Federal Interagency Forum on Child and Family Statistics, 2011, AM CHILDR KEY NAT IN; Finkelhor D, 2003, CHILD ABUSE NEGLECT, V27, P77, DOI 10.1016/S0145-2134(02)00508-2; Finkelhor D, 2009, UPDATED TRENDS CHILD; Finkelhor D, 2011, UPDATED TRENDS CHILD; Finkelhor D, 2010, ARCH PEDIAT ADOL MED, V164, P238, DOI 10.1001/archpediatrics.2009.283; Freisthler B, 2007, SOC WORK, V52, P7, DOI 10.1093/sw/52.1.7; Gallup Organization, 1995, DISC CHILDR AM GALL; GIL DG, 1969, PEDIATRICS, V44, P857; Gilbert R, 2009, LANCET, V373, P68, DOI 10.1016/S0140-6736(08)61706-7; Gilbert R, 2009, LANCET, V373, P167, DOI 10.1016/S0140-6736(08)61707-9; Huang MI, 2011, J NEUROSURG-PEDIATR, V8, P171, DOI 10.3171/2011.5.PEDS1139; Hughes S, 2009, CBS NEWS; Kan J, 2008, MBA RES DATANOTES; KRUGMAN RD, 1986, CHILD ABUSE NEGLECT, V10, P415, DOI 10.1016/0145-2134(86)90018-9; Leventhal JM, 2008, PEDIATRICS, V122, P599, DOI 10.1542/peds.2007-1959; Leventhal JM, 2012, PEDIATRICS, V129, P458, DOI 10.1542/peds.2011-1277; Lovell P, 2008, IMPACT MORTGAGE CRIS; Madan AK, 2007, WORLD J SURG, V31, P1930, DOI 10.1007/s00268-007-9190-4; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Menoch MJA, 2012, PEDIATRICS, V129, pE690, DOI 10.1542/peds.2011-2548; Mersky JP, 2009, CHILD MALTREATMENT, V14, P73, DOI 10.1177/1077559508318399; Millett L, 2011, CHILD YOUTH SERV REV, V33, P1280, DOI 10.1016/j.childyouth.2011.03.001; Minnesota Departments of Education Health Human Services & Public Safety, 2010, MINN STUD SURV 1992; MULLER A, 1989, AM J PUBLIC HEALTH, V79, P1366, DOI 10.2105/AJPH.79.10.1366; Pare J, 1992, 8 NAT S CHILD VICT M; Sedlak A, 1996, 3 NAT INC STUD CHILD; Sedlak A.J., 2010, 4 NATL INCIDENCE STU; Sermons MW, 2011, STATE HOMELESSNESS A; Shattuck A., 2010, UPDATED TRENDS CHILD; STEINBERG LD, 1981, CHILD DEV, V52, P975; Stuckler D, 2011, LANCET, V378, P124, DOI 10.1016/S0140-6736(11)61079-9; Stuckler D, 2009, LANCET, V374, P315, DOI 10.1016/S0140-6736(09)61124-7; Szep J, 2009, REUTERS NEWS SERVICE; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; Trokel M, 2006, PEDIATRICS, V117, P722, DOI 10.1542/peds.2004-2731; U.S. Department of Health and Human Services Administration on Children Youth and Families, 2009, CHILD MALTR 2007; U. S. Department of Health & Human Services (USDHHS) Administration for Children Youth and Families & Children's Bureau, 2011, CHILD MALTR 2010; *US ADM CHILDR YOU, 2008, CHILD MALTR 2006; US Bureau of Labor Statistics, LOC AR UNEMPL STAT D; US Census Bureau, METR MICR STAT AR; US Department of Health and Human Services Administration for Children Youth and Families, 2010, CHILD MALTR 2009; US Department of Health and Human Services Administration on Children Youth and Families, 2002, CHILD MALTR 2000; US Department of Health and Human Services Administration on Children Youth and Families, 2010, CHILD MALTR 2008; US Department of Health and Human Services Administration on Children Youth and Families, 2005, CHILD MALTR 2005; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	59	67	67	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	2012	130	2					E358	E364		10.1542/peds.2011-3755			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	983MI	WOS:000307123000015	22802600				2022-02-06	
J	Mao, SS; Hua, R; Zhao, XP; Qin, X; Sun, ZQ; Zhang, Y; Wu, YQ; Jia, MX; Cao, JL; Zhang, YM				Mao, Shan-Shan; Hua, Rong; Zhao, Xiao-Ping; Qin, Xia; Sun, Zhen-Quan; Zhang, Yang; Wu, Yu-Qing; Jia, Meng-Xing; Cao, Jun-Li; Zhang, Yong-Mei			Exogenous Administration of PACAP Alleviates Traumatic Brain Injury in Rats through a Mechanism Involving the TLR4/MyD88/NF-kappa B Pathway	JOURNAL OF NEUROTRAUMA			English	Article						inflammatory cytokines; MyD88; PACAP; toll-like receptor 4; traumatic brain injury	CYCLASE-ACTIVATING POLYPEPTIDE; TOLL-LIKE RECEPTORS; FOCAL CEREBRAL-ISCHEMIA; INNATE IMMUNE-RESPONSE; CENTRAL-NERVOUS-SYSTEM; ADENYLATE-CYCLASE; HEAD-INJURY; CELL-DEATH; PARAVENTRICULAR NUCLEUS; PATHOGEN RECOGNITION	Pituitary adenylate cyclase-activating polypeptide (PACAP) is effective in reducing axonal damage associated with traumatic brain injury (TBI), and has immunomodulatory properties. Toll-like receptor 4 (TLR4) is an important mediator of the innate immune response. It significantly contributes to neuroinflammation induced by brain injury. However, it remains unknown whether exogenous PACAP can modulate TBI through the TLR4/adapter protein myeloid differentiation factor 88 (MyD88)/nuclear factor-kappa B (NF-kappa B) signaling pathway. In this study, we investigated the potential neuroprotective mechanisms of PACAP pretreatment in a weight-drop model of TBI. PACAP38 was microinjected intracerebroventricularly before TBI. Brain samples were extracted from the pericontusional area in the cortex and hippocampus. We found that TBI induced significant upregulation of TLR4, with peak expression occurring 24 h post-trauma, and that pretreatment with PACAP significantly improved motor and cognitive dysfunction, attenuated neuronal apoptosis, and decreased brain edema. Pretreatment with PACAP inhibited upregulation of TLR4 and its downstream signaling molecules MyD88, p-I kappa B, and NF-kappa B, and suppressed increases in the levels of the downstream inflammatory agents interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), in the brain tissue around the injured cortex and in the hippocampus. Administration of PACAP both in vitro and in vivo attenuated the ability of the TLR4 agonist lipopolysaccharide (LPS) to increase TLR4 protein levels. Therefore, PACAP exerts a neuroprotective effect in this rat model of TBI, by inhibiting a secondary inflammatory response mediated by the TLR4/MyD88/NF-kappa B signaling pathway in microglia and neurons, thereby reducing neuronal death and improving the outcome following TBI.	[Cao, Jun-Li; Zhang, Yong-Mei] Xuzhou Med Coll, Affiliated Hosp, Dept Anesthesiol, Jiangsu Prov Key Lab Anesthesiol, Xuzhou 221002, Jiangsu, Peoples R China; [Zhang, Yong-Mei] Xuzhou Med Coll, Jiangsu Key Lab Brain Dis Bioinformat, Xuzhou 221002, Jiangsu, Peoples R China; [Hua, Rong] PLA, Hosp 97, Dept Emergency Med, Xuzhou, Jiangsu, Peoples R China		Zhang, YM (corresponding author), Xuzhou Med Coll, Affiliated Hosp, Dept Anesthesiol, Jiangsu Prov Key Lab Anesthesiol, 84 W Huaihai Rd, Xuzhou 221002, Jiangsu, Peoples R China.	caojl0310@yahoo.com.cn; zhangym700@163.com		Cao, Jun-Li/0000-0002-8932-4743	National Natural Science of ChinaNational Natural Science Foundation of China (NSFC) [81171041, 81171013]; Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province [BK2011197]; Educational Department Science Research Foundation of Jiangsu Province [09KJD310009]; Jiangsu Key Laboratory of Brain Disease Bioinformation [JSBL0804]; Innovation Project of Nanjing Military Region [09MA036]; Research Foundation of President of Xuzhou Medical College [09KJZ17]; Priority Academic Program Development of Jiangsu Higher Education Institutions of Jiangsu Province	This project was supported by grants from the National Natural Science of China (81171041 and 81171013), the Natural Science Foundation of Jiangsu Province (BK2011197), the Educational Department Science Research Foundation of Jiangsu Province (09KJD310009), a project from the Jiangsu Key Laboratory of Brain Disease Bioinformation (JSBL0804), the Innovation Project of Nanjing Military Region (09MA036), the Research Foundation of President of Xuzhou Medical College (no. 09KJZ17), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions of Jiangsu Province.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Allais A, 2010, J NEUROCHEM, V113, P329, DOI 10.1111/j.1471-4159.2009.06555.x; Aravalli RN, 2008, J NEUROIMMUNE PHARM, V3, P5, DOI 10.1007/s11481-007-9097-8; Aravalli RN, 2007, J NEUROIMMUNE PHARM, V2, P297, DOI 10.1007/s11481-007-9071-5; Armant MA, 2002, GENOME BIOL, V3; Armstrong BD, 2008, NEUROSCIENCE, V151, P63, DOI 10.1016/j.neuroscience.2007.09.084; Arslan F, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/704202; Arumugam TV, 2009, SHOCK, V32, P4, DOI 10.1097/SHK.0b013e318193e333; Autret A, 2009, MOL CELL, V36, P355, DOI 10.1016/j.molcel.2009.10.011; Barichello T, 2011, NEUROCHEM RES, V36, P1922, DOI 10.1007/s11064-011-0514-2; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Brea D, 2011, REV NEUROLOGIA, V52, P12, DOI 10.33588/rn.5201.2010494; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Choi DC, 2008, ENDOCRINOLOGY, V149, P818, DOI 10.1210/en.2007-0883; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Das M, 2007, J COMP NEUROL, V500, P761, DOI 10.1002/cne.21212; Ding BJ, 2011, INT J DEV NEUROSCI, V29, P537, DOI 10.1016/j.ijdevneu.2011.04.002; Dong XQ, 2011, INFLAMM RES, V60, P533, DOI 10.1007/s00011-010-0300-7; Du J, 2009, FLUIDS BARRIERS CNS, V6, DOI 10.1186/1743-8454-6-3; Fang KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015299; Farina C, 2005, J NEUROIMMUNOL, V159, P12, DOI 10.1016/j.jneuroim.2004.09.009; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fletcher JI, 2008, CELL CYCLE, V7, P39, DOI 10.4161/cc.7.1.5178; Gomariz RP, 2007, PEPTIDES, V28, P1825, DOI 10.1016/j.peptides.2007.07.005; Gressens P, 2000, J NEUROPATH EXP NEUR, V59, P1051, DOI 10.1093/jnen/59.12.1051; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hyakkoku K, 2010, NEUROSCIENCE, V171, P258, DOI 10.1016/j.neuroscience.2010.08.054; Jang HR, 2009, CLIN IMMUNOL, V130, P41, DOI 10.1016/j.clim.2008.08.016; Johanson C, 2011, J NEURAL TRANSM, V118, P115, DOI 10.1007/s00702-010-0498-0; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Jung DY, 2005, J IMMUNOL, V174, P6467, DOI 10.4049/jimmunol.174.10.6467; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kojro E, 2006, FASEB J, V20, P512, DOI 10.1096/fj.05-4812fje; Kovesdi E, 2008, NEUROTOX RES, V13, P71, DOI 10.1007/BF03033558; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mack WJ, 2006, J NEUROSCI RES, V83, P883, DOI 10.1002/jnr.20775; Marklund N, 2009, NEUROSCIENCE, V163, P540, DOI 10.1016/j.neuroscience.2009.06.042; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Matsttzaki S, 2008, EXPERT OPIN THER TAR, V12, P1097, DOI [10.1517/14728222.12.9.1097 , 10.1517/14728220802321783]; Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nakamachi T, 2010, ACTA NEUROCHIR SUPPL, V106, P43, DOI 10.1007/978-3-211-98811-4_6; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Norrholm SD, 2005, REGUL PEPTIDES, V128, P33, DOI 10.1016/j.regpep.2004.12.023; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/bst0310643; Panaro MA, 2008, IMMUNOPHARM IMMUNOT, V30, P729, DOI [10.1080/08923970802278557, 10.1080/08923970802278557 ]; Pulskens WP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003596; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reglodi D, 2006, NEUROPEPTIDES, V40, P265, DOI 10.1016/j.npep.2006.06.001; Reglodi D, 2004, BEHAV BRAIN RES, V151, P303, DOI 10.1016/j.bbr.2003.09.007; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Rock RB, 2006, J NEUROIMMUNE PHARM, V1, P117, DOI 10.1007/s11481-006-9012-8; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Stetler RA, 2010, P NATL ACAD SCI USA, V107, P3204, DOI 10.1073/pnas.1000030107; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tamas A, 2006, J NEUROTRAUM, V23, P686, DOI 10.1089/neu.2006.23.686; Tanaka K, 2006, J NEUROSCI, V26, P5091, DOI 10.1523/JNEUROSCI.4376-05.2006; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; van Landeghem FKH, 2007, ACTA NEUROPATHOL, V113, P683, DOI 10.1007/s00401-007-0208-7; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Vollmar P, 2010, J IMMUNOL, V185, P6338, DOI 10.4049/jimmunol.1001765; Waak J, 2009, FASEB J, V23, P2478, DOI 10.1096/fj.08-125153; Watanabe J, 2007, PEPTIDES, V28, P1713, DOI 10.1016/j.peptides.2007.06.029; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Xia Y, 2006, BRAIN RES, V1095, P85, DOI 10.1016/j.brainres.2006.03.112; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yu JW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-141; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	88	67	74	0	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1941	1959		10.1089/neu.2011.2244			19	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400397	22583372				2022-02-06	
J	Hanlon, EM; Bir, CA				Hanlon, Erin M.; Bir, Cynthia A.			Real-Time Head Acceleration Measurement in Girls' Youth Soccer	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; INJURY; ON-FIELD MEASUREMENT; SOCCER HEADING; COLLISION	FOOTBALL; IMPACT; CONCUSSION; INJURIES	HANLON, E. M., and C. A. BIR. Real-Time Head Acceleration Measurement in Girls' Youth Soccer. Med. Sci. Sports Exerc., Vol. 44, No. 6, pp. 1102-1108,2012. Purpose: The purpose of the current study was to collect real-time head acceleration data for soccer impacts during girls' youth (U14) soccer play. Methods: Linear and angular head accelerations were collected during girls' youth soccer scrimmages using a wireless head acceleration measurement device (the Head Impact Telemetry System). After field data collection, each individual impact was analyzed. The type of impact, header or nonheader, was determined, and nonheader impacts were further assessed by the category of impact. The head injury criterion and resultant linear and angular accelerations were analyzed and compared with current injury tolerance values for all impacts. Results: A total of 47 header and 20 nonheader impacts were observed during the study. The front of the head experienced more headers than the other locations (n = 17). Header impacts ranged in peak linear acceleration from 4.5g to 62.9g and in peak angular head acceleration from 444.8 to 8869.1 rad.s(-2). The majority of the nonheader impacts (40%) were player collisions with other players. Only one goalpost collision occurred, but it resulted in the highest peak angular acceleration (5179.5 rad.s(-2)) and was the only nonheader impact to exceed any of the tolerance levels. Conclusions: Head accelerations were found to exceed the majority of previous laboratory studies. None of the impacts exceeded linear acceleration tolerance values for concussion, but angular accelerations did exceed the suggested limits. Three angular acceleration measurements for heading events (4509.8, 5298.3, and 8869.1 rad.s(-2)) exceeded the concussion tolerance values, but no concussions were diagnosed during the study.	[Hanlon, Erin M.; Bir, Cynthia A.] Wayne State Univ, Coll Engn, Dept Biomed Engn, Detroit, MI 48201 USA		Bir, CA (corresponding author), Wayne State Univ, Coll Engn, Dept Biomed Engn, 818 W Hancock, Detroit, MI 48201 USA.	cbir@wayne.edu		Bir, Cynthia/0000-0002-0777-0951	Anthony and Joyce Danielski Kales Scholarship; National Organizing Committee on Standards for Athletic Equipment	This study was also supported in part by the Anthony and Joyce Danielski Kales Scholarship.; The authors thank the National Organizing Committee on Standards for Athletic Equipment for funding this project.	Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gadd CW., 1966, 660793 SAE, P164; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; JANDA DH, 1995, AM J SPORT MED, V23, P340, DOI 10.1177/036354659502300316; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Newman J A, 2000, Stapp Car Crash J, V44, P215; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson Steven, 2009, Biomed Sci Instrum, V45, P113; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Self BP, 2006, ENG SPORT 6, V6, P81; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI26, DOI 10.1136/bjsm.2005.019042; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	27	67	67	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2012	44	6					1102	1108		10.1249/MSS.0b013e3182444d7d			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	944TQ	WOS:000304227100017	22592278				2022-02-06	
J	Fernandez-Ortega, JF; Prieto-Palomino, MA; Garcia-Caballero, M; Galeas-Lopez, JL; Quesada-Garcia, G; Baguley, IJ				Francisco Fernandez-Ortega, Juan; Angel Prieto-Palomino, Miguel; Garcia-Caballero, Manuel; Luis Galeas-Lopez, Juan; Quesada-Garcia, Guillermo; Baguley, Ian J.			Paroxysmal Sympathetic Hyperactivity after Traumatic Brain Injury: Clinical and Prognostic Implications	JOURNAL OF NEUROTRAUMA			English	Article						computed tomography; intensive care unit; paroxysmal sympathetic hyperactivity; prognosis; traumatic brain injury	SEVERE HEAD-INJURY; INTENSIVE-CARE-UNIT; AUTONOMIC INSTABILITY; DIENCEPHALIC SEIZURES; DYSAUTONOMIA; DYSTONIA; BROMOCRIPTINE; MANAGEMENT; PRESSURE	A proportion of patients surviving severe traumatic brain injury (TBI) have symptoms suggestive of excessive sympathetic discharge, here termed paroxysmal sympathetic hyperactivity (PSH). The goals of this study were: (1) to describe the clinical associations and radiological findings of PSH, its incidence, and features in subjects with severe TBI in the intensive care unit (ICU); (2) to investigate the potential role of increased intracranial pressure in the pathogenesis of PSH; and (3) to determine the prognostic influence of PSH during the ICU stay, on discharge from the ICU, and at 12 months post-injury. A prospective cohort study was undertaken of all ICU admissions with severe TBI older than 14 years over an 18-month period. The PSH symptoms consisted of paroxysmal increases in blood pressure, respiratory rate, and heart rate; worsening level of consciousness; muscle rigidity; and hyperhidrosis. Subjects demonstrating PSH episodes were compared with a group of non-PSH consecutive subjects studied over the first 6 months of the study period. Data were recorded on the clinical variables associated with PSH episodes, early post-injury cerebral CT findings, and neurological status at 1 year. Of 179 severe TBI patients admitted over the study period, 18 (10.1%) experienced PSH. Injury severity-related variables (e. g., initial APACHE II score, admission coma level, and proportion with intracranial hypertension) were similar between the two groups. The PSH group had a longer ICU stay and a greater incidence of infectious complications. At 1 year post-injury, 20% of this group demonstrated ongoing PSH episodes. Over 18 months, 10.1% of admissions following severe TBI demonstrated PSH features in ICU. Subjects with PSH had a longer ICU stay and higher rate of complications, although this did not appear to compromise their long-term neurological recovery.	[Francisco Fernandez-Ortega, Juan; Angel Prieto-Palomino, Miguel; Garcia-Caballero, Manuel; Luis Galeas-Lopez, Juan; Quesada-Garcia, Guillermo] Univ Hosp Carlos Haya, ICU Serv, Malaga, Spain; [Baguley, Ian J.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia		Fernandez-Ortega, JF (corresponding author), C Mirador Candado 1, Malaga 29018, Spain.	patferon@gmail.com	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705; Fernandez Ortega, Juan F/0000-0003-2130-1331; Galeas Lopez, Juan Luis/0000-0002-1612-7730			Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BHIGJEE AI, 1985, J NEUROL SCI, V71, P77, DOI 10.1016/0022-510X(85)90038-3; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; CARMEL PW, 1985, ACTA NEUROCHIR, V75, P113, DOI 10.1007/BF01406331; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Diesing TS, 2006, MOVEMENT DISORD, V21, P868, DOI 10.1002/mds.20831; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Fernandez-Ortega JF, 2004, REV NEUROLOGIA, V39, P715, DOI 10.33588/rn.3908.2004034; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Goddeau RP, 2007, NEUROCRIT CARE, V7, P217, DOI 10.1007/s12028-007-0066-0; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KLUG N, 1984, ACTA NEUROCHIR, V72, P219, DOI 10.1007/BF01406872; Lv LQ, 2010, J NEUROTRAUM, V27, P1945, DOI 10.1089/neu.2010.1391; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Penfield W, 1929, ARCH NEURO PSYCHIATR, V22, P358, DOI 10.1001/archneurpsyc.1929.02220020174010; Perkes I.E., BRAIN INJ IN PRESS; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Srinivasan S, 2007, CLIN AUTON RES, V17, P378, DOI 10.1007/s10286-007-0428-x; SUAREZALVAREZ JR, 1995, INTENS CARE MED, V21, P729, DOI 10.1007/BF01704740; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698; Wang VY, 2008, J TRAUMA, V64, P500, DOI 10.1097/TA.0b013e31804a5738; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049	39	67	75	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1364	1370		10.1089/neu.2011.2033			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600010	22150061				2022-02-06	
J	Cruse, D; Chennu, S; Chatelle, C; Fernandez-Espejo, D; Bekinschtein, TA; Pickard, JD; Laureys, S; Owen, AM				Cruse, D.; Chennu, S.; Chatelle, C.; Fernandez-Espejo, D.; Bekinschtein, T. A.; Pickard, J. D.; Laureys, S.; Owen, A. M.			Relationship between etiology and covert cognition in the minimally conscious state	NEUROLOGY			English	Article							PERSISTENT VEGETATIVE STATE; DIFFUSE AXONAL INJURY; BRAIN-INJURY; HEAD-INJURY; LATE RECOVERY; DISORDERS; NEUROPATHOLOGY; AWARENESS; REHABILITATION; DIAGNOSIS	Objectives: Functional neuroimaging has shown that the absence of externally observable signs of consciousness and cognition in severely brain-injured patients does not necessarily indicate the true absence of such abilities. However, relative to traumatic brain injury, nontraumatic injury is known to be associated with a reduced likelihood of regaining overtly measurable levels of consciousness. We investigated the relationships between etiology and both overt and covert cognitive abilities in a group of patients in the minimally conscious state (MCS). Methods: Twenty-three MCS patients (15 traumatic and 8 nontraumatic) completed a motor imagery EEG task in which they were required to imagine movements of their right-hand and toes to command. When successfully performed, these imagined movements appear as distinct sensorimotor modulations, which can be used to determine the presence of reliable command-following. The utility of this task has been demonstrated previously in a group of vegetative state patients. Results: Consistent and robust responses to command were observed in the EEG of 22% of the MCS patients (5 of 23). Etiology had a significant impact on the ability to successfully complete this task, with 33% of traumatic patients (5 of 15) returning positive EEG outcomes compared with none of the nontraumatic patients (0 of 8). Conclusions: The overt behavioral signs of awareness (measured with the Coma Recovery Scale-Revised) exhibited by nontraumatic MCS patients appear to be an accurate reflection of their covert cognitive abilities. In contrast, one-third of a group of traumatically injured patients in the MCS possess a range of high-level cognitive faculties that are not evident from their overt behavior. Neurology (R) 2012;78:816-822	[Cruse, D.; Fernandez-Espejo, D.; Owen, A. M.] Univ Western Ontario, Ctr Brain & Mind, London, ON, Canada; [Cruse, D.; Bekinschtein, T. A.; Owen, A. M.] MRC, Cognit & Brain Sci Unit, Cambridge, England; [Chennu, S.] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 1TN, England; Univ Hosp Liege, Liege, Belgium; [Chatelle, C.; Laureys, S.] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Chatelle, C.; Laureys, S.] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Pickard, J. D.] Addenbrookes Hosp, Div Acad Neurosurg, Cambridge, England		Cruse, D (corresponding author), Univ Western Ontario, Ctr Brain & Mind, London, ON, Canada.	dcruse@uwo.ca	Owen, Adrian M/B-4997-2015; Laureys, Steven/A-3349-2011; Cruse, Damian/ABA-6346-2021; Fernandez-Espejo, Davinia/AAT-5481-2021; Laureys, Steven/AAN-2097-2021	Cruse, Damian/0000-0003-4363-5981; Fernandez-Espejo, Davinia/0000-0001-5941-7546; Laureys, Steven/0000-0002-3096-3807; Chennu, Srivas/0000-0002-6840-2941; Chatelle, Camille/0000-0002-7526-2107; Bekinschtein, Tristan/0000-0001-5501-8628	Medical Research Council UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Canada Excellence Research Chair Program; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); McDonnell Foundation; James S. McDonnell Foundation; Guarantors of Brain	Dr. Cruse has received research support from Medical Research Council UK and the Canada Excellence Research Chair Program. Dr. Chennu receives research support from Medical Research Council UK, Visiting Worker, James S. McDonnell Foundation, and Guarantors of Brain. Dr. Chatelle, Dr. Fernandez-Espejo, and Dr. Bekinschtein report no disclosures. Dr. Pickard serves on scientific advisory boards for Codman and Johnson & Johnson; serves as Chief Editor for Advances and Technical Standards in Neurosurgery; receives publishing royalties for Pseudotumor Cerebro Syndrome (Cambridge University Press, 2008); and receives research support from MRC Translational Grant and the McDonnell Foundation. Dr. Laureys reports no disclosures. Dr. Owen serves as an Associate Editor for Journal of Neuroscience and on the editorial advisory board of Annals of the New York Academy of Sciences; receives publishing royalties for Cognitive Deficits in Neurological Disorders (Dunitz, 2001); and receives research support from Medical Research Council UK and the James S. McDonnell Foundation.	Adams J. H., 1992, GREENFIELDS NEUROPAT; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Fins JJ, 2007, NEUROLOGY, V68, P304, DOI 10.1212/01.wnl.0000252376.43779.96; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Monti MM, 2010, J PSYCHOPHY IN PRESS; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Whyte J, 2009, PROG BRAIN RES, V177, P63, DOI 10.1016/S0079-6123(09)17706-3	31	67	70	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	MAR	2012	78	11					816	822		10.1212/WNL.0b013e318249f764			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	907VW	WOS:000301448300011	22377810	Green Accepted, Green Published			2022-02-06	
J	Peter, SJ; Mofrad, MRK				Peter, Stephen J.; Mofrad, Mohammad R. K.			Computational Modeling of Axonal Microtubule Bundles under Tension	BIOPHYSICAL JOURNAL			English	Article							BRAIN-INJURY; TAU-PROTEIN; MECHANICS; TRANSPORT; NETWORKS; CELLS; DEGENERATION; DENDRITES; FILAMENTS; NEURONS	Microtubule bundles cross-linked by tau protein serve a variety of neurological functions including maintaining mechanical integrity of the axon, promoting axonal growth, and facilitating cargo transport. It has been observed that axonal damage in traumatic brain injury leads to bundle disorientation, loss of axonal viability, and cognitive impairment. This study investigates the initial mechanical response of axonal microtubule bundles under uniaxial tension using a discrete bead-spring representation. Mechanisms of failure due to traumatic stretch loading and their impact on the mechanical response and stability are also characterized. This study indicates that cross-linked axonal microtubule bundles in tension display stiffening behavior similar to a power-law relationship from nonaffine network deformations. Stretching of cross-links and microtubule bending were the primary deformation modes at low stresses. Microtubule stretch was negligible up to tensile stresses of similar to 1 MPa. Bundle failure occurred by failure of cross-links leading to pull-out of microtubules and loss of bundle integrity. This may explain the elongation, undulation, and delayed elasticity of axons following traumatic stretch loading. More extensively cross-linked bundles withstood higher tensile stresses before failing. The bundle mechanical behavior uncovered by these computational techniques should guide future experiments on stretch-injured axons.	[Peter, Stephen J.; Mofrad, Mohammad R. K.] Univ Calif Berkeley, Mol Cell Biomech Lab, Dept Bioengn, Berkeley, CA 94720 USA; [Peter, Stephen J.] Univ Calif Berkeley, Mol Cell Biomech Lab, Dept Mech Engn, Berkeley, CA 94720 USA		Mofrad, MRK (corresponding author), Univ Calif Berkeley, Mol Cell Biomech Lab, Dept Bioengn, Berkeley, CA 94720 USA.	mofrad@berkeley.edu	/R-6010-2019	/0000-0001-7004-4859	Div Of Chem, Bioeng, Env, & Transp SysNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [0829205] Funding Source: National Science Foundation		[Anonymous], 2010, TRAUM BRAIN INJ US; Baas PW, 2006, TRAFFIC, V7, P490, DOI 10.1111/j.1600-0854.2006.00392.x; Bathe M, 2008, BIOPHYS J, V94, P2955, DOI 10.1529/biophysj.107.119743; Becker JS, 2007, J ANAL ATOM SPECTROM, V22, P761, DOI 10.1039/b701440f; Bertaud J, 2010, ACTA BIOMATER, V6, P2457, DOI 10.1016/j.actbio.2010.01.028; Blundell JR, 2009, MACROMOLECULES, V42, P5388, DOI 10.1021/ma9004633; Brangwynne CP, 2006, J CELL BIOL, V173, P733, DOI 10.1083/jcb.200601060; Chandran PL, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.011906; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Claessens MMAE, 2006, NAT MATER, V5, P748, DOI 10.1038/nmat1718; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Erturk A, 2007, J NEUROSCI, V27, P9169, DOI 10.1523/JNEUROSCI.0612-07.2007; FADIC R, 1985, J COMP NEUROL, V236, P258, DOI 10.1002/cne.902360209; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Guzik BW, 2004, CURR OPIN CELL BIOL, V16, P443, DOI 10.1016/j.ceb.2004.06.002; Head DA, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.108102; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Kim T, 2009, EXP MECH, V49, P91, DOI 10.1007/s11340-007-9091-3; Lele TP, 2007, CELL BIOCHEM BIOPHYS, V47, P348, DOI 10.1007/s12013-007-0013-x; MANDELKOW E, 1995, NEUROBIOL AGING, V16, P347, DOI 10.1016/0197-4580(95)00026-B; Mehrbod M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025627; Mofrad MRK, 2009, ANNU REV FLUID MECH, V41, P433, DOI 10.1146/annurev.fluid.010908.165236; Onck PR, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.178102; Pampaloni F, 2006, P NATL ACAD SCI USA, V103, P10248, DOI 10.1073/pnas.0603931103; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Rodney D, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.108004; Rosenberg KJ, 2008, P NATL ACAD SCI USA, V105, P7445, DOI 10.1073/pnas.0802036105; Sandersius SA, 2008, PHYS BIOL, V5, DOI 10.1088/1478-3975/5/1/015002; Silber J, 2004, HEARING RES, V197, P112, DOI 10.1016/j.heares.2004.06.006; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tolomeo JA, 1997, BIOPHYS J, V73, P2241, DOI 10.1016/S0006-3495(97)78255-9; YU WQ, 1994, J NEUROSCI, V14, P2818	34	67	68	0	22	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0006-3495			BIOPHYS J	Biophys. J.	FEB 22	2012	102	4					749	757		10.1016/j.bpj.2011.11.4024			9	Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics	900WE	WOS:000300921600005	22385845	Bronze, Green Published			2022-02-06	
J	Gupta, A; Elgammal, FS; Proddutur, A; Shah, S; Santhakumar, V				Gupta, Akshay; Elgammal, Fatima S.; Proddutur, Archana; Shah, Samik; Santhakumar, Vijayalakshmi			Decrease in Tonic Inhibition Contributes to Increase in Dentate Semilunar Granule Cell Excitability after Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							TEMPORAL-LOBE EPILEPSY; CONTAINING GABA(A) RECEPTORS; PRINCIPAL NEURON SYNAPSE; POSTTRAUMATIC EPILEPSY; DELTA-SUBUNIT; SEIZURE SUSCEPTIBILITY; MOSSY CELLS; HEAD TRAUMA; MOUSE MODEL; GYRUS	Brain injury is an etiological factor for temporal lobe epilepsy and can lead to memory and cognitive impairments. A recently characterized excitatory neuronal class in the dentate molecular layer, semilunar granule cell (SGC), has been proposed to regulate dentate network activity patterns and working memory formation. Although SGCs, like granule cells, project to CA3, their typical sustained firing and associational axon collaterals suggest that they are functionally distinct from granule cells. We find that brain injury results in an enhancement of SGC excitability associated with an increase in input resistance 1 week after trauma. In addition to prolonging miniature and spontaneous IPSC interevent intervals, brain injury significantly reduces the amplitude of tonic GABA currents in SGCs. The postinjury decrease in SGC tonic GABA currents is in direct contrast to the increase observed in granule cells after trauma. Although our observation that SGCs express Prox1 indicates a shared lineage with granule cells, data from control rats show that SGC tonic GABA currents are larger and sIPSC interevent intervals shorter than in granule cells, demonstrating inherent differences in inhibition between these cell types. GABA(A) receptor antagonists selectively augmented SGC input resistance in controls but not in head-injured rats. Moreover, post-traumatic differences in SGC firing were abolished in GABAA receptor blockers. Our data show that cell-type-specific post-traumatic decreases in tonic GABA currents boost SGC excitability after brain injury. Hyperexcitable SGCs could augment dentate throughput to CA3 and contribute substantively to the enhanced risk for epilepsy and memory dysfunction after traumatic brain injury.	[Gupta, Akshay; Elgammal, Fatima S.; Proddutur, Archana; Shah, Samik; Santhakumar, Vijayalakshmi] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA; [Santhakumar, Vijayalakshmi] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA		Santhakumar, V (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, MSB-H-512,185 S Orange Ave, Newark, NJ 07103 USA.	santhavi@umdnj.edu	Santhakumar, Vijayalakshmi/M-4192-2013; Santhakumar, Viji/K-4856-2019	Santhakumar, Viji/0000-0001-6278-4187	New Jersey Commission for Brain Injury Research [09.003-BIR1, 11-3223-BIR-E-0]	This work was supported by New Jersey Commission for Brain Injury Research Grants 09.003-BIR1 (to V.S.) and 11-3223-BIR-E-0 (to A.G.). We thank Takahiro Ito for technical assistance and Drs. Stella Elkabes and Robert F. Heary for equipment and discussions.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; Brown N, 2002, BRIT J PHARMACOL, V136, P965, DOI 10.1038/sj.bjp.0704795; Chadderton P, 2004, NATURE, V428, P856, DOI 10.1038/nature02442; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cooper DC, 2003, J NEUROSCI, V23, P9937; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Farrant M, 2005, NAT REV NEUROSCI, V6, P215, DOI 10.1038/nrn1625; Foldy C, 2007, NAT NEUROSCI, V10, P1128, DOI 10.1038/nn1952; Glykys J, 2007, J PHYSIOL-LONDON, V582, P1163, DOI 10.1113/jphysiol.2007.134460; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Hefft S, 2005, NAT NEUROSCI, V8, P1319, DOI 10.1038/nn1542; HEINEMANN U, 1992, EPILEPSY RES, P273; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Howard AL, 2007, J NEUROPHYSIOL, V97, P2394, DOI 10.1152/jn.00509.2006; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Jessberger S, 2008, NAT NEUROSCI, V11, P888, DOI 10.1038/nn.2148; Karalay O, 2011, CELL CYCLE, V10, P2239, DOI 10.4161/cc.10.14.15850; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kraushaar U, 2000, J NEUROSCI, V20, P5594, DOI 10.1523/JNEUROSCI.20-15-05594.2000; Larimer P, 2010, NAT NEUROSCI, V13, P213, DOI 10.1038/nn.2458; Lavado A, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000460; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lubke J, 1998, J NEUROPHYSIOL, V79, P1518, DOI 10.1152/jn.1998.79.3.1518; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maguire JL, 2005, NAT NEUROSCI, V8, P797, DOI 10.1038/nn1469; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mitchell SJ, 2003, NEURON, V38, P433, DOI 10.1016/S0896-6273(03)00200-9; Morgan RJ, 2008, P NATL ACAD SCI USA, V105, P6179, DOI 10.1073/pnas.0801372105; Mtchedlishvili Z, 2006, MOL PHARMACOL, V69, P564, DOI 10.1124/mol.105.016683; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Pathak HR, 2007, J NEUROSCI, V27, P14012, DOI 10.1523/JNEUROSCI.4390-07.2007; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Rajasekaran K, 2010, NEUROBIOL DIS, V40, P490, DOI 10.1016/j.nbd.2010.07.016; Ramon y Cajal S., 1995, HISTOLOGY NERVOUS SY; Ratzliff ADH, 2004, J NEUROSCI, V24, P2259, DOI 10.1523/JNEUROSCI.5191-03.2004; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Ruiz A, 2003, NEURON, V39, P961, DOI 10.1016/S0896-6273(03)00559-2; Santhakumar V, 2006, J NEUROSCI, V26, P3357, DOI 10.1523/JNEUROSCI.4799-05.2006; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Santhakumar V, 2010, NEUROSCIENCE, V167, P644, DOI 10.1016/j.neuroscience.2010.02.048; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Silver RA, 2010, NAT REV NEUROSCI, V11, P474, DOI 10.1038/nrn2864; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346, DOI 10.1152/jn.1992.67.5.1346; Stell BM, 2003, P NATL ACAD SCI USA, V100, P14439, DOI 10.1073/pnas.2435457100; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Szabadics J, 2010, J NEUROSCI, V30, P8296, DOI 10.1523/JNEUROSCI.5602-09.2010; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; Walker MC, 2010, NAT NEUROSCI, V13, P145, DOI 10.1038/nn0210-146; Wei WZ, 2003, J NEUROSCI, V23, P10650; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Williams PA, 2007, J NEUROSCI, V27, P13756, DOI 10.1523/JNEUROSCI.4053-07.2007; Zhan RZ, 2009, J NEUROPHYSIOL, V102, P670, DOI 10.1152/jn.00147.2009; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007	64	67	67	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 15	2012	32	7					2523	2537		10.1523/JNEUROSCI.4141-11.2012			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	895ZO	WOS:000300535400028	22396425	Green Published, Bronze			2022-02-06	
J	Dean, PJA; O'Neill, D; Sterr, A				Dean, Philip J. A.; O'Neill, Darragh; Sterr, Annette			Post-concussion syndrome: Prevalence after mild traumatic brain injury in comparison with a sample without head injury	BRAIN INJURY			English	Article						Mild traumatic brain injury; persistent post-concussion syndrome; Rivermead post-concussion symptoms questionnaire; base rates	POSTCONCUSSION-LIKE SYMPTOMS; DIAGNOSTIC-CRITERIA; UNITED-STATES; TASK-FORCE; ANXIETY; QUESTIONNAIRE; DEPRESSION; COMPLAINTS; DISORDER; STRESS	Primary objective: To compare the prevalence of persistent post-concussion syndrome (PCS; >1 year post-injury) in participants with mild traumatic brain injury (mTBI) and those without head injury. Research design: A cross-sectional sample of 119 participants with mTBI and 246 without previous head injury. Methods: Online questionnaires collected data about post-concussion symptoms, cognitive failures, anxiety, depression, sleep behaviour and post-traumatic stress disorder. Variability within the sample was addressed by splitting by PCS diagnosis to create four groups: mTBI + PCS, mTBI-PCS, Control + PCS and Control-PCS. PCS was diagnosed using ICD-10 criteria in all groups, with controls not requiring previous head injury. Main outcomes and results: PCS was present to a similar extent in participants with no head injury (34%) compared to those with mTBI (31%). Only report of headaches, which could be caused by expectation bias, distinguished between mTBI + PCS and Control + PCS groups. In addition, significantly higher cognitive problems were observed in participants with mTBI compared with the control group. Conclusions: Persistent PCS, as currently defined, is not specific to mTBI. These data suggest that somatic and cognitive symptoms are most likely to be able to distinguish PCS after mTBI from that present in the general population. Further research is necessary into these factors in order to create more specific PCS diagnostic criteria.	[Dean, Philip J. A.; O'Neill, Darragh; Sterr, Annette] Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England		Dean, PJA (corresponding author), Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England.	p.dean@surrey.ac.uk		Dean, Philip/0000-0002-2362-513X; O'Neill, Dara/0000-0002-8830-0264	Wingate Foundation, UK	This study was supported by a Wingate Foundation Scholarship, UK.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baumert J, 2004, J AFFECT DISORDERS, V82, P29, DOI 10.1016/j.jad.2003.09.006; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chan RCK, 2005, BRAIN INJURY, V19, P1117, DOI 10.1080/026990500150088; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Miletin MS, 2003, SLEEP MED, V4, P195, DOI 10.1016/S1389-9457(03)00031-5; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; O'Jile JR, 2006, ARCH CLIN NEUROPSYCH, V21, P293, DOI 10.1016/j.acn.2006.03.003; *OFF NAT SAT, 2004, CENS 2001 KEY STAT R; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; World Health Organization, 2004, ICD 10 INT STAT CLAS; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543	85	67	68	1	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2012	26	1					14	26		10.3109/02699052.2011.635354			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900002	22107176				2022-02-06	
J	Griffin, JM; Friedemann-Sanchez, G; Jensen, AC; Taylor, BC; Gravely, A; Clothier, B; Simon, AB; Bangerter, A; Pickett, T; Thors, C; Ceperich, S; Poole, J; van Ryn, M				Griffin, Joan M.; Friedemann-Sanchez, Greta; Jensen, Agnes C.; Taylor, Brent C.; Gravely, Amy; Clothier, Barbara; Simon, Alisha Baines; Bangerter, Ann; Pickett, Treven; Thors, Christina; Ceperich, Sherry; Poole, John; van Ryn, Michelle			The Invisible Side of War: Families Caring for US Service Members With Traumatic Brain Injuries and Polytrauma	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						polytrauma; caregiving; families; traumatic brain injury; veterans	CAREGIVER; REHABILITATION; QUALITY; PREDICTORS; DEPRESSION; DEMENTIA; BURDEN; CARE	Objectives: To (1) identify informal caregivers to injured US service members following acute rehabilitation for polytraumatic injuries, principally traumatic brain injury (TBI), and (2) describe the prevalence and variation of care recipient and caregiver experiences. Design: Cross-sectional survey of caregivers. Participants: Caregivers (N = 564) of service members with TBI who received inpatient rehabilitation care in a Veterans Affairs' Polytrauma Rehabilitation Center between 2001 and 2009. Main Outcome Measures: Questions about caregiver and patient characteristics, type, and quantity of care currently being provided. Results: Caregiving responsibilities fall primarily on women (79%), typically a parent (62%) or spouse (32%). After a median 4 years since injury, 22% of patients still required assistance with activities of daily living and instrumental activities of daily living. An additional 48% required assistance with only instrumental activities of daily living. Nearly 25% of caregivers reported more than 40 h/wk of care and another 20% reported 5 to 40 h/wk of care. Of caregivers providing assistance with activities of daily living, 49% provided care >= 80 h/wk. Nearly 60% of caregivers were solely responsible for the caregiving. Most caregivers also reported providing other help, including managing emotions and navigating health and legal systems. Conclusions: Caregivers who provide assistance with either activities of daily living or instrumental activities of daily living may need additional resources to meet the long-term needs of their injured family member.	[Griffin, Joan M.; Jensen, Agnes C.; Taylor, Brent C.; Gravely, Amy; Clothier, Barbara; Simon, Alisha Baines; Bangerter, Ann] Dept Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Griffin, Joan M.; Taylor, Brent C.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Friedemann-Sanchez, Greta] Univ Minnesota, Humphrey Sch Publ Affairs, Minneapolis, MN USA; [Taylor, Brent C.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Pickett, Treven; Ceperich, Sherry] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Pickett, Treven] Virginia Commonwealth Univ, Dept Psychiat, Sch Med, Richmond, VA 23284 USA; [Pickett, Treven] Virginia Commonwealth Univ, Dept PM&R, Sch Med, Richmond, VA 23284 USA; [Pickett, Treven] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Thors, Christina] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Poole, John] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; [van Ryn, Michelle] Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Minneapolis, MN 55455 USA		Griffin, JM (corresponding author), VA Med Ctr, Ctr Chron Dis Outcomes Res, 1 Vet Dr,Mailstop 110, Minneapolis, MN 55417 USA.	joan.griffin2@va.gov	Taylor, Brent C/A-8069-2009	Taylor, Brent C/0000-0002-2140-8377; Friedemann-Sanchez, Greta/0000-0002-0493-7218	Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs; Health Services Research and Development (HSRD) service [SDR-07-044]	This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development and a grant from the Health Services Research and Development (HSR&D) service (SDR-07-044). The findings and conclusions presented in this manuscript are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or HSR&D. The sponsor was not involved in any aspect of the study's design and conduct; data collection, management, analysis, or interpretation of data; or the preparation, review, or approval of the manuscript.	Badr H, 2010, RISK RESILIENCE US M; Bakas T, 2001, Oncol Nurs Forum, V28, P847; Belle SH, 2006, ANN INTERN MED, V145, P727, DOI 10.7326/0003-4819-145-10-200611210-00005; Burg MM, 1994, ANN BEHAV MED, V16, P115; CARNWATH TCM, 1987, BRIT MED J, V294, P409, DOI 10.1136/bmj.294.6569.409; Chandra A, 2011, RISK AND RESILIENCE IN U S MILITARY FAMILIES, P175, DOI 10.1007/978-1-4419-7064-0_9; Covinsky KE, 2003, J GEN INTERN MED, V18, P1006, DOI 10.1111/j.1525-1497.2003.30103.x; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Faul M, 2010, TRAUMATIC BRAIN INJU; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Griffin JM, 2009, J REHABIL RES DEV, V46, P879, DOI 10.1682/JRRD.2008.08.0104; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kreutzer JS, 2010, J HEAD TRAUMA REHAB, V25, P113, DOI 10.1097/HTR.0b013e3181cf0712; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lilly MB, 2007, MILBANK Q, V85, P641, DOI 10.1111/j.1468-0009.2007.00504.x; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; National Alliance for Caregiving AARP, 2010, CAR US 2009; Naumann RB, 2010, TRAFFIC INJ PREV, V11, P353, DOI 10.1080/15389588.2010.486429; Navaie-Waliser M, 2002, AM J PUBLIC HEALTH, V92, P409, DOI 10.2105/AJPH.92.3.409; Navaie-Waliser M, 2002, MED CARE, V40, P1249, DOI 10.1097/00005650-200212000-00012; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Ory MG, 1999, GERONTOLOGIST, V39, P177, DOI 10.1093/geront/39.2.177; Pruchno RA, 2008, GERONTOLOGIST, V48, P820, DOI 10.1093/geront/48.6.820; Sady MD, 2010, ARCH PHYS MED REHAB, V91, P1542, DOI 10.1016/j.apmr.2010.07.012; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; The American Association for Public Opinion Research, 2009, STAND DEF FIN DISP C; Tooth L, 2005, BRAIN INJURY, V19, P963, DOI 10.1080/02699050500110785; van Ryn M, 2011, PSYCHO-ONCOLOGY, V20, P44, DOI 10.1002/pon.1703; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Williamson GM, 2002, HEALTH PSYCHOL, V21, P405, DOI 10.1037//0278-6133.21.4.405; Williamson GM, 2001, PSYCHOL AGING, V16, P217, DOI 10.1037//0882-7974.16.2.217	36	67	67	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					3	13		10.1097/HTR.0b013e3182274260			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400001	21873883				2022-02-06	
J	Koepsell, TD; Rivara, FP; Vavilala, MS; Wang, J; Temkin, N; Jaffe, KM; Durbin, DR				Koepsell, Thomas D.; Rivara, Frederick P.; Vavilala, Monica S.; Wang, Jin; Temkin, Nancy; Jaffe, Kenneth M.; Durbin, Dennis R.			Incidence and Descriptive Epidemiologic Features of Traumatic Brain Injury in King County, Washington	PEDIATRICS			English	Article						brain injury; epidemiology; population surveillance	UNITED-STATES; OUTCOMES; CHILDREN; MILD	OBJECTIVE: Traumatic brain injury (TBI) is a major cause of disability among US children. Our goal was to obtain population-based data on TBI incidence rates. METHODS: We conducted surveillance through a stratified random sample of hospital emergency departments in King County, Washington, to identify children 0 to 17 years of age with medically treated TBIs during an 18-month study period in 2007-2008. Additional cases were identified through hospital admission logs and the medical examiner's office. For a sample of nonfatal cases, parents were interviewed to verify TBIs, and medical record data on severity and mechanisms were obtained. RESULTS: The estimated incidence of TBIs in this setting was 304 cases per 100 000 child-years. The incidence was highest for preschool-aged children and lowest for children aged 5 to 9 years. Rates were uniformly higher for boys than for girls; there was a larger gender gap at older ages. Falls were the main mechanism of injury, especially among preschool-aged children, whereas being struck by or against an object and motor vehicle-related trauma were important contributors for older children. Approximately 97% of TBI cases were mild, although moderate/severe TBI incidence increased with age. CONCLUSIONS: TBIs led to many emergency department visits involving children, but a large majority of the cases were clinically mild. Incidence rates for King County were well below recent national estimates but within the range reported in previous US studies. Because mechanisms of injury varied greatly according to age, prevention strategies almost certainly must be customized to each age group for greatest impact. Pediatrics 2011;128:946-954	[Koepsell, Thomas D.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Koepsell, Thomas D.; Rivara, Frederick P.; Vavilala, Monica S.; Wang, Jin; Jaffe, Kenneth M.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy; Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Sch Med, Seattle, WA 98195 USA; [Durbin, Dennis R.] Childrens Hosp Philadelphia, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA		Koepsell, TD (corresponding author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA.	koepsell@u.washington.edu	Durbin, Dennis/AAD-7829-2022		Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025014] Funding Source: NIH RePORTER	This work was supported by Centers for Disease Control and Prevention grant R49 CE 001021.	Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Atabaki SM, 2007, PEDIATR REV, V28, P215, DOI 10.1542/pir.28-6-215; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Day Heather, 2006, Minn Med, V89, P40; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; Ebel BE, 2003, JAMA-J AM MED ASSOC, V289, P879, DOI 10.1001/jama.289.7.879; Efron B., 1993, INTRO BOOTSTRAP; Eisele JA, 2006, J HEAD TRAUMA REHAB, V21, P537, DOI 10.1097/00001199-200611000-00008; Faul M, 2010, TRAUMATIC BRAIN INJU; Fleiss JH., 1981, STAT METHODS RATES P; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEVY P, 1999, SAMPLING POPULATIONS; Minnesota Department of Health Injury and Violence Prevention Unit, 2005, EM DEP TREAT TRAUM B; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; R Development Core Team, 2010, R LANG ENV STAT COMP; Rodriguez SR, 2006, PUBLIC HEALTH REP, V121, P282, DOI 10.1177/003335490612100310; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Sosin DM, 1996, BRAIN INJURY, V10, P47; Washington State Office of Financial Management, 2008, RAC CAT PERC COUNT P; Weiss NS., 2003, EPIDEMIOLOGIC METHOD; Xiang HY, 2007, BRAIN INJURY, V21, P293, DOI 10.1080/02699050701311034	31	67	67	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2011	128	5					946	954		10.1542/peds.2010-2259			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	843YO	WOS:000296714000062	21969286				2022-02-06	
J	Ding, MC; Wang, Q; Lo, EH; Stanley, GB				Ding, Ming-Chieh; Wang, Qi; Lo, Eng H.; Stanley, Garrett B.			Cortical Excitation and Inhibition following Focal Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article							RECEPTIVE-FIELD PROPERTIES; MOUSE BARREL CORTEX; SPREADING DEPRESSION; SOMATOSENSORY CORTEX; FUNCTIONAL RECOVERY; CEREBRAL-ISCHEMIA; IN-VIVO; MOLECULAR-MECHANISMS; SENSORY RESPONSES; NEURONAL-ACTIVITY	Cortical compression can be a significant problem in many types of brain injuries, such as brain trauma, localized brain edema, hematoma, focal cerebral ischemia, or brain tumors. Mechanical and cellular alterations can result in global changes in excitation and inhibition on the neuronal network level even in the absence of histologically significant cell injury, often manifesting clinically as seizures. Despite the importance and prevalence of this problem, however, the precise electrophysiological effects of brain injury have not been well characterized. In this study, the changes in electrophysiology were characterized following sustained cortical compression using large-scale, multielectrode measurement of multiunit activity in primary somatosensory cortex in a sensory-evoked, in vivo animal model. Immediately following the initiation of injury at a distal site, there was a period of suppression of the evoked response in the rat somatosensory cortex, followed by hyper-excitability that was accompanied by an increase in the spatial extent of cortical activation. Paired-pulse tactile stimulation revealed a dramatic shift in the excitatory/inhibitory dynamics, suggesting a longer term hyperexcitability of the cortical circuit following the initial suppression that could be linked to the disruption of one or more inhibitory mechanisms of the thalamocortical circuit. Together, our results showed that the use of a sensory-evoked response provided a robust and repeatable functional marker of the evolution of the consequences of mild injury, serving as an important step toward in vivo quantification of alterations in excitation and inhibition in the cortex in the setting of traumatic brain injury.	[Wang, Qi; Stanley, Garrett B.] Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; [Wang, Qi; Stanley, Garrett B.] Emory Univ, Atlanta, GA 30332 USA; [Ding, Ming-Chieh] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Ding, Ming-Chieh] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Lo, Eng H.] Harvard Univ, Sch Med, Neuroprotect Res Lab, Charlestown, MA 02129 USA		Stanley, GB (corresponding author), Georgia Inst Technol, Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	garrett.stanley@bme.gatech.edu	Wang, Qi/D-6997-2012	Stanley, Garrett/0000-0003-2039-7706; Ding, Ming-Chieh/0000-0002-2278-5326	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS48285]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048285] Funding Source: NIH RePORTER	This work was supported by NINDS Grant R01 NS48285.	Adamo PF, 2005, J AM ANIM HOSP ASSOC, V41, P400, DOI 10.5326/0410400; Ahissar E, 2001, Prog Brain Res, V130, P75; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Andermann ML, 2006, NAT NEUROSCI, V9, P543, DOI 10.1038/nn1671; ARMSTRONGJAMES M, 1992, J NEUROPHYSIOL, V68, P1345, DOI 10.1152/jn.1992.68.4.1345; Aronoff R, 2010, EUR J NEUROSCI, V31, P2221, DOI 10.1111/j.1460-9568.2010.07264.x; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Baker AJ, 2008, J TRAUMA, V64, P348, DOI 10.1097/01.ta.0000245973.71929.db; Berger M, 2008, CEPHALALGIA, V28, P558, DOI 10.1111/j.1468-2982.2008.01556.x; Boloori AR, 2010, J NEUROSCI, V30, P9990, DOI 10.1523/JNEUROSCI.0807-10.2010; Boloori AR, 2006, J NEUROSCI, V26, P3767, DOI 10.1523/JNEUROSCI.4056-05.2006; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Chen JR, 2004, J NEUROTRAUM, V21, P1640, DOI 10.1089/0897715042441729; Chung S, 2002, NEURON, V34, P437, DOI 10.1016/S0896-6273(02)00659-1; Church AJ, 2005, J NEUROTRAUM, V22, P277, DOI 10.1089/neu.2005.22.277; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; David-Jurgens M, 2010, CEREB CORTEX, V20, P1208, DOI 10.1093/cercor/bhp185; Desilets-Roy B, 2002, J NEUROSCI, V22; Dijkhuizen RM, 2001, P NATL ACAD SCI USA, V98, P12766, DOI 10.1073/pnas.231235598; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; Ding MC, 2008, NEUROSCIENCE, V154, P551, DOI 10.1016/j.neuroscience.2008.03.088; EBNER FF, 1990, PROG BRAIN RES, V86, P129; Eikermann-Haerter K, 2008, CURR OPIN NEUROL, V21, P294, DOI 10.1097/WCO.0b013e3282fc25de; Fanselow EE, 1999, J NEUROSCI, V19, P7603, DOI 10.1523/JNEUROSCI.19-17-07603.1999; Fox K, 2003, J NEUROSCI, V23, P8380; Fox K, 2002, NEUROSCIENCE, V111, P799, DOI 10.1016/S0306-4522(02)00027-1; Fujioka H, 2004, STROKE, V35, pE346, DOI 10.1161/01.STR.0000130990.28734.9c; Gil Z, 1997, NEURON, V19, P679, DOI 10.1016/S0896-6273(00)80380-3; Glass TF, 2004, NEUROBIOL DIS, V17, P378, DOI 10.1016/j.nbd.2004.07.017; HARRIS RM, 1987, NEUROSCIENCE, V21, P229, DOI 10.1016/0306-4522(87)90335-6; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Higley MJ, 2006, J NEUROSCI, V26, P448, DOI 10.1523/JNEUROSCI.3506-05.2006; Higley MJ, 2003, J NEUROSCI, V23, P10190; Jefferys JGR, 2003, EPILEPSIA, V44, P44, DOI 10.1111/j.0013-9580.2003.12004.x; Kim DS, 2004, NEUROIMAGE, V21, P876, DOI 10.1016/j.neuroimage.2003.10.018; Kim YR, 2005, J CEREBR BLOOD F MET, V25, P820, DOI 10.1038/sj.jcbfm.9600084; Koistinaho J, 2000, NEUROCHEM RES, V25, P645, DOI 10.1023/A:1007559003261; Kwegyir-Afful EE, 2009, J NEUROSCI, V29, P964, DOI 10.1523/JNEUROSCI.3924-08.2009; Kyriazi H, 1998, SOMATOSENS MOT RES, V15, P146, DOI 10.1080/08990229870871; Kyriazi HT, 1996, J NEUROPHYSIOL, V75, P547, DOI 10.1152/jn.1996.75.2.547; Larrosa B, 2006, NEUROSCIENCE, V141, P1057, DOI 10.1016/j.neuroscience.2006.04.005; Lee KR, 1997, J NEUROSURG, V87, P73, DOI 10.3171/jns.1997.87.1.0073; Longoni M, 2006, NEUROL SCI, V27, pS107, DOI 10.1007/s10072-006-0582-2; Maeda M, 1998, ACT NEUR S, V71, P293; Manor T, 2008, NEUROL RES, V30, P1075, DOI 10.1179/174313208X346107; Marino R, 2006, NEUROLOGY, V67, P1165, DOI 10.1212/01.wnl.0000238081.35281.b5; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Miller KD, 2001, CURR OPIN NEUROBIOL, V11, P488, DOI 10.1016/S0959-4388(00)00239-7; Misonou H, 2005, J NEUROSCI, V25, P11184, DOI 10.1523/JNEUROSCI.3370-05.2005; Moore CI, 1998, J NEUROPHYSIOL, V80, P2882, DOI 10.1152/jn.1998.80.6.2882; Moreira T, 2007, NEUROSCIENCE, V144, P1169, DOI 10.1016/j.neuroscience.2006.10.054; Petersen CCH, 2007, NEURON, V56, P339, DOI 10.1016/j.neuron.2007.09.017; PINAULT D, 1995, EUR J NEUROSCI, V7, P31, DOI 10.1111/j.1460-9568.1995.tb01017.x; Porter JT, 2004, J NEUROPHYSIOL, V92, P2762, DOI 10.1152/jn.00196.2004; Reinert M, 2000, Neurosurg Focus, V8, pe10; Salci K, 2006, NEUROSURGERY, V59, P367, DOI 10.1227/01.NEU.0000222648.61065.38; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Sato TR, 2010, J NEUROSCI, V30, P4256, DOI 10.1523/JNEUROSCI.3774-09.2010; SILVER IA, 1994, J NEUROSCI, V14, P5068; SIMONS DJ, 1979, BRAIN RES, V165, P327, DOI 10.1016/0006-8993(79)90564-X; SIMONS DJ, 1989, J NEUROPHYSIOL, V61, P311, DOI 10.1152/jn.1989.61.2.311; SIMONS DJ, 1985, J NEUROPHYSIOL, V54, P615, DOI 10.1152/jn.1985.54.3.615; Smith JM, 2006, BIOL REV, V81, P457, DOI 10.1017/S1464793106007081; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Sosnik R, 2001, J NEUROPHYSIOL, V86, P339, DOI 10.1152/jn.2001.86.1.339; SPACEK J, 1974, J ANAT, V117, P487; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Takatsuru Y, 2009, J NEUROSCI, V29, P10081, DOI 10.1523/JNEUROSCI.1638-09.2009; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Urbain N, 2007, J NEUROSCI, V27, P12407, DOI 10.1523/JNEUROSCI.2914-07.2007; Voronin LL, 2003, NEUROPHARMACOLOGY, V45, P439, DOI 10.1016/S0028-3908(03)00173-4; Voronin LL, 2004, J PHYSIOL-LONDON, V557, P3, DOI 10.1113/jphysiol.2003.058966; Wang JH, 2003, BRAIN RES BULL, V60, P53, DOI 10.1016/S0361-9230(03)00026-1; Watanabe S, 2001, STROKE, V32, P2615, DOI 10.1161/hs1101.097384; Webber RM, 2004, J NEUROPHYSIOL, V91, P2010, DOI 10.1152/jn.00906.2003; Welch KM, 2005, HEADACHE, V45, pS25, DOI 10.1111/j.1526-4610.2005.4501008.x; WELKER C, 1976, J COMP NEUROL, V166, P173, DOI 10.1002/cne.901660205; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; Yang HY, 2006, BEHAV BRAIN RES, V172, P80, DOI 10.1016/j.bbr.2006.04.023; Yang HY, 2006, EXP NEUROL, V200, P262, DOI 10.1016/j.expneurol.2006.02.007; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005; Yang L, 2010, J NEUROTRAUM, V27, P1541, DOI 10.1089/neu.2009.1244; Yu Z, 2009, C P IEEE ENG MED BIO, P1135; Zhao XR, 2009, STROKE, V40, pS92, DOI 10.1161/STROKEAHA.108.533158	89	67	68	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 5	2011	31	40					14085	14094		10.1523/JNEUROSCI.3572-11.2011			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832LD	WOS:000295805500005	21976493	Bronze, Green Accepted, Green Published			2022-02-06	
J	Brien, M; Sveistrup, H				Brien, Marie; Sveistrup, Heidi			An Intensive Virtual Reality Program Improves Functional Balance and Mobility of Adolescents With Cerebral Palsy	PEDIATRIC PHYSICAL THERAPY			English	Article						adolescent; cerebral palsy; computer simulation; computer-user interface; motor activity; postural balance; psychomotor performance; walking	GROSS MOTOR FUNCTION; TRAUMATIC BRAIN-INJURY; SCHOOL-AGED CHILDREN; 6-MINUTE WALK TEST; COMMUNITY BALANCE; CLASSIFICATION; FEASIBILITY; RELIABILITY; STABILITY; EXERCISE	Purpose: To examine functional balance and mobility in adolescents with cerebral palsy classified at Gross Motor Function Classification System (GMFCS) level I following an intensive short-duration virtual reality (VR) intervention. Methods: Single-subject, multiple-baseline design with 4 adolescents. Outcomes included the Community Balance and Mobility Scale (CB&M), the 6-Minute Walk Test (6MWT), the Timed Up and Down Stairs, and the Gross Motor Function Measure Dimension E. Assessments were recorded 3 to 6 times at baseline, 5 times during intervention, and 4 times at follow-up. Daily 90-minute VR intervention was completed for 5 consecutive days. Visual, statistical, and clinical significance analyses were used. Results: Statistically significant improvements were shown in all adolescents on CB&M and 6MWT. True change was recorded in all for the CB&M and in 3 for the 6MWT. Conclusions: Functional balance and mobility in adolescents with cerebral palsy classified at GMFCS level I improve with intense, short duration VR intervention, and changes are maintained at 1-month posttraining. (Pediatr Phys Ther 2011;23:258-266)	[Brien, Marie] Univ Ottawa, Ottawa Childrens Treatment Ctr, Fac Hlth Sci, Ottawa, ON, Canada; [Sveistrup, Heidi] Univ Ottawa, Sch Rehabil Sci, Fac Hlth Sci, Ottawa, ON, Canada		Brien, M (corresponding author), 395 Smyth Rd, Ottawa, ON K1H 8L2, Canada.	mbrien@octc.ca			TD Bank Financial Group	This project was funded by the TD Bank Financial Group, which provided a TD grant in medical excellence.	Bjornson KF, 2007, PHYS THER, V87, P248, DOI 10.2522/ptj.20060157; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Burtner P A, 2007, Dev Neurorehabil, V10, P249, DOI 10.1080/17518420701303066; Chen YP, 2007, PHYS THER, V87, P1441, DOI 10.2522/ptj.20060062; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Damiano DL, 2006, PHYS THER, V86, P1534, DOI 10.2522/ptj.20050397; Damiano DL, 2009, J CHILD NEUROL, V24, P1200, DOI 10.1177/0883073809337919; Hanna SE, 2009, DEV MED CHILD NEUROL, V51, P295, DOI 10.1111/j.1469-8749.2008.03196.x; Howe JA, 2006, CLIN REHABIL, V20, P885, DOI 10.1177/0269215506072183; Logan LR, 2008, DEV MED CHILD NEUROL, V50, P99, DOI 10.1111/j.1469-8749.2007.02005.x; Maher CA, 2008, INT J REHABIL RES, V31, P185, DOI 10.1097/MRR.0b013e32830150f9; Oeffinger D, 2007, DEV MED CHILD NEUROL, V49, P172, DOI 10.1111/j.1469-8749.2007.00172.x; Ottenbacher K. J., 1986, EVALUATING CLIN CHAN; Palisano RJ, 2008, DEV MED CHILD NEUROL, V50, P744, DOI 10.1111/j.1469-8749.2008.03089.x; Penn PR, 2009, DEV NEUROREHABIL, V12, P32, DOI 10.1080/17518420902739365; Portney L.G., 2009, FDN CLIN RES APPL PR, V3rd ed.; Provost Beth, 2007, Pediatr Phys Ther, V19, P2, DOI 10.1097/01.pep.0000249418.25913.a3; Reid DT, 2002, TECHNOL DISABIL, V14, P53; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Rosenbaum PL, 2002, JAMA-J AM MED ASSOC, V288, P1357, DOI 10.1001/jama.288.11.1357; Russell D., 2002, CLIN DEV MED, V1st ed.; Sandstrom K, 2004, DISABIL REHABIL, V26, P1023, DOI 10.1080/09638280410001703503; Thompson P, 2008, DEV MED CHILD NEUROL, V50, P370, DOI 10.1111/j.1469-8749.2008.02048.x; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Wilson A, 2011, PHYS OCCUP THER PEDI, V31, P135, DOI 10.3109/01942638.2010.489543; Woollacott M, 2005, DEV MED CHILD NEUROL, V47, P455, DOI 10.1017/S0012162205000885; Wright FV, 2010, BRAIN INJURY, V24, P1585, DOI 10.3109/02699052.2010.523045; You SH, 2005, DEV MED CHILD NEUROL, V47, P628, DOI 10.1017/S0012162205001234; Zaino Christopher A, 2004, Pediatr Phys Ther, V16, P90, DOI 10.1097/01.PEP.0000127564.08922.6A	29	67	71	1	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-5669	1538-005X		PEDIATR PHYS THER	Pediatr. Phys. Ther.	FAL	2011	23	3					258	266		10.1097/PEP.0b013e318227ca0f			9	Pediatrics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Rehabilitation	896HO	WOS:000300556500010	21829120				2022-02-06	
J	Chang, YJ; Yeh, ML; Li, YC; Hsu, CY; Lin, CC; Hsu, MS; Chiu, WT				Chang, Ying-Jui; Yeh, Min-Li; Li, Yu-Chuan; Hsu, Chien-Yeh; Lin, Chao-Cheng; Hsu, Meng-Shiuan; Chiu, Wen-Ta			Predicting Hospital-Acquired Infections by Scoring System with Simple Parameters	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; BLOOD-STREAM INFECTIONS; ADMINISTRATIVE CODING DATA; TRAUMATIC BRAIN-INJURY; NOSOCOMIAL INFECTIONS; RISK-FACTORS; SURVEILLANCE; PREVENTION; MORTALITY; COSTS	Background: Hospital-acquired infections (HAI) are associated with increased attributable morbidity, mortality, prolonged hospitalization, and economic costs. A simple, reliable prediction model for HAI has great clinical relevance. The objective of this study is to develop a scoring system to predict HAI that was derived from Logistic Regression (LR) and validated by Artificial Neural Networks (ANN) simultaneously. Methodology/Principal Findings: A total of 476 patients from all the 806 HAI inpatients were included for the study between 2004 and 2005. A sample of 1,376 non-HAI inpatients was randomly drawn from all the admitted patients in the same period of time as the control group. External validation of 2,500 patients was abstracted from another academic teaching center. Sixteen variables were extracted from the Electronic Health Records (EHR) and fed into ANN and LR models. With stepwise selection, the following seven variables were identified by LR models as statistically significant: Foley catheterization, central venous catheterization, arterial line, nasogastric tube, hemodialysis, stress ulcer prophylaxes and systemic glucocorticosteroids. Both ANN and LR models displayed excellent discrimination (area under the receiver operating characteristic curve [AUC]: 0.964 versus 0.969, p = 0.507) to identify infection in internal validation. During external validation, high AUC was obtained from both models (AUC: 0.850 versus 0.870, p = 0.447). The scoring system also performed extremely well in the internal (AUC: 0.965) and external (AUC: 0.871) validations. Conclusions: We developed a scoring system to predict HAI with simple parameters validated with ANN and LR models. Armed with this scoring system, infectious disease specialists can more efficiently identify patients at high risk for HAI during hospitalization. Further, using parameters either by observation of medical devices used or data obtained from EHR also provided good prediction outcome that can be utilized in different clinical settings.	[Chang, Ying-Jui; Yeh, Min-Li] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Chang, Ying-Jui] Far Eastern Mem Hosp, Dept Dermatol, New Taipei, Taiwan; [Yeh, Min-Li] Oriental Inst Technol, Dept Nursing, New Taipei, Taiwan; [Li, Yu-Chuan] Taipei Med Univ, Dept Dermatol, Wan Fang Hosp, Taipei, Taiwan; [Li, Yu-Chuan; Hsu, Chien-Yeh] Taipei Med Univ, Grad Inst Biomed Informat, Coll Med Sci & Technol, Taipei, Taiwan; [Hsu, Chien-Yeh] Taipei Med Univ, CECR, Taipei, Taiwan; [Lin, Chao-Cheng] Natl Taiwan Univ Hosp, Dept Psychiat, Taipei, Taiwan; [Hsu, Meng-Shiuan] Far Eastern Mem Hosp, Infect Dis Sect, Dept Internal Med, New Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei, Taiwan		Chang, YJ (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.	jack@tmu.edu.tw; cyhsu@tmu.edu.tw	Liu, Hao-Ping/AAJ-3038-2020	Liu, Hao-Ping/0000-0001-5915-5128; Chang, Yu-Sun/0000-0002-6457-3890; Yu, Jau-Song/0000-0002-4295-983X; Hsu, Chien-Yeh/0000-0001-8233-6461; Wu, Chih-Ching/0000-0002-7264-9672; Chang, Ying-Jui/0000-0003-0294-4657; Li, Yu-Chuan (Jack)/0000-0001-6497-4232			Archibald LK, 2007, BENNETT BRACHMANS HO, P483; Artigas AT, 2001, CRIT CARE MED, V29, P304, DOI 10.1097/00003246-200102000-00015; Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001; Cevik MA, 2005, J HOSP INFECT, V59, P324, DOI 10.1016/j.jhin.2004.10.012; Chong Chee-Fah, 2003, AMIA Annu Symp Proc, P160; D'Agata EMC, 2000, AM J KIDNEY DIS, V35, P1083, DOI 10.1016/S0272-6386(00)70044-8; Darouiche RO, 2001, CLIN INFECT DIS, V33, P1567, DOI 10.1086/323130; Department of Health EY Taiwan, 2010, EL MED REC; DiGiovine B, 1999, AM J RESP CRIT CARE, V160, P976, DOI 10.1164/ajrccm.160.3.9808145; Dreiseitl S, 2002, J BIOMED INFORM, V35, P352, DOI 10.1016/S1532-0464(03)00034-0; EMORI TG, 1991, AM J INFECT CONTROL, V19, P19, DOI 10.1016/0196-6553(91)90157-8; Escolano S, 2000, STAT MED, V19, P3465, DOI 10.1002/1097-0258(20001230)19:24&lt;3465::AID-SIM658&gt;3.0.CO;2-6; Ferrer M, 1999, ANN INTERN MED, V130, P991, DOI 10.7326/0003-4819-130-12-199906150-00007; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Girou E, 1998, AM J RESP CRIT CARE, V157, P1151, DOI 10.1164/ajrccm.157.4.9701129; Goldstein MM, 2010, PERSPECT HLTH INF MA, V7; HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Jhung MA, 2009, CLIN INFECT DIS, V49, P949, DOI 10.1086/605086; Kallen AJ, 2010, CLIN INFECT DIS, V51, P335, DOI 10.1086/653942; Kamp-Hopmans TEM, 2003, INFECT CONT HOSP EP, V24, P584, DOI 10.1086/502258; Kostadima E, 2006, EUR RESPIR J, V27, P437, DOI 10.1183/09031936.06.00127405; Leblebicioglu H, 2007, J HOSP INFECT, V65, P251, DOI 10.1016/j.jhin.2006.10.012; Li YC, 2000, INT J MED INFORM, V57, P1, DOI 10.1016/S1386-5056(99)00054-4; Lin CC, 2008, COMPUT METH PROG BIO, V91, P91, DOI 10.1016/j.cmpb.2008.02.004; Mahieu LM, 2001, J HOSP INFECT, V47, P223, DOI 10.1053/jhin.2000.0852; McGovern B, 2010, J HOSP INFECT, V75, P138, DOI 10.1016/j.jhin.2009.12.008; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Saint S, 2009, ANN INTERN MED, V150, P877, DOI 10.7326/0003-4819-150-12-200906160-00013; Shang J S, 2000, Health Care Manag Sci, V3, P287, DOI 10.1023/A:1019018129822; Sheng WH, 2005, J HOSP INFECT, V59, P205, DOI 10.1016/j.jhin.2004.06.003; Stevenson KB, 2008, AM J INFECT CONTROL, V36, P155, DOI 10.1016/j.ajic.2008.01.004; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Strand K, 2008, ACTA ANAESTH SCAND, V52, P467, DOI 10.1111/j.1399-6576.2008.01586.x; Taylor G, 2002, INFECT CONT HOSP EP, V23, P716, DOI 10.1086/501999; Teramoto S, 2006, EUR RESPIR J, V27, P436, DOI 10.1183/09031936.06.00113405; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Vincent JL, 2003, LANCET, V361, P2068, DOI 10.1016/S0140-6736(03)13644-6; Vonberg RP, 2006, INFECT CONT HOSP EP, V27, P357, DOI 10.1086/503339; Wald HL, 2007, JAMA-J AM MED ASSOC, V298, P2782, DOI 10.1001/jama.298.23.2782; Wilson JS, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-47; Woeltje KF, 2010, CRIT CARE MED, V38, pS399, DOI 10.1097/CCM.0b013e3181e6d11d	42	67	69	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2011	6	8							e23137	10.1371/journal.pone.0023137			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832TW	WOS:000295832000008	21625447	gold, Green Submitted, Green Published			2022-02-06	
J	Wang, JY; Bakhadirov, K; Abdi, H; Devous, MD; de la Plata, CDM; Moore, C; Madden, CJ; Diaz-Arrastia, R				Wang, J. Y.; Bakhadirov, K.; Abdi, H.; Devous, M. D., Sr.; de la Plata, C. D. Marquez; Moore, C.; Madden, C. J.; Diaz-Arrastia, R.			Longitudinal changes of structural connectivity in traumatic axonal injury	NEUROLOGY			English	Article							DIFFUSION-TENSOR; BRAIN-INJURY; TRACTOGRAPHY; INTEGRITY; RECOVERY; ROBUST	Objectives: To identify structural connectivity change occurring during the first 6 months after traumatic brain injury and to evaluate the utility of diffusion tensor tractography for predicting long-term outcome. Methods: The participants were 28 patients with mild to severe traumatic axonal injury and 20 age-and sex-matched healthy control subjects. Neuroimaging was obtained 0-9 days postinjury for acute scans and 6-14 months postinjury for chronic scans. Long-term outcome was evaluated on the day of the chronic scan. Twenty-eight fiber regions of 9 major white matter structures were reconstructed, and reliable tractography measurements were determined and used. Results: Although most (23 of 28) patients had severe brain injury, their long-term outcome ranged from good recovery (16 patients) to moderately (5 patients) and severely disabled (7 patients). In concordance with the diverse outcome, the white matter change in patients was heterogeneous, ranging from improved structural connectivity, through no change, to deteriorated connectivity. At the group level, all 9 fiber tracts deteriorated significantly with 7 (corpus callosum, cingulum, angular bundle, cerebral peduncular fibers, uncinate fasciculus, and inferior longitudinal and fronto-occipital fasciculi) showing structural damage acutely and 2 (fornix body and left arcuate fasciculus) chronically. Importantly, the amount of change in tractography measurements correlated with patients' long-term outcome. Acute tractography measurements were able to predict patients' learning and memory performance; chronic measurements also determined performance on processing speed and executive function. Conclusions: Diffusion tensor tractography is a valuable tool for identifying structural connectivity changes occurring between the acute and chronic stages of traumatic brain injury and for predicting patients' long-term outcome. Neurology (R) 2011;77:818-826	[Wang, J. Y.; Bakhadirov, K.; Abdi, H.; Devous, M. D., Sr.] Univ Texas Dallas, Dept Cognit & Neurosci, Richardson, TX 75083 USA; [de la Plata, C. D. Marquez] Univ Texas Dallas, Ctr Brain Hlth, Richardson, TX 75083 USA; [Abdi, H.; Devous, M. D., Sr.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [Moore, C.; Diaz-Arrastia, R.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Madden, C. J.] Univ Texas SW Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA		Diaz-Arrastia, R (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 12725 Twinbrook Pkwy, Rockville, MD 20852 USA.	Ramon.Diaz-Arrastia@usuhs.mil	Abdi, Herve/G-6620-2011	Diaz-Arrastia, Ramon/0000-0001-6051-3594; Abdi, Herve/0000-0002-9522-1978	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-HD48179, U01-HD042652, K23-NS060827]; US Department of EducationUS Department of Education [H133 A020526]; Avid Radiopharmaceuticals, Inc.; NIH (NIA, NIDRR/US Dept. Ed.)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Alzheimer's AssociationAlzheimer's Association; UCBUCB Pharma SA; NIH/NIDRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS060827] Funding Source: NIH RePORTER	Study funding: Supported by the NIH (R01-HD48179 and U01-HD042652 to R. D.-A. and K23-NS060827 to C. D. M.) and the US Department of Education (H133 A020526 to R.D.-A.).; Dr. Wang, Dr. Bakhadirov, and Dr. Abdi report no disclosures. Dr. Devous serves on a scientific advisory board and as a consultant for Avid Radiopharmaceuticals, Inc.; served as an Associate Editor for the Journal of Experimental Biology; receives research support from Avid Radiopharmaceuticals, Inc., the NIH (NIA, NIDRR/US Dept. Ed.), and the Alzheimer's Association; and holds stock/stock options in Avid Radiopharmaceuticals, Inc. Dr. Marquez de la Plata, C. Moore, and Dr. Madden report no disclosures. Dr. Diaz-Arrastia serves on the speakers' bureau for and has received funding for travel and speaker honoraria from UCB; serves on the editorial board of the Journal of Neurotrauma; and receives research support from the NIH/NIDRR and the Alzheimer's Association.	ABDI H, 2010, ENCY RES DESIGNS, P6556; ABDI H, 2007, ENCY MEASUREMENT STA, P2702; Abdi H, 2010, WIRES COMPUT STAT, V2, P97, DOI 10.1002/wics.51; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Catani M, 2005, ANN NEUROL, V57, P8, DOI 10.1002/ana.20319; Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136; Concha L, 2005, AM J NEURORADIOL, V26, P2267; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Delis D.C., 2000, CALIFORNIA VERBAL LE; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Huang H, 2004, MAGN RESON MED, V52, P559, DOI 10.1002/mrm.20147; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058	36	67	70	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG	2011	77	9					818	826		10.1212/WNL.0b013e31822c61d7			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	815PH	WOS:000294537000009	21813787	Green Published			2022-02-06	
J	Leblanc, E; Trensz, F; Haroun, S; Drouin, G; Bergeron, E; Penton, CM; Montanaro, F; Roux, S; Faucheux, N; Grenier, G				Leblanc, Elisabeth; Trensz, Frederic; Haroun, Sonia; Drouin, Genevieve; Bergeron, Eric; Penton, Christopher M.; Montanaro, Federica; Roux, Sophie; Faucheux, Nathalie; Grenier, Guillaume			BMP-9-Induced Muscle Heterotopic Ossification Requires Changes to the Skeletal Muscle Microenvironment	JOURNAL OF BONE AND MINERAL RESEARCH			English	Article						MUSCLE RESIDENT STROMAL CELLS; SCA1; MUSCLE DAMAGE; mu CT SCAN; ALK1	SPINAL-CORD-INJURY; ENDOTHELIAL-CELLS; SATELLITE CELLS; BONE; DIFFERENTIATION; PROGRESSIVA; IDENTIFICATION; INDOMETHACIN; PREVENTION; EXPRESSION	Heterotopic ossification (HO) is defined as the formation of bone inside soft tissue. Symptoms include joint stiffness, swelling, and pain. Apart from the inherited form, the common traumatic form generally occurs at sites of injury in damaged muscles and is often associated with brain injury. We investigated bone morphogenetic protein 9 (BMP-9), which possesses a strong osteoinductive capacity, for its involvement in muscle HO physiopathology. We found that BMP-9 had an osteoinductive influence on mouse muscle resident stromal cells by increasing their alkaline phosphatase activity and bone-specific marker expression. Interestingly, BMP-9 induced HO only in damaged muscle, whereas BMP-2 promoted HO in skeletal muscle regardless of its state. The addition of the soluble form of the ALK1 protein (the BMP-9 receptor) significantly inhibited the osteoinductive potential of BMP-9 in cells and HO in damaged muscles. BMP-9 thus should be considered a candidate for involvement in HO physiopathology, with its activity depending on the skeletal muscle microenvironment. (C) 2011 American Society for Bone and Mineral Research.	[Leblanc, Elisabeth; Trensz, Frederic; Haroun, Sonia; Drouin, Genevieve; Grenier, Guillaume] Univ Sherbrooke, Fac Med, Dept Orthoped Surg, Sherbrooke, PQ J1H 5N4, Canada; [Leblanc, Elisabeth; Trensz, Frederic; Haroun, Sonia; Drouin, Genevieve; Grenier, Guillaume] Res Ctr Ageing, Sherbrooke, PQ, Canada; [Roux, Sophie; Faucheux, Nathalie; Grenier, Guillaume] Etienne Lebel Clin Res Ctr, Sherbrooke, PQ, Canada; [Bergeron, Eric; Faucheux, Nathalie] Univ Sherbrooke, Fac Engn, Dept Chem & Biotechnol Engn, Sherbrooke, PQ J1H 5N4, Canada; [Penton, Christopher M.; Montanaro, Federica] Nationwide Childrens Hosp, Res Inst, Ctr Gene Therapy, Columbus, OH USA; [Montanaro, Federica] Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; [Montanaro, Federica] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA; [Roux, Sophie] Univ Sherbrooke, Fac Med, Dept Med, Sherbrooke, PQ J1H 5N4, Canada		Grenier, G (corresponding author), Univ Sherbrooke, Fac Med, Dept Orthoped Surg, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.	guillaume.grenier@usherbrooke.ca	Bergeron, Eric/G-6544-2011; Montanaro, Federica/E-3691-2011	Montanaro, Federica/0000-0002-3338-0498	Fondation pour la Recherche et l'Enseignement en Orthopedie de Sherbrooke (FREOS); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Fonds de la Recherche en Sante du Quebec (FRSQ)Fonds de la Recherche en Sante du Quebec; National Science and Engineering Research of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for Innovation (CFI)Canada Foundation for Innovation; Cell and Tissue Therapy Network of FRSQ	We are grateful to Dr Anthony Scime for his critical reading of the manuscript. We thank Paul Oleynick for technical assistance with the MoFloCytometer as well as Nancy Charland at the Anatomopathology Service. EL received scholarships from the Fondation pour la Recherche et l'Enseignement en Orthopedie de Sherbrooke (FREOS) and the Canadian Institutes of Health Research (CIHR). GG received a New Investigator Award from Fonds de la Recherche en Sante du Quebec (FRSQ). This work was supported by grants from the CIHR, the National Science and Engineering Research of Canada (NSERC), the Canada Foundation for Innovation (CFI), and the Cell and Tissue Therapy Network of FRSQ.	Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI [DOI 10.1117/1.3589100, DOI 10.1201/9781420005615.AX4]; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Banovac K, 2001, SPINAL CORD, V39, P370, DOI 10.1038/sj.sc.3101166; Beiner JM, 2002, CLIN ORTHOP RELAT R, pS110, DOI 10.1097/01.blo.0000037969.69509.2c; Bergeron E, 2007, J MATER SCI-MATER M, V18, P255, DOI 10.1007/s10856-006-0687-4; Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Caron AZ, 2009, J APPL PHYSIOL, V106, P2049, DOI 10.1152/japplphysiol.91505.2008; CHALMERS J, 1975, J BONE JOINT SURG BR, VB 57, P36, DOI 10.1302/0301-620X.57B1.36; CHANTRAINE A, 1981, SCAND J REHABIL MED, V13, P31; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133; Christov C, 2007, MOL BIOL CELL, V18, P1397, DOI 10.1091/mbc.E06-08-0693; CRAVEN PL, 1971, CLIN ORTHOP RELAT R, P231; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Depew Michael J., 2008, V461, P37, DOI 10.1007/978-1-60327-483-8_5; Egermann M, 2006, HUM GENE THER, V17, P507, DOI 10.1089/hum.2006.17.507; Forsberg Jonathan Agner, 2010, J Surg Orthop Adv, V19, P54; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Grenier G, 2007, STEM CELLS, V25, P3101, DOI 10.1634/stemcells.2006-0795; Hosoyama T, 2009, DIFFERENTIATION, V77, P350, DOI 10.1016/j.diff.2008.11.001; Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015; Kablar B, 1997, DEVELOPMENT, V124, P4729; Kan LX, 2004, AM J PATHOL, V165, P1107, DOI 10.1016/S0002-9440(10)63372-X; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Kaplan FS, 2008, J BONE MINER METAB, V26, P521, DOI 10.1007/s00774-008-0879-8; Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437; King JB, 1998, BRIT J SPORT MED, V32, P287, DOI 10.1136/bjsm.32.4.287; KITISIN K, 2007, SCI STKE, V399; Kozlowski Piotr, 2004, Chir Narzadow Ruchu Ortop Pol, V69, P241; Lopez-Coviella I, 2006, BRAIN RES, V1088, P49, DOI 10.1016/j.brainres.2006.02.073; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009; MOLLAN RAB, 1979, J BONE JOINT SURG BR, V61, P432, DOI 10.1302/0301-620X.61B4.115891; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; Reddi AH, 2003, J BONE JOINT SURG AM, V85A, P3, DOI 10.2106/00004623-200300003-00002; Romano CL, 2004, J ARTHROPLASTY, V19, P14, DOI 10.1016/S0883-5403(03)00279-1; ROTHWELL AG, 1982, CLIN ORTHOP RELAT R, P97; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Scime A, 2010, MECH AGEING DEV, V131, P9, DOI 10.1016/j.mad.2009.11.001; Senta H, 2009, CYTOKINE GROWTH F R, V20, P213, DOI 10.1016/j.cytogfr.2009.05.006; Shehab D, 2002, J NUCL MED, V43, P346; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Teasell RW, 2010, SPINAL CORD, V48, P512, DOI 10.1038/sc.2009.175; Trensz F, 2010, AM J PHYSIOL-CELL PH, V299, pC939, DOI 10.1152/ajpcell.00253.2010; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628; Walker MR, 2009, J PATHOL, V217, P169, DOI 10.1002/path.2474; WALTON M, 1983, CLIN ORTHOP RELAT R, P273; Wick L, 2005, EUR RADIOL, V15, P1867, DOI 10.1007/s00330-005-2769-y; Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917	55	67	71	0	7	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0884-0431			J BONE MINER RES	J. Bone Miner. Res.	JUN	2011	26	6					1166	1177		10.1002/jbmr.311			12	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	770SP	WOS:000291109100003	21611960				2022-02-06	
J	Samuels, O; Webb, A; Culler, S; Martin, K; Barrow, D				Samuels, Owen; Webb, Adam; Culler, Steve; Martin, Kathleen; Barrow, Daniel			Impact of a Dedicated Neurocritical Care Team in Treating Patients with Aneurysmal Subarachnoid Hemorrhage	NEUROCRITICAL CARE			English	Article						Subarachnoid hemorrhage; Neurocritical care; Discharge outcomes; Cerebral aneurysm; Neurointensivist	INTENSIVE-CARE; INTRACRANIAL ANEURYSMS; ILL PATIENTS; UNIT; OUTCOMES; MORTALITY; LENGTH; TIME	Background Intensivist staffing of intensive care units (ICUs) has been associated with a reduction in in-hospital mortality. These improvements in patient outcomes have been extended to neurointensivist staffing of neuroscience ICUs for patients with intracranial hemorrhage and traumatic brain injury. Objective The primary objective of this study is to determine if hospital outcomes (measured by discharge status) for patients admitted with aneurysmal subarachnoid hemorrhage changed after the introduction of a neurointensivist-led multidisciplinary neurocritical care team. Methods The authors retrospectively identified 703 patients admitted to the neuroscience ICU with a diagnosis of aneurysmal subarachnoid hemorrhage at a single academic tertiary care hospital between January 1, 1995 and December 31, 2002. It was compared with discharge outcomes for those patients treated prior to and following the development of a multidisciplinary neurocritical care team. Results Patients treated after the introduction of a neurocritical care team were significantly more likely to be discharged to home (25.2% vs. 36.5%) and less likely to be discharged to a rehab facility (25.2% vs. 36.5%). Patients treated after introduction of a neurocritical care team were also more likely to receive definitive aneurysm treatment (10.9% vs. 18%). Conclusion The implementation of a neurointensivist-led neurocritical care team is associated with improved hospital discharge disposition for patients with aneurysmal subarachnoid hemorrhage.	[Samuels, Owen; Webb, Adam; Martin, Kathleen; Barrow, Daniel] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA; [Samuels, Owen; Webb, Adam] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Samuels, Owen; Webb, Adam; Culler, Steve; Martin, Kathleen; Barrow, Daniel] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA		Samuels, O (corresponding author), Emory Univ, Sch Med, Dept Neurosurg, 1365 Clifton Rd NE, Atlanta, GA 30322 USA.	obsamue@emory.edu		Culler, Steven/0000-0002-6905-1186; Barrow, Daniel/0000-0003-0413-7883			Andaluz N, 2008, J NEUROSURG, V108, P1163, DOI 10.3171/JNS/2008/108/6/1163; Blunt MC, 2000, LANCET, V356, P735, DOI 10.1016/S0140-6736(00)02634-9; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; Dimick JB, 2000, CRIT CARE MED, V28, pA77; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Krishnamurthy S, 2007, NEUROSURGERY, V61, P475, DOI 10.1227/01.NEU.0000290892.46954.12; *LEAPF GROUP PAT S, 2004, FACT SHEET ICU PHYS; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; Manthous CA, 1997, MAYO CLIN PROC, V72, P391, DOI 10.4065/72.5.391; Milstein A, 2000, Eff Clin Pract, V3, P313; Mirski MA, 2001, J NEUROSURG ANESTH, V13, P83, DOI 10.1097/00008506-200104000-00004; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; POLLACK MM, 1994, JAMA-J AM MED ASSOC, V272, P941, DOI 10.1001/jama.272.12.941; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Rosenfeld BA, 2000, CRIT CARE MED, V28, P3925, DOI 10.1097/00003246-200012000-00034; Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713	21	67	71	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	JUN	2011	14	3					334	340		10.1007/s12028-011-9505-z			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	759FT	WOS:000290226800002	21424884				2022-02-06	
J	Tien, HCN; Jung, V; Pinto, R; Mainprize, T; Scales, DC; Rizoli, SB				Tien, Homer C. N.; Jung, Vincent; Pinto, Ruxandra; Mainprize, Todd; Scales, Damon C.; Rizoli, Sandro B.			Reducing Time-to-Treatment Decreases Mortality of Trauma Patients with Acute Subdural Hematoma	ANNALS OF SURGERY			English	Article							SEVERE HEAD-INJURY; RAPID-SEQUENCE INTUBATION; COMPUTERIZED-TOMOGRAPHY; OUTCOME PREDICTION; COMATOSE PATIENTS; BRAIN-INJURY; CT-SCAN; MORBIDITY; SURVIVAL; IMPACT	Objectives: To determine if reducing prehospital time and time-to-craniotomy is associated with decreased mortality in trauma patients with acute subdural hematomas. Background: Time-to-treatment is an important performance filter for trauma systems, yet very little evidence exists to support its use. Despite the biological rationale supporting the notion of the "Golden Hour" for trauma patients, no evidence exists to support it. Likewise, it remains controversial whether or not time-to-craniotomy is associated with survival in patients with subdural hematomas. Previous studies may have been affected by selection bias. Methods: Retrospective cohort study of all trauma patients who arrived directly from the scene of injury. Study patients were all patients with acute subdural hematomas and without severe torso injuries, who required craniotomy at a Canadian level 1 trauma center from January 1 1996 to December 31 2007. The independent variables of interest were prehospital time and time-to-craniotomy. The primary outcome measure was in-hospital mortality. Results: Of 12,105 trauma patients assessed, 149 patients met inclusion criteria. Overall, 40% (n = 60) patients died. On univariate analysis, there was a strong trend suggesting that patients arriving within the "Golden Hour after trauma" had decreased mortality (37% vs. 53%, P = 0.09). However, there was no difference in mortality for patients undergoing craniotomy within 4 hours and after 4 hours (42% vs. 36%, P = 0.4). On multivariate logistic regression, increased prehospital time was found to be associated with increased mortality (odds ratio 1.03 per minute, 95% CI 1.004-1.05, P = 0.024). Surprisingly, there was a trend showing that increased trauma room to craniotomy times were associated with lower mortality (odds ratio 0.995 per minute, 95% CI 0.99-1.0, P = 0.056). However, patients who quickly had their craniotomy seemed to have more severe neurological injury. Conclusion: Rapid transport of patients with traumatic subdural hematomas hospital is associated with decreased mortality.	[Tien, Homer C. N.; Jung, Vincent; Rizoli, Sandro B.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Gen Surg, Tory Reg Trauma Ctr, Toronto, ON M4N 3M5, Canada; [Pinto, Ruxandra; Scales, Damon C.; Rizoli, Sandro B.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Mainprize, Todd] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Neurosurg, Tory Reg Trauma Ctr, Toronto, ON M4N 3M5, Canada		Tien, HCN (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Gen Surg, Tory Reg Trauma Ctr, 2075 Bayview Ave,Suite H186, Toronto, ON M4N 3M5, Canada.	homer.tien@sunnybrook.ca					*ATLS AM COLL SURG, 2008, ADV TRAUM LIF SUPP D; Austin PC, 2006, J EVAL CLIN PRACT, V12, P601, DOI 10.1111/j.1365-2753.2005.00624.x; BULLARD MJ, REVISIONS CANADIAN E; BULLOCK MR, 2002, SURG MANAG ACUTE SUB, V58; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; *COMM TRAUM TASK F, 2006, RES OPT CAR INJ PAT; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; De Maio VJ, 2003, ANN EMERG MED, V42, P242, DOI 10.1067/mem.2003.266; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Johnson JM, 2009, ADV EMERG NURS J, V31, P221, DOI 10.1097/TME.0b013e3181afbf3a; Kleinbaum D.G., 2002, LOGISTIC REGRESSION; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marion DW, 2006, NEUROSURGERY, V58, P655; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; NEWGARD CD, 2009, ANN EMERG MED, V22; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; RAFTOPOULOS C, 1990, CLIN NEUROL NEUROSUR, V92, P57, DOI 10.1016/0303-8467(90)90008-S; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Scales DC, 2008, CRIT CARE MED, V36, P2547, DOI 10.1097/CCM.0b013e31818444a5; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; Taussky P, 2008, SWISS MED WKLY, V138, P281, DOI 2008/19/smw-12056; TIAN HL, 2008, CHIN MED J, V20, P1080; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; van Walraven C, 2004, J CLIN EPIDEMIOL, V57, P672, DOI 10.1016/j.jclinepi.2003.12.008; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; [No title captured]	43	67	67	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	JUN	2011	253	6					1178	1183		10.1097/SLA.0b013e318217e339			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	764WB	WOS:000290664100020	21494125				2022-02-06	
J	Moore, FO; Goslar, PW; Coimbra, R; Velmahos, G; Brown, CVR; Coopwood, TB; Lottenberg, L; Phelan, HA; Bruns, BR; Sherck, JP; Norwood, SH; Barnes, SL; Matthews, MR; Hoff, WS; de Moya, MA; Bansal, V; Hu, CKC; Karmy-Jones, RC; Vinces, F; Pembaur, K; Notrica, DM; Haan, JM				Moore, Forrest O.; Goslar, Pamela W.; Coimbra, Raul; Velmahos, George; Brown, Carlos V. R.; Coopwood, Thomas B., Jr.; Lottenberg, Lawrence; Phelan, Herb A.; Bruns, Brandon R.; Sherck, John P.; Norwood, Scott H.; Barnes, Stephen L.; Matthews, Marc R.; Hoff, William S.; de Moya, Marc A.; Bansal, Vishal; Hu, Charles K. C.; Karmy-Jones, Riyad C.; Vinces, Fausto; Pembaur, Karl; Notrica, David M.; Haan, James M.			Blunt Traumatic Occult Pneumothorax: Is Observation Safe?-Results of a Prospective, AAST Multicenter Study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Occult pneumothorax; Tube thoracostomy; Computed tomography	TUBE THORACOSTOMY; COMPUTED-TOMOGRAPHY; CRITICAL-CARE; CHEST TRAUMA; MANAGEMENT; CT; COMPLICATIONS; PATIENT	Background: An occult pneumothorax (OPTX) is found incidentally in 2% to 10% of all blunt trauma patients. Indications for intervention remain controversial. We sought to determine which factors predicted failed observation in blunt trauma patients. Methods: A prospective, observational, multicenter study was undertaken to identify patients with OPTX. Successfully observed patients and patients who failed observation were compared. Multivariate logistic regression was used to identify predictors of failure of observation. OPTX size was calculated by measuring the largest air collection along a line perpendicular from the chest wall to the lung or mediastinum. Results: Sixteen trauma centers identified 588 OPTXs in 569 blunt trauma patients. One hundred twenty-one patients (21%) underwent immediate tube thoracostomy and 448 (79%) were observed. Twenty-seven patients (6%) failed observation and required tube thoracostomy for OPTX progression, respiratory distress, or subsequent hemothorax. Fourteen percent (10 of 73) failed observation during positive pressure ventilation. Hospital and intensive care unit lengths of stay, and ventilator days were longer in the failed observation group. OPTX progression and respiratory distress were significant predictors of failed observation. Most patient deaths were from traumatic brain injury. Fifteen percentage of patients in the failed observation group developed complications. No patient who failed observation developed a tension PTX, or experienced adverse events by delaying tube thoracostomy. Conclusion: Most blunt trauma patients with OPTX can be carefully monitored without tube thoracostomy; however, OPTX progression and respiratory distress are independently associated with observation failure.	[Moore, Forrest O.; Goslar, Pamela W.] St Josephs Hosp, Phoenix, AZ 85013 USA; [Moore, Forrest O.; Goslar, Pamela W.] Med Ctr, Phoenix, AZ 85013 USA; [Coimbra, Raul; Bansal, Vishal] Univ Calif San Diego, Med Ctr, San Diego, CA USA; [Velmahos, George; de Moya, Marc A.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Brown, Carlos V. R.; Coopwood, Thomas B., Jr.] Univ Med Ctr Brackenridge, Austin, TX USA; [Lottenberg, Lawrence] Univ Florida, Hlth Sci Ctr, Gainesville, FL USA; [Phelan, Herb A.] UT Southwestern, Med Ctr, Dallas, TX USA; [Bruns, Brandon R.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; [Sherck, John P.] Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; [Norwood, Scott H.] E Texas Med Ctr, Tyler, TX USA; [Barnes, Stephen L.] Univ Missouri, Columbia, MO USA; [Matthews, Marc R.] Maricopa Cty Gen Hosp, Phoenix, AZ USA; [Hoff, William S.] St Lukes Hosp, Bethlehem, PA USA; [Hoff, William S.] Med Ctr, Bethlehem, PA USA; [Hu, Charles K. C.] Scottsdale Osborne Med Ctr, Scottsdale, AZ USA; [Karmy-Jones, Riyad C.] Southwest Washington Med Ctr, Vancouver, WA USA; [Vinces, Fausto; Pembaur, Karl] Lutheran Med Ctr, Brooklyn, NY USA; [Notrica, David M.] Phoenix Childrens Hosp, Phoenix, AZ USA; [Haan, James M.] Via Christi Reg Med Ctr, Wichita, KS USA		Moore, FO (corresponding author), St Josephs Hosp, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	moore677@aol.com	Coimbra, Raul/AAP-3019-2020; Notrica, David/D-4616-2014	Coimbra, Raul/0000-0002-3759-6851; Barnes, Stephen/0000-0001-6186-1435; Notrica, David/0000-0002-2939-1119			Bailey RC, 2000, J ACCID EMERG MED, V17, P111; Ball CG, 2005, J TRAUMA, V59, P917, DOI 10.1097/01.ta.0000174663.46453.86; Ball CG, 2003, CAN J SURG, V46, P373; Barrios C, 2008, AM SURGEON, V74, P958; Brasel KJ, 1999, J TRAUMA, V46, P987, DOI 10.1097/00005373-199906000-00001; COLLINS JC, 1992, AM SURGEON, V58, P743; de Moya MA, 2007, J TRAUMA, V63, P13, DOI 10.1097/TA.0b013e31806864fc; ENDERSON BL, 1993, J TRAUMA, V35, P726, DOI 10.1097/00005373-199311000-00013; ETOCH SW, 1995, ARCH SURG-CHICAGO, V130, P521; GARRAMONE RR, 1991, SURG GYNECOL OBSTET, V173, P257; Guerrero-Lopez F, 2000, CRIT CARE MED, V28, P1370, DOI 10.1097/00003246-200005000-00018; Hill SL, 1999, AM SURGEON, V65, P254; Lamb ADG, 2007, EUR J EMERG MED, V14, P65, DOI 10.1097/01.mej.0000228439.87286.ed; Lee KL, 2010, INJURY, V41, P492, DOI 10.1016/j.injury.2009.12.017; Misthos P, 2004, EUR J CARDIO-THORAC, V25, P859, DOI 10.1016/j.ejcts.2004.01.044; Ouellet JF, 2009, AM J SURG, V197, P581, DOI 10.1016/j.amjsurg.2008.12.007; Plurad D, 2007, J TRAUMA, V62, P631, DOI 10.1097/TA.0b013e31802bf009; RHEA JT, 1989, J TRAUMA, V29, P502, DOI 10.1097/00005373-198904000-00015; TOCINO IM, 1984, AM J ROENTGENOL, V143, P987, DOI 10.2214/ajr.143.5.987; Wilson H, 2009, INJURY, V40, P928, DOI 10.1016/j.injury.2009.04.005; WOLFMAN NT, 1993, J COMPUT ASSIST TOMO, V17, P56, DOI 10.1097/00004728-199301000-00009	21	67	71	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2011	70	5					1019	1023		10.1097/TA.0b013e318213f727			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	762LQ	WOS:000290480300009	21610419				2022-02-06	
J	Peiniger, S; Nienaber, U; Lefering, R; Braun, M; Wafaisade, A; Wutzler, S; Borgmann, M; Spinella, PC; Maegele, M				Peiniger, Sigune; Nienaber, Ulrike; Lefering, Rolf; Braun, Maximilian; Wafaisade, Arasch; Wutzler, Sebastian; Borgmann, Matthew; Spinella, Philip C.; Maegele, Marc		TR-DGU	Balanced massive transfusion ratios in multiple injury patients with traumatic brain injury	CRITICAL CARE			English	Article							FRESH-FROZEN PLASMA; RED-BLOOD-CELL; MORTALITY; COAGULOPATHY; SURVIVAL; REGISTRY; IMPACT; SCORE	Introduction: Retrospective studies have demonstrated a potential survival benefit from transfusion strategies using an early and more balanced ratio between fresh frozen plasma (FFP) concentration and packed red blood cell (pRBC) transfusions in patients with acute traumatic coagulopathy requiring massive transfusions. These results have mostly been derived from non-head-injured patients. The aim of the present study was to analyze whether a regime using a high FFP: pRBC transfusion ratio (FFP: pRBC ratio > 1:2) would be associated with a similar survival benefit in severely injured patients with traumatic brain injury (TBI) (Abbreviated Injury Scale (AIS) score, head >= 3) as demonstrated for patients without TBI requiring massive transfusion (>= 10 U of pRBCs). Methods: A retrospective analysis of severely injured patients from the Trauma Registry of the Deutsche Gesellschaft fur Unfallchirurgie (TR-DGU) was conducted. Inclusion criteria were primary admission, age >= 16 years, severe injury (Injury Severity Score (ISS) >= 16) and massive transfusion (>= 10 U of pRBCs) from emergency room to intensive care unit (ICU). Patients were subdivided into patients with TBI (AIS score, head >= 3) and patients without TBI (AIS score, head < 3), as well as according to the transfusion ratio they had received: high FFP: pRBC ratio (FFP: pRBC ratio > 1:2) and low FFP: pRBC ratio (FFP: pRBC ratio <= 1:2). In addition, morbidity and mortality between the two groups were compared. Results: A total of 1,250 data sets of severely injured patients from the TR-DGU between 2002 and 2008 were analyzed. The mean patient age was 42 years, the majority of patients were male (72.3%), the mean ISS was 41.7 points (+/- 15.4 SD) and the principal mechanism of injury was blunt force trauma (90%). Mortality was statistically lower in the high FFP:pRBC ratio groups versus the low FFP: pRBC ratio groups, regardless of the presence or absence of TBI and across all time points studied (P < 0.001). The frequency of sepsis and multiple organ failure did not differ among groups, except for sepsis in patients with TBI who received a high FFP: pRBC ratio transfusion. Other secondary end points such as ventilator-free days, length of stay in the ICU and overall in-hospital length of stay differed significantly between the two study groups, but not when only data for survivors were analyzed. Conclusions: These results add more detailed knowledge to the concept of a high FFP:pRBC ratio during early aggressive resuscitation, including massive transfusion, to decrease mortality in severely injured patients both with and without accompanying TBI. Future research should be conducted with a larger number of patients to prove these results in a prospective study.	[Peiniger, Sigune; Braun, Maximilian; Wafaisade, Arasch; Wutzler, Sebastian; Maegele, Marc] Univ Witten Herdecke, CMMC, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany; [Peiniger, Sigune; Nienaber, Ulrike; Lefering, Rolf; Braun, Maximilian; Wafaisade, Arasch; Maegele, Marc] Univ Witten Herdecke, CMMC, Inst Res Operat Med IFOM, D-51109 Cologne, Germany; [Borgmann, Matthew] San Antonio Mil Med Ctr, Ft Sam Houston, TX 78234 USA; [Spinella, Philip C.] CCMC, Dept Surg, Dept Pediat, Hartford, CT 06106 USA		Maegele, M (corresponding author), Univ Witten Herdecke, CMMC, Dept Trauma & Orthoped Surg, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de	Borgman, Matthew A/L-9477-2015	Borgman, Matthew A/0000-0002-2008-7380			BJORKLIND A, 1977, ACTA PATH MICRO IM B, V85, P277; BONE RC, 1991, CRIT CARE MED, V19, P973, DOI 10.1097/00003246-199107000-00024; BORGMAN MA, VOX SANG IN PRESS; Borgman M, 2009, CRIT CARE MED, V37, pA264; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Cotton BA, 2010, J TRAUMA, V69, pS33, DOI 10.1097/TA.0b013e3181e42411; Duchesne JC, 2008, J TRAUMA, V65, P272, DOI 10.1097/TA.0b013e31817e5166; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Gunter OL, 2008, J TRAUMA, V65, P527, DOI 10.1097/TA.0b013e3181826ddf; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2010, BIOLOGICALS, V38, P72, DOI 10.1016/j.biologicals.2009.10.007; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Lefering R, 2009, EUR J TRAUMA EMERG S, V35, P437, DOI 10.1007/s00068-009-9122-0; Maegele M, 2008, VOX SANG, V95, P112, DOI 10.1111/j.1423-0410.2008.01074.x; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; MAUERSBERGER W, 1979, NEUROCHIRURGIA, V22, P68; McLaughlin DF, 2008, J TRAUMA, V64, pS57, DOI 10.1097/TA.0b013e318160a566; Nascimento B, 2010, CRIT CARE, V14, DOI 10.1186/cc8205; Pathak A, 2005, Neurol India, V53, P178; Perkins JG, 2008, CRIT CARE MED, V36, pS325, DOI 10.1097/CCM.0b013e31817e2ec5; Perkins JG, 2009, J TRAUMA, V66, pS77, DOI 10.1097/TA.0b013e31819d8936; Popovsky MA, 2006, TRANSFUS APHER SCI, V34, P243, DOI 10.1016/j.transci.2006.01.005; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Scalea TM, 2008, ANN SURG, V248, P578, DOI 10.1097/SLA.0b013e31818990ed; Snyder CW, 2009, J TRAUMA, V66, P358, DOI 10.1097/TA.0b013e318196c3ac; Spahn DR, 2007, CRIT CARE, V11, DOI 10.1186/cc5686; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Stainsby D, 2006, TRANSFUS MED REV, V20, P273, DOI 10.1016/j.tmrv.2006.05.002; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf; Zehtabchi S, 2009, ACAD EMERG MED, V16, P371, DOI 10.1111/j.1553-2712.2009.00386.x	33	67	74	1	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2011	15	1							R68	10.1186/cc10048			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742RJ	WOS:000288961900068	21342499	gold, Green Published			2022-02-06	
J	Syam, SS; Cote, MJ				Syam, Siddhartha S.; Cote, Murray J.			A location-allocation model for service providers with application to not-for-profit health care organizations	OMEGA-INTERNATIONAL JOURNAL OF MANAGEMENT SCIENCE			English	Article						Health care; Integer programming; Location-allocation; Simulated annealing	FACILITY LOCATION	In this paper, we develop and solve a model for the location and allocation of specialized health care services such as traumatic brain injury (TBI) treatment. The model is based on and applied to one of the Department of Veterans Affairs' integrated service networks. A cost minimization model with service proportion requirements is solved using simulated annealing. Large instances of the model with 100 candidate medical center locations and 15 open treatment units are solved in about 1000s. In order to test the real-world applicability of our model, an extensive managerial experiment is conducted using data derived from our health care setting. In this experiment, the effects of three critical factors: (1) degree of centralization of services, (2) the role of patient retention as a function of distance to a treatment unit, and (3) the geographic density of the patient population are investigated with respect to the important trade-off between the cost of providing service and the need to provide such service. Our analysis shows that all three factors of the experiment are both relevant and useful to decision-makers when selecting locations for their services. (C) 2009 Elsevier Ltd. All rights reserved.	[Syam, Siddhartha S.] Marquette Univ, Dept Management, Milwaukee, WI 53201 USA; [Cote, Murray J.] Univ Colorado Denver, Dept Med, Div Hlth Care Policy & Res, Aurora, CO 80045 USA		Syam, SS (corresponding author), Marquette Univ, Dept Management, Milwaukee, WI 53201 USA.	syams@mu.edu; murray.cote@ucdenver.edu			Department of Veterans Affairs (VA) Rehabilitation Research and Development (RR&D) Service through the VA RR&D Rehabilitation Outcomes Research Center at the Malcolm Randall VA Medical Center in Gainesville, FloridaUS Department of Veterans Affairs [B2610R]	This work was funded by the Department of Veterans Affairs (VA) Rehabilitation Research and Development (RR&D) Service through the VA RR&D Rehabilitation Outcomes Research Center at the Malcolm Randall VA Medical Center in Gainesville, Florida (Project #B2610R, W. Bruce Vogel, Principal Investigator).	Branas CC, 2000, HEALTH SERV RES, V35, P489; Cornuejols G., 1990, DISCRETE LOCATION TH; CRAINIC TG, 1993, TRANSPORT SCI, V27, P90, DOI 10.1287/trsc.27.2.90; DASKIN M, 2004, OPERATIONS RES HLTH; ERLENKOTTER D, 1978, OPER RES, V26, P992, DOI 10.1287/opre.26.6.992; FISHER ML, 1985, INTERFACES, V15, P10, DOI 10.1287/inte.15.2.10; Geoffrion AM, 1974, MATH PROGRAMMING STU, V2, P82; Harper PR, 2005, OMEGA-INT J MANAGE S, V33, P141, DOI 10.1016/j.omega.2004.03.011; Johnson DS., 1979, COMPUTERS INTRACTABI; Knuth D.E, 1997, ART COMPUTER PROGRAM, V3; Love R.F., 1988, FACILITIES LOCATION; Mehrez A, 1996, J OPER RES SOC, V47, P612, DOI 10.1057/palgrave.jors.0470502; Muppani VR, 2008, OMEGA-INT J MANAGE S, V36, P609, DOI 10.1016/j.omega.2007.01.006; OLSON DL, 1996, DECISION AIDS SELECT; PIERSKALLA WP, 1989, REV OPERATIONS RES I; PRICE WL, 1986, INTERFACES, V16, P17, DOI 10.1287/inte.16.5.17; Schrage LE., 1997, OPTIMIZATION MODELIN; SCHWEIKHART SB, 1993, SOCIO ECON PLAN SCI, V27, P289, DOI 10.1016/0038-0121(93)90021-A; Scniederjans M.J., 1995, GOAL PROGRAMMING MET; SMITHDANIELS VL, 1988, DECISION SCI, V19, P889, DOI 10.1111/j.1540-5915.1988.tb00310.x; Stahl JE, 2005, MED DECIS MAKING, V25, P35, DOI 10.1177/0272989X04273137; Syam SS, 2002, COMPUT OPER RES, V29, P1173, DOI 10.1016/S0305-0548(01)00023-5; [No title captured]	23	67	67	1	20	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0305-0483			OMEGA-INT J MANAGE S	Omega-Int. J. Manage. Sci.	JUN-AUG	2010	38	3-4					157	166		10.1016/j.omega.2009.08.001			10	Management; Operations Research & Management Science	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Business & Economics; Operations Research & Management Science	539GH	WOS:000273241400005					2022-02-06	
J	Tanriverdi, F; De Bellis, A; Battaglia, M; Bellastella, G; Bizzarro, A; Sinisi, AA; Bellastella, A; Unluhizarci, K; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; De Bellis, Annamaria; Battaglia, Marina; Bellastella, Giuseppe; Bizzarro, Antonio; Sinisi, Antonio A.; Bellastella, Antonio; Unluhizarci, Kursad; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Investigation of antihypothalamus and antipituitary antibodies in amateur boxers: is chronic repetitive head trauma-induced pituitary dysfunction associated with autoimmunity?	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							BRAIN-INJURY; GH DEFICIENCY; HYPOPITUITARISM; HORMONE; AUTOANTIBODIES; INSUFFICIENCY; EPIDEMIOLOGY; HYPOPHYSITIS; AUSTRALIA; CHILDREN	Objective: Current data clearly demonstrate that sports-related chronic repetitive head trauma due to boxing might result in hypopituitarism. However, the mechanism of sports-related traumatic brain injury-induced pituitary dysfunction is still unclear. In order to understand whether autoimmune mechanisms could play a role in the pituitary dysfunction due to sports-related head trauma, we investigated the presence of antipituitary antibodies (APAs) and antihypothalamus antibodies (AHAs) in amateur boxers. Patients and design: Sixty-one actively competing (n = 44) or retired (n = 17) male boxers (mean age, 26 years; range, 17-53) who had been evaluated regarding pituitary functions previously were included in the study. In all boxers and in 60 age/sex-similar normal controls, AHAs and APAs were investigated by an indirect immunofluorescence method. Results: AHAs were detected in 13 of 61 boxers (21.3%), and APAs were detected in 14 of 61 boxers (22.9%), but in none of the normal controls. Pituitary dysfunction was significantly higher in AHA-positive boxers (46.2%) than in AHA-negative boxers (10.4%) (P = 0.003). There was a significant association between AHA positivity and hypopituitarism due to boxing (odds ratio: 7.37, 95% confidence interval 1.8-30.8). There was no significant association between APA positivity and hypopituitarism. Conclusions: This study demonstrates for the first time the presence of AHAs and APAs in boxers who were exposed to sports-related head trauma. Moreover, the present investigation provides preliminary evidence that AHAs are associated with the development of pituitary dysfunction in boxers, thus suggesting that autoimmunity may have a role in the pathogenesis.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Dept Endocrinol, Sch Med, TR-38039 Kayseri, Turkey; [De Bellis, Annamaria; Battaglia, Marina; Bellastella, Giuseppe; Sinisi, Antonio A.; Bellastella, Antonio] Univ Naples 2, Chair Endocrinol, I-80131 Naples, Italy; [Bizzarro, Antonio] Univ Naples 2, Chair Immunol, I-80131 Naples, Italy; [Selcuklu, Ahmet] Erciyes Univ, Dept Neurosurg, Sch Med, TR-38039 Kayseri, Turkey; [Casanueva, Felipe F.] Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Dept Med, Santiago De Compostela, Spain		Kelestimur, F (corresponding author), Erciyes Univ, Dept Endocrinol, Sch Med, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr	kelestimur, f/ABE-9873-2021	DE BELLIS, Annamaria/0000-0002-0611-4506			Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Bensing S, 2007, P NATL ACAD SCI USA, V104, P949, DOI 10.1073/pnas.0610070104; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; Caturegli P, 2005, ENDOCR REV, V26, P599, DOI 10.1210/er.2004-0011; De Bellis A, 2005, BEST PRACT RES CL EN, V19, P67, DOI 10.1016/j.beem.2004.11.007; De Bellis A, 2003, J CLIN ENDOCR METAB, V88, P650, DOI 10.1210/jc.2002-021054; De Bellis A, 1999, J CLIN ENDOCR METAB, V84, P3047, DOI 10.1210/jc.84.9.3047; De Bellis A, 2008, EUR J ENDOCRINOL, V158, P147, DOI 10.1530/EJE-07-0647; De Bellis A, 2006, J CLIN ENDOCR METAB, V91, P2484, DOI 10.1210/jc.2006-0040; Falorni A, 2004, J CLIN ENDOCR METAB, V89, P1598, DOI 10.1210/jc.2003-030954; Ferriero DM, 2004, NEW ENGL J MED, V351, P1985, DOI 10.1056/NEJMra041996; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gionis D, 2003, J PEDIATR ENDOCR MET, V16, P49; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; Hillier SL, 1997, BRAIN INJURY, V11, P649; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Manetti L, 2007, J CLIN ENDOCR METAB, V92, P2176, DOI 10.1210/jc.2006-2748; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Powell JW, 2001, J ATHL TRAINING, V36, P307; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Salehi F, 2007, BRAIN INJURY, V21, P651, DOI 10.1080/02699050701426956; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; Stein TD, 2002, J NEUROPATH EXP NEUR, V61, P1100, DOI 10.1093/jnen/61.12.1100; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448	34	67	68	0	4	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	MAY	2010	162	5					861	867		10.1530/EJE-09-1024			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	587YH	WOS:000277032100005	20176736	Bronze			2022-02-06	
J	Klevens, J; Leeb, RT				Klevens, Joanne; Leeb, Rebecca T.			Child maltreatment fatalities in children under 5: Findings from the National Violence Death Reporting System	CHILD ABUSE & NEGLECT			English	Article						Surveillance; Child physical abuse; Inflicted traumatic brain injury; Inflicted childhood neurotrauma; Abusive head trauma	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; UNITED-STATES; ABUSE; IMPACT	Objective: To describe the distribution of child maltreatment fatalities of children under 5 by age, sex, race/ethnicity, type of maltreatment, and relationship to alleged perpetrator using data from the National Violent Death Reporting System (NVDRS). Study design: Two independent coders reviewed information from death certificates, medical examiner and police reports corresponding to all deaths in children less than 5 years of age reported to NVDRS in 16 states. Results: Of the 1,374 deaths for children under 5 reported to NVDRS, 600 were considered attributable to child maltreatment. Over a half of the 600 victims of child maltreatment in this age group were under 1 year old, 59% were male, 42% non-Hispanic Whites, and 38% were non-Hispanic Blacks. Two thirds of child maltreatment fatalities in children under 5 were classified as being due to abusive head trauma (AHT), 27.5% as other types of physical abuse, and 10% as neglect. Based on these data, fathers or their substitutes were significantly more likely than mothers to be identified as alleged perpetrators for AHT and other types of physical abuse, while mothers were more likely to be assigned responsibility for neglect. Conclusions: Among children under 5 years, children under 1 are the main age group contributing to child maltreatment fatalities in the NVDRS. AHT is the main cause of death in these data. These findings are limited by underascertainment of cases and fair inter-rater reliability of coding. Practice implications: The findings suggest the need to develop and evaluate interventions targeting AHT to reduce the overall number of child maltreatment deaths in young children. These interventions should make special efforts to include fathers and their substitutes. Published by Elsevier Ltd.	[Klevens, Joanne; Leeb, Rebecca T.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA		Klevens, J (corresponding author), Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop F-64, Atlanta, GA 30341 USA.						Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Bennett MD, 2006, INJURY PREV, V12, P39, DOI 10.1136/ip.2006.012658; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Brewster AL, 1998, CHILD ABUSE NEGLECT, V22, P91, DOI 10.1016/S0145-2134(97)00132-4; CANIANO DA, 1986, ANN SURG, V203, P219, DOI 10.1097/00000658-198602000-00017; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P187; Crume TL, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.2.e18; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Duggan A, 2004, CHILD ABUSE NEGLECT, V28, P597, DOI 10.1016/j.chiabu.2003.08.007; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Graupman P, 2006, J NEUROSURG, V104, P245, DOI 10.3171/ped.2006.104.4.245; Hahn Robert A, 2003, MMWR Recomm Rep, V52, P1; Herman-Giddens ME, 1999, JAMA-J AM MED ASSOC, V282, P463, DOI 10.1001/jama.282.5.463; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KLEVENS J, 2002, INFLICTED CHILDHOOD, P269; Krugman R D, 1983, Pediatrician, V12, P68; Leeb RT, 2008, CHILD MALTREATMENT S; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; *NAT CTR INJ PREV, 2006, WISQARS LEAD CAUS DE; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P27; Schnitzer PG, 2008, AM J PUBLIC HEALTH, V98, P296, DOI 10.2105/AJPH.2006.087783; Schnitzer PG, 2005, PEDIATRICS, V116, pE687, DOI 10.1542/peds.2005-0296; Showers J, 1985, Pediatr Emerg Care, V1, P66; Steenkamp M, 2006, INJURY PREV, V12, P3, DOI 10.1136/ip.2006.012518; Stiffman MN, 2002, PEDIATRICS, V109, P615, DOI 10.1542/peds.109.4.615; US Census Bureau, 2007, 2005 2007 AM COMM SU; *UUS DEP HLTH HHS, 2005, CHILD MALTR 2003; *UUS DEP HLTH HHS, 2008, CHILD MALTR 2006; *UUS DEP HLTH HHS, 2007, CHILD MALTR 2005; *UUS DEP HLTH HHS, 2006, CHILD MALTR 2004; *WHO, 1999, INT STAT CLASS DIS R	35	67	67	1	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	APR	2010	34	4					262	266		10.1016/j.chiabu.2009.07.005			5	Family Studies; Psychology, Social; Social Work	Social Science Citation Index (SSCI)	Family Studies; Psychology; Social Work	588LW	WOS:000277072700006	20304491				2022-02-06	
J	Smits, M; Dippel, DWJ; Nederkoorn, PJ; Dekker, HM; Vos, PE; Kool, DR; van Rijssel, DA; Hofman, PAM; Twijnstra, A; Tanghe, HLJ; Hunink, MGM				Smits, Marion; Dippel, Diederik W. J.; Nederkoorn, Paul J.; Dekker, Helena M.; Vos, Pieter E.; Kool, Digna R.; van Rijssel, Daphne A.; Hofman, Paul A. M.; Twijnstra, Albert; Tanghe, Herve L. J.; Hunink, M. G. Myriam			Minor Head Injury: CT-based Strategies for Management - A Cost-effectiveness Analysis	RADIOLOGY			English	Article							RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; EXTRADURAL HEMATOMA; RULE; RECOMMENDATIONS; SCALE; VALIDATION; ADMISSION	Purpose: To compare the cost-effectiveness of using selective computed tomographic (CT) strategies with that of performing CT in all patients with minor head injury (MHI). Materials and methods: The internal review board approved the study; written informed consent was obtained from all interviewed patients. Five strategies were evaluated, with CT performed in all patients with MHI; selectively according to the New Orleans criteria (NOC), Canadian CT head rule (CCHR), or CT in head injury patients ( CHIP) rule; or in no patients. A decision tree was used to analyze short-term costs and effectiveness, and a Markov model was used to analyze long-term costs and effectiveness. n-Way and probabilistic sensitivity analyses and value-of-information (VOI) analysis were performed. Data from the multicenter CHIP Study involving 3181 patients with MHI were used. Outcome measures were first-year and lifetime costs, quality-adjusted life-years, and incremental cost-effectiveness ratios. Results: Study results showed that performing CT selectively according to the CCHR or the CHIP rule could lead to substantial U. S. cost savings ($120 million and $71 million, respectively), and the CCHR was the most cost-effective at reference-case analysis. When the prediction rule had lower than 97% sensitivity for the identification of patients who required neurosurgery, performing CT in all patients was cost-effective. The CHIP rule was most likely to be cost-effective. At VOI analysis, the expected value of perfect information was $7 billion, mainly because of uncertainty about long-term functional outcomes. Conclusion: Selecting patients with MHI for CT renders cost savings and may be cost-effective, provided the sensitivity for the identification of patients who require neurosurgery is extremely high. Uncertainty regarding long-term functional outcomes after MHI justifies the routine use of CT in all patients with these injuries.	[Smits, Marion; van Rijssel, Daphne A.; Tanghe, Herve L. J.; Hunink, M. G. Myriam] Erasmus MC, Univ Med Ctr Rotterdam, Dept Radiol, NL-3000 CA Rotterdam, Netherlands; [Dippel, Diederik W. J.] Erasmus MC, Univ Med Ctr Rotterdam, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; [van Rijssel, Daphne A.; Hunink, M. G. Myriam] Erasmus MC, Univ Med Ctr Rotterdam, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands; [Nederkoorn, Paul J.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; [Dekker, Helena M.; Kool, Digna R.] Univ Med Ctr Nijmegen St Radboud, Dept Radiol, Nijmegen, Netherlands; [Vos, Pieter E.] Univ Med Ctr Nijmegen St Radboud, Dept Neurol, Nijmegen, Netherlands; [Hofman, Paul A. M.] Univ Hosp Maastricht, Dept Radiol, Maastricht, Netherlands; [Twijnstra, Albert] Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands; [Hunink, M. G. Myriam] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA		Hunink, MGM (corresponding author), Erasmus MC, Univ Med Ctr Rotterdam, Dept Radiol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	m.hunink@erasmusmc.nl	Dippel, Diederik/AAJ-2192-2020; Smits, Marion/AAB-3985-2019; Dekker, H.M./L-4262-2015; Smits, Marion/E-4795-2011; Vos, Pieter/A-6043-2012	Dippel, Diederik/0000-0002-9234-3515; Smits, Marion/0000-0001-5563-2871; 	ZonMW (ZonMW DO)Netherlands Organization for Health Research and Development [945-06-309]; College voorZorgverzekeringen (CVZ) [VAZ 01-104]; Radiologisch onderzoek Nederland (RADION)	From the Departments of Radiology ( M. S., D. A. v. R., H.L.J.T., M. G. M. H.), Neurology (D.W.J.D.), and Epide miology & Biostatistics ( M. G. M. H., D. A. v. R.), Erasmus MC-University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, Rotterdam, the Netherlands; Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands (P.J.N.); Departments of Radiology ( H. M. D., D. R. K.) and Neurology ( P. E. V.), University Medical Center Nijmegen St. Radboud, Nijmegen, the Netherlands; Departments of Radiology ( P. A. M. H.) and Neurology ( A. T.), University Hospital Maastricht, Maastricht, the Netherlands; and Department of Health Policy & Management, Harvard School of Public Health, Boston, Mass ( M. G. M. H.). Received September 18, 2008; revision requested December 12; revision received May 5, 2009; accepted May 27; final version accepted August 10. Supported by grants from ZonMW (ZonMW DO: 945-06-309) and by College voorZorgverzekeringen (CVZ: VAZ 01-104) and Radiologisch onderzoek Nederland (RADION). Address correspondence to M. G. M. H. (e-mail: m.hunink@erasmusmc.nl).	Ades AE, 2004, MED DECIS MAKING, V24, P207, DOI 10.1177/0272989X04263162; af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; af Geijerstam JL, 2004, EMERG MED J, V21, P54, DOI 10.1136/emj.2003.003178; AFGEIJERSTAM JL, 2003, ACTA NEUROCHIR WIEN, V145, P850; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; *CENTR BUR STAT, STATLINE DAT; Claxton K, 2002, LANCET, V360, P711, DOI 10.1016/S0140-6736(02)09832-X; *COLL ZORGV, 2006, GUID PHARM EC RES; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; DEANDRADE AF, 2006, SURG NERUOL S1, V65; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Gold M., 1996, COST EFFECTIVENESS H; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; JENNETT B, 1975, LANCET, V1, P480; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Lamers LM, 2005, NED TIJDSCHR GENEES, V149, P1574; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MENDELOW AD, 1979, BRIT MED J, V2, P134, DOI 10.1136/bmj.2.6182.134-a; Miller J D, 1988, Brain Inj, V2, P83, DOI 10.3109/02699058809150934; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; *OAND, FXHISTORY HIST CURR; Ouwendijk R, 2005, RADIOLOGY, V236, P1094, DOI 10.1148/radiol.2363041140; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2007, J TRAUMA, V62, P1314, DOI 10.1097/TA.0b013e3180342959; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253	50	67	70	0	6	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	FEB	2010	254	2					532	540		10.1148/radiol.2541081672			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	546QF	WOS:000273824600025	20093524	Bronze			2022-02-06	
J	Geyer, C; Ulrich, A; Grafe, G; Stach, B; Till, H				Geyer, Chrisrian; Ulrich, Anett; Graefe, Gerd; Stach, Barbara; Till, Holger			Diagnostic value of S100B and neuron-specific enolase in mild pediatric traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						S100B; neuron-specific enolase; biomarkers; traumatic brain injury	S-100 PROTEIN MEASUREMENTS; BIOCHEMICAL SERUM MARKERS; SEVERE HEAD-INJURY; CHILDREN; DAMAGE; BLOOD; PREDICTOR; BIOMARKERS; APOPTOSIS; PATHOLOGY	Object. During recent years, several biomarkers have been introduced for use in the diagnosis of traumatic brain injury (TBI). The primary objective of this investigation was to determine if S100B (or S100 calcium-binding protein B) and neuron-specific enolase (NSE) serum concentrations can effectively be used to discriminate between symptomatic and asymptomatic children with minor head trauma. Methods. The authors conducted a prospective clinical study that involved patients age 6 months to 15 years who had sustained minor head trauma. Children with concomitant extracranial injuries were excluded. Blood samples were obtained within 6 hours of injury to measure S100B and NSE levels in serum. The authors defined 2 diagnostic groups: a mild TBI group (patients with Glasgow Coma Scale [GCS] scores of 13-15) in whom there were clinical signs of concussion (short loss of consciousness, amnesia, nausea, vomiting, somnolence, headache, dizziness, or impaired vision) and a head contusion group (patients with a GCS score of 15) in whom symptoms were absent. Both S100B and NSE concentrations were compared between the 2 groups. Secondary end points were defined its follows: correlation of S100B/NSE and a) the presence of scalp lacerations, b) GCS score, c) age, and d) correlation between S100B and NSE. Results. One hundred forty-eight patients were enrolled (53 in the contusion group, 95 in the mild TBI group). After adjusting for differences in age and time of injury to blood sample withdrawal, there was no significant difference in S100B or NSE between patients in the 2 groups. Scalp lacerations and GCS score had no affect on posttraumatic S100B or NSE concentrations. The correlation between S100B and NSE was significant. Both markers showed a significant negative correlation with age. Conclusions. The authors demonstrated that S100B and NSE do not discriminate between symptomatic and asymptomatic children with minor head injury. There seem to be limitations in marker sensitivity when investigating pediatric patients with mild TBI. (DOI: 10.317112009.5.PEDS08481)	[Geyer, Chrisrian; Ulrich, Anett; Graefe, Gerd; Till, Holger] Univ Leipzig, Dept Pediat Surg, D-04103 Leipzig, Germany; [Stach, Barbara] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, D-04103 Leipzig, Germany		Geyer, C (corresponding author), Univ Leipzig, Dept Pediat Surg, Liebigstr 20A, D-04103 Leipzig, Germany.	christian.geyer@medizin.uni-leipzig.de					Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BERTHOLD F, 1991, In Vivo (Attiki), V5, P245; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Cotena S, 2006, J NEUROSURG, V104, P435, DOI 10.3171/ped.2006.104.6.435; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; ELDIK LJV, 1991, BRAIN RES, V542, P280; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Fulle S, 2000, EXP PHYSIOL, V85, P243; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; MARIGGIO MA, 1994, NEUROSCIENCE, V60, P29, DOI 10.1016/0306-4522(94)90201-1; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; Meyer S, 2006, KLIN PADIATR, V218, P49, DOI 10.1055/s-2005-836607; Park ES, 2004, BRAIN DEV-JPN, V26, P190, DOI 10.1016/S0387-7604(03)00126-8; Portela LVC, 2002, CLIN CHEM, V48, P950; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Smit LHM, 2005, INT J BIOL MARKER, V20, P34, DOI 10.1177/172460080502000106; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; van Passel R, 2001, Eur J Paediatr Neurol, V5, P15, DOI 10.1053/ejpn.2001.0399; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	48	67	75	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROS-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2009	4	4					339	344		10.3171/2009.5.PEDS08481			6	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	503FS	WOS:000270519400010	19795965				2022-02-06	
J	Tan, G; Fink, B; Dao, TK; Hebert, R; Farmer, LS; Sanders, A; Pastorek, N; Gevirtz, R				Tan, Gabriel; Fink, Brandi; Dao, Tam K.; Hebert, Russell; Farmer, Lorie S.; Sanders, April; Pastorek, Nicholas; Gevirtz, Richard			Associations among Pain, PTSD, mTBI, and Heart Rate Variability in Veterans of Operation Enduring and Iraqi Freedom: A Pilot Study	PAIN MEDICINE			English	Article						Pain; PTSD; mTBI; Heart Rate Variability; Polytrauma	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; PSYCHOPHYSIOLOGICAL ASSESSMENT; CLINICAL-IMPLICATIONS; HEALTH; DYSAUTONOMIA; BIOFEEDBACK; PREDICTOR; DEATH	Objective. The objective of the study was to determine if there is dysregulated autonomic nervous system activity as manifested by depressed heart rate variability (HRV) among veterans of Operations Enduring and Iraqi Freedom (OEF/OIF). Participants and Setting. The study used a convenience sample of OEF/OIF veterans (n = 28) seen at a Level II Polytrauma Network Site at the Michael E. DeBakey VA Medical Center. Participants were similar to other OEF/OIF veterans who received care at this site. Design. Cross sectional study. Measures. Time domain analysis (standard deviation of beat-to-beat intervals [SDNN]) of HRV, diagnoses of mild traumatic brain injury and post-traumatic stress disorder (PTSD), and pain ratings from medical records. Results. As a group, the sample evidenced markedly depressed HRV (as reflected by SDNN) as compared with available age and gender corrected normative data. Pain (71%), PTSD (57%), and mild traumatic brain injury (mTBI) (64%) were prevalent. Thirty-six percent had all three measures (P3). Pain and P3 were significantly and negatively associated with SDNN (r = -0.460, P = 0.014; r = -0.373, P = 0.05, respectively). Conclusions. These preliminary findings support the high prevalence of depressed HRV and P3 among veterans seen in a level II Polytrauma Center. The findings also suggest a possible synergistic effect of pain, PTSD, and mTBI on depressed HRV. The nature and implications of these relationships require additional research to elucidate.	[Tan, Gabriel; Fink, Brandi; Dao, Tam K.; Hebert, Russell; Farmer, Lorie S.; Sanders, April; Pastorek, Nicholas] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Tan, Gabriel; Dao, Tam K.; Farmer, Lorie S.; Pastorek, Nicholas] Baylor Coll Med, Houston, TX 77030 USA; [Gevirtz, Richard] Alliant Int Univ, CSPP, San Diego, CA USA		Tan, G (corresponding author), Michael E DeBakey VA Med Ctr, 2002 Holcombe 145, Houston, TX 77030 USA.	tan.gabriel@va.gov		Pastorek, Nicholas/0000-0002-9290-380X			Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 2008, SEMIN NEUROL, V28, P716, DOI 10.1055/s-0028-1105971; BENGE JF, 2009, 37 ANN M INT NEUR SO; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; BLECHERT J, 1998, BIOL PSYCHIAT, V44, P1054; Bornstein MH, 2000, CHILD DEV, V71, P273, DOI 10.1111/1467-8624.00143; Carney RM, 2000, PSYCHOSOM MED, V62, P639, DOI 10.1097/00006842-200009000-00007; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CLARK ME, 2009, NAT VA PAIN MAN C E; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Cohen H, 1997, BIOL PSYCHIAT, V41, P627, DOI 10.1016/S0006-3223(96)00525-2; GALER BS, 1995, J PAIN SYMPTOM MANAG, V10, P385, DOI 10.1016/0885-3924(95)00061-3; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; GIRONDA RJ, REHAB PSYCH IN PRESS; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Hassett AL, 2007, APPL PSYCHOPHYS BIOF, V32, P1, DOI 10.1007/s10484-006-9028-0; Helmer DA, 2007, J OCCUP ENVIRON MED, V49, P475, DOI 10.1097/JOM.0b013e318042d682; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hopper JW, 2006, J PSYCHOSOM RES, V60, P83, DOI 10.1016/j.jpsychores.2005.06.002; Jensen MP, 2001, HDB PAIN ASSESSMENT, P15; Karavidas M., 2008, BIOFEEDBACK, V36; Lehrer PM, 2004, CHEST, V126, P352, DOI 10.1378/chest.126.2.352; McCraty R, 2001, BIOL PSYCHOL, V56, P131, DOI 10.1016/S0301-0511(01)00074-6; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Norman SB, 2008, PSYCHOL MED, V38, P533, DOI 10.1017/S0033291707001389; Orr SP, 2000, J AFFECT DISORDERS, V61, P225, DOI 10.1016/S0165-0327(00)00340-2; OTIS JD, 2008, COMPREHENSIVE HDB CL, P349; PITMAN RK, 1987, ARCH GEN PSYCHIAT, V44, P970; Porges SW, 1996, DEV PSYCHOBIOL, V29, P697, DOI 10.1002/(SICI)1098-2302(199612)29:8<697::AID-DEV5>3.0.CO;2-O; Rapenne T, 2000, ANESTH ANALG, V91, P329, DOI 10.1097/00000539-200008000-00018; RECHLIN T, 1994, J AFFECT DISORDERS, V32, P271, DOI 10.1016/0165-0327(94)90091-4; RESICK PA, 1992, J CONSULT CLIN PSYCH, V60, P748, DOI 10.1037/0022-006X.60.5.748; Sahar T, 2001, BIOL PSYCHIAT, V49, P637, DOI 10.1016/S0006-3223(00)01045-3; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Umetani K, 1998, J AM COLL CARDIOL, V31, P593, DOI 10.1016/S0735-1097(97)00554-8; Van der Kolk BA, 2006, ANN NY ACAD SCI, V1071, P277, DOI 10.1196/annals.1364.022; Veterans Health Administration, 2005, VHA HDB; Weathers F., 1994, PTSD RES Q, V5, P2, DOI [DOI 10.1037/E572192010-003, DOI 10.1037/PAS0000486]; Wijnen VJM, 2006, CLIN NEUROPHYSIOL, V117, P1794, DOI 10.1016/j.clinph.2006.03.006; Winchell RJ, 1997, J TRAUMA, V43, P927, DOI 10.1097/00005373-199712000-00010; [No title captured], DOI DOI 10.1177/15248380020032001	53	67	68	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	OCT	2009	10	7					1237	1245		10.1111/j.1526-4637.2009.00712.x			9	Anesthesiology; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anesthesiology; General & Internal Medicine	504BT	WOS:000270589100009	19818034	Bronze			2022-02-06	
J	Gilmer, LK; Roberts, KN; Joy, K; Sullivan, PG; Scheff, SW				Gilmer, Lesley K.; Roberts, Kelly N.; Joy, Kelly; Sullivan, Patrick G.; Scheff, Stephen W.			Early Mitochondrial Dysfunction after Cortical Contusion Injury	JOURNAL OF NEUROTRAUMA			English	Article						Clark-type electrode; cortical contusion injury; mitochondrial bioenergetics; total mitochondria; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION; OXIDATIVE DAMAGE; FOREBRAIN MITOCHONDRIA; CELL-DEATH; RATS; PROTECTION; MEMBRANE; HIPPOCAMPUS	Following traumatic brain injury, mitochondria sustain structural and functional impairment, which contributes to secondary damage that can continue for days after the initial injury. The present study investigated mitochondrial bioenergetic changes in the rat neocortex at 1 and 3 h after mild, moderate, and severe injuries. Brains from young adult Sprague-Dawley rats were harvested from the injured and contralateral cortex to assess possible changes in mitochondrial respiration abilities following a unilateral cortical contusion injury. Differential centrifugation was used to isolate synaptic and extrasynaptic mitochondria from cortical tissue. Bioenergetics was assessed using a Clark-type electrode and results were graphed as a function of injury severity and time post-injury. Respiration was significantly affected by all injury severity levels compared to uninjured tissue. Complex 1- and complex 2-driven respirations were affected proportionally to the severity of the injury, indicating that damage to mitochondria may occur on a gradient. Total oxygen utilization, respiratory control ratio, ATP production, and maximal respiration capabilities were all significantly decreased in the injured cortex at both 1 and 3 h post-trauma. Although mitochondria displayed bioenergetic deficits at 1 h following injury, damage was not exacerbated by 3 h. This study stresses the importance of early therapeutic intervention and suggests a window of approximately 1-3 h before greater dysfunction occurs.	[Gilmer, Lesley K.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Sullivan, Patrick G.; Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Sullivan, Patrick G.; Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown Bldg, Lexington, KY 40536 USA.	sscheff@email.uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981, T32 DA022738-01]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	We thank Paula Thomason for carefully reading the manuscript. This work was supported by NIH grant AG21981 and training grant T32 DA022738-01.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Baldwin SA, 1996, GLIA, V16, P266; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Finsterer J, 2008, J NEUROL SCI, V272, P20, DOI 10.1016/j.jns.2008.05.011; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hino K, 2005, BRAIN RES, V1053, P77, DOI 10.1016/j.brainres.2005.06.062; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Khodorov B, 1996, FEBS LETT, V393, P135, DOI 10.1016/0014-5793(96)00873-3; Kovesdi E, 2007, PROG BRAIN RES, V161, P81, DOI 10.1016/S0079-6123(06)61006-6; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Long JG, 2006, LIFE SCI, V79, P1466, DOI 10.1016/j.lfs.2006.04.024; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SCIAMANNA MA, 1993, ARCH BIOCHEM BIOPHYS, V305, P215, DOI 10.1006/abbi.1993.1414; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sugden Mary C, 2003, Biochem J, V374, pe1, DOI 10.1042/BJ20031105; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Vergun O, 2003, BIOPHYS J, V85, P3358, DOI 10.1016/S0006-3495(03)74755-9; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vyssokikh MY, 2003, ACTA BIOCHIM POL, V50, P389; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001	43	67	70	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1271	1280		10.1089/neu.2008.0857			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900010	19637966	Green Published			2022-02-06	
J	Catena, RD; van Donkelaar, P; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan			Different gait tasks distinguish immediate vs. long-term effects of concussion on balance control	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; CENTER-OF-MASS; STABILITY FOLLOWING CONCUSSION; HEAD-INJURY; HIGH-SCHOOL; RECOVERY; ATTENTION; DEFICITS; INSTABILITY; COLLEGIATE	The purpose of this study was to longitudinally compare the sensitivity of previously documented paradigms for measuring balance control during gait following a concussion. We hypothesized that gait with a concurrent cognitive task would be most sensitive to the effects of concussion on dynamic balance control. Individuals with concussion (n = 30) and matched controls ( n = 30) performed a single task of level walking, attention divided walking, and an obstacle-crossing task at two heights. Testing occurred four times post-injury. Balance control during gait was assessed with whole-body center of mass and center of pressure motion. The single-task level walking task did not result in any significant differences in balance control between individuals with concussion and control subjects. Within 48 hours post-injury, individuals with concussion walked slower and allowed less motion of their center of mass in the sagittal plane when attention was divided during walking, but there were no group differences by day 6 for this task. Group differences in balance control during obstacle crossing was unremarkable during the first two testing sessions, but by day 14 individuals with concussion displayed less mediolateral motion of their center of mass. Attention divided gait is able to better distinguish gait adaptations immediately following a concussion, but obstacle crossing can be used further along in the recovery process to detect new gait adaptations.	[Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	rcatena@uoregon.edu; paulvd@uoregon.edu; chou@uoregon.edu	Catena, Robert/AAT-1510-2021	Catena, Robert/0000-0001-9128-1343	Center for Disease Control and Prevention [R49/CCR021735, CCR023203]	This study was supported by the Center for Disease Control and Prevention (R49/CCR021735 and CCR023203). The authors would like to thank Tonya Parker for help with data collection.	BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2003, GAIT POSTURE, V18, P125, DOI 10.1016/S0966-6362(02)00067-X; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; IVERSON GL, 2002, NAT AC NEUR MIAM FL; Kelly JP, 1997, NEUROLOGY, V48, P581; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; Krauss JK, 1997, MOVEMENT DISORD, V12, P428, DOI 10.1002/mds.870120326; Lee HJ, 2006, ARCH PHYS MED REHAB, V87, P569, DOI 10.1016/j.apmr.2005.11.033; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Pai YC, 1997, J BIOMECH, V30, P347, DOI 10.1016/S0021-9290(96)00165-0; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Vallis LA, 2004, EXP BRAIN RES, V157, P94, DOI 10.1007/s00221-003-1824-7; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; Westfall P. H., 1999, MULTIPLE COMP MULTIP; Winter, 1995, ABC BALANCE STANDING; Winter D.A., 1990, BIOMECHANICS MOTOR C, VVol. 1; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	32	67	67	0	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	JUL 7	2009	6								25	10.1186/1743-0003-6-25			7	Engineering, Biomedical; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology; Rehabilitation	478FZ	WOS:000268574500001	19580680	gold, Green Published			2022-02-06	
J	Echegoyen, J; Armstrong, C; Morgan, RJ; Soltesz, I				Echegoyen, Julio; Armstrong, Caren; Morgan, Robert J.; Soltesz, Ivan			Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model	EPILEPSY RESEARCH			English	Article						Traumatic brain injury; Epilepsy; Rimonabant; CB1	TEMPORAL-LOBE EPILEPSY; BRAIN-INJURY; RISK-FACTORS; EPILEPTOGENESIS; HIPPOCAMPUS; RIMONABANT; OVERWEIGHT; SEIZURES; DISEASE	Effective prophylaxis for post-traumatic epilepsy currently does not exist, and clinical trials using anticonvulsant drugs have yielded no long-term antiepileptogenic effects. We report that a single, rapid post-traumatic application of the proconvulsant cannabinoid type-1 (CB1) receptor antagonist SR141716A (Rimonabant-Acomplia (R)) abolishes the long-term increase in seizure susceptibility caused by head injury in rats. These results indicate that, paradoxically, a seizure-enhancing drug may disrupt the epileptogenic process if applied within a short therapeutic time window. (C) 2009 Elsevier B.V. All rights reserved.	[Echegoyen, Julio; Armstrong, Caren; Morgan, Robert J.; Soltesz, Ivan] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA		Armstrong, C (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	cmarmstr@uci.edu	Armstrong, Caren/AAM-2033-2021	Armstrong, Caren/0000-0001-8010-0850	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS35915]; UCI Medical Scientist Training Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035915, R29NS035915, R37NS035915] Funding Source: NIH RePORTER	We thank R. Zhu and E. Kim for technical assistance. Supported by the US National Institutes of Health grant NS35915 and the UCI Medical Scientist Training Program.	Chen K, 2007, J NEUROSCI, V27, P46, DOI 10.1523/JNEUROSCI.3966-06.2007; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Howard AL, 2007, J NEUROPHYSIOL, V97, P2394, DOI 10.1152/jn.00509.2006; Katona I, 2008, NAT MED, V14, P923, DOI 10.1038/nm.f.1869; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lutz B, 2008, NAT MED, V14, P721, DOI 10.1038/nm0708-721; Monory K, 2006, NEURON, V51, P455, DOI 10.1016/j.neuron.2006.07.006; Pi-Sunyer F, 2006, JAMA-J AM MED ASSOC, V295, P761, DOI 10.1001/jama.295.7.761; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Toth Z, 1997, J NEUROSCI, V17, P8106; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920	19	67	68	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	JUL	2009	85	1					123	127		10.1016/j.eplepsyres.2009.02.019			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	470VV	WOS:000268011100014	19369036	Green Accepted			2022-02-06	
J	Hoskison, MM; Moore, AN; Hu, B; Orsi, S; Koboric, N; Dash, PK				Hoskison, M. M.; Moore, A. N.; Hu, B.; Orsi, S.; Koboric, N.; Dash, P. K.			PERSISTENT WORKING MEMORY DYSFUNCTION FOLLOWING TRAUMATIC BRAIN INJURY: EVIDENCE FOR A TIME-DEPENDENT MECHANISM	NEUROSCIENCE			English	Article						Golgi staining; neuronal morphology; prelimbic cortex; delayed alternation T-maze; delay match-to-place; GAD	MEDIAL PREFRONTAL CORTEX; ALTERS DENDRITIC MORPHOLOGY; CONTROLLED CORTICAL IMPACT; PYRAMIDAL NEURONS; DEFICITS; MODEL; RATS; HISTOPATHOLOGY; EXPRESSION; REVERSAL	The prefrontal cortex is highly vulnerable to traumatic brain injury (TBI) resulting in the dysfunction of many high-level cognitive and executive functions such as planning, information processing speed, language, memory, attention, and perception. All of these processes require some degree of working memory. Interestingly, in many cases, post-injury working memory deficits can arise in the absence of overt damage to the prefrontal cortex. Recently, excess GABA-mediated inhibition of prefrontal neuronal activity has been identified as a contributor to working memory dysfunction within the first month following cortical impact injury of rats. However, it has not been examined if these working memory deficits persist, and if so, whether they remain amenable to treatment by GABA antagonism. Our findings show that working memory dysfunction, assessed using both the delay match-to-place and delayed alternation T-maze tasks, following lateral cortical impact injury persists for at least 16 weeks post-injury. These deficits were found to be no longer the direct result of excess GABA-mediated inhibition of medial prefrontal cortex neuronal activity. Golgi staining of prelimbic pyramidal neurons revealed that TBI causes a significant shortening of layers V/VI basal dendrite arbors by 4 months post-injury, as well as an increase in the density of both basal and apical spines in these neurons. These changes were not observed in animals 14 days post-injury, a time point at which administration of GABA receptor antagonists improves working memory function. Taken together, the present findings, along with previously published reports, suggest that temporal considerations must be taken into account when designing mechanism-based therapies to improve working memory function in TBI patients. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[Moore, A. N.; Orsi, S.; Dash, P. K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hoskison, M. M.] Univ Texas Houston, Sch Med, Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77225 USA; [Hu, B.; Koboric, N.; Dash, P. K.] Univ Texas Houston, Sch Med, Dept Neurosurg, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049160] Funding Source: NIH RePORTER	The authors would like to thank Tim Graham and Melanie Moody for technical assistance. The work performed in the authors' laboratories was made possible by grants from NIH.	Amat J, 2005, NAT NEUROSCI, V8, P365, DOI 10.1038/nn1399; Arnsten AFT, 1997, J PSYCHOPHARMACOL, V11, P151, DOI 10.1177/026988119701100208; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Blum S, 2006, NEUROREPORT, V17, P341, DOI 10.1097/01.wnr.0000201509.53750.bc; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brown SM, 2005, CEREB CORTEX, V15, P1714, DOI 10.1093/cercor/bhi048; Cerqueira JJ, 2007, J NEUROSCI, V27, P2781, DOI 10.1523/JNEUROSCI.4372-06.2007; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cook SC, 2004, J NEUROBIOL, V60, P236, DOI 10.1002/neu.20025; D 'Esposito M, 2000, SEMIN NEUROL, V20, P487, DOI 10.1055/s-2000-13182; Dash PK, 2007, LEARN MEMORY, V14, P554, DOI 10.1101/lm.558707; DESCARRIES L, 1987, NEUROSCIENCE, V21, P807, DOI 10.1016/0306-4522(87)90038-8; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EMSON PC, 1978, BRAIN RES, V142, P249, DOI 10.1016/0006-8993(78)90634-0; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; Finley JW, 2005, J NUTR, V135, P1236, DOI 10.1093/jn/135.5.1236; Flores G, 2005, NEUROSCIENCE, V133, P463, DOI 10.1016/j.neuroscience.2005.02.021; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Glantz LA, 2000, ARCH GEN PSYCHIAT, V57, P65, DOI 10.1001/archpsyc.57.1.65; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Jo YS, 2007, J NEUROSCI, V27, P13567, DOI 10.1523/JNEUROSCI.3589-07.2007; Kalus P, 2000, NEUROREPORT, V11, P3621, DOI 10.1097/00001756-200011090-00044; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; KRAUS J, 2005, NEUROPSYCHIATRY TRAU; Locchi F, 2007, NEUROSCI LETT, V422, P213, DOI 10.1016/j.neulet.2007.06.023; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; Papadeas ST, 2008, J COMP NEUROL, V511, P271, DOI 10.1002/cne.21835; Rajkowska G, 2000, PROG BRAIN RES, V126, P397; Ramos BP, 2003, NEURON, V40, P835, DOI 10.1016/S0896-6273(03)00694-9; Runyan JD, 2005, LEARN MEMORY, V12, P103, DOI 10.1101/lm.89405; SHOLL DA, 1956, PROG NEUROBIOL, V2, P324; Siddall ORM, 2005, ANN PHARMACOTHER, V39, P1309, DOI 10.1345/aph.1E637; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Verbois SL, 2003, NEUROSCIENCE, V119, P1199, DOI 10.1016/S0306-4522(03)00206-9; Wang HD, 2008, NEUROPSYCHOPHARMACOL, V33, P1276, DOI 10.1038/sj.npp.1301521	42	67	74	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	MAR 17	2009	159	2					483	491		10.1016/j.neuroscience.2008.12.050			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	418QC	WOS:000264162300005	19167462	Green Accepted			2022-02-06	
J	Neumann, M; Wang, YG; Kim, S; Hong, SM; Jeng, L; Bilgen, M; Liu, JL				Neumann, Melanie; Wang, Yonggang; Kim, Sharon; Hong, Shwuhey M.; Jeng, Lareine; Bilgen, Mehmet; Liu, Jialing			Assessing gait impairment following experimental traumatic brain injury in mice	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Controlled cortical impact; Catwalk; Motor function; Corticospinal tract; Neuroplasticity	ACUTE PREDICTORS; LOCOMOTION; ADULT; SPEED; RATS; DEFICITS; RELIABILITY; MOVEMENT; STRAIN; RETURN	Although gait disturbance is frequently documented among patients with traumatic brain injury (TBI), gait data from animal models of TBI are lacking. To determine the effect of TBI on gait function in adult mice, we assessed gait changes following unilateral controlled cortical impact (CCI) using a computer-assisted automated gait analysis system. Three days after CCI, intensity, area or width of paw contact were significantly decreased in forepaw(s) while the relative paw placement between the fore and hindpaws altered, suggesting that TBI affected sensorimotor status and reduced interlimb coordination. Similar to TBI patients, CCI decreased gait velocity and stride length, and prolonged stance and swing phase in mice. Following CCI, step pattern was also changed with increasing use in the ipsilateral-diagonal limb sequence. Our results indicate that gait analysis provides great insight into both spatial and temporal aspects of limb function changes during overground locomotion in quadruped species with head injury that are valuable for the purpose of treatment and rehabilitation. Our study also provides additional functional validation for the established mouse CCI model that is relevant to human head injury. Published by Elsevier B.V.	[Liu, Jialing] Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Dept Neurol Surg, San Francisco, CA 94121 USA; [Neumann, Melanie; Wang, Yonggang; Kim, Sharon; Hong, Shwuhey M.; Jeng, Lareine; Liu, Jialing] San Francisco & SFVAMC, San Francisco, CA 94121 USA; [Neumann, Melanie] Univ Klinikum Hamburg Eppendorf, D-20246 Hamburg, Germany; [Wang, Yonggang] Capital Univ Med Sci, Beijing Tiantan Hosp, Dept Neurol Surg, Beijing 100050, Peoples R China; [Jeng, Lareine] Watchung Hills Reg High Sch, Warren, NJ 07059 USA; [Bilgen, Mehmet] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA		Liu, JL (corresponding author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Dept Neurol Surg, 112C,4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Liu, Jialing/A-8627-2012	Liu, Jialing/0000-0003-4420-4382	VAUS Department of Veterans Affairs; Department of DefenseUnited States Department of Defense; Northern California Institute for Research and Education; Department of Defense collaborative in Neuroscience Center of ExcellenceUnited States Department of Defense; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS051576, R01NS071050, R01NS040469] Funding Source: NIH RePORTER	The authors are grateful for the technical assistance and overall expertise on experimental TBI model provided by Drs. Linda J. Noble-Haeusslein and Kyoko Tsuru. This work was supported by a VA Merit award (JL), Department of Defense (JL) and infrastructural fund by Northern California Institute for Research and Education and the Department of Defense collaborative in Neuroscience Center of Excellence.	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Chen G, 2005, GAIT POSTURE, V22, P51, DOI 10.1016/j.gaitpost.2004.06.009; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELLON ES, 1991, PLAST RECONSTR SURG, V88, P686, DOI 10.1097/00006534-199110000-00020; Deumens R, 2007, J NEUROSCI METH, V164, P120, DOI 10.1016/j.jneumeth.2007.04.009; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gabriel AF, 2007, J NEUROSCI METH, V163, P9, DOI 10.1016/j.jneumeth.2007.02.003; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Gillis GB, 2001, J EXP BIOL, V204, P2717; Gorska T, 1998, ACTA NEUROBIOL EXP, V58, P227; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Johnk K, 1999, RESTOR NEUROL NEUROS, V14, P143; Katz-Leurer M, 2008, BRAIN INJURY, V22, P153, DOI 10.1080/02699050801895399; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Koopmans GC, 2007, PHYSIOL BEHAV, V92, P993, DOI 10.1016/j.physbeh.2007.07.018; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Ng SS, 2005, ARCH PHYS MED REHAB, V86, P1641, DOI 10.1016/j.apmr.2005.01.011; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Starkey ML, 2005, EXP NEUROL, V195, P524, DOI 10.1016/j.expneurol.2005.06.017; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Van Loo MA, 2004, BRAIN INJURY, V18, P1041, DOI 10.1080/02699050410001672314; Vlamings R, 2007, NEUROSCIENCE, V148, P815, DOI 10.1016/j.neuroscience.2007.06.043; Vogelaar CF, 2004, BRAIN RES, V1027, P67, DOI 10.1016/j.brainres.2004.08.036; Vrinten DH, 2003, PAIN, V102, P203, DOI 10.1016/S0304-3959(02)00382-2; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720; Zverev Y, 2002, East Afr Med J, V79, P420	35	67	70	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JAN 15	2009	176	1					34	44		10.1016/j.jneumeth.2008.08.026			11	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	375MK	WOS:000261117800004	18805438	Green Accepted			2022-02-06	
J	Yard, EE; Comstock, RD				Yard, Ellen E.; Comstock, R. Dawn			Compliance with return to play guidelines following concussion in US high school athletes, 2005-2008	BRAIN INJURY			English	Article						concussion; traumatic brain injury; sports; recovery; time loss	SPORT-RELATED CONCUSSION; RECURRENT CONCUSSION; FOOTBALL PLAYERS; COLLEGIATE; ASSOCIATION; MANAGEMENT; RECOVERY; STATEMENT	Primary objective: To determine whether US concussed high school athletes complied with recommended return-to-play guidelines during the 2005-2008 school years. Research design: Prospective cohort study in 100 nationally-representative US high schools. Methods and procedures: Certified athletic trainers submitted injury reports for concussed athletes in five boys' (football, soccer, basketball, wrestling, baseball) and four girls' (soccer, basketball, volleyball, softball) sports via High School RIO (Reporting Information Online). Concussions were retrospectively graded and it was determined whether athletes followed American Academy of Neurology (AAN) or Prague return-to-play guidelines. Main outcomes and results: There were 1308 concussions reported during 5 627 921 athlete-exposures (23.2 concussions per 100 000 athlete-exposures), reflecting an estimated 395 274 concussions sustained nationally. At least 40.5% and 15.0% of concussed athletes returned to play prematurely under AAN and Prague return-to-play guidelines, respectively. In football, 15.8% of athletes sustaining a concussion that resulted in loss-of-consciousness returned to play in 1 day. Males (12.6%) were more likely than females (5.9%) to return 1-2 days after sustaining an initial grade II concussion. Conclusions: Too many adolescent athletes are failing to comply with recommended return-to-play guidelines. Sports medicine professionals, parents, coaches and sports administrators must work together to ensure athletes follow recommended guidelines.	[Yard, Ellen E.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Comstock, R. Dawn] Ohio State Univ, Dept Pediat, Coll Med, Columbus, OH 43210 USA; [Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA		Comstock, RD (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	dawn.comstock@nationwidechildrens.org			Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01]; DonJoy Orthotics; National Federation of State High School Associations; EyeBlack; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674] Funding Source: NIH RePORTER	The content of this report was funded in part by the Centers for Disease Control and Prevention (CDC) grant #R49/CE000674-01. The content of this report is solely the responsibility of the authors and does not necessarily reflect the official view of the CDC. We would also like to acknowledge the generous research funding contributions of DonJoy Orthotics, the National Federation of State High School Associations, and EyeBlack.	[Anonymous], CAS HIGH SCH ACT; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; *NAT FED STAT HIGH, 2007, 2006 07 HIGH SCH ATH; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; United States Census Bureau, CENS REG US; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	32	67	69	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					888	898	PII 915243307	10.1080/02699050903283171			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300005	20100125				2022-02-06	
J	Gong, YS; Liu, LG; Xie, BJ; Liao, YC; Yang, EL; Sun, ZD				Gong, Yushi; Liu, Liegang; Xie, Bijun; Liao, Yongcheng; Yang, Erling; Sun, Zhida			Ameliorative effects of lotus seedpod proanthocyanidins on cognitive deficits and oxidative damage in senescence-accelerated mice	BEHAVIOURAL BRAIN RESEARCH			English	Article						LSPC (lotus seedpod proanthocyanidins); aging; oxidative stress; brain; serum; senescence-accelerated mouse (SAM); antioxidants	TRAUMATIC BRAIN-INJURY; ALPHA-LIPOIC ACID; NITRIC-OXIDE; LIPID-PEROXIDATION; FREE-RADICALS; MOUSE SAM; ALZHEIMERS-DISEASE; MURINE MODEL; MEMORY; STRESS	We investigated the effects of lotus seedpod proanthocyanidins (LSPC) administration by oral gavage for 3 months on body weight, learning and memory deficits using Y-maze test, oxidative stress and antioxidative enzyme activity in brain and serum of the senescence-accelerated mice (SAMP8) and the senescence-resistant mice (SAMR1). Mice of each group were weighed weekly. Brain was obtained from SAMP8 and SAMR1 (the control mouse for SAMP8) at 6 months of age and serum was available from SAMP8 and SAMR1 at 3, 4, 5 and 6 months of age. The results of body weight showed that 90 mg/kg LSPC administration significantly increased body weight at 5.5 and 6 months of age in SAMP8 when compared with control SAMP8 of the same age. Y-maze test indicated that learning and memory abilities of mice were deteriorated significantly at 6 months of age in SAMP8 compared with age-matched SAMR1, but were remarkably improved after LSPC (60, 90,120 mg/kg body weight) administration beginning at 3 months of ages. Malondialdehyde (MDA), nitric oxide (NO) and nitric oxide synthase (NOS) exhibited significant increases mostly at 5 and 6 months of age in SAMPS. Glutathione (GSH). glutathione peroxidase (GPx) and Superoxide dismutase (SOD) activities decreased significantly mostly at 5 and 6 months of age in SAMP8. LSPC (60, 90, 120 mg/kg body weight) administration beginning at 3 months of ages decreased MDA, NO content and lowered NOS activity in the brain and serum of SAMP8. Furthermore, LSPC significantly increased GSH level and augmented GPx, SOD activity in the brain and serum of SAMP8. These results suggest that an age-related increase in brain tissue vulnerability to oxidation and deterioration in learning and memory abilities in SAM that can be modified by LSPC, most likely through the ability of LSPC to scavenge oxygen free radicals and to stimulate antioxidant enzyme activity. (C) 2008 Elsevier B.V. All rights reserved.	[Gong, Yushi; Xie, Bijun; Liao, Yongcheng; Yang, Erling; Sun, Zhida] Huazhong Agr Univ, Dept Food Sci & Technol, Nat Prod Lab, Wuhan 430070, Peoples R China; [Liu, Liegang] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Food Hyg & Nutr, Wuhan 430030, Peoples R China		Xie, BJ (corresponding author), Huazhong Agr Univ, Dept Food Sci & Technol, Nat Prod Lab, Wuhan 430070, Peoples R China.	tortoise39@163.com; bijunxie@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30270938, u0731005]; National Key Technology RD programNational Key Technology R&D Program [2006BAD27B08]; Ministry of Science and Technology of ChinaMinistry of Science and Technology, China; Ministry of Education of ChinaMinistry of Education, China [20040504013]	This work was supported by grants from the National Natural Science Foundation of China (NSFC, No. 30270938), National Natural Science Foundation of China (NSFC, No. u0731005), and the National Key Technology R&D program (No. 2006BAD27B08) of the Ministry of Science and Technology of China and the Doctoral Fund (20040504013) of the Ministry of Education of China.	Bagchi D, 2000, TOXICOLOGY, V148, P187, DOI 10.1016/S0300-483X(00)00210-9; Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005; Biesalski HK, 2002, CURR OPIN CLIN NUTR, V5, P5, DOI 10.1097/00075197-200201000-00002; CINI M, 1994, NEUROCHEM RES, V19, P283, DOI 10.1007/BF00971576; Colas D, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-81; Devasagayam T P A, 2004, J Assoc Physicians India, V52, P794; Drew B, 2002, ANN NY ACAD SCI, V959, P66, DOI 10.1111/j.1749-6632.2002.tb02084.x; Duan YuQing, 2003, Acta Nutrimenta Sinica, V25, P306; Duan YuQing, 2005, Acta Nutrimenta Sinica, V27, P30; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Erickson CA, 2003, EXP GERONTOL, V38, P61, DOI 10.1016/S0531-5565(02)00160-2; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Grady CL, 2000, CURR OPIN NEUROBIOL, V10, P224, DOI 10.1016/S0959-4388(00)00073-8; Gutierrez-Cuesta J, 2007, J PINEAL RES, V42, P394, DOI 10.1111/j.1600-079X.2007.00433.x; Hua XD, 2007, LIFE SCI, V80, P1897, DOI 10.1016/j.lfs.2007.02.030; Law A, 2001, BRAIN RES REV, V35, P73, DOI 10.1016/S0165-0173(00)00051-5; [凌智群 Ling Zhiqun], 2002, [营养学报, Acta Nutrimenta Sinica], V24, P121; [凌智群 Ling Zhiqun], 2002, [食品科学, Food Science], V23, P98; Ling ZQ, 2005, J AGR FOOD CHEM, V53, P2441, DOI 10.1021/jf040325p; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luth HJ, 2001, BRAIN RES, V913, P57, DOI 10.1016/S0006-8993(01)02758-5; Markesbery WR, 2005, ANN NEUROL, V58, P730, DOI 10.1002/ana.20629; Markowska AL, 1998, PHYSIOL BEHAV, V64, P15, DOI 10.1016/S0031-9384(98)00011-0; Matsugo S, 2004, INT CONGR SER, V1260, P251, DOI 10.1016/S0531-5131(03)01571-1; Mishra OP, 2002, NEUROSCI LETT, V318, P93, DOI 10.1016/S0304-3940(01)02484-3; MIYAMOTO M, 1992, PHYSIOL BEHAV, V51, P979, DOI 10.1016/0031-9384(92)90081-C; Moriguchi T, 1996, BIOL PHARM BULL, V19, P305, DOI 10.1248/bpb.19.305; Morley JE, 2002, BIOGERONTOLOGY, V3, P57, DOI 10.1023/A:1015207429786; Nishikawa T, 1998, NEUROSCI LETT, V254, P69, DOI 10.1016/S0304-3940(98)00646-6; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pang KCH, 2006, AGE, V28, P283, DOI 10.1007/s11357-006-9013-9; Poon HF, 2004, CLIN GERIATR MED, V20, P329, DOI 10.1016/j.cger.2004.02.005; Poona HF, 2005, NEUROCHEM INT, V46, P159, DOI 10.1016/j.neuint.2004.07.008; Porter L., 1986, PHYTOCHEMISTRY, V36, P523; Rebrin I, 2005, FREE RADICAL BIO MED, V39, P549, DOI 10.1016/j.freeradbiomed.2005.04.008; Reiter RJ, 2001, ANN NY ACAD SCI, V939, P200; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; RONALD LP, 2005, PHYTOCHEMISTRY, V66, P2264; Rubaj A, 2003, BEHAV BRAIN RES, V141, P11, DOI 10.1016/S0166-4328(02)00314-5; SCHROEDER RA, 1995, ANESTH ANALG, V81, P1052, DOI 10.1097/00000539-199511000-00027; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Suganuma H, 2004, INT CONGR SER, V1260, P129, DOI 10.1016/S0531-5131(03)01601-7; TAKEDA T, 1991, J AM GERIATR SOC, V39, P911, DOI 10.1111/j.1532-5415.1991.tb04460.x; TAKEDA T, 1981, MECH AGEING DEV, V17, P183, DOI 10.1016/0047-6374(81)90084-1; THOMAS BLK, 2005, MECH AGEING DEV, V126, P1011; Thorns V, 1998, EXP NEUROL, V150, P14, DOI 10.1006/exnr.1997.6751; Unno K, 2004, INT CONGR SER, V1260, P409, DOI 10.1016/S0531-5131(03)01429-8; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; Williams TI, 2006, NEUROBIOL AGING, V27, P1094, DOI 10.1016/j.neurobiolaging.2005.06.004; WU ZQ, 2007, NEURAL REGEN RES, V2, P355; Yamada K, 1999, NEUROSCIENCE, V88, P281, DOI 10.1016/S0306-4522(98)00237-1; YAMADA K, 1995, BRIT J PHARMACOL, V115, P852, DOI 10.1111/j.1476-5381.1995.tb15011.x; Yasui F, 2003, NEUROSCI LETT, V350, P66, DOI 10.1016/S0304-3940(03)00827-9; ZHENG JX, 1999, FUNCTIONAL FOOD, P294	58	67	75	5	25	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	DEC 1	2008	194	1					100	107		10.1016/j.bbr.2008.06.029			8	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	355MM	WOS:000259713000014	18652848				2022-02-06	
J	Wade, SL; Walz, NC; Carey, JC; Williams, KM				Wade, Shari L.; Walz, Nicolay Chertkoff; Carey, JoAnne C.; Williams, Kendra M.			Preliminary Efficacy of a Web-Based Family Problem-Solving Treatment Program for Adolescents With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; online intervention; problem solving	PSYCHIATRIC-DISORDERS; SOCIAL COMPETENCE; CHILDREN; INTERVENTION; BEHAVIOR; SKILLS	Preliminary report of the efficacy of a Web-based treatment program to improve adolescent and family psychosocial functioning following traumatic brain injury (TBI). Participants: Families of 9 adolescents with TBI (2 severe and 7 moderate) injured less than 24 months ago participated in this study. Intervention: A Web-based family treatment program designed to enhance family problem solving and adjustment, as well as reduce adolescent behavioral and social problems that are common sequelae of moderate-to-severe TBI was used as intervention. The program consisted of 10 core sessions and up to 4 supplemental sessions, each consisting of self-guided Web exercises followed by a videoconference therapy session. Results: Significant improvements were found in parent-reported adolescent internalizing behaviors, self-reported adolescent depressive symptoms, parental depression, and parent-adolescent conflict. Effect sizes were in the medium-to-high range for these same contrasts. Exploratory analyses suggested that providing audio with the Web site may enhance some outcomes. Conclusions: This study provides preliminary evidence of the feasibility and efficacy of family-centered online intervention for improving adolescent and family adaptation following pediatric TBI.	[Wade, Shari L.] Univ Cincinnati, Div Pediat Phys Med & Rehabil, Cincinnati Childrens Hosp, Dept Pediat,Med Ctr,Coll Med, Cincinnati, OH 45229 USA		Wade, SL (corresponding author), Univ Cincinnati, Div Pediat Phys Med & Rehabil, Cincinnati Childrens Hosp, Dept Pediat,Med Ctr,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Catroppa C, 2006, Pediatr Rehabil, V9, P89, DOI 10.1080/13638490500155458; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; GLUECKAUF RL, 1992, REHABIL PSYCHOL, V37, P291, DOI 10.1037/h0079109; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Norman S, 2006, J PSYCHIATR MENT HLT, V13, P771, DOI 10.1111/j.1365-2850.2006.01033.x; Patterson GeraldR., 1988, STRESS COPING DEV CH, P235; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Puskar Kathryn, 2003, J Child Adolesc Psychiatr Nurs, V16, P71, DOI 10.1111/j.1744-6171.2003.tb00350.x; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; ROBIN AL, 1989, NEGOTIATING PARENT A; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; SCHWARTZ D, 2007, MONITOR PSYCHOL, V38, P54; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sitarenios G., 1999, USE PSYCHOL TESTING, P267; Spence SH, 2003, J CONSULT CLIN PSYCH, V71, P3, DOI 10.1037/0022-006X.71.1.3; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2006, J CONSULT CLIN PSYCH, V51, P178; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	33	67	67	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2008	23	6					369	377		10.1097/01.HTR.0000341432.67251.48			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	379WZ	WOS:000261428300002	19033829				2022-02-06	
J	Jin, W; Wang, HD; Ji, Y; Hu, QG; Yan, W; Chen, G; Yin, HX				Jin, Wei; Wang, Handong; Ji, Yan; Hu, Qingang; Yan, Wei; Chen, Gang; Yin, Hongxia			Increased intestinal inflammatory response and gut barrier dysfunction in Nrf2-deficient mice after traumatic brain injury	CYTOKINE			English	Article						Nuclear factor E2-related factor 2; Traumatic brain injury; Intestine; Inflammation	NF-KAPPA-B; NRF2 ENHANCES SUSCEPTIBILITY; MULTIPLE ORGAN FAILURE; TRANSCRIPTION FACTOR; MUCOSA STRUCTURE; HEAD-INJURY; RATS; PERMEABILITY; EXPRESSION; INDUCTION	Aim: To explore the role of nuclear factor erythroid 2-related factor 2 (Nrf2) in traumatic brain injury (TBI)-induced intestinal inflammatory response and gut barrier dysfunction in the mice. Methods: Wild-type Nrf2 (+/+) and Nrf2 (-/-)-deficient mice were subjected to a moderately severe weight-drop impact-acceleration head injury. We measured nuclear factor kappa B (NF-kappa B) by electrophoretic mobility shift assay (EMSA); tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay (ELISA); intercellular adhesion molecule-1 (ICAM-1) by immunohistochernistry; intestinal permeability by lactulose/mannitol (L/M) test; plasma endotoxin by chromogenic limulus amebocyte lysate test. Results: Intestinal levels of NF-kappa B, pro-inflammatory cytokines and ICAM-1 in Nrf2 (-/-)-deficient mice were significantly higher compared with Nrf2 (+/+) mice at 24 h after TBI. Furthermore, higher intestinal permeability and plasma level of endotoxin were observed in the Nrf2 (-/-) mice compared with Nrf2 (+/+) mice. Conclusion: Nrf2 plays an important protective role in limiting intestinal inflammatory response and gut barrier dysfunction after TBI. (C) 2008 Elsevier Ltd. All rights reserved.	[Jin, Wei; Wang, Handong; Yan, Wei; Chen, Gang; Yin, Hongxia] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Hu, Qingang; Yan, Wei] Nanjing Univ, Sch Med, Affiliated Stomatol Hosp, Dept Oral & Maxillofacial Surg, Nanjing 210008, Jiangsu, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hdwang_nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020	Yan, Wei/0000-0002-1123-0835	Jinling Hospital of China	This work was supported by grants from Jinling Hospital of China. The authors thank Dr. Bo Wu and Dr. Geng-bao Feng for technical assistance.	Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chen F, 1999, CLIN CHEM, V45, P7; Chen G, 2008, J SURG RES, V147, P92, DOI 10.1016/j.jss.2007.05.029; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Gomes A, 2005, J BIOCHEM BIOPH METH, V65, P45, DOI 10.1016/j.jbbm.2005.10.003; Gong JP, 2002, WORLD J GASTROENTERO, V8, P923, DOI 10.3748/wjg.v8.i5.923; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Guo RF, 2007, ANTIOXID REDOX SIGN, V9, P1991, DOI 10.1089/ars.2007.1785; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Moore FA, 1999, AM J SURG, V178, P449, DOI 10.1016/S0002-9610(99)00231-7; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Shanahan F, 1999, Semin Gastrointest Dis, V10, P8; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Sun J, 2007, CYTOKINE, V40, P151, DOI 10.1016/j.cyto.2007.09.003; Surh YJ, 2005, J NUTR, V135, p2993S, DOI 10.1093/jn/135.12.2993S; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Wang P, 1998, J SURG RES, V74, P141, DOI 10.1006/jsre.1997.5246	32	67	69	2	16	ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666			CYTOKINE	Cytokine	OCT	2008	44	1					135	140		10.1016/j.cyto.2008.07.005			6	Biochemistry & Molecular Biology; Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Immunology	369NG	WOS:000260700600021	18722136				2022-02-06	
J	Wu, HT; Lu, DY; Jiang, H; Xiong, Y; Qu, CS; Li, B; Mahmood, A; Zhou, D; Chopp, M				Wu, Hongtao; Lu, Dunyue; Jiang, Hao; Xiong, Ye; Qu, Changsheng; Li, Bo; Mahmood, Asim; Zhou, Dong; Chopp, Michael			Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						Akt; apoptosis; FOXO1; I kappa B; rat; simvastatin; traumatic brain injury	NF-KAPPA-B; REDUCES NEUROLOGICAL DEFICIT; GLUCOSE-INDUCED APOPTOSIS; NITRIC-OXIDE SYNTHASE; TRANSCRIPTION FACTOR; NEURONAL DEATH; IN-VIVO; MORPHOLOGICAL CONSEQUENCES; PI3K/AKT/ENOS PATHWAY; ENDOTHELIAL-CELLS	Object. In their previous Studies, the authors found that simvastatin treatment of traumatic brain injury (TBI) in rats had beneficial effects oil spatial learning functions. In the Current study they wanted to determine whether simvastatin Suppressed neuronal cell apoptosis after TBI, and if so, they wanted to examine the underlying mechanisms of this process. Methods. Saline or simvastatin (1 mg/kg) was administered orally to rats starting oil Day I after TBI and then daily for 14 days. Modified Neurological Severity Scores were used to evaluate the sensory motor functional recovery. Rats were killed at 1, 3, 7, 14, and 35 clays after treatment, and brain tissue was harvested for terminal deoxynucleotidyl nick-end labeling (TUNEL) staining, caspase-3 activity assay, and Western blot analysis. Results. Simvastatin significantly decreased the modified Neurological Severity Scores from Days 7 to 35 after TBI, significantly reduced the number of TUNEL-positive cells at Day 3, suppressed the caspase-3 activity at Days I and 3 after TBI, and increased phosphorylation of Akt as well as Forkhead transcription factor 1, inhibitory-kappa B, and enclothelial nitric oxide synthase, which are the downstream targets of the prosurvival Akt signaling protein. Conclusions. These data suggested that simvastatin reduces the apoptosis in neuronal cells and improves the sensory motor function recovery after TBI. These beneficial effects of simvastatin may be mediated through activation of Akt, Forkhead transcription factor 1 and nuclear factor-kappa 13 signaling pathways, which suppress the activation of caspase-3 and apoptotic cell death, and thereby, lead to neuronal function recovery after TBI.	[Chopp, Michael] Henry Ford Hosp, Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Wu, Hongtao; Xiong, Ye; Qu, Changsheng; Li, Bo; Mahmood, Asim; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Wu, Hongtao; Zhou, Dong] Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610064, Peoples R China; [Lu, Dunyue] SUNY, Dept Psychiat, Brooklyn, NY USA		Chopp, M (corresponding author), Henry Ford Hosp, Henry Ford Hlth Syst, Dept Neurol, E&R Bldg 3056,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu	Wu, Hongtao/A-8602-2011	Xiong, Ye/0000-0001-9770-6031	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1NS052280-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280] Funding Source: NIH RePORTER	This Study Was Supported by National Institutes of Health Grant No. RO1NS052280-01A1.	Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Balduini W, 2001, STROKE, V32, P2185, DOI 10.1161/hs0901.094287; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Carloni S, 2006, NEUROBIOL DIS, V21, P119, DOI 10.1016/j.nbd.2005.06.014; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fukunaga K, 2005, J PHARMACOL SCI, V98, P205, DOI 10.1254/jphs.FMJ05001X3; Ho FM, 2006, CELL SIGNAL, V18, P391, DOI 10.1016/j.cellsig.2005.05.009; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kretz A, 2006, NEUROBIOL DIS, V21, P421, DOI 10.1016/j.nbd.2005.08.003; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Murohara T, 2002, ANTIOXID REDOX SIGN, V4, P825, DOI 10.1089/152308602760598981; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Vaughan CJ, 2001, CURR OPIN CARDIOL, V16, P219, DOI 10.1097/00001573-200107000-00001; Wang L, 2005, J CEREBR BLOOD F MET, V25, P1150, DOI 10.1038/sj.jcbfm.9600112; Wolfrum S, 2004, J CARDIOVASC PHARM, V44, P348, DOI 10.1097/01.fjc.0000137162.14735.30; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhang W, 2007, NUTRITION, V23, P762, DOI 10.1016/j.nut.2007.07.003	36	67	69	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					691	698		10.3171/JNS/2008/109/10/0691			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100015	18826357	Green Accepted			2022-02-06	
J	Signoretti, S; Marmarou, A; Aygok, GA; Fatouros, PP; Portella, G; Bullock, RM				Signoretti, Stefano; Marmarou, Anthony; Aygok, Gunes A.; Fatouros, Panos P.; Portella, Gina; Bullock, Ross M.			Assessment of mitochondrial impairment in traumatic brain injury using high-resolution proton magnetic resonance spectroscopy	JOURNAL OF NEUROSURGERY			English	Article						diffuse brain injury; focal brain injury; mitochondrial impairment; N-acetylaspartate; trauma	SEVERE HEAD-INJURY; N-ACETYL-ASPARTATE; AXONAL INJURY; CHROMATOGRAPHIC METHOD; WHITE-MATTER; IN-VIVO; H-1 MRS; ACETYLASPARTATE; DYSFUNCTION; METABOLISM	Object. The goal of this study was to demonstrate the posttraumatic neurochemical damage in normal-appearing brain and to assess mitochondrial dysfunction by measuring N-acetylaspartate (NAA) levels in patients with severe head injuries, using proton (H-1) magnetic resonance (MR) spectroscopy. Methods. Semiquantitative analysis of NAA relative to creatine-containing compounds (Cr) and choline (Cho) was carried out from proton spectra obtained by means of chemical shift (CS) imaging and single-voxel (SV) methods in 25 patients with severe traumatic brain injuries (TBIs) (Glasgow Coma Scale scores <= 8) using a 1.5-tesla MR unit. Proton MR spectroscopy was also performed in 5 healthy volunteers (controls). Results. The SV studies in patients with diffuse TBI showed partial reduction of NAA/Cho and NAA/Cr ratios within the first 10 days after injury (means +/- standard deviations 1.59 +/- 0.46 and 1.44 +/- 0.21, respectively, in the patients compared with 2.08 +/- 0.26 and 2.04 +/- 0.3 1, respectively, in the controls; nonsignificant difference). The ratios gradually declined in all patients as time from injury increased (mean minimum values NAA/Cho 1.05 +/- 0.44 and NAA/Cr 1.05 +/- 0.30, p < 0.03 and p < 0.02, respectively). This reduction was greater in patients with less favorable outcomes. In patients with focal injuries, the periphery of the lesions revealed identical trends of NAA/Cho and NAA/Cr decrease. These reductions correlated with outcome at 6 months (p < 0.01). Assessment with multivoxel methods (CS imaging) demonstrated that, in diffuse injury, NAA levels declined uniformly throughout the brain. At 40 days postinjury, initially low NAA/Cho levels had recovered to near baseline in patients who had good outcomes, whereas no recovery was evident in patients with poor outcomes (p < 0.01). Conclusions. Using H-1-MR spectroscopy, it is possible to detect the posttraumatic neurochemical damage of the injured brain when conventional neuroimaging techniques reveal no abnormality. Reduction of NAA levels is a dynamic process, evolving over time, decreasing and remaining low throughout the involved tissue in patients with poor outcomes. Recovery of NAA levels in patients with favorable outcomes suggests marginal mitochondrial impairment and possible resynthesis from vital neurons.	[Signoretti, Stefano; Marmarou, Anthony; Aygok, Gunes A.; Portella, Gina; Bullock, Ross M.] Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA 23298 USA; [Fatouros, Panos P.] Virginia Commonwealth Univ, Med Ctr, Dept Radiol, Richmond, VA 23298 USA		Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, 1001 E Broad St,Suite 235,POB 980508, Richmond, VA 23298 USA.	amannaro@vcu.edu	Signoretti, stefano/AAL-5631-2020	Signoretti, stefano/0000-0002-8086-1622	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587, NS19235] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, R56NS019235, P50NS012587, P01NS012587] Funding Source: NIH RePORTER		Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; [Anonymous], 2000, J Head Trauma Rehabil, V15, P750; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOTTOMLEY PA, 1987, ANN NY ACAD SCI, V508, P333, DOI 10.1111/j.1749-6632.1987.tb32915.x; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ERNST T, 1991, MAGN RESON MED, V21, P82, DOI 10.1002/mrm.1910210111; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HU XP, 1988, MAGNET RESON MED, V8, P314, DOI 10.1002/mrm.1910080308; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kushi H, 1999, ACT NEUR S, V75, P67; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Marmarou A, 2005, ACT NEUR S, V95, P149; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1996, LAB INVEST, V74, P315; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Sinson G, 2001, AM J NEURORADIOL, V22, P143; STACHNIAK J, 1994, J CLIN ANESTH, V6, P437, DOI 10.1016/S0952-8180(05)80020-0; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; TEDESCHI G, 1995, MAGNET RESON MED, V33, P127, DOI 10.1002/mrm.1910330120; TRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658, DOI 10.1111/j.1471-4159.1985.tb07240.x; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	58	67	69	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2008	108	1					42	52		10.3171/JNS/2008/108/01/0042			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	248AI	WOS:000252123300006	18173309				2022-02-06	
J	Sperry, JL; Frankel, HL; Vanek, SL; Nathens, AB; Moore, EE; Maier, RV; Minei, JP				Sperry, Jason L.; Frankel, Heidi L.; Vanek, Sue L.; Nathens, Avery B.; Moore, Ernest E.; Maier, Ronald V.; Minei, Jospeh P.			Early hyperglycemia predicts multiple organ failure and mortality but not infection	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		early hyperglycemia; strict glycemic control; multiple organ failure; nosocomial infection	STANDARD OPERATING PROCEDURES; SCALE COLLABORATIVE PROJECT; ORIENTED RESEARCH CORE; INTENSIVE INSULIN THERAPY; CONFOUNDER SELECTION CRITERIA; CLINICAL CARE; CRITICALLY-ILL; HOST RESPONSE; ADMISSION HYPERGLYCEMIA; HOSPITAL MORTALITY	Background: Previous studies attempting to characterize the association between early hyperglycemia (EH) and subsequent outcome have been performed without utilization of a strict glycemic control protocol. We sought to characterize the clinical outcomes associated with EH in a cohort of severely injured trauma patients, when a strict glycemic control protocol was used. Methods: Data were obtained from a multicenter prospective cohort study evaluating clinical outcomes in blunt injured adults with hemorrhagic shock. Known diabetics and patients with isolated traumatic brain injury were excluded from the analysis. A strict glycemic protocol (target glucose, 80-110 mg/dL) was employed. Cox proportional hazard regression was used to evaluate the effects of EH on multiple organ failure (MOF), nosocomial infection (NI), and mortality, after adjusting for the effects of early death on subsequent infection rates. Results: Overall mortality, MOF, and NI rates for the entire cohort were 19.6%, 37.5%, and 42.2%, respectively, with a mean Injury Severity Score of 31.6 +/- 14. Cox proportional hazard regression confirmed that EH was independently associated with almost a twofold higher mortality rate and a 30% higher incidence of MOF, but was not an independent risk factor for NI, after control-ling for all important confounders. There continued to be no independent association between ER and NI, even when stratified by infection type (pneumonia, catheter-related blood stream infection, or urinary tract infection). Conclusion: These results suggest that EH is a marker of severe physiologic insult after injury, and that strict glycemic control may reduce or prevent the infectious complications previously shown to be associated with hyperglycemia early after injury.	Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Crit Care, Dallas, TX 75390 USA; Univ Toronto, Dept Surg, Toronto, ON, Canada; St Michaels Hosp, Div Gen Surg & Trauma, Toronto, ON M5B 1W8, Canada; Denver Hlth Med Ctr, Dept Surg, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Div Gen Surg & Trauma, Seattle, WA 98104 USA		Minei, JP (corresponding author), Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Crit Care, 5323 Harry Hines Blvd,Mail Stop 9158, Dallas, TX 75390 USA.	joseph.minei@utsouthwestem.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM062119] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54 GM062119-1] Funding Source: Medline		ANAND KJS, 1986, PROG FOOD NUTR SCI, V10, P67; Angus DC, 2005, AM J RESP CRIT CARE, V172, P1358, DOI 10.1164/rccm.2508009; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Brandt C A, 2003, AMIA Annu Symp Proc, P794; CAREY LC, 1970, ANN SURG, V172, P342, DOI 10.1097/00000658-197009000-00004; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; CHERNOW B, 1987, ARCH INTERN MED, V147, P1273, DOI 10.1001/archinte.147.7.1273; Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI [10.1007/s00134-004-2210-z, 10.1097/CCM.0b013e31827e83af, 10.1007/s00134-012-2769-8]; Epstein J, 1999, CRIT CARE CLIN, V15, P17, DOI 10.1016/S0749-0704(05)70037-3; GREENLAND S, 1989, AM J EPIDEMIOL, V130, P1066, DOI 10.1093/oxfordjournals.aje.a115409; Hirsch IB, 2002, J CLIN ENDOCR METAB, V87, P975, DOI 10.1210/jc.87.3.975; Khoury W, 2004, J TRAUMA, V57, P1132, DOI 10.1097/01.TA.0000141889.31903.9C; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LINDSEY A, 1974, JAMA-J AM MED ASSOC, V227, P757, DOI 10.1001/jama.227.7.757; Maier RV, 2005, J TRAUMA, V59, P762, DOI 10.1097/01.ta.0000177656.85206.cd; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Marshall JC, 1999, EUR J SURG, V163, P62; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Minei JP, 2006, J TRAUMA, V60, P1106, DOI 10.1097/01.ta.0000220424.34835.f1; Moore FA, 2006, J TRAUMA, V61, P82, DOI 10.1097/01.ta.0000225933.08478.65; Nathens AB, 2005, J TRAUMA, V59, P764, DOI 10.1097/01.ta.0000177759.17704.35; SKILLMAN JJ, 1971, ANN SURG, V174, P911, DOI 10.1097/00000658-197112000-00006; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vogelzang M, 2006, J TRAUMA, V60, P873, DOI 10.1097/01.ta.0000195715.63978.80; West MA, 2006, J TRAUMA, V61, P436, DOI 10.1097/01.ta.0000232517.83039.c4; Whitcomb BW, 2005, CRIT CARE MED, V33, P2772, DOI 10.1097/01.CCM.0000189741.44071.25; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72	30	67	67	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2007	63	3					487	494		10.1097/TA.0b013e31812e51fc			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	211DA	WOS:000249503300001	18073591				2022-02-06	
J	Wagner, AK; Kline, AE; Ren, DX; Willard, LA; Wenger, MK; Zafonte, RD; Dixon, CE				Wagner, Amy K.; Kline, Anthony E.; Ren, Dianxu; Willard, Lauren A.; Wenger, Michael K.; Zafonte, Ross D.; Dixon, C. Edward			Gender associations with chronic methylphenidate treatment and behavioral performance following experimental traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						traumatic brain injury; gender; methylphenidate; spatial learning; behavioral performance	WATER MAZE PERFORMANCE; DOPAMINE TRANSPORTER; ENVIRONMENTAL ENRICHMENT; STRIATAL DOPAMINE; FRONTAL-CORTEX; AMPHETAMINE; RAT; RECOVERY; IMPACT; PROGESTERONE	Evidence suggests that dopamine (DA) agonists improve cognition after traumatic brain injury (TBI). Methylphenidate (MPH) is a DA agonist that blocks the dopamine transporter (DAT). Moreover, female sex hormones modulate DAT expression. Therefore, the purpose of this study was to evaluate how MPH affects behavioral performance in male and female rats. Under anesthesia, rats underwent either controlled cortical impact (CCI) or sham injury operations. Beginning post-operative day 1, rats received daily intraperitoneal injections of MPH (5 mg/kg) or saline. Beam balance (BB) and beam-walking (BW) were assessed on post-operative days 1-5. Exploratory behavior was assessed using an open field free choice novelty (FCN) task on day 13. Spatial memory was assessed with a Morris water maze (MWM) task on days 14-20. Multivariate analyses showed TBI females performed better than TBI males on both motor tasks (P < 0.05 both comparisons), and MPH improved BB performance for both male and female injury groups (P = 0.05) compared to their respective vehicle treated injury groups. Multivariate analysis showed that MPH enhanced MWM performance (spatial learning and retention) after TBI. Significant improvements were noted only in injured males treated with MPH compared to their vehicle control (P < 0.05) with respect to improvements in memory acquisition and retention. Further, injured females treated with MPH had faster swimming speeds than all other groups (P < 0.05 all comparisons), and MPH increased activity in TBI females but not males in the FCN task (P < 0.05). These results sug gest that MPH is beneficial after TBI. However there are gender specific drug differences in 9 behavioral performance and sensitivity to treatment with MPH that may have implications for treatment efficacy and dosing clinically after TBI. (c) 2007 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Neruosci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03 HD041399, K08 HD040833-05, K08 HD040833-03, K08 HD040833, K08 HD040833-01, K08 HD040833-02, K08 HD040833-04, R03HD41399, R03 HD041399-01, K08HD40833, R03 HD041399-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833, R03HD041399] Funding Source: NIH RePORTER		Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P803, DOI 10.1016/S0091-3057(99)00168-9; Becker JB, 2001, ANN NY ACAD SCI, V937, P172, DOI 10.1111/j.1749-6632.2001.tb03564.x; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P53, DOI 10.1016/S0091-3057(99)00091-X; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Kelly SJ, 1999, PHARMACOL BIOCHEM BE, V64, P655, DOI 10.1016/S0091-3057(99)00167-7; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KUHN CM, 1978, J PHARMACOL EXP THER, V207, P544; Lavalaye J, 2000, EUR J NUCL MED, V27, P867, DOI 10.1007/s002590000279; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MORISSETTE M, 1993, NEUROENDOCRINOLOGY, V58, P16, DOI 10.1159/000126507; PERIS J, 1991, BRAIN RES, V566, P255, DOI 10.1016/0006-8993(91)91706-7; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rebec GV, 1997, NEUROSCIENCE, V76, P707, DOI 10.1016/S0306-4522(96)00382-X; REBEC GV, 1984, NEUROSCI BIOBEHAV R, V8, P153, DOI 10.1016/0149-7634(84)90030-7; RIVEST R, 1995, BRAIN RES, V692, P269, DOI 10.1016/0006-8993(95)00611-S; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; SHARP PE, 1998, LABORATORY; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	44	67	69	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	AUG 6	2007	181	2					200	209		10.1016/j.bbr.2007.04.006			10	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	185MS	WOS:000247715700004	17517440	Green Accepted			2022-02-06	
J	Pompucci, A; De Bonis, P; Pettorini, B; Petrella, G; Di Chirico, A; Anile, C				Pompucci, Angelo; De Bonis, Pasquale; Pettorini, Benedetta; Petrella, Gianpaolo; Di Chirico, Alessandro; Anile, Carmelo			Decompressive craniectomy for traumatic brain injury: Patient age and outcome	JOURNAL OF NEUROTRAUMA			English	Article						age; decompressive craniectomy; head trauma; intracranial pressure; outcome	SEVERE HEAD-INJURIES; INTRACRANIAL HYPERTENSION; MANAGEMENT; CHILDREN; SURGERY	The overall degree by which different patients may benefit from decompressive craniectomy ( DC) remains controversial. In particular, the prognostic value of age has been investigated by very few studies. Many authors state there is no significant benefit in performing a DC in severe head injury after a certain age limit, with most placing the limit at 30-50 years of age. Between 1994 and 2004, 55 patients underwent DC at our institution. Advanced age did not constitute a contraindication to surgery for both ethical and cultural reasons. Thus, the data obtained were not biased by a selection of patients based on age. We analyzed potential predictors of outcome after DC, including sex, age, Glasgow Coma Scale (GCS), and presence of mass lesion. Chi-square test was used to compare categorical variables. The independent contribution of predictive factors to outcome was studied using logistic regression analysis. Initial GCS score was found to be an independent predictor of outcome (p = 0.001). No difference in the outcome was observed between patients with GCS 6-8 and GCS 9-15. These two groups have a better prognosis than patients with GCS 3-5. Logistic regression analysis showed age as an independent predictive factor to outcome (p = 0.005). A difference in outcome exists among patients over 65 and patients aged <= 65, while groups aged < 40 and 40-65 showed no difference in outcome. Based on these findings, we believe that the age limit for performing DC should be revised.	Univ Cattolica Sacro Cuore, Sch Med, Inst Neurosurg, I-00168 Rome, Italy		De Bonis, P (corresponding author), Univ Cattolica Sacro Cuore, Sch Med, Inst Neurosurg, I-00168 Rome, Italy.	debonisvox@gmail.com	de bonis, pasquale/K-8200-2016	de bonis, pasquale/0000-0002-9879-8940			*AANS, 1996, J NEUROTRAUM, V13, P639; Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ANILE C, 1993, INTRACRANIAL PRESSUR, V8, P682; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kocher T., 1901, HIRNERSCHUTTERUNG HI, V3, P262; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; Meier U, 2006, ACTA NEUROCHIR SUPPL, V96, P373; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311	21	67	74	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1182	1188		10.1089/neu.2006.0244			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200009	17610357				2022-02-06	
J	Alexander, S; Kerr, ME; Kim, Y; Kamboh, MI; Beers, SR; Conley, YP				Alexander, Sheila; Kerr, Mary E.; Kim, Yookyung; Kamboh, M. Ilyas; Beers, Sue R.; Conley, Yvette P.			Apolipoprotein E4 allele presence and functional outcome after severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; genotype; outcome; traumatic brain injury	TRANSGENIC MICE; APOE GENOTYPE; HEAD-INJURY; E EPSILON-4; E4; E3; POLYMORPHISM; CHOLESTEROL; LIPOPROTEIN; PROTEIN	Presence of the apolipoprotein E (APOE) 4 allele has been associated with increased incidence and faster progression of neurodegenerative diseases, poorer recovery from neurologic insult, and decreased cognitive function in the well-elderly. The specific association between APOE genotype and recovery from severe traumatic brain injury (TBI) is conflicting with many groups finding the APOE 4 allele to be associated with poorer outcome while others have found no association. The purpose of this study was to investigate the association between APOE 4 allele presence and recovery during the two years after injury from severe TBI in light of other potential covariates, such as age, race, gender, hypotension or hypoxia before hospital admission and severity of injury. APOE genotype was determined for 123 subjects with severe TBI. Glasgow outcome score (GOS) and mortality were collected at 3, 6, 12, and 24 months after injury. Results showed individuals improved over the two year period following injury and those with the 4 allele had a slower recovery rate than those without the APOE 4 allele over the two year period. We did not however find significant differences in GOS at individual time points when controlling for other covariates. Our findings suggest that APOE 4 allele presence influences recovery rate from severe TBI independent of other covariates. The findings of this study are unique in that they address not only the relationship between APOE 4 allele presence and outcome from severe TBI, but also describe differences in trajectory of recovery by APOE 4 allele presence.	Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA; NINR, Bethesda, MD 20892 USA; Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA 15261 USA		Conley, YP (corresponding author), Univ Pittsburgh, Dept Human Genet, 440 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.	yconley@pitt.edu		Kamboh, M. Ilyas/0000-0002-3453-1438	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [NR04801] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004801] Funding Source: NIH RePORTER		Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; DeMattos RB, 2001, NEUROCHEM INT, V39, P415, DOI 10.1016/S0197-0186(01)00049-3; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Hayashi H, 2002, NEUROREPORT, V13, P383, DOI 10.1097/00001756-200203250-00004; HIXSON JE, 1990, J LIPID RES, V31, P545; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KAMBOH MI, 1995, ATHEROSCLEROSIS, V112, P145, DOI 10.1016/0021-9150(94)05409-C; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Muller W, 1998, BRAIN PATHOL, V8, P641; Nathan BP, 2002, BRAIN RES, V928, P96, DOI 10.1016/S0006-8993(01)03367-4; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; PEPE MG, 1986, J IMMUNOL, V136, P3716; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Sun YL, 1998, J NEUROSCI, V18, P3261; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Veinbergs I, 2002, J NEUROSCI RES, V67, P379, DOI 10.1002/jnr.10138; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059	37	67	70	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2007	24	5					790	797		10.1089/neu.2006.0133			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	167YT	WOS:000246489300004	17518534				2022-02-06	
J	Lifshitz, J; Kelley, BJ; Povlishock, JT				Lifshitz, Jonathan; Kelley, Brian Joseph; Povlishock, John Theodore			Perisomatic thalamic Axotomy after diffuse traumatic brain injury is associated with atrophy rather than cell death	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						disector; fractionator; head injury; nucleator; stereology; thalamus; traumatic brain injury	FLUID PERCUSSION INJURY; AXONAL INJURY; TOTAL NUMBER; NEURONS; DAMAGE; RESPONSES; CORTEX; FRACTIONATOR; HIPPOCAMPUS; ACTIVATION	Morbidity and mortality associated with traumatic brain injury (TBI) stem from diffuse axonal injury (DAI) throughout subcortical and brainstem white matter and subcortical nuclei. After midline fluid percussion brain injury, DAI in the thalamus includes perisomatic axotomy and resembles human post-traumatic pathology where the degree of morbidity correlates with thalamic damage. After axotomy, acute somatic perturbations resolve and appear compatible with cell survival; however, the long-term fate of neurons in an area with perisomatic axotomy is unknown. From brain-injured and uninjured rats at 1, 7 and 28 days after injury (injury, n = 5/group; sham, n =.4), alternate sections were immunostained for amyloid precursor protein (APP) to detect perisomatic axotomy or Giemsa stained for quantification of neuronal number, neuronal density, regional volume, and neuronal nuclear volume using design-based stercology. One day postinjury, APP-immunoreactive axons were identified consistently within the perisomatic domains of thalamic neurons of the ventral basal complex. Bilateral systematic-random quantification of the ventral basal complex indicated a significant reduction in neuronal density (number per mm 3, but not number alone) at 1 week after injury, compared with sham and 1 day postinjury. Furthermore, by I day and persisting through I week after injury, the mean neuronal nuclear volume was atrophied significantly compared with sham. Therefore, diffuse TBI results in early perisomatic axonal injury followed by neuronal atrophy in the ventral basal complex, without gross degeneration. Enduring atrophy in thalamic relays could underlie circuit disruption responsible for post-traumatic morbidity.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Med Ctr, Lexington, KY 40536 USA; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Hlth Syst, Richmond, VA USA		Lifshitz, J (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Med Ctr, Lexington, KY 40536 USA.	jlifshitz@uky.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS045824, R01NS020193] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32-HD049343, F32 HD049343] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30-NS047463, R01-NS020193, R01-NS045824] Funding Source: Medline		Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Ahmed FAKM, 2001, EXP NEUROL, V167, P451, DOI 10.1006/exnr.2000.7562; Andersen BB, 2004, BRAIN RES, V1007, P10, DOI 10.1016/j.brainres.2004.01.058; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barron KD., 1983, SPINAL CORD RECONSTR, P7; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bothwell S, 2001, J NEUROSCI, V21, P4789, DOI 10.1523/JNEUROSCI.21-13-04789.2001; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; EMERY DG, 1987, EXP BRAIN RES, V67, P41, DOI 10.1007/BF00269451; EMERY DG, 1991, EXP BRAIN RES, V86, P60; FINCH CE, 1993, TRENDS NEUROSCI, V16, P104, DOI 10.1016/0166-2236(93)90134-8; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1988, J MICROSC-OXFORD, V151, P3, DOI 10.1111/j.1365-2818.1988.tb04609.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley B, 2006, J NEUROTRAUM, V23, P1031; Kreutzberg Georg W., 1995, P355; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; LAND PW, 1995, J COMP NEUROL, V355, P573, DOI 10.1002/cne.903550407; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; NYENGAARD JR, 1992, J MICROSC-OXFORD, V165, P427, DOI 10.1111/j.1365-2818.1992.tb01497.x; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Passineau MJ, 2000, AM J PHYSIOL-HEART C, V279, pH924, DOI 10.1152/ajpheart.2000.279.3.H924; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PETERSON DA, 1994, J NEUROSCI, V14, P6872; Pierce JES, 1996, J NEUROSCI, V16, P1083; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Price Joseph L., 1995, P629; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; Sa MJ, 2000, ACTA NEUROPATHOL, V99, P643, DOI 10.1007/s004010051175; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SOFRONIEW MV, 1993, J NEUROSCI, V13, P5263, DOI 10.1523/JNEUROSCI.13-12-05263.1993; Stamatakis EA, 2002, J NUCL MED, V43, P476; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Waite Phil M. E., 1995, P705; West MJ, 1998, HIPPOCAMPUS, V8, P69; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; [No title captured]	73	67	67	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2007	66	3					218	229		10.1097/01.jnen.0000248558.75950.4d			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	173DB	WOS:000246852600006	17356383	Bronze			2022-02-06	
J	Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Chopp, M				Mahmood, Asim; Lu, Dunyue; Qu, Changsheng; Goussev, Anton; Chopp, Michael			Treatment of traumatic brain injury with a combination therapy of marrow stromal cells and atorvastatin in rats	NEUROSURGERY			English	Article							GROWTH-FACTOR; FUNCTIONAL RECOVERY; NERVOUS-SYSTEM; HEAD-INJURY; ADULT RATS; TRANSPLANTATION; NEUROTROPHINS; NEURONS; DIFFERENTIATE; GENERATION	OBJECTIVE: This study investigated the effects of a combination therapy of marrow stromal cells (MSCs) and statins (atorvastatin) after traumatic brain injury in rats. METHODS: Thirty-two female Wistar rats were injured by controlled cortical impact and divided into four groups. Group I was injected with MSCs (1 x 10(6)) intravenously 24 hrs after traumatic brain injury. Group II was administered atorvastatin (0.5 mg/kg) orally for 14 days starting 24 hours after traumatic brain injury. Group III received MSCs (1 x 10(6)) combined with atorvastatin (0.5 mg/kg). Group IV (control) was injected with saline. MSCs were harvested from the bone marrow of male rats to identify male donor cells within female recipient animals by localization of Y chromosomes. Functional analysis was performed using modified neurological severity scores and the Morris water maze test. Animals were sacrificed 35 days after injury and brain sections stained with RESULTS: No functional improvement was seen in animals treated with MSCs or atorvastatin alone (Groups I and II). However, functional improvement was seen with both testing modalities (modified neurological severity scores and Morris water maze) in animals receiving combination therapy (Group III1). Microscopic analysis showed that significantly more MSCs were present in animals receiving combination therapy than in those receiving MSCs alone. Also, significantly more endogenous cellular proliferation was seen in the hippocampus and injury boundary zone of the combination therapy group than in the monotherapy or control groups. CONCLUSION: When administered in combination with MSCs, atorvastatin increases MSC access and/or survival within the injured brain and enhances functional recovery compared with monotherapy.	Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA		Mahmood, A (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu					Alder J, 1999, NAT NEUROSCI, V2, P535, DOI 10.1038/9189; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; DEGROOT CJA, 1992, GLIA, V6, P301, DOI 10.1002/glia.440060408; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/neu.2004.21.1756; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; POSTMANTUR R, 1997, NEUROSCIENCE, V77, P875; Pujol BF, 2001, EUR J CELL BIOL, V80, P99, DOI 10.1078/0171-9335-00136; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Silverman WF, 1999, NEUROSCIENCE, V90, P1529, DOI 10.1016/S0306-4522(98)00540-5; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011	34	67	75	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2007	60	3					546	553		10.1227/01.NEU.0000255346.25959.99			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	144LH	WOS:000244797000028	17327800				2022-02-06	
J	Lammertse, D; Dungan, D; Dreisbach, J; Falci, S; Flanders, A; Marino, R; Schwartz, E				Lammertse, Daniel; Dungan, David; Dreisbach, James; Falci, Scott; Flanders, Adam; Marino, Ralph; Schwartz, Eric			From the 2006 NIDRR SCI measures FTI - Neuroimaging in traumatic spinal an evidence-based meeting cord injury: An evidence-based review for clinical practice and research	JOURNAL OF SPINAL CORD MEDICINE			English	Article; Proceedings Paper	American-Spinal-Injury-Association/45th Annual Meeting of the International-Spinal-Cord-Society	JUN 27, 2006	Boston, MA	Amer Spinal Injury Assoc, Int Spinal Cord Soc		spinal cord injuries; evidence-based medicine; neuroimaging; spinal sonography; magnetic resonance imaging; MRI-diffusion weighted imaging; functional MRI; positron emission tomography; computerized tomography; national institute on disability and rehabilitation research	APPARENT DIFFUSION-COEFFICIENTS; RESONANCE-IMAGING FINDINGS; OPTIMAL RADIOLOGIC METHOD; MOTOR CORTEX; IN-VIVO; NEUROLOGIC RECOVERY; INTRAOPERATIVE SONOGRAPHY; CORTICAL REPRESENTATION; CANAL COMPROMISE; MR	Objective: To perform an evidence-based review of the literature on neuroimaging techniques utilized in spinal cord injury clinical practice and research. Methods: A search of the medical literature for articles on specific neuroimaging techniques used in SCI resulted in 2,302 published reports. Review at the abstract and full report level yielded 99 clinical and preclinical articles that were evaluated in detail. Sixty nine were clinical research studies subjected to quality of evidence grading. Twenty-three articles were drawn from the pre-clinical animal model literature and used for supportive evidence. Seven review articles were included to add an element of previous syntheses of current thinking on neuroimaging topics to the committee process (the review articles were not graded for quality of evidence). A list of clinical and research questions that might be answered on a variety of neuroimaging topics was created for use in article review. Recommendations on the use of neuroimaging in spinal cord injury treatment and research were made based on the quality of evidence. Results: Of the 69 original clinical research articles covering a range of neuroimaging questions, only one was judged to provide Class I evidence, 22 provided Class 11 evidence, 17 Class III evidence, and 29 Class IV evidence. Recommendations: MRI should be used as the imaging modality of choice for evaluation of the spinal cord after injury. CT and plain radiography should be used to assess the bony anatomy of the spine in patients with SCI. MRI may be used to identify the location of spinal cord injury. MRI may be used to demonstrate the degree of spinal cord compression after SCI. MRI findings of parenchymal hemorrhage/contusion, edema, and spinal cord disruption in acute and subacute SCI may contribute to the understanding of severity of injury and prognosis for neurological improvement. MRI-Diffusion Weighted Imaging may be useful in quantifying the extent of axonal loss after spinal cord injury. Functional MRI may be useful in measuring the anatomic functional/metabolic correlates of sensory-motor activities in persons with SCI. MR Spectroscopy may be used to measure the biochemical characteristics of the brain and spinal cord following SCI. Intraoperative Spinal Sonography may be used to identify spinal and spinal cord anatomy and gross pathology during surgical procedures. Further research in these areas is warranted to improve the strength of evidence supporting the use of neuroimaging modalities. Positron Emission Tomography may be used to assess metabolic activity of CNS tissue (brain and spinal cord) in patients with SCI.	CNS, Craig Hosp, Rocky Mt Regional Spinal Injury Syst, Englewood, CO 80110 USA; Univ Colorado, Denver Hlth Sci Ctr, Dept Phys Med & Rehabil, Denver, CO USA; Hosp Rocky Mt Reg Spinal Injury Syst, Englewood, CO USA; Swedish Med Ctr, Dept Radiol, Englewood, CO 80110 USA; Thomas Jefferson Univ, Dept Radiol, Philadelphia, PA USA; Reg Spinal Cord Injury Syst, Philadelphia, PA USA; Thomas Jefferson Univ, Dept Phys Med & Rehabil, Philadelphia, PA USA; Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA USA		Lammertse, D (corresponding author), CNS, Craig Hosp, Rocky Mt Regional Spinal Injury Syst, 3425s Clarkson St, Englewood, CO 80110 USA.	dlammertse@craighospital.org		Marino, Ralph/0000-0003-2670-4113; Falci, Scott/0000-0003-4209-0959; Lammertse, Daniel/0000-0003-4590-2481			Bammer R, 2000, AM J NEURORADIOL, V21, P587; Bammer Roland, 2003, Top Magn Reson Imaging, V14, P461, DOI 10.1097/00002142-200312000-00004; BECERRA JL, 1995, AM J NEURORADIOL, V16, P125; Berens SA, 2005, AM J NEURORADIOL, V26, P1612; Boldin C, 2006, SPINE, V31, P554, DOI 10.1097/01.brs.0000201274.59427.a4; BONDURANT FJ, 1990, SPINE, V15, P161, DOI 10.1097/00007632-199003000-00002; Bruehlmeier M, 1998, EUR J NEUROSCI, V10, P3918, DOI 10.1046/j.1460-9568.1998.00454.x; Clifton GL, 1996, SPINAL CORD, V34, P193, DOI 10.1038/sc.1996.38; Collignon FD, 2002, J NEUROSURG, V96, P29, DOI 10.3171/spi.2002.96.1.0029; Corbetta M, 2002, P NATL ACAD SCI USA, V99, P17066, DOI 10.1073/pnas.262669099; Cramer SC, 2005, BRAIN, V128, P2941, DOI 10.1093/brain/awh648; Curt A, 2002, J NEUROTRAUM, V19, P43, DOI 10.1089/089771502753460222; Curt A, 2002, BRAIN, V125, P2567, DOI 10.1093/brain/awf250; Dai Liyang, 2001, Chinese Medical Sciences Journal, V16, P107; Demir A, 2003, RADIOLOGY, V229, P37, DOI 10.1148/radiol.2291020658; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; Dohrmann GJ, 1997, NEUROL RES, V19, P317, DOI 10.1080/01616412.1997.11740819; DUNN EA, 2005, MOLE IMAGING, V4, P58; Dunning MD, 2004, J NEUROSCI, V24, P9799, DOI 10.1523/JNEUROSCI.3126-04.2004; EDLUND W, 2004, AM ACAD NEUROLOGY CL; Falci S, 1997, J NEUROTRAUM, V14, P875, DOI 10.1089/neu.1997.14.875; Falci S P, 1999, J Spinal Cord Med, V22, P173; Fehlings MG, 1999, SPINE, V24, P605, DOI 10.1097/00007632-199903150-00023; Feron F, 2005, BRAIN, V128, P2951, DOI 10.1093/brain/awh657; Finnerup NB, 2003, NEUROLOGY, V61, P1569, DOI 10.1212/01.WNL.0000096016.29134.FA; Flanders AE, 1996, RADIOLOGY, V201, P649, DOI 10.1148/radiology.201.3.8939210; FLANDERS AE, 1990, RADIOLOGY, V177, P25, DOI 10.1148/radiology.177.1.2399326; Flanders AE, 1999, AM J NEURORADIOL, V20, P926; Fukuoka M, 1998, SPINE, V23, P1540, DOI 10.1097/00007632-199807150-00008; HACKNEY DB, 1994, NEUROSURGERY, V35, P1104, DOI 10.1227/00006123-199412000-00013; Ishida Y, 2002, SPINE, V27, P1652, DOI 10.1097/00007632-200208010-00011; ITOH D, 2005, J AM VET MED ASSOC, V227, P1454; Krzyzak AT, 2005, ACTA NEUROBIOL EXP, V65, P255; KULKARNI MV, 1987, RADIOLOGY, V164, P837, DOI 10.1148/radiology.164.3.3615885; Liao CC, 2005, J NEUROSURG, V103, P17, DOI 10.3171/ped.2005.103.1.0017; Lotze M, 1999, RESTOR NEUROL NEUROS, V14, P183; Madi S, 2001, AM J NEURORADIOL, V22, P1768; MARCIELLO MA, 1993, ARCH PHYS MED REHAB, V74, P940; Mikulis DJ, 2002, NEUROLOGY, V58, P794, DOI 10.1212/WNL.58.5.794; MIRVIS SE, 1990, AM J NEURORADIOL, V11, P755; MONTALVO BM, 1984, RADIOLOGY, V153, P125, DOI 10.1148/radiology.153.1.6473773; Moore CI, 2000, P NATL ACAD SCI USA, V97, P14703, DOI 10.1073/pnas.250348997; Morio Y, 2001, SPINE, V26, P1238, DOI 10.1097/00007632-200106010-00012; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; OHSHIO I, 1993, SPINE, V18, P1140, DOI 10.1097/00007632-199307000-00005; Ohta K, 1999, SPINAL CORD, V37, P580, DOI 10.1038/sj.sc.3100881; Pattany PM, 2002, AM J NEURORADIOL, V23, P901; Peyron R, 2004, NEUROLOGY, V63, P1838, DOI 10.1212/01.WNL.0000144177.61125.85; Puri BK, 1998, J NEUROL NEUROSUR PS, V65, P748, DOI 10.1136/jnnp.65.5.748; QUENCER RM, 1984, AM J ROENTGENOL, V143, P1301, DOI 10.2214/ajr.143.6.1301; QUENCER RM, 1992, NEURORADIOLOGY, V34, P85, DOI 10.1007/BF00588148; Quencer RM, 1996, SPINE, V21, P2064, DOI 10.1097/00007632-199609150-00002; Ramon S, 1997, SPINAL CORD, V35, P664, DOI 10.1038/sj.sc.3100490; Rao SC, 1999, SPINE, V24, P598, DOI 10.1097/00007632-199903150-00022; Roelcke U, 1997, J NEUROL NEUROSUR PS, V62, P61, DOI 10.1136/jnnp.62.1.61; RUBIN JM, 1985, RADIOLOGY, V155, P197, DOI 10.1148/radiology.155.1.3883416; Sabbah P, 2002, J NEUROTRAUM, V19, P53, DOI 10.1089/089771502753460231; Sagiuchi T, 2002, J COMPUT ASSIST TOMO, V26, P654, DOI 10.1097/00004728-200207000-00032; SATO T, 1994, PARAPLEGIA, V32, P81, DOI 10.1038/sc.1994.14; SCHAEFER DM, 1992, J NEUROSURG, V76, P218, DOI 10.3171/jns.1992.76.2.0218; SCHAEFER DM, 1989, SPINE, V14, P1090, DOI 10.1097/00007632-198910000-00011; Schwartz ED, 2005, J NEUROTRAUM, V22, P1388, DOI 10.1089/neu.2005.22.1388; Schwartz ED, 2005, AM J NEURORADIOL, V26, P390; Schwartz ED, 2005, AM J NEURORADIOL, V26, P7; Schwartz ED, 2005, NEUROREPORT, V16, P73, DOI 10.1097/00001756-200501190-00017; Schwartz ED, 2003, EXP NEUROL, V184, P570, DOI 10.1016/S0014-4886(03)00295-4; Schwartz ED, 2003, EXP NEUROL, V182, P49, DOI 10.1016/S0014-4886(03)00036-0; Schwartz ED, 1999, AM J NEURORADIOL, V20, P1422; Selden NR, 1999, NEUROSURGERY, V44, P785, DOI 10.1097/00006123-199904000-00057; Shepard MJ, 1999, SPINAL CORD, V37, P833, DOI 10.1038/sj.sc.3100927; Shimada K, 1999, SPINAL CORD, V37, P410, DOI 10.1038/sj.sc.3100858; Shin JC, 2005, YONSEI MED J, V46, P379, DOI 10.3349/ymj.2005.46.3.379; Shoham S, 2001, NATURE, V413, P793, DOI 10.1038/35101651; SILBERSTEIN M, 1992, AM J NEURORADIOL, V13, P1597; Stroman PW, 2002, NEUROIMAGE, V17, P1854, DOI 10.1006/nimg.2002.1305; Stroman PW, 2004, SPINAL CORD, V42, P59, DOI 10.1038/sj.sc.3101559; Sykova E, 2005, ANN NY ACAD SCI, V1049, P146, DOI 10.1196/annals.1334.014; Takahashi M, 1993, Radiat Med, V11, P127; Takahashi M, 2002, J Orthop Surg (Hong Kong), V10, P129; Takahashi T, 1996, SPINE, V21, P166, DOI 10.1097/00007632-199601150-00002; Tewari MK, 2005, SURG NEUROL, V63, P204, DOI 10.1016/j.surneu.2004.05.042; Turner JA, 2001, IEEE T NEUR SYS REH, V9, P154, DOI 10.1109/7333.928575; Tuszynski MH, 1999, J NEUROTRAUM, V16, P523, DOI 10.1089/neu.1999.16.523; Uchida K, 2004, J NEUROSURG-SPINE, V1, P72, DOI 10.3171/spi.2004.1.1.0072; Wasenko JJ, 1997, CLIN IMAG, V21, P246, DOI 10.1016/S0899-7071(96)00041-1; WEIRICH SD, 1990, SPINE, V15, P630, DOI 10.1097/00007632-199007000-00004; Whipple B, 2002, J SEX MARITAL THER, V28, P79, DOI 10.1080/009262302317251043; Winchester P, 2005, NEUROREHAB NEURAL RE, V19, P313, DOI 10.1177/1545968305281515; WIRTH ED, 1992, J NEUROSURG, V76, P261, DOI 10.3171/jns.1992.76.2.0261; Wirth ED, 2001, J NEUROTRAUM, V18, P911, DOI 10.1089/089771501750451839; Yamazaki T, 2005, SURG NEUROL, V63, P95, DOI 10.1016/j.surneu.2004.03.020	91	67	69	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.		2007	30	3					205	214		10.1080/10790268.2007.11753928			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	187ZT	WOS:000247888700002	17684886	Green Published			2022-02-06	
J	Hoane, MR; Kaplan, SA; Ellis, AL				Hoane, Michael R.; Kaplan, Shelby A.; Ellis, Amy L.			The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury	BRAIN RESEARCH			English	Article						TBI; neuronal death; neuroprotection; treatment; vitamin B3; nicotinamide; rat	FOCAL CEREBRAL-ISCHEMIA; POLY(ADP-RIBOSE) POLYMERASE; INFARCTION	Nicotinamide has been shown to protect against many of the pathophysiological factors associated with both ischemic and traumatic brain injuries. The present study evaluated the neuroprotective effect of nicotinamide on the breakdown of the blood-brain barrier (BBB) and apoptosis expression following traumatic brain injury (TBI). Animals were prepared with a unilateral cortical contusion injury (CCI). Fifteen minutes following injury the animals received either nicotinamide (500 mg/kg, ip) or 0.9% saline. The animals were perfused at 5, 24, and 72 h post-injury. BBB integrity was assessed by endogenous rat IgG immunoreactivity. Recent studies have shown that IgG immunoreactivity is a reliable measure of BBB integrity. The results indicated that IgG immunoreactivity was greatest at 5 h and declined at 24 h after injury. Nicotinamide significantly reduced IgG expression at every time point following injury. Apoptosis was examined using the TUNEL method. The results indicated that TUNEL immunoreactivity peaked at 24 h. TUNEL+ cells were classified morphologically as nonapoptotic (Type I) or apoptotic (Type II) to verify that the neuroprotective effects of nicotinamide occur by inhibiting apoptosis or necrosis. Administration of nicotinamide significantly reduced the expression of all TUNEL+ cells in the tissue surrounding the lesion cavity. Specifically there was a significant reduction in the number of Type I, Type II and Total TUNEL+ cells in the nicotinamide-treated animals. in addition, nicotinamide reduced lesion cavity expansion 72 h following CCI. These findings suggest that nicotinamide reduces BBB breach and neuronal cell loss acutely following injury and that these reductions may account for the beneficial behavioral effects seen in previous studies. (c) 2006 Elsevier B.V. All rights reserved.	So Illinois Univ, Restorat Neurosci Lab, Brain & Cognit Sci Program, Dept Psychol,Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA		Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Brain & Cognit Sci Program, Dept Psychol,Ctr Integrat Res Cognit & Neural Sci, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647-03] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R15] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Brewer KL, 2004, ACAD EMERG MED, V11, P125, DOI 10.1197/j.aem.2003.09.010; CALINGASAN NY, 1995, EXP NEUROL, V134, P64, DOI 10.1006/exnr.1995.1037; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Conti AC, 1998, J NEUROSCI, V18, P5663; Hartl R, 1997, ACT NEUR S, V70, P240; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liaudet L, 2003, CORONARY ARTERY DIS, V14, P115, DOI 10.1097/00019501-200304000-00004; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Maiese K, 2003, TRENDS PHARMACOL SCI, V24, P228, DOI 10.1016/S0165-6147(03)00078-6; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; Mokudai T, 2000, STROKE, V31, P1679, DOI 10.1161/01.STR.31.7.1679; Muellner A, 2003, J NEUROTRAUM, V20, P745, DOI 10.1089/089771503767869971; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Tannock GW, 1992, LACTIC ACID BACTERIA, V1, P21; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Yang J, 2002, MINI-REV MED CHEM, V2, P125, DOI 10.2174/1389557024605483; Yang J, 2002, PHARMACOL BIOCHEM BE, V73, P901, DOI 10.1016/S0091-3057(02)00939-5; Yang J, 2002, NEUROSCI LETT, V333, P91, DOI 10.1016/S0304-3940(02)01005-4	32	67	69	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 13	2006	1125						185	193		10.1016/j.brainres.2006.10.019			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	122TZ	WOS:000243251200022	17109832				2022-02-06	
J	Browne, KD; Iwata, A; Putt, ME; Smith, DH				Browne, Kevin D.; Iwata, Akira; Putt, M. E.; Smith, Douglas H.			Chronic ibuprofen administration worsens cognitive outcome following traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						ibuprofen; NSAIDs; cognitive function; traumatic brain injury; COX inhibition	ALZHEIMERS-DISEASE; HEAD-INJURY; CYCLOOXYGENASE INHIBITION; PROGRESSIVE ATROPHY; NEURONAL INJURY; PATHOLOGY; INFLAMMATION; ISCHEMIA; RISK; DEFICITS	Traumatic brain injury (TBI) can induce progressive neurodegeneration in association with chronic inflammation. Since chronic treatment with the non-steroidal anti-inflammatory drug (NSAID), ibuprofen, improves functional and histopathologic outcome in a mouse model of Alzheimer's disease (AD), we investigated whether it would also improve long-term outcome following TBI. Anesthetized adult rats were subjected to fluid percussion brain injury. Over the following 4 months the injured animals received ibuprofen per os (formulated in feed) at the approximate doses of 20 mg/kg body wt/day (it = 13), 40 mg/kg body wt/day (n = 13), or control (feed only, n = 12). Sham animals underwent surgery without injury or ibuprofen treatment (n = 9). At 4 months post-injury, a Morris water maze task revealed a profound learning dysfunction in all three injured groups compared to the sham group. Surprisingly, the learning ability of injured animals treated with either chronic ibuprofen regimen was significantly worsened compared to non-treated injured animals. However, there was no difference in the extent of progressive atrophy of the cortex or hippocampus between treated and non-treated injured animals. These data may have important implications for TBI patients who are often prescribed NSAIDs for chronic pain. (c) 2006 Elsevier Inc. All rights reserved.	Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; Univ Penn, Dept Biostat & Clin Epidemiol, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	kbrowne@mail.med.upenn.edu; iwata-nsu@umin.ac.jp; mputt@cceb.upenn.edu; smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21527] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD026979-16] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS38104] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD026979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER		Antezana DF, 2003, J NEUROSURG, V98, P860, DOI 10.3171/jns.2003.98.4.0860; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; Browne KD, 2004, J NEUROSCI RES, V77, P878, DOI 10.1002/jnr.20215; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; COLE DJ, 1993, J PHARMACOL EXP THER, V266, P1713; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Etminan M, 2003, BMJ-BRIT MED J, V327, P128, DOI 10.1136/bmj.327.7407.128; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; Holscher C, 1995, EUR J PHARMACOL, V294, P253, DOI 10.1016/0014-2999(95)00541-2; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Lim GP, 2001, NEUROBIOL AGING, V22, P983, DOI 10.1016/S0197-4580(01)00299-8; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morihara T, 2005, NEUROPSYCHOPHARMACOL, V30, P1111, DOI 10.1038/sj.npp.1300668; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Park EM, 2005, NEUROSCIENCE, V132, P625, DOI 10.1016/j.neuroscience.2005.01.021; PATEL PM, 1993, BRAIN RES, V614, P315, DOI 10.1016/0006-8993(93)91050-3; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Richardson RL, 2005, BEHAV PHARMACOL, V16, P531, DOI 10.1097/01.fbp.0000179278.03868.96; Richardson RL, 2002, BRAIN RES, V954, P1, DOI 10.1016/S0006-8993(02)03006-8; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shaw KN, 2005, BRAIN RES, V1038, P231, DOI 10.1016/j.brainres.2005.01.035; Shaw KN, 2003, EUR J NEUROSCI, V17, P2438, DOI 10.1046/j.1460-9568.2003.02643.x; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Teather LA, 2002, LEARN MEMORY, V9, P41, DOI 10.1101/lm.43602; Therneau T.M., 2000, STAT BIOL HEALTH; Townsend KP, 2005, FASEB J, V19, P1592, DOI 10.1096/fj.04-3620rev; Veld BAIT, 2002, EPIDEMIOL REV, V24, P248, DOI 10.1093/epirev/mxf001	48	67	70	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2006	201	2					301	307		10.1016/j.expneurol.2006.04.008			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	096RG	WOS:000241393900004	16764859				2022-02-06	
J	McCrimmon, S; Oddy, M				McCrimmon, Sarah; Oddy, Michael			Return to work following moderate-to-severe traumatic brain injury	BRAIN INJURY			English	Article						return to work; traumatic brain injury; fatigue; cognitive functioning; mood; self-report measures	SEVERE HEAD-INJURY; VOCATIONAL-REHABILITATION; ACUTE PREDICTORS; EMPLOYMENT; OUTCOMES; INDICATORS; IMPAIRMENT; EXPERIENCE; DISABILITY; FATIGUE	Primary objective: To investigate the role of cognitive functioning, fatigue, mood and behaviour in return to work (RTW) following moderate-to-severe traumatic brain injury. Design and methods: Between-groups comparisons were conducted with 20 participants who had RTW and 13 who had not. Participants were well matched for age, pre-morbid intellectual functioning, years of education, injury severity and time since injury. Outcomes and results: The unemployed group reported significantly higher levels of fatigue and depression and significantly more problems on self-report questionnaires. A significantly higher proportion of this group was seeking compensation. No significant differences were obtained on neuropsychological measures of cognitive functioning. Conclusions: Mood, fatigue and behavioural problems may impede a person's ability to RTW. Subjective measures may be more superior to objective measures in predicting RTW. The litigation process may affect people's motivation to RTW.	Sevenoaks Hosp, W Kent Neurorehabil Unit, Sevenoaks TN13 3PG, Kent, England; Brain Injury Rehabil Trust, Burgess Hill, W Sussex, England		McCrimmon, S (corresponding author), Sevenoaks Hosp, W Kent Neurorehabil Unit, Darent House,Hosp Rd, Sevenoaks TN13 3PG, Kent, England.	smccrimmon@ukonline.co.uk					Baddeley A., 1992, SPEED CAPACITY LANGU; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; COUGHLIN AK, 1985, ADULT MEMORY INFORM; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CRISP R, 1992, J REHABIL, V58, P27; Delis DC., 2001, DELIS KAPLAN EXECUTI; DERNAALT J, 1999, J NEUROL NEUROSUR PS, V66, P207; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FRASER RT, 1994, TOP LANG DISORD, V15, P55, DOI 10.1097/00011363-199411000-00006; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hillier SL, 1997, BRAIN INJURY, V11, P661; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KOSCIULEK JF, 1991, VOCATIONAL EVALUATIO, V24, P137; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; NAJENSON T, 1995, INT J REHABILITATION, V2, P17; Nybo T, 1999, BRAIN INJURY, V13, P759; Power PW, 2003, BRAIN INJURY, V17, P1021, DOI 10.1080/0269905031000110526; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; SCHWARTZ JE, 1993, J PSYCHOSOM RES, V37, P753, DOI 10.1016/0022-3999(93)90104-N; SERIO CD, 1993, NEUROREHABILITATION, V4, P53; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Voogt RD, 1998, NEUROREHABILITATION, V11, P107, DOI 10.1016/S1053-8135(98)00015-8; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; West M, 1990, Int J Rehabil Res, V13, P291, DOI 10.1097/00004356-199012000-00002; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	43	67	69	1	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2006	20	10					1037	1046		10.1080/02699050600909656			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100005	17060136				2022-02-06	
J	Wang, MC; Linnau, KF; Tirschwell, DL; Hollingworth, W				Wang, Marjorie C.; Linnau, Ken F.; Tirschwell, David L.; Hollingworth, William			Utility of repeat head computed tomography after blunt head trauma: A systematic review	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-of-Neurological-Surgeons/Congress of Neurological Surgeons Cerebrovascular Section/American-Society-of-Interventional-and-Therapeutic-Neuroradiology	APR 16-21, 2005	New Orleans, LA	Amer Assoc Neurol Surg		repeat head CT; systematic review	PROGRESSIVE BRAIN INJURY; SUBARACHNOID HEMORRHAGE; EXTRADURAL HEMATOMA; IONIZING-RADIATION; PEDIATRIC CT; CANCER-RISKS; FOLLOW-UP; MANAGEMENT; MODERATE; CHILDREN	Background: Repeat head computed tomography (CT) is standard practice for head-injured patients at many trauma centers. Utilization of CT has increased over time, yet effects on outcome and associated risks are unknown. We systematically reviewed the literature to determine the incidence of progression of injury on repeat CT and resulting treatment changes. Methods: Studies were included from Medline, Embase, and a hand search of citations in reviewed articles. Main outcome measures were progression of injury on repeat CT and resulting intervention. Data were abstracted from 30 eligible studies and discrepancies were settled by consensus. Results: Progression of injury on repeat CT was evident in 8 to 67% of patients in the included studies. Neurosurgical intervention resulting subsequent to a repeat CT occurred in 0 to 54% of patients. More severe traumatic brain injury, defined by Glasgow Coma Scale, was associated with a higher proportion of patients with progression of injury on CT and subsequent neurosurgical interventions. Risk factors associated with progression of injury on CT or resulting intervention were inconsistently reported, but coagulopathy and injury severity were most commonly reported. Few studies reported changes in nonsurgical management, in-hospital disposition, or adverse events associated with obtaining repeat CTs. Conclusion:. Indications for repeat head CT after traumatic brain injury are unclear. The wide range of reported injury progression on CT and resulting surgical and medical treatment changes suggest there may be a subset of patients who benefit from repeat CT. Further research should stratify by severity of traumatic brain injury, clearly define inclusion and exclusion criteria, address selection bias, quantify progression of injury on CT, determine factors predictive of injury progression and intervention, and assess risks associated with repeat CT.	Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; Univ Washington, Harborview Med Ctr, Dept Radiol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Neurol, Seattle, WA 98104 USA		Wang, MC (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	mcwang@u.washington.edu		Hollingworth, William/0000-0002-0840-6254; Tirschwell, David/0000-0002-8059-2901			BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Etzel RA, 1998, PEDIATRICS, V101, P717; Fainardi E, 2004, ACTA NEUROCHIR, V146, P257, DOI 10.1007/s00701-003-0207-y; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; FRENCH BN, 1977, SURG NEUROL, V7, P171; Givner A, 2002, J PEDIATR SURG, V37, P381, DOI 10.1053/jpsu.2002.30825; Glasziou P., 2001, SYSTEMATIC REV HLTH; Greenhalgh T, 2005, BRIT MED J, V331, P1064, DOI 10.1136/bmj.38636.593461.68; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; HUNEIDI AHS, 1992, ANN ROY COLL SURG, V74, P345; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LUND E, 1982, NEURORADIOLOGY, V22, P181, DOI 10.1007/BF00341246; MACPHERSON P, 1990, CLIN RADIOL, V42, P85, DOI 10.1016/S0009-9260(05)82072-0; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Mettler Fred A. Jr., 2000, Journal of Radiological Protection, V20, P353, DOI 10.1088/0952-4746/20/4/301; Muszynski CA, 1999, NEURORADIOLOGY, V41, P875, DOI 10.1007/s002340050859; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Ron E, 2003, HEALTH PHYS, V85, P47, DOI 10.1097/00004032-200307000-00011; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, ACT NEUR S, V81, P81; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; Stearley H E, 1998, Am J Crit Care, V7, P282; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Subramanian SK, 2002, NEUROL RES, V24, P125, DOI 10.1179/016164102101199657; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; *US COCHR CTR, 2005, COCHR CENTR REG CONT; *US COCHR CTR, 2004, COCHR CENTR REG SYST; Vano E, 1998, BRIT J RADIOL, V71, P728, DOI 10.1259/bjr.71.847.9771383; Zahari M., 1996, Singapore Medical Journal, V37, P285; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729	48	67	67	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2006	61	1					226	233		10.1097/01.ta.0000197385.18452.89			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	065TV	WOS:000239183600051	16832279				2022-02-06	
J	Dubreuil, CI; Marklund, N; Deschamps, K; McIntosh, TK; McKerracher, L				Dubreuil, CI; Marklund, N; Deschamps, K; McIntosh, TK; McKerracher, L			Activation of Rho after traumatic brain injury and seizure in rats	EXPERIMENTAL NEUROLOGY			English	Article						Rho; TBI; kainic acid; seisure; cortex; hippocampus	FLUID-PERCUSSION INJURY; RECEPTOR FAMILY-MEMBER; CORTICAL IMPACT INJURY; NECROSIS-FACTOR-ALPHA; NEURONAL DEATH; CELL-DEATH; NEUTROPHIL INFILTRATION; HIPPOCAMPAL-NEURONS; AXONAL REGENERATION; ACTIN CYTOSKELETON	Traumatic brain injury (TBI) is characterized by a progressive cell loss and a lack of axonal regeneration. In the central nervous system (CNS), the Rho signaling pathway regulates the neuronal response to growth inhibitory proteins and regeneration of damaged axons, and Rho activation is also correlated with an increased susceptibility to apoptosis. To evaluate whether traumatic brain injury (TBI) results in changes in Rho activation in vulnerable regions of the brain, GTP-RhoA pull down assays were performed on rat cortical and hippocampal tissue homogenates obtained from 24 h to 3 days following lateral fluid percussion brain injury (FPI). Following FPI, a significantly increased RhoA activation was observed from 24 h to 3 days post-injury in the cortex and by 3 days in the hippocampus ipsilateral to the injury. We also detected activated RhoA in the cortex and hippocampus contralateral to the injury, without concomitant changes in total RhoA levels. To determine if immediate post-traumatic events such as seizures may activate Rho, we examined RhoA activation in the brains of rats with kainic acid-induced seizures. Severe seizures resulted in bilateral RhoA activation in the cortex and hippocampus. Together, these results indicate that RhoA is activated in vulnerable brain regions following traumatic and epileptic insults to the CNS. (C) 2005 Elsevier Inc. All rights reserved.	Univ Montreal, Fac Med, Dept Pathol & Biol Cellulaire, Montreal, PQ H3T 1J4, Canada; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Pittsburgh, PA 15261 USA		McKerracher, L (corresponding author), Univ Montreal, Fac Med, Dept Pathol & Biol Cellulaire, 2900 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	c.dubreuil@umontreal.ca; niklas.marklund@neurokir.uu.se; kathleen7deschamps@hotmail.com; tkm53@comcast.net; lisa.mckerracher@bioaxone.com		Marklund, Niklas/0000-0002-9797-5626	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS40978, P50-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978] Funding Source: NIH RePORTER		Benitah SA, 2004, BBA-REV CANCER, V1705, P121, DOI 10.1016/j.bbcan.2004.10.002; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conti AC, 1998, J NEUROSCI, V18, P5663; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dergham P, 2002, J NEUROSCI, V22, P6570; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Jourquin J, 2003, EUR J NEUROSCI, V18, P1507, DOI 10.1046/j.1460-9568.2003.02876.x; Kim SW, 2004, BRAIN RES, V1007, P188, DOI 10.1016/j.brainres.2004.02.009; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kinouchi T, 2002, BIOL GROW ANIM, V1, P203, DOI 10.1016/S1877-1823(09)70123-7; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Marklund N, 2005, RESTOR NEUROL NEUROS, V23, P31; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Niederost B, 2002, J NEUROSCI, V22, P10368; O'Kane EM, 2004, NEUROPHARMACOLOGY, V46, P879, DOI 10.1016/j.neuropharm.2003.11.020; O'Kane EM, 2003, J NEUROCHEM, V87, P1309, DOI 10.1046/j.1471-4159.2003.02102.x; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Peterson S, 2003, J BIOL CHEM, V278, P33943, DOI 10.1074/jbc.M302376200; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Trapp T, 2001, MOL CELL NEUROSCI, V17, P883, DOI 10.1006/mcne.2001.0971; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; Wu KY, 2005, NATURE, V436, P1020, DOI 10.1038/nature03885; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yi JS, 2003, NEUROSCI LETT, V347, P126, DOI 10.1016/S0304-3940(03)00656-6; Zhang XA, 1997, EUR J NEUROSCI, V9, P760, DOI 10.1111/j.1460-9568.1997.tb01424.x	62	67	69	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2006	198	2					361	369		10.1016/j.expneurol.2005.12.002			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	033RJ	WOS:000236866400009	16448651				2022-02-06	
J	Henry, JD; Phillips, LH; Crawford, JR; Theodorou, G; Summers, F				Henry, JD; Phillips, LH; Crawford, JR; Theodorou, G; Summers, F			Cognitive and psychosocial correlates of alexithymia following traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						emotional change; 'Organic' alexithymia; executive dysfunction	VERBAL FLUENCY PERFORMANCE; QUALITY-OF-LIFE; TORONTO-ALEXITHYMIA; FRONTAL-LOBE; EMOTION RECOGNITION; FACTORIAL VALIDITY; HEAD-INJURY; DEPRESSION; SCALE; ANXIETY	Changes in emotional and social behaviour are considered to be amongst the most common and debilitating consequences of traumatic brain injury (TBI). Little is known of the effects of TBI on alexithymia, which refers to impairment in aspects of understanding emotions. In the current study TBI patients (N = 28) were compared with demographically matched healthy controls (N = 31) on the Toronto Alexithymia Scale-20 (TAS-20), a measure that taps three distinct characteristics of the alexithymia concept; difficulty in identifying emotions, difficulty in describing emotions and externally oriented thinking. Patients and controls also completed measures of anxiety, depression, quality of life, and measures of fluency to assess executive function. Patients showed greater levels of alexithymia, in terms of difficulty identifying emotions and reduced introspection. Difficulty in identifying emotions was associated with poorer quality of life, even when depression and anxiety were controlled. Difficulty in identifying emotions was also uniquely associated with executive function deficits. Thus, although studies typically focus on aspects of cognitive change following head injury, these results lend support to Becerra et al.'s (Becerra, R., Amos, A., & Jongenelis, S. (2002). Organic alexithymia: a study of acquired emotional blindness. Brain Injury, 16, 633-645.) notion of an 'organic alexithymia', and suggest that more attention should be focused upon assessment of emotional change post-head injury. (c) 2005 Elsevier Ltd. All rights reserved.	Univ New S Wales, Sch Psychol, Sydney, NSW, Australia; Univ Aberdeen, Sch Psychol, Aberdeen, Scotland; Univ Aberdeen, Dept Neurosurg, Aberdeen, Scotland		Henry, JD (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW, Australia.	julie.henry@unsw.edu.au	Crawford, John R/A-4165-2008; Phillips, Louise H/A-7952-2008	Crawford, John R/0000-0003-3403-3428; Phillips, Louise H/0000-0003-1005-8567; Phillips, Louise/0000-0002-0988-3028; Henry, Julie/0000-0002-2081-3717			Allerdings MD, 2001, BRAIN COGNITION, V47, P304; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; Benson D.F., 1986, FRONTAL LOBES; Berthoz S, 2002, AM J PSYCHIAT, V159, P961, DOI 10.1176/appi.ajp.159.6.961; Cohen J., 2013, STAT POWER ANAL BEHA; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Crawford J.R, 2005, EFFECTIVENESS REHABI, P233, DOI DOI 10.1093/ACPROF:OSO/9780198526544.003.0019; De Leo D, 1998, BEHAV MED, V24, P17, DOI 10.1080/08964289809596377; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DOWNES JJ, 1993, BRAIN, V116, P887, DOI 10.1093/brain/116.4.887; Eizaguirre AE, 2004, PERS INDIV DIFFER, V36, P321, DOI 10.1016/S0191-8869(03)00099-0; Gundel H, 2004, PSYCHOSOM MED, V66, P132, DOI 10.1097/01.PSY.0000097348.45087.96; Gunzelmann T, 2002, COMPR PSYCHIAT, V43, P74, DOI 10.1053/comp.2002.29855; Henry JD, 2005, J CLIN EXP NEUROPSYC, V27, P78, DOI 10.1080/138033990513654; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; HENRY JD, IN PRESS AGING NEURO; HENRY JD, 2005, UNPUB NEW CONCEPTUAL; Hintikka J, 2001, COMPR PSYCHIAT, V42, P234, DOI 10.1053/comp.2001.23147; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kano M, 2003, BRAIN, V126, P1474, DOI 10.1093/brain/awg131; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; LANE RD, 1990, J PERS ASSESS, V55, P124, DOI 10.1207/s15327752jpa5501&2_12; Lane RD, 2000, PSYCHOSOM MED, V62, P492, DOI 10.1097/00006842-200007000-00007; Larsen JK, 2003, J PSYCHOSOM RES, V54, P533, DOI 10.1016/S0022-3999(02)00466-X; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lipsanen T, 2004, PSYCHOPATHOLOGY, V37, P200, DOI 10.1159/000080132; Loas G, 2001, J PSYCHOSOM RES, V50, P255, DOI 10.1016/S0022-3999(01)00197-0; Lumley MA, 1996, J PSYCHOSOM RES, V41, P519, DOI 10.1016/S0022-3999(96)00227-9; Lundh LG, 2001, J PERS, V69, P483, DOI 10.1111/1467-6494.00153; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; Marchesi C, 2000, J PSYCHOSOM RES, V49, P43, DOI 10.1016/S0022-3999(00)00084-2; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MILLER E, 1984, BRIT J CLIN PSYCHOL, V23, P53, DOI 10.1111/j.2044-8260.1984.tb00626.x; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Monsen J T, 1996, J Psychother Pract Res, V5, P238; Muller J, 2003, PSYCHOPATHOLOGY, V36, P71, DOI 10.1159/000070361; Ochsner KN, 2001, AM PSYCHOL, V56, P717, DOI 10.1037//0003-066X.56.9.717; Parker JDA, 2003, J PSYCHOSOM RES, V55, P269, DOI 10.1016/S0022-3999(02)00578-0; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Phillips L. H, 1997, METHODOLOGY FRONTAL, P191; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; SCMITZ M, 2000, DISS ABSTR INT B, V60, P5790; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Spalletta G, 2001, PSYCHOSOM MED, V63, P944, DOI 10.1097/00006842-200111000-00013; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Taylor G. J., 1997, DISORDERS AFFECT REG; Taylor GJ, 2003, J PSYCHOSOM RES, V55, P277, DOI 10.1016/S0022-3999(02)00601-3; Taylor GJ, 2000, CAN J PSYCHIAT, V45, P134, DOI 10.1177/070674370004500203; Waldstein SR, 2002, PSYCHOL HEALTH, V17, P597, DOI 10.1080/08870440290025803; Waller E, 2004, J PSYCHOSOM RES, V57, P239, DOI 10.1016/S0022-3999(03)00613-5; Welsh MC, 1999, BRAIN COGNITION, V41, P231, DOI 10.1006/brcg.1999.1123; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1016/S0960-9822(02)01374-X, 10.1080/09602010244000444]; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	62	67	69	1	27	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	1					62	72		10.1016/j.neuropsychologia.2005.04.011			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	004FJ	WOS:000234737100005	15896816				2022-02-06	
J	Ownsworth, T; Fleming, J; Desbois, J; Strong, J; Kuipers, P				Ownsworth, T; Fleming, J; Desbois, J; Strong, J; Kuipers, P			A metacognitive contextual intervention to enhance error awareness and functional outcome following traumatic brain injury: A single-case experimental design	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						self-awareness; errors; behavior; executive function; observation; rehabilitation; traumatic brain injury; real-life setting; case study	SELF-AWARENESS; PSYCHOSOCIAL ADJUSTMENT; ANOSOGNOSIA; DEFICITS; REHABILITATION; DAMAGE	Very few empirically validated interventions for improving metacognitive skills (i.e., self-awareness and self-regulation) and functional outcomes have been reported. This single-case experimental study presents JM, a 36-year-old man with a very severe traumatic brain injury (TBI) who demonstrated long-term awareness deficits. Treatment at four years post-injury involved a metacognitive contextual intervention based on a conceptualization of neuro-cognitive, psychological, and socio-environmental factors contributing to his awareness deficits. The 16-week intervention targeted error awareness and self-correction in two real life settings: (a) cooking at home: and (b) volunteer work. Outcome measures included behavioral observation of error behavior and standardized awareness measures. Relative to baseline performance in the cooking setting, JM demonstrated a 44% reduction in error frequency and increased self-correction. Although no spontaneous generalization was evident in the volunteer work setting, specific training in this environment led to a 39% decrease in errors. JM later gained paid employment and received brief metacognitive training in his work environment. JM's global self-knowledge of deficits assessed by self-report was unchanged after the program. Overall, the study provides preliminary support for a metacognitive contextual approach to improve error awareness and functional Outcome in real life settings.	Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Occupat Therapy Dept, Woolloongabba, Qld 4102, Australia; Univ Queensland, CONROD, St Lucia, Qld, Australia		Ownsworth, T (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Therapies Bldg 84A, Brisbane, Qld 4072, Australia.	t.ownsworth@shrs.uq.edu.au	Fleming, Jennifer M/B-4436-2011; Strong, Jenny/F-1211-2010; Ownsworth, Tamara/ABB-6961-2021	Strong, Jenny/0000-0002-9367-8755; Ownsworth, Tamara/0000-0003-1835-7094; Kuipers, Pim/0000-0003-0340-2286			Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; Burgess P, 1996, BEHAV ASSESSMENT DYS; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cocchini G, 2002, NEUROPSYCHOLOGIA, V40, P2030, DOI 10.1016/S0028-3932(02)00054-4; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; DOMHOLDTZ E, 2005, REHABILITATION RES P; Fleming JM, 1996, BRAIN INJURY, V10, P1; FLEMING JM, 2006, IN PRESS NEUROPSYCHO, V16; GLYNN T, 1979, REMEDIAL READING HOM; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hersen M., 1990, INT HDB BEHAV MODIFI, P175, DOI DOI 10.1007/978-1-4613-0523-1_9; Katz N, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P323; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Lezak MD., 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Loeb, 1996, INDEPENDENT LIVING S; Marcel AJ, 2004, CORTEX, V40, P19, DOI 10.1016/S0010-9452(08)70919-5; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; McNaughton S., 1987, PAUSE PROMPT PRAISE; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morris RG, 2004, COGNITIVE NEUROPSYCH, P275; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T., 2005, NEUROPSYCHOANALYSIS, V7, P83; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; OWNSWORTH TL, 2005, NEUR REH C JUL 11 12; OWNSWORTH TL, 2006, IN PRESS NEUROPSYCHO, V10; Pia L, 2004, CORTEX, V40, P367, DOI 10.1016/S0010-9452(08)70131-X; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; SNITH RP, 1994, HOSP ANXIETY DEPRESS; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss D.T., 2001, FRONTAL LOBES NEUROP, P101; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [https://doi.org/10.1037/0894-4105.8.3.355, DOI 10.1037/0894-4105.8.3.355]; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Toglia JP, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P5; Vikki Juhani, 1994, Journal of Clinical and Experimental Neuropsychology, V16, P325; YLIVISAKER M, 1998, TRAUMATIC BRAIN INJU, P221; [No title captured]; [No title captured]	50	67	68	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2006	12	1					54	63		10.1017/S135561770606005X			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	012BS	WOS:000235313800007	16433944	Green Published			2022-02-06	
J	Rapport, L; Hanks, RA; Bryer, RC				Rapport, L; Hanks, RA; Bryer, RC			Barriers to driving and community integration after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						community integration; driving; traumatic brain injury	OLDER DRIVERS; STROKE; DAMAGE; CONSEQUENCES; RESTRICTIONS; VALIDATION; PREDICTORS; AWARENESS; DOCTORS; FITNESS	Objective: To examine the relations among driving status, perceptions of barriers to the resumption of driving, and community integration outcomes after traumatic brain injury (17131). Design: Correlational research using logistic and multiple regression analyses, analyses of variance, and covariance. Participants: Fifty-one survivors of TBI, 6 months to 10 years postinjury. Main outcome measures: Driving status postinjury, Community Integration Measure, and Craig Hospital Assessment and Reporting Technique. Results: Perceptions of barriers to driving provided unique information in predicting Subjective and objective indices of community integration, even after accounting for other potentially pertinent variables (eg, injury severity social support, negative affectivity, and use of alternative transportation). Moreover, survivors who had not resumed driving showed poorer community integration than did those who had resumed driving. Social barriers such as directives against driving from significant others accounted for the most variance in survivor driving status. Decisions to cease driving were more common among those with no formal driving evaluation than among survivors who had been evaluated. Conclusions: Significant others have substantial influence on post-TBI driving outcome. The findings highlight the importance of independent driving to community integration, as well as psychoeducation of survivors and their families.	Wayne State Univ, Dept Psychol, Detroit, MI 48226 USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48226 USA		Rapport, L (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave,5057 Woodward Ave,7th Floor, Detroit, MI 48226 USA.	rapport@sun.science.wayne.edu		Rapport, Lisa/0000-0001-8014-9523			Anderson CJ, 2002, ARCH PHYS MED REHAB, V83, P791, DOI 10.1053/apmr.2002.32742; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; Cohen J., 2013, STAT POWER ANAL BEHA; Coleman Bryer R, 2005, DRIVER REHABILITATIO, P165; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; Cutrona EC., 1987, ADV PERSONAL RELATIO, V1, P37, DOI DOI 10.1037/0882-7974.1.1.47; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; FINN P, 1986, ACCIDENT ANAL PREV, V18, P289, DOI 10.1016/0001-4575(86)90043-6; Fisk GD, 1998, BRAIN INJURY, V12, P683; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Glass TA, 1999, BRIT MED J, V319, P478, DOI 10.1136/bmj.319.7208.478; Goodyear K, 2003, CLIN MED, V3, P86, DOI 10.7861/clinmedicine.3-1-86; Groeger JA, 1996, BRIT J PSYCHOL, V87, P61, DOI 10.1111/j.2044-8295.1996.tb02577.x; GROEGER JA, 1989, ACCIDENT ANAL PREV, V21, P155, DOI 10.1016/0001-4575(89)90083-3; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Hopewell CA, 2002, J HEAD TRAUMA REHAB, V17, P48, DOI 10.1097/00001199-200202000-00007; Jewkes R, 1996, SOC SCI MED, V43, P555, DOI 10.1016/0277-9536(95)00439-4; Johnson J E, 1999, J Gerontol Nurs, V25, P12; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Kelly R, 1999, POSTGRAD MED J, V75, P537, DOI 10.1136/pgmj.75.887.537; Kiyono Y, 2001, ARCH PHYS MED REHAB, V82, P1389, DOI 10.1053/apmr.2001.26089; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Mackenzie C, 2003, APHASIOLOGY, V17, P107, DOI 10.1080/729255215; MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037/0003-066X.41.9.954; Marottoli RA, 2000, J GERONTOL B-PSYCHOL, V55, pS334, DOI 10.1093/geronb/55.6.S334; Marottoli RA, 1998, ACCIDENT ANAL PREV, V30, P331, DOI 10.1016/S0001-4575(97)00100-0; Mazer BL, 2003, ARCH PHYS MED REHAB, V84, P541, DOI 10.1053/apmr.2003.50085; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; MCKENNA FP, 1991, ACCIDENT ANAL PREV, V23, P45, DOI 10.1016/0001-4575(91)90034-3; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RAPPORT LJ, 2004, M INT NEUR SOC JUL B; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; SHORE D, 1980, ARCH PHYS MED REHAB, V61, P481; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; SVENSON O, 1981, ACTA PSYCHOL, V47, P143, DOI 10.1016/0001-6918(81)90005-6; Taylor J, 2002, CLIN PSYCHOL REV, V22, P631, DOI 10.1016/S0272-7358(01)00114-3; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WHITENECK GG, 1997, HANDICAP ASSESSMENT	46	67	67	2	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2006	21	1					34	44		10.1097/00001199-200601000-00004			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	004WW	WOS:000234784300004	16456390				2022-02-06	
J	Ahmad, I; Lope-Piedrafita, S; Bi, XN; Hicks, C; Yao, YQ; Yu, C; Chaitkin, E; Howison, CM; Weberg, L; Trouard, TP; Erickson, RP				Ahmad, I; Lope-Piedrafita, S; Bi, XN; Hicks, C; Yao, YQ; Yu, C; Chaitkin, E; Howison, CM; Weberg, L; Trouard, TP; Erickson, RP			Allopregnanolone treatment, both as a single injection or repetitively, delays demyelination and enhances survival of Niemann-Pick C mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neurodegeneration; neurosteroids; mouse models; magnetic resonance imaging; Niemann-Pick C	ORGANOTYPIC SLICE CULTURES; TRAUMATIC BRAIN-INJURY; RAT PREFRONTAL CORTEX; DISEASE TYPE-C; CHOLESTEROL ACCUMULATION; GENE-EXPRESSION; MURINE MODEL; MOUSE MODEL; CELL-DEATH; PROTEIN	Niemann-Pick C disease (NPC) is an irreversible neurodegenerative disorder without current treatment. It is thought to result from deficient intracellular cholesterol and/or ganglioside trafficking. We have investigated the effects of allopregnanolone treatments on survival, weight loss, motor function, magnetic resonance imaging (MRI), and neuropathology in the mouse model of NPC (Npc1(-/-) mice). We confirmed previous results showing that a single injection of 250 mu g of allopregnanolone on postnatal day 7 significantly extended the life span of Npc1(-/-) mice. This caused a marked difference in the weight curves of the treated mice but no statistical difference in the Rota-Rod performance. T2-weighted MRI and diffusion tensor imaging (DTI) of treated mice showed values of signal intensity and fractional anisotropy closer to those of wildtype mice than those of untreated Npc1(-/-) mice. Neuropathology showed that day-7 treatment markedly suppressed astrocyte reaction and significantly reduced microglial activation. Furthermore, the steroid treatment also increased myelination in brains of Npc1(-/-) mice. Similar effects of allopregnanolone treatment were observed in Npc1(-/-), mdr1a(-/-) double-mutant mice, which have a deficient blood-brain barrier, resulting in increased steroid uptake. The effects on survival and weight loss of a single injection on day 7 followed by injections every 2 weeks were also evaluated in Npc1(-/-) mice, and the beneficial effects were found to be greater than with the single injection at day 7. We conclude that allopregnanolone treatment significantly ameliorates several symptoms of NPC in Npc1(-/-) mice, presumably by effects on myelination or neuronal connectivity. (c) 2005 Wiley-Liss, Inc.	Univ Arizona, Dept Pediat 4341 B, Tucson, AZ 85724 USA; Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA; Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA; Univ Arizona, Ctr Opt Sci, Tucson, AZ 85724 USA; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Biomed Engn Program, Tucson, AZ 85724 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; Univ Arizona, Interdept Program Genet, Tucson, AZ 85724 USA		Erickson, RP (corresponding author), Univ Arizona, Dept Pediat 4341 B, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.	erickson@peds.arizona.edu	Lope-Piedrafita, Silvia/I-4808-2012	Lope-Piedrafita, Silvia/0000-0002-8127-6425	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000343] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB00343] Funding Source: Medline		Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baudry M, 2003, EXP NEUROL, V184, P887, DOI 10.1016/S0014-4886(03)00345-5; Bi XN, 2004, J BIOL CHEM, V279, P48238, DOI 10.1074/jbc.M405442200; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; Camargo F, 2001, LIFE SCI, V70, P131, DOI 10.1016/S0024-3205(01)01384-4; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Erickson RP, 2000, J INHERIT METAB DIS, V23, P54, DOI 10.1023/A:1005650930330; Erickson RP, 2002, MOL REPROD DEV, V62, P167, DOI 10.1002/mrd.10093; Erickson RP, 2002, J NEUROSCI RES, V68, P738, DOI 10.1002/jnr.10257; Garver WS, 2002, J LIPID RES, V43, P579; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Ghoumari AM, 2003, P NATL ACAD SCI USA, V100, P7953, DOI 10.1073/pnas.1332667100; Gizerian SS, 2004, BRAIN RES, V1012, P66, DOI 10.1016/j.brainres.2004.03.049; Gondre-Lewis MC, 2003, CURR BIOL, V13, P1324, DOI 10.1016/S0960-9822(03)00531-1; Griffin LD, 2004, NAT MED, V10, P704, DOI 10.1038/nm1073; Grobin AC, 2003, J NEUROSCI, V23, P1832; Hasan KM, 2001, J MAGN RESON, V152, P41, DOI 10.1006/jmre.2001.2400; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Kramer W, 2005, J BIOL CHEM, V280, P1306, DOI 10.1074/jbc.M406309200; Lamba V, 2004, TOXICOL APPL PHARM, V199, P251, DOI 10.1016/j.taap.2003.12.027; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Leventhal AR, 2004, J BIOL CHEM, V279, P8084, DOI 10.1074/jbc.M310672200; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Loftus SK, 2002, HUM MOL GENET, V11, P3107, DOI 10.1093/hmg/11.24.3107; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Mascia MP, 2002, J PHARMACOL EXP THER, V303, P1014, DOI 10.1124/jpet.102.040063; Meijer OC, 1998, ENDOCRINOLOGY, V139, P1789, DOI 10.1210/en.139.4.1789; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.0.CO;2-H; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Passeggio J, 2005, J BIOL CHEM, V280, P10333, DOI 10.1074/jbc.M413657200; Patterson M, 2001, METABOLIC MOL BASES, VIII, P3611; PATTERSON MC, 1993, NEUROLOGY, V43, P61, DOI 10.1212/WNL.43.1_Part_1.61; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; ROFF CF, 1993, ENDOCRINOLOGY, V133, P2913, DOI 10.1210/en.133.6.2913; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Sleat DE, 2004, P NATL ACAD SCI USA, V101, P5886, DOI 10.1073/pnas.0308456101; Sooksawate T, 2001, BRIT J PHARMACOL, V134, P1303, DOI 10.1038/sj.bjp.0704360; Swanson LW, 1992, BRAIN MAPS STRUCTURE; Trouard TP, 1999, MAGNET RESON MED, V42, P11, DOI 10.1002/(SICI)1522-2594(199907)42:1<11::AID-MRM3>3.0.CO;2-J; Vincent I, 2003, CURR OPIN NEUROL, V16, P155, DOI 10.1097/00019052-200304000-00006; Wu YP, 2005, MOL GENET METAB, V84, P9, DOI 10.1016/j.ymgme.2004.08.017; Zervas M, 2001, CURR BIOL, V11, P1283, DOI 10.1016/S0960-9822(01)00396-7	49	67	68	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 15	2005	82	6					811	821		10.1002/jnr.20685			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	993GV	WOS:000233943500009	16273542				2022-02-06	
J	Kim, HJ; Fillmore, HL; Reeves, TM; Phillips, LL				Kim, HJ; Fillmore, HL; Reeves, TM; Phillips, LL			Elevation of hippocampal MMP-3 expression and activity during trauma-induced synaptogenesis	EXPERIMENTAL NEUROLOGY			English	Article						MMP-3 expression; trauma; synaptogenesis	COMBINED FLUID PERCUSSION; MATRIX METALLOPROTEINASES; BRAIN-INJURY; DENTATE GYRUS; MESSENGER-RNA; WHITE-MATTER; ADULT-RATS; PLASMINOGEN-ACTIVATOR; MULTIPLE-SCLEROSIS; DENDRITIC SPINES	The matrix metalloproteinase (MMP) enzyme family contributes to the regulation of a variety of brain extracellular matrix molecules. In order to assess their role in synaptic plasticity following traumatic brain injury (TBI), we compared expression of stromelysin-1 (MMP-3) protein and mRNA in two rodent models of TBI exhibiting different levels of recovery: adaptive synaptic plasticity following central fluid percussion injury and maladaptive synaptic plasticity generated by combined TBI and bilateral entorhinal cortical lesion (TBI + BEC). We sampled the hippocampus at 7 days postinjury, targeting a selectively vulnerable brain region and a survival interval exhibiting rapid synaptogenesis. We report elevated expression of hippocampal MMP-3 mRNA and protein after TBI. MMP-3 immunohistochemical staining showed increased protein levels relative to sham-injured controls, primarily localized to cell bodies within the deafferented dendritic laminae. Injury-related differences in MMP-3 protein were also observed. TBI alone elevated MMP-3 immunobinding over the stratum lacunosum moleculare (SLM). inner molecular layer and hilus, while TBI + BEC generated more robust increases in MMP-3 reactivity within the deafferented SLM and dentate molecular layer (DML). Double labeling with GFAP confirmed the presence of MMP-3 within reactive astrocytes induced by each injury model. Semi-quantitative RT-PCR revealed that MMP-3 mRNA also increased after each injury, however, the combined insult induced a much greater elevation than fluid percussion alone: 1.9-fold vs. 79%, respectively. In the TBI + BEC model, MMP-3 up-regulation was spatio-temporally correlated with increased enzyme activity, an effect which was attenuated with the neuroprotective compound MK-801. These results show that distinct pathological conditions elicited by TBI can differentially affect MMP-3 expression during reactive synaptic plasticity. Notably, these effects are both transcriptional and translational and are correlated with functionally active enzyme. (C) 2004 Elsevier Inc. All rights reserved.	Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Neurosurg, Richmond, VA 23298 USA		Phillips, LL (corresponding author), Virginia Commonwealth Univ, Med Ctr, Sch Med, Dept Anat & Neurobiol, Med Sci Bldg Room 736,1217 E Marshall St,POB 9807, Richmond, VA 23298 USA.	llphilli@vcu.edu		Fillmore, Helen/0000-0003-4131-579X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044372, R56NS044372] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS44372] Funding Source: Medline		Anan H, 1996, J ENDODONT, V22, P668, DOI 10.1016/S0099-2399(96)80061-6; Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Baldwin SA, 1996, GLIA, V16, P266; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; BEJARANO PA, 1988, BIOCHEM J, V256, P413, DOI 10.1042/bj2560413; BRODKEY JA, 1995, J NEUROSURG, V82, P106, DOI 10.3171/jns.1995.82.1.0106; BRODKEY JA, 1993, EXP NEUROL, V123, P251, DOI 10.1006/exnr.1993.1158; CROTTY P, 1994, HUM PATHOL, V25, P572, DOI 10.1016/0046-8177(94)90221-6; Cuzner ML, 1996, J NEUROPATH EXP NEUR, V55, P1194, DOI 10.1097/00005072-199612000-00002; D'Souza CA, 2002, J BIOL CHEM, V277, P13589, DOI 10.1074/jbc.M108817200; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Deller T, 2001, RESTOR NEUROL NEUROS, V19, P159; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ethell IM, 1999, J CELL BIOL, V144, P575, DOI 10.1083/jcb.144.3.575; GARCIA DY, 1999, J NEUROCHEM, V73, P812; Giraudon P, 1997, MOL PSYCHIATR, V2, P107, DOI 10.1038/sj.mp.4000218; HASTY KA, 1990, ARTHRITIS RHEUM, V33, P388, DOI 10.1002/art.1780330312; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; IMAI K, 1994, FEBS LETT, V352, P216, DOI 10.1016/0014-5793(94)00960-0; Jaworski DM, 2000, J NEUROSCI RES, V61, P396, DOI 10.1002/1097-4547(20000815)61:4<396::AID-JNR6>3.0.CO;2-S; KALB RG, 1988, J NEUROSCI, V8, P2350; KIGASAWA K, 1995, JPN J OPHTHALMOL, V39, P35; Kim D, 1999, IEEE COMMUN LETT, V3, P9, DOI 10.1109/4234.740114; KIM HJ, 1997, J NEUROTRAUM, V14, P803; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Larsen PH, 2003, J NEUROSCI, V23, P11127, DOI 10.1523/jneurosci.23-35-11127.2003; LEGENDRE DI, 1994, J NEUROTRAUM, V11, P333, DOI 10.1089/neu.1994.11.333; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; Mun-Bryce S, 2002, BRAIN RES, V933, P42, DOI 10.1016/S0006-8993(02)02303-X; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NELSON RB, 1989, J NEUROSCI, V9, P381; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Oh LYS, 1999, J NEUROSCI, V19, P8464; OKADA Y, 1986, J BIOL CHEM, V261, P14245; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 2003, J NEUROSCI, V23, P10182; REEVES TM, 1986, EXP BRAIN RES, V65, P167; Rivera S, 2002, EUR J NEUROSCI, V15, P19, DOI 10.1046/j.0953-816x.2001.01838.x; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 2001, STROKE, V32, P1162, DOI 10.1161/01.STR.32.5.1162; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; SHEFFIELD JB, 1994, DEV DYNAM, V200, P79, DOI 10.1002/aja.1002000108; Sole S, 2004, J NEUROPATH EXP NEUR, V63, P338, DOI 10.1093/jnen/63.4.338; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STEWARD O, 1988, J COMP NEUROL, V267, P203, DOI 10.1002/cne.902670205; STEWARD O, 1992, HIPPOCAMPUS, V2, P247, DOI 10.1002/hipo.450020305; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STEWARD O, 1990, J NEUROSCI, V10, P2373; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STEWARD O, 1983, J NEUROSCI, V3, P177; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Uhm JH, 1998, GLIA, V22, P53, DOI 10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9; Vaillant C, 1999, J NEUROSCI, V19, P4994; VanSaun M, 2000, J NEUROBIOL, V43, P140, DOI 10.1002/(SICI)1097-4695(200005)43:2<140::AID-NEU4>3.3.CO;2-B; Vansaun M, 2003, J NEUROCYTOL, V32, P1129, DOI 10.1023/B:NEUR.0000021907.68461.9c; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Werle MJ, 2003, J NEUROCYTOL, V32, P905, DOI 10.1023/B:NEUR.0000020631.69804.f5; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zuo J, 1998, J NEUROSCI, V18, P5203, DOI 10.1523/JNEUROSCI.18-14-05203.1998; Zuo J, 1998, J NEUROBIOL, V34, P41, DOI 10.1002/(SICI)1097-4695(199801)34:1<41::AID-NEU4>3.3.CO;2-4	86	67	67	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2005	192	1					60	72		10.1016/j.expneurol.2004.10.014			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	899LZ	WOS:000227147200007	15698619				2022-02-06	
J	Tateno, A; Jorge, RE; Robinson, RG				Tateno, A; Jorge, RE; Robinson, RG			Pathological laughing and crying following traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; COMPUTERIZED-TOMOGRAPHY; MULTIPLE-SCLEROSIS; STROKE PATIENTS; HEAD-INJURY; LAUGHTER; SCALE; DEPRESSION; EMOTIONALISM; PREVALENCE	The authors examined the prevalence and clinical correlates of pathological laughing and crying (PLC) using the Pathological Laughter and Crying Scale (PLAC) in 92 consecutive patients with acute symptoms 3, 6, and 12 months after traumatic brain injury (TBI). The prevalence of PLC during the first year after TBI was 10.9%. Compared to patients without PLC, patients with PLC had significantly more depressive, anxious, and aggressive behaviors and had poorer social functioning. Additionally, PLC was associated with the presence of anxiety disorder, and focal frontal lobe lesions, especially in the lateral aspect of the left frontal lobe. Findings revealed that prefrontal regulation of limbic circuits may be involved in the pathophysiology of this disturbed emotional expression.	Univ Iowa, Coll Med, Dept Psychiat, MEB Psychiat Res, Iowa City, IA 52242 USA; Nippon Med Coll, Dept Neuropsychiat, Tokyo 113, Japan		Jorge, RE (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, MEB Psychiat Res, 500 Newton Rd, Iowa City, IA 52242 USA.	ricardo-jorge@uiowa.edu	Robinson, Robert/AAF-6191-2021		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH053592, R01MH052879, R01MH040355] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-40355, MH-52879, MH-53592] Funding Source: Medline		ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; Calvert T, 1998, J NEUROL NEUROSUR PS, V65, P928, DOI 10.1136/jnnp.65.6.928; CURTIS G, 1993, WISCONSIN CARD SORT; Damasio H., 1989, LESION ANAL NEUROPSY; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; London ED, 2000, CEREB CORTEX, V10, P334, DOI 10.1093/cercor/10.3.334; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McCullagh S, 1999, J NEUROL SCI, V169, P43, DOI 10.1016/S0022-510X(99)00214-2; Mendez MF, 1999, J NEUROPSYCH CLIN N, V11, P253; MINDEN SL, 1990, ARCH NEUROL-CHICAGO, V47, P98, DOI 10.1001/archneur.1990.00530010124031; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; Mukand J, 1996, ARCH PHYS MED REHAB, V77, P1309, DOI 10.1016/S0003-9993(96)90198-7; Padberg F, 2001, J NEUROPSYCH CLIN N, V13, P206, DOI 10.1176/appi.neuropsych.13.2.206; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; ROBINSON RG, 1985, AM J PSYCHIAT, V142, P1424; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SACKEIM HA, 1982, ARCH NEUROL-CHICAGO, V39, P210, DOI 10.1001/archneur.1982.00510160016003; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; Spitzer R. L., 1990, STRUCTURED CLIN INTE; STARKSTEIN SE, 1995, J NEUROL NEUROSUR PS, V59, P55, DOI 10.1136/jnnp.59.1.55; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81; WILSON SAK, 1923, J NEUROL PSYCHOPATH, V4, P299; Wing J. K., 1974, MEASUREMENT CLASSIFI; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160; Ziegler LH, 1930, ARCH NEURO PSYCHIATR, V24, P930, DOI 10.1001/archneurpsyc.1930.02220170050006	39	67	68	2	9	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2004	16	4					426	434		10.1176/appi.neuropsych.16.4.426			9	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	881VN	WOS:000225897600004	15616168				2022-02-06	
J	Lee, CA; Birkedal, JP; Dickerson, EA; Vieta, PA; Webb, LX; Teasdall, RD				Lee, CA; Birkedal, JP; Dickerson, EA; Vieta, PA; Webb, LX; Teasdall, RD			Stabilization of Lisfranc joint injuries: A biomechanical study	FOOT & ANKLE INTERNATIONAL			English	Article						Lisfranc joint; rigid fixation; stabilization	FRACTURE-DISLOCATIONS; TARSOMETATARSAL JOINT; COMPLEX	Background: Lisfranc joint injuries are often misdiagnosed, leading to significant morbidity. Methods for anatomic reduction of the tarsometatarsal joint include closed reduction with casting or surgical stabilization with either Kirschner wires and/or cortical screw fixation. Controversy exists as to which fixation technique offers optimal stability. In the present study, the biomechanical stability of three fixation methods was tested: (1) four Kirschner wires, (2) three cortical screws plus two Kirschner wires, and (3) five cortical screws. Methods: Ten matched pairs of fresh-frozen cadaveric feet were dissected to their ligamentous and capsular elements. The tarsometatarsal ligaments were completely transected to replicate a Lisfranc dislocation; the "injury" was reduced and stabilized using one of the three methods. Biomechanical studies were performed by applying a 100-N cyclic load physiologically distributed to the plantar aspect of the metatarsal heads. Displacement and force measurements were taken from the first and fifth metatarsal heads. Average stiffness of each construct was calculated from the force displacement curves. Results and Conclusions' Method 2 provided significantly more stability than Kirschner wire fixation. Method 3 created more stiffness than method 2 at the medial portion of the foot; no statistical difference between the two methods was evident at the lateral foot. Clinical Relevance: Cortical screw fixation provides a more rigid and stable method of fixation for Lisfranc injuries as compared to Kirschner wire fixation. This fixation method allows maintenance of anatomic reduction and possibly earlier mobilization with a decreased risk of posttraumatic arthrosis.	Wake Forest Univ, Sch Med, Dept Orthopaed Surg, Baptist Med Ctr, Winston Salem, NC 27157 USA; Orthofix Inc, Winston Salem, NC USA		Teasdall, RD (corresponding author), Wake Forest Univ, Sch Med, Dept Orthopaed Surg, Baptist Med Ctr, Med Ctr Blvd,4th Floor,Watlington Hall, Winston Salem, NC 27157 USA.	teasdall@wfubmc.edu					ARNTZ CT, 1987, ORTHOP CLIN N AM, V18, P105; ARNTZ CT, 1988, J BONE JOINT SURG AM, V70A, P173, DOI 10.2106/00004623-198870020-00003; BLANCO RP, 1988, J ORTHOP TRAUMA, V2, P188; BRUNET JA, 1987, J BONE JOINT SURG BR, V69, P437, DOI 10.1302/0301-620X.69B3.3108261; Buzzard BM, 1998, CLIN ORTHOP RELAT R, P125; CAVANAGH PR, 1987, FOOT ANKLE, V7, P262, DOI 10.1177/107110078700700502; dePalma L, 1997, FOOT ANKLE INT, V18, P356, DOI 10.1177/107110079701800609; FERRIS LR, 1995, ORTHOP CLIN N AM, V26, P393; GOOSENS M, 1983, CLIN ORTHOP RELAT R, V176, P165; HANSEN ST, 1992, SKELETAL TRAUMA; HARDCASTLE PH, 1982, J BONE JOINT SURG BR, V64, P349, DOI 10.1302/0301-620X.64B3.7096403; JEFFREYS TE, 1963, J BONE JOINT SURG BR, V45, P546, DOI 10.1302/0301-620X.45B3.546; Kuo RS, 2000, J BONE JOINT SURG AM, V82A, P1609, DOI 10.2106/00004623-200011000-00015; LENCZNER EM, 1974, J TRAUMA, V14, P1012, DOI 10.1097/00005373-197412000-00003; Murphy W., 2000, AO PRINCIPLES FRACTU; MYERSON M, 1989, ORTHOP CLIN N AM, V20, P655; MYERSON MS, 1986, FOOT ANKLE, V6, P225, DOI 10.1177/107110078600600504; RESCH S, 1990, FOOT ANKLE, V11, P117, DOI 10.1177/107110079001100301; TREVINO SG, 1995, ORTHOP CLIN N AM, V26, P229	19	67	87	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1071-1007	1944-7876		FOOT ANKLE INT	Foot Ankle Int.	MAY	2004	25	5					365	370		10.1177/107110070402500515			6	Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics	854FD	WOS:000223885800015	15134620				2022-02-06	
J	Davis, DP; Dunford, JV; Ochs, M; Park, K; Hoyt, DB				Davis, DP; Dunford, JV; Ochs, M; Park, K; Hoyt, DB			The use of quantitative end-tidal capnometry to avoid inadvertent severe hyperventilation in patients with head injury after paramedic rapid sequence intubation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						rapid sequence intubating; paramedic; traumatic brain injury; capnometry; hyperventilation	CEREBRAL-BLOOD-FLOW; CARBON-DIOXIDE; INTRAHOSPITAL TRANSPORT; HEMORRHAGIC-SHOCK; OXYGENATION; VOLUME; GASES	Background. This study aimed to determine whether field end-tidal carbon dioxide CO2 (ETCO2) monitoring decreases inadvertent severe hyperventilation after paramedic rapid sequence intubation. Methods. Data were collected prospectively as part of the San Diego Paramedic Rapid Sequence Intubation Trial, which enrolled adults with severe head injuries (Glasgow Coma Score, 3-8) that could not be intubated without neuromuscular blockade. After preoxygenation, the patients underwent rapid sequence intubation using midazolam and succinylcholine. A maximum of three intubation attempts were allowed before Combitube insertion was mandated. Tube confirmation was accomplished by physical examination, qualitative capnometry, pulse oximetry, and syringe aspiration. Standard ventilation parameters (tidal volume, 800 mL; 12 breaths/minute) were taught. One agency used portable ETCO2 monitors, with ventilation modified to target ETCO2 values of 30 to 35 rum Hg. Trial patients transported by aeromedical crews also underwent ETCO2 monitoring. The primary outcome measure was the incidence of inadvertent severe hyperventilation, defined as arterial blood gas partial pressure of CO2 (PCO2) of less than 25 mm Hg at arrival, for patients with and those without ETCO2 monitoring. These groups also were compared in terms of age, gender, clinical presentation, Abbreviated Injury Score, Injury Severity Score, arrival arterial blood gas data, and survival. Results: The study enrolled 426 patients and administered neuromuscular blocking agents to 418 patients. Endotracheal intubation was successful for 355 of these patients (85.2%). Another 58 patients (13.6%) underwent Combitube insertion. For 291 successfully intubated patients, arrival pCO(2) values were documented, with continuous ETCO2 monitoring performed for 144 of these patients (49.4%). Patients with ETCO2 monitoring had a lower incidence of inadvertent severe hyperventilation than those without ETCO2 monitoring (5.6% vs. 13.4%; odds ratio, 2.64; 95% confidence interval, 1.12-6.20; p = 0.035). There were no significant differences in terms of age, gender, clinical presentation, Abbreviated Injury Score, Injury Severity Score, arrival partial pressure of oxygen (pO(2)) and pH, or survival. The patients in both groups with severe hyperventilation had a significantly higher mortality rate than the patients without hyperventilation (56 vs. 30%; odds ratio, 2.9; 95% confidence interval, 1.3-6.6; p = 0.016), which could not be explained solely on the basis of their injuries. Conclusions. The use of ETCO2 monitoring is associated with a decrease in inadvertent severe hyperventilation.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA USA; San Diego Cty Emergency Med Serv, San Diego, CA USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Univ Calif San Diego, Div Trauma, Dept Surg, San Diego, CA USA		Davis, DP (corresponding author), 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Benallal H, 2002, MED SCI SPORT EXER, V34, P622, DOI 10.1097/00005768-200204000-00010; Bhende M, 1999, PEDIATR EMERG CARE, V15, P64, DOI 10.1097/00006565-199902000-00019; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Fletcher R, 2000, EUR J ANAESTH, V17, P306, DOI 10.1046/j.1365-2346.2000.00660.x; FLETCHER R, 1984, BRIT J ANAESTH, V56, P109, DOI 10.1093/bja/56.2.109; FORTUNE JB, 1995, J TRAUMA, V39, P463; GERVAIS HW, 1987, CRIT CARE MED, V15, P761, DOI 10.1097/00003246-198708000-00010; GRAHAM DI, 1971, LANCET, V1, P265; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HEFFNER JE, 1983, ARCH INTERN MED, V143, P765, DOI 10.1001/archinte.143.4.765; HURST JM, 1989, J TRAUMA, V29, P1637, DOI 10.1097/00005373-198912000-00008; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Prause G, 1997, RESUSCITATION, V35, P145, DOI 10.1016/S0300-9572(97)00043-9; RELLER MD, 1985, PEDIATR RES, V19, P337, DOI 10.1203/00006450-198519040-00003; RUTA TS, 1993, ANESTHESIOLOGY, V78, P134, DOI 10.1097/00000542-199301000-00019; SANTHI PB, 1994, SOLVENT EXTR ION EXC, V12, P633, DOI 10.1080/07366299408918229; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tobias JD, 1996, PEDIATR EMERG CARE, V12, P249, DOI 10.1097/00006565-199608000-00003; TUOR UI, 1984, AM J PHYSIOL, V247, pH40, DOI 10.1152/ajpheart.1984.247.1.H40; VALENTINE C, 2002, PREHOSP EMERG CARE, V6, P144; Weckesser M, 1999, MAGN RESON MED, V41, P213, DOI 10.1002/(SICI)1522-2594(199901)41:1<213::AID-MRM31>3.0.CO;2-S; WEI EP, 1980, AM J PHYSIOL, V238, pH697, DOI 10.1152/ajpheart.1980.238.5.H697; Williams JS, 1997, J APPL PHYSIOL, V83, P312, DOI 10.1152/jappl.1997.83.1.312	31	67	67	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2004	56	4					808	814		10.1097/01.TA.0000100217.05066.87			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	818TZ	WOS:000221268700020	15187747				2022-02-06	
J	Wu, HM; Huang, SC; Hattori, N; Glenn, TC; Vespa, PM; Yu, CL; Hovda, DA; Phelps, ME; Bergsneider, M				Wu, HM; Huang, SC; Hattori, N; Glenn, TC; Vespa, PM; Yu, CL; Hovda, DA; Phelps, ME; Bergsneider, M			Selective metabolic reduction in gray matter acutely following human traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						2-deoxy-2-[F-18]fluoro-D-glucose; glucose; lumped constant; metabolism; positron emission tomography; traumatic brain injury	CEREBRAL BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; FDG LUMPED CONSTANT; HEAD-INJURY; GLUCOSE-UTILIZATION; PARAMETRIC IMAGES; PRACTICAL SCALE; PET; ISCHEMIA; RAT	The aim of this study was to determine whether the apparent loss of overall gray-white matter contrast (GNMM) seen on FDG-PET imaging reflects the differential changes of glucose metabolic rate (CMRglc) in cortical gray mater (GM) and subcortical white mater (WM) following TBI. The clinical significance of the CMRglc GM-to-WM ratio was also evaluated. Nineteen normal volunteers and 14 TBI patients were studied. Each subject had a quantitative FDG-PET, a quantitative (H2O)-O-15- PET and a MR scan acutely following TBI. Stabilities of the global and regional FDG lumped constants (LC) were studied. Parametric images (pixel unit: mg/min/100g) of FDG uptake rate (CURFDG) and CMRglc were generated. The changes of CMRglc in whole brain, GM and WM were studied separately by using a MRI-segmentation-based technique. The GM-to-WM ratios of both CURFDG and CMRglc images were significantly (p < 0.001) decreased (>31%) in TBI patients. The global LC value reduced significantly (p < 0.01) in TBI patients. The CMRglc decreased significantly (p < 0.001) in GM but not in WM (p > 0.1). Kinetic analysis revealed significant (P < 0.001) decrease of GM hexokinase activity in TBI patients. The GM-to-WM ratios of CMRgl, correlated (r = 0.64) with the initial Glasgow Coma Score (GCS) of TBI patients. The patients with higher CMRglc GM-to-WM ratios (>1.54) showed good recovery 12 months after TBI. There was a selective CMRglc reduction in cortical GM following TBI. The pathophysiological basis for the reduction in GM-to-WM CMRglc ratio seen on FDG-PET imaging following TBI remains to be determined.	Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA USA		Wu, HM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Injury Res Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA.	cwu@mednet.ucla.edu	Hattori, Naoya/AAR-6405-2020; Hattori, Naoya/G-2298-2012	Glenn, Thomas/0000-0003-4273-3408	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [Z01DE000387] Funding Source: NIH RePORTER; NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [DE-FC03-02ER63420, DE FC0387-ER60615] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [30308] Funding Source: Medline		Alavi A, 1997, J NUCL MED, V38, P1717; Alkire MT, 1997, ANESTHESIOLOGY, V86, P549, DOI 10.1097/00000542-199703000-00006; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brix G, 1997, J NUCL MED, V38, P1614; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; CHOI Y, 1991, J NUCL MED, V32, P733; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GJEDDE A, 1982, BRAIN RES REV, V4, P237, DOI 10.1016/0165-0173(82)90018-2; Graham MM, 2002, J NUCL MED, V43, P1157; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hasselbalch SG, 1998, J CEREBR BLOOD F MET, V18, P154, DOI 10.1097/00004647-199802000-00005; HAWKINS RA, 1986, J CEREBR BLOOD F MET, V6, P170, DOI 10.1038/jcbfm.1986.30; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOFFMAN EJ, 1979, J COMPUT ASSIST TOMO, V3, P299, DOI 10.1097/00004728-197906000-00001; HUANG SC, 1982, J CEREBR BLOOD F MET, V2, P99, DOI 10.1038/jcbfm.1982.11; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KUWABARA H, 1990, J CEREBR BLOOD F MET, V10, P180, DOI 10.1038/jcbfm.1990.33; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P161, DOI 10.1038/jcbfm.1987.39; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; MADSEN PL, 1995, J CEREBR BLOOD F MET, V15, P485, DOI 10.1038/jcbfm.1995.60; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NAKAI H, 1987, J CEREBR BLOOD F MET, V7, P640, DOI 10.1038/jcbfm.1987.117; OBRIST WD, 1990, CEREBROVAS BRAIN MET, V2, P283; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PHELPS ME, 1983, J CEREB BLOOD FLO S1, V3, pS13; RISCHKE R, 1991, J CEREBR BLOOD F MET, V11, P106, DOI 10.1038/jcbfm.1991.12; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; STEWART L, 1994, ACTA NEUROCHIR, P544; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; VANNUCCI RC, 1989, PEDIATR RES, V26, P208, DOI 10.1203/00006450-198909000-00011; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WU HM, 2003, MOL IMAGING BIOL, V4, P1; WU HM, 2002, BRAIN IMAGING USING, P147; Yang J, 1996, IEEE T NUCL SCI, V43, P3322, DOI 10.1109/23.552745; Zhou Y, 2001, IEEE T NUCL SCI, V48, P125, DOI 10.1109/23.910842	47	67	67	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					149	161		10.1089/089771504322778613			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200003	15000756				2022-02-06	
J	Bao, F; Liu, D				Bao, F; Liu, D			Hydroxyl radicals generated in the rat spinal cord at the level produced by impact injury induce cell death by necrosis and apoptosis: Protection by a metalloporphyrin	NEUROSCIENCE			English	Article						reactive oxygen species; hydrogen peroxide; secondary cell death; spinal cord injury; Fenton reaction; Mn (III) tetrakis (4-benzoic acid) porphyrin	MANGANESE SUPEROXIDE-DISMUTASE; MODEL COMBINING MICRODIALYSIS; EXPERIMENTAL HEAD-INJURY; ISCHEMIC BRAIN-INJURY; NITRIC-OXIDE; OXIDATIVE STRESS; IN-VIVO; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; PEROXYNITRITE	We previously measured the time courses of hydrogen peroxide (H2O2), hydroxyl radical ((OH)-O-.), and catalytic iron increases following traumatic spinal cord injury (SCI). This study determines whether the SCI-elevated level of (OH)-O-. causes cell death. OH was generated by administering H2O2 and Fe2+ at the concentrations attained following SCI, each through a separate microdialysis fiber inserted laterally into the gray matter of the cord. The duration of (OH)-O-. generation mimics the duration of its elevation after SCI. The death of neurons and astrocytes was characterized at 24 h post-(OH)-O-. exposure and quantitated by counting surviving cells along the fiber track in sections stained with Cresyl Violet, or immunohistochemically stained with anti-neuron-specific enolase (anti-NSE) and anti-glial fibrillary acidic protein (antiGFAP). DNA fragmentation in neurons was characterized by double staining with terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling JUNEL) and anti-NSE. Using a one way ANOVA followed by the Tukey test, we demonstrated that (OH)-O-. generated in the cord induced significant losses of neurons in both Cresyl Violet (P<0.001) and anti-NSE-stained sections (P<0.001), and of astrocytes in GFAP-stained sections (P=0.001). (OH)-O-. generated in the cord increased numbers of TUNEL-positive neurons compared with Ringer's solution administered as a control (P=0.001). Mn (111) tetrakis (4-benzoic acid) porphyrin (MnTBAP), a superoxide dismutase mimetic and a broad spectrum reactive species scavenger, significantly reduced (OH)-O-.-induced death of neurons (P<0.001 in anti-NSE stained sections and P=0.002 in the Cresyl Violet-stained sections) and astrocytes (P=0.03). It also reduced the numbers of TUNEL-positive neurons (P=0.01). Electron microscopy confirmed that generated (OH)-O-. induced neuronal and glial death with characteristic features of both necrosis and apoptosis. We conclude that 1) SCI-elevated (OH)-O-. is sufficient to induce both necrosis and apoptosis, criteria for identifying an endogenous secondary damaging agent; 2) MnTBAP reduces (OH)-O-.-induced cell death, perhaps by removing H2O2 administered in the tissue, thereby blocking formation of (OH)-O-., and also by scavenging downstream reactive species. (C) 2004 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA		Liu, D (corresponding author), Univ Texas, Med Branch, Dept Neurol, 301 Univ Blvd, Galveston, TX 77555 USA.	dliu@utmb.edu		liu, danxia/0000-0001-8172-2344	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035119, R01NS044324] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS44324, NS35119] Funding Source: Medline		Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; BALENTINE JD, 1985, CENTRAL NERVOUS SYST, P455; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; Carriedo SG, 1998, J NEUROSCI, V18, P7727; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, J NEUROSCI RES, V34, P107, DOI 10.1002/jnr.490340111; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; IKEDA Y, 1989, Neurological Research, V11, P213; Keller JN, 1998, J NEUROSCI, V18, P687; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Liang LP, 2000, NEUROSCIENCE, V101, P563, DOI 10.1016/S0306-4522(00)00397-3; LING X, 2001, J NEUROTRAUM, V18, P1169; Lipscomb DC, 1998, STROKE, V29, P487, DOI 10.1161/01.STR.29.2.487; LIU D, 2004, IN PRESS J NEUROTRAU; LIU DX, 1995, FREE RADICAL BIO MED, V18, P861, DOI 10.1016/0891-5849(94)00214-5; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J BIOCHEM BIOPH METH, V27, P281, DOI 10.1016/0165-022X(93)90009-D; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; LIU DX, 1994, MOL CHEM NEUROPATHOL, V23, P77, DOI 10.1007/BF02815402; Liu DX, 1999, FREE RADICAL BIO MED, V27, P478, DOI 10.1016/S0891-5849(99)00073-8; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 2003, FREE RADICAL BIO MED, V34, P64, DOI 10.1016/S0891-5849(02)01184-X; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOKANATHA V, 2002, J NEUROTRAUM, V19, P1297; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Oury TD, 2001, AM J RESP CELL MOL, V25, P164, DOI 10.1165/ajrcmb.25.2.4235; Patel M, 1998, J NEUROCHEM, V71, P1068, DOI 10.1046/j.1471-4159.1998.71031068.x; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; ROTHSTEIN JD, 1994, P NATL ACAD SCI USA, V91, P4155, DOI 10.1073/pnas.91.10.4155; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872	54	67	67	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2004	126	2					285	295		10.1016/j.neuroscience.2004.03.054			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	829SJ	WOS:000222069700005	15207346				2022-02-06	
J	Song, S; Kamath, S; Mosquera, D; Zigova, T; Sanberg, P; Vesely, DL; Sanchez-Ramos, J				Song, S; Kamath, S; Mosquera, D; Zigova, T; Sanberg, P; Vesely, DL; Sanchez-Ramos, J			Expression of brain natriuretic peptide by human bone marrow stromal cells	EXPERIMENTAL NEUROLOGY			English	Article						bone marrow stromal cells; brain natriuretic factor; stroke	GROWTH-FACTOR PRODUCTION; FUNCTIONAL RECOVERY; INTRACEREBRAL TRANSPLANTATION; STEM-CELLS; ADULT RATS; INJURY; EXTRACTS; STROKE; EDEMA	Bone marrow stromal cells (BMSC) have been shown to generate neural cells under experimental conditions in vitro and following transplantation into animal models of stroke and traumatic CNS injury. Hastened recovery from the neurological deficit has not correlated with structural repair of the lesion in the stroke model. Secretory functions of BMSC, such as the elaboration of growth factors and cytokines, have been hypothesized to play a role in the enhanced recovery of neurological function. Using gene expression arrays, real time RT-PCR and radioimmunoassay, we have found that brain natriuretic peptide (BNP) is synthesized and released by BMSC at physiologically relevant levels in vitro. BNP, like its close homolog atrial natriuretic peptide (ANP), exerts powerful natriuretic, diuretic and vasodilatory effects. We speculate that transplanted BMSCs facilitate recovery from brain and spinal cord lesions by releasing BNP and other vasoactive factors that reduce edema, decrease intracranial pressure and improve cerebral perfusion. (C) 2003 Elsevier Inc. All rights reserved.	Univ S Florida, Dept Neurol, Ctr Aging & Brain Repair, Tampa, FL 33612 USA; James A Haley VA Hosp, Tampa, FL 33612 USA; Univ S Florida, Dept Med, Ctr Aging & Brain Repair, Tampa, FL 33612 USA; Univ S Florida, Dept Neurosurg, Ctr Aging & Brain Repair, Tampa, FL 33612 USA		Sanchez-Ramos, J (corresponding author), Univ S Florida, Dept Neurol, Ctr Aging & Brain Repair, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Sanchez-Ramos, Juan/O-7870-2014; Sanberg, Paul/A-6753-2009; Sanchez-Ramos, Juan/A-1188-2009	Sanchez-Ramos, Juan/0000-0002-3391-7857			Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; DOCZI TP, 1995, ACTA NEUROCHIR, V132, P87, DOI 10.1007/BF01404853; Jensen KT, 1997, SCAND J CLIN LAB INV, V57, P529, DOI 10.3109/00365519709084604; KANEKO T, 1993, BRAIN RES, V612, P104, DOI 10.1016/0006-8993(93)91649-D; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; NAKAO N, 1990, NEUROSURGERY, V27, P39, DOI 10.1227/00006123-199007000-00005; NARUSE S, 1990, ACT NEUR S, V51, P118; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sanchez-Ramos JR, 2001, EXP NEUROL, V171, P109, DOI 10.1006/exnr.2001.7748; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; SONG S, 2002, PROTOCOLS NEURAL STE, P79; SUDOH T, 1988, BIOCHEM BIOPH RES CO, V155, P726, DOI 10.1016/S0006-291X(88)80555-2; VESELY DL, 1992, RENAL PHYSIOL BIOCH, V15, P23; VESELY DL, 1992, MOL CELL BIOCHEM, V109, P43	24	67	82	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2004	185	1					191	197		10.1016/j.expneurol.2003.09.003			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	760JM	WOS:000187807900018	14697330				2022-02-06	
J	Collie, A; Maruff, P; McStephen, M; Darby, DG				Collie, A; Maruff, P; McStephen, M; Darby, DG			Psychometric issues associated with computerised neuropsychological assessment of concussed athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							REACTION-TIME; COGNITIVE ASSESSMENT; PERFORMANCE; CONSISTENCY; INJURY; LONG	Psychometric issues associated with computerised neuropsychological assessment in sports concussion are put forward. Issues critical to ensuring test reliability and sensitivity are discussed, with particular reference to how inappropriate test design can affect clinical decision making.	CogState Ltd, Carlton, Vic 3053, Australia; Univ Melbourne, Ctr Neurosci, Melbourne, Vic, Australia; La Trobe Univ, Dept Psychol, Melbourne, Vic, Australia		Collie, A (corresponding author), CogState Ltd, 51 Leicester St, Carlton, Vic 3053, Australia.		Maruff, Paul/ABA-1673-2020; Maruff, Paul/AAD-2454-2021	Maruff, Paul/0000-0002-6947-9537; Collie, Alex/0000-0003-2617-9339			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCaffrey RJ, 2000, PRACTITIONERS GUIDE; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	18	67	67	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC 1	2003	37	6					556	559		10.1136/bjsm.37.6.556			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	751YN	WOS:000187118300025	14665603	Green Published, Bronze			2022-02-06	
J	Gouvier, WD; Sytsma-Jordan, S; Mayville, S				Gouvier, WD; Sytsma-Jordan, S; Mayville, S			Patterns of discrimination in hiring job applicants with disabilities: The role of disability type, job complexity, and public contact	REHABILITATION PSYCHOLOGY			English	Article							EMPLOYER CONCERNS; BIAS; SELECTION; WORKERS	Objective: To evaluate the effects of disability type, job complexity, and public contact on hiring decisions. Design and Participants: An Americans With Disabilities Act (ADA; 1990) fact sheet and matched resumes with vocational and medical histories including chronic mental illness, developmental disability, closed head injury, and back injury were provided to 295 undergraduate business-related majors, who rated the applicants' suitability for 2 job positions and work shifts. Results: Findings indicated disparities in ratings of employability as a function of disability type. Paired comparisons yielded complementary findings, with effects of disability type and Disability Type X Job Complexity, but no effects of public contact. Conclusions: Stereotyping and discrimination in employment decisions apparently persist, more than 10 years after the ADA.	Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA; Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, University, MS 38677 USA		Gouvier, WD (corresponding author), Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA.						Bell BS, 2001, REHABIL PSYCHOL, V46, P229, DOI 10.1037/0090-5550.46.3.229; BORDIERI JE, 1990, J APPL SOC PSYCHOL, V20, P244, DOI 10.1111/j.1559-1816.1990.tb00409.x; BORDIERI JE, 1988, REHABIL PSYCHOL, V33, P239, DOI 10.1037//0090-5550.33.4.239; Colella A, 1997, HUM RESOUR MANAGE R, V7, P27, DOI 10.1016/S1053-4822(97)90004-8; COMBS IH, 1986, J REHABIL, V52, P42; Diksa E, 1996, REHABIL COUNS BULL, V40, P31; DREHMER DE, 1985, REHABIL PSYCHOL, V30, P157, DOI 10.1037//0090-5550.30.3.157; FARINA A, 1973, J CONSULT CLIN PSYCH, V41, P363, DOI 10.1037/h0035329; GOUVIER WD, 1991, REHABIL PSYCHOL, V36, P121, DOI 10.1037/0090-5550.36.2.121; Guion R. M., 1965, PERSONNEL TESTING; Loo R, 2001, REHABIL PSYCHOL, V46, P288, DOI 10.1037/0090-5550.46.3.288; MILLINGTON MJ, 1994, REHABIL COUNS BULL, V38, P27; STONE CI, 1980, J VOCAT BEHAV, V16, P96, DOI 10.1016/0001-8791(80)90041-X; *US BUR CENS, 1993, POV US 1992	14	67	67	1	31	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2003	48	3					175	181		10.1037/0090-5550.48.3.175			7	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	717FY	WOS:000185077900007					2022-02-06	
J	Popovich, PG; van Rooijen, N; Hickey, WF; Preidis, G; McGaughy, V				Popovich, PG; van Rooijen, N; Hickey, WF; Preidis, G; McGaughy, V			Hematogenous macrophages express CD8 and distribute to regions of lesion cavitation after spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NITRIC-OXIDE PRODUCTION; MOTOR-NEURON INJURY; MONONUCLEAR PHAGOCYTES; MICROGLIAL CELLS; RAT-BRAIN; PERITONEAL-MACROPHAGES; INFLAMMATORY RESPONSE; TRAUMATIC INJURY	Historically, CD4 and CD8 antigens have been used to designate functionally distinct T-lymphocyte subsets. However, these antigens also have been described on macrophages in the normal and pathologic central nervous system (CNS). Signaling through CD4 or CD8 may impart unique functions in macrophage subsets that express these antigens. In the current study, the distribution and temporal patterns of expression of CD4 and CD8 were evaluated on various cell types within the traumatically injured spinal cord. The data reveal divergent patterns of CD4 and CD8 expression on unique macrophage populations. Specifically, we show sustained elevations of CD4 expression on microglia and macrophages throughout the lesion site and spared white matter. In contrast, CD8 is predominantly associated with hematogenous macrophages that are recruited from the blood during the first week postinjury. The distribution of CD8-positive cells is restricted to areas of necrotic cavitation. Differential signaling of resident and recruited macrophages through CD4 or CD8 may explain the apparent dichotomy of CNS-macrophage-mediated injury and repair. (C) 2003 Elsevier Science (USA). All rights reserved.	Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Vrije Univ Amsterdam, Dept Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands; DHMC, Dartmouth Med Sch, Dept Pathol, Lebanon, NH 03756 USA		Popovich, PG (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, 2078 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.		Popovich, Phillip/C-9187-2009; Van Rooijen, Nico/Z-1578-2019; Preidis, Geoffrey A./W-5538-2019	Popovich, Phillip/0000-0003-1329-7395; Preidis, Geoffrey A./0000-0002-2206-6452	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037846] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37846] Funding Source: Medline		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; AlberatiGiani D, 1996, J NEUROCHEM, V66, P996; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; Buttini M, 1998, NAT MED, V4, P441, DOI 10.1038/nm0498-441; CROCKER PR, 1987, J EXP MED, V166, P613, DOI 10.1084/jem.166.2.613; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DeJong BA, 1997, NEUROCHEM RES, V22, P491, DOI 10.1023/A:1027372129989; DSOUZA S, 1995, J NEUROSCI, V15, P7293; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Giulian D, 1996, J NEUROSCI, V16, P3139; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HICKEY WF, 1983, J IMMUNOL, V131, P2805; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Hirji N, 1997, J IMMUNOL, V158, P1833; Hirji N, 1998, J IMMUNOL, V160, P6004; Jander S, 1998, EUR J NEUROSCI, V10, P680, DOI 10.1046/j.1460-9568.1998.00078.x; Jander S, 2001, BRAIN PATHOL, V11, P27; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; Lin TJ, 2000, J IMMUNOL, V164, P1783, DOI 10.4049/jimmunol.164.4.1783; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; MATSUMOTO Y, 1986, J IMMUNOL, V136, P3668; MORIOKA T, 1992, ACTA NEUROPATHOL, V83, P590, DOI 10.1007/BF00299407; Mosley K, 1996, NEUROCHEM RES, V21, P481, DOI 10.1007/BF02527713; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; PERRY VH, 1987, J EXP MED, V166, P1138, DOI 10.1084/jem.166.4.1138; POPOVICH PG, 1993, J NEUROTRAUM, V10, P37, DOI 10.1089/neu.1993.10.37; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Schroeter M, 2001, ACTA NEUROPATHOL, V101, P440; Soares HD, 1995, J NEUROSCI, V15, P8223; SROGA JM, 2001, J NEUROTRAUM, V18, P1155; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Weissenbock H, 2000, BRAIN PATHOL, V10, P260, DOI 10.1111/j.1750-3639.2000.tb00259.x	53	67	68	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	AUG	2003	182	2					275	287		10.1016/S0014-4886(03)00120-1			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	707RY	WOS:000184524700003	12895439				2022-02-06	
J	Krassioukov, AV; Furlan, JC; Fehlings, MG				Krassioukov, AV; Furlan, JC; Fehlings, MG			Medical co-morbidities, secondary complications, and mortality in elderly with acute spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						elderly; medical co-morbidity; mortality; neurotrauma; secondary complication; spinal cord injury	AGE; EPIDEMIOLOGY; COSTS; POPULATION; OUTCOMES; OLDER	Despite an increasing incidence of spinal cord injury (SCI) in the elderly and evidence that age appears to influence outcome after neurotrauma, surprisingly little is known regarding clinical outcomes and secondary complications in elderly with an acute SCI. This study was undertaken to evaluate the effect of age on clinical outcomes after acute traumatic SCI managed in an acute care unit by a multidisciplinary team. A retrospective chart review of all patients with acute SCI admitted to an acute care unit at a university hospital between 1998 and 2000 was performed. Data on clinical outcomes and secondary complications in younger individuals (group 1: age < 60 years) were compared to elderly subjects (group 2: age : 60 years). There were 28 elderly (age 60-89 years) and 30 younger (age 17-56 years) individuals. The severity and level of SCI were similar in both groups (p = 0.11; p = 0.93). Co-morbidities were more frequent in the elderly (p < 0.01). There was a trend, which did not achieve significance, for an increased incidence of secondary complications in the elderly (57.1% versus 33.3%; p = 0.11). The most common secondary complications in both groups were infections, psychiatric disorders, pressure sores, and cardiovascular complications. Mortality rates in elderly and younger individuals with acute SCI (p = 0.41) were not significantly different. Our data suggest that rigorous attention to principles of acute SCI care can minimize previously reported higher susceptibility for secondary complications in the elderly. A multidisciplinary team approach to the management of the elderly with acute SCI is essential to minimize or prevent secondary complications.	Univ Hlth Network, Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON, Canada; Univ Hlth Network, Krembil Neurosci Ctr, Spinal Program, Toronto, ON, Canada; Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada		Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Dept Surg,, Div Neurosurg, McLaughlin Pavil,Room 12-407,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	Michael.Fehlings@uhn.on.ca	Krassioukov, Andrei V/K-3131-2017; Furlan, Julio/Q-8290-2018	Furlan, Julio/0000-0002-2038-0018; Fehlings, Michael/0000-0002-5722-6364			ALANDER DH, 1994, SPINE, V19, P2299, DOI 10.1097/00007632-199410150-00008; BENEDICT RC, 1981, J REHABIL, V47, P10; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; *CAN I HLTH INF, 2001, 5432 CAN I HLTH INF; CHARLES ED, 1978, PARAPLEGIA, V15, P302, DOI 10.1038/sc.1977.46; CHEN CF, 1985, PARAPLEGIA, V23, P364, DOI 10.1038/sc.1985.58; Chen HY, 1997, NEUROEPIDEMIOLOGY, V16, P241, DOI 10.1159/000109693; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P733, DOI 10.1016/S0003-9993(99)90219-8; Cifu DX, 1999, J NEUROTRAUM, V16, P805, DOI 10.1089/neu.1999.16.805; Dai LY, 2001, INJURY, V32, P195, DOI 10.1016/S0020-1383(00)00176-5; DEVIVO MJ, 1990, ARCH NEUROL-CHICAGO, V47, P687, DOI 10.1001/archneur.1990.00530060101026; EISENBERG MG, 1985, PARAPLEGIA, V23, P335, DOI 10.1038/sc.1985.53; GERHART KA, 1994, ANN EMERG MED, V23, P807, DOI 10.1016/S0196-0644(94)70318-3; Gershkoff A M, 1993, Arch Phys Med Rehabil, V74, pS402; HARVEY C, 1992, PARAPLEGIA, V30, P834, DOI 10.1038/sc.1992.160; HESSE KA, 1984, J AM GERIATR SOC, V32, P747, DOI 10.1111/j.1532-5415.1984.tb04174.x; Ide M, 2001, SPINAL CORD, V39, P387, DOI 10.1038/sj.sc.3101171; Imai K, 1996, J CLIN EPIDEMIOL, V49, P505, DOI 10.1016/0895-4356(95)00576-5; KARAMEHMETOGLU SS, 1995, PARAPLEGIA, V33, P469, DOI 10.1038/sc.1995.102; Karlsson AK, 1999, SPINAL CORD, V37, P383, DOI 10.1038/sj.sc.3100867; Liang HW, 2001, SPINAL CORD, V39, P375, DOI 10.1038/sj.sc.3101169; Mathias CF, 1992, AUTONOMIC FAILURE TX, P839; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; MEYERS AR, 1985, ARCH PHYS MED REHAB, V66, P704; MILLER RA, 1998, PRINCIPLES GERIATRIC, P3; MINAIRE P, 1978, PARAPLEGIA, V16, P76, DOI 10.1038/sc.1978.13; Mylotte JM, 2000, CLIN INFECT DIS, V30, P425, DOI 10.1086/313708; Noreau L, 2000, AM J PHYS MED REHAB, V79, P526, DOI 10.1097/00002060-200011000-00009; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; ROTH EJ, 1992, PARAPLEGIA, V30, P520, DOI 10.1038/sc.1992.109; Seel R T, 2001, J Spinal Cord Med, V24, P241; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; STEINBERG FU, 1984, ARCH PHYS MED REHAB, V65, P8; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Subbarao J V, 1987, J Am Paraplegia Soc, V10, P30; Sumida M, 2001, ARCH PHYS MED REHAB, V82, P391, DOI 10.1053/apmr.2001.19780; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; *U AL, 2002, NAT SPIN CORD INJ DA; van Asbeck FWA, 2000, SPINAL CORD, V38, P420, DOI 10.1038/sj.sc.3101003; Villanueva N E, 2000, Crit Care Nurs Clin North Am, V12, P509; Watson N, 1976, Paraplegia, V14, P36; WILLIAMS ME, 1998, PRINCIPLES GERIATRIC, P249; Yeo JD, 1998, SPINAL CORD, V36, P329, DOI 10.1038/sj.sc.3100628	43	67	73	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2003	20	4					391	399		10.1089/089771503765172345			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	673YY	WOS:000182609900008	12866818				2022-02-06	
J	Lew, HL; Dikmen, S; Slimp, J; Temkin, N; Lee, EH; Newell, D; Robinson, LR				Lew, HL; Dikmen, S; Slimp, J; Temkin, N; Lee, EH; Newell, D; Robinson, LR			Use of somatosensory-evoked potentials and cognitive event-related potentials in predicting outcomes of patients with severe traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Academic-Physiatrists	MAR 01-03, 2001	Hilton Head Isl, SC	Assoc Acad Phsyiatrists		traumatic brain injury; event-related potentials; N100; P300; somatosensory-evoked potential; Glasgow Coma Scale; Glasgow Outcome Scale-Extended; functional outcome	GLASGOW COMA SCALE; HEAD-INJURY; P300; RECOVERY; LATENCY	Objective: This study was performed to evaluate the usefulness of somatosensory-evoked potentials (SEPs) and cognitive event-related potentials (ERPs) in predicting functional outcomes of severe traumatic brain injury patients. Design: Prospective study of 22 patients with severe traumatic brain injury. Demographic information, Glasgow Coma Scale, and electrophysiologic measurements were recorded. Functional outcomes, as quantified by the Glasgow Outcome Scale-Extended, were obtained. Results: Bilateral absence of median nerve SEP was strongly predictive of the worst functional outcome. The specificity and positive predictive value of absent SEP for predicting death or persistent vegetative state at 6 mo after traumatic brain injury were as high as 100%. If the definition of unfavorable outcome was ex-expanded to include Glasgow Outcome Scale-Extended 1-4, absence of ERP was equivalent to the absence of SEP in specificity and positive predictive value. On the other hand, normal ERPs showed higher sensitivity and negative predictive value for prognosticating the best outcomes compared with normal SEPs. If the definition of favorable outcome was expanded to include Glasgow Outcome Scale-Extended 5-8, ERP was still superior to SEP for prognosticating good outcome. Interestingly, the highest sensitivity and negative predictive value for favorable outcomes were associated with the presence of any discernible waveform. Conclusions: Although median nerve SEP continues to make reliable prediction of ominous outcome in severe traumatic brain injury, the addition of the speech-evoked ERPs may be helpful in predicting favorable outcomes. The strength of the latter test seems to complement the weakness of the former.	Stanford Univ, Comprehens Rehabil Ctr, Phys Med & Rehabil Serv, VAPAHCS,Sch Med, Palo Alto, CA 94304 USA; Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Dept Neurosurg, Seattle, WA 98195 USA		Lew, HL (corresponding author), Stanford Univ, Comprehens Rehabil Ctr, Phys Med & Rehabil Serv, VAPAHCS,Sch Med, MS-B117,3801 Miranda Ave, Palo Alto, CA 94304 USA.		Robinson, Lawrence/D-8455-2013		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K12HD01097] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER		Ashley MJ, 1997, BRAIN INJURY, V11, P677; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; FIORETTO M, 1995, J MED ENG TECHNOL, V19, P80, DOI 10.3109/03091909509030280; Fowler B, 1997, BIOL PSYCHOL, V46, P113, DOI 10.1016/S0301-0511(97)05253-8; GREENBERG RP, 1982, J NEUROSURG, V56, P1, DOI 10.3171/jns.1982.56.1.0001; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lew H, 1997, J Am Acad Audiol, V8, P104; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Lew HL, 2002, AM J PHYS MED REHAB, V81, P524, DOI 10.1097/00002060-200207000-00011; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; Mazzini L, 1999, ARCH PHYS MED REHAB, V80, P33, DOI 10.1016/S0003-9993(99)90304-0; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; NISHIMURA N, 1995, PSYCHIAT CLIN NEUROS, V49, P79, DOI 10.1111/j.1440-1819.1995.tb01863.x; OMAHONY D, 1990, LANCET, V336, P1265, DOI 10.1016/0140-6736(90)92887-N; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; POLICH J, 1989, ELECTROEN CLIN NEURO, V74, P312, DOI 10.1016/0168-5597(89)90061-0; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; WAYMAN JW, 1992, J ACOUST SOC AM, V91, P3527, DOI 10.1121/1.402841; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	32	67	76	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JAN	2003	82	1					53	61		10.1097/00002060-200301000-00009			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	632AA	WOS:000180199700009	12510186				2022-02-06	
J	Suhr, JA; Gunstad, J				Suhr, JA; Gunstad, J			Postconcussive symptom report: The relative influence of head injury and depression	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; CHRONIC-FATIGUE-SYNDROME; BASE RATES; SUBJECTIVE COMPLAINTS; COGNITIVE COMPLAINTS; ETIOLOGY; PERFORMANCE; SENSITIVITY; SPECIFICITY; INDIVIDUALS	The present study explored whether any subset of self-reported postconcussion (PCS) symptoms or specific PCS symptom is sensitive and/or specific to head injury in non-self-selected samples of individuals aged 18-21 with head injury and depression (n=32), head injury without depression (n=31), depression without head injury (n=25), and controls (n=50). All participants completed a self-report PCS symptom scale based on their current symptoms. Results showed that depression. not head-injury status, largely accounted for elevation in PCS symptom reports, including cognitive symptoms. Thus, report of cognitive PCS symptoms is not specific to head injury, raising concerns about using such items to screen for head injury in the general population.	Ohio Univ, Dept Psychol, Athens, OH 45701 USA		Suhr, JA (corresponding author), Ohio Univ, Dept Psychol, Porter Hall 200, Athens, OH 45701 USA.						Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; ERRICO AL, 1990, PSYCHOL ASSESSMENT, V2, P45, DOI DOI 10.1037/1040-3590.2.1.45; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GFELLER J, 1996, ASSESSMENT, V3, P393; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jonker C, 2000, INT J GERIATR PSYCH, V15, P983, DOI 10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MANDEL S, 1989, POSTGRAD MED, V85, P213; McClelland RJ, 1996, J PSYCHOSOM RES, V40, P563, DOI 10.1016/0022-3999(95)00616-8; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Schwartz CE, 1996, ANN BEHAV MED, V18, P177, DOI 10.1007/BF02883395; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; VINGERHOETS G, 1995, J PSYCHOSOM RES, V39, P843, DOI 10.1016/0022-3999(95)00021-3; Wearden AJ, 1996, J PSYCHOSOM RES, V41, P197, DOI 10.1016/0022-3999(96)00131-6; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	35	67	68	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2002	24	8					981	993		10.1076/jcen.24.8.981.8372			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	642HA	WOS:000180797100001	12650225				2022-02-06	
J	Okada, Y; Akai, T; Okamoto, K; Iida, T; Takata, H; Iizuka, H				Okada, Y; Akai, T; Okamoto, K; Iida, T; Takata, H; Iizuka, H			A comparative study of the treatment of chronic subdural hematoma-burr hole: Drainage versus burr hole irrigation	SURGICAL NEUROLOGY			English	Article						chronic subdural hematoma; irrigation; drainage; recurrence	CLOSED-SYSTEM DRAINAGE; CRANIOSTOMY	BACKGROUND Several surgical procedures have been reported for the treatment of chronic subdural hematoma. Whether irrigation is required is not clear, We compared the results of treatment of chronic subdural hematoma obtained with burr hole drainage and burr hole irrigation retrospectively. METHODS Forty patients with chronic subdural hematoma underwent surgery at our institution in the last 3 years. The first 20 patients were treated by burr hole irrigation (irrigation group), while the last 20 patients underwent burr hole drainage (drainage group). The rates of recurrence changes in hematoma size, and number of days of postoperative hospitalization for the two groups were compared. No significant differences were found between the two groups in the presence of head injury, alcohol consumption, age, gender, or preoperative hematoma size. RESULTS Duration of postoperative hospitalization was 14.1 days in the drainage group and 25.5 days in the irrigation group. Recurrence was observed in 1 case (5%) in the drainage group, and in 5 cases (25%) in the irrigation group. In the drainage group, postoperative hematoma size was significantly decreased compared to preoperative hematoma size on the first postoperative day, after which change in hematoma size was minimal. On the other hand, in the irrigation group, hematoma size was decreased on the first postoperative day, but not to a significant extent, CONCLUSION For treatment of chronic subdural hematoma, postoperative hospitalization was shorter and the recurrence was less frequent with drainage than with irrigation. (C) 2002 by Elsevier Science Inc.	Kanazawa Med Univ, Dept Neurosurg, Kanazawa, Ishikawa 9200293, Japan		Akai, T (corresponding author), Kanazawa Med Univ, Dept Neurosurg, 1-1 Uchinada Machi, Kanazawa, Ishikawa 9200293, Japan.						Asano Y, 1992, No To Shinkei, V44, P827; BENDER MB, 1974, ARCH NEUROL-CHICAGO, V31, P73, DOI 10.1001/archneur.1974.00490380021001; Ernestus RI, 1997, SURG NEUROL, V48, P220, DOI 10.1016/S0090-3019(97)80031-6; FOGELHOLM R, 1975, ACTA NEUROCHIR, V32, P247, DOI 10.1007/BF01405457; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; IWATA T, 1980, NEUROTRAUMATOLOGY, V3, P202; KOTWICA Z, 1991, British Journal of Neurosurgery, V5, P461, DOI 10.3109/02688699108998474; KRUPP WF, 1995, BRIT J NEUROSURG, V9, P619, DOI 10.1080/02688699550040909; LUSINS J, 1978, J COMPUT ASSIST TOMO, V2, P460, DOI 10.1097/00004728-197809000-00016; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; RICHTER HP, 1984, ACTA NEUROCHIR, V71, P179, DOI 10.1007/BF01401313; ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263; Sato M, 1999, NEUROL SURG TOKYO, V27, P323; SHIMAZAKI M, 1998, NEUROTRAUMATOLOGY, V21, P161; Smely C, 1997, ACTA NEUROCHIR, V139, P818, DOI 10.1007/BF01411399; SUZUKI J, 1970, J NEUROSURG, V33, P548, DOI 10.3171/jns.1970.33.5.0548; Suzuki K, 1998, SURG NEUROL, V50, P231, DOI 10.1016/S0090-3019(97)00339-X; TABADDOR K, 1977, J NEUROSURG, V46, P220, DOI 10.3171/jns.1977.46.2.0220; WAKAI S, 1990, NEUROSURGERY, V26, P771, DOI 10.1227/00006123-199005000-00006; WEIR BKA, 1983, CAN J NEUROL SCI, V10, P22, DOI 10.1017/S0317167100044516	20	67	76	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	2002	57	6					405	410	PII S0090-3019(02)00720-6	10.1016/S0090-3019(02)00720-6			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	586DN	WOS:000177569500007	12176202				2022-02-06	
J	Hensler, T; Sauerland, S; Bouillon, B; Raum, A; Rixen, D; Helling, HJ; Andermahr, J; Neugebatter, EAM				Hensler, T; Sauerland, S; Bouillon, B; Raum, A; Rixen, D; Helling, HJ; Andermahr, J; Neugebatter, EAM			Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6 and interleukin-10, and polymorphonuclear neutrophil elastase	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						human; multiple injuries; cytokine receptors; cytokines	FACTOR TNF RECEPTOR; ANTIINFLAMMATORY CYTOKINE; BRAIN INJURY; TRAUMA; RELEASE; SEPSIS; INDUCTION; RESPONSES; SEVERITY; PROTECT	Background. Our knowledge about the bidirectional interactions between brain and whole organism after trauma is still limited. It was the purpose of this prospective clinical study to determine the influence of severe head trauma (SHT) as well as trauma in different anatomic injury regions on posttraumatic inflammatory mediator levels from patients with multiple injuries. Methods: Thirty-five healthy controls, 33 patients with an isolated SHT, 47 patients with multiple injuries without SHT, and 45 patients with both SHT and multiple injuries were studied. The posttraumatic plasma levels of soluble tumor necrosis factor receptors p55 and p75, interleukin (IL)-6, IL-10, and polymorphonuclear neutrophil (ENIN) elastase were monitored using enzyme-linked immunosorbent assay technique. The influence of head injuries as well as thorax, abdomen, and extremity injuries on the mediator release from patients with multiple injuries was investigated by multivariate linear regression models. Results: The soluble tumor necrosis factor receptor p55/p75 ratio was significantly elevated within 3 hours of trauma in all three injury groups and returned to reference ratios after 12 hours. The lowest increase was found in patients suffering from an isolated SHT. Lowest mediator levels in this patient population were also found for IL-6, IL-10, and PININ elastase during the first 36 hours after trauma. Additional injuries to the head, thorax, abdomen, and extremity modulated mediator levels to a different degree. No specific effect was found for SHT when compared with other injury groups. Thorax injuries caused the quickest rise in mediator levels, whereas abdominal injuries significantly increased PMN elastase levels 12 to 24 hours after trauma. Conclusion: Traumatic injuries cause the liberation of various mediators, without any specific association between anatomic injury pattern and the pattern of mediator release.	Univ Cologne, Biochem & Exptl Div, Dept Surg 2, D-51109 Cologne, Germany; Univ Cologne, Clin & Policlin Trauma Hand & Reconstruct Surg, D-51109 Cologne, Germany		Neugebatter, EAM (corresponding author), Univ Cologne, Biochem & Exptl Div, Dept Surg 2, Ostmerheimer Str 200, D-51109 Cologne, Germany.			Sauerland, Stefan/0000-0003-1048-796X			ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; Balogh Z, 2000, J TRAUMA, V48, P624, DOI 10.1097/00005373-200004000-00007; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; Calvano SE, 1996, ARCH SURG-CHICAGO, V131, P434; CINAT ME, 1994, J AM COLL SURGEONS, V179, P529; COPE AP, 1995, IMMUNOLOGY, V84, P21; Davies MG, 1997, BRIT J SURG, V84, P920, DOI 10.1002/bjs.1800840707; DEITCH EA, 1990, J TRAUMA, V30, P184; ERTEL W, 1995, J TRAUMA, V39, P879, DOI 10.1097/00005373-199511000-00011; ERTEL W, 1994, ARCH SURG-CHICAGO, V129, P1330; GUIRAO X, 1996, WORLD J SURG, V20, P443; Hart PH, 1996, J IMMUNOL, V157, P3672; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; LANTZ M, 1990, Cytokine, V2, P402, DOI 10.1016/1043-4666(90)90048-X; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Neugebauer E, 2000, UNFALLCHIRURG, V103, P122, DOI 10.1007/s001130050023; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; REGEL G, 1993, UNFALLCHIRURG, V96, P350; RUSH BF, 1988, ANN SURG, V207, P549, DOI 10.1097/00000658-198805000-00009; SAUERLAND S, 2001, CHIRURGISCHES FORUM, V30, P425; Selzman CH, 1998, SHOCK, V10, P309, DOI 10.1097/00024382-199811000-00001; *STAT BUND WIESB, 1999, GES RTOD DTSCH 1997, P1; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; STYLIANOS S, 1991, J TRAUMA, V31, P1063, DOI 10.1097/00005373-199131080-00003; TAN LR, 1993, J TRAUMA, V34, P634, DOI 10.1097/00005373-199305000-00004; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TILG H, 1994, BLOOD, V83, P113; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368	39	67	69	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2002	52	5					962	970		10.1097/00005373-200205000-00023			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	552DM	WOS:000175603600032	11988666				2022-02-06	
S	Flor, PJ; Battaglia, G; Nicoletti, F; Gasparini, F; Bruno, V		Alzheimer, C		Flor, PJ; Battaglia, G; Nicoletti, F; Gasparini, F; Bruno, V			Neuroprotective activity of metabotropic glutamate receptor ligands	MOLECULAR AND CELLULAR BIOLOGY OF NEUROPROTECTION IN THE CNS	Advances in Experimental Medicine and Biology		English	Article							GROWTH-FACTOR-BETA; EXCITOTOXIC NEURONAL DEATH; CEREBELLAR GRANULE CELLS; (+)-2-AMINOBICYCLO<3.1.0>HEXANE-2,6-DICARBOXYLIC ACID LY354740; CEREBROCORTICAL NERVE-TERMINALS; CULTURED CORTICAL-NEURONS; RAT HIPPOCAMPAL-NEURONS; GROUP-II; SYNAPTIC-TRANSMISSION; PHARMACOLOGICAL CHARACTERIZATION	Metabotropic glutamate receptors forma family of currently eight subtypes (mGluR1-8), subdivided into three groups (I-III). Activation of group-II (mGluR2 and -3) or group-Ill metabotropic glutamate receptors (mGluR4, -6, -7 and -8) has been established to be neuroprotective in vitro and in vivo. In contrast, group-I mGluRs (mGluR1 and -5) need to be antagonized in order to evoke protection. Initially, all neuroprotective mGluR ligands were analogues of L-glutamate. Those compounds were valuable to demonstrate protection in vitro, but showed limited applicability in animal models, particularly in chronic tests, due to low blood-brain-barrier penetration. Recently, systemically active and more potent and selective ligands. became available, e.g., the group-II mGluR agonists LY354740 and LY379268 or group-I antagonists like MPEP (mGluR5-selective) and BAY36-7620 (mGluR1-selective). This new generation of pharmacological agents allows a more stringent assessment of the role of individual mGluR-subtypes or groups of receptors in various nervous system disorders, including ischaemia-induced brain damage, traumatic brain injury, Huntington s and Parkinson s-like pathology or epilepsy. Moreover, the use of genetically modified animals (e.g., knock-out mice) is starting to shed light on specific functions of mGluR-subtypes in experimental neuropathologies.	Novartis Pharma AG, Nervous Syst Res, Basel, Switzerland; Ist Neurol Med Neuromed, Pozzilli, Italy; Univ Rome, Dept Human Physiol & Pharmacol, Rome, Italy		Flor, PJ (corresponding author), Novartis Pharma AG, Nervous Syst Res, Basel, Switzerland.		Battaglia, Giuseppe/A-7709-2010; Nicoletti, Ferdinando/K-4410-2016; Nicoletti, Ferdinando/T-4898-2019; bruno, Valeria/F-3146-2012	Battaglia, Giuseppe/0000-0001-7571-3417; bruno, Valeria/0000-0003-4231-0739; NICOLETTI, Ferdinando/0000-0003-3366-7269			AbdulGhani AS, 1997, BRAIN RES, V755, P202, DOI 10.1016/S0006-8993(97)00098-X; Alagarsamy S, 1999, NAT NEUROSCI, V2, P234, DOI 10.1038/6338; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; AMBROSINI A, 1995, MOL PHARMACOL, V47, P1057; Ango F, 2000, J NEUROSCI, V20, P8710; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; Awad H, 2000, J NEUROSCI, V20, P7871; Battaglia G, 1998, EUR J PHARMACOL, V356, P271, DOI 10.1016/S0014-2999(98)00551-2; BATTAGLIA G, 2001, IN PRESS MOL CELL NE; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Behrens MM, 1999, NEUROPHARMACOLOGY, V38, P1621, DOI 10.1016/S0028-3908(99)00098-2; Bond A, 1999, NEUROSCI LETT, V273, P191, DOI 10.1016/S0304-3940(99)00663-1; Bond A, 1998, NEUROREPORT, V9, P1191, DOI 10.1097/00001756-199804200-00042; Bond A, 2000, J PHARMACOL EXP THER, V294, P800; Brabet I, 1998, NEUROPHARMACOLOGY, V37, P1043, DOI 10.1016/S0028-3908(98)00091-4; Bradley SR, 1999, J COMP NEUROL, V407, P33; Brauner-Osborne H, 2000, J MED CHEM, V43, P2609, DOI 10.1021/jm000007r; Bruno V, 2000, NEUROPHARMACOLOGY, V39, P2223, DOI 10.1016/S0028-3908(00)00079-4; Bruno V, 1999, NEUROPHARMACOLOGY, V38, P199, DOI 10.1016/S0028-3908(98)00159-2; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x; Bruno V, 2001, EUR J NEUROSCI, V13, P1469, DOI 10.1046/j.0953-816x.2001.01541.x; Bruno V, 1996, EUR J PHARMACOL, V310, P61, DOI 10.1016/0014-2999(96)00358-5; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Bruno V, 1998, J NEUROSCI, V18, P9594; Bruno V, 2000, J NEUROSCI, V20, P6413, DOI 10.1523/JNEUROSCI.20-17-06413.2000; Bruno V, 1997, J NEUROSCI, V17, P1891; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; Bushell TJ, 1999, NEUROPHARMACOLOGY, V38, P1553, DOI 10.1016/S0028-3908(99)00103-3; Cai ZW, 1999, NEUROREPORT, V10, P3927, DOI 10.1097/00001756-199912160-00037; Carroll FY, 2001, MOL PHARMACOL, V59, P965, DOI 10.1124/mol.59.5.965; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; Chapman AG, 1999, EUR J PHARMACOL, V383, P23, DOI 10.1016/S0014-2999(99)00615-9; Chuang SC, 2000, J NEUROPHYSIOL, V83, P2844, DOI 10.1152/jn.2000.83.5.2844; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Copani A, 1999, FASEB J, V13, P2225, DOI 10.1096/fasebj.13.15.2225; COPANI A, 1995, J NEUROCHEM, V64, P101; COPANI A, 1995, MOL PHARMACOL, V47, P890; Copani A, 1998, EUR J NEUROSCI, V10, P2173, DOI 10.1046/j.1460-9568.1998.00230.x; Corti C., 1997, Society for Neuroscience Abstracts, V23, P939; De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165-6147(00)01635-7; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Doherty AJ, 2000, BRIT J PHARMACOL, V131, P239, DOI 10.1038/sj.bjp.0703574; DONOFRIO M, 2001, IN PRESS J NEUROCHEM; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; FLOR PJ, 1995, EUR J NEUROSCI, V7, P622, DOI 10.1111/j.1460-9568.1995.tb00666.x; Flor PJ, 1996, J NEUROCHEM, V67, P58; Flor PJ, 1997, NEUROPHARMACOLOGY, V36, P153, DOI 10.1016/S0028-3908(96)00176-1; FLOR PJ, 1995, NEUROPHARMACOLOGY, V34, P149, DOI 10.1016/0028-3908(94)00149-M; Gasparini F, 2000, BIOORG MED CHEM LETT, V10, P1241, DOI 10.1016/S0960-894X(00)00197-9; Gasparini F, 1999, J PHARMACOL EXP THER, V289, P1678; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; GEREAU RW, 1995, J NEUROSCI, V15, P6879; GOTTRON F, 1995, NEUROSCI LETT, V194, P1, DOI 10.1016/0304-3940(95)11698-V; GRAHAM ME, 1994, EUR J PHARM-MOLEC PH, V288, P115, DOI 10.1016/0922-4106(94)90016-7; Helton DR, 1997, NEUROPHARMACOLOGY, V36, P1511, DOI 10.1016/S0028-3908(97)00170-6; Helton DR, 1998, J PHARMACOL EXP THER, V284, P651; Henrich-Noack P, 1998, NEUROREPORT, V9, P985, DOI 10.1097/00001756-199804200-00006; Henrich-Noack P, 2000, NEUROPHARMACOLOGY, V39, P911, DOI 10.1016/S0028-3908(99)00256-7; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; HERRERO I, 1994, EUR J NEUROSCI, V6, P115, DOI 10.1111/j.1460-9568.1994.tb00253.x; Herrero I, 1998, J BIOL CHEM, V273, P1951, DOI 10.1074/jbc.273.4.1951; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IVERSEN L, 1994, J NEUROCHEM, V63, P625; Jia ZP, 1998, LEARN MEMORY, V5, P331; JOHANSEN PA, 1995, MOL PHARMACOL, V48, P140; JOLY C, 1995, J NEUROSCI, V15, P3970; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kingston AE, 1999, EUR J PHARMACOL, V377, P155, DOI 10.1016/S0014-2999(99)00397-0; Kingston AE, 1999, ANN NY ACAD SCI, V890, P438, DOI 10.1111/j.1749-6632.1999.tb08022.x; Klodzinska A, 2000, N-S ARCH PHARMACOL, V361, P283, DOI 10.1007/s002109900197; Klodzinska A, 1999, POL J PHARMACOL, V51, P543; Konieczny J, 1998, N-S ARCH PHARMACOL, V358, P500, DOI 10.1007/PL00005284; Kosinski CM, 1999, J COMP NEUROL, V415, P266; Lafon-Cazal M, 1999, EUR J NEUROSCI, V11, P663, DOI 10.1046/j.1460-9568.1999.00475.x; Lam AGM, 1998, NEUROSCI LETT, V254, P121, DOI 10.1016/S0304-3940(98)00651-X; Laurie DJ, 1996, EUR J PHARMACOL, V296, pR1, DOI 10.1016/0014-2999(95)00868-3; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Litschig S, 1999, MOL PHARMACOL, V55, P453; Lujan R, 1997, J CHEM NEUROANAT, V13, P219, DOI 10.1016/S0891-0618(97)00051-3; Maiese K, 2000, J NEUROSCI RES, V62, P257, DOI 10.1002/1097-4547(20001015)62:2<257::AID-JNR10>3.0.CO;2-H; Martin G, 1997, J NEUROPHYSIOL, V78, P3028, DOI 10.1152/jn.1997.78.6.3028; McNamara JO, 1999, NATURE, V399, pA15, DOI 10.1038/399a015; Meucci O, 1996, J NEUROSCI, V16, P4080; MINAKAMI R, 1994, BIOCHEM BIOPH RES CO, V199, P1136, DOI 10.1006/bbrc.1994.1349; Mineff E, 1999, NEUROSCI LETT, V270, P95, DOI 10.1016/S0304-3940(99)00484-X; MIYAMOTO M, 1994, EUR J PHARMACOL, V260, P99, DOI 10.1016/0014-2999(94)90016-7; Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349; Monn JA, 1999, J MED CHEM, V42, P1027, DOI 10.1021/jm980616n; Monn JA, 1997, J MED CHEM, V40, P528, DOI 10.1021/jm9606756; MONYER H, 1992, NEURON, V8, P967, DOI 10.1016/0896-6273(92)90211-U; Morishita W, 1998, J NEUROSCI, V18, P4870; MULLER T, 2000, SOC NEUR ABSTR, V26, P1650; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Neugebauer V, 2000, J NEUROPHYSIOL, V84, P759, DOI 10.1152/jn.2000.84.2.759; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1993, J COMP NEUROL, V335, P252, DOI 10.1002/cne.903350209; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; Orlando LR, 2001, EXP NEUROL, V167, P196, DOI 10.1006/exnr.2000.7542; PAQUET M, 2000, SOC NEUR ABS, V26, P13; Pekhletski R, 1996, J NEUROSCI, V16, P6364; Pellegrini-Giampietro DE, 1999, EUR J NEUROSCI, V11, P3637, DOI 10.1046/j.1460-9568.1999.00786.x; Pellegrini-Giampietro DE, 1999, NEUROPHARMACOLOGY, V38, P1607, DOI 10.1016/S0028-3908(99)00097-0; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pisani A, 1997, BRIT J PHARMACOL, V120, P1007, DOI 10.1038/sj.bjp.0700999; Pizzi M, 1999, EUR J NEUROSCI, V11, P2489, DOI 10.1046/j.1460-9568.1999.00669.x; Pizzi M, 2000, NEUROPHARMACOLOGY, V39, P903, DOI 10.1016/S0028-3908(99)00257-9; PIZZI M, 1993, J NEUROCHEM, V61, P683; Popik P, 2000, BRIT J PHARMACOL, V130, P1425, DOI 10.1038/sj.bjp.0703438; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; Prehn JHM, 1996, NEUROPHARMACOLOGY, V35, P249, DOI 10.1016/0028-3908(96)00001-9; Ren RF, 1997, MOL BRAIN RES, V48, P315, DOI 10.1016/S0169-328X(97)00108-3; Rodriguez-Moreno A, 1998, NEURON, V21, P1477, DOI 10.1016/S0896-6273(00)80665-0; Ruocco A, 1999, J CEREBR BLOOD F MET, V19, P1345, DOI 10.1097/00004647-199912000-00008; Sabelhaus CF, 2000, BRIT J PHARMACOL, V131, P655, DOI 10.1038/sj.bjp.0703646; Salt TE, 2000, NEUROSCIENCE, V100, P375, DOI 10.1016/S0306-4522(00)00265-7; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Scorziello A, 1997, J NEUROSCI RES, V49, P600, DOI 10.1002/(SICI)1097-4547(19970901)49:5&lt;600::AID-JNR10&gt;3.0.CO;2-Z; Shekhar A, 2000, NEUROPHARMACOLOGY, V39, P1139, DOI 10.1016/S0028-3908(99)00215-4; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Sistiaga A, 1998, NEUROPHARMACOLOGY, V37, P1485, DOI 10.1016/S0028-3908(98)00129-4; Sistiaga A, 2000, J NEUROCHEM, V75, P1566, DOI 10.1046/j.1471-4159.2000.0751566.x; SPOOREN WPJ, 2001, IN PRESS TRENDS PHAR, V22; Strasser U, 1998, EUR J NEUROSCI, V10, P2848, DOI 10.1046/j.1460-9568.1998.00291.x; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Tang E, 1997, EUR J PHARMACOL, V327, P109, DOI 10.1016/S0014-2999(97)89649-5; Thomsen C, 1999, J NEUROCHEM, V72, P835, DOI 10.1046/j.1471-4159.1999.0720835.x; Thomsen C, 1996, MOL PHARMACOL, V50, P6; Tomoda T, 1996, DEV BIOL, V179, P79, DOI 10.1006/dbio.1996.0242; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Ugolini A, 1999, NEUROPHARMACOLOGY, V38, P1569, DOI 10.1016/S0028-3908(99)00095-7; Vandergriff J, 1999, NEUROPHARMACOLOGY, V38, P217, DOI 10.1016/S0028-3908(98)00196-8; Walker K, 2001, NEUROPHARMACOLOGY, V40, P1, DOI 10.1016/S0028-3908(00)00113-1; Wolfarth S, 2000, AMINO ACIDS, V19, P95, DOI 10.1007/s007260070038; Wood P L, 1998, Expert Opin Investig Drugs, V7, P1505, DOI 10.1517/13543784.7.9.1505; Wroblewska B, 1997, J NEUROCHEM, V69, P174	152	67	73	0	4	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0065-2598	2214-8019	0-306-47414-X	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2002	513						197	223					27	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	BW92A	WOS:000183600500007	12575822				2022-02-06	
J	Rowles, DJ; McGrory, JE				Rowles, DJ; McGrory, JE			Percutaneous pinning of the proximal part of the humerus - An anatomic study	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							SURGICAL NECK; FRACTURES; FIXATION	Background: Closed reduction and percutaneous pinning of unstable proximal humeral fractures is a well-described technique with some theoretical advantages over open techniques. To our knowledge, the risk of injury to neurovascular structures from percutaneous pinning of the proximal part of the humerus has not been studied. We sought to quantify this risk using a cadaveric model. Methods: In ten fresh-frozen cadaveric shoulders, the intact proximal part of the humerus was pinned under fluoroscopic guidance with use of an identical published technique. A total of five 2.5-mm terminally threaded AO pins, including two lateral, one anterior, and two greater tuberosity pins, were used in each shoulder. The specimens were then dissected to determine the distance of each pin from adjacent neurovascular structures as well as key anatomic relationships. Results: The proximal lateral pins were located at a mean distance of 3 mm from the anterior branch of the axillary nerve. Four of the twenty lateral pins were noted to penetrate the articular cartilage of the humeral head. The anterior pins were located at a mean distance of 2 mm from the tendon of the long head of the biceps (perforating the tendon in three specimens) and of 11 mm from the cephalic vein (perforating the vein in one specimen). The proximal tuberosity pins were located at a mean distance of 6 and 7 mm from the axillary nerve and the posterior humeral circumflex artery (tenting the structures in two specimens with internal rotation), respectively. These pins moved away from the nerve with external rotation of the humerus. Conclusions: The technique used in this study may be associated with a risk of injury to important anatomic structures about the shoulder. Lateral pins should be distal enough to avoid injury to the anterior branch of the axillary nerve, and multiple fluoroscopic views should be obtained to avoid penetration of the humeral head cartilage. There may be a risk of injury to the cephalic vein, the biceps tendon, and the musculocutaneous nerve with use of anterior pins, and these pins should be employed with caution. Greater tuberosity pins should be placed with the arm in external rotation, should be aimed for a point greater than or equal to 20 mm from the inferior aspect of the humeral head, and should not overpenetrate the cortex.	USN, Med Ctr, Charette Hlth Care Ctr, Dept Orthopaed Surg, Portsmouth, VA 23708 USA		Rowles, DJ (corresponding author), 2144 Sunset Maple Lane, Chesapeake, VA 23323 USA.						Chen CY, 1998, J TRAUMA, V45, P1039, DOI 10.1097/00005373-199812000-00011; Ebraheim N, 1996, Am J Orthop (Belle Mead NJ), V25, P506; FLEISCHMANN W, 1993, ORTHOPEDICS, V16, P59; JABERG H, 1992, J BONE JOINT SURG AM, V74A, P508, DOI 10.2106/00004623-199274040-00006; JAKOB RP, 1991, J BONE JOINT SURG BR, V73, P295, DOI 10.1302/0301-620X.73B2.2005159; KOCIALKOWSKI A, 1990, INJURY, V21, P209, DOI 10.1016/0020-1383(90)90003-D; Koval KJ, 1996, J TRAUMA, V40, P778, DOI 10.1097/00005373-199605000-00017; Maurer F, 1993, Aktuelle Traumatol, V23, P380; Naidu SH, 1997, ORTHOPEDICS, V20, P1073; NEER CS, 1963, SURG CLIN N AM, V43, P1581; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1090, DOI 10.2106/00004623-197052060-00002; OLMEDA A, 1989, Italian Journal of Orthopaedics and Traumatology, V15, P353; Povacz P, 1998, Ther Umsch, V55, P192	13	67	69	0	0	JOURNAL BONE JOINT SURGERY INC	NEEDHAM	20 PICKERING ST, NEEDHAM, MA 02192 USA	0021-9355			J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	NOV	2001	83A	11					1695	1699		10.2106/00004623-200111000-00012			5	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	490YR	WOS:000172081700013	11701793				2022-02-06	
J	Glenn, MB; O'Neil-Pirozzi, T; Goldstein, R; Burke, D; Jacob, L				Glenn, MB; O'Neil-Pirozzi, T; Goldstein, R; Burke, D; Jacob, L			Depression amongst outpatients with traumatic brain injury	BRAIN INJURY			English	Article							DISABILITY RATING-SCALE; HEAD-INJURY; INDIVIDUALS; INVENTORY; RECOVERY	The incidence of depression and its association with subject characteristics in outpatients with traumatic brain injury (TBI) were investigated. Logistic regression was estimated with depressed/not-depressed as the dependent variable in 41 outpatients with TBI who filled out the Beck Depression Inventory-II (BDI-II). Twenty-four of 41 subjects (59%) scored in the depressed categories based on BDI-II scores >13. Fourteen (34%) scored in the moderate or severe depression categories (BDI >19). Logistic regression demonstrated a positive relationship amongst depression and age, female gender, mild TBI, and use of antidepressant and stimulant drugs; and a negative relationship between depression and violent aetiology of injury. ANOVA demonstrated that individuals with mild TBI were significantly older than those with moderate or severe TBI, which might account for the association between depression and age. The implications of these results are discussed.	Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Boston, MA 02114 USA		Glenn, MB (corresponding author), Spaulding Rehabil Hosp, 125 Nashua St, Boston, MA 02114 USA.						Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXOPOULOS GS, 2000, KAPLAN SADOCKS COMPR, P3060; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P317; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P151; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; GOLDSTEIN MZ, 2000, KAPLAIN SADOCKS COMP, P3174; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1984, MNAGEMENT HEAD INJUR, P317; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vollmer DG, 1991, J NEUROSURG S, V75, P37	27	67	74	0	13	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2001	15	9					811	818		10.1080/02699050010025777			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400006	11516349				2022-02-06	
J	Lewen, A; Fujimura, M; Sugawara, T; Matz, P; Copin, JC; Chan, PH				Lewen, A; Fujimura, M; Sugawara, T; Matz, P; Copin, JC; Chan, PH			Oxidative stress-dependent release of mitochondrial cytochrome c after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						aconitase; cell death; head injury; outcome; reactive oxygen species; SOD2	FOCAL CEREBRAL-ISCHEMIA; COPPER/ZINC-SUPEROXIDE-DISMUTASE; PERMEABILITY TRANSITION PORE; DNA FRAGMENTATION; CASPASE ACTIVATION; MUTANT MICE; CELL-DEATH; APOPTOSIS; INDUCTION; PEROXYNITRITE	Mitochondrial cytochrome c translocation to the cytosol initiates the mitochondrial-dependent apoptotic pathway. This event has not been previously reported in traumatic; brain injury (TBI). The authors determined the expression of cytochrome c in cytosolic and mitochondrial fractions after severe TBI produced by the controlled cortical impact model in the mouse. One hour after trauma there was an increase in cytosolic cytochrome c immunoreactivity. The increases in cytosolic cytochrome c preceded DNA fragmentation, which started at 4 hours. Western blots of mitochondrial and cytosolic fractions confirmed that there was a translocation of cytochrome c from the mitochondria after TBI. Mice deficient in manganese superoxide dismutase (MnSOD) showed an increased loss of mitochondrial cytochrome c after trauma, but less apoptotic cell death 4 and 24 hours after injury compared with wild-type control mice. However, the overall cell death was increased in MnSOD mice, as illustrated by a larger cortical lesion in these animals. The results show that cytochrome c is released from the mitochondria after severe TBI partly by a free radical-dependent mechanism, and that massive mitochondrial cytochrome c release is a predictor of necrotic cell death rather than apoptosis.	Stanford Univ, Neurosurg Labs, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol & Neurosci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Neurosci Program, Sch Med, Stanford, CA 94305 USA		Chan, PH (corresponding author), Stanford Univ, Neurosurg Labs, Sch Med, Dept Neurosurg, 1201 Welch Rd,MSLS P304, Stanford, CA 94305 USA.		Copin, Jean-Christophe/K-6890-2012; Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 36147, NS 25372, NS 37530, NS 82386, NS 38653, NS 14543] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS025372, P01NS014543, R01NS036147, R01NS038653, P50NS014543] Funding Source: NIH RePORTER		Araya R, 1998, FEBS LETT, V439, P168, DOI 10.1016/S0014-5793(98)01363-5; Buki A, 2000, J NEUROSCI, V20, P2825; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Copin JC, 2000, FREE RADICAL BIO MED, V28, P1571, DOI 10.1016/S0891-5849(00)00280-X; Crapo J D, 1978, Methods Enzymol, V53, P382; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 2000, J NEUROSCI, V20, P2817; Fujimura M, 1999, J NEUROSCI, V19, P3414; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hortelano S, 1999, FASEB J, V13, P2311, DOI 10.1096/fasebj.13.15.2311; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LEIST M, 1998, BIOCHEMICA, V2, P25; LEWIN A, 2001, IN PRESS J CEREB BLO; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Matz PG, 2001, STROKE, V32, P506, DOI 10.1161/01.STR.32.2.506; Matz PG, 2000, BRAIN RES, V858, P312, DOI 10.1016/S0006-8993(99)02454-3; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Murakami K, 1998, J NEUROSCI, V18, P205; Namura S, 1998, J NEUROSCI, V18, P3659; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nicotera P, 1998, TOXICOL LETT, V103, P139; O'Dell DM, 2000, J NEUROSCI, V20, P4821; RINK A, 1995, AM J PATHOL, V147, P1575; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Sugawara T, 1999, J NEUROSCI, V19, part. no.; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5	38	67	70	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2001	21	8					914	920		10.1097/00004647-200108000-00003			7	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	459AQ	WOS:000170228000003	11487726	Bronze			2022-02-06	
J	Marklund, N; Clausen, F; McIntosh, TK; Hillered, L				Marklund, N; Clausen, F; McIntosh, TK; Hillered, L			Free radical scavenger posttreatment improves functional and morphological outcome after fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion; Morris Water Maze; neuroprotection; nitrone scavengers; rat; reactive oxygen species; traumatic brain injury (TBI)	TRAUMATIC BRAIN INJURY; BUTYL-NITRONE PBN; SPATIAL MEMORY PERFORMANCE; CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; EXCITATORY AMINO-ACIDS; CLOSED-HEAD-INJURY; ALPHA-PHENYLNITRONE; MITOCHONDRIAL DYSFUNCTION; DELAYED TREATMENT	Reactive oxygen species (ROS) are thought to contribute to the secondary injury process after traumatic brain injury (TBI). ROS scavenging compounds have shown neuroprotective properties in various models of experimental brain injury, including TBI. Administration of nitrone radical scavengers has emerged as a promising pharmacological concept in focal experimental ischemia due to their low toxicity and neuroprotective properties, with a time window of several hours. The aim of this study was to test the neuroprotective efficacy of two nitrones, the readily blood-brain barrier (BBB) penetrating alpha -phenyl-N-tert-butyl nitrone (PBN) and the poorly BBB penetrating sulfo-derivative, 2-sulfo-phenyl-N-tert-butyl nitrone (S-PBN) after moderate (2.20-2.45 atm) lateral fluid percussion injury (FPI) in rats. Twenty-six rats received a 24-h intravenous infusion (30 mg/kg/h) of saline, PBN, or an equimolar dose of S-PBN beginning 30 min after FPI. Eight sham-operated animals were used as controls. Cognitive function was assessed using the Morris Water Maze at day 11-15 after TBI, neurological status at day 1, 4, and 8 and morphological outcome at day 15. PBN and S-PBN treatment significantly reduced the loss of ipsilateral hemispheric tissue whereas only S-PBN tended to reduce the cortical lesion volume. PBN treatment caused a significant improvement in the neurological score as compared to saline-treated animals, while S-PBN alone attenuated the cognitive deficit. Our results suggest that nitrone radical scavengers are neuroprotective when administered 30 min after FPI in rats. Differences in pharmacokinetics may account for the observed individual neuroprotective profiles of the two nitrones.	Univ Hosp, Dept Neurol & Neurosurg, Uppsala, Sweden; Univ Hosp, Dept Med Sci & Clin Chem, Uppsala, Sweden; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Marklund, N (corresponding author), Univ Hosp, Dept Neurol & Neurosurg, Uppsala, Sweden.			Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626			Atlante A, 1998, NEUROSCI LETT, V245, P127, DOI 10.1016/S0304-3940(98)00195-5; AU AM, 1985, J CELL BIOCHEM, V27, P449, DOI 10.1002/jcb.240270413; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Butterfield DA, 1998, ANN NY ACAD SCI, V854, P448, DOI 10.1111/j.1749-6632.1998.tb09924.x; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHEN GM, 1990, FREE RADICAL RES COM, V9, P317, DOI 10.3109/10715769009145690; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Floyd RA, 1992, ANN NEUROL, V32, P22; FOLBERGROVA J, 1995, P NATL ACAD SCI USA, V92, P5057, DOI 10.1073/pnas.92.11.5057; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hall ED, 1997, NEUROSURG CLIN N AM, V8, P195; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hartl R, 1997, ACT NEUR S, V70, P240; HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kumar M, 1996, BIOCHEM BIOPH RES CO, V219, P497, DOI 10.1006/bbrc.1996.0262; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Kuroda S, 1996, NEUROBIOL DIS, V3, P149, DOI 10.1006/nbdi.1996.0015; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; MALIS CD, 1986, J BIOL CHEM, V261, P14201; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Pahlmark K, 1996, ACTA PHYSIOL SCAND, V157, P41, DOI 10.1046/j.1365-201X.1996.440167000.x; Paxinos G, 1997, RAT BRAIN STEREOTAXI; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; PHILLIS JW, 1990, NEUROSCI LETT, V116, P315, DOI 10.1016/0304-3940(90)90093-O; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stewart CA, 1999, ARCH BIOCHEM BIOPHYS, V365, P71, DOI 10.1006/abbi.1999.1159; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	62	67	71	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2001	18	8					821	832		10.1089/089771501316919184			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	464AG	WOS:000170509600008	11526988				2022-02-06	
J	McCrory, P; Johnston, KM; Mohtadi, NG; Meeuwisse, W				McCrory, P; Johnston, KM; Mohtadi, NG; Meeuwisse, W			Evidence-based review of sport-related concussion: Basic science	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; traumatic brain injury; sport	DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; TRAUMATIC BRAIN INJURY; 2ND IMPACT SYNDROME; E-DEFICIENT MICE; DELAYED DETERIORATION; ALZHEIMERS-DISEASE; SOCCER INJURIES; NECK INJURIES; DAMAGE	The evidence base for sport-related concussive brain injury is reviewed in this paper. In the past, pathophysiological understanding of this common condition has been extrapolated from studies of severe brain trauma. More recent scientific study demonstrates that this approach is unsatisfactory, and the clinical features of concussion represent a predominantly functional brain injury rather than manifest by structural or neuropathological damage. Such understanding of this condition remains incomplete at this stage.	Univ Melbourne, Ctr Sports Med Res & Educ, Melbourne, Vic, Australia; Univ Melbourne, Brain Res Inst, Melbourne, Vic, Australia; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2T5, Canada; Univ Calgary, Sport Med Ctr, Calgary, AB, Canada		McCrory, P (corresponding author), 31 Grosvenor Parade, Balwyn, Vic 3103, Australia.	pmccrory@compuserve.com	McCrory, Paul/Q-8688-2019				ADAMS J M, 1986, P1; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1989, SCOT MED J, V34, P399, DOI 10.1177/003693308903400106; ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; ALVES WM, 1987, CLIN SPORT MED, V6, P211; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barth JT, 1989, MILD HEAD INJURY, P257; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BROWN WJ, 1972, AM J PATHOL, V67, P41; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; CANTU R, 1995, BOXING MED; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CHOPP M, 1993, CURR OPIN NEUROL NEU, V6, P6; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1982, ATHLETIC INJURIES HE, P93; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gilbert M M, 1968, Headache, V8, P57, DOI 10.1111/j.1526-4610.1968.hed0802057.x; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HALL ED, 1993, CURRENT CONCEPTS UPJ, P1; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JANE JA, 1985, TRAUMA CENTRAL NERVO, P27; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1998, PHYSICIAN SPORTSMED, V26, P25, DOI 10.3810/psm.1998.02.928; JORDAN BD, 1993, MED ASPECTS BOXING; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MADDOCKS DL, 1995, THESIS U MELBOURNE M; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; Mcintosh TK, 1999, TRAUMATIC BRAIN INJU, P39; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; NARAYANA R, 1996, NEUROTRAUMA; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1990, SPORTS NEUROLOGY; OPPENHEIMER D, 1968, J EXP NEUROL, V26, P77; PALMER AC, 1982, VET REC, V111, P575; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; PARKINSON D, 1988, NEUROSURGERY, V23, P682, DOI 10.1097/00006123-198811000-00029; PARKINSON D, 1988, SURG NEUROL, V30, P102, DOI 10.1016/0090-3019(88)90094-8; PARKINSON D, 1977, MAYO CLIN PROC, V52, P492; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; POVISHLOK J, 1996, ACTA NEUROCHIR SUPP, V66, P81; POVISHLOK J, 1983, J NEUROPATH EXP NEUR, V42, P225; RICE SG, 1995, SPORTS MED PRIM CARE, V1, P9; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shetter A G, 1979, Adv Neurol, V22, P5; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; SYMONDS C, 1962, LANCET, V1, P1; Symonds C.P., 1940, INJURIES SKULL BRAIN, P69; TAYLOR AR, 1966, HEAD INJURY, P235; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THORNDIEK A, 1952, NEW ENGL J MED, V246, P552; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; WARD A, 1964, CLIN NEUROSURG, V12, P129; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	83	67	67	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2001	11	3					160	165		10.1097/00042752-200107000-00006			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	454YG	WOS:000169998900005	11495320				2022-02-06	
J	Geddes, DM; Cargill, RS				Geddes, DM; Cargill, RS			An in vitro model of neural trauma: Devise characterization and calcium response to mechanical stretch	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article							IN-VITRO; NG108-15 CELLS; BRAIN INJURY; STRAIN; TISSUE; FLUORESCENCE; DEFORMATION; ASTROCYTES; CULTURE; NEURONS	An in vitro model for neural trauma was characterized and validated. The model is based on a novel device that is capable of applying high strain rate, homogeneous, and equibiaxial deformation to neural cells in culture. The deformation waveform is fully arbitrary and controlled via closed-loop feedback. Intracellular calcium ([Ca2+](i)) alterations were recorded in real time throughout the imposed strain with an epifluorescent microscopy system. Peak change in [Ca2+](i), recovery of [Ca2+](i), and percent responding NG108-15 cells were shown to be dependent on strain rate (1(-1) to 10(-1)) and magnitude (0.1 to 0.3 Green's Strain). These measures were also shown to depend significantly on the interaction between strain rate and magnitude. This model for neural trauma is a robust system that can be used to investigate the cellular tolerance and response to traumatic brain injury.	Georgia Inst Technol, Sch Biomed Engn, Atlanta, GA 30332 USA; Georgia Inst Technol, Sch Mech Engn, Atlanta, GA 30332 USA		Geddes, DM (corresponding author), Georgia Inst Technol, Sch Biomed Engn, Atlanta, GA 30332 USA.						Adams J. H., 1982, HEAD INJURY BASIC CL, P141; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; *CDC, 1998, TRAUM BRAIN INJ US R; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GILBERT JA, 1994, J BIOMECH, V27, P1169, DOI 10.1016/0021-9290(94)90057-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNG CT, 1994, J BIOMECH, V27, P227, DOI 10.1016/0021-9290(94)90212-7; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Linares-Hernandez L, 1998, BBA-BIOMEMBRANES, V1372, P1, DOI 10.1016/S0005-2736(98)00035-2; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MISRA JC, 1984, J BIOMECH, V17, P459, DOI 10.1016/0021-9290(84)90014-9; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; NORONHABLOB L, 1988, J NEUROCHEM, V50, P1381, DOI 10.1111/j.1471-4159.1988.tb03020.x; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; SCHAFFER JL, 1994, J ORTHOP RES, V12, P709, DOI 10.1002/jor.1100120514; Sotoudeh M, 1998, ANN BIOMED ENG, V26, P181, DOI 10.1114/1.88; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; THIBAULT LE, 1983, J BIOMECH ENG-T ASME, V105, P31, DOI 10.1115/1.3138381; Tymianski M, 1996, NEUROSURGERY, V38, P1176; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WILLIAMS JL, 1992, J BIOMECH ENG-T ASME, V114, P377, DOI 10.1115/1.2891398; ZAUNER A, 1995, J NEUROTRAUM, V12, P457	28	67	68	0	5	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JUN	2001	123	3					247	255		10.1115/1.1374201			9	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	452UU	WOS:000169878700007	11476368				2022-02-06	
J	Norwood, SH; McAuley, CE; Berne, JD; Vallina, VL; Kerns, DB; Grahm, TW; McLarty, JW				Norwood, SH; McAuley, CE; Berne, JD; Vallina, VL; Kerns, DB; Grahm, TW; McLarty, JW			A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							MOLECULAR-WEIGHT HEPARIN; CAVA FILTER INSERTION; LOW-DOSE HEPARIN; PULMONARY-EMBOLISM; MAJOR TRAUMA; COMPRESSION STOCKINGS; PROPHYLAXIS; THROMBOSIS; NEUROSURGERY; PLACEMENT	BACKGROUND: Venous thromboembolism (VTE) is a frequent and potentially life-threatening complication after trauma. The purpose of this study is to investigate the effectiveness of enoxaparin in preventing deep venous thrombosis (DVT) and pulmonary embolism (PE) after injury in patients who are at high risk for developing VTE. STUDY DESIGN: A prospective single-cohort observational study was initiated for seriously injured blunt trauma patients admitted to a Level I trauma center during a 7-month period. Patients were eligible for the study if time hospitalized was greater than or equal to 72 hours, Injury Severity Score (ISS) was greater than or equal to 9, enoxaparin was started within 24 hours after admission, and one or more of the following high risk criteria were met: age > 50 years, ISS greater than or equal to 16, presence of a femoral vein catheter, Abbreviated Injury Score (AIS) greater than or equal to 3 for any body region, Glasgow Coma Scale (GCS) Score less than or equal to 8, presence of major pelvic, femur, or tibia fracture, and presence of direct blunt mechanism venous injury. Patients with closed head injuries and nonoperatively treated solid abdominal organ injuries were also potential participants. The primary outcomes measured were thromboembolic events-either a documented lower extremity DVT by duplex color-flow doppler ultrasonography or a PE documented by rapid infusion CT pulmonary angiography or conventional pulmonary angiography. RESULTS: There were 118 patients enrolled in the study. Two patients (2%) developed DVT, one of which was proximal to the calf (95% confidence interval, 0% to 6%). Two of 12 patients (17%) with splenic injuries who received enoxaparin failed initial nonoperative management. There were no other bleeding complications, and no clinical evidence or documented episodes of PE. One patient died from multiple system organ failure. CONCLUSIONS: Enoxaparin is a practical and effective method for reducing the incidence of VTE in high risk, seriously injured patients. This study supports further investigation into the safety of enoxaparin prophylaxis in patients with closed head injuries and nonoperatively treated solid abdominal organ injuries. (J Am Coll Surg 2001;192:161-167. (C) 2001 by the American College of Surgeons).	E Texas Med Ctr, Trauma Serv, Tyler, TX USA; E Texas Med Ctr, Neurosurg Serv, Tyler, TX USA; Univ Texas, Ctr Hlth, Tyler, TX USA		Norwood, SH (corresponding author), 1020 E Idel St, Tyler, TX 75701 USA.						Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; CERRATO D, 1978, J NEUROSURG, V49, P378, DOI 10.3171/jns.1978.49.3.0378; Clagett GP, 1998, CHEST, V114, p531S, DOI 10.1378/chest.114.5_Supplement.531S; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; Greenfield LJ, 1997, J TRAUMA, V42, P100, DOI 10.1097/00005373-199701000-00017; Headrick JR, 1997, AM SURGEON, V63, P1; Horlocker TT, 1997, ANESTH ANALG, V85, P874, DOI 10.1097/00000539-199710000-00031; KHANSARINIA S, 1995, J VASC SURG, V22, P231, DOI 10.1016/S0741-5214(95)70135-4; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; McMurtry AL, 1999, J AM COLL SURGEONS, V189, P314, DOI 10.1016/S1072-7515(99)00137-4; *MED EC CO INC, 1998, PHYS DESK REF, P2369; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; NURMOHAMED MT, 1992, LANCET, V340, P152, DOI 10.1016/0140-6736(92)93223-A; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Peitzman AB, 2000, J TRAUMA, V49, P177, DOI 10.1097/00005373-200008000-00002; Quader MA, 1998, J AM COLL SURGEONS, V187, P641, DOI 10.1016/S1072-7515(98)00255-5; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; ROGERS FB, 1995, SURG CLIN N AM, V75, P279, DOI 10.1016/S0039-6109(16)46588-6; ROTONDO MF, 2000, TRAUMA, P1267; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; Spain DA, 1997, J TRAUMA, V42, P463, DOI 10.1097/00005373-199703000-00014; TuttleNewhall JE, 1997, J TRAUMA, V42, P90, DOI 10.1097/00005373-199701000-00016; Velmahos GC, 1998, J AM COLL SURGEONS, V187, P529, DOI 10.1016/S1072-7515(98)00223-3; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020	31	67	68	0	3	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	FEB	2001	192	2					161	167		10.1016/S1072-7515(00)00802-4			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	401BA	WOS:000166906000003	11220715				2022-02-06	
J	Clarke, WE; Berry, M; Smith, C; Kent, A; Logan, A				Clarke, WE; Berry, M; Smith, C; Kent, A; Logan, A			Coordination of fibroblast growth factor receptor 1 (FGFR1) and fibroblast growth factor-2 (FGF-2) trafficking to nuclei of reactive astrocytes around cerebral lesions in adult rats	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article							MOLECULAR-WEIGHT FORMS; FACTOR-LIKE IMMUNOREACTIVITY; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; FACTOR BFGF; ENDOTHELIAL-CELLS; CYTOPLASMIC LOCALIZATION; FOREBRAIN ISCHEMIA; BRAIN-INJURY; IN-VITRO	Traumatic injury to the adult central nervous system initiates a cascade of cellular and trophic events, culminating in the formation of a reactive gliotic scar through which transected axons fail to regenerate. Levels of fibroblast growth factor-2 (FGF-2), a potent gliogenic and neurotrophic factor, together with its full-length receptor, FGF receptor 1 (FGFR1) are coordinately and significantly increased postinjury in both nuclear and cytoplasmic fractions of extracted cerebral cortex biopsies after a penetrant injury. FGFR1 is colocalized with FGF-2 in the nuclei of reactive astrocytes, and here FGF-2 is associated with nuclear euchromatin. This study unequivocally demonstrates coordinate up-regulation and trafficking of FGF-2 and full-length FGFR1 to the nucleus of reactive astrocytes in an in vivo model of brain injury, thereby implicating a role in nuclear activity for these molecules. However, the precise contribution of nuclear FGF-2/FGFR1 to the pathophysiological response of astrocytes after injury is undetermined.	Univ Birmingham, Dept Med, Birmingham B15 2TT, W Midlands, England; GKT, Ctr Neurosci Neural Damage & Repair, London SE1 1UL, England		Clarke, WE (corresponding author), Univ Birmingham, Dept Med, Birmingham B15 2TT, W Midlands, England.			Logan, Ann/0000-0003-3215-5042			AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; Arnaud E, 1999, MOL CELL BIOL, V19, P505; Bailly K, 2000, FASEB J, V14, P333, DOI 10.1096/fasebj.14.2.333; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; Ballabriga J, 1997, BRAIN RES, V752, P315, DOI 10.1016/S0006-8993(96)01308-X; BAROTTE C, 1989, NEUROSCI LETT, V101, P197, DOI 10.1016/0304-3940(89)90530-2; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bonnet H, 1996, J BIOL CHEM, V271, P24781, DOI 10.1074/jbc.271.40.24781; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CUEVAS P, 1993, SURG NEUROL, V39, P380, DOI 10.1016/0090-3019(93)90205-F; DUVERGER E, 1995, J CELL SCI, V108, P1325; Eclancher F, 1996, BRAIN RES, V737, P201, DOI 10.1016/0006-8993(96)00732-9; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Emoto N, 1989, GROWTH FACTORS, V2, P21, DOI 10.3109/08977198909069078; ENGELE J, 1991, J NEUROSCI, V11, P3070; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1991, ANN NY ACAD SCI, V638, P109, DOI 10.1111/j.1749-6632.1991.tb49022.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; GomezPinilla F, 1997, NEUROSCIENCE, V76, P137; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021, DOI 10.1523/JNEUROSCI.15-03-02021.1995; GONZALEZ AM, 1995, BRAIN RES, V701, P201, DOI 10.1016/0006-8993(95)01002-X; GROTHE C, 1999, CNS INJURIES CELLULA, P201; GUALANDRIS A, 1993, GROWTH FACTORS, V8, P49, DOI 10.3109/08977199309029134; HANNEKEN A, 1994, P NATL ACAD SCI USA, V91, P9170, DOI 10.1073/pnas.91.19.9170; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; HAWKER JR, 1992, AM J PHYSIOL, V262, pH1525, DOI 10.1152/ajpheart.1992.262.5.H1525; Henderson JE, 1997, MOL CELL ENDOCRINOL, V129, P1, DOI 10.1016/S0303-7207(97)04021-5; Hill C, 2000, ENDOCRINOLOGY, V141, P1196, DOI 10.1210/en.141.3.1196; KAN M, 1993, SCIENCE, V259, P1919; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; KIYOTA Y, 1991, BRAIN RES, V545, P322, DOI 10.1016/0006-8993(91)91307-M; Klein S, 1996, GROWTH FACTORS, V13, P219, DOI 10.3109/08977199609003223; KNISS DA, 1988, BRAIN RES, V439, P281, DOI 10.1016/0006-8993(88)91485-0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Lippoldt A, 1996, BRAIN RES, V730, P1; LOGAN A, 1990, J ENDOCRINOL, V125, P339, DOI 10.1677/joe.0.1250339; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOGAN A, 1990, BRIT J HOSP MED, V43, P428; Logan Ann, 1994, Progress in Growth Factor Research, V5, P379, DOI 10.1016/0955-2235(94)00008-9; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; Masumura M, 1996, NEUROSCI LETT, V213, P119, DOI 10.1016/0304-3940(96)12841-X; MATSUDA S, 1992, BRAIN RES, V577, P92, DOI 10.1016/0006-8993(92)90541-G; MENON VK, 1994, EXP NEUROL, V129, P142, DOI 10.1006/exnr.1994.1155; OKUMURA N, 1989, J BIOCHEM-TOKYO, V106, P904, DOI 10.1093/oxfordjournals.jbchem.a122950; Patry V, 1997, BIOCHEM J, V326, P259, DOI 10.1042/bj3260259; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Reilly JF, 1998, GLIA, V22, P202, DOI 10.1002/(SICI)1098-1136(199802)22:2<202::AID-GLIA11>3.0.CO;2-1; Reilly JF, 1996, EXP NEUROL, V140, P139, DOI 10.1006/exnr.1996.0124; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; Seidman KJN, 1997, BRAIN RES, V753, P18, DOI 10.1016/S0006-8993(96)01481-3; Speliotes EK, 1996, MOL BRAIN RES, V39, P31, DOI 10.1016/0169-328X(95)00351-R; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; TAKAMI K, 1993, EXP BRAIN RES, V97, P185; VIJAYAN VK, 1993, INT J DEV NEUROSCI, V11, P257, DOI 10.1016/0736-5748(93)90084-Q; WALICKE PA, 1991, J NEUROSCI, V11, P2249; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WEIBEL M, 1985, INT J DEV NEUROSCI, V3, P617, DOI 10.1016/0736-5748(85)90052-8; WOLBURG H, 1996, NEUROSCI LETT, V72, P25; WOODWARD WR, 1992, J NEUROSCI, V12, P142; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F	74	67	67	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431			MOL CELL NEUROSCI	Mol. Cell. Neurosci.	JAN	2001	17	1					17	30		10.1006/mcne.2000.0920			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	397GA	WOS:000166683900002	11161466				2022-02-06	
J	Mellman, TA; David, D; Bustamante, V; Fins, AI; Esposito, K				Mellman, TA; David, D; Bustamante, V; Fins, AI; Esposito, K			Predictors of post-traumatic stress disorder following severe injury	DEPRESSION AND ANXIETY			English	Article						stress disorder; post-traumatic; risk factors; injury; dissociation; coping; arousal	VEHICLE ACCIDENT VICTIMS; POSTTRAUMATIC-STRESS; COPING STRATEGIES; FEMALE VICTIMS; RAPE; SURVIVORS; VETERANS; OUTCOMES; ASSAULT; SCALE	The chronicity and morbidity of established post-traumatic stress disorder (PTSD) has stimulated interest in recognizing and understanding the early development of the disorder. Acute stress disorder, a new diagnosis intended to facilitate early case detection, res-ts on the occurrence of dissociative reactions. It remains uncertain whether dissociation is a universal or unique early predictor of subsequent PTSD. Traumatic injury is an important and relatively understudied antecedent of PTSD. The objective of this Study was to preliminarily identify which previously implicated early reactions and risk factors would apply to the prediction of PTSD following severe traumatic injury. Patients admitted to a regional Level I trauma center following life threatening events who bad recall of the incident and did not have signs of traumatic brain injury or recent psychopathology were enrolled. Comprehensive assessments were conducted during hospitalization and after discharge approximately 2 months after the traumatic event. At follow-up, 24% of the available 50 subjects met full criteria for PTSD and an additional 22% met criteria for two of three symptom clusters. Early symptoms of heightened arousal and coping with disengagement were independent predictors of PTSD severity at follow-up. Relationships to initial dissociative reactions and a diagnosis of ASD were not significant. These early predictors found in a setting of severe injury only partially overlap findings front previous PTSD studies. (C) 2001 Wiley-Liss, Inc.	Univ Miami, Sch Med, Dept Psychiat & Behav Sci, Miami, FL USA; Dartmouth Coll Sch Med, Dept Psychiat, Lebanon, NH USA		Mellman, TA (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.		Esposito, Karin/AAG-6878-2019		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH54006] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH054006] Funding Source: NIH RePORTER		*AM COLL SURG, 1999, REP COMM TRAUM RES O; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blake D. D., 1990, BEHAV THER, V13, P187, DOI DOI 10.1007/BF02105408; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; Buckley TC, 1996, J ABNORM PSYCHOL, V105, P617, DOI 10.1037/0021-843X.105.4.617; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Classen C, 1998, AM J PSYCHIAT, V155, P620, DOI 10.1176/ajp.155.5.620; Dancu CV, 1996, J TRAUMA STRESS, V9, P253, DOI 10.1007/BF02110659; FLEMING R, 1992, J HUMAN STRESS, V9, P14; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; MARMAR CR, 1994, AM J PSYCHIAT, V151, P902; Marshall RD, 1999, AM J PSYCHIAT, V156, P1677; MAYOU R, 1993, BRIT MED J, V307, P9; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; North CS, 1997, AM J PSYCHIAT, V154, P1696, DOI 10.1176/ajp.154.12.1696; Resnick H., 1997, NCP CLIN Q, V7, P41; RESNICK HS, 1995, AM J PSYCHIAT, V152, P1675; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; SPITZER R, 1994, INSTRUCTION MANUAL S; TEASDALE G, 1974, LANCET, V2, P81; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Valentiner DP, 1996, J ABNORM PSYCHOL, V105, P455, DOI 10.1037/0021-843X.105.3.455; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690	30	67	67	0	8	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	1091-4269			DEPRESS ANXIETY	Depress. Anxiety		2001	14	4					226	231		10.1002/da.1071			6	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	504YB	WOS:000172882800005	11754130				2022-02-06	
J	Swaab-Barneveld, H; de Sonneville, L; Cohen-Kettenis, P; Gielen, A; Buitelaar, J; van Engeland, H				Swaab-Barneveld, H; de Sonneville, L; Cohen-Kettenis, P; Gielen, A; Buitelaar, J; van Engeland, H			Visual sustained attention in a child psychiatric population	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						sustained attention; vigilance; continuous performance; attention-deficit hyperactivity disorder	CONTINUOUS PERFORMANCE TASK; CLOSED-HEAD INJURY; VIGILANCE PERFORMANCE; HYPERACTIVITY; DEFICIT; METHYLPHENIDATE; DISORDER; ADHD; TIME; INTELLIGENCE	Objective: To increase knowledge of the diversity and specificity of sustained attention deficits in children with attention-deficit hyperactivity disorder (ADHD), with special reference to the issue of distinguishing between children with ADHD and children with other psychiatric diagnoses. Method: A Visual sustained attention task was used to compare 52 boys with ADHD with 55 normal controls, 29 boys with oppositional defiant disorder or conduct disorder (ODD/CD), 29 boys with anxiety or dysthymia (ANX/DYS), 43 boys with pervasive developmental disorder, 24 boys with ADHD plus ODD/CD, and 14 boys with ADHD plus ANX/DYS. Results: Compared with normal controls, children with ADHD were slower, were more inaccurate, were more impulsive, were less responsive to feedback, and showed less perceptual sensitivity and stability of performance, resulting in a marked decrease in vigilance over time. Unresponsiveness to feedback and the extent of the decrease in Vigilance during time on task were found to be the only factors that distinguished children with ADHD from children with other diagnoses. Conclusion: Although only children with ADHD are characterized primarily by "attention deficit" sustained attention deficit is common to a certain extent to all children with psychiatric disorders.	Univ Utrecht Hosp, Dept Child & Adolescent Psychiat, NL-3508 GA Utrecht, Netherlands; Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; Free Univ Amsterdam Hosp, Div Pediat Neurol, Amsterdam, Netherlands		Swaab-Barneveld, H (corresponding author), Univ Utrecht Hosp, Dept Child & Adolescent Psychiat, POB 85500, NL-3508 GA Utrecht, Netherlands.	H.Swaab@Psych.azu.nl	Buitelaar, Jan K/E-4584-2012	Buitelaar, Jan K/0000-0001-8288-7757; de Sonneville, Leo/0000-0003-0133-4953; Swaab, Hanna/0000-0003-3697-060X			Achenbach T., 1991, INTEGRATIVE GUIDE 19; Althaus M, 1996, CHILD NEUROPSYCHOL, V2, P30, DOI 10.1080/09297049608401348; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; AYLWARD GP, 1990, J PSYCHOEDUC ASSESS, V8, P497, DOI 10.1177/073428299000800405; Ballard JC, 1996, J CLIN EXP NEUROPSYC, V18, P843, DOI 10.1080/01688639608408307; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; BERCH DB, 1984, SUSTAINED ATTENTION, P143; CAMPBELL JW, 1991, J SCHOOL PSYCHOL, V29, P143; CHEE P, 1989, J ABNORM CHILD PSYCH, V17, P371, DOI 10.1007/BF00915033; CORKUM PV, 1993, J CHILD PSYCHOL PSYC, V34, P1217, DOI 10.1111/j.1469-7610.1993.tb01784.x; de Sonneville LMJ, 1999, COMP PSYCH, V6, P187; DESONNEVILLE LMJ, 1994, J CLIN EXP NEUROPSYC, V16, P877, DOI 10.1080/01688639408402700; HOCHHAUS L, 1972, PSYCHOL BULL, V77, P375, DOI 10.1037/h0032459; KAUFMAN AS, 1975, J CONSULT CLIN PSYCH, V43, P135, DOI 10.1037/h0076502; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KOELEGA HS, 1992, BIOL PSYCHOL, V34, P59, DOI 10.1016/0301-0511(92)90024-O; Koelega HS, 1995, J CHILD PSYCHOL PSYC, V36, P1477, DOI 10.1111/j.1469-7610.1995.tb01677.x; KOPP MS, 1989, PSYCHOTHER PSYCHOSOM, V52, P74, DOI 10.1159/000288302; LAM CM, 1991, REM SPEC EDUC, V12, P40, DOI 10.1177/074193259101200208; Losier BJ, 1996, J CHILD PSYCHOL PSYC, V37, P971, DOI 10.1111/j.1469-7610.1996.tb01494.x; LUEGER RJ, 1990, J CLIN PSYCHOL, V46, P696; Mackworth J.F., 1970, VIGILANCE ATTENTION; MICHAEL RL, 1981, PSYCHOPHYSIOLOGY, V18, P665, DOI 10.1111/j.1469-8986.1981.tb01841.x; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Parasuraman R, 1984, VARIETIES ATTENTION; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; RUND BR, 1992, ACTA PSYCHIAT SCAND, V86, P207, DOI 10.1111/j.1600-0447.1992.tb03253.x; RUTSCHMANN J, 1986, J ABNORM CHILD PSYCH, V14, P365, DOI 10.1007/BF00915432; SCHACHAR R, 1988, J ABNORM CHILD PSYCH, V16, P361, DOI 10.1007/BF00914169; SERGEANT JA, 1985, J CHILD PSYCHOL PSYC, V26, P97, DOI 10.1111/j.1469-7610.1985.tb01631.x; SWANSON HL, 1989, J SCHOOL PSYCHOL, V27, P141, DOI 10.1016/0022-4405(89)90002-2; SWANSON L, 1981, J CHILD PSYCHOL PSYC, V22, P393, DOI 10.1111/j.1469-7610.1981.tb00563.x; SYKES DH, 1971, J CHILD PSYCHOL PSYC, V12, P129, DOI 10.1111/j.1469-7610.1971.tb01056.x; Vander Steene G, 1986, WECHSLER INTELLIGENC; VANDERMEERE J, 1988, J ABNORM CHILD PSYCH, V16, P641, DOI 10.1007/BF00913475; WERRY JS, 1987, J ABNORM CHILD PSYCH, V15, P409, DOI 10.1007/BF00916458	37	67	71	1	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAY	2000	39	5					651	659		10.1097/00004583-200005000-00020			9	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	308DC	WOS:000086694400020	10802984				2022-02-06	
J	Koshinaga, M; Katayama, Y; Fukushima, M; Oshima, H; Suma, T; Takahata, T				Koshinaga, M; Katayama, Y; Fukushima, M; Oshima, H; Suma, T; Takahata, T			Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices	JOURNAL OF NEUROTRAUMA			English	Article						brain slice; C3b complement receptor (CR3); controlled impact injury; microglial activation; OX42	COLONY-STIMULATING FACTORS; NITRIC-OXIDE; EXTRACELLULAR POTASSIUM; MONONUCLEAR PHAGOCYTES; SPREADING DEPRESSION; MACROPHAGES; INVITRO; ADULT; CELLS; EXPRESSION	In order to assess the role of circulating blood in early microglial activation after traumatic brain injury (TBI), controlled cortical impact injury was applied to adult rat brain slices (400 mu m in thickness) and the microglial response was examined. The complement receptor (CR3) expression and morphological transformation of the microglia were evaluated by OX42 immunohistochemistry. At 5 min following injury, activated microglia with intense CR3 expression appeared throughout the hemisphere on the injured side. In contrast, the morphology and CR3 expression of the microglia on the contralateral side were indistinguishable from those of the resident ramified microglia seen in normal brains, At 30 min following injury, microglial activation was more pronounced on the injured side, while the microglia on the contralateral side still retained a ramified morphology, These results are consistent with our previous observations made in in vivo experiments, which indicate that, as the brain slice paradigm excludes variables arising from the circulating blood, the rapid and widespread microglial activation observed following TBI can not be attributed exclusively to the infiltration of blood-borne macrophages or molecules. Rather this activation is most likely caused by intrinsic mechanisms within the brain tissue, such as traumatic depolarization.	Nihon Univ, Sch Med, Dept Neurol Surg, Itabashi Ku, Tokyo 1738610, Japan		Koshinaga, M (corresponding author), Nihon Univ, Sch Med, Dept Neurol Surg, Itabashi Ku, 30-1 Oyaguchi Kamimachi, Tokyo 1738610, Japan.						AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; BANATI RB, 1994, J CEREBR BLOOD F MET, V14, P145, DOI 10.1038/jcbfm.1994.19; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Caggiano AO, 1996, J COMP NEUROL, V369, P93, DOI 10.1002/(SICI)1096-9861(19960520)369:1<93::AID-CNE7>3.0.CO;2-F; CHAO CC, 1992, J IMMUNOL, V149, P2736; COLTON CA, 1993, J NEUROSCI RES, V35, P297, DOI 10.1002/jnr.490350309; Del Rio-Hortega R., 1965, CYTOLOGY CELLULAR PA, P483; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elkabes S, 1996, J NEUROSCI, V16, P2508; FINSEN BR, 1993, J CHEM NEUROANAT, V6, P267, DOI 10.1016/0891-0618(93)90048-9; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; HADDAD GG, 1989, J NEUROPHYSIOL, V62, P1213, DOI 10.1152/jn.1989.62.6.1213; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; KREUTZBERG GW, 1989, METAB BRAIN DIS, V4, P81, DOI 10.1007/BF00999498; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LIGHTHALL JW, J NEUROTRAUMA, V5, P1; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; SHIMOHAMA S, 1989, MOL BRAIN RES, V5, P271, DOI 10.1016/0169-328X(89)90061-2; SHIPLEY MT, 1994, SOC NEUR ABSTR, V365, P4; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; SUZUMURA A, 1990, J NEUROIMMUNOL, V30, P111, DOI 10.1016/0165-5728(90)90094-4; SUZUMURA A, 1994, NEUROIMMUNOLOGY TOKY, V1, P122; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708	35	67	69	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2000	17	3					185	192		10.1089/neu.2000.17.185			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	297QY	WOS:000086095200002	10757324				2022-02-06	
J	Allen, JW; Ivanova, SA; Fan, L; Espey, MG; Basile, AS; Faden, AI				Allen, JW; Ivanova, SA; Fan, L; Espey, MG; Basile, AS; Faden, AI			Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							DEPENDENT PROTEIN-KINASE; RAT HIPPOCAMPAL SLICES; CYCLIC-AMP FORMATION; NMDA-RECEPTORS; SPINAL-CORD; PHARMACOLOGICAL CHARACTERIZATION; SYNERGISTIC INTERACTION; MGLUR AGONIST; DCG-IV; DEATH	We examined the effects of modulating group II metabotropic glutamate receptors (mGluRs) on traumatic neuronal injury using both in vitro and in vivo models. Treatment with various selective group II mGluR agonists significantly decreased lactate dehydrogenase release, a marker of cell death, after traumatic injury to rat neuronal-glial cultures; injury-induced increases in cyclic AMP and glutamate levels were also significantly reduced by a group Il agonist. The neuroprotective effects of group II agonists were markedly attenuated by co-administration of a group II antagonist or a membrane-permeable cyclic AMP analog and were additive to those provided by an N-methyl-D-aspartate receptor antagonist or a selective group I mGluR antagonist. Administration of a group II mGluR agonist 30 min after lateral fluid percussion-induced brain injury in rats significantly improved subsequent behavioral recovery as compared with vehicle-treated controls. Together these studies indicate that group II mGluR agonists protect against traumatic neuronal injury by attenuating glutamate release and cAMP levels and suggest a potential role for these agents in the treatment of clinical neurotrauma.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA		Faden, AI (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [Z01DK032200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 37313] Funding Source: Medline		ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Bruno V, 1997, J NEUROSCI, V17, P1891; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; Bushell TJ, 1996, BRIT J PHARMACOL, V117, P1457, DOI 10.1111/j.1476-5381.1996.tb15306.x; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; ESPEY MG, 1997, CURRENT PROTOCOLS NE; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Fitzjohn SM, 1996, NEUROSCI LETT, V203, P211, DOI 10.1016/0304-3940(96)12301-6; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HEI YJ, 1991, MOL PHARMACOL, V39, P233; ISHIDA M, 1993, BRIT J PHARMACOL, V109, P1169, DOI 10.1111/j.1476-5381.1993.tb13745.x; JANE DE, 1994, BRIT J PHARMACOL, V112, P809; Jane DE, 1996, NEUROPHARMACOLOGY, V35, P1029, DOI 10.1016/S0028-3908(96)00048-2; KEMP M, 1994, EUR J PHARM-MOLEC PH, V266, P187, DOI 10.1016/0922-4106(94)90109-0; KNOPFEL T, 1995, NEUROPHARMACOLOGY, V34, P1099, DOI 10.1016/0028-3908(95)00111-I; Monn JA, 1997, J MED CHEM, V40, P528, DOI 10.1021/jm9606756; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PEDARZANI P, 1995, P NATL ACAD SCI USA, V92, P11716, DOI 10.1073/pnas.92.25.11716; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; PIN JP, 1990, NEUROPHARMACOLOGY, V34, P1; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; ROMANI A, 1991, J BIOL CHEM, V266, P24376; Schoepp DD, 1996, J NEUROCHEM, V66, P1981; SCHOEPP DD, 1995, NEUROPHARMACOLOGY, V34, P843, DOI 10.1016/0028-3908(95)00061-A; Schoepp DD, 1996, NEUROPHARMACOLOGY, V35, P1661, DOI 10.1016/S0028-3908(96)00121-9; Sekiyama N, 1996, BRIT J PHARMACOL, V117, P1493, DOI 10.1111/j.1476-5381.1996.tb15312.x; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SUYAMA K, 1995, J CEREBR BLOOD F MET, V15, P877, DOI 10.1038/jcbfm.1995.109; VINK R, 1988, J BIOL CHEM, V263, P757; WHITTINGHAM TS, 1984, J NEUROSCI, V4, P798; WILSCH VW, 1994, EUR J PHARMACOL, V262, P287, DOI 10.1016/0014-2999(94)90743-9	41	67	68	0	4	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUL	1999	290	1					112	120					9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	209GM	WOS:000081039900015	10381766				2022-02-06	
J	Packard, RC				Packard, RC			Epidemiology and pathogenesis of posttraumatic headache	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						epidemiology; mild head injury; pathophysiology; posttraumatic headache	TRAUMATIC BRAIN INJURY; MINOR HEAD; MIGRAINE; MILD; PATHOPHYSIOLOGY; GLUTAMATE; MAGNESIUM; MYTH	This article presents an overview of the epidemiology and pathophysiology of posttraumatic headache. It reviews definitions of mild head injury (MHI), mild traumatic brain injury (MTBI), and concussion, and discusses the confusion that often occurs with these terms. Headache types and their pathophysiology are examined in detail. Just as the exact pathophysiology is unknown for migraine and other types of headache, the exact pathophysiology of headache after trauma is also still unknown in many cases. Possible connections between head or neck injuries and headache are reviewed, as well as hypothesized neurochemical changes that may occur in both migraine and traumatic brain injury (TBI). Psychological and legal factors are also considered.	Univ W Florida, Dept Psychol, Pensacola, FL 32503 USA		Packard, RC (corresponding author), Univ W Florida, Dept Psychol, Pensacola, FL 32503 USA.						ADLER CS, 1987, PSYCHIAT ASPECTS HEA; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Balla J, 1987, Clin Exp Neurol, V23, P179; BARCELLOS S, 1996, HEAD INJURY POSTCONC; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; BROWN DSO, 1991, SOC SCI MED, V33, P283, DOI 10.1016/0277-9536(91)90362-G; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CANTU RC, 1988, CLIN SPORT MED, V7, P459; CHOI D, 1989, TRENDS NEUROSCI, V11, P21; DANDREA G, 1991, CEPHALALGIA, V11, P197, DOI 10.1046/j.1468-2982.1991.1104197.x; DENNYBRO.D, 1973, BRAIN, V96, P783, DOI 10.1093/brain/96.4.783; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; Duckro PN, 1997, HEADACHE Q-CURR TREA, V8, P228; DUCKRO PN, 1992, HEADACHE Q-CURR TREA, V3, P295; EDVINSSON L, 1985, TRENDS NEUROSCI, V8, P126, DOI 10.1016/0166-2236(85)90050-5; Erichsen JE, 1882, CONCUSSION SPINE NER; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; EVANS RW, 1992, NEUROL CLIN, V10, P975, DOI 10.1016/S0733-8619(18)30191-9; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; EVANS RW, 1996, NEUROLOGY TRAUMA; FERRARI MD, 1990, NEUROLOGY, V40, P1582, DOI 10.1212/WNL.40.10.1582; FOREMAN SM, 1995, WHIPLASH INJURIES CE; FOREMAN SM, 1995, WHIPLASH INJURIES AC; Gean AD, 1994, IMAGING HEAD TRAUMA; GENARELLI T, 1993, HEAD INJURY; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HAM LP, 1994, CEPHALALGIA, V14, P118, DOI 10.1046/j.1468-2982.1994.1402118.x; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Holbourn AHS, 1943, LANCET, V2, P438; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KELLY R, 1981, J ROY SOC MED, V74, P275, DOI 10.1177/014107688107400407; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LARSSON LI, 1976, BRAIN RES, V113, P400, DOI 10.1016/0006-8993(76)90951-3; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; MAUSKOP A, 1993, HEADACHE, V33, P135, DOI 10.1111/j.1526-4610.1993.hed3303135.x; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MEDINA JL, 1992, HEADACHE, V32, P180, DOI 10.1111/j.1526-4610.1992.hed3204180.x; MOSKOWITZ MA, 1993, NEUROLOGY, V43, P16; OMAYA AK, 1979, BRAIN, V97, P644; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; PACKARD RC, 1993, HEADACHE, V33, P133, DOI 10.1111/j.1526-4610.1993.hed3303133.x; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PACKARD RC, 1979, HEADACHE, V19, P370, DOI 10.1111/j.1526-4610.1979.hed1907370.x; PACKARD RC, 1994, SEMIN NEUROL, V14, P40, DOI 10.1055/s-2008-1041057; PACKARD RC, 1994, SEMIN NEUROL, V14, P74, DOI 10.1055/s-2008-1041062; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; Packard RC, 1996, HEADACHE Q-CURR TREA, V7, P139; PAGE H, 1885, INJURIES SPINE SPINA; PERNOW B, 1983, PHARMACOL REV, V35, P85; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, NEUROTRAUMA; POVLISHOK JT, 1989, MILD HEAD INJURY; RAMADAN NM, 1989, HEADACHE, V29, P590, DOI 10.1111/j.1526-4610.1989.hed2909590.x; RASKIN NH, 1991, NEW ENGL J MED, V325, P353, DOI 10.1056/NEJM199108013250509; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIZZO M, 1996, HEAD INJURY POSTCONC; RUTHERFORD WH, 1989, MILD HEAD INJURY; Salzman SK, 1994, NEUROBIOLOGY CENTRAL; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STRAUSS I, 1904, ARCH NEUROL PSYCHIAT, V31, P893; STURZENEGGER M, 1994, NEUROLOGY, V44, P688, DOI 10.1212/WNL.44.4.688; TAYLOR AR, 1966, LANCET, V2, P178; TEASDALE G, 1974, LANCET, V2, P81; Trimble M.R., 1981, POSTTRAUMATIC NEUROS; VIJAYAN N, 1977, HEADACHE, V17, P19, DOI 10.1111/j.1526-4610.1977.hed1701019.x; VINK R, 1988, J BIOL CHEM, V263, P757; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; WOLFF HG, 1963, HEADACHE OTHER HEAD; YAGAMUCHI M, 1992, HEADACHE, V32, P427; YOUNG WB, 1997, HEADACHE; 1993, J HEAT TRAUMA REHABI, V6, P86	78	67	68	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1999	14	1					9	21		10.1097/00001199-199902000-00004			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	165LT	WOS:000078523100004	9949243				2022-02-06	
J	Anderson, V; Fenwick, T; Manly, T; Robertson, I				Anderson, V; Fenwick, T; Manly, T; Robertson, I			Attentional skills following traumatic brain injury in childhood: a componential analysis	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; SUSTAINED ATTENTION; CONDUCT DISORDER; CHILDREN; DEFICITS; SURVIVORS; BEHAVIOR; AGE	Recent research has documented residual deficits in attention following traumatic brain injury in childhood. The present study aimed to investigate whether such deficits are global, or affect specific components of attention differentially. Four attentional domains were examined using a newly developed test of attention, the Test of Everyday Attention for Children: sustained attention, focussed attention, divided attention, and response inhibition. Eighteen children with a history of traumatic brain injury, aged between 8 and 14 years, and 18 non-injured matched controls participated in the study. Results indicated that attentional skills may be differentially impaired after TBI, with children who have sustained moderate-to-severe TBI exhibiting significant deficits for sustained and divided attention, and response inhibition, but relatively intact focussed attention.	MRC, Cognit & Brain Sci Unit, Cambridge, England		Anderson, V (corresponding author), Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia.			Robertson, Ian H/0000-0001-8637-561X			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, NEUROPSYCHOLOGICAL R, P319; ANDERSON V, NEUROPSYCHOLOGICAL R, P283; AUGUST GJ, 1990, J ABNORM CHILD PSYCH, V18, P29, DOI 10.1007/BF00919454; BAKKER K, 1996, J INT NEUROPSYCHOLOG, V2, P205; Barkley R. A., 1990, ATTENTION DEFICIT HY; Barkley R. A., 1988, ASSESSMENT ISSUES CH, P145; Barkley Russell A., 1994, DISRUPTIVE BEHAV DIS, P11; Begali V., 1992, HEAD INJURY CHILDREN; BERK LE, 1991, J ABNORM CHILD PSYCH, V19, P357, DOI 10.1007/BF00911237; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BROUWERS P, 1984, J CLIN NEUROPSYCHOL, V6, P325, DOI 10.1080/01688638408401222; CATROPPA C, J INT NEUROPSYCHOLOG; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FENWICK T, UNPUB IMPAIRMENTS AT; Fuster J M, 1993, Curr Opin Neurobiol, V3, P160, DOI 10.1016/0959-4388(93)90204-C; GRIMWOOD K, 1995, PEDIATRICS, V95, P646; HEILMAN KM, 1979, NEUROPSYCHOLOGIA, V17, P315, DOI 10.1016/0028-3932(79)90077-0; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; MANLY T, IN PRESS TEST EVERYD; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Newman H, 1988, BRAIN IMPAIR, P223; ODOUGHERTY M, 1984, J ABNORM PSYCHOL, V93, P178, DOI 10.1037/0021-843X.93.2.178; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Posner MI., 1994, IMAGES MIND; Robertson I., 1994, TEST EVERYDAY ATTENT; ROWE KS, 1993, RBRI USERS MANUAL PA; Sattler J. M., 1988, ASSESSMENT CHILDREN; SCHAUGHENCY EA, 1989, LEARN INDIVID DIFFER, V1, P423, DOI DOI 10.1016/1041-6080(89)90022-8; SHAPIRO SK, 1986, J AM ACAD CHILD PSY, V25, P809, DOI 10.1016/S0002-7138(09)60200-4; SHAYWITZ BA, 1991, J CHILD NEUROL, V6, pS13, DOI 10.1177/0883073891006001S03; SHAYWITZ SE, 1987, PEDIATR NEUROL, V3, P129, DOI 10.1016/0887-8994(87)90077-4; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Strang J.D., 1983, CHILD NEUROPSYCHOLOG; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; SZATMARI P, 1989, J AM ACAD CHILD PSY, V28, P865, DOI 10.1097/00004583-198911000-00010; TAYLOR HG, 1997, J INT NEUROPSYCHOLOG, V3, P557; TEASDALE G, 1974, LANCET, V2, P81; TIMMERMAN S, 1991, COGNITIVE REHABILITA, P26; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VILLELLA S, UNPUB SUSTAINED SELE; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; YLIVASAKER M, 1985, HEAD INJURY REHABILI; [No title captured]; [No title captured], DOI DOI 10.1080/13854048708520056; [No title captured]	56	67	67	1	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1998	12	11					937	949		10.1080/026990598121990			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	143NR	WOS:000077262300003	9839027				2022-02-06	
J	Fisk, GD; Schneider, J; Novack, TA				Fisk, GD; Schneider, J; Novack, TA			Driving following traumatic brain injury: prevalence, exposure, advice and evaluations	BRAIN INJURY			English	Article							DAMAGE; PERFORMANCE; RECOVERY; DRIVER	Survivors of traumatic brain injury often have long-term sensory, cognitive and motor deficits that may impair vehicle operation. However, relatively little is known about the driving status and driving characteristics of brain injury survivors. To better understand driving following traumatic brain injury, a survey of driving status, driving exposure, advice received about driving and evaluations of driving competency was administered to a convenience sample of traumatic brain injury survivors (n = 83). The majority of survey participants had experienced either moderate or severe traumatic brain injuries based on the Glasgow Coma Scale. A total of 60% of the survey participants reported that they were currently active drivers. Most individuals (> 60%) who had returned to driving reported driving every day and more than 50 miles per week. Traumatic brain injury survivors frequently received advice about driving from family members, physicians or non-physician health care professionals, but over half (63%) had not been professionally evaluated for driving competency. The presence of high driving exposure, coupled with a lack of widespread driving fitness testing, suggests that some traumatic brain injury survivors have characteristics that may evaluate their risk for vehicle crashes. However, subsequent prospective studies that directly assess driver safety will be needed to confirm this possibility.	Gordon Coll, Dept Psychol, Div Business & Social Sci, Barnesville, GA 30204 USA; Birmingham So Coll, Dept Psychol, Birmingham, AL USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA		Fisk, GD (corresponding author), Gordon Coll, Dept Psychol, Div Business & Social Sci, 419 Coll Dr, Barnesville, GA 30204 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [D07420-06] Funding Source: Medline		BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; DANIEL W, 1995, BIOSTATISTICS FDN AN; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Devani Serio C., 1994, NEUROREHABILITATION, V4, P53; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DRESSER AC, 1973, ARCH NEUROL-CHICAGO, V29, P111, DOI 10.1001/archneur.1973.00490260055011; EVANS L, 1988, J GERONTOL, V43, pS186, DOI 10.1093/geronj/43.6.S186; Fisk GD, 1997, ARCH PHYS MED REHAB, V78, P1338, DOI 10.1016/S0003-9993(97)90307-5; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HANDLER BS, 1995, J REHABIL, V61, P43; HOPEWELL CA, 1990, NEUROPSYCHOLOGY EVER, P307; Johnson R, 1987, Int Disabil Stud, V9, P49; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; KIERNAN WE, 1988, VOCATIONAL REHABILIT, P221; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x; MAROTTOLI RA, 1993, J GERONTOL, V48, pS255, DOI 10.1093/geronj/48.5.S255; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; PIDIKITI RD, 1991, ARCH PHYS MED REHAB, V72, P109; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; ROTHKE S, 1989, INT J CLIN NEUROPSYC, V11, P134; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WILLIAMS AF, 1989, AM J PUBLIC HEALTH, V79, P326, DOI 10.2105/AJPH.79.3.326; [No title captured]	37	67	68	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1998	12	8					683	695					13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	108AN	WOS:000075243800005	9724839				2022-02-06	
J	Mesenge, C; Charriaut-Marlangue, C; Verrecchia, C; Allix, M; Boulu, RR; Plotkine, M				Mesenge, C; Charriaut-Marlangue, C; Verrecchia, C; Allix, M; Boulu, RR; Plotkine, M			Reduction of tyrosine nitration after N-omega-nitro-L-arginine-methylester treatment of mice with traumatic brain injury	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						traumatic brain injury; nitric oxide (NO); nitrotyrosine; peroxynitrite; mouse	EXPERIMENTAL HEAD-INJURY; OXYGEN RADICALS; OXIDE; PEROXYNITRITE; SUPEROXIDE	Oxygen free radicals and nitric oxide (NO) have been proposed to be involved in the cascade of injury elicited by traumatic brain injury. However, the mechanism(s) of injury remain to be explored. Since superoxide generation is triggered by traumatic brain injury, the cytotoxic peroxynitrite could be formed, but it is not known if this actually occurs. Dot blot and immunohistochemistry studies were performed to quantify tyrosine nitration and identify cell types in which such reactions occur in the brain of mice submitted to traumatic brain injury. Nitrotyrosine formation increased from 4 to 24 h after traumatic brain injury and was primarily observed in degenerating neurons, in areas corresponding to the sites of direct impact (frontal cortex) and diffuse impact (frontoparietal cortex and ventromedial hypothalamic nucleus). Furthermore, N-omega-nitro-L-arginine-methylester (L-NAME), a NO-synthase inhibitor which has previously been shown to promote neurological recovery in traumatic brain injury, reduced nitrotyrosine formation and the number of nitrotyrosine-positive neurons. These results indicate that traumatic brain injury induces peroxynitrite formation which may contribute to cell damage. (C) 1998 Elsevier Science B.V. All rights reserved.	Univ Paris 05, Pharmacol Lab, F-75270 Paris 06, France; INSERM, U29, F-75014 Paris, France		Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, 4 Ave Observ, F-75270 Paris 06, France.		MARCHAND-LEROUX, Catherine/L-7453-2017; , CHARRIAUT-MARLANGUE/H-3249-2019	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; 			Ayata C, 1997, J NEUROSCI, V17, P6908; BEAL M, 1997, ANN NEUROL, V42, P554; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, ADV NEUROL, V71, P339; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; COERELI L, 1998, IN PRESS J NEUROCHEM, V70; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Forman LJ, 1998, NEUROCHEM RES, V23, P141, DOI 10.1023/A:1022468522564; Fukuyama N, 1998, J CEREBR BLOOD F MET, V18, P123, DOI 10.1097/00004647-199802000-00001; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Ischiropoulos H, 1996, J CLIN INVEST, V97, P2260, DOI 10.1172/JCI118667; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MESENGE C, 1998, IN PRESS J PINEAL RE, V24; Smith MA, 1997, J NEUROSCI, V17, P2653; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VILET AVD, 1994, FEBS LETT, V339, P89; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Ye YZ, 1996, METHOD ENZYMOL, V269, P201	27	67	67	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	JUL 17	1998	353	1					53	57		10.1016/S0014-2999(98)00432-4			5	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	105UK	WOS:000075091800007	9721039				2022-02-06	
J	Semlyen, JK; Summers, SJ; Barnes, MP				Semlyen, JK; Summers, SJ; Barnes, MP			Traumatic brain injury: Efficacy of multidisciplinary rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; BLUNT HEAD-INJURY; RELATIVES	Objective: To establish efficacy of a coordinated multidisciplinary rehabilitation service for severe head injury, provided at Hunters Moor Regional Rehabilitation Centre. Design: A quasi-experimental design to compare treatment effects between two groups. The first group received a coordinated, multidisciplinary regional rehabilitation service; the other, a single discipline approach provided by local, district hospitals. Follow-up was for 2 years postinjury. Patients or Other Participants: Fifty-six consecutive severe head injury admissions, with an identified main caregiver, referred for rehabilitation within 4 weeks of their injury. Main Outcome Measures: The Barthel index, the Functional Independence Measure (FIM), and the Newcastle Independence Assessment Form (NIAF), a newly developed, real-life, comprehensive measure. In addition, caregivers completed the General Health Questionnaire. Results: The group that received coordinated multidisciplinary rehabilitation not only demonstrated significant gains throughout the study period but also maintained treatment effect after input ended. Furthermore, caregivers of this group had significantly reduced levels of distress. The comparison group, despite initial lower injury severity and shorter hospital stay, did not demonstrate equivalent gains or any posttreatment effect. Conclusions: The results show the efficacy of a comprehensive, specialist multidisciplinary regional service. There are significant implications for service provision for people with severe traumatic head injury. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Newcastle Upon Tyne, Acad Univ Neurol Rehabil, Hunters Moor Reg Rehabil Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England		Barnes, MP (corresponding author), Univ Newcastle Upon Tyne, Acad Univ Neurol Rehabil, Hunters Moor Reg Rehabil Ctr, Hunters Rd, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.			SEMLYEN, JOANNA/0000-0001-5372-1344			ANDERSON SI, 1992, BRAIN INJURY, V10, P115; ANDERSON SI, 1994, CLIN REHABIL, V8, P301; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BAUER D, 1989, FDN PHYSICAL REHABIL; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Bowers D., 1989, ARCH PHYS MED REHAB, V70, pA58; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BROOKS N, 1984, CLOSED HEAD INJURY P; Chau N, 1994, Disabil Rehabil, V16, P63; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Cook TD., 1979, QUASIEXPERIMENTATION; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P1; EAMES P, 1995, BRAIN INJURY, V10, P631; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; Goldberg D., 1978, MANUAL GEN HLTH QUES; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JENNETT B, 1975, LANCET, V1, P480; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; Johnstone B, 1996, BRAIN INJURY, V10, P627, DOI 10.1080/026990596124052; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, BMJ-BRIT MED J, V291, P919, DOI 10.1136/bmj.291.6500.919; MAHONEY F I, 1965, Md State Med J, V14, P61; Marks JA, 1995, CLIN REHABIL, V9, P320; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Olver JH, 1995, CURR OPIN NEUROL, V8, P443, DOI 10.1097/00019052-199512000-00008; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; SANDEL ME, 1995, J NEUROL REHABIL, V9, P111; Semlyen JK, 1997, J NEUROL REHABIL, V11, P213; Semlyen JK, 1996, J NEUROL REHABIL, V10, P251; SEMLYENJK, 1998, BRAIN INJ, V12, P155; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; TENNANT A, 1996, CLIN REHABIL, V0010, P00301, DOI DOI 10.1177/026921559601000407; [No title captured], DOI DOI 10.1097/00001199-198812000-00004; [No title captured]	53	67	69	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1998	79	6					678	683		10.1016/S0003-9993(98)90044-2			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	ZT554	WOS:000074099500014	9630149				2022-02-06	
J	Gervasio, AH; Kreutzer, JS				Gervasio, AH; Kreutzer, JS			Kinship and family members' psychological distress after traumatic brain injury: A large sample study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; RELATIVES; PATIENT	Objective: To describe the level and type of psychological distress experienced by live-in relatives of people with traumatic brain injury (TBI) and to compare the distress of spouses with that of other relatives. Design: A 2 x 3 x 4 cross-sectional design was used, with two levels of kinship (parent/spouse); three categories of duration of coma (no coma, coma <1 week, coma >1 week); and three categories of time since injury (10-24 months; 25-48 months; >48 months), Multivariate analysis of variance ascertained differences in psychological distress among spouses and relatives. Regression analysis identified the psychiatric symptoms that accounted for ratings of perceived stress. Setting and Participants: Family members (N = 116) of a sample of outpatients with TBI, drawn from a database at a large urban medical center. Main Outcome Measures: The Brief Symptom inventory (BSI) and a perceived stress measure. Results: Over 40% of the relatives had clinically elevated scores on the BSI. The Obsessive Compulsive, Psychoticism, Paranoid Ideation and Hostility subscales were the most elevated. The BSI's Global Severity Index (GSI) correlated moderately with perceived stress. Spouses reported significantly more distress than other relatives (who were mostly parents) on all but three subscales. Male caregivers of female relatives with TBI displayed mote distress on the GSI than other gender combinations. Time since injury and patients' days In coma did not affect relatives' levels of distress. Conclusions: Standardized measures of psychological distress confirm the clinical impression that family caregivers of people with TBI feel alienated, isolated, overwhelmed, and mentally preoccupied. Spouses experience more distress, which suggests that earlier marital intervention may be useful. Further research should address the needs of male caregivers and ''cross-gender'' caregiving.			Gervasio, AH (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, POB 9809661, RICHMOND, VA 23298 USA.						BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BUCHANAN K, 1992, COGN REH COMM INT SC; CAMPLAIR P, 1990, COMMUNITY INTEGRATIO; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; COHEN P, 1977, SOC CASEWORK-JCSW, V58, P223, DOI 10.1177/104438947705800404; Derogatis L.R., 1975, BRIEF SYMPTOM INVENT; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DiMatteo MR, 1982, ACHIEVING PATIENT CO; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST, V109; Gatz M., 1990, HDB PSYCHOL AGING; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; GRIFFITH ER, 1992, SEXUALITY PERSON TRA; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HOROWITZ A, 1985, ANN REV GERONTOLOGY, V5, P195; KAY T, 1991, HEAD INJURY FAMILY M; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LITMAN TJ, 1974, SOC SCI MED, V8, P495, DOI 10.1016/0037-7856(74)90072-9; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER L, 1993, AM J FAM THER, V21, P111, DOI 10.1080/01926189308250910; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [10.1097/00001199-199303000-00010, DOI 10.1097/00001199-199303000-00010]; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SANDER AM, 1995, RELATIONSHIP COPING; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLIAMS J, 1991, HEAD INJURY FAMILY M; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009	38	67	68	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1997	12	3					14	26		10.1097/00001199-199706000-00003			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	XC699	WOS:A1997XC69900003					2022-02-06	
J	Koizumi, H; Fujisawa, H; Ito, H; Maekawa, T; Di, X; Bullock, R				Koizumi, H; Fujisawa, H; Ito, H; Maekawa, T; Di, X; Bullock, R			Effects of mild hypothermia on cerebral blood flow-independent changes in cortical extracellular levels of amino acids following contusion trauma in the rat	BRAIN RESEARCH			English	Article						cerebral contusion; excitatory amino acid; microdialysis; cerebral blood flow; extravasation; autoradiography; rat	CONCUSSIVE BRAIN INJURY; FREE FATTY-ACIDS; HEAD-INJURY; MODERATE HYPOTHERMIA; ISCHEMIA; GLUTAMATE; BARRIER; RELEASE; MICRODIALYSIS; DAMAGE	The mechanism of hypothermic cerebroprotection after traumatic brain injury (TBI) is unknown. The present study was conducted to investigate the effects of mild hypothermia on the changes in cortical extracellular amino acids and cerebral blood flow (CBF) caused by cerebral contusion created in the rat parietal cortex by a weight-drop method. CBF in both normothermia (37 degrees C) and hypothermia (32 degrees C) groups, which was monitored using the hydrogen clearance technique, decreased significantly after contusion, but never fell below the threshold for ischemia. Cortical levels of glutamate, aspartate, glycine and taurine, which were measured by intracerebral microdialysis, were significantly increased after contusion in each group. However, these increases were greater in the herpothermic than in the normothermic rats. Normal plasma amino acid levels were high, and autoradiography following intravenous injection of C-14-labeled glutamate revealed marked extravasation of [C-14]glutamate at the site of cortical impact. These results suggest that the post-traumatic increase in extracellular amino acids occurs independently of CBF reduction, and that extravasation of amino acids from the vascular compartment partly contributes to this increase. Hypothermic cerebroprotection in TBI is thus likely to occur through a mechanism other than reduction in interstitial excitatory amino acids. In TBI, it is postulated that the postsynaptic effects of hypothermia may be more important than the presynaptic effects, when CBF is kept above the ischemic threshold.	YAMAGUCHI UNIV,SCH MED,DEPT NEUROSURG,UBE,YAMAGUCHI 755,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT CRIT CARE & EMERGENCY MED,UBE,YAMAGUCHI 755,JAPAN; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,MCV STN,RICHMOND,VA 23298								BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BETZ AL, 1978, SCIENCE, V202, P225, DOI 10.1126/science.211586; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUTCHER SP, 1990, STROKE, V21, P1727, DOI 10.1161/01.STR.21.12.1727; CHOI DW, 1987, J NEUROSCI, V7, P369; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRAHAM SH, 1990, NEUROSCI LETT, V110, P124, DOI 10.1016/0304-3940(90)90799-F; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HUTCHISON HT, 1985, EXP NEUROL, V87, P260, DOI 10.1016/0014-4886(85)90216-X; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATSURA K, 1992, BRAIN RES, V590, P6, DOI 10.1016/0006-8993(92)91075-P; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; KRANTIS A, 1983, ACTA NEUROPATHOL, V60, P61, DOI 10.1007/BF00685348; KRISTIAN T, 1992, ACTA PHYSIOL SCAND, V146, P531, DOI 10.1111/j.1748-1716.1992.tb09457.x; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCCULLOCH J, 1991, EXCITATORY AMINO ACI, P287; MINAMISAWA H, 1990, STROKE, V21, P758, DOI 10.1161/01.STR.21.5.758; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORWOOD WI, 1982, AM J PHYSIOL, V243, pC62, DOI 10.1152/ajpcell.1982.243.1.C62; OLDENDORF WH, 1976, AM J PHYSIOL, V230, P94, DOI 10.1152/ajplegacy.1976.230.1.94; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHIMADA N, 1989, J CEREBR BLOOD F MET, V9, P603, DOI 10.1038/jcbfm.1989.86; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V128, P9, DOI 10.1111/j.1748-1716.1986.tb07943.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	51	67	67	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 7	1997	747	2					304	312		10.1016/S0006-8993(96)01240-1			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WJ069	WOS:A1997WJ06900015	9046006				2022-02-06	
J	Armstead, WM				Armstead, WM			Role of endothelin in pial artery vasoconstriction and altered responses to vasopressin after brain injury	JOURNAL OF NEUROSURGERY			English	Article						fluid-percussion injury; neonate model; cerebral blood flow; vasopressin; pig	CEREBRAL BLOOD-FLOW; CANINE BASILAR ARTERY; PROTEIN-KINASE-C; NEWBORN PIGS; HEMODYNAMIC-RESPONSES; ETA RECEPTOR; SPINAL-CORD; HEAD-INJURY; RAT; VASOSPASM	Pial artery constriction following fluid-percussion injury to the brain is associated with elevated cerebrospinal fluid (CSF) vasopressin concentration in newborn pigs. It has also been observed the fluid-percussion injury reverse the function of vasopressin from that of a dilator to a constrictor. Endothelin-1 (ET-1), a purported mediator of cerebral vasospasm, can be released by several stimuli, including vasopressin. The present study was designed to investigate the role of ET-1 in pial artery constriction and in the reversal of vasopressin from a dilator to a constrictor, which is observed after fluid-percussion injury. Brain injury of moderate severity (1.9-2.3 atm) was produced in anesthetized newborn pigs that had been equipped with a closed cranial window. Endothelin-1 elicited pial dilation at low concentrations and vasoconstriction at higher concentrations. Fluid-percussion injury reversed the process of dilation to that of constriction at the low ET-1 concentration and potentiated this constriction at high ET-1 concentrations (10% +/- 1%, -8% +/- 1%, and -15% +/- 1% vs. -6% +/- 1%, -17% +/- 1%, and -26% +/- 2% for 10(-12), 10(-10), 10(-8) M ET-1 before and after fluid-percussion injury, respectively). Vasopressin modestly increased CSF ET-1 concentration before fluid-percussion injury. Fluid-percussion injury markedly increased CSF ET-1 concentration and the ability of vasopressin to release ET-1 (20 +/- 2, 26 +/- 3, and 40 +/- 4 pg/ml vs. 93 +/- 6, 141 +/- 9, and 247 +/- 31 pg/ml for control, 40 pg/ml vasopressin, and 400 pg/ml vasopressin before and after fluid-percussion injury, respectively). An ET-1 antagonist, BQ 123 (10(-6) M) blunted pial artery constriction following fluid-percussion injury (146 +/- 5 mu m-127 +/- 6 mu m vs. 144 +/- 5 mu m-136 +/- 4 mu m). The BQ 123 also blocked the reversal of vasopressin's function from that of a dilator to a constrictor after fluid-percussion injury (8% +/- 1%, 21% +/- 3%, and -5% +/- 1%, -14% +/- 2% vs. 8% +/- 1%, 21% +/- 2% and 4% +/- 1%, 2% +/- 1% for 40 and 4000 pg/ml vasopressin before and after fluid-percussion injury in the absence and presence of BQ 123, respectively). The BQ 123 blocked the constrictor component to ET-1, whereas it had no effect on the dilator component. These data show that ET-1 contributes to the reversal of vasopressin from a dilator to a constrictor following fluid-percussion injury. Furthermore, these data indicate the elevated CSF vasopressin and ET-1 interact in a positive feedback manner to promote pial artery constriction following fluid-percussion injury.	UNIV PENN, DEPT ANESTHESIA & PHARMACOL, PHILADELPHIA, PA 19104 USA		Armstead, WM (corresponding author), CHILDRENS HOSP, DEPT ANESTHESIA, 34TH ST & CIV CTR BLVD, PHILADELPHIA, PA 19104 USA.						Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; ARMSTEAD WM, 1995, BRAIN RES, V689, P183, DOI 10.1016/0006-8993(95)00533-V; Armstead WM, 1996, J NEUROTRAUM, V13, P115, DOI 10.1089/neu.1996.13.115; ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; ARMSTEAD WM, 1989, AM J PHYSIOL, V257, pH707, DOI 10.1152/ajpheart.1989.257.2.H707; ARMSTEAD WM, 1990, AM J PHYSIOL, V258, pH408, DOI 10.1152/ajpheart.1990.258.2.H408; ARMSTEAD WM, 1989, CIRC RES, V64, P136, DOI 10.1161/01.RES.64.1.136; ARMSTEAD WM, 1992, J PHARMACOL EXP THER, V260, P1107; ARMSTEAD WM, 1992, AM J PHYSIOL, V262, pH862, DOI 10.1152/ajpheart.1992.262.3.H862; ASANO T, 1989, BIOCHEM BIOPH RES CO, V159, P1345, DOI 10.1016/0006-291X(89)92258-4; BROOKS DP, 1994, J PHARMACOL EXP THER, V268, P1091; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; COLOMBANI PM, 1985, J PEDIATR SURG, V20, P8, DOI 10.1016/S0022-3468(85)80382-1; COSENTINO F, 1994, STROKE, V25, P904, DOI 10.1161/01.STR.25.4.904; DOUGLAS SA, 1992, EUR J PHARMACOL, V221, P315, DOI 10.1016/0014-2999(92)90718-J; EKELUND L, 1974, NEURORADIOLOGY, V7, P209, DOI 10.1007/BF00342700; FIESCHI C, 1972, EUR NEUROL, V8, P192, DOI 10.1159/000114577; GREENBERG DA, 1992, NEUROLOGY, V42, P25, DOI 10.1212/WNL.42.1.25; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; HANKO J, 1981, CEREBRAL MICROCIRCUL, P157; HEMSEN A, 1991, ACTA PHYSIOL SCAND, V142, P1; HINO A, 1995, J NEUROSURG, V83, P503, DOI 10.3171/jns.1995.83.3.0503; HOSLI E, 1991, NEUROSCI LETT, V129, P55, DOI 10.1016/0304-3940(91)90719-A; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ITAKURA T, 1988, J CEREBR BLOOD F MET, V8, P606, DOI 10.1038/jcbfm.1988.102; KATUSIC ZS, 1984, CIRC RES, V55, P575, DOI 10.1161/01.RES.55.5.575; LASSOFF S, 1980, BRAIN RES, V196, P266, DOI 10.1016/0006-8993(80)90736-2; LLUCH S, 1984, J PHARMACOL EXP THER, V228, P749; MCCULLOUGH D, 1971, J TRAUM, V11, P422, DOI 10.1097/00005373-197105000-00007; MCKENZIE AL, 1995, J NEUROTRAUM, V12, P257, DOI 10.1089/neu.1995.12.257; MURRAY MA, 1992, AM J PHYSIOL, V263, pH1643; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; SHARE L, 1988, PHYSIOL REV, V68, P1248, DOI 10.1152/physrev.1988.68.4.1248; SIMON JS, 1992, AM J PHYSIOL, V262, pH799, DOI 10.1152/ajpheart.1992.262.3.H799; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; TOMOBE Y, 1993, BIOCHEM BIOPH RES CO, V191, P654, DOI 10.1006/bbrc.1993.1267; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WILLETTE RN, 1990, AM J PHYSIOL, V259, pH1688; YAMAURA I, 1992, J NEUROSURG, V76, P99, DOI 10.3171/jns.1992.76.1.0099; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	42	67	68	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	1996	85	5					901	907		10.3171/jns.1996.85.5.0901			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	VP489	WOS:A1996VP48900022	8893730				2022-02-06	
J	Hollrigel, GS; Toth, K; Soltesz, I				Hollrigel, GS; Toth, K; Soltesz, I			Neuroprotection by propofol in acute mechanical injury: Role of GABAergic inhibition	JOURNAL OF NEUROPHYSIOLOGY			English	Article							RAT HIPPOCAMPAL-NEURONS; GYRUS GRANULE CELLS; GENERAL ANESTHETIC PROPOFOL; TRAUMATIC BRAIN INJURY; POSTSYNAPTIC CURRENTS; VOLATILE ANESTHETICS; GABA(A) RECEPTORS; GUNSHOT WOUNDS; PYRAMIDAL NEURONS; CALCIUM CURRENT	1. Whole cell patch-clamp and extracellular field recordings were obtained from granule cells of the dentate gyrus in 400-mu m-thick brain slices of the adult rat to determine the actions of the intravenous general anesthetic 2,6-diisopropylphenol (propofol) on acute neuronal survival and preservation of synaptic integrity after amputation of dendrites (dendrotomy), and to determine the role of gamma-aminobutyric acid-A (GABA(A))-receptor-mediated inhibition in the neuroprotective effects of propofol. The actions of propofol were compared with those exerted by another widely used intravenous general anesthetic, 5-ethyl-5-[1-methylbutyl]-2-thiobarbituric acid (thiopental). 2. Propofol (10 mu M) increased the frequency (control: 5.9 +/- 0.9 Hz, mean +/- SE; propofol: 10.5 +/- 1.3 Hz) and the single-exponential decay time constant (tau(D)) (control: 4.5 +/- 0.2 ms; propofol: 15.3 +/- 1.5 ms) of miniature inhibitory postsynaptic currents (mIPSCs) recorded in control neurons. Thiopental (25 mu M) also increased the tau(D) (14.3 +/- 0.9 ms) Of mISPCs, but had no effect on mIPSC frequency. Both anesthetics potentiated mIPSCs at low concentrations (propofol: 5 mu M; thiopental: 1 mu M) Propofol and thiopental did not change the peak amplitude and rise times of mIPSCs. 3. Propofol (10 mu M) was able to depress the excitability of control granule cells, as determined by the reduction in the amplitude of the orthodromic population spikes. This depression could be prevented by the GABA(A) receptor antagonist bicuculline (50 mu M), indicating that propofol reduces excitability via GABA(A) receptor functions. 4. Propofol and thiopental were neuroprotectant (assessed by antidromic population responses 2-5 h after injury) if present before and during the amputation of the granule cell dendrites. The protective actions were dose dependent, and at high doses (propofol: 200 mu M; thiopental: 400 mu M) the anesthetics were as neuroprotective against dendrotomy-induced cell death as 2-amino-5-phosphovaleric acid (APV) and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). The protective effects of the anesthetics were completely blocked with the GABA(A) receptor antagonists picrotoxin or bicuculline, and were mimicked by the GABA(A) receptor agonist muscimol (100 mu M). 5. Propofol, in contrast to APV and CNQX, could not prevent the dendrotomy-induced Ca2+ dependent and long-lasting changes in mIPSC decay kinetics (appearance of a double-exponential, prolonged decay). 6. The protective effects of the anesthetics and those of APV and CNQX on neuronal survival were not significant when the drugs were applied after dendrotomy, indicating that dendrotomy carried out 150-200 mu m from the soma without neuroprotective agents rapidly induces irreversible acute degeneration in most injured neurons. The failure to rescue cells from dendrotomy-induced injury did not result from a decreased sensitivity of the GABA(A) receptors to the anesthetics, because the potentiating effects of the anesthetics on mIPSCs from control and dendrotomized neurons were not different. 7. These data indicate that propofol potentiates synaptic inhibition pre- and postsynaptically, and, when present during dendrotomy, it can protect neurons from acute mechanical-injury-induced cell death via potentiation of GABAA receptor functions. However, propofol fails to provide neuroprotection against dendrotomy-induced changes in synaptic physiology.	UNIV CALIF IRVINE, DEPT ANAT & NEUROBIOL, IRVINE, CA 92717 USA; HUNGARIAN ACAD SCI, INST EXPT MED, DEPT FUNCT NEUROANAT, H-1450 BUDAPEST, HUNGARY								ADODRA S, 1995, BRIT J PHARMACOL, V115, P953, DOI 10.1111/j.1476-5381.1995.tb15903.x; AMORIM P, 1995, ANESTHESIOLOGY, V83, P1254, DOI 10.1097/00000542-199512000-00016; BARKER JL, 1987, J PHYSIOL-LONDON, V386, P485, DOI 10.1113/jphysiol.1987.sp016547; BENDO AA, 1987, BRAIN RES, V403, P136, DOI 10.1016/0006-8993(87)90132-6; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; Chong K. Y., 1994, Annals Academy of Medicine Singapore, V23, P145; COLLINS GGS, 1988, BRIT J PHARMACOL, V95, P939, DOI 10.1111/j.1476-5381.1988.tb11724.x; CONCAS A, 1992, ADV BIOCHEM PSYCHOPH, V47, P349; DRUMMOND JC, 1993, ANESTHESIOLOGY, V79, P877; EMERY DG, 1987, EXP BRAIN RES, V67, P41, DOI 10.1007/BF00269451; ERB DE, 1991, EXP BRAIN RES, V83, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FFRENCHMULLEN JMH, 1993, J NEUROSCI, V13, P3211; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GLEN JB, 1980, BRIT J ANAESTH, V52, P731, DOI 10.1093/bja/52.8.731; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HANS P, 1994, J NEUROSURG ANESTH, V6, P249; HARA M, 1994, ANESTHESIOLOGY, V81, P988, DOI 10.1097/00000542-199410000-00026; HARA M, 1993, ANESTHESIOLOGY, V79, P781, DOI 10.1097/00000542-199310000-00021; HARRIS BD, 1995, MOL PHARMACOL, V47, P363; HARRY GJ, 1992, MOL NEUROBIOL, V6, P203; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; JENSEN AG, 1994, ANESTHESIOLOGY, V81, P1220, DOI 10.1097/00000542-199411000-00016; JONES MV, 1993, J NEUROPHYSIOL, V70, P1339, DOI 10.1152/jn.1993.70.4.1339; KASS IS, 1992, NEUROSCIENCE, V49, P537, DOI 10.1016/0306-4522(92)90224-P; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KENDIG JJ, 1991, ANN NY ACAD SCI, V625, P37, DOI 10.1111/j.1749-6632.1991.tb33828.x; LEROUX PD, 1995, ANESTHETIC MANAGEMEN, P1; LIPTON SA, 1993, CURR OPIN NEUROL NEU, V6, P588; LUCAS J H, 1990, Journal of Neurotrauma, V7, P169, DOI 10.1089/neu.1990.7.169; MACDONALD RL, 1989, J PHYSIOL-LONDON, V417, P483, DOI 10.1113/jphysiol.1989.sp017814; MACIVER MB, 1991, ANN NY ACAD SCI, V625, P91, DOI 10.1111/j.1749-6632.1991.tb33832.x; MIENVILLE JM, 1989, BRAIN RES, V489, P190, DOI 10.1016/0006-8993(89)90024-3; MODY I, 1991, BRAIN RES, V538, P319, DOI 10.1016/0006-8993(91)90447-4; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; OLCESE R, 1994, ANESTH ANALG, V78, P955; ORSER BA, 1994, J NEUROSCI, V14, P7747; ORSER BA, 1995, BRIT J PHARMACOL, V116, P1761, DOI 10.1111/j.1476-5381.1995.tb16660.x; OTIS TS, 1991, BRAIN RES, V545, P142, DOI 10.1016/0006-8993(91)91280-E; OTIS TS, 1992, NEUROSCIENCE, V49, P13, DOI 10.1016/0306-4522(92)90073-B; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; PRINCE RJ, 1992, BRAIN RES, V596, P238, DOI 10.1016/0006-8993(92)91553-Q; RAVUSSIN P, 1994, J NEUROSURG ANESTH, V6, P285; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; ROBERTSON B, 1989, BRIT J PHARMACOL, V98, P167, DOI 10.1111/j.1476-5381.1989.tb16878.x; RUTLEDGE LT, 1978, J COMP NEUROL, V178, P117, DOI 10.1002/cne.901780107; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1992, CHALLENGES NEUROLOGY, P55; Salin P, 1995, J NEUROSCI, V15, P8234; SALZMAN SK, 1993, RES COMMUN CHEM PATH, V80, P59; SANNA E, 1995, MOL PHARMACOL, V47, P213; SANO T, 1993, ANESTH ANALG, V76, P990; SCHALEN W, 1992, ACTA NEUROCHIR, V117, P153, DOI 10.1007/BF01400613; SCHWARTZ RD, 1995, J NEUROSCI, V15, P529; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; SOLTESZ I, 1995, J NEUROPHYSIOL, V73, P1763, DOI 10.1152/jn.1995.73.5.1763; SOLTESZ I, 1994, J NEUROSCI, V14, P2365; STALEY KJ, 1991, SYNAPSE, V9, P219, DOI 10.1002/syn.890090308; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197, DOI 10.1152/jn.1992.68.1.197; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346, DOI 10.1152/jn.1992.67.5.1346; STEWART L, 1994, ACTA NEUROCHIR, P544; SZTARK F, 1995, ANESTHESIOLOGY, V83, P1386, DOI 10.1097/00000542-199512000-00051; TANELIAN DL, 1993, ANESTHESIOLOGY, V78, P757, DOI 10.1097/00000542-199304000-00020; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; TEMPELHOFF R, 1995, ANN FR ANESTH, V14, P129, DOI 10.1016/S0750-7658(05)80161-3; VICINI S, 1987, J PHARMACOL EXP THER, V243, P1195; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; YANG J, 1992, FASEB J, V6, P914, DOI 10.1096/fasebj.6.3.1740240; YEH JZ, 1991, ANN NY ACAD SCI, V625, P155, DOI 10.1111/j.1749-6632.1991.tb33839.x; ZIMMERMAN SA, 1994, J PHARMACOL EXP THER, V270, P987	73	67	69	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	OCT	1996	76	4					2412	2422		10.1152/jn.1996.76.4.2412			11	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	VN613	WOS:A1996VN61300025	8899614				2022-02-06	
J	Lewis, SB; Finnie, JW; Blumbergs, PC; Scott, G; Manavis, J; Brown, C; Reilly, PL; Jones, NR; McLean, AJ				Lewis, SB; Finnie, JW; Blumbergs, PC; Scott, G; Manavis, J; Brown, C; Reilly, PL; Jones, NR; McLean, AJ			A head impact model of early axonal injury in the sheep	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; axonal injury; head injury model; pathophysiological correlation; sheep	AMYLOID PRECURSOR PROTEIN; BRAIN INJURY; TRAUMA	Axonal injury (AI), one of the principal determinants of clinical outcome after head injury, may evolve over several hours after injury, raising the future possibility of therapeutic intervention during this period. A new head impact model of AI in sheep was developed to examine pathological and physiological changes in the brain resulting from a graded traumatic insult. In this preliminary study 10 anesthetized and ventilated Merino ewes were used. Head injury was produced by impact from a humane stunner to the temporal region of an unrestrained head. Eight sheep were studied for 1, 2, 4, or 6 h after impact. Two sham animals (no impact, 6 h survival) were also examined. Arterial blood pressure, intracranial pressure, and cerebral blood flow were monitored continuously. A physiological index of injury severity was calculated by weighting the percentage shift from preinjury values for each monitored parameter over the first hour after injury. Immunostaining with amyloid precursor protein (APP) was used as a marker of axonal damage and the distribution of APP positive axons was recorded according to a sector scoring method (APPS). Widespread AI was identified in 7 of the 8 impacted animals, around cerebral contusions and in hemispheric white matter, central gray matter, brain stem, and cerebellum, and was detected as early as 1 h after injury. The degree of axonal injury (APPS) correlated well with an index of physiological response to injury (r = 0.83, p = 0.005).	ROYAL ADELAIDE HOSP,DEPT NEUROSURG,ADELAIDE,SA 5000,AUSTRALIA; UNIV ADELAIDE,INST MED & VET SCI,NEUROPATHOL LAB,ADELAIDE,SA 5005,AUSTRALIA; UNIV ADELAIDE,DEPT NEUROSURG,ADELAIDE,SA 5005,AUSTRALIA; UNIV ADELAIDE,NHMRC ROAD ACCID RES UNIT,ADELAIDE,SA 5005,AUSTRALIA					Reilly, Peter/0000-0003-3173-0666			ANDREWS EJ, 1993, J AM VET MED ASSOC, V202, P230; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Faden AI., 1994, NEUROBIOLOGY CENTRAL, P3; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTLEMAN SM, 1993, PATHOLOGY DOMESTIC A, V1, P323; JUBB KVF, 1933, PATHOLOGY DOMESTIC A, V1, P323; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRKPATRICK JB, 1988, FORENSIC NEUROPATHOL, P276; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; May NDS, 1964, ANATOMY SHEEP; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1966, HEAD INJURY, P260; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROBERTS GW, 1993, NEUROSCI LETT, V160, P139; RYAN GA, 1994, J TRAUMA, V36, P469; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHIGEMATSU K, 1992, BRAIN RES, V592, P353, DOI 10.1016/0006-8993(92)91697-D; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; UPTON R, 1994, J CEREBR BLOOD F MET, V14, P680, DOI 10.1038/jcbfm.1994.85; Yoshikawa T., 1967, ATLAS BRAINS DOMESTI	26	67	69	1	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					505	514		10.1089/neu.1996.13.505			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600003	8913967				2022-02-06	
J	Rao, SM				Rao, SM			White matter disease and dementia	BRAIN AND COGNITION			English	Article; Proceedings Paper	Annual Conference on the Dementias - Diagnosis and Implications for Management	MAR, 1994	TORONTO, CANADA	Baycrest Ctr Geriatr Care, Rotman Res Inst, Univ Calif Los Angeles, Alzheimers Res Ctr			PROGRESSIVE MULTIPLE-SCLEROSIS; SORTING TEST-PERFORMANCE; CLINICALLY ISOLATED LESIONS; EVENT-RELATED POTENTIALS; FRONTAL-LOBE LESIONS; MAGNETIC-RESONANCE; COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL PERFORMANCE; ALZHEIMERS-DISEASE; MEMORY IMPAIRMENT	Dementia is a common occurrence in patients with disorders affecting cerebral hemispheric white matter. Relatively little is known, however, about the specific pattern of neurobehavioral changes associated with abnormal white matter function. This review examines in detail the neurobehavioral features of a common white matter disease, multiple sclerosis (MS). The neuropsychological characteristics of MS-related dementia are compared and contrasted with those observed in three other white matter disorders (acquired immune deficiency syndrome, Binswanger's disease, and closed head injury) to determine if ''white matter dementia'' should be recognized as a unique diagnostic entity distinct from other dementing conditions. Finally, possible mechanisms by which white matter disease affects behavior are proposed. (C) 1996 Academic Press, Inc.			Rao, SM (corresponding author), MED COLL WISCONSIN, SECT NEUROPSYCHOL, DEPT NEUROL, 9200 W WISCONSIN AVE, MILWAUKEE, WI 53226 USA.		Rao, Stephen M/A-2460-2010	Rao, Stephen M/0000-0002-6463-7460	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K04 NS01055, R01 NS22128] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS022128, K04NS001055] Funding Source: NIH RePORTER		ALBERT ML, 1978, ALZHEIMERS DISEASE S, P173; [Anonymous], 1993, NEUROPSYCHOLOGY, V7, P364, DOI [DOI 10.1037/0894-4105.7.3.364, 10.1037/0894-4105.7.3.364]; ANZOLA GP, 1990, J NEUROL NEUROSUR PS, V53, P142, DOI 10.1136/jnnp.53.2.142; ARNETT PA, 1994, NEUROLOGY, V44, P420, DOI 10.1212/WNL.44.3_Part_1.420; ARNETT PA, UNPUB TEMPORAL ORDER; Baddeley A.D., 1986, WORKING MEMORY; BARNARD RO, 1974, J NEUROL NEUROSUR PS, V37, P1259, DOI 10.1136/jnnp.37.11.1259; BEATTY PA, 1977, J NERV MENT DIS, V164, P42, DOI 10.1097/00005053-197701000-00008; Beatty W W, 1989, J Geriatr Psychiatry Neurol, V2, P145, DOI 10.1177/089198878900200305; Beatty W W, 1989, J Geriatr Psychiatry Neurol, V2, P153, DOI 10.1177/089198878900200306; BEATTY WW, 1989, ARCH NEUROL-CHICAGO, V46, P1113, DOI 10.1001/archneur.1989.00520460103020; BEATTY WW, 1989, BRAIN COGNITION, V11, P73, DOI 10.1016/0278-2626(89)90006-7; BEATTY WW, 1988, ARCH NEUROL-CHICAGO, V45, P611, DOI 10.1001/archneur.1988.00520300029013; BEATTY WW, 1994, J CLIN EXP NEUROPSYC, V16, P165, DOI 10.1080/01688639408402627; BEATTY WW, 1990, INT J CLIN NEUROPSYC, V12, P166; BEATTY WW, 1990, B PSYCHONOMIC SOC, V28, P397; BERGIN JD, 1957, J NEUROL NEUROSUR PS, V20, P285, DOI 10.1136/jnnp.20.4.285; BERNARD BA, 1990, J CLIN EXP NEUROPSYC, V12, P22; Bernard Bryan A, 1992, Clin Neuropsychol, V6, P230, DOI 10.1080/13854049208401857; BERNARDIN LJ, 1993, J CLIN EXP NEUROPSYC, V15, P17; BERRIOS GE, 1990, BRIT J PSYCHIAT, V156, P10, DOI 10.1192/bjp.156.1.10; Bertrando P, 1983, Acta Psychiatr Belg, V83, P13; BORNSTEIN RA, 1991, ARCH NEUROL-CHICAGO, V48, P704, DOI 10.1001/archneur.1991.00530190050015; BRADLEY WG, 1984, NONINVASIVE MED IMAG, V1, P35; BRAININ M, 1988, J NEUROL, V235, P362, DOI 10.1007/BF00314234; BROOKS DJ, 1984, J NEUROL NEUROSUR PS, V47, P1182, DOI 10.1136/jnnp.47.11.1182; BROWN S, 1992, ARCH NEUROLOGY PSYCH, V7, P629; BROWNELL B, 1962, J NEUROL NEUROSUR PS, V25, P315, DOI 10.1136/jnnp.25.4.315; Bruyn GW, 1970, HDB CLIN NEUROLOGY, V9, P217; CAINE ED, 1986, ARCH NEUROL-CHICAGO, V43, P249, DOI 10.1001/archneur.1986.00520030039009; CALLANAN MM, 1989, BRAIN, V112, P361, DOI 10.1093/brain/112.2.361; Canter AH, 1951, J GEN PSYCHOL, V44, P3, DOI 10.1080/00221309.1951.9711235; CARROLL M, 1984, NEUROPSYCHOLOGIA, V22, P297, DOI 10.1016/0028-3932(84)90076-9; CLARK CM, 1992, CAN J NEUROL SCI, V19, P352, DOI 10.1017/S0317167100041986; COMI G, 1993, J NEUROL SCI, V115, pS66, DOI 10.1016/0022-510X(93)90212-H; CUMMINGS JL, 1984, ARCH NEUROL-CHICAGO, V41, P874, DOI 10.1001/archneur.1984.04050190080019; DELUCA J, 1993, ARCH NEUROL-CHICAGO, V50, P301, DOI 10.1001/archneur.1993.00540030065016; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; DESMEDT L, 1984, IMMUNOLOGICAL CLIN A, P342; DEVINS GM, 1987, PSYCHOL BULL, V101, P363, DOI 10.1037/0033-2909.101.3.363; DUNBAR N, 1992, AIDS, V6, P691, DOI 10.1097/00002030-199207000-00012; FAZEKAS F, 1989, EUR NEUROL, V29, P164, DOI 10.1159/000116401; FEINSTEIN A, 1992, J NEUROL NEUROSUR PS, V55, P869, DOI 10.1136/jnnp.55.10.869; Filley CM, 1988, NEUROPSY NEUROPSY BE, V1, P239; FILLEY CM, 1996, NEUROPSYCHIATRY, P913; FINK STEPHEN L., 1966, ARCH PHYS MED REHABIL, V47, P56; FISCHER G, 1994, J ADHES SCI TECHNOL, V8, P151, DOI 10.1163/156856194X00122; Fischer J.S., 1988, CLIN NEUROPSYCHOL, V2, P149, DOI [10.1080/13854048808520097, DOI 10.1080/13854048808520097]; FRANKLIN GM, 1988, NEUROLOGY, V38, P1826, DOI 10.1212/WNL.38.12.1826; FRANZBLAU A, 1991, ARCH NEUROL-CHICAGO, V48, P263, DOI 10.1001/archneur.1991.00530150031013; FRIEDMAN JH, 1983, ANN NEUROL, V13, P222, DOI 10.1002/ana.410130234; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GEORGE AE, 1986, AM J NEURORADIOL, V7, P567; GERARD G, 1986, NEUROLOGY, V36, P998, DOI 10.1212/WNL.36.7.998; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GIESSER BS, 1992, ELECTROEN CLIN NEURO, V82, P320, DOI 10.1016/0013-4694(92)90002-Y; GOLDSTEIN FC, 1992, ARCH NEUROL-CHICAGO, V49, P1060, DOI 10.1001/archneur.1992.00530340080021; GRAFMAN J, 1991, ARCH NEUROL-CHICAGO, V48, P1072, DOI 10.1001/archneur.1991.00530220094025; Grafman J, 1990, NEUROBEHAVIORAL ASPE, P102; GRANT I, 1990, J CONSULT CLIN PSYCH, V58, P22, DOI 10.1037/0022-006X.58.1.22; GRAY F, 1988, BRAIN, V111, P245, DOI 10.1093/brain/111.2.245; GRIGSBY J, 1994, PERCEPT MOTOR SKILL, V78, P883, DOI 10.2466/pms.1994.78.3.883; HACHINSKI VC, 1987, ARCH NEUROL-CHICAGO, V44, P21, DOI 10.1001/archneur.1987.00520130013009; HEATON RK, 1985, J CONSULT CLIN PSYCH, V53, P103, DOI 10.1037/0022-006X.53.1.103; HEINDEL WC, 1988, BEHAV NEUROSCI, V102, P141, DOI 10.1037/0735-7044.102.1.141; HEINDEL WC, 1989, J NEUROSCI, V9, P582; HOTOPF MH, 1994, PSYCHOL MED, V24, P525, DOI 10.1017/S0033291700027483; HUBER SJ, 1987, ARCH NEUROL-CHICAGO, V44, P732, DOI 10.1001/archneur.1987.00520190040015; HUBER SJ, 1992, J NEUROPSYCH CLIN N, V4, P152; INZITARI D, 1987, ARCH NEUROL-CHICAGO, V44, P42, DOI 10.1001/archneur.1987.00520130034014; IVNIK RJ, 1978, J CLIN PSYCHIAT, V39, P304; IVNIK RJ, 1978, J CONSULT CLIN PSYCH, V46, P913, DOI 10.1037/0022-006X.46.5.913; JACOBSON JT, 1983, EAR HEARING, V4, P311, DOI 10.1097/00003446-198311000-00009; JAMBOR KL, 1969, BRIT J PSYCHIAT, V115, P765, DOI 10.1192/bjp.115.524.765; JENNEKENSSCHINKEL A, 1990, J NEUROL SCI, V99, P229, DOI 10.1016/0022-510X(90)90158-J; JERNIGAN TL, 1990, ARCH NEUROL-CHICAGO, V47, P27, DOI 10.1001/archneur.1990.00530010035015; JOFFE RT, 1987, ARCH NEUROL-CHICAGO, V44, P376, DOI 10.1001/archneur.1987.00520160018007; JONES RD, 1991, J CLIN EXP NEUROPSYC, V13, P74; KAEMINGK KL, 1989, CLIN NEUROPSYCHOL, V3, P309; KINKEL WR, 1985, ARCH NEUROL-CHICAGO, V42, P951, DOI 10.1001/archneur.1985.04060090033010; Krikorian R, 1990, J Neuropsychiatry Clin Neurosci, V2, P256; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; Levin HS., 1982, NEUROBEHAVIORAL CONS; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P281, DOI 10.1001/archneur.1988.00520270059021; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P607, DOI 10.1001/archneur.1988.00520300025012; LYONCAEN O, 1986, ARCH NEUROL-CHICAGO, V43, P1138, DOI 10.1001/archneur.1986.00520110034010; MARSH GG, 1980, J NERV MENT DIS, V168, P758, DOI 10.1097/00005053-198012000-00009; MATEER EJ, 1993, NEUROPSYCHOLOGY ALZH, P416; MAURELLI M, 1992, ACTA NEUROL SCAND, V86, P124, DOI 10.1111/j.1600-0404.1992.tb05052.x; MCALLISTER RH, 1992, J NEUROL NEUROSUR PS, V55, P143, DOI 10.1136/jnnp.55.2.143; MCINTOSHMICHAELIS SA, 1991, BRIT J CLIN PSYCHOL, V30, P333, DOI 10.1111/j.2044-8260.1991.tb00954.x; MCKEGNEY FP, 1990, AIDS, V4, P565, DOI 10.1097/00002030-199006000-00011; MEDAER R, 1987, J NEUROL, V235, P86, DOI 10.1007/BF00718015; MILLER AKH, 1980, NEUROPATH APPL NEURO, V6, P119, DOI 10.1111/j.1365-2990.1980.tb00283.x; MINDEN SL, 1990, J CLIN EXP NEUROPSYC, V12, P566, DOI 10.1080/01688639008401002; MINDEN SL, 1990, ARCH NEUROL-CHICAGO, V47, P98, DOI 10.1001/archneur.1990.00530010124031; MINDEN SL, 1987, GEN HOSP PSYCHIAT, V9, P426, DOI 10.1016/0163-8343(87)90052-1; MOLLER A, 1994, ACTA PSYCHIAT SCAND, V89, P117, DOI 10.1111/j.1600-0447.1994.tb01497.x; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; NEWTON MR, 1989, BRAIN, V112, P1637, DOI 10.1093/brain/112.6.1637; OLMOSLAU N, 1977, NEUROLOGY, V27, P623, DOI 10.1212/WNL.27.7.623; PARSONS OA, 1957, J NERV MENT DIS, V125, P221, DOI 10.1097/00005053-195704000-00006; PERDICES M, 1990, J ACQ IMMUN DEF SYND, V3, P555; PEYSER JM, 1980, ARCH NEUROL-CHICAGO, V37, P577, DOI 10.1001/archneur.1980.00500580073013; POUTIAINEN E, 1993, ACTA NEUROL SCAND, V87, P88; POZZILLI C, 1991, J NEUROL NEUROSUR PS, V54, P110, DOI 10.1136/jnnp.54.2.110; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PUGNETTI L, 1993, J NEUROL SCI, V115, pS59, DOI 10.1016/0022-510X(93)90211-G; RABINS PV, 1986, BRAIN, V109, P585, DOI 10.1093/brain/109.4.585; RAO SM, 1990, J CLIN EXP NEUROPSYC, V12, P74; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P699, DOI 10.1080/01688638908400926; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1986, J CLIN EXP NEUROPSYC, V8, P503, DOI 10.1080/01688638608405173; RAO SM, 1984, ARCH NEUROL-CHICAGO, V41, P625, DOI 10.1001/archneur.1984.04210080033010; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; RAO SM, 1989, ARCH NEUROL-CHICAGO, V46, P40, DOI 10.1001/archneur.1989.00520370042017; RAO SM, 1989, NEUROLOGY, V39, P161, DOI 10.1212/WNL.39.2.161; RAO SM, 1992, J CONSULT CLIN PSYCH, V60, P369, DOI 10.1037/0022-006X.60.3.369; RAO SM, 1987, J CONSULT CLIN PSYCH, V55, P263, DOI 10.1037/0022-006X.55.2.263; RAO SM, 1984, BRAIN COGNITION, V3, P94, DOI 10.1016/0278-2626(84)90010-1; RAO SM, 1989, ARCH NEUROL-CHICAGO, V46, P918, DOI 10.1001/archneur.1989.00520440114028; RAO SM, 1990, SUBCORTICAL DEMENTIA, P164; RAO VA, 1987, INT J SYST BACTERIOL, V37, P181; REISCHIES FM, 1988, ARCH NEUROL-CHICAGO, V45, P1114, DOI 10.1001/archneur.1988.00520340068014; REITAN RM, 1971, J NERV MENT DIS, V153, P218, DOI 10.1097/00005053-197109000-00006; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; RON MA, 1986, J PSYCHOSOM RES, V30, P3, DOI 10.1016/0022-3999(86)90060-7; RUBENS AB, 1985, ANN NEUROL, V18, P459, DOI 10.1002/ana.410180408; SALMON DP, 1988, J CLIN EXP NEUROPSYC, V10, P477, DOI 10.1080/01688638808408254; SCHIFFER RB, 1984, ARCH NEUROL-CHICAGO, V41, P1067, DOI 10.1001/archneur.1984.04050210065016; SCHIFFER RB, 1987, ARCH NEUROL-CHICAGO, V44, P596, DOI 10.1001/archneur.1987.00520180020009; STAPLES D, 1979, RHEUMATOL REHABIL, V18, P153, DOI 10.1093/rheumatology/18.3.153; STERN Y, 1991, ARCH GEN PSYCHIAT, V48, P131; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; SWIRSKYSACCHETTI T, 1992, NEUROLOGY, V42, P1291, DOI 10.1212/WNL.42.7.1291; VANDENBURG W, 1987, ARCH NEUROL-CHICAGO, V44, P494, DOI 10.1001/archneur.1987.00520170024017; VANDIJK JG, 1992, J NEUROL SCI, V109, P18, DOI 10.1016/0022-510X(92)90088-3; VANGORP WG, 1993, NEUROPSYCHOLOGY ALZH, P153; VOWELS LM, 1979, BRAIN IMPAIR, P10; WHITLOCK FA, 1980, J NEUROL NEUROSUR PS, V43, P861, DOI 10.1136/jnnp.43.10.861; WICKENS DD, 1970, PSYCHOL REV, V77, P1, DOI 10.1037/h0028569; YOUNG AC, 1976, J NEUROL NEUROSUR PS, V39, P1008, DOI 10.1136/jnnp.39.10.1008; [No title captured]	144	67	69	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626	1090-2147		BRAIN COGNITION	Brain Cogn.	JUL	1996	31	2					250	268		10.1006/brcg.1996.0044			19	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Neurosciences & Neurology; Psychology	UX223	WOS:A1996UX22300010	8812003				2022-02-06	
J	Long, DA; Ghosh, K; Moore, AN; Dixon, CE; Dash, PK				Long, DA; Ghosh, K; Moore, AN; Dixon, CE; Dash, PK			Deferoxamine improves spatial memory performance following experimental brain injury in rats	BRAIN RESEARCH			English	Article						spatial memory; free radical; deferoxamine; brain injury	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE; SUPEROXIDE; MODEL; EDEMA; PEROXYNITRITE; IMPAIRMENT; MICE	Traumatic brain injury (TBI) causes impairments of both motor and spatial memory performances. Research is only beginning to reveal the biochemical mechanism(s) underlying these deficits. It has been postulated that reactive oxygen species such as the superoxide and hydroxyl radicals, as well as the peroxynitrite anion,are generated by injury and may play a critical role in the observed memory deficits. The highly reactive hydroxyl radical, which is thought to contribute to neuronal toxicity, can be generated by an iron-catalyzed reaction. The source of this iron (or iron-bound proteins) could be a compromise of the blood-brain barrier, which can occur following TBI. In this report, we investigate the ability of deferoxamine, a scavenger of free iron, the hydroxyl radical and the peroxynitrite anion, to facilitate behavioral recovery following a controlled cortical impact of rats. Intraperitoneal administration of this drug prior to the injury did not affect the rate of recovery from motor deficits in comparison to vehicle (saline)-injected animals. However, deferoxamine-treated animals showed significant improvement in spatial memory performance in a Morris water maze task. Volumetric analysis of cortical tissue loss showed no significant differences between vehicle- and drug-injected animals. Similarly, histological examination of the hippocampus did not reveal any gross differences between the two groups. These results indicate that deferoxamine improves spatial memory performance, possibly through protection from neuronal dysfunction.	UNIV TEXAS,HLTH SCI CTR,DEPT ANAT & NEUROBIOL,HOUSTON,TX 77225; UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77225						NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49962] Funding Source: Medline		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ARONOWSKI J, 1994, STROKE, V25, P2235, DOI 10.1161/01.STR.25.11.2235; ARONOWSKI J, IN PRESS J CEREB BLO; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRYAN RM, 1993, 1993 NEUR SOC M; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, IN PRESS PHARM BIOCH; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Halliwell, 1989, FREE RADICAL BIO MED, P1; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOE S, 1982, CHEM-BIOL INTERACT, V41, P75, DOI 10.1016/0009-2797(82)90018-7; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; IYENGAR J, 1990, J VASC SURG, V12, P545, DOI 10.1067/mva.1990.24155; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; NEWLON PG, 1991, BRAIN RES, V544, P320, DOI 10.1016/0006-8993(91)90072-4; OURY TD, 1993, J BIOL CHEM, V268, P15394; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; PATT A, 1990, J PEDIATR SURG, V25, P224, DOI 10.1016/0022-3468(90)90407-Z; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393	37	67	68	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 22	1996	717	1-2					109	117		10.1016/0006-8993(95)01500-0			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UM505	WOS:A1996UM50500014	8738260				2022-02-06	
J	Mesenge, C; Verrecchia, C; Allix, M; Boulu, RR; Plotkine, M				Mesenge, C; Verrecchia, C; Allix, M; Boulu, RR; Plotkine, M			Reduction of the neurological deficit in mice with traumatic brain injury by nitric oxide synthase inhibitors	JOURNAL OF NEUROTRAUMA			English	Article						head injury; L-NAME; nitric oxide, 7-nitroindazole; mice	FOCAL CEREBRAL-ISCHEMIA	This study investigates the effect of the NO synthase inhibitors, N-G-nitro-L-arginine methyl ester (L-NAME) and 7-nitroindazole (7-NI), on the neurological deficit 24 h after a moderate closed head injury in mice, Low doses of L-NAME or 7-NI given soon after the injury significantly reduced the neurological deficit compared to the vehicle-treated group, L-Arginine (300 mg/kg) did not alter the neurological deficit, but reversed the protective effects of both L-NAME and 7-NI when given at the same time, Both L-NAME and 7-NI had dose-related effects, The neuroprotective effects of L-NAME and 7-NI occurred when the drugs were given 5, 30, or 60 min after brain injury, but not when treatment was begun 2 h after brain injury, suggesting a short therapeutic window for both drugs, These results suggest that NO synthesis by neuronal NO synthase plays an important role in the early neurotoxic cascade leading to neurological deficit following traumatic brain injury.			Mesenge, C (corresponding author), UNIV PARIS 05,PHARMACOL LAB,4 AVE OBSERV,F-75270 PARIS 06,FRANCE.		MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348			BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BUISSON A, 1992, BRIT J PHARMACOL, V106, P766, DOI 10.1111/j.1476-5381.1992.tb14410.x; CARREAU A, 1994, EUR J PHARMACOL, V256, P241, DOI 10.1016/0014-2999(94)90549-5; DAWSON DA, 1994, CEREBROVAS BRAIN MET, V6, P299; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GREENWOOD J, 1991, NEURORADIOLOGY, V33, P95, DOI 10.1007/BF00588242; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1995, IN PRESS CENTRAL NER; HUANG ZH, 1994, SCIENCE, V265, P1833; IADECOLA C, 1994, NEUROCHEM RES, V19, P501, DOI 10.1007/BF00967330; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; MACKENZIE GM, 1994, NEUROREPORT, V5, P1993, DOI 10.1097/00001756-199410000-00039; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; ZHANG FY, 1995, J CEREBR BLOOD F MET, V15, P595, DOI 10.1038/jcbfm.1995.73	22	67	67	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1996	13	4					209	214		10.1089/neu.1996.13.209			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	UK144	WOS:A1996UK14400004	8860201				2022-02-06	
J	PRASAD, MR; RAMAIAH, C; MCINTOSH, TK; DEMPSEY, RJ; HIPKENS, S; YUREK, D				PRASAD, MR; RAMAIAH, C; MCINTOSH, TK; DEMPSEY, RJ; HIPKENS, S; YUREK, D			REGIONAL LEVELS OF LACTATE AND NOREPINEPHRINE AFTER EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROCHEMISTRY			English	Article						ATP; BRAIN INJURY; CORTICAL IMPACT; CATECHOLAMINES; NOREPINEPHRINE; LACTATE; PHOSPHOCREATINE	INCREASED PROSTAGLANDIN SYNTHESIS; CONTROLLED CORTICAL IMPACT; EXPERIMENTAL HEAD-INJURY; TRANSIENT ISCHEMIA; FOREBRAIN ISCHEMIA; CEREBRAL-CORTEX; RAT-BRAIN; MAGNETIC-RESONANCE; LACTIC-ACIDOSIS; AMINO-ACIDS	The recently developed controlled cortical impact model of brain injury in rats may be an excellent tool by which to attempt to understand the neurochemical mechanisms mediating the pathophysiology of traumatic brain injury. In this study, rats were subjected to lateral controlled cortical impact brain injury of low grade severity; their brains were frozen in situ at various times after injury to measure regional levels of lactate, high energy phosphates, and norepinephrine. Tissue lactate concentration in the injury site left cortex was increased in injured animals by sixfold at 30 min and twofold at 2.5 h and 24 h after injury (p < 0.05). At all postinjury times, lactate concentration was also increased in injured animals by about twofold in the cortex and hippocampus adjacent to the injury site (p < 0.05). No significant changes occurred in the levels of ATP and phosphocreatine in most of the brain regions of injured animals. However, in the primary site of injury (left cortex), phosphocreatine concentration was decreased by 40% in injured animals at 30 min after injury (p < 0.05). The norepinephrine concentration was decreased in the injury site left cortex of injured animals by 38% at 30 min, 29% at 2.5 h, and 30% at 24 h after injury (p < 0.05). The level of norepinephrine was also reduced by similar to 20% in the cortex adjacent to the injury site in injured animals. The present results suggest that controlled cortical impact brain injury produces disorder in the neuronal oxidative and norepinephrine metabolism.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA		PRASAD, MR (corresponding author), UNIV KENTUCKY,MED CTR,DEPT SURG,DIV NEUROSURG,LEXINGTON,KY 40536, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031816, R29NS029994, R55NS031816] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 31816, NS 29994] Funding Source: Medline		ADACHI N, 1991, J NEUROCHEM, V57, P61, DOI 10.1111/j.1471-4159.1991.tb02099.x; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; CALDERINI G, 1978, BRAIN RES, V157, P303, DOI 10.1016/0006-8993(78)90032-X; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; COMBS DJ, 1990, STROKE, V21, P936, DOI 10.1161/01.STR.21.6.936; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROWDER JM, 1987, EUR J PHARMACOL, V143, P343, DOI 10.1016/0014-2999(87)90458-4; CVEJIC V, 1980, ACTA NEUROPATHOL, V51, P71, DOI 10.1007/BF00688852; DELANGEN CDJ, 1980, BRAIN RES, V185, P399; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; GAUDET R, 1978, J NEUROCHEM, V30, P751, DOI 10.1111/j.1471-4159.1978.tb10781.x; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARIK SI, 1986, NEUROLOGY, V36, P971, DOI 10.1212/WNL.36.7.971; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HILLERED L, 1985, J CEREBR BLOOD F MET, V5, P259, DOI 10.1038/jcbfm.1985.33; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1992, BRAIN RES, V567, P1; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENNETT B, 1981, MANAGEMENT HEAD INJU, V20; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; Lowry O. H., 1972, A Flexible System of Enzymatic Analysis, P146; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYNCH MA, 1986, NEUROPHARMACOLOGY, V25, P493, DOI 10.1016/0028-3908(86)90173-5; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1989, J CEREB BLOOD FLO S1, V9, pS78; MIYAUCHI Y, 1989, J NEUROCHEM, V53, P408, DOI 10.1111/j.1471-4159.1989.tb07349.x; MIYAZUKI M, 1988, BRAIN RES B, V22, P207; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; PRASAD MR, 1993, 11TH P ANN M SOC NEU; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; TZIGARET C, 1993, J NEUROCHEM, V60, P827, DOI 10.1111/j.1471-4159.1993.tb03226.x; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	55	67	68	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	SEP	1994	63	3					1086	1094					9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	PC937	WOS:A1994PC93700033	8051549				2022-02-06	
J	JIANG, MH; HOOG, A; MA, KC; NIE, XJ; OLSSON, Y; ZHANG, WW				JIANG, MH; HOOG, A; MA, KC; NIE, XJ; OLSSON, Y; ZHANG, WW			ENDOTHELIN-1-LIKE IMMUNOREACTIVITY IS EXPRESSED IN HUMAN REACTIVE ASTROCYTES	NEUROREPORT			English	Article						CEREBROVASCULAR DISEASE; LACUNES; TRAUMA; HUMAN BRAIN; ALZHEIMERS DISEASE; ENDOTHELIN-1; ASTROCYTES	BINDING-SITES; RAT-BRAIN; CEREBROSPINAL-FLUID; CEREBRAL-ARTERIES; RECEPTORS; PEPTIDE; LOCALIZATION; NEURONS; CELLS; FAMILY	THE expression of endothelin-1-like immunoreactivity in astrocytes of the human brain was investigated by the avidin-biotin-peroxidase complex method in post mortem material. A marked immunoreaction was present in reactive astrocytes around infarcts, lacunes, traumatic injuries, the lesions of progressive multifocal leucoencephalopathy and in the cerebral cortex and white matter of Alzheimer's disease. The brains of patients who had neither history nor signs of cerebral disease exhibited only occasional immunoreactive astrocytes. A hypothesis is presented that endothelin-1 may be released from reactive astrocytes in many organic diseases of the human brain with considerable pathogenic consequences. It is known from experimental investigations that endothelin-1 may for instance cause severe vasoconstriction resulting in cell injury and that it may act as a growth factor for glial cells.	UNIV HOSP UPPSALA, NEUROPATHOL LAB, S-75185 UPPSALA, SWEDEN; KAROLINSKA HOSP, DEPT PATHOL, S-10401 STOCKHOLM 60, SWEDEN								CINTRA A, 1989, ACTA PHYSIOL SCAND, V137, P557, DOI 10.1111/j.1748-1716.1989.tb08799.x; FUXE K, 1989, ACTA PHYSIOL SCAND, V137, P563, DOI 10.1111/j.1748-1716.1989.tb08802.x; FUXE K, 1991, METHODS NEUROSCIENCE, V7, P256; GIAID A, 1991, HISTOCHEMISTRY, V95, P303; GIAID A, 1989, P NATL ACAD SCI USA, V86, P7634, DOI 10.1073/pnas.86.19.7634; HIRATA Y, 1990, BIOCHEM BIOPH RES CO, V166, P1274, DOI 10.1016/0006-291X(90)91003-B; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JANSEN I, 1989, J CEREBR BLOOD F MET, V9, P743, DOI 10.1038/jcbfm.1989.106; JONES CR, 1989, NEUROSCI LETT, V97, P276, DOI 10.1016/0304-3940(89)90610-1; KOBAYASHI H, 1990, NEUROSURGERY, V27, P357, DOI 10.1227/00006123-199009000-00003; KOSEKI C, 1989, AM J PHYSIOL, V256, pR858, DOI 10.1152/ajpregu.1989.256.4.R858; KOSEKI C, 1989, NEUROSCI RES, V6, P581, DOI 10.1016/0168-0102(89)90047-3; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MILLER RC, 1993, TRENDS PHARMACOL SCI, V14, P54, DOI 10.1016/0165-6147(93)90031-E; NAMBI P, 1990, NEUROPEPTIDES, V16, P195, DOI 10.1016/0143-4179(90)90062-4; SAITO A, 1989, EUR J PHARMACOL, V162, P353, DOI 10.1016/0014-2999(89)90299-9; SCHIFFRIN EL, 1991, AM J PHYSIOL, V260, pH58, DOI 10.1152/ajpheart.1991.260.1.H58; SHIGENO T, 1989, J CARDIOVASC PHARM, V13, pS174, DOI 10.1097/00005344-198900135-00047; TAKAHASHI K, 1991, J CLIN ENDOCR METAB, V72, P693, DOI 10.1210/jcem-72-3-693; YAMAJI T, 1990, J CLIN ENDOCR METAB, V71, P1611, DOI 10.1210/jcem-71-6-1611; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZAWA T, 1989, NEUROSCI LETT, V102, P179, DOI 10.1016/0304-3940(89)90075-X	24	67	67	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	JUL	1993	4	7					935	937		10.1097/00001756-199307000-00024			3	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	LM114	WOS:A1993LM11400024	8369484				2022-02-06	
J	LEZAK, MD				LEZAK, MD			RECOVERY OF MEMORY AND LEARNING FUNCTIONS FOLLOWING TRAUMATIC BRAIN INJURY	CORTEX			English	Article									UNIV OREGON,HLTH SCI CTR,PORTLAND,OR 97201		LEZAK, MD (corresponding author), VET ADM HOSP,PORTLAND,OR 97207, USA.						BLAKEMORE CB, 1967, J NEUROL NEUROSUR PS, V30, P364, DOI 10.1136/jnnp.30.4.364; Diller L, 1974, STUDIES COGNITION RE; GRONWALL D, 1974, PSYCHOLOGICAL EFFECT; JENNETT B, 1975, 34 S OUTC SEV DAM CE; LEZAK MD, 1976, NEUROPSYCHOLOGICAL A; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MARSHALL JC, 1975, 34 S OUTC SEV DAM CT; Naquet R, 1970, Med Leg Dommage Corpor, V3, P32; NEWCOMBE F, 1975, J NEUROL SCI, V24, P127, DOI 10.1016/0022-510X(75)90013-1; Rey A., 1964, EXAMEN CLIN PSYCHOLO; Ruesch J, 1943, ARCH NEURO PSYCHIATR, V50, P165, DOI 10.1001/archneurpsyc.1943.02290200065005; Russell W Ritchie, 1934, Edinb Med J, V41, P129; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SMITH A, 1964, J NEUROL NEUROSUR PS, V27, P511, DOI 10.1136/jnnp.27.6.511; SMITH A, 1960, J MENT SCI, V106, P767; SMITH E, 1974, J NEUROL NEUROSURG P, V37, P726; TEUBER HL, 1975, 34 S OUTC SEV DAM CT; VIGOUROUX RP, 1971, INT S HEAD INJURIES; WARRINGTON EK, 1966, BRAIN, V82, P53; WESCHSLER D, 1955, WECHSLER ADULT INTEL; [No title captured]	22	67	68	1	9	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex		1979	15	1					63	72		10.1016/S0010-9452(79)80007-6			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	GU709	WOS:A1979GU70900006	446047	Bronze			2022-02-06	
J	Deshpande, SK; Hasegawa, RB; Rabinowitz, AR; Whyte, J; Roan, CL; Tabatabaei, A; Baiocchi, M; Karlawish, JH; Master, CL; Small, DS				Deshpande, Sameer K.; Hasegawa, Raiden B.; Rabinowitz, Amanda R.; Whyte, John; Roan, Carol L.; Tabatabaei, Andrew; Baiocchi, Michael; Karlawish, Jason H.; Master, Christina L.; Small, Dylan S.			Association of Playing High School Football With Cognition and Mental Health Later in Life	JAMA NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; RECURRENT CONCUSSION; REGRESSION ADJUSTMENT; NCAA CONCUSSION; LEAGUE PLAYERS; BIAS; ENCEPHALOPATHY; RECOVERY; METAANALYSIS; PREDICTORS	IMPORTANCE American football is the largest participation sport in US high schools and is a leading cause of concussion among adolescents. Little is known about the long-term cognitive and mental health consequences of exposure to football-related head trauma at the high school level. OBJECTIVE To estimate the association of playing high school football with cognitive impairment and depression at 65 years of age. DESIGN, SETTING, AND PARTICIPANTS A representative sample of male high school students who graduated from high school in Wisconsin in 1957 was studied. In this cohort study using data from the Wisconsin Longitudinal Study, football players were matched between March 1 and July 1, 2017, with controls along several baseline covariates such as adolescent IQ, family background, and educational level. For robustness, 3 versions of the control condition were considered: all controls, those who played a noncollision sport, and those who did not play any sport. EXPOSURES Athletic participation in high school football. MAIN OUTCOMES AND MEASURES A composite cognition measure of verbal fluency and memory and attention constructed from results of cognitive assessments administered at 65 years of age. A modified Center for Epidemiological Studies' Depression Scale score was used to measure depression. Secondary outcomes include results of individual cognitive tests, anger, anxiety, hostility, and heavy use of alcohol. RESULTS Among the 3904 men (mean [SD] age, 64.4 [0.8] years at time of primary outcome measurement) in the study, after matching and model-based covariate adjustment, compared with each control condition, there was no statistically significant harmful association of playing football with a reduced composite cognition score (-0.04 reduction in cognition vs all controls; 97.5% CI, -0.14 to 0.05) or an increased modified Center for Epidemiological Studies' Depression Scale depression score (-1.75 reduction vs all controls; 97.5% CI, -3.24 to -0.26). After adjustment for multiple testing, playing football did not have a significant adverse association with any of the secondary outcomes, such as the likelihood of heavy alcohol use at 65 years of age (odds ratio, 0.68; 95% CI, 0.32-1.43). CONCLUSIONS AND RELEVANCE Cognitive and depression outcomes later in life were found to be similar for high school football players and their nonplaying counterparts from mid-1950s in Wisconsin. The risks of playing football today might be different than in the 1950s, but for current athletes, this study provides information on the risk of playing sports today that have a similar risk of head trauma as high school football played in the 1950s.	[Deshpande, Sameer K.; Hasegawa, Raiden B.; Small, Dylan S.] Univ Penn, Wharton Sch, Dept Stat, 400 Huntsman Hall,3730 Walnut St, Philadelphia, PA 19104 USA; [Rabinowitz, Amanda R.] Moss Rehabil Res Inst, Brain Injury Neuropsychol Lab, Elkins Pk, PA USA; [Whyte, John] Moss Rehabil Res Inst, TBI Rehabil Res Lab, Elkins Pk, PA USA; [Roan, Carol L.] Univ Wisconsin, Ctr Demog & Ecol, Madison, WI 53706 USA; [Tabatabaei, Andrew] NYU, New York, NY USA; [Baiocchi, Michael] Stanford Univ, Stanford Sch Med, Standard Prevent Res Ctr, Palo Alto, CA 94304 USA; [Karlawish, Jason H.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Karlawish, Jason H.] Univ Penn, Dept Med Eth & Hlth Policy, Perelman Sch Med, Philadelphia, PA 19104 USA; [Karlawish, Jason H.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Master, Christina L.] Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Philadelphia, PA 19104 USA; [Master, Christina L.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA		Small, DS (corresponding author), Univ Penn, Wharton Sch, Dept Stat, 400 Huntsman Hall,3730 Walnut St, Philadelphia, PA 19104 USA.	dsmall@wharton.upenn.edu		Whyte, John/0000-0002-4381-1474; Master, Christina/0000-0002-6717-4270	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG010124] Funding Source: Medline		Anzell AR, 2013, J STRENGTH COND RES, V27, P277, DOI 10.1519/JSC.0b013e31827f4c08; Bachynski KE, 2016, NEW ENGL J MED, V374, P405, DOI 10.1056/NEJMp1513993; Ban VS, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.2.FOCUS15609; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Chen HN, 2010, COMMUN STAT-SIMUL C, V39, P860, DOI 10.1080/03610911003650383; COCHRAN WG, 1973, SANKHYA SER A, V35, P417; Cohen J., 2013, STAT POWER ANAL BEHA; Der G, 2009, INTELLIGENCE, V37, P573, DOI 10.1016/j.intell.2008.12.002; Everson-Rose SA, 2003, AM J EPIDEMIOL, V158, P1083, DOI 10.1093/aje/kwg263; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hansen BB, 2004, J AM STAT ASSOC, V99, P609, DOI 10.1198/016214504000000647; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hauser R.M., 2008, CRAFT LIFE COURSE RE, P29; Herd P, 2014, INT J EPIDEMIOL, V43, P34, DOI 10.1093/ije/dys194; Kaplan GA, 2001, INT J EPIDEMIOL, V30, P256, DOI 10.1093/ije/30.2.256; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; Miles SH, 2016, AM J BIOETHICS, V16, P6, DOI 10.1080/15265161.2016.1128751; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; National Federation of State High School Associations (NFHS), 2015, NFHS HDB 2015 16; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Richards M, 2003, SOC SCI MED, V56, P785, DOI 10.1016/S0277-9536(02)00075-8; Rogers MAM, 2009, J GERIATR PSYCH NEUR, V22, P71, DOI 10.1177/0891988708328220; Rosenbaum P. R., 2002, OBSERVATIONAL STUDIE; Rosenbaum PR, 2008, BIOMETRIKA, V95, P248, DOI 10.1093/biomet/asm085; Rosenbaum PR, 2010, SPRINGER SER STAT, P1, DOI 10.1007/978-1-4419-1213-8; ROSENBAUM PR, 1991, J ROY STAT SOC B MET, V53, P597; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Rothman K.J., 2008, Modern epidemiology, V3rd; RUBIN DB, 1979, J AM STAT ASSOC, V74, P318, DOI 10.2307/2286330; RUBIN DB, 1973, BIOMETRICS, V29, P185, DOI 10.2307/2529685; Rubin DB, 2007, STAT MED, V26, P20, DOI 10.1002/sim.2739; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Silber JH, 2001, MED CARE, V39, P1048, DOI 10.1097/00005650-200110000-00003; Spielberger C. D., 1999, STATE TRAIT ANGER EX; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033	54	66	66	0	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	AUG	2017	74	8					909	918		10.1001/jamaneurol.2017.1317			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	FD7EB	WOS:000407688300010	28672325	Green Published			2022-02-06	
J	Oliver, JM; Jones, MT; Kirk, KM; Gable, DA; Repshas, JT; Johnson, TA; Andreasson, U; Norgren, N; Blennow, K; Zetterberg, H				Oliver, Jonathan M.; Jones, Margaret T.; Kirk, K. Michele; Gable, David A.; Repshas, Justin T.; Johnson, Torie A.; Andreasson, Ulf; Norgren, Niklas; Blennow, Kaj; Zetterberg, Henrik			Serum Neurofilament Light in American Football Athletes over the Course of a Season	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; biomarkers; head trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURE; DIFFUSE AXONAL INJURY; HIGH-SCHOOL FOOTBALL; CEREBROSPINAL-FLUID; SPORTS-MEDICINE; YOUTH FOOTBALL; IN-VIVO; CONCUSSION; PLAYERS	Despite being underreported, American football boasts the highest incidence of concussion among all team sports, likely due to exposure to head impacts that vary in number and magnitude over the season. This study compared a biological marker of head trauma in American football athletes with non-contact sport athletes and examined changes over the course of a season. Baseline serum neurofilament light polypeptide (NFL) was measured after 9 weeks of no contact and compared with a non-contact sport. Serum NFL was then measured over the course of the entire season at eight time-points coincident with expected changes in likelihood of increased head impacts. Data were compared between starters (n = 11) and non-starters (n = 9). Compared with non-starters (mean +/- standard deviation) (7.30 +/- 3.57 pg . mL(-1)) and controls (6.75 +/- 1.68 pg . mL(-1)), serum NFL in starters (8.45 +/- 5.90 pg . mL(-1)) was higher at baseline (mean difference; +/-90% confidence interval) (1.69; +/-1.96 pg . mL(-1) and 1.15; +/-1.4 pg . mL(-1), respectively). Over the course of the season, an increase (effect size [ES] = 1.8; p < 0.001) was observed post-camp relative to baseline (1.52 +/- 1.18 pg . mL(-1)), which remained elevated until conference play, when a second increase was observed (ES = 2.6; p = 0.008) over baseline (4.82 +/- 2.64 pg . mL(-1)). A lack of change in non-starters resulted in substantial differences between starters and non-starters over the course of the season. These data suggest that a season of collegiate American football is associated with elevations in serum NFL, which is indicative of axonal injury, as a result of head impacts.	[Oliver, Jonathan M.; Kirk, K. Michele; Gable, David A.; Repshas, Justin T.; Johnson, Torie A.] Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, TCU Box 297730, Ft Worth, TX 76129 USA; [Kirk, K. Michele; Gable, David A.] Texas Christian Univ, Dept Sport Med, Ft Worth, TX 76129 USA; [Jones, Margaret T.] George Mason Univ, Div Hlth & Human Performance, Manassas, VA USA; [Kirk, K. Michele] John Peter Smith Hosp, Dept Sport Med, Ft Worth, TX 76104 USA; [Norgren, Niklas] UmanDiagnostics, Umea, Sweden; [Andreasson, Ulf; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL, Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England		Oliver, JM (corresponding author), Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, TCU Box 297730, Ft Worth, TX 76129 USA.	jonathan.oliver@tcu.edu					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Andreasson Ulf, 2016, Alzheimers Dement (Amst), V3, P98, DOI 10.1016/j.dadm.2016.05.005; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Johan Ljungqvist, J NEUROTRAUMA; Khademi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063172; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Millecamps S, 2007, J NEUROSCI, V27, P4947, DOI 10.1523/JNEUROSCI.5299-06.2007; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Neselius S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099870; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Oliver JM, 2012, J ATHL TRAINING, V47, P257, DOI 10.4085/1062-6050-47.3.12; Oliver Jonathan M., 2016, J NEUROTRAUM, V33, P1784; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Rowlands DS, 2015, MED SCI SPORT EXER, V47, P547, DOI 10.1249/MSS.0000000000000447; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Tortelli R, 2012, EUR J NEUROL, V19, P1561, DOI 10.1111/j.1468-1331.2012.03777.x; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Yamamoto Joelle B, 2008, Res Sports Med, V16, P111, DOI 10.1080/15438620802103320; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	50	66	66	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2016	33	19					1784	+		10.1089/neu.2015.4295			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DY8KP	WOS:000385379100007	26700106	Green Submitted			2022-02-06	
J	Winkler, EA; Minter, D; Yue, JK; Manley, GT				Winkler, Ethan A.; Minter, Daniel; Yue, John K.; Manley, Geoffrey T.			Cerebral Edema in Traumatic Brain Injury Pathophysiology and Prospective Therapeutic Targets	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Cerebral edema; Traumatic brain injury; Pathophysiology; Therapeutic targets; Blood-brain barrier	LIGHT-CHAIN KINASE; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; NONSELECTIVE CATION CHANNEL; OSMOTIC WATER PERMEABILITY; ADULT-RAT BRAIN; ISCHEMIC-STROKE; BARRIER DISRUPTION; SUBSTANCE-P; INTRACRANIAL HYPERTENSION	Traumatic brain injury is a heterogeneous disorder resulting from an external force applied to the head. The development of cerebral edema plays a central role in the evolution of injury following brain trauma and is closely associated with neurologic outcomes. Recent advances in the understanding of the molecular and cellular pathways contributing to the posttraumatic development of cerebral edema have led to the identification of multiple prospective therapeutic targets. The authors summarize the pathogenic mechanisms underlying cerebral edema and highlight the molecular pathways that may be therapeutically targeted to mitigate cerebral edema and associated sequelae following traumatic brain injury.	[Winkler, Ethan A.; Yue, John K.; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Winkler, Ethan A.; Minter, Daniel; Yue, John K.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M779, San Francisco, CA 94143 USA		Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722			Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Ameli PA, 2014, J NEUROSCI RES, V92, P1091, DOI 10.1002/jnr.23407; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Chen MK, 2003, J NEUROSCI, V23, P8568; Chen MK, 2001, J NEUROSCI, V21, P6512, DOI 10.1523/JNEUROSCI.21-17-06512.2001; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cotte J, 2014, NEW ENGL J MED, V371, P971, DOI 10.1056/NEJMc1407775; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Donkin JJ, 2011, J NEUROTRAUM, V28, P217, DOI 10.1089/neu.2010.1632; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Dore-Duffy P, 2007, NEUROL RES, V29, P395, DOI 10.1179/016164107X204729; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Faul M, 2010, TRAUMATIC BRAIN INJU; Filippidis AS, 2014, J NEUROTRAUM, V31, P1258, DOI 10.1089/neu.2013.3063; FILIPPINI G, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001331; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; HALL JM, 1995, NEUROCHEM INT, V26, P17, DOI 10.1016/0197-0186(94)00115-B; Haorah J, 2005, ALCOHOL CLIN EXP RES, V29, P999, DOI 10.1097/01.ALC.0000166944.79914.0A; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hirose T, 2013, NEUROL MED-CHIR, V53, P609; Huang WD, 2008, J ENDOCRINOL INVEST, V31, P996, DOI 10.1007/BF03345638; Hudak AM, 2014, BRAIN INJURY, V28, P1602, DOI 10.3109/02699052.2014.936039; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Ishmael JE, 2008, ACTA HISTOCHEM, V110, P172, DOI 10.1016/j.acthis.2007.08.005; Jayakumar AR, 2011, J NEUROCHEM, V117, P437, DOI 10.1111/j.1471-4159.2011.07211.x; Jia F, 2014, J NEUROTRAUM, V31, P1225, DOI 10.1089/neu.2013.3230; Kahle KT, 2009, PHYSIOLOGY, V24, P257, DOI 10.1152/physiol.00015.2009; Kim DJ, 2012, J NEUROTRAUM, V29, P1354, DOI 10.1089/neu.2011.2018; Kimberly WT, 2014, NEUROCRIT CARE, V20, P193, DOI 10.1007/s12028-013-9917-z; Kimura R, 2005, STROKE, V36, P1259, DOI 10.1161/01.STR.0000165925.20413.14; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; Koyama Junji, 2007, Kobe J Med Sci, V53, P199; Krieg SM, 2015, J NEUROTRAUM, V32, P221, DOI 10.1089/neu.2013.3274; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Kunte H, 2007, STROKE, V38, P2526, DOI 10.1161/STROKEAHA.107.482216; Kunte H, 2012, ANN NEUROL, V72, P799, DOI 10.1002/ana.23680; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee M, 2015, ACS CHEM NEUROSCI, V6, P1658, DOI 10.1021/acschemneuro.5b00140; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Mori K, 2002, J NEUROTRAUM, V19, P1261, DOI 10.1089/08977150260338047; Mysiorek C, 2009, CURR NEUROVASC RES, V6, P181, DOI 10.2174/156720209788970081; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nagelhus EA, 2004, NEUROSCIENCE, V129, P905, DOI 10.1016/j.neuroscience.2004.08.053; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Oshio K, 2003, ACT NEUR S, V86, P525; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Ramirez SH, 2009, J CEREBR BLOOD F MET, V29, P1933, DOI 10.1038/jcbfm.2009.112; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rossi JL, 2013, J NEUROTRAUM, V30, P1672, DOI 10.1089/neu.2013.2898; Rungta RL, 2015, CELL, V161, P610, DOI 10.1016/j.cell.2015.03.029; Ryken TC, 2010, J NEURO-ONCOL, V96, P103, DOI 10.1007/s11060-009-0057-4; Salvador E, 2014, CELL TISSUE RES, V355, P597, DOI 10.1007/s00441-013-1762-z; Sandercock PAG, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000064.pub2; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Shen QA, 2010, CARDIOVASC RES, V87, P272, DOI 10.1093/cvr/cvq144; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Sheth KN, 2014, STROKE, V45, P281, DOI 10.1161/STROKEAHA.113.003352; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Shohami E, 2014, CNS NEUROL DISORD-DR, V13, P567, DOI 10.2174/18715273113126660196; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Stahel PF, 2008, PPAR RES, V2008, DOI 10.1155/2008/538141; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Storkebaum E, 2011, NAT NEUROSCI, V14, P1390, DOI 10.1038/nn.2947; Szmydynger-Chodobska J, 2011, J CEREBR BLOOD F MET, V31, P47, DOI 10.1038/jcbfm.2010.188; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Tang XQ, 2014, NEUROL RES, V36, P118, DOI 10.1179/1743132813Y.0000000266; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Turner RJ, 2011, BRAIN RES, V1393, P84, DOI 10.1016/j.brainres.2011.03.066; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Walcott BP, 2012, NEUROTHERAPEUTICS, V9, P65, DOI 10.1007/s13311-011-0087-4; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; Watanabe M, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00371; Winkler EA, 2014, BRAIN PATHOL, V24, P371, DOI 10.1111/bpa.12152; Winkler EA, 2014, P NATL ACAD SCI USA, V111, pE1035, DOI 10.1073/pnas.1401595111; Winkler EA, 2012, J CEREBR BLOOD F MET, V32, P1841, DOI 10.1038/jcbfm.2012.113; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yan YP, 2003, BRAIN RES, V961, P22, DOI 10.1016/S0006-8993(02)03832-5; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39; Zador Z, 2007, PROG BRAIN RES, V161, P185, DOI 10.1016/S0079-6123(06)61012-1; Zehendner CM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13497; Zhu DH, 2010, BLOOD, V115, P4963, DOI 10.1182/blood-2010-01-262386; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	144	66	72	1	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					473	+		10.1016/j.nec.2016.05.008			17	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800009	27637397				2022-02-06	
J	Fischer, M; Kehrberger, E; Marung, H; Moecke, H; Pruckner, S; Trentzsch, H; Urban, B				Fischer, M.; Kehrberger, E.; Marung, H.; Moecke, H.; Prueckner, S.; Trentzsch, H.; Urban, B.		Fachexperten Eckpunktepapier	The 2016 consensus document on emergency care for the general public during the pre-hospital phase and at the hospital	NOTFALL & RETTUNGSMEDIZIN			German	Article						Tracer diagnosis; Pre-hospital time; Structural planning; Quality management; Adequate Hospital	ACUTE MEDICINE; MAIN POINTS; POPULATION; PROJECT; DRAFT	The 2007 consensus document for emergency medical care (Eckpunktepapier) has defined a framework for structure and planning. The increasing demands for emergency medical care for the general public require the 2007 consensus document for to be updated and expanded. The results of the revision are presented in this article. The draft of the new Eckpunktepapier was developed at a symposium with representatives of the associations, institutions, and organisations involved in emergency medical care and was presented at a plenary session. In order to define the exact terminology of technical terms, a glossary was issued. In a two-tiered consencus process the documents were circulated for revision and finally approved. Thirty specialist associations, institutions and organisations participated in the consensus, and the approval rate of 96.7 % mirrors a strong consensus. The Eckpunktepapier 2016 contains recommendations for structural planning and emergency medical procedures in accordance with the applicable guidelines, and the need for a adequate hospital. In addition to the current tracer diagnoses severe traumatic brain injury, stroke, severely injured multiple trauma, and ST- elevation myocardial infarction, additional recommendations have been included for sudden cardiac death and sepsis. The process quality of the dispatch centre, requirements for diagnosis and therapy by emergency physician/paramedics, tactical approaches and time management, initial emergency medical treatment in the field and at the adequate hospital, as well as quality management instruments have in turn been taken into consideration. Also, the special requirements of paediatric patients are presented. Furthermore, the paper includes essential recommendations for the first link in the rescue chain (risk assessment, first aid and the emergency call). The 2016 Consensus Paper takes into account the entire emergency medical process chain from the occurrence of the emergency and when the emergency call is received, the care of the emergency physician/paramedics, through to the continuation of treatment in hospital, and serves as a guideline for the integrated planning of access-oriented emergency medical care.	[Fischer, M.; Kehrberger, E.] Arbeitsgemeinschaft Sudwestdeutscher Notarzte eV, Filderstadt, Germany; [Fischer, M.] Klin Eichert, Klin Anasthesiol Operat Intens Med Notfallmed & S, Goppingen, Germany; [Kehrberger, E.] Kreiskliniken Esslingen Paracelsus Krankenhaus, Klin Anasthesiol & Operat Intens Med, Ruit, Germany; [Marung, H.] Univ Klinikum Schleswig Holstein, Inst Rettungs & Notfallmed, Kiel, Germany; [Marung, H.; Moecke, H.] Asklepios Kliniken Harburg, Inst Notfallmed IfN, Hamburg, Germany; [Prueckner, S.; Trentzsch, H.; Urban, B.] Univ Munich, Klinikum Univ Munchen, INM, Schillerstr 53, D-80336 Munich, Germany		Pruckner, S (corresponding author), Univ Munich, Klinikum Univ Munchen, INM, Schillerstr 53, D-80336 Munich, Germany.	stephan.prueckner@med.uni-muenchen.de	Prueckner, Stephan/AAB-2280-2021; Trentzsch, Heiko/I-7679-2014; Trentzsch, Heiko/ABF-3979-2020	Prueckner, Stephan/0000-0002-5128-7625; Trentzsch, Heiko/0000-0002-6395-6873; Trentzsch, Heiko/0000-0002-6395-6873			Ahnefeld FW, 2008, NOTFALL RETTUNGSMED, V11, P421; Altemeyer KH, 2008, NOTFALL RETTUNGSMED, V11, P419, DOI 10.1007/s10049-008-1105-x; Landesarztekammer Bayerische, 2013, BAYERISCHES ARZTEBL, V68, P564	3	66	68	1	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1434-6222	1436-0578		NOTFALL RETTUNGSMED	Notfall Rettungsmed.	AUG	2016	19	5					387	395		10.1007/s10049-016-0187-0			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	DS3UE	WOS:000380707400013					2022-02-06	
J	Gupta, R; Sen, N				Gupta, Rajaneesh; Sen, Nilkantha			Traumatic brain injury: a risk factor for neurodegenerative diseases	REVIEWS IN THE NEUROSCIENCES			English	Article						Alzheimer disease; amyotrophic lateral sclerosis; chronic traumatic encephalopathy; neurodegeneration; traumatic brain injury	AMYOTROPHIC-LATERAL-SCLEROSIS; UBIQUITIN-PROTEASOME PATHWAY; UP-REGULATION; HEAD-INJURY; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; MOUSE-BRAIN; CELL-DEATH; KAPPA-B; EXPRESSION	Traumatic brain injury (TBI), a major global health and socioeconomic problem, is now established as a chronic disease process with a broad spectrum of pathophysiological symptoms followed by long-term disabilities. It triggers multiple and multidirectional biochemical events that lead to neurodegeneration and cognitive impairment. Recent studies have presented strong evidence that patients with TBI history have a tendency to develop proteinopathy, which is the pathophysiological feature of neurodegenerative disorders such as Alzheimer disease (AD), chronic traumatic encephalopathy (CTE), and amyotrophic lateral sclerosis (ALS). This review mainly focuses on mechanisms related to AD, CTE, and ALS that are induced after TBI and their relevance to the advancement of these neurodegenerative diseases. This review encompasses acute effects and chronic neurodegenerative consequences after TBI for a better understanding of TBI-induced neuronal death and to design therapies that will effectively treat patients in the primary or secondary progressive stages.	[Sen, Nilkantha] Georgia Regents Univ, Augusta, GA 30912 USA; [Gupta, Rajaneesh] Georgia Regents Univ, Neurosci & Regenerat Med, Augusta, GA 30912 USA		Sen, N (corresponding author), Georgia Regents Univ, 1120 15th St CA 2018, Augusta, GA 30912 USA.	nsen@gru.edu	Sen, Nilkantha/AAW-9788-2020; Gupta, Rajaneesh/AAD-5893-2019	Gupta, Rajaneesh/0000-0003-0212-6478	NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01 EY025622] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS094516] Funding Source: Medline; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY025622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094516] Funding Source: NIH RePORTER		Achi EY, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/806306; Bettcher BM, 2014, CLIN PHARMACOL THER, V96, P464, DOI 10.1038/clpt.2014.147; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Bolmont T, 2007, AM J PATHOL, V171, P2012, DOI 10.2353/ajpath.2007.070403; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen Y, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00022; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Chow VW, 2010, NEUROMOL MED, V12, P1, DOI 10.1007/s12017-009-8104-z; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gupta RK, 2013, BIOGERONTOLOGY, V14, P531, DOI 10.1007/s10522-013-9459-y; Gupta RK, 2016, MOL NEUROBIOL, V53, P3377, DOI 10.1007/s12035-015-9287-y; Gupta RK, 2014, NEUROCHEM RES, V39, P150, DOI 10.1007/s11064-013-1200-3; Gupta RK, 2013, AGE, V35, P59, DOI 10.1007/s11357-011-9330-5; Haass C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006270; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Huang RQ, 2010, NEUROSCI LETT, V473, P22, DOI 10.1016/j.neulet.2010.02.011; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan Barry D, 2014, Continuum (Minneap Minn), V20, P1588, DOI 10.1212/01.CON.0000458972.94013.e1; Jucker M, 2011, ANN NEUROL, V70, P532, DOI 10.1002/ana.22615; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Lee J, 2014, J TRAUMA ACUTE CARE, V77, P709, DOI 10.1097/TA.0000000000000445; LEIGH PN, 1991, BRAIN, V114, P775, DOI 10.1093/brain/114.2.775; Luo P, 2011, BRAIN RES BULL, V85, P313, DOI 10.1016/j.brainresbull.2011.05.004; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Massaad CA, 2011, ANTIOXID REDOX SIGN, V14, P2013, DOI 10.1089/ars.2010.3208; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nonaka T, 2009, FEBS LETT, V583, P394, DOI 10.1016/j.febslet.2008.12.031; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RIGGS JE, 1993, MIL MED, V158, P55, DOI 10.1093/milmed/158.1.55; RIGGS JE, 1985, ARCH NEUROL-CHICAGO, V42, P205, DOI 10.1001/archneur.1985.04060030015004; RIGGS JE, 1995, CLIN NEUROPHARMACOL, V18, P273, DOI 10.1097/00002826-199506000-00008; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Roman GC, 1996, J NEUROL NEUROSUR PS, V61, P131, DOI 10.1136/jnnp.61.2.131; Rosen RF, 2012, J NEUROCHEM, V120, P660, DOI 10.1111/j.1471-4159.2011.07551.x; Rosenbohm A, 2014, J NEUROL, V261, P283, DOI 10.1007/s00415-013-7185-7; Saulle M, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/816069; Schwartz AL, 1999, ANNU REV MED, V50, P57; Shi P, 2010, BBA-MOL BASIS DIS, V1802, P707, DOI 10.1016/j.bbadis.2010.05.008; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Staal JA, 2009, J NEUROTRAUM, V26, P781, DOI 10.1089/neu.2008.0669; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Tsaousides T, 2009, MT SINAI J MED, V76, P173, DOI 10.1002/msj.20099; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang X, 2010, EXP NEUROL, V223, P299, DOI 10.1016/j.expneurol.2009.07.033	75	66	69	0	26	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	JAN	2016	27	1					93	100		10.1515/revneuro-2015-0017			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CZ3QR	WOS:000367019600006	26352199				2022-02-06	
J	Mez, J; Solomon, TM; Daneshvar, DH; Murphy, L; Kiernan, PT; Montenigro, PH; Kriegel, J; Abdolmohammadi, B; Fry, B; Babcock, KJ; Adams, JW; Bourlas, AP; Papadopoulos, Z; McHale, L; Ardaugh, BM; Martin, BR; Dixon, D; Nowinski, CJ; Chaisson, C; Alvarez, VE; Tripodis, Y; Stein, TD; Goldstein, LE; Katz, DI; Kowall, NW; Cantu, RC; Stern, RA; McKee, AC				Mez, Jesse; Solomon, Todd M.; Daneshvar, Daniel H.; Murphy, Lauren; Kiernan, Patrick T.; Montenigro, Philip H.; Kriegel, Joshua; Abdolmohammadi, Bobak; Fry, Brian; Babcock, Katharine J.; Adams, Jason W.; Bourlas, Alexandra P.; Papadopoulos, Zachary; McHale, Lisa; Ardaugh, Brent M.; Martin, Brett R.; Dixon, Diane; Nowinski, Christopher J.; Chaisson, Christine; Alvarez, Victor E.; Tripodis, Yorghos; Stein, Thor D.; Goldstein, Lee E.; Katz, Douglas I.; Kowall, Neil W.; Cantu, Robert C.; Stern, Robert A.; McKee, Ann C.			Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study	ALZHEIMERS RESEARCH & THERAPY			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; ALZHEIMERS ASSOCIATION WORKGROUPS; RESEARCH DIAGNOSTIC-CRITERIA; 21ST-CENTURY BRAIN BANKING; MILD COGNITIVE IMPAIRMENT; FOOTBALL-LEAGUE PLAYER; NATIONAL-INSTITUTE; NEUROPATHOLOGIC ASSESSMENT; COLUMBIA-UNIVERSITY; PARKINSON-DISEASE	Introduction: Chronic traumatic encephalopathy (CTE) is a progressive neurodegeneration associated with repetitive head impacts. Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) is a U01 project recently funded by the National Institute of Neurological Disorders and Stroke and the National Institute of Biomedical Imaging and Bioengineering. The goal of the UNITE project is to examine the neuropathology and clinical presentation of brain donors designated as "at risk" for the development of CTE based on prior athletic or military exposure. Here, we present the rationale and methodology for UNITE. Methods: Over the course of 4 years, we will analyze the brains and spinal cords of 300 deceased subjects who had a history of repetitive head impacts sustained during participation in contact sports at the professional or collegiate level or during military service. Clinical data are collected through medical record review and retrospective structured and unstructured family interviews conducted by a behavioral neurologist or neuropsychologist. Blinded to the clinical data, a neuropathologist conducts a comprehensive assessment for neurodegenerative disease, including CTE, using published criteria. At a clinicopathological conference, a panel of physicians and neuropsychologists, blinded to the neuropathological data, reaches a clinical consensus diagnosis using published criteria, including proposed clinical research criteria for CTE. Results: We will investigate the validity of these clinical criteria and sources of error by using recently validated neuropathological criteria as a gold standard for CTE diagnosis. We also will use statistical modeling to identify diagnostic features that best predict CTE pathology. Conclusions: The UNITE study is a novel and methodologically rigorous means of assessing clinicopathological correlation in CTE. Our findings will be critical for developing future iterations of CTE clinical diagnostic criteria.	[Mez, Jesse; Solomon, Todd M.; Daneshvar, Daniel H.; Murphy, Lauren; Kiernan, Patrick T.; Montenigro, Philip H.; Kriegel, Joshua; Abdolmohammadi, Bobak; Fry, Brian; Babcock, Katharine J.; Adams, Jason W.; Bourlas, Alexandra P.; Papadopoulos, Zachary; Alvarez, Victor E.; Stein, Thor D.; Goldstein, Lee E.; Kowall, Neil W.; Cantu, Robert C.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Mez, Jesse; Murphy, Lauren; Kiernan, Patrick T.; Kriegel, Joshua; Abdolmohammadi, Bobak; Fry, Brian; Babcock, Katharine J.; Adams, Jason W.; Bourlas, Alexandra P.; Papadopoulos, Zachary; Goldstein, Lee E.; Katz, Douglas I.; Cantu, Robert C.; Stern, Robert A.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Daneshvar, Daniel H.; McHale, Lisa; Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Waltham, MA 02451 USA; [Montenigro, Philip H.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Ardaugh, Brent M.; Martin, Brett R.; Dixon, Diane; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Alvarez, Victor E.; Stein, Thor D.; Kowall, Neil W.; McKee, Ann C.] VA Boston Healthcare Syst, US Dept Vet Affairs, Jamaica Plain, MA 02130 USA; [Alvarez, Victor E.; Stein, Thor D.; McKee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA 01730 USA; [Alvarez, Victor E.; Stein, Thor D.; Kowall, Neil W.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA 02184 USA; [Kowall, Neil W.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA		McKee, AC (corresponding author), Boston Univ, Sch Med, Alzheimers Dis Ctr, 72 East Concord St,B-7800, Boston, MA 02118 USA.	amckee@bu.edu	, Bob/ABA-8507-2020; Kowall, Neil/M-5378-2019	Kowall, Neil/0000-0002-6624-0213; Tripodis, Yorghos/0000-0003-2190-7608; Stein, Thor/0000-0001-6954-4477; Papadopoulos, Zachary/0000-0001-5681-1388; Daneshvar, Daniel/0000-0003-3691-9513; Montenigro, Philip/0000-0003-4442-9207	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1UO1NS086659-01, R01 NS078337, R56 NS078337]; U.S. Department of DefenseUnited States Department of Defense [W81XWH-13-2-0064]; U.S. Department of Veterans Affairs, the Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS); Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute on Aging Boston University Alzheimer's Disease Center [P30AG13846]; Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP grant) [13267017]; National Institute on Aging Boston University Framingham Heart Study [R01 AG1649]; National Operating Committee on Standards for Athletic Equipment; Sports Legacy Institute; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS078337, U01NS086659, R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, K23AG046377] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	The authors gratefully acknowledge the use of the resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA, USA). We also gratefully acknowledge the help of all members of the Chronic Traumatic Encephalopathy Program at Boston University School of Medicine, the VA Boston Healthcare System, and the individuals and families whose participation and contributions made this work possible. This work was supported by the National Institute of Neurological Disorders and Stroke (grants 1UO1NS086659-01, R01 NS078337, R56 NS078337), the U.S. Department of Defense (grant W81XWH-13-2-0064), the U.S. Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501), the Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS), the Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (grant B6796-C), the National Institute on Aging Boston University Alzheimer's Disease Center (grant P30AG13846; supplement 0572063345-5), the Department of Defense Peer Reviewed Alzheimer's Research Program (DoD-PRARP grant 13267017), the National Institute on Aging Boston University Framingham Heart Study (grant R01 AG1649), the National Operating Committee on Standards for Athletic Equipment, and the Sports Legacy Institute. This work was also supported by unrestricted gifts from the Andlinger Family Foundation, the WWE, and the NFL.	Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Armstrong MJ, 2013, NEUROLOGY, V80, P496, DOI 10.1212/WNL.0b013e31827f0fd1; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Berk RA, 2008, SPRINGER SER STAT, P1, DOI 10.1007/978-0-387-77501-2_1; Bertens LCM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001531; Bigio EH, 2008, J NEUROPATH EXP NEUR, V67, P635, DOI 10.1097/NEN.0b013e31817d751c; BLACKER D, 1994, ARCH NEUROL-CHICAGO, V51, P1198, DOI 10.1001/archneur.1994.00540240042014; BRAAK H, 1993, EUR NEUROL, V33, P403, DOI 10.1159/000116984; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Braak H, 2008, NEUROLOGY, V70, P1916, DOI 10.1212/01.wnl.0000312279.49272.9f; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; BROWNELL B, 1970, J NEUROL NEUROSUR PS, V33, P338, DOI 10.1136/jnnp.33.3.338; Burke W J, 1991, J Geriatr Psychiatry Neurol, V4, P173, DOI 10.1177/089198879100400310; Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5; Cleveland Clinic Canada, 2009, HEAD INT QUEST; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dawson-Saunders B, 1994, BASIC CLIN BIOSTATIS, P232; Del Tredici K, 2002, J NEUROPATH EXP NEUR, V61, P413, DOI 10.1093/jnen/61.5.413; Dickson DW, 2010, INT J CLIN EXP PATHO, V3, P1; First MB, 1995, STRUCTURED CLIN INTE; Gabel MJ, 2004, J HEALTH ECON, V23, P543, DOI 10.1016/j.jhealeco.2003.10.004; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gioia GA, 2005, PSYCHOL ASSESS RESOU; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gorno-Tempini ML, 2011, NEUROLOGY, V76, P1006, DOI 10.1212/WNL.0b013e31821103e6; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kiernan PT, 2015, SEMIN NEUROL, V35, P20, DOI 10.1055/s-0035-1545080; Kraemer HC, 2014, ANNU REV CLIN PSYCHO, V10, P111, DOI 10.1146/annurev-clinpsy-032813-153739; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Love S., 2008, GREENFIELDS NEUROPAT; Mackenzie IRA, 2010, ACTA NEUROPATHOL, V119, P1, DOI 10.1007/s00401-009-0612-2; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKeith IG, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P417; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; McNair D. M., 1983, ASSESSMENT GERIATRIC; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1147, DOI 10.1097/00005072-199911000-00004; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Rascovsky K, 2011, BRAIN, V134, P2456, DOI 10.1093/brain/awr179; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Shen H, 2015, NATURE, V518, P466, DOI 10.1038/518466a; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Vonsattel JPG, 2008, CELL TISSUE BANK, V9, P247, DOI 10.1007/s10561-008-9079-y; Vonsattel JPG, 2008, ACTA NEUROPATHOL, V115, P509, DOI 10.1007/s00401-007-0311-9; Walker MP, 2000, BRIT J PSYCHIAT, V177, P252, DOI 10.1192/bjp.177.3.252; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x	78	66	66	0	19	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1758-9193			ALZHEIMERS RES THER	Alzheimers Res. Ther.	OCT 12	2015	7								62	10.1186/s13195-015-0148-8			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT2KD	WOS:000362629500001	26455775	Green Published, gold			2022-02-06	
J	Farbood, Y; Sarkaki, A; Dianat, M; Khodadadi, A; Haddad, MK; Mashhadizadeh, S				Farbood, Yaghoob; Sarkaki, Alireza; Dianat, Mahin; Khodadadi, Ali; Haddad, Mohammad Khaksari; Mashhadizadeh, Shahram			Ellagic acid prevents cognitive and hippocampal long-term potentiation deficits and brain inflammation in rat with traumatic brain injury	LIFE SCIENCES			English	Article						Traumatic brain injury; Long term potentiation; Ellagic acid; IL-1 beta; IL-6	DENTATE GYRUS; INTRACRANIAL-PRESSURE; SYNAPTIC PLASTICITY; OXIDATIVE STRESS; AMPA RECEPTORS; CA1 REGION; DUAL ROLE; KAPPA-B; INTERLEUKIN-1; MEMORY	Aims: Traumatic brain injury (TBI) remains one of the main clinical problems globally and is a common cause of death among youth. Cognitive defects such as thinking, memory and behavior or mental health disorders are considered as the most frequent effects of severe and moderate TBI. It has been reported that ellagic acid (EA), a natural polyphenol, exhibits protective effects against oxidative damage. This study was performed to examine the EA preventive effects on cognitive impairments, long-term potentiation (LTP) deficits in hippocampus and brain inflammation induced by diffuse TBI in rat. Main methods: Subchronic oral administration of 100 mg/kg EA, 7 consecutive days before induction of trauma (once daily) was used to elucidate the EA effects on passive avoidance memory and hippocampal LTP following TBI. To illustrate the possible mechanisms related to the preventive effects of EA on brain function following TBI, brain content of IL-1 beta, IL-6 and blood-brain barrier (BBB) permeability were determined. Key findings: EA pretreatment significantly (P < 0.001) prevented TBI-induced memory and hippocampal LTP impairments in rat. Furthermore TBI induced elevation in brain content of IL-1 beta, IL-6 and BBB permeability were decreased significantly (P < 0.001) due to EA pre-treatment. Significance: Our findings suggest that EA can prevent cognitive and LTP deficits and also prevent brain inflammation following TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Farbood, Yaghoob; Sarkaki, Alireza; Dianat, Mahin; Mashhadizadeh, Shahram] Ahvaz Jundishapur Univ Med Sci, Sch Med, Physiol Res Ctr, Golestan Blvd,POB 45, Ahvaz 6135715794, Iran; [Farbood, Yaghoob; Sarkaki, Alireza; Dianat, Mahin; Mashhadizadeh, Shahram] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Physiol, Ahvaz 6135715794, Iran; [Khodadadi, Ali] Ahvaz Jundishapur Univ Med Sci, Sch Med, Dept Immunol, Ahvaz 6135715794, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Sch Med, Physiol Res Ctr, Kerman, Iran; [Haddad, Mohammad Khaksari] Kerman Univ Med Sci, Sch Med, Dept Physiol, Kerman, Iran		Mashhadizadeh, S (corresponding author), Ahvaz Jundishapur Univ Med Sci, Sch Med, Physiol Res Ctr, Golestan Blvd,POB 45, Ahvaz 6135715794, Iran.	mashhadizadeh.s@ajums.ac.ir	khodadadi, ali/N-2130-2017; Mashhadizadeh, Shahram/AAN-2926-2021; Farbood, Yaghoob/M-3076-2017; Sarkaki, Alireza/Q-8363-2017; Haddad, Mohammad Khaksari/AAB-9025-2019	khodadadi, ali/0000-0003-0442-273X; Mashhadizadeh, Shahram/0000-0003-2614-5657; Farbood, Yaghoob/0000-0002-6390-0079; Sarkaki, Alireza/0000-0001-9272-6228; Haddad, Mohammad Khaksari/0000-0003-0770-4281	Ahvaz Physiology Research Center - Vice Chancellor of Research, Ahvaz Jundishapur University of Medical Sciences (Iran) [APRC-147]	This research was supported by a grant (APRC-147) from the Ahvaz Physiology Research Center, funded by the Vice Chancellor of Research, Ahvaz Jundishapur University of Medical Sciences (Iran). Also it was extracted from the Ph.D. thesis of Mr. Shahram Mashhadizadeh. The authors would like to thank of Dr. Soltani Z, Miss Naderi V and Mr. Mirshekar M, our colleagues in Kerman and Ahvaz Universities of Medical Sciences (Iran), for their kind help and technical support.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Arisi G.M., 2014, EPILEPSY BEHAV; Atta-Ur-Rahman, 2001, PLANTA MED, V67, P335, DOI 10.1055/s-2001-14306; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; BenNasr C, 1996, Z LEBENSM UNTERS FOR, V203, P374, DOI 10.1007/BF01231077; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broutman G, 2001, J NEUROSCI, V21, P27, DOI 10.1523/JNEUROSCI.21-01-00027.2001; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chao PC, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-33; Chen HS, 2011, J FOOD SCI, V76, pT192, DOI 10.1111/j.1750-3841.2011.02373.x; Citri A, 2008, NEUROPSYCHOPHARMACOL, V33, P18, DOI 10.1038/sj.npp.1301559; Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI [10.1002/(SICI)1097-0010(20000515)80:7<1118::AID-JSFA570>3.0.CO;2-9, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1118::AID-JSFA570&gt;3.0.CO;2-9]; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Edderkaoui M, 2008, WORLD J GASTROENTERO, V14, P3672, DOI 10.3748/wjg.14.3672; Faul M., 2010, TRAUMATIC BRAIN INJU, P7; Festa F, 2001, ANTICANCER RES, V21, P3903; Freir DB, 2003, BRAIN RES, V967, P27, DOI 10.1016/S0006-8993(02)04190-2; Garber J, 2010, GUIDE CARE USE LAB A, V8, P220; Gellerman DM, 1997, J NEUROCHEM, V69, P131; Girish C, 2009, FUND CLIN PHARMACOL, V23, P735, DOI 10.1111/j.1472-8206.2009.00722.x; Goshen I, 2007, PSYCHONEUROENDOCRINO, V32, P1106, DOI 10.1016/j.psyneuen.2007.09.004; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huh JW, 2011, J NEUROTRAUM, V28, P245, DOI 10.1089/neu.2010.1639; Keshavarzi Z, 2012, IRAN J BASIC MED SCI, V15, P1102; Khaksari M, 2013, IRAN J BASIC MED SCI, V16, P858; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Kostrzewa RM, 2003, NEUROTOX RES, V5, P375, DOI 10.1007/BF03033166; Lai AY, 2006, J NEUROIMMUNOL, V175, P97, DOI 10.1016/j.jneuroim.2006.03.001; Lashgari R, 2006, BEHAV BRAIN RES, V171, P324, DOI 10.1016/j.bbr.2006.04.013; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Loane DJ, 2011, J NEUROTRAUM, V28, P225, DOI 10.1089/neu.2010.1595; Manahan-Vaughan D, 1998, NEUROSCIENCE, V86, P709, DOI 10.1016/S0306-4522(98)00111-0; Mansouri MT, 2013, PHARMACOL BIOCHEM BE, V111, P90, DOI 10.1016/j.pbb.2013.09.002; Mansouri MT, 2013, EUR J PHARMACOL, V707, P46, DOI 10.1016/j.ejphar.2013.03.031; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morton LW, 2000, CLIN EXP PHARMACOL P, V27, P152, DOI 10.1046/j.1440-1681.2000.03214.x; Narayanan BA, 1999, CANCER LETT, V136, P215, DOI 10.1016/S0304-3835(98)00323-1; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor JJ, 1999, EXP PHYSIOL, V84, P601, DOI 10.1111/j.1469-445X.1999.01892.x; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Ota Y, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/185463; PARNET P, 1994, MOL BRAIN RES, V27, P63, DOI 10.1016/0169-328X(94)90185-6; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; REEVES TM, 1995, EXP BRAIN RES, V106, P248; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rogerio AP, 2006, J PHARM PHARMACOL, V58, P1265, DOI 10.1211/jpp.58.9.0014; Ross FM, 2003, J NEUROIMMUNOL, V144, P61, DOI 10.1016/j.jneuroim.2003.08.030; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sakthivel M, 2008, EXP EYE RES, V86, P251, DOI 10.1016/j.exer.2007.10.016; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sarkaki A, 2008, BEHAV BRAIN RES, V186, P72, DOI 10.1016/j.bbr.2007.07.041; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Sarkaki A, 2013, IRAN J BASIC MED SCI, V16, P1004; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Selig DK, 1996, LEARN MEMORY, V3, P42, DOI 10.1101/lm.3.1.42; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Tancredi V, 2000, J NEUROCHEM, V75, P634, DOI 10.1046/j.1471-4159.2000.0750634.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thomson I.A., 2014, PAK J BIOL SCI, V17, P978; Tsakini N, 2008, MOL CELL NEUROSCI, V37, P110, DOI 10.1016/j.mcn.2007.09.001; Umesalma S, 2010, BASIC CLIN PHARMACOL, V107, P650, DOI 10.1111/j.1742-7843.2010.00565.x; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Viviani B, 2003, J NEUROSCI, V23, P8692; Whitley AC, 2003, BIOCHEM PHARMACOL, V66, P907, DOI 10.1016/S0006-2952(03)00413-1; Ye F, 2014, EXP THER MED, V7, P223, DOI 10.3892/etm.2013.1396; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Yu YM, 2005, J NUTR BIOCHEM, V16, P675, DOI 10.1016/j.jnutbio.2005.03.013; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	80	66	67	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	MAR 1	2015	124						120	127		10.1016/j.lfs.2015.01.013			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	CE8TX	WOS:000352118100015	25637685				2022-02-06	
J	Edelmann, MN; Krull, KR; Liu, W; Glass, JO; Ji, Q; Ogg, RJ; Sabin, ND; Srivastava, DK; Robison, LL; Hudson, MM; Reddick, WE				Edelmann, Michelle N.; Krull, Kevin R.; Liu, Wei; Glass, John O.; Ji, Qing; Ogg, Robert J.; Sabin, Noah D.; Srivastava, Deo Kumar; Robison, Leslie L.; Hudson, Melissa M.; Reddick, Wilburn E.			Diffusion tensor imaging and neurocognition in survivors of childhood acute lymphoblastic leukaemia	BRAIN			English	Article						brain fraction; neuropsychology; neuroimaging; anisotropy; cancer	LONG-TERM SURVIVORS; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; FRACTIONAL ANISOTROPY; MEMORY; LEUKOENCEPHALOPATHY; IMPAIRMENT; ATTENTION; OUTCOMES; THERAPY	Survivors of childhood acute lymphoblastic leukaemia are at risk for neurocognitive impairment, though little information is available on its association with brain integrity, particularly for survivors treated without cranial radiation therapy. This study compares neurocognitive function and brain morphology in long-term adult survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy alone (n = 36) to those treated with cranial radiation therapy (n = 39) and to healthy control subjects (n = 23). Mean (standard deviation) age at evaluation was 24.9 (3.6) years for the chemotherapy group and 26.7 (3.4) years for the cranial radiation therapy group, while time since diagnosis was 15.0 (1.7) and 23.9 (3.1) years, respectively. Brain grey and white matter volume and diffusion tensor imaging was compared between survivor groups and to 23 healthy controls with a mean (standard deviation) age of 23.1 (2.6) years. Survivors treated with chemotherapy alone had higher fractional anisotropy in fibre tracts within the left (P < 0.05), but not in the right, hemisphere when compared to controls. Survivors of acute lymphoblastic leukaemia, regardless of treatment, had a lower ratio of white matter to intracranial volume in frontal and temporal lobes (P < 0.05) compared with control subjects. Survivors of acute lymphoblastic leukaemia treated with chemotherapy alone performed worse in processing speed (P < 0.001), verbal selective reminding (P = 0.01), and academics (P < 0.05) compared to population norms and performed better than survivors treated with cranial radiation therapy on verbal selective reminding (P = 0.02), processing speed (P = 0.05) and memory span (P = 0.009). There were significant associations between neurocognitive performance and brain imaging, particularly for frontal and temporal white and grey matter volume. Survivors of acute lymphoblastic leukaemia treated with chemotherapy alone demonstrated significant long-term differences in neurocognitive function and altered neuroanatomical integrity. These results suggest substantial region-specific white matter alterations in survivors of acute lymphoblastic leukaemia possibly resulting in restricted radial diffusion due to the compaction of neuronal fibres.	[Edelmann, Michelle N.; Krull, Kevin R.; Robison, Leslie L.; Hudson, Melissa M.] St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA; [Liu, Wei; Srivastava, Deo Kumar] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Glass, John O.; Ji, Qing; Ogg, Robert J.; Sabin, Noah D.; Reddick, Wilburn E.] St Jude Childrens Res Hosp, Dept Radiol Sci, Memphis, TN 38105 USA; [Hudson, Melissa M.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA		Krull, KR (corresponding author), St Jude Childrens Res Hosp, Dept Epidemiol & Canc Control, 262 Danny Thomas Pl,MS 735, Memphis, TN 38105 USA.	kevin.krull@stjude.org	Robison, Leslie/N-8122-2018; Sabin, Noah/N-8144-2018; Krull, Kevin R/N-3882-2018; Srivastava, Deo Kumar/P-2435-2017; Reddick, Wilburn E/G-8763-2018; Hudson, Melissa M/N-4441-2018	Sabin, Noah/0000-0002-7584-2574; Krull, Kevin R/0000-0002-0476-7001; Srivastava, Deo Kumar/0000-0001-6693-8120; Reddick, Wilburn E/0000-0002-1054-1201; Hudson, Melissa M/0000-0001-6984-2407; Glass, John/0000-0001-9679-2054	Cancer Centre Support (CORE) grant from the National Cancer Institute [CA21765]; National Institute for Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD049888]; National Centre for Research Resources [RR029005]; ALSACAmerican Lebanese Syrian Associated Charities (ALSAC); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD049888] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA021765, R01CA090246] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR029005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007507] Funding Source: NIH RePORTER	This work was supported by the Cancer Centre Support (CORE) grant CA21765 from the National Cancer Institute, grant HD049888 from the National Institute for Child Health and Human Development, grant RR029005 from the National Centre for Research Resources, and by ALSAC.	Armstrong GT, 2013, JNCI-J NATL CANCER I, V105, P899, DOI 10.1093/jnci/djt089; Assaf Y, 2006, AM J NEURORADIOL, V27, P1717; Benton A, 1983, MULTILINGUAL APHASI; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Carey ME, 2008, AM J NEURORADIOL, V29, P792, DOI 10.3174/ajnr.A0904; Conners CK., 2001, CONNERS CONTINUOUS P; Delis D.C., 2000, CALIFORNIA VERBAL LE; Dellani PR, 2008, J MAGN RESON IMAGING, V27, P1250, DOI 10.1002/jmri.21364; Genschaft M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078599; Glass JO, 2006, MAGN RESON IMAGING, V24, P785, DOI 10.1016/j.mri.2006.02.001; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hertzberg H, 1997, MED PEDIATR ONCOL, V28, P387, DOI 10.1002/(SICI)1096-911X(199706)28:6<387::AID-MPO1>3.0.CO;2-C; Howlander N, 2011, SEER CANC STAT REV 1; Hudson MM, 2013, JAMA-J AM MED ASSOC, V309, P2371, DOI 10.1001/jama.2013.6296; Hudson MM, 2011, PEDIATR BLOOD CANCER, V56, P825, DOI 10.1002/pbc.22875; Huppi PS, 2006, SEMIN FETAL NEONAT M, V11, P489, DOI 10.1016/j.siny.2006.07.006; Khong PL, 2006, J CLIN ONCOL, V24, P884, DOI 10.1200/JCO.2005.02.4505; Kochunov P, 2007, NEUROIMAGE, V35, P478, DOI 10.1016/j.neuroimage.2006.12.021; Krull KR, 2013, J CLIN ONCOL, V31, P4407, DOI 10.1200/JCO.2012.48.2315; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Mariotto AB, 2009, CANCER EPIDEM BIOMAR, V18, P1033, DOI 10.1158/1055-9965.EPI-08-0988; Metzler-Baddeley C, 2011, J NEUROSCI, V31, P13236, DOI 10.1523/JNEUROSCI.2317-11.2011; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Peterson CC, 2008, PEDIATR BLOOD CANCER, V51, P99, DOI 10.1002/pbc.21544; Peterson DJ, 2011, J CHILD NEUROL, V26, P1296, DOI 10.1177/0883073811405662; Porto L, 2008, EUR RADIOL, V18, P2691, DOI 10.1007/s00330-008-1038-2; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Reddick WE, 2005, AM J NEURORADIOL, V26, P1263; REYNOLDS C. R., 2007, TEST MEMORY LEARNING; Schuitema I, 2013, J CLIN ONCOL, V31, P3378, DOI 10.1200/JCO.2012.46.7050; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Styner Martin, 2006, Insight J, P242; Trites R. L., 1977, NEUROPSYCHOLOGICAL T; Vestergaard M, 2011, J COGNITIVE NEUROSCI, V23, P2135, DOI 10.1162/jocn.2010.21592; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wolfson, 1993, HALSTEAD REITAN NEUR; Woodcock R. W., 2001, WOODCOCKJOHNSON 3 TE; Yu HJ, 2012, NEUROIMAGE, V59, P3713, DOI 10.1016/j.neuroimage.2011.10.053; Zeller B, 2013, J CLIN ONCOL, V31, P2078, DOI 10.1200/JCO.2012.47.4031	44	66	68	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2014	137		11				2973	2983		10.1093/brain/awu230			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX2GG	WOS:000346760900020	25125614	Bronze, Green Published			2022-02-06	
J	Hartings, JA; Wilson, JA; Hinzman, JM; Pollandt, S; Dreier, JP; DiNapoli, V; Ficker, DM; Shutter, LA; Andaluz, N				Hartings, Jed A.; Wilson, J. Adam; Hinzman, Jason M.; Pollandt, Sebastian; Dreier, Jens P.; DiNapoli, Vince; Ficker, David M.; Shutter, Lori A.; Andaluz, Norberto			Spreading Depression in Continuous Electroencephalography of Brain Trauma	ANNALS OF NEUROLOGY			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; FOCAL CEREBRAL-ISCHEMIA; INJURED HUMAN BRAIN; PERIINFARCT DEPOLARIZATIONS; MALIGNANT STROKE; BREACH RHYTHM; EEG; CORTEX; SEIZURES; SPIKES	ObjectiveCortical spreading depolarizations are a pathophysiological mechanism and candidate target for advanced monitoring in acute brain injury. Here we investigated manifestations of spreading depolarization in continuous electroencephalography (EEG) as a broadly applicable, noninvasive method for neuromonitoring. MethodsEighteen patients requiring surgical treatment of traumatic brain injury were monitored by invasive electrocorticography (ECoG; subdural electrodes) and noninvasive scalp EEG during intensive care. Spreading depolarizations were first identified in subdural recordings, and EEG was then examined visually and quantitatively to identify correlates. ResultsA total of 455 spreading depolarizations occurred during 65.9 days of simultaneous ECoG/EEG monitoring. For 179 of 455 events (39%), depolarizations caused temporally isolated, transient depressions of spontaneous EEG amplitudes to 57% (median) of baseline power. Depressions lasted 21 minutes (median) and occurred as suppressions of high-amplitude delta activity present as a baseline pattern in the injured hemisphere. For 62 of 179 (35%) events, isolated depressions showed a clear spread of depression between EEG channels with delays of 17 minutes (median), sometimes spanning the entire hemisphere. A further 188 of 455 (41%) depolarizations were associated with continuous EEG depression that lasted hours to days due to ongoing depolarizations. Depolarizations were also evidenced in EEG as shifts in direct current potentials. InterpretationLeAo's spreading depression can be observed in clinically standard, continuous scalp EEG, and underlying depolarizations can spread widely across the injured cerebral hemisphere. These results open the possibility of monitoring noninvasively a neuronal pathophysiological mechanism in a wide range of disorders including ischemic stroke, subarachnoid hemorrhage, and brain trauma, and suggest a novel application for continuous EEG. Ann Neurol 2014;76:681-694	[Hartings, Jed A.; Wilson, J. Adam; Hinzman, Jason M.; DiNapoli, Vince; Shutter, Lori A.; Andaluz, Norberto] Univ Cincinnati, Dept Neurosurg, Coll Med, Cincinnati, OH 45267 USA; [Hartings, Jed A.; Shutter, Lori A.; Andaluz, Norberto] Univ Cincinnati, Neurosci Inst, Neurotrauma Ctr, Cincinnati, OH 45267 USA; [Hartings, Jed A.; DiNapoli, Vince; Shutter, Lori A.; Andaluz, Norberto] Mayfield Clin, Cincinnati, OH USA; [Pollandt, Sebastian; Ficker, David M.; Shutter, Lori A.] Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA; [Dreier, Jens P.] Charite, Dept Expt Neurol, Ctr Stroke Res, D-13353 Berlin, Germany; [Dreier, Jens P.] Charite, Ctr Stroke Res, Dept Neurol, D-13353 Berlin, Germany		Hartings, JA (corresponding author), Univ Cincinnati, Dept Neurosurg, 231 Albert Sabin Way,ML0517, Cincinnati, OH 45267 USA.	jed.hartings@uc.edu	Shutter, Lori A/G-2957-2013; Pollandt, Sebastian/I-8055-2019	Pollandt, Sebastian/0000-0003-1540-7439; Dreier, Jens/0000-0001-7459-2828; Hartings, Jed/0000-0001-8583-3471; Shutter, Lori/0000-0002-1390-0628	US Army CDMRP PH/TBI Research Program [W81XWH-08-2-0016]; Mayfield Education and Research Foundation; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG DR323/5-1]; Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin)Federal Ministry of Education & Research (BMBF) [01 EO 0801]; Bundesministerium fur Bildung und Forschung (Bernstein Center for Computational Neuroscience Berlin)Federal Ministry of Education & Research (BMBF) [01GQ1001C B2]	This work was funded by the US Army CDMRP PH/TBI Research Program (Contract No. W81XWH-08-2-0016) and the Mayfield Education and Research Foundation. J.P.D. acknowledges support from the Deutsche Forschungsgemeinschaft (DFG DR323/5-1) and the Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 0801; Bernstein Center for Computational Neuroscience Berlin 01GQ1001C B2).	[Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Brigo F, 2011, CLIN NEUROPHYSIOL, V122, P2116, DOI 10.1016/j.clinph.2011.07.024; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A; COBB WA, 1979, ELECTROEN CLIN NEURO, V47, P251, DOI 10.1016/0013-4694(79)90278-5; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; FAUGHT E, 1993, STROKE, V24, P609, DOI 10.1161/01.STR.24.4.609; Foreman B, 2012, CRIT CARE, V16, DOI 10.1186/cc11230; Gorji A, 2004, EUR J NEUROSCI, V19, P3371, DOI 10.1111/j.0953-816X.2004.03436.x; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2006, J CEREBR BLOOD F MET, V26, P696, DOI 10.1038/sj.jcbfm.9600223; Hartings JA, 2013, ACTA NEUROCHIR SUPPL, V115, P131, DOI 10.1007/978-3-7091-1192-5_27; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; Kobayashi K, 2005, EPILEPSIA, V46, P397, DOI 10.1111/j.0013-9580.2005.31404.x; Kruger H, 1996, NEUROREPORT, V7, P2733; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LEAO AAP, 1947, J NEUROPHYSIOL, V10, P409, DOI 10.1152/jn.1947.10.6.409; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Tao JX, 2005, EPILEPSIA, V46, P669, DOI 10.1111/j.1528-1167.2005.11404.x; Vanhatalo S, 2005, CLIN NEUROPHYSIOL, V116, P1, DOI 10.1016/j.clinph.2004.09.015; VansHarreveld A, 1953, J NEUROPHYSIOL, V16, P352; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Voytek B, 2010, J COGNITIVE NEUROSCI, V22, P2491, DOI 10.1162/jocn.2009.21384; Wilson JA, 2013, ACTA NEUROCHIR SUPPL, V115, P67, DOI 10.1007/978-3-7091-1192-5_15; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932	40	66	66	1	20	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	NOV	2014	76	5					681	694		10.1002/ana.24256			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AS9ZE	WOS:000344596000006	25154587				2022-02-06	
J	Pandya, JD; Readnower, RD; Patel, SP; Yonutas, HM; Pauly, JR; Goldstein, GA; Rabchevsky, AG; Sullivan, PG				Pandya, Jignesh D.; Readnower, Ryan D.; Patel, Samir P.; Yonutas, Heather M.; Pauly, James R.; Goldstein, Glenn A.; Rabchevsky, Alexander G.; Sullivan, Patrick G.			N-acetylcysteine amide confers neuroprotection, improves bioenergetics and behavioral outcome following TBI	EXPERIMENTAL NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; CONTROLLED CORTICAL IMPACT; CELL-DEATH; OXIDATIVE STRESS; PROTEOMIC IDENTIFICATION; SYNAPTIC PROTEINS; TIME-COURSE; RAT MODEL; ANTIOXIDANT	Traumatic brain injury (TBI) has become a growing epidemic but no approved pharmacological treatment has been identified. Our previous work indicates that mitochondrial oxidative stress/damage and loss of bioenergetics play a pivotal role in neuronal cell death and behavioral outcome following experimental TBI. One tactic that has had some experimental success is to target glutathione using its precursor N-acetylcysteine (NAC). However, this approach has been hindered by the low CNS bioavailability of NAC. The current study evaluated a novel, cell permeant amide form of N-acetylcysteine (NACA), which has high permeability through cellular and mitochondrial membranes resulting in increased CNS bioavailability. Cortical tissue sparing, cognitive function and oxidative stress markers were assessed in rats treated with NACA, NAC, or vehicle following a TBI. At 15 days post-injury, animals treated with NACA demonstrated significant improvements in cognitive function and cortical tissue sparing compared to NAC or vehicle treated animals. NACA treatment also was shown to reduce oxidative damage (HNE levels) at 7 days post-injury. Mechanistically, post-injury NACA administration was demonstrated to maintain levels of mitochondrial glutathione and mitochondrial bioenergetics comparable to sham animals. Collectively these data provide a basic platform to consider NACA as a novel therapeutic agent for treatment of TBI. (C) 2014 Elsevier Inc All rights reserved.	[Pandya, Jignesh D.; Readnower, Ryan D.; Patel, Samir P.; Yonutas, Heather M.; Pauly, James R.; Rabchevsky, Alexander G.; Sullivan, Patrick G.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Readnower, Ryan D.; Yonutas, Heather M.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Patel, Samir P.; Rabchevsky, Alexander G.] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40536 USA; [Goldstein, Glenn A.] Karolinska Inst, Pediat Endocrinol Dept Womens & Childrens Hlth, Stockholm, Sweden		Sullivan, PG (corresponding author), Univ Kentucky, Chandler Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Dept Anat & Neurobiol,Endowed Chair, 475 BBSRB,741 South Limestone St, Lexington, KY 40536 USA.	Patsull@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS062993, R01NS069633, P30NS051220]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, F31NS086395, R01NS069633, R01NS062993] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS R01 NS062993 (JWG and PGS), R01NS069633 (AGR and PGS), NIH/NINDS P30NS051220 and funding from the Kentucky Spinal Cord and Head Injury Research Trust. We would like to thank Andrea Sebastian for expert technical assistance.	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Avery MA, 2012, CURR BIOL, V22, P596, DOI 10.1016/j.cub.2012.02.043; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bartov O, 2006, BRAIN RES, V1069, P198, DOI 10.1016/j.brainres.2005.10.079; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; CHOI DW, 1987, J NEUROSCI, V7, P357; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Dykens J.A., 1994, J NEUROCHEM, V63, P584; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Grinberg L, 2005, FREE RADICAL BIO MED, V38, P136, DOI 10.1016/j.freeradbiomed.2004.09.025; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HALLIWELL B, 1991, DRUGS, V42, P569, DOI 10.2165/00003495-199142040-00003; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Offen D, 2004, J NEUROCHEM, V89, P1241, DOI 10.1111/j.1471-4159.2004.02428.x; Offen D., 1999, BRAIN TARGETED LOW M; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Penugonda S, 2005, BRAIN RES, V1056, P132, DOI 10.1016/j.brainres.2005.07.032; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; Reed TT, 2009, J NEUROSCI RES, V87, P408, DOI 10.1002/jnr.21872; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sauerbeck A, 2011, J NEUROSCI METH, V198, P36, DOI 10.1016/j.jneumeth.2011.03.007; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sims NR, 2004, J BIOENERG BIOMEMBR, V36, P329, DOI 10.1023/B:JOBB.0000041763.63958.e7; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Stelmasiak Z, 2000, Med Sci Monit, V6, P426; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sunitha K, 2013, FREE RADICAL RES, V47, P357, DOI 10.3109/10715762.2013.781595; Thomale UW, 2005, ACT NEUR S, V95, P429; Thomale UW, 2006, INTENS CARE MED, V32, P149, DOI 10.1007/s00134-005-2845-4; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2006, J NEUROTRAUM, V23, P86, DOI 10.1089/neu.2006.23.86; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	59	66	66	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2014	257						106	113		10.1016/j.expneurol.2014.04.020			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK1MU	WOS:000338180000012	24792639	Green Accepted			2022-02-06	
J	Ponsford, J; Bayley, M; Wiseman-Hakes, C; Togher, L; Velikonja, D; McIntyre, A; Janzen, S; Tate, R				Ponsford, Jennie; Bayley, Mark; Wiseman-Hakes, Catherine; Togher, Leanne; Velikonja, Diana; McIntyre, Amanda; Janzen, Shannon; Tate, Robyn		INCOG Expert Panel	INCOG Recommendations for Management of Cognition Following Traumatic Brain Injury, Part II: Attention and Information Processing Speed	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						attention; cognitive rehabilitation; information processing; traumatic brain injury	TIME PRESSURE MANAGEMENT; CLOSED-HEAD INJURY; OF-THE-LITERATURE; DOUBLE-BLIND; WORKING-MEMORY; EXECUTIVE FUNCTION; METHYLPHENIDATE TREATMENT; CONSTRUCT-VALIDITY; REHABILITATION; DEFICITS	Introduction: Traumatic brain injury, due to its diffuse nature and high frequency of injury to frontotemporal and midbrain reticular activating systems, may cause disruption in many aspects of attention: arousal, selective attention, speed of information processing, and strategic control of attention, including sustained attention, shifting and dividing of attention, and working memory. An international team of researchers and clinicians (known as INCOG) convened to develop recommendations for the management of attentional problems. Methods: The experts selected recommendations from published guidelines and then reviewed literature to ensure that recommendations were current. Decision algorithms incorporating the recommendations based on inclusion and exclusion criteria of published trials were developed. The team then prioritized recommendations for implementation and developed audit criteria to evaluate adherence to these best practices. Results: The recommendations and discussion highlight that metacognitive strategy training focused on functional everyday activities is appropriate. Appropriate use of dual task training, environmental modifications, and cognitive behavioral therapy is also discussed. There is insufficient evidence to support mindfulness meditation and practice on de-contextualized computer-based tasks for attention. Administration of the medication methylphenidate should be considered to improve information-processing speed. Conclusion: The INCOG recommendations for rehabilitation of attention provide up-to-date guidance for clinicians treating people with traumatic brain injury.	[Ponsford, Jennie; Togher, Leanne; Tate, Robyn] NHMRC Ctr Res Excellence Traumat Brain Injury Psy, Canberra, ACT, Australia; [Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Melbourne, Vic, Australia; [Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Alfred Hosp, Melbourne, Vic, Australia; [Bayley, Mark] Univ Toronto, Toronto Rehabil Inst, Neuro Rehabil Program, Toronto, ON, Canada; [Wiseman-Hakes, Catherine] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [Togher, Leanne] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia; [Velikonja, Diana] Hamilton Hlth Sci, Acquired Brain Injury Program, Neuropsychol, Hamilton, ON, Canada; [Velikonja, Diana] McMaster Univ, DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [McIntyre, Amanda; Janzen, Shannon] Lawson Hlth Res Inst, London, ON, Canada; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia; [Tate, Robyn] Univ Sydney, Sydney Med Sch Northern, Kolling Inst, Rehabil Res Ctr, Sydney, NSW 2006, Australia		Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Togher, Leanne/AAC-7083-2019; Wiseman-Hakes, Catherine/AAC-8303-2021	Wiseman-Hakes, Catherine/0000-0001-8441-884X; Bayley, Mark/0000-0001-7860-9463; Togher, Leanne/0000-0002-4518-6748	Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University; Ontario Neurotrauma Foundation (ONF)	The authors gratefully acknowledge the support of the Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University, and the Ontario Neurotrauma Foundation (ONF) for their support of this project.	ADAPTE Collaboration, 2009, ADAPTE PROC RES TOOL; [Anonymous], AGREE ADV SCI PRACT; Arnsten AFT, 2005, BEHAV BRAIN FUNCT, V1, DOI 10.1186/1744-9081-1-2; Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Baddeley A.D., 1986, WORKING MEMORY; Banks S, 2007, J CLIN SLEEP MED, V3, P519; Bayley M., 2007, ABIKUS EVIDENCE BASE; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Ben-Yishay Y., 1987, NEUROPSYCHOLOGICAL R, P165; Benson D.F., 1986, FRONTAL LOBES; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Cappa SF, 2003, EUR J NEUROL, V10, P11, DOI 10.1046/j.1468-1331.2003.00537.x; Carroll LJ, 2004, J REHABIL MED S, V43, P84; Chen AJW, 2011, BRAIN, V134, P1541, DOI 10.1093/brain/awr067; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; Couillet J, 2010, NEUROPSYCHOL REHABIL, V20, P321, DOI 10.1080/09602010903467746; Dirette DK, 1999, OCCUP THER J RES, V19, P223, DOI 10.1177/153944929901900401; Evans JJ, 2009, J INT NEUROPSYCH SOC, V15, P112, DOI 10.1017/S1355617708090152; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Gansler D A, 1991, Arch Clin Neuropsychol, V6, P335, DOI 10.1016/0887-6177(91)90010-7; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, J CLIN EXP IN PRESS; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Hart T, 2009, NEUROPSYCHOLOGY, V23, P729, DOI 10.1037/a0016153; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; James W., 1890, PRINCIPLES PSYCHOL; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Knight R. T, 2002, PRINCIPLES FRONTAL L, P51, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0004; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; Lindsay P, 2008, CAN MED ASSOC J, V179, pS1, DOI 10.1503/cmaj.081148.R2; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; Murray LL, 2006, J COMMUN DISORD, V39, P37, DOI 10.1016/j.jcomdis.2005.06.001; NEISTADT ME, 1994, AM J OCCUP THER, V48, P421, DOI 10.5014/ajot.48.5.421; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; Palmese CA, 2000, BRAIN INJURY, V14, P535; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; Pavlovskaya M, 2007, BRAIN INJURY, V21, P489, DOI 10.1080/02699050701311117; Penkam I, 2004, J COG REHABIL, V2, P13; Pero S, 2006, BRAIN INJURY, V20, P1207, DOI 10.1080/02699050600983271; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Renison B, 2012, J INT NEUROPSYCH SOC, V18, P440, DOI 10.1017/S1355617711001883; Robertson I, 1988, Brain Inj, V2, P151, DOI 10.3109/02699058809150939; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Rugg M. D., 1992, NEUROPSYCHOLOGY CONS, P91, DOI [10.1016/B978-0-12-498045-7.50010-4, DOI 10.1016/B978-0-12-498045-7.50010-4]; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; Schneider WN, 1999, BRAIN INJURY, V13, P863; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Sloan S., 2012, TRAUMATIC BRAIN INJU, P99; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Sweeney S, 2010, NEUROPSYCHOL REHABIL, V20, P239, DOI 10.1080/09602010903080531; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate R, 2014, J HEAD TRAUMA REHAB, V29, P338, DOI 10.1097/HTR.0000000000000068; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Vallat-Azouvi C, 2009, BRAIN INJURY, V23, P585, DOI 10.1080/02699050902970711; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WEBSTER JS, 1983, INT J CLIN NEUROPSYC, V5, P69; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; Whyte J, 2010, DELISAS PHYS MED REH, V5, P575; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; WILSON C, 1992, NEUROPSYCHOL REHABIL, V2, P193; Winkens I, 2009, CLIN REHABIL, V23, P79, DOI 10.1177/0269215508097855; Winkens I, 2009, ARCH PHYS MED REHAB, V90, P1672, DOI 10.1016/j.apmr.2009.04.016; Wiseman-Hakes C, 2013, BRAIN INJURY, V27, P1364, DOI 10.3109/02699052.2013.823663; Wood R L, 1987, Int Disabil Stud, V9, P149; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; WOOD RL, 1986, J HEAD TRAUMA REHAB, V1, P43, DOI DOI 10.1097/00001199-198609000-00008; Zickefoose S, 2013, BRAIN INJURY, V27, P707, DOI 10.3109/02699052.2013.775484; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	124	66	67	2	56	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					321	337		10.1097/HTR.0000000000000072			17	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300009	24984095				2022-02-06	
J	Claassen, J; Albers, D; Schmidt, JM; De Marchis, GM; Pugin, D; Falo, CM; Mayer, SA; Cremers, S; Agarwal, S; Elkind, MSV; Connolly, ES; Dukic, V; Hripcsak, G; Badjatia, N				Claassen, Jan; Albers, David; Schmidt, J. Michael; De Marchis, Gian Marco; Pugin, Deborah; Falo, Christina Maria; Mayer, Stephan A.; Cremers, Serge; Agarwal, Sachin; Elkind, Mitchell S. V.; Connolly, E. Sander; Dukic, Vanja; Hripcsak, George; Badjatia, Neeraj			Nonconvulsive Seizures in Subarachnoid Hemorrhage Link Inflammation and Outcome	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; C-REACTIVE PROTEIN; STATUS EPILEPTICUS; INTRACEREBRAL HEMORRHAGE; RESPONSE SYNDROME; TNF-ALPHA; RECEPTOR; STROKE; MECHANISMS; MANAGEMENT	Objective: Nonconvulsive seizures (NCSz) are frequent following acute brain injury and have been implicated as a cause of secondary brain injury, but mechanisms that cause NCSz are controversial. Proinflammatory states are common after many brain injuries, and inflammation-mediated changes in blood-brain barrier permeability have been experimentally linked to seizures. Methods: In this prospective observational study of aneurysmal subarachnoid hemorrhage (SAH) patients, we explored the link between the inflammatory response following SAH and in-hospital NCSz studying clinical (systemic inflammatory response syndrome [SIRS]) and laboratory (tumor necrosis factor receptor 1 [TNF-R1], high-sensitivity C-reactive protein [hsCRP]) markers of inflammation. Logistic regression, Cox proportional hazards regression, and mediation analyses were performed to investigate temporal and causal relationships. Results: Among 479 SAH patients, 53 (11%) had in-hospital NCSz. Patients with in-hospital NCSz had a more pronounced SIRS response (odds ratio [OR]=1.9 per point increase in SIRS, 95% confidence interval [CI]=1.3-2.9), inflammatory surges were more likely immediately preceding NCSz onset, and the negative impact of SIRS on functional outcome at 3 months was mediated in part through in-hospital NCSz. In a subset with inflammatory serum biomarkers, we confirmed these findings linking higher serum TNF-R1 and hsCRP to in-hospital NCSz (OR=1.2 per 20-point hsCRP increase, 95% CI=1.1-1.4; OR=2.5 per 100-point TNF-R1 increase, 95% CI=2.1-2.9). The association of inflammatory biomarkers with poor outcome was mediated in part through NCSz. Interpretation: In-hospital NCSz were independently associated with a proinflammatory state following SAH as reflected in clinical symptoms and serum biomarkers of inflammation. Our findings suggest that inflammation following SAH is associated with poor outcome and that this effect is at least in part mediated through in-hospital NCSz.	[Claassen, Jan; Schmidt, J. Michael; De Marchis, Gian Marco; Pugin, Deborah; Falo, Christina Maria; Mayer, Stephan A.; Agarwal, Sachin; Badjatia, Neeraj] Columbia Univ, Coll Phys & Surg, Dept Neurol, Div Crit Care Neurol, New York, NY 10032 USA; [Claassen, Jan] Columbia Univ, Coll Phys & Surg, Dept Neurol, Comprehens Epilepsy Ctr, New York, NY 10032 USA; [Claassen, Jan; Mayer, Stephan A.; Agarwal, Sachin; Connolly, E. Sander; Badjatia, Neeraj] Columbia Univ, Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; [Albers, David; Hripcsak, George] Columbia Univ, Coll Phys & Surg, Dept Biomed Informat, New York, NY 10032 USA; [Cremers, Serge] Columbia Univ, Coll Phys & Surg, Irving Inst, Biomarkers Core Lab, New York, NY 10032 USA; [Elkind, Mitchell S. V.] Columbia Univ, Coll Phys & Surg, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Elkind, Mitchell S. V.] Columbia Univ, Coll Phys & Surg, Div Stroke, Dept Neurol, New York, NY 10032 USA; [Dukic, Vanja] Univ Colorado, Dept Appl Math, Boulder, CO 80309 USA		Claassen, J (corresponding author), Columbia Univ, Div Crit Care Neurol, 177 Ft Washington Ave,MHB 8 Ctr,Room 300, New York, NY 10032 USA.	jc1439@columbia.edu	De Marchis, Gian Marco/J-5414-2019; Claassen, Jan/AAA-5451-2020; Badjatia, Neeraj/AAS-4855-2021; Dukic, Vanja/AAI-1494-2020	De Marchis, Gian Marco/0000-0002-0342-9780; Dukic, Vanja/0000-0002-0348-0834; Badjatia, Neeraj/0000-0003-1509-9034; Schmidt, J. Michael/0000-0001-8141-2944	NIH National Center for Advancing Translational Sciences [UL1 TR000040, UL1 RR024156]; National Library of Medicine, "Discovering and Applying Knowledge in Clinical Databases" [R01 LM006910]; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBBEP3_139388]; Swisslife Jubilaumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr. Ettore Balli; De Quervain Research Grant; Dana Foundation; National Science FoundationNational Science Foundation (NSF) [1211668]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000040] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM006910] Funding Source: NIH RePORTER	This publication was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1 TR000040 (formerly the National Center for Research Resources, grant number UL1 RR024156). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Both J.C. and N.B. received grants through this funding mechanism. Additional support for this work included a grant from the National Library of Medicine, "Discovering and Applying Knowledge in Clinical Databases" (R01 LM006910; G. H., D. A.). G. M. D. M. received grants from the Swiss National Science Foundation (PBBEP3_139388), Swisslife Jubilaumsstiftung for Medical Research, Swiss Neurological Society, and Fondazione Dr. Ettore Balli, and a De Quervain Research Grant. J.M.S. received a grant from the Dana Foundation. V. D. received grants from National Science Foundation (#1211668) and the NIH.	Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Badjatia N, 2011, STROKE, V42, P2436, DOI 10.1161/STROKEAHA.111.614685; Bernstein LH, 2007, CLIN CHEM LAB MED, V45, P1566, DOI 10.1515/CCLM.2007.334; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2013, ANN NEUROL, V74, P53, DOI 10.1002/ana.23859; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; DUNCOMBE AS, 1988, NEW ENGL J MED, V319, P1227; Elkind MS, 2002, STROKE, V33, P31, DOI 10.1161/hs0102.100531; Frigerio F, 2012, EPILEPSIA, V53, P1887, DOI 10.1111/j.1528-1167.2012.03666.x; Furuya K, 2001, STROKE, V32, P2665, DOI 10.1161/hs3211.098535; Greenhalgh AD, 2012, DIS MODEL MECH, V5, P823, DOI 10.1242/dmm.008557; Haley EC, 2005, STROKE, V36, P1006, DOI 10.1161/01.STR.0000163053.77982.8d; Hanafy KA, 2010, J NEUROL SCI, V291, P69, DOI 10.1016/j.jns.2009.12.023; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Komotar RJ, 2009, NEUROSURGERY, V64, P397, DOI 10.1227/01.NEU.0000338946.42939.C7; KOMOTAR RJ, 2009, NEUROSURGERY, V64, P411; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Librizzi L, 2012, ANN NEUROL, V72, P82, DOI 10.1002/ana.23567; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Marchi N, 2012, EPILEPSIA, V53, P1877, DOI 10.1111/j.1528-1167.2012.03637.x; Marchi N, 2011, EPILEPSIA, V52, P1627, DOI 10.1111/j.1528-1167.2011.03080.x; Marchi N, 2009, NEUROBIOL DIS, V33, P171, DOI 10.1016/j.nbd.2008.10.002; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Meierkord H, 2010, EUR J NEUROL, V17, P348, DOI 10.1111/j.1468-1331.2009.02917.x; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pearl J., 2009, CAUSALITY MODELS REA; Piccinini AM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/672395; Pinilla JC, 1998, SURGERY, V124, P799, DOI 10.1067/msy.1998.91365; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Riazi K, 2008, P NATL ACAD SCI USA, V105, P17151, DOI 10.1073/pnas.0806682105; Rogawski, 2012, JASPERS BASIC MECH E; Rossato M, 2012, P NATL ACAD SCI USA, V109, pE3101, DOI 10.1073/pnas.1209100109; Rossetti AO, 2011, NEUROCRIT CARE, V14, P4, DOI 10.1007/s12028-010-9445-z; Rossetti AO, 2005, ARCH NEUROL-CHICAGO, V62, P1698, DOI 10.1001/archneur.62.11.1698; Sarrafzadeh A, 2010, NEUROCRIT CARE, V13, P339, DOI 10.1007/s12028-010-9432-4; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Sutter R, 2013, CRIT CARE MED, V41, P1526, DOI 10.1097/CCM.0b013e318287f2ac; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646; Zhang SH, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006778.pub2; Ziv Y, 2007, STROKE, V38, P774, DOI 10.1161/01.STR.0000255784.27298.23	50	66	66	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	MAY	2014	75	5					771	781		10.1002/ana.24166			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AJ5EV	WOS:000337706100017	24771589	Green Accepted			2022-02-06	
J	Pandit, V; Rhee, P; Hashmi, A; Kulvatunyou, N; Tang, A; Khalil, M; O'Keeffe, T; Green, D; Friese, RS; Joseph, B				Pandit, Viraj; Rhee, Peter; Hashmi, Ammar; Kulvatunyou, Narong; Tang, Andrew; Khalil, Mazhar; O'Keeffe, Terence; Green, Donald; Friese, Randall S.; Joseph, Bellal			Shock index predicts mortality in geriatric trauma patients: An analysis of the National Trauma Data Bank	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Geriatric; shock index; vitals on presentation; mortality; blood transfusion	110 MM HG; REDEFINING HYPOTENSION; VITAL SIGNS; HEART-RATE; CORRELATE; UTILITY; BEGINS	BACKGROUND Heart rate and systolic blood pressure are unreliable in geriatric trauma patients. Shock index (SI) (heart rate/systolic blood pressure) is a simple marker of worse outcomes after injury. The aim of this study was to assess the utility of SI in predicting outcomes. We hypothesized that SI predicts mortality in geriatric trauma patients. METHODS We performed a 4-year (2007-2010) retrospective analysis using the National Trauma Data Bank. Patients 65 years or older were included. Transferred patients, patients dead on arrival, missing vitals on presentation, and patients with burns and traumatic brain injury were excluded. A cutoff value of SI greater than or equal to 1 (sensitivity, 81%; specificity, 79%) was used to define hemodynamic instability. The primary outcome measure was mortality. Secondary outcome measures were need for blood transfusion, need for exploratory laparotomy, and development of in-hospital complications. Multiple logistic regressions were performed. RESULTS A total of 485,595 geriatric patients were reviewed, of whom 217,190 were included. The mean (SD) age was 77.7 (7.1) years, 60% were males, median Glasgow Coma Scale (GCS) score was 14 (range, 3-15), median Injury Severity Score (ISS) was 9 (range, 4-18), and mean (SD) SI was 0.58 (0.18). Three percent (n = 6,585) had an SI greater than or equal to 1. Patients with SI greater than or equal to 1 were more likely to require blood product requirement (p = 0.001), require an exploratory laparotomy (p = 0.01), and have in-hospital complications (p = 0.02). The overall mortality rate was 4.1% (n = 8,952). SI greater than or equal to 1 was the strongest predictor for mortality (odds ratio, 3.1; 95% confidence interval, 2.6-3.3; p = 0.001) in geriatric trauma patients. Systolic blood pressure (p = 0.09) and heart rate (p = 0.2) were not predictive of mortality. CONCLUSION SI is an accurate and specific predictor of morbidity and mortality in geriatric trauma patients. SI is superior to heart rate and systolic blood pressure for predicting mortality in geriatric trauma patients. Geriatric trauma patients with SI greater than or equal to 1 should be transferred to a Level 1 trauma center. LEVEL OF EVIDENCE Prognostic/epidemiologic study, level III.	[Pandit, Viraj; Rhee, Peter; Hashmi, Ammar; Kulvatunyou, Narong; Tang, Andrew; Khalil, Mazhar; O'Keeffe, Terence; Green, Donald; Friese, Randall S.; Joseph, Bellal] Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Allgower M, 1968, Ger Med Mon, V13, P14; ALLGOWER M, 1967, DEUT MED WOCHENSCHR, V92, P1947, DOI 10.1055/s-0028-1106070; Birkhahn RH, 2005, AM J EMERG MED, V23, P323, DOI 10.1016/j.ajem.2005.02.029; Birkhahn RH, 2003, AM J OBSTET GYNECOL, V189, P1293, DOI 10.1067/S0002-9378(03)00663-X; BROOS PLO, 1993, INJURY, V24, P365, DOI 10.1016/0020-1383(93)90096-O; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; Cancio LC, 2008, J TRAUMA, V65, P813, DOI 10.1097/TA.0b013e3181848241; Cannon CM, 2009, J TRAUMA, V67, P1426, DOI 10.1097/TA.0b013e3181bbf728; Eastridge BJ, 2007, J TRAUMA, V63, P291, DOI 10.1097/TA.0b013e31809ed924; Franklin GA, 2007, J TRAUMA, V63, P297; Hashmi A, 2014, PREDICTORS MORTALITY; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P196, DOI 10.1097/TA.0b013e3182a833ac; King RW, 1996, ACAD EMERG MED, V3, P1041, DOI 10.1111/j.1553-2712.1996.tb03351.x; Mcnab A, 2013, SURGERY, V154, P384, DOI 10.1016/j.surg.2013.05.007; Oyetunji TA, 2011, ARCH SURG-CHICAGO, V146, P865, DOI 10.1001/archsurg.2011.154; RADY MY, 1992, RESUSCITATION, V23, P227, DOI 10.1016/0300-9572(92)90006-X; RADY MY, 1994, ANN EMERG MED, V24, P685, DOI 10.1016/S0196-0644(94)70279-9; Rady MY, 1996, AM J EMERG MED, V14, P218, DOI 10.1016/S0735-6757(96)90136-9; Rogers A, 2012, AM SURGEON, V78, P711; Summers RL, 2009, RESUSCITATION, V80, P1405, DOI 10.1016/j.resuscitation.2009.09.001; Vandromme MJ, 2011, J TRAUMA, V70, P384, DOI 10.1097/TA.0b013e3182095a0a; Victorino GP, 2003, J AM COLL SURGEONS, V196, P679, DOI 10.1016/S1072-7515(03)00128-5; Zarzaur BL, 2010, J TRAUMA, V68, P1134, DOI 10.1097/TA.0b013e3181d87488	23	66	68	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2014	76	4					1111	1115		10.1097/TA.0000000000000160			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AE7FF	WOS:000334161500037	24662879				2022-02-06	
J	Ryan, NP; Anderson, V; Godfrey, C; Beauchamp, MH; Coleman, L; Eren, S; Rosema, S; Taylor, K; Catroppa, C				Ryan, Nicholas P.; Anderson, Vicki; Godfrey, Celia; Beauchamp, Miriam H.; Coleman, Lee; Eren, Senem; Rosema, Stefanie; Taylor, Kaitlyn; Catroppa, Cathy			Predictors of Very-Long-Term Sociocognitive Function after Pediatric Traumatic Brain Injury: Evidence for the Vulnerability of the Immature "Social Brain"	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; emotion perception; sociocognitive function; childhood	EMOTION RECOGNITION; CORPUS-CALLOSUM; FAMILY ENVIRONMENT; FACIAL EXPRESSION; HEAD-INJURY; PERCEPTION; CHILDHOOD; CHILDREN; DEFICITS; OUTCOMES	Emotion perception (EP) forms an integral part of social communication and is critical to attain developmentally appropriate goals. This skill, which emerges relatively early in development, is driven by increasing connectivity among regions of a distributed sociocognitive neural network and may be vulnerable to disruption from early-childhood traumatic brain injury (TBI). The present study aimed to evaluate the very-long-term effect of childhood TBI on EP, as well as examine the contribution of injury- and non-injury-related risk and resilience factors to variability in sociocognitive outcomes. Thirty-four young adult survivors of early-childhood TBI (mean [M], 20.62 years; M time since injury, 16.55 years) and 16 typically developing controls matched for age, gender, and socioeconomic status were assessed using tasks that required recognition and interpretation of facial and prosodic emotional cues. Survivors of severe childhood TBI were found to have significantly poorer emotion perception than controls and young adults with mild-to-moderate injuries. Further, poorer emotion perception was associated with reduced volume of the posterior corpus callosum, presence of frontal pathology, lower SES, and a less-intimate family environment. Our findings lend support to the vulnerability of the immature "social brain" network to early disruption and underscore the need for context-sensitive rehabilitation that optimizes early family environments to enhance recovery of EP skills after childhood TBI.	[Ryan, Nicholas P.; Anderson, Vicki; Godfrey, Celia; Eren, Senem; Rosema, Stefanie; Taylor, Kaitlyn; Catroppa, Cathy] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Parkville, Vic 3052, Australia; [Anderson, Vicki; Catroppa, Cathy] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Anderson, Vicki; Taylor, Kaitlyn; Catroppa, Cathy] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada; [Coleman, Lee] Royal Childrens Hosp, Dept Radiol, Melbourne, Vic, Australia; [Godfrey, Celia; Rosema, Stefanie] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia		Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au	Ryan, Nicholas/K-5445-2019; Catroppa, Cathy/AAX-9458-2021	Ryan, Nicholas/0000-0002-0878-8889; Catroppa, Cathy/0000-0002-9750-0436	Victorian Neurotrauma Initiative; National Health and Medical Research Council (NHMRC) FellowshipNational Health and Medical Research Council of Australia; NHMRC Career Development AwardNational Health and Medical Research Council of Australia; Victorian Government Operational Infrastructure Scheme	This work was supprted by the Victorian Neurotrauma Initiative, a National Health and Medical Research Council (NHMRC) Fellowship (to V. A.), a NHMRC Career Development Award (to C. C.), and the Victorian Government Operational Infrastructure Scheme.	Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Beauchamp MH, 2011, BRAIN INJURY, V25, P950, DOI 10.3109/02699052.2011.589791; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Cohen J., 2013, STAT POWER ANAL BEHA; Daniel A., 1983, POWER PRIVILEGE PRES; DEMOREST A, 1984, CHILD DEV, V55, P1527, DOI 10.2307/1130022; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dimoska A, 2010, J INT NEUROPSYCH SOC, V16, P369, DOI 10.1017/S1355617709991445; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gilliam M, 2011, BIOL PSYCHIAT, V69, P839, DOI 10.1016/j.biopsych.2010.11.024; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Holdnack J, 2011, ASSESSMENT, V18, P192, DOI 10.1177/1073191110394771; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Johnson MH, 2001, NAT REV NEUROSCI, V2, P475, DOI 10.1038/35081509; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S., 2012, DEV SOCIAL NEUROSCIE, P325; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; National Scientific Council on the Developing Child, 2007, 5 NAT SCI COUNC DEV; NOLLER P, 1992, J ADOLESCENCE, V15, P101, DOI 10.1016/0140-1971(92)90041-3; Noller P., 1988, ICPS FAMILY FUNCTION; Pearson, 2009, ADV CLIN SOLUTIONS W; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Schmidt AT, 2010, BRAIN INJURY, V24, P1550, DOI 10.3109/02699052.2010.523047; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Sengpiel F, 2007, CURR BIOL, V17, pR742, DOI 10.1016/j.cub.2007.06.017; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Tabachnick B.G., 2001, USING MULTIVARIATE S; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tonks J., 2007, BRAIN IMPAIR, V18, P458; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P113, DOI 10.1080/13803390902806543; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Woods D., 2012, DEV SOCIAL NEUROSCIE, P350; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K. O., 2009, PEDIAT NEUROPSYCHOLO; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	60	66	66	1	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					649	657		10.1089/neu.2013.3153			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000006	24147615				2022-02-06	
J	Qin, LY; Jing, DQ; Parauda, S; Carmel, J; Ratan, RR; Lee, FS; Cho, S				Qin, Luye; Jing, Deqiang; Parauda, Sarah; Carmel, Jason; Ratan, Rajiv R.; Lee, Francis S.; Cho, Sunghee			An Adaptive Role for BDNF Val66Met Polymorphism in Motor Recovery in Chronic Stroke	JOURNAL OF NEUROSCIENCE			English	Article						BDNF; cerebral ischemia; gait; motor function; striatum; Val66Met polymorphism	ANEURYSMAL SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN-INJURY; FUNCTIONAL RECOVERY; GENETIC VARIANT; MOUSE MODEL; MET ALLELE; PLASTICITY; CORTEX; INHIBITION; RECEPTOR	Little is known about the influence of genetic diversity on stroke recovery. One exception is the polymorphism in brain derived neurotrophic factor (BDNF), a critical neurotrophin for brain repair and plasticity. Humans have a high-frequency single nucleotide polymorphism (SNP) in the prodomain of the BDNF gene. Previous studies show that the BDNF Val66Met variant negatively affects motor learning and severity of acute stroke. To investigate the impact of this common BDNF SNP on stroke recovery, we used a mouse model that contains the human BDNF Val66Met variant in both alleles (BDNFM/M). Male BDNF+/+ and BDNFM/M littermates received sham or transient middle cerebral artery occlusion. We assessed motor function regularly for 6 months after stroke and then performed anatomical analyses. Despite reported negative association of the SNP with motor learning and acute deficits, we unexpectedly found that BDNFM/M mice displayed significantly enhanced motor/kinematic performance in the chronic phase of motor recovery, especially in ipsilesional hindlimb. The enhanced recovery was associated with significant increases in striatum volume, dendritic arbor, and elevated excitatory synaptic markers in the contralesional striatum. Transient inactivation of the contralateral striatum during recovery transiently abolished the enhanced function. This study showed an unexpected benefit of the BDNFVal66Met carriers for functional recovery, involving structural and molecular plasticity in the nonstroked hemisphere. Clinically, this study suggests a role for BDNF genotype in predicting stroke recovery and identifies a novel systems-level mechanism for enhanced motor recovery.	[Qin, Luye; Parauda, Sarah; Carmel, Jason; Ratan, Rajiv R.; Cho, Sunghee] Burke Med Res Inst, Weill Cornell Med Coll, White Plains, NY 10605 USA; [Jing, Deqiang; Lee, Francis S.] Weill Cornell Med Coll, New York, NY 10021 USA		Cho, S (corresponding author), Burke Med Res Inst, Weill Cornell Med Coll, Dept Neurosci, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	suc2002@med.cornell.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1RR024996, NS077897, HL082511, NS073796]; Dr. Miriam and Sheldon G. Adelson Foundation; Burke Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000457] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077897, K08NS073796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG014930] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health under award numbers UL1RR024996 (to S. C. and F. L.), NS077897 and HL082511 (to S. C.), and NS073796 (to J.C.), Dr. Miriam and Sheldon G. Adelson Foundation (to R. R.), and the Burke Foundation (to S. C.). We thank C. Beltran and S. Bhosle for technical assistance and Dr. E. Shipp and N. Geibel for editorial assistance.	BAMFORD J, 1987, STROKE, V18, P545, DOI 10.1161/01.STR.18.3.545; Bateup HS, 2010, P NATL ACAD SCI USA, V107, P14845, DOI 10.1073/pnas.1009874107; Bejot Y, 2008, STROKE, V39, P1945, DOI 10.1161/STROKEAHA.107.510933; Brown P, 1996, BRAIN, V119, P309, DOI 10.1093/brain/119.1.309; Calautti C, 2001, STROKE, V32, P2534, DOI 10.1161/hs1101.097401; Carmichael S Thomas, 2005, NeuroRx, V2, P396; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005; Clarkson AN, 2011, J NEUROSCI, V31, P3766, DOI 10.1523/JNEUROSCI.5780-10.2011; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Cline H, 2005, CURR BIOL, V15, pR203, DOI 10.1016/j.cub.2005.03.010; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Dang MT, 2006, P NATL ACAD SCI USA, V103, P15254, DOI 10.1073/pnas.0601758103; Darling WG, 2011, EXP NEUROL, V231, P56, DOI 10.1016/j.expneurol.2011.05.015; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Gerasimenko Y, 2008, EXP NEUROL, V209, P417, DOI 10.1016/j.expneurol.2007.07.015; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Gonzalez CLR, 2004, EUR J NEUROSCI, V20, P3442, DOI 10.1111/j.1460-9568.2004.03751.x; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; Harris Jocelyn E, 2004, Physiother Can, V56, P171, DOI 10.2310/6640.2004.00017; He XM, 2007, NEUROPSYCHOBIOLOGY, V55, P151, DOI 10.1159/000106473; Hong EJ, 2008, NEURON, V60, P610, DOI 10.1016/j.neuron.2008.09.024; Kermani P, 2005, J CLIN INVEST, V115, P653, DOI 10.1172/JCI200522655; Kim E, 2008, J NEUROSCI, V28, P4661, DOI 10.1523/JNEUROSCI.0982-08.2008; Kleim JA, 2006, NAT NEUROSCI, V9, P735, DOI 10.1038/nn1699; Kline DD, 2010, J NEUROSCI, V30, P5303, DOI 10.1523/JNEUROSCI.5503-09.2010; Kozorovitskiy Y, 2012, NATURE, V485, P646, DOI 10.1038/nature11052; Kreitzer AC, 2008, NEURON, V60, P543, DOI 10.1016/j.neuron.2008.11.005; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Longstreth WT, 1998, ARCH NEUROL-CHICAGO, V55, P1217, DOI 10.1001/archneur.55.9.1217; Martin JH, 1999, J NEUROSCI METH, V86, P145, DOI 10.1016/S0165-0270(98)00163-0; McHughen SA, 2010, CEREB CORTEX, V20, P1254, DOI 10.1093/cercor/bhp189; Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C; Mirowska-Guzel D, 2012, J NEUROIMMUNOL, V249, P71, DOI 10.1016/j.jneuroim.2012.04.011; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Nudo RJ, 2007, STROKE, V38, P840, DOI 10.1161/01.STR.0000247943.12887.d2; Pandian S, 2013, J BODYW MOV THER, V17, P495, DOI 10.1016/j.jbmt.2013.03.008; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Qin LY, 2011, J NEUROSCI, V31, P775, DOI 10.1523/JNEUROSCI.4547-10.2011; Rossignol S, 2006, PHILOS T R SOC B, V361, P1647, DOI 10.1098/rstb.2006.1889; Schaefer SY, 2009, NEUROPSYCHOLOGIA, V47, P2953, DOI 10.1016/j.neuropsychologia.2009.06.025; Seil FJ, 2000, J NEUROSCI, V20, P5367, DOI 10.1523/JNEUROSCI.20-14-05367.2000; Sen S, 2003, NEUROPSYCHOPHARMACOL, V28, P397, DOI 10.1038/sj.npp.1300053; Siironen J, 2007, STROKE, V38, P2858, DOI 10.1161/STROKEAHA.107.485441; Sklar P, 2002, MOL PSYCHIATR, V7, P579, DOI 10.1038/sj.mp.4001058; SWANSON LW, 1995, TRENDS NEUROSCI, V18, P471, DOI 10.1016/0166-2236(95)92766-J; van Meer MPA, 2010, J NEUROSCI, V30, P3964, DOI 10.1523/JNEUROSCI.5709-09.2010; Vilkki J, 2008, NEUROSURGERY, V63, P198, DOI 10.1227/01.NEU.0000320382.21577.8E; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Xie YX, 2010, J NEUROSCI, V30, P14708, DOI 10.1523/JNEUROSCI.1637-10.2010; Zeiler SR, 2013, STROKE, V44, P483, DOI 10.1161/STROKEAHA.112.676940; Zhang JY, 2010, NEUROIMAGE, V49, P2340, DOI 10.1016/j.neuroimage.2009.10.027	55	66	67	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 12	2014	34	7					2493	2502		10.1523/JNEUROSCI.4140-13.2014			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AB2HV	WOS:000331614700012	24523540	Bronze, Green Published			2022-02-06	
J	Peck, KA; Calvo, RY; Schechter, MS; Sise, CB; Kahl, JE; Shackford, MC; Shackford, SR; Sise, MJ; Blaskiewicz, DJ				Peck, Kimberly A.; Calvo, Richard Y.; Schechter, Mark S.; Sise, C. Beth; Kahl, Jessica E.; Shackford, Meghan C.; Shackford, Steven R.; Sise, Michael J.; Blaskiewicz, Donald J.			The impact of preinjury anticoagulants and prescription antiplatelet agents on outcomes in older patients with traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Anticoagulant; antiplatelet; older adult; elderly; traumatic brain injury	ELDERLY-PATIENTS; INTRACRANIAL HEMORRHAGE; MORTALITY; CLOPIDOGREL	BACKGROUND: Anticoagulants and prescription antiplatelet (ACAP) agents widely used by older adults have the potential to adversely affect traumatic brain injury (TBI) outcomes. We hypothesized that TBI patients on preinjury ACAP agents would have worse outcomes than non-ACAP patients. METHODS: This was a 5.5-year retrospective review of patients 55 years and older admitted to a Level I trauma center with blunt force TBI. Patients were categorized as ACAP (warfarin, clopidogrel, dipyridamole/aspirin, enoxaparin, subcutaneous heparin, or multiple agents) or non-ACAP. ACAP patients were further stratified by class of agent (anticoagulant or antiplatelet). Initial and subsequent head computerized tomographic results were examined for type and progression of TBI. Patient preadmission living status and discharge destination were identified. Primary outcome was in-hospital mortality. Secondary outcomes were progression of initial TBI, development of new intracranial hemorrhage (remote from initial), and the need for an increased level of care at discharge. RESULTS: A total of 353 patients met inclusion criteria: 273 non-ACAP (77%) and 80 ACAP (23%). Upon exclusion of three patients taking a combination of agents, 350 were available for advanced analyses. ACAP status was significantly related to in-hospital mortality. After adjustment for patient and injury characteristics, anticoagulant users were more likely than non-ACAP patients to show progression of initial hemorrhage and develop a new hemorrhagic focus. However, compared with non-ACAP users, antiplatelet users were more likely to die in the hospital. Among survivors to discharge, anticoagulant users were more likely to be discharged to a care facility, but this finding was not robust to adjustment. CONCLUSION: Older TBI patients on preinjury ACAP agents experience a comparatively higher rate of inpatient mortality and other adverse outcomes caused by the effects of antiplatelet agents. Our findings should inform decision making regarding prognosis and caution against grouping anticoagulant and antiplatelet users together in considering outcomes. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Peck, Kimberly A.; Calvo, Richard Y.; Schechter, Mark S.; Sise, C. Beth; Kahl, Jessica E.; Shackford, Meghan C.; Shackford, Steven R.; Sise, Michael J.; Blaskiewicz, Donald J.] Scripps Mercy Hosp, Trauma Serv, San Diego, CA 92103 USA		Peck, KA (corresponding author), Scripps Mercy Hosp, Trauma Serv MER 62, 4077 5th Ave, San Diego, CA 92103 USA.	peck.kimberly@scrippshealth.org		Calvo, Richard/0000-0001-9147-2668			Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; Fabbri A, 2013, CRIT CARE, V17, DOI 10.1186/cc12575; Faul M, 2010, TRAUMATIC BRAIN INJU; Ferraris VA, 2012, J TRAUMA ACUTE CARE, V73, P492, DOI 10.1097/TA.0b013e31825b85f1; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Karni A, 2001, AM SURGEON, V67, P1098; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Siracuse JJ, 2010, SURGERY, V148, P724, DOI 10.1016/j.surg.2010.07.014; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	14	66	69	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2014	76	2					431	436		10.1097/TA.0000000000000107			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AH8KG	WOS:000336386100025	24458049				2022-02-06	
J	Taccone, FS; Su, FH; De Deyne, C; Abdellhai, A; Pierrakos, C; He, XR; Donadello, K; Dewitte, O; Vincent, JL; De Backer, D				Taccone, Fabio Silvio; Su, Fuhong; De Deyne, Cathy; Abdellhai, Ali; Pierrakos, Charalampos; He, Xinrong; Donadello, Katia; Dewitte, Olivier; Vincent, Jean-Louis; De Backer, Daniel			Sepsis Is Associated With Altered Cerebral Microcirculation and Tissue Hypoxia in Experimental Peritonitis	CRITICAL CARE MEDICINE			English	Article						brain oxygenation; cerebral microcirculation; microdialysis; sepsis; sidestream dark-field videomicroscopy	TRAUMATIC BRAIN-INJURY; PERFUSION-PRESSURE; OXYGEN-TENSION; ORGAN FAILURE; BLOOD-FLOW; METABOLISM; DYSFUNCTION; AUTOREGULATION; HETEROGENEITY; REACTIVITY	Objective: Alterations in cerebral microvascular blood flow may develop during sepsis, but the consequences of these abnormalities on tissue oxygenation and metabolism are not well defined. We studied the evolution of microvascular blood flow, brain oxygen tension (Pbo(2)), and metabolism in a clinically relevant animal model of septic shock. Design: Prospective randomized animal study. Setting: University hospital research laboratory. Subjects: Fifteen invasively monitored and mechanically ventilated female sheep. Interventions: The sheep were randomized to fecal peritonitis (n = 10) or a sham procedure (n = 5), and craniectomies were performed to enable evaluation of cerebral microvascular blood flow, Pbo(2), and metabolism. The microvascular network of the left frontal cortex was evaluated (at baseline, 6, 12, and 18 hr) using sidestream dark-field videomicroscopy. Using an off-line semiquantitative method, functional capillary density and the proportion of small perfused vessels were calculated. Pbo(2) was measured hourly by a parenchymal Clark electrode, and cerebral metabolism was assessed by the lactate/pyruvate ratio using brain microdialysis; both these systems were placed in the right frontal cortex. Measurement and Main Results: In septic animals, cerebral functional capillary density (from 3.1 0.5 to 1.9 +/- 0.4 n/mm, p < 0.001) and proportion of small perfused vessels (from 98% +/- 2% to 84% +/- 7%, p = 0.004) decreased over the 18-hour study period. Concomitantly, Pbo(2) decreased (61 +/- 5 to 41 +/- 7 mm Hg, p < 0.001) and lactate/pyruvate ratio increased (23 +/- 5 to 36 +/- 19, p < 0.001). At 18 hours, when shock was present, animals with a mean arterial pressure less than 65 mm Hg (n = 6) had similar functional capillary density, proportion of small perfused vessels, and Pbo(2) values but significantly higher lactate/pyruvate ratio (46 +/- 18 vs 20 +/- 4, p = 0.009) compared with animals with an mean arterial pressure of 65-70 mm Hg (n = 4). Conclusions: Impaired cerebral microcirculation during sepsis is associated with progressive impairment in Pbo(2) and brain metabolism. Development of severe hypotension was responsible for a further increase in anaerobic metabolism. These alterations may play an important role in the pathogenesis of brain dysfunction during sepsis.	[Taccone, Fabio Silvio; Su, Fuhong; Abdellhai, Ali; Pierrakos, Charalampos; He, Xinrong; Donadello, Katia; Vincent, Jean-Louis; De Backer, Daniel] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [De Deyne, Cathy] ZOL St Jan, Dept Anesthesia & Intens Care, Genk, Belgium; [Dewitte, Olivier] Univ Libre Bruxelles, Erasme Hosp, Dept Neurosurg, Brussels, Belgium		Taccone, FS (corresponding author), Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium.	ftaccone@ulb.ac.be	DONADELLO, KATIA/R-9442-2018; De Backer, Daniel/AAF-4177-2020	DONADELLO, KATIA/0000-0002-7053-8434; De Backer, Daniel/0000-0001-9841-5762; He, Xinrong/0000-0003-3426-1420; Vincent, Jean-Louis/0000-0001-6011-6951; Su, Fuhong/0000-0003-4962-7907	Fondation Erasme (Bourse de Recherche); Integra Lifesciences Service SAS; European Critical Care Research Network (ECCRN)	Supported, in part, by grants from Fondation Erasme (Bourse de Recherche 2008-2011) and Integra Lifesciences Service SAS.; Dr. Taccone received the Basic Science Research Award from the European Critical Care Research Network (ECCRN; October 2009). The remaining authors have disclosed that they do not have any potential conflicts of interest.	Awan ZA, 2011, MICROVASC RES, V81, P245, DOI 10.1016/j.mvr.2011.02.004; Bateman RM, 2007, AM J PHYSIOL-HEART C, V293, pH448, DOI 10.1152/ajpheart.00035.2007; Cardoso FL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035919; Comim CM, 2011, INTENS CARE MED, V37, P711, DOI 10.1007/s00134-011-2151-2; De Backer D, 2002, AM J RESP CRIT CARE, V166, P98, DOI 10.1164/rccm.200109-016OC; Diller R, 2008, J SURG RES, V150, P3, DOI 10.1016/j.jss.2007.12.795; Doerschug KC, 2007, AM J PHYSIOL-HEART C, V293, pH1065, DOI 10.1152/ajpheart.01237.2006; Frykholm P, 2005, J NEUROSURG, V102, P1076, DOI 10.3171/jns.2005.102.6.1076; Goldman D, 2004, AM J PHYSIOL-HEART C, V287, pH2535, DOI 10.1152/ajpheart.00889.2003; Humer MF, 1996, J APPL PHYSIOL, V81, P895, DOI 10.1152/jappl.1996.81.2.895; Iacobone Emanuele, 2009, Crit Care Med, V37, pS331, DOI 10.1097/CCM.0b013e3181b6ed58; Klaus S, 2003, CARDIOVASC RES, V59, P105, DOI 10.1016/S0008-6363(03)00347-X; Knotzer H, 2006, INTENS CARE MED, V32, P170, DOI 10.1007/s00134-005-2858-z; Lawerenz J, 2010, J NEUROCHEM, V113, P502, DOI 10.1111/j.1471-4159.2010.06621.x; Legrand M, 2011, INTENS CARE MED, V37, P1534, DOI 10.1007/s00134-011-2267-4; Levy B, 2010, INTENS CARE MED, V36, P1703, DOI 10.1007/s00134-010-1938-x; MAEKAWA T, 1991, AM J EMERG MED, V9, P139, DOI 10.1016/0735-6757(91)90175-J; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P229, DOI 10.1111/j.1399-6576.2012.02783.x; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Papadopoulos MC, 1999, CLIN SCI, V96, P461, DOI 10.1042/CS19980327; Pfister D, 2008, CRIT CARE, V12, DOI 10.1186/cc6891; Rosengarten B, 2007, CEREBROVASC DIS, V23, P140, DOI 10.1159/000097051; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Sair M, 2001, CRIT CARE MED, V29, P1343, DOI 10.1097/00003246-200107000-00008; Sakr Y, 2004, CRIT CARE MED, V32, P1825, DOI 10.1097/01.CCM.0000138558.16257.3F; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Taccone FS, 2013, CURR VASC PHARMACOL, V11, P170; Taccone FS, 2010, CRIT CARE, V14, DOI 10.1186/cc9205; Taccone FS, 2010, NEUROCRIT CARE, V12, P35, DOI 10.1007/s12028-009-9289-6; Thees C, 2007, CRIT CARE, V11, DOI 10.1186/cc6185; Vachharjani V, 2005, MICROCIRCULATION, V12, P183, DOI 10.1080/10739680590904982; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Wang NS, 2013, AM J PHYSIOL-ENDOC M, V304, pE538, DOI 10.1152/ajpendo.00537.2012; Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980	39	66	70	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2014	42	2					E114	E122		10.1097/CCM.0b013e3182a641b8			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291WS	WOS:000329863400004	24196192				2022-02-06	
J	Ferreira, LCB; Regner, A; Miotto, KD; de Moura, S; Ikuta, N; Vargas, AE; Chies, JAB; Simon, D				Brasiliano Ferreira, Luiz Carlos; Regner, Andrea; Miotto, Karen Dal Lago; de Moura, Silvana; Ikuta, Nilo; Vargas, Andreia Escosteguy; Bogo Chies, Jose Artur; Simon, Daniel			Increased levels of interleukin-6,-8 and-10 are associated with fatal outcome following severe traumatic brain injury	BRAIN INJURY			English	Article						Interleukins; IL-6; IL-8; IL-10; traumatic brain injury	CEREBROSPINAL-FLUID; MAJOR TRAUMA; HEAD-INJURY; CYTOKINE; PLASMA; MORTALITY; CHILDREN; MEDIATOR; RELEASE; IL-6	Background: Despite the involvement of cytokine production in neurotrauma, there is still controversy regarding cytokines levels and clinical outcome following severe traumatic brain injury (TBI). Objective: The present study was designed to investigate whether cytokine levels (of IL-1 beta, IL-6, IL-8, IL-10, IL-12p70 and TNF-alpha) are associated with primary outcome (death or survival) after severe TBI. Methods: This prospective study enrolled 24 male patients, victims of severe TBI. Venous blood samples were taken in the Intensive Care Unit (ICU) (study entry), 24 and 48 hours later. Plasma cytokine levels were assayed by flow cytometry. Results: Severe TBI was associated with a 42% mortality rate. TBI patients had a significant increase in the levels of all cytokines measured, except for IL-1 beta, compared to controls. Statistically significant increases in the IL-10, -8 and -6 levels were observed in the non-survivors TBI patients compared to the survivors sub-group measured in the first sample (study entry) and in the subsequent sample (24 hours later). There were no significant differences in IL-1 beta, TNF-alpha and IL-12p70 levels between survivors and non-survivors in any time sampled. Conclusions: The findings indicate that increased IL-10, -8 and -6 levels may constitute an early predictor of unfavourable outcome in severe TBI patients.	[Brasiliano Ferreira, Luiz Carlos; Regner, Andrea; Ikuta, Nilo; Simon, Daniel] Univ Luterana Brasil ULBRA, Programa Posgrad Diagnost Genet & Mol, Canoas, Brazil; [Regner, Andrea; Simon, Daniel] Univ Luterana Brasil, Programa Posgrad Biol Celular & Mol Aplicada Saud, Canoas, Brazil; [Miotto, Karen Dal Lago; de Moura, Silvana] Univ Luterana Brasil, Curso Med, Canoas, Brazil; [Vargas, Andreia Escosteguy] FUC, Porto Alegre, RS, Brazil; [Bogo Chies, Jose Artur] Univ Fed Rio Grande do Sul, Dept Genet, Porto Alegre, RS, Brazil		Simon, D (corresponding author), Univ Luterana Brasil, PPG Biol Celular & Mol Aplicada Saude, Av Farroupilha,8001 Predio 22-5 Andar, BR-92425900 Canoas, RS, Brazil.	daniel.simon@ulbra.br	Simon, Daniel/A-9087-2011; Regner, Andrea/M-2596-2014; Chies, Jose Artur Bogo/K-9664-2015	Simon, Daniel/0000-0003-1122-8468; Regner, Andrea/0000-0002-6657-7991; Chies, Jose Artur Bogo/0000-0001-7025-0660; Vargas-Seymour, Andreia/0000-0003-3275-0829	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [484391/2007-0, 568691/2008-3]; Fundacao de Amparo a Pesquisa do Rio Grande do Sul (FAPERGS)Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [09/0041-5, 1630-25.51/09-0]	The authors report no conflicts of interest. The present study received financial support from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, grant 484391/2007-0 and 568691/2008-3) and from Fundacao de Amparo a Pesquisa do Rio Grande do Sul (FAPERGS, grant 09/0041-5, 1630-25.51/09-0).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Dalla Libera AL, 2011, BRAIN INJURY, V25, P365, DOI 10.3109/02699052.2011.556107; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015, DOI 10.1152/ajpheart.2000.279.3.H1015; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kraus J, 1996, NEUROTRAUMA, P13; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MALEFYT RD, 1991, J EXP MED, V174, P1209; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Ng PC, 2004, PEDIATRICS, V113, pE7, DOI 10.1542/peds.113.1.e7; Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Seekamp A, 2002, EUR J TRAUMA, V3, P183; Shimonkevitz R, 1999, SHOCK, V12, P10, DOI 10.1097/00024382-199907000-00002; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stensballe J, 2009, ACTA ANAESTH SCAND, V53, P515, DOI 10.1111/j.1399-6576.2008.01801.x; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039	43	66	71	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	10					1311	1316		10.3109/02699052.2014.916818			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AN2ZZ	WOS:000340455900012	24830571				2022-02-06	
J	Robbins, CA; Daneshvar, DH; Picano, JD; Gavett, BE; Baugh, CM; Riley, DO; Nowinski, CJ; McKee, AC; Cantu, RC; Stern, RA				Robbins, Clifford A.; Daneshvar, Daniel H.; Picano, John D.; Gavett, Brandon E.; Baugh, Christine M.; Riley, David O.; Nowinski, Christopher J.; McKee, Ann C.; Cantu, Robert C.; Stern, Robert A.			Self-reported concussion history: impact of providing a definition of concussion	OPEN ACCESS JOURNAL OF SPORTS MEDICINE			English	Article						concussion; self-report; sports-related concussion		Background: In recent years, the understanding of concussion has evolved in the research and medical communities to include more subtle and transient symptoms. The accepted definition of concussion in these communities has reflected this change. However, it is unclear whether this shift is also reflected in the understanding of the athletic community. What is known about the subject: Self-reported concussion history is an inaccurate assessment of someone's lifetime exposure to concussive brain trauma. However, unfortunately, in many cases it is the only available tool. Hypothesis/purpose: We hypothesize that athletes' self-reported concussion histories will be significantly greater after reading them the current definition of concussion, relative to the reporting when no definition was provided. An increase from baseline to post-definition response will suggest that athletes are unaware of the currently accepted medical definition. Study design: Cross-sectional study of 472 current and former athletes. Methods: Investigators conducted structured telephone interviews with current and former athletes between January 2010 and January 2013, asking participants to report how many concussions they had received in their lives. Interviewers then read participants a current definition of concussion, and asked them to re-estimate based on that definition. Results: The two estimates were significantly different (Wilcoxon signed rank test: z=15.636, P< 0.001). Comparison of the baseline and post-definition medians (7 and 15, respectively) indicated that the post-definition estimate was approximately twice the baseline. Follow-up analyses indicated that this effect was consistent across all levels of competition examined and across type of sport (contact versus non-contact). Conclusion: Our results indicate that athletes' current understandings of concussions are not consistent with a currently accepted medical definition. We strongly recommend that clinicians and researchers preface requests for self-reported concussion history with a definition. In addition, it is extremely important that researchers report the definition they used in published manuscripts of their work. What this study adds to existing knowledge: Our study shows that unprompted reporting of concussion history produces results that are significantly different from those provided after a definition has been given, suggesting one possible mechanism to improve the reliability of self-reported concussion history across multiple individuals.	[Robbins, Clifford A.; Daneshvar, Daniel H.; Picano, John D.; Gavett, Brandon E.; Baugh, Christine M.; Riley, David O.; Nowinski, Christopher J.; McKee, Ann C.; Cantu, Robert C.; Stern, Robert A.] Boston Univ, Ctr Study Traumat Encephalopathy, Sch Med, Boston, MA 02108 USA; [Daneshvar, Daniel H.; Baugh, Christine M.; Nowinski, Christopher J.; McKee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02108 USA; [Picano, John D.] Univ Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14228 USA; [Gavett, Brandon E.] Univ Colorado, Dept Psychol, Colorado Springs, CO 80309 USA; [Nowinski, Christopher J.; Cantu, Robert C.] Sports Legacy Inst, Waltham, MA 02451 USA; [McKee, Ann C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Boston, MA USA; [McKee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02108 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02108 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA 01742 USA		Stern, RA (corresponding author), Boston Univ, Ctr Study Traumat Encephalopathy, 72 East Concord St,Suite B-7800, Boston, MA 02118 USA.	bobstern@bu.edu	, Bob/ABA-8507-2020; Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Gavett, Brandon/0000-0003-1938-1854; Stern, Robert/0000-0002-5008-077X; Daneshvar, Daniel/0000-0003-3691-9513	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG013846] Funding Source: Medline		Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2007, NEW ENGL J MED, V356, P1787; Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, VIn: Vol 12, P386; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; NCAA, 2010, CONC MAN PLAN MEM; NFL, 2010, NEW NFL RUL DES LIM; NFL, 2012, ZACH LYST LAW; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f	19	66	66	0	6	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1179-1543			OPEN ACCESS J SPORTS	Open Access J. Sports Med.		2014	5						99	103		10.2147/OAJSM.S58005			5	Sport Sciences	Emerging Sources Citation Index (ESCI)	Sport Sciences	V04SA	WOS:000213823500012	24891816	gold, Green Published			2022-02-06	
J	Broglio, SP; Martini, D; Kasper, L; Eckner, JT; Kutcher, JS				Broglio, Steven P.; Martini, Douglas; Kasper, Luke; Eckner, James T.; Kutcher, Jeffery S.			Estimation of Head Impact Exposure in High School Football Implications for Regulating Contact Practices	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries; concussions; impact magnitude; impact frequency; football (American)	CHRONIC TRAUMATIC ENCEPHALOPATHY; PROFESSIONAL FOOTBALL; BRAIN-INJURY; RECURRENT CONCUSSION; COLLEGIATE; SPORT; EPIDEMIOLOGY; IMPAIRMENT; PLAYERS; RISK	Background: Increased attention is being placed on the role of subconcussive impacts to the head during football participation and long-term cognitive health. Some have suggested that mitigating impacts to the head can be achieved by reducing or eliminating contact football practices. The effect that this might have on the number and magnitude of impacts is unknown. Purpose: To estimate the effect of limiting contact practices on the frequency and magnitude of head impacts through the retrospective assessment of in vivo head impact data. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Data on impact magnitude and frequency were collected with the Head Impact Telemetry System during the 2009 football season among 42 varsity high school football athletes (mean age, 16.2 0.6 years; mean height, 180.9 7.2 cm; mean weight, 89.8 +/- 20.1 kg). Head impacts were compared between player positions and session types (noncontact practice, contact practice, and game). These results were used to estimate the frequency and magnitude of head impacts when contact sessions were restricted. Results: The participants collectively sustained 32,510 impacts over the 15-week season. The typical athlete sustained a mean of 774 +/- 502 impacts during the season, with linemen (center, guard, and offensive or defensive tackle positions) sustaining the highest number of impacts per athlete (1076 +/- 541), followed by tight ends, running backs, and linebackers (779 +/- 286); wide receivers, cornerbacks, and safeties (417 +/- 266); and quarterbacks (356 +/- 433). When viewed by session type, noncontact practices (n = 21) accounted for 1998 total impacts (2.4 +/- 1.4 per athlete per session), contact practices (n = 36) accounted for 16,346 impacts (10.5 +/- 7.7 per athlete per session), and games (n = 14) accounted for 14,166 impacts (24.1 +/- 19.1 per athlete per session). Significantly more impacts occurred during games when compared with contact (P = .02) and noncontact practices (P < .001), and contact practices yielded significantly more impacts than noncontact practices (P = .02). Limiting contact practices to once per week would result in a 18% reduction in impacts for the duration of a season, while eliminating all contact practices would further reduce seasonal impacts by 39% across all players. Impact magnitudes were significantly highest during game sessions compared with contact and noncontact practices. Conclusion: Our findings suggest that limiting or eliminating contact football practices may reduce the number of head impacts sustained by athletes over the course of a season, although the effect that such rule changes may have on the magnitude of head impacts during practice sessions is less clear. As such, the potential effect of reductions in contact practices on athletes' long-term cerebral health remains unknown.	[Broglio, Steven P.; Martini, Douglas; Kasper, Luke; Eckner, James T.; Kutcher, Jeffery S.] Univ Michigan, Ann Arbor, MI 48109 USA		Broglio, SP (corresponding author), Univ Michigan, Neurosport Res Lab, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu			Scott Hamilton; Unity Rockets; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	The authors thank Scott Hamilton and the Unity Rockets for their support in this study.	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cantu RC, 2012, SPORTS LEGACY I HIT; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Greenwald RM, 2012, CLIN J SPORT MED, V22, P83, DOI 10.1097/JSM.0b013e31824cc5d3; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kim J, 2011, REPORT REGARDING IVY; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Patrick L., 1963, 7 STAPP CAR CRASH C, P470; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512	37	66	66	0	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2013	41	12					2877	2884		10.1177/0363546513502458			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	258QH	WOS:000327473300021	24001576	Green Accepted			2022-02-06	
J	Spencer, RJ; Axelrod, BN; Drag, LL; Waldron-Perrine, B; Pangilinan, PH; Bieliauskas, LA				Spencer, Robert J.; Axelrod, Bradley N.; Drag, Lauren L.; Waldron-Perrine, Brigid; Pangilinan, Percival H.; Bieliauskas, Linas A.			WAIS-IV Reliable Digit Span is no More Accurate Than Age Corrected Scaled Score as an Indicator of Invalid Performance in a Veteran Sample Undergoing Evaluation for mTBI	CLINICAL NEUROPSYCHOLOGIST			English	Article						Cognition; Effort; Neuropsychological assessment; Traumatic brain injury; Veterans	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; POOR EFFORT; INDEXES	Reliable Digit Span (RDS) is a measure of effort derived from the Digit Span subtest of the Wechsler intelligence scales. Some authors have suggested that the age-corrected scaled score provides a more accurate measure of effort than RDS. This study examined the relative diagnostic accuracy of the traditional RDS, an extended RDS including the new Sequencing task from the Wechsler Adult Intelligence Scale-IV, and the age-corrected scaled score, relative to performance validity as determined by the Test of Memory Malingering. Data were collected from 138 Veterans seen in a traumatic brain injury clinic. The traditional RDS ( 7), revised RDS ( 11), and Digit Span age-corrected scaled score ( 6) had respective sensitivities of 39%, 39%, and 33%, and respective specificities of 82%, 89%, and 91%. Of these indices, revised RDS and the Digit Span age-corrected scaled score provide the most accurate measure of performance validity among the three measures.	[Spencer, Robert J.; Waldron-Perrine, Brigid; Bieliauskas, Linas A.] VA Ann Arbor Healthcare Syst, Dept Mental Hlth Serv, Ann Arbor, MI USA; [Axelrod, Bradley N.] John D Dingell Dept Vet Affairs Med Ctr, Psychol Sect, Detroit, MI USA; [Drag, Lauren L.] Stanford Univ Med Ctr, Palo Alto, CA USA; [Pangilinan, Percival H.] Univ Michigan Hlth Syst, Dept Phys Med & Rehabil, Ann Arbor, MI USA; [Bieliauskas, Linas A.] Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI USA		Bieliauskas, LA (corresponding author), 2101 Commonwealth Blvd,Ste C, Ann Arbor, MI 48105 USA.	linas@umich.edu					Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Boone K., 2002, B TEST MANUAL; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Green P, 1997, WORD MEMORY TEST USE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schutte C, 2012, MILD TRAUMATIC BRAIN, P159; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stulemeijer M, 2007, BRAIN INJURY, V21, P309, DOI 10.1080/02699050701209980; Suhr J.A., 2007, ASSESSMENT MALINGERE, P131; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wechsler, 2008, WAIS 4 ADM SCORING M; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Wechsler D., 1981, WAIS R MANUAL; Whitney KA, 2013, APPL NEUROPSYCH-ADUL, V20, P83, DOI 10.1080/09084282.2012.670167; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083	23	66	66	0	22	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 1	2013	27	8					1362	1372		10.1080/13854046.2013.845248			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	273KW	WOS:000328534700010	24099142				2022-02-06	
J	Chamard, E; Lassonde, M; Henry, L; Tremblay, J; Boulanger, Y; De Beaumont, L; Theoret, H				Chamard, Emilie; Lassonde, Maryse; Henry, Luke; Tremblay, Julie; Boulanger, Yvan; De Beaumont, Louis; Theoret, Hugo			Neurometabolic and microstructural alterations following a sports-related concussion in female athletes	BRAIN INJURY			English	Article						Diffusion tensor imaging; magnetic resonance spectroscopy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; GENDER-DIFFERENCES; HEAD ACCELERATION; METABOLIC-CHANGES; SEX-DIFFERENCES; WHITE-MATTER; POSTCONCUSSION SYMPTOMS; DIFFUSION; ABNORMALITIES	Background: Sports-related concussions are a major public health concern affecting millions of individuals annually. Neurometabolic and microstructural alterations have been reported in the chronic phase following a concussion in male athletes, while no study has investigated these alterations in female athletes. Methods: Neurometabolic and microstructural alterations following a concussion were investigated by comparing 10 female athletes with a concussion and 10 control female athletes, using magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI). Athletes with concussion were scanned at least 7 months post-concussion (mean = 18.9 months). Results: MRS revealed a significant lower level of myo-inositol in the hippocampus and the primary motor cortices (M1) bilaterally. DTI analysis using Tract-Based Spatial Statistics (TBSS) showed no difference in fractional anisotropy (FA) while higher level of mean diffusivity (MD) in athletes with concussion was detected in large white matter tracts including the forceps minors, inferior/superior longitudinal fasciculi, inferior fronto-occipital fasciculus, cingulum, uncinate fasciculus, anterior thalamic radiations and corticospinal tract. Moreover, a region of interest approach for the corpus callosum revealed a significant lower level of FA in the segment containing fibres projecting to M1. Conclusions: This study demonstrates persistent neurometabolic and microstructural alterations in female athletes suffering a sports-related concussion.	[Chamard, Emilie; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H2V 2S9, Canada; [Henry, Luke] UPMC Sports Concuss Clin, Pittsburgh, PA USA; [Tremblay, Julie] Hop Ste Justine, Montreal, PQ, Canada; [Boulanger, Yvan] Univ Montreal, Dept Radiol, Montreal, PQ H2V 2S9, Canada; [Boulanger, Yvan] Hop St Luc, Montreal, PQ H2X 1P1, Canada; [De Beaumont, Louis] UQTR, Ctr Rech Neuropsychol & Cognit, Dept Psychol, Montreal, PQ, Canada		Chamard, E (corresponding author), Univ Montreal, Dept Psychol, 90 Ave Vincent DIndy, Montreal, PQ H2V 2S9, Canada.	emilie.chamard@umontreal.ca		Theoret, Hugo/0000-0002-7458-8797			Acosta-Cabronero J, 2010, BRAIN, V133, P529, DOI 10.1093/brain/awp257; Andersson JL, 2007, FMRIB TECH REP TRO7J FMRIB TECHNICAL REPO; Andersson JLR, 2007, TR07JA9 FMRIB CTR; BADARGOFFER RS, 1992, BIOCHEM J, V282, P225, DOI 10.1042/bj2820225; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barr M., 2005, HUMAN NERVOS SYSTEM; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bear M.F., 2007, NEUROSCIENCE EXPLORI; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Braun CMJ, 2002, LATERALITY, V7, P97, DOI 10.1080/13576500143000212; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Castillo M, 2000, AM J NEURORADIOL, V21, P1645; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cotran R.S., 1994, PATHOLOGICAL BASIS D, P1; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia R., 2006, SPORTS NEUROPSYCHOLO; Esposito G, 1996, J NUCL MED, V37, P559; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Geurts JJG, 2004, J MAGN RESON IMAGING, V20, P366, DOI 10.1002/jmri.20138; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kandel E. R., 2000, PRINCIPLES NEUROSCIE; King KG, 2008, RADIOLOGY, V249, P242, DOI 10.1148/radiol.2491071500; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Szentkuti A, 2004, J NEUROL, V251, P1345, DOI 10.1007/s00415-004-0540-y; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Toga A.W., 2002, BRAIN MAPPING METHOD, Vsecond; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zimmerman ME, 2008, NEUROLOGY, V70, P1594, DOI 10.1212/01.wnl.0000306314.77311.be	75	66	66	0	40	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2013	27	9					1038	1046		10.3109/02699052.2013.794968			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	180HZ	WOS:000321586100008	23834633				2022-02-06	
J	Cavaco, S; Goncalves, A; Pinto, C; Almeida, E; Gomes, F; Moreira, I; Fernandes, J; Teixeira-Pinto, A				Cavaco, Sara; Goncalves, Alexandra; Pinto, Claudia; Almeida, Eduarda; Gomes, Filomena; Moreira, Ines; Fernandes, Joana; Teixeira-Pinto, Armando			Trail Making Test: Regression-based Norms for the Portuguese Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Cognition; Neuropsychological tests; Standardization; Executive functions; Educational achievement	MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ORAL WORD-ASSOCIATION; EXECUTIVE FUNCTION; FRONTAL-LOBE; STROOP TEST; NEUROPSYCHOLOGICAL TESTS; ALZHEIMER-DISEASE; TEST INDEXES; TEST-A	The main goal of this study was to produce normative data for the Portuguese population on the Trail Making Test (TMT). The study included 1,038 community-dwelling individuals aged between 18 and 93 years, who had educational backgrounds ranging from 3 to 22 years. The results showed that sex, age, and education were significantly associated with TMT performance. These demographic characteristics accounted for 57 of the performance variance at part A and 50 at part B. The normative data are presented as regression-based algorithms to adjust direct and derived test scores for sex, age, and education. The adjusted scores percentile distributions and their correspondence with scaled scores are also provided.	[Cavaco, Sara; Goncalves, Alexandra; Pinto, Claudia; Almeida, Eduarda; Gomes, Filomena; Moreira, Ines; Fernandes, Joana] Ctr Hosp Porto, Lab Neurobiol Comportamento Humano, P-4099001 Oporto, Portugal; [Cavaco, Sara; Goncalves, Alexandra; Pinto, Claudia; Almeida, Eduarda; Gomes, Filomena; Moreira, Ines; Fernandes, Joana] Univ Porto, Unidade Multidisciplinar Invest Biomed, P-4100 Oporto, Portugal; [Cavaco, Sara] Univ Iowa Carver Coll Med, Div Behav Neurol & Cognit Neurosci, Iowa City, IA USA; [Teixeira-Pinto, Armando] Univ Porto, CIDES, CINTESIS, Fac Med, P-4100 Oporto, Portugal; [Teixeira-Pinto, Armando] Univ Sydney, Screening & Test Evaluat Program, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia		Cavaco, S (corresponding author), Ctr Hosp Porto, Serv Neurol, P-4099001 Oporto, Portugal.	saramscavaco@gmail.com	Teixeira-Pinto, Armando/H-7947-2013; , CINTESIS/C-6631-2014	Teixeira-Pinto, Armando/0000-0002-9389-2516; Goncalves, Alexandra/0000-0001-9030-3686; Cavaco, Sara/0000-0001-7428-2854; , CINTESIS/0000-0001-7248-2086	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [402764]	This research received no specific grant from any funding agency, commercial or not-for-profit sectors. Armando Teixeira-Pinto was supported by the Australian National Health and Medical Research Council Grant 402764 to the Screening and Test Evaluation Program.	Amieva H, 1998, J CLIN EXP NEUROPSYC, V20, P280, DOI 10.1076/jcen.20.2.280.1161; Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Armitage S. G., 1946, PSYCHOL MONOGRAPHS, V60; Army Individual Test Battery, 1944, MAN DIR SCOR; Ashendorf L, 2008, ARCH CLIN NEUROPSYCH, V23, P129, DOI 10.1016/j.acn.2007.11.005; Atkinson TM, 2011, CLIN NEUROPSYCHOL, V25, P1193, DOI 10.1080/13854046.2011.589410; Axelrod B N, 2000, Appl Neuropsychol, V7, P186; Bell-McGinty S, 2002, INT J GERIATR PSYCH, V17, P828, DOI 10.1002/gps.646; Cangoz B, 2009, J NEUROL SCI, V283, P73, DOI 10.1016/j.jns.2009.02.313; Chapman RM, 2011, J CLIN EXP NEUROPSYC, V33, P187, DOI 10.1080/13803395.2010.499356; Chen PJ, 2001, ARCH GEN PSYCHIAT, V58, P853, DOI 10.1001/archpsyc.58.9.853; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; Dawson JD, 2009, NEUROLOGY, V72, P521, DOI 10.1212/01.wnl.0000341931.35870.49; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Drane DL, 2002, NEUROPSY NEUROPSY BE, V15, P39; Emerson JL, 2012, PSYCHOL AGING, V27, P550, DOI 10.1037/a0026359; Ewers M, 2012, NEUROBIOL AGING, V33, P1203, DOI 10.1016/j.neurobiolaging.2010.10.019; Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250; Ferman TJ, 2006, CLIN NEUROPSYCHOL, V20, P623, DOI 10.1080/13854040500376831; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Gomar JJ, 2011, ARCH GEN PSYCHIAT, V68, P961, DOI 10.1001/archgenpsychiatry.2011.96; GOUL WR, 1970, PERCEPT MOTOR SKILL, V30, P319, DOI 10.2466/pms.1970.30.1.319; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; HEATON RK, 1985, J CONSULT CLIN PSYCH, V53, P103, DOI 10.1037/0022-006X.53.1.103; Heidler-Gary J, 2007, DEMENT GERIATR COGN, V23, P184, DOI 10.1159/000098562; Heled E, 2012, J CLIN EXP NEUROPSYC, V34, P151, DOI 10.1080/13803395.2011.625351; Hester RL, 2005, CLIN NEUROPSYCHOL, V19, P45, DOI 10.1080/13854040490524137; Horton AM, 2001, INT J NEUROSCI, V111, P123, DOI 10.3109/00207450108986557; Instituto Nacional de Estatistica, 2001, CENS 2011 RES PROV; Ivnik RJ, 1996, CLIN NEUROPSYCHOL, V10, P262, DOI 10.1080/13854049608406689; Johnson JK, 2007, J GERONTOL A-BIOL, V62, P1134, DOI 10.1093/gerona/62.10.1134; Kaleita TA, 2004, J NEURO-ONCOL, V67, P245, DOI 10.1023/B:NEON.0000021900.29176.58; KENNEDY KJ, 1981, PERCEPT MOTOR SKILL, V52, P671, DOI 10.2466/pms.1981.52.2.671; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P813, DOI 10.1080/13854040701625846; Lemiere J, 2004, J NEUROL, V251, P935, DOI 10.1007/s00415-004-0461-9; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lucas JA, 2005, CLIN NEUROPSYCHOL, V19, P243, DOI 10.1080/13854040590945337; McDonald CR, 2005, J INT NEUROPSYCH SOC, V11, P477, DOI 10.1017/S1355617705050484; Mitchell M, 2008, J CLIN EXP NEUROPSYC, V30, P683, DOI 10.1080/13803390701679893; Mitrushina MN, 1999, HDB NORMATIVE DATA N; O'Rourke JJF, 2011, J CLIN EXP NEUROPSYC, V33, P567, DOI 10.1080/13803395.2010.541228; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P321, DOI 10.1093/arclin/acp038; Potter G. G., AM J GERIAT IN PRESS; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Gouveia PAR, 2007, BRAIN COGNITION, V63, P240, DOI 10.1016/j.bandc.2006.09.001; Salthouse TA, 2000, NEUROPSYCHOLOGY, V14, P102, DOI 10.1037/0894-4105.14.1.102; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Seo EH, 2006, INT J GERIATR PSYCH, V21, P844, DOI 10.1002/gps.1570; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Vazzana R, 2010, J AM GERIATR SOC, V58, P719, DOI 10.1111/j.1532-5415.2010.02780.x; Wiberg B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000458; Wolfson, 1993, HALSTEAD REITAN NEUR; Zalonis I, 2008, CLIN NEUROPSYCHOL, V22, P842, DOI 10.1080/13854040701629301	59	66	67	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2013	28	2					189	198		10.1093/arclin/acs115			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	092YS	WOS:000315159500011	23299183	Bronze			2022-02-06	
J	Risbud, RM; Porter, BE				Risbud, Rashmi M.; Porter, Brenda E.			Changes in MicroRNA Expression in the Whole Hippocampus and Hippocampal Synaptoneurosome Fraction following Pilocarpine Induced Status Epilepticus	PLOS ONE			English	Article							KINASE-II ACTIVITY; CONTROLS DENDRITIC PLASTICITY; ACTIVITY-REGULATED MICRORNA; TRAUMATIC BRAIN-INJURY; NEURONAL CULTURE MODEL; TEMPORAL-LOBE EPILEPSY; IN-VIVO; SEIZURES; MORPHOGENESIS; DECREASE	MicroRNAs regulate protein synthesis by binding non-translated regions of mRNAs and suppressing translation and/or increasing mRNA degradation. MicroRNAs play an important role in the nervous system including controlling synaptic plasticity. Their expression is altered in disease states including stroke, head injury and epilepsy. To better understand microRNA expression changes that might contribute to the development of epilepsy, microRNA arrays were performed on rat hippocampus 4 hours, 48 hours and 3 weeks following an episode of pilocarpine induced status epilepticus. Eighty microRNAs increased at one or more of the time points. No microRNAs decreased at 4 hours, and only a few decreased at 3 weeks, but 188 decreased 48 hours after status epilepticus. The large number of microRNAs with altered expression following status epilepticus suggests that microRNA regulation of translation has the potential to contribute to changes in protein expression during epileptogenesis. We carried out a second set of array's comparing microRNA expression at 48 hours in synaptoneurosome and nuclear fractions of the hippocampus. In control rat hippocampi multiple microRNAs were enriched in the synaptoneurosomal fraction as compared to the nuclear fraction. In contrast, 48 hours after status epilepticus only one microRNA was enriched in the synaptoneurosome fraction. The loss of microRNAs enriched in the synaptoneurosomal fraction implies a dramatic change in translational regulation in synapses 48 hours after status epilepticus.	[Risbud, Rashmi M.; Porter, Brenda E.] Childrens Hosp Philadelphia, Dept Pediat, Div Pediat Neurol, Philadelphia, PA 19104 USA; [Porter, Brenda E.] Univ Penn, Perelman Sch Med, Dept Neurol, Div Pediat Neurol, Philadelphia, PA 19104 USA		Porter, BE (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Div Pediat Neurol, Philadelphia, PA 19104 USA.	Brenda2@stanford.edu			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)	NINDS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman Naomi, 2005, Appl Bioinformatics, V4, P33, DOI 10.2165/00822942-200504010-00004; Aronica E, 2010, EUR J NEUROSCI, V31, P1100, DOI 10.1111/j.1460-9568.2010.07122.x; Bail S, 2010, RNA, V16, P1032, DOI 10.1261/rna.1851510; Blair RE, 1999, BRAIN RES, V851, P54, DOI 10.1016/S0006-8993(99)02100-9; Blair RE, 2008, EUR J PHARMACOL, V588, P64, DOI 10.1016/j.ejphar.2008.04.021; Booth RFG, 1978, BIOCHEM SOC T, V6, P128, DOI 10.1042/bst0060128; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; Ceman S, 2011, PHARMACOL THERAPEUT, V130, P26, DOI 10.1016/j.pharmthera.2011.01.004; Churn SB, 2000, BRAIN RES, V875, P66, DOI 10.1016/S0006-8993(00)02623-8; Cougot N, 2008, J NEUROSCI, V28, P13793, DOI 10.1523/JNEUROSCI.4155-08.2008; Glanzer J, 2005, P NATL ACAD SCI USA, V102, P16859, DOI 10.1073/pnas.0503783102; Guo DJ, 2012, NEUROBIOL DIS, V45, P348, DOI 10.1016/j.nbd.2011.08.020; Hu K, 2011, NEUROSCI LETT, V488, P252, DOI 10.1016/j.neulet.2010.11.040; Huang YF, 2002, J NEUROSCI, V22, P8422; Jimenez-Mateos EM, 2012, NAT MED, V18, P1087, DOI 10.1038/nm.2834; Jimenez-Mateos EM, 2011, AM J PATHOL, V179, P2519, DOI 10.1016/j.ajpath.2011.07.036; Kim YK, 2011, MOL CELL, V43, P1005, DOI 10.1016/j.molcel.2011.07.031; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039; Kye MJ, 2007, RNA, V13, P1224, DOI 10.1261/rna.480407; Lambert TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015182; Lee K, 2012, J NEUROSCI, V32, P5678, DOI 10.1523/JNEUROSCI.6471-11.2012; Lippi G, 2011, J CELL BIOL, V194, P889, DOI 10.1083/jcb.201103006; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Lugli G, 2008, J NEUROCHEM, V106, P650, DOI 10.1111/j.1471-4159.2008.05413.x; McKiernan RC, 2012, EXP NEUROL, V237, P346, DOI 10.1016/j.expneurol.2012.06.029; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; MULTANI P, 1994, EPILEPSIA, V35, P728, DOI 10.1111/j.1528-1157.1994.tb02503.x; Pichardo-Casas I, 2012, BRAIN RES, V1436, P20, DOI 10.1016/j.brainres.2011.12.001; Poon MM, 2006, J NEUROSCI, V26, P13390, DOI 10.1523/JNEUROSCI.3432-06.2006; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raol YH, 2006, J NEUROSCI, V26, P11342, DOI 10.1523/JNEUROSCI.3329-06.2006; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Rensing N, 2005, ANN NEUROL, V58, P888, DOI 10.1002/ana.20658; Risbud RM, 2011, BRAIN RES, V1424, P53, DOI 10.1016/j.brainres.2011.09.039; Ross JR, 2011, J NEUROCHEM, V117, P812, DOI 10.1111/j.1471-4159.2011.07233.x; Sano T, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.23; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Siegel G, 2009, NAT CELL BIOL, V11, P705, DOI 10.1038/ncb1876; Song YJ, 2011, BRAIN RES, V1387, P134, DOI 10.1016/j.brainres.2011.02.073; Swann JW, 2000, HIPPOCAMPUS, V10, P617, DOI 10.1002/1098-1063(2000)10:5<617::AID-HIPO13>3.0.CO;2-R; Tsai CA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng052; Vo N, 2005, P NATL ACAD SCI USA, V102, P16426, DOI 10.1073/pnas.0508448102; Wayman GA, 2008, P NATL ACAD SCI USA, V105, P9093, DOI 10.1073/pnas.0803072105; Wong M, 2012, NEUROSCIENCE; Zeng LH, 2007, J NEUROSCI, V27, P11604, DOI 10.1523/JNEUROSCI.0983-07.2007	47	66	68	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2013	8	1							e53464	10.1371/journal.pone.0053464			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	069IS	WOS:000313429100071	23308228	Green Submitted, Green Published, gold			2022-02-06	
J	Chrisman, SP; Rivara, FP; Schiff, MA; Zhou, C; Comstock, RD				Chrisman, Sara P.; Rivara, Frederick P.; Schiff, Melissa A.; Zhou, Chuan; Comstock, R. Dawn			Risk factors for concussive symptoms 1 week or longer in high school athletes	BRAIN INJURY			English	Article						Brain concussion; adolescent; recovery of function; athletic injuries; athletic trainer; return to play	SEX-DIFFERENCES; PLAY GUIDELINES; RECOVERY; PREDICTORS; SEVERITY; FOOTBALL; INJURY; RETURN	Objective: To identify risk factors for concussive symptoms >= 1 week. Methods: Retrospective cohort study of concussions in the RIO (TM) database 2006-2009 (n=1412) analysing risk factors for concussive symptoms >= 1 week. This study examined athlete's age, sex, weight, history of concussion, number of symptoms and specific symptoms. Data were stratified by football vs. non-football and analysed using Poisson regression to calculate relative risks and 95% confidence intervals. Results: Presenting with four or more symptoms was associated with double the risk for concussive symptoms >= 1 week for both football (95% CI=1.3-3.5) and non-football players (95% CI=1.4-4.6). History of prior concussion was associated with double the risk for concussive symptoms >= 1 week in football players only (95% CI=1.3-3.5). Several symptoms were associated with concussive symptoms >= 1 week in all athletes: drowsiness, nausea and concentration difficulties. Sensitivity to light and noise was associated with concussive symptoms >= 1 week in non-football players only. Amnesia was associated with concussive symptoms >= 1 week in males, but not females. Loss of consciousness was not significant. Conclusions: Risk factors for concussive symptoms >= 1 week are identifiable and can potentially be used to prognosticate for athletes and design evidence-based return-to-play guidelines.	[Chrisman, Sara P.] Univ Washington, Div Adolescent Med, Seattle, WA 98195 USA; [Rivara, Frederick P.; Schiff, Melissa A.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Rivara, Frederick P.; Zhou, Chuan] Univ Washington, Div Gen Pediat, Seattle, WA 98195 USA; [Schiff, Melissa A.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA; [Zhou, Chuan] Ctr Child Hlth Behav & Dev, Seattle Childrens Res Inst, Seattle, WA USA; [Comstock, R. Dawn] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Columbus, OH USA; [Comstock, R. Dawn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA		Chrisman, SP (corresponding author), POB 5371,M-S CW8-6, Seattle, WA 98145 USA.	sara.chrisman@seattlechildrens.org	Zhou, Chuan/AAJ-1935-2020	Chrisman, Sara/0000-0001-5373-7223	Ruth L. Kirschstein National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	The authors report no conflicts of interest. This research was supported in part by a fellowship from the Ruth L. Kirschstein National Research Service Award.	Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hershey AD, 2007, JAMA-J AM MED ASSOC, V19, p[663, 2549]; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	26	66	66	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					1	9		10.3109/02699052.2012.722251			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300001	23252433				2022-02-06	
J	Sosa, MAG; De Gasperi, R; Paulino, AJ; Pricop, PE; Shaughness, MC; Maudlin-Jeronimo, E; Hall, AA; Janssen, WGM; Yuk, FJ; Dorr, NP; Dickstein, DL; McCarron, RM; Chavko, M; Hof, PR; Ahlers, ST; Elder, GA				Sosa, Miguel A. Gama; De Gasperi, Rita; Paulino, Alejandro J.; Pricop, Paul E.; Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; Janssen, William G. M.; Yuk, Frank J.; Dorr, Nathan P.; Dickstein, Dara L.; McCarron, Richard M.; Chavko, Mikulas; Hof, Patrick R.; Ahlers, Stephen T.; Elder, Gregory A.			Blast overpressure induces shear-related injuries in the brain of rats exposed to a mild traumatic brain injury	ACTA NEUROPATHOLOGICA COMMUNICATIONS			English	Article						Blast overpressure injury; Neuropathology; Shear injury; Traumatic brain injury		Background: Blast-related traumatic brain injury (TBI) has been a significant cause of injury in the military operations of Iraq and Afghanistan, affecting as many as 10-20% of returning veterans. However, how blast waves affect the brain is poorly understood. To understand their effects, we analyzed the brains of rats exposed to single or multiple (three) 74.5 kPa blast exposures, conditions that mimic a mild TBI. Results: Rats were sacrificed 24 hours or between 4 and 10 months after exposure. Intraventricular hemorrhages were commonly observed after 24 hrs. A screen for neuropathology did not reveal any generalized histopathology. However, focal lesions resembling rips or tears in the tissue were found in many brains. These lesions disrupted cortical organization resulting in some cases in unusual tissue realignments. The lesions frequently appeared to follow the lines of penetrating cortical vessels and microhemorrhages were found within some but not most acute lesions. Conclusions: These lesions likely represent a type of shear injury that is unique to blast trauma. The observation that lesions often appeared to follow penetrating cortical vessels suggests a vascular mechanism of injury and that blood vessels may represent the fault lines along which the most damaging effect of the blast pressure is transmitted.	[Sosa, Miguel A. Gama] Vet Affairs Med Ctr, Dept Vet, Gen Med Res Serv, Bronx, NY 10468 USA; [De Gasperi, Rita; Paulino, Alejandro J.; Pricop, Paul E.; Dorr, Nathan P.] Vet Affairs Med Ctr, Dept Vet, Res & Dev Serv, Bronx, NY 10468 USA; [Elder, Gregory A.] Vet Affairs Med Ctr, Dept Vet, Neurol Serv, Bronx, NY 10468 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Paulino, Alejandro J.; Pricop, Paul E.; Dorr, Nathan P.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Janssen, William G. M.; Yuk, Frank J.; Dickstein, Dara L.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Dickstein, Dara L.; Hof, Patrick R.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Care, New York, NY 10029 USA; [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Sosa, Miguel A. Gama; De Gasperi, Rita; Dickstein, Dara L.; Hof, Patrick R.; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Shaughness, Michael C.; Maudlin-Jeronimo, Eric; Hall, Aaron A.; McCarron, Richard M.; Chavko, Mikulas; Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Silver Spring, MD USA		Sosa, MAG (corresponding author), Vet Affairs Med Ctr, Dept Vet, Gen Med Res Serv, Bronx, NY 10468 USA.	miguel.gama-sosa@mssm.edu	Dickstein, Dara/AAH-6603-2020		Department of Veterans AffairsUS Department of Veterans Affairs [1I01RX000179-01]; General Medical Research Service, James J. Peters VA Medical Center	We thank Bridget Wicinski for expert technical assistance. We thank Drs. Peter Davies, and Robert Lazzarini for gifts of antibodies. This work was supported by grant 1I01RX000179-01 from the Department of Veterans Affairs. MAGS is supported by the General Medical Research Service, James J. Peters VA Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense nor the U.S. Government.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Assari S, 2013, 9 ANN INJ BIOM S COL; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2011, NATO S SURV BLAST IN; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336, DOI 10.1152/physrev.1956.36.3.336; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ganpule S, 2013, BIOMECH MODEL MECHAN, V12, P511, DOI 10.1007/s10237-012-0421-8; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Romba JJ, 1961, ECHNICAL MEMORANDUM, P1; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Sosa MAG, 2010, AM J PATHOL, V176, P353, DOI 10.2353/ajpath.2010.090482; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Yarnell AM, 2013, CURR PROTOC NEUROSCI, V9, P9, DOI DOI 10.1002/0471142301.NS0941S62; Zhu Feng, 2010, Stapp Car Crash J, V54, P211	34	66	67	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	2051-5960			ACTA NEUROPATHOL COM	Acta Neuropathol. Commun.		2013	1								51	10.1186/2051-5960-1-51			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V9K2F	WOS:000422387200041	24252601	Green Published, gold			2022-02-06	
J	Nigrovic, LE; Lee, LK; Hoyle, J; Stanley, RM; Gorelick, MH; Miskin, M; Atabaki, SM; Dayan, PS; Holmes, JF; Kuppermann, N				Nigrovic, Lise E.; Lee, Lois K.; Hoyle, John; Stanley, Rachel M.; Gorelick, Marc H.; Miskin, Michelle; Atabaki, Shireen M.; Dayan, Peter S.; Holmes, James F.; Kuppermann, Nathan		Pediat Emergency Care Appl Res Ne	Prevalence of Clinically Important Traumatic Brain Injuries in Children With Minor Blunt Head Trauma and Isolated Severe Injury Mechanisms	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							COMPUTED-TOMOGRAPHY; DECISION RULE; INTRACRANIAL INJURY; PREDICTION; RADIATION; CT	Objective: To determine the prevalence of clinically important traumatic brain injuries (TBIs) with severe injury mechanisms in children with minor blunt head trauma but with no other risk factors from the Pediatric Emergency Care Applied Research Network (PECARN) TBI prediction rules (defined as isolated severe injury mechanisms). Design: Secondary analysis of a large prospective observational cohort study. Setting: Twenty-five emergency departments participating in the PECARN. Patients: Children with minor blunt head trauma and Glasgow Coma Scale scores of at least 14. Intervention: Treating clinicians completed a structured data form that included injury mechanism (severity categories defined a priori). Main Outcome Measures: Clinically important TBIs were defined as intracranial injuries resulting in death, neurosurgical intervention, intubation for more than 24 hours, or hospital admission for at least 2 nights. We investigated the rate of clinically important TBIs in children with either severe injury mechanisms or isolated severe injury mechanisms. Results: Of the 42 412 patients enrolled in the overall study, 42 099 (99%) had injury mechanisms recorded, and their data were included for analysis. Of all study patients, 5869 (14%) had severe injury mechanisms, and 3302 (8%) had isolated severe injury mechanisms. Overall, 367 children had clinically important TBIs (0.9%; 95% CI, 0.8%-1.0%). Of the 1327 children younger than 2 years with isolated severe injury mechanisms, 4 (0.3%; 95% CI, 0.1%-0.8%) had clinically important TBIs, as did 12 of the 1975 children 2 years or older (0.6%; 95% CI, 0.3%-1.1%). Conclusion: Children with isolated severe injury mechanisms are at low risk of clinically important TBI, and many do not require emergent neuroimaging.	[Nigrovic, Lise E.; Lee, Lois K.] Harvard Univ, Childrens Hosp, Div Emergency Med, Sch Med, Boston, MA 02115 USA; [Hoyle, John] Michigan State Univ, Sch Med, Div Emergency Med, Helen DeVos Childrens Hosp, Grand Rapids, MI USA; [Stanley, Rachel M.] Univ Michigan, Univ Michigan Hlth Syst, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Gorelick, Marc H.] Med Coll Wisconsin, Childrens Hosp Wisconsin, Div Emergency Med, Milwaukee, WI 53226 USA; [Miskin, Michelle] Univ Utah, Sch Med, Salt Lake City, UT USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Pediat, Childrens Natl Med Ctr, Washington, DC 20052 USA; [Atabaki, Shireen M.] George Washington Univ, Sch Med, Dept Emergency Med, Childrens Natl Med Ctr, Washington, DC 20052 USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Dept Pediat, Morgan Stanley Childrens Hosp New York Presbyteri, New York, NY 10032 USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Dept Emergency Med, Sch Med, Davis, CA 95616 USA; [Kuppermann, Nathan] Univ Calif Davis, Med Ctr, Dept Pediat, Sch Med, Davis, CA 95616 USA		Nigrovic, LE (corresponding author), Harvard Univ, Childrens Hosp, Div Emergency Med, Sch Med, 300 Longwood Ave, Boston, MA 02115 USA.	lise.nigrovic@childrens.harvard.edu		Nigrovic, Lise/0000-0002-6369-3997; Tsung, James/0000-0002-4718-8325	Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Division of Research, Training and Education (DRTE); Emergency Medical Services of Children (EMSC) [R40MC02461]; MCHB/HRSA [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008]	This work was supported by a grant from the Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Training and Education (DRTE), and the Emergency Medical Services of Children (EMSC) Program (R40MC02461). The Pediatric Emergency Care Applied Research Network (PECARN) is supported by cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008 from the EMSC program of the MCHB/HRSA.	Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Dorfman AL, 2011, ARCH PEDIAT ADOL MED, V165, P458, DOI 10.1001/archpediatrics.2010.270; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Frush DP, 2009, RADIOLOGY, V252, P4, DOI 10.1148/radiol.2521090661; Frush DP, 2008, PEDIATR RADIOL, V38, pS629, DOI 10.1007/s00247-008-1006-7; Gorelick MH, 2008, ACAD EMERG MED, V15, P812, DOI 10.1111/j.1553-2712.2008.00206.x; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kuppermann N, 2004, ARCH DIS CHILD, V89, P593, DOI 10.1136/adc.2003.046821; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6	17	66	66	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	APR	2012	166	4					356	361					6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	918UU	WOS:000302277500009	22147762	Bronze			2022-02-06	
J	Saing, T; Dick, M; Nelson, PT; Kim, RC; Cribbs, DH; Head, E				Saing, Tommy; Dick, Malcolm; Nelson, Peter T.; Kim, Ronald C.; Cribbs, David H.; Head, Elizabeth			Frontal Cortex Neuropathology in Dementia Pugilistica	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid; C1q; chronic traumatic encephalopathy; tauopathy; TDP-43	FRONTOTEMPORAL LOBAR DEGENERATION; TRAUMATIC BRAIN-INJURY; AMYLOID-BETA-PROTEIN; MOTOR-NEURON DISEASE; REPETITIVE HEAD-INJURY; ALZHEIMERS-DISEASE; A-BETA; NEUROFIBRILLARY TANGLES; CASPASE ACTIVATION; NEURODEGENERATIVE DISEASES	Dementia pugilistica (DP) is associated with chronic traumatic brain injury (CTBI), and leads to a "punch drunk'' syndrome characterized by impairments in memory and executive function, behavioral changes, and motor signs. Microscopic features include the accumulation of neurofibrillary tangles (NFTs), beta-amyloid (A beta), and TAR DNA binding protein 43 (TDP-43) pathology. Here we describe detailed clinical and neuropathological data about a 55-year-old retired boxer (ApoE3/4), who presented with executive dysfunction and behavioral impairments. At autopsy, significant A beta pathology was seen, primarily in the form of diffuse plaques. Tau pathology was extensive and was determined to be of Braak and Braak stage VI. Frontal white matter showed evidence of glial tau inclusions (astrocytes and oligodendroglia). Cerebrovascular pathology was minimal with patchy amyloid angiopathy. Inflammation was another key feature, including microglial activation and significant C1q labeling of neurons, along with NFTs. TDP-43-positive pathology was also observed. Inflammation may be a key inciting as well as propagating feature of DP neuropathology.	[Nelson, Peter T.; Head, Elizabeth] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Saing, Tommy; Dick, Malcolm; Kim, Ronald C.; Cribbs, David H.; Head, Elizabeth] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA USA; [Kim, Ronald C.] Univ Calif Irvine, Dept Pathol, Irvine, CA USA; [Cribbs, David H.; Head, Elizabeth] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; [Head, Elizabeth] Univ Kentucky, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; [Nelson, Peter T.] Univ Kentucky, Dept Pathol, Lexington, KY 40536 USA		Head, E (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 203 Sanders Brown Bldg,800 S Limestone St, Lexington, KY 40536 USA.	Elizabeth.head@uky.edu			University of California Irvine Alzheimer' Disease Research Center (National Institutes on Health/National Institutes on Aging) [P50 AG16573]; National Institutes on Health/National Institutes on Aging [AG21912, AG00538]; University of Kentucky Alzheimer's Disease Center [P30 AG028383]; National Institute of Child Health and Human Development Brain [N01-HD-4-3368, N01-HD-4-3383]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG000538, P30AG028383, P50AG016573, R01AG021912] Funding Source: NIH RePORTER	Funding supported by the University of California Irvine Alzheimer' Disease Research Center (National Institutes on Health/National Institutes on Aging Grant #P50 AG16573), National Institutes on Health/National Institutes on Aging Grant #AG21912, and #AG00538. Additional support was received from the University of Kentucky Alzheimer's Disease Center Grant #P30 AG028383. A subset of human tissues was obtained from the National Institute of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders under contracts N01-HD-4-3368 and N01-HD-4-3383. We are grateful to the family and to our patient with DP for their contributions to the study.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; Aguzzi A, 2009, NEURON, V64, P783, DOI 10.1016/j.neuron.2009.12.016; ALLSOP D, 1990, AM J PATHOL, V136, P255; Angot E, 2010, LANCET NEUROL, V9, P1128, DOI 10.1016/S1474-4422(10)70213-1; Areza-Fegyveres R, 2007, ARQ NEURO-PSIQUIAT, V65, P830, DOI 10.1590/S0004-282X2007000500019; Armstrong RA, 2010, J NEURAL TRANSM, V117, P227, DOI 10.1007/s00702-009-0350-6; Arnold SE, 2000, NEUROBIOL AGING, V21, P913, DOI 10.1016/S0197-4580(00)00173-1; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Belfor N, 2006, MECH AGEING DEV, V127, P203, DOI 10.1016/j.mad.2005.09.013; Brandmeir NJ, 2008, ACTA NEUROPATHOL, V115, P123, DOI 10.1007/s00401-007-0315-5; Brundin P, 2008, NAT REV NEUROSCI, V9, P741, DOI 10.1038/nrn2477; Cagnin A, 2004, ANN NEUROL, V56, P894, DOI 10.1002/ana.20332; Cairns NJ, 2007, ACTA NEUROPATHOL, V114, P5, DOI 10.1007/s00401-007-0237-2; Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; de Calignon A, 2010, NATURE, V464, P1201, DOI 10.1038/nature08890; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Drachman DA, 1999, NEW ENGL J MED, V340, P1269, DOI 10.1056/NEJM199904223401609; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Fonseca MI, 2004, NEUROBIOL DIS, V15, P40, DOI 10.1016/j.nbd.2003.09.004; Forman MS, 2007, CURR OPIN NEUROBIOL, V17, P548, DOI 10.1016/j.conb.2007.08.005; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gitcho MA, 2008, ANN NEUROL, V63, P535, DOI 10.1002/ana.21344; Goedert M, 2010, TRENDS NEUROSCI, V33, P317, DOI 10.1016/j.tins.2010.04.003; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Head E, 2006, ACTA NEUROPATHOL, V112, P217, DOI 10.1007/s00401-006-0098-0; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hyman BT, 2011, NAT NEUROSCI, V14, P5, DOI 10.1038/nn0111-5; Ikeda K, 1998, NEUROBIOL AGING, V19, pS85, DOI 10.1016/S0197-4580(98)00034-7; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; JIANG HX, 1994, J IMMUNOL, V152, P5050; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Kordower JH, 2008, NAT MED, V14, P504, DOI 10.1038/nm1747; Kordower JH, 2011, NEUROBIOL DIS, V43, P552, DOI 10.1016/j.nbd.2011.05.001; Kumar-Singh S, 2007, BRAIN PATHOL, V17, P104, DOI 10.1111/j.1750-3639.2007.00055.x; Kwong LK, 2007, ACTA NEUROPATHOL, V114, P63, DOI 10.1007/s00401-007-0226-5; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; Langer F, 2011, J NEUROSCI, V31, P14488, DOI 10.1523/JNEUROSCI.3088-11.2011; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKenzie JE, 1996, NEURODEGENERATION, V5, P259, DOI 10.1006/neur.1996.0034; McKhann GM, 2001, ARCH NEUROL-CHICAGO, V58, P1803, DOI 10.1001/archneur.58.11.1803; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Morales R., 2011, MOL PSYCHIATR; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Newman J, 2005, ACTA NEUROPATHOL, V110, P135, DOI 10.1007/s00401-005-1027-3; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Nowak LA, 2009, CLIN NEUROPATHOL, V28, P275, DOI 10.2379/NPX0800; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Petrushina I, 2007, J NEUROSCI, V27, P12721, DOI 10.1523/JNEUROSCI.3201-07.2007; Rissman RA, 2004, J CLIN INVEST, V114, P121, DOI 10.1172/JCI200420640; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1988, LANCET, V2, P1456; Rohn TT, 2008, REV NEUROSCIENCE, V19, P383; Schofield E, 2003, BRAIN, V126, P827, DOI 10.1093/brain/awg085; SPILLANE J D, 1962, Br Med J, V2, P1205; Spires-Jones TL, 2008, J NEUROSCI, V28, P862, DOI 10.1523/JNEUROSCI.3072-08.2008; SU JH, 1994, NEUROREPORT, V5, P2358, DOI 10.1097/00001756-199411000-00037; Thal DR, 2005, ACTA NEUROPATHOL, V110, P459, DOI 10.1007/s00401-005-1053-1; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uboga NV, 2000, NEUROBIOL AGING, V21, P1, DOI 10.1016/S0197-4580(00)00091-9; UHL GR, 1982, ANN NEUROL, V12, P99; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Volpicelli-Daley LA, 2011, NEURON, V72, P57, DOI 10.1016/j.neuron.2011.08.033; Webster S, 1997, J NEUROCHEM, V69, P388; Wilson AC, 2011, INT J CLIN EXP PATHO, V4, P147; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	94	66	66	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1054	1070		10.1089/neu.2011.1957			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100004	22017610	Green Published, Green Submitted			2022-02-06	
J	Shi, W; Nie, DK; Jin, GH; Chen, WW; Xia, L; Wu, XJ; Su, X; Xu, XD; Ni, LC; Zhang, XA; Zhang, XH; Chen, J				Shi, Wei; Nie, Dekang; Jin, Guohua; Chen, Weiwei; Xia, Liang; Wu, Xiujie; Su, Xing; Xu, Xide; Ni, Lanchun; Zhang, Xianan; Zhang, Xinhua; Chen, Jian			BDNF blended chitosan scaffolds for human umbilical cord MSC transplants in traumatic brain injury therapy	BIOMATERIALS			English	Article						Human umbilical cord mesenchymal stem cells; Chitosan scaffold; Co-culture; Brain-derived neurotrophic factor; Genipin; Neural stem cell	MESENCHYMAL STEM-CELLS; JELLY-DERIVED CELLS; IN-VITRO; NERVE REGENERATION; CEREBRAL-CORTEX; RAT; BLOOD; EXPRESSION; DEFICIT; TUBE	This study tested the cytotoxicity of a BDNF blended chitosan scaffold with human umbilical cord mesenchymal stem cells (hUC-MSCs), and the in vitro effect of BDNF blended chitosan scaffolds on neural stem cell differentiation with the aim of contributing alternative methods in tissue engineering for the treatment of traumatic brain injury (TBI). The chitosan scaffold based on immobilization of BDNF by genipin (GP) as a crosslinking agent referred to hereafter as a CGB scaffold was prepared by freezing-drying technique. hUC-MSCs were co-cultured with the CGB scaffold. Fluorescent nuclear staining (Hoechst 33342) was employed to determine the attachment of the hUC-MSCs to CGB scaffolds on the 1st, 3rd, 7th and 10th day of co-culture. The viability of hUC-MSCs adhered to the CGB scaffold was determined by digesting with 0.25% trypsin and evaluating with the cell counting kit-8 (CCK-8). Prior to this, the diameter and porosity of CGB scaffolds were measured. The amount of BDNF released from CGB over a 30 day period was determined by ELISA Finally, we investigated whether the released BDNF can induce NSC to differentiate into neurons. There were no significant differences in diameter and porosity of individual CGB scaffolds (P > 0.05). There were on average more cells on the CGB scaffold on the first day than on any other day sampled (P < 0.05). The CGB scaffolds released BDNF in a uniform profile, whereas the CB scaffolds only released BDNF during the first 3 days. BDNF released from CGB scaffold promoted neuronal differentiation of NSCs and led to significant differences in differentiation rate and average neuron perimeter compared with the control group. The results of this study demonstrate that CGB scaffolds are biocompatible with hUC-MSCs and that granular CGB scaffolds covered with hUC-MSCs are expected to generate new advances for future treatment of traumatic brain injury. Crown Copyright (c) 2012 Published by Elsevier Ltd. All rights reserved.	[Shi, Wei; Nie, Dekang; Xia, Liang; Wu, Xiujie; Su, Xing; Xu, Xide; Ni, Lanchun; Chen, Jian] Nantong Univ, Affiliated Hosp, Surg Comprehens Lab, Dept Neurosurg, Nantong 226001, Peoples R China; [Nie, Dekang; Jin, Guohua; Chen, Weiwei; Zhang, Xianan; Zhang, Xinhua] Nantong Univ, Dept Anat & Neurobiol, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Peoples R China; [Chen, Weiwei] Ningxia Med Univ, Dept Anat, Yinchuan 750004, Peoples R China		Chen, J (corresponding author), Nantong Univ, Affiliated Hosp, Surg Comprehens Lab, Dept Neurosurg, Nantong 226001, Peoples R China.	zhangxinhua@ntu.edu.cn; chenjian9079@126.com	Zhang, Xinhua/A-3225-2011	Zhang, Xin-hua/0000-0002-5702-6733	National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171130]; Priority Academic Program Development of Jiangsu Higher Education institutions; Application Research Project of Nantong City [K2010040]; Nantong University for Innovation Talent	We thank Department of Human Anatomy of Medical College in Nantong University and Surgical Comprehensive Laboratory in Affiliated Hospital of Nantong University for technical assistance and equipment support. This work was supported by National Nature Science Foundation of China (Grant No. 81171130); A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education institutions; Application Research Project of Nantong City (Grant No. K2010040); The Grant of Nantong University for Innovation Talent.	Cheng MY, 2003, J BIOMAT SCI-POLYM E, V14, P1155, DOI 10.1163/156856203769231628; Dokmeci MR, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3594781; Fukuda J, 2006, BIOMATERIALS, V27, P5259, DOI 10.1016/j.biomaterials.2006.05.044; Hsu YY, 1997, J BIOMED MATER RES, V35, P107, DOI 10.1002/(SICI)1097-4636(199704)35:1<107::AID-JBM11>3.3.CO;2-7; Itoh S, 2003, ARTIF ORGANS, V27, P1079, DOI 10.1111/j.1525-1594.2003.07208.x; Itoh S, 2003, BRAIN RES, V993, P111, DOI 10.1016/j.brainres.2003.09.003; Jiang QS, 2011, CHINESE MED J-PEKING, V124, P1540, DOI 10.3760/cma.j.issn.0366-6999.2011.10.019; Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006-0286; Keilhoff G, 2006, CELL MOL NEUROBIOL, V26, P1235, DOI 10.1007/s10571-006-9029-9; Kim Ju-Yeon, 2010, World J Stem Cells, V2, P34, DOI 10.4252/wjsc.v2.i2.34; Lee JH, 2011, J NEUROL SCI, V300, P86, DOI 10.1016/j.jns.2010.09.025; Lenas P, 2009, TISSUE ENG PART B-RE, V15, P381, DOI [10.1089/ten.teb.2008.0575, 10.1089/ten.TEB.2008.0575]; Li HM, 2011, HISTOCHEM CELL BIOL, V136, P515, DOI 10.1007/s00418-011-0864-5; Li XG, 2009, BIOMATERIALS, V30, P1121, DOI 10.1016/j.biomaterials.2008.10.063; Li ZS, 2005, BIOMATERIALS, V26, P3919, DOI 10.1016/j.biomaterials.2004.09.062; Lim JY, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt79; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mi FL, 2002, BIOMATERIALS, V23, P181, DOI 10.1016/S0142-9612(01)00094-1; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Sanchez-Ramos JR, 2001, EXP NEUROL, V171, P109, DOI 10.1006/exnr.2001.7748; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Sung HW, 1999, J BIOMAT SCI-POLYM E, V10, P63, DOI 10.1163/156856299X00289; Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439; Vindigni V, 2009, INT J MOL SCI, V10, P2972, DOI 10.3390/ijms10072972; Wang G, 2010, ACTA BIOMATER, V6, P3630, DOI 10.1016/j.actbio.2010.03.039; Wang HW, 2011, CHINESE MED J-PEKING, V124, P1534, DOI 10.3760/cma.j.issn.0366-6999.2011.10.018; Weiss ML, 2008, STEM CELLS, V26, P2865, DOI 10.1634/stemcells.2007-1028; Yan Xiao-hua, 2006, Zhonghua Er Ke Za Zhi, V44, P214; Yang YM, 2011, EUR J PHARM BIOPHARM, V79, P519, DOI 10.1016/j.ejpb.2011.06.008; Zhang HT, 2011, NEUROSCI LETT, V487, P118, DOI 10.1016/j.neulet.2010.10.008; Zhang S, 2009, CHIN J TRAUMATOL, V12, P195, DOI 10.3760/cma.j.issn.1008-1275.2009.04.001; Zhao ZQ, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-37	34	66	68	3	64	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	APR	2012	33	11					3119	3126		10.1016/j.biomaterials.2012.01.009			8	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	909JR	WOS:000301561300005	22264526				2022-02-06	
J	Gomes, JR; Costa, JT; Melo, CV; Felizzi, F; Monteiro, P; Pinto, MJ; Inacio, AR; Wieloch, T; Almeida, RD; Graos, M; Duarte, CB				Gomes, Joao R.; Costa, Joao T.; Melo, Carlos V.; Felizzi, Federico; Monteiro, Patricia; Pinto, Maria J.; Inacio, Ana R.; Wieloch, Tadeusz; Almeida, Ramiro D.; Graos, Mario; Duarte, Carlos B.			Excitotoxicity Downregulates TrkB.FL Signaling and Upregulates the Neuroprotective Truncated TrkB Receptors in Cultured Hippocampal and Striatal Neurons	JOURNAL OF NEUROSCIENCE			English	Article							IN-VIVO ROLE; CELL-DEATH; NEUROTROPHIN RECEPTORS; CEREBRAL-ISCHEMIA; CALPAIN; EXPRESSION; CASPASE; MICE; BDNF; GENE	Brain-derived neurotrophic factor (BDNF) plays an important role in neuronal survival through activation of TrkB receptors. The trkB gene encodes a full-length receptor tyrosine kinase (TrkB.FL) and its truncated (T1/T2) isoforms. We investigated the changes in TrkB protein levels and signaling activity under excitotoxic conditions, which are characteristic of brain ischemia, traumatic brain injury, and neurodegenerative disorders. Excitotoxic stimulation of cultured rat hippocampal or striatal neurons downregulated TrkB.FL and upregulated a truncated form of the receptor (TrkB.T). Downregulation of TrkB.FL was mediated by calpains, whereas the increase in TrkB.T protein levels required transcription and translation activities. Downregulation of TrkB.FL receptors in hippocampal neurons correlated with a decrease in BDNF-induced activation of the Ras/ERK and PLC gamma pathways. However, calpain inhibition, which prevents TrkB.FL degradation, did not preclude the decrease in signaling activity of these receptors. On the other hand, incubation with anisomycin, to prevent the upregulation of TrkB.T, protected to a large extent the TrkB.FL signaling activity, suggesting that truncated receptors may act as dominant-negatives. The upregulation of TrkB.T under excitotoxic conditions was correlated with an increase in BDNF-induced inhibition of RhoA, a mediator of excitotoxic neuronal death. BDNF fully protected hippocampal neurons transduced with TrkB.T when present during excitotoxic stimulation with glutamate, in contrast with the partial protection observed in cells overexpressing TrkB.FL or expressing GFP. These results indicate that BDNF protects hippocampal neurons by two distinct mechanisms: through the neurotrophic effects of TrkB.FL receptors and by activation of TrkB.T receptors coupled to inhibition of the excitotoxic signaling.	[Gomes, Joao R.; Costa, Joao T.; Melo, Carlos V.; Pinto, Maria J.; Almeida, Ramiro D.; Duarte, Carlos B.] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal; [Felizzi, Federico] ETH, Dept Biosyst Sci & Engn DBSSE, CH-4058 Basel, Switzerland; [Monteiro, Patricia; Graos, Mario; Duarte, Carlos B.] Biocant, P-3060197 Cantanhede, Portugal; [Inacio, Ana R.; Wieloch, Tadeusz] Lund Univ, Wallenberg Neurosci Ctr, S-22184 Lund, Sweden; [Duarte, Carlos B.] Univ Coimbra, Ctr Neurosci & Cell Biol, Dept Life Sci, P-3004517 Coimbra, Portugal		Duarte, CB (corresponding author), Univ Coimbra, Ctr Neurosci & Cell Biol, Dept Life Sci, P-3004517 Coimbra, Portugal.	cbduarte@ci.uc.pt	Inacio, Ana/M-6905-2016; Monteiro, Patricia/Q-7646-2017; Almeida, Ramiro D./J-2656-2013; Duarte, Carlos B/K-6358-2013; Gomes, Joao/D-5115-2011; Graos, Mario/O-7273-2017; Pinto, Maria Joana MJ Guimaraes/L-8990-2016	Monteiro, Patricia/0000-0003-3288-4560; Almeida, Ramiro D./0000-0001-5830-2595; Duarte, Carlos B/0000-0002-1474-0208; Gomes, Joao/0000-0002-5710-8819; Graos, Mario/0000-0002-2707-1488; Pinto, Maria Joana MJ Guimaraes/0000-0001-9730-5772; Wieloch, Tadeusz/0000-0002-7669-2520; Vieira Melo, Carlos/0000-0001-5392-1258; Costa, Joao/0000-0003-1018-2875	FCT, PortugalPortuguese Foundation for Science and TechnologyEuropean Commission; FCTPortuguese Foundation for Science and TechnologyEuropean Commission; FEDER, PortugalEuropean Commission [PTDC/SAU-NEU/65846/2006]	J.R.G, J.T.C, A. R. I., and C. V. M. were supported by FCT, Portugal. This work was supported by FCT and FEDER, Portugal (PTDC/SAU-NEU/65846/2006). We thank Elisabete Carvalho for the assistance in the preparation of cultured hippocampal neurons and Andrea Lobo for the pull-down of active RhoA optimization.	Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Caldeira MV, 2007, J BIOL CHEM, V282, P12619, DOI 10.1074/jbc.M700607200; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Counts SE, 2010, J NEUROCHEM, V113, P649, DOI 10.1111/j.1471-4159.2010.06622.x; De Wit J, 2006, J NEUROSCI, V26, P1516, DOI 10.1523/JNEUROSCI.4543-05.2006; Dorsey SG, 2006, NEURON, V51, P21, DOI 10.1016/j.neuron.2006.06.009; Dos-Anjos S, 2009, NEUROCHEM INT, V54, P180, DOI 10.1016/j.neuint.2008.09.016; Drukarch B, 2001, EXPERT OPIN INV DRUG, V10, P1855, DOI 10.1517/13543784.10.10.1855; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eide FF, 1996, J NEUROSCI, V16, P3123; Ferrer I, 2001, ACTA NEUROPATHOL, V101, P229; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gomes JR, 2011, J NEUROSCI, V31, P4622, DOI 10.1523/JNEUROSCI.3541-10.2011; Goutan E, 1998, MOL BRAIN RES, V59, P154, DOI 10.1016/S0169-328X(98)00156-9; Grumelli C, 2008, MOL CELL NEUROSCI, V39, P314, DOI 10.1016/j.mcn.2008.07.011; Haacke A, 2007, J BIOL CHEM, V282, P18851, DOI 10.1074/jbc.M611914200; Haapasalo A, 2001, BIOCHEM BIOPH RES CO, V280, P1352, DOI 10.1006/bbrc.2001.4296; Hartmann M, 2004, J CELL SCI, V117, P5803, DOI 10.1242/jcs.01511; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Li YX, 1998, P NATL ACAD SCI USA, V95, P10884, DOI 10.1073/pnas.95.18.10884; Li ZK, 2009, CANCER RES, V69, P7851, DOI 10.1158/0008-5472.CAN-08-4002; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Luberg K, 2010, J NEUROCHEM, V113, P952, DOI 10.1111/j.1471-4159.2010.06662.x; Luikart BW, 2003, NEUROSCIENCE, V117, P847, DOI 10.1016/S0306-4522(02)00719-4; Manadas Bruno J., 2007, P137, DOI 10.1007/978-0-387-70830-0_7; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Martin KJ, 2011, NEUROPHARMACOLOGY, V61, P148, DOI 10.1016/j.neuropharm.2011.03.021; Meary F, 2007, J BIOL CHEM, V282, P14226, DOI 10.1074/jbc.M700028200; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; Nygren J, 2005, J CEREBR BLOOD F MET, V25, P1625, DOI 10.1038/sj.jcbfm.9600157; Ohira K, 2006, BIOCHEM BIOPH RES CO, V342, P867, DOI 10.1016/j.bbrc.2006.02.033; Ohira K, 2005, NEUROSCI LETT, V385, P105, DOI 10.1016/j.neulet.2005.05.033; Ohira K, 2005, J NEUROSCI, V25, P1343, DOI 10.1523/JNEUROSCI.4436-04.2005; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Rose CR, 2003, NATURE, V426, P74, DOI 10.1038/nature01983; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Saarelainen T, 2000, MOL CELL NEUROSCI, V16, P87, DOI 10.1006/mcne.2000.0863; Santos ARA, 2008, J NEUROSCI RES, V86, P3684, DOI 10.1002/jnr.21796; Semenova MM, 2007, NAT NEUROSCI, V10, P436, DOI 10.1038/nn1869; Silhol M, 2007, NEUROSCIENCE, V146, P962, DOI 10.1016/j.neuroscience.2007.02.013; Stoilov P, 2002, BIOCHEM BIOPH RES CO, V290, P1054, DOI 10.1006/bbrc.2001.6301; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Tolosa L, 2009, NEUROSCIENCE, V158, P1348, DOI 10.1016/j.neuroscience.2008.10.060; Tomioka M, 2002, MOL BRAIN RES, V108, P18, DOI 10.1016/S0169-328X(02)00486-2; Traystman RJ, 2003, ILAR J, V44, P85, DOI 10.1093/ilar.44.2.85; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Xu W, 2007, NEURON, V53, P399, DOI 10.1016/j.neuron.2006.12.020; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	60	66	70	0	23	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 28	2012	32	13					4610	4622		10.1523/JNEUROSCI.0374-12.2012			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	917GA	WOS:000302159400024	22457507	Bronze, Green Published			2022-02-06	
J	Barr, WB; Prichep, LS; Chabot, R; Powell, MR; Mccrea, M				Barr, William B.; Prichep, Leslie S.; Chabot, Robert; Powell, Matthew R.; Mccrea, Michael			Measuring brain electrical activity to track recovery from sport-related concussion	BRAIN INJURY			English	Article						Electroencephalography; traumatic brain injury; concussion; athletes	INJURY; EEG; FOOTBALL	Primary objective: To follow recovery from concussion in a sample of athletes using an electroencephalographic (EEG) index of quantitative brain activity developed previously on an independent Emergency Department (ED) sample of head-injured subjects with traumatic brain injury. Methods and procedures: EEG recordings from five frontal electrode sites were obtained on 59 injured athletes and 31 controls at the time of injury and at 8 and 45 days afterward. All subjects also completed standardized clinical assessment of post-concussion symptoms, postural stability and cognitive functioning at injury and 8 and 45 days post-injury. Results: Abnormalities in clinical assessment measures were observed in injured subjects only at time of injury. Statistical analysis of brain electrical activity measures with the ED-based algorithm revealed significant differences between injured athletes vs controls at the time of injury and at day 8. Measures from the two groups did not differ on day 45. Conclusions: This study demonstrated that an algorithm of brain electrical activity developed on an independent sample of ED subjects with head injury is sensitive to the effects of sport-related concussion. Using this algorithm, abnormal features of brain electrical activity were detected in athletes with concussion at the time of injury and persisted beyond the point of recovery on clinical measures.	[Barr, William B.] NYU, Sch Med, Dept Neurol, New York, NY USA; [Prichep, Leslie S.; Chabot, Robert] NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY USA; [Prichep, Leslie S.] Nathan S Kline Inst Psychiat Res, New York State Dept Mental Hlth, Orangeburg, NY 10962 USA; [Powell, Matthew R.] Minocqua Ctr, Marshfield Clin, Neuropsychol Serv, Minoqua, WI USA; [Mccrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Mccrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA		Barr, WB (corresponding author), NYU, Comprehens Epilepsy Ctr, 223 E 34th St, New York, NY 10016 USA.	william.barr@nyumc.org		Barr, William/0000-0001-7711-7758	BrainScope, Inc.	This research was supported by a clinical research grant from BrainScope, Inc. as an investigator-initiated study, with Dr Barr and Dr McCrea as principal investigators. The investigators thank the certified athletic trainers and student athletes from those high schools and colleges that participated. We also acknowledge the insights of E. Roy John, PhD, in the concept and design of this study. Dr McCrea and Dr Barr had full access to all of the clinical data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis; Dr Prichep holds the same responsibility for the integrity and accuracy of the electrophysiological data.	Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2000, STANDARDIZED ASSESSM; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Naunheim RS, 2010, BRAIN INJURY, V24, P1324, DOI 10.3109/02699052.2010.506862; ONEIL B, 2011, ANN EMERG MED, V58, pS228; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Prichep LS, 2005, CLIN EEG NEUROSCI, V36, P82, DOI 10.1177/155005940503600207; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thakor NV, 2004, ANNU REV BIOMED ENG, V6, P453, DOI 10.1146/annurev.bioeng.5.040202.121601; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200	35	66	66	1	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2012	26	1					58	66		10.3109/02699052.2011.608216			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900006	22107157				2022-02-06	
J	Rona, RJ; Jones, M; Fear, NT; Hull, L; Murphy, D; Machell, L; Coker, B; Iversen, AC; Jones, N; David, AS; Greenberg, N; Hotopf, M; Wessely, S				Rona, Roberto J.; Jones, Margaret; Fear, Nicola T.; Hull, Lisa; Murphy, Dominic; Machell, Louise; Coker, Bolaji; Iversen, Amy C.; Jones, Norman; David, Anthony S.; Greenberg, Neil; Hotopf, Matthew; Wessely, Simon			Mild Traumatic Brain Injury in UK Military Personnel Returning From Afghanistan and Iraq: Cohort and Cross-sectional Analyses	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; postconcussion symptoms; posttraumatic stress disorder; prevalence	POSTTRAUMATIC-STRESS-DISORDER; ENDURING FREEDOM; WAR; VETERANS; HEALTH; DEPLOYMENT; SYMPTOMS	Objectives: To assess (a) the prevalence of mild traumatic brain injury (mTBI) in UK military personnel deployed to Iraq and/or Afghanistan, (b) the risk factors associated with mTBI, and (c) the association between mTBI and subsequent postconcussion symptoms (PCS). Participants: A total of 4620 personnel deployed to Iraq and/or Afghanistan who completed a questionnaire between 2007 and 2009, of whom 2333 were also studied in 2005, participated in the study. Main Outcome Measures: Mild traumatic brain injury during deployment, as identified using a modified version of the Brief Traumatic Brain Injury Screen questionnaire; symptoms associated with PCS in the month before questionnaire completion. Results: The prevalence of mTBI was 4.4%, and the prevalence in those with a combat role was 9.5%. Having an mTBI was associated with current symptoms of posttraumatic stress disorder (adjusted odds ratio (AOR), 5.2; 95% confidence interval [CI], 2.3-11.4), alcohol misuse (AOR, 2.3; 95% CI, 1.4-3.7), and multiple physical symptoms (AOR, 2.6; 95% CI, 1.3-5.2). Only 3 of 9 symptoms remained associated with mTBI after adjustment. Psychological distress and alcohol misuse recorded before deployment were associated with subsequent mTBI. Conclusions: The prevalence of mTBI in UK military is lower than that in the US military. Symptoms of current posttraumatic stress disorder and alcohol misuse are associated with mTBI. Symptoms of mental disorder predated occurrence of mTBI. The majority PCS were not associated with mTBI.	[Rona, Roberto J.] Kings Coll London, Weston Educ Ctr, Kings Ctr Mil Hlth Res, London SE5 9RJ, England; [Fear, Nicola T.; Jones, Norman; Greenberg, Neil] Kings Coll London, Acad Ctr Def Mental Hlth, London SE5 9RJ, England; [David, Anthony S.] Kings Coll London, Inst Psychiat, Sect Cognit Neuropsychiat, London SE5 9RJ, England		Rona, RJ (corresponding author), Kings Coll London, Weston Educ Ctr, Kings Ctr Mil Hlth Res, 10 Cutcombe Rd, London SE5 9RJ, England.	Roberto.rona@kcl.ac.uk	David, Anthony S/C-1315-2011; David, Anthony/O-1750-2019; Wessely, Simon C/A-8713-2008; Fear, Nicola/A-1917-2012; Hotopf, Matthew/E-4971-2010	David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X; Fear, Nicola/0000-0002-5792-2925; greenberg, neil/0000-0003-4550-2971; Hotopf, Matthew/0000-0002-3980-4466; Wessely, Simon Charles/0000-0002-6743-9929; Rona, Roberto/0000-0003-3739-5571	UK Ministry of Defence	The UK Ministry of Defence funded this project.	Babor TF, 2001, AU DIT ALCOHOL USE D; Belasco A, 2009, C RES SERV TROOP LEV; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Carlson KF, 2010, J HEAD TRAUMA REHABI, DOI 1097/HTR.0b013e3181e50ef1; Evans RW, 2008, HEADACHE, V48, P1216, DOI 10.1111/j.1526-4610.2008.01216.x; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-6736(10)60672-1; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Goldberg D., 1988, USERS GUIDE GEN HLTH; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, LANCET, V368, P837, DOI 10.1016/S0140-6736(06)69315-X; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Horn O, 2010, EUR J EPIDEMIOL, V25, P87, DOI 10.1007/s10654-009-9414-z; Hotopf M, 2006, LANCET, V368, P837, DOI 10.1016/S0140-6736(06)69316-1; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Lange RL, J CLIN EXPT NEUROPSY, DOI [10.1080/13803391003645757, DOI 10.1080/13803391003645757]; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shephard Ben, 2000, WAR NERVES SOLDIERS; Tanielian T, 2008, PSYCHOL COGNITIVE IN; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilson J, 2008, J TRAUMA STRESS, V21, P385, DOI 10.1002/jts.20352; IRAQ COALITION CASUA	34	66	67	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					33	44		10.1097/HTR.0b013e318212f814			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400004	22241066				2022-02-06	
J	Viano, DC; Withnall, C; Halstead, D				Viano, David C.; Withnall, Chris; Halstead, David			Impact Performance of Modern Football Helmets	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Protective headgear; Recreation and sport; Concussion; Helmets; Sport equipment	PROFESSIONAL FOOTBALL; GAME IMPACTS; CONCUSSION; BIOMECHANICS; INJURIES; PLAYER	Linear impact tests were conducted on 17 modern football helmets. The helmets were placed on the Hybrid III head with the neck attached to a sliding table. The head was instrumented with an array of 3-2-2-2 accelerometers to determine translational acceleration, rotational acceleration, and HIC. Twenty-three (23) different impacts were conducted on four identical helmets of each model at eight sites on the shell and facemask, four speeds (5.5, 7.4, 9.3, and 11.2 m/s) and two temperatures (22.2 and 37.8 degrees C). There were 1,850 tests in total; 276 established the 1990s helmet performance (baseline) and 1,564 were on the 17 different helmet models. Differences from the 1990s baseline were evaluated using the Student t test (p < 0.05 as significant). Four of the helmets had significantly lower HICs and head accelerations than the 1990s baseline with average reductions of 14.6-21.9% in HIC, 7.3-14.0% in translational acceleration, and 8.4-15.9% in rotational acceleration. Four other helmets showed some improvements. Eight were not statistically different from the 1990s baseline and one had significantly poorer performance. Of the 17 helmet models, four provided a significant reduction in head responses compared to 1990s helmets.	[Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI 48304 USA; [Withnall, Chris] Biokinet & Associates Ltd, Ottawa, ON K1H 1E1, Canada; [Halstead, David] Univ Tennessee, Coll Engn, Sports Biomech Impact Res Lab, Knoxville, TN 37996 USA; [Halstead, David] So Impact Res Ctr LLC, Rockford, TN 37853 USA		Viano, DC (corresponding author), ProBiomechanics LLC, 265 Warrington Rd,Hills, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net			NFL	The testing reported here was completed while the lead author was a member of the NFL's MTBI Committee and oversaw the evaluation program. The test plan was developed in mid-2009. The testing at Biokinetics and Associates Ltd. and Southern Impact Research Center, LLC was commissioned and the raw data was verified and accepted by ProBiomechanics LLC. The testing was funded by the NFL. The cooperation of Riddell, Schutt Sports, Adams USA, PSE (Protective Sport Equipment) and Xenith for supplying helmets for testing at Biokinetics and SIRC is appreciated. Both laboratories have previous and ongoing relationships with some of the helmet manufacturers. These were acknowledged at the onset. Xenith withdrew from participation in the program after receiving their test results. All manufacturers received a copy of their verified and analyzed data as well as the raw transducer responses and test video of their helmets. Identical helmet testing was conducted at each laboratory and the results were not shared between them. The merging of data and analysis was done by ProBiomechanics LLC without the involvement of the two laboratories, which were blinded from the others test results. The views presented here are those of the authors and not necessarily those of the NFL or any helmet manufacturer. Many individuals contributed to this helmet testing program and their assistance is greatly appreciated. Mr. Michael Wonnacott ran the impact tests and processed the raw data at Biokinetics and Associates, Ltd. Ms. Elizabeth McCalley ran the impact tests and processed the raw data at SIRC. Dr. Chantal Parenteau merged, tabulated and analyzed the combined data at ProBiomechanics LLC. All of the analyzed data, tables and figures were developed by ProBiomechanics LLC. Two independent researchers reviewed the data and subjected a subset to ANOVA analysis. Those results were shared with the NFL teams and players, and were included in a press release by the league about the helmet testing on July 23, 2010. The ANOVA analysis reached similar but not identical results to those presented here.	[Anonymous], 1998, 00298M03 NOCSAE; [Anonymous], 1998, 02198M05 NOCSAE; [Anonymous], 2004, 00104M05 NOCSAE; Bland M., 2000, INTRO MED STAT; Craig M. J., 2007, THESIS WAYNE STATE U; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Horsch J. D., 1987, 870222 SAE INT; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S., 2009, J BIOMECH ENG, V131, P610; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; *SAE, 1980, J855 SAE; SAE (Society of Automotive Engineers), 1995, J2111 SAE; Society of Automotive Engineer (SAE), 1994, J1733 SAE; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C	21	66	66	0	36	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964			ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		160	174		10.1007/s10439-011-0384-4			15	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	895HJ	WOS:000300486700015	22012079				2022-02-06	
J	Mena, JH; Sanchez, AI; Rubiano, AM; Peitzman, AB; Sperry, JL; Gutierrez, MI; Puyana, JC				Humberto Mena, Jorge; Ignacio Sanchez, Alvaro; Rubiano, Andres M.; Peitzman, Andrew B.; Sperry, Jason L.; Isabel Gutierrez, Maria; Puyana, Juan Carlos			Effect of the Modified Glasgow Coma Scale Score Criteria for Mild Traumatic Brain Injury on Mortality Prediction: Comparing Classic and Modified Glasgow Coma Scale Score Model Scores of 13	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Traumatic brain injury; Glasgow Coma Scale; Mortality; Prediction	MODERATE HEAD-INJURY; NEW-ORLEANS CRITERIA; INTERRATER RELIABILITY; PROGNOSTIC-FACTORS; PRACTICAL SCALE; HOSPITALIZATION; MANAGEMENT; HYPOTHERMIA; VALIDATION; ADMISSION	Background: The Glasgow Coma Scale (GCS) classifies traumatic brain injuries (TBIs) as mild (14-15), moderate (9-13), or severe (3-8). The Advanced Trauma Life Support modified this classification so that a GCS score of 13 is categorized as mild TBI. We investigated the effect of this modification on mortality prediction, comparing patients with a GCS score of 13 classified as moderate TBI (classic model) to patients with GCS score of 13 classified as mild TBI (modified model). Methods: We selected adult TBI patients from the Pennsylvania Outcome Study database. Logistic regressions adjusting for age, sex, cause, severity, trauma center level, comorbidities, and isolated TBI were performed. A second evaluation included the time trend of mortality. A third evaluation also included hypothermia, hypotension, mechanical ventilation, screening for drugs, and severity of TBI. Discrimination of the models was evaluated using the area under receiver operating characteristic curve (AUC). Calibration was evaluated using the Hosmer-Lemershow goodness of fit test. Results: In the first evaluation, the AUCs were 0.922 (95% CI, 0.917-0.926) and 0.908 (95% CI, 0.903-0.912) for classic and modified models, respectively. Both models showed poor calibration (p < 0.001). In the third evaluation, the AUCs were 0.946 (95% CI, 0.943-0.949) and 0.938 (95% CI, 0.934-0.940) for the classic and modified models, respectively, with improvements in calibration (p = 0.30 and p = 0.02 for the classic and modified models, respectively). Conclusion: The lack of overlap between receiver operating characteristic curves of both models reveals a statistically significant difference in their ability to predict mortality. The classic model demonstrated better goodness of fit than the modified model. A GCS score of 13 classified as moderate TBI in a multivariate logistic regression model performed better than a GCS score of 13 classified as mild.	[Humberto Mena, Jorge; Ignacio Sanchez, Alvaro; Peitzman, Andrew B.; Sperry, Jason L.; Puyana, Juan Carlos] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Humberto Mena, Jorge; Ignacio Sanchez, Alvaro; Isabel Gutierrez, Maria] Univ Valle, CISALVA Inst, Cali, Colombia; [Rubiano, Andres M.] Neiva Univ Hosp, Neiva City, Colombia		Mena, JH (corresponding author), IROQU 400 4C Pittsburgh Off, Dept Emergency Med Off, Pittsburgh, PA USA.	jhm26@pitt.edu	RUBIANO, ANDRES M/K-6704-2012	RUBIANO, ANDRES M/0000-0001-8931-3254	FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW007560] Funding Source: NIH RePORTER; FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43 TW007560, 1 D43 TW007560 05, D43 TW007560-05] Funding Source: Medline		Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; Elliott M, 1996, J Neurosci Nurs, V28, P213; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; Fischer J, 2001, Crit Care Nurs Q, V23, P52; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; FRANKE CL, 1992, J NEUROL NEUROSUR PS, V55, P653, DOI 10.1136/jnnp.55.8.653; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; JENNETT B, 1975, LANCET, V1, P480; JONES C, 1979, AM J NURS, V79, P1551; Juarez V J, 1995, J Neurosci Nurs, V27, P283; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; LEE KL, 1986, AM J MED, V80, P553, DOI 10.1016/0002-9343(86)90807-7; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Matis G, 2008, ACTA NEUROL BELG, V108, P75; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; Rosner B., 2006, FUNDAMENTALS BIOSTAT; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Santrucek M, 1978, Cas Lek Cesk, V117, P225; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Strachan R D, 1989, Brain Inj, V3, P51, DOI 10.3109/02699058909008073; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Ting HW, 2010, J CHIN MED ASSOC, V73, P139, DOI 10.1016/S1726-4901(10)70028-9; Vittinghoff E, 2005, STAT BIOL HEALTH, pVII; Wang HE, 2005, CRIT CARE MED, V33, P1296, DOI 10.1097/01.CCM.0000165965.31895.80; Yanagawa Y, 2007, AM J EMERG MED, V25, P757, DOI 10.1016/j.ajem.2006.12.006; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	49	66	68	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1185	1192		10.1097/TA.0b013e31823321f8			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	849IG	WOS:000297118600022	22071923	Green Accepted			2022-02-06	
J	Kuehn, R; Simard, PF; Driscoll, I; Keledjian, K; Ivanova, S; Tosun, C; Williams, A; Bochicchio, G; Gerzanich, V; Simard, JM				Kuehn, Reed; Simard, Philippe F.; Driscoll, Ian; Keledjian, Kaspar; Ivanova, Svetlana; Tosun, Cigdem; Williams, Alicia; Bochicchio, Grant; Gerzanich, Volodymyr; Simard, J. Marc			Rodent Model of Direct Cranial Blast Injury	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid precursor protein; caspase-3; primary blast injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; RAT-BRAIN; INTRACRANIAL-PRESSURE; COGNITIVE FUNCTION; CIVILIAN INJURIES; EXPLOSIVE BLAST; AXONAL INJURY	Traumatic brain injury resulting from an explosive blast is one of the most serious wounds suffered by war-fighters, yet the effects of explosive blast overpressure directly impacting the head are poorly understood. We developed a rodent model of direct cranial blast injury (dcBI), in which a blast overpressure could be delivered exclusively to the head, precluding indirect brain injury via thoracic transmission of the blast wave. We constructed and validated a Cranium Only Blast Injury Apparatus (COBIA) to deliver blast overpressures generated by detonating .22 caliber cartridges of smokeless powder. Blast waveforms generated by COBIA replicated those recorded within armored vehicles penetrated by munitions. Lethal dcBI (LD(50) similar to 515 kPa) was associated with: (1) apparent brainstem failure, characterized by immediate opisthotonus and apnea leading to cardiac arrest that could not be overcome by cardiopulmonary resuscitation; (2) widespread subarachnoid hemorrhages without cortical contusions or intracerebral or intraventricular hemorrhages; and (3) no pulmonary abnormalities. Sublethal dcBI was associated with: (1) apnea lasting up to 15 sec, with transient abnormalities in oxygen saturation; (2) very few delayed deaths; (3) subarachnoid hemorrhages, especially in the path of the blast wave; (4) abnormal immunolabeling for IgG, cleaved caspase-3, and beta-amyloid precursor protein (beta-APP), and staining for Fluoro-Jade C, all in deep brain regions away from the subarachnoid hemorrhages, but in the path of the blast wave; and (5) abnormalities on the accelerating Rotarod that persisted for the 1 week period of observation. We conclude that exposure of the head alone to severe explosive blast predisposes to significant neurological dysfunction.	[Simard, Philippe F.; Keledjian, Kaspar; Ivanova, Svetlana; Tosun, Cigdem; Gerzanich, Volodymyr; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Bochicchio, Grant] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Kuehn, Reed; Driscoll, Ian; Williams, Alicia] Walter Reed Army Med Ctr, Dept Surg, Washington, DC 20307 USA; [Bochicchio, Grant] R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA		Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Tosun, Cigdem/AAG-4026-2020; Shaheen, Ahmed/AAP-4054-2021	Shaheen, Ahmed/0000-0002-2216-1951	Department of the Army (U.S. Army Medical Research Acquisition Activity) [PT074766, MD 21702-5014]	This work was supported by a grant to J.M.S. from the Department of the Army (PT074766; the U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding and administering acquisition office). The information in this article does not necessarily reflect the position or the policy of the United States Government, and no official endorsement should be inferred.	Aboutanos MB, 1997, J TRAUMA, V43, P719, DOI 10.1097/00005373-199710000-00031; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 1997, TOXICOLOGY, V121, P65, DOI 10.1016/S0300-483X(97)03656-1; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bochicchio GV, 2008, AM SURGEON, V74, P267; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Clemedson J. C., 1956, PHYSIOL REV, V36, P336; Coupland RM, 1999, BRIT MED J, V319, P410, DOI 10.1136/bmj.319.7207.410; Coupland RM, 1999, BRIT MED J, V319, P407, DOI 10.1136/bmj.319.7207.407; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296, DOI 10.1152/physrev.1945.25.2.296; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FRYKBERG ER, 1988, ANN SURG, V208, P569, DOI 10.1097/00000658-198811000-00005; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HARVEY J, 1984, PRAMANA, V22, P447, DOI 10.1007/BF02847111; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Pierce JES, 1996, J NEUROSCI, V16, P1083; RICHMOND R, 1961, AEROSPACE MED, V32, P997; RICHMOND R, 1962, AEROSPACE MED, V33, P1; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stuhmiller J.H., 1991, CONVENTIONAL WARFARE, P241; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Zel'dovich Y.B, 1966, PHYS SHOCK WAVES HIG	49	66	67	0	20	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2155	2169		10.1089/neu.2010.1532			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500016	21639724	Bronze			2022-02-06	
J	Hilz, MJ; DeFina, PA; Anders, S; Koehn, J; Lang, CJ; Pauli, E; Flanagan, SR; Schwab, S; Marthol, H				Hilz, Max J.; DeFina, Philip A.; Anders, Stefan; Koehn, Julia; Lang, Christoph J.; Pauli, Elisabeth; Flanagan, Steven R.; Schwab, Stefan; Marthol, Harald			Frequency Analysis Unveils Cardiac Autonomic Dysfunction after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autonomic dysfunction; baroreflex; cardiovascular modulation; head trauma; TBI	HEART-RATE-VARIABILITY; BAROREFLEX EFFECTIVENESS INDEX; HYPERTENSIVE PATIENTS; PROGNOSTIC VALUE; BLOOD-PRESSURE; SUDDEN-DEATH; SENSITIVITY; ARRHYTHMIAS; MORTALITY; MODULATION	Long-term mortality is increased after mild traumatic brain injury (mTBI). Central cardiovascular-autonomic dysregulation resulting from subtle, trauma-induced brain lesions might contribute to cardiovascular events and fatalities. We investigated whether there is cardiovascular-autonomic dysregulation after mTBI. In 20 mTBI patients (37 +/- 13 years, 5-43 months post-injury) and 20 healthy persons (26 +/- 9 years), we monitored respiration, RR intervals (RRI), blood pressures (BP), while supine and upon standing. We calculated the root mean square successive RRI differences (RMSSD) reflecting cardiovagal modulation, the ratio of maximal and minimal RRIs around the 30th and 15th RRI upon standing (30:15 ratio) reflecting baroreflex sensitivity (BRS), spectral powers of parasympathetic high-frequency (HF: 0.15-0.5 Hz) RRI oscillations, of mainly sympathetic low-frequency (LF: 0.04-0.15 Hz) RRI oscillations, of sympathetic LF-BP oscillations, RRI-LF/HF-ratios reflecting sympathovagal balance, and the gain between BP and RRI oscillations as additional BRS index (BRSgain). We compared supine and standing parameters of patients and controls (repeated measures analysis of variance; significance: p < 0.05). While supine, patients had lower RRIs (874.2 +/- 157.8 vs. 1024.3 +/- 165.4 ms), RMSSDs (30.1 +/- 23.6 vs. 56.3 +/- 31.4 ms), RRI-HF powers (298.1 +/- 309.8 vs. 1507.2 +/- 1591.4 ms(2)), and BRSgain (8.1 +/- 4.4 vs. 12.5 +/- 8.1 ms.mmHg(-1)), but higher RRI-LF/HF-ratios (3.0 +/- 1.9 vs. 1.2 +/- 0.7) than controls. Upon standing, RMSSDs and RRI-HF-powers decreased significantly in controls, but not in patients; patients had lower RRI-30:15-ratios (1.3 +/- 0.3 vs. 1.6 +/- 0.3) and RRI-LF-powers (2450.0 +/- 2110.3 vs. 4805.9 +/- 3453.5 ms(2)) than controls. While supine, mTBI patients had reduced cardiovagal modulation and BRS. Upon standing, their BRS was still reduced, and patients did not withdraw parasympathetic or augment sympathetic modulation adequately. Impaired autonomic modulation probably contributes to cardiovascular irregularities post-mTBI.	[Hilz, Max J.] NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; [Hilz, Max J.] NYU, Dept Med, New York, NY 10016 USA; [Hilz, Max J.] NYU, Dept Psychiat, New York, NY 10016 USA; [Hilz, Max J.; Anders, Stefan; Koehn, Julia; Lang, Christoph J.; Pauli, Elisabeth; Schwab, Stefan; Marthol, Harald] Univ Erlangen Nurnberg, Dept Neurol, D-8520 Erlangen, Germany; [DeFina, Philip A.] Int Brain Res Fdn, Edison, NJ USA; [Flanagan, Steven R.] NYU, Sch Med, Dept Rehabil Med, New York, NY 10016 USA		Hilz, MJ (corresponding author), NYU, Sch Med, Dept Neurol, 550 1st Ave,Suite NB 7W11, New York, NY 10016 USA.	max.hilz@nyumc.org		Flanagan, Steven/0000-0001-9005-5897	International Brain Research Foundation Inc.; Genzyme Corporation, Cambridge, MASanofi-AventisGenzyme Corporation; IBRF, Edison, NJ	The study was partially funded by the International Brain Research Foundation Inc., IBRF, Edison, NJ.; Dr. Hilz received compensation for lectures and consulting services, and received research support from Genzyme Corporation, Cambridge, MA and IBRF, Edison, NJ.	Aminoff, 2002, NEUROMUSCULAR FUNCTI, P1899; Barbic F, 2007, HYPERTENSION, V49, P120, DOI 10.1161/01.HYP.0000250939.71343.7c; Barron HV, 1998, LANCET, V351, P461, DOI 10.1016/S0140-6736(05)78676-1; Benarroch EE, 1997, CENTRAL AUTONOMIC NE; Black M, 2002, J CLIN PATHOL, V55, P44, DOI 10.1136/jcp.55.1.44; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Camm AJ, 1996, CIRCULATION, V93, P1043; CDC, 2003, REP C MILD TRAUM BRA; Cencetti S, 1999, HEART, V82, P365, DOI 10.1136/hrt.82.3.365; Chan CT, 2008, J HYPERTENS, V26, P1795, DOI 10.1097/HJH.0b013e328308b7c8; Chan CT, 2005, KIDNEY INT, V68, P338, DOI 10.1111/j.1523-1755.2005.00411.x; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; DREIFUS LS, 1993, J AM COLL CARDIOL, V22, P948, DOI 10.1016/0735-1097(93)90217-O; Dutsch M, 2007, NEUROLOGY, V69, P2249, DOI 10.1212/01.wnl.0000286946.06639.a7; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Hilz MJ, 2008, STROKE, V39, P2421, DOI 10.1161/STROKEAHA.108.518613; Hilz MJ, 2010, J HYPERTENS, V28, P1438, DOI 10.1097/HJH.0b013e328336a077; Hilz MJ, 2002, BRAIN, V125, P985, DOI 10.1093/brain/awf092; Hilz MJ, 2001, ANN NEUROL, V49, P575, DOI 10.1002/ana.1006; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Honzikova N, 2000, PHYSIOL RES, V49, P643; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huikuri HV, 1999, J AM COLL CARDIOL, V34, P1878, DOI 10.1016/S0735-1097(99)00468-4; Johansson M, 2007, J HYPERTENS, V25, P163, DOI 10.1097/01.hjh.0000254377.18983.eb; Krause M, 2009, PEDIATR DIABETES, V10, P255, DOI 10.1111/j.1399-5448.2008.00447.x; La Rovere MT, 2001, CIRCULATION, V103, P2072; La Rovere MT, 1998, LANCET, V351, P478; Lanfranchi PA, 2002, AM J PHYSIOL-REG I, V283, pR815, DOI 10.1152/ajpregu.00051.2002; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; MCMILLAN TM, 2011, J NEUROL NEUROS 0131; NATELSON BH, 1993, NEUROL CLIN, V11, P293, DOI 10.1016/S0733-8619(18)30154-3; National Institute of Neurological Disorders and Stroke, 2002, NIH PUBL, V02-158; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; NOVAK V, 1997, CLIN AUTONOMIC DISOR, P323; Oppenheimer S, 2006, CLIN AUTON RES, V16, P6, DOI 10.1007/s10286-006-0276-0; OPPENHEIMER SM, 1991, BRAIN RES, V550, P115, DOI 10.1016/0006-8993(91)90412-O; OPPENHEIMER SM, 1990, ARCH NEUROL-CHICAGO, V47, P513, DOI 10.1001/archneur.1990.00530050029008; Orlandi G, 2000, ACTA NEUROL SCAND, V102, P317, DOI 10.1034/j.1600-0404.2000.102005317.x; Ormezzano O, 2008, J HYPERTENS, V26, P1373, DOI 10.1097/HJH.0b013e3283015e5a; PAGANI M, 1988, HYPERTENSION, V12, P600, DOI 10.1161/01.HYP.12.6.600; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; Parati G, 2001, ANN NY ACAD SCI, V940, P469; Rosengard-Barlund M, 2009, DIABETOLOGIA, V52, P1164, DOI 10.1007/s00125-009-1340-9; Rudiger H, 2001, AUTON NEUROSCI-BASIC, V93, P71, DOI 10.1016/S1566-0702(01)00326-5; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schwartz PJ, 1998, EUR HEART J, V19, P1593, DOI 10.1053/euhj.1998.1292; SINGER DH, 1995, HEART RATE VARIABILI, P429; Sykora M, 2008, CRIT CARE MED, V36, P3074, DOI 10.1097/CCM.0b013e31818b306d; Sykora M, 2009, STROKE, V40, P737, DOI 10.1161/STROKEAHA.108.519967; Tokgozoglu SL, 1999, STROKE, V30, P1307, DOI 10.1161/01.STR.30.7.1307; Tsuji H, 1996, CIRCULATION, V94, P2850, DOI 10.1161/01.CIR.94.11.2850; Wieling W, 1997, CLIN AUTONOMIC DISOR, P73; WIELING W, 1999, AUTONOMIC FAILURE, P197	55	66	66	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1727	1738		10.1089/neu.2010.1497			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000006	21355816				2022-02-06	
J	Scudday, T; Brasel, K; Webb, T; Codner, P; Somberg, L; Weigelt, J; Herrmann, D; Peppard, W				Scudday, Travis; Brasel, Karen; Webb, Travis; Codner, Panna; Somberg, Lewis; Weigelt, John; Herrmann, David; Peppard, William			Safety and Efficacy of Prophylactic Anticoagulation in Patients with Traumatic Brain Injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article; Proceedings Paper	118th Scientific Session of the Western-Surgical-Association	NOV 07-10, 2010	Chicago, IL	Western Surg Assoc			MOLECULAR-WEIGHT HEPARIN; INTRACRANIAL HEMORRHAGIC INJURIES; VENOUS THROMBOEMBOLISM; ENOXAPARIN PROPHYLAXIS; 1602 EPISODES; DATA-BANK; THROMBOSIS	BACKGROUND: Patients with traumatic brain injury (TBI) are at high risk for venous thromboembolism (VTE), but physicians are cautious with chemical prophylaxis in these patients because of concern about exacerbating intracranial hemorrhage. We hypothesized that early use of chemical thromboprophylaxis would reduce VTE incidence without increasing intracranial hemorrhage. STUDY DESIGN: Records of all patients admitted with a TBI to a Level I trauma center from 2006 to 2008 were reviewed. TBI was defined as intracranial hemorrhage, hematoma, contusion, or diffuse axonal injury with a head Abbreviated Injury Scale score >2. Patients were excluded if they were discharged or died within 72 hours of admission. Chemical prophylaxis was defined as subcutaneous or intravenous unfractionated heparin or low molecular weight heparin before any VTE diagnosis. Progression of TBI was defined by worsening CT findings. VTE was defined as deep venous thrombosis or pulmonary embolus confirmed by radiology reports. Primary outcomes were progression of hemorrhage and VTE events. RESULTS: Eight hundred and twelve of the 1,258 patients admitted to the trauma center with a TBI met study criteria. Chemical thromboprophylaxis was given to 49.5% (n = 402). Mean head Abbreviated Injury Scale score was 3.4 in both groups. One hundred and sixty-nine patients started prophylaxis within 48 hours and 242 patients began within 72 hours. Patients receiving chemical prophylaxis had a lower incidence of VTE (1% versus 3%; p = 0.019). Although not statistically significant, they also had a lower rate of injury progression, 3% versus 6% (p = 0.055). CONCLUSIONS: Use of chemical thromboprophylaxis in TBI patients with a stable or improved head CT after 24 hours substantially reduces the incidence of VTE and does not increase the risk of progression of intracranial hemorrhage. (J Am Coll Surg 2011; 213: 148-154. (C) 2011 by the American College of Surgeons)	[Scudday, Travis; Brasel, Karen; Webb, Travis; Codner, Panna; Somberg, Lewis; Weigelt, John] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Herrmann, David; Peppard, William] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Dept Pharm, Milwaukee, WI 53226 USA		Brasel, K (corresponding author), Med Coll Wisconsin, Dept Surg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	kbrasel@mcw.edu		Scudday, Travis/0000-0001-8865-492X			BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; *BRAIN TRAUM FDN A, 2007, J NEUROTRAUMA S1, V24, pS32, DOI DOI 10.1089/NEU.2007.9991; Brandt MM, 2007, AM J SURG, V193, P383; Cohn SM, 1999, VASCULAR SURG, V33, P219, DOI 10.1177/153857449903300219; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Depew AJ, 2008, AM SURGEON, V74, P906; Fowkes FJI, 2003, EUR J VASC ENDOVASC, V25, P1, DOI 10.1053/ejvs.2002.1778; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Hirsh J, 2001, CHEST, V119, p64S, DOI 10.1378/chest.119.1_suppl.64S; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Martinelli I, 2001, THROMB HAEMOSTASIS, V86, P395; Meissner MH, 2003, J TRAUMA, V54, P224, DOI 10.1097/01.TA.0000046253.33495.70; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Shackford SR, 2004, ANN SURG, V240, P496; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Tooher R, 2005, ANN SURG, V241, P397, DOI 10.1097/01.sla.0000154120.96169.99	20	66	71	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	JUL	2011	213	1					148	153		10.1016/j.jamcollsurg.2011.02.027			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	794SU	WOS:000292922400033	21459632				2022-02-06	
J	Sakellaridis, N; Pavlou, E; Karatzas, S; Chroni, D; Vlachos, K; Chatzopoulos, K; Dimopoulou, E; Kelesis, C; Karaouli, V				Sakellaridis, Nikolaos; Pavlou, Elias; Karatzas, Stylianos; Chroni, Despina; Vlachos, Konstantinos; Chatzopoulos, Konstantinos; Dimopoulou, Eleni; Kelesis, Christos; Karaouli, Vasiliki			Comparison of mannitol and hypertonic saline in the treatment of severe brain injuries	JOURNAL OF NEUROSURGERY			English	Article						mannitol; hypertonic saline; trauma; brain injury; intracranial hypertension; osmotic burden		Object. The purpose of this study was to compare the effects of mannitol and hypertonic saline in doses of similar osmotic burden for the treatment of intracranial hypertension in patients with severe traumatic brain injury. Methods. The authors used an alternating treatment protocol to compare the effect of hypertonic saline with that of mannitol given for episodes of increased intracranial pressure in patients treated for severe head injury at their hospital during 2006-2008. Standard guidelines for the management of severe traumatic brain injury were followed. Elevated intracranial pressure (ICP) was treated either with mannitol or hypertonic saline. Doses of similar osmotic burden (mannitol 20%, 2 ml/kg, infused over 20 minutes, or saline 15%, 0.42 ml/kg, administered as a bolus via a central venous catheter) were given alternately to the individual patient with severe brain injury during episodes of increased pressure. The dependent variables were the extent and duration of reduction of increased ICP. The choice of agent for treatment of the initial hypertensive event was determined on a randomized basis; treatment was alternated for every subsequent event in each individual patient. Reduction of ICP and duration of action were recorded after each event. Results obtained after mannitol administration were statistically compared with those obtained after hypertonic saline administration. Results. Data pertaining to 199 hypertensive events in 29 patients were collected. The mean decrease in ICP obtained with mannitol was 7.96 mm Hg and that obtained with hypertonic saline was 8.43 mm Hg (p = 0.586, equal variances assumed). The mean duration of effect was 3 hours 33 minutes for mannitol and 4 hours 17 minutes for hypertonic saline (p = 0.40, equal variances assumed). Conclusions. No difference between the 2 medications could be found with respect to the extent of reduction of ICP or duration of action. (DOI: 10.3171/2010.5.JNS091685)	[Sakellaridis, Nikolaos; Vlachos, Konstantinos; Kelesis, Christos] Dept Neurosurg, Attica, Greece; [Pavlou, Elias; Chatzopoulos, Konstantinos] Intens Care Unit 1, Attica, Greece; [Karatzas, Stylianos; Karaouli, Vasiliki] Univ Athens, Dept Intens Care, Attica, Greece; [Chroni, Despina; Dimopoulou, Eleni] KAT Natl Hosp, Intens Care Unit 2, Attica, Greece		Sakellaridis, N (corresponding author), Karaiskaki 23, Neo Psychiko 15451, Attica, Greece.	nicksac2@hotmail.com		Vlachos, Konstantinos/0000-0003-2794-1065			Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; LEHR R, 1992, STAT MED, V11, P1099, DOI 10.1002/sim.4780110811; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; Thomas L, 1997, CONSERV BIOL, V11, P276, DOI 10.1046/j.1523-1739.1997.96102.x; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; Yilmaz N, 2007, BRAIN RES, V1164, P132, DOI 10.1016/j.brainres.2007.06.017	11	66	72	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2011	114	2					545	548		10.3171/2010.5.JNS091685			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	710WU	WOS:000286548500043	21087203				2022-02-06	
J	DuBose, JJ; Barmparas, G; Inaba, K; Stein, DM; Scalea, T; Cancio, LC; Cole, J; Eastridge, B; Blackbourne, L				DuBose, Joseph J.; Barmparas, Gallinos; Inaba, Kenji; Stein, Deborah M.; Scalea, Tom; Cancio, Leopoldo C.; Cole, John; Eastridge, Brian; Blackbourne, Lorne			Isolated Severe Traumatic Brain Injuries Sustained During Combat Operations: Demographics, Mortality Outcomes, and Lessons to be Learned From Contrasts to Civilian Counterparts	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Severe traumatic brain injury; Combat; Civilian; Outcomes	RECEIVING MASSIVE TRANSFUSIONS; CENTER DESIGNATION; PLASMA; GUIDELINES; MANAGEMENT; SURVIVAL; MODERATE; RATIO	Background: Severe traumatic brain injuries occurring in the context of modern military conflict are entities about which little has been reported. We reviewed the epidemiology of these injuries from the Joint Trauma Theater Registry (JTTR), contrasting these results with civilian counterparts from the National Trauma Databank (NTDB). Methods: Isolated severe brain injuries (defined as head abbreviated injury scale [AIS] >= 3 and no other body region AIS >2) were queried from the JTTR over a period from 2003 to 2007. The demographics and outcomes of these injuries were reviewed. These results were then contrasted to findings of similar patients, age 18 years to 55 years, over the same period from the NTDB using propensity score matching derived from age, gender, systolic blood pressure, Glasgow Coma Scale, and AIS. Results: JTTR review identified 604 patients meeting study criteria, with a mean age of 25.7 years. Glasgow Coma Scale was <8 in 27.8%, and 98.0% were men. Hypotension at presentation was noted in 5.5%. Blast (61.9%) and gunshot wound (19.5%) mechanisms accounted for the majority of combat injuries. Intracranial pressure monitoring was used in 15.2%, and 27.0% underwent some form of operative cranial decompression, lobectomy, or debridement. When compared with matched civilian NTDB counterparts, JTTR patients were significantly more likely to undergo intracranial pressure monitoring (13.8% vs. 1.7%; p < 0.001) and operative neurosurgical intervention (21.5% vs. 7.2%; p < 0.001). Mortality was also significantly better among military casualties overall (7.7% vs. 21.0%; p < 0.001; odds ratio, 0.32 [0.16-0.61]) and particularly after penetrating mechanisms of injury (5.6% vs. 47.9%; p < 0.001; odds ratio, 0.07 [0.02-0.20]) compared with propensity score-matched NTDB counterparts. Conclusion: Patients sustaining severe traumatic brain injury during military operations represent a unique population. Comparison with civilian counterparts has inherent limitations but reveals higher rates of neurosurgical intervention performed after penetrating injuries and a corresponding improvement in survival. Many factors likely contribute to these findings, which highlight the need for additional research on the optimal management of penetrating brain injury.	[DuBose, Joseph J.; Stein, Deborah M.; Scalea, Tom] Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Barmparas, Gallinos; Inaba, Kenji] Univ So Calif, Los Angeles Cty Med Ctr, Div Trauma Surg & Surg Crit Care, Los Angeles, CA 90033 USA; [Cancio, Leopoldo C.; Cole, John; Eastridge, Brian; Blackbourne, Lorne] USA, Inst Surg Res, Ft Sam Houston, TX 78234 USA		DuBose, JJ (corresponding author), Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, 22 S Greene St,Room T5R46, Baltimore, MD 21201 USA.	jdubose@umm.edu	INABA, KENJI/AAC-8532-2020	Stein, Deborah/0000-0003-3683-3963			Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; BRIDGES E, 2010, AACN ADV CRIT CARE, V21, P278; Bridges E, 2010, AACN ADV CRIT CARE, V21, P260, DOI 10.1097/NCI.0b013e3181e67385; Brown JB, 2010, J TRAUMA, V69, P263, DOI 10.1097/TA.0b013e3181e5d72e; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Johannigman JA, 2008, CRIT CARE MED, V36, pS377, DOI 10.1097/CCM.0b013e31817e31e1; Li LM, 2010, ANESTH ANALG, V111, P736, DOI 10.1213/ANE.0b013e3181e75cd1; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; Perkins JG, 2007, J TRAUMA, V62, P1095, DOI 10.1097/TA.0b013e31804798a4; Scalea TM, 2008, ANN SURG, V248, P578, DOI 10.1097/SLA.0b013e31818990ed; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	23	66	68	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2011	70	1					11	18		10.1097/TA.0b013e318207c563			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	707WD	WOS:000286320300006	21217475				2022-02-06	
J	Liu, JH				Liu, Jianghong			Early health risk factors for violence: Conceptualization, evidence, and implications	AGGRESSION AND VIOLENT BEHAVIOR			English	Article						Health risk factors; Alcohol during pregnancy; Tobacco during pregnancy; Toxicity and drugs during pregnancy; Head injury during early childhood; Teenage pregnancy; Birth complications; Malnutrition of the pregnant mother; Malnutrition during early postnatal years; Brain dysfunction; Aggression; Child behavior problems; Violence prevention; Protective factors; Mediating factors; Biosocial interaction	LIFE-COURSE-PERSISTENT; AGE 3 YEARS; DEFICIT HYPERACTIVITY DISORDER; LIMITED ANTISOCIAL PATHWAYS; PRENATAL NICOTINE EXPOSURE; TRAUMATIC BRAIN-INJURY; ONSET CONDUCT PROBLEMS; SHAKEN BABY SYNDROME; MATERNAL DEPRESSION; DISRUPTIVE BEHAVIOR	Violence and aggression are public health problems that can benefit from ongoing research into risk reduction and prevention. Current developmental theories of violence and aggression emphasize biological and psychosocial factors, particularly during adolescence. However, there has been less focus on understanding the interactive, multiplicative effects of these processes. Furthermore, little attention has been given to the pre-, peri-, and postnatal periods, where prevention and intervention may yield effective results. Early health risk factors that influence negative behavioral outcomes include prenatal and postnatal nutrition, tobacco use during pregnancy, maternal depression, birth complications, traumatic brain injury, lead exposure, and child abuse. There is an ample literature to suggest that these early health risk factors may increase the likelihood of childhood externalizing behaviors, aggression, juvenile delinquency, adult criminal behavior, and/or violence. This paper proposes an early health risk factors framework for violence prediction, built on existing developmental theories of criminal behavior and supported by empirical findings. This framework addresses gaps in the adolescent psychopathology literature and presents a novel conceptualization of behavioral disturbance that emphasizes the pre-, peri-, and post-natal periods, when a child's development is critical and the opportunity for behavioral and environmental modification is high. Implications for such a framework on violence prevention programs are discussed. (C) 2010 Elsevier Ltd. All rights reserved.	[Liu, Jianghong] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; [Liu, Jianghong] Univ Penn, Sch Med, Philadelphia, PA 19104 USA		Liu, JH (corresponding author), Univ Penn, Sch Nursing, 418 Curie Blvd,Room 426,Claire M Fagin Hall, Philadelphia, PA 19104 USA.	jhliu@nursing.upenn.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES018858, K01ES015877, K02ES019878] Funding Source: NIH RePORTER; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01 ES018858, K01 ES015877, K01 ES015877-04, K02 ES019878, R01 ES018858-01] Funding Source: Medline		Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Arseneault L, 2002, CHILD DEV, V73, P496, DOI 10.1111/1467-8624.00420; Ashford J, 2008, J AM ACAD CHILD PSY, V47, P779, DOI 10.1097/CHI.0b013e318172eefb; Ashton R, 2010, J CHILD PSYCHOL PSYC, V51, P967, DOI 10.1111/j.1469-7610.2010.02272.x; Baker LA, 2008, J ABNORM CHILD PSYCH, V36, P1265, DOI 10.1007/s10802-008-9249-1; Bellinger DC, 2008, PLOS MED, V5, P690, DOI 10.1371/journal.pmed.0050115; Bellinger DC, 2005, INT J OCCUP ENV HEAL, V11, P138, DOI 10.1179/oeh.2005.11.2.138; BETHEA L, 1999, AM FAMILY PHYS  0315; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bishop D., 2009, RUTTERS CHILD ADOLES; Bjork JM, 1999, PSYCHOPHARMACOLOGY, V142, P24, DOI 10.1007/s002130050858; Blair RJR, 2004, BRAIN COGNITION, V55, P198, DOI 10.1016/s0278-2626(03)00276-8; Blatt-Eisengart I, 2009, DEV PSYCHOL, V45, P491, DOI 10.1037/a0014942; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; Breakey J, 1997, J PAEDIATR CHILD H, V33, P190, DOI 10.1111/j.1440-1754.1997.tb01578.x; Brennan PA, 1999, ARCH GEN PSYCHIAT, V56, P215, DOI 10.1001/archpsyc.56.3.215; Brennan PA, 2002, AM J PSYCHIAT, V159, P48, DOI 10.1176/appi.ajp.159.1.48; BROPHY MH, 1986, BIOL PSYCHIAT, V21, P704, DOI 10.1016/0006-3223(86)90137-X; Burns JM, 1999, AM J EPIDEMIOL, V149, P740, DOI 10.1093/oxfordjournals.aje.a009883; Burt KB, 2005, J CHILD PSYCHOL PSYC, V46, P490, DOI 10.1111/j.1469-7610.2004.00367.x; Campbell JC, 2007, TRAUMA VIOLENCE ABUS, V8, P246, DOI 10.1177/1524838007303505; Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290; Cecil KM, 2008, PLOS MED, V5, P741, DOI 10.1371/journal.pmed.0050112; Centers for Disease Control and Prevention, 2006, PRACT GUID WORK HLTH; Chen AM, 2005, J PEDIATR-US, V147, P570, DOI 10.1016/j.jpeds.2005.08.044; Coccaro EF, 1997, BIOL PSYCHIAT, V42, P546, DOI 10.1016/S0006-3223(97)00309-0; Curran GM, 2000, J DRUG ISSUES, V30, P375, DOI 10.1177/002204260003000208; D'Onofrio BM, 2010, ARCH GEN PSYCHIAT, V67, P529, DOI 10.1001/archgenpsychiatry.2010.33; de Haan M, 2006, DEVELOPMENTAL SCI, V9, P350, DOI 10.1111/j.1467-7687.2006.00499.x; Delville Y, 1999, NEUROTOXICOL TERATOL, V21, P445, DOI 10.1016/S0892-0362(98)00062-2; Department of Health and Human Services (DHHS), 2001, YOUTH VIOL REP SURG; Dietrich KN, 2001, NEUROTOXICOL TERATOL, V23, P511, DOI 10.1016/S0892-0362(01)00184-2; Donnellan MB, 2005, PSYCHOL SCI, V16, P328, DOI 10.1111/j.0956-7976.2005.01535.x; Eckstein LW, 1997, DEV BRAIN RES, V103, P59, DOI 10.1016/S0165-3806(97)00117-X; English DJ, 2002, CHILDHOOD VICTIMIZAT; Entringer S, 2009, HORM BEHAV, V55, P292, DOI 10.1016/j.yhbeh.2008.11.006; Evans LM, 2008, ARCH WOMEN MENT HLTH, V11, P239, DOI 10.1007/s00737-008-0019-4; Ezzati M., 2004, COMP QUANTIFICATION, V1; Farrington D P, 1989, Violence Vict, V4, P79; Farrington DP, 2005, ADV CRIM THEOR, V14, P73; Farrington DP, 2001, CLINICAL ASSESSMENT OF DANGEROUSNESS, P66; FARRINGTON DP, 1995, J CHILD PSYCHOL PSYC, V36, P929, DOI 10.1111/j.1469-7610.1995.tb01342.x; Farrington DP, 2000, BEHAV SCI LAW, V18, P605, DOI 10.1002/1099-0798(200010)18:5<605::AID-BSL406>3.0.CO;2-0; Farrington DP, 2007, SAVING CHILDREN LIFE; FERGUSSON DM, 1994, J CHILD PSYCHOL PSYC, V35, P1123, DOI 10.1111/j.1469-7610.1994.tb01813.x; FERGUSSON DM, 1995, J ABNORM CHILD PSYCH, V23, P183, DOI 10.1007/BF01447088; Fergusson DM, 2002, DEV PSYCHOPATHOL, V14, P159, DOI 10.1017/S0954579402001098; Fergusson DM, 2001, AUST NZ J PSYCHIAT, V35, P287, DOI 10.1046/j.1440-1614.2001.00902.x; Ferris C, 1996, UNDERSTANDING AGGRES; Fishbein D., 2001, BIOBEHAVIORAL PERSPE; Fushiki S., 2009, No To Hattatsu, V41, P219; Gatzke-Kopp LM, 2007, CHILD PSYCHIAT HUM D, V38, P255, DOI 10.1007/s10578-007-0059-4; GELFAND DM, 1990, CLIN PSYCHOL REV, V10, P329, DOI 10.1016/0272-7358(90)90065-I; Gibson CL, 2000, PSYCHOL REP, V86, P509, DOI 10.2466/PR0.86.2.509-518; Glover V, 2009, PSYCHONEUROENDOCRINO, V34, P430, DOI 10.1016/j.psyneuen.2008.10.005; HATZITASKOS P, 1994, JUVENILE FAM COURT J, V45, P29; Hawkins JD, 1999, ARCH PEDIAT ADOL MED, V153, P226, DOI 10.1001/archpedi.153.3.226; HIRSCHI T, 1977, AM SOCIOL REV, V42, P571, DOI 10.2307/2094556; Hodgins S, 2001, ARCH GEN PSYCHIAT, V58, P746, DOI 10.1001/archpsyc.58.8.746; Hoffman C, 2006, PARENT-SCI PRACT, V6, P271, DOI 10.1207/s15327922par0604_1; Hubbs-Tait Laura, 2005, Psychol Sci Public Interest, V6, P57, DOI 10.1111/j.1529-1006.2005.00024.x; Kairys SW, 2001, PEDIATRICS, V108, P206; Kelly TP, 1997, IRISH J PSYCHOL MED, V14, P136, DOI 10.1017/S0790966700003359; Kemppainen L, 2001, AM J PSYCHIAT, V158, P960, DOI 10.1176/appi.ajp.158.6.960; Kim-Cohen J, 2006, MOL PSYCHIATR, V11, P903, DOI 10.1038/sj.mp.4001851; Koller K, 2004, ENVIRON HEALTH PERSP, V112, P987, DOI 10.1289/ehp.6941; Korkman M, 2003, CHILD NEUROPSYCHOL, V9, P117, DOI 10.1076/chin.9.2.117.14503; Lester BM, 2010, J PEDIATR-US, V157, P288, DOI 10.1016/j.jpeds.2010.02.039; Lichtenberger EO., 2006, ASSESSING ADOLESCENT; Lister JP, 2005, HIPPOCAMPUS, V15, P393, DOI 10.1002/hipo.20065; LIU J, 2010, INT J NURSING STUDIE; Liu JH, 2005, INT J NURS STUD, V42, P229, DOI 10.1016/j.ijnurstu.2004.06.007; Liu JH, 2004, AM J PSYCHIAT, V161, P2005, DOI 10.1176/appi.ajp.161.11.2005; Liu JH, 2003, ARCH PEDIAT ADOL MED, V157, P593, DOI 10.1001/archpedi.157.6.593; Liu Jianghong, 2004, J Child Adolesc Psychiatr Nurs, V17, P93, DOI 10.1111/j.1744-6171.2004.tb00003.x; Liu JH, 2006, CURR OPIN PEDIATR, V18, P565, DOI 10.1007/0-387-29026-5_20; Liu JH, 2009, J RES ADOLESCENCE, V19, P93, DOI 10.1111/j.1532-7795.2009.00583.x; Mairesse J, 2007, AM J PHYSIOL-ENDOC M, V292, pE1526, DOI 10.1152/ajpendo.00574.2006; Malik NM, 2007, INFANT MENT HEALTH J, V28, P171, DOI 10.1002/imhj.20128; Marchand JF, 2002, PARENT-SCI PRACT, V2, P335, DOI 10.1207/S15327922PAR0204_01; MARGOLIN G, 1988, J CONSULT CLIN PSYCH, V56, P24, DOI 10.1037/0022-006X.56.1.24; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; McCarthy S, 2008, J HUM NUTR DIET, V21, P547, DOI 10.1111/j.1365-277X.2008.00913.x; Moffitt TE, 2002, DEV PSYCHOPATHOL, V14, P179, DOI 10.1017/S0954579402001104; MOFFITT TE, 1990, CRIME JUSTICE, V12, P99, DOI 10.1086/449165; Moffitt TE, 2001, DEV PSYCHOPATHOL, V13, P355, DOI 10.1017/S0954579401002097; MOFFITT TE, 1994, CRIMINOLOGY, V32, P277, DOI 10.1111/j.1745-9125.1994.tb01155.x; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Mohan D, 1998, IRISH J PSYCHOL MED, V15, P10, DOI 10.1017/S0790966700004602; Moore Colleen F, 2005, Psychol Sci Public Interest, V6, pi, DOI 10.1111/j.1529-1006.2005.00023.x; Muneoka K, 1997, DEV BRAIN RES, V102, P117, DOI 10.1016/S0165-3806(97)00092-8; National Institute on Drug Abuse, 2009, PRINC DRUG ADD TREAT; Needleman HL, 1996, JAMA-J AM MED ASSOC, V275, P363, DOI 10.1001/jama.275.5.363; NEUGEBAUER R, 1999, JAMA-J AM MED ASSOC, V282, P479; O'Donnell K, 2009, DEV NEUROSCI-BASEL, V31, P285, DOI 10.1159/000216539; Olds D, 1997, MENT RETARD DEV D R, V3, P257, DOI 10.1002/(SICI)1098-2779(1997)3:3<257::AID-MRDD6>3.3.CO;2-7; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Phelan K, 2007, INJURY PREV, V13, P403, DOI 10.1136/ip.2006.014571; Piquero A., 1999, STUDIES CRIME CRIME, V8, P52; Raine A, 1997, J AM ACAD CHILD PSY, V36, P1457, DOI 10.1097/00004583-199710000-00029; Raine A, 2005, J ABNORM PSYCHOL, V114, P38, DOI 10.1037/0021-843X.114.1.38; RAINE A, 1994, ARCH GEN PSYCHIAT, V51, P984; Raine A, 2003, ARCH GEN PSYCHIAT, V60, P1134, DOI 10.1001/archpsyc.60.11.1134; Raine A, 2002, DEV PSYCHOPATHOL, V14, P25, DOI 10.1017/S0954579402001025; Raine A, 2002, J CHILD PSYCHOL PSYC, V43, P417, DOI 10.1111/1469-7610.00034; RAINE A, 1997, BIOSOCIAL BASIS VIOL; Rasanen P, 1999, AM J PSYCHIAT, V156, P857; Rice DC, 2000, ENVIRON HEALTH PERSP, V108, P405, DOI 10.2307/3454528; ROBERTSON CM, 1989, J PEDIAT, V114, P343; ROSEN GM, 1985, J ADOLESCENT HEALTH, V6, P419, DOI 10.1016/S0197-0070(85)80045-0; Royal College of Nursing, 2006, MALN WHAT NURS WORK; Scarpa A, 2006, AGGRESSIVE BEHAV, V32, P502, DOI 10.1002/ab.20151; SCHUTZMAN S, 2008, PATIENT INFORM HEAD; SCIARILLO WG, 1992, AM J PUBLIC HEALTH, V82, P1356, DOI 10.2105/AJPH.82.10.1356; Sever Y, 1997, NEUROPSYCHOBIOLOGY, V35, P178, DOI 10.1159/000119341; Sie LTL, 2000, NEUROPEDIATRICS, V31, P128, DOI 10.1055/s-2000-7496; Sjostrom K, 1997, EUR J OBSTET GYN R B, V74, P149, DOI 10.1016/S0301-2115(97)00100-0; Sowell ER, 2007, NEUROREPORT, V18, P635, DOI 10.1097/WNR.0b013e3280bad8dc; Speltz ML, 1999, J ABNORM PSYCHOL, V108, P315, DOI 10.1037/0021-843X.108.2.315; Stoff D.M., 1997, HDB ANTISOCIAL BEHAV; Susman EJ, 2010, PSYCHONEUROENDOCRINO, V35, P557, DOI 10.1016/j.psyneuen.2009.09.004; Teicher M.H., 2000, CEREBRUM, V2, P50; Tremblay R.E., 2002, ENCY EARLY CHILDHOOD, P1; TREMBLAY RE, 1995, BUILDING SAFER SOC S, P151; Tremblay RE, 2010, J CHILD PSYCHOL PSYC, V51, P341, DOI 10.1111/j.1469-7610.2010.02211.x; U.S. DEP'T OF HEALTH & HUMAN SERVS, 2008, LONG TERM CONS CHILD; *US DEP HHS, 1992, ATSDR IMP LEAD CONT; *US DEP HHS, 2001, YOUTH VIOL REP SURG; VIRKKUNEN M, 1995, J PSYCHIATR NEUROSCI, V20, P271; Wadhwa P D, 2001, Prog Brain Res, V133, P131; WAKSCHLAG LS, 2009, MOL PSYCHIAT; WALL JE, 1994, J CLIN CHILD PSYCHOL, V23, P382, DOI 10.1207/s15374424jccp2304_4; WATTS DL, 1990, J ORTHOMOL MED, V5, P159; Webster-Stratton C, 1999, J CHILD PSYCHOL PSYC, V40, P917, DOI 10.1111/1469-7610.00509; WebsterStratton C, 1997, J CONSULT CLIN PSYCH, V65, P93, DOI 10.1037/0022-006X.65.1.93; Weitzman M, 2002, NEUROTOXICOL TERATOL, V24, P397, DOI 10.1016/S0892-0362(02)00201-5; Werbach M., 1992, J ORTHOMOL MED, V7, P45; WERBACH M, 1995, J ORTHOMOLECULAR MED, V7, P45; WIDOM CS, 1989, PSYCHOL BULL, V106, P3, DOI 10.1037/0033-2909.106.1.3; *WISC COUNC FAM CH, 2000, ASS INT CHILD LEAD P, pCH8; WRIGHT JP, 2009, PLOS MED, V5, P101	142	66	67	2	91	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-1789	1873-6335		AGGRESS VIOLENT BEH	Aggress. Violent Behav.	JAN-FEB	2011	16	1					63	73		10.1016/j.avb.2010.12.003			11	Criminology & Penology; Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Criminology & Penology; Psychology	739NY	WOS:000288726100007	21399727	Green Accepted			2022-02-06	
J	McCrory, P				McCrory, Paul			Sports Concussion and the Risk of Chronic Neurological Impairment	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sports concussion; neurological impairment	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; AMATEUR BOXING LEAD; AMYOTROPHIC-LATERAL-SCLEROSIS; APOLIPOPROTEIN-E EPSILON-4; REPETITIVE HEAD-INJURY; DEMENTIA-PUGILISTICA; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; RECURRENT CONCUSSION	Intense recent media focus on long-term outcomes from sports concussion has highlighted concerns on both cognitive deterioration and mental health issues, such as depression and suicide. At this time, the scientific evidence to support these views is limited, with only a handful of cases thus far reported. Based on the literature on this topic that extends back over 50 years, it is clear that only a small percentage of athletes suffer such sequelae presumably due to recurrent concussive or subconcussive head impacts. At this stage, determining which athletes are at future risk is not possible; however, following existing concussion guidelines (eg, Zurich guidelines) is likely to be the safest option based on current evidence.	Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia		McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia.	paulmccr@bigpond.net.au	McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568			Aotsuka A, 1990, Rinsho Shinkeigaku, V30, P1243; Bouras C, 1997, EUR NEUROL, V38, P53, DOI 10.1159/000112903; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; CANTU R, 1995, BOXING MED; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; Critchley M, 1937, MED ANNU, P318; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1046/j.1365-2990.1996.2598025.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; Iqbal K, CURR ALZHEIMER RES; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; Jordan B. D., 1998, SPORTS NEUROLOGY, P351; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; JORDAN BD, 1993, MED ASPECTS BOXING; KASTE M, 1982, LANCET, V2, P1186; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LACAVA G, 1963, J Sports Med Phys Fitness, V3, P87; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; LEVIN HS, 1993, MED ASPECTS BOXING, P197; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAWDSLEY C, 1963, LANCET, V2, P795; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; ROBERTS GW, 1988, LANCET, V2, P1456; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; Ross RT, 1999, MIL MED, V164, P68, DOI 10.1093/milmed/164.1.68; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; Sironi V A, 1982, J Neurosurg Sci, V26, P165; SPILLANE J D, 1962, Br Med J, V2, P1205; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; Unterharnscheidt F, 1995, Rev Neurol, V23, P661; Unterharnscheidt F J, 1972, Scand J Rehabil Med, V4, P77; Vandrovcova J, CURR ALZHEIMER RES; Williams DJ, 1996, PATHOLOGY, V28, P102, DOI 10.1080/00313029600169653; Zazryn T, 2007, SPORTS MED, V37, P467, DOI 10.2165/00007256-200737060-00001; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518; Zimmerman RD, 1993, MED ASPECTS BOXING, P188	85	66	66	1	63	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2011	21	1					6	12		10.1097/JSM.0b013e318204db50			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	702AM	WOS:000285866300011	21200164				2022-02-06	
J	Sarkamo, T; Pihko, E; Laitinen, S; Forsblom, A; Soinila, S; Mikkonen, M; Autti, T; Silvennoinen, HM; Erkkila, J; Laine, M; Peretz, I; Hietanen, M; Tervaniemi, M				Sarkamo, Teppo; Pihko, Elina; Laitinen, Sari; Forsblom, Anita; Soinila, Seppo; Mikkonen, Mikko; Autti, Taina; Silvennoinen, Heli M.; Erkkila, Jaakko; Laine, Matti; Peretz, Isabelle; Hietanen, Marja; Tervaniemi, Mari			Music and Speech Listening Enhance the Recovery of Early Sensory Processing after Stroke	JOURNAL OF COGNITIVE NEUROSCIENCE			English	Article							NMDA-RECEPTOR ANTAGONIST; MISMATCH NEGATIVITY MMN; AUDITORY CHANGE-DETECTION; EVENT-RELATED POTENTIALS; EARLY-ONSET STIMULATION; TRAUMATIC BRAIN-INJURY; ENVIRONMENTAL ENRICHMENT; NEUROTROPHIC FACTOR; NEURAL CHANGES; DURATION	Our surrounding auditory environment has a dramatic influence on the development of basic auditory and cognitive skills, but little is known about how it influences the recovery of these skills after neural damage. Here, we studied the long-term effects of daily music and speech listening on auditory sensory memory after middle cerebral artery (MCA) stroke. In the acute recovery phase, 60 patients who had middle cerebral artery stroke were randomly assigned to a music listening group, an audio book listening group, or a control group. Auditory sensory memory, as indexed by the magnetic MMN (MMNm) response to changes in sound frequency and duration, was measured 1 week (baseline), 3 months, and 6 months after the stroke with whole-head magnetoencephalography recordings. Fifty-four patients completed the study. Results showed that the amplitude of the frequency MMNm increased significantly more in both music and audio book groups than in the control group during the 6-month poststroke period. In contrast, the duration MMNm amplitude increased more in the audio book group than in the other groups. Moreover, changes in the frequency MMNm amplitude correlated significantly with the behavioral improvement of verbal memory and focused attention induced by music listening. These findings demonstrate that merely listening to music and speech after neural damage can induce long-term plastic changes in early sensory processing, which, in turn, may facilitate the recovery of higher cognitive functions. The neural mechanisms potentially underlying this effect are discussed.	[Sarkamo, Teppo] Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, FIN-00014 Helsinki, Finland; [Pihko, Elina] BioMag Lab, Helsinki, Finland; [Laitinen, Sari; Forsblom, Anita; Erkkila, Jaakko] Univ Jyvaskyla, SF-40351 Jyvaskyla, Finland; [Soinila, Seppo; Autti, Taina; Silvennoinen, Heli M.; Hietanen, Marja] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; [Peretz, Isabelle] Univ Montreal, Montreal, PQ H3C 3J7, Canada		Sarkamo, T (corresponding author), Univ Helsinki, Dept Psychol, Cognit Brain Res Unit, POB 9,Siltavuorenpenger 20 C, FIN-00014 Helsinki, Finland.	teppo.sarkamo@helsinki.fi	Pihko, Elina/J-6026-2012	Tervaniemi, Mari/0000-0002-9651-2929; Sarkamo, Teppo/0000-0002-1470-4530; Erkkila, Jaakko/0000-0003-1130-837X	Academy of FinlandAcademy of FinlandEuropean Commission [77322]; Jenny and Antti Wihuri Foundation (Helsinki, Finland); National Graduate School of Psychology; Neurology Foundation (Helsinki, Finland)	This work was supported by the Academy of Finland (project no. 77322), the Jenny and Antti Wihuri Foundation (Helsinki, Finland), the National Graduate School of Psychology, and the Neurology Foundation (Helsinki, Finland). The authors thank the staff of the HUCH Department of Neurology and other rehabilitation hospitals in the Helsinki metropolitan area for their collaboration, the patient subjects and their families for their participation and effort, and Minna Huotilainen, Anna Shestakova, Irina Anourova, Suvi Heikkila, Jyrki Makela, and Jussi Nurminen for their technical assistance.	AHLFORS S, 1989, P 7 INT C BIOM, P693; Ahveninen J, 1999, ALCOHOL CLIN EXP RES, V23, P1507, DOI 10.1111/j.1530-0277.1999.tb04674.x; ALHO K, 1995, EAR HEARING, V16, P38, DOI 10.1097/00003446-199502000-00004; ALHO K, 1989, PSYCHOPHYSIOLOGY, V26, P514, DOI 10.1111/j.1469-8986.1989.tb00704.x; Amenedo E, 2000, EUR J NEUROSCI, V12, P2570, DOI 10.1046/j.1460-9568.2000.00114.x; Angelucci F, 2007, NEUROSCI LETT, V429, P152, DOI 10.1016/j.neulet.2007.10.005; Angelucci F, 2007, BEHAV PHARMACOL, V18, P491, DOI 10.1097/FBP.0b013e3282d28f50; Atienza M, 2002, LEARN MEMORY, V9, P138, DOI 10.1101/lm.46502; Baldeweg T, 2004, SCHIZOPHR RES, V69, P203, DOI 10.1016/j.schres.2003.09.009; Bi CX, 2006, BRAIN RES, V1110, P30, DOI 10.1016/j.brainres.2006.06.056; Blood AJ, 1999, NAT NEUROSCI, V2, P382, DOI 10.1038/7299; Brown S, 2004, NEUROREPORT, V15, P2033, DOI 10.1097/00001756-200409150-00008; Centonze D, 2007, NEUROBIOL DIS, V27, P44, DOI 10.1016/j.nbd.2007.03.012; Chikahisa S, 2006, BEHAV BRAIN RES, V169, P312, DOI 10.1016/j.bbr.2006.01.021; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.ne.11.030188.000425; COWAN N, 1988, PSYCHOL BULL, V104, P163, DOI 10.1037/0033-2909.104.2.163; Csepe V, 2001, NEUROPSYCHOLOGIA, V39, P1194, DOI 10.1016/S0028-3932(01)00052-5; Deouell LY, 2000, BRAIN, V123, P353, DOI 10.1093/brain/123.2.353; Ehrlichman RS, 2008, J COGNITIVE NEUROSCI, V20, P1403, DOI 10.1162/jocn.2008.20097; Engineer ND, 2004, J NEUROPHYSIOL, V92, P73, DOI 10.1152/jn.00059.2004; Flores-Gutierrez EO, 2007, INT J PSYCHOPHYSIOL, V65, P69, DOI 10.1016/j.ijpsycho.2007.03.004; Garrido MI, 2009, CLIN NEUROPHYSIOL, V120, P453, DOI 10.1016/j.clinph.2008.11.029; GIARD MH, 1990, PSYCHOPHYSIOLOGY, V27, P627, DOI 10.1111/j.1469-8986.1990.tb03184.x; Griffiths TD, 1999, NEUROREPORT, V10, P3825, DOI 10.1097/00001756-199912160-00019; Ilvonen TM, 2003, STROKE, V34, P1746, DOI 10.1161/01.STR.0000078836.26328.3B; Jaaskelainen IP, 2007, TRENDS NEUROSCI, V30, P653, DOI 10.1016/j.tins.2007.09.003; Janata P, 2002, COGN AFFECT BEHAV NE, V2, P121, DOI 10.3758/CABN.2.2.121; Jansson-Verkasalo E, 2004, CLIN NEUROPHYSIOL, V115, P179, DOI 10.1016/S1388-2457(03)00319-5; Jaramillo M, 2000, NEUROSCI LETT, V290, P101, DOI 10.1016/S0304-3940(00)01344-6; Javitt DC, 1996, P NATL ACAD SCI USA, V93, P11962, DOI 10.1073/pnas.93.21.11962; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Johansson BB, 2004, RESTOR NEUROL NEUROS, V22, P163; Kawakubo Y, 2006, NEUROREPORT, V17, P1043, DOI 10.1097/01.wnr.0000221828.10846.ba; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Kiang M, 2007, J INT NEUROPSYCH SOC, V13, P653, DOI 10.1017/S1355617707070816; Kim H, 2006, BRAIN DEV-JPN, V28, P109, DOI 10.1016/j.braindev.2005.05.008; Korostenskaja M, 2007, BRAIN RES BULL, V72, P275, DOI 10.1016/j.brainresbull.2007.01.007; Kreisel SH, 2006, CEREBROVASC DIS, V21, P6, DOI 10.1159/000089588; Kreitschmann-Andermahr I, 2001, COGNITIVE BRAIN RES, V12, P109, DOI 10.1016/S0926-6410(01)00043-X; Kujala T, 2001, P NATL ACAD SCI USA, V98, P10509, DOI 10.1073/pnas.181589198; Kujala T, 2007, BIOL PSYCHOL, V74, P1, DOI 10.1016/j.biopsycho.2006.06.001; Levanen S, 1996, CEREB CORTEX, V6, P288, DOI 10.1093/cercor/6.2.288; Light GA, 2005, ARCH GEN PSYCHIAT, V62, P127, DOI 10.1001/archpsyc.62.2.127; Light GA, 2007, J COGNITIVE NEUROSCI, V19, P1624, DOI 10.1162/jocn.2007.19.10.1624; Lindenberg R, 2007, NEUROPSYCHOLOGIA, V45, P2407, DOI 10.1016/j.neuropsychologia.2007.02.008; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; MAZOYER BM, 1993, J COGNITIVE NEUROSCI, V5, P467, DOI 10.1162/jocn.1993.5.4.467; Menning H, 2002, LEARN MEMORY, V9, P253, DOI 10.1101/lm.49402; Mikkola K, 2007, CLIN NEUROPHYSIOL, V118, P1494, DOI 10.1016/j.clinph.2007.04.012; Molholm S, 2005, CEREB CORTEX, V15, P545, DOI 10.1093/cercor/bhh155; Naatanen R, 2007, CLIN NEUROPHYSIOL, V118, P2544, DOI 10.1016/j.clinph.2007.04.026; NAATANEN R, 1991, PSYCHOPHYSIOLOGY, V28, P478, DOI 10.1111/j.1469-8986.1991.tb00735.x; Nenadic I, 2003, EXP BRAIN RES, V148, P238, DOI 10.1007/s00221-002-1188-4; Nichols JA, 2007, NEUROSCIENCE, V145, P832, DOI 10.1016/j.neuroscience.2006.12.061; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Novitski N, 2004, COGNITIVE BRAIN RES, V20, P26, DOI 10.1016/j.cogbrainres.2003.12.011; Opitz B, 2002, NEUROIMAGE, V15, P167, DOI 10.1006/nimg.2001.0970; PAAVILAINEN P, 1991, ELECTROEN CLIN NEURO, V78, P466, DOI 10.1016/0013-4694(91)90064-B; Papathanassiou D, 2000, NEUROIMAGE, V11, P347, DOI 10.1006/nimg.2000.0546; Pekkonen E, 2000, AUDIOL NEURO-OTOL, V5, P216, DOI 10.1159/000013883; Percaccio CR, 2005, J NEUROPHYSIOL, V94, P3590, DOI 10.1152/jn.00433.2005; Pettigrew CM, 2005, APHASIOLOGY, V19, P131, DOI 10.1080/02687030444000642; Reiterer SM, 2005, NEUROREPORT, V16, P239, DOI 10.1097/00001756-200502280-00007; Restuccia D, 2005, COGNITIVE BRAIN RES, V25, P891, DOI 10.1016/j.cogbrainres.2005.09.023; Rinne T, 2000, NEUROIMAGE, V12, P14, DOI 10.1006/nimg.2000.0591; Santos Marco Aurelio Rocha, 2006, Braz J Otorhinolaryngol, V72, P800; Sarkamo T, 2008, BRAIN, V131, P866, DOI 10.1093/brain/awn013; Schabitz WR, 2007, STROKE, V38, P2165, DOI 10.1161/STROKEAHA.106.477331; Schmithorst VJ, 2006, NEUROIMAGE, V29, P254, DOI 10.1016/j.neuroimage.2005.07.020; Srinivasan N, 2007, NEUROREPORT, V18, P1709, DOI 10.1097/WNR.0b013e3282f0d2d8; Tallal P, 2006, TRENDS NEUROSCI, V29, P382, DOI 10.1016/j.tins.2006.06.003; Tervaniemi M, 2005, CLIN NEUROPHYSIOL, V116, P1897, DOI 10.1016/j.clinph.2005.03.025; Tervaniemi M, 1999, CLIN NEUROPHYSIOL, V110, P1388, DOI 10.1016/S1388-2457(99)00108-X; Tervaniemi M, 2006, EUR J NEUROSCI, V23, P2538, DOI 10.1111/j.1460-9568.2006.04752.x; TIITINEN H, 1994, NATURE, V372, P90, DOI 10.1038/372090a0; Tikhonravov D, 2008, BRAIN RES, V1203, P97, DOI 10.1016/j.brainres.2008.02.006; Toyomaki A, 2008, PROG NEURO-PSYCHOPH, V32, P95, DOI 10.1016/j.pnpbp.2007.07.020; Turetsky BI, 2007, SCHIZOPHRENIA BULL, V33, P69, DOI 10.1093/schbul/sbl060; Tzourio-Mazoyer N, 2004, NEUROIMAGE, V21, P422, DOI 10.1016/j.neuroimage.2003.08.032; Umbricht D, 2002, BIOL PSYCHIAT, V51, P400, DOI 10.1016/S0006-3223(01)01242-2; Uutela K, 1999, NEUROIMAGE, V10, P173, DOI 10.1006/nimg.1999.0454; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Xu F, 2007, NEUROSCI LETT, V420, P179, DOI 10.1016/j.neulet.2007.05.005	84	66	72	1	29	MIT PRESS	CAMBRIDGE	ONE ROGERS ST, CAMBRIDGE, MA 02142-1209 USA	0898-929X	1530-8898		J COGNITIVE NEUROSCI	J. Cogn. Neurosci.	DEC	2010	22	12					2716	2727		10.1162/jocn.2009.21376			12	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	641MB	WOS:000281129400004	19925203				2022-02-06	
J	Schonberger, M; Ponsford, J				Schoenberger, Michael; Ponsford, Jennie			The factor structure of the Hospital Anxiety and Depression Scale in individuals with traumatic brain injury	PSYCHIATRY RESEARCH			English	Article						Hospital Anxiety and Depression Scale (HADS); Traumatic Brain Injury (TBI); Confirmatory Factor Analysis; Multi-Trait Multi-Method/Correlated; Trait-Correlated Method approach; Diagnosis	SELF-ESTEEM SCALE; MOOD DISORDERS; MODEL; DIMENSIONALITY; VALIDATION; INVARIANCE; VALIDITY	There is a lack of validated scales for screening for anxiety and depression in individuals with traumatic brain injury (TB!). The purpose of this study was to examine the factor structure of the Hospital Anxiety and Depression Scale (HADS) in individuals with TBI. A total of 294 individuals with TBI (72.1% male; mean age 37.1 years, S.D. 17.5, median post-traumatic amnesia (PTA) duration 17 days) completed the HADS 1 year post-injury. A series of confirmatory factor analyses was conducted to examine the fit of a one-, two- and three-factor solution, with and without controlling for item wording effects (Multi-Trait Multi-Method approach). The one-, two- or three-factor model fit the data only when controlling for negative item wording. The results are in support of the validity of the original anxiety and depression subscales of the HADS and demonstrate the importance of evaluating item wording effects when examining the factor structure of a questionnaire. The results would also justify the use of the HADS as a single scale of emotional distress. However, even though the three-factor solution fit the data, alternative scales should be used if the purpose of the assessment is to measure stress symptoms separately from anxiety and depression. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Schoenberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3004, Australia; [Schoenberger, Michael; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia		Schonberger, M (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	michael_schoenberger@web.de					Abbott RA, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-76; Aluja A, 2007, J PERS ASSESS, V88, P246, DOI 10.1080/00223890701268116; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Caci H, 2003, PSYCHIAT RES, V118, P89, DOI 10.1016/S0165-1781(03)00044-1; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Dawkins N, 2006, BRAIN INJURY, V20, P1235, DOI 10.1080/02699050601076414; Desmond DM, 2005, INT J GERIATR PSYCH, V20, P344, DOI 10.1002/gps.1289; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DiStefano C, 2009, STRUCT EQU MODELING, V16, P134, DOI 10.1080/10705510802565403; DiStefano C, 2009, PERS INDIV DIFFER, V46, P309, DOI 10.1016/j.paid.2008.10.020; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Dunbar M, 2000, BRIT J CLIN PSYCHOL, V39, P79, DOI 10.1348/014466500163121; Eid M, 2000, PSYCHOMETRIKA, V65, P241, DOI 10.1007/BF02294377; Graham JM, 2006, EDUC PSYCHOL MEAS, V66, P930, DOI 10.1177/0013164406288165; Greenberger E, 2003, PERS INDIV DIFFER, V35, P1241, DOI 10.1016/S0191-8869(02)00331-8; HANCOCK GR, 2001, EQUATION MODELING PR; Haslam N, 2003, AUST NZ J PSYCHIAT, V37, P696, DOI 10.1111/j.1440-1614.2003.01258.x; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Horan PM, 2003, STRUCT EQU MODELING, V10, P435, DOI 10.1207/S15328007SEM1003_6; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kaufman J, 2000, DEPRESS ANXIETY, V12, P69, DOI 10.1002/1520-6394(2000)12:1+<69::AID-DA9>3.0.CO;2-K; Lance CE, 2002, PSYCHOL METHODS, V7, P228, DOI 10.1037//1082-989X.7.2.228; Lord F. M., 1968, STAT THEORIES MENTAL; Marsh H.W., 1995, STRUCTURAL EQUATION, P177; Marsh HW, 1996, J PERS SOC PSYCHOL, V70, P810, DOI 10.1037/0022-3514.70.4.810; MARSH HW, 1989, APPL PSYCH MEAS, V13, P335, DOI 10.1177/014662168901300402; Martin C, 2004, PSYCHOL HEALTH MED, V9, P327, DOI DOI 10.1080/13548500410001721891; Martin CR, 2005, CURR PSYCHIATRY REV, V1, P69, DOI 10.2174/1573400052953510; Martin CR, 2004, PSYCHIAT RES, V129, P279, DOI 10.1016/j.psychres.2004.06.012; Martin CR, 2004, BRIT J CLIN PSYCHOL, V43, P51, DOI 10.1348/014466504772812968; Motl RW, 2002, STRUCT EQU MODELING, V9, P562, DOI 10.1207/S15328007SEM0904_6; Muthen B., 1997, ROBUST INFERENCE USI; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pallant JF, 2007, BRIT J CLIN PSYCHOL, V46, P1, DOI 10.1348/014466506X96931; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Quilty LC, 2006, STRUCT EQU MODELING, V13, P99, DOI 10.1207/s15328007sem1301_5; RAZAVI D, 1990, BRIT J PSYCHIAT, V156, P79, DOI 10.1192/bjp.156.1.79; SCHRIESHEIM CA, 1981, EDUC PSYCHOL MEAS, V41, P1101, DOI 10.1177/001316448104100420; Snaith R., 1983, HOSP ANXIETY DEPRESS; Tomas JM, 1999, STRUCT EQU MODELING, V6, P84, DOI 10.1080/10705519909540120; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Wu CH, 2008, J SOC PSYCHOL, V148, P535, DOI 10.3200/SOCP.148.5.535-552	52	66	67	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	OCT 30	2010	179	3					342	349		10.1016/j.psychres.2009.07.003			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	676FV	WOS:000283897300018	20483471				2022-02-06	
J	Varma, A; Hill, EG; Nicholas, J; Selassie, A				Varma, Abhay; Hill, Elizabeth G.; Nicholas, Joyce; Selassie, Anbesaw			Predictors of Early Mortality After Traumatic Spinal Cord Injury A Population-Based Study	SPINE			English	Article						spinal cord injury; mortality; comorbidities; ISS; TBI; Frankel grade	LONG-TERM SURVIVAL; SEVERITY SCORE; MULTIPLE INJURIES; IMPROVES ACCURACY; OLMSTED COUNTY; UNITED-STATES; PREVALENCE; OBESITY; TRENDS; DEATH	Study Design. Retrospective cohort study. Objective. To identify predictors of early mortality following traumatic spinal cord injury (TSCI). Summary of Background Data. Limited information is available on factors associated with early mortality following TSCI. Ability to identify high risk individuals can help to appropriately treat them, and reduce mortality. Methods. Early mortality was defined as death occurring during the initial hospital admission. Retrospective analysis of 1995 patients with TSCI, admitted to various hospitals of South Carolina from 1993 to 2003, was performed. There were 251 patients with early mortality. Multivariable logistic regression was used in modeling of early death following TSCI with gender, race, age, Frankel grade, trauma center, level of injury, injury severity score (ISS), traumatic brain injury (TBI), and medical comorbidities as covariates. Results. Increasing age after 20 years (OR: 1.2, P = <0.0001), male gender (OR: 1.6, P = 0.016), severe (ISS >= 15) systemic injuries (OR: 1.9, P = 0.012), TBI (OR: 3.7, P < 0.0001), 1 or more comorbidities (P < 0.0001), poor neurologic status (P = 0.015), and level 1 trauma center (OR: 1.4, P = 0.026) were significantly associated with early mortality, after adjusting for other covariates. Conclusion. Early mortality following TSCI is influenced by multiple factors. Timely recognition of these factors is crucial for improving survival in the acute care setting. Severe systemic injuries, medical comorbidities, and TBI continue to be the main limiting factors affecting the outcome. These findings also suggest the need to allocate resources for trauma prevention, and promote research towards improving the care of acutely injured patients.	[Varma, Abhay] Med Univ S Carolina, Div Neurosurg, Dept Neurosci, Charleston, SC 29425 USA; [Hill, Elizabeth G.; Nicholas, Joyce; Selassie, Anbesaw] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA		Varma, A (corresponding author), Med Univ S Carolina, Div Neurosurg, Dept Neurosci, 96 Jonathan Lucas St,Suite 428-CSB, Charleston, SC 29425 USA.	varma@musc.edu					[Anonymous], 1996, INT CLASS DIS 9 REV; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bilello JF, 2003, ARCH SURG-CHICAGO, V138, P1127, DOI 10.1001/archsurg.138.10.1127; Damadi AA, 2008, J TRAUMA, V64, P745, DOI 10.1097/TA.0b013e3180341fc6; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Frankel H L, 1969, Paraplegia, V7, P179; Frankel HL, 1998, SPINAL CORD, V36, P266, DOI 10.1038/sj.sc.3100638; Garshick E, 2005, SPINAL CORD, V43, P408, DOI 10.1038/sj.sc.3101729; Gregg EW, 2004, DIABETES CARE, V27, P2806, DOI 10.2337/diacare.27.12.2806; GRIFFIN MR, 1985, AM J EPIDEMIOL, V121, P884, DOI 10.1093/oxfordjournals.aje.a114058; GRIFFIN MR, 1985, J CHRON DIS, V38, P643, DOI 10.1016/0021-9681(85)90018-9; Harsha DW, 2008, HYPERTENSION, V51, P1420, DOI 10.1161/HYPERTENSIONAHA.107.094011; Hosalkar HS, 2005, J BONE JOINT SURG AM, V87A, P2480, DOI 10.2106/JBJS.D.01897; KRAUS JF, 1980, J NEUROSURG, V53, pS3; Krause JS, 1997, ARCH PHYS MED REHAB, V78, P815, DOI 10.1016/S0003-9993(97)90193-3; Kuhne CA, 2005, WORLD J SURG, V29, P1476, DOI 10.1007/s00268-005-7796-y; Lavoie A, 2004, J TRAUMA, V56, P1312, DOI 10.1097/01.TA.0000075342.36072.EF; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacLeod JBA, 2004, AM SURGEON, V70, P805; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; National Spinal Cord Injury Statistical Center, 2005, J SPINAL CORD MED, V28, P379; Nijboer JMM, 2007, J TRAUMA, V63, P670, DOI 10.1097/01.ta.0000228890.65522.53; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ong KL, 2007, HYPERTENSION, V49, P69, DOI 10.1161/01.HYP.0000252676.46043.18; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; SAMSA GP, 1993, ARCH NEUROL-CHICAGO, V50, P909, DOI 10.1001/archneur.1993.00540090018005; Saunders LL, 2009, J TRAUMA, V66, P184, DOI 10.1097/TA.0b013e31815644e5; Seeman Teresa E., 1997, Archives of Internal Medicine, V157, P2259, DOI 10.1001/archinte.157.19.2259; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Soderstrom CA, 1997, J TRAUMA, V43, P925; Surkin J, 2000, SPINE, V25, P716, DOI 10.1097/00007632-200003150-00011; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; Yeo JD, 1998, SPINAL CORD, V36, P329, DOI 10.1038/sj.sc.3100628	39	66	67	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	APR 1	2010	35	7					778	783		10.1097/BRS.0b013e3181ba1359			6	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	585NV	WOS:000276833500010	20228715				2022-02-06	
J	Liu, Y; Figley, S; Spratt, SK; Lee, G; Ando, D; Surosky, R; Fehlings, MG				Liu, Yang; Figley, Sarah; Spratt, S. Kaye; Lee, Gary; Ando, Dale; Surosky, Richard; Fehlings, Michael G.			An engineered transcription factor which activates VEGF-A enhances recovery after spinal cord injury	NEUROBIOLOGY OF DISEASE			English	Article						SCI; ZFP-VEGF; Angiogenesis; Neuroprotection; Molecular therapy	ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; THERAPEUTIC ANGIOGENESIS; HINDLIMB ISCHEMIA; GENE-TRANSFER; NEUROLOGICAL FUNCTION; NERVOUS-SYSTEM; BLOOD-FLOW; EXPRESSION; RAT	Spinal cord injury (SCI) leads to local vascular disruption and progressive ischemia, which contribute to secondary degeneration. Enhancing angiogenesis through the induction of vascular endothelial growth factor (VEGF)-A expression therefore constitutes an attractive therapeutic approach. Moreover. emerging evidence suggests that VEGF-A may also exhibit neurotrophic, neuroprotective, and neuroproliferative effects. Building on this previous work, we seek to examine the potential therapeutic benefits of an engineered zinc finger protein (ZFP) transcription factor designed to activate expression of all isoforms of endogenous VEGF-A (ZFP-VEGF). Administration of ZFP-VEGF resulted in increased VEGF-A mRNA and protein levels, an attenuation of axonal degradation, a significant increase in vascularity and decreased levels of apoptosis. Furthermore, ZFP-VEGF treated animals showed significant improvements in tissue preservation and neurobehavioural outcomes. These data suggest that activation of VEGF-A via the administration of an engineered ZFP transcription factor holds promise as a therapy for SCI and potentially other forms of neurotrauma. (c) 2009 Elsevier Inc. All rights reserved.	[Liu, Yang; Figley, Sarah; Fehlings, Michael G.] Univ Hlth Network, Toronto Western Res Inst, Dept Genet & Dev, Toronto, ON, Canada; [Liu, Yang; Figley, Sarah; Fehlings, Michael G.] Univ Hlth Network, Krembil Neurosci Ctr, Spinal Program, Toronto, ON, Canada; [Spratt, S. Kaye; Lee, Gary; Ando, Dale; Surosky, Richard] Sangamo BioSci, Dept Therapeut Dev, Richmond, CA USA; [Fehlings, Michael G.] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Figley, Sarah; Fehlings, Michael G.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada		Fehlings, MG (corresponding author), Univ Toronto, Univ Hlth Network, Div Neurosurg, 399 Bathurst St,4WW 449, Toronto, ON M5T 2S8, Canada.	Michael.Fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364	Sangamo BioSciences; Krembil Chair in Neural Repair and Regeneration	The authors would like to thank Wendy Zhang for assistance with the histochemistry experiments, Jian Wang and Behzad Azad for their help with behavioural testing, Julio Furlan for assistance with data analysis and Allyson Tighe for her editorial reviews. This study was supported by Sangamo BioSciences and the Krembil Chair in Neural Repair and Regeneration (held by Dr. Michael G. Fehlings). The authors thank Philip Gregory and Edward Rebar of Sangamo BioSciences for scientific review.	Adris S, 2005, CELL MOL NEUROBIOL, V25, P1035, DOI 10.1007/s10571-005-8472-3; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Baumgartner I, 2000, ANN INTERN MED, V132, P880, DOI 10.7326/0003-4819-132-11-200006060-00005; Benton RL, 2003, NEUROCHEM RES, V28, P1693, DOI 10.1023/A:1026013106016; Burger C, 2004, MOL THER, V10, P302, DOI 10.1016/j.ymthe.2004.05.024; Bustin Stephen A, 2004, J Biomol Tech, V15, P155; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Choi BH, 2007, J NEUROSURG-SPINE, V7, P54, DOI 10.3171/SPI-07/07/054; Dai QS, 2004, CIRCULATION, V110, P2467, DOI 10.1161/01.CIR.0000145139.53840.49; Facchiano F, 2002, J NEUROSURG, V97, P161, DOI 10.3171/jns.2002.97.1.0161; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481; Hermens WTJMC, 1997, J NEUROSCI METH, V71, P85, DOI 10.1016/S0165-0270(96)00129-X; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Karimi-Abdolrezaee S, 2004, EUR J NEUROSCI, V19, P577, DOI 10.1111/j.0953-816X.2004.03164.x; Kaya D, 2005, J CEREBR BLOOD F MET, V25, P1111, DOI 10.1038/sj.jcbfm.9600109; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Larrivee B, 2000, INT J MOL MED, V5, P447; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li YJ, 2007, DIABETES, V56, P656, DOI 10.2337/db06-0999; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Marti HH, 2002, ADV EXP MED BIOL, V513, P375; McMahon SS, 2009, J ANAT, V215, P267, DOI 10.1111/j.1469-7580.2009.01107.x; Price SA, 2006, DIABETES, V55, P1847, DOI 10.2337/db05-1060; Rajagopalan S, 2003, CIRCULATION, V108, P1933, DOI 10.1161/01.CIR.0000093398.16124.29; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170, DOI 10.1097/01.wcb.0000037988.07114.98; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wang YM, 2006, BRAIN RES, V1115, P186, DOI 10.1016/j.brainres.2006.07.060; Xie DH, 2006, J VASC SURG, V44, P166, DOI 10.1016/j.jvs.2006.03.024; Yu J, 2006, FASEB J, V20, P479, DOI 10.1096/fj.04-3670fje; Zhang L, 2002, BIOCHEM BIOPH RES CO, V292, P860, DOI 10.1006/bbrc.2002.6710; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	42	66	73	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2010	37	2			SI		384	393		10.1016/j.nbd.2009.10.018			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	551QP	WOS:000274224400018	19879362				2022-02-06	
S	Atlasz, T; Szabadfi, K; Kiss, P; Racz, B; Gallyas, F; Tamas, A; Gaal, V; Marton, Z; Gabriel, R; Reglodi, D		Vaudry, H; Shioda, S		Atlasz, T.; Szabadfi, K.; Kiss, P.; Racz, B.; Gallyas, F.; Tamas, A.; Gaal, V.; Marton, Zs.; Gabriel, R.; Reglodi, D.			Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects	PHYLOGENETIC ASPECTS OF NEUROPEPTIDES: FROM INVERTEBRATES TO HUMANS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	9th International Symposium on VIP, PACAP and Related Peptides	OCT 02-03, 2009	Yakushima Island, JAPAN			retinal injury; retinoprotection; neuropeptide; PACAP	MONOSODIUM GLUTAMATE TREATMENT; VASOACTIVE-INTESTINAL-PEPTIDE; CHICKEN PINEAL-GLAND; RAT MULLER CELLS; MESSENGER-RNA; GANGLION-CELLS; SIGNALING PATHWAYS; ULTRASTRUCTURAL-LOCALIZATION; INDUCED NEUROTOXICITY; MELATONIN RELEASE	Pituitary adenylate cyclase activating polypeptide (PACAP) is a neurotrophic and neuroprotective peptide that has been shown to exert protective effects against different neuronal injuries, such as traumatic brain and spinal cord injury, models of neurodegenerative diseases, and cerebral ischemia. PACAP and its receptors are present in the retina. In this study, we summarize the current knowledge on retinal PACAP with focus on the retinoprotective effects. Results of histological, immunohistochemical, and molecular biological analysis are reviewed. In vitro, PACAP shows protection against glutamate, thapsigargin, anisomycin, and anoxia. In vivo, the protective effects of intravitreal PACAP treatment have been shown in the following models of retinal degeneration in rats: excitotoxic injury induced by glutamate and kainate, ischemic injury, degeneration caused by UV-A light, optic nerve transection, and streptozotocin-induced diabetic retinopathy. Studying the molecular mechanism has revealed that PACAP acts by activating antiapoptotic and inhibiting proapoptotic signaling pathways in the retina in vivo. These studies strongly suggest that PACAP is an excellent candidate retinoprotective agent that could be a potential therapeutic substance in various retinal diseases.	[Reglodi, D.] Univ Pecs, Dept Anat, Sch Med, H-7624 Pecs, Hungary; [Atlasz, T.] Univ Pecs, Dept Sportbiol, H-7624 Pecs, Hungary; [Szabadfi, K.; Gabriel, R.] Univ Pecs, Dept Expt Zool & Neurobiol, H-7624 Pecs, Hungary; [Racz, B.; Gallyas, F.] Univ Pecs, Dept Biochem & Med Chem, H-7624 Pecs, Hungary; [Gaal, V.] Univ Pecs, Dept Ophthalmol, H-7624 Pecs, Hungary; [Marton, Zs.] Univ Pecs, Dept Environm & Laser Spect, H-7624 Pecs, Hungary		Reglodi, D (corresponding author), Univ Pecs, Dept Anat, Sch Med, Szigeti U 12, H-7624 Pecs, Hungary.	dora.reglodi@aok.pte.hu	Szabadfi, Krisztina/K-5955-2012; Gallyas, Ferenc/AAY-5343-2020; Marton, Zsuzsanna/A-5158-2012; Racz, Boglarka/M-2160-2015; Gallyas, Ferenc/C-2272-2012	Szabadfi, Krisztina/0000-0002-8390-5408; Gallyas, Ferenc/0000-0002-1906-4333; Atlasz, Tamas/0000-0002-8112-8633	Hungarian National Scientific Grants OTKAOrszagos Tudomanyos Kutatasi Alapprogramok (OTKA) [T061766, K72592, F67830, CNK 78480, ETT278-04/2009]; Richter Gedeon Centenary Foundation; Bolyai ScholarshipHungarian Academy of Sciences; University of Pecs Medical School;  [GVOP-3.2.1-2004-04-0172/3.0]	This work was supported by Hungarian National Scientific Grants OTKA T061766, K72592, F67830, CNK 78480, ETT278-04/2009, Richter Gedeon Centenary Foundation, GVOP-3.2.1-2004-04-0172/3.0, Bolyai Scholarship, University of Pecs Medical School Research Grant 2009.	Arimura A, 2007, PEPTIDES, V28, P1617, DOI 10.1016/j.peptides.2007.06.006; ATLASZ T, 2009, SAT S 9 INT S VIP PA; Atlasz T, 2007, GEN COMP ENDOCR, V153, P108, DOI 10.1016/j.ygcen.2006.12.022; Atlasz T, 2010, BRAIN RES BULL, V81, P497, DOI 10.1016/j.brainresbull.2009.09.004; Atlasz T, 2008, J MOL NEUROSCI, V36, P97, DOI 10.1007/s12031-008-9059-5; Atlasz T, 2009, ANN NY ACAD SCI, V1163, P348, DOI 10.1111/j.1749-6632.2008.03650.x; Babai N, 2005, NEUROTOX RES, V8, P227, DOI 10.1007/BF03033976; Babai N, 2006, ANN NY ACAD SCI, V1070, P149, DOI 10.1196/annals.1317.003; Bagnoli P, 2003, HISTOL HISTOPATHOL, V18, P1219, DOI 10.14670/HH-18.1219; Beaule C, 2009, J BIOL RHYTHM, V24, P126, DOI 10.1177/0748730409332037; Borba JC, 2005, DEV BRAIN RES, V156, P193, DOI 10.1016/j.devbrainres.2005.02.016; Csernus V, 2004, GEN COMP ENDOCR, V135, P62, DOI 10.1016/S0016-6480(03)00284-3; D'Agata V, 1998, MOL BRAIN RES, V54, P161, DOI 10.1016/S0169-328X(97)00335-5; Elsas T, 1996, GRAEF ARCH CLIN EXP, V234, P573, DOI 10.1007/BF00448802; Falluel-Morel A, 2007, J NEUROENDOCRINOL, V19, P321, DOI 10.1111/j.1365-2826.2007.01537.x; Faluhelyi N, 2004, REGUL PEPTIDES, V123, P23, DOI 10.1016/j.regpep.2004.05.009; Fukiage C, 2007, AM J OPHTHALMOL, V143, P255, DOI 10.1016/j.ajo.2006.10.034; Gaal V, 2008, J MOL NEUROSCI, V36, P321, DOI 10.1007/s12031-008-9067-5; Grone BP, 2007, J BIOL RHYTHM, V22, P558, DOI 10.1177/0748730407308285; Hannibal J, 2004, CELL TISSUE RES, V316, P99, DOI 10.1007/s00441-004-0858-x; ITOH H, 2009, SAT S 9 INT S VIP PA; Izumi S, 2000, ANN NY ACAD SCI, V921, P317; Jarkman S, 1998, OPHTHALMIC RES, V30, P199, DOI 10.1159/000055476; Jozsa R, 2001, PEPTIDES, V22, P1371, DOI 10.1016/S0196-9781(01)00477-6; Kiss P, 2006, ANN NY ACAD SCI, V1070, P365, DOI 10.1196/annals.1317.046; Koves K, 2000, ANN NY ACAD SCI, V921, P321; Kubrusly RCC, 2005, BRAIN RES, V1038, P141, DOI 10.1016/j.brainres.2005.01.031; Lang B, 2010, NEUROPHARMACOLOGY, V58, P215, DOI 10.1016/j.neuropharm.2009.07.003; Markhotina N, 2007, IET NANOBIOTECHNOL, V1, P44, DOI 10.1049/iet-nbt:20060019; Mathieu M, 2005, EUR J HISTOCHEM, V49, P167; Mathieu M, 2004, DEV BRAIN RES, V151, P169, DOI 10.1016/j.devbrainres.2004.05.003; Mathis U, 2007, GRAEF ARCH CLIN EXP, V245, P267, DOI 10.1007/s00417-006-0282-x; Mester L, 2009, NEUROTOX RES, V16, P68, DOI 10.1007/s12640-009-9049-6; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Nagy AD, 2007, PEPTIDES, V28, P1767, DOI 10.1016/j.peptides.2007.07.013; Nakatani M, 2006, PEPTIDES, V27, P1871, DOI 10.1016/j.peptides.2005.12.011; NILSSON SFE, 1994, EUR J PHARMACOL, V253, P17, DOI 10.1016/0014-2999(94)90752-8; NILSSON SFE, 1994, EXP EYE RES, V58, P459, DOI 10.1006/exer.1994.1039; Ohtaki H, 2008, J MOL NEUROSCI, V36, P16, DOI 10.1007/s12031-008-9077-3; Olianas MC, 1997, J NEUROCHEM, V69, P1213; Olianas MC, 1996, J NEUROCHEM, V67, P1293; ONALI P, 1994, BRAIN RES, V641, P132, DOI 10.1016/0006-8993(94)91825-2; Pucci S, 2008, PROG BRAIN RES, V173, P555, DOI 10.1016/S0079-6123(08)01138-2; Rabl K, 2002, REGUL PEPTIDES, V109, P71, DOI 10.1016/S0167-0115(02)00189-1; Racz B, 2006, REGUL PEPTIDES, V137, P20, DOI 10.1016/j.regpep.2006.02.009; Racz B, 2007, NEUROTOX RES, V12, P95, DOI 10.1007/BF03033918; Racz B, 2006, ANN NY ACAD SCI, V1070, P507, DOI 10.1196/annals.1317.070; Racz B, 2008, J MOL NEUROSCI, V36, P220, DOI 10.1007/s12031-008-9112-4; Reglodi D, 2001, PEPTIDES, V22, P873, DOI 10.1016/S0196-9781(01)00412-0; Rekasi Z, 2002, J MOL ENDOCRINOL, V28, P19, DOI 10.1677/jme.0.0280019; Sakamoto K, 2005, EUR J NEUROSCI, V22, P3129, DOI 10.1111/j.1460-9568.2005.04512.x; Seki M, 2004, DIABETES, V53, P2412, DOI 10.2337/diabetes.53.9.2412; Seki T, 2006, ANN NY ACAD SCI, V1070, P535, DOI 10.1196/annals.1317.043; Seki T, 2000, ANN NY ACAD SCI, V921, P366; Seki T, 1997, NEUROSCI LETT, V238, P127, DOI 10.1016/S0304-3940(97)00869-0; Seki T, 2000, PEPTIDES, V21, P109, DOI 10.1016/S0196-9781(99)00180-1; Seki T, 2006, ANN NY ACAD SCI, V1070, P531, DOI 10.1196/annals.1317.074; Seki T, 2008, J MOL NEUROSCI, V36, P57, DOI 10.1007/s12031-008-9091-5; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Shoge K, 1998, BRAIN RES, V809, P127, DOI 10.1016/S0006-8993(98)00789-6; Silveira MS, 2002, J BIOL CHEM, V277, P16075, DOI 10.1074/jbc.M110106200; Skoglosa Y, 1999, MOL BRAIN RES, V65, P1, DOI 10.1016/S0169-328X(98)00294-0; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Son YJ, 2007, MOL CELLS, V23, P215; Szabadfi K, 2009, BRAIN RES, V1259, P107, DOI 10.1016/j.brainres.2009.01.004; Tamas A, 2004, NEUROSCI LETT, V372, P110, DOI 10.1016/j.neulet.2004.09.021; Tuncel N, 1996, ANN NY ACAD SCI, V805, P489; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Vereczki V, 2006, NEUROSCIENCE, V140, P1089, DOI 10.1016/j.neuroscience.2006.02.081; Wan J, 2006, NEUROSCI LETT, V400, P48, DOI 10.1016/j.neulet.2006.02.084; WANG ZY, 1995, NEUROSCIENCE, V69, P297, DOI 10.1016/0306-4522(95)00258-K; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; Yamaji K, 2005, EXP EYE RES, V80, P815, DOI 10.1016/j.exer.2004.12.020; Yoshitomi T, 2002, INVEST OPHTH VIS SCI, V43, P780; ZHANG D, 1995, NEUROSCIENCE, V67, P177, DOI 10.1016/0306-4522(94)00627-H; Zhang XY, 2005, CURR EYE RES, V30, P1105, DOI 10.1080/02713680500421444	77	66	67	0	13	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-798-6	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1200						128	139		10.1111/j.1749-6632.2010.05512.x			12	Multidisciplinary Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	BRJ61	WOS:000282839600013	20633141				2022-02-06	
J	Figaji, AA; Zwane, E; Thompson, C; Fieggen, AG; Argent, AC; Le Roux, PD; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Thompson, Crispin; Fieggen, A. Graham; Argent, Andrew C.; Le Roux, Peter D.; Peter, Jonathan C.			Brain tissue oxygen tension monitoring in pediatric severe traumatic brain injury	CHILDS NERVOUS SYSTEM			English	Article						Brain tissue oxygen tension; Outcome; Hypoxia; Children; Traumatic; Brain injury	SEVERE HEAD-INJURY; CEREBRAL OXYGENATION; COMPUTERIZED-TOMOGRAPHY; INTENSIVE-CARE; DELIVERY; SATURATION; PRESSURE; ISCHEMIA; THERAPY; DAMAGE	Introduction Intracranial pressure (ICP) monitoring and cerebral perfusion pressure (CPP) management are the current standards to guide care of severe traumatic brain injury (TBI). However, brain hypoxia and secondary brain injury can occur despite optimal ICP and CPP. In this study, we used brain tissue oxygen tension (PbtO(2)) monitoring to examine the association between multiple patient factors, including PbtO(2), and outcome in pediatric severe TBI. Materials and methods In this prospective observational study, 52 children (less than 15 years) with severe TBI were managed with continuous PbtO(2) and ICP monitoring. The relationships between outcome [Glasgow Outcome Score (GOS) and Pediatric Cerebral Performance Category Scale] and clinical, radiologic, treatment, and physiological variables, including PbtO(2), were examined using multiple logistic regression analysis. Results Outcome was favorable in 40 patients (77%) and unfavorable (mortality, 9.6%; n = 5) in 12 (23%). In univariate analysis, the following variables had a significant association with unfavorable outcome: initial GCS, computed tomography classification, ICP(peak), mICP(24), mICP, CPP(low), CPP(< 40), pupil reactivity, PbtO(2low), PbtO(2) < 5 mmHg, PbtO(2) < 10 mmHg, mPbtO(224), and time-severity product. PbtO(2) parameters had the strongest independent association with poor outcome in multiple regression analysis. In particular, when PbtO(2) was < 5 mmHg for > 1 h, the adjusted OR for poor outcome was 27.4 (95% confidence interval, 1.9-391). No variables apart from PbtO(2) were independently associated with mortality when controlled for PbtO(2). Conclusion Reduced PbtO(2) is shown to be an independent factor associated with poor outcome in pediatric severe TBI in the largest study to date. It appears to have a stronger association with outcome than conventionally evaluated measures.	[Figaji, Anthony A.; Thompson, Crispin; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Div Neurosurg, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, ZA-7925 Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town, Infect Dis Epidemiol Unit Biostat, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa; [Le Roux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA		Figaji, AA (corresponding author), Univ Cape Town, Div Neurosurg, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, ZA-7925 Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Argent, Andrew/J-1605-2019; Fieggen, Anthony Graham/AAT-6510-2021	Argent, Andrew/0000-0001-9333-2036; Fieggen, Anthony Graham/0000-0001-6541-8377; Figaji, Anthony/0000-0002-3357-6490			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Flynn EP, 2002, ANN NEUROL, V52, P566, DOI 10.1002/ana.10322; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; JENNETT B, 1975, LANCET, V1, P480; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; MALONEYWILENSKY E, 2009, CRIT CARE M IN PRESS; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Rossi S, 2000, ACTA NEUROCHIR SUPPL, V76, P199; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; SIMPSON D, 1982, LANCET, V2, P450; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Slater A, 2003, INTENS CARE MED, V29, P278, DOI 10.1007/s00134-002-1601-2; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 1998, J NEUROTRAUM, V15, P813, DOI 10.1089/neu.1998.15.813; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; ZAUNER A, 1997, NEUROSURGERY, V41, P1091; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	45	66	68	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	OCT	2009	25	10					1325	1333		10.1007/s00381-009-0822-x			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	494TE	WOS:000269838900021	19214532				2022-02-06	
J	Abrahamson, EE; Ikonomovic, MD; Dixon, CE; DeKosky, ST				Abrahamson, Eric E.; Ikonomovic, Milos D.; Dixon, C. Edward; DeKosky, Steven T.			Simvastatin Therapy Prevents Brain Trauma-Induced Increases in beta-Amyloid Peptide Levels	ANNALS OF NEUROLOGY			English	Article							A REDUCTASE INHIBITORS; GENE-TARGETED MICE; SEVERE HEAD-INJURY; PRECURSOR PROTEIN; IN-VIVO; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY; NEURONAL SURVIVAL; CORTICAL-NEURONS; ATORVASTATIN	Elevations in beta-amyloid peptide (A beta) levels after traumatic brain injury (TBI) may confer risk for developing Alzheimer's disease in head trauma patients. We investigated the effects of simvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, on hippocampal A beta burden in a clinically relevant head injury/intervention model using mice expressing human A beta. Simvastatin therapy blunted TBI-induced increases in A beta, reduced hippocampal tissue damage and microglial activation, and improved behavioral outcome. The ability of statins to reduce post-injury A beta load and ameliorate pathological sequelae of brain injury makes them potentially effective in reducing the risk of developing Alzheimer's disease in TBI patients.	[DeKosky, Steven T.] Univ Virginia, Off Dean, Sch Med, Charlottesville, VA 22908 USA; [Abrahamson, Eric E.; Ikonomovic, Milos D.; DeKosky, Steven T.] Univ Pittsburgh, Sch Med, Dept Neurol, Brain Trauma Res Ctr, Pittsburgh, PA 15261 USA; [Ikonomovic, Milos D.; DeKosky, Steven T.] Univ Pittsburgh, Sch Med, Dept Psychiat, Brain Trauma Res Ctr, Pittsburgh, PA USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15261 USA		DeKosky, ST (corresponding author), Univ Virginia, Off Dean, Sch Med, POB 800793, Charlottesville, VA 22908 USA.	dekosky@virginia.edu		DeKosky, Steven/0000-0003-3743-2758	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS30318]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P50NS030318, P20NS030318, R01NS060672] Funding Source: NIH RePORTER	This work was supported by the NIH (National Institute of Neurological Disorders and Stroke, NS30318) (S.D., M.I., E.D.).	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burns M, 2003, J NEUROSCI, V23, P5645; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Clarke RM, 2007, NEUROPHARMACOLOGY, V52, P136, DOI 10.1016/j.neuropharm.2006.07.031; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Cotman CW, 1996, NEUROBIOL AGING, V17, P723; Cotman CW, 1997, ANN NY ACAD SCI, V814, P1, DOI 10.1111/j.1749-6632.1997.tb46140.x; DeKosky ST, 2005, AM J MED, V118, p48S, DOI 10.1016/j.amjmed.2005.09.006; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Flood DG, 2002, NEUROBIOL AGING, V23, P335, DOI 10.1016/S0197-4580(01)00330-X; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; He X, 2006, J NEUROPATH EXP NEUR, V65, P652, DOI 10.1097/01.jnen.0000225906.82428.69; HOEG JM, 1987, JAMA-J AM MED ASSOC, V258, P3532, DOI 10.1001/jama.258.24.3532; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Li L, 2006, ANN NEUROL, V60, P729, DOI 10.1002/ana.21053; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Miida T, 2007, PHARMACOL THERAPEUT, V113, P378, DOI 10.1016/j.pharmthera.2006.09.003; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Parvathy S, 2009, NEUROBIOL AGING, V30, P1792, DOI 10.1016/j.neurobiolaging.2008.01.011; Pedrini S, 2005, PLOS MED, V2, P69, DOI 10.1371/journal.pmed.0020018; Petanceska SS, 2003, J MOL NEUROSCI, V20, P395, DOI 10.1385/JMN:20:3:395; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; Refolo LM, 2001, NEUROBIOL DIS, V8, P890, DOI 10.1006/nbdi.2001.0422; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Shabanzadeh AP, 2005, BRAIN RES, V1042, P1, DOI 10.1016/j.brainres.2005.01.105; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Sparks DL, 2006, ACTA NEUROL SCAND, V114, P78, DOI 10.1111/j.1600-0404.2006.00689.x; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walsh DM, 2007, J NEUROCHEM, V101, P1172, DOI 10.1111/j.1471-4159.2006.04426.x; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Xie ZC, 2008, ANN NEUROL, V64, P618, DOI 10.1002/ana.21548; Zacco A, 2003, J NEUROSCI, V23, P11104	63	66	66	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	SEP	2009	66	3					407	414		10.1002/ana.21731			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	503WX	WOS:000270573700022	19798641				2022-02-06	
J	Kraft, AD; McPherson, CA; Harry, GJ				Kraft, Andrew D.; McPherson, Christopher A.; Harry, G. Jean			Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival	NEUROTOXICOLOGY			English	Article; Proceedings Paper	25th International Neurotoxicology Conference	OCT 12-16, 2008	Rochester, NY			Microglia; Neuroinflammation; Hippocampus; Trimethyltin; TNF alpha; TNF receptors	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE NEURITIS; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN INJURY; FACTOR RECEPTOR P75; KAPPA-B ACTIVATION; FACTOR-ALPHA; MOUSE MODEL; MESSENGER-RNA	Microglia do not constitute a single, uniform cell population, but rather comprise cells with varied phenotypes, some which are beneficial and others that may require active regulatory control. Thus, gaining a better understanding of the heterogeneity of resident microglia responses will contribute to any interpretation regarding the impact of any such response in the brain. Microglia are the primary source of the pro-inflammatory cytokine, tumor necrosis factor (TNF) that can initiate various effects through the activation of membrane receptors. The TNF p55 receptor contains a death domain and activation normally leads to cellular apoptosis; however, under specific conditions, receptor activation can also lead to the activation of NF-kappa B and contribute to cell survival. These divergent outcomes have been linked to receptor localization with receptor internalization leading to cell death and membrane localization supporting cell survival. A second TNF receptor, TNF p75 receptor, is normally linked to cell growth and survival, however, it can cooperate with the p55 receptor and contribute to cell death. Thus, while an elevation in TNF alpha in the brain is often considered an indicator of microglia activation and neuroinflammation, a number of factors come into play to determine the final outcome. Data are reviewed demonstrating that heterogeneity in morphological response of microglia and the expression of TNF alpha and TNF receptors are critical in identifying and characterizing neurotoxic events as they relate to neuroinflammation, neuronal damage and in stimulating neuroprotection. Published by Elsevier Inc.	[Kraft, Andrew D.; McPherson, Christopher A.; Harry, G. Jean] NIEHS, Neurotoxicol Grp, Mol Toxicol Lab, NIH,Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA		Harry, GJ (corresponding author), NIEHS, Neurotoxicol Grp, Mol Toxicol Lab, NIH,Dept Hlth & Human Serv, POB 12233,MD C1-04, Res Triangle Pk, NC 27709 USA.	harry@niehs.nih.gov	Harry, Gaylia Jean/AAC-1171-2022	Harry, Gaylia Jean/0000-0002-0829-7318	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ZIAES101623, ZIAES021164] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ZIA ES101623-08, ZIA ES021164-14] Funding Source: Medline		Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Akassoglou K, 2003, P NATL ACAD SCI USA, V100, P709, DOI 10.1073/pnas.0236046100; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; Badie B, 2000, EXP NEUROL, V162, P290, DOI 10.1006/exnr.1999.7345; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; Bohatschek M, 2004, J COMP NEUROL, V470, P382, DOI 10.1002/cne.20017; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Botchkina GI, 1999, MOL MED, V5, P372, DOI 10.1007/BF03402126; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Brochard V, 2009, J CLIN INVEST, V119, P182, DOI 10.1172/JCI36470; Bruccoleri A, 2000, J NEUROSCI RES, V62, P146, DOI 10.1002/1097-4547(20001001)62:1<146::AID-JNR15>3.0.CO;2-L; Bruccoleri A, 1998, J NEUROCHEM, V71, P1577; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Carson MJ, 1998, GLIA, V22, P72, DOI 10.1002/(SICI)1098-1136(199801)22:1<72::AID-GLIA7>3.0.CO;2-A; Carson MJ, 2007, NEUROTHERAPEUTICS, V4, P571, DOI 10.1016/j.nurt.2007.07.002; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; CORSARO A, 2009, NEUROTOX RES, V15, P102; Cunningham O, 2009, GLIA, V57, P1802, DOI 10.1002/glia.20892; d'Hellencourt CL, 2005, J NEUROCHEM, V93, P206, DOI 10.1111/j.1471-4159.2004.03017.x; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Declercq W, 1998, J IMMUNOL, V161, P390; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Eskes C, 2003, J NEUROSCI RES, V71, P583, DOI 10.1002/jnr.10508; Fiedorowicz A, 2001, BRAIN RES, V912, P116, DOI 10.1016/S0006-8993(01)02675-0; Fiers W, 1996, J INFLAMM, V47, P67; Figiel I, 2007, BRAIN RES, V1131, P17, DOI 10.1016/j.brainres.2006.10.095; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; GebickeHaerter PJ, 1996, NEUROCHEM INT, V29, P1; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; Gendelman HE, 1999, J LEUKOCYTE BIOL, V65, P407, DOI 10.1002/jlb.65.4.407; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; Haddad EB, 2002, J IMMUNOL, V169, P974, DOI 10.4049/jimmunol.169.2.974; Haga S, 2002, ACTA NEUROPATHOL, V103, P575, DOI 10.1007/s00401-001-0505-5; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Harry GJ, 2008, J NEUROCHEM, V106, P281, DOI 10.1111/j.1471-4159.2008.05382.x; Harry GJ, 2008, BRAIN RES, V1194, P8, DOI 10.1016/j.brainres.2007.11.076; Harry GJ, 2003, J NEUROSCI RES, V73, P526, DOI 10.1002/jnr.10653; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; Harry GJ, 2002, TOXICOL APPL PHARM, V180, P205, DOI 10.1006/taap.2002.9390; Henshall DC, 2005, J CEREBR BLOOD F MET, V25, P1557, DOI 10.1038/sj.jcbfm.9600149; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Imai H, 2001, STROKE, V32, P2149, DOI 10.1161/hs0901.095725; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; KIMOTO H, 2009, CELL MOL NEUROBIOL, DOI DOI 10.1007/S10571-009-9412A; KINOUCHI K, 1991, BIOCHEM BIOPH RES CO, V181, P1532, DOI 10.1016/0006-291X(91)92113-X; KODA T, 2009, CELL MOL NEUROBIOL, DOI DOI 10.1007/SL0571-008-9344-4; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lambertsen KL, 2007, NEUROSCIENCE, V144, P934, DOI 10.1016/j.neuroscience.2006.10.046; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Little AR, 2002, NEUROSCIENCE, V115, P307, DOI 10.1016/S0306-4522(02)00359-7; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu MO, 2007, J NEUROIMMUNOL, V186, P19, DOI 10.1016/j.jneuroim.2007.02.004; Maier WE, 1997, NEUROCHEM INT, V30, P385, DOI 10.1016/S0197-0186(96)00073-3; Malm TM, 2008, GLIA, V56, P1767, DOI 10.1002/glia.20726; Mao HY, 2007, BRAIN RES, V1186, P267, DOI 10.1016/j.brainres.2007.10.020; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; MATSUMOTO Y, 1987, J NEUROIMMUNOL, V17, P71, DOI 10.1016/0165-5728(87)90032-4; McGeer PL, 2001, ADV NEUROL, V86, P83; MEAGER A, 1993, CYTOKINE, V5, P556, DOI 10.1016/S1043-4666(05)80004-3; MEDVEDEV AE, 1994, EUR J IMMUNOL, V24, P2842, DOI 10.1002/eji.1830241139; Medvedev AE, 1996, SCAND J IMMUNOL, V43, P439, DOI 10.1046/j.1365-3083.1996.d01-58.x; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MONNETTSCHUDI F, 1995, BRAIN RES, V690, P8, DOI 10.1016/0006-8993(95)00509-O; Namura S, 2001, STROKE, V32, P1906, DOI 10.1161/01.STR.32.8.1906; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2; Parnham M, 2000, EXPERT OPIN INV DRUG, V9, P607, DOI 10.1517/13543784.9.3.607; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Qiu JH, 2002, J NEUROSCI, V22, P3504; Quintana A, 2005, J NEUROSCI RES, V82, P701, DOI 10.1002/jnr.20680; Raivich G, 2005, TRENDS NEUROSCI, V28, P571, DOI 10.1016/j.tins.2005.09.001; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; RENNO T, 1995, J IMMUNOL, V154, P944; Rohl C, 2009, TOXICOL IN VITRO, V23, P1541, DOI 10.1016/j.tiv.2009.04.013; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Rousselet E, 2002, EXP NEUROL, V177, P183, DOI 10.1006/exnr.2002.7960; Sairanen TR, 2001, J NEUROL SCI, V186, P87, DOI 10.1016/S0022-510X(01)00508-1; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sawada M, 2006, J NEURAL TRANSM-SUPP, P373; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/S1074-7613(04)00234-1; Schwartz M, 2006, TRENDS NEUROSCI, V29, P68, DOI 10.1016/j.tins.2005.12.005; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sriram K, 2006, J NEUROCHEM, V96, P706, DOI 10.1111/j.1471-4159.2005.03566.x; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Suvannavejh GC, 2000, CELL IMMUNOL, V205, P24, DOI 10.1006/cimm.2000.1706; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Taylor DL, 2005, J NEUROSCI, V25, P2952, DOI 10.1523/JNEUROSCI.4456-04.2005; Tchelingerian JL, 1996, J NEUROSCI RES, V43, P99, DOI 10.1002/jnr.490430113; THOMAS WE, 1992, BRAIN RES REV, V17, P61; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Tikka TM, 2002, BRAIN, V125, P722, DOI 10.1093/brain/awf068; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Viviani B, 1998, TOXICOL APPL PHARM, V150, P271, DOI 10.1006/taap.1998.8406; Wajant H, 1999, CYTOKINE GROWTH F R, V10, P15, DOI 10.1016/S1359-6101(98)00023-9; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Weishaupt A, 2000, J NEUROPATH EXP NEUR, V59, P368, DOI 10.1093/jnen/59.5.368; Weiss T, 1997, J IMMUNOL, V158, P2398; Whitton PS, 2007, BRIT J PHARMACOL, V150, P963, DOI 10.1038/sj.bjp.0707167; WINE RN, 2009, NEUROTOX RES, V20; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; Yang RN, 2001, CHIN J STRUCT CHEM, V20, P4; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	132	66	72	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	SEP	2009	30	5			SI		785	793		10.1016/j.neuro.2009.07.001			9	Neurosciences; Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	513AC	WOS:000271292900008	19596372	Green Accepted			2022-02-06	
J	Scherer, MR; Schubert, MC				Scherer, Matthew R.; Schubert, Michael C.			Traumatic Brain Injury and Vestibular Pathology as a Comorbidity After Blast Exposure	PHYSICAL THERAPY			English	Article							ARMY MEDICAL-CENTER; HEAD-INJURY; BATTLE CASUALTIES; GLOBAL WAR; BASE RATES; REHABILITATION; DIZZINESS; GAIT; SYMPTOMS; RECOVERY	Blasts or explosions are the most common mechanisms of injury in modern warfare. Traumatic brain injury (TBI) is a frequent consequence of exposure to such attacks. Although the management of orthopedic, integumentary, neurocognitive, and neurobehavioral sequelae in survivors of blasts has been described in the literature, less attention has been paid to the physical therapist examination and care of people with dizziness and blast-induced TBI (BITBI). Dizziness is a common clinical finding in people with BITBI; however, many US military service members who have been exposed to blasts and who are returning from Iraq and Afghanistan also complain of vertigo, gaze instability, motion intolerance, and other symptoms consistent with peripheral vestibular pathology. To date, few studies have addressed such "vestibular" complaints in service members injured by blasts. Given the demonstrated efficacy of treating the signs and symptoms associated with vestibular pathology, vestibular rehabilitation may have important implications for the successful care of service members who have been injured by blasts and who are complaining of vertigo or other symptoms consistent with vestibular pathology. In addition, there is a great need to build consensus on the clinical best practices for the assessment and management of BITBI and blast-related dizziness. The purpose of this review is to summarize the findings of clinicians and scientists conducting research on the effects of blasts with the aims of defining the scope of the problem, describing and characterizing the effects of blasts, reviewing relevant patients' characteristics and sensorimotor deficits associated with BITBI, and suggesting clinical best practices for the rehabilitation of BITBI and blast-related dizziness.	[Scherer, Matthew R.] Univ Maryland, Dept Phys Therapy & Rehabil Sci, Sch Med, Baltimore, MD 21201 USA; [Schubert, Michael C.] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA		Scherer, MR (corresponding author), Univ Maryland, Dept Phys Therapy & Rehabil Sci, Sch Med, 100 Penn St, Baltimore, MD 21201 USA.	matthew.scherer@us.army.mil					Argyros GJ, 1997, TOXICOLOGY, V121, P105, DOI 10.1016/S0300-483X(97)03659-7; BARBER HO, 1969, ANN OTO RHINOL LARYN, V78, P239, DOI 10.1177/000348946907800204; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BERMAN JM, 1978, J OTOLARYNGOL, V7, P237; Bockisch CJ, 2004, NEUROREPORT, V15, P2617, DOI 10.1097/00001756-200412030-00011; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Cancio LC, 2005, J BURN CARE REHABIL, V26, P151, DOI 10.1097/01.BCR.0000155540.31879.FB; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; *CDCP, BLAST INJ ESS FACTS; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 1997, WORLD J SURG, V21, P240, DOI 10.1007/s002689900223; Chandler D W, 1997, J Am Acad Audiol, V8, P81; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; CUDENNEC YF, 1995, MIL MED, V160, P467, DOI 10.1093/milmed/160.9.467; *DEF VET BRAIN INJ, 2008, OIF OEF FACT SHEET J; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs Veterans health Administration, VHA HDB; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; *DVBIC WORK GROUP, 2008, SYMPT MAN MILD TRAUM; Fife TD, 2000, NEUROLOGY, V55, P1431, DOI 10.1212/WNL.55.10.1431; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; French L., 2008, J SPECIAL OPERATIONS, V8, P68; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Gajewski Donald, 2006, J Am Acad Orthop Surg, V14, pS183; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; GIBSON W, 1984, VERTIGO; Godbout A, 1997, BRAIN INJURY, V11, P629, DOI 10.1080/026990597123188; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; GOTTSHALL K, 2009, ASS RES OT MIDW M FE; GRIFFITHS MV, 1979, J LARYNGOL OTOL, V93, P253, DOI 10.1017/S0022215100086990; HALMAGYI GM, 1988, ARCH NEUROL-CHICAGO, V45, P737, DOI 10.1001/archneur.1988.00520310043015; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; HERDMAN SJ, 1993, ARCH OTOLARYNGOL, V119, P450; Herdman SJ, 1998, AM J OTOL, V19, P790; Herdman SJ., 1990, J HEAD TRAUMA REHAB, V5, P63, DOI 10.1097/00001199-199012000-00008; HOFFER M, 2008, ASS RES OT MIDW M FE; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer ME, 2003, OTOL NEUROTOL, V24, P633, DOI 10.1097/00129492-200307000-00017; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Javernick MA, 2006, MIL MED, V171, P200, DOI 10.7205/MILMED.171.3.200; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kerr A G, 1987, Rev Environ Health, V7, P65; KERR AG, 1978, PRACTITIONER, V221, P677; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Mott FW, 1917, J ROY ARMY MED CORPS, V29, P662; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Murray CK, 2008, J TRAUMA, V64, pS232, DOI 10.1097/TA.0b013e318163c3f5; Nelson J R, 1979, Adv Neurol, V22, P107; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pasquina PF, 2006, MIL MED, V171, P206, DOI 10.7205/MILMED.171.3.206; PEARSON BW, 1973, ARCH OTOLARYNGOL, V97, P81; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Roberts R. A., 2008, BALANCE FUNCTION ASS, P171; Rustemeyer J, 2007, BRIT J ORAL MAX SURG, V45, P556, DOI 10.1016/j.bjoms.2007.01.003; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; Scherer M, 2007, BRAIN INJURY, V21, P93, DOI 10.1080/02699050601149104; Schubert MC, 2004, PHYS THER, V84, P373, DOI 10.1093/ptj/84.4.373; Schubert MC, 2006, J VESTIBUL RES-EQUIL, V16, P1; Schubert MC, 2008, ARCH PHYS MED REHAB, V89, P500, DOI 10.1016/j.apmr.2007.11.010; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Semont A, 1988, Adv Otorhinolaryngol, V42, P290; SHEPARD N, 2008, BALANCE FUNCTION ASS, P359; Shumway-Cook A., 1995, MOTOR CONTROL THEORY; Shumway-Cook A, 2007, VESTIBULAR REHABILIT, P444; SHUPAK A, 1993, ARCH OTOLARYNGOL, V119, P1362; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; SMITHWHEELOCK M, 1991, AM J OTOL, V12, P218; Springer BA, 2006, MIL MED, V171, P203, DOI 10.7205/MILMED.171.3.203; Sylvia FR, 2001, MIL MED, V166, P918, DOI 10.1093/milmed/166.10.918; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *USA MED DEP, TRAUM BRAIN INJ TBI; Van Campen L E, 1999, J Am Acad Audiol, V10, P231; Van Campen L E, 1999, J Am Acad Audiol, V10, P467; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; World Health Organization, 2007, INT CLASS FUNCT DIS; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; 2001, PHYS THER, V81, P307	99	66	66	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	SEP	2009	89	9					980	992		10.2522/ptj.20080353			13	Orthopedics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rehabilitation	499XN	WOS:000270260200013	19628578	Bronze			2022-02-06	
J	von Elm, E; Schoettker, P; Henzi, I; Osterwalder, J; Walder, B				von Elm, E.; Schoettker, P.; Henzi, I.; Osterwalder, J.; Walder, B.			Pre-hospital tracheal intubation in patients with traumatic brain injury: systematic review of current evidence	BRITISH JOURNAL OF ANAESTHESIA			English	Article						airway; brain, injury; complications, intubation tracheal; ventilation, mechanical	RAPID-SEQUENCE INTUBATION; ADVANCED LIFE-SUPPORT; ENDOTRACHEAL INTUBATION; SURVIVAL; FIELD; VENTILATION; MANAGEMENT; MODERATE; IMPACT; GUIDELINES	Background. We reviewed the current evidence on the benefit and harm of pre-hospital tracheal intubation and mechanical ventilation after traumatic brain injury (TBI). Methods. We conducted a systematic literature search up to December 2007 without language restriction to identify interventional and observational studies comparing pre-hospital intubation with other airway management (e. g. bag-valve-mask or oxygen administration) in patients with TBI. Information on study design, population, interventions, and outcomes was abstracted by two investigators and cross-checked by two others. Seventeen studies were included with data for 15 335 patients collected from 1985 to 2004. There were 12 retrospective analyses of trauma registries or hospital databases, three cohort studies, one case-control study, and one controlled trial. Using Brain Trauma Foundation classification of evidence, there were 14 class 3 studies, three class 2 studies, and no class 1 study. Six studies were of adults, five of children, and three of both; age groups were unclear in three studies. Maximum follow-up was up to 6 months or hospital discharge. Results. In 13 studies, the unadjusted odds ratios (ORs) for an effect of pre-hospital intubation on in-hospital mortality ranged from 0.17 (favouring control interventions) to 2.43 (favouring pre-hospital intubation); adjusted ORs ranged from 0.24 to 1.42. Estimates for functional outcomes after TBI were equivocal. Three studies indicated higher risk of pneumonia associated with pre-hospital (when compared with in-hospital) intubation. Conclusions. Overall, the available evidence did not support any benefit from pre-hospital intubation and mechanical ventilation after TBI. Additional arguments need to be taken into account, including medical and procedural aspects.	[von Elm, E.] Univ Med Ctr Freiburg, Dept Med Biometry & Stat, German Cochrane Ctr, D-79104 Freiburg, Germany; [von Elm, E.] Swiss Paraplegia Res, Nottwil, Switzerland; [Schoettker, P.] Univ Hosp Vaud, Dept Anaesthesiol, Lausanne, Switzerland; [Henzi, I.; Walder, B.] Univ Hosp Geneva, Div Anaesthesiol, Geneva, Switzerland; [Osterwalder, J.] St Gallen Cantonal Hosp, Emergency Dept, St Gallen, Switzerland		von Elm, E (corresponding author), Univ Med Ctr Freiburg, Dept Med Biometry & Stat, German Cochrane Ctr, Stefan Meier Str 26, D-79104 Freiburg, Germany.	vonelm@cochrane.de	Schoettker, Patrick/AAE-4462-2020	Schoettker, Patrick/0000-0001-5370-048X; von Elm, Erik/0000-0002-7412-0406			ADELSON PD, 2003, PEDIATR CRIT CARE ME, V4, P9; Arozullah AM, 2001, ANN INTERN MED, V135, P847, DOI 10.7326/0003-4819-135-10-200111200-00005; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Baker CC, 2005, J TRAUMA, V58, P723; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Christensen EF, 2003, BRIT MED J, V327, P533, DOI 10.1136/bmj.327.7414.533; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; Davis D P, 2001, Prehosp Emerg Care, V5, P163, DOI 10.1080/10903120190940065; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Deitch Sean, 2003, Prehosp Emerg Care, V7, P380, DOI 10.1080/10903120390936617; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; DiRusso SM, 2005, J TRAUMA, V59, P84, DOI 10.1097/01.TA.0000171462.28379.F3; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Eckert MJ, 2004, J TRAUMA, V57, P750, DOI 10.1097/01.TA.0000147499.73570.12; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; ERLER C, 1993, AIR MED J, V7, P223; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Grmec S, 2004, EMERG MED J, V21, P518, DOI 10.1136/emj.2002.001974; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; KOENIG KL, 1992, ANN EMERG MED, V21, P929, DOI 10.1016/S0196-0644(05)82930-0; Konrad C, 1998, ANESTH ANALG, V86, P635; Lenartova L, 2007, WIEN KLIN WOCHENSCHR, V119, P35, DOI 10.1007/s00508-006-0762-3; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; Mackway-Jones K, 2005, Emerg Med J, V22, P887, DOI 10.1136/emj.2005.031708; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; NAKAYAMA DK, 1990, ANN SURG, V211, P218, DOI 10.1097/00000658-199002000-00015; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; ROSE DK, 1994, CAN J ANAESTH, V41, P372, DOI 10.1007/BF03009858; Salomone JP, 2005, J TRAUMA, V58, P509, DOI 10.1097/01.TA.0000152807.63559.2E; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shatz DV, 2005, J TRAUMA, V58, P515; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stanic-Canji D, 2006, Acta Chir Iugosl, V53, P45; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Suominen P, 2000, Eur J Emerg Med, V7, P3; von Elm E, 2008, SWISS MED WKLY, V138, P327, DOI 2008/23/smw-12025; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2006, ANN EMERG MED, V47, P532, DOI 10.1016/j.annemergmed.2006.01.016; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	59	66	68	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	SEP	2009	103	3					371	386		10.1093/bja/aep202			16	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	483ZV	WOS:000269013300008	19648153	Green Published, Bronze			2022-02-06	
J	Pandya, JD; Pauly, JR; Sullivan, PG				Pandya, Jignesh D.; Pauly, James R.; Sullivan, Patrick G.			The optimal dosage and window of opportunity to maintain mitochondrial homeostasis following traumatic brain injury using the uncoupler FCCP	EXPERIMENTAL NEUROLOGY			English	Article						Neuronal injury; Mitochondrial bioenergetics; Mitochondrial uncoupling; Neuroprotection; Mitochondrial Ca2+	NEURONAL DEATH; CELL-DEATH; PERMEABILITY TRANSITION; THERAPEUTIC TARGET; PROTEIN-2 PROTECTS; FOREBRAIN NEURONS; NMDA RECEPTOR; GLUTAMATE; CALCIUM; OXYGEN	Experimental traumatic brain injury (TBI) leads to a rapid and extensive necrosis at the primary site of injury that appears to be driven in part by significant mitochondrial dysfunction. The present Study is based oil the hypothesis that TBI-induced, aberrant glutamate release increases mitochondriai Ca2+ cycling/overload Ultimately leading to mitochondrial damage. Previous work from Our laboratory demonstrates that mitochondrial uncoupling during the acute phases of TBI-induced excitotoxicity can reduce mitochondrial Ca2+ uptake (cycling), ROS production and mitochondrial damage resulting in neuroprotection and improved behavioral outcome. The current study was designed to determine the optimal dosage and therapeutic window of opportunity for the potent mitochondrial uncoupler FCCP following moderate TBI. For this study, we used Young adult male Sprague-Dawley rats (300-350 g): either sham-operated or moderately (1.5 mm) injured using the controlled cortical impactor (CCI) model of TBI. In the first set of studies animals were injected with either vehicle (100% DMSO) or different Concentrations of FCCP (0.5, 1, 2.5 and 5 mg/kg in 100% DMSO) intraperitoneally at 5 min post-injury; tested behaviorally at 10 days and cortical sparing assessed at 18 days post-injury. The results demonstrate that of all the dosages tested, 2.5 mg/kg tendered the maximum improvement in behavioral outcomes and tissue spared. Using this optimal dose (2.5 mg/kg) and time point for intervention (5 min post-injury). we assessed mitochondrial bioenergetics and mitochondrial structural integrity 24 h post-injury. Furthermore,, using this dosage we assessed mitochondrial bioenergetics and Ca2+ loading at 3 and 6 h post-injury to further verify our target mechanism and establish these assessments as a valid endpoint to use as a means to determine the therapeutic window of FCCP. To begin to address the window of opportunity for maintaining mitochondrial homeostasis, the optimal dose of FCCP was then administered at 5 min, 3, 6, or 24 h post-injury and several parameters of mitochondrial function were used as outcome measures. The results demonstrate that a prolonged window of opportunity exists for targeting mitochondrial dysfunction using uncouplers following TBI and give insight into the cellular pathology associated with TBI. (C) 2009 Elseviei Inc. All rights reserved.	[Sullivan, Patrick G.] Univ Kentucky, Chandler Coll Med, SCoBIRC, Lexington, KY 40536 USA; [Pandya, Jignesh D.; Sullivan, Patrick G.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Pauly, James R.] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA		Sullivan, PG (corresponding author), Univ Kentucky, Chandler Coll Med, SCoBIRC, 375 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	patsull@uky.edu			National Institute of Health, U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health Service [NS 48191, NS 42196]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042196, R01NS048191] Funding Source: NIH RePORTER	The research was supported by funding from the National Institute of Health, U.S. Public Health Service grant NS 48191 (to P.G.S.) and NS 42196 (to J.R.P.). The authors also thank Andrea H. Sebastian, Kristen M. Day, and Mary E. Jennes for expert technical assistance.	ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CHOI DW, 1987, J NEUROSCI, V7, P357; Conti B, 2005, J NEUROCHEM, V93, P493, DOI 10.1111/j.1471-4159.2005.03052.x; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HEYTLER PG, 1962, BIOCHEM BIOPH RES CO, V7, P272, DOI 10.1016/0006-291X(62)90189-4; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; LARDY H, 1954, NATURE, V174, P231, DOI 10.1038/174231b0; Liu SS, 1997, BIOSCIENCE REP, V17, P259, DOI 10.1023/A:1027328510931; LOOMIS WF, 1949, J BIOL CHEM, V179, P503; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; Mattiasson G, 2006, ANTIOXID REDOX SIGN, V8, P1, DOI 10.1089/ars.2006.8.1; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MITCHELL P, 1967, NATURE, V213, P137, DOI 10.1038/213137a0; Nicholls DG, 1999, ANN NY ACAD SCI, V893, P1, DOI 10.1111/j.1749-6632.1999.tb07813.x; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rothman Steven M., 1995, Trends in Neurosciences, V18, P57, DOI 10.1016/0166-2236(95)93869-Y; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Starkov AA, 1997, BIOSCIENCE REP, V17, P273, DOI 10.1023/A:1027380527769; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Stelmasiak Z, 2000, Med Sci Monit, V6, P426; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Wallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	51	66	67	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2009	218	2			SI		381	389		10.1016/j.expneurol.2009.05.023			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	472GE	WOS:000268117400025	19477175				2022-02-06	
J	Ngo, QN; Ranger, A; Singh, RN; Kornecki, A; Seabrook, JA; Fraser, DD				Ngo, Quang N.; Ranger, Adrianna; Singh, Ram N.; Kornecki, Alik; Seabrook, Jamie A.; Fraser, Douglas D.			External ventricular drains in pediatric patients	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						ventriculostomy; cerebrospinal fluid; traumatic brain injury; hydrocephalus	CEREBROSPINAL-FLUID; INFECTIONS; COMPLICATIONS; CATHETERS; DURATION; HYDROCEPHALUS; HYPONATREMIA; MANAGEMENT; CHILDREN; RATES	Objective: To determine the indications and complications of external ventricular drain (EVD) placement in pediatric patients. Design: Retrospective chart review. Setting., University associated, tertiary-level Children's Hospital. Patients: Sixty-six [median age, 10.1 years (interquartile range, 5.9)] patients between 1994 and 2006 with 96 EVDs. Measurements and Results: Clinical indications for EVD insertion include traumatic brain injury (TBI; 36%), acute hydrocephalus (35%), and ventriculoperitoneal shunt failure (29%). Of the 96 EVDs, 65% were inserted at the bedside in the pediatric critical care unit (PCCU) and 33% in the operating room (OR). Median duration of EVD insertion was 7.0 days (interquartile range, 8.8). Complications occurred with 26% of EVD insertions and included infection (9.4%), misplacement (6.3%), hemorrhage (4.2%), obstruction (3.1%), and malfunction (3.1%). The primary infectious etiology was coagulase-negative Staphylococcus (67% of infections). Despite patients with TBI having significantly smaller lateral ventricles than hydrocephalus patients (p < 0.05), EVD complications were similar (risk ratios 1.41; 95% confidence interval 0.68-2.72). Furthermore, the complication rate was the same for EVDs inserted in either the PCCU or OR (risk ratios 1.10; 95% confidence interval 0.55-2.29). Conclusion. EVDs were placed for TBI, ventriculoperitoneal shunt failure and new-onset hydrocephalus. The overall complication rate was 26%. Complication rates were similar in TBI and hydrocephalus patients, and with EVDs inserted in either the PCCU or OR. Prophylactic antibiotics or antimicrobial-impregnated catheters directed against coagulase-negative Staphylococcus may reduce EVD infections. (Pediatr Crit Care Med 2009; 10:346-351)	[Ngo, Quang N.; Singh, Ram N.; Kornecki, Alik; Seabrook, Jamie A.; Fraser, Douglas D.] Univ Western Ontario, Dept Paediat, London, ON, Canada; [Ranger, Adrianna; Fraser, Douglas D.] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; [Fraser, Douglas D.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Singh, Ram N.; Kornecki, Alik; Seabrook, Jamie A.; Fraser, Douglas D.] Childrens Hlth Res Inst, London, ON, Canada; [Singh, Ram N.; Kornecki, Alik; Fraser, Douglas D.] Ctr Crit Illness Res, London, ON, Canada		Ngo, QN (corresponding author), Univ Western Ontario, Dept Paediat, London, ON, Canada.	fraserd@lhsc.on.ca	Ngo, Quang Nhut/ABA-7410-2021	Ngo, Quang Nhut/0000-0002-8244-4208			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Berger A, 2000, CHILD NERV SYST, V16, P103, DOI 10.1007/s003810050022; BREIMAN RS, 1982, AM J ROENTGENOL, V138, P329, DOI 10.2214/ajr.138.2.329; Dasic D, 2006, BRIT J NEUROSURG, V20, P296, DOI 10.1080/02688690600999901; DIAS MS, 1989, PEDIATR NEUROSCI, V15, P283; EDDY VA, 1995, AM SURGEON, V61, P24; Hader WJ, 2000, NEUROSURGERY, V46, P1149, DOI 10.1097/00006123-200005000-00025; Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JAMES HE, 1982, NEUROSURGERY, V10, P50, DOI 10.1227/00006123-198201000-00009; KANTER RK, 1984, NEW ENGL J MED, V311, P987; Khalil BA, 2005, CHILD NERV SYST, V21, P355, DOI 10.1007/s00381-004-1080-6; Khan SH, 1998, ACT NEUR S, V71, P50; KIM DK, 1995, J NEUROL NEUROSUR PS, V58, P444, DOI 10.1136/jnnp.58.4.444; Korinek AM, 2005, ACTA NEUROCHIR, V147, P39, DOI 10.1007/s00701-004-0416-z; Lo CH, 2007, J NEUROSURG, V106, P378, DOI 10.3171/jns.2007.106.3.378; Lucey M A, 2003, Crit Care Resusc, V5, P182; MACMAHON P, 1983, ARCH DIS CHILD, V58, P385, DOI 10.1136/adc.58.5.385; Maniker AH, 2006, NEUROSURGERY, V59, P419, DOI 10.1227/01.NEU.0000222817.99752.E6; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; PAPO I, 1982, NEUROSURGERY, V10, P13, DOI 10.1227/00006123-198201000-00002; Pfisterer W, 2003, J NEUROL NEUROSUR PS, V74, P929, DOI 10.1136/jnnp.74.7.929; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; RHODES TT, 1987, PEDIATR NEUROSCI, V13, P255, DOI 10.1159/000120339; Roitberg BZ, 2001, BRIT J NEUROSURG, V15, P324; Rossi S, 1998, ACT NEUR S, V71, P91; SCARFF TB, 1978, CHILD BRAIN, V4, P129; Schade RP, 2005, J NEUROSURG, V102, P229, DOI 10.3171/jns.2005.102.2.0229; Simpson S, 2006, ANAESTH INTENS CARE, V34, P659, DOI 10.1177/0310057X0603400502; Sloffer CA, 2005, NEUROSURGERY, V56, P1041, DOI 10.1227/01.NEU.0000158193.99783.35; SMITH RW, 1976, J NEUROSURG, V44, P567, DOI 10.3171/jns.1976.44.5.0567; STENAGER E, 1986, ACTA NEUROCHIR, V83, P20, DOI 10.1007/BF01420503; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P497; TOBIAS JD, 1991, SOUTHERN MED J, V84, P279, DOI 10.1097/00007611-199102000-00035; WENINGER M, 1992, NEUROSURGERY, V31, P52, DOI 10.1227/00006123-199207000-00008; Whitehead WE, 2001, PEDIATR NEUROSURG, V35, P205, DOI 10.1159/000050422; WINFIELD JA, 1993, NEUROSURGERY, V33, P424; Wong GKC, 2006, J CLIN PHARM THER, V31, P231, DOI 10.1111/j.1365-2710.2006.00729.x; WYLER AR, 1972, J NEUROSURG, V37, P185, DOI 10.3171/jns.1972.37.2.0185; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725	41	66	67	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2009	10	3					346	351		10.1097/PCC.0b013e3181a320cd			6	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	444YG	WOS:000266016200011	19325503				2022-02-06	
J	Theeler, BJ; Erickson, JC				Theeler, Brett J.; Erickson, Jay C.			Mild Head Trauma and Chronic Headaches in Returning US Soldiers	HEADACHE			English	Article						headache; Iraq; traumatic brain injury; post-traumatic headache	BRAIN-INJURY; POSTTRAUMATIC HEADACHES; NECK; MIGRAINE; AFGHANISTAN; PREVALENCE; IRAQ	To determine the incidence and types of head or neck trauma and headache characteristics among US Army soldiers evaluated for chronic headaches at a military neurology clinic following a combat tour in Iraq. Head or neck trauma and headaches are common in US soldiers deployed to Iraq. The temporal association between mild head trauma and headaches, as well as the clinical characteristics of headaches associated with mild head trauma, has not been systematically studied in US soldiers returning from Iraq. A retrospective cohort study was conducted with 81 US Army soldiers from the same brigade who were evaluated at a single military neurology clinic for recurrent headaches after a 1-year combat tour in Iraq. All subjects underwent a standardized interview and evaluation to determine the occurrence of head or neck trauma during deployment, mechanism and type of trauma, headache type, and headache characteristics. In total, 33 of 81 (41%) soldiers evaluated for headaches reported a history of head or neck trauma while deployed to Iraq. A total of 18 (22%) subjects had concussion without loss of consciousness and 15 (19%) had concussion with loss of consciousness. Ten subjects also had an accompanying traumatic neck injury. No subjects had moderate or severe traumatic brain injury. Exposure to blasts was the most common cause of trauma, accounting for 67% of head and neck injuries. Headaches began within one week after trauma in 12 of 33 (36%) soldiers with head or neck injury. Another 12 (36%) reported worsening of pre-existing headaches after trauma. Headaches were classified as migraine type in 78% of soldiers with head or neck trauma. Headache types, frequency, severity, duration, and disability were similar for soldiers with and without a history of head or neck trauma. A history of mild head trauma, usually caused by exposure to blasts, is found in almost half of returning US combat troops who receive specialized care for headaches. In many cases, head trauma was temporally associated with either the onset of headaches or the worsening of pre-existing headaches, implicating trauma as a precipitating or exacerbating factor, respectively. Headaches in head trauma-exposed soldiers are usually migraine type and are similar to nontraumatic headaches encountered at a military specialty clinic.	[Theeler, Brett J.] Madigan Army Med Ctr, Neurol Serv, Dept Neurol, Tacoma, WA 98431 USA		Theeler, BJ (corresponding author), Madigan Army Med Ctr, Neurol Serv, Dept Neurol, 9040A Fitzsimmons Dr, Tacoma, WA 98431 USA.						Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Defense and Veterans Brain Injury Center, 2006, DEF VET BRAIN INJ CT; Evans RW, 2008, HEADACHE, V48, P1216, DOI 10.1111/j.1526-4610.2008.01216.x; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Sheftell FD, 2007, NEUROL SCI, V28, pS203, DOI 10.1007/s10072-007-0777-1; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Solomon S, 2005, HEADACHE, V45, P53, DOI 10.1111/j.1526-4610.2005.05011.x; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F.W., 1993, 9 ANN C ISTSS; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	21	66	67	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	APR	2009	49	4					529	534		10.1111/j.1526-4610.2009.01345.x			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	424JZ	WOS:000264564300004	19220499	Bronze			2022-02-06	
J	Riggio, S; Wong, M				Riggio, Silvana; Wong, Meredith			Neurobehavioral Sequelae of Traumatic Brain Injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						frontal lobe seizures; neuropsychiatric disorders; postconcussive syndrome; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; PSYCHIATRIC-DISORDERS; CHRONIC PAIN; FATIGUE; ASSOCIATION; DISABILITY; COMPLAINTS; SYMPTOMS; RISK	The neurobehavioral sequelae of traumatic brain injury consist of a spectrum of somatic and neuropsychiatric symptoms. The neuropsychiatric symptoms are divided into cognitive and behavioral presentations. In the literature, these neurobehavioral sequelae have been called postconcussive symptoms, postconcussive syndrome, and postconcussive disorder; however, the authors of this review do not use this terminology because the symptoms are not restricted to patients with concussion but instead can be found in all traumatic brain injury patients of all injury severities. The development of neurobehavioral sequelae after traumatic brain injury is a multifactorial process. The patient evaluation requires a multidisciplinary approach in order to delineate psysiologic dysfunction and place deficits in the context of the patient's preinjury and postinjury psychiatric status. Consequently, the evaluation of the posttraumatic brain injury patient with neurobehavioral sequelae requires a carefully structured history and physical examination with an emphasis on neurological and psychiatric function. Adjunctive evaluations must be trailored to the patient with neuroimaging, neurophysiological, and neuropsychiatric testing. Maximized outcomes may be achieved by the performance of a careful and detailed assessment that places compliants with the context of the individual. Mt Sinai J Med 76:163-172, 2009 (C) 2009 Mount Sinai School of Medicine	[Riggio, Silvana; Wong, Meredith] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA; [Riggio, Silvana] Mt Sinai Sch Med, Dept Neurol, New York, NY USA		Riggio, S (corresponding author), Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.	silvana.riggio@mssm.edu					Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; *DIV INJ DIS OUTC, 2004, TRAUM BRAIN INJ US E; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Greve KW, 2001, BRAIN INJURY, V15, P255; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Quesney LF, 1986, RECENT ADV EPILEPSY, V3, P81; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; RIGGIO S, 1995, ADV NEUROL, V66, P153; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Ruff RM, 1996, BRAIN INJURY, V8, P61; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	58	66	68	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					163	172		10.1002/msj.20097			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	427OE	WOS:000264787800009	19306386	Bronze			2022-02-06	
J	DuBose, JJ; Browder, T; Inaba, K; Teixeira, PGR; Chan, LS; Demetriades, D				DuBose, Joseph J.; Browder, Timothy; Inaba, Kenji; Teixeira, Pedro G. R.; Chan, Linda S.; Demetriades, Demetrios			Effect of Trauma Center Designation on Outcome in Patients With Severe Traumatic Brain Injury	ARCHIVES OF SURGERY			English	Article							AMERICAN-COLLEGE; LEVEL-I; SYSTEM; SURGEONS; MORTALITY; VOLUME; VERIFICATION; IMPACT; CARE	Objective: To determine the association of the American College of Surgeons ( ACS) designation with outcomes in patients, specifically those with severe traumatic brain injuries. Design: A retrospective review. Logistic regression was performed for mortality, complications, and progression of initial neurologic insult. Setting: Data from the National Trauma Data Bank. Patients: A total of 16 037 patients with isolated severe head injury ( head acute injury score, >= 3 and other body region abbreviated injury score, < 3) classified into 2 groups ( level 1 and level 2) according to ACS designation. Results: Patients admitted to a level 2 center had higher mortality rates ( 13.9% vs 9.6%; P < .001), higher rates of complication ( 15.5% vs 10.6%; P < .001), and higher rates of progression of initial neurologic insult ( 2.0% vs 1.1%; P < .001). After adjustment for the factors that were different between the 2 groups, admission to a level 2 facility remained an independent predictor of mortality ( adjusted odds ratio [ OR], 1.57; 95% confidence interval [ CI], 1.41-1.75; P < .001), complications ( adjusted OR, 1.55; 95% CI, 1.40-1.71; P < .001), and progression of neurologic insult ( adjusted OR, 1.78; 95% CI, 1.37-2.31; P < .001). Other independent risk factors for mortality were penetrating mechanism, age of 55 years or older, Injury Severity Score of 20 or higher, Glasgow Coma Scale score of 8 or lower, and hypotension ( systolic blood pressure, < 90 mm Hg). Conclusion: Patients with severe traumatic brain injury treated in ACS-designated level 1 trauma centers have better survival rates and outcomes than those treated in ACS-designated level 2 centers.	[DuBose, Joseph J.; Browder, Timothy; Inaba, Kenji; Teixeira, Pedro G. R.; Chan, Linda S.; Demetriades, Demetrios] Univ So Calif, Los Angeles Cty Hosp, Sch Med, Los Angeles, CA 90033 USA		DuBose, JJ (corresponding author), Univ So Calif, 1200 N State St,Room 10-750, Los Angeles, CA 90033 USA.	jjd3c@yahoo.com	INABA, KENJI/AAC-8532-2020; Teixeira, Pedro/H-2239-2011	Teixeira, Pedro/0000-0002-7258-7977			Biffl WL, 2005, J AM COLL SURGEONS, V200, P922, DOI 10.1016/j.jamcollsurg.2005.01.014; Clancy TV, 2001, J TRAUMA, V51, P346, DOI 10.1097/00005373-200108000-00021; Committee on Trauma of the American College of Surgeons, 2000, RES OPT CAR INJ PAT; Cooper A, 2000, J TRAUMA, V48, P16, DOI 10.1097/00005373-200001000-00004; Cornwell EE, 2003, ARCH SURG-CHICAGO, V138, P838, DOI 10.1001/archsurg.138.8.838; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; Demetriades D, 1998, BRIT J SURG, V85, P379; DiRusso S, 2001, J TRAUMA, V51, P294, DOI 10.1097/00005373-200108000-00011; Ehrlich PF, 2002, J TRAUMA, V53, P811, DOI 10.1097/00005373-200211000-00001; Harbrecht BG, 2005, AM SURGEON, V71, P942; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Helling TS, 1997, J TRAUMA, V42, P1091, DOI 10.1097/00005373-199706000-00018; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; NORWOOD S, 1995, J TRAUMA, V39, P240, DOI 10.1097/00005373-199508000-00009; Pasquale MD, 2001, J TRAUMA, V50, P465, DOI 10.1097/00005373-200103000-00010; Piontek FA, 2003, J TRAUMA, V54, P1041, DOI 10.1097/01.TA.0000061107.55798.31; SAMPALIS JS, 1995, J TRAUMA, V39, P232, DOI 10.1097/00005373-199508000-00008; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; SMITH RF, 1990, J TRAUMA, V30, P1066, DOI 10.1097/00005373-199009000-00002; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778	22	66	70	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0004-0010	1538-3644		ARCH SURG-CHICAGO	Arch. Surg.	DEC	2008	143	12					1213	1217		10.1001/archsurg.143.12.1213			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	384JO	WOS:000261741300015	19075174	Bronze			2022-02-06	
J	Kemp, CD; Johnson, JC; Riordan, WP; Cotton, BA				Kemp, Clinton D.; Johnson, J. Chad; Riordan, William P.; Cotton, Bryan A.			How we die: The impact of nonneurologic organ dysfunction after severe traumatic brain injury	AMERICAN SURGEON			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; HEAD-INJURY; DEATH; COMPLICATIONS; PULMONARY; ABNORMALITIES; EPIDEMIOLOGY; GUIDELINES; SURVIVAL; FAILURE	Although nonneurologic organ dysfunction (NNOD) has been shown to significantly affect mortality in subarachnoid hemorrhage, the contribution of NNOD to mortality after severe traumatic brain injury (TBI) has yet to be defined. We hypothesized that NNOD has a significant impact on mortality after severe TBI. The trauma registry was queried for all patients admitted between January 2004 and December 2004 who died during their initial hospitalization after severe TBI (head Abbreviated Injury Score 3 or greater). Cause of death and contributing factors to mortality were determined by an attending trauma surgeon from the medical record. The data were analyzed using both Fisher's exact and Wilcoxon rank sum. One hundred thirty-five patients met inclusion criteria. Sixty-seven per cent were males, 83 per cent were white, and the mean age was 38.5 years. Mean length of stay was 2.9 days. Fifty-four patients (40%) had isolated TBI (chest Abbreviated Injury Score = 0, abdominal Abbreviated Injury Score = 0). Of the 81 deaths attributed to a single cause, 48 (60%) patients died from nonsurvivable TBI or brain death, whereas 33 (40%) died of a nonneurologic cause. Cardiovascular and respiratory dysfunction (excluding pneumonia) contributed to mortality in 51.1 per cent and 34.1 per cent of patients, respectively. NNOD contributes to approximately two-thirds of all deaths after severe TBI. These complications occur early and are seen even among those with isolated head injuries. These findings demonstrate the impact of the extracranial manifestations of severe TBI on overall mortality and highlight potential areas for future intervention and research.	[Kemp, Clinton D.; Johnson, J. Chad; Riordan, William P.; Cotton, Bryan A.] Vanderbilt Univ, Sch Med, Div Trauma & Surg Crit Care, Dept Surg, Nashville, TN 37212 USA		Cotton, BA (corresponding author), Vanderbilt Univ, Sch Med, Div Trauma & Surg Crit Care, Dept Surg, 121st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	bryan.cotton@vanderbilt.cdu	Cotton, Bryan/A-7107-2009				Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Collier BR, 2004, J NEUROSURG ANESTH, V16, P196, DOI 10.1097/00008506-200407000-00003; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Friedman JA, 2003, NEUROSURGERY, V52, P1025, DOI 10.1227/01.NEU.0000058222.59289.F1; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Gilroy D, 2005, INJURY, V36, P47, DOI 10.1016/j.injury.2004.04.015; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Huang CH, 2004, AM J EMERG MED, V22, P141, DOI 10.1016/j.ajem.2004.02.029; Kemp CD, 2008, J TRAUMA, V64, P1573, DOI 10.1097/TA.0b013e318068fc2f; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LANZINO G, 1994, J NEUROSURG ANESTH, V6, P156; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; Macmillan CSA, 2002, INTENS CARE MED, V28, P1012, DOI 10.1007/s00134-002-1382-7; Macrea LM, 2005, RESUSCITATION, V65, P139, DOI 10.1016/j.resuscitation.2004.11.010; MARION DW, 1986, NEUROSURGERY, V18, P101, DOI 10.1227/00006123-198601000-00019; Parekh N, 2000, J AM COLL CARDIOL, V36, P1328, DOI 10.1016/S0735-1097(00)00857-3; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; THURMAN D, 1999, JAMA-J AM MED ASSOC, V282, P989; THURMAN D, 2001, HEAD TRAUMA BASIC PR; Vespa PM, 2004, NEUROCRIT CARE, V1, P157, DOI 10.1385/NCC:1:2:157; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	33	66	67	0	3	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	SEP	2008	74	9					866	872					7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	344NC	WOS:000258933400021	18807680				2022-02-06	
J	Goel, RS; Goyal, NK; Dharap, SB; Kumar, M; Gore, MA				Goel, Ravishankar S.; Goyal, Navin K.; Dharap, Satish B.; Kumar, Meena; Gore, Madhuri A.			Utility of optic nerve ultrasonography in head injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						optic nerve ultrasonography; optic nerve sheath diameter; raised intracranial pressure	ELEVATED INTRACRANIAL-PRESSURE; CEREBROSPINAL-FLUID PRESSURE; EMERGENCY ULTRASONOGRAPHY; OCULAR ULTRASONOGRAPHY; SONOGRAPHIC EVALUATION; SHEATH DIAMETER; ULTRASOUND; PATIENT	Background: CT has evolved as the gold standard for evaluation of head injury, but early CT is not always possible. Bedside ultrasonography is available in most trauma units and optic nerve ultrasound (ONUS) examination should be feasible. Objective: To evaluate the role of ONUS for people with head injury. Setting: Tertiary care trauma service in a teaching hospital in a large metropolitan city in India. Design: Prospective, blinded, observational study. Methods: From April 2006 to January 2007, all adult patients with head injury but without obvious ocular trauma, for whom it was possible to perform CT, were enrolled. Using a 7.5-MHz ultrasonographic probe on the closed eyelids, optic nerve sheath diameter (ONSD) was measured on either side. A mean binocular ONSD Less than 5.00 mm was considered normal. Cranial CT findings were used as a reference standard to evaluate ONUS. Results: The study included 100 participants (72 men, 28 women, median age 28 years, median Glasgow Coma Scale score 11). Clinical features did not correlate with CT for signs of raised intracranial pressure (ICP). The mean binocular ONSD (5.8 +/- 0.57 mm) was significantly increased among individuals with signs of raised ICP on CT compared with the mean ONSD (3.5 +/- 0.75 mm) among those without such signs. ONUS revealed evidence of raised ICP in 74 cases (confirmed by CT in 72 cases), 59 of whom had significant intracranial haematoma needing surgical evacuation. Of the 26 cases with negative ONUS, confirmed by CT in 25 cases, only 1 needed surgical intervention for drainage of intracranial haematoma. ONUS was false positive for two and false negative for one person. The sensitivity of ONUS in detecting elevated ICP was 98.6%, specificity 92.8%, positive predictive value 97.26% and negative predictive value 96.3%. Conclusion: ONUS has potential as a sensitive bedside screening test for detecting raised ICP and the presence of intracranial haematoma needing surgical intervention in adult head injury. This can be of immense help for unstable patients, in mass casualty situations and in remote locations. (C) 2007 Elsevier Ltd. All rights reserved.	[Goel, Ravishankar S.] LTM Med Coll, Dept Surg, Trauma Serv, Bombay 400022, Maharashtra, India; LTMG Hosp, Bombay 400022, Maharashtra, India		Goel, RS (corresponding author), LTM Med Coll, Dept Surg, Trauma Serv, Bombay 400022, Maharashtra, India.	docravishankar@yahoo.co.in	Dharap, Satish/AAE-8565-2020	Dharap, Satish/0000-0002-9304-9617			Ballantyne S A, 2002, Eur J Ultrasound, V15, P145, DOI 10.1016/S0929-8266(02)00036-8; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Blaivas M, 2002, ACAD EMERG MED, V9, P791, DOI 10.1111/j.1553-2712.2002.tb02166.x; Czarnik T, 2007, J TRAUMA, V62, P207, DOI 10.1097/01.ta.0000219128.29515.d5; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GALETTA S, 1989, J CLIN NEURO-OPHTHAL, V9, P79; Girisgin AS, 2007, EMERG MED J, V24, P251, DOI 10.1136/emj.2006.040931; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; HAYREH SS, 1968, DOC OPHTHALMOL, V24, P289, DOI 10.1007/BF02550944; Helmke K, 1996, PEDIATR RADIOL, V26, P706, DOI 10.1007/BF01383384; Jang T, 2005, ANN EMERG MED, V45, P336, DOI 10.1016/j.annemergmed.2004.09.031; Kahraman S, 2006, J TRAUMA, V61, P1480, DOI 10.1097/01.ta.0000197616.10279.48; Malayeri AA, 2005, J ULTRAS MED, V24, P143, DOI 10.7863/jum.2005.24.2.143; MATEER J, 1994, ANN EMERG MED, V23, P95, DOI 10.1016/S0196-0644(94)70014-1; OSSOINIG KC, 1993, DOC OPHTH P, V55, P3; Romagnuolo L, 2005, AM J EMERG MED, V23, P686, DOI 10.1016/j.ajem.2004.11.004; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; [The American Association of Neurological Surgeons The Brain Trauma Foundation], 2000, J NEUROTRAUM, V17, P463; Tsung JW, 2005, PEDIATR EMERG CARE, V21, P94, DOI 10.1097/01.pec.0000159052.64930.64	19	66	69	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAY	2008	39	5					519	524		10.1016/j.injury.2007.09.029			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	298OZ	WOS:000255698300004	18325519				2022-02-06	
J	Freeman, SS; Udomphom, Y; Armstead, WM; Fisk, DM; Vavilala, MS				Freeman, Serena S.; Udomphom, Yuthana; Armstead, William M.; Fisk, Dana M.; Vavilala, Monica S.			Young age as a risk factor for impaired cerebral autoregulation after moderate to severe pediatric traumatic brain injury	ANESTHESIOLOGY			English	Article							BLOOD-FLOW VELOCITY; TRANSCRANIAL DOPPLER; CHANNEL FUNCTION; CHILDREN; HEMODYNAMICS; METABOLISM; INFANTS; RESPONSES; IMMATURE; TIME	Background: Little is known about age and cerebral autoregulation in children with traumatic brain injury (TBI). The authors compared cerebral autoregulation between young (aged <4 yr) and older (aged >= 4 yr) children with TBI. Methods. After University of Washington's institutional review board approval, a retrospective analysis of prospectively collected data (May 2002 and June 2007) was performed. Eligibility criteria included age 16 yr or younger, moderate to severe (admission Glasgow Coma Scale score <13) TBI, TBI on computed tomography scan, and tracheal intubation. Cerebral antoregulation testing was performed within 72 h after TBI, and antoregulation was quantified using the autoregulatory index. An antoregulatory index less than 0.4 represents impaired cerebral autoregulation. The 12-month Glasgow outcome score was measured. Data arc presented as mean +/- SD or range. Results: Thirty-seven children (8.9 +/- 5.1 yr; 0.8-16 yr) were enrolled. Children younger than 4 yr had a higher incidence of impaired cerebral autoregulation (8 of 10 vs. 7 of 27; P = 0.006) and worse 12-month outcome (Glasgow outcome score 3.0 +/- 1.0 vs. 4.0 +/- 1.0; P = 0.02) than older children. Age less than 4 yr (adjusted odds ratio, 12.2; 95% confidence interval, 1.5-98-5) and low Glasgow Coma Scale score (adjusted odds ratio for higher Glasgow Coma Scale, 0.53; 95% confidence interval, 0.30-0.96) were independently associated with impaired cerebral autoregulation. Conclusions: Age less than 4 yr was a risk factor for impaired cerebral autoregulation, independent of TBI severity. Age-related factors may play a role in the mechanisms maintaining or worsening cerebral autoregulation in children after TBI.	[Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; [Fisk, Dana M.; Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Pediat, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Seattle, WA 98104 USA; [Vavilala, Monica S.] Childrens Hosp & Reg Med Ctr, Seattle, WA USA; [Freeman, Serena S.] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA; [Armstead, William M.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA		Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9Th Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T35HD007446] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T35-HD007446, K23-HD044632] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Armstead WM, 1999, EXP TOXICOL PATHOL, V51, P137, DOI 10.1016/S0940-2993(99)80087-6; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bode H, 1988, APPL PEDIAT TRANSCRA, P114; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; GERMARELLI TA, 1994, J NEUROTRAUM, V11, P357; Jennett B, 1979, Acta Neurochir Suppl (Wien), V28, P149; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Karsli C, 2002, CAN J ANAESTH, V49, P830, DOI 10.1007/BF03017417; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; McCulloch TJ, 2000, ANESTHESIOLOGY, V93, P1205, DOI 10.1097/00000542-200011000-00012; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sahuquillo J, 1998, ACT NEUR S, V71, P233; SEVERINGHAUS JW, 1967, CIRC RES, V20, P272, DOI 10.1161/01.RES.20.2.272; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Suz P, 2006, J NEUROSURG ANESTH, V18, P5, DOI 10.1097/01.ana.0000189079.26212.37; Tontisirin N, 2007, CHILD NERV SYST, V23, P1163, DOI 10.1007/s00381-007-0339-0; Tontisirin N, 2007, PEDIATRICS, V119, pE610, DOI 10.1542/peds.2006-2110; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2007, J NEUROTRAUM, V24, P87, DOI 10.1089/neu.2006.0058; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2005, PEDIATR RES, V58, P574, DOI 10.1203/01.PDR.0000179405.30737.0F	34	66	67	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2008	108	4					588	595		10.1097/ALN.0b013e31816725d7			8	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	281AE	WOS:000254467500008	18362589	Bronze			2022-02-06	
J	Lyons, KE; Pahwa, R				Lyons, Kelly E.; Pahwa, Rajesh			Deep brain stimulation and tremor	NEUROTHERAPEUTICS			English	Article						deep brain stimulation; tremor; essential tremor; primary writing tremor; multiple sclerosis tremor; post-traumatic tremor	CHRONIC THALAMIC-STIMULATION; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; ELECTRICAL-STIMULATION; SUBTHALAMIC AREA; THALAMOTOMY; NUCLEUS; EFFICACY; MANAGEMENT	Deep brain stimulation (DBS) has been used to treat various tremor disorders for several decades. Medication-resistant, disabling essential tremor (ET) is the most common tremor disorder treated with DBS. The treatment has been consistently reported to result in significant benefit in upper extremity, as well as head and voice tremor, all of which were improved more dramatically with bilateral procedures. These benefits have been demonstrated to be sustained for up to 7 years. DBS has also been shown to be beneficial for the tremor associated with multiple sclerosis and post-traumatic tremor; however, fewer cases have been reported and the benefit is less consistent, less dramatic, and more transient than that seen with ET. The ventral intermediate nucleus of the thalamus is the most common DBS target for tremor disorders, but more recent studies have demonstrated benefits in tremor front DBS of the subthalamic area, primarily the zona incerta, Surgical complications are relatively uncommon and are generally less frequent than those seen with thalamotomy. Stimulation-related effects are usually mild and resolve with adjustment of stimulation parameters. DBS is thus a relatively safe and effective treatment for tremor disorders, particularly for medication-resistant, disabling ET, but may also have some role in medication-resistant, disabling tremor associated with multiple sclerosis and traumatic head injury.	[Lyons, Kelly E.; Pahwa, Rajesh] Univ Kansas, Med Ctr, Dept Neurol, Parkinsons Dis & Movement Disorder Ctr, Kansas City, KS 66160 USA		Lyons, KE (corresponding author), Univ Kansas, Med Ctr, Dept Neurol, Parkinsons Dis & Movement Disorder Ctr, 3599 Rainbow Blvd,Mailstop 2012, Kansas City, KS 66160 USA.	lyons.kelly@att.net					ALESCH F, 1995, ACTA NEUROCHIR, V136, P75, DOI 10.1007/BF01411439; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; Berk C, 2002, J NEUROSURG, V96, P615, DOI 10.3171/jns.2002.96.3.0615; Berk C, 2002, J NEUROSURG, V97, P815, DOI 10.3171/jns.2002.97.4.0815; BLOND S, 2001, ACTA NEUROCHIR S, V52, P109; BROGGI G, 1993, MOVEMENT DISORD, V8, P206, DOI 10.1002/mds.870080217; Deuschl G, 2002, MOVEMENT DISORD, V17, pS102, DOI 10.1002/mds.10150; Deuschl G, 1998, MOVEMENT DISORD, V13, P2, DOI 10.1002/mds.870131303; Foote KD, 2005, NEUROSURGERY, V56, P415, DOI 10.1227/01.NEU.0000147978.67424.42; Geny C, 1996, MOVEMENT DISORD, V11, P489, DOI 10.1002/mds.870110503; Hariz GM, 1998, MOVEMENT DISORD, V13, P78, DOI 10.1002/mds.870130117; HASSLER R, 1960, BRAIN, V83, P337, DOI 10.1093/brain/83.2.337; Kitagawa M, 2000, NEUROLOGY, V55, P114, DOI 10.1212/WNL.55.1.114; Koller W, 1997, ANN NEUROL, V42, P292, DOI 10.1002/ana.410420304; Koller WC, 1999, MOVEMENT DISORD, V14, P847, DOI 10.1002/1531-8257(199909)14:5<847::AID-MDS1021>3.0.CO;2-G; Koller WC, 2001, MOVEMENT DISORD, V16, P464, DOI 10.1002/mds.1089; Krauss JK, 2002, NEUROSURGERY, V50, P927, DOI 10.1097/00006123-200205000-00003; Krauss JK, 2001, NEUROSURGERY, V48, P535, DOI 10.1097/00006123-200103000-00015; Kumar K, 1999, STEREOT FUNCT NEUROS, V72, P47, DOI 10.1159/000029671; Limousin P, 1999, J NEUROL NEUROSUR PS, V66, P289, DOI 10.1136/jnnp.66.3.289; Lyons KE, 2003, DRUG SAFETY, V26, P461, DOI 10.2165/00002018-200326070-00003; Minguez-Castellanos A, 1999, MOVEMENT DISORD, V14, P1030, DOI 10.1002/1531-8257(199911)14:6<1030::AID-MDS1021>3.0.CO;2-O; Montgomery EB, 1999, NEUROLOGY, V53, P625, DOI 10.1212/WNL.53.3.625; Murata J, 2003, J NEUROSURG, V99, P708, DOI 10.3171/jns.2003.99.4.0708; Nandi D, 2004, J CLIN NEUROPHYSIOL, V21, P31, DOI 10.1097/00004691-200401000-00005; Olanow CW, 2001, NEUROLOGY, V56, pS1, DOI 10.1212/WNL.56.suppl_5.S1; Ondo W, 1998, NEUROLOGY, V51, P1063, DOI 10.1212/WNL.51.4.1063; Pahwa R, 2006, J NEUROSURG, V104, P506, DOI 10.3171/jns.2006.104.4.506; Pahwa R, 2003, AM J MED, V115, P134, DOI 10.1016/S0002-9343(03)00259-6; Pahwa R, 2001, MOVEMENT DISORD, V16, P140, DOI 10.1002/1531-8257(200101)16:1<140::AID-MDS1025>3.0.CO;2-T; Plaha P, 2004, J NEUROSURG, V101, P48, DOI 10.3171/jns.2004.101.1.0048; Putzke JD, 2005, J NEUROL NEUROSUR PS, V76, P684, DOI 10.1136/jnnp.2004.041434; Putzke JD, 2004, CAN J NEUROL SCI, V31, P333, DOI 10.1017/S0317167100003413; Putzke JD, 2003, PARKINSONISM RELAT D, V10, P81, DOI 10.1016/j.parkreldis.2003.09.002; Racette BA, 2001, J NEUROL, V248, P380, DOI 10.1007/s004150170177; Rehncrona S, 2003, MOVEMENT DISORD, V18, P163, DOI 10.1002/mds.10309; Schulder M, 2003, STEREOT FUNCT NEUROS, V80, P48, DOI 10.1159/000075160; Schulder M, 1999, STEREOT FUNCT NEUROS, V72, P196, DOI 10.1159/000029726; Schuurman PR, 2000, NEW ENGL J MED, V342, P461, DOI 10.1056/NEJM200002173420703; Sydow O, 2003, J NEUROL NEUROSUR PS, V74, P1387, DOI 10.1136/jnnp.74.10.1387; Tasker RR, 1998, SURG NEUROL, V49, P145, DOI 10.1016/S0090-3019(97)00459-X; Umemura A, 2004, CLIN NEUROL NEUROSUR, V106, P280, DOI 10.1016/j.clineuro.2003.12.004; Wishart HA, 2003, J NEUROL NEUROSUR PS, V74, P1392, DOI 10.1136/jnnp.74.10.1392; Yap L, 2007, BRIT J NEUROSURG, V21, P349, DOI 10.1080/02688690701544002	44	66	67	1	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	APR	2008	5	2					331	338		10.1016/j.nurt.2008.01.004			8	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	288SC	WOS:000255005100015	18394574	Green Published, Bronze			2022-02-06	
J	Seifman, MA; Adamides, AA; Nguyen, PN; Vallance, SA; Cooper, DJ; Kossmann, T; Rosenfeld, JV; Morganti-Kossmann, MC				Seifman, Marc A.; Adamides, Alexios A.; Nguyen, Phuong N.; Vallance, Shirley A.; Cooper, David James; Kossmann, Thomas; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina			Endogenous melatonin increases in cerebrospinal fluid of patients after severe traumatic brain injury and correlates with oxidative stress and metabolic disarray	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebrospinal fluid; lipid peroxidation; melatonin; metabolism; oxidative stress; traumatic brain injury	HEAD-INJURY; OXYGEN RADICALS; DAMAGE; PHASE; ANTIOXIDANTS; SEIZURES; DISEASE; SERUM	Oxidative stress plays a significant role in secondary damage after severe traumatic brain injury (TBI); and melatonin exhibits both direct and indirect antioxidant effects. Melatonin deficiency is deleterious in TBI animal models, and its administration confers neuroprotection, reducing cerebral oedema, and improving neurobehavioural outcome. This study aimed to measure the endogenous cerebrospinal fluid (CSF) and serum melatonin levels post-TBI in humans and to identify relationships with markers of oxidative stress via 8-isoprostaglandin-F-2 alpha (isoprostane), brain metabolism and neurologic outcome. Cerebrospinal fluid and serum samples of 39 TBI patients were assessed for melatonin, isoprostane, and various metabolites. Cerebrospinal fluid but not serum melatonin levels were markedly elevated (7.28 +/- 0.92 versus 1.47 +/- 0.35 pg/mL, P<0.0005). Isoprostane levels also increased in both CSF (127.62 +/- 16.85 versus 18.28 +/- 4.88 pg/mL, P<0.0005) and serum (562.46 +/- 50.78 versus 126.15 +/- 40.08 pg/mL (P<0.0005). A strong correlation between CSF melatonin and CSF isoprostane on day 1 after injury (r = 0.563, P = 0.002) suggests that melatonin production increases in conjunction with lipid peroxidation in TBI. Relationships between CSF melatonin and pyruvate (r = 0.369, P = 0.049) and glutamate (r = 0.373, P = 0.046) indicate that melatonin production increases with metabolic disarray. In conclusion, endogenous CSF melatonin levels increase after TBI, whereas serum levels do not. This elevation is likely to represent a response to oxidative stress and metabolic disarray, although further studies are required to elucidate these relationships.	[Seifman, Marc A.; Adamides, Alexios A.; Nguyen, Phuong N.; Vallance, Shirley A.; Cooper, David James; Kossmann, Thomas; Rosenfeld, Jeffrey V.; Morganti-Kossmann, M. Cristina] Natl Trauma Res Ctr, Melbourne, Vic 3004, Australia; [Seifman, Marc A.; Adamides, Alexios A.; Rosenfeld, Jeffrey V.] Dept Neurosurg, Melbourne, Vic, Australia; [Seifman, Marc A.; Kossmann, Thomas] Dept Trauma Surg, Melbourne, Vic, Australia; [Seifman, Marc A.; Kossmann, Thomas; Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Adamides, Alexios A.; Nguyen, Phuong N.; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Vallance, Shirley A.; Cooper, David James] Dept Intens Care, Melbourne, Vic 3004, Australia		Morganti-Kossmann, MC (corresponding author), Natl Trauma Res Ctr, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@med.monash.edu	Rosenfeld, Jeffrey V/B-7249-2011; Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051; Morganti-Kossmann, Cristina/0000-0002-0807-2063			Antolin I, 2002, BRAIN RES, V943, P163, DOI 10.1016/S0006-8993(02)02551-9; Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; BAYIR H, 2001, MO CL BI CC, V2, P115; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Easton AS, 1998, J PHYSIOL-LONDON, V507, P541, DOI 10.1111/j.1469-7793.1998.541bt.x; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Jimenez-Caliani AJ, 2005, J PINEAL RES, V38, P93, DOI 10.1111/j.1600-079X.2004.00175.x; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; KONTOS HA, 1983, ADV EXP MED BIOL, V161, P365; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Krauchi K, 1997, AM J PHYSIOL-REG I, V272, pR1178, DOI 10.1152/ajpregu.1997.272.4.R1178; Lapin IP, 1998, J PINEAL RES, V24, P215; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Lissoni P, 1997, J BIOL REG HOMEOS AG, V11, P157; Liu RY, 1999, J CLIN ENDOCR METAB, V84, P323, DOI 10.1210/jc.84.1.323; Longatti P, 2007, J PINEAL RES, V42, P113, DOI 10.1111/j.1600-079X.2006.00391.x; Longoni B, 1998, LIFE SCI, V62, P853, DOI 10.1016/S0024-3205(98)00002-2; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; Rizzo V, 2002, J CHROMATOGR B, V774, P17, DOI 10.1016/S1570-0232(02)00168-X; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rousseau A, 1999, J NEURAL TRANSM, V106, P883, DOI 10.1007/s007020050208; Sano K, 1980, Neurol Res, V2, P253; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tricoire H, 2002, ENDOCRINOLOGY, V143, P84, DOI 10.1210/en.143.1.84; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu YH, 2003, J CLIN ENDOCR METAB, V88, P5898, DOI 10.1210/jc.2003-030833; Zhou JN, 2003, J PINEAL RES, V35, P125, DOI 10.1034/j.1600-079X.2003.00065.x	42	66	66	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2008	28	4					684	696		10.1038/sj.jcbfm.9600603			13	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	280GS	WOS:000254414500003	18183032	Bronze			2022-02-06	
J	Raymont, V; Greathouse, A; Reding, K; Lipsky, R; Salazar, A; Grafman, J				Raymont, Vanessa; Greathouse, Amanda; Reding, Katherine; Lipsky, Robert; Salazar, Andres; Grafman, Jordan			Demographic, structural and genetic predictors of late cognitive decline after penetrating head injury	BRAIN			English	Article						cognitive decline; brain injury; penetrating brain injury; genetics; predictors	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E EPSILON-4; AMYLOID BETA-PROTEIN; MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; RISK-FACTOR; VAL(158)MET POLYMORPHISM; FUNCTIONAL POLYMORPHISM; GENOTYPE PREDICTS; APOE GENOTYPE	We examined the relationship of pre-injury intelligence, demographic variables, lesion location, brain tissue volume loss and a number of genetic markers to long-term cognitive decline in a group of Vietnam veterans with predominantly penetrating head injury (PHI) suffered more than 30 years ago. Using linear and stepwise regression procedures, we found that those with PHI demonstrated a greater degree of cognitive decline overall during the years following recovery from injury compared with a control group of uninjured Vietnam veterans. This became increasingly significant later in life. We also found that pre-injury intelligence was the most consistent predictor of cognitive outcome across all phases of potential recovery and decline after such injuries. While laterality of lesion was not a factor, we did find some associations between atrophy and specific regions of tissue loss and long-term cognitive functioning. Finally, we found evidence for an association between level of cognitive decline following PHI and the possession of certain genetic markers that have been linked with brain injury and neurodegeneration. Thus exacerbated decline does occur in Vietnam veterans with PHI and it is apparently unrelated to dementia and is determined by multiple factors (most notably pre-injury intelligence).	[Raymont, Vanessa; Greathouse, Amanda; Reding, Katherine; Salazar, Andres; Grafman, Jordan] Natl Naval Med Ctr, Vietnam Head Injury Study, Henry M Jackson Fdn, Bethesda, MD 20889 USA; [Lipsky, Robert] NIAAA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA		Grafman, J (corresponding author), NINDS, Cognit Neurosci Sect, NIH, Bldg 10,Room 7D43,MSC 1440, Bethesda, MD 20892 USA.	grafmanj@ninds.nih.gov		Cole, Katherine/0000-0002-1910-127X; Lipsky, Robert/0000-0001-7753-1473; Grafman, Jordan H./0000-0001-8645-4457	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003024, Z01NS003024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [Z01AA000325] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA Funding Source: Medline		Aalto S, 2005, J NEUROSCI, V25, P2471, DOI 10.1523/JNEUROSCI.2097-04.2005; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Arning L, 2005, NEUROGENETICS, V6, P25, DOI 10.1007/s10048-004-0198-8; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Brooks N, 2003, J NEUROL NEUROSUR PS, V74, P1014, DOI 10.1136/jnnp.74.8.1014; CAREY ME, 1987, MIL MED, V152, P6; Cervilla J, 2004, J NEUROL NEUROSUR PS, V75, P1100, DOI 10.1136/jnnp.2003.028076; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; CHUNN MM, 2007, CURR OPIN NEUROBIOL; Chuu JYJ, 2006, J ALZHEIMERS DIS, V9, P43; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CORKIN S, 1989, J NEUROSCI, V9, P3876; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DAMAASIO H, 1983, LESION NEUROPSYCHOLO; de Frias CM, 2005, J COGNITIVE NEUROSCI, V17, P1018, DOI 10.1162/0898929054475136; *DEP DEF, 1960, AFQT7A; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Ekstrom AD, 2003, NATURE, V425, P184, DOI 10.1038/nature01964; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Giubilei F, 2004, DEMENT GERIATR COGN, V18, P338, DOI 10.1159/000080128; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Gothelf D, 2005, NAT NEUROSCI, V8, P1500, DOI 10.1038/nn1572; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; GRAFMAN J, 1986, J NEUROSCI, V6, P301; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Grossman M, 2002, HUM BRAIN MAPP, V15, P124, DOI 10.1002/hbm.10117; HAMMOND W, 1986, J NEUROSURG, V34, P127; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007; Laske C, 2006, J NEURAL TRANSM, V113, P1217, DOI 10.1007/s00702-005-0397-y; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Lendon CL, 2003, NEUROLOGY, V61, P683, DOI 10.1212/01.WNL.0000078033.81925.80; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Marczynski TJ, 1998, BRAIN RES BULL, V45, P341, DOI 10.1016/S0361-9230(97)00347-X; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Mayeux R, 1996, NEUROLOGY, V46, P891; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P594, DOI 10.1038/nn1438; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1992, NEUROLOGY, V42, P1689, DOI 10.1212/WNL.42.9.1689; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Newcombe F, 1996, J CLIN EXP NEUROPSYC, V18, P1, DOI 10.1080/01688639608408258; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramsey MM, 2004, NEUROSCIENCE, V129, P119, DOI 10.1016/j.neuroscience.2004.08.001; RAPOPORT M, 2004, CAN ALZHEIMERS DIS R, V1, P4; Reider-Groswasser II, 2002, BRAIN INJURY, V16, P517, DOI 10.1080/02699050110119141; Richardson MP, 2003, NEUROIMAGE, V20, pS112, DOI 10.1016/j.neuroimage.2003.09.008; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Robert PH, 2006, DEMENT GERIATR COGN, V21, P192, DOI 10.1159/000090766; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Robinson S, 2006, J NEUROSURG, V104, P396, DOI 10.3171/ped.2006.104.6.396; SACK AT, 2007, CEREB CORTEX; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Stefanis NC, 2005, AM J PSYCHIAT, V162, P1752, DOI 10.1176/appi.ajp.162.9.1752; STERN Y, 1995, ANN NEUROL, V37, P590, DOI 10.1002/ana.410370508; STERN Y, 2006, COGNITIVE RESERVE TH; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Talairach J., 1988, COPLANAR STEREOTAXIC, P122; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Tariq SH, 2006, AM J GERIAT PSYCHIAT, V14, P900, DOI 10.1097/01.JGP.0000221510.33817.86; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WALKER AE, 1989, ARCH NEUROL-CHICAGO, V46, P23, DOI 10.1001/archneur.1989.00520370025013; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	88	66	67	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2008	131		2				543	558		10.1093/brain/awm300			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	258XO	WOS:000252903900024	18094019	Bronze			2022-02-06	
J	Slobounov, S; Cao, C; Sebastianelli, W; Slobounov, E; Newell, K				Slobounov, Semyon; Cao, Cheng; Sebastianelli, Wayne; Slobounov, Elena; Newell, Karl			Residual deficits from concussion as revealed by virtual time-to-contact measures of postural stability	CLINICAL NEUROPHYSIOLOGY			English	Article						VTC; mild traumatic brain injury (MTBI); postural control	CEREBRAL CONCUSSION; BRAIN-INJURY; RECOVERY; BOUNDARIES; SUPPORT; SWAY	Objective: Traumatic brain injury (TBI), including mild traumatic brain injury (MTBI), commonly known as a "concussion", is still one of the most puzzling neurological disorders and least understood injuries facing sport medicine and the scientific community Cantu R. Concussion assessment Ongoing controversy. In: Slobounov S, Sebastianelli W, editors. Foundations of sport-related brain injuries. New York: Springer Press; 2006. p. 87-111.]. It was our primary objective to assess the dynamic properties of postural control in subjects prior to and after sport-related MTBI using the traditional center of pressure (COP) and virtual time-to-contact (VTC) measures. Methods: We assessed 12 student-athletes prior to and 30 days after they suffered sport-related MTBI on a number of standing still and dynamic postural tasks. All subjects were clinically asymptomatic at day 30 of testing and were cleared for full sport participation based upon neurological and neuropsychological assessments, as well as clinical symptoms resolution. Results: The findings showed: (1) no significant differences for any of the standard COP-based measures of postural control (i.e., 90% ellipse COP area, COP velocity and Stability Index) as a function of testing day (prior to and 30 days post-injury, p >.05); (2) no differences in terms of VTC shape, distribution and nominal values before and after concussion during standing still postural tasks regardless of vision conditions, p >.05; and (3) there were significant alterations in VTC in terms of absolute values, range of VTC at the deflection points and mode at the day 30 post-injury. Conclusions: The deficits in VTC control are indicative of residual postural abnormality in subjects suffering from mild traumatic brain injuries and provide further evidence that VTC is used to regulate dynamic postural movement. Significance: The results show that residual postural abnormalities in concussed individuals may be undetected using conventional research methods and the implications of this for clinical practice are discussed. (c) 2007 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Slobounov, Semyon; Cao, Cheng; Newell, Karl] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Sebastianelli, Wayne] Penn State Univ, Athlet Med Clin, University Pk, PA 16802 USA; [Slobounov, Elena] Penn State Univ, Informat Technol Serv, University Pk, PA 16802 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu					BARIN K, 1992, IEEE ENG MED BIOL, V11, P52, DOI 10.1109/51.256960; Barth JT, 2001, J ATHL TRAINING, V36, P253; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; CARELLO C, 1985, BEHAV BRAIN SCI, V8, P151, DOI 10.1017/S0140525X00020021; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; Guskiewicz KM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P65, DOI 10.1007/0-387-32565-4_4; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Haddad JM, 2006, J APPL BIOMECH, V22, P155, DOI 10.1123/jab.22.2.155; Haibach PS, 2007, EXP BRAIN RES, V177, P471, DOI 10.1007/s00221-006-0703-4; Hallett M, 2001, BRAIN RES REV, V36, P169, DOI 10.1016/S0165-0173(01)00092-3; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Hertel J, 2006, J APPL BIOMECH, V22, P67, DOI 10.1123/jab.22.1.67; HERTEL J, 2007, GAIT POSTURE, V40, P69; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Kahneman D., 1973, ATTENTION EFFORT; Krishnamoorthy V, 2005, J PHYSIOL-LONDON, V565, P675, DOI 10.1113/jphysiol.2005.084772; Kugler P.N., 1987, INFORM NATURAL LAW S; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Newell K, 1994, GAIT POSTURE, V2, P85, DOI [10.1016/0966-6362(94)90097-3, DOI 10.1016/0966-6362(94)90097-3]; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; RICCIO GE, 1993, VARIABILITY AND MOTOR CONTROL, P317; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; SLOBOUNOV S, 2006, FDN SPORT RELATED BR; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Slobounov SM, 1997, J MOTOR BEHAV, V29, P263, DOI 10.1080/00222899709600841; Slobounov SM, 1998, J GERONTOL A-BIOL, V53, pB71, DOI 10.1093/gerona/53A.1.B71; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Valovich TC, 2003, J ATHL TRAINING, V38, P51; van Wegen EEH, 2002, HUM MOVEMENT SCI, V21, P61, DOI 10.1016/S0167-9457(02)00077-5; van Wegen EEH, 2001, MOTOR CONTROL, V5, P254, DOI 10.1123/mcj.5.3.254; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	44	66	66	0	24	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	FEB	2008	119	2					281	289		10.1016/j.clinph.2007.10.006			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	260SB	WOS:000253029600005	18068428				2022-02-06	
J	Glang, A; Todis, B; Thomas, C; Hood, D; Bedell, G; Cockrell, J				Glang, Ann; Todis, Bonnie; Thomas, CatherineW.; Hood, Donald; Bedell, Gary; Cockrell, Janice			Return to school following childhood TBI: Who gets services?	NEUROREHABILITATION			English	Article						Special education; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ACADEMIC-ACHIEVEMENT; CHILDREN; ADOLESCENTS; REHABILITATION; INTERVENTIONS; TRANSITION; PLACEMENT; RECOVERY; STUDENTS	Long-term follow-up studies of children conducted during the K-12 school years suggest that problems associated with TBI tend to persist or worsen as children progress through school. A critical issue in service delivery for students with TBI is the significant discrepancy between the incidence of TBI and the identification of children with TBI for special education services. The purpose of this study was to examine factors that influence identification and service practices for students with TBI. Parents of 56 youth with TBI completed a questionnaire and interview about the hospital-school transition and educational services provided within the first year of school re-entry. A subsample participated in a concurrent qualitative study. Results document that 25% of the sample were identified for formal services (via individual education plan or 504 plan) while over 41% received informal supports (e. g., schedule change, extra time on tests). Results from chi-square and logistic regression analyses suggest that injury severity and hospital-school transition services (e. g., written or verbal communication between hospital and school) were related to the provision of formal special education or 504 services. A critical factor contributing to the identification of students with TBI for special education is the link between hospital and school.	[Glang, Ann; Todis, Bonnie; Thomas, CatherineW.; Hood, Donald] Teaching Res Inst Eugene, Eugene, OR 97401 USA; [Hood, Donald] Tufts Univ, Boston, MA 02111 USA; [Cockrell, Janice] Legacy Emanuel Childrens Hosp, Portland, OR USA		Glang, A (corresponding author), Teaching Res Inst Eugene, 99 W 10th Ave,Suite 370, Eugene, OR 97401 USA.	glanga@wou.edu		Glang, Ann/0000-0002-3057-1977; Bedell, Gary/0000-0002-9555-8861			Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Blosser J, 1997, J HEAD TRAUMA REHAB, V12, P21, DOI 10.1097/00001199-199704000-00004; Dettmer JL, 2007, J HEAD TRAUMA REHAB, V22, P339, DOI 10.1097/01.HTR.0000300229.13490.c7; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; Dishion TJ, 2005, J CLIN CHILD ADOLESC, V34, P62, DOI 10.1207/s15374424jccp3401_6; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Frank EM, 1997, J CHILDRENS COMMUNIC, V18, P49, DOI 10.1177/152574019701800206; FUNK P, 1996, PHYS DISABILITIES ED, V15, P49; Gioia GA IP, 2000, BEHAV RATING INVENTO; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; GLANG A, 1996, CHILDREN ACQUIRED BR, P149; GLANG A, 2006, J HEAD TRAUMA REHAB, V21, P408; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; HOLLER RA, 2008, NASSP B, V2; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; LANGLOIS JA, 2002, TRAUMATIC BRAIN INJU, P1; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; MARINO MJ, 2000, TBI CHALLENGE, V4, P18; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Todis B, 1997, CHILDREN ACQUIRED BR; *US DEP ED, 2003, 21 ANN REP C IMPL IN; van Lier PAC, 2005, J ABNORM CHILD PSYCH, V33, P99, DOI 10.1007/s10802-005-0938-8; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P42, DOI 10.1097/00001199-199512000-00007; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	45	66	68	1	16	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2008	23	6					477	486					10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	391CI	WOS:000262210200004	19127001				2022-02-06	
J	Wong, DY; Hollister, SJ; Krebsbach, PH; Nosrat, C				Wong, Darice Y.; Hollister, Scott J.; Krebsbach, Paul H.; Nosrat, Christopher			Poly(epsilon-caprolactone) and poly (L-lactic-co-glycolic acid) degradable polymer sponges attenuate astrocyte response and lesion growth in acute traumatic brain injury	TISSUE ENGINEERING			English	Article							RAT; BIOCOMPATIBILITY; CELLS; MICROGLIA; TIME; CNS; IDENTIFICATION; DISEASES; TISSUE	This study evaluated the response of rat brain to 2 degradable polymers (poly (L-lactic-co-glycolic acid) (PLGA), and poly(epsilon-caprolactone) (PCL)), two common materials in tissue engineering. PLGA has been extensively studied in the brain for controlled drug release as injectable microspheres and is generally accepted as biocompatible in that capacity. Biocompatibility in other forms and for different functions in the brain has not been widely studied. PCL was chosen as an alternative to PLGA for its slower degradation and less-acidic pH upon degradation. Porous scaffolds were made from both polymers and implanted into rat cerebral cortex for 1 and 4 weeks. Morphology, defect size, activation of microglia (OX-42) and astrocytes ( glial fibrillary acidic protein (GFAP)), infiltration of activated macrophages ( major histocompatibility complex ( MHC)-II), and ingrowth of neurons (b-tubulin type III (Tuj-1)) and progenitor cells ( nestin) were analyzed using hematoxylin and eosin staining and immunofluorescence. PCL induced a lower inflammatory response than PLGA, as demonstrated by lower MHC-II and GFAP expression and greater ingrowth. Both polymers alleviated astrocytic activation and prevented enlargement of the defect. Tuj-1-, nestin-, and GFAP-positive cells were observed growing on both polymers at the peripheries of the sponge implants, demonstrating their permissiveness to neural ingrowth. These findings suggest that both polymers attenuate secondary death and scarring and that PCL might have advantages over PLGA.	Univ Tennessee, Coll Dent, Hlth Sci Ctr, Canc Res Bldg, Memphis, TN USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA		Wong, DY (corresponding author), Univ Tennessee, Coll Dent, Hlth Sci Ctr, Canc Res Bldg, Memphis, TN USA.	dywong@umich.edu	Hollister, Scott/ABH-3463-2021; Krebsbach, Paul H./AAC-4765-2021	Hollister, Scott/0000-0001-7625-892X; 	NIDCR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [DE007057] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE007057] Funding Source: NIH RePORTER		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Bianco F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/jimmunol.174.11.7268; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Dehay C, 2001, J NEUROSCI, V21, P201, DOI 10.1523/JNEUROSCI.21-01-00201.2001; Fournier E, 2003, BIOMATERIALS, V24, P3311, DOI 10.1016/S0142-9612(03)00161-3; Hartfuss E, 2001, DEV BIOL, V229, P15, DOI 10.1006/dbio.2000.9962; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Johann V, 2007, EXP BRAIN RES, V177, P458, DOI 10.1007/s00221-006-0689-y; Jones NM, 2004, J NEUROCHEM, V89, P157, DOI 10.1111/j.1471-4159.2004.02324.x; Kerwin BA, 2002, PROTEIN SCI, V11, P1825, DOI 10.1110/ps.0208102; Kou JH, 1997, J CONTROL RELEASE, V43, P123, DOI 10.1016/S0168-3659(96)01477-0; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; MCMASTER WR, 1979, EUR J IMMUNOL, V9, P426, DOI 10.1002/eji.1830090603; MENEI P, 1994, J BIOMED MATER RES, V28, P1079, DOI 10.1002/jbm.820280913; Mozzetti S, 2005, CLIN CANCER RES, V11, P298; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Polikov VS, 2005, J NEUROSCI METH, V148, P1, DOI 10.1016/j.jneumeth.2005.08.015; Popovic N, 2006, INT J PHARMACEUT, V314, P120, DOI 10.1016/j.ijpharm.2005.09.040; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Stidworthy MF, 2004, BRAIN, V127, P1928, DOI 10.1093/brain/awh217; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Sun HF, 2006, BIOMATERIALS, V27, P1735, DOI 10.1016/j.biomaterials.2005.09.019; Sung HJ, 2004, BIOMATERIALS, V25, P5735, DOI 10.1016/j.biomaterials.2004.01.066; Tang ZG, 2004, BIOMATERIALS, V25, P4741, DOI 10.1016/j.biomaterials.2003.12.003; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; TAYLOR MS, 1994, J APPL BIOMATER, V5, P151, DOI 10.1002/jab.770050208; Thompson TP, 1999, NEUROSURGERY, V45, P741, DOI 10.1097/00006123-199910000-00001; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; WHITELAND JL, 1995, J HISTOCHEM CYTOCHEM, V43, P313, DOI 10.1177/43.3.7868861; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Zhang YW, 2006, STEM CELLS DEV, V15, P943, DOI 10.1089/scd.2006.15.943; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027	35	66	68	0	16	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1076-3279			TISSUE ENG	Tissue Eng.	OCT	2007	13	10					2515	2523		10.1089/ten.2006.0440			9	Cell & Tissue Engineering	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	220NE	WOS:000250162600014	17655492	Green Submitted			2022-02-06	
J	Parvizi, J; Joseph, J; Press, DZ; Schmahmann, JD				Parvizi, Josef; Joseph, Jeffrey; Press, Daniel Z.; Schmahmann, Jeremy D.			Pathological laughter and crying in patients with multiple system atrophy-cerebellar type	MOVEMENT DISORDERS			English	Article						olivopontocerebellar atrophy; disinhibition; emotion; behavior; pseudobulbar affect	SPORADIC OLIVOPONTOCEREBELLAR ATROPHY; TRAUMATIC BRAIN-INJURY; PSEUDOBULBAR AFFECT; SCLEROSIS; PREVALENCE; DISORDERS; DIAGNOSIS; STROKE	In the cerebellar type of multiple system atrophy (MSA-C), the burden of pathological changes involves the cerebellum and its associated brainstem structures in the basis pontis and the inferior olivary nucleus, and as a result, the clinical phenotype is dominated early on by the cerebellar dysfunction. We report our clinical and post mortem findings in a patient with MSA-C who exhibited pathological laughter in the absence of any congruent changes of mood. A review of the clinical notes of 27 other patients with MSA-C revealed a problem with pathological laughter, or crying, or both in 9 more patients. Our finding of about 36% occurrence suggests that the problem of dysregulation of emotional expression is more prevalent in MSA-C than the paucity of reports in the literature suggests. Our findings are consistent with the view that the cerebellum and its interconnected structures may be involved in the regulation of emotional expression. (c) 2007 Movement Disorder Society.	Harvard Univ, Sch Med, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA		Parvizi, J (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	jparvizi@ucla.edu	Schmahmann, Jeremy/ABF-1215-2021	Schmahmann, Jeremy/0000-0003-0706-5125			ASFORA WT, 1989, J NEUROL NEUROSUR PS, V52, P523, DOI 10.1136/jnnp.52.4.523; BLACK DW, 1982, J NERV MENT DIS, V170, P67, DOI 10.1097/00005053-198202000-00001; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; Feinstein A, 1999, MULT SCLER, V5, P69, DOI 10.1177/135245859900500201; GALLAGHER JP, 1989, ACTA NEUROL SCAND, V80, P114, DOI 10.1111/j.1600-0404.1989.tb03851.x; Geser F, 2006, MOVEMENT DISORD, V21, P179, DOI 10.1002/mds.20678; Gilman S, 2000, NEUROLOGY, V55, P527, DOI 10.1212/WNL.55.4.527; Gilman S, 1999, J NEUROL SCI, V163, P94, DOI 10.1016/S0022-510X(98)00304-9; Gilman S, 1996, NEUROLOGY, V46, P1197, DOI 10.1212/WNL.46.5.1197; HOUSE A, 1989, BMJ-BRIT MED J, V298, P991, DOI 10.1136/bmj.298.6679.991; Jellinger KA, 2005, MOVEMENT DISORD, V20, pS29, DOI 10.1002/mds.20537; Kim JS, 2000, NEUROLOGY, V54, P1805, DOI 10.1212/WNL.54.9.1805; MINDEN SL, 1990, ARCH NEUROL-CHICAGO, V47, P98, DOI 10.1001/archneur.1990.00530010124031; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P601, DOI 10.3109/00048679309075822; Oppenheim H, 1886, BERL KLI WOCH, V46; Ozawa T, 2004, BRAIN, V127, P2657, DOI 10.1093/brain/awh303; Parvizi J, 2001, BRAIN, V124, P1708, DOI 10.1093/brain/124.9.1708; Parvizi J, 2006, MAYO CLIN PROC, V81, P1482, DOI 10.4065/81.11.1482; POECK K, 1985, CLIN NEUROPSYCHOLOGY, P219; POECK K, 1985, DISORDERS HIGHER NER, P343; Quinn NP, 2005, MOVEMENT DISORD, V20, pS5, DOI 10.1002/mds.20534; Schiffer R, 2005, J NEUROPSYCH CLIN N, V17, P447, DOI 10.1176/appi.neuropsych.17.4.447; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; Siddiqui MS, 2006, NEUROLOGY, V66, pA369; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Wenning GK, 2004, LANCET NEUROL, V3, P93, DOI 10.1016/S1474-4422(03)00662-8; Wild B, 2003, BRAIN, V126, P2121, DOI 10.1093/brain/awg226; Wilson SAK, 1924, J NEUROL PSYCHOPATHO, V4, P299; Zeilig G, 1996, BRAIN INJURY, V10, P591, DOI 10.1080/026990596124160	30	66	68	0	7	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0885-3185			MOVEMENT DISORD	Mov. Disord.	APR 30	2007	22	6					798	803		10.1002/mds.21348			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	163KQ	WOS:000246159000006	17290465				2022-02-06	
J	Denson, K; Morgan, D; Cunningham, R; Nigliazzo, A; Brackett, D; Lane, M; Smith, B; Albrecht, R				Denson, Kent; Morgan, Daniel; Cunningham, Rob; Nigliazzo, Anthony; Brackett, Daniel; Lane, Mary; Smith, Brenda; Albrecht, Roxie			Incidence of venous thromboembolism in patients with traumatic brain injury	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	49th Annual Meeting of the Midwest-Surgical-Association	AUG 06-09, 2006	Mackinac Isl, MI	Midwest Surg Assoc		venous thromboembolism; intraparenchymal hemorrhage; trauma; prophylaxis	PROPHYLAXIS; ENOXAPARIN; HEAD; SURVEILLANCE; THROMBOSIS; HEPARIN; SAFETY; RISK	Background: Traumatic brain injury (TBI) may be a risk factor for venous thromboembolism (VTE). This study was designed to review the incidence of VTE in critically injured patients with an isolated TBI using a standardized venous duplex color-flow Doppler imaging program and to compare it with the overall and high-risk trauma populations. Methods: Trauma patients who underwent lower-extremity surveillance color-flow Doppler imaging for VTE were identified. Analyses included patient demographics, characteristics of TBI, VTE risk factors, prophylaxis, incidence, location, and patient outcome. Results: A total of 5,787 patients were admitted during the study period. Of these, 539 (9%) were deemed high risk for VTE. The incidence of VTE in patients with isolated TBI (88, 16%) was 25%. All patients and the high-risk population had incidences of 2% and 17%, respectively. Conclusions: The incidence of VTE in isolated TBI is greatest in patients with intraparenchymal hemorrhage. Early VTE prophylaxis is warranted in TBI patients. (c) 2007 Excerpta Medica Inc. All rights reserved.	Univ Oklahoma, Hlth Sci Ctr, Dept Gen Surg, Oklahoma City, OK 73190 USA		Denson, K (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Gen Surg, POB 26901,1122 NE 13th 3rd Floor, Oklahoma City, OK 73190 USA.	kent-denson@cox.net					Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; Cipolle MD, 2002, J TRAUMA, V52, P453, DOI 10.1097/00005373-200203000-00007; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P191, DOI 10.1097/01.PHM.0000113401.47681.A6; KAUFMAN HH, 1983, ANGIOLOGY, V34, P627, DOI 10.1177/000331978303401001; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Merrer J, 2001, JAMA-J AM MED ASSOC, V286, P700, DOI 10.1001/jama.286.6.700; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Proctor MC, 2006, J TRAUMA, V60, P147, DOI 10.1097/01.ta.0000197180.79965.bc; Skaf E, 2005, AM J CARDIOL, V96, P1731, DOI 10.1016/j.amjcard.2005.07.097; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160	14	66	70	3	3	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010 USA	0002-9610			AM J SURG	Am. J. Surg.	MAR	2007	193	3					380	383		10.1016/j.amjsurg.2006.12.004			4	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	146MS	WOS:000244939200034	17320539				2022-02-06	
J	Chafetz, MD; Abrahams, JP; Kohlmaier, J				Chafetz, Michael D.; Abrahams, Joel P.; Kohlmaier, Joy			Malingering on the social security disability consultative exam: A new rating scale	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; disability; social security; mental retardation	ADULT INTELLIGENCE SCALE; TRAUMATIC BRAIN-INJURY; MENTAL-RETARDATION; PERFORMANCE; VALIDATION; TESTS	In disability examinations, benefits may depend on the findings of a psychological consultative examination (PCE), which in Louisiana usually involves a mental status examination and a Wechsler Scale. The disability determinations service (DDS) requires a warning that failure to do one's best may result in an unfavorable decision on the claim, but psychologists are officially discouraged from determining effort by the use of formal effort tests. Consequently, there is a need for internal indicators of effort. Formal testing of effort was undertaken in order to identify indicators of effort within the PCE in WAIS-age and WISC-age claimants. Our findings indicated that the total score of indicators was more predictive of effort than any single indicator. Regression equations yielded information on how much effort contributes to IQ. Classification accuracy for the new rating scale was described for a "dose-response" of effort. Disincentives for malingering detection in the PCE were identified. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	River Oaks Hosp, Harahan, LA 70123 USA		Chafetz, MD (corresponding author), 3520 Gen DeGaulle Dr 4098, New Orleans, LA 70114 USA.	mikechaf@yahoo.com	Chafetz, Michael/AAC-2579-2020				American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; CHAFETZ MD, 2005, ANN M AM AC CLIN NEU; CHAFETZ MD, 2005, ANN M NAT AC NEUR; Cohen J., 1983, APPL MULTIPLE REGRES; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; DROB SL, 2000, AM J FORENSIC PSYCH, V18, P57; Evans S., 1984, J GEN PSYCHOL, V111, P12; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2004, MED SYMPTOM VALIDITY; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Hayes J S, 1998, Appl Neuropsychol, V5, P33, DOI 10.1207/s15324826an0501_4; Hayes JS, 1997, J PSYCHOL, V131, P575, DOI 10.1080/00223989709603549; Hurley KE, 2006, MENT RETARD, V44, P112, DOI 10.1352/0047-6765(2006)44[112:AIMMUW]2.0.CO;2; Kim JO., 1978, FACTOR ANAL STAT MET; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; Larrabee GJ, 2000, J CLIN EXP NEUROPSYC, V22, P702, DOI 10.1076/1380-3395(200010)22:5;1-9;FT702; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; MILLER LS, 2006, ANN M INT NEUR SOC; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Rogers R, 1990, Bull Am Acad Psychiatry Law, V18, P323; Rohling M. L., 2004, NEWSLETTER, V22, P1; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; *SOC SEC ADM, 2003, SOC SEC ADM BUDG REQ; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; *US DEH HHS SOC SE, 2006, SSA PUBL; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009	33	66	66	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2007	22	1					1	14		10.1016/j.acn.2006.10.003			14	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	144RV	WOS:000244814700001	17097263	Bronze			2022-02-06	
J	Ratcliff, JJ; Greenspan, AI; Goldstein, FC; Stringer, AY; Bushnik, T; Hammond, FM; Novack, TA; Whyte, J; Wright, DW				Ratcliff, Jonathan J.; Greenspan, Arlene I.; Goldstein, Felicia C.; Stringer, Anthony Y.; Bushnik, Tamara; Hammond, Flora M.; Novack, Thomas A.; Whyte, John; Wright, David W.			Gender and traumatic brain injury: Do the sexes fare differently?	BRAIN INJURY			English	Article						traumatic brain injury; closed head injury; gender; outcome	HEAD-INJURY; TBI; PROGESTERONE; METAANALYSIS; ABILITIES; VARIABLES; SEVERITY; DAMAGE; TASK; AGE	Objective: To examine the relationship between gender and cognitive recovery 1 year following traumatic brain injury (TBI). Methods: Patients with blunt TBI were identified from the TBI Model Systems of Care National Database, multi-centre cohort study. The included patients ( n = 325) were 16 - 45 years at injury, admitted to an acute care facility within 24 hours, received inpatient rehabilitation, had documented admission Glasgow Coma Scale (GCS) scores, completed neuropsychological follow-up 1 year post-injury and did not report pre-morbid learning problems. Multivariate analyses of variance examined the unadjusted association between gender and six cognitive domains examining attention/working memory, verbal memory, language, visual analytic skills, problem-solving and motor functioning. Analyses of covariance models were constructed to determine if confounding factors biased the observed associations. Results: Females performed significantly better than males on tests of attention/working memory and language. Males outperformed females in visual analytic skills. Gender remained significantly associated with performance in these areas when controlling for confounding variables. Conclusions: These results suggest a better cognitive recovery of females than males following TBI. However, future studies need to include non-TBI patients to control for possible pre-injury gender-related differences, as well as to conduct extended follow-ups to determine the stability of the observed differences.	Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA USA; Emory Univ, Sch Med, Dept Rehabil Med, Atlanta, GA USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Santa Clara Valley Med Ctr, No CA TBI Model Syst Care, Rehabil Res Ctr, San Jose, CA 95128 USA; Carolinas Rehabil, Charlotte, NC USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA; Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA USA		Wright, DW (corresponding author), 49 Jessie Hill Jr Dr, Atlanta, GA 30303 USA.	david.wright@emory.edu	Wright, David/F-1209-2013	Wright, David/0000-0002-7145-9105; Whyte, John/0000-0002-4381-1474; Bushnik, Tamara/0000-0003-3328-257X			Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BECHTOLDT HP, 1962, PSYCHOL REC, V12, P147, DOI 10.1007/BF03393452; Benton A, 1994, CONTRIBUTION NEUROPS; Benton A., 1978, MULTILINGUAL APHASIA; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; DABNER EF, 1993, J HEAD TRAUMA REHAB, V8, P12; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Georgopoulos AP, 2001, J COGNITIVE NEUROSCI, V13, P72, DOI 10.1162/089892901564180; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Heaton RK, 1991, COMPREHENSIVE NORMS; Jorm AF, 2004, INTELLIGENCE, V32, P7, DOI 10.1016/j.intell.2003.08.001; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KRAUS JF, 2000, NEUROSURGERY FOCUS, V8; MITRUSHINA MN, 1999, HANDBOOD NORMATIVE D; *PSYCH CORP, 1999, WAIS 3 WMS 3 TECHN M; *PSYCH CORP, 1997, WECHSL ADULT INT SCA; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); VOYER D, 1995, PSYCHOL BULL, V117, P250, DOI 10.1037/0033-2909.117.2.250; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WALDMANN BW, 1992, J CLIN PSYCHOL, V48, P360, DOI 10.1002/1097-4679(199205)48:3<360::AID-JCLP2270480314>3.0.CO;2-P; Wechsler D., 1981, WECHSLER INTELLIGENC, V3rd; Weiss E, 2003, NEUROSCI LETT, V344, P169, DOI 10.1016/S0304-3940(03)00406-3; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932	36	66	66	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	10					1023	1030		10.1080/02699050701633072			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600004	17891564				2022-02-06	
J	VanLandingham, JW; Cutler, SM; Virmani, S; Hoffman, SW; Covey, DF; Krishnan, K; Hammes, SR; Jamnongjit, M; Stein, DG				VanLandingham, Jacob W.; Cutler, Sarah M.; Virmani, Sharad; Hoffman, Stuart W.; Covey, Douglas F.; Krishnan, Kathiresan; Hammes, Stephen R.; Jamnongjit, Michelle; Stein, Donald G.			The enantiomer of progesterone acts as a molecular neuroprotectant after traumatic brain injury	NEUROPHARMACOLOGY			English	Article						progesterone; enantiomer; allopregnanolone; traumatic brain injury; neuroprotection; progesterone receptor	HIPPOCAMPAL-NEURONS; LIPID-PEROXIDATION; CEREBRAL EDEMA; CELL-DEATH; RATS; ALLOPREGNANOLONE; STEROIDS; RECEPTOR; EXCITOTOXICITY; ANTIOXIDANT	Previous work shows that neurosteroid enantiomers activate specific molecular receptors that relay neuroprotection. However, the actions of the enantiomer of progesterone (ent-PROG) at the PROG receptor (PR) are unknown. PR binding and transcriptional assays were performed to determine the actions of ent-PROG at the classical PR. Additionally, the neuroprotective effects of ent-PROG in traumatic brain injury (TBI) were investigated and compared to the actions of PROG and its metabolite allopregnanolone (ALLO), both of which have been shown to have neuroprotective properties when given after TBI. Binding studies performed in COS cells over-expressing the PR showed that ent-PROG inhibited PROG binding to the PR. In contrast, ent-PROG did not activate PR-mediated transcription. Rats received bilateral medial frontal cortex injury followed by treatments at 1, 6, 24 and 48 h with PROG, ALLO or ent-PROG. Brains were processed for edema, protein and enzyme activity. ent-PROG treatment in vivo decreased cerebral edema, cell death mediators, inflammatory cytokines, and reactive gliosis, and increased antioxidant activity. These findings suggest that the progestin-mediated pro-survival response seen with TBI is regulated either independently of the classical PR or via nongenomic PR-regulated actions. (c) 2006 Elsevier Ltd. All rights reserved.	Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Atlanta, GA 30322 USA; Washington Univ, Dept Mol Biol & Pharmacol, Sch Med, St Louis, MO USA; Texas SW Med Ctr, Dept Pharmacol, Dallas, TX USA		VanLandingham, JW (corresponding author), Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Suite 5100,1365B Clifton Rd NE, Atlanta, GA 30322 USA.	jvanlan@emory.edu	Stein, Donald/AAJ-5139-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P01GM047969] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5P01GM47969] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1R01N540825, 1R01N538664] Funding Source: Medline		Akwa Y, 2001, P NATL ACAD SCI USA, V98, P14033, DOI 10.1073/pnas.241503698; Auchus RJ, 2003, ARCH BIOCHEM BIOPHYS, V409, P134, DOI 10.1016/S0003-9861(02)00491-5; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Cassidy RA, 2003, SHOCK, V20, P85, DOI 10.1097/01.shk.0000070740.34700.cd; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Green PS, 2001, ENDOCRINOLOGY, V142, P400, DOI 10.1210/en.142.1.400; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hoffman S. W, 2001, ACAD EMERG MED, V8, P496; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Kirsch M, 2001, FASEB J, V15, P1569, DOI 10.1096/fj.00-0823hyp; Kuebler JF, 2003, CRIT CARE MED, V31, P1786, DOI 10.1097/01.CCM.0000063441.41446.23; LANGLOIS JA, 2004, TRUMATIC BRAIN INJUR; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Moorthy K, 2005, EXP GERONTOL, V40, P295, DOI 10.1016/j.exger.2005.01.004; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pearson D, 1999, CHILD CARE HLTH DEV, V25, P3, DOI 10.1046/j.1365-2214.1999.00086.x; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1999, PHYSIOL BEHAV, V68, P81, DOI 10.1016/S0031-9384(99)00162-6; ROOF RL, 1994, 21 ANN M SOC NEUR MI, P191; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Telci A, 2002, GYNECOL OBSTET INVES, V54, P88, DOI 10.1159/000067718; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toell A, 2002, J CELL BIOCHEM, V85, P72, DOI 10.1002/jcb.10104; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wittmer LL, 1996, MOL PHARMACOL, V50, P1581; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xia S, 2002, NEUROBIOL DIS, V9, P282, DOI 10.1006/nbdi.2002.0478; Zorumski CF, 1998, SYNAPSE, V29, P162, DOI 10.1002/(SICI)1098-2396(199806)29:2<162::AID-SYN7>3.0.CO;2-5; Zucchini N, 2005, BBA-MOL CELL RES, V1745, P48, DOI 10.1016/j.bbamcr.2005.02.005	48	66	68	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	NOV	2006	51	6					1078	1085		10.1016/j.neuropharm.2006.07.015			8	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	112WS	WOS:000242559200007	16926035				2022-02-06	
J	Dyer, KFW; Bell, R; McCann, J; Rauch, R				Dyer, Kevin F. W.; Bell, Rob; McCann, John; Rauch, Robert			Aggression after traumatic brain injury: Analysing socially desirable responses and the nature of aggressive traits	BRAIN INJURY			English	Article						traumatic brain injury; spinal cord injury; aggression; social desirability	LONG-TERM SURVIVORS; HEAD-INJURY; PERSONALITY; MANAGEMENT; IMPULSIVENESS; QUESTIONNAIRE; BEHAVIOR; ANGER	Primary objective: To compare patients with traumatic brain injury ( TBI) with controls on sub-types of aggression and explore the role of social desirability. Design: Quasi- experimental, matched-participants design. Methods and procedures: Sixty- nine participants were included in the study. The sample comprised a TBI group ( n = 24), a spinal cord injury ( SCI) group (n = 21) and an uninjured (UI) group of matched healthy volunteers ( n = 24). Participants were given self-report measures of aggression, social desirability and impulsivity. Sixty- one independent 'otherraters' were nominated, who rated participant pre-morbid and post- morbid aggression. Main outcomes and results: Using standardized norms, 25 - 39% of participants with TBI were classified as high average - very high on anger and 35 - 38% as high average - very high on verbal aggression. Other- raters rated participants with TBI as significantly higher on verbal aggression than SCI and UI participants. There were no differences between the groups on physical aggression. The TBI group also had higher levels of impulsivity than SCI and UI groups. Social desirability was a highly significant predictor of self- reported aggression for the entire sample. Conclusions: Impulsive verbal aggression and anger are the principal aggressive traits after brain injury. Physical aggression may present in extreme cases after TBI, but appears less prominent overall in this population. Social desirability, previously overlooked in research examining TBI aggression, emerged as an influential variable that should be considered in future TBI research.	Queens Univ Belfast, Sch Psychol, Belfast BT9 5BP, Antrim, North Ireland; Joss Cardwell Ctr, Belfast, Antrim, North Ireland		Dyer, KFW (corresponding author), Queens Univ Belfast, Sch Psychol, Belfast BT9 5BP, Antrim, North Ireland.	kdyer01@qub.ac.uk					Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Archer J, 1995, AGGRESSIVE BEHAV, V21, P371, DOI 10.1002/1098-2337(1995)21:5<371::AID-AB2480210506>3.0.CO;2-P; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; BLAKE JF, 2006, PERSONALITY INDIVIDU, V40, P1625; Bockian NR, 2003, J CLIN PSYCHOL MED S, V10, P307, DOI 10.1023/A:1026309622586; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bowman M. L., 1997, IMPULSIVITY THEORY A, P116; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; Buss AH, 2000, AGGRESSION QUESTIONN; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Diaz F G, 1995, Med Law, V14, P131; Edwards A. L., 1957, SOCIAL DESIRABILITY; FISCHER DG, 1993, ED PSYHOL MEASUREMEN, V4, P699; GARCIALEON A, 2004, SPANISH J PSYCHOL, V5, P45; Gisi TM, 2000, INT J NEUROSCI, V105, P121, DOI 10.3109/00207450009003271; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greve KW, 2002, PERS INDIV DIFFER, V32, P639, DOI 10.1016/S0191-8869(01)00066-6; Greve KW, 2001, BRAIN INJURY, V15, P255; Harris JA, 1997, BEHAV RES THER, V35, P1047, DOI 10.1016/S0005-7967(97)00064-8; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Jamner LD, 1999, PSYCHIAT RES, V85, P17, DOI 10.1016/S0165-1781(98)00134-6; JARVIE HF, 1954, J NEUROL NEUROSUR PS, V17, P14, DOI 10.1136/jnnp.17.1.14; Lazaro F, 2000, PSYCHIAT B, V24, P264; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LUENGO MA, 1991, PERS INDIV DIFFER, V12, P657, DOI 10.1016/0191-8869(91)90220-6; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Miller E, 1999, J FORENSIC PSYCHIATR, V10, P157, DOI 10.1080/09585189908402146; NOBLE M, 2001, MEASURES DEPRIVATION; Novaco RW., 1975, ANGER CONTROL DEV EV; O'Connor DB, 2001, AGGRESSIVE BEHAV, V27, P79, DOI 10.1002/ab.2; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; OWNSWORTH T, 2002, NEUROPSYCHOL REHABIL, V14, P291; OWNSWORTH T, 2004, BRAIN INJURY, V16, P535; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; PAULHUS DL, 1991, ROLE CONSTRUCTS PSYC, P49; Pauls CA, 2004, PERS INDIV DIFFER, V37, P1137, DOI 10.1016/j.paid.2003.11.018; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Stuss D., 1991, AWARENESS DEFICIT BR, P63; Swann AC, 2002, BIOL PSYCHIAT, V51, P988, DOI 10.1016/S0006-3223(01)01357-9; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THOMSEN IV, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P52; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Warnken W J, 1994, Violence Vict, V9, P153; Wolfson AM, 2000, ARCH PHYS MED REHAB, V81, P1567, DOI 10.1053/apmr.2000.16345; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408	54	66	66	1	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2006	20	11					1163	1173		10.1080/02699050601049312			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	110DD	WOS:000242357600007	17123933				2022-02-06	
J	Thompson, SN; Gibson, TR; Thompson, BM; Deng, Y; Hall, ED				Thompson, Stephanie N.; Gibson, Tonya R.; Thompson, Brian M.; Deng, Ying; Hall, Edward D.			Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity markers following traumatic brain injury in mice	EXPERIMENTAL NEUROLOGY			English	Article						GAP-43; synaptophysin; calpain; neuroplasticity; controlled cortical impact; de Olmos silver staining; neurodegeneration	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; COGNITIVE DEFICITS; FLUID PERCUSSION; ALPHA-SPECTRIN; REACTIVE SYNAPTOGENESIS; BEHAVIORAL RECOVERY; BREAKDOWN PRODUCTS; NEURONAL APOPTOSIS; STRUCTURAL EVENTS	The role of neuronal plasticity and repair on the final functional outcome following traumatic brain injury (TBI) remains poorly understood. Moreover, the relationship of the magnitude of post-traumatic secondary injury and neurodegeneration to the potential for neuronal repair has not been explored. To address these questions, we employed Western immunoblotting techniques to examine how injury severity affects the spatial and temporal expression of markers of axonal growth (growth-associated protein GAP-43) and synaptogenesis (pre-synaptic vesicular protein synaptophysin) following either moderate (0.5 mm, 3.5 M/s) or severe (1.0 mm, 3.5 M/s) lateral controlled cortical impact traumatic brain injury (CCI-TBI) in young adult male CF-1 mice. Moderate CCI increased GAP-43 levels at 24 and 48 h post-insult in the ipsilateral hippocampus relative to sham, non-injured animals. This increase in axonal plasticity occurred prior to maximal hippocampal neurodegeneration, as revealed by de Olmos silver staining, at 72 h. However, moderate CCI-TBI did not elevate GAP-43 expression in the ipsilateral cortex where neurodegeneration was extensive by 6 h post-TBI. In contrast to moderate injury, severe CCI-TBI failed to increase hippocampal GAP-43 levels and instead resulted in depressed GAP-43 expression in the ipsilateral hippocampus and cortex at 48 h post-insult. In regards to injury-induced changes in synaptogenesis, we found that moderate CCI-TBI elevated synaptophysin levels in the ipsilateral hippocampus at 24, 48, 72 h and 21 days, but this effect was not present after severe injury. Together, these data highlights the adult brain's ability for axonal and synaptic plasticity following a focal cortical injury, but that severe injuries may diminish these endogenous repair mechanisms. The differential effects of moderate versus severe TBI on the post-traumatic plasticity response may be related to the calpain-mediated proteolytic activity occurring after a severe injury preventing increased expression of proteins required for plasticity. Supporting this hypothesis is the fact that GAP-43 is a substrate for calpain along with our data demonstrating that calpain-mediated degradation of the cytoskeletal protein, alpha-spectrin, is approximately 10 times greater in ipsilateral hippocampal tissue following severe compared to moderate CCI-TBI. Thus, TBI severity has a differential effect on the injury-induced neurorestorative response with calpain activation being one putative factor contributing to neuroregenerative failure following severe CCI-TBI. If true, then calpain inhibition may lead to both neuroprotective effects and an enhancement of neuronal plasticity/repair mechanisms post-TBI. (c) 2006 Elsevier Inc. All rights reserved.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Med Ctr, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Chandler Med Ctr, B383 Biomed & Biol Sci Res Bldg,741 S Limestone S, Lexington, KY 40536 USA.	edhall@uky.edu	Thompson, Stephanie/AAB-8272-2020; Hall, Edward D/F-8930-2013	Thompson, Stephanie/0000-0002-9128-7515; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS046566] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566] Funding Source: NIH RePORTER		Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bareyre FM, 2001, J NEUROCHEM, V77, P173, DOI 10.1046/j.1471-4159.2001.t01-1-00215.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bendotti C, 1997, EUR J NEUROSCI, V9, P93, DOI 10.1111/j.1460-9568.1997.tb01357.x; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BENOWITZ LI, 1990, MOL BRAIN RES, V8, P17, DOI 10.1016/0169-328X(90)90004-W; Bergmann M, 1997, EXP BRAIN RES, V117, P80, DOI 10.1007/s002210050201; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BROCK TO, 1987, J NEUROSCI, V7, P931; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CABALKA LM, 1990, J COMP NEUROL, V295, P83, DOI 10.1002/cne.902950108; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; DOSEMECI A, 1995, SYNAPSE, V20, P91, DOI 10.1002/syn.890200113; Emery DL, 2000, J COMP NEUROL, V424, P521; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1998, DRUG NEWS PERSPECT, V11, P215; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; KALIL K, 1986, J NEUROSCI, V6, P2563; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Keyvani K, 2002, J NEUROPATH EXP NEUR, V61, P831, DOI 10.1093/jnen/61.10.831; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Liu YL, 1996, BRAIN RES, V732, P36, DOI 10.1016/0006-8993(96)00484-2; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; OESTREICHER AB, 1986, BRAIN RES, V375, P267, DOI 10.1016/0006-8993(86)90747-X; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; RINK A, 1995, AM J PATHOL, V147, P1575; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SAITO S, 1994, J NEUROSCI RES, V39, P57, DOI 10.1002/jnr.490390108; Schallert T, 2000, J CEREBR BLOOD F MET, V20, P1513, DOI 10.1097/00004647-200011000-00001; Schauwecker PE, 2000, EXP NEUROL, V161, P139, DOI 10.1006/exnr.1999.7251; SCHAUWECKER PE, 1995, J NEUROSCI, V15, P2462, DOI 10.1523/JNEUROSCI.15-03-02462.1995; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; SHEPPARD A, 1991, BIOCHIM BIOPHYS ACTA, V1076, P156, DOI 10.1016/0167-4838(91)90234-Q; SIMAN R, 1987, J NEUROSCI, V7, P55; SINGH IN, 2006, J CEREB BLOOD FLOW M, P1; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Villa PG, 1998, J CELL SCI, V111, P713; Vinade L, 2001, SYNAPSE, V40, P302, DOI 10.1002/syn.1053; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zakharov IA, 2001, RUSS EDUC SOC, V43, P39; Zakharov VV, 2005, BIOCHEMISTRY-MOSCOW+, V70, P897, DOI 10.1007/s10541-005-0200-6	86	66	71	1	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2006	201	1					253	265		10.1016/j.expneurol.2006.04.013			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	079CC	WOS:000240152100027	16814284				2022-02-06	
J	McCarthy, ML; Dikmen, SS; Langlois, JA; Selassie, AW; Gu, JK; Horner, MD				McCarthy, Melissa L.; Dikmen, Sureyya S.; Langlois, Jean A.; Selassie, Anbesaw W.; Gu, Ja K.; Horner, Michael D.			Self-reported psychosocial health among adults with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation	QUALITY-OF-LIFE; HEAD-INJURY; PSYCHIATRIC-DISORDERS; SURVEY SF-36; SOCIOECONOMIC-STATUS; DEPRESSION; VALIDITY; 1-YEAR; PRODUCTIVITY; INDIVIDUALS	Objective: To measure the subjective psychosocial health of a population-based sample of adults with traumatic brain injury (TBI). Design: Retrospective, cohort study involving a 1-year postinjury interview. Setting: Sixty-two acute care, nonfederal hospitals in South Carolina. Participants: Persons (>= 15y) hospitalized with TBI. Interventions: Not applicable. Main Outcome Measure: The psychosocial health scales of the Medical Outcomes Study 36-Item Short-Form Health Survey. Results: Of the 7612 participants, 29% reported poor psychosocial health. Factors associated with poor psychosocial well-being included younger age, female sex, Medicaid coverage, no health insurance, inadequate or moderate social support, comorbidities (eg, a preinjury substance abuse problem), cognitive complaints, and some or a lot of limitation with activities of daily living. Only 36% of participants who reported poor psychosocial health reported receiving any mental health services. Conclusions: A substantial proportion of persons hospitalized with TBI reported poor psychosocial health at 1 year postinjury. To optimize recovery, clinicians need to ensure that patients' psychosocial health needs are addressed during the postacute period.	Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21209 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA; Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA		McCarthy, ML (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, 5801 Smith Ave,Davis Bldg,Ste 3220, Baltimore, MD 21209 USA.	mmccarth@jhmi.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU421926] Funding Source: Medline		Adler NE, 1999, ANN NY ACAD SCI, V896, P3, DOI 10.1111/j.1749-6632.1999.tb08101.x; Atchison TB, 2004, CLIN NEUROPSYCHOL, V18, P249, DOI 10.1080/13854040490501475; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARRERA M, 1981, AM J COMMUN PSYCHOL, V9, P435, DOI 10.1007/BF00918174; BARRERA M, 1983, AM J COMMUN PSYCHOL, V11, P133; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Calsyn DA, 2004, DRUG ALCOHOL DEPEN, V76, P165, DOI 10.1016/j.drugalcdep.2004.04.018; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Damiano AM, 1996, SICKNESS IMPACT PROF; de Zwaan M, 2002, OBES SURG, V12, P773, DOI 10.1381/096089202320995547; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FEINSTEIN JS, 1993, MILBANK Q, V71, P279, DOI 10.2307/3350401; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; Green CA, 1999, SOC SCI MED, V48, P1363, DOI 10.1016/S0277-9536(98)00440-7; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KANDRACK MA, 1991, SOC SCI MED, V32, P579, DOI 10.1016/0277-9536(91)90293-L; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; Machamer JE, 2003, J HEAD TRAUMA REHAB, V18, P387, DOI 10.1097/00001199-200309000-00001; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Marmot M, 1997, SOC SCI MED, V44, P901, DOI 10.1016/S0277-9536(96)00194-3; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; McCarthy ML, 2003, J BONE JOINT SURG AM, V85A, P1689, DOI 10.2106/00004623-200309000-00006; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MCLEAN A, 2002, ARCH PHYS MED REH S2, V74, P1041; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Myrdal G, 2003, THORAX, V58, P194, DOI 10.1136/thorax.58.3.194; PETRUCELLI E, 1981, ACCIDENT ANAL PREV, V13, P29, DOI 10.1016/0001-4575(81)90040-3; Revicki DA, 1998, MED CARE, V36, P126, DOI 10.1097/00005650-199802000-00003; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Selassie A, 2004, S CAROLINA TRAUMATIC; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sullivan M, 1998, J CLIN EPIDEMIOL, V51, P1105, DOI 10.1016/S0895-4356(98)00102-4; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thurman DJ., 1995, GUIDELINES SURVEILLA; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VERBRUGGE L M, 1979, Women and Health, V4, P61; Ware J, 1994, SF 36 PHYS MENTAL SU; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WHITTY RW, 1985, SOFTW MICROSYST, V4, P2, DOI 10.1049/sm.1985.0002; 1993, INT CLASSIFICATION D	76	66	66	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2006	87	7					953	961		10.1016/j.apmr.2006.03.007			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	059MY	WOS:000238738100011	16813783				2022-02-06	
J	Delaney, JS; Puni, V; Rouah, F				Delaney, JS; Puni, V; Rouah, F			Mechanisms of injury for concussions in university football, ice hockey, and soccer - A pilot study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; football; ice hockey; mechanisms; soccer	IMPACTS	Objective: To examine the mechanisms of injury for concussions in university football, ice hockey, and soccer. Design: Prospective analysis. Setting: McGill University. Patients: All athletes participating in varsity football, ice hockey, and soccer. Main Outcome Measures: Athletes participating in university varsity football, ice hockey, and soccer were followed prospectively to determine the mechanisms of injury for concussions, whether certain mechanisms of injury causing concussions were more common in any of the three sports, whether different areas of the body seem to be more vulnerable to a concussion after contact, and whether these areas might be predisposed to higher grades of concussion after contact. Results: There were 69 concussions in 60 athletes over a 3-year period. Being hit in the head or helmet was the most common mechanism of injury for all 3 sports. The side/temporal area of the head or helmet was the most probable area to be struck, resulting in concussion for both football and soccer. When examining the body part or object delivering the concussive blow, contact with another player's helmet was the most probable mechanism in football. Conclusion: The mechanisms of injury for concussions in football are similar to previously published research on professional football players. The mechanisms of injury for concussions in soccer are similar to past research on Australian rules football and rugby.	McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; McGill Univ, Dept Emergency Med, Hlth Ctr 2, Montreal, PQ H3A 2T5, Canada; McGill Univ, Fac Management, Montreal, PQ, Canada		Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave, Montreal, PQ H2W 1S4, Canada.	j.delaney@mcgill.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5	10	66	66	2	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2006	16	2					162	165		10.1097/00042752-200603000-00013			4	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	029KC	WOS:000236560200013	16603887				2022-02-06	
J	Duhaime, AC				Duhaime, Ann-Christine			Large animal models of traumatic injury to the immature brain	DEVELOPMENTAL NEUROSCIENCE			English	Article						injury forces; large animal models; traumatic brain injury	CEREBRAL-BLOOD-FLOW; NONACCIDENTAL HEAD-INJURY; AXONAL INJURY; PROFESSIONAL FOOTBALL; DEVELOPMENTAL-CHANGES; OXYGEN-SATURATION; HYPOXIA-ISCHEMIA; NEONATAL BRAIN; AGE; NEWBORN	Large animal models have been used much less frequently than rodent models to study traumatic brain injury. However, large animal models offer distinct advantages in replicating specific mechanisms, morphology and maturational stages relevant to age-dependent injury responses. This paper reviews how each of these features is relevant in matching a model to a particular scientific question and discusses various scaling strategies, advantages and disadvantages of large animal models for studying traumatic brain injury in infants and children. Progress to date and future directions are outlined. Copyright (c) 2006 S. Karger AG, Basel.	Dartmouth Hitchcock Med Ctr, Childrens Hosp Dartmouth, Lebanon, NH 03756 USA		Duhaime, AC (corresponding author), Dartmouth Hitchcock Med Ctr, Childrens Hosp Dartmouth, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	acd@hitchcock.org	Dilger, Ryan N./E-7031-2010	Dilger, Ryan N./0000-0003-2538-2845			Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 2002, DEV BRAIN RES, V139, P19, DOI 10.1016/S0165-3806(02)00511-4; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1080/713773978; BARKS JDE, 1992, BRAIN PATHOL, V2, P235, DOI 10.1111/j.1750-3639.1992.tb00697.x; Bauer R, 1999, PEDIATR NEUROSURG, V30, P62, DOI 10.1159/000028765; Bauer R, 2004, PEDIATR RES, V56, P639, DOI 10.1203/01.PDR.0000139425.94975.77; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bittigau P, 1998, RESTOR NEUROL NEUROS, V13, P11; BUCKLEY NM, 1986, COMP BIOCHEM PHYS A, V83, P1, DOI 10.1016/0300-9629(86)90080-0; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; DIGIACOMO JE, 1992, BIOL NEONATE, V61, P25, DOI 10.1159/000243527; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 2006, J NEUROSURG, V104, P259, DOI 10.3171/ped.2006.104.4.259; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; DURHAM SR, 2004, 33 ANN M AM ASS NEUR; Finnie JW, 2003, AUST VET J, V81, P153, DOI 10.1111/j.1751-0813.2003.tb11078.x; Finnie JW, 1999, VET PATHOL, V36, P256, DOI 10.1354/vp.36-3-256; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Finnie JW, 2001, J COMP PATHOL, V124, P159, DOI 10.1053/jcpa.2000.0446; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Gavilanes AWD, 2001, CLIN NEUROPHYSIOL, V112, P52, DOI 10.1016/S1388-2457(00)00499-5; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1985, NEUROSURGERY, P1531; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Hagberg H, 2002, MENT RETARD DEV D R, V8, P30, DOI 10.1002/mrdd.10007; HARADA J, 1991, J NEUROSURG, V75, P103, DOI 10.3171/jns.1991.75.1.0103; Inder T, 2004, SEMIN PERINATOL, V28, P396, DOI 10.1053/j.semperi.2004.10.002; Ioroi T, 2002, EXP BRAIN RES, V144, P172, DOI 10.1007/s00221-002-1030-z; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011; Loepke AW, 2005, ANESTH ANALG, V101, P340, DOI 10.1213/01.ANE.0000154199.67104.6A; Luerssen T G, 1991, Neurosurg Clin N Am, V2, P399; MADSEN FF, 1987, ACTA NEUROCHIR, V88, P65, DOI 10.1007/BF01400517; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Roohey T, 1997, EARLY HUM DEV, V47, P115, DOI 10.1016/S0378-3782(96)01773-2; Saito T, 2005, PHYSIOL BEHAV, V84, P725, DOI 10.1016/j.physbeh.2005.02.018; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Takahashi T, 1999, AM J NEURORADIOL, V20, P917; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; WAGERLE LC, 1986, PEDIATR RES, V20, P131, DOI 10.1203/00006450-198602000-00007; WOOTTON R, 1982, BIOL NEONATE, V41, P209; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	64	66	71	1	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					380	387		10.1159/000094164			8	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600015	16943661				2022-02-06	
J	Bakshi, A; Keck, CA; Koshkin, VS; LeBold, DG; Siman, R; Snyder, EY; McIntosh, TK				Bakshi, A; Keck, CA; Koshkin, VS; LeBold, DG; Siman, R; Snyder, EY; McIntosh, TK			Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain	BRAIN RESEARCH			English	Article						traumatic brain injury; neural progenitor cell; transplantation; graft cell death mechanism	SITU DNA FRAGMENTATION; NITRIC-OXIDE; STEM-CELLS; DOPAMINERGIC-NEURONS; TIME-COURSE; 3-NITROPROPIONIC ACID; MESENCEPHALIC TISSUE; WHITE-MATTER; CROSS-TALK; CALPAIN-I	Neural progenitor cells (NPCs) have been shown to be a promising therapy for cell replacement and gene transfer in neurological diseases including traumatic brain injury (TBI). However, NPCs often survive poorly after transplantation despite immunosuppression, and the mechanisms of graft cell death are unknown. In this study, we evaluated caspase- and calpain-mediated mechanisms of cell death of neonatal mouse C17.2 progenitor cells, transplanted at 24 It following lateral fluid percussion brain injury (FP) in rats. Adult Male Sprague-Dawley rats (n = 30) were subjected to lateral FP injury (n = 18) or sham surgery (n = 12). C 17.2 cells labeled with green fluorescent dye (CMFDA) were engrafted in the perilesional deep cortex, and animals were sacrificed at 24 h, 72 h and I week post-transplantation. Pro-apoptotic caspase-mediated cleavage products (Ab246) and calpain-mediated cleavage products (Ab38) were detected in the engrafted cells using immunohistochemistry. Only 2 to 4.5% of grafted NPCs were found to survive at 24 h post-transplantation, regardless of injury status of the host brain, although brain-injured animals had significantly fewer graft cells than sham-injured animals. Limited caspase and calpain-mediated graft cell death was observed in both sham- and brain-injured animals, and caspase-mediated graft cell death was significantly greater than calpain-mediated graft cell death in all animals. Brain-injured animals had significantly increased caspase-mediated graft cell death compared to sham-injured animals. These results suggest that both the caspase and calpain family of proteases are involved in graft cell death, and that caspase-mediated apoptotic graft cell death predominates in the acute post-traumatic period following TBI. (C) 2005 Elsevier B.V. All rights reserved.	Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Burnham Inst, Program Dev & Regenerat Cell Biol, La Jolla, CA 92037 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		Bakshi, A (corresponding author), Univ Penn, 105,Hayden Hall,3320,Smith Walk, Philadelphia, PA 19144 USA.	ashabakshi@gmail.com			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40978] Funding Source: Medline		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Akerud P, 2001, J NEUROSCI, V21, P8108, DOI 10.1523/JNEUROSCI.21-20-08108.2001; Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Baker GR, 1997, AM J HEMATOL, V56, P17; Barker RA, 1996, EXP NEUROL, V141, P79, DOI 10.1006/exnr.1996.0141; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Berardi P, 2004, CELL MOL LIFE SCI, V61, P2173, DOI 10.1007/s00018-004-4179-8; Bizat N, 2003, J BIOL CHEM, V278, P43245, DOI 10.1074/jbc.M305057200; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Branton RL, 1999, EXP NEUROL, V160, P88, DOI 10.1006/exnr.1999.7207; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; Cambray N, 2002, DEVELOPMENT, V129, P4855; Ceccatelli S, 2004, TOXICOL LETT, V149, P59, DOI 10.1016/j.toxlet.2003.12.060; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Cicchetti F, 2002, EXP NEUROL, V177, P376, DOI 10.1006/exnr.2002.8007; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Davenne M, 2005, CHEM SENSES, V30, pI115, DOI 10.1093/chemse/bjh141; DUAN WM, 1995, NEUROSCIENCE, V64, P629, DOI 10.1016/0306-4522(94)00416-3; Emgard M, 1999, EXP NEUROL, V160, P279, DOI 10.1006/exnr.1999.7198; Emgard M, 2003, J NEUROCHEM, V86, P1223, DOI 10.1046/j.1471-4159.2003.01931.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; Hansson O, 2000, EXP NEUROL, V164, P102, DOI 10.1006/exnr.2000.7406; Helt CE, 2001, EXP NEUROL, V170, P258, DOI 10.1006/exnr.2001.7709; Hurelbrink CB, 2001, EXP NEUROL, V171, P46, DOI 10.1006/exnr.2001.7749; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Khaldi A, 2002, ANN NY ACAD SCI, V962, P53, DOI 10.1111/j.1749-6632.2002.tb04055.x; Kim DE, 2004, STROKE, V35, P952, DOI 10.1161/01.STR.0000120308.21946.5D; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; MAHALIK TJ, 1994, EXP NEUROL, V129, P27, DOI 10.1006/exnr.1994.1144; Marchionini DM, 2004, CELL TRANSPLANT, V13, P273, DOI 10.3727/000000004783983972; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nadarajah B, 2002, NAT NEUROSCI, V5, P218, DOI 10.1038/nn813; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; NIKKHAH G, 1994, NEUROSCIENCE, V63, P57, DOI 10.1016/0306-4522(94)90007-8; Oo TF, 2002, EXP NEUROL, V175, P1, DOI 10.1006/exnr.2002.7881; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Ray SK, 2000, NEUROCHEM RES, V25, P1191, DOI 10.1023/A:1007631826160; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rosario CM, 1997, DEVELOPMENT, V124, P4213; ROSEN GD, 1990, J NEUROSCI METH, V35, P115, DOI 10.1016/0165-0270(90)90101-K; Rosenblad C, 1999, NEUROREPORT, V10, P1783, DOI 10.1097/00001756-199906030-00029; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Slagsvold HH, 2003, BRAIN RES, V984, P111, DOI 10.1016/S0006-8993(03)03119-6; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Soares HD, 1995, J NEUROSCI, V15, P8223; Sortwell CE, 2000, EXP NEUROL, V165, P268, DOI 10.1006/exnr.2000.7476; Sortwell CE, 2003, FRONT BIOSCI, V8, pS522, DOI 10.2741/1096; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Tamm C, 2004, EUR J NEUROSCI, V19, P2613, DOI 10.1111/j.0953-816X.2004.03391.x; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wennberg L, 2001, TRANSPLANTATION, V71, P1797, DOI 10.1097/00007890-200106270-00016; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WILLIAMS S, UNPUB J NEUROTRAUMA; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zaman V, 2003, HIPPOCAMPUS, V13, P618, DOI 10.1002/hipo.10091; Zaman V, 2002, NEUROSCIENCE, V109, P537, DOI 10.1016/S0306-4522(01)00478-X; Zawada WM, 1998, BRAIN RES, V786, P96, DOI 10.1016/S0006-8993(97)01408-X; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526; Zietlow R, 2002, CELL TRANSPLANT, V11, P637, DOI 10.3727/000000002783985396	91	66	76	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 14	2005	1065	1-2					8	19		10.1016/j.brainres.2005.09.059			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	997FA	WOS:000234229200002	16309635				2022-02-06	
J	Schwab, JM; Monnier, PP; Schluesener, HJ; Conrad, S; Beschorner, R; Chen, L; Meyermann, R; Mueller, BK				Schwab, JM; Monnier, PP; Schluesener, HJ; Conrad, S; Beschorner, R; Chen, L; Meyermann, R; Mueller, BK			Central nervous system injury-induced repulsive guidance molecule expression in the adult human brain	ARCHIVES OF NEUROLOGY			English	Article							OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; CHONDROITIN SULFATE PROTEOGLYCANS; CNS GLIAL SCAR; NEURITE GROWTH; AXONAL REGENERATION; REACTIVE ASTROCYTES; VISUAL-SYSTEM; SPINAL-CORD; INHIBITOR; OUTGROWTH	Background: The repulsive guidance molecule (RGM) is involved in formation of the central nervous system during development by moderating the repulsion of growing axons. However, the role of RGM in adult central nervous system lesions remains to be clarified. Objective: To identify and determine RGM expression in adult brains with focal cerebral ischemia or traumatic brain injury and in neuropathologically unaffected control brains. Patients: Twenty-one brains of patients with focal cerebral ischemia, 25 brains after traumatic brain injury, and 4 control brains. Main Outcome Measure: Expression of RGM as assessed by immunohistochemical analysis. Results: In normal brains, RGM expression was detected on the perikarya of some neurons, choroid plexus, smooth muscle and endothelial cells, oligodendrocytes, and myelinated white matter fibers. After focal cerebral ischemia and traumatic brain injury, RGM-mummopositive cells accumulated in lesional and perilesional areas. In hemorrhagic lesions, a massive accumulation of RGM-immunopositive cells was observed. During the first week after insult, RGM expression remained confined to neurons, smooth muscle and endothelial cells, and leukocytes infiltrating the lesion. Thereafter, with maturation of the lesion, we observed RGM expression by components of the developing scar tissue, such as fibroblastoid cells, reactive astrocytes, and a pronounced extracellular RGM deposition resembling neo-laminae. Conclusions: This is the first study of RGM in the human central nervous system. Following central nervous system injury, RGM, a novel, potent axonal growth inhibitor, is present in axonal growth impediments: the mature myelin, choroid plexus, and components of the developing scar.	Univ Tubingen, Brain Res Inst, Sch Med, Tubingen, Germany; Univ Tubingen, Inst Anat, Tubingen, Germany; Univ Paris 06, CNRS, UMR 7102, Equipe Dev Neuronal, Paris, France; Univ Toronto, Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON, Canada; Kafides GmbH, Dusslingen, Germany		Schwab, JM (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut, Thorn Bldg 724,75 Francis St, Boston, MA 02115 USA.	Jschwab@.zeus.bwh.harvard.edu	Beschorner, Rudi/M-6397-2014	Beschorner, Rudi/0000-0003-1109-915X; monnier, philippe/0000-0002-6221-4130; Schwab, Jan/0000-0001-6784-4919			Buffo A, 2000, J NEUROSCI, V20, P2275; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; DOU CL, 1994, J NEUROSCI, V14, P7616; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GRAHAM DI, 1996, GREENFIELDS NEUROPAT, P197; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; KALIMO H, 1996, GREENFIELDS NEUROPAT, P315; Kottis V, 2002, J NEUROCHEM, V82, P1566, DOI 10.1046/j.1471-4159.2002.01146.x; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Oldekamp J, 2004, GENE EXPR PATTERNS, V4, P283, DOI 10.1016/j.modgep.2003.11.008; Pasterkamp RJ, 2001, BRAIN RES REV, V35, P36, DOI 10.1016/S0165-0173(00)00050-3; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Samad TA, 2004, J NEUROSCI, V24, P2027, DOI 10.1523/JNEUROSCI.4115-03.2004; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schwab JM, 2001, J NEUROIMMUNOL, V114, P232, DOI 10.1016/S0165-5728(00)00433-1; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; WIZENMANN A, 1993, NEURON, V11, P975, DOI 10.1016/0896-6273(93)90126-C	32	66	70	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	OCT	2005	62	10					1561	1568		10.1001/archneur.62.10.1561			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	973DK	WOS:000232502900009	16216939	Bronze			2022-02-06	
J	Bandyopadhyay, S; Hennes, H; Gorelick, MH; Wells, RG; Walsh-Kelly, CM				Bandyopadhyay, S; Hennes, H; Gorelick, MH; Wells, RG; Walsh-Kelly, CM			Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies	MAY 01-04, 2004	San Francisco, CA	Pediat Acad Soc		neuron-specific enolase; enolase; prediction; pediatrics; children; disability; outcomes	SEVERE HEAD-INJURY; CREATINE-KINASE BB; S-100 PROTEIN; CEREBROSPINAL-FLUID; FOLLOW-UP; DAMAGE; MILD; MARKER; SCALE; MODERATE	Background: Closed traumatic brain injury (cTBI) is a significant cause of mortality and morbidity in children. The natural course and extent of recovery from cTBI in children are poorly understood. Neuron-specific enolase (NSE), an enzyme detected in serum following structural damage of neuronal brain cells, appears to be a good marker for intracranial injury. However, to the best of the authors' knowledge, the usefulness of NSE as a predictor of disability in children with cTBI has not been reported. Objectives: To examine the association between posttraumatic serum NSE level and short-term physical disability in children with cTBI. Methods: This was a retrospective analysis of a prospectively enrolled cohort of children aged 0-18 years with isolated cTBI presenting to the emergency department (ED) within 24 hours of injury, and having a cranial computed tomography (CT) scan as part of the evaluation. The NSE level was obtained at the time of ED evaluation. Physical disability was measured using the Glasgow Outcome Scale (GOS). The GOS score was assigned retrospectively for enrolled patients by a single investigator blinded to NSE level. Patient outcomes were categorized as good (GOS = 5) or poor (GOS < 5). A single radiologist reviewed all cranial CT scans. Results: Ninety eligible subjects with NSE levels were identified; 86 met the enrollment criteria. Seven subjects (8%) had poor outcome. There was a significant difference in NSE levels between the poor and good outcome groups, even within high-risk subgroups. The area under the curve (AUC) for NSE prediction of poor vs. good outcome was 0.83. A serum NSE level of 21.2 ng/dL was 86% sensitive and 74% specific in predicting poor outcome. Conclusions: It appears that the serum NSE level can be used as a predictor of global short-term physical disability in children following cTBI.	Emory Univ, Sch Med, Dept Pediat, Emergency Med Div, Atlanta, GA 30329 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA; Childrens Hosp Wisconsin, Dept Radiol, Milwaukee, WI 53201 USA		Bandyopadhyay, S (corresponding author), Emory Univ, Sch Med, Dept Pediat, Emergency Med Div, 1645 Tullie Circle, Atlanta, GA 30329 USA.	sbandy2@emory.edu	Hennes, Halim/H-6592-2019	Hennes, Halim/0000-0002-1230-7371			Abdul-Khaliq H, 2000, CLIN CHEM LAB MED, V38, P1173, DOI 10.1515/CCLM.2000.181; Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Beaudeux JL, 1999, ANN BIOL CLIN-PARIS, V57, P261; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Ergun R, 1998, NEUROL RES, V20, P418; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; FISHER DH, 1992, J PEDIATR, V121, P68; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; HANS P, 1993, J NEUROSURG ANESTH, V5, P111; Hellawell DJ, 2000, SCAND J REHABIL MED, V32, P25; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Khan NE, 2001, ANN THORAC SURG, V72, P666, DOI 10.1016/S0003-4975(01)02605-4; Kieslich M, 2001, DISABIL REHABIL, V23, P665; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; KRUSE A, 1991, ACTA NEUROCHIR, V110, P106, DOI 10.1007/BF01400675; Kusch B, 2001, THORAC CARDIOV SURG, V49, P179, DOI 10.1055/s-2001-14297; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Linstedt U, 2000, ANAESTHESIST, V49, P887, DOI 10.1007/s001010070042; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; RIVARA FP, 1984, DEV MED CHILD NEUROL, V26, P81; Robertson Charlene M T, 2002, Pediatr Crit Care Med, V3, P345, DOI 10.1097/00130478-200210000-00003; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Sosin DM, 1996, BRAIN INJURY, V10, P47; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; UZAN M, 1995, ACTA NEUROCHIR, V135, P141, DOI 10.1007/BF02187758; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woischneck D, 1998, ACT NEUR S, V71, P138; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	50	66	74	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2005	12	8					732	738		10.1197/j.aem.2005.02.017			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	951TL	WOS:000230953800007	16079426	Bronze			2022-02-06	
J	Wade, SL; Wolfe, C; Brown, TM; Pestian, JP				Wade, SL; Wolfe, C; Brown, TM; Pestian, JP			Putting the pieces together: Preliminary efficacy of a web-based family intervention for children with traumatic brain injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article; Proceedings Paper	112th Annual Convention of the American-Psychological-Association	JUL 28-AUG 01, 2004	Honolulu, HI	Amer Psychol Assoc		telehealth; acquired brain injury; intervention; problem-solving; online	PROBLEM-SOLVING SKILLS; PREDICTORS; ADOLESCENTS	Objective To report preliminary efficacy data from a Web-based family problem-solving intervention to improve parent and child adaptation. Method Eight parents and six children with moderate to severe traumatic brain injury (TBI) who were injured more than 15 months earlier (M = 16 months) participated in the intervention. Families were given computers, Web cameras, and high-speed Internet access. Weekly videoconferences with the therapist were conducted after they completed self-guided Web exercises on problem-solving, communication, and antecedent behavior management strategies. Results Paired t tests comparing pre- and post-intervention scores revealed significant improvements in injury-related burden, parental psychiatric symptoms, depression, and parenting stress. There were also significant reductions in antisocial behaviors in the injured child, but not in self-reported depressive symptoms. Conclusions These findings suggest that a computer-based intervention may successfully be used to improve both parent and child outcomes following TBI in children.	Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Miami Univ, Sch Interdisciplinary Studies, Oxford, OH 45056 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA		Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Div Pediat Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD040942] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40942-02] Funding Source: Medline		Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; LOYD BH, 1985, J PEDIATR PSYCHOL, V10, P169, DOI 10.1093/jpepsy/10.2.169; Marks I, 1998, CLIN PSYCHOL-SCI PR, V5, P151, DOI 10.1111/j.1468-2850.1998.tb00141.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; Patterson GeraldR., 1988, STRESS COPING DEV CH, P235; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Sitarenios G., 1999, USE PSYCHOL TESTING, P267; Speilberger CD., 1983, STATE TRAIT ANXIETY; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; WADE SL, 2004, UNPUB PUTTING PIECES; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; YLVSAKER M, 1998, COLLABORATIVE BRAIN	27	66	66	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUL-AUG	2005	30	5					437	442		10.1093/jpepsy/jsi067			6	Psychology, Developmental	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology	938KT	WOS:000230003000007	15944171	Bronze			2022-02-06	
J	Acquarolo, A; Urli, T; Perone, G; Giannotti, C; Candiani, A; Latronico, N				Acquarolo, A; Urli, T; Perone, G; Giannotti, C; Candiani, A; Latronico, N			Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study	INTENSIVE CARE MEDICINE			English	Article						pneumonia; antibiotic prophylaxis; coma; brain injury	VENTILATOR-ASSOCIATED PNEUMONIA; INTENSIVE-CARE UNITS; NOSOCOMIAL PNEUMONIA; RISK-FACTORS; TRAUMA PATIENTS; HEAD TRAUMA; COLONIZATION; INFECTIONS; INJURY; MORTALITY	Objective: To evaluate if a 3-day ampicillin-sulbactam prophylaxis can reduce the occurrence of early-onset pneumonia (EOP) in comatose mechanically-ventilated patients. Design: This was a single-centre, prospective, randomised, open study. Setting: A 10-bed general-neurological ICU in a 2,000-bed university hospital. Patients and participants: Comatose mechanically-ventilated patients with traumatic, surgical or medical brain injury. Interventions: Patients were randomized to either ampicillin-sulbactam prophylaxis (3 g every 6 h for 3 days) plus standard treatment or standard treatment alone. Measurements and results: Main outcome was the occurrence of EOP. Secondary outcome measures were occurrence of late-onset pneumonia, percentage of non-pulmonary infections and of emerging multiresistant bacteria, duration of mechanical ventilation and of ICU stay and ICU mortality. Interim analysis at 1 year demonstrated a statistically significant reduction of EOP in the ampicillin-sulbactam group, and the study was interrupted. Overall, 39.5% of the patients developed EOP, 57.9% in the standard treatment group and 21.0% in the ampicillin-sulbactam group (chi-square 5.3971; P = 0.022). Relative risk reduction of EOP in patients receiving ampicillin-sulbactam prophylaxis was 64%; the number of patients to be treated to avoid one episode of EOP was three. No differences in other outcome parameters were found; however, the small sample size precluded a definite analysis. Conclusions: Antibiotic prophylaxis with ampicillin-sulbactam significantly reduced the occurrence of EOP in critically ill comatose mechanically ventilated patients. This result should encourage a large multicenter trial to demonstrate whether ampicillin-sulbactam prophylaxis reduces patient mortality, and whether antibiotic resistance is increased in patients receiving prophylaxis.	Univ Brescia Spedali Civili, Inst Anesthesiol Intens Care, I-25125 Brescia, Italy		Acquarolo, A (corresponding author), Univ Brescia Spedali Civili, Inst Anesthesiol Intens Care, Piazzale Osped Civili 1, I-25125 Brescia, Italy.	a.acquarolo@tiscali.it	Latronico, Nicola/F-1557-2010	Latronico, Nicola/0000-0002-2521-5871			Abraham E, 2004, INTENS CARE MED, V30, P1017, DOI 10.1007/s00134-004-2321-6; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; Fridkin SK, 1999, CLIN CHEST MED, V20, P303, DOI 10.1016/S0272-5231(05)70143-X; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hamel Mary Beth, 1995, JAMA (Journal of the American Medical Association), V273, P1842, DOI 10.1001/jama.273.23.1842; Hoth JJ, 2003, J TRAUMA, V55, P249, DOI 10.1097/01.TA.0000083334.93868.65; JENNETT B, 1977, LANCET, V1, P878; LANGER M, 1987, INTENS CARE MED, V13, P342; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Plum F, 1972, Contemp Neurol Ser, V10, P1; POCOCK SJ, 1982, BIOMETRICS, V38, P153, DOI 10.2307/2530298; Rello J, 2003, CRIT CARE MED, V31, P2544, DOI 10.1097/01.CCM.0000089928.84326.D2; RELLO J, 1992, EUR RESPIR J, V5, P1249; Robert R, 2003, INTENS CARE MED, V29, P1062, DOI 10.1007/s00134-003-1729-8; Sirvent JM, 2000, INTENS CARE MED, V26, P1369, DOI 10.1007/s001340000611; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Teoh LSG, 2000, INTENS CARE MED, V26, P157, DOI 10.1007/s001340050039; Urli T, 2002, J HOSP INFECT, V52, P130, DOI 10.1053/jhin.2002.1271; VALCKE YJ, 1990, ANTIMICROB AGENTS CH, V34, P958, DOI 10.1128/AAC.34.6.958	25	66	68	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	APR	2005	31	4					510	516		10.1007/s00134-005-2585-5			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910WR	WOS:000227963400006	15754197				2022-02-06	
J	Guo, XL; Meiyu, G; Guanhua, D				Guo, XL; Meiyu, G; Guanhua, D			Glucose transporter 1, distribution in the brain and in neural disorders: Its relationship with transport of neuroactive drugs through the blood-brain barrier	BIOCHEMICAL GENETICS			English	Article						glucose transporter; distribution in brain; expression in brain disease; neuroactive drug; saccharide; blood-brain barrier	GLUT1 GLUCOSE-TRANSPORTER; ELECTRON-MICROSCOPIC IMMUNOGOLD; POSITRON-EMISSION-TOMOGRAPHY; ANALOGS PRODUCE ANALGESIA; ALZHEIMERS-DISEASE; GLYCOPEPTIDE ANALOGS; BIOLOGICAL-ACTIVITY; ENKEPHALIN ANALOGS; MOLECULAR-CLONING; GENE-EXPRESSION	Facilitative glucose transport is mediated by one or more of the members of the closely related glucose transporter ( GLUT) family. Thirteen members of the GLUT family have been described thus far. GLUT1 is a widely expressed isoform that provides many cells with their basic glucose requirement. It is also the primary transporter across the blood-brain barrier. This review describes the distribution and expression of GLUT1 in brain in different pathophysiological conditions including Alzheimer's disease, epilepsy, ischemia, or traumatic brain injury. Recent investigations show that GLUT1 mediates the transport of some neuroactive drugs, such as glycosylated neuropeptides, low molecular weight heparin, and D-glucose derivatives, across the blood-brain barrier as a delivery system. By utilizing such highly specific transport mechanisms, it should be possible to establish strategies to regulate the entry of candidate drugs.	Ocean Univ China, Marine Drug & Food Inst, Dept Pharmacol, Qingdao 266003, Peoples R China; Shandong Univ, Sch Pharm, Dept Pharmacol, Jinan 250012, Peoples R China; Chinese Acad Med Sci, Beijing 100050, Peoples R China; Peking Union Med Coll, Beijing 100050, Peoples R China		Meiyu, G (corresponding author), Ocean Univ China, Marine Drug & Food Inst, Dept Pharmacol, Qingdao 266003, Peoples R China.	gengmy@ouc.edu.cn					Au KK, 1997, J CELL BIOCHEM, V67, P131, DOI 10.1002/(SICI)1097-4644(19971001)67:1<131::AID-JCB13>3.0.CO;2-K; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bilsky EJ, 2000, J MED CHEM, V43, P2586, DOI 10.1021/jm000077y; Boado RJ, 1998, NEUROSCI LETT, V255, P147, DOI 10.1016/S0304-3940(98)00731-9; Boado RJ, 1998, J NEURAL TRANSM-SUPP, P323; Bolz S, 1996, CELL TISSUE RES, V284, P355, DOI 10.1007/s004410050596; Bourasset F, 2003, J NEUROCHEM, V86, P1564, DOI 10.1046/j.1471-4159.2003.01990.x; Chavez JC, 2002, J NEUROSCI, V22, P8922; Cheng CM, 2001, FASEB J, V15, P907, DOI 10.1096/fj.00-0398com; CORNFORD EM, 1995, J NEUROPATH EXP NEUR, V54, P842, DOI 10.1097/00005072-199511000-00011; Cornford EM, 1998, J CEREBR BLOOD F MET, V18, P26, DOI 10.1097/00004647-199801000-00003; CORNFORD EM, 1993, J CEREBR BLOOD F MET, V13, P841, DOI 10.1038/jcbfm.1993.106; Cornford EM, 1998, ANN NEUROL, V43, P801, DOI 10.1002/ana.410430615; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; Doege H, 2000, J BIOL CHEM, V275, P16275, DOI 10.1074/jbc.275.21.16275; Doege H, 2001, BIOCHEM J, V358, P791; Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8; Egleton RD, 2000, BRAIN RES, V881, P37, DOI 10.1016/S0006-8993(00)02794-3; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; FILIRA F, 1990, INT J PEPT PROT RES, V36, P86; Halmos T, 1997, CARBOHYD RES, V299, P15, DOI 10.1016/S0008-6215(96)00328-X; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; HARR SD, 1995, J NEUROPATH EXP NEUR, V54, P38, DOI 10.1097/00005072-199501000-00005; HORVAT S, 1993, INT J PEPT PROT RES, V41, P399; Janigro D, 1999, EPILEPSY RES, V37, P223, DOI 10.1016/S0920-1211(99)00074-1; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; KAYANO T, 1990, J BIOL CHEM, V265, P13276; Klepper J, 2004, PROSTAG LEUKOTR ESS, V70, P321, DOI 10.1016/j.plefa.2003.07.004; Kondo F, 2001, NEUROSCI RES, V39, P339, DOI 10.1016/S0168-0102(00)00233-9; Kriss CT, 2000, TETRAHEDRON-ASYMMETR, V11, P9, DOI 10.1016/S0957-4166(99)00544-3; Leino RL, 2001, NEUROCHEM INT, V38, P519, DOI 10.1016/S0197-0186(00)00102-9; Leveugle B, 1998, J NEUROCHEM, V70, P736; Ma Q, 2002, THROMB RES, V105, P447, DOI 10.1016/S0049-3848(02)00050-6; MAHER F, 1991, Molecular and Cellular Neuroscience, V2, P351, DOI 10.1016/1044-7431(91)90066-W; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MAHER F, 1995, J NEUROSCI RES, V42, P459, DOI 10.1002/jnr.490420404; McVie-Wylie AJ, 2001, GENOMICS, V72, P113, DOI 10.1006/geno.2000.6457; Mitchell SA, 2001, J ORG CHEM, V66, P2327, DOI 10.1021/jo005712m; Mooradian AD, 1997, NEUROBIOL AGING, V18, P469, DOI 10.1016/S0197-4580(97)00111-5; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; PARDRIDGE WM, 2000, BLOOD BRAIN BARRIER, P395; Phay JE, 2000, GENOMICS, V66, P217, DOI 10.1006/geno.2000.6195; POLT R, 1994, P NATL ACAD SCI USA, V91, P7114, DOI 10.1073/pnas.91.15.7114; RICHARD DE, 1997, PEPTIDES, V18, P1431; RODRIGUEZ RE, 1989, NEUROSCI LETT, V101, P89, DOI 10.1016/0304-3940(89)90446-1; Rogers S, 2002, AM J PHYSIOL-ENDOC M, V282, pE733, DOI 10.1152/ajpendo.2002.282.3.E733; Sasaki T, 2001, BIOCHEM BIOPH RES CO, V289, P1218, DOI 10.1006/bbrc.2001.6101; Schurmamn A, 2001, DIABETES, V50, pA277; Simpson IA, 2001, J BIOL CHEM, V276, P12725, DOI 10.1074/jbc.M010897200; SIMPSON IA, 1994, ANN NEUROL, V35, P546, DOI 10.1002/ana.410350507; Simpson IA, 1999, J NEUROCHEM, V72, P238, DOI 10.1046/j.1471-4159.1999.0720238.x; Tomatis R, 1997, J MED CHEM, V40, P2948, DOI 10.1021/jm970119r; Vannucci SJ, 1998, DEV BRAIN RES, V107, P255, DOI 10.1016/S0165-3806(98)00021-2; VARGADEFTERDAROVIC L, 1992, INT J PEPT PROT RES, V39, P12; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173	57	66	66	1	23	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0006-2928	1573-4927		BIOCHEM GENET	Biochem. Genet.	APR	2005	43	3-4					175	187		10.1007/s10528-005-1510-5			13	Biochemistry & Molecular Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Genetics & Heredity	910CX	WOS:000227908200008	15932065				2022-02-06	
J	Neary, JT; Kang, Y; Tran, M; Feld, J				Neary, JT; Kang, Y; Tran, M; Feld, J			Traumatic injury activates protein kinase B/Akt in cultured astrocytes: Role of extracellular ATP and P2 purinergic receptors	JOURNAL OF NEUROTRAUMA			English	Article						Akt; ATP; ERK; gliosis; protein kinases; purinergic receptors; trauma	STRETCH-INDUCED INJURY; DNA-SYNTHESIS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; NEURONAL SURVIVAL; BRAIN-INJURY; RELEASE; CALCIUM; AKT; MECHANISMS	Protein kinase B/Akt is a key signaling molecule that regulates cell survival, growth, and metabolism, and inhibits apoptosis. Traumatic brain injury (TBI) activates Akt, and. Akt has been implicated in neuronal survival after TBI, but little is known about injury-induced Akt activation in astrocytes, cells that exhibit hypertrophic and hyperplastic responses to CNS injury. Here we have investigated the effect of mechanical strain on Akt activation in primary cultures of rat cortical astrocytes growing on deformable Silastic membranes. When astrocytes were subjected to mechanical strain (50 msec; 5-7.5 mm displacement), we observed an increase in phosphorylation of serine 473, a key indicator of Akt activation. Akt phosphorylation was increased at 3 min postinjury, was maximal from 5 to 10 min, and declined gradually thereafter. Akt activation was also dependent on the severity of the injury. Stretch-induced Akt phosphorylation was attenuated by blocking calcium influx and phosphoinositide 3-kinase (PI3K), an upstream activator of Akt. In addition, we found that ATP is rapidly released after mechanical strain and that the P2 purinergic receptor antagonist iso-pyridoxal-5'-phosphate-6-azophenyl-2',5'disulfonate (PPADS) attenuated trauma-induced Akt activation. We conclude that mechanical strain causes activation of Akt in astrocytes via stimulation of P2 receptors. This suggests that P2 receptor/Akt signaling promotes astrocyte survival and growth, and this process may play a role in the generation of reactive gliosis after TBI.	Univ Miami, Sch Med, Res Serv,VA Med Ctr, Dept Pathol, Miami, FL 33125 USA; Univ Miami, Sch Med, Res Serv,VA Med Ctr, Dept Biochem, Miami, FL 33125 USA; Univ Miami, Sch Med, Res Serv,VA Med Ctr, Mol Biol & Neurosci Program, Miami, FL 33125 USA		Neary, JT (corresponding author), Univ Miami, Sch Med, Res Serv,VA Med Ctr, Dept Pathol, 1201 NW 16th St, Miami, FL 33125 USA.	jneary@med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046651] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 46651] Funding Source: Medline		ABBRACCHIO MP, 1994, NEUROSCIENCE, V59, P67, DOI 10.1016/0306-4522(94)90099-X; Adam RM, 2003, J UROLOGY, V169, P2388, DOI 10.1097/01.ju.0000063980.99368.35; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Anderson CM, 2004, J NEUROCHEM, V88, P246, DOI 10.1046/j.1471-4159.2003.02204.x; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; BODIN P, 1992, P ROY SOC B-BIOL SCI, V247, P131, DOI 10.1098/rspb.1992.0019; Bolego C, 1997, BRIT J PHARMACOL, V121, P1692, DOI 10.1038/sj.bjp.0701294; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; CHAN TO, 2001, UNPUB AKT SCI S 0123; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cheng AW, 2003, J BIOL CHEM, V278, P7591, DOI 10.1074/jbc.M207232200; Chorna NE, 2004, J NEUROCHEM, V91, P119, DOI 10.1111/j.1471-4159.2004.02699.x; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014-5793(03)00055-3; Deb TB, 2004, J BIOL CHEM, V279, P38903, DOI 10.1074/jbc.M405314200; Egea J, 2001, J CELL BIOL, V154, P585, DOI 10.1083/jcb.200101023; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frank C, 1999, J Sci Med Sport, V2, P190, DOI 10.1016/S1440-2440(99)80173-X; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Haga M, 2003, ENDOTHELIUM-J ENDOTH, V10, P149, DOI 10.1080/713715223; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Jiang ZJ, 2002, BIOCHEM BIOPH RES CO, V294, P726, DOI 10.1016/S0006-291X(02)00540-5; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Joseph SM, 2003, J BIOL CHEM, V278, P23331, DOI 10.1074/jbc.M302680200; Khakh BS, 2001, PHARMACOL REV, V53, P107; Knight GE, 2002, AM J PHYSIOL-RENAL, V282, pF281, DOI 10.1152/ajprenal.00293.2000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI KM, 1991, J NEUROCHEM, V57, P1510, DOI 10.1111/j.1471-4159.1991.tb06345.x; Lenz G, 2000, BRIT J PHARMACOL, V129, P927, DOI 10.1038/sj.bjp.0703138; Murashov AK, 2001, MOL BRAIN RES, V93, P199, DOI 10.1016/S0169-328X(01)00212-1; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Namikawa K, 2000, J NEUROSCI, V20, P2875; NEARY JT, 1992, PROG BRAIN RES, V94, P145; NEARY JT, 1994, J NEUROCHEM, V63, P490; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Perez-Garcia MJ, 2004, J BIOL CHEM, V279, P6132, DOI 10.1074/jbc.M308367200; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Petroff MGV, 2001, NAT CELL BIOL, V3, P867, DOI 10.1038/ncb1001-867; Ralevic V, 1998, PHARMACOL REV, V50, P413; RATHBONE MP, 1992, NEUROSCI RES, V13, P1, DOI 10.1016/0168-0102(92)90030-G; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Schwiebert ER, 2001, CLIN EXP PHARMACOL P, V28, P340, DOI 10.1046/j.1440-1681.2001.03451.x; Sedding DG, 2003, CIRCULATION, V108, P616, DOI 10.1161/01.CIR.0000079102.08464.E2; SHREIBER D, 1995, P 1995 INT RES C BIO; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	60	66	66	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2005	22	4					491	500		10.1089/neu.2005.22.491			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	920YM	WOS:000228731400006	15853465				2022-02-06	
J	Levine, B; Black, SE; Cheung, G; Campbell, A; O'Toole, C; Schwartz, ML				Levine, B; Black, SE; Cheung, G; Campbell, A; O'Toole, C; Schwartz, ML			Gambling task performance in traumatic brain injury - Relationships to injury severity, atrophy, lesion location, and cognitive and psychosocial outcome	COGNITIVE AND BEHAVIORAL NEUROLOGY			English	Article						prefrontal cortex; self-regulation; magnetic resonance imaging; neuropsychological assessment; psychosocial outcome	VENTROMEDIAL PREFRONTAL CORTEX; NEUROBEHAVIORAL RATING-SCALE; CLOSED-HEAD-INJURY; DECISION-MAKING; FRONTAL-LOBE; STRATEGY APPLICATION; EPISODIC MEMORY; WORKING-MEMORY; DAMAGE; DEFICITS	Objective: To determine the sensitivity of the Gambling Test (GT) to the neurocognitive effects of traumatic brain injury (TBI) and to examine the cognitive, neural, and psychosocial correlates of impaired GT performance in patients with TBI. Background: The GT is sensitive to behavioral deficits in patients with prefrontal brain damage, especially in ventral regions. Patients with TBI and behavioral deficits often have focal ventral prefrontal damage as well as diffuse damage. Analysis of the correlates of the GT in this population has implications for interpretation of the GT in other groups. Method: Seventy-one TBI patients were administered the GT, neuropsychological tests, and psychosocial outcome questionnaires. Patients also had high-resolution structural magnetic resonance imaging analyzed for both lesion location and tissue compartment volumes. Results: The GT was sensitive to TBI in general, but not to TBI severity or quantified chronic phase atrophy. Marked impairment was observed in (but not limited to) patients with large frontal lesions. There were modest correlations between the GT and tests of working memory and executive functioning as well as between self- and other-rated real-life memory, executive, and emotional problems. Conclusions: The GT can be a useful adjunct to assessment of patients with TBI. Interpretation of GT performance in patients with complex neuropsychological deficits such as TBI should consider the influence of domain-general resources in addition to specific ventral prefrontal function.	Univ Toronto, Baycrest Ctr Geriatr Care, Rotman Res Inst, Dept Psychol, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON M6A 2E1, Canada; Univ Toronto, Sunnybrook & Womens Hlth Sci Ctr, Dept Med Imaging, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Surg, Toronto, ON M6A 2E1, Canada		Levine, B (corresponding author), Univ Toronto, Baycrest Ctr Geriatr Care, Rotman Res Inst, Dept Psychol, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	levine@psych.utoronto.ca	Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010; Black, Sandra E./C-7294-2011	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Black, Sandra/0000-0001-7093-8289			ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bar-On R, 2003, BRAIN, V126, P1790, DOI 10.1093/brain/awg177; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 2002, NEUROPSYCHOLOGIA, V40, P1675, DOI 10.1016/S0028-3932(02)00015-5; Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benson D.F., 1986, FRONTAL LOBES; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; Craik F. I. M., 1982, AGING COGNITIVE PROC, P191, DOI [DOI 10.1007/978-1-4684-4178-9_11, 10.1007/978-1-4684-4178-9_11]; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; Denburg NL, 2001, BRAIN COGNITION, V47, P156; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A, P552; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; Ernst M, 2002, NEUROPSYCHOPHARMACOL, V26, P682, DOI 10.1016/S0893-133X(01)00414-6; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; ESLINGER PJ, 1994, NEUROPSYCHOLOGIA, V32, P729, DOI 10.1016/0028-3932(94)90032-9; Fuster, 2015, PREFRONTAL CORTEX; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Green P, 1996, WORD MEMORY TEST; Hinson JM, 2002, COGN AFFECT BEHAV NE, V2, P341, DOI 10.3758/CABN.2.4.341; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JonesGotman M, 1997, BRAIN, V120, P1845, DOI 10.1093/brain/120.10.1845; Kovacevic N, 2002, NEUROIMAGE, V17, P1087, DOI 10.1006/nimg.2002.1221; KURTZKE JF, 1982, NEUROLOGY, V32, P1207, DOI 10.1212/WNL.32.11.1207; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2000, MEMORY, CONSCIOUSNESS, AND THE BRAIN, P200; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B., 2002, PRINCIPLES FRONTAL L, P448; LEWIN ICF, 1992, COST DISORDERS BRAIN; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MESULAM MM, 1986, ANN NEUROL, V19, P320, DOI 10.1002/ana.410190403; MISHKIN M, 1964, FRONTAL GRANULAR COR, P219; MOSCOVITCH M, 1992, NEUROPSYCHOLOGY MEMO, P5; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Pandya DN, 1987, FRONTAL LOBES REVISI, P41; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Smith A., 1978, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stout JC, 2001, J INT NEUROPSYCH SOC, V7, P92, DOI 10.1017/S1355617701711095; Stuss D., 1991, AWARENESS DEFICIT BR, P63; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [https://doi.org/10.1037/0894-4105.8.3.355, DOI 10.1037/0894-4105.8.3.355]; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; *WAR DEP ADJ GEN O, 1944, ARM IND TEST BATT; Wilson B.A., 1997, METHODOLOGY FRONTAL, P239; Winocur G., 1992, HDB AGING COGNITION, P315; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8	88	66	71	2	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1543-3633	1543-3641		COGN BEHAV NEUROL	Cogn. Behav. Neurol.	MAR	2005	18	1					45	54		10.1097/01.wnn.0000152227.13001.c3			10	Behavioral Sciences; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	927YF	WOS:000229236600006	15761276				2022-02-06	
J	Trommer, BL; Shah, C; Yun, SH; Gamkrelidze, G; Pasternak, ES; Stine, WB; Manelli, A; Sullivan, P; Pasternak, JF; LaDu, MJ				Trommer, BL; Shah, C; Yun, SH; Gamkrelidze, G; Pasternak, ES; Stine, WB; Manelli, A; Sullivan, P; Pasternak, JF; LaDu, MJ			ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta 1-42	NEUROBIOLOGY OF DISEASE			English	Article						ApoE; amyloid-beta; long-term potentiation (LTP); dentate gyrus; Alzheimer disease; ApoE transgenic mice; A beta oligomers; neuroplasticity; hippocampal slices	AMYLOID-BETA-PEPTIDE; LONG-TERM POTENTIATION; HUMAN APOLIPOPROTEIN E4; TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; TRANSGENIC MICE; DENTATE GYRUS; PRECURSOR PROTEIN; CHOLINERGIC DEFICITS; SYNAPTIC PLASTICITY	Amyloid-beta1-42 (Abeta1-42) is crucial to Alzheimer disease (AD) pathogenesis but the conformation of the toxic A species remains uncertain. AD risk is increased by apolipoprotein E4 (apoE4) and decreased by apoE2 compared with the apoE3 isoform, but whether inheritance of apoE4 represents a gain of negative or a loss of protective function is also unresolved. Using hippocampal slices from apoE knockout (apoE-KO) and human apoE2, E3, and E4 targeted replacement (apoE-TR) mice, we found that oligomeric Abeta1-42 inhibited long-term potentiation (LTP) with a hierarchy of susceptibility mirroring clinical AD risk (apoE4-TR > apoE3-TR = apoE-KO > apoE2-TR), and that comparable doses of unaggregated Abeta1-42 did not affect LTP. These data provide a novel link among apoE isoform, Abeta1-42, and a functional cellular model of memory. In this model, apoE4 confers a gain of negative function synergistic with Abeta1-42, apoE2 is protective, and the apoE-Abeta interaction is specific to oligomeric Abeta1-42. (C) 2004 Elsevier Inc. All rights reserved.	Evanston Northwestern Healthcare, Div Neurol, Dept Pediat, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60614 USA; ENH Res Inst, Evanston, IL 60202 USA; Duke Univ, Dept Med, Div Neurol & Bryan ARDC, Durham, NC 27710 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Geriatr, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Alzheimers Dis Core Ctr, Chicago, IL 60614 USA; Evanston Northwestern Healthcare, Div Geriatr, Dept Med, Evanston, IL 60201 USA		Trommer, BL (corresponding author), Evanston Northwestern Healthcare, Div Neurol, Dept Pediat, 2650 Ridge Ave, Evanston, IL 60201 USA.	btrommer@northwestern.edu	Gamkrelidze, Georgi/ABC-6891-2021	LaDu, Mary Jo/0000-0003-2141-1450	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG18121] Funding Source: Medline		Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Barger SW, 1997, J NEUROCHEM, V69, P60; Buttini M, 2002, J NEUROSCI, V22, P10539; Buttini M, 1999, J NEUROSCI, V19, P4867; Cambon K, 2000, NEUROSCIENCE, V97, P685, DOI 10.1016/S0306-4522(00)00065-8; Carter DB, 2001, ANN NEUROL, V50, P468, DOI 10.1002/ana.1134; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chen QS, 2000, J NEUROSCI RES, V60, P65, DOI 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q; Chen QS, 2002, NEUROBIOL LEARN MEM, V77, P354, DOI 10.1006/nlme.2001.4034; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; Cullen WK, 1997, NEUROREPORT, V8, P3213, DOI 10.1097/00001756-199710200-00006; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Deb S, 2000, BRIT J PSYCHIAT, V176, P468, DOI 10.1192/bjp.176.5.468; Drouet B, 2001, J NEUROCHEM, V76, P117, DOI 10.1046/j.1471-4159.2001.00047.x; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Greenberg SM, 1998, NEUROLOGY, V50, P961, DOI 10.1212/WNL.50.4.961; Grehan S, 2001, J NEUROSCI, V21, P812, DOI 10.1523/JNEUROSCI.21-03-00812.2001; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartman RE, 2002, J NEUROSCI, V22, P10083; HOFFER MJV, 1993, GENOMICS, V15, P62, DOI 10.1006/geno.1993.1010; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Irizarry MC, 2000, ACTA NEUROPATHOL, V100, P451, DOI 10.1007/s004010000263; Irizarry MC, 2000, ANN NY ACAD SCI, V920, P171; Ji D, 2001, NEURON, V31, P131, DOI 10.1016/S0896-6273(01)00332-4; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan J, 1998, J NEUROSCI, V18, P195; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; LADU MJ, 1994, J BIOL CHEM, V269, P23403; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lanz TA, 2003, NEUROBIOL DIS, V13, P246, DOI 10.1016/S0969-9961(03)00079-2; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Manelli AM, 2004, J MOL NEUROSCI, V23, P235, DOI 10.1385/JMN:23:3:235; Mesulam NM, 1999, NEURON, V24, P521, DOI 10.1016/S0896-6273(00)81109-5; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Palop JJ, 2003, P NATL ACAD SCI USA, V100, P9572, DOI 10.1073/pnas.1133381100; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Raymond CR, 2003, BRAIN RES, V968, P263, DOI 10.1016/S0006-8993(03)02269-8; Rebeck GW, 2002, J ALZHEIMERS DIS, V4, P145, DOI 10.3233/JAD-2002-4304; REBECK GW, 1993, NEURON, V11, P575; Saunders AM, 2000, J NEUROPATH EXP NEUR, V59, P751, DOI 10.1093/jnen/59.9.751; Scheff SW, 2003, NEUROBIOL AGING, V24, P1029, DOI 10.1016/j.neurobiolaging.2003.08.002; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Small D H, 1998, Amyloid, V5, P301, DOI 10.3109/13506129809007304; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sun YL, 1998, J NEUROSCI, V18, P3261; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Teter B, 2002, J ALZHEIMERS DIS, V4, P155, DOI 10.3233/JAD-2002-4305; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang QW, 2004, J NEUROSCI, V24, P3370, DOI 10.1523/JNEUROSCI.1633-03.2004; Wang XS, 1997, J CELL PHYSIOL, V173, P73, DOI 10.1002/(SICI)1097-4652(199710)173:1<73::AID-JCP9>3.0.CO;2-G; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Zhu YJ, 2003, J BIOL CHEM, V278, P36257, DOI 10.1074/jbc.M303171200	71	66	68	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2005	18	1					75	82		10.1016/j.nbd.2004.08.011			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	889OO	WOS:000226452500006	15649697				2022-02-06	
J	Tsung, JW; Blaivas, M; Cooper, A; Levick, NR				Tsung, JW; Blaivas, M; Cooper, A; Levick, NR			A rapid noninvasive method of detecting elevated intracranial pressure using bedside ocular ultrasound - Application to 3 cases of head trauma in the pediatric emergency department	PEDIATRIC EMERGENCY CARE			English	Article						optic nerve sheath diameter; ocular ultrasound; emergency ultrasonography; elevated intracranial pressure; traumatic brain injury	NERVE; ULTRASONOGRAPHY; HEMORRHAGES	Managing pediatric head trauma with elevated intracranial pressure in the acute setting can be challenging. Bedside ocular ultrasound for measuring optic nerve sheath diameters has been recently proposed as a portable noninvasive method to rapidly detect increased intracranial pressure in emergency department patients with head trauma. Prior study data agree that the upper limit of normal optic nerve sheath diameters is 5.0 turn in adults, 4.5 turn in children aged 1 to 15, and 4.0 min in infants up to I year of age. We report the application of this technique to 3 cases of head trauma in the pediatric emergency department.	Columbia Univ, Div Pediat Emergency Med, Dept Pediat, Harlem Hosp,Coll Phys & Surgeons, New York, NY USA; Med Coll Georgia, Dept Emergency Med, Augusta, GA 30912 USA; Columbia Univ, Coll Phys & Surg, Div Pediat Surg, Dept Surg,Harlem Hosp, New York, NY USA		Tsung, JW (corresponding author), NYU, Sch Med, Bellevue Hosp Ctr, 462 1st Ave,Room 1 E 9, New York, NY 10016 USA.	james.tsung@med.nyu.edu	Tsung, James W/I-6343-2019	Tsung, James/0000-0002-4718-8325			Ballantyne J, 1999, CLIN RADIOL, V54, P740, DOI 10.1016/S0009-9260(99)91176-5; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Blaivas M, 2002, ACAD EMERG MED, V9, P791, DOI 10.1111/j.1553-2712.2002.tb02166.x; Blaivas M, 2001, ACAD EMERG MED, V8, P90, DOI 10.1111/j.1553-2712.2001.tb00563.x; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; *CTR DIS CONTR PRE, 2002, 2000 NAT HOSP AMB ME; ELNER SG, 1990, ARCH OPHTHALMOL-CHIC, V108, P1094, DOI 10.1001/archopht.1990.01070100050033; Foster T, 2003, ACAD EMERG MED, V10, P487; GALETTA S, 1989, J CLIN NEURO-OPHTHAL, V9, P79; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; JOHNSON LN, 1991, J FAM PRACTICE, V33, P4; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; Ma O. J., 2003, EMERGENCY ULTRASOUND; National Center for Injury Prevention and Control, 2002, TRAUM BRAIN INJ US A; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; YEH K, 2002, PEDIATR EMERG CARE, V18, P226	17	66	68	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	2005	21	2					94	98		10.1097/01.pec.0000159052.64930.64			5	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	897ZC	WOS:000227044400004	15699817				2022-02-06	
J	Kline, AE; Massucci, JL; Ma, XC; Zafonte, RD; Dixon, CE				Kline, AE; Massucci, JL; Ma, XC; Zafonte, RD; Dixon, CE			Bromocriptine reduces lipid peroxidation and enhances spatial learning and hippocampal neuron survival in a rodent model of focal brain trauma	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; function; learning; memory; MWM; recovery	RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; CONTROLLED CORTICAL IMPACT; WATER MAZE PERFORMANCE; OXIDATIVE STRESS; COGNITIVE DEFICITS; HEAD-INJURY; STILBAZULENYL NITRONE; CEREBROSPINAL-FLUID; ALPHA-TOCOPHEROL; ANTIOXIDANT	Oxidative stress is a significant contributor to the secondary sequelae of traumatic brain injury (TBI), and may mediate subsequent neurobehavioral deficits and histopathology. The present study examined the neuroprotective effects of bromocriptine (BRO), a dopamine D2 receptor agonist with significant antioxidant properties, on cognition, histopathology, and lipid peroxidation in a rodent model of focal brain trauma. BRO (5 mg/kg) or a comparable volume of vehicle (VEH) was administered intraperitoneally 15 min prior to cortical impact or sham injury. In experiment 1, spatial learning was assessed in an established water maze task on post-surgery days 14-18, followed by quantification of hippocampal cell survival and cortical lesion volume at 4 weeks. In experiment 2, rats were sacrificed 1 hr post-surgery, and malondialdehyde (MDA), the end product of lipid peroxidation, was measured in the frontal cortex, striatum, and substantia nigra using a thiobarbituric acid reactive substances assay. The TBI+BRO group was significantly more adept at locating a hidden platform in the water maze compared to the TBI+VEH group and also exhibited a greater percentage of surviving CA(3) hippocampal neurons. TBI increased MDA in all examined regions of the VEH-treated, but not BRO-treated group versus SHAMS. MDA was significantly decreased in both the striatum (4.22 +/- 0.52 versus 5.60 +/- 0.44 nmol per mg/tissue +/-SEM) and substantia nigra (4.18 +/- 0.35 versus 7.76 +/- 2.05) of the TBI+BRO versus TBI+VEH groups, respectively, while only a trend toward decreased MDA was observed in the frontal cortex (5.44 +/- 0.44 versus 6.96 +/- 0.77). These findings suggest that TBI-induced oxidative stress is attenuated by acute BRO treatment, which may, in part, explain the benefit in cognitive and histological outcome.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Kaufmann Bldg,Ste 201,3471 5th Ave, Pittsburgh, PA 15213 USA.	klineae@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD043851] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS033150] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Belayev L, 2002, J NEUROSURG, V96, P1077, DOI 10.3171/jns.2002.96.6.1077; Bozbuga M, 1998, NEUROSURG REV, V21, P36, DOI 10.1007/BF01111483; BRANNAN T, 1993, J NEURAL TRANSM-PARK, V6, P81, DOI 10.1007/BF02261001; Chen YK, 2001, BRAIN RES, V896, P165, DOI 10.1016/S0006-8993(01)02081-9; CRISMON ML, 1988, CLIN NEUROPHARMACOL, V11, P462, DOI 10.1097/00002826-198810000-00007; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Ginsberg MD, 2003, ANN NEUROL, V54, P330, DOI 10.1002/ana.10659; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Golden K. M., 2000, Journal of Neurotrauma, V17, P960; Hall ED, 1996, BRAIN RES, V742, P80, DOI 10.1016/S0006-8993(96)00968-7; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALLIWELL B, 1996, FREE RADICAL BIO MED, P351; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; Iida M, 1999, BRAIN RES, V838, P51, DOI 10.1016/S0006-8993(99)01688-1; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Kato N, 2003, ACTA NEUROCHIR, V145, P489, DOI 10.1007/s00701-003-0036-z; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LIU XH, 1995, J NEUROL SCI, V129, P9, DOI 10.1016/0022-510X(94)00239-K; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Muralikrishnan D, 1998, FASEB J, V12, P905, DOI 10.1096/fasebj.12.10.905; O'Neill MJ, 1998, EUR J PHARMACOL, V352, P37, DOI 10.1016/S0014-2999(98)00333-1; PALKOVITS M, 1988, MAP GUIDE MICRODISSE; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Powell WC, 1996, CURR TOP MICROBIOL, V213, P1; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; PULASKI KH, 1994, AM J OCCUP THER, V48, P263, DOI 10.5014/ajot.48.3.263; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Tanaka K, 2001, NEUROCHEM RES, V26, P31, DOI 10.1023/A:1007672414239; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; YOSHIKAWA T, 1994, J NEUROCHEM, V62, P1034	63	66	71	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1712	1722		10.1089/0897715042664849			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400003	15684763				2022-02-06	
J	Ashwal, S; Holshouser, B; Tong, K; Serna, T; Osterdock, R; Gross, M; Kido, D				Ashwal, S; Holshouser, B; Tong, K; Serna, T; Osterdock, R; Gross, M; Kido, D			Proton spectroscopy detected myoinositol in children with traumatic brain injury	PEDIATRIC RESEARCH			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; PEDIATRIC INTENSIVE-CARE; AMINO-ACID RELEASE; CLOSED-HEAD INJURY; MR SPECTROSCOPY; INOSITOL; HYPERNATREMIA; INFANTS; ASTROGLIOSIS; SPECTRA	Previous studies have shown that proton magnetic resonance spectroscopy (MRS) is useful in predicting neurologic prognosis in children with traumatic brain injury (TBI). Reductions in N-acetyl derived metabolites and presence of lactate have been predictive of poor outcomes. We examined another spectroscopy metabolite, myoinositol (ml), to determine whether it is altered after TBI. Found primarily in astrocytes, ml functions as an osmolyte and is involved in hormone response pathways and protein-kinase C activation. Myoinositol is elevated in the newborn brain and is increased in a variety of diseases. We studied 38 children (mean age 11 y; range 1.6-17 y) with TBI using quantitative short echo time occipital gray and parietal white matter proton MRS at a mean of 7 d (range 1-17 d) after injury. We found that occipital gray matter ml levels were increased in children with TBI (4.30 +/- 0.73) compared with controls (3.53 +/- 0.48; p = 0.003). We also found that patients with poor outcomes 6-12 mo after injury had higher ml levels (4.78 +/- 0.68) than patients with good outcomes (4.15 +/- 0.69; p < 0.05). Myoinositol is elevated after pediatric TBI and is associated with a poor neurologic outcome. The reasons for its elevation remain unclear but may be due to astrogliosis or to a disturbance in osmotic function.	Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Pediat, Div Crit Care Med, Loma Linda, CA 92350 USA		Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, 11175 Campus St,Room A1120G, Loma Linda, CA 92350 USA.	sashwal@ahs.llumc.edu					Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; BATTAGLIA F, 1961, Q J EXP PHYSIOL CMS, V46, P188, DOI 10.1113/expphysiol.1961.sp001532; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chang L, 1999, NEUROLOGY, V53, P782, DOI 10.1212/WNL.53.4.782; Cotran R.S., 1994, PATHOLOGICAL BASIS D, P1; DANIELSEN ER, 1999, MAGNETIC RESONANCE S, P349; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Frahm J., 1997, MAGNETIC RESONANCE S, P329; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; JACKSON PS, 1994, AM J PHYSIOL-CELL PH, V267, pC1203, DOI 10.1152/ajpcell.1994.267.5.C1203; Koura SS, 1998, ACT NEUR S, V71, P244; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; LOHR JW, 1988, LIFE SCI, V43, P271, DOI 10.1016/0024-3205(88)90317-7; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Robertson NJ, 2001, PEDIATR RES, V50, P692, DOI 10.1203/00006450-200112000-00011; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Staub F, 1997, BRAIN RES, V766, P285, DOI 10.1016/S0006-8993(97)00751-8; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Uldry M, 2001, EMBO J, V20, P4467, DOI 10.1093/emboj/20.16.4467; Yamashita T, 1997, MOL BRAIN RES, V46, P236, DOI 10.1016/S0169-328X(97)00020-X	37	66	68	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	OCT	2004	56	4					630	638		10.1203/01.PDR.0000139928.60530.7D			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	855WG	WOS:000224005000018	15295080	Bronze			2022-02-06	
J	Clausen, F; Lundqvist, H; Ekmark, S; Lewen, A; Ebendal, T; Hillered, L				Clausen, F; Lundqvist, H; Ekmark, S; Lewen, A; Ebendal, T; Hillered, L			Oxygen free radical-dependent activation of extracellular signal-regulated kinase mediates apoptosis-like cell death after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						ERK; MEK inhibition; neuroprotection; rats; ROS; TUNEL	FOCAL CEREBRAL-ISCHEMIA; PROTEIN-KINASE; NITRIC-OXIDE; C-FOS; OXIDATIVE STRESS; AMINO-ACIDS; S-PBN; RECEPTOR; INHIBITION; EXPRESSION	Mitogen-activated protein kinase (MAPK) cascades are membrane-to-nucleus signaling modules that recently have been implicated as mediators of cellular injury. In this study, we investigated the involvement of the MAP kinase p44/p42 (extracellular signal-regulated kinase [ERK1/2]) in traumatic brain injury (TBI) in rats. There was a strong increase in activated, phosphorylated ERK 1/2 (p-ERK 1/2) protein at 10 min up to 24 h after the injury. Expression of p-ERK occurred in cells identified as neurons, astrocytes, and microglia. Most of the cells expressing p-ERK were TUNEL positive at later time points. Treatment with the MEK inhibitor U0126 or the free radical scavenger S-PBN, both with neuroprotective properties in TBI, attenuated the early activation of ERK and resulted in less activation of caspase-3 and subsequent DNA fragmentation. Post-treatment with U0126 resulted in a significant decrease (-60%) in cortical cavity size and cortical atrophy at 2 weeks after trauma. Overall, the results suggest that ERK activation is initiated by increased oxygen radical activity and that overactivation of ERK sets off secondary cell death mechanisms in TBI. Clinical studies are warranted to evaluate the concept of MEK inhibition in head-injured patients.	Uppsala Univ, Dept Neurosci, Uppsala, Sweden; Uppsala Univ, Dept Neurosurg, Uppsala, Sweden; Uppsala Univ, Dept Dev Neurosci, Uppsala, Sweden		Clausen, F (corresponding author), Univ Uppsala Hosp, Dept Neurosci & Neurosurg, S-75185 Uppsala, Sweden.	fredrik.clausen@neurokir.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348; Clausen, Fredrik/0000-0003-3592-4417			Abe K, 2001, J NEUROCHEM, V76, P217, DOI 10.1046/j.1471-4159.2001.00062.x; Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Hassan WN, 2002, FREE RADICAL BIO MED, V32, P551, DOI 10.1016/S0891-5849(02)00744-X; Huang CY, 2001, STROKE, V32, P741, DOI 10.1161/01.STR.32.3.741; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KURINO M, 1995, J NEUROCHEM, V65, P1282; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MANTYLA M, 1981, ANN CLIN RES, V13, P5; Maples KR, 2001, FREE RADICAL RES, V34, P417, DOI 10.1080/10715760100300351; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Noshita N, 2002, J NEUROSCI, V22, P7923; Oo TF, 1999, J NEUROCHEM, V72, P557, DOI 10.1046/j.1471-4159.1999.0720557.x; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Regan RF, 2001, J NEUROCHEM, V79, P545, DOI 10.1046/j.1471-4159.2001.00590.x; Satoh T, 2000, NEUROSCI LETT, V288, P163, DOI 10.1016/S0304-3940(00)01229-5; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Skaper SD, 2001, ANN NY ACAD SCI, V939, P11; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yin KJ, 2002, J NEUROSCI, V22, P9764; Yu CR, 2002, CANCER RES, V62, P188	59	66	82	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1168	1182		10.1089/neu.2004.21.1168			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900006	15453987				2022-02-06	
J	Massagli, TL; Fann, JR; Burington, BE; Jaffe, KM; Katon, WJ; Thompson, RS				Massagli, TL; Fann, JR; Burington, BE; Jaffe, KM; Katon, WJ; Thompson, RS			Psychiatric illness after mild traumatic brain injury in children	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; psychiatry; rehabilitation	CLOSED-HEAD-INJURY; DISORDERS; ADOLESCENTS; SEQUELAE; ADJUSTMENT	Objective: To determine the incidence of psychiatric illness 3 years after mild traumatic brain injury (TBI) in children. Design: Prospective cohort study with 3-year follow-up. Setting: Emergency department, hospital, and outpatient clinics in a large health maintenance organization. Participants: Children, 14 years old or less (n=490), who sustained a mild TBI in 1993. Three TBI unexposed subjects per TBI exposed patient were matched by sex, age, and enrollment at the time of injury (n=1470). Interventions: Not applicable. Main Outcome Measures: Computerized records were examined to identify psychiatric diagnoses, psychiatric medication prescription, and utilization of psychiatric services for the year before TBI and 3 years after. Adjusted relative risks for incidence of psychiatric illness were estimated for those with and without a premorbid psychiatric disorder. Results: The cumulative incidence estimates for any psychiatric illness in the 3 years after mild TBI were 30% in children exposed to mild TBI and 20% in unexposed children (P=.0001). Cumulative incidence estimates were particularly high in both TBI exposed (55%) and unexposed children (63%) who had psychiatric illness in the year before the index TBI (psychiatric history). The exposed and unexposed children with psychiatric history did not have significantly different estimates of incidence during follow-up for any of the studied indicators of psychiatric illness. In those with no psychiatric history, 26% of exposed and 16% of unexposed children (P<.0001) had evidence of a psychiatric illness in the 3 years after mild TBI. For those with no psychiatric history, the adjusted relative risk estimate of any psychiatric illness in TBI exposed versus unexposed children, in the first year after TBI, was 2.03 (95% confidence interval [CI], 1.4-2.9). Children with mild TBI but no psychiatric history were at higher risk for hyperactivity (diagnosis of hyperkinetic syndrome of childhood or prescription of psychostimulants) in the first year after injury (incidence, 3%; first year relative risk, 7.59; 95% CI, 2.7-21.6). Conclusions: In the 3 years after mild TBI, children with no evidence of prior-year psychiatric history were at significantly increased risk for psychiatric illness, particularly hyperactivity in the first year after injury. Prior-year psychiatric history conferred a significant independent risk for subsequent psychiatric illness. There was no evidence for an additional increase in risk in the 3-year follow-up that is attributable to mild TBI in children with prior psychiatric history.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98121 USA		Massagli, TL (corresponding author), Childrens Hosp & Med Ctr, POB 5371,Mail Stop 6G3, Seattle, WA 98105 USA.	massagli@u.washington.edu					Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; BIJUR PE, 1990, PEDIATRICS, V86, P337; BLACK P, 1981, BRAIN DYSFUNCTION CH, P171; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Hosmer D. W., 1999, APPL SURVIVAL ANAL; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; National Center for Health Statistics, 1991, NAT CTR HLTH STAT PU; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; Sokol DK, 1996, BRAIN INJURY, V10, P439, DOI 10.1080/026990596124296; THRUMAN DJ, 1995, GUIDELINES SURVEILL; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; THURMAN DJ, 1996, PROPOSED CLASIFICATI; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	37	66	66	0	12	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2004	85	9					1428	1434		10.1016/j.apmr.2003.12.036			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	852DW	WOS:000223736400007	15375812				2022-02-06	
J	Ergh, TC; Hanks, RA; Rapport, LJ; Coleman, RD				Ergh, TC; Hanks, RA; Rapport, LJ; Coleman, RD			Social support moderates caregiver life satisfaction following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							REHABILITATION; DISABILITY; RELATIVES; PREDICTORS; VALIDITY; MEDIATOR; SCALE	Social support is an important determinant of adjustment following traumatic brain injury (TBI) sustained by a family member. The present study examined the extent to which social support moderates the influence of characteristics of the person with injury on caregiver subjective well-being. Sixty pairs of individuals who had sustained a moderate to severe TBI and their caregivers (N = 120) participated. Years postinjury ranged from 0.3 to 9.9 (M = 4.8, SD = 2.6). Cognitive, functional, and neurobehavioral functioning of participants with TBI were assessed using neuropsychological tests and rating scales. Caregiver life satisfaction and perceived social support were assessed using self-report questionnaires. Results indicated that time since injury was unrelated to life satisfaction. Neurobehavioral disturbances showed an inverse relation with life satisfaction. Social support emerged as an important moderator of fife satisfaction. Only among caregivers with low social support was cognitive dysfunction adversely related to life satisfaction. Similarly, a trend suggested that patient unawareness of deficit was associated with caregiver life dissatisfaction only among caregivers with low social support. In contrast, these characteristics were unrelated to life satisfaction among caregivers with adequate social support.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Inst Rehabil, Dept Rehabil Psychol & Neuropsychol, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA		Ergh, TC (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	tergh@sun.science.wayne.edu		Rapport, Lisa/0000-0001-8014-9523			ARRINDELL WA, 1991, PERS INDIV DIFFER, V12, P117, DOI 10.1016/0191-8869(91)90094-R; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BLAIS MR, 1989, CAN J BEHAV SCI, V21, P210, DOI 10.1037/h0079854; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cantor N., 1996, PSYCHOL ACTION LINKI, P338; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Conoley JC, 1996, J LEARN DISABIL-US, V29, P662, DOI 10.1177/002221949602900610; Cummins RA, 2001, J INTELLECT DEV DIS, V26, P83, DOI 10.1080/13668250020032787; Cutrona EC., 1987, ADV PERSONAL RELATIO, V1, P37, DOI DOI 10.1037/0882-7974.1.1.47; DELIA LF, 1996, COLOR TRIALS TEST; DIENER E, 1995, J PERS SOC PSYCHOL, V68, P653, DOI 10.1037/0022-3514.69.1.120; Diener E, 1999, PSYCHOL BULL, V125, P276, DOI 10.1037//0033-2909.125.2.276; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E, 2002, PERS SOC PSYCHOL B, V28, P437, DOI 10.1177/0146167202287002; Diener E., 2002, HDB POSITIVE PSYCHOL, V2, P63; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FENGLER AP, 1979, GERONTOLOGIST, V19, P175, DOI 10.1093/geront/19.2.175; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; GEORGE JM, 1991, J APPL SOC PSYCHOL, V21, P296, DOI 10.1111/j.1559-1816.1991.tb00522.x; GERVASOI AH, 1997, J MARITAL FAMILY THE, V15, P65; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Harlow RE, 1996, J PERS SOC PSYCHOL, V71, P1235, DOI 10.1037/0022-3514.71.6.1235; JUDGE T, 1990, THESIS U ILLINOIS; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Lucas RE, 1996, J PERS SOC PSYCHOL, V71, P616, DOI 10.1037/0022-3514.71.3.616; MOHIDE EA, 1993, DEPRESSION SOCIAL EN, P289; NELSON L, 1994, NEUROPSYCHOLOGY BEHA; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OMODEI MM, 1990, J PERS SOC PSYCHOL, V59, P762, DOI 10.1037/0022-3514.59.4.762; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; *PSYCH CORP, 1997, WAIS 3 WMS 3 TECHN M; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; Schwarz, 1999, WELL BEING FDN HEDON, P61, DOI DOI 10.7758/9781610443258; Singer GHS, 1989, SUPPORT CAREGIVING F, P3; Smead V. S., 1991, ANN CONV AM ASS APPL; Suh E, 1998, J PERS SOC PSYCHOL, V74, P482, DOI 10.1037/0022-3514.74.2.482; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76; [No title captured]	50	66	67	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	2003	25	8					1090	1101		10.1076/jcen.25.8.1090.16735			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	744LK	WOS:000186631900006	14566583				2022-02-06	
J	Lang, EW; Lagopoulos, J; Griffith, J; Yip, K; Yam, A; Mudaliar, Y; Mehdorn, HM; Dorsch, NWC				Lang, EW; Lagopoulos, J; Griffith, J; Yip, K; Yam, A; Mudaliar, Y; Mehdorn, HM; Dorsch, NWC			Cerebral vasomotor reactivity testing in head injury: the link between pressure and flow	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; TRANSCRANIAL DOPPLER; PERFUSION-PRESSURE; HEALTHY-VOLUNTEERS; AUTOREGULATION; VELOCITY; VASOSPASM; THRESHOLDS; VALIDATION	Background: It has been suggested that a moving correlation index between mean arterial blood pressure and intracranial pressure, called PRx, can be used to monitor and quantify cerebral vasomotor reactivity in patients with head injury. Objectives: To validate this index and study its relation with cerebral blood flow velocity and cerebral autoregulation; and to identify variables associated with impairment or preservation of cerebral vasomotor reactivity. Methods: The PRx was validated in a prospective study of 40 head injured patients. A PRx value of less than 0.3 indicates intact cerebral vasomotor reactivity, and a value of more than 0.3, impaired reactivity. Arterial blood pressure, intracranial pressure, mean cerebral perfusion pressure, and cerebral blood flow velocity, measured bilaterally with transcranial Doppler ultrasound, were recorded. Dynamic cerebrovascular autoregulation was measured using a moving correlation coefficient between arterial blood pressure and cerebral blood flow velocity, the Mx, for each cerebral hemisphere. All variables were compared in patients with intact and impaired cerebral vasomotor reactivity. Results: No correlation between arterial blood pressure or cerebral perfusion pressure and cerebral blood flow velocity was seen in 19 patients with intact cerebral vasomotor reactivity. In contrast, the correlation between these variables was significant in 21 patients with impaired cerebral vasomotor reactivity, whose cerebral autoregulation was reduced. There was no correlation with intracranial pressure, arterial blood pressure, cerebral perfusion pressure, or interhemispheric cerebral autoregulation differences, but the values for these indices were largely within normal limits. Conclusions: The PRx is valid for monitoring and quantifying cerebral vasomotor reactivity in patients with head injury. This intracranial pressure based index reflects changes in cerebral blood flow and cerebral autoregulatory capacity, suggesting a close link between blood flow and intracranial pressure in head injured patients. This explains why increases in arterial blood pressure and cerebral perfusion pressure may be useful for reducing intracranial pressure in selected head injured patients ( those with intact cerebral vasomotor reactivity).	Univ Sydney, Dept Neurosurg, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Sydney, Dept Neurol, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Sydney, Dept Intens Care, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Kiel, Dept Neurosurg, Kiel, Germany		Lang, EW (corresponding author), Dept Neurosurg, Weimarer Str 8, D-24106 Kiel, Germany.		Mehdorn, Maximilian/D-2495-2010				BULLOCK R, 1996, GUIDELINES MANAGEMEN; Carey BJ, 2000, STROKE, V31, P2895, DOI 10.1161/01.STR.31.12.2895; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; DAFFERTSHOFER M, 1991, J NEUROL SCI, V104, P32, DOI 10.1016/0022-510X(91)90212-P; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; LANG EW, IN PRESS J CLIN NEUR; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; Lewis SB, 2001, NEUROSURGERY, V48, P369, DOI 10.1097/00006123-200102000-00026; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; RINGELSTEIN RB, 1989, NONINVASIVE IMAGING, P75; Rosner Michael J., 1993, P57; Schmidt EA, 2002, ACT NEUR S, V81, P133; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steinmeier R, 2002, CRIT CARE MED, V30, P1969, DOI 10.1097/00003246-200209000-00004; TAKEUCHI H, 1991, NEUROSURGERY, V28, P41, DOI 10.1227/00006123-199101000-00007; Vavilala MS, 2002, ACTA ANAESTH SCAND, V46, P393, DOI 10.1034/j.1399-6576.2002.460411.x; Wallis SJ, 1996, STROKE, V27, P2287, DOI 10.1161/01.STR.27.12.2287; Yundt KD, 1998, J CEREBR BLOOD F MET, V18, P419, DOI 10.1097/00004647-199804000-00010	32	66	70	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2003	74	8					1053	1059		10.1136/jnnp.74.8.1053			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	703MJ	WOS:000184283100012	12876233	Green Submitted, Green Published, Bronze			2022-02-06	
J	Varma, S; Janesko, KL; Wisniewski, SR; Bayir, H; Adelson, PD; Thomas, NJ; Kochanek, PM				Varma, S; Janesko, KL; Wisniewski, SR; Bayir, H; Adelson, PD; Thomas, NJ; Kochanek, PM			F-2-isoprostane and neuron-specific enolase in cerebrospinal fluid after severe traumatic brain injury in infants and children	JOURNAL OF NEUROTRAUMA			English	Article						child abuse; free radical; head injury; inflicted childhood trauma; oxidative stress; pediatric	FOCAL CEREBRAL-ISCHEMIA; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; LIPID-PEROXIDATION; GENDER-DIFFERENCES; RELEASE; ACID; ESTROGEN; EFFICACY; CSF	It has been hypothesized that oxidative stress plays an important role in mediating secondary damage after traumatic brain injury (TBI). To study the relationship between lipid peroxidation, clinical variables, and neuronal damage in pediatric TBI, we measured levels of F-2-isoprostane, a marker of lipid peroxidation, and neuron-specific enolase (NSE), a marker of neuronal damage, in serial cerebrospinal fluid (CSF) samples from 23 infants and children with severe TBI (Glasgow Coma Scale score < 8). These were compared to CSF samples from 10 uninjured pediatric controls. On d1 after injury, F2-isoprostane was increased 6-fold vs. control (36.59 +/- 8.96 pg/ml vs. 5.64 +/- 8.08 pg/ml, p = 0.0035) and NSE was increased 10-fold (100.62 +/- 17.34 ng/ml vs. 8.63 +/- 2.76 ng/ml, p = 0.0002). Multivariate analysis of F-2-isoprostane levels and selected clinical variables showed a trend toward an inverse association with time after injury (p = 0.0708). Multivariate analysis of NSE levels and selected variables showed a positive association between d1 NSE and F-2-isoprostane (P = 0.0426). CSF F-2-isoprostane increases early after TBI in infants and children and is correlated with NSE, supporting a role for oxidative stress in the evolution of secondary damage early after severe TBI in infants and children.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol & Publ Hlth, Pittsburgh, PA 15260 USA; Penn State Childrens Hosp, Dept Pediat, Div Pediat Crit Care Med, Hershey, PA USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Varma, Sumeeta/0000-0002-6955-2634; Thomas, Neal/0000-0002-7991-7510; Wisniewski, Stephen/0000-0002-3877-9860			Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bayir H, 2001, CRIT CARE MED, V29, pA5; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CHADWICK DL, 1992, PEDIATR ANN, V21, P477, DOI 10.3928/0090-4481-19920801-07; CHENG Y, 1994, NEUROCHEM RES, V19, P1557, DOI 10.1007/BF00969006; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Fujimura M, 1999, J NEUROSCI, V19, P3414; Hall ED, 1996, ACT NEUR S, V66, P107; Ikeda Y, 1990, Adv Neurol, V52, P441; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Marin JG, 2000, NEUROREPORT, V11, P1357, DOI 10.1097/00001756-200004270-00041; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Montine TJ, 1999, NEUROLOGY, V52, P562, DOI 10.1212/WNL.52.3.562; MORRIS HC, 1992, THEOR PSYCHOL, V2, P89, DOI 10.1177/0959354392021005; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Pratico D, 1998, FASEB J, V12, P1777, DOI 10.1096/fasebj.12.15.1777; Proteggente AR, 2002, FREE RADICAL RES, V36, P157, DOI 10.1080/10715760290006475; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; UZAN M, 1995, ACTA NEUROCHIR, V135, P141, DOI 10.1007/BF02187758; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907	38	66	71	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2003	20	8					781	786		10.1089/089771503767870005			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	712BU	WOS:000184777000008	12965056				2022-02-06	
J	Vink, R; O'Connor, CA; Nimmo, AJ; Heath, DL				Vink, R; O'Connor, CA; Nimmo, AJ; Heath, DL			Magnesium attenuates persistent functional deficits following diffuse traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						diffuse axonal injury; magnesium; neurotrauma; deficits	BLOOD; THERAPY; STRESS; ACIDS	Although a number of studies have demonstrated that magnesium improves acute motor and cognitive outcome after traumatic brain injury, others have failed to show positive effects on cognitive outcome and none have examined persistent functional deficits. The present study shows that severe impact-acceleration induced, diffuse traumatic brain injury in rats produced profound motor and cognitive deficits that persisted for at least 4 weeks after trauma. Intravenous administration of magnesium sulfate (250 [mumoles/kg) at 30 min after injury significantly improved rotarod (sensorimotor) and open field (stress/anxiety) performance, and led to a faster rate of recovery in the Barnes maze (learning). We conclude that posttraumatic magnesium administration attenuates long-term motor and cognitive deficits after traumatic brain injury, and that this improvement may include some reduction of post-traumatic stress and anxiety. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld 4811, Australia		Vink, R (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA 5005, Australia.	robert.vink@adelaide.edu.au	Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Nimmo, Alan/0000-0002-0718-7934			ALTURA BM, 1992, J APPL PHYSIOL, V72, P194, DOI 10.1152/jappl.1992.72.1.194; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; COX IM, 1991, LANCET, V337, P757, DOI 10.1016/0140-6736(91)91371-Z; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Galland L, 1991, Magnes Trace Elem, V10, P287; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; HENROTTE JG, 1985, J AM COLL NUTR, V4, P165, DOI 10.1080/07315724.1985.10720073; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Vallee M, 1997, J NEUROSCI, V17, P2626; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink	24	66	70	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 9	2003	336	1					41	44	PII S0304-3940(02)01244-2	10.1016/S0304-3940(02)01244-2			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	636BD	WOS:000180433900011	12493598				2022-02-06	
J	Raivich, G; Liu, ZQ; Kloss, CUA; Labow, M; Bluethmann, H; Bohatschek, M				Raivich, G; Liu, ZQ; Kloss, CUA; Labow, M; Bluethmann, H; Bohatschek, M			Cytotoxic potential of proinflammatory cytokines: combined deletion of TNF receptors TNFR1 and TNFR2 prevents motoneuron cell death after facial axotomy in adult mouse	EXPERIMENTAL NEUROLOGY			English	Article						motoneuron; microglia; phagocytosis; cell death; alphaX beta2; CD11c/CD18 integrin; cytokine receptor	TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; CENTRAL-NERVOUS-SYSTEM; MOTOR NUCLEUS; DEFICIENT MICE; INJURED BRAIN; FACTOR-ALPHA; LYMPHOCYTE RECRUITMENT; NEUROGLIAL ACTIVATION; MICROGLIAL ACTIVATION	Neural injury is known to trigger inflammatory changes, including the synthesis of proinflammatory cytokines such as interleukin-1-beta (IL1beta), tumor necrosis factor-alpha (TNFalpha), and interferon-gamma (IFNgamma) [G. Raivich, L. L. Jones, C. U. A. Kloss, A. Werner, H. Neumann, and G. W. Kreutzberg, 1998, J Neurosci, 18: 5804 -5816] that may play a pivotal role in mediating the cellular response in the affected brain tissue. Here we examined the effects of transgenic deletion of receptors for these cytokines on neuronal cell loss in the adult mouse facial motor nucleus after a peripheral, facial nerve cut. Homozygous deletion of IL1 receptor 1 (ILIRl), TNF receptor 1 or 2 (TNFR1 or TNFR2), or IFNgamma receptor 1 (IFNgammaR1) alone had no effect but combined deletion of TNFR1 and TNFR2 caused a striking absence of alphaX beta2 integrin/IBA1-double-labeled, phagocytic microglial nodules in the axotomized facial motor nucleus 14 days after nerve cut. Moreover, this combined deletion also led to an almost complete prevention of cell loss by Day 29. Additional neuronal cell counts at Day 60 revealed a second phase of motoneuron cell disappearance, which did not depend on the presence of TNF receptors. However, there was still the same 22% difference in the total number of motoneurons between the wild-type and TNFR1 & 2-deficient mice, underlining the role of TNF ligands and both TNF receptors in mediating the early phase of neuronal cell loss after traumatic injury. (C) 2002 Elsevier Science (USA).	UCL, Dept Anat, Dept Obstet & Gynaecol, Perinatal Brain Repair Grp, London WC1E 6HX, England; MPI Neurobiol, Dept Neuromorphol, D-82152 Martinsried, Germany; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland; Hoffmann La Roche Inc, Nutley, NJ 07110 USA		Raivich, G (corresponding author), UCL, Dept Anat, Dept Obstet & Gynaecol, Perinatal Brain Repair Grp, 86-96 Chenies Mews, London WC1E 6HX, England.	g.raivich@ucl.ac.uk	Raivich, Gennadij/A-6770-2011; Raivich, Gennadij/AAL-7229-2021				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Allan SM, 2000, P NATL ACAD SCI USA, V97, P5580, DOI 10.1073/pnas.090464197; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7; Bernardes-Silva M, 2001, J CEREBR BLOOD F MET, V21, P1115, DOI 10.1097/00004647-200109000-00009; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bohatschek M., 1999, Society for Neuroscience Abstracts, V25, P1535; Bohatschek M, 2001, EXP NEUROL, V172, P137, DOI 10.1006/exnr.2001.7764; Bohatschek M, 2001, J NEUROSCI RES, V64, P508, DOI 10.1002/jnr.1103; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FERNANDES KJL, 2000, SOC NEUR ABS, V26; Flugel A, 2001, J NEUROSCI RES, V66, P74, DOI 10.1002/jnr.1198; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; FREI K, 1988, J EXP MED, V168, P449, DOI 10.1084/jem.168.1.449; Galiano M, 2001, EUR J NEUROSCI, V14, P327, DOI 10.1046/j.0953-816x.2001.01647.x; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Kalla R, 2001, J COMP NEUROL, V436, P182; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kloss CUA, 1999, J COMP NEUROL, V411, P162, DOI 10.1002/(SICI)1096-9861(19990816)411:1<162::AID-CNE12>3.0.CO;2-W; Krieglstein K, 2000, NAT NEUROSCI, V3, P1085, DOI 10.1038/80598; Labow M, 1997, J IMMUNOL, V159, P2452; Matsuda S, 1996, NEUROSCI LETT, V204, P109, DOI 10.1016/0304-3940(96)12340-5; MERRILL JE, 1992, P NATL ACAD SCI USA, V89, P574, DOI 10.1073/pnas.89.2.574; Moller JC, 1996, GLIA, V17, P121; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Raivich G, 1998, J NEUROSCI, V18, P5804; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Seilhean D, 1997, ACTA NEUROPATHOL, V93, P508, DOI 10.1007/s004010050646; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Terrado J, 2000, EUR J NEUROSCI, V12, P3443, DOI 10.1046/j.1460-9568.2000.00240.x; TORVIK A, 1971, ACTA NEUROPATHOL, V17, P265, DOI 10.1007/BF00685059; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002	48	66	68	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	DEC	2002	178	2					186	193		10.1006/exnr.2002.8024			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	628HX	WOS:000179988500004	12504878				2022-02-06	
J	McMillan, T; Robertson, IH; Brock, D; Chorlton, L				McMillan, T; Robertson, IH; Brock, D; Chorlton, L			Brief mindfulness training for attentional problems after traumatic brain injury: A randomised control treatment trial	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SEVERE HEAD-INJURY; REHABILITATION; FAILURES; QUESTIONNAIRE; DEFICITS; WORK	A mindfulness meditation technique has been shown to be effective in reducing self-reports of pain and mood disorder in chronic pain patients. Although a pilot study on traumatic brain injury patients showed improvement in self-report of cognitive impairment, a larger scale randomised control treatment trial found no differences on objective or self-report measures of cognitive function, mood or symptom reporting. Brief exposure to mindfulness meditation cannot be recommended as a treatment technique for traumatic brain injury cases.	Univ Glasgow, Glasgow, Lanark, Scotland; Trinity Coll Dublin, Dublin, Ireland; St Georges Healthcare, Wolfson Neurorehabil Ctr, London, England		McMillan, T (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Dept Psychol Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.			Robertson, Ian H/0000-0001-8637-561X			BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Goldberg D., 1988, USERS GUIDE GEN HLTH; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; Kabat-Zinn J., 1987, CLIN J PAIN, V2, P159, DOI [10.1097/00002508-198602030-00004, DOI 10.1097/00002508-198602030-00004]; KABATZINN J, 1993, MINDFULNESS MEDITA 2; KABATZINN J, 1988, J BEHAV MED, V11, P335; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; McMillan TM, 2001, NEUROBEHAVIOURAL DIS; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; Robertson I., 1994, TEST EVERYDAY ATTENT; ROBERTSON IH, 1995, J CLIN EXP NEUROPSYC, V17, P416, DOI 10.1080/01688639508405133; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; Sturm W, 1991, NEUROPSYCHOL REHABIL, V1, P259, DOI DOI 10.1080/09602019108402258; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WILSON C, 1992, NEUROPSYCHOL REHABIL, V2, P193; Wood R L, 1987, Int Disabil Stud, V9, P149; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21; [No title captured]	28	66	68	0	32	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR	2002	12	2					117	125		10.1080/09602010143000202			9	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	535RQ	WOS:000174660400003					2022-02-06	
J	Fujii, D; Ahmed, I				Fujii, D; Ahmed, I			Characteristics of psychotic disorder due to traumatic brain injury: An analysis of case studies in the literature	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							HEAD-INJURY; REDUPLICATIVE PARAMNESIA; COMPUTERIZED-TOMOGRAPHY; CHRONIC-SCHIZOPHRENIA; CAPGRAS SYNDROME; SEX-DIFFERENCES; EPILEPSY; DAMAGE; MISIDENTIFICATION; PREVALENCE	The authors analyzed data from 69 published case studies of Psychotic Disorder Due to Traumatic Brain Injury (PDTBI) in order to describe its common characteristics and assist in its diagnosis and differentiation from schizophrenia. The majority of these PDTBI patients were males with onset of symptoms occurring within the first 2 years after moderate to severe head injury. A majority showed abnormalities on MRI/CT and EEG with localization in the frontal and temporal areas. The general presentation included delusions and hallucinations without co-occurring negative symptoms. The findings demonstrate that patients with PDTBI have a profile that distinguishes itself front schizophrenia.	Hawaii State Hosp, Dept Neuropsychol, Kaneohe, HI 96744 USA		Fujii, D (corresponding author), Hawaii State Hosp, Dept Neuropsychol, Kaneohe, HI 96744 USA.	defujii@hsh.health.state.hi.us					ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Ahmed I, 1998, Semin Clin Neuropsychiatry, V3, P23; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAMRAH JS, 1991, BRIT J PSYCHIAT, V158, P117, DOI 10.1192/bjp.158.1.117; BARNHILL LJ, 1989, NEUROPSY NEUROPSY BE, V2, P211; BASSO A, 1982, CORTEX, V18, P469, DOI 10.1016/S0010-9452(82)80044-0; BENSON DF, 1990, SCHIZOPHRENIA BULL, V16, P403, DOI 10.1093/schbul/16.3.403; BIENENFELD D, 1989, J CLIN PSYCHIAT, V50, P68; BOUVY PF, 1988, ACTA PSYCHIAT SCAND, V77, P361, DOI 10.1111/j.1600-0447.1988.tb05136.x; BREIER A, 1991, ARCH GEN PSYCHIAT, V48, P239; BUCKLEY P, 1993, AM J PSYCHIAT, V150, P146; Burg JS, 1996, J CLIN PSYCHOL MED S, V3, P243, DOI 10.1007/BF01993910; CAZZULLO CL, 1989, PSYCHIAT RES, V29, P257, DOI 10.1016/0165-1781(89)90055-3; COHEN MAA, 1994, GEN HOSP PSYCHIAT, V16, P141, DOI 10.1016/0163-8343(94)90060-4; Cummings J, 1985, CLIN NEUROPSYCHIATRY; DALBY JT, 1989, NEUROPSY NEUROPSY BE, V2, P306; DAVISON K, 1969, BRIT J PSYCHIAT, V114, P113; DOLINAR LJ, 1991, PSYCHOSOMATICS, V32, P460, DOI 10.1016/S0033-3182(91)72054-9; DRAKE ME, 1988, PSYCHIAT J U OTTAWA, V13, P36; FEINSTEIN A, 1990, PSYCHOL MED, V20, P793, DOI 10.1017/S0033291700036485; FENTON WS, 1996, HDB MENTAL HLTH EC H, V1, P79; FILLEY CM, 1987, NEUROLOGY, V37, P701, DOI 10.1212/WNL.37.4.701; Fujii DEM, 1996, NEUROPSY NEUROPSY BE, V9, P133; GEREZ M, 1995, BIOL PSYCHIAT, V38, P34, DOI 10.1016/0006-3223(94)00205-H; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; GUR RC, 1982, SCIENCE, V217, P659, DOI 10.1126/science.7089587; HAYMAN MA, 1977, BRIT J PSYCHIAT, V130, P68, DOI 10.1192/bjp.130.1.68; Hillbom E., 1960, ACTA PSYCHIATRICA S, VS142, P1; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; IKEMURA Y, 1987, FUNCT NEUROL, V11, P87; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; KENDLER KS, 1982, AM J PSYCHIAT, V139, P1557; KOUFEN DI, 1987, EUR ARCH PSY NEUR SC, V237, P2; LEVINE DN, 1982, NEUROLOGY, V32, P267, DOI 10.1212/WNL.32.3.267; Levy J., 1992, HDB BEHAVIORAL NEURO, P245; LEWIS SW, 1990, BRIT J PSYCHIAT, V157, P16, DOI 10.1192/S0007125000291824; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LOYD DW, 1981, J CLIN PSYCHIAT, V42, P246; MARSHALL JC, 1995, CORTEX, V31, P183, DOI 10.1016/S0010-9452(13)80116-5; McCarley RW, 1999, BIOL PSYCHIAT, V45, P1099, DOI 10.1016/S0006-3223(99)00018-9; MCKENNA PJ, 1985, AM J PSYCHIAT, V142, P895; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Murai T, 1997, NEUROPSY NEUROPSY BE, V10, P190; NASRALLAH HA, 1983, J CLIN PSYCHIAT, V44, P407; NASRALLAH HA, 1981, PSYCHOSOMATICS, V22, P359; NASRALLAH HA, 1992, TXB NEUROPSYCHIATRY, P621; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; OConnor M, 1996, NEUROPSY NEUROPSY BE, V9, P265; OWENS DGC, 1980, J NEUROL NEUROSUR PS, V43, P1065, DOI 10.1136/jnnp.43.12.1065; Pearlson GD, 1999, BIOL PSYCHIAT, V46, P627, DOI 10.1016/S0006-3223(99)00071-2; PIZZAMIGLIO L, 1985, BRAIN LANG, V25, P213, DOI 10.1016/0093-934X(85)90081-1; PRIGATANO GP, 1988, J HEAD TRAUMA REHAB, V3, P23; PURI BK, 1994, BRIT J PSYCHIAT, V164, P841, DOI 10.1192/bjp.164.6.841; ROGERS M J C, 1992, Brain Injury, V6, P469, DOI 10.3109/02699059209008142; Sabhesan S, 1988, Indian J Psychiatry, V30, P39; Sabhesan S, 1988, Indian J Psychiatry, V30, P177; Sabhesan S, 1990, Indian J Psychiatry, V32, P180; SACCHETTI E, 1992, BRIT J PSYCHIAT, V160, P390, DOI 10.1192/bjp.160.3.390; SANDEL ME, 1993, BRAIN INJURY, V7, P77, DOI 10.3109/02699059309008159; SIGNER SF, 1987, BRIT J PSYCHIAT, V151, P402, DOI 10.1192/bjp.151.3.402; SILVA JA, 1993, CAN J PSYCHIAT, V38, P239, DOI 10.1177/070674379303800401; SILVA JA, 1989, CAN J PSYCHIAT, V34, P728, DOI 10.1177/070674378903400719; STATON RD, 1982, CORTEX, V18, P23, DOI 10.1016/S0010-9452(82)80016-6; TISHER PW, 1993, HARVARD REV PSYCHIAT, V1, P219, DOI 10.3109/10673229309017082; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; VITA A, 1991, AM J PSYCHIAT, V148, P1577; VITA A, 1988, SCHIZOPHR RES, V1, P329, DOI 10.1016/0920-9964(88)90046-1; WALDFOGEL S, 1994, BRAIN INJURY, V8, P377, DOI 10.3109/02699059409150988; WESTON MJ, 1971, BRIT J PSYCHIAT, V119, P25, DOI 10.1192/bjp.119.548.25; WHITE AC, 1987, BRIT J PSYCHIAT, V150, P692, DOI 10.1192/bjp.150.5.692; WILL RG, 1988, BRIT J PSYCHIAT, V152, P410, DOI 10.1192/bjp.152.3.410; YOUNG AW, 1992, PSYCHOL MED, V22, P799, DOI 10.1017/S003329170003823X	74	66	68	1	6	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2002	14	2					130	140		10.1176/appi.neuropsych.14.2.130			11	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	555JB	WOS:000175790000002	11983787				2022-02-06	
J	Dash, PK; Mach, SA; Moore, AN				Dash, PK; Mach, SA; Moore, AN			The role of extracellular signal-regulated kinase in cognitive and motor deficits following experimental traumatic brain injury	NEUROSCIENCE			English	Article						spatial memory; plasticity; hippocampus; conditioned emotional response; mitogen-activated protein kinase; brain injury	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; SPATIAL MEMORY; CELL-DEATH; RAT HIPPOCAMPUS; IN-VIVO; ACTIVATION; NEUROPROTECTION; INHIBITION; CASCADE	Traumatic brain injury (TBI) causes neuronal death and alters the plasticity (e.g. morphology) of surviving neurons. Both of these events contribute to TBI-associated neurological deficits, such as memory dysfunction. Although a majority of current research is directed towards identifying biochemical cascades responsible for cell death, little is known about mechanisms of altered neuronal plasticity following TBI. Extracellular signal-regulated kinases (Erk1 and 2) play a critical role in growth and have been implicated in long-lasting neuronal plasticity and memory storage. The activation of Erk following TBI was investigated utilizing an antibody that specifically binds to dually phosphorylated Erk. Using this antibody, we report that lateral cortical impact injury in rats increases Erk phosphorylation both in the cortex and the hippocampus as early as 10 min post-injury. Double immunostaining experiments using either a neuron-specific or an astroglial-specific marker show that the active Erk is localized almost exclusively in neuronal cells. Furthermore, the increase in phospho-Erk immunoreactivity was initially localized to axons and at later time points was observed to be predominantly in the cell soma. This suggests that Erk redistributed over time and may play a role in retrograde signaling. Administration of inhibitors of the Erk cascade worsened retrograde amnesia, impaired performances in hippocampus- and amygdala-dependent memory tasks, and exacerbated motor deficits following TBI. Furthermore, inhibition of this cascade did not have any overt effects on cell survival, but altered neuronal morphology as detected by a dendritic-specific marker. These findings suggest that the Erk cascade plays an essential role for the maintenance of neuronal function and plasticity following TBI. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, POB 20708, Houston, TX 77225 USA.				NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49662] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS3545, P50NS23327] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH049662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS023327] Funding Source: NIH RePORTER		Alberini CM, 1999, J EXP BIOL, V202, P2887; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ambron RT, 1996, MOL NEUROBIOL, V13, P61, DOI 10.1007/BF02740752; Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BARNES CA, 1994, J NEUROSCI, V14, P5793; Blum S, 1999, J NEUROSCI, V19, P3535; Bunsey M, 1996, NATURE, V379, P255, DOI 10.1038/379255a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; D'Onofrio M, 2001, J NEUROCHEM, V78, P435, DOI 10.1046/j.1471-4159.2001.00435.x; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; KLANN E, 1991, J BIOL CHEM, V266, P24253; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NEWLON PG, 1991, BRAIN RES, V544, P320, DOI 10.1016/0006-8993(91)90072-4; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; Satoh T, 2000, NEUROSCI LETT, V288, P163, DOI 10.1016/S0304-3940(00)01229-5; Schafe GE, 2000, J NEUROSCI, V20, P8177; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Sung YJ, 2001, J NEUROBIOL, V47, P67, DOI 10.1002/neu.1016; SUZUKI WA, 1993, J NEUROSCI, V13, P2430, DOI 10.1523/JNEUROSCI.13-06-02430.1993; Valjent E, 2000, J NEUROSCI, V20, P8701; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	47	66	68	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	114	3					755	767	PII S0306-4522(02)00277-4	10.1016/S0306-4522(02)00277-4			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	601GZ	WOS:000178439300022	12220576				2022-02-06	
J	Boddeke, EWGM				Boddeke, EWGM			Involvement of chemokines in pain	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article; Proceedings Paper	Spring Meeting of the European-Journal-of-Pharmacology	JUN 08-10, 2001	ZEIST, NETHERLANDS	European Journal Pharmacol		chemokine; nociception; hyperalgesia; inflammation	RECEPTOR EXPRESSION; CNS; HYPERALGESIA; INFLAMMATION; ACTIVATION; NOCICEPTIN; CYTOKINES; CELLS; NEUROINFLAMMATION; INTERLEUKIN-8	It is well established that neuroinflammation plays an important role in neurodegenerative diseases like Alzheimer's disease, stroke, traumatic brain- and spinal cord injury and demyelinating diseases. Likewise, it has been suggested that neuroinflammation plays an important role in nociception and hyperalgesia. Most research concerning inflammatory aspects of pain has concerned the effects of proinflammatory cytokines, prostaglandins and growth factors. Recently, it has been suggested that chemokines play a role in inflammatory pain. Chemokines do not only attract blood leukocytes to the site of injury but also contribute directly to nociception. (C) 2001 Published by Elsevier Science B.V.	Univ Groningen, Dept Med Physiol, NL-9713 AV Groningen, Netherlands		Boddeke, EWGM (corresponding author), Univ Groningen, Dept Med Physiol, A Deusinglaan 1,Bld 3125, NL-9713 AV Groningen, Netherlands.	h.w.g.m.boddeke@med.rug.nl					ANTONY VB, 1985, J CLIN INVEST, V76, P1514, DOI 10.1172/JCI112131; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Bacon KB, 2000, J NEUROIMMUNOL, V104, P92, DOI 10.1016/S0165-5728(99)00266-0; Boom A, 1999, NEUROSCIENCE, V91, P991, DOI 10.1016/S0306-4522(98)00683-6; CLATWORTHY AL, 1995, NEUROSCI LETT, V184, P5, DOI 10.1016/0304-3940(94)11154-B; CUNHA FQ, 1991, BRIT J PHARMACOL, V107, P660; DEGROOT CJA, 2001, PROG BRAIN RES, V132, P543; DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5; Gazvani MR, 1998, HUM REPROD, V13, P1957, DOI 10.1093/humrep/13.7.1957; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Hochreiter WW, 2000, UROLOGY, V56, P1025, DOI 10.1016/S0090-4295(00)00844-X; Huber JD, 2001, AM J PHYSIOL-HEART C, V280, pH1241, DOI 10.1152/ajpheart.2001.280.3.H1241; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Laughlin TM, 2000, PAIN, V84, P159, DOI 10.1016/S0304-3959(99)00195-5; Limatola C, 2000, EUR J NEUROSCI, V12, P2497, DOI 10.1046/j.1460-9568.2000.00139.x; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Mark KS, 1999, LIFE SCI, V64, P1941, DOI 10.1016/S0024-3205(99)00139-3; Mennicken F, 1999, TRENDS PHARMACOL SCI, V20, P73, DOI 10.1016/S0165-6147(99)01308-5; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Miller DW, 1999, J NEUROVIROL, V5, P570, DOI 10.3109/13550289909021286; Mizumura K, 1996, PROG BRAIN RES, V113, P115, DOI 10.1016/S0079-6123(08)61084-5; Murphy PM, 2000, PHARMACOL REV, V52, P145; Noda Y, 1998, J BIOL CHEM, V273, P18047, DOI 10.1074/jbc.273.29.18047; Oh SB, 2001, J NEUROSCI, V21, P5027, DOI 10.1523/JNEUROSCI.21-14-05027.2001; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Ramer MS, 1997, PAIN, V72, P71, DOI 10.1016/S0304-3959(97)00019-5; RANG HP, 1991, BRIT MED BULL, V47, P534, DOI 10.1093/oxfordjournals.bmb.a072491; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Ribeiro RA, 2000, EUR J PHARMACOL, V387, P111, DOI 10.1016/S0014-2999(99)00790-6; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Serhan CN, 2001, J IMMUNOL, V166, P3650, DOI 10.4049/jimmunol.166.6.3650; Sommer C, 1998, PAIN, V74, P83, DOI 10.1016/S0304-3959(97)00154-1; SOUZA GEP, 1988, AGENTS ACTIONS, V24, P377, DOI 10.1007/BF02028296; Sweitzer SM, 1999, BRAIN RES, V829, P209, DOI 10.1016/S0006-8993(99)01326-8; TAIWO YO, 1990, BRAIN RES, V537, P372, DOI 10.1016/0006-8993(90)90389-S; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; Wagner G, 1998, INT J IMPOT RES, V10, P74, DOI 10.1038/sj.ijir.3900335; WAGNER R, 1995, EXP NEUROL, V133, P256, DOI 10.1006/exnr.1995.1028; Wagner R, 1996, NEUROSCIENCE, V73, P625, DOI 10.1016/0306-4522(96)00127-3; Wagner R, 1996, NEUROREPORT, V7, P2897, DOI 10.1097/00001756-199611250-00018; Watkins LR, 1997, PAIN, V71, P225, DOI 10.1016/S0304-3959(97)03369-1; Watkins LR, 1995, PAIN, V63, P289, DOI 10.1016/0304-3959(95)00186-7; Wong D, 1999, J NEUROPATH EXP NEUR, V58, P138, DOI 10.1097/00005072-199902000-00004; Woolf CJ, 1997, BRIT J PHARMACOL, V121, P417, DOI 10.1038/sj.bjp.0701148; Wu DT, 2000, J NEUROVIROL, V6, pS82	53	66	67	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	OCT 19	2001	429	1-3			SI		115	119		10.1016/S0014-2999(01)01311-5			5	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pharmacology & Pharmacy	495UP	WOS:000172359000012	11698032				2022-02-06	
J	Curtiss, G; Vanderploeg, RD; Spencer, J; Salazar, AM				Curtiss, G; Vanderploeg, RD; Spencer, J; Salazar, AM			Patterns of verbal learning and memory in traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI; memory deficits; consolidation; retention; retrieval; CVLT	EPISODIC MEMORY; RETRIEVAL; COMA	CVLT and WMS-R Digit Span variables were used to calculate indexes of seven specific short- and long-term memory processes: working memory span and central executive functions, and long-term memory encoding, consolidation, retention. retrieval, control abilities. Scores on these indexes were then cluster-analyzed to determine whether subtypes of memory performance exist that correspond to deficits in these theoretical memory constructs. Parallel analyses were conducted with two large samples (N = 150 and N = 151) of individuals who had sustained a traumatic brain injury (TBI). Findings showed that TBI results in subgroups of memory disorders with specific deficits in consolidation, retention, and retrieval processes. Control problems (keeping track of list versus non-list items) only appeared in conjunction with retrieval deficits. Working memory span and central executive functioning (i.e., the ability to manipulate information in working memory) do not appear to be deficits characteristic of TBI as no such clusters emerged in the analyses. By using specific indexes of memory processes, and in contrast to previous studies, patterns of memory dysfunction were found that correspond to deficits in theoretically meaningful memory constructs.	James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA; Univ S Florida, Tampa, FL USA; Henry M Jackson Fdn, Rockville, MD USA; Univ S Florida, Tampa, FL USA; Henry M Jackson Fdn, Rockville, MD USA		Curtiss, G (corresponding author), James A Haley Vet Adm Med Ctr, Phys Med & Rehabil 117,13000 N Bruce B Downs Blvd, Tampa, FL 33612 USA.		Curtiss, Glenn/ABB-5566-2020				ALBERT M S, 1981, Journal of Clinical Neuropsychology, V3, P1, DOI 10.1080/01688638108403109; Baddeley A. D., 1976, PSYCHOL MEMORY; BENTON AL, 1989, MULTINGUAL APHASIA; Blashfield R.K., 1984, CLUSTER ANAL; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Calinski TT., 1974, COMMUN STAT, V3, P1, DOI 10.1080/03610927408827101; CERMAK LS, 1972, NEUROPSYCHOLOGIA, V10, P89, DOI 10.1016/0028-3932(72)90045-0; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; DELIS D, 1987, CALIFORNIA VERBAL LE; DELIS DC, 1988, J CONSULT CLIN PSYCH, V56, P123, DOI 10.1037/0022-006X.56.1.123; Delis DC, 1991, CLIN NEUROPSYCHOL, V5, P154; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; Duda R.O., 1973, PATTERN CLASSIFICATI; FRIDLUND AJ, 1987, IBM USERS GUIDE CVTL; Golden CJ, 1978, STROOP COLOR WORD TE; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Heaton PDRK., 1993, WISCONSIN CARD SORTI; KAPUR S, 1995, NEUROREPORT, V6, P1880, DOI 10.1097/00001756-199510020-00014; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levin HS., 1982, NEUROBEHAVIORAL CONS; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Nyberg L, 1996, NATURE, V380, P715, DOI 10.1038/380715a0; Randolph C., 1993, NEUROPSYCHOLOGY, V7, P82, DOI [10.1037/0894-4105.7.1.82, DOI 10.1037/0894-4105.7.1.82]; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sane W. S., 1983, A108 SAS; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2016, DOI 10.1073/pnas.91.6.2016; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; [No title captured]	35	66	66	0	6	CAMBRIDGE UNIV PRESS	PORT CHESTER	110 MIDLAND AVE, PORT CHESTER, NY 10573-9863 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2001	7	5					574	585		10.1017/S1355617701755051			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	451XM	WOS:000169827900005	11459109				2022-02-06	
J	Niskakangas, T; Ohman, J; Niemela, M; Ilveskoski, E; Kunnas, TA; Karhunen, PJ				Niskakangas, T; Ohman, J; Niemela, M; Ilveskoski, E; Kunnas, TA; Karhunen, PJ			Association of apolipoprotein E polymorphism with outcome after aneurysmal subarachnoid hemorrhage - A preliminary study	STROKE			English	Article						apolipoproteins; genetics; outcome; subarachnoid hemorrhage	E EPSILON-4 ALLELE; ALZHEIMERS-DISEASE; E IMMUNOREACTIVITY; INTRACEREBRAL HEMORRHAGE; CEREBRAL-ISCHEMIA; TERM SURVIVAL; BRAIN INJURY; BETA-PROTEIN; HEAD-INJURY; POPULATION	Background and Purpose-Variation in the outcome after aneurysmal subarachnoid hemorrhage (SAH) is not fully explained by known prognostic factors. APOE genotype is the most important genetic determinant of susceptibility to Alzheimer's disease, and it is also shown to be associated with the outcome after traumatic brain injury. We studied the association of apolipoprotein E polymorphism with the outcome after aneurysmal SAH. Methods-A total of 160 consecutive patients were admitted after SAH to a neurosurgical unit. The clinical assessment after the SAH was performed with the Hunt and Hess grading scale. The severity of the bleeding as visualized on CT was assessed by Fisher's grading system, Outcome was assessed with the Glasgow Outcome Scale. APOE genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism. Results-126 patients had aneurysmatic SAH, and detailed information on outcome and APOE genotype was available for 108 patients (86%). Sixteen (40%) of 40 patients with APOE epsilon4 had an unfavorable outcome compared with 13 (19%) of 68 without the APOE epsilon4 allele (OR 2.8, 95% CI 1.18 to 6.77). Association was more significant after adjustment for age, rebleeding, clinical status on admission, and CT scan findings (OR 7.1, 95% CI 1.9 to 26.3; P=0.0035). Conclusions-Our findings show a significant genetic association of APOE polymorphism with outcome after spontaneous aneurysmal SAH, Genetic factors thus seem to explain a part of individual differences in the recovery of SAH,	Univ Helsinki, Cent Hosp, Dept Neurosurg, FIN-00260 Helsinki, Finland; Univ Tampere, Dept Forens Med, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Univ Kuopio, Dept Clin Pathol & Forens Med, Kuopio, Finland		Niskakangas, T (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurosurg, Topeliuksenkatu 5, FIN-00260 Helsinki, Finland.		Niemela, Mika R/F-2539-2015	Niemela, Mika R/0000-0003-1526-0684; Ohman, Juha/0000-0002-6592-1367; Kunnas, Tarja/0000-0002-9647-642X			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; EHNHOLM C, 1986, J LIPID RES, V27, P227; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FOGELHOLM R, 1981, STROKE, V12, P296, DOI 10.1161/01.STR.12.3.296; FOGELHOLM R, 1993, STROKE, V24, P1649, DOI 10.1161/01.STR.24.11.1649; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HIXSON JE, 1990, J LIPID RES, V31, P545; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1996, ALZHEIMER RES, V2, P37; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Ilveskoski E, 1998, J NEUROSCI METH, V79, P5, DOI 10.1016/S0165-0270(97)00157-X; INAGAWA T, 1995, STROKE, V26, P761, DOI 10.1161/01.STR.26.5.761; Jakobsson KE, 1996, J NEUROSURG, V85, P995, DOI 10.3171/jns.1996.85.6.0995; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KASSELL NF, 1990, J NEUROSURG, V73, P37, DOI 10.3171/jns.1990.73.1.0037; KIDA E, 1995, BRAIN RES, V674, P341, DOI 10.1016/0006-8993(94)01467-V; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; LONGSTRETH WT, 1993, NEUROLOGY, V43, P712, DOI 10.1212/WNL.43.4.712; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Neil-Dwyer G, 1998, ACTA NEUROCHIR, V140, P1019, DOI 10.1007/s007010050210; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PHILLIPS LH, 1980, NEUROLOGY, V30, P1034, DOI 10.1212/WNL.30.10.1034; Pluta R, 1997, NEUROSCI LETT, V232, P95, DOI 10.1016/S0304-3940(97)00571-5; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; SACCO RL, 1984, NEUROLOGY, V34, P847, DOI 10.1212/WNL.34.7.847; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHIEVINK WI, 1995, NEUROLOGY, V45, P871, DOI 10.1212/WNL.45.5.871; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Wijdicks EFM, 1998, MAYO CLIN PROC, V73, P745, DOI 10.4065/73.8.745; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423	42	66	73	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAY	2001	32	5					1181	1184		10.1161/01.STR.32.5.1181			4	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	430MG	WOS:000168577200028	11340230	Bronze			2022-02-06	
J	Lu, J; Moochhala, S; Kaur, C; Ling, EA				Lu, J; Moochhala, S; Kaur, C; Ling, EA			Changes in apoptosis-related protein (p53, Bax, Bcl-2 and Fos) expression with DNA fragmentation in the central nervous system in rats after closed head injury	NEUROSCIENCE LETTERS			English	Article						closed head injury; apoptosis; transferase d-UTP nick-end labelling; Bax; Bl-2; p53; Fos; rat	CELL-DEATH; BRAIN INJURY; C-FOS; IN-VIVO; DAMAGE; INVOLVEMENT; NEURONS	This study aimed to examine the temporal profile of neuronal apoptosis in the central nervous system (CNS) following closed head injury in rat. Fos immunoreactivity was detected in neuronal nuclei in the cerebral cortex at 2 h after head injury. At 4 h, Bax protein expression was elevated with a concomitant down-regulation of Bcl-2 expression. Along with this, a marked immunoexpression of p53 was also observed in these cells. Double immunolabelling study has shown the colocalization of Bax immunoreactivity with Bcl-2 and p53. In rats killed 1 day after injury, a variable number of transferase d-UTP nick-end labelling positive cells were observed. Present findings suggest that the upregulation of p53 and a shift in the ratio of Bcl-2 to Bax may contribute to neuronal apoptosis in the CNS after closed head injury. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Def Med Res Inst, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 119260, Singapore		Lu, J (corresponding author), Def Med Res Inst, 18 Med Dr,01-06,MD2, Singapore 117597, Singapore.			MOOCHHALA, SHABBIR/0000-0003-4521-3192			Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morrison RS, 1996, J NEUROSCI, V16, P1337; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Rich KA, 1997, J NEUROBIOL, V32, P593, DOI 10.1002/(SICI)1097-4695(19970605)32:6<593::AID-NEU5>3.0.CO;2-V; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Xiang H, 1998, J NEUROSCI, V18, P1363	16	66	75	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	AUG 25	2000	290	2					89	92		10.1016/S0304-3940(00)01307-0			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	347RL	WOS:000088942900002	10936684				2022-02-06	
J	Huang, ME; Cifu, DX; Keyser-Marcus, L				Huang, ME; Cifu, DX; Keyser-Marcus, L			Functional outcomes in patients with brain tumor after inpatient rehabilitation - Comparison with traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						rehabilitation; function; outcome; brain tumor; traumatic brain injury	STROKE REHABILITATION; CANCER-PATIENT; EFFICACY	Objective: To compare the functional outcome, length of stay, and discharge disposition of individuals with brain tumor versus those with acute traumatic brain injury. Design: In this study, 78 brain tumor patients were one-to-one matched by location of lesion and age with 78 acute traumatic brain injury patients. Outcome was measured by using the Functional Independence Measure (FIM 228) on admission and discharge. The FIM change and FIM efficiency were also calculated. FIM data were analyzed in three subsets, i.e., activities of daily living, mobility, and cognition. Discharge disposition and rehabilitation length of stay were also compared. Results: Demographic variables of race, marital status, and payer source were comparable for the two groups. No significant difference was found between the brain tumor and the traumatic brain injury populations with respect to total admission FIM, total discharge FIM, and FIM efficiency. The brain injury population had a significantly greater change in FIM. The tumor group had a significantly shorter rehabilitation length of stay and a greater discharge to community rate. Conclusions: Thus, individuals with brain tumor can achieve comparable functional outcome and have a shorter rehabilitation length of stay and greater discharge to community rate than individuals with brain injury.	Virginia Commonwealth Univ, Med Coll Virginia Hosp, Dept Phys Med & Rehabil, Rehabil & Res Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia Hosp, Rehabil & Res Training Ctr Support Employment, Dept Phys Med & Rehabil, Richmond, VA 23298 USA		Huang, ME (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia Hosp, Dept Phys Med & Rehabil, Rehabil & Res Ctr, POB 980661, Richmond, VA 23298 USA.			Cifu, David/0000-0003-1600-9387; Keyser-Marcus, Lori/0000-0001-6014-2500			ALEXANDER MP, 1994, STROKE, V25, P128, DOI 10.1161/01.STR.25.1.128; ANDERSON TP, 1974, ARCH PHYS MED REHAB, V55, P545; Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS37, DOI 10.1016/S0003-9993(98)90120-4; Bloomfield SS., 1991, NEUROREHABILITATION, V1, P39, DOI 10.3233/NRE-1991-1206; Bontke CF, 1996, PHYS MED REHABILITAT, P1027; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; CIFU DX, 1994, ARCH PHYS MED REHAB, V75, P56; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Garden FH, 1996, PHYSICAL MED REHABIL, P1199; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; Huang ME, 1998, ARCH PHYS MED REHAB, V79, P1386, DOI 10.1016/S0003-9993(98)90232-5; IMPERATO JP, 1990, ANN NEUROL, V28, P818, DOI 10.1002/ana.410280614; Karnofsky D.A., 1949, EVALUATION CHEMOTHER, P191; KEITH RA, 1987, ADV CLIN REHABILITAT, V2, P6; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LEHMANN JF, 1975, ARCH PHYS MED REHAB, V56, P375; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Marciniak CM, 1996, ARCH PHYS MED REHAB, V77, P54, DOI 10.1016/S0003-9993(96)90220-8; McKinley WO, 1996, ARCH PHYS MED REHAB, V77, P892, DOI 10.1016/S0003-9993(96)90276-2; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, P1530, DOI 10.1016/S0003-9993(98)90414-2; Patchell RA, 1998, JAMA-J AM MED ASSOC, V280, P1485, DOI 10.1001/jama.280.17.1485; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Sherer M, 1997, CANCER, V80, P250, DOI 10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; YOSHIOKA H, 1994, AM J PHYS MED REHAB, V73, P199, DOI 10.1097/00002060-199406000-00009; 1995, GUIDE UNIFORM DATA S	29	66	66	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL-AUG	2000	79	4					327	335		10.1097/00002060-200007000-00003			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	329HY	WOS:000087902600003	10892618				2022-02-06	
J	Johanson, CE; Palm, DE; Primiano, MJ; McMillan, PN; Chan, P; Knuckey, NW; Stopa, EG				Johanson, CE; Palm, DE; Primiano, MJ; McMillan, PN; Chan, P; Knuckey, NW; Stopa, EG			Choroid plexus recovery after transient forebrain ischemia: Role of growth factors and other repair mechanisms	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						choroidal epithelium; lateral ventricle; cerebrospinal fluid (CSF); blood-CSF barrier; choroid plexus reperfusion injury; necrosis; epithelial restitution; growth factors and brain repair; autocrine; paracrine; CSF bulk flow; hippocampus	CEREBROSPINAL-FLUID FORMATION; RAT-BRAIN; MESSENGER-RNA; FACTOR-BETA; IMMUNOHISTOCHEMICAL LOCALIZATION; RECEPTOR IMMUNOREACTIVITY; INSITU HYBRIDIZATION; CEREBRAL-ISCHEMIA; CHLORIDE EFFLUX; ANGIOTENSIN-II	1. Transient forebrain ischemia in adult rats, induced by 10 min of bilateral carotid occlusion and an arterial hypotension of 40 mmHg, caused substantial damage not only to CA-1 neurons in hippocampus but also to epithelial cells in lateral ventricle choroid plexus. 2 When transient forebrain ischemia was followed by reperfusion (recovery) intervals of 0 to 12 hr, there was moderate to severe damage to many frond regions of the choroidal epithelium. In some areas, epithelial debris was sloughed into cerebrospinal fluid (CSF). Although some epithelial cells were disrupted and necrotic, their neighbors exhibited normal morphology. This patchy response to ischemia was probably due to regional differences in reperfusion or cellular metabolism. 3. Between 12 and 24 hr postischemia, there was marked restoration of the Na+, K+, water content, and ultrastructure of the choroid plexus epithelium. Since there was no microscopical evidence for mitosis, we postulate that healthy epithelial cells either were compressed together on the villus or migrated from the choroid plexus stalk to more distal regions, in order to "fill in gaps" along the basal lamina caused by necrotic epithelial cell disintegration. 4. Epithelial cells of mammalian choroid plexus synthesize and secrete many growth factors and other peptides that are of trophic benefit following injury to regions of the cerebroventricular system. For example, several growth factors are upregulated in choroid plexus after ischemic and traumatic insults to the central nervous system. 5. The presence of numerous types of growth factor receptors in choroid plexus allows growth factor mediation of recovery processes by autocrine and paracrine mechanisms. 6. The capability of choroid plexus after acute ischemia to recover its barrier and CSF formation functions is an important factor in stabilizing brain fluid balance. 7. Moreover, growth factors secreted by choroid plexus into CSF are distributed by diffusion and convection into brain tissue near the ventricular system, e.g., hippocampus. By this endocrine-like mechanism, growth factors are conveyed throughout the choroid plexus-CSF-brain nexus and can consequently promote repair of ischemia-damaged tissue in the ventricular wall and underlying brain.	Brown Univ, Rhode Isl Hosp, Dept Clin Neurosci, Providence, RI 02903 USA; Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Tallahassee, FL 32307 USA; Brown Univ, Rhode Isl Hosp, Dept Pathol, Providence, RI 02903 USA; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Neurosurg, Nedlands, WA 6009, Australia		Johanson, CE (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Clin Neurosci, 593 Eddy St, Providence, RI 02903 USA.	Conrad_Johanson@Brown.edu		Johanson, Conrad/0000-0002-1297-5484	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27601, NS/AG-91-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027601] Funding Source: NIH RePORTER		BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BASKIN DG, 1988, TRENDS NEUROSCI, V11, P107, DOI 10.1016/0166-2236(88)90155-5; BLOCH B, 1992, DEV BRAIN RES, V70, P267, DOI 10.1016/0165-3806(92)90206-C; BOHANNON NJ, 1988, BRAIN RES, V444, P205, DOI 10.1016/0006-8993(88)90931-6; CHALAZONITIS A, 1992, DEV BIOL, V152, P121, DOI 10.1016/0012-1606(92)90162-A; Chodobski A, 1997, MOL BRAIN RES, V48, P67, DOI 10.1016/S0169-328X(97)00079-X; CHODOBSKI A, 1994, REGUL PEPTIDES, V53, P123, DOI 10.1016/0167-0115(94)90613-0; Cortez S., 1995, Society for Neuroscience Abstracts, V21, P741; CUEVAS P, 1994, NEUROL RES, V16, P310; DIAZRUIZ C, 1993, NEUROSCI LETT, V164, P44, DOI 10.1016/0304-3940(93)90853-D; ENDOH M, 1994, MOL BRAIN RES, V22, P76, DOI 10.1016/0169-328X(94)90034-5; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; GARNER C, 1992, BRAIN RES, V591, P137, DOI 10.1016/0006-8993(92)90988-L; Gillardon F, 1996, NEUROSCI LETT, V207, P113, DOI 10.1016/0304-3940(96)12508-8; GLAUMANN B, 1977, VIRCHOWS ARCH B, V24, P1; GOSPODAROWICZ D, 1975, J CELL BIOL, V66, P451, DOI 10.1083/jcb.66.2.451; HOLLOWAY LS, 1972, AM J PHYSIOL, V223, P499; HYNES MA, 1988, MOL ENDOCRINOL, V2, P47, DOI 10.1210/mend-2-1-47; IKEDA J, 1992, NEUROSCI LETT, V142, P257, DOI 10.1016/0304-3940(92)90386-L; Johanson C, 1993, PHARM BIOTECHNOLOGY, V5, P467; JOHANSON CE, 1990, AM J PHYSIOL, V258, pF1538, DOI 10.1152/ajprenal.1990.258.6.F1538; JOHANSON CE, 1978, J PHYSIOL-LONDON, V275, P167, DOI 10.1113/jphysiol.1978.sp012183; JOHANSON CE, 1974, J PHYSIOL-LONDON, V241, P359, DOI 10.1113/jphysiol.1974.sp010660; JOHANSON CE, 1989, IMPLICATIONS BLOOD B, V1, P101; JOHANSON CE, 1998, INTRO BLOOD BRAIN BA, P259; JOHNSON NF, 1978, EXP EYE RES, V27, P45, DOI 10.1016/0014-4835(78)90052-0; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; Knuckey NW, 1996, MOL BRAIN RES, V40, P1; KNUCKEY NW, 1995, STROKE, V26, P305, DOI 10.1161/01.STR.26.2.305; KNUCKEY NW, 1993, BRAIN RES, V618, P313, DOI 10.1016/0006-8993(93)91282-W; KOZLOWSKI GP, 1982, FRONTIERS HORMONE RE, V9, P105; LAFOND RE, 1995, TRANSGENIC RES, V4, P306, DOI 10.1007/BF01972527; LEE BCP, 1978, RADIOLOGY, V128, P647, DOI 10.1148/128.3.647; LEVINE S, 1987, LAB INVEST, V56, P231; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MAKTABI MA, 1994, STROKE, V25, P1489, DOI 10.1161/01.STR.25.7.1489; MARMOR MF, 1993, INVEST OPHTH VIS SCI, V34, P2570; MICHAEL DK, 1973, EXP NEUROL, V41, P769, DOI 10.1016/0014-4886(73)90067-8; MURPHY VA, 1985, J CEREBR BLOOD F MET, V5, P401, DOI 10.1038/jcbfm.1985.55; NAGAHIRO S, 1994, BRAIN RES, V633, P305, DOI 10.1016/0006-8993(94)91553-9; NILSSON C, 1992, BRAIN RES REV, V17, P109, DOI 10.1016/0165-0173(92)90011-A; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; OHTA S, 1992, J CEREBR BLOOD F MET, V12, P525, DOI 10.1038/jcbfm.1992.72; PALM D, 1995, AM J PHYSIOL-REG I, V269, pR73, DOI 10.1152/ajpregu.1995.269.1.R73; PALM DE, 1995, BRAIN RES, V691, P1, DOI 10.1016/0006-8993(95)00520-Z; POLLAY M, 1974, FED PROC, V33, P2064; POLLAY M, 1985, NEUROSURGERY, V17, P768, DOI 10.1227/00006123-198511000-00007; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Riegler M, 1997, SCAND J GASTROENTERO, V32, P925, DOI 10.3109/00365529709011204; SCHREIBER G, 1990, FERNS FOUND SERIES, V14, P89; SMITH QR, 1991, BRAIN RES, V562, P306, DOI 10.1016/0006-8993(91)90636-A; SMITH QR, 1980, AM J PHYSIOL, V238, pF399, DOI 10.1152/ajprenal.1980.238.5.F399; SOLEM M, 1990, BIOCHEM BIOPH RES CO, V172, P945, DOI 10.1016/0006-291X(90)90767-H; SPECTOR R, 1989, SCI AM, V261, P68, DOI 10.1038/scientificamerican1189-68; STOPA EG, 1990, ALZHEIMERS DIS BASIC, pCH37; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; VALENTINO KL, 1988, ENDOCRINOLOGY, V122, P2753, DOI 10.1210/endo-122-6-2753; VEGA JA, 1992, CELL MOL BIOL, V38, P145; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; Yanaka A, 1996, AM J PHYSIOL-GASTR L, V271, pG75, DOI 10.1152/ajpgi.1996.271.1.G75; [No title captured]	69	66	66	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	APR	2000	20	2					197	216		10.1023/A:1007097622590			20	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	283ET	WOS:000085263700006	10696510				2022-02-06	
J	Nakamura, M; Raghupathi, R; Merry, DE; Scherbel, U; Saatman, KE; McIntosh, TK				Nakamura, M; Raghupathi, R; Merry, DE; Scherbel, U; Saatman, KE; McIntosh, TK			Overexpression of Bcl-2 is neuroprotective after experimental brain injury in transgenic mice	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						apoptosis; cognitive function; hippocampus; Morris water maze; neuroprotection; protooncogene	CONTROLLED CORTICAL IMPACT; PROGRAMMED CELL-DEATH; PROTOONCOGENE BCL-2; COGNITIVE DEFICITS; NEURONAL APOPTOSIS; MEMORY IMPAIRMENT; SPATIAL MEMORY; NERVOUS-SYSTEM; CYTOCHROME-C; RATS	The cell death regulatory protein, Bcl-2, has been suggested to participate in the pathophysiology of various neurological disorders, including traumatic brain injury (TBI), The cognitive function and histopathologic sequelae after controlled cortical impact brain injury were evaluated in transgenic (TG) mice that overexpress human Bcl-2 protein (n = 13) and their wild type (WT) controls (n = 9). Although brain-injured Bcl-2 TG mice exhibited similar posttraumatic deficits in a Morris water maze (MWM) test of spatial memory as their WT counterparts at 1 week postinjury, the preinjury learning ability of Bcl-2 TG mice was impaired significantly compared with their WT littermates (P < 0.05). In contrast, histopathologic analysis revealed significantly attenuated tissue loss in the ipsilateral hemisphere (p < 0.01) and decreased tissue loss in ipsilateral hippocampal area CA3 (P < 0.001) and the dentate gyrus (P < 0.01) in brain-injured Bcl-2 TG mice compared with brain-injured WT mice. Immunohistochemical evaluation of glial fibrillary acidic protein also revealed a significant decrease in reactive astrocytosis in the ipsilateral dorsal thalamus (P < 0.05) and the ventral thalamus (P < 0.01) in brain-injured Bcl-2 TG mice. These results suggest that overexpression of Bcl-2 protein may play a protective role in neuropathologic sequelae after TBI. J. Comp. Neurol. 412:681-692, 1999. (C) 1999 Wiley-Liss, Inc.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3320 Smith Walk,102B Hayden Hall, Philadelphia, PA 19104 USA.		Raghupathi, Ramesh/AAX-5538-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026818, R29NS036248, R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29-NS36248, R01-NS26818, P50-NS26818] Funding Source: Medline		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; BECKER JT, 1980, BRAIN RES, V200, P307, DOI 10.1016/0006-8993(80)90922-1; BEHL C, 1993, BIOCHEM BIOPH RES CO, V197, P949, DOI 10.1006/bbrc.1993.2571; Bonfanti L, 1996, J NEUROSCI, V16, P4186; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Brown W. J., 1987, EPILEPSY, P300; BULLOCK R, 1994, J NEUROTRAUMA, V11, P214; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crawley JN, 1996, TRENDS NEUROSCI, V19, P181, DOI 10.1016/S0166-2236(96)20021-9; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FADEN AI, 1989, SCIENCE, V244, P789; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IIZUKA H, 1990, STROKE, V21, P7990; Isono M, 1997, BRAIN RES, V765, P319, DOI 10.1016/S0006-8993(97)00661-6; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIRINO T, 1982, BRAIN RES, V239, P56; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; LATHE R, 1994, NEUROPATH APPL NEURO, V20, P350, DOI 10.1111/j.1365-2990.1994.tb00980.x; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Lawrence MS, 1996, J NEUROSCI, V16, P486; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MERRY DE, 1994, DEVELOPMENT, V120, P301; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; OLTON DS, 1982, BRAIN RES, V233, P241, DOI 10.1016/0006-8993(82)91200-8; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Paxinos G., 1985, RAT NERVOUS SYSTEM; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shimizu S, 1996, ONCOGENE, V12, P2251; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROSCI, V15, P8223; Srinivasan A, 1996, J NEUROSCI, V16, P5654; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; TSUJIMOTO Y, 1985, SCIENCE, V229, P1300; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VOLPE BT, 1988, BEHAV BRAIN RES, V27, P259, DOI 10.1016/0166-4328(88)90122-2; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZHONG LT, 1993, MOL BRAIN RES, V19, P353, DOI 10.1016/0169-328X(93)90139-G; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	81	66	76	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	OCT 4	1999	412	4					681	692		10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F			12	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	230FL	WOS:000082241100009	10464363				2022-02-06	
J	Lee, TT; Green, BA; Dietrich, WD; Yezierski, RP				Lee, TT; Green, BA; Dietrich, WD; Yezierski, RP			Neuroprotective effects of basic fibroblast growth factor following spinal cord contusion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						ciliary neurotrophic factor; cytokine; interleukin-4; nerve growth factor; neurotrophic factor	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; NEUROTROPHIC FACTOR; FACTOR PROTECTS; NERVOUS-SYSTEM; MESSENGER-RNA; IN-VIVO; EXPRESSION; CELLS; INTERLEUKIN-6	Cytokines and neurotrophic factors have been implicated in the pathophysiology of injury to the central nervous system. While some cytokines are considered pro-inflammatory, other factors promote neuronal growth and survival. The present study investigated the neuroprotective effects of interleukins 1 (IL-1), 4 (IL-4), and 6 (IL-6), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), and basic fibroblast growth factor (bFGF) in a contusion model of spinal cord injury. Female Sprague-Dawley rats (n = 55) sustained a 10-g weight-drop injury to the lower thoracic spinal cord (T10) from a height of 12.5 mm using the NYU impactor. A micro-infusion system (Alzet minipump) was used to continuously deliver drugs or vehicle directly into the epicenter of the contused spinal cord starting 1 or three h postinjury. At the end of 7 days, animals were perfused and the cords removed for histopathological analysis. Longitudinal serial sections were cut on a freezing microtome and stained with cresyl violet. Areas of central necrosis, partial preservation, and total zone of tissue injury were identified and traced by an independent reviewer using a computer based imaging system. The mean total zone of injury in five animals receiving vehicle infusion was 18.04 +/- 4.20 mm(3). The mean zone of partial preservation in these animals was 16.46 +/- 3.32 mm. Basic fibroblast growth factor reduced the total zone of injury by 33% [p < 0.01, least significant difference (LSD) of Fisher] in five animals and the zone of partial preservation by 32% (p < 0.01, LSD of Fisher) when compared to controls. There were trends toward reduction in total zone of injury and zone of partial preservation in rats treated with IL-4, CNTF, and NGF versus vehicle; however, none of these reached statistical significance. No significant differences were observed between animals receiving vehicle versus bFGF treatment commencing 3 h after injury. These data demonstrate that the continuous intramedullary infusion of bFGF initiated one hour after moderate contusion injury of the spinal cord significantly reduces the total zone of injury and the zone of partial preservation. These results support the further investigation and possible future clinical application of bFGF in the treatment of acute spinal cord contusion injury.	Miami Univ, Dept Neurol Surg, Sch Med, Miami, FL 33101 USA; Miami Univ, Miami Project Cure Paralysis, Sch Med, Miami, FL 33101 USA		Lee, TT (corresponding author), Miami Univ, Dept Neurol Surg, Sch Med, POB 016960 M813, Miami, FL 33101 USA.						Aebischer P, 1996, NAT MED, V2, P696, DOI 10.1038/nm0696-696; AY I, 1998, NEUROPROTECTIVE SIGN, P111; BAFOUR R, 1995, J NEUROSURG, V83, P103; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BIRDSALL HH, 1991, AM J PATHOL, V139, P1341; BLOTTNER D, 1994, ACTA ANAT, V150, P235; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; FISHER M, 1995, J CEREBR BLOOD F MET, V15, P953, DOI 10.1038/jcbfm.1995.121; FOLLESA P, 1994, MOL BRAIN RES, V22, P1, DOI 10.1016/0169-328X(94)90026-4; GIULIAN D, 1988, J NEUROSCI RES, V21, P487, DOI 10.1002/jnr.490210240; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HEFTI F, 1997, NEUROPROTECTION CNS, P243; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; JIMENEZ O, 1997, J NEUROTRAUM, V14, P772; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; KOSHINAGA M, 1993, EXP NEUROL, V120, P32, DOI 10.1006/exnr.1993.1038; KRUSHEL LA, 1995, P NATL ACAD SCI USA, V92, P4323, DOI 10.1073/pnas.92.10.4323; KUSHIMA Y, 1992, NEUROSCI LETT, V143, P110, DOI 10.1016/0304-3940(92)90244-2; LEE SC, 1993, J IMMUNOL, V150, P2659; LEE TT, 1993, GLIA, V8, P51, DOI 10.1002/glia.440080107; Lugering N, 1997, IMMUNOLOGY, V91, P130, DOI 10.1046/j.1365-2567.1997.00221.x; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Mocchetti I, 1996, EXP NEUROL, V141, P154, DOI 10.1006/exnr.1996.0149; MURPHY M, 1994, DEVELOPMENT, V120, P3519; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; Niiro H, 1997, BLOOD, V89, P1621, DOI 10.1182/blood.V89.5.1621.1621_1621_1628; OLSON L, 1994, J NEUROL, V242, P12; Oudega M, 1996, EXP NEUROL, V140, P218, DOI 10.1006/exnr.1996.0131; Peterson DA, 1996, J NEUROSCI, V16, P886; QUIRION R, 1991, CAN J NEUROL SCI, V18, P390, DOI 10.1017/S0317167100032510; RELTON JK, 1997, NEUROPROTECTION CNS, P225; SAAD B, 1991, J CELL BIOL, V115, P473, DOI 10.1083/jcb.115.2.473; SARIOLA H, 1994, ANN MED, V26, P355, DOI 10.3109/07853899409148351; Teng Y. D., 1997, Society for Neuroscience Abstracts, V23, P1382; Teng YD, 1998, EUR J NEUROSCI, V10, P798, DOI 10.1046/j.1460-9568.1998.00100.x; Toulmond S, 1996, TRENDS NEUROSCI, V19, P409; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; YABUUCHI K, 1994, MOL BRAIN RES, V27, P27, DOI 10.1016/0169-328X(94)90180-5; Yezierski RP, 1996, J CEREBR BLOOD F MET, V16, P996, DOI 10.1097/00004647-199609000-00025; YUEN EC, 1996, NEURAL NOTES, V1, P3	51	66	78	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1999	16	5					347	356		10.1089/neu.1999.16.347			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	200WC	WOS:000080562200001	10369555				2022-02-06	
J	Shohami, E; Gati, I; Beit-Yannai, E; Trembovler, V; Kohen, R				Shohami, E; Gati, I; Beit-Yannai, E; Trembovler, V; Kohen, R			Closed head injury in the rat induces whole body oxidative stress: Overall reducing antioxidant profile	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cyclic voltammetry; peripheral organs; total antioxidant power	CYCLIC VOLTAMMETRY; ENHANCED OSTEOGENESIS; MICROBIAL HEMOLYSINS; ALZHEIMERS-DISEASE; CATIONIC PROTEINS; BRAIN INJURY; URIC-ACID; OXIDANTS; CAPACITY; PLASMA	Traumatic injury to the brain triggers the accumulation of harmful mediators, including highly toxic reactive oxygen species (ROS). Endogenous defense mechanism against ROS is provided by low molecular weight antioxidants (LMWA), reflected in the reducing power of the tissue, which can be measured by cyclic voltammetry (CV). CV records biological peak potential (type of scavenger), and anodic current intensity (scavenger concentration). The effect of closed head injury (CHI) on the reducing power of various organs was studied. Water and lipid soluble extracts were prepared from the brain, heart, lung, kidney, intestine, skin, and liver of control and traumatized rats (1 and 24 h after injury) and total LMWA was determined. Ascorbic acid, uric acid, a-tocopherol, carotene and ubiquinol-10 were also identified by HPLC. The dynamic changes in LMWA levels indicate that the whole body responds to CHI. For example, transient reduction in LMWA (p < 0.01) in the heart, kidney, lung and liver at 1 h suggests their consumption, probably due to interaction with locally produced ROS. However, in some tissues (e.g., skin) there was an increase (p < 0.01), arguing for recruitment of higher than normal levels of LMWA to neutralize the ROS. alpha-tocopherol levels in the brain, liver, lung, skin, and kidney were significantly reduced (p < 0.01) even up to 24 h. We conclude that although the injury was delivered over the left cerebral hemisphere, the whole body appeared to be under oxidative stress, within 24 h after brain injury.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharm, IL-91120 Jerusalem, Israel		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Behl C, 1997, CELL TISSUE RES, V290, P471, DOI 10.1007/s004410050955; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Chevion S, 1997, FREE RADICAL BIO MED, V22, P411, DOI 10.1016/S0891-5849(96)00337-1; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COHEN AM, 1984, FEBS LETT, V174, P147, DOI 10.1016/0014-5793(84)81094-7; COTEV S, 1990, INT CONGR SER, V885, P237; DAVIES KJA, 1986, BIOCHEM J, V235, P747, DOI 10.1042/bj2350747; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; GINSBURG I, 1995, FREE RADICAL RES, V22, P489, DOI 10.3109/10715769509150323; GINSBURG I, 1992, INFLAMMATION, V16, P519, DOI 10.1007/BF00918977; GREENHOO.JH, 1969, J NEUROSURG, V30, P521, DOI 10.3171/jns.1969.30.5.0521; HACKENBERRY LE, 1982, CRIT CARE MED, V10, P641; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; Halliwell B, 1996, FREE RADICAL RES, V25, P439, DOI 10.3109/10715769609149066; Halliwell B., 1989, FREE RADICALS BIOL M, VSecond; KISSINGER PT, 1973, BRAIN RES, V55, P209, DOI 10.1016/0006-8993(73)90503-9; Kohen R., 1996, Cellular Pharmacology, V3, P355; KOHEN R, 1992, FREE RADICAL RES COM, V17, P239, DOI 10.3109/10715769209079516; Kohen R, 1999, METHOD ENZYMOL, V300, P285; KOHEN R, 1988, P NATL ACAD SCI USA, V85, P3175, DOI 10.1073/pnas.85.9.3175; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; KOHEN R, 1993, INT S ANT DIS PREV I; LANG SA, 1989, AM J PHYSIOL, V256, pE345, DOI 10.1152/ajpendo.1989.256.3.E345; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Lyras L, 1997, J NEUROCHEM, V68, P2061; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P269; NATALE JE, 1988, STROKE, V19, P1371, DOI 10.1161/01.STR.19.11.1371; OGIHARA H, 1995, PEDIATR RES, V37, P219, DOI 10.1203/00006450-199502000-00016; OLANOW CW, 1994, CURR OPIN NEUROL, V7, P548, DOI 10.1097/00019052-199412000-00013; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; PIETRONIGRO DD, 1983, J NEUROCHEM, V41, P1071; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; ROTEM M, 1988, NEUROSURGERY, V23, P89, DOI 10.1227/00006123-198807000-00015; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; THEODORE J, 1976, AM REV RESPIR DIS, V113, P405; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; WILLMORE LJ, 1990, EPILEPSIA, V31, P67; YAMAMOTO Y, 1985, BIOCHIM BIOPHYS ACTA, V819, P29, DOI 10.1016/0005-2736(85)90192-0; Youdim MBH, 1997, SCI AM, V276, P52, DOI 10.1038/scientificamerican0197-52; Yukido I, 1990, NEUROSURGERY, V27, P1	47	66	71	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1999	16	5					365	376		10.1089/neu.1999.16.365			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	200WC	WOS:000080562200003	10369557				2022-02-06	
J	Ruffolo, CF; Friedland, JF; Dawson, DR; Colantonio, A; Lindsay, PH				Ruffolo, CF; Friedland, JF; Dawson, DR; Colantonio, A; Lindsay, PH			Mild traumatic brain injury from motor vehicle accidents: Factors associated with return to work	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							MINOR HEAD-INJURY; SOCIAL SUPPORT; SYMPTOMS; PERFORMANCE; SEVERITY; IMPACT; TIME	Objectives: To describe return to work (RTW) for motor vehicle accident (MVA) survivors with mild traumatic brain injury (MTBI) and to examine relationships between RTW and injury severity, cognitive impairment, social interaction, discharge disposition, and sociodemographics. Design: Inception cohort assessed within 1 month of injury and at follow-up 6 to 9 months (mean = 7.4) after injury, for comparisons on outcome of RTW. Setting: Tertiary care center in Toronto (time 1); at home for follow-up. Participants: Fifty patients with MTBI resulting from MVA who were consecutively admitted during a 20-month period ending April 1994. Thirteen of 63 eligible patients refused consent or were lost to follow-up. Mean age was 31; 62% were men. Eligibility criteria: (1)patients had been working; (2) they had no history of head injury, neurologic disease, or psychiatric illness requiring hospitalization; and (3) they had no catastrophic impairment from accident. Main Outcome Measure: Return to work (at premorbid or modified level). Results: Of the 42% who returned to work, 12% resumed their premorbid level of employment and 30% returned to modified work. There were significant differences (p <.05) between the groups in level of social interaction, premorbid occupation, and discharge disposition. On one test of cognitive functioning the difference was at p =.06. Conclusion: Social interaction, jobs with greater decisionmaking latitude, and discharge home were positively related to RTW for this population. Cognitive impairment within the first month was not a reliable indicator of RTW potential. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Toronto, Fac Med, Dept Occupat Therapy, Toronto, ON M5T 1W5, Canada; Univ Toronto, Ontario Inst Studies Educ, Dept Human Dev & Appl Psychol, Toronto, ON, Canada		Friedland, JF (corresponding author), Univ Toronto, Fac Med, Dept Occupat Therapy, 256 McCaul St, Toronto, ON M5T 1W5, Canada.		Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121; Colantonio, Angela/0000-0003-2094-4765			*AM ASS ADV AUT ME, 1990, ABB INJ SCAL 1990 RE; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Baker J E, 1990, J Neurosci Nurs, V22, P232; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barth JT, 1989, MILD HEAD INJURY, P257; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; CLEARY PD, 1982, J HEALTH SOC BEHAV, V23, P159, DOI 10.2307/2136512; COOK JV, 1990, REHABILITATION ADULT, P236; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Florian V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; FRIEDLAND J, 1987, ARCH PHYS MED REHAB, V68, P475; GRAY JM, 1990, COGNITIVE REHABILITA, P29; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GRONWALL DMA, 1974, LANCET, V14, P605; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Karasek R., 1990, HLTH WORK STRESS PRO; KIRSCH NL, 1989, MILD MODERATE HEAD I, P145; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KRAUS JF, 1989, MILD MODERATE HEAD I, P9; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; Ocampo S, 1997, OCCUP THER INT, V4, P161; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTLEDGE R, 1995, J TRAUMA, V38, P590, DOI 10.1097/00005373-199504000-00022; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SCHAPIRO SR, 1993, MINOR HEAD TRAUMA AS, P86; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V2, P81; VanDongen S, 1993, Rehabil Nurs, V18, P76; WANG P, 1991, CAN PSYCHOL 2A, V32, P216; WANG PL, 1992, NEW VERSION PASATR R; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	51	66	67	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1999	80	4					392	398		10.1016/S0003-9993(99)90275-7			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	184TG	WOS:000079629100006	10206600				2022-02-06	
J	Whalen, MJ; Carlos, TM; Dixon, CE; Schiding, JK; Clark, RSB; Baum, E; Yan, HQ; Marion, DW; Kochanek, PM				Whalen, MJ; Carlos, TM; Dixon, CE; Schiding, JK; Clark, RSB; Baum, E; Yan, HQ; Marion, DW; Kochanek, PM			Effect of traumatic brain injury in mice deficient in intercellular adhesion molecule-1: Assessment of histopathologic and functional outcome	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	16th Annual National Neurotrauma-Society Meeting	NOV 06-07, 1998	LOS ANGELES, CA	Natl Neurotrauma Soc		brain vascular endothelium; ICAM-I; neutrophil accumulation; traumatic brain injury	CONTROLLED CORTICAL IMPACT; CEREBRAL-ARTERY OCCLUSION; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; ACUTE LUNG INJURY; RAT-BRAIN; PULMONARY INFLAMMATION; BACTERIAL-MENINGITIS; CEREBROSPINAL-FLUID; VASCULAR INJURY	Intercellular adhesion molecule-1 (ICAM-1) is an adhesion molecule of the immunoglobulin family expressed on endothelial cells that is upregulated in brain as part of the acute inflammatory response to traumatic brain injury (TBI). ICAM-1 mediates neurologic injury in experimental meningitis and stroke; however, its role in the pathogenesis of TBI is unknown. We hypothesized that mutant mice deficient in ICAM-1 (-/-) would have decreased neutrophil accumulation, diminished histologic injury, and improved functional neurologic outcome versus ICAM-1 +/+ wild type control mice after TBI. Anesthetized ICAM-1 -/- mice and wild-type controls were subjected to controlled cortical impact (CCI, 6 m/sec, 1.2 mm depth). Neutrophils in brain parenchyma and ICAM-1 on vascular endothelium were assessed by immunohistochemistry in cryostat brain sections from the center of the contusion 24 h after TBI (n = 4/group). Separate groups of wild-type and ICAM-1-deficient mice (n = 9-10/group) underwent motor (wire grip test, days 1-5) and cognitive (Morris water maze [MWM], days 14-20) testing. Lesion volume was determined by image analysis 21 days following TBI. Robust expression of ICAM-1 was readily detected in choroid plexus and cerebral endothelium at 24 h in ICAM-1 +/+ mice but not in ICAM-1 -/- mice, No differences between groups were observed in brain neutrophil accumulation (9.4 +/- 2.2 versus 11.1 +/- 3.0 per x 100 field, -/- versus +/+), wire grip score, MWM latency, or lesion volume (7.24 +/- 0.63 versus 7.21 +/- 0.45 mm(3), -/- versus +/+). These studies fail to support a role for ICAM-1 in the pathogenesis of TBI.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	Kochanek@smtp.anes.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; ALOISI F, 1992, J NEUROSCI RES, V32, P494, DOI 10.1002/jnr.490320405; BANBURY POT, 1997, NEURON, V19, P755; BELL M, 1998, CRIT CARE MED, V26, pA86; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BIRDSALL HH, 1991, AM J PATHOL, V139, P1341; Bullard DC, 1996, J IMMUNOL, V157, P3153; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Doerschuk CM, 1996, J IMMUNOL, V157, P4609; Eppihimer MJ, 1997, AM J PHYSIOL-HEART C, V273, pH1903, DOI 10.1152/ajpheart.1997.273.4.H1903; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; Hallahan DE, 1997, P NATL ACAD SCI USA, V94, P6432, DOI 10.1073/pnas.94.12.6432; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hatfield CA, 1997, AM J PHYSIOL-LUNG C, V273, pL513, DOI 10.1152/ajplung.1997.273.3.L513; HINES D, 1993, SOC NEUR ABSTR, V18, P1875; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HORGAN MJ, 1991, AM J PHYSIOL, V261, pH1578; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; KING PD, 1995, J IMMUNOL, V154, P6080; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lloyd CM, 1997, J CLIN INVEST, V100, P963, DOI 10.1172/JCI119647; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOSSINSKY AS, 1995, BRAIN PATHOL, V5, P339, DOI 10.1111/j.1750-3639.1995.tb00614.x; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MULLIGAN MS, 1994, AM J PATHOL, V144, P1008; MULLIGAN MS, 1993, J IMMUNOL, V150, P2407; Mulligan MS, 1996, P ASSOC AM PHYSICIAN, V108, P198; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; Que LG, 1998, SHOCK, V9, P304, DOI 10.1097/00024382-199804000-00011; SARMAN G, 1995, J INFECT DIS, V172, P1001, DOI 10.1093/infdis/172.4.1001; Scherbel U., 1997, J NEUROTRAUM, V14, P781; SHERMAN DG, 1997, NEUROLOGY, V48, pA270; Shibayama M, 1996, J NEUROTRAUM, V13, P801, DOI 10.1089/neu.1996.13.801; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SINZ EH, 1997, 10 INT S INTR PRESS; SINZ EH, 1997, J NEUROTRAUM, V14, P769; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soriano SG, 1998, BRAIN RES, V780, P337, DOI 10.1016/S0006-8993(97)01298-5; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; TAN TQ, 1995, J INFECT DIS, V171, P342, DOI 10.1093/infdis/171.2.342; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Vougioukas VI, 1998, AM J PATHOL, V152, P241; Wang CY, 1998, CIRC RES, V82, P762, DOI 10.1161/01.RES.82.7.762; Weber JR, 1995, J NEUROIMMUNOL, V63, P63; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; ZIELASEK J, 1993, NEUROSCI LETT, V153, P136, DOI 10.1016/0304-3940(93)90306-6; ZU H, 1994, J EXP MED, V180, P95	57	66	66	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	1999	16	4					299	309		10.1089/neu.1999.16.299			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	190AM	WOS:000079939400003	10225216				2022-02-06	
J	King, NS; Crawford, S; Wenden, FJ; Caldwell, FE; Wade, DT				King, NS; Crawford, S; Wenden, FJ; Caldwell, FE; Wade, DT			Early prediction of persisting post-concussion symptoms following mild and moderate head injuries	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							CONTROLLED TRIAL; SCALE; QUESTIONNAIRE; EPIDEMIOLOGY; SEQUELAE; RECOVERY	Objectives. King (1996) reported that a combination of emotional, organic and neuropsychological measures taken at 7-10 days following mild and moderate head injury may significantly help predict patients most likely to suffer persisting postconcussion symptoms (PCS) at three months post-injury. This study investigated a cross-validation sample (N = 57) to determine whether the results would be replicated for the early prediction of longer-term sufferers (i.e. those with persisting symptoms at 6 months post-injury). Design. Multiple regression analyses were used in which scores on the Hospital Anxiety and Depression Scale, Impact of Event Scale, Short Orientation Memory and Concentration Test, Rivermead Post-Concussion Symptoms Questionnaire and Post-Traumatic Amnesia taken at 7-10 days post-injury were the independent measures. Scoring on the Rivermead Post-Concussion Symptoms Questionnaire taken at 6 months post-injury was the dependent measure. Methods. Sixty-six consecutive patients admitted to any trauma ward in Oxfordshire with a mild or moderate head injury were recruited from a largescale randomized controlled sample. The assessment measures were administered at 7-10 days post-injury and the Rivermead Post-Concussion Symptoms Questionnaire at 6 months post-injury. Nine patients were unable to be followed up, leaving an active sample of 57. Results. The cross-validation data confirmed that a similar combination of measures to that found in the original study best predicted persisting PCS but that the strength of prediction diminished for the longer term prediction (i.e. 6 months post-injury). Conclusions. The Hospital Anxiety and Depression Scale, Impact of Event Scale and Post-Traumatic Amnesia in combination are recommended as useful prognostic screening instruments for predicting persisting PCS, but great caution is required if they are used to aid predictions beyond 3 months post-injury.	Warneford Hosp, Isis Educ Ctr, Oxford Reg Training Course Clin Psychol, Oxford OX3 7JX, England; Rivermead Rehabil Ctr, Oxford, England		King, NS (corresponding author), Warneford Hosp, Isis Educ Ctr, Oxford Reg Training Course Clin Psychol, Warneford Lane, Oxford OX3 7JX, England.			Wade, Derick/0000-0002-1188-8442			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ANDRASIK F, 1994, SEMIN NEUROL, V14, P60, DOI 10.1055/s-2008-1041060; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FOX DD, 1995, CLIN NEUROPSYCHOLOGI, V9, P78; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; INGEBRIGSTEN T, IN PRESS J NEUROLOGY; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACKAY R P, 1960, Ind Med Surg, V29, P200; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Trennery M. R., 1989, STROOP NEUROPSYCHOLO; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	33	66	66	0	5	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	0144-6657			BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	MAR	1999	38		1				15	25		10.1348/014466599162638			11	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	180FT	WOS:000079376000003	10212734				2022-02-06	
J	Hulsebosch, CE; DeWitt, DS; Jenkins, LW; Prough, DS				Hulsebosch, CE; DeWitt, DS; Jenkins, LW; Prough, DS			Traumatic brain injury in rats results in increased expression of Gap-43 that correlates with behavioral recovery	NEUROSCIENCE LETTERS			English	Article						GAP-43; rat; traumatic brain injury; neocortex; hippocampus	PROTEIN-KINASE-C; ADULT-RAT; REACTIVE SYNAPTOGENESIS; MODEL; MEMBRANE; LIGHT	Traumatic brain injury is associated with behavioral deficits, often in the absence of histopathological or ultrastructural changes. To determine whether membrane remodeling occurs, immunocytochemical techniques were used and the density and distribution of GAP-43 were measured. GAP-43 is a membrane-bound protein, which, when phosphorylated, is thought to regulate metabolic pathways involved in membrane remodeling and neurite growth. Moderate central fluid percussion injury (FPI, 1.9-2.2 atm.) was performed on anesthetized, spontaneously hypertensive Wistar rats (SHR). Behavioral reflex recovery was consistent with moderate levels of brain injury. One, 3, 5, 7 and 9 days after injury, both sham control (n = 4) and FPI (n = 4) animals were sacrificed, the brains were removed, cryosectioned and processed. Density measurements were taken from histological sections taken at interaural 6.20 mm and bregma -2.80 mm and were found to be statistically greater (P < 0.05) than background grey matter readings in the agranular cortices, the frontal, hindlimb, parietal 1 and 2 cortices, and the hippocampus and dentate gyrus, excluding the pyramidal and granular cell layers. Density measurements taken in forelimb and hindlimb cortical regions correlate with forelimb and hindlimb recovery in foot-fault and beam balance tests (P < 0.05). We interpret these data to indicate neuronal membrane remodeling as a result of the disruption of neuronal membranes due to the impact and shearing forces associated with the FPI. The disruption and remodeling of neuronal membranes are in areas that are consistent with the loss and recovery of locomotor and spatial behavior as a result of FPI. (C) 1998 Published by Elsevier Science Ireland Ltd. All rights reserved.	Dept Anat & Neurosci, Galveston, TX 77555 USA; Inst Marine Biomed, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA		Hulsebosch, CE (corresponding author), Dept Anat & Neurosci, Galveston, TX 77555 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 11255, NS 25450] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS011255, S15NS025450] Funding Source: NIH RePORTER		BENOWITZ LI, 1990, MOL BRAIN RES, V8, P17, DOI 10.1016/0169-328X(90)90004-W; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; COGGESHALL RE, 1991, NEUROSCI LETT, V131, P37, DOI 10.1016/0304-3940(91)90331-M; DELAHUNTY TM, 1995, NEUROCHEM RES, V20, P405; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Oestreicher AB, 1997, PROG NEUROBIOL, V53, P627, DOI 10.1016/S0301-0082(97)00043-9; Padmaperuma B, 1996, BRAIN RES, V714, P19, DOI 10.1016/0006-8993(95)01579-5; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; STROEMER RP, 1993, NEUROSCI LETT, V162, P51, DOI 10.1016/0304-3940(93)90557-2; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287	28	66	68	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	OCT 16	1998	255	2					83	86		10.1016/S0304-3940(98)00712-5			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	134BT	WOS:000076723500006	9835220				2022-02-06	
J	Powell, JH; Beckers, K; Greenwood, RJ				Powell, JH; Beckers, K; Greenwood, RJ			Measuring progress and outcome in community rehabilitation after brain injury with a new assessment instrument - The BICRO-39 scales	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							INTEGRATION QUESTIONNAIRE; PERFORMANCE; DISABILITY	Objective: Construction and validation of a new instrument, the Brain Injury Community Rehabilitation Outcome scales, to assess problems experienced by brain-injured patients living in the community. Design: Seventy-six items describing aspects of personal and social functioning were generated. Two hundred thirty-five patients and/or their carers (separately) rated the items on 6-point scales, and patients retrospectively rated their functioning before injury. Seven scales were derived from factor analysis; one was included a priori. Thirty-nine items with high factor loadings were retained. Test-retest reliability, interrater reliability, and construct validity were examined in subsamples. Setting: Patients were recruited from four centers: two community-based teams, a day-patient clinic, and an outpatient clinic. Patients: Of the patients, 127 had traumatic brain injury, 72 had cerebrovascular accidents, 15 had multiple sclerosis, and 21 had acquired brain injury of other origins. Mean time since brain injury was 2.6 years; mean age was 43 years; 164 were men and 71 were women. Results: All scales showed good test-retest reliability, and agreement between patient and carer ratings was moderate to high. They showed predicted moderate correlations with other relevant scales. Postinjury scores differed significantly from preinjury scores, and 6 of the 8 scales showed change over a period of recovery/rehabilitation. Conclusions: The scales appear reliable and easy to complete. They may have utility as quantitative measures of outcome for clinical and treatment evaluations. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ London Goldsmiths Coll, Dept Psychol, London SE14 6NW, England; Homerton Hosp, Reg Neurol Rehabil Unit, London, England; Neurol Therapy Ctr, Dusseldorf, Germany		Powell, JH (corresponding author), Univ London Goldsmiths Coll, Dept Psychol, New Cross, London SE14 6NW, England.						BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Glass CA, 1997, SPINAL CORD, V35, P320, DOI 10.1038/sj.sc.3100447; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 1997, ARCH PHYS MED REHAB, V78, pS5, DOI 10.1016/S0003-9993(97)90149-0; HARVEY RF, 1981, ARCH PHYS MED REHAB, V62, P456; Harwood R H, 1994, Qual Health Care, V3, P11, DOI 10.1136/qshc.3.1.11; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KLINE P, 1983, ADV BEHAV RES THER, V5, P141, DOI 10.1016/0146-6402(83)90017-6; MAHONEY F I, 1965, Md State Med J, V14, P61; PORT MWM, 1996, ARCH PHYS MED REHAB, V77, P440; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SEGAL ME, 1995, AM J PHYS MED REHABI, V74, P277; *STAT U NY BUFF, 1993, GUID UN DAT SYST MED; vanBennekom CAM, 1996, J CLIN EPIDEMIOL, V49, P39, DOI 10.1016/0895-4356(95)00559-5; Wade D T, 1985, Int Rehabil Med, V7, P176; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; World Health Organization, 1980, INT CLASS IMP DIS HA; Young NL, 1996, J CLIN EPIDEMIOL, V49, P1097, DOI 10.1016/0895-4356(96)00214-4; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	25	66	69	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1998	79	10					1213	1225		10.1016/S0003-9993(98)90265-9			13	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	128CC	WOS:000076386800005	9779674				2022-02-06	
J	Madsen, JE; Hukkanen, M; Aune, AK; Basran, I; Moller, JF; Polak, JM; Nordsletten, L				Madsen, JE; Hukkanen, M; Aune, AK; Basran, I; Moller, JF; Polak, JM; Nordsletten, L			Fracture healing and callus innervation after peripheral nerve resection in rats	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							GENE-RELATED PEPTIDE; IMMUNOREACTIVE NERVES; NEURAL INVOLVEMENT; GROWTH-FACTOR; HEAD-INJURY; BONE-CELLS; DENERVATION; IMMOBILIZATION; PROLIFERATION; RECOVERY	The effects of femoral and sciatic nerve resection on fracture healing and innervation of the fracture callus were studied using a stable fracture model, In 34 rats the right tibia was subjected to a standardized closed fracture and stabilized with a modular intramedullary nail, In half of the animals, resection of 1 cm of the femoral and sciatic nerves was performed (nerve resection group), whereas the other animals had sham operations (sham group). To avoid unequal loadbearing between the two groups, all fractured hindlimbs were immobilized in a plaster of Paris cast. The trial was terminated after 5 weeks of fracture healing. Callus size was scored radiographically, and bone mineralization was measured by (85)Strontium incorporation, Seven rats from each group had immunohistochemical examination for neural regeneration and ingrowth, Antisera for protein gene product 9.5, neurofilaments, neural growth associated protein 43/B-50, calcitonin gene related peptide, and substance P were used, The mechanical properties of the healing fractures were recorded in a three-point cantilever bending test, After 5 weeks, the normally innervated, fractured tibias had regained approximately 50% strength compared with the unfractured side, in comparison with only 20% in the animals that had nerve resection, Although the fracture calluses were mechanically weaker, they were significantly larger in the nerve resection group, indicating defects in tissue composition or organization rendered by the nerve injury The mineralization rate, as measured by (85)Strontium incorporation, was the same in the two groups. However, the nerve resection did not provide complete denervation but changed the innervation pattern of the healing fracture, as the density of sensory nerve fibers immunostaining for substance P and neurofilaments was less in the group with femoral and sciatic nerve resection, The results suggest that intact innervation is essential for normal fracture healing because nerve injury induced a large, but mechanically insufficient, fracture callus.	Univ Oslo, Natl Hosp, Rikshosp, Inst Surg Res, N-0316 Oslo, Norway; Martina Hansens Hosp, Sandvika, Norway; Royal Postgrad Med Sch, Dept Histochem, London, England; Univ Aarhus, Inst Expt Clin Res, DK-8000 Aarhus C, Denmark		Madsen, JE (corresponding author), Martina Hansens Hosp, N-1355 Baerum, Norway.			Hukkanen, Mika/0000-0001-9687-9571			ARO H, 1985, J ORTHOPAED RES, V3, P101, DOI 10.1002/jor.1100030113; ARO H, 1981, CLIN ORTHOP RELAT R, P211; ARO H, 1982, CLIN ORTHOP RELAT R, P292; ARO H, 1985, CLIN ORTHOP RELAT R, P292; ARO H, 1985, ACTA ORTHOP SCAND, V56, P233, DOI 10.3109/17453678508993002; Augat P, 1996, CLIN ORTHOP RELAT R, P194; BJURHOLM A, 1992, J BONE MINER RES, V7, P1011; BJURHOLM A, 1988, J AUTONOM NERV SYST, V25, P119, DOI 10.1016/0165-1838(88)90016-1; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; CHEN LE, 1992, J ORTHOPAED RES, V10, P657, DOI 10.1002/jor.1100100508; EKELAND A, 1981, ACTA ORTHOP SCAND, V52, P605, DOI 10.3109/17453678108992155; FRENKEL SR, 1990, CELL TISSUE RES, V260, P507, DOI 10.1007/BF00297230; FRENKEL SR, 1990, BIOMATERIALS, V11, P38; FROST HM, 1966, J BONE JOINT SURG AM, VA 48, P1192, DOI 10.2106/00004623-196648060-00018; FRYMOYER JW, 1977, J TRAUMA, V17, P355, DOI 10.1097/00005373-197705000-00004; HAEGERSTRAND A, 1990, P NATL ACAD SCI USA, V87, P3299, DOI 10.1073/pnas.87.9.3299; HUKKANEN M, 1993, NEUROSCIENCE, V54, P969, DOI 10.1016/0306-4522(93)90588-7; HUKKANEN M, 1995, CLIN ORTHOP RELAT R, P247; HUKKANEN M, 1992, INT J TISSUE REACT, V15, P1; Hulth A, 1965, J Trauma, V5, P571, DOI 10.1097/00005373-196509000-00001; KLEIN L, 1977, J BONE JOINT SURG AM, V59, P1065, DOI 10.2106/00004623-197759080-00011; KONTTINEN YT, 1990, J RHEUMATOL, V17, P1586; KONTTINEN YT, 1992, SCAND J RHEUMATOL, V21, P55, DOI 10.3109/03009749209095068; LINDBOE CF, 1985, ACTA NEUROPATHOL, V66, P42, DOI 10.1007/BF00698294; Madsen JE, 1996, BONE, V18, P411, DOI 10.1016/8756-3282(96)00027-0; Madsen JE, 1996, ACTA ORTHOP SCAND, V67, P217, DOI 10.3109/17453679608994676; NORDSLETTEN L, 1994, ACTA ORTHOP SCAND, V65, P299, DOI 10.3109/17453679408995457; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; QUILIS AN, 1974, ACTA ORTHOP SCAND, V45, P820, DOI 10.3109/17453677408989693; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; SANTAVIRTA S, 1992, ACTA ORTHOP SCAND, V63, P579; SARMIENTO A, 1977, J BONE JOINT SURG AM, V59, P369, DOI 10.2106/00004623-197759030-00014; SIEMIONOW M, 1994, MICROSURG, V15, P891, DOI 10.1002/micr.1920151213; SMITH WS, 1955, SURG FORUM, V6, P559; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; TUUKKANEN J, 1992, ACTA PHYSIOL SCAND, V145, P407, DOI 10.1111/j.1748-1716.1992.tb09382.x; VARON SS, 1978, ANNU REV NEUROSCI, V1, P327, DOI 10.1146/annurev.ne.01.030178.001551; WHITESIDE LA, 1978, J BONE JOINT SURG AM, V60, P26, DOI 10.2106/00004623-197860010-00004; WILLIAMS PL, 1980, GRAYS ANATOMY, P1131; ZAIDI M, 1988, Q J EXP PHYSIOL CMS, V73, P471, DOI 10.1113/expphysiol.1988.sp003168; ZAIDI M, 1990, BIOCHEM J, V269, P775, DOI 10.1042/bj2690775	41	66	84	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	JUN	1998		351					230	240					11	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	ZU050	WOS:000074156200028	9646767				2022-02-06	
J	Pleines, UE; Stover, JF; Kossmann, T; Trentz, O; Morganti-Kossmann, MC				Pleines, UE; Stover, JF; Kossmann, T; Trentz, O; Morganti-Kossmann, MC			Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adhesion molecules; blood-brain barrier; sICAM-1; traumatic brain injury	INTERCELLULAR-ADHESION MOLECULE-1; CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID BARRIER; ENDOTHELIAL-CELLS; ARTERY OCCLUSION; MULTIPLE-SCLEROSIS; CIRCULATING ICAM-1; CORTICAL CONTUSION; RAT-BRAIN; EXPRESSION	The intercellular adhesion molecule-1 (ICAM-1) expressed by endothelial cells is crucial in promoting adhesion and transmigration of circulating leukocytes across the blood-brain barrier (BBB), Migrated immunocompetent cells, in turn, release mediators that stimulate glial and endothelial cells to express ICAM-1 and release cytokines, possibly sustaining cerebral damage. Following activation, proteolytic cleavage of membrane-anchored ICAM-1 results in measurable levels of a soluble form, sICAM-1, The aims of this study were to investigate the changes of sICAM-1 levels in ventricular CSF and serum and to elucidate the influence of structural brain damage as estimated by computerized tomography (CT) as well as the extent of BBB dysfunction as calculated by the CSF/serum albumin ratio (Q(A)) in patients with severe traumatic brain injury (TBI), All investigated parameters revealed two subgroups, Patients belonging to group A had sICAM-1 levels in CSF above normal range, presented marked cerebral damage and a disturbance of the BBB (range 0.6-24.7 ng/ml, n = 8), In contrast, patients belonging to group B had no elevation of sICAM-1 values in CSF (range 0.3-3.9 ng/ml, n = 5; p < 0.017) acid showed minor cerebral damage with an intact BBB in most cases. In addition, overall analysis showed that sICAM-1 in CSF correlated with the extent of BBB damage as indicated by the Q(A) (r = 10.76; P < 0.001), These results suggest that increased sICAM-1 levels in CSF might depict ongoing immunologic activation and that sICAM-1 correlates with the extent of tissue and BBB damage. The origin of soluble ICAM-1 in CSF and its pathophysiologic role after TBI remains to be clarified.	Univ Hosp Zuerich, Div Res, Zurich, Switzerland; Univ Hosp Zuerich, Dept Surg, Div Trauma Surg, Zurich, Switzerland		Morganti-Kossmann, MC (corresponding author), Univ Hosp Zuerich, Div Res, Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ALOISI F, 1992, J NEUROSCI RES, V32, P494, DOI 10.1002/jnr.490320405; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; Budnik A, 1996, EXP HEMATOL, V24, P352; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; CARLOS TM, 1994, BLOOD, V84, P2068; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; CROSS AH, 1991, J NEUROIMMUNOL, V33, P237, DOI 10.1016/0165-5728(91)90111-J; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; GEARING AJH, 1992, ANN NY ACAD SCI, V667, P324, DOI 10.1111/j.1749-6632.1992.tb51633.x; GREENWOOD J, 1991, NEURORADIOLOGY, V33, P95, DOI 10.1007/BF00588242; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; JANDER S, 1993, NEUROLOGY, V43, P1809, DOI 10.1212/WNL.43.9.1809; JENNETT B, 1975, LANCET, V1, P480; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; MANDI Y, 1995, RES EXP MED, V195, P297, DOI 10.1007/BF02576800; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MEYER DM, 1995, J IMMUNOL, V155, P3578; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; OHATA K, 1990, ACTA NEUROPATHOL, V81, P162, DOI 10.1007/BF00334505; OHATA K, 1992, J NEUROSURG, V77, P387, DOI 10.3171/jns.1992.77.3.0387; Onal C, 1997, ACTA NEUROCHIR, V139, P661, DOI 10.1007/BF01412002; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; RIECKMANN P, 1995, NEUROSCI LETT, V186, P61, DOI 10.1016/0304-3940(95)11282-2; RIECKMANN P, 1993, J NEUROIMMUNOL, V47, P133, DOI 10.1016/0165-5728(93)90023-R; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; Rieckmann P, 1996, J NEUROIMMUNOL, V64, P193, DOI 10.1016/0165-5728(95)00176-X; ROSENBERG GA, 1980, AM J PHYSIOL, V238, pF42, DOI 10.1152/ajprenal.1980.238.1.F42; ROSSLER K, 1992, J NEUROSCI RES, V31, P365, DOI 10.1002/jnr.490310219; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; SATOH J, 1991, J NEUROSCI RES, V29, P1, DOI 10.1002/jnr.490290102; SATOH JI, 1991, J NEUROPATH EXP NEUR, V50, P215, DOI 10.1097/00005072-199105000-00004; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; Shibayama M, 1996, J NEUROTRAUM, V13, P801, DOI 10.1089/neu.1996.13.801; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Staub F, 1996, ACT NEUR S, V66, P56; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STOCKER R, 1995, INTEGRATED APPROACH, P197; TENGVAR C, 1982, ACTA NEUROPATHOL, V57, P233, DOI 10.1007/BF00685395; VORBRODT AW, 1985, ACTA NEUROPATHOL, V66, P265, DOI 10.1007/BF00690958; Wakatsuki T, 1995, CELL ADHES COMMUN, V3, P283, DOI 10.3109/15419069509081014; WECKERLE H, 1993, BLOOD BRAIN BARRIER, P67; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	61	66	69	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1998	15	6					399	409		10.1089/neu.1998.15.399			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZR931	WOS:000074030700002	9624625	Green Accepted			2022-02-06	
J	Whalen, MJ; Carlos, TM; Clark, RSB; Marion, DW; DeKosky, ST; Heineman, S; Schiding, JK; Memarzadeh, F; Kochanek, PM				Whalen, MJ; Carlos, TM; Clark, RSB; Marion, DW; DeKosky, ST; Heineman, S; Schiding, JK; Memarzadeh, F; Kochanek, PM			The effect of brain temperature on acute inflammation after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	13th Annual Houston Conference on Biomedical Engineering Research	FEB09, 1996	HOUSTON, TX			brain injury; cell adhesion; controlled cortical impact; hypothermia; inflammation; rat	CONTROLLED CORTICAL IMPACT; ANTI-CD18 MONOCLONAL-ANTIBODIES; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; NEUTROPHIL ACCUMULATION; MYELOPEROXIDASE ACTIVITY; ADHESION MOLECULE-1; CEREBRAL-ISCHEMIA; PROTECTION; EDEMA	The effect of varying brain temperature on neutrophil accumulation in brain and the expression of E-selectin and intercellular adhesion molecule-1 (ICAM-1) on cerebrovascular endothelium after controlled cortical impact (CCI) was studied in rats. Sprague Dawley rats were anesthetized and subjected to CCI to the left parietal cortex. Ten minutes after CCI, brain temperature was modulated and maintained at 32 degrees C, 37 degrees C, or 39 degrees C (n = 8 per group) for 4 h. Rats were then decapitated and immunohistochemistry on brain sections was performed using monoclonal antibodies (MoAb) that recognize neutrophils (RP-3), ICAM-1 (TM-8, Athena Neurosciences), or MoAb that react with E-selectin (La-Roche). Each of these markers was quantified in 100 x fields. Neutrophil accumulation was also quantified with myeloperoxidase (MPO) assay. Absolute neutrophil count (ANC) was measured in blood samples before and 1 h and 4 h after CCI. Neutrophil accumulation in injured brain was decreased in rats maintained at 32 degrees C vs 39 degrees C (4-fold difference as assessed by immunohistochemistry, p < 0.05; 8-fold difference as assessed by MPO assay, p < 0.05). Peripheral blood ANC was not affected by temperature. E-selectin was induced on cerebrovascular endothelium after CCI (p < 0.05), but was only decreased modestly at 32 degrees C versus 39 degrees C (p = 0.11). ICAM-1 was not upregulated on cerebrovascular endothelium at this early time following CCI. Neutrophil accumulation is directly dependent on brain temperature during the initial 4 h after CCI. This appears to be mediated by mechanisms other than effects of temperature on E-selectin or ICAM-1 expression or systemic ANC.	UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT PEDIAT, PITTSBURGH, PA USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT NEUROL SURG, PITTSBURGH, PA USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, DEPT PSYCHIAT, PITTSBURGH, PA USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA USA				Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51, DOI 10.1002/jlb.37.1.51; BALCH HH, 1955, SURGERY, V38, P1036; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Brooks B, 1941, ANN SURG, V114, P1069, DOI 10.1097/00000658-194112000-00013; Brundeau J, 1944, ANN SURG, V120, P716, DOI 10.1097/00000658-194411000-00004; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; DELAUNAY A, 1954, ANN I PASTEUR PARIS, V86, P520; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; Duerschner DR, 1943, J INFECT DIS, V72, P183, DOI 10.1093/infdis/72.3.183; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HAGERDAL M, 1975, J NEUROCHEM, V24, P311, DOI 10.1111/j.1471-4159.1975.tb11881.x; Hartl R, 1996, J NEUROSURG, V84, P845; HINES D, 1983, SOC NEUR ABSTR, V19, P1875; HORNER HC, 1992, SOC NEUR ABSTR, V8, P173; JANSSEN CW, 1967, ACTA PATHOL MIC SC, V69, P557; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; KUBES P, 1994, J IMMUNOL, V152, P3570; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; ROSOMOFF HL, 1965, ARCH NEUROL-CHICAGO, V13, P337, DOI 10.1001/archneur.1965.00470040003001; SAEZLLORENS X, 1991, J CLIN INVEST, V88, P2003, DOI 10.1172/JCI115527; SANDERS F, 1959, SURG FORUM, V10, P92; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96, DOI 10.1002/jlb.46.2.96; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Soares HD, 1995, J NEUROSCI, V15, P8223; SVANES K, 1965, ACTA PATHOL MIC SC, V65, P1; SVANES K, 1964, ACTA ANAESTH SCAND, V8, P143, DOI 10.1111/j.1399-6576.1964.tb00236.x; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAUBER MG, 1988, J INFECT DIS, V157, P456, DOI 10.1093/infdis/157.3.456; THOMAS G, 1986, J PHARM PHARMACOL, V38, P936, DOI 10.1111/j.2042-7158.1986.tb03390.x; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VANEEDEN S, 1995, AM J RESP CRIT CARE, V151, P500, DOI 10.1164/ajrccm.151.2.7531098; WONG D, 1992, J NEUROIMMUNOL, V39, P11, DOI 10.1016/0165-5728(92)90170-P; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; ZHANG ZG, 1995, BRAIN RES, V698, P79, DOI 10.1016/0006-8993(95)00830-J	70	66	67	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	1997	14	8					561	572		10.1089/neu.1997.14.561			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	XU894	WOS:A1997XU89400007	9300566				2022-02-06	
J	Homayoun, P; deTurco, EBR; Parkins, NE; Lane, DC; Soblosky, J; Carey, ME; Bazan, NG				Homayoun, P; deTurco, EBR; Parkins, NE; Lane, DC; Soblosky, J; Carey, ME; Bazan, NG			Delayed phospholipid degradation in rat brain after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						free fatty acids; diacylglycerols; phospholipase A(2); phospholipase C; phospholipase D; traumatic brain injury	AMYLOID PROTEIN DEPOSITION; SEVERE HEAD-INJURY; FREE FATTY-ACIDS; NERVOUS-SYSTEM; PHOSPHATIDYLINOSITOL BISPHOSPHATE; CEREBRAL-CORTEX; MESSENGER-RNA; KINASE-C; ACTIVATION; ISCHEMIA	Lipid second messengers such as arachidonic acid and its metabolites and diacylglycerols (DAGs) are affected in brain injury. Therefore, changes in the pool size and the fatty acid composition of free fatty acids (FFAs) and DAGs were analyzed in different rat brain areas 4 and 35 days after traumatic injury. Cortical impact injury of low-grade severity was applied in the right frontal somatosensory cortex. Four days after injury, FFAs and DAGs were increased by three- and twofold, respectively, in the injured cortex and to a lesser extent in the contralateral cortex compared with sham-operated animals. Docosahexaenoic acid followed by stearic acid, and arachidonic acid, displayed the greatest changes in both FFAs and DAGs. By day 35, free stearic, oleic, and arachidonic acids remained elevated in the damaged cortex(1.5-fold each), DAGs showed the greatest change, reaching values 2.7-fold higher than sham in all frontal and occipital cortical areas, including brainstem. Oleoyl- and arachidonoyl-DAGs (four- and threefold increase, respectively) followed by docosahexaenoyl-DAGs (twofold) contributed to the DAG accumulation. These results reveal that traumatic brain injury triggers a sustained and time-dependent activation of phospholipase-mediated signaling pathways leading to membrane phospholipid degradation and targeting, early on, docosahexaenoyl phospholipid-enriched excitable membranes.	LOUISIANA STATE UNIV,MED CTR,DEPT NEUROSURG,NEW ORLEANS,LA 70112		Homayoun, P (corresponding author), LOUISIANA STATE UNIV,MED CTR,NEUROSCI CTR EXCELLENCE,2020 GRAVIER ST,NEW ORLEANS,LA 70112, USA.		Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444; Lane, Diane/0000-0001-7313-557X			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; BAZAN NG, 1993, PROG BRAIN RES, V96, P247; BAZAN NG, 1995, J NEUROTRAUM, V12, P789; BAZAN NG, 1980, ADV NEUROL, P197; BAZAN NG, 1990, LIPID MEDIATORS ISCH, P277; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COTMAN C, 1967, BIOCHEMISTRY-US, V3, P4606; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DELAHUNTY TM, 1995, NEUROCHEM RES, V20, P405; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FADEN AI, 1989, UPDATE INTENSIVE CAR, V9, P14; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HAYES RL, 1991, CENTRAL NERVOUS SYST, P9; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KLEIN J, 1995, J NEUROCHEM, V65, P1445; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; MARCHESELLI VL, 1990, J NUTR BIOCHEM, V1, P382, DOI 10.1016/0955-2863(90)90009-A; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; NAKANO S, 1990, J NEUROCHEM, V54, P1911, DOI 10.1111/j.1471-4159.1990.tb04890.x; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Pierce JES, 1996, J NEUROSCI, V16, P1083; PRASAD MR, 1994, J NEUROCHEM, V63, P773; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9; SUN GY, 1972, BIOCHIM BIOPHYS ACTA, V280, P306, DOI 10.1016/0005-2760(72)90098-7; Tymianski M, 1996, NEUROSURGERY, V38, P1176; UMEMURA A, 1992, J NEUROSURG, V76, P648, DOI 10.3171/jns.1992.76.4.0648; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YOSHIHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P484, DOI 10.1016/0006-291X(90)92117-I	53	66	68	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	1997	69	1					199	205					7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	XF431	WOS:A1997XF43100024	9202311				2022-02-06	
J	King, ML; Lichtman, SW; Seliger, G; Ehert, FA; Steinberg, JS				King, ML; Lichtman, SW; Seliger, G; Ehert, FA; Steinberg, JS			Heart-rate variability in chronic traumatic brain injury	BRAIN INJURY			English	Article							MYOCARDIAL-INFARCTION	Heart-rate variability (HRV), a measure of fluctuation around the mean heart rate, reflects the sympathetic and parasympathetic balance of the autonomic nervous system, and is an excellent technique to study cardiovascular tone in patients with neurological injuries. The purpose of this study was to determine whether abnormal HRV is present in patients with traumatic brain injury (TBI) during the post-acute recovery phase. Using a prospective, case/control design, we performed 24-h ambulatory ECG monitoring in seven TBI patients and in seven controls (C). There was a significant difference in root mean squared successive difference of RR intervals (C 40.4 +/- 10.3, TBI 23.3 +/- 16.5, p = 0.04) between TBI and C. Four patients with TBI (compared to one control) had abnormal standard deviation of the RR interval. When these four patients were compared to their matched controls, significant differences were found in frequency domain measure (In total po TBI 4.4 +/- 0.9 ms(2), C 7.1 +/- 1.4 ms(2). In low frequency: TBI 3.3 +/- 1.1 ms(2), C 6.4 +/- 1.4 ms(2); In high frequency TBI 2.0 +/- 1.0 ms(2), C 4.8 +/- 1.3 ms(2), all p < 0.05). Thus, abnormalities in both time and frequency domains of HRV are present in TBI during the pose-acute recovery phase.	HELEN HAYES HOSP, DEPT NEUROL, W HAVERSTRAW, NY 10993 USA; ST LUKES ROOSEVELT HOSP, DIV CARDIOL, ARRHYTHMIA SERV, NEW YORK, NY USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10027 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT NEUROL, NEW YORK, NY 10027 USA		King, ML (corresponding author), HELEN HAYES HOSP, DEPT INTERNAL MED, ROUTE 9W, W HAVERSTRAW, NY 10993 USA.						BIGGER JT, 1993, J AM COLL CARDIOL, V21, P729, DOI 10.1016/0735-1097(93)90106-B; BINKLEY PF, 1993, J AM COLL CARDIOL, V21, P655, DOI 10.1016/0735-1097(93)90098-L; Camm AJ, 1996, CIRCULATION, V93, P1043; FRANK JI, 1992, ARCH NEUROL-CHICAGO, V49, P1200, DOI 10.1001/archneur.1992.00530350122028; GOLDSMITH RL, 1992, J AM COLL CARDIOL, V20, P552, DOI 10.1016/0735-1097(92)90007-A; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LATHERS CM, 1987, J CLIN PHARMACOL, V27, P346, DOI 10.1002/j.1552-4604.1987.tb03030.x; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; LOWENSOHN RI, 1977, LANCET, V1, P626; NIEMELA MJ, 1994, J AM COLL CARDIOL, V23, P1370, DOI 10.1016/0735-1097(94)90379-4; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; TEASDALE G, 1974, LANCET, V2, P81; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008	14	66	66	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	1997	11	6					445	453					9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	WZ726	WOS:A1997WZ72600005	9171929				2022-02-06	
J	Wahl, F; Renou, E; Mary, V; Stutzmann, JM				Wahl, F; Renou, E; Mary, V; Stutzmann, JM			Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury	BRAIN RESEARCH			English	Article						brain injury; head trauma; fluid percussion; neurological deficit; neuroprotection; riluzole	FOCAL CEREBRAL-ISCHEMIA; AMINO-ACID NEUROTRANSMISSION; SODIUM-CHANNEL BLOCKER; CLOSED-HEAD INJURY; 2-AMINO-6-TRIFLUOROMETHOXY BENZOTHIAZOLE; ELIPRODIL SL-82.0715; POSSIBLE ANTAGONIST; MAGNETIC-RESONANCE; GLUTAMATE RELEASE; NMDA RECEPTORS	Riluzole (2-amino 6-trifluoromethoxy-benzothiazole) was studied in a rat model of traumatic brain injury (TBI) induced by a fluid percussion applied laterally to the right parietal cortex. Study I: vehicle or riluzole (4 or 8 mg/kg) was administered 15 min (i.v.), 6 h and 24 h (s.c.), after TBI. Brain lesions were quantified 1 week after insult. Riluzole significantly reduced the size of TBI-induced lesions by approximately 44% with either dose regime(P < 0.05). Study II: vehicle or riluzole (8 mg/kg) was administered 15 min (i.v.), 6 h (i.p.) and then twice daily (i.p.) for 6 days, after injury. One, 2 and 3 weeks after TBI, a neurological examination was performed. Control injured rats had a significant neurological deficit at 1, 2 and 3 weeks (P < 0.001). Riluzole treatment did not modify the neurological status evaluated for the first 2 weeks after TBI. However at 3 weeks, riluzole significant improved the neurological function of injured rats (P < 0.05). These results suggest that riluzole may be beneficial in the clinical treatment of TBI. The protective action of riluzole may result from (i) stabilization of the inactivated state of voltage-dependent sodium channels, (ii) indirect action on the glutamatergic pathway, and/or (iii) indirect neurotrophic effect.			Wahl, F (corresponding author), RHONE POULENC RORER, PHARMACEUT DISCOVERY, NEURODEGENERAT DIS DEPT, 13 QUAI JULES GUESDE, F-94403 VITRY SUR SEINE, FRANCE.						BARBEITO L, 1996, J NEUROTRAUM, V13, P629; BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENAZZOUZ A, 1995, EUR J PHARMACOL, V284, P299, DOI 10.1016/0014-2999(95)00362-O; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BITON B, 1994, EUR J PHARMACOL, V257, P297, DOI 10.1016/0014-2999(94)90142-2; BOIREAU A, 1994, NEUROREPORT, V5, P2157, DOI 10.1097/00001756-199410270-00042; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Dargent B, 1996, NEUROSCIENCE, V73, P209, DOI 10.1016/0306-4522(95)00608-7; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; Mary V, 1995, NEUROSCI LETT, V201, P92, DOI 10.1016/0304-3940(95)12137-S; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; MIZOULE J, 1985, NEUROPHARMACOLOGY, V24, P767, DOI 10.1016/0028-3908(85)90011-5; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; RENUKAPRASAD M, 1994, J NEUROCHEM, V63, P1086; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; STUTZMANN JM, 1993, NEURODEGENER DIS, P205; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; Urenjak J, 1996, PHARMACOL REV, V48, P21; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	61	66	68	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 9	1997	756	1-2					247	255		10.1016/S0006-8993(97)00144-3			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XA015	WOS:A1997XA01500032	9187339				2022-02-06	
J	Stella, N; Estelles, A; Siciliano, J; Tence, M; Desagher, S; Piomelli, D; Glowinski, J; Premont, J				Stella, N; Estelles, A; Siciliano, J; Tence, M; Desagher, S; Piomelli, D; Glowinski, J; Premont, J			Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes	JOURNAL OF NEUROSCIENCE			English	Article						purinoceptor; phospholipase; cytokine; inflammation; glutamate; neurotoxicity	CENTRAL-NERVOUS-SYSTEM; CEREBRAL CORTICAL ASTROCYTES; NECROSIS-FACTOR-ALPHA; PRIMARY CULTURES; GENE-EXPRESSION; CYTOSOLIC PHOSPHOLIPASE-A2; STRIATAL ASTROCYTES; PURINERGIC RECEPTOR; EXTRACELLULAR ATP; BRAIN ASTROCYTES	During neuropathological states associated with inflammation, the levels of cytokines such as interleukin-1 beta (IL-1 beta) are increased. Several studies have suggested that the neuronal damage observed in pathogenesis implicating IL-1 beta are caused by an alteration in the neurochemical interactions between neurons and astrocytes. We report here that treating striatal astrocytes in primary culture with IL-1 beta for 22-24 hr enhances the ATP-evoked release of arachidonic acid (AA) with no effect on the ATP-induced accumulation of inositol phosphates. The molecular mechanism responsible for this effect involves the expression of P-2Y2 receptors (a subtype of purinoceptor activated by ATP) and cytosolic phospholipase A2 (cPLA(2), an enzyme that mediates AA release). Indeed, P-2Y2 antisense oligonucleotides reduce the ATP-evoked release of AA only from IL-1 beta-treated astrocytes. Further, both the amount of cPLA2 (as assessed by Western blotting) and the release of AA resulting from direct activation of cPLA(2) increased fourfold in cells treated with IL-1 beta. We also report evidence indicating that the coupling of newly expressed P-2Y2 receptors to cPLA(2) is dependent on PKC activity. These results suggest that during inflammatory conditions, IL-1 beta reveals a functional P-2Y2 signaling pathway in astrocytes that results in a dramatic increase in the levels of free AA. This pathway may thus contribute to the neuronal loss associated with cerebral ischemia or traumatic brain injury.	COLL FRANCE,INSERM U114,NEUROPHARMACOL LAB,F-75231 PARIS 05,FRANCE		Stella, N (corresponding author), INST NEUROSCI,10640 JOHN J HOPKINS DR,SAN DIEGO,CA 92121, USA.						ABBRACCHIO MP, 1994, NEUROSCIENCE, V59, P67, DOI 10.1016/0306-4522(94)90099-X; AKBAR MGK, 1996, J BIOL CHEM, V271, P18363; BAN EM, 1993, NEUROSCIENCE, V52, P725, DOI 10.1016/0306-4522(93)90421-B; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNER G, 1990, J NEUROCHEM, V55, P1569, DOI 10.1111/j.1471-4159.1990.tb04940.x; CAMERON RS, 1991, GLIA, V4, P124, DOI 10.1002/glia.440040204; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P812; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTJANSON LJ, 1993, GLIA, V7, P176, DOI 10.1002/glia.440070207; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DELUMEAU JC, 1991, EUR J NEUROSCI, V3, P539, DOI 10.1111/j.1460-9568.1991.tb00841.x; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; ELETR M, 1989, J NEUROSCI, V9, P1473; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; GALLIGAN JJ, 1994, J NEUROSCI, V14, P7563; GEBICKEHAERTER PJ, 1988, N-S ARCH PHARMACOL, V338, P704, DOI 10.1007/BF00165638; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HERTIER E, 1988, J NEUROSCI RES, V21, P391; KASTRITSIS CHC, 1992, J NEUROCHEM, V58, P1277; KATCHMAN AN, 1994, NEUROSCI LETT, V168, P217, DOI 10.1016/0304-3940(94)90454-5; KATSUURA G, 1989, ENDOCRINOLOGY, V124, P3125, DOI 10.1210/endo-124-6-3125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Magistretti Pierre J., 1995, P657; MARIN P, 1993, MOL PHARMACOL, V44, P1176; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; NEARY JT, 1994, J NEUROCHEM, V63, P490; NEGRO A, 1992, GLIA, V6, P206, DOI 10.1002/glia.440060308; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; OKA S, 1991, J BIOL CHEM, V266, P9956; OKUDA S, 1994, NEUROSCIENCE, V63, P691, DOI 10.1016/0306-4522(94)90515-0; OZAKI M, 1994, BIOCHEM BIOPH RES CO, V205, P12, DOI 10.1006/bbrc.1994.2622; PEARCE B, 1989, J NEUROCHEM, V52, P971, DOI 10.1111/j.1471-4159.1989.tb02549.x; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; RICHARDSON PJ, 1987, J NEUROCHEM, V48, P622, DOI 10.1111/j.1471-4159.1987.tb04138.x; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORG O, 1995, NEUROSCI LETT, V188, P109, DOI 10.1016/0304-3940(95)11410-X; STELLA N, 1994, J NEUROSCI, V14, P568; STELLA N, 1994, RENAL PHYSIOL BIOCH, V17, P153; THERY C, 1992, J NEUROCHEM, V59, P1183, DOI 10.1111/j.1471-4159.1992.tb08366.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Webb TE, 1996, MOL PHARMACOL, V50, P258; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMAMOTO K, 1988, BIOCHEM BIOPH RES CO, V156, P882, DOI 10.1016/S0006-291X(88)80926-4; YU ACH, 1986, J NEUROCHEM, V47, P1181; YU NC, 1995, MOL PHARMACOL, V48, P550; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	76	66	68	0	0	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036	0270-6474			J NEUROSCI	J. Neurosci.	MAY 1	1997	17	9					2939	2946					8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WU675	WOS:A1997WU67500003	9096130				2022-02-06	
J	Kreutzer, JS; Witol, AD; Marwitz, JH				Kreutzer, JS; Witol, AD; Marwitz, JH			Alcohol and drug use among young persons with traumatic brain injury	JOURNAL OF LEARNING DISABILITIES			English	Article							HEAD-INJURY; SUBSTANCE USE; FOLLOW-UP; HYPERACTIVE BOYS; ADOLESCENTS; POPULATION; REHABILITATION; DISABILITIES; PREVALENCE; PATTERNS	The pre- and postinjury patterns of alcohol and illicit drug use of 87 persons with traumatic brain injury ages 16 to 20 were examined. Follow-up data were collected at two time intervals averaging 8 and 28 months postinjury. A comparison with large-sample studies revealed that patients had preinjury drinking patterns similar to those in the general population. A review of data provided evidence of a decline in alcohol use at initial follow-up; however, preinjury and second follow-up alcohol use patterns were similar. Analyses suggested that drinking quantity and frequency increased over time, perhaps eventually returning to postinjury levels. A review of the literature and the findings of the present investigation indicate that men and persons with a history of preinjury heavy drinking are at greatest risk for long-term alcohol abuse postinjury. Postinjury illicit drug use rates remained relatively low, falling below 10% at both follow-up intervals. Among persons taking prescribed medications, 17% reported moderate or heavy drinking at second follow-up.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROL SURG,DEPT SURG,RICHMOND,VA 23298								Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; ALLDADI V, 1986, PHARM ALERT, V16, P2; AUGUST GJ, 1983, BRIT J PSYCHIAT, V143, P192, DOI 10.1192/bjp.143.2.192; BECK L, 1975, AM J PSYCHIAT, V132, P436, DOI 10.1176/ajp.132.4.436; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Bruck M., 1985, ADV APPLIED DEV PSYC, P91; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; CLAMPIT MK, 1983, ADOLESCENCE, V18, P811; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Drubach D A, 1993, Md Med J, V42, P989; ENGS RC, 1988, PUBLIC HEALTH REP, V103, P667; GALBRAITH S, 1976, BRIT J SURG, V63, P735; GITTELMAN R, 1985, ARCH GEN PSYCHIAT, V42, P937; GLOW BA, 1989, ALCOHOLISM SUBSTANCE, P65; GOLD MA, 1993, J ADOLESCENT HEALTH, V14, P80, DOI 10.1016/1054-139X(93)90089-8; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HILTON ME, 1987, ALCOHOL CLIN EXP RES, V11, P167, DOI 10.1111/j.1530-0277.1987.tb01283.x; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAAG JW, 1994, J LEARN DISABIL, V27, P223, DOI 10.1177/002221949402700404; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MAISTO SA, 1979, J CONSULT CLIN PSYCH, V47, P106, DOI 10.1037/0022-006X.47.1.106; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MEILMAN PW, 1990, J STUD ALCOHOL, V51, P389, DOI 10.15288/jsa.1990.51.389; MILLS CJ, 1984, J CONSULT CLIN PSYCH, V52, P231, DOI 10.1037/0022-006X.52.2.231; MOORE D, 1991, INT J ADDICT, V26, P65, DOI 10.3109/10826089109056240; MOTETGRIGORAS CN, 1986, J CLIN PSYCHIAT, V47, P234; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; National Institute on Drug Abuse, 1991, DHHS PUBL; Newcomb MD, 1987, J APPLIED DEV PSYCHO, V8, P221, DOI DOI 10.1016/0193-3973(87)90001-3; OSHANICK GJ, 1990, COMMUNITY INTEGRATIO, P15; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROBINSON TN, 1987, JAMA-J AM MED ASSOC, V258, P2072, DOI 10.1001/jama.258.15.2072; SANDER A, 1996, 20 ANN POSTGR COURS; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; *WI DEP HLTH SOC S, 1985, ALC US PERS DIS PREL; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955	51	66	66	0	6	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	NOV	1996	29	6					643	651		10.1177/002221949602900608			9	Education, Special; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Rehabilitation	VU234	WOS:A1996VU23400008	8942308				2022-02-06	
J	Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO				Wade, SL; Taylor, HG; Drotar, D; Stancin, T; Yeates, KO			Childhood traumatic brain injury: Initial impact on the family	JOURNAL OF LEARNING DISABILITIES			English	Article							CLOSED HEAD-INJURY; ASSESSMENT DEVICE; CHILDREN; SEQUELAE; RELIABILITY; VALIDITY	Traumatic brain injury (TBI) is a significant source of morbidity and mortality in children, resulting in a wide range of cognitive and behavioral sequelae. However, little is known about the effects of pediatric TBI and its aftermath on families. The current investigation examined the impact of TBI on families during the first month following injury. Children with orthopedic injuries requiring hospitalization served as a control group. The sample consisted of 44 families of children of severe TBI, 52 families of children with moderate TBI, and 69 families of children with orthopedic injuries not involving the central nervous system (CNS). Families of children with severe TBI experienced significantly more injury-related stress than the other two groups of families. Parents of children with TBI also reported higher levels of psychological symptoms than parents of children with orthopedic injuries. Findings from regression analyses suggested that families facing multiple stressors in addition to the injury and those who cope poorly may be at greatest risk for adverse consequences. Future interventions could provide anticipatory guidance and support to at-risk families.	RAINBOW BABIES & CHILDRENS HOSP,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PSYCHOL,SCH MED,CLEVELAND,OH 44106; METROHLTH MED CTR,DEPT PSYCHIAT,CLEVELAND,OH 44109; OHIO STATE UNIV,COLUMBUS,OH 43210; COLUMBUS CHILDRENS HOSP,COLUMBUS,OH 43205				Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Derogatis L. R., 1982, ADM PROCEDURES BSI M; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DROTAR S, 1996, FAMILY BURDEN INJURY; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; JENNETT B, 1975, LANCET, V1, P480; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; Levin HS., 1982, NEUROBEHAVIORAL CONS; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos RH, 1988, J SUBSTANCE ABUSE, V1, P135, DOI DOI 10.1016/S0899-3289(88)80017-8; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; ROLLAND JS, 1987, FAM PROCESS, V26, P203, DOI 10.1111/j.1545-5300.1987.00203.x; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P83; Stein R, 1985, PACTS PAPERS AECOM T; TAYLOR HG, IN PRESS TRAUMATIC B; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; [No title captured], DOI DOI 10.1097/00001199-198812000-00004	30	66	68	0	3	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	NOV	1996	29	6					652	661		10.1177/002221949602900609			10	Education, Special; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Rehabilitation	VU234	WOS:A1996VU23400009	8942309				2022-02-06	
J	Gorman, LK; Fu, K; Hovda, DA; Murray, M; Traystman, RJ				Gorman, LK; Fu, K; Hovda, DA; Murray, M; Traystman, RJ			Effects of traumatic brain injury on the cholinergic system in the rat	JOURNAL OF NEUROTRAUMA			English	Article						basal forebrain; hippocampus; fluid percussion; medial septal area; septohippocampal	RECEPTOR-BINDING; BASAL FOREBRAIN; NUCLEUS BASALIS; SPATIAL MEMORY; LONG-TERM; HIPPOCAMPAL; NEURONS; SEPTUM; PROJECTIONS; DEFICITS	Rats subjected to a mild to moderate fluid percussion injury exhibit memory deficits that are similar to rats that have received lesions of the septohippocampal system. Because the cholinergic system plays a major role in septohippocampal function, we studied the kinetics of the synthetic enzyme for acetylcholine, choline acetyltransferase (ChAT), at 1 h, 24 h, or 5 days after a fluid percussion injury. Decreases in ChAT activity were found in the dorsal hippocampus (25%), frontal (32%), and temporal (23%) cortices 1 h after injury. In the parietal cortex, a greater than 50% increase in ChAT activity was observed at all time intervals assessed. At 5 days after TBI, there was an 18% increase in ChAT activity in the medial septal area. These data provide evidence that a mild to moderate fluid percussion injury produces changes in the cholinergic system in brain areas related to memory.	UNIV CALIF LOS ANGELES,DEPT SURG,DIV NEUROSURG,LOS ANGELES,CA 90024		Gorman, LK (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT ANESTHESIOL CRIT CARE MED,1404 BLALOCK,600 N WOLFE ST,BALTIMORE,MD 21287, USA.		Murray, Micah/A-8851-2008	Murray, Micah/0000-0002-7821-117X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30308] Funding Source: Medline		BECKER DP, 1989, SOC NEUR ABSTR 1, P131; BIGL V, 1982, BRAIN RES BULL, V8, P727, DOI 10.1016/0361-9230(82)90101-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cooper JR, 1991, BIOCH BASIS NEUROPHA; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNNETT SB, 1985, PSYCHOPHARMACOLOGY, V87, P357, DOI 10.1007/BF00432721; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; GALLAGHER M, 1990, NEUROBIOL AGING, V11, P507, DOI 10.1016/0197-4580(90)90111-C; GAYKEMA RPA, 1990, J COMP NEUROL, V293, P103, DOI 10.1002/cne.902930109; GAYKEMA RPA, 1991, J COMP NEUROL, V303, P563, DOI 10.1002/cne.903030405; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GORMANLK, 1995, SOC NEUR ABSTR, V21, P471; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; LAMOUR Y, 1984, BRAIN RES, V309, P227; LERANTH C, 1992, BRAIN RES, V583, P1, DOI 10.1016/S0006-8993(10)80004-6; LUINE V, 1990, BRAIN RES, V523, P321, DOI 10.1016/0006-8993(90)91507-D; LYETH B, 1988, BRAIN RES, V488, P88; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; OLTON DS, 1979, NEUROPSYCHOLOGIA, V17, P669, DOI 10.1016/0028-3932(79)90042-3; OLTON DS, 1993, MEMORY ORG LOCUS CHA; ROBBINS TW, 1989, BEHAV BRAIN RES, V35, P221, DOI 10.1016/S0166-4328(89)80143-3; RYLETT RJ, 1993, J NEUROSCI, V13, P3956; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833	33	66	69	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1996	13	8					457	463		10.1089/neu.1996.13.457			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	VH009	WOS:A1996VH00900003	8880609				2022-02-06	
J	Vink, R; Heath, DL; McIntosh, TK				Vink, R; Heath, DL; McIntosh, TK			Acute and prolonged alterations in brain free magnesium following fluid percussion-induced brain trauma in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						magnesium; magnetic resonance; injury; bioenergetics	MAGNETIC-RESONANCE SPECTROSCOPY; METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; INJURY; NEURONS; DAMAGE; HIPPOCAMPUS; METABOLISM; ENERGY; CELL	Several studies have reported declines in brain total and free magnesium concentration after a traumatic insult to the CNS. Although the evidence suggests that this magnesium decline is associated with eventual neurologic outcome after trauma, the duration of free magnesium decline and its impact on related bioenergetic variables are relatively unknown. The present study has therefore used phosphorus magnetic resonance spectroscopy to determine the length of time that free magnesium remains suppressed after traumatic brain injury in rats. Immediately after the traumatic event, brain intracellular free magnesium declined to <60% of preinjury values and remained significantly depressed (50 +/- 8%; p < 0.001) for 5 days before recovering to preinjury levels by day 8. Cytosolic phosphorylation ratio and mitochondrial oxidative capacity also significantly decreased (p = 0.008) and increased (p = 0.002), respectively, after trauma. However, unlike the time of maximum magnesium change, the maximum changes in these bioenergetic variables occurred at 16-24 h after trauma and thereafter remained stable until after the magnesium had recovered. We conclude that free magnesium decline after trauma precedes changes in bioenergetic variables. Furthermore, therapies targeted at reestablishing magnesium homeostasis after trauma may require administration over a 1-week period.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104		Vink, R (corresponding author), JAMES COOK UNIV N QUEENSLAND,DEPT PHYSIOL & PHARMACOL,TOWNSVILLE,QLD 4811,AUSTRALIA.		Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R55NS026818, R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS26818] Funding Source: Medline		ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; AVISON MJ, 1986, ANNU REV BIOPHYS BIO, V15, P377; Bara M., 1984, MAGNESIUM, V3, P212; BENYOSEPH O, 1990, J NEUROCHEM, V55, P1446, DOI 10.1111/j.1471-4159.1990.tb03160.x; BUCHLI R, 1994, MAGNET RESON MED, V32, P447, DOI 10.1002/mrm.1910320404; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; CHANCE B, 1986, FED PROC, V45, P2915; COHN M, 1962, J BIOL CHEM, V237, P176; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; EVELHOCH JL, 1984, J MAGN RESON, V56, P110, DOI 10.1016/0022-2364(84)90195-1; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GAWAZ M, 1994, THROMB HAEMOSTASIS, V72, P912; GORDON RE, 1982, J MAGN RESON, V46, P322, DOI 10.1016/0022-2364(82)90148-2; GUNTHER T, 1994, MAGNESIUM-B, V16, P38; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HOVDA DA, 1992, CENTRAL NERVOUS SYST, P47; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; JENKINS WT, 1994, ARCH BIOCHEM BIOPHYS, V313, P89, DOI 10.1006/abbi.1994.1363; KASS IS, 1988, ANESTHESIOLOGY, V69, P710, DOI 10.1097/00000542-198811000-00012; KWACK H, 1992, CURR TOP CELL REGUL, V33, P185; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Nelson KB, 1995, PEDIATRICS, V95, P1; NICOLETTI F, 1987, J NEUROCHEM, V48, P967, DOI 10.1111/j.1471-4159.1987.tb05611.x; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PRASAD MR, 1994, J NEUROCHEM, V63, P773; RAJDEV S, 1995, J NEUROPHYSIOL, V74, P942, DOI 10.1152/jn.1995.74.3.942; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; RODRIGUEZ FD, 1992, J NEUROCHEM, V59, P467, DOI 10.1111/j.1471-4159.1992.tb09393.x; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; RUBIN H, 1977, J CELL PHYSIOL, V91, P449, DOI 10.1002/jcp.1040910315; SEELIG JM, 1983, AM J PHYSIOL, V245, P22; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TERASAKI M, 1985, P NATL ACAD SCI USA, V82, P7324, DOI 10.1073/pnas.82.21.7324; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, J NEUROTRAUMA, V5, P365; WOLF G, 1990, NEUROSCI LETT, V117, P207, DOI 10.1016/0304-3940(90)90145-Y; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	62	66	69	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	JUN	1996	66	6					2477	2483					7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	UL589	WOS:A1996UL58900030	8632172				2022-02-06	
J	Raghupathi, R; McIntosh, TK				Raghupathi, R; McIntosh, TK			Regionally and temporally distinct patterns of induction of c-fos, c-jun and junB mRNAs following experimental brain injury in the rat	MOLECULAR BRAIN RESEARCH			English	Article						immediate early genes; c-fos; c-jun; JunB; traumatic brain injury	DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; MAMMALIAN BRAIN; NMDA RECEPTORS; GROWTH-FACTORS; NERVE; ACCUMULATION; HIPPOCAMPUS; MODEL; PROMOTER	Lateral (parasagittal) fluid-percussion brain injury of mild (1.0-1.5 atm) and moderate (2.1-2.4 atm) severity induced expression of mRNAs for the immediate early genes (IEGs) c-fos, c-jun and junB. At 5 min following mild brain injury, c-fos and junB mRNA were co-induced in the cortex ipsilateral to the impact site. Expression remained elevated up to 2 h after injury and returned to control levels by 6 h. Levels of c-fos mRNA increased in the cells of the hippocampal dentate gyrus as early as 5 min after mild brain injury and additionally in the areas CA(1-3) by 30 min. By 2 h, no hippocampal c-fos mRNA was detectable. Induction of junB mRNA in the hippocampus was delayed, occurring at 30 min after injury, and remained elevated up to 2 h post injury. Increased levels of junB mRNA were also observed in the striatum ipsilateral to the injury. Increased expression of c-jun mRNA was restricted to the ipsilateral dentate gyrus and was observed at 5 min after injury and remained elevated up to 6 h. Although the temporal pattern of induction of individual IEGs after brain injury of moderate severity was similar to that observed after mild severity, moderate injury induced IEG mRNA in both injured and contralateral hemispheres. These data suggest that traumatic brain injury invokes a complex acute regional and cellular response which may involve the activation of multiple signal transduction pathways.			Raghupathi, R (corresponding author), UNIV PENN, SCH MED,DEPT SURG,DIV NEUROSURG,HAYDEN HALL, RM 7, 3320 SMITH WALK, PHILADELPHIA, PA 19104 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0-1 NS26818, P0-1 NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; ARENANDER A, 1992, PROG BRAIN RES, V94, P177; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; CURRAN T, 1987, ONCOGENE, V2, P79; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DRAGUNOW M, 1990, NEUROSCI LETT, V109, P128, DOI 10.1016/0304-3940(90)90550-S; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; DRAGUNOW M, 1993, INT J DEV NEUROSCI, V11, P249, DOI 10.1016/0736-5748(93)90083-P; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; KINOUCHI H, 1994, J CEREBR BLOOD F MET, V14, P808, DOI 10.1038/jcbfm.1994.101; KINOUCHI H, 1994, NEUROSCI LETT, V179, P111, DOI 10.1016/0304-3940(94)90947-4; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEAH JD, 1993, NEUROSCIENCE, V57, P53, DOI 10.1016/0306-4522(93)90111-R; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORATALLA R, 1993, J NEUROSCI, V13, P423; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NEUMANNHAEFELIN T, 1994, J CEREBR BLOOD F MET, V14, P206, DOI 10.1038/jcbfm.1994.27; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Pierce JES, 1996, J NEUROSCI, V16, P1083; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi Ramesh, 1994, Society for Neuroscience Abstracts, V20, P542; RINK A, 1995, AM J PATHOL, V147, P1575; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIMONATO M, 1991, MOL BRAIN RES, V11, P115, DOI 10.1016/0169-328X(91)90113-C; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	46	66	69	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	APR	1996	37	1-2					134	144		10.1016/0169-328X(95)00289-5			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UL348	WOS:A1996UL34800015	8738144				2022-02-06	
J	Posmantur, RM; Kampfl, A; Taft, WC; Bhattacharjee, M; Dixon, CE; Bao, J; Hayes, RL				Posmantur, RM; Kampfl, A; Taft, WC; Bhattacharjee, M; Dixon, CE; Bao, J; Hayes, RL			Diminished microtubule-associated protein 2 (MAP2) immunoreactivity following cortical impact brain injury	JOURNAL OF NEUROTRAUMA			English	Article						microtubule-associated protein 2; Western blotting; immunocytochemistry; dendritic change; rat	FLUID-PERCUSSION MODEL; MIDDLE CEREBRAL-ARTERY; HIPPOCAMPAL SLICES; CALPAIN-I; HEAD-INJURY; RAT; NEURONS; PROTEOLYSIS; OCCLUSION; HYPOXIA	This study employed Western blotting and qualitative immunohistochemistry to analyze the effects of cortical impact traumatic brain injury (TBI) on acute changes in MAP2 immunoreactivity in the rat cortex, We employed a lateral cortical impact injury device to induce severe TBI, which is associated with focal cortical contusion and neuronal death at the impact site, Three hours following TBI, Western blotting detected substantial MAP2 loss only in the cortex ipsilateral to the site of injury, Light microscopic studies of MAP2 revealed a prominent loss of MAP2 immunofluorescence in apical dendrites of pyramidal neurons within layers 3 and 5, as well as a loss of fine dendritic arborization within layer 1, These changes in MAP2 immunolabeling were associated with, but not exclusively restricted to, the presence of dark shrunken neurons labeled by hematoxylin and eosin staining, suggesting impending cell death, Alterations in MAP2 immunofluorescence were found both within and beyond areas of focal contusion and necrosis in the ipsilateral cortex, Thus, traumatic brain injury in rats can produce rapid and significant dendritic pathology within sites of contusion, However, immunohistochemical changes in MAP2 labeling outside of contused regions suggests that TBI-induced dendritic damage may not be exclusively associated with acute cell death.	UNIV TEXAS, HOUSTON HLTH SCI CTR, DEPT NEUROSURG, HOUSTON, TX 77030 USA; UNIV TEXAS, HOUSTON HLTH SCI CTR, DEPT PATHOL, HOUSTON, TX 77030 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31998, R01 NS21458] Funding Source: Medline		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; ARAI A, 1991, BRAIN RES, V555, P276, DOI 10.1016/0006-8993(91)90352-V; BARINAGA M, 1995, SCIENCE, V268, P200, DOI 10.1126/science.7536341; BERKOWITZ SA, 1977, BIOCHEMISTRY-US, V16, P5610, DOI 10.1021/bi00644a035; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; CROALL DE, 1990, INTRACELLULAR CALCIU, P103; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1995, IN PRESS CATASTROPHI; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; ISOKAWA M, 1991, NEUROSCI LETT, V132, P212, DOI 10.1016/0304-3940(91)90304-C; KAMPFL A, 1995, NEUROSCI LETT, V194, P149, DOI 10.1016/0304-3940(95)11745-I; KAMPFL A, 1995, IN PRESS EUR J NEURO; KAMPFL AW, 1994, SOC NEUR ABSTR, V20; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LEWIS SA, 1986, J CELL BIOL, V102, P2098, DOI 10.1083/jcb.102.6.2098; LI Z, 1995, IN PRESS NEUROCHEM I; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELLOR GW, 1989, BIOCHEM J, V290, P75; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MULTANI P, 1994, EPILEPSIA, V35, P728, DOI 10.1111/j.1528-1157.1994.tb02503.x; North M, 1989, PROTEOLYTIC ENZYMES, P105; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POSMANTUR RM, 1995, UNPUB J NEUROSCI; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Regehr Wade G., 1994, Current Opinion in Neurobiology, V4, P373, DOI 10.1016/0959-4388(94)90099-X; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SAATMAN KE, 1994, IN PRESS J NEUR ABST; SCHORMAIR C, 1993, BRAIN RES BULL, V32, P329, DOI 10.1016/0361-9230(93)90196-I; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALDIVIA MM, 1982, BIOCHEM BIOPH RES CO, V105, P1241, DOI 10.1016/0006-291X(82)90920-2; WHITSON JS, 1995, NEUROSCI LETT, V197, P159, DOI 10.1016/0304-3940(95)11921-I; WHITSON JS, 1995, BRAIN RES, V948, P213; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X	60	66	66	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1996	13	3					125	137		10.1089/neu.1996.13.125			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	UD469	WOS:A1996UD46900002	8965322				2022-02-06	
J	GREENE, KA; MARCIANO, FF; JOHNSON, BA; JACOBOWITZ, R; SPETZLER, RF; HARRINGTON, TR				GREENE, KA; MARCIANO, FF; JOHNSON, BA; JACOBOWITZ, R; SPETZLER, RF; HARRINGTON, TR			IMPACT OF TRAUMATIC SUBARACHNOID HEMORRHAGE ON OUTCOME IN NONPENETRATING HEAD-INJURY .1. A PROPOSED COMPUTERIZED-TOMOGRAPHY GRADING SCALE	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC SUBARACHNOID HEMORRHAGE; NONPENETRATING HEAD INJURY; OUTCOME; GRADING SCALE	DIFFUSE AXONAL INJURY; TRANSCRANIAL DOPPLER ULTRASOUND; CEREBRAL BLOOD-FLOW; BRAIN INJURY; CT SCAN; INTRAVENTRICULAR HEMORRHAGE; VASOSPASM; SPASM; HUMANS; COMA	The presence of traumatic subarachnoid hemorrhage (tSAH) on admission computerized tomography (CT) scans obtained from patients suffering from severe, nonpenetrating head injury has been shown to be associated with a worse outcome than the injury alone would warrant. However, no previous study has provided a simple means of relating the amount of tSAH, its location, or other abnormal findings on initial head CT scans to outcome in patients with nonpenetrating head injury. In this study, admission head CT scans from 252 patients with tSAH, treated at a single institution, were reviewed to ascertain thickness of the tSAH; its location; evidence of mass lesion(s); shift of midline structures (less than or equal to 5 mm vs. > 5 mm); basal cistern effacement; and cortical sulcal effacement. The CT scans were then organized into Grades 1 to 4 with 1 indicating thin tSAH (less than or equal to 5 mm); 2, thick tSAH (> 5 mm); 3, thin tSAH with mass a lesion(s); and 4, thick tSAH with mass lesion(s). A stepwise regression analysis of CT features ranked them in descending order of contribution to Glasgow Outcome Scale (GOS) scores at the time of discharge from acute hospitalization as follows: basal cistern effacement, thickness of tSAH, cortical sulcal effacement, presence of mass lesion(s), and location of tSAH. A shift of midline structures was not found to be a significant variable. Further analysis comparing CT grades and admission postresuscitation Glasgow Coma Scale (GCS) scores was highly significant. Patients with lower CT grades had better admission GCS values and discharge GOS scores than those with higher CT grades. From their experience: the authors conclude that their CT grading scale is simple and reliable and relates significantly to outcome at the time of discharge from acute hospitalization.	ST JOSEPHS HOSP,BARROW NEUROL INST,DIV NEUROL SURG,EDITORIAL OFF,PHOENIX,AZ 85013; ST JOSEPHS HOSP,BARROW NEUROL INST,DIV NEURORADIOL,PHOENIX,AZ 85013; ARIZONA STATE UNIV,DEPT MATH,TEMPE,AZ 85287								ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; AWAD IA, 1987, STROKE, V18, P365, DOI 10.1161/01.STR.18.2.365; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRAAKMAN R, 1993, J NEUROTRAUMA S, V10, pS85; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CHAN KH, 1992, NEUROSURGERY, V30, P697; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CORDOBES F, 1983, J NEUROSURG, V58, P217, DOI 10.3171/jns.1983.58.2.0217; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; HILL AB, 1977, SHORT TXB MED STATIS, P118; HUNT WE, 1988, J NEUROSURG, V68, P985; JENNETT B, 1975, LANCET, V1, P480; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; LUERSSEN TG, 1989, INTRACRANIAL PRESSUR, V7, P598; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, J NEUROTRAUMA S, V10, pS84; RINKEL GJE, 1991, ANN NEUROL, V29, P463, DOI 10.1002/ana.410290503; RINKEL GJE, 1990, NEUROLOGY, V40, P1130, DOI 10.1212/WNL.40.7.1130; RINKEL GJE, 1991, AM J NEURORADIOL, V12, P829; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SHIGEMORI M, 1991, Neurologia Medico-Chirurgica, V31, P390, DOI 10.2176/nmc.31.390; SPETZLER RF, 1986, J NEUROSURG, V66, P476; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1974, LANCET, V2, P81; The European Study Group on Nimodipine in Severe Head Injury, 1994, J NEUROSURG, V80, P797; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WILBERGER JE, 1990, NEUROSURGERY, V27, P208, DOI 10.1227/00006123-199008000-00006; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	47	66	68	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1995	83	3					445	452		10.3171/jns.1995.83.3.0445			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	RR001	WOS:A1995RR00100010	7666221				2022-02-06	
J	HALL, KM; JOHNSTON, MV				HALL, KM; JOHNSTON, MV			OUTCOMES EVALUATION IN TBI REHABILITATION .2. MEASUREMENT TOOLS FOR A NATIONWIDE DATA SYSTEM	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article								In Part II we address tools for describing general functional levels of clients in acute care, in traumatic brain injury (TBI) rehabilitation programs, and in the community. Tools must be brief, have proven reliability, and measure characteristics common to moderately and severely brain-injured individuals. Possible components of a uniform dataset dedicated to TBI are described.	KESSLER INST REHABIL,E ORANGE,NJ; KESSLER INST REHABIL,W ORANGE,NJ		HALL, KM (corresponding author), SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128, USA.							0	66	66	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1994	75	12			SI		SC10	SC18					9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	PY709	WOS:A1994PY70900003	7993177				2022-02-06	
J	EVANS, RW				EVANS, RW			THE POSTCONCUSSION SYNDROME - 130 YEARS OF CONTROVERSY	SEMINARS IN NEUROLOGY			English	Article							MINOR HEAD-INJURY; POST-CONCUSSIONAL SYMPTOMS; MILD CONCUSSION; SEQUELAE; NEUROLOGY; LIGHT; SOUND; LONG	Controversial best describes the postconcussion syndrome. This controversy is expressed in the many terms proposed since the lectures of Erichsen in 1866 for the sequelae of usually mild head injury: spinal concussion, railway spine, railway brain, traumatic neurosis, nervous shock, traumatic hysteria, traumatic hysteroneurasthenia, spinal anemia, vasomotor symptom complex, litigation neurosis, compensation neurosis, accident neurosis, Erichsen's disease, Friedmann's disease, traumatic neurasthenia, the posttraumatic concussion state, the posttraumatic psychoneurotic state, traumatic encephalopathy, posttraumatic cerebral syndrome, posttraumatic syndrome, posttraumatic nervous instability, postconcussion syndrome, postconcussive syndrome, postconcussional syndrome, posttraumatic stress syndrome, and the persistent postconcussive syndrome. This article will selectively review definitions, historical aspects, causation, symptoms and signs, testing, prognosis, medicolegal aspects, and treatment. Other articles in this issue of Seminars review epidemiology, pathophysiology, neuropathology, posttraumatic headache, testing, and neuropsychologic testing. Areas of current controversy will be illustrated by some of the responses of neurologists in a recent nationwide survey we have conducted by mail, ''The Physician Survey on the Postconcussion and Whiplash Syndromes,'' of family physicians, neurologists, neurosurgeons, and orthopedists.1 Although the results may be biased because of a low response rate (21% of neurologists surveyed), the survey is the best information currently available on this topic. According to the survey results, neurologists see an average of five patients per month with postconcussion syndrome, and 7.1% of the neurology respondents had personally had a postconcussion syndrome with a mean duration of 1 month.	UNIV TEXAS,SCH MED,DEPT NEUROL,HOUSTON,TX 77025; BAYLOR COLL MED,HOUSTON,TX 77030; PK PLAZA HOSP,AMI,NEUROL SECT,HOUSTON,TX								Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; [Anonymous], 1989, Neurology, V39, P1100; Boake C., 1991, NEUROREHABILITATION, V1, P70; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CARTLIDGE NEF, 1978, SCOT MED J, V23, P103, DOI 10.1177/003693307802300146; CHILVERS CD, 1985, NEW ZEAL MED J, V98, P658; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; Denker P., 1944, NY STATE J MED, V44, P379; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Erichsen JE, 1882, CONCUSSION SPINE NER; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Evans RW., 1992, PROGNOSIS NEUROLOGIC, P97; EVANS RW, 1994, IN PRESS PHYSICIAN S; FEE CRA, 1988, ARCH EMERG MED, V5, P12; Friedmann M., 1892, ARCH PSYCHIAT, V23, P230; GENTILINI M, 1989, MILD HEAD INJURY, P163; Gray LC, 1893, TREATISE NERVOUS MEN, P570; GRINKER RR, 1934, NEUROLOGY, P790; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; Hodges R. M., 1881, BOSTON MED SURG J, V104, P361, DOI [10.1056/NEJM188104211041601, DOI 10.1056/NEJM188104211041601]; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jennett B, 1990, HDB CLIN NEUROLOGY, V13, P1; KEANE JR, 1992, NEUROL CLIN, V10, P849, DOI 10.1016/S0733-8619(18)30183-X; KOWAL L, 1992, AUST NZ J OPHTHALMOL, V20, P35, DOI 10.1111/j.1442-9071.1992.tb00701.x; KROHEL GB, 1986, ANN OPHTHALMOL, V18, P101; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MANDEL S, 1989, POSTGRAD MED, V85, P213; MENDELSON G, 1982, MED J AUSTRALIA, V2, P132, DOI 10.5694/j.1326-5377.1982.tb124267.x; MERSKEY H, 1992, NEUROL CLIN, V10, P895, DOI 10.1016/S0733-8619(18)30186-5; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Page Herbert, 1883, INJURIES SPINE SPINA; PRIGATANO GP, 1993, NEUROL CLIN, V11, P219, DOI 10.1016/S0733-8619(18)30179-8; PUTNAM RJ, 1883, BOSTON MED SURG J, V109, P217; Rigler Johannes, 1879, FOLGEN VERLETZUNGEN; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTSON A, 1988, AUST NZ J PSYCHIAT, V22, P396, DOI 10.3109/00048678809161348; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1978, INJURY, V10, P225; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; STEADMAN JH, 1969, P ROY SOC MED, V63, P23; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; TRIMBLE MR, 1981, POST TRAUMATIC NEURO; UOMOTO JM, 1992, WESTERN J MED, V157, P665; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Walton G. L., 1881, BOSTON MED SURG J, V109, P337, DOI 10.1056/NEJM188310111091501; 1881, LANCET, V1, P462; 1883, BOSTON MED SURG J, V109, P400	63	66	67	0	4	THIEME MEDICAL PUBL INC	NEW YORK	381 PARK AVE SOUTH, NEW YORK, NY 10016	0271-8235			SEMIN NEUROL	Semin. Neurol.	MAR	1994	14	1					32	39		10.1055/s-2008-1041056			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NE151	WOS:A1994NE15100007	8029557				2022-02-06	
J	LEESHALEY, PR; DUNN, JT				LEESHALEY, PR; DUNN, JT			THE ABILITY OF NAIVE SUBJECTS TO REPORT SYMPTOMS OF MILD BRAIN INJURY, POSTTRAUMATIC-STRESS-DISORDER, MAJOR DEPRESSION, AND GENERALIZED ANXIETY DISORDER	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							HEAD-INJURY	Diagnoses of major depression, post-traumatic stress disorder, generalized anxiety disorder, and mild brain injury are based in substantial part on the self-reported symptoms of patients. This study found that 96.9% of untrained subjects were able to endorse symptoms on checklists to meet the DSM-III-R self-report criteria for major depression, 96.9% for generalized anxiety disorder, and 86% for PTSD. For the non-DSM-III-R diagnosis of mild brain injury, 63.3% of subjects were able to correctly identify 5 or more of 10 symptoms associated with this condition. Forensic examiners are advised to exercise special care in utilizing evaluation procedures that are of a leading nature, such as symptom checklists in which examinees may exhibit response biases.									American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CAVANAUGH JL, 1984, BEHAVIORAL SCI LAW, V2, P1; GOUVIER WD, 1988, NEUROPSYCHOLOGY, V3, P273; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRICE JR, 1992, MALINGERING MENTAL D; ROGERS R, 1988, CLIN ASSESSMENT MALI; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1977, LANCET           JAN, P1; SILVAN P, 1992, DEFENDING PTSD DEPRE; Weissman H. N., 1990, BEHAVIORAL SCI LAW, V8, P67; WEISSMAN HN, 1991, FORENSIC REPORTS, V4, P417	14	66	66	0	0	CLINICAL PSYCHOLOGY PUBL CO	BRANDON	4 CONANT SQUARE, BRANDON, VT 05733	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	MAR	1994	50	2					252	256		10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T			5	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	NE675	WOS:A1994NE67500016	8014250				2022-02-06	
J	CHEN, TY; WONG, CW; CHANG, CN; LUI, TN; CHENG, WC; TSAI, MD; LIN, TK; EPSTEIN, MH; HORWITZ, NH				CHEN, TY; WONG, CW; CHANG, CN; LUI, TN; CHENG, WC; TSAI, MD; LIN, TK; EPSTEIN, MH; HORWITZ, NH			THE EXPECTANT TREATMENT OF ASYMPTOMATIC SUPRATENTORIAL EPIDURAL HEMATOMAS	NEUROSURGERY			English	Article						COMPUTED TOMOGRAMS; EPIDURAL HEMATOMA; EXPECTANT TREATMENT; HEAD INJURY; HOSPITALIZATION; SUPRATENTORIAL EPIDURAL HEMATOMA	NON-SURGICAL MANAGEMENT; EXTRADURAL HEMATOMAS; SPONTANEOUS RESOLUTION; CHILDREN; SIZE	SEVENTY-FOUR PATIENTS WITH a traumatic epidural hematoma (EDH) and a Glasgow Coma Scale score of more than 12 received expectant treatment; 14 subsequently underwent surgical evacuation of the EDH. A patient with initial brain computed tomograms (CT) showing an EDH volume of more than 30 ml, a thickness of more than 15 mm, and a midline shift beyond 5 mm tended to require surgery within 3 days of the injury when the brain had exhausted its compensatory mechanism and yielded to the expanding EDH. After the 3-day period, in the absence of neurological symptoms, the presence of the EDH may not be an indication for surgical evacuation or hospitalization beyond 7 days. In our patients, the presence of a skull fracture in the temporal bone, the heterogeneous density of the EDH in the CT scan, or the 6-hour period between the CT study and the injury did not significantly increase the failure rate of nonsurgical treatment. Although a zero mortality was achieved in this series, these guidelines may not be applicable to the management of an infratentorial EDH.			CHEN, TY (corresponding author), CHANG GUNG MEM HOSP,DEPT SURG,DIV NEUROSURG,199 TUNG HWA N RD,TAIPEI 10591,TAIWAN.						ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; BUCCI MN, 1986, NEUROSURGERY, V19, P65, DOI 10.1227/00006123-198607000-00009; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; COOK RJ, 1988, ACTA NEUROCHIR, V95, P90, DOI 10.1007/BF01790766; GARZAMERCADO R, 1979, NEUROSURGERY, V5, P500, DOI 10.1227/00006123-197910000-00018; GURDJIAN F, 1947, AM J SURG, V73, P267; HANDA J, 1979, SURG NEUROL, V11, P217; ILLINGWORTH R, 1983, J NEUROL NEUROSUR PS, V46, P558, DOI 10.1136/jnnp.46.6.558; JENNETT B, 1975, LANCET, V1, P480; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; MARSHALL LF, 1985, NEUROSURGERY, V16, P606; MCLAURIN RL, 1964, J NEUROSURG, V21, P364, DOI 10.3171/jns.1964.21.5.0364; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P285; POZZATI E, 1987, J TRAUMA, V27, P579, DOI 10.1097/00005373-198705000-00024; POZZATI E, 1986, NEUROSURGERY, V18, P696, DOI 10.1227/00006123-198606000-00003; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; SERVADEI F, 1988, J NEUROL NEUROSUR PS, V1, P526; TOCHIO H, 1984, NEUROSURGERY, V15, P96, DOI 10.1227/00006123-198407000-00018; WEAVER D, 1981, J NEUROSURG, V54, P248, DOI 10.3171/jns.1981.54.2.0248; WONG C-W, 1991, Asian Journal of Surgery, V14, P64; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; ZUCCARELLO M, 1981, NEUROSURGERY, V8, P434, DOI 10.1227/00006123-198104000-00005	27	66	71	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	FEB	1993	32	2					176	179		10.1227/00006123-199302000-00004			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	KL520	WOS:A1993KL52000004	8437654				2022-02-06	
J	HALL, ED				HALL, ED			NOVEL INHIBITORS OF IRON-DEPENDENT LIPID-PEROXIDATION FOR NEURODEGENERATIVE DISORDERS	ANNALS OF NEUROLOGY			English	Article; Proceedings Paper	SYMP ON THE ROLE OF IRON AND OXIDANT STRESS IN THE NORMAL AND PARKINSONIAN BRAIN	NOV 14-17, 1991	SARASOTA, FL	UNIV S FLORIDA			NERVOUS-SYSTEM TRAUMA; CEREBRAL-ARTERY OCCLUSION; EARLY DEGENERATION; BRAIN; ISCHEMIA; U74006F; INJURY; 21-AMINOSTEROIDS; PRESERVATION; RADICALS	A considerable body of information supports the occurrence and pathophysiological importance of oxygen radical-mediated lipid peroxidation in acute cerebral damage secondary to traumatic or ischemic injury. Moreover, peroxidative mechanisms have been implicated in chronic neurodegenerative (e.g., Alzheimer's and Parkinson's diseases) and demyelinating (e.g., multiple sclerosis) disorders. Consequently, there has been interest in identification of pharmacological agents with potent ability to interrupt oxygen radical formation or cell membrane lipid peroxidative mechanisms. Our laboratories have developed a novel series of potent lipid peroxidation inhibitors known as the 21-aminosteroids or "lazaroids." One of these compounds, U-74006F or tirilazad mesylate, has shown efficacy in animal models of brain injury and focal cerebral ischemia. In addition, the compound has been found to attenuate the increased lipid peroxidation observed in Alzheimer's brain tissue, to retard anterograde degeneration of motor nerve fibers, and to be effective in decreasing the clinical disease severity and blood-brain barrier disruption observed in the multiple sclerosis model of experimental allergic encephalomyelitis. Another series of antioxidants, the 2-methylaminochromans typified by the compound U-78517F, have been discovered that are even more potent and effective inhibitors of lipid peroxidation than the 21-aminosteroids.			HALL, ED (corresponding author), UPJOHN CO,CNS DIS RES,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013				ALTHAUS J S, 1991, Society for Neuroscience Abstracts, V17, P164; ANDORN AC, 1990, NEUROBIOL AGING, V11, P316; ANDRUS P K, 1991, Society for Neuroscience Abstracts, V17, P1086; AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; BECK T, 1991, BRAIN RES, V560, P159, DOI 10.1016/0006-8993(91)91226-Q; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V7, P125, DOI 10.1016/0891-5849(89)90003-8; BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; BRAUGHLER JM, 1988, J PHARMACOL EXP THER, V244, P423; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Dimlich R V, 1990, Adv Neurol, V52, P365; GELB AW, 1990, J NEUROSURG ANESTHES, V2, P240; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1990, BRAIN RES, V513, P244, DOI 10.1016/0006-8993(90)90462-K; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1984, EXP NEUROL, V84, P715, DOI 10.1016/0014-4886(84)90219-X; HALL ED, 1987, BRAIN RES, V413, P175, DOI 10.1016/0006-8993(87)90166-1; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1991, STROKE, V22, P361, DOI 10.1161/01.STR.22.3.361; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALL ED, 1992, IN PRESS NEW DRUG ST; KARLIK SJ, 1991, NEUR ABSTR, V17, P1453; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LYTHGOE D J, 1990, British Journal of Pharmacology, V100, p454P; MCINTOSH L J, 1991, Society for Neuroscience Abstracts, V17, P1071; MCINTOSH T, 1991, ACTA NEUROCHIR S, V51, P329; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; MYERS RE, 1990, STROKE, V21, P179; PANETTA JA, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P351; SATO PH, 1992, J NEUROCHEM, V58, P2263, DOI 10.1111/j.1471-4159.1992.tb10972.x; SILVIA RC, 1987, NEUR ABST, V13, P1499; SUBBARAO KV, 1990, J NEUROCHEM, V55, P342, DOI 10.1111/j.1471-4159.1990.tb08858.x; XUE D, 1992, STROKE, V23, P894, DOI 10.1161/01.STR.23.6.894; XUE D, 1990, Stroke, V21, P178; YOUNG W, 1988, STROKE, V19, P1013, DOI 10.1161/01.STR.19.8.1013	37	66	69	0	1	LITTLE BROWN CO	BOSTON	34 BEACON STREET, BOSTON, MA 02108-1493	0364-5134			ANN NEUROL	Ann. Neurol.		1992	32			S			S137	S142		10.1002/ana.410320724			6	Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JH405	WOS:A1992JH40500023	1510373				2022-02-06	
J	Hooker, DR				Hooker, DR			Physiological effects of air concussion	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article									Johns Hopkins Univ, Physiol Lab, Baltimore, MD USA								BURGE, 1918, AM J PHYSIOL, V45, P246; CANNON, 1918, JAMA-J AM MED ASSOC, V70, P611; CARVER, 1919, BRAIN, V42, P113; COMMANDER, 1916, REV GEN SCI     0415, P213; CRAMER, 1919, ARCH MAL COEUR, V11, P66; CRILE, OFFICIAL REPORT SURG; Dale HH, 1919, J PHYSIOL-LONDON, V52, P355; ERLANGER, 1919, AM J PHYSL, V49, P90; ERLANGER, 1919, AM J PHYSIOL, V49, P99; GATTI, 1918, RIFORMA MED, V34, P102; GITHENS, 1919, AM J PHYSIOL, V49, P120; HILL, 1912, CAISSON SICKNESS; HOOKER, 1918, AM J PHYSL, V46, P591; MAIRET, 1919, REV NEUROL, V26, P97; MAIRET, 1917, PRESSE MED      0816; MCKIBBEN, 1919, AM J PHYSIOL, V48, P331; MEEK, 1918, AM J PHYSIOL, V47, P302; MORISON, 1915, AM J PHYSIOL, V37, P86; MOTT, 1916, LANCET, V1, P441; MOTT, 1916, LANCET          0212; MOTT, 1917, BRIT MED J      0519; MOTT, 1917, J ROY ARMY MED CORPS, V29, P662; Mott FW, 1916, LANCET, V1, P331; Penfield WG, 1919, AM J PHYSIOL, V48, P121, DOI 10.1152/ajplegacy.1919.48.1.121; PORTER, 1908, AM J PHYSIOL, V20, P500; PORTER, 1916, AM J PHYSIOL, V39, P236; PORTER, 1918, BOSTON MED SURG J, V179, P273; SEELIG, 1908, J AM MED ASS, V52, P45; VANSLYKE, 1917, J BIOL CHEM, V30, P347; WALLACE, 1917, LANCET, V2, P727; WIGGERS, 1918, AM J PHYSIOL, V45, P485	31	66	68	0	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9513			AM J PHYSIOL	Am. J. Physiol.	JAN	1924	67	2					219	274					56	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	V35SW	WOS:000202415000001					2022-02-06	
J	Pulliam, L; Sun, B; Mustapic, M; Chawla, S; Kapogiannis, D				Pulliam, Lynn; Sun, Bing; Mustapic, Maja; Chawla, Sahil; Kapogiannis, Dimitrios			Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease	JOURNAL OF NEUROVIROLOGY			English	Article						Exosomes; Neurons; Biomarker; HIV; Alzheimer's; Dementia	NEUROFILAMENT LIGHT; SYNAPTIC PROTEINS; BLOOD EXOSOMES; AMYLOID-BETA; HYPOTHESIS; MARKERS	Fluid biomarkers for cognitive impairment have the advantage of being relatively noninvasive and capable of monitoring neuronal and other brain cell health in real time. Biomarkers can predict the onset of dementing illness, but also correlate with cognition in a dynamic way allowing us to follow treatment responses and determine brain recovery. Chronic HIV infection causes cognitive impairment in a subset of individuals suggesting "premature aging." Exosomes are small extracellular vesicles that are shed from all cells. They are important in normal cell-to-cell communication as they contain cellular proteins, mRNA transcripts, and miRNAs. Exosome cargo varies depending on the health of the cell and pathological state; specific proteins/mRNAs and/or miRNAs are present and may serve as biomarkers. Exosomes of variable cellular origin can be isolated from peripheral blood by various methods. Neuron-derived exosomes (NDEs) can be isolated using a precipitation/immunoaffinity approach using antibodies against neuronal cell adhesion molecule L1CAM and the contents queried for central nervous system (CNS) disorders including HIV-associated neurological disorders (HAND) and Alzheimer's disease (AD). As these studies are recent, numerous questions arise including which neuronal proteins are in NDEs and whether their contents differ in different CNS pathologies or with age. In addition, can the NDE cargo predict as well as diagnose cognitive impairment and could exosomal contents be used as therapeutic biomarkers, or theramarkers, of neuronal recovery from effective treatment? This mini-review will show some new data and review recent studies on NDE from individuals with HIV infection and AD. HIV-associated neurocognitive disorders (HAND) are pathologies seen in a subset of individuals with chronic HIV infection. They belong to the spectrum of neurodegenerative diseases that result in death or dysfunction of neurons with similarities to Alzheimer disease (AD) but also distinctive differences (reviewed (Canet et al., Front Cell Neurosci 12: 307, 2018)). Both disorders are difficult to diagnose without neuropsychological testing and both need new biomarkers to judge progression as well as recovery with treatment. Both disorders involve neuroinflammation and several common targets. AD is associated with aging and HIV is thought to initiate premature aging. In HIV infection, amyloid beta (A beta), which is deposited in "plaques" in AD, is soluble and its relevance to HIV-associated cognitive impairment is controversial (Achim et al., J Neuroimmune Pharmacol 4: 190-199, 2009; Rempel and Pulliam, AIDS 19: 127-135, 2005). A beta deposition is required for AD pathological diagnosis, but is not necessarily causative (Barage and Sonawane, Neuropeptides 52: 1-18, 2015; Hardy and Selkoe, Science 297: 353-356, 2002; Morris et al., Acta Neuropathol Commun 2: 135, 2014). Neurofilament light (NF-L) is a surrogate marker in plasma and cerebrospinal fluid (CSF) for neurodegeneration (Abu-Rumeileh et al., Alzheimers Res Ther 10: 3, 2018; Mattsson et al., JAMA Neurol 74: 557-566, 2017) but continues to be a controversial biomarker for both HAND and AD (Gisslen et al., EBioMedicine 3: 135-140, 2016; Kovacs et al., Eur J Neurol 24:1326-e77, 2017; Norgren et al., Brain Res 987: 25-31, 2003; Rolstad et al., J Alzheimers Dis 45: 873-881, 2015; Yilmaz et al., Expert Rev Mol Diagn 17: 761-770, 2017). Blood biomarkers are needed to advance both HAND and AD fields, as blood draws are less costly than neuroimaging and are minimally invasive compared to lumbar punctures required for CSF acquisition. Extracellular vesicles (EVs) are nanoscale membranous vesicles shed from all cells including those of the central nervous system (CNS) and found in all biofluids; they are divided into exosomes (30-150 nm) originating from late endosomes/multivesicular bodies and microvesicles (150-1000 nm) produced through budding of the plasma membrane. Both types of vesicles are implicated in the pathogenesis of neurodegenerative diseases and may provide biomarkers (Bellingham et al., Front Physiol 3: 124, 2012). In this report, we call the vesicles exosomes, since they are the predominant vesicles in our preparations. They are involved in cell-to-cell communication in normal homeostasis and can be carriers of toxic proteins (A beta, tau) (Sardar Sinha et al., Acta Neuropathol 136: 41-56, 2018) shed by cells as waste or actively secreted in a degenerative process (review Gupta and Pulliam, J Neuroinflammation 11: 68, 2014). The idea that exosomes originating from a specific cell can be recovered in the plasma using cellular surface markers of interest is intriguing. Neuron derived exosomes (NDEs) were first described in 2015 and isolated using antibodies against neural cell adhesion molecules NCAM or L1CAM, after total plasma exosome isolation (Fiandaca et al., Alzheimers Dement 11: 600-607 e1, 2015). Characterization of NDEs follows guidelines endorsed by the International Society for Extracellular Vesicles and includes Nanoparticle Tracking Analysis (NTA) to determine EV concentration and average diameter; Western Blots for EV markers; ELISAs for neuronal proteins and transmission EM for visualization (Sun et al., AIDS 31: F9-F17, 2017; Tang et al., FASEB J 30: 3097-106, 2016). This innovative isolation of an exosome sub-population has generated interest in using NDE as biomarkers for neurodegenerative diseases like AD, HAND, traumatic brain injury, posttraumatic stress disorder and more (reviews Agoston et al., Brain Inj 31: 1195-1203, 2017; Gupta and Pulliam, J Neuroinflammation 11: 68, 2014; Hu et al., Cell Death Dis 7: e2481, 2016; Karnati et al., J Neurotrauma, 2018; Osier et al., Mol Neurobiol, 2018). Several biomarkers from plasma NDEs were recently reported by the Pulliam lab to be elevated in general cognitive impairment (Sun et al., AIDS 31: F9-F17, 2017). We review our collective data here on HAND and AD and add to the characterization of plasma NDEs as exciting biomarkers of neurodegeneration.	[Pulliam, Lynn] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Pulliam, Lynn] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Pulliam, Lynn; Sun, Bing] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Mustapic, Maja; Chawla, Sahil; Kapogiannis, Dimitrios] NIA, Neurosci Lab, Intramural Res Program, NIH, Bldg 10, Bethesda, MD 20892 USA		Pulliam, L (corresponding author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.; Pulliam, L (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Pulliam, L (corresponding author), Vet Affairs Med Ctr, San Francisco, CA 94121 USA.; Kapogiannis, D (corresponding author), NIA, Neurosci Lab, Intramural Res Program, NIH, Bldg 10, Bethesda, MD 20892 USA.	Lynn.Pulliam@ucsf.edu; kapogiannisd@mail.nih.gov	Kapogiannis, Dimitrios/AAW-4934-2020; Mustapic, Maja/AAV-3212-2020	Kapogiannis, Dimitrios/0000-0003-2181-3118; Pulliam, Lynn/0000-0001-9120-134X	NIMH/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH112483] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21 MH112483] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH112483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000975] Funding Source: NIH RePORTER		Abner EL, 2016, ANN CLIN TRANSL NEUR, V3, P399, DOI 10.1002/acn3.309; Abu-Rumeileh S, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-017-0331-1; Achim CL, 2009, J NEUROIMMUNE PHARM, V4, P190, DOI 10.1007/s11481-009-9152-8; Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Anderson AM, 2018, J NEUROONCOL; Barage SH, 2015, NEUROPEPTIDES, V52, P1, DOI 10.1016/j.npep.2015.06.008; Bellingham SA, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00124; Canet G, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00307; Daily A, 2006, J NEUROVIROL, V12, P153, DOI 10.1080/13550280600760677; Eitan E, 2017, AGING CELL, V16, P1430, DOI 10.1111/acel.12657; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Gillies JA, 2019, BOUND-LAY METEOROL, V170, P443, DOI 10.1007/s10546-018-0402-2; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Goetzl EJ, 2018, FASEB J, V32, P888, DOI 10.1096/fj.201700731R; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Goetzl EJ, 2015, ANN CLIN TRANSL NEUR, V2, P769, DOI 10.1002/acn3.211; Goetzl EJ, 2015, NEUROLOGY, V85, P40, DOI 10.1212/WNL.0000000000001702; Goetzl EJ, 2018, FASEB J; Green DA, 2005, AIDS, V19, P407, DOI 10.1097/01.aids.0000161770.06158.5c; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Gupta A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-68; Hamlett E.D., 2016, ALZHEIMERS DEMENT; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hu GK, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.336; Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048; Karnati H.K., 2018, J NEUROTRAUMA; Kovacs GG, 2017, EUR J NEUROL, V24, P1326, DOI 10.1111/ene.13389; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; Morris GP, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0135-5; Mustapic M, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00278; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Osier N, 2018, MOL NEUROBIOL, V55, P9280, DOI 10.1007/s12035-018-1054-4; Peterson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116081; Rempel HC, 2005, AIDS, V19, P127, DOI 10.1097/00002030-200501280-00004; Rolstad S, 2015, J ALZHEIMERS DIS, V45, P873, DOI 10.3233/JAD-142694; Sinha MS, 2018, ACTA NEUROPATHOL, V136, P41, DOI 10.1007/s00401-018-1868-1; Sun B, 2017, AIDS, V31, pF9, DOI [10.1097/QAD.0000000000001595, 10.1097/qad.0000000000001595]; Tang N, 2016, FASEB J, V30, P3097, DOI 10.1096/fj.201600368RR; Winston Charisse N, 2016, Alzheimers Dement (Amst), V3, P63, DOI 10.1016/j.dadm.2016.04.001; Yilmaz A, 2017, EXPERT REV MOL DIAGN, V17, P761, DOI 10.1080/14737159.2017.1341313	41	65	67	6	78	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1355-0284	1538-2443		J NEUROVIROL	J. Neurovirol.	OCT	2019	25	5					702	709		10.1007/s13365-018-0695-4			8	Neurosciences; Virology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Virology	JJ9NL	WOS:000494478600008	30610738	Green Accepted			2022-02-06	
J	Lu, YH; Zhou, Y; Zhang, RY; Wen, LL; Wu, KM; Li, YF; Yao, YB; Duan, RR; Jia, YJ				Lu, Yanhui; Zhou, Yan; Zhang, Ruiyi; Wen, Lulu; Wu, Kaimin; Li, Yanfei; Yao, Yaobing; Duan, Ranran; Jia, Yanjie			Bone Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Recovery Following Spinal Cord Injury via Improvement of the Integrity of the Blood-Spinal Cord Barrier	FRONTIERS IN NEUROSCIENCE			English	Article						extracellular vesicles; bone mesenchymal stromal cells; spinal cord injury; blood spinal cord barrier; pericytes; migration; NF-kappa B	STROMAL CELLS; FUNCTIONAL RECOVERY; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; CONTRIBUTES; PERICYTES; EXOSOMES; MSC	Mesenchymal stem cell (MSC) transplantation has been shown to represent a potential treatment for traumatic spinal cord injury (SCI). However, there are several obstacles that need to be overcome before MSCs can be considered for clinical application, such as failure of MSCs to reach the spinal cord lesion core and possible tumor formation. Recent studies have suggested that MSC treatment is beneficial owing to paracrine-secreted factors. Extracellular vesicles are considered to be some of the most valuable paracrine molecules. However, the therapeutic mechanism of extracellular vesicles on spinal cord injury has not been studied clearly. Therefore, our study investigated the effect of systemic administration of extracellular vesicles on the loss of motor function after SCI and examined the potential mechanisms underlying their effects. Disruption of the blood-spinal cord barrier (BSCB) is a crucial factor that can be detrimental to motor function recovery. Pericytes are an important component of the neurovascular unit, and play a pivotal role in maintaining the structural integrity of the BSCB. Our study demonstrated that administration of bone mesenchymal stem cell-derived extracellular vesicles (BMSC-EV) reduced brain cell death, enhanced neuronal survival and regeneration, and improved motor function compared with the administration of BMSC-EV free culture media (EV-free CM). Besides, the BSCB was attenuated and pericyte coverage was significantly decreased in vivo. Furthermore, we found that exosomes reduced pericyte migration via downregulation of NF-kappa B p65 signaling, with a consequent decrease in the permeability of the BSCB. In summary, we identified that extracellular vesicles treatment suppressed the migration of pericytes and further improved the integrity of the BSCB via NF-kappa B p65 signaling in pericytes. Our data suggest that extracellular vesicles may serve as a promising treatment strategy for SCI.	[Lu, Yanhui; Zhang, Ruiyi; Wen, Lulu; Wu, Kaimin; Li, Yanfei; Yao, Yaobing; Duan, Ranran; Jia, Yanjie] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Henan, Peoples R China; [Lu, Yanhui; Zhang, Ruiyi] Zhengzhou Univ, Acad Med Sci, Zhengzhou, Henan, Peoples R China; [Zhou, Yan] Zhengzhou Univ, Affiliated Hosp 1, Dept Radiol, Zhengzhou, Henan, Peoples R China		Jia, YJ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Henan, Peoples R China.	jiayanjie1971@zzu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [U1604170]	This study was supported by National Natural Science Foundation of China (U1604170).	Bartanusz V, 2011, ANN NEUROL, V70, P194, DOI 10.1002/ana.22421; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008; Cheng JP, 2018, ACTA NEUROPATHOL, V136, P507, DOI 10.1007/s00401-018-1893-0; Cizkova D, 2011, J NEUROTRAUM, V28, P1951, DOI 10.1089/neu.2010.1413; Eckert MJ, 2017, SURG CLIN N AM, V97, P1031, DOI 10.1016/j.suc.2017.06.008; Figley SA, 2014, J NEUROTRAUM, V31, P541, DOI 10.1089/neu.2013.3034; Goodarzi P, 2018, ADV EXP MED BIOL, V1119, P119, DOI 10.1007/5584_2018_251; He QW, 2013, MOL NEUROBIOL, V47, P976, DOI 10.1007/s12035-013-8396-8; He ZL, 2017, AM J TRANSL RES, V9, P1012; Jo DH, 2013, MOL CELLS, V36, P465, DOI 10.1007/s10059-013-0228-1; Juan T, 2018, SEMIN CELL DEV BIOL, V74, P66, DOI 10.1016/j.semcdb.2017.08.022; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kjell J, 2016, DIS MODEL MECH, V9, P1125, DOI 10.1242/dmm.025833; Li D, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00845; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu W, 2019, J NEUROTRAUM, V36, P469, DOI 10.1089/neu.2018.5835; Marote A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00231; Pfister F, 2008, DIABETES, V57, pA234, DOI 10.2337/db08-0325; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; Rahimifard M, 2017, AGEING RES REV, V36, P11, DOI 10.1016/j.arr.2017.02.004; Ratajczak MZ, 2014, POL ARCH MED WEWN, V124, P417, DOI 10.20452/pamw.2355; Ren K, 2019, ODONTOLOGY, V107, P271, DOI 10.1007/s10266-018-0395-9; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Shende P, 2017, BIOMED PHARMACOTHER, V91, P693, DOI 10.1016/j.biopha.2017.04.126; Shostak K, 2015, TRENDS MOL MED, V21, P385, DOI 10.1016/j.molmed.2015.04.001; Sun F, 2011, NATURE, V480, P372, DOI 10.1038/nature10594; Sweeney MD, 2016, NAT NEUROSCI, V19, P771, DOI 10.1038/nn.4288; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Venkatesh K, 2017, CURR STEM CELL RES T, V12, P326, DOI 10.2174/1574888X12666161114122059; Wan Y, 2018, FASEB J, V32, P3133, DOI 10.1096/fj.201701121R; Wang Y, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4971261; Winkler EA, 2013, ACTA NEUROPATHOL, V125, P111, DOI 10.1007/s00401-012-1039-8; Xu PF, 2019, CELL TRANSPLANT, V28, P36, DOI 10.1177/0963689718808471; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Zagrean AM, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00811; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhou HJ, 2016, EXP CELL RES, V349, P60, DOI 10.1016/j.yexcr.2016.09.020	42	65	69	10	22	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-453X		FRONT NEUROSCI-SWITZ	Front. Neurosci.	MAR 12	2019	13								209	10.3389/fnins.2019.00209			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HO7FK	WOS:000461102300001	30914918	gold, Green Published	Y	N	2022-02-06	
J	Johnson, VE; Weber, MT; Xiao, R; Cullen, DK; Meaney, DF; Stewart, W; Smith, DH				Johnson, Victoria E.; Weber, Maura T.; Xiao, Rui; Cullen, D. Kacy; Meaney, David F.; Stewart, William; Smith, Douglas H.			Mechanical disruption of the blood-brain barrier following experimental concussion	ACTA NEUROPATHOLOGICA			English	Article						Mild traumatic brain injury; Concussion; Blood-brain barrier; Fibrinogen; Gliosis; Biomechanics	DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; CHRONIC TRAUMATIC ENCEPHALOPATHY; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; WHITE-MATTER INJURY; ICE HOCKEY PLAYERS; MULTIPLE-SCLEROSIS; IMMUNOHISTOCHEMICAL LOCALIZATION; CORTICAL CONTUSION	Although concussion is now recognized as a major health issue, its non-lethal nature has limited characterization of the underlying pathophysiology. In particular, potential neuropathological changes have typically been inferred from non-invasive techniques or post-mortem examinations of severe traumatic brain injury (TBI). Here, we used a swine model of head rotational acceleration based on human concussion to examine blood-brain barrier (BBB) integrity after injury in association with diffuse axonal injury and glial responses. We then determined the potential clinical relevance of the swine concussion findings through comparisons with pathological changes in human severe TBI, where post-mortem examinations are possible. At 6-72 h post-injury in swine, we observed multifocal disruption of the BBB, demonstrated by extravasation of serum proteins, fibrinogen and immunoglobulin-G, in the absence of hemorrhage or other focal pathology. BBB disruption was observed in a stereotyped distribution consistent with biomechanical insult. Specifically, extravasated serum proteins were frequently observed at interfaces between regions of tissue with differing material properties, including the gray-white boundary, periventricular and subpial regions. In addition, there was substantial overlap of BBB disruption with regions of axonal pathology in the white matter. Acute perivascular cellular uptake of blood-borne proteins was observed to be prominent in astrocytes (GFAP-positive) and neurons (MAP-2-positive), but not microglia (IBA1-positive). Parallel examination of human severe TBI revealed similar patterns of serum extravasation and glial uptake of serum proteins, but to a much greater extent than in the swine model, attributed to the higher injury severity. These data suggest that BBB disruption represents a new and important pathological feature of concussion.	[Johnson, Victoria E.; Weber, Maura T.; Cullen, D. Kacy; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Penn Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA; [Xiao, Rui] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA; [Cullen, D. Kacy; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19103 USA; [Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland; [Cullen, D. Kacy] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Penn Ctr Brain Injury & Repair, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@pennmedicine.upenn.edu		Meaney, David/0000-0002-0954-4122; Stewart, William/0000-0003-2199-2582	Department of DefenseUnited States Department of Defense [W81XWH-13-1-0052]; National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092398, R01NS094003, R01NS038104]; Department of Veterans AffairsUS Department of Veterans Affairs [I01RX001097]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094003, R01NS092398, R01NS038104] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001097] Funding Source: NIH RePORTER	The authors thank Kathryn Wofford for assistant with kinematic measurements. Research reported in this publication was supported by the Department of Defense Grant W81XWH-13-1-0052, and the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award numbers R01NS092398, R01NS094003 and R01NS038104, and the Department of Veterans Affairs under Merit Review number I01RX001097.	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams RA, 2004, MOL INTERV, V4, P163; Adams RA, 2007, J EXP MED, V204, P571, DOI 10.1084/jem.20061931; Akassoglou K, 2004, P NATL ACAD SCI USA, V101, P6698, DOI 10.1073/pnas.0303859101; Alvarez JI, 2015, NEUROBIOL DIS, V74, P14, DOI 10.1016/j.nbd.2014.09.016; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bridges LR, 2014, J NEUROPATH EXP NEUR, V73, P1026, DOI 10.1097/NEN.0000000000000124; Brown H, 1999, NEUROPATH APPL NEURO, V25, P331; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Cullen DK, 2016, METHODS MOL BIOL, V1462, P289, DOI 10.1007/978-1-4939-3816-2_17; Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Graham D.I., 2002, GREENFIELDS NEUROPAT; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Hayashi Takahito, 2009, Leg Med (Tokyo), V11 Suppl 1, pS171, DOI 10.1016/j.legalmed.2009.01.076; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Hsiao TW, 2013, ACTA BIOMATER, V9, P7200, DOI 10.1016/j.actbio.2013.02.047; Ibrahim NG, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000956; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kirk J, 2003, J PATHOL, V201, P319, DOI 10.1002/path.1434; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P270, DOI 10.1093/jnen/nlx007; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; KWON EE, 1994, J NEUROPATH EXP NEUR, V53, P625, DOI 10.1097/00005072-199411000-00010; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lee P, 2012, EXP NEUROL, V234, P50, DOI 10.1016/j.expneurol.2011.12.016; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; LIU HM, 1989, ACTA NEUROPATHOL, V78, P16, DOI 10.1007/BF00687397; Liu JYW, 2012, BRAIN, V135, P3115, DOI 10.1093/brain/aws147; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OMMAYA AK, 1967, P 11 STAPP CAR CRASH, P73; Patton DA, 2015, J APPL BIOMECH, V31, P264, DOI 10.1123/jab.2014-0223; PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Ryu JK, 2009, J CELL MOL MED, V13, P2911, DOI 10.1111/j.1582-4934.2008.00434.x; Ryu JK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9164; Schachtrup C, 2007, P NATL ACAD SCI USA, V104, P11814, DOI 10.1073/pnas.0704045104; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Shreiber D. I, 1997, 973335 SAE, DOI [10.4271/973335, DOI 10.4271/973335]; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; STRICH SJ, 1961, LANCET, V2, P443; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Thibault L.E., 1990, P INT C BIOM IMP LYO, P191; Tomimoto H, 1996, STROKE, V27, P2069, DOI 10.1161/01.STR.27.11.2069; Veksler R, 2014, ARCH MED RES, V45, P646, DOI 10.1016/j.arcmed.2014.11.016; Viggars AP, 2011, NEUROSCI LETT, V505, P25, DOI 10.1016/j.neulet.2011.09.049; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Zhang HQ, 2010, NEUROSCIENTIST, V16, P156, DOI 10.1177/1073858409355830	95	65	65	1	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAY	2018	135	5					711	726		10.1007/s00401-018-1824-0			16	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	GD1VF	WOS:000430288700005	29460006	Green Accepted			2022-02-06	
J	Master, CL; Master, SR; Wiebe, DJ; Storey, EP; Lockyer, JE; Podolak, OE; Grady, MF				Master, Christina L.; Master, Stephen R.; Wiebe, Douglas J.; Storey, Eileen P.; Lockyer, Julia E.; Podolak, Olivia E.; Grady, Matthew F.			Vision and Vestibular System Dysfunction Predicts Prolonged Concussion Recovery in Children	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; pediatric; vision; accommodative amplitude; near point of convergence; vestibular	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; FRONTAL EYE-FIELD; HIGH-SCHOOL; ACTIVE REHABILITATION; STIMULATION; BALANCE; ADOLESCENTS; DISORDERS; SCORES	Objective: Up to one-third of children with concussion have prolonged symptoms lasting beyond 4 weeks. Vision and vestibular dysfunction is common after concussion. It is unknown whether such dysfunction predicts prolonged recovery. We sought to determine which vision or vestibular problems predict prolonged recovery in children. Design: A retrospective cohort of pediatric patients with concussion. Setting: A subspecialty pediatric concussion program. Patients (or Participants): Four hundred thirty-two patient records were abstracted. Assessment of Risk Factors: Presence of vision or vestibular dysfunction upon presentation to the subspecialty concussion program. Main Outcome Measures: The main outcome of interest was time to clinical recovery, defined by discharge from clinical follow-up, including resolution of acute symptoms, resumption of normal physical and cognitive activity, and normalization of physical examination findings to functional levels. Results: Study subjects were 5 to 18 years (median - 14). A total of 378 of 432 subjects (88%) presented with vision or vestibular problems. A history of motion sickness was associated with vestibular dysfunction. Younger age, public insurance, and presence of headache were associated with later presentation for subspecialty concussion care. Vision and vestibular problems were associated within distinct clusters. Provocable symptoms with vestibulo-ocular reflex (VOR) and smooth pursuits and abnormal balance and accommodative amplitude (AA) predicted prolonged recovery time. Conclusions: Vision and vestibular problems predict prolonged concussion recovery in children. A history of motion sickness may be an important premorbid factor. Public insurance status may represent problems with disparities in access to concussion care. Vision assessments in concussion must include smooth pursuits, saccades, near point of convergence (NPC), and accommodative amplitude (AA). A comprehensive, multidomain assessment is essential to predict prolonged recovery time and enable active intervention with specific school accommodations and targeted rehabilitation.	[Master, Christina L.; Storey, Eileen P.; Lockyer, Julia E.; Podolak, Olivia E.; Grady, Matthew F.] Childrens Hosp Philadelphia, Div Orthopaed, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Master, Stephen R.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA; [Wiebe, Douglas J.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA		Master, CL (corresponding author), Childrens Hosp Philadelphia, Div Orthopaed, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	masterc@email.chop.edu		Master, Christina/0000-0002-6717-4270			Aligene K, 2013, NEUROREHABILITATION, V32, P543, DOI 10.3233/NRE-130876; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Blanke O, 2000, J NEUROL NEUROSUR PS, V69, P553, DOI 10.1136/jnnp.69.4.553; Blanke O, 2003, EXP BRAIN RES, V150, P174, DOI 10.1007/s00221-003-1395-7; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Custer A, 2016, J ATHL TRAINING, V51, P136, DOI 10.4085/1062-6050-51.2.12; de Waele C, 2001, EXP BRAIN RES, V141, P541, DOI 10.1007/s00221-001-0894-7; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Fasold O, 2002, NEUROIMAGE, V17, P1384, DOI 10.1006/nimg.2002.1241; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gamlin PDR, 2002, ANN NY ACAD SCI, V956, P264, DOI 10.1111/j.1749-6632.2002.tb02825.x; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Houston MN, 2016, BRAIN INJURY, V30, P891, DOI 10.3109/02699052.2016.1146960; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Li H, 2015, PLOS ONE, V10; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDougal DH, 2015, COMPR PHYSIOL, V5, P439, DOI 10.1002/cphy.c140014; Meier TB, 2017, BRAIN IMAGING BEHAV, V11, P129, DOI 10.1007/s11682-016-9520-y; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Nelson LD, 2016, J ATHL TRAINING, V51, P142, DOI 10.4085/1062-6050-51.4.04; Pardini D., 2004, BR J SPORTS MED, V38, P661; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; Petit L, 1997, J NEUROPHYSIOL, V77, P3386, DOI 10.1152/jn.1997.77.6.3386; Scheiman M, 2011, OPTOMETRY VISION SCI, V88, P1343, DOI 10.1097/OPX.0b013e31822f4d7c; Storey EP, 2017, OPTOMETRY VISION SCI, V94, P96, DOI 10.1097/OPX.0000000000000910; Thiagarajan P, 2014, J REHABIL RES DEV, V51, P175, DOI 10.1682/JRRD.2013.01.0027; Ventura RE, 2016, J NEUROL SCI, V361, P79, DOI 10.1016/j.jns.2015.12.010; Ventura RE, 2015, SEMIN NEUROL, V35, P599, DOI 10.1055/s-0035-1563567; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	43	65	67	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2018	28	2					139	145		10.1097/JSM.0000000000000507			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	GP1HC	WOS:000440564900009	29064869				2022-02-06	
J	Yao, XL; Liu, SW; Ding, W; Yue, PJ; Jiang, Q; Zhao, M; Hu, F; Zhang, HQ				Yao, Xiaolong; Liu, Shengwen; Ding, Wei; Yue, Pengjie; Jiang, Qian; Zhao, Min; Hu, Feng; Zhang, Huaqiu			TLR4 signal ablation attenuated neurological deficits by regulating microglial M1/M2 phenotype after traumatic brain injury in mice	JOURNAL OF NEUROIMMUNOLOGY			English	Article							TOLL-LIKE RECEPTOR-4; INNATE IMMUNE-SYSTEM; SPINAL-CORD-INJURY; NERVOUS-SYSTEM; MACROPHAGE ACTIVATION; CELLS; POLARIZATION; DAMAGE; NEUROPROTECTION; RECOGNITION	Traumatic brain injury (TBI) initiates inflammatory responses that result in an enduring cascade of secondary neuronal loss and behavioural impairment. Toll-like receptor 4 (TLR4), predominantly expressed by microglia, recognizes damage-associated molecular patterns (DAMPs) and regulates inflammatory processes. Interestingly, the switch of microglial M1/M2 phenotypes after TBI is highly important regarding damage and restoration of neurological function. Therefore, we investigated the role and mechanisms of the TLR4 signalling pathway in regulating microglial M1/M2 phenotypes. Using a controlled cortical impact (CCI) model, we found that TLR4 knockout (KO) mice exhibited decreased infarct volumes and improved outcomes in behavioural tests. In addition, mice lacking TLR4 had higher expression of M2 phenotype biomarkers but lower expression of M1 phenotype biomarkers. Compared with microglia derived from wild-type (WT) mice, increased expression of M2 phenotype biomarkers and decreased expression of M1 phenotype biomarkers were also noted in primary cultures of microglia from TLR4 KO mice. In TLR4 KO mice, the expression levels of downstream signalling molecules of TLR4, such as active Rac-1 and phospho-AKT, were higher, while MyD88 and phospho-NF-kappa B p65 expression levels were lower than in WT mice. Our results demonstrate that the absence of TLR4 induces microglial polarization toward the M2 phenotype and promotes microglial migration and, in turn, alleviates the development of neuroinflammation, which indicates potential neuroprotective effects in the TBI mouse model. Furthermore, up-regulation of IL-4 expression in TLR4 KO mice could contribute to anti-inflammatory functions and promote microglial polarization toward the M2 phenotype, which might be mediated by active Rac-1 expression. Taken together, TLR4 deficiency contributes to regulating microglia to switch to the M2 phenotype, which ameliorates neurological impairment after TBI.	[Yao, Xiaolong; Liu, Shengwen; Ding, Wei; Yue, Pengjie; Jiang, Qian; Zhao, Min; Hu, Feng; Zhang, Huaqiu] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Neurosurg, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China		Zhang, HQ (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Neurosurg, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	zhanghq_04@yahoo.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371381]	This article was funded by the Natural Science Foundation of China (81371381).	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Barcia C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002977; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Chakravarty S, 2005, J NEUROSCI, V25, P1788, DOI 10.1523/jneurosci.4268-04.2005; Lima IVDA, 2015, EXP NEUROL, V267, P123, DOI 10.1016/j.expneurol.2015.02.021; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kim D, 2007, J BIOL CHEM, V282, P14975, DOI 10.1074/jbc.M607277200; Kim YM, 2004, AM J OBSTET GYNECOL, V191, pS6, DOI 10.1016/j.ajog.2004.09.044; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee H, 2013, CURR PROTEIN PEPT SC, V14, P33, DOI 10.2174/1389203711314010006; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/bst0310643; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Qi ZF, 2012, CNS NEUROSCI THER, V18, P965, DOI 10.1111/cns.12016; Saponaro C, 2012, IMMUNOPHARM IMMUNOT, V34, P858, DOI 10.3109/08923973.2012.665461; Tanaka T, 2015, GLIA, V63, P595, DOI 10.1002/glia.22770; Yang H, 2012, NEUROCHEM INT, V61, P175, DOI 10.1016/j.neuint.2012.04.020; Zhang YK, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-112; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhao XR, 2015, J NEUROSCI, V35, P11281, DOI 10.1523/JNEUROSCI.1685-15.2015; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	33	65	71	2	27	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	SEP 15	2017	310						38	45		10.1016/j.jneuroim.2017.06.006			8	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	FE4KT	WOS:000408183500007	28778443				2022-02-06	
J	Albalawi, F; Lu, WN; Beckel, JM; Lim, JC; McCaughey, SA; Mitchell, CH				Albalawi, Farraj; Lu, Wennan; Beckel, Jonathan M.; Lim, Jason C.; McCaughey, Stuart A.; Mitchell, Claire H.			The P2X7 Receptor Primes IL-1 beta and the NLRP3 Inflammasome in Astrocytes Exposed to Mechanical Strain	FRONTIERS IN CELLULAR NEUROSCIENCE			English	Article						IL-1 beta; astrocytes; glaucoma; pannexin; ATP release; NF kappa B; caspase 1; NLRP3	OPTIC-NERVE HEAD; NF-KAPPA-B; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; EXTRACELLULAR ATP; P2X(7) RECEPTOR; PANNEXIN HEMICHANNELS; SUSTAINED ELEVATION; ACUTE GLAUCOMA; UP-REGULATION	Inflammatory responses play a key role in many neural pathologies, with localized signaling from the non-immune cells making critical contributions. The NLRP3 inflammasome is an important component of innate immune signaling and can link neural insult to chronic inflammation. The NLRP3 inflammasome requires two stages to contribute: priming and activation. The priming stage involves upregulation of inflammasome components while the activation stage results in the assembly and activation of the inflammasome complex. The priming step can be rate limiting and can connect insult to chronic inflammation, but our knowledge of the signals that regulate NLRP3 inflammasome priming in sterile inflammation is limited. This study examined the link between mechanical strain and inflammasome priming in neural systems. Transient non-ischemic elevation of intraocular pressure increased mRNA for inflammasome components IL-1 beta, NLRP3, ASC, and CASP1 in rat and mouse retinas. The elevation was greater 1 day after the insult, with the rise in IL-1 beta most pronounced. The P2X7 receptor was implicated in the mechanosensitive priming of IL-1 beta mRNA in vivo, as the antagonist Brilliant Blue G (BBG) blocked the increased expression, the agonist BzATP mimicked the pressure-dependent rise in IL-1 beta, and the rise was absent in P2X7 knockout mice. In vitro measurements from optic nerve head astrocytes demonstrated an increased expression of IL-1 beta following stretch or swelling. This increase in IL-1 beta was eliminated by degradation of extracellular ATP with apyrase, or by the block of pannexin hemichannels with carbenoxolone, probenecid, or 10panx1 peptide. The rise in IL-1 beta expression was also blocked by P2X7 receptor antagonists BBG, A839977 or A740003. The rise in IL-1 beta was prevented by blocking transcription factor NF kappa B with Bay 11-7082, while the swelling-dependent fall in NF kappa B inhibitor I kappa B-alpha was reduced by A839977 and in P2X7 knockout mice. In summary, mechanical trauma to the retina primed NLRP3 inflammasome components, but only if there was ATP release through pannexin hemichannels, and autostimulation of the P2X7 receptor. As the P2X7 receptor can also trigger stage two of inflammasome assembly and activation, the P2X7 receptor may have a central role in linking mechanical strain to neuroinflammation.	[Albalawi, Farraj; Lu, Wennan; Beckel, Jonathan M.; Lim, Jason C.; McCaughey, Stuart A.; Mitchell, Claire H.] Univ Penn, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; [Albalawi, Farraj] Univ Penn, Dept Orthodont, Philadelphia, PA 19104 USA; [Beckel, Jonathan M.] Pittsburgh Univ, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Mitchell, Claire H.] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA; [Mitchell, Claire H.] Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA		Mitchell, CH (corresponding author), Univ Penn, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA.; Mitchell, CH (corresponding author), Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.; Mitchell, CH (corresponding author), Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA.	chm@upenn.edu	Beckel, Jonathan M./A-6758-2008	Beckel, Jonathan M./0000-0003-1390-2292	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EY015537, EY013434, EY001583, DK106115]; Jody Sack Fund; King Saud bin Abdulaziz University for Health Sciences; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY015537, R01EY013434, P30EY001583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R03DK114492, K01DK106115] Funding Source: NIH RePORTER	This work is supported by grants from the NIH EY015537 and EY013434 and core grant EY001583 (CM), NIH DK106115 (JB), Jody Sack Fund (WL) and King Saud bin Abdulaziz University for Health Sciences (FA). These funding bodies had no direct role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript.	Albalawi F, 2016, FASEB J, V30; Beckel JM, 2014, GLIA, V62, P1486, DOI 10.1002/glia.22695; Bernier LP, 2012, J GEN PHYSIOL, V140, P571, DOI 10.1085/jgp.201210875; Boaru SG, 2015, BIOCHEM BIOPH RES CO, V458, P700, DOI 10.1016/j.bbrc.2015.02.029; Bruzzone R, 2005, J NEUROCHEM, V92, P1033, DOI 10.1111/j.1471-4159.2004.02947.x; Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001; Chi W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0360-2; Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111; Choi HJ, 2015, MOL VIS, V21; Coffey EE, 2014, NEUROSCIENCE, V263, P111, DOI 10.1016/j.neuroscience.2014.01.001; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Crowston JG, 2015, EXP EYE RES, V141, P3, DOI 10.1016/j.exer.2015.03.006; Dinarello CA, 2007, EUR J IMMUNOL, V37, pS34, DOI 10.1002/eji.200737772; Donnelly-Roberts DL, 2009, BRIT J PHARMACOL, V157, P1203, DOI 10.1111/j.1476-5381.2009.00233.x; Downs JC, 2008, OPTOMETRY VISION SCI, V85, P425, DOI 10.1097/OPX.0b013e31817841cb; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Guha S, 2012, J NEUROCHEM, V122, P823, DOI 10.1111/j.1471-4159.2012.07804.x; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Honore P, 2009, BEHAV BRAIN RES, V204, P77, DOI 10.1016/j.bbr.2009.05.018; Hu HL, 2010, EXP EYE RES, V91, P425, DOI 10.1016/j.exer.2010.06.017; Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6; Karmakar M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10555; Katsnelson MA, 2015, J IMMUNOL, V194, P3937, DOI 10.4049/jimmunol.1402658; Kaushik DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032270; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Li A, 2011, EXP EYE RES, V93, P528, DOI 10.1016/j.exer.2011.06.020; Lim JC, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00270; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu YH, 2011, CYTOKINE, V55, P229, DOI 10.1016/j.cyto.2011.05.003; Lu WN, 2017, J NEUROCHEM, V141, P436, DOI 10.1111/jnc.13998; Lu W, 2013, INVEST OPHTH VIS SCI, V54; Lu WN, 2015, INVEST OPHTH VIS SCI, V56, P3075, DOI 10.1167/iovs.14-15891; Lye-Barthel M, 2013, INVEST OPHTH VIS SCI, V54, P909, DOI 10.1167/iovs.12-10109; Mandal A, 2009, AM J PHYSIOL-CELL PH, V297, pC111, DOI 10.1152/ajpcell.00539.2008; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Masin M, 2012, BRIT J PHARMACOL, V165, P978, DOI 10.1111/j.1476-5381.2011.01624.x; Mitchell CH, 2017, INVEST OPHTH VIS SCI, V58; Mitchell CH, 2016, INVEST OPHTH VIS SCI, V57; Mitchell CH, 2009, PURINERG SIGNAL, V5, P241, DOI 10.1007/s11302-009-9142-6; Morgan JE, 2000, EYE, V14, P437, DOI 10.1038/eye.2000.128; Morrison JC, 2010, INVEST OPHTH VIS SCI, V51; Morrison JC, 2014, INVEST OPHTH VIS SCI, V55; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Nadal-Nicolas FM, 2016, SCI REP-UK, V6, DOI 10.1038/srep38499; Patel MN, 2017, TRENDS MOL MED, V23, P165, DOI 10.1016/j.molmed.2016.12.007; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; Reigada D, 2005, AM J PHYSIOL-CELL PH, V289, pC617, DOI 10.1152/ajpcell.00542.2004; Reigada D, 2008, NEUROSCIENCE, V157, P396, DOI 10.1016/j.neuroscience.2008.08.036; Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009; Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P3860, DOI 10.1167/iovs.05-1408; Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489; Sperlagh B, 2014, TRENDS PHARMACOL SCI, V35, P537, DOI 10.1016/j.tips.2014.08.002; Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599; Tehrani S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167364; Miras-Portugal MT, 2015, COMPUT STRUCT BIOTEC, V13, P176, DOI 10.1016/j.csbj.2015.02.005; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983; Yilmaz O, 2015, PERIODONTOL 2000, V69, P83, DOI 10.1111/prd.12084; Zhang X, 2007, EXP EYE RES, V85, P637, DOI 10.1016/j.exer.2007.07.016; Zhang XL, 2005, INVEST OPHTH VIS SCI, V46, P2183, DOI 10.1167/iovs.05-0052; Zode GS, 2011, J CLIN INVEST, V121, P3542, DOI 10.1172/JCI58183	70	65	67	2	23	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5102			FRONT CELL NEUROSCI	Front. Cell. Neurosci.	AUG 8	2017	11								227	10.3389/fncel.2017.00227			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FD1JN	WOS:000407293700001	28848393	Green Published, gold			2022-02-06	
J	Yang, WY; Huang, JD				Yang, Wuyang; Huang, Judy			Chronic Subdural Hematoma: Epidemiology and Natural History	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Chronic subdural hematoma; Epidemiology; Natural history; Pathogenesis	TRAUMATIC BRAIN-INJURY; PACHYMENINGITIS HEMORRHAGICA INTERNA; SPONTANEOUS RESOLUTION; SURGICAL-TREATMENT; NONSURGICAL TREATMENT; RISK-FACTORS; RECURRENCE; MANAGEMENT; ANTICOAGULATION; POPULATION	This article discusses the epidemiology and natural history of chronic subdural hematoma (CSDH), a common disease prevalent in the elderly population. The incidence of CSDH ranges from 1.72 to 20.6 per 100,000 persons per year. Risk factors include advancing age, male gender, and antiplatelet or anticoagulant use. Clinical progression is separated into 3 distinct periods, including the initial traumatic event, the latency period, and the clinical presentation period. The recurrence of CSDH and nonsurgical predictive factors are described in detail to provide a comprehensive understanding of the outcome of this disease.	[Yang, Wuyang; Huang, Judy] Johns Hopkins Univ, Sch Med, Dept Neurosurg, 1800 Orleans St,Zayed Tower,Suite 6115F, Baltimore, MD 21287 USA		Huang, JD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, 1800 Orleans St,Zayed Tower,Suite 6115F, Baltimore, MD 21287 USA.	jhuang24@jhmi.edu	BAJAJ, JITIN/N-6601-2016; Yang, Wuyang/G-6367-2016	BAJAJ, JITIN/0000-0002-1638-0015; Yang, Wuyang/0000-0001-5934-7795; Huang, Judy/0000-0002-0675-1935			Adhiyaman V, 2002, POSTGRAD MED J, V78, P71, DOI 10.1136/pmj.78.916.71; Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255; Asghar M, 2002, J ROY SOC MED, V95, P290, DOI 10.1258/jrsm.95.6.290; Aspegren OP, 2013, CLIN NEUROL NEUROSUR, V115, P981, DOI 10.1016/j.clineuro.2012.10.008; Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6; Balser D, 2015, J NEUROSURG, V123, P1209, DOI 10.3171/2014.9.JNS141550; BENDER MB, 1974, ARCH NEUROL-CHICAGO, V31, P73, DOI 10.1001/archneur.1974.00490380021001; CAMERON MM, 1978, J NEUROL NEUROSUR PS, V41, P834, DOI 10.1136/jnnp.41.9.834; Chen JCT, 2000, NEUROSURG CLIN N AM, V11, P399, DOI 10.1016/S1042-3680(18)30101-3; Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y; FARHAT NETO JAMIL, 2015, Rev. Col. Bras. Cir., V42, P283, DOI 10.1590/0100-69912015005003; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; FOGELHOLM R, 1975, ACTA NEUROCHIR, V32, P247, DOI 10.1007/BF01405457; Gardner W.J., 1932, ARCH NEUROL PSYCHIAT, V27, P847; Gelabert-Gonzalez M, 2005, CLIN NEUROL NEUROSUR, V107, P223, DOI 10.1016/j.clineuro.2004.09.015; Gonugunta V, 2001, BRIT J NEUROSURG, V15, P514, DOI 10.1080/02688690120097822; Guha D, 2016, J NEUROSURG, V124, P750, DOI 10.3171/2015.2.JNS141889; Holmes WH, 1928, ARCH NEURO PSYCHIATR, V20, P162, DOI 10.1001/archneurpsyc.1928.02210130165011; Horikoshi T, 1998, NEUROL MED-CHIR, V38, P527, DOI 10.2176/nmc.38.527; Iliescu I A, 2015, J Med Life, V8 Spec Issue, P26; Ivamoto HS, 2016, WORLD NEUROSURG, V86, P399, DOI 10.1016/j.wneu.2015.10.025; Kageyama H, 2013, J NEUROSURG, V119, P332, DOI 10.3171/2013.3.JNS122162; Karibe Hiroshi, 2011, No Shinkei Geka, V39, P1149; Kim Junhak, 2015, Korean J Neurotrauma, V11, P63, DOI 10.13004/kjnt.2015.11.2.63; Kolias AG, 2014, NAT REV NEUROL, V10, P570, DOI 10.1038/nrneurol.2014.163; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; KOTWICA Z, 1987, ACTA NEUROCHIR, V85, P44, DOI 10.1007/BF01402369; KUDO H, 1992, Neurologia Medico-Chirurgica, V32, P207, DOI 10.2176/nmc.32.207; Lee KS, 1998, BRAIN INJURY, V12, P901; Lee KS, 2004, BRAIN INJURY, V18, P351, DOI 10.1080/02699050310001645801; Lee Kyeong-Seok, 2015, Korean J Neurotrauma, V11, P27, DOI 10.13004/kjnt.2015.11.2.27; Liliang PC, 2002, INJURY, V33, P345, DOI 10.1016/S0020-1383(02)00020-7; Liu WM, 2014, J NEUROSURG, V121, P665, DOI 10.3171/2014.5.JNS132715; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; Maurice-Williams RS, 1999, BRIT J NEUROSURG, V13, P547, DOI 10.1080/02688699943033; Mellergard P, 1996, ACTA NEUROCHIR, V138, P708, DOI 10.1007/BF01411476; Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298; Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371; NAGANUMA H, 1986, NEUROSURGERY, V19, P794, DOI 10.1227/00006123-198611000-00013; Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256; Parlato C, 2000, SURG NEUROL, V53, P312, DOI 10.1016/S0090-3019(00)00200-7; Putnam TJ, 1925, ARCH SURG-CHICAGO, V11, P329, DOI 10.1001/archsurg.1925.01120150002001; Rust T, 2006, J CLIN NEUROSCI, V13, P823, DOI 10.1016/j.jocn.2004.12.013; Sambasivan M, 1997, SURG NEUROL, V47, P418, DOI 10.1016/S0090-3019(97)00188-2; Santarius Thomas, 2010, Clin Neurosurg, V57, P112; SARTI C, 1991, STROKE, V22, P848, DOI 10.1161/01.STR.22.7.848; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Schwartz AB, 1916, AM J DIS CHILD, V11, P23; SUZUKI J, 1970, J NEUROSURG, V33, P548, DOI 10.3171/jns.1970.33.5.0548; Tanaka Yoji, 2013, J Med Dent Sci, V60, P55; Torihashi K, 2008, NEUROSURGERY, V63, P1125, DOI 10.1227/01.NEU.0000335782.60059.17; Trotter W, 1914, BRIT J SURG, V2, P271, DOI 10.1002/bjs.1800020608; Ventsel G, 2008, NEUROEPIDEMIOLOGY, V30, P20, DOI 10.1159/000113302; Virchow R., 1857, VERH PHYS MED GES WU, V7, P134; Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937; WEIR B, 1980, J NEUROSURG, V53, P512, DOI 10.3171/jns.1980.53.4.0512; WEIR B, 1971, J NEUROSURG, V34, P528, DOI 10.3171/jns.1971.34.4.0528; Zollinger R, 1934, J AMER MED ASSOC, V103, P0245, DOI 10.1001/jama.1934.02750300019008	58	65	68	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	APR	2017	28	2					205	+		10.1016/j.nec.2016.11.002			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	ES1AJ	WOS:000399260000003	28325454				2022-02-06	
J	Henderson, FC; Austin, C; Benzel, E; Bolognese, P; Ellenbogen, R; Francomano, CA; Ireton, C; Klinge, P; Koby, M; Long, DL; Patel, S; Singman, EL; Voermans, NC				Henderson, Fraser C., Sr.; Austin, Claudiu; Benzel, Edward; Bolognese, Paolo; Ellenbogen, Richard; Francomano, Clair A.; Ireton, Candace; Klinge, Petra; Koby, Myles; Long, Donlin; Patel, Sunil; Singman, Eric L.; Voermans, Nicol C.			Neurological and Spinal Manifestations of the Ehlers-Danlos Syndromes	AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS			English	Article						Ehlers-Danlos syndrome; headache; craniocervical instability; atlantoaxial instability; tethered cord syndrome	MALFORMATION TYPE-I; JOINT HYPERMOBILITY SYNDROME; TETHERED CORD SYNDROME; IDIOPATHIC INTRACRANIAL HYPERTENSION; PSYCHOGENIC MOVEMENT-DISORDERS; TRAUMATIC AXONAL INJURY; UPPER CERVICAL-SPINE; CRANIOVERTEBRAL JUNCTION; BRAIN-STEM; CONSERVATIVE TREATMENT	The Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders characterized by joint hypermobility, skin extensibility, and tissue fragility. This communication briefly reports upon the neurological manifestations that arise including the weakness of the ligaments of the craniocervical junction and spine, early disc degeneration, and the weakness of the epineurium and perineurium surrounding peripheral nerves. Entrapment, deformation, and biophysical deformative stresses exerted upon the nervous system may alter gene expression, neuronal function and phenotypic expression. This report also discusses increased prevalence of migraine, idiopathic intracranial hypertension, Tarlov cysts, tethered cord syndrome, and dystonia, where associations with EDS have been anecdotally reported, but where epidemiological evidence is not yet available. Chiari Malformation Type I (CMI) has been reported to be a comorbid condition to EDS, and may be complicated by craniocervical instability or basilar invagination. Motor delay, headache, and quadriparesis have been attributed to ligamentous laxity and instability at the atlanto-occipital and atlantoaxial joints, which may complicate all forms of EDS. Discopathy and early degenerative spondylotic disease manifest by spinal segmental instability and kyphosis, rendering EDS patients prone to mechanical pain, and myelopathy. Musculoskeletal pain starts early, is chronic and debilitating, and the neuromuscular disease of EDS manifests symptomatically with weakness, myalgia, easy fatigability, limited walking, reduction of vibration sense, and mild impairment of mobility and daily activities. Consensus criteria and clinical practice guidelines, based upon stronger epidemiological and pathophysiological evidence, are needed to refine diagnosis and treatment of the various neurological and spinal manifestations of EDS. (C) 2017 Wiley Periodicals, Inc.	[Henderson, Fraser C., Sr.] Natl Hosp Neurol & Neurosurg, Disorders Craniocerv Junct, Queens Sq London, London, England; [Henderson, Fraser C., Sr.] Georgetown Univ, Neurosurg Spine & Craniocerv Junct, Washington, DC 20057 USA; [Henderson, Fraser C., Sr.] Ehlers Danlos Soc, Execut Board, Mclean, VA USA; [Henderson, Fraser C., Sr.] Chiari Syringomyelia Fdn, Execut Board, Staten Isl, NY USA; [Henderson, Fraser C., Sr.] ILC, Execut Board, Toronto, ON, Canada; [Henderson, Fraser C., Sr.] TCAPP Fdn, Execut Board, Chicago, IL USA; [Koby, Myles] NIH, Bldg 10, Bethesda, MD 20892 USA; [Austin, Claudiu; Koby, Myles] Doctors Community Hosp, Lanham, MD USA; [Francomano, Clair A.] Harvey Inst Human Genet, Adult Genet, London, England; [Francomano, Clair A.] Harvey Inst Human Genet, Ehlers Danlos Soc, Ctr Clin Care & Res, London, England; [Francomano, Clair A.] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD USA; [Francomano, Clair A.] Ehlers Danlos Soc, Execut Board, Mclean, VA USA; [Francomano, Clair A.] Ehlers Danlos Soc, Med & Sci Board, Mclean, VA USA; [Bolognese, Paolo] North Shore Univ Hosp, Manhasset, NY USA; [Ellenbogen, Richard] Dept Neurol Adult Brain Tumors Trauma Surg Cranio, Mclean, VA USA; [Ireton, Candace] Grp Visit Program Primary Care EDS Patients, Asheville, NC USA; [Klinge, Petra] Brown Univ, Sch Med, Neurosurg, Providence, RI 02912 USA; [Patel, Sunil] Med Univ South Carolina, Neurosurg, Charleston, SC USA; [Singman, Eric L.] Johns Hopkins Univ Hosp, Ophthalmol, Baltimore, MD 21287 USA; [Singman, Eric L.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Baltimore, MD 21287 USA; [Voermans, Nicol C.] Radboud Univ Nijmegen, Neuromuscular Ctr, Med Ctr, Nijmegen, Netherlands		Henderson, FC (corresponding author), Greater Baltimore Med Ctr, Metropolitan Neurosurg Grp, Ehlers Danlos Soc, Ctr Clin Care & Res, 8401 Connecticut Ave,Suite 220, Baltimore, MD 20815 USA.	henderson@fraserhendersonMD.com	Voermans, N.C./L-4724-2015				Adib N, 2005, RHEUMATOLOGY, V44, P744, DOI 10.1093/rheumatology/keh557; ARNASSON O, 1987, ACTA NEUROCHIR, V84, P48, DOI 10.1007/BF01456351; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Aufschnaiter K, 2008, NEUROSURG REV, V31, P371, DOI 10.1007/s10143-008-0140-x; Bademci G, 2006, PEDIATR NEUROSURG, V42, P4, DOI 10.1159/000089503; Ball AK, 2006, LANCET NEUROL, V5, P433, DOI 10.1016/S1474-4422(06)70442-2; BANERJEE G, 1988, POSTGRAD MED J, V64, P126, DOI 10.1136/pgmj.64.748.126; Bathen T, 2013, AM J MED GENET A, V161, P3005, DOI 10.1002/ajmg.a.36060; Batzdorf U, 2015, COMORBIDITIES COMPLI; Bendik EM, 2011, CEPHALALGIA, V31, P603, DOI 10.1177/0333102410392606; Bui CJ., 2007, NEUROSURG FOCUS, V23, P1, DOI [DOI 10.3171/FOC-07/08/E2, 10.3171/FOC-07/08/E2]; Burstein R, 2015, J NEUROSCI, V35, P6619, DOI 10.1523/JNEUROSCI.0373-15.2015; CASTILLO M, 1995, AM J NEURORADIOL, V16, P1158; Castori M, 2014, IRAN J NEUROL, V13, P195; Castori M, 2015, AM J MED GENET C, V169, P84, DOI 10.1002/ajmg.c.31426; Casucci G, 2012, NEUROL SCI, V33, pS81, DOI 10.1007/s10072-012-1047-4; Celletti C, 2012, RES DEV DISABIL, V33, P1914, DOI 10.1016/j.ridd.2012.06.018; CORBETT JJ, 1982, ARCH NEUROL-CHICAGO, V39, P461, DOI 10.1001/archneur.1982.00510200003001; CUSICK JF, 1977, J NEUROSURG, V46, P767, DOI 10.3171/jns.1977.46.6.0767; DEBARROS MC, 1968, J NEUROL NEUROSUR PS, V31, P596; Donkervoort S, 2015, AM J MED GENET C, V169, P23, DOI 10.1002/ajmg.c.31433; DVORAK J, 1987, SPINE, V12, P726, DOI 10.1097/00007632-198710000-00002; Ellenbogen RG, 2000, NEUROSURG FOCUS, V8, P1; Estemalik E, 2013, NEUROPSYCH DIS TREAT, V9, P709, DOI 10.2147/NDT.S33769; Fabiano AJ, 2009, PEDIATR NEUROSURG, V45, P256, DOI 10.1159/000228983; Farb RI, 2003, NEUROLOGY, V60, P1418, DOI 10.1212/01.WNL.0000066683.34093.E2; Feigenbaum F, 2006, SEMIN SPINE SURG, V18, P154; Ferrari MD, 2015, LANCET NEUROL, V14, P65, DOI 10.1016/S1474-4422(14)70220-0; FIELDING JW, 1978, J BONE JOINT SURG AM, V60, P1102, DOI 10.2106/00004623-197860080-00015; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Gelfanda AA, 2013, MULT SCLER RELAT DIS, V2, P73, DOI 10.1016/j.msard.2012.10.003; Goel A, 2005, NEUROL MED-CHIR, V45, P512, DOI 10.2176/nmc.45.512; Grabb PA, 1999, NEUROSURGERY, V44, P520, DOI 10.1097/00006123-199903000-00050; Granata G, 2013, CLIN NEUROPHYSIOL, V124, P1689, DOI 10.1016/j.clinph.2012.12.051; HALKO GJ, 1995, J RHEUMATOL, V22, P2152; Hallett M, 2016, PARKINSONISM RELAT D, V22, pS149, DOI 10.1016/j.parkreldis.2015.08.036; Hankinson TC, 2010, NEUROSURGERY, V66, pA32, DOI 10.1227/01.NEU.0000365803.22786.F0; HARRIS JH, 1994, AM J ROENTGENOL, V162, P881, DOI 10.2214/ajr.162.4.8141012; HENDERSON FC, 1993, ANN RHEUM DIS, V52, P629, DOI 10.1136/ard.52.9.629; Henderson FC, 2005, NEUROSURGERY, V56, P1101, DOI 10.1227/01.NEU.0000157929.85251.7C; Henderson Fraser C, 2010, Surg Neurol Int, V1, DOI 10.4103/2152-7806.66461; HOFFMAN HJ, 1976, CHILD BRAIN, V2, P145; Huijing PA, 2010, J APPL PHYSIOL, V109, P986, DOI 10.1152/japplphysiol.00723.2009; Jacome DE, 1999, CEPHALALGIA, V19, P791, DOI 10.1046/j.1468-2982.1999.1909791.x; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jang HS, 2016, PEDIATR NEUROSURG, V51, P9, DOI 10.1159/000439284; Jelsma LD, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-35; Kahn EN, 2015, NEUROSURG CLIN N AM, V26, P501, DOI 10.1016/j.nec.2015.06.006; Kassavetis P, 2012, MOVEMENT DISORD, V27, P1070, DOI 10.1002/mds.25004; Klekamp J, 2012, J NEUROSURG-PEDIATR, V10, P538, DOI 10.3171/2012.9.PEDS12110; Klimo P, 2008, J NEUROSURG-SPINE, V9, P332, DOI 10.3171/SPI.2008.9.10.332; Klinge PM, 2015, CSF RES COLL C P SEP; Kothari P, 2000, J BONE JOINT SURG BR, V82B, P1034, DOI 10.1302/0301-620X.82B7.10641; Kress HG, 2015, CURR MED RES OPIN, V31, P1743, DOI 10.1185/03007995.2015.1072088; Lang AE, 2006, NEUROL REF SER, P35; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; Liu XZ, 1997, J NEUROSCI, V17, P5395; MacKenzie JM, 2003, AM J FOREN MED PATH, V24, P369, DOI 10.1097/01.paf.0000097853.26115.bb; Martin MD, 2010, NEUROSURGERY, V66, pA2, DOI 10.1227/01.NEU.0000365830.10052.87; Martin VT, 2014, HEADACHE, V54, P1403, DOI 10.1111/head.12417; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Menendez JA, 2007, NEUROSURGERY, V60, P103, DOI 10.1227/01.NEU.0000249220.50085.E4; Menezes AH, 2008, CHILD NERV SYST, V24, P1091, DOI 10.1007/s00381-008-0606-8; Menezes AH, 2012, J NEUROSURG, V116, P301, DOI 10.3171/2011.9.JNS11386; Merrison A F A, 2009, Pract Neurol, V9, P54, DOI 10.1136/jnnp.2008.167171; Milhorat TH, 1999, NEUROSURGERY, V44, P1005, DOI 10.1097/00006123-199905000-00042; Milhorat TH, 2007, J NEUROSURG-SPINE, V7, P601, DOI 10.3171/SPI-07/12/601; Milhorat TH, 2010, ACTA NEUROCHIR, V152, P1117, DOI 10.1007/s00701-010-0636-3; Milhorat TH, 2009, SURG NEUROL, V72, P20, DOI 10.1016/j.surneu.2009.03.008; Muellbacher W, 1998, MUSCLE NERVE, V21, P972, DOI 10.1002/(SICI)1097-4598(199807)21:7<972::AID-MUS25>3.0.CO;2-R; Muhle C, 1998, INVEST RADIOL, V33, P444, DOI 10.1097/00004424-199808000-00004; NABORS MW, 1988, J NEUROSURG, V68, P366, DOI 10.3171/jns.1988.68.3.0366; NAGASHIMA C, 1981, Neurological Surgery, V9, P601; Nappi RE, 2012, GYNECOL ENDOCRINOL, V28, P37, DOI 10.3109/09513590.2012.651931; NINDS Common Data Elements, 2016, CLIN RES COMM DAT EL; Novegno F, 2008, J NEUROSURG-PEDIATR, V2, P179, DOI 10.3171/PED/2008/2/9/179; Palmer S, 2016, PHYSIOTHERAPY, V102, P93, DOI 10.1016/j.physio.2015.05.001; Palmeri S, 2003, CLIN GENET, V63, P510, DOI 10.1034/j.1399-0004.2003.00075.x; PANG D, 1982, J NEUROSURG, V57, P32, DOI 10.3171/jns.1982.57.1.0032; Panjabi, 1990, CLIN BIOMECHANICS SP; Patel MR, 1997, AM J ROENTGENOL, V168, P367, DOI 10.2214/ajr.168.2.9016209; Penisson-Besnier I, 2013, NEUROMUSCULAR DISORD, V23, P664, DOI 10.1016/j.nmd.2013.04.009; Pierangeli G, 2012, NEUROL SCI, V33, pS47, DOI 10.1007/s10072-012-1040-y; RADHAKRISHNAN K, 1993, J NEUROL SCI, V116, P18, DOI 10.1016/0022-510X(93)90084-C; Ripa P, 2015, INT J WOMENS HEALTH, V7, P773, DOI 10.2147/IJWH.S70073; Rombaut L, 2012, ARTHRIT CARE RES, V64, P1584, DOI 10.1002/acr.21726; Rombaut L, 2011, ARCH PHYS MED REHAB, V92, P1106, DOI 10.1016/j.apmr.2011.01.016; Royo-Salvador M B, 1996, Rev Neurol, V24, P937; Rubio-Agusti I, 2012, MOVEMENT DISORD, V27, P203, DOI 10.1002/mds.24013; Satti SR, 2015, AM J NEURORADIOL, V36, P1899, DOI 10.3174/ajnr.A4377; Savasta S, 2011, CHILD NERV SYST, V27, P365, DOI 10.1007/s00381-010-1256-1; Schurks M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3914; SELECKI BR, 1969, MED J AUSTRALIA, V1, P1012, DOI 10.5694/j.1326-5377.1969.tb49865.x; Shedid D, 2007, NEUROSURGERY, V60, P7, DOI 10.1227/01.NEU.0000215430.86569.C4; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Steilen Danielle, 2014, Open Orthop J, V8, P326, DOI 10.2174/1874325001408010326; STERN WE, 1988, J NEUROSURG, V69, P221, DOI 10.3171/jns.1988.69.2.0221; Strahle J, 2011, J NEUROSURG-PEDIATR, V8, P214, DOI 10.3171/2011.5.PEDS1122; Syx D, 2015, HUM MUTAT, V36, P535, DOI 10.1002/humu.22774; Taniguchi D, 2008, CLIN RHEUMATOL, V27, P851, DOI 10.1007/s10067-007-0809-5; Thompson EM, 2014, J NEUROSURG-PEDIATR, V13, P255, DOI 10.3171/2013.12.PEDS13370; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; TREDWELL SJ, 1990, J PEDIATR ORTHOPED, V10, P602, DOI 10.1097/01241398-199009000-00006; Tu A, 2013, CHILD NERV SYST, V29, P1635, DOI 10.1007/s00381-013-2129-1; Tubbs RS, 2011, J NEUROSURG-SPINE, V14, P697, DOI 10.3171/2011.1.SPINE10612; Tubbs RS, 2011, J NEUROSURG-PEDIATR, V7, P248, DOI 10.3171/2010.12.PEDS10379; van Hemert S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00241; van Rooijen DE, 2011, J NEUROL NEUROSUR PS, V82, P892, DOI 10.1136/jnnp.2010.232504; Voermans NC, 2008, NEUROMUSCULAR DISORD, V18, P843, DOI 10.1016/j.nmd.2008.05.017; Voermans NC, 2012, AM J MED GENET A, V158A, P850, DOI 10.1002/ajmg.a.35232; Voermans NC, 2011, CONNECT TISSUE RES, V52, P422, DOI 10.3109/03008207.2010.551616; Voermans NC, 2009, AM J MED GENET A, V149A, P2311, DOI 10.1002/ajmg.a.32997; Voermans NC, 2006, J NEUROL, V253, P670, DOI 10.1007/s00415-005-0056-0; Voermans NC, 2010, J PAIN SYMPTOM MANAG, V40, P370, DOI 10.1016/j.jpainsymman.2009.12.026; Voermans NC, 2009, ANN NEUROL, V65, P687, DOI 10.1002/ana.21643; Volman M, 2013, CATHETER CARDIO INTE, V81, P643, DOI 10.1002/ccd.24635; Voyadzis JM, 2001, J NEUROSURG, V95, P25, DOI 10.3171/spi.2001.95.1.0025; WIESEL S W, 1979, Spine, V4, P187, DOI 10.1097/00007632-197905000-00001; Wilson WA, 2010, SPINE SURG TECHNIQUE, V1; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yamada S, 2007, NEUROSURG FOCUS, V23, P1, DOI DOI 10.3171/FOC-07/08/E6; Yarbrough CK, 2011, J NEUROSURG-PEDIATR, V7, P244, DOI 10.3171/2010.11.PEDS1097; Yoshizumi T, 2014, NEUROSURG REV, V37, P519, DOI 10.1007/s10143-014-0531-0; Zhang H, 2007, SPINE, V32, P968, DOI 10.1097/01.brs.0000261036.04919.91	124	65	66	1	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4868	1552-4876		AM J MED GENET C	Am. J. Med. Genet. C	MAR	2017	175	1			SI		195	211		10.1002/ajmg.c.31549			17	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	EV2RP	WOS:000401603100014	28220607	Bronze			2022-02-06	
J	Shahim, P; Tegner, Y; Gustafsson, B; Gren, M; Arlig, J; Olsson, M; Lehto, N; Engstrom, A; Hoglund, K; Portelius, E; Zetterberg, H; Blennow, K				Shahim, Pashtun; Tegner, Yelverton; Gustafsson, Bengt; Gren, Magnus; Arlig, Johan; Olsson, Martin; Lehto, Niklas; Engstrom, Asa; Hoglund, Kina; Portelius, Erik; Zetterberg, Henrik; Blennow, Kaj			Neurochemical Aftermath of Repetitive Mild Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; CSF BIOMARKERS; INTERNATIONAL-CONFERENCE; HEAD-INJURY; ASSOCIATION; ENCEPHALOPATHY; CONCUSSION; STATEMENT	IMPORTANCE Evidence is accumulating that repeated mild traumatic brain injury (mTBI) incidents can lead to persistent, long-term debilitating symptoms and in some cases a progressive neurodegenerative condition referred to as chronic traumatic encephalopathy. However, to our knowledge, there are no objective tools to examine to which degree persistent symptoms after mTBI are caused by neuronal injury. OBJECTIVE To determine whether persistent symptoms after mTBI are associated with brain injury as evaluated by cerebrospinal fluid biochemical markers for axonal damage and other aspects of central nervous system injury. DESIGN, SETTINGS, AND PARTICIPANTS A multicenter cross-sectional study involving professional Swedish ice hockey players who have had repeated mTBI, had postconcussion symptoms for more than 3 months, and fulfilled the criteria for postconcussion syndrome (PCS) according to the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) matched with neurologically healthy control individuals. The participants were enrolled between January 2014 and February 2016. The players were also assessed with Rivermead Post Concussion Symptoms Questionnaire and magnetic resonance imaging. MAIN OUTCOMES AND MEASURES Neurofilament light protein, total tau, glial fibrillary acidic protein, amyloid beta, phosphorylated tau, and neurogranin concentrations in cerebrospinal fluid. RESULTS A total of 31 participants (16 men with PCS; median age, 31 years; range, 22-53 years; and 15 control individuals [11 men and 4 women]; median age, 25 years; range, 21-35 years) were assessed. Of 16 players with PCS, 9 had PCS symptoms for more than 1 year, while the remaining 7 returned to play within a year. Neurofilament light proteins were significantly increased in players with PCS for more than 1 year (median, 410 pg/mL; range, 230-1440 pg/mL) compared with players whose PCS resolved within 1 year (median, 210 pg/mL; range, 140-460 pg/mL) as well as control individuals (median 238 pg/mL, range 128-526 pg/mL; P =.04 and P =.02, respectively). Furthermore, neurofilament light protein concentrations correlated with Rivermead Post Concussion Symptoms Questionnaire scores and lifetime concussion events (rho = 0.58, P =.02 and rho = 0.52, P =.04, respectively). Overall, players with PCS had significantly lower cerebrospinal fluid amyloid-beta levels compared with control individuals (median, 1094 pg/mL; range, 845-1305 pg/mL; P =.05). CONCLUSIONS AND RELEVANCE Increased cerebrospinal fluid neurofilament light proteins and reduced amyloid beta were observed in patients with PCS, suggestive of axonal white matter injury and amyloid deposition. Measurement of these biomarkers may be an objective tool to assess the degree of central nervous system injury in individuals with PCS and to distinguish individuals who are at risk of developing chronic traumatic encephalopathy.	[Shahim, Pashtun; Gren, Magnus; Arlig, Johan; Olsson, Martin; Hoglund, Kina; Portelius, Erik; Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Clin Neurochem Lab, Inst Neurosci & Physiol, Sahlgrenska Acad,Sahlgrenska Univ Hosp, Molndal, Sweden; [Tegner, Yelverton; Lehto, Niklas; Engstrom, Asa] Lulea Univ Technol, Div Med Sci, Dept Hlth Sci, Lulea, Sweden; [Gustafsson, Bengt] Capio Artro Clin, Stockholm, Sweden; [Zetterberg, Henrik] UCL, Inst Neurol, Dept Mol Neurosci, London, England		Blennow, K (corresponding author), Univ Gothenburg, Molndal Hosp, Sahlgrenska Univ Hosp, Clin Neurochem Lab,Dept Neurosci & Physiol, SE-43180 Molndal, Sweden.	kaj.blennow@neuro.gu.se		Olsson, Martin/0000-0001-5531-5972; Tegner, Yelverton/0000-0003-3628-0705; Hoglund, Kina/0000-0002-1213-9953	Swedish Research CouncilSwedish Research CouncilEuropean Commission; European Research CouncilEuropean Research Council (ERC)European Commission; Centrum for Idrottsforskning; Torsten Soderberg Foundation; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Frimurarestiftelsen	The study was supported by grants from the Swedish Research Council, the European Research Council, Centrum for Idrottsforskning, the Torsten Soderberg Foundation, the Knut and Alice Wallenberg Foundation, and Frimurarestiftelsen.	Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Blennow K, 2015, TRENDS PHARMACOL SCI, V36, P297, DOI 10.1016/j.tips.2015.03.002; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kvartsberg H, 2015, ALZHEIMERS DEMENT, V11, P1180, DOI 10.1016/j.jalz.2014.10.009; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Mattsson N, 2012, NEUROLOGY, V78, P468, DOI 10.1212/WNL.0b013e3182477eed; Mattsson N, 2009, JAMA-J AM MED ASSOC, V302, P385, DOI 10.1001/jama.2009.1064; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Neselius S, 2015, KNEE SURG SPORT TR A, V23, P2536, DOI 10.1007/s00167-014-3066-6; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Norgren N, 2003, BRAIN RES, V987, P25, DOI 10.1016/S0006-8993(03)03219-0; Palmqvist S, 2016, BRAIN, V139, P1226, DOI 10.1093/brain/aww015; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Portelius E, 2015, BRAIN, V138, DOI 10.1093/brain/awv267; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Skillback T, 2014, NEUROLOGY, V83, P1945, DOI 10.1212/WNL.0000000000001015; Tarawneh R, 2016, JAMA NEUROL, V73, P561, DOI 10.1001/jamaneurol.2016.0086; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Toledo JB, 2015, BRAIN, V138, P2701, DOI 10.1093/brain/awv199; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; WISNIEWSKI K, 1979, ANN NEUROL, V5, P288, DOI 10.1002/ana.410050311; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2016, JAMA NEUROL, V73, P60, DOI 10.1001/jamaneurol.2015.3037	36	65	65	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	NOV 1	2016	73	11					1308	1315		10.1001/jamaneurol.2016.2038			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ED1BL	WOS:000388578600011	27654934	Green Submitted, Bronze			2022-02-06	
J	Sun, J; Wang, FY; Ling, ZX; Yu, XC; Chen, WQ; Li, HX; Jin, JT; Pang, MQ; Zhang, HQ; Yu, JJ; Liu, JM				Sun, Jing; Wang, Fangyan; Ling, Zongxin; Yu, Xichong; Chen, Wenqian; Li, Haixiao; Jin, Jiangtao; Pang, Mengqi; Zhang, Huiqing; Yu, Junjie; Liu, Jiaming			Clostridium butyricum attenuates cerebral ischemia/reperfusion injury in diabetic mice via modulation of gut microbiota	BRAIN RESEARCH			English	Article						Diabetes; Cerebral ischemia/reperfusion; Clostridium butyricum; Apoptosis; Gut microbiota; Butyrate	IRRITABLE-BOWEL-SYNDROME; TRAUMATIC BRAIN-INJURY; SIGNALING PATHWAY; ISCHEMIC-STROKE; AXIS; RATS; PROBIOTICS; APOPTOSIS; MELLITUS; TYPE-2	Diabetes is known to exacerbate cerebral ischemia/reperfusion (I/R) injury. Here, we investigated the effects of Clostridium butyricum on cerebral I/R injury in the diabetic mice subjected to 30 min of bilateral common carotid arteries occlusion (BCCAO). The cognitive impairment, the blood glucose level, neuronal injury, apoptosis, and expressions of Akt, phospho-Akt (p-Akt), and caspase-3 level were assessed. Meanwhile, the changes of gut microbiota in composition and diversity in the colonic feces were evaluated. Our results showed that diabetic mice subjected to BCCAO exhibited worsened cognitive impairment, cell damage and apoptosis. These were all attenuated by C butyricum. Moreover, C butyricum reversed cerebral I/R induced decreases in p-Akt expression and increases in caspase-3 expression, leading to inhibiting neuronal apoptosis. C butyricum partly restored cerebral I/R induced decreases of fecal microbiota diversity, changes of fecal microbiota composition. Together, these findings highlight the important role of bacteria in the bidirectional communication of the gut-brain axis and suggest that certain probiotics might prove to be useful therapeutic adjuncts in cerebral I/R injury with diabetes. (C) 2016 Elsevier B.V. All rights reserved.	[Sun, Jing] Wenzhou Med Univ, Affiliated Hosp 2, Dept Neurol, 109 Coll West Rd, Wenzhou 325027, Zhejiang, Peoples R China; [Wang, Fangyan] Wenzhou Med Univ, Dept Pathophysiol, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China; [Ling, Zongxin] Zhejiang Univ, Sch Med, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis,Collabo, Hangzhou 310003, Zhejiang, Peoples R China; [Yu, Xichong] Wenzhou Med Univ, Sch Pharmaceut Sci, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China; [Chen, Wenqian; Li, Haixiao; Jin, Jiangtao; Pang, Mengqi; Zhang, Huiqing; Yu, Junjie; Liu, Jiaming] Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China		Liu, JM (corresponding author), Wenzhou Med Univ, Sch Environm Sci & Publ Hlth, 1210 Univ Town, Wenzhou 325035, Zhejiang, Peoples R China.	wzjiaming_liu@163.com	Ling, Zongxin/M-1657-2018; Ling, Zongxin/AAM-4059-2021	Ling, Zongxin/0000-0001-9662-099X; 	Wenzhou Science and Technology Development Funds [Y20150174]	The research was supported by Wenzhou Science and Technology Development Funds (Y20150174).	Air EL, 2007, DIABETES CARE, V30, P3131, DOI 10.2337/dc06-1537; Asfandiyarova Nailya, 2006, Diab Vasc Dis Res, V3, P57, DOI 10.3132/dvdr.2006.009; Baliga Bantwal Suresh, 2006, Curr Cardiol Rep, V8, P23, DOI 10.1007/s11886-006-0006-1; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; Bercik P, 2012, NEUROGASTROENT MOTIL, V24, P405, DOI 10.1111/j.1365-2982.2012.01906.x; Burcelin R, 2011, ACTA DIABETOL, V48, P257, DOI 10.1007/s00592-011-0333-6; Camilleri M, 2006, J CLIN GASTROENTEROL, V40, P264, DOI 10.1097/00004836-200603000-00020; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2009, AM J CLIN NUTR, V90, P1236, DOI 10.3945/ajcn.2009.28095; Chen ZF, 2015, FUTURE MICROBIOL, V10, P1433, DOI 10.2217/fmb.15.66; Chugunova LA, 2006, TERAPEVT ARKH, V78, P21; Cruz-Herranz A, 2015, J DIABETES, V7, P657, DOI 10.1111/1753-0407.12222; Cumbler E, 2015, NEUROHOSPITALIST, V5, P173, DOI 10.1177/1941874415588319; Delzenne NM, 2015, DIABETOLOGIA, V58, P2206, DOI 10.1007/s00125-015-3712-7; Desbonnet L, 2014, MOL PSYCHIATR, V19, P146, DOI 10.1038/mp.2013.65; Dinan TG, 2013, BIOL PSYCHIAT, V74, P720, DOI 10.1016/j.biopsych.2013.05.001; Duan J., 2015, MOL NEUROBIOL; Dutkiewicz J., 2015, J NEURAL TRANSM; El-Sahar AE, 2015, PHARMACOL REP, V67, P901, DOI 10.1016/j.pharep.2015.03.018; Espinera AR, 2013, NEUROSCIENCE, V247, P1, DOI 10.1016/j.neuroscience.2013.04.011; Furie K, 2008, CURR NEUROL NEUROSCI, V8, P12, DOI 10.1007/s11910-008-0004-3; Gillingwater TH, 2004, J CEREBR BLOOD F MET, V24, P62, DOI 10.1097/01.WCB.0000095798.98378.34; Gomes AC, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-60; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Heckmann JG, 2005, DEUT MED WOCHENSCHR, V130, P291, DOI 10.1055/s-2005-863045; Hill Michael D, 2014, Handb Clin Neurol, V126, P167, DOI 10.1016/B978-0-444-53480-4.00012-6; Hu CY, 2015, PHARMACOL RES, V98, P9, DOI 10.1016/j.phrs.2015.02.006; Kanai T., 2015, J GASTROENTEROL; Kasinska M.A., 2015, POL ARCH MED WEWN; Kim HJ, 2003, ALIMENT PHARM THER, V17, P895, DOI 10.1046/j.1365-2036.2003.01543.x; Kim HJ, 2009, J NEUROCHEM, V110, P1226, DOI 10.1111/j.1471-4159.2009.06212.x; Kim JS, 2015, J MOV DISORD, V8, P76, DOI 10.14802/jmd.15008; Kootte RS, 2012, DIABETES OBES METAB, V14, P112, DOI 10.1111/j.1463-1326.2011.01483.x; Kumar P, 2014, INT J BIOCHEM CELL B, V53, P302, DOI 10.1016/j.biocel.2014.05.038; Li WY, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00048; Liu AH, 2008, CELL PHYSIOL BIOCHEM, V22, P177, DOI 10.1159/000149795; Liu H, 2015, AM J MED SCI, V350, P204, DOI 10.1097/MAJ.0000000000000540; Liu JM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/412946; Luna RA, 2015, CURR OPIN BIOTECH, V32, P35, DOI 10.1016/j.copbio.2014.10.007; MacFabe Derrick F., 2012, Microbial Ecology in Health and Disease, V23, P19260, DOI 10.3402/mehd.v23i0.19260; Martinez-Sanchez P, 2007, Cerebrovasc Dis, V24 Suppl 1, P143, DOI 10.1159/000107390; Mayer EA, 2015, J CLIN INVEST, V125, P926, DOI 10.1172/JCI76304; Mendzheritskii A M, 2011, Adv Gerontol, V24, P74; Messaoudi M, 2011, GUT MICROBES, V2, P256, DOI 10.4161/gmic.2.4.16108; Messaoudi M, 2011, BRIT J NUTR, V105, P755, DOI 10.1017/S0007114510004319; Mikelsaar Marika, 2009, Microbial Ecology in Health and Disease, V21, P1, DOI 10.1080/08910600902815561; Mulak A, 2015, WORLD J GASTROENTERO, V21, P10609, DOI 10.3748/wjg.v21.i37.10609; Pamenter ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060804; Park S., 2015, EXP BIOL MED; Qu YY, 2015, NEUROCHEM RES, V40, P1, DOI 10.1007/s11064-014-1456-2; Rhee SH, 2009, NAT REV GASTRO HEPAT, V6, P306, DOI 10.1038/nrgastro.2009.35; Savignac HM, 2015, BEHAV BRAIN RES, V287, P59, DOI 10.1016/j.bbr.2015.02.044; Savignac HM, 2014, NEUROGASTROENT MOTIL, V26, P1615, DOI 10.1111/nmo.12427; Shinnoh M, 2013, INT J ONCOL, V42, P903, DOI 10.3892/ijo.2013.1790; Shou J., 2015, J STROKE CEREBROVASC; Stenman LK, 2015, DIABETOL METAB SYNDR, V7, DOI 10.1186/s13098-015-0075-7; STORM T, 1985, BRIT MED J, V291, P1577, DOI 10.1136/bmj.291.6508.1577-a; Sun J, 2016, NEUROSCI LETT, V613, P30, DOI 10.1016/j.neulet.2015.12.047; Sun J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/395895; Terashima T, 1998, NEUROSURGERY, V43, P900, DOI 10.1097/00006123-199810000-00102; Vanderhoof JA, 1998, J PEDIATR GASTR NUTR, V27, P323, DOI 10.1097/00005176-199809000-00011; Wang GX, 2001, LIFE SCI, V69, P2801, DOI 10.1016/S0024-3205(01)01354-6; Wang XT, 2007, CELL SIGNAL, V19, P1844, DOI 10.1016/j.cellsig.2007.04.005; Wu CR, 2001, J NEUROSCI METH, V107, P101, DOI 10.1016/S0165-0270(01)00356-9; Yadav H, 2013, J BIOL CHEM, V288, P25088, DOI 10.1074/jbc.M113.452516; Yakovlieva M, 2015, BENEF MICROBES, V6, P505, DOI 10.3920/BM2014.0012; Yoo DY, 2015, NEUROL RES, V37, P69, DOI 10.1179/1743132814Y.0000000416; Yu Z, 2015, CELL PHYSIOL BIOCHEM, V37, P67, DOI 10.1159/000430334; Yun SI, 2009, J APPL MICROBIOL, V107, P1681, DOI 10.1111/j.1365-2672.2009.04350.x	69	65	70	5	43	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 1	2016	1642						180	188		10.1016/j.brainres.2016.03.042			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DP7EI	WOS:000378661600021	27037183				2022-02-06	
J	Muccigrosso, MM; Ford, J; Benner, B; Moussa, D; Burnsides, C; Fenn, AM; Popovich, PG; Lifshitz, J; Walker, FR; Eiferman, DS; Godbout, JP				Muccigrosso, Megan M.; Ford, Joni; Benner, Brooke; Moussa, Daniel; Burnsides, Christopher; Fenn, Ashley M.; Popovich, Phillip G.; Lifshitz, Jonathan; Walker, Fredrick Rohan; Eiferman, Daniel S.; Godbout, Jonathan P.			Cognitive deficits develop 1 month after diffuse brain injury and are exaggerated by microglia-associated reactivity to peripheral immune challenge	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Fluid percussion injury; Microglia; Astrocytes; Cognitive decline; Lipopolysaccharide; Neuroinflammation	DEPRESSIVE-LIKE BEHAVIOR; LONG-TERM POTENTIATION; AGED MICE; HIPPOCAMPAL NEUROGENESIS; EXPERIMENTAL-MODELS; SICKNESS BEHAVIOR; NEURONAL LOSS; HEAD-INJURY; ACTIVATION; MEMORY	Traumatic brain injury (TBI) elicits immediate neuroinflammatory events that contribute to acute cognitive, motor, and affective disturbance. Despite resolution of these acute complications, significant neuropsychiatric and cognitive issues can develop and progress after TBI. We and others have provided novel evidence that these complications are potentiated by repeated injuries, immune challenges and stressors. A key component to this may be increased sensitization or priming of glia after TBI. Therefore, our objectives were to determine the degree to which cognitive deterioration occurred after diffuse TBI (moderate midline fluid percussion injury) and ascertain if glial reactivity induced by an acute immune challenge potentiated cognitive decline 30 days post injury (dpi). In post-recovery assessments, hippocampal-dependent learning and memory recall were normal 7 dpi, but anterograde learning was impaired by 30 dpi. Examination of mRNA and morphological profiles of glia 30 dpi indicated a low but persistent level of inflammation with elevated expression of GFAP and IL-1 beta in astrocytes and MHCII and IL-1 beta in microglia. Moreover, an acute immune challenge 30 dpi robustly interrupted memory consolidation specifically in TBI mice. These deficits were associated with exaggerated microglia-mediated inflammation with amplified (IL-1 beta, CCL2, TNF alpha) and prolonged (TNF alpha) cytokine/chemokine expression, and a marked reactive morphological profile of microglia in the CA3 of the hippocampus. Collectively, these data indicate that microglia remain sensitized 30 dpi after moderate TBI and a secondary inflammatory challenge elicits robust microglial reactivity that augments cognitive decline. Statement of Significance: Traumatic brain injury (TBI) is a major risk factor in development of neuropsychiatric problems long after injury, negatively affecting quality of life. Mounting evidence indicates that inflammatory processes worsen with time after a brain injury and are likely mediated by glia. Here, we show that primed microglia and astrocytes developed in mice 1 month following moderate diffuse TBI, coinciding with cognitive deficits that were not initially evident after injury. Additionally, TBI-induced glial priming may adversely affect the ability of glia to appropriately respond to immune challenges, which occur regularly across the lifespan. Indeed, we show that an acute immune challenge augmented microglial reactivity and cognitive deficits. This idea may provide new avenues of clinical assessments and treatments following TBI. (C) 2016 Elsevier Inc. All rights reserved.	[Muccigrosso, Megan M.; Ford, Joni; Benner, Brooke; Moussa, Daniel; Burnsides, Christopher; Fenn, Ashley M.; Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Dept Neurosci, 333 W 10th Ave, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, 460 W 12th Ave, Columbus, OH 43210 USA; [Popovich, Phillip G.; Godbout, Jonathan P.] Ohio State Univ, Inst Behav Med Res, 460 Med Ctr Dr, Columbus, OH 43210 USA; [Lifshitz, Jonathan] Univ Arizona, Coll Med Phoenix, Barrow Neurol Inst, Phoenix Childrens Hosp,Dept Child Hlth, Phoenix, AZ USA; [Walker, Fredrick Rohan] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia; [Eiferman, Daniel S.] Ohio State Univ, Dept Surg, 395 W 12th Ave, Columbus, OH 43210 USA		Godbout, JP (corresponding author), Ohio State Univ, 231 IBMR Bldg,460 Med Ctr Dr, Columbus, OH 43210 USA.	jonathan.godbout@osumc.edu			NIA Grant [R01-AG-033028]; College of Medicine Dean's Discovery Grant; Center for Brain and Spinal Cord Repair; American Surgical Society Fellowship; P30 Core Grant [NINDS P30-NS045758]; National Institute of Dental and Craniofacial Research Training Grant [T32-DE-01-4320]; OSU Presidential Fellowship; Ray W. Poppleton Endowment; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE014320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033028] Funding Source: NIH RePORTER	This research was supported by an NIA Grant (R01-AG-033028 to J.P.G.), College of Medicine Dean's Discovery Grant (to J.P.G.), Funding from the Center for Brain and Spinal Cord Repair (to J.P.G), an American Surgical Society Fellowship (to D.S.E). In addition, this work was supported by a P30 Core Grant NINDS P30-NS045758. M.M.M. was supported by a National Institute of Dental and Craniofacial Research Training Grant (T32-DE-01-4320), A.M.F. was supported by the OSU Presidential Fellowship, and P.G.P was supported by a Ray W. Poppleton Endowment.	Almeida O.P., 2015, INT J GERIATR PSYCHI; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barrientos RM, 2010, AGING DIS, V1, P212; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P450, DOI 10.1016/j.bbi.2009.01.016; Barrientos RM, 2009, BRAIN BEHAV IMMUN, V23, P46, DOI 10.1016/j.bbi.2008.07.002; Battista D, 2006, EUR J NEUROSCI, V23, P83, DOI 10.1111/j.1460-9568.2005.04539.x; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Ben Menachem-Zidon O, 2011, BRAIN BEHAV IMMUN, V25, P1008, DOI 10.1016/j.bbi.2010.11.007; Berg BM, 2004, BRAIN BEHAV IMMUN, V18, P149, DOI 10.1016/S0889-1591(03)00113-2; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cavaglia M, 2001, BRAIN RES, V910, P81, DOI 10.1016/S0006-8993(01)02637-3; Chen J, 2008, BRAIN BEHAV IMMUN, V22, P301, DOI 10.1016/j.bbi.2007.08.014; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Fenn AM, 2015, J NEUROTRAUM, V32, P127, DOI 10.1089/neu.2014.3514; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Godbout JP, 2008, NEUROPSYCHOPHARMACOL, V33, P2341, DOI 10.1038/sj.npp.1301649; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hazra A, 2014, J NEUROSCI RES, V92, P1434, DOI 10.1002/jnr.23430; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Jo S, 2014, NAT MED, V20, P886, DOI 10.1038/nm.3639; Johnson SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10607; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kheirbek MA, 2011, NEUROPSYCHOPHARMACOL, V36, P373, DOI 10.1038/npp.2010.148; Kongsui R, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0182-7; Kongsui R, 2014, BRAIN BEHAV IMMUN, V42, P69, DOI 10.1016/j.bbi.2014.05.017; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Molofsky AV, 2012, GENE DEV, V26, P891, DOI 10.1101/gad.188326.112; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; [National Center for Injury Prevention and Control National Institute of Health (NIH) Centers for Disease Control and Prevention C], 2015, TRAUM BRAIN INJ US E; Norden D.M., 2015, GLIA; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Radler ME, 2015, NEUROSCIENCE, V285, P236, DOI 10.1016/j.neuroscience.2014.11.014; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Sahinkaya FR, 2014, EXP NEUROL, V255, P113, DOI 10.1016/j.expneurol.2014.02.025; Salmond CH, 2006, NEUROPSYCHOLOGIA, V44, P1995, DOI 10.1016/j.neuropsychologia.2006.03.013; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Valero J, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00083; Walker FR, 2014, BRAIN BEHAV IMMUN, V37, P1, DOI 10.1016/j.bbi.2013.12.010; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Whiting MD, 2008, BRAIN RES, V1213, P69, DOI 10.1016/j.brainres.2008.01.107; Witcher KG, 2015, TRENDS NEUROSCI, V38, P609, DOI 10.1016/j.tins.2015.08.002; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Wohleb ES, 2014, BIOL PSYCHIAT, V75, P970, DOI 10.1016/j.biopsych.2013.11.029; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Wohleb ES, 2012, PSYCHONEUROENDOCRINO, V37, P1491, DOI 10.1016/j.psyneuen.2012.02.003; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	70	65	69	0	19	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAY	2016	54						95	109		10.1016/j.bbi.2016.01.009			15	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	DJ4VW	WOS:000374207200010	26774527	Green Accepted			2022-02-06	
J	Louw, AM; Kolar, MK; Novikova, LN; Kingham, PJ; Wiberg, M; Kjems, J; Novikov, LN				Louw, Andrew M.; Kolar, Mallappa K.; Novikova, Liudmila N.; Kingham, Paul J.; Wiberg, Mikael; Kjems, Jorgen; Novikov, Lev N.			Chitosan polyplex mediated delivery of miRNA-124 reduces activation of microglial cells in vitro and in rat models of spinal cord injury	NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE			English	Article						Chitosan polyplex system; miRNA-124; Microglia/macrophage; Inflammation; Spinal cord injury	TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; SUBSTANTIA-NIGRA; GLIAL SCAR; MACROPHAGE; NANOPARTICLES; ALPHA; CNS; DIFFERENTIATION	Traumatic injury to the central nervous system (CNS) is further complicated by an increase in secondary neuronal damage imposed by activated microglia/macrophages. MicroRNA-124 (miR-124) is responsible for mouse monocyte quiescence and reduction of their inflammatory cytokine production. We describe the formulation and ex vivo transfection of chitosan/miR-124 polyplex particles into rat microglia and the resulting reduction of reactive oxygen species (ROS) and TNF-alpha and lower expression of MHC-II. Upon microinjection into uninjured rat spinal cords, particles formed with Cy3-labeled control sequence RNA, were specifically internalized by OX42 positive macrophages and microglia cells. Alternatively particles injected in the peritoneum were transported by macrophages to the site of spinal cord injury 72h post injection. Microinjections of chitosan/miR-124 particles significantly reduced the number of ED-1 positive macrophages in the injured spinal cord. Taken together, these data present a potential treatment technique to reduce inflammation for a multitude of CNS neurodegenerative conditions. (C) 2015 The Authors. Published by Elsevier Inc.	[Louw, Andrew M.; Kjems, Jorgen] Aarhus Univ, Interdisciplinary Nanosci Ctr, Aarhus C, Denmark; [Kolar, Mallappa K.; Novikova, Liudmila N.; Kingham, Paul J.; Wiberg, Mikael; Novikov, Lev N.] Umea Univ, Dept Integrat Med Biol, Umea, Sweden		Kjems, J (corresponding author), Aarhus Univ, Interdisciplinary Nanosci Ctr, Aarhus C, Denmark.; Novikov, LN (corresponding author), Umea Univ, Dept Integrat Med Biol, Umea, Sweden.	jk@mbg.au.dk; lev.novikov@umu.se	Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317; Novikov, Lev/0000-0001-5520-3890; Kingham, Paul/0000-0003-2596-5936	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2014-2306]; Lundbeck Foundation Nanomedicine Centre for Individualized Management of Tissue Damage and Regeneration (LUNA); ERA-Net European transnational collaborative project: "Nano-Functionalised Implants for the Regenerative Treatment of Spinal Cord and Nerve Lesions" (Nano4Neuro)	The authors would like to acknowledge The Lundbeck Foundation Nanomedicine Centre for Individualized Management of Tissue Damage and Regeneration (LUNA), ERA-Net European transnational collaborative project: "Nano-Functionalised Implants for the Regenerative Treatment of Spinal Cord and Nerve Lesions" (Nano4Neuro) and the Swedish Research Council (grant 2014-2306, Medicine and Health) for their support of this research.	Akiyama H, 1994, Nihon Rinsho, V52, P2990; Andersen MO, 2008, BIOMATERIALS, V29, P506, DOI 10.1016/j.biomaterials.2007.10.003; Ballarin-Gonzalez B, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.2; Banerjee S, 2013, J IMMUNOL, V190, P6542, DOI 10.4049/jimmunol.1202496; Bao F, 2009, EXP NEUROL, V215, P308, DOI 10.1016/j.expneurol.2008.10.022; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Behr JP, 1997, CHIMIA, V51, P34; Cai DH, 2008, ONCOGENE, V27, P2772, DOI 10.1038/sj.onc.1210940; Center NSCIS, 2013, ANN STAT REP SPIN CO; Chung MJ, 2012, INT IMMUNOPHARMACOL, V12, P453, DOI 10.1016/j.intimp.2011.12.027; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Feng R, 2008, P NATL ACAD SCI USA, V105, P6057, DOI 10.1073/pnas.0711961105; Frank MG, 2006, J NEUROSCI METH, V151, P121, DOI 10.1016/j.jneumeth.2005.06.026; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Havenith CEG, 1998, GLIA, V22, P348, DOI 10.1002/(SICI)1098-1136(199804)22:4<348::AID-GLIA4>3.0.CO;2-#; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Howard KA, 2006, MOL THER, V14, P476, DOI 10.1016/j.ymthe.2006.04.010; Howard KA, 2009, MOL THER, V17, P162, DOI 10.1038/mt.2008.220; Howell OW, 2010, J NEUROPATH EXP NEUR, V69, P1017, DOI 10.1097/NEN.0b013e3181f3a5b1; Huh Y, 2003, NEUROSCI LETT, V349, P63, DOI 10.1016/S0304-3940(03)00743-2; Kaushal V, 2007, J NEUROSCI, V27, P234, DOI 10.1523/JNEUROSCI.3593-06.2007; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Klyachko NL, 2014, NANOMEDICINE-UK, V9, P1403, DOI [10.2217/NNM.13.115, 10.2217/nnm.13.115]; Kook SY, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23993; Kurkowska-Jastrzebska I, 1999, ACTA NEUROBIOL EXP, V59, P1; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Lee H, 2014, FRONT BIOSCI-LANDMRK, V19, P272, DOI 10.2741/4206; Liu XD, 2007, BIOMATERIALS, V28, P1280, DOI 10.1016/j.biomaterials.2006.11.004; Ma ZW, 2015, J ORAL PATHOL MED, V44, P538, DOI 10.1111/jop.12269; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8; McGeer PL, 2003, ANN NEUROL, V54, P599, DOI 10.1002/ana.10728; Minagar A, 2003, MULT SCLER J, V9, P540, DOI 10.1191/1352458503ms965oa; Mishima T, 2007, BRAIN RES, V1131, P37, DOI 10.1016/j.brainres.2006.11.035; Mittnacht U, 2010, NANO LETT, V10, P3933, DOI 10.1021/nl1016909; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Nawroth I, 2013, ACTA ONCOL, V52, P1730, DOI 10.3109/0284186X.2012.726373; Nawroth I, 2010, RADIOTHER ONCOL, V97, P143, DOI 10.1016/j.radonc.2010.09.010; Noble LJ, 2002, J NEUROSCI, V22, P7526; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Qi L, 2010, INT J CLIN EXP MED, V3, P283; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sun Y, 2013, CELL RES, V23, P1270, DOI 10.1038/cr.2013.116; Traynor D, 2007, J CELL SCI, V120, P2318, DOI 10.1242/jcs.007732; Walton M, 1998, MOL BRAIN RES, V61, P11, DOI 10.1016/S0169-328X(98)00169-7; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Yang CX, 2015, THERANOSTICS, V5, P110, DOI 10.7150/thno.9717; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yoon HJ, 2007, BIOCHEM BIOPH RES CO, V358, P954, DOI 10.1016/j.bbrc.2007.05.042	57	65	70	4	32	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1549-9634	1549-9642		NANOMED-NANOTECHNOL	Nanomed.-Nanotechnol. Biol. Med.	APR	2016	12	3					643	653		10.1016/j.nano.2015.10.011			11	Nanoscience & Nanotechnology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Research & Experimental Medicine	DJ0WB	WOS:000373924000007	26582736	hybrid			2022-02-06	
J	Lillie, EM; Urban, JE; Lynch, SK; Weaver, AA; Stitzel, JD				Lillie, Elizabeth M.; Urban, Jillian E.; Lynch, Sarah K.; Weaver, Ashley A.; Stitzel, Joel D.			Evaluation of Skull Cortical Thickness Changes With Age and Sex From Computed Tomography Scans	JOURNAL OF BONE AND MINERAL RESEARCH			English	Article						CORTICAL THICKNESS; SKULL; CRANIAL VAULT; COMPUTED TOMOGRAPHY; AGE CHANGES	TRAUMATIC BRAIN-INJURY; PARATHYROID-HORMONE; MECHANICAL-PROPERTIES; THIN STRUCTURES; BONE; PATHOPHYSIOLOGY; DENSITY; FLEXURE; CT	Head injuries resulting from motor vehicle crashes (MVC) are extremely common, yet the details of the mechanism of injury remain to be well characterized. Skull deformation is believed to be a contributing factor to some types of traumatic brain injury (TBI). Understanding biomechanical contributors to skull deformation would provide further insight into the mechanism of head injury resulting from blunt trauma. In particular, skull thickness is thought be a very important factor governing deformation of the skull and its propensity for fracture. Previously, age- and sex-based skull cortical thickness changes were difficult to evaluate based on the need for cadaveric skulls. In this cross-sectional study, skull thickness changes with age and sex have been evaluated at homologous locations using a validated cortical density-based algorithm to accurately quantify cortical thickness from 123 high-resolution clinical computed tomography (CT) scans. The flat bones of the skull have a sandwich structure; therefore, skull thickness was evaluated for the inner and outer tables as well the full thickness. General trends indicated an increase in the full skull thickness, mostly attributed to an increase in the thickness of the diploic layer; however, these trends were not found to be statistically significant. There was a significant relationship between cortical thinning and age for both tables of the frontal, occipital, and parietal bones ranging between a 36% and 60% decrease from ages 20 to 100 years in females, whereas males exhibited no significant changes. Understanding how cortical and full skull thickness changes with age from a wide range of subjects can have implications in improving the biofidelity of age- and sex-specific finite element models and therefore aid in the prediction and understanding of TBI from impact and blast injuries. (c) 2015 American Society for Bone and Mineral Research.	[Lillie, Elizabeth M.; Urban, Jillian E.; Lynch, Sarah K.; Weaver, Ashley A.; Stitzel, Joel D.] Virginia Tech Wake Forest Univ, Ctr Injury Biomech, Winston Salem, NC USA; [Lillie, Elizabeth M.; Urban, Jillian E.; Lynch, Sarah K.; Weaver, Ashley A.; Stitzel, Joel D.] Wake Forest Univ, Bowman Gray Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA		Stitzel, JD (corresponding author), Virginia Tech Wake Forest Univ, Ctr Injury Biomech, Winston Salem, NC USA.; Stitzel, JD (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	jdstitzel@gmail.com	Stitzel, Joel/B-4045-2012; Weaver, Ashley/ABB-5845-2021	Stitzel, Joel/0000-0001-9762-3033; Weaver, Ashley/0000-0002-4383-0106	National Highway Traffic Safety Administration [DTN22-09-H-00242]	This work was supported by grants from the National Highway Traffic Safety Administration under Cooperative Agreement Number DTN22-09-H-00242. Views expressed are those of the authors and do not represent the views of NHTSA. We thank Callistus Nguyen and Mimin Meliyani for assisting with data collection.	Angel JL., 2005, AM J PHYS ANTHROPOL, V58, P297; Avants B, 2004, NEUROIMAGE, V23, pS139, DOI 10.1016/j.neuroimage.2004.07.010; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Chakkalakal DA, 2005, ALCOHOL CLIN EXP RES, V29, P2077, DOI 10.1097/01.alc.0000192039.21305.55; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032; Dougherty G, 1999, MED PHYS, V26, P1341, DOI 10.1118/1.598629; Faul M, 2010, TRAUMATIC BRAIN INJU; FEHLING PC, 1995, BONE, V17, P205, DOI 10.1016/8756-3282(95)00171-9; GALLAGHER JC, 1980, J LAB CLIN MED, V95, P373; Gayzik FS, 2011, ANN BIOMED ENG, V39, P2568, DOI 10.1007/s10439-011-0359-5; Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076; Greenspan SL, 1999, ANN INTERN MED, V130, P750, DOI 10.7326/0003-4819-130-9-199905040-00016; Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035; Hodgson V., 1970, P 14 STAPP CAR CRASH, P341; HUBBARD RP, 1971, J BIOMECH, V4, P251, DOI 10.1016/0021-9290(71)90031-5; HUBBARD RP, 1971, J BIOMECH, V4, P491, DOI 10.1016/0021-9290(71)90039-X; JASLOW CR, 1990, J BIOMECH, V23, P313, DOI 10.1016/0021-9290(90)90059-C; Khan MN, 2008, CURR ONCOL, V15, pS30; Kim CH, 2003, J BONE MINER RES, V18, P2116, DOI 10.1359/jbmr.2003.18.12.2116; Lillie EM, 2015, J ANAT, V226, P73, DOI 10.1111/joa.12259; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MARCUS R, 1984, J CLIN ENDOCR METAB, V58, P223, DOI 10.1210/jcem-58-2-223; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; Newman DL, 1998, PHYS MED BIOL, V43, P619, DOI 10.1088/0031-9155/43/3/013; Nusholtz G.S., 1984, 841657 SAE, P41; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Peterson J, 2003, ANAT REC PART A, V274A, P785, DOI 10.1002/ar.a.10096; Peterson J, 2002, ANAT REC, V268, P7, DOI 10.1002/ar.10131; Poole KES, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038466; Prevrhal S, 2003, MED PHYS, V30, P1, DOI 10.1118/1.1521940; Raisz LG, 1999, CLIN CHEM, V45, P1353; Ruan J, 2001, Stapp Car Crash J, V45, P395; Saladin K. S., 2007, ANATOMY PHYSL UNITY; Shatsky SA, 1974, P STAPP CAR CRASH C, P351; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Treece GM, 2012, MED IMAGE ANAL, V16, P952, DOI 10.1016/j.media.2012.02.008; Treece GM, 2010, MED IMAGE ANAL, V14, P276, DOI 10.1016/j.media.2010.01.003; Urban JE, 2016, J ANAT, V229, P838, DOI 10.1111/joa.12247; Urban JE, 2012, J NEUROTRAUM, V29, P2774, DOI 10.1089/neu.2012.2373; Yoganandan N, 2007, J TRAUMA, V66, P7; Yoganandan N, 2010, ACCIDENT ANAL PREV, V42, P1370, DOI 10.1016/j.aap.2010.02.017	44	65	66	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0884-0431	1523-4681		J BONE MINER RES	J. Bone Miner. Res.	FEB	2016	31	2					299	307		10.1002/jbmr.2613			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	DD8NE	WOS:000370182900007	26255873	Bronze			2022-02-06	
J	Lei, J; Gao, GY; Feng, JF; Jin, YC; Wang, CF; Mao, Q; Jiang, JY				Lei, Jin; Gao, Guoyi; Feng, Junfeng; Jin, Yichao; Wang, Chuanfang; Mao, Qing; Jiang, Jiyao			Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study	CRITICAL CARE			English	Article							THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; CLINICAL-TRIALS; SERUM; MODERATE; BLOOD; GFAP; PREDICTION; MANAGEMENT; PROGNOSIS	Introduction: Glial fibrillary acidic protein (GFAP) may serve as a serum marker of traumatic brain injury (TBI) that can be used to monitor biochemical changes in patients and gauge the response to treatment. However, the temporal profile of serum GFAP in the acute period of brain injury and the associated utility for outcome prediction has not been elucidated. Methods: We conducted a prospective longitudinal cohort study of consecutive severe TBI patients in a local tertiary neurotrauma center in Shanghai, China, between March 2011 and September 2014. All patients were monitored and managed with a standardized protocol with inclusion of hypothermia and other intensive care treatments. Serum specimens were collected on admission and then daily for the first 5 days. GFAP levels were measured using enzyme-linked immunosorbent assay techniques. Patient outcome was assessed at 6 months post injury with the Glasgow Outcome Scale and further grouped into death versus survival and unfavorable versus favorable. Results: A total of 67 patients were enrolled in the study. The mean time from injury to admission was 2.6 hours, and the median admission Glasgow Coma Scale score was 6. Compared with healthy subjects, patients with severe TBI had increased GFAP levels on admission and over the subsequent 5 days post injury. Serum GFAP levels showed a gradual reduction from admission to day 3, and then rebounded on day 4 when hypothermia was discontinued with slow rewarming. GFAP levels were significantly higher in patients who died or had an unfavorable outcome across all time points than in those who were alive or had a favorable outcome. Results of receiver operating characteristic curve analysis indicated that serum GFAP at each time point could predict neurological outcome at 6 months. The areas under the curve for GFAP on admission were 0.761 for death and 0.823 for unfavorable outcome, which were higher than those for clinical variables such as age, Glasgow Coma Scale score, and pupil reactions. Conclusions: Serum GFAP levels on admission and during the first 5 days of injury were increased in patients with severe TBI and were predictive of neurological outcome at 6 months.	[Lei, Jin; Gao, Guoyi; Feng, Junfeng; Jin, Yichao; Wang, Chuanfang; Mao, Qing; Jiang, Jiyao] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Inst Head Trauma,Dept Neurosurg, Shanghai 200127, Peoples R China; [Lei, Jin; Gao, Guoyi; Feng, Junfeng; Jin, Yichao; Wang, Chuanfang; Mao, Qing; Jiang, Jiyao] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China		Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Inst Head Trauma,Dept Neurosurg, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	jiyaojiangrenji@126.com			National Key Basic Research ProjectNational Basic Research Program of China [2012CB518100]; National Natural Scientific FoundationNational Natural Science Foundation of China (NSFC) [81271381]; Program for Outstanding Medical Academic Leader of Shanghai [2014529]	This research was supported by grants from the National Key Basic Research Project (No. 2012CB518100), the National Natural Scientific Foundation (No. 81271381) and the Program for Outstanding Medical Academic Leader of Shanghai (No. 2014529). We thank Dr. Xiao Zhang from Pharmaceutical Product Development, LLC (PPD (R)) for her valuable statistical assistance in our work. We are also grateful to Dr. Justin Dean from University of Auckland for his important assistance in English.	Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Choi HA, 2012, NAT REV NEUROL, V8, P214, DOI 10.1038/nrneurol.2012.21; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dvorak F, 2009, CEREBROVASC DIS, V27, P37, DOI 10.1159/000172632; Fox JL, 2010, CAN J EMERG MED, V12, P355; Gao L, 2015, FRONT BIOSCI-LANDMRK, V20, P763, DOI 10.2741/4335; Hemingway H, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e5595; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Jacobs B, 2013, NEUROCRIT CARE, V19, P79, DOI 10.1007/s12028-012-9795-9; Lei J, 2015, CONTEMP CLIN TRIALS, V40, P9, DOI 10.1016/j.cct.2014.11.008; Lei J, 2013, J NEUROTRAUM, V30, P529, DOI 10.1089/neu.2012.2548; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mouser PE, 2006, AM J PATHOL, V168, P936, DOI 10.2353/ajpath.2006.050798; Mrozek S, 2014, CRIT CARE, V18, DOI 10.1186/cc13841; Nichol AD, 2009, INJURY, V40, P471, DOI 10.1016/j.injury.2009.01.002; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Shann F, 2003, LANCET, V362, P1950, DOI 10.1016/S0140-6736(03)15083-0; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; WARE JH, 1993, EUR RESPIR J, V6, P325; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003; Yokobori S, 2013, J NEUROSURG, V118, P370, DOI 10.3171/2012.10.JNS12725	44	65	66	1	13	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	OCT 12	2015	19								362	10.1186/s13054-015-1081-8			12	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CT0IM	WOS:000362478400001	26455520	gold, Green Published			2022-02-06	
J	Shi, H; Hu, XM; Leak, RK; Shi, YJ; An, CR; Suenaga, J; Chen, J; Gao, YQ				Shi, Hong; Hu, Xiaoming; Leak, Rehana K.; Shi, Yejie; An, Chengrui; Suenaga, Jun; Chen, Jun; Gao, Yanqin			Demyelination as a rational therapeutic target for ischemic or traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	3rd Pangu Stroke Conference	OCT 10-12, 2014	Beijing, PEOPLES R CHINA			Demyelination; Oligodendrocyte; Remyelination; Cerebral ischemia; Traumatic brain injury	OLIGODENDROCYTE PROGENITOR CELLS; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER INJURY; FOCAL CEREBRAL-ISCHEMIA; NECROSIS-FACTOR-ALPHA; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; RECEPTOR/IL-6 FUSION PROTEIN; SPINAL-CORD-INJURY; MITOCHONDRIAL DYSFUNCTION; MULTIPLE-SCLEROSIS	Previous research on stroke and traumatic brain injury (TBI) heavily emphasized pathological alterations in neuronal cells within gray matter. However, recent studies have highlighted the equal importance of white matter integrity in long-term recovery from these conditions. Demyelination is a major component of white matter injury and is characterized by loss of the myelin sheath and oligodendrocyte cell death. Demyelination contributes significantly to long-term sensorimotor and cognitive deficits because the adult brain only has limited capacity for oligodendrocyte regeneration and axonal remyelination. In the current review, we will provide an overview of the major causes of demyelination and oligodendrocyte cell death following acute brain injuries, and discuss the crosstalk between myelin, axons, microglia, and astrocytes during the process of demyelination. Recent discoveries of molecules that regulate the processes of remyelination may provide novel therapeutic targets to restore white matter integrity and improve long-term neurological recovery in stroke or TBI patients. (C) 2015 Elsevier Inc. All rights reserved.	[Shi, Hong; Hu, Xiaoming; Shi, Yejie; An, Chengrui; Chen, Jun; Gao, Yanqin] Fudan Univ, State Key Lab Med Neurobiol, Inst Brain Sci, Shanghai 200032, Peoples R China; [Shi, Hong; Hu, Xiaoming; Shi, Yejie; An, Chengrui; Chen, Jun; Gao, Yanqin] Fudan Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200032, Peoples R China; [Shi, Hong] Tongji Univ, Shanghai Pulm Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China; [Hu, Xiaoming; Shi, Yejie; Suenaga, Jun; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, Pittsburgh, PA 15213 USA; [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA; [Hu, Xiaoming; Shi, Yejie; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA		Chen, J (corresponding author), Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Sch Med, 3500 Terrace St, Pittsburgh, PA 15213 USA.	chenj2@upmc.edu; yqgao@shmu.edu.cn	Leak, Rehana K/I-2607-2019; Gao, Yanqin/I-6790-2016; Shi, Yejie/C-2355-2018	Leak, Rehana K/0000-0003-2817-7417; Gao, Yanqin/0000-0002-4915-9819; Shi, Yejie/0000-0001-7502-9201	Natural Science Foundation of ShanghaiNatural Science Foundation of Shanghai [14ZR1434600]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171149, 81371306, 81228008]; Shanghai Committee of Science and Technology Research Program [14431907002]; American Heart Association Scientist DevelopmentAmerican Heart Association [13SDG14570025]; Doctoral Training Fund from the Chinese Ministry of EducationMinistry of Education, China [20120071110042]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36736, NS43802, NS45048, NS089534]; Department of Veterans Affairs Research Career Scientist Award and RR D Merit ReviewUS Department of Veterans Affairs [1l01IX000420]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045048, R01NS043802, R01NS089534, R01NS036736, R01NS095029] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000420] Funding Source: NIH RePORTER	This work was supported by the Natural Science Foundation of Shanghai grant 14ZR1434600 (to H.S.), the Natural Science Foundation of China grants 81171149 and 81371306 (to Y.G.), and 81228008 (to J.C.), the Shanghai Committee of Science and Technology Research Program 14431907002 (to Y.G.), the American Heart Association Scientist Development grant 13SDG14570025 (to X.H.), Doctoral Training Fund from the Chinese Ministry of Education 20120071110042 (to J.C.), NIH/NINDS grants NS36736, NS43802, NS45048 and NS089534 (to J.C.), and the Department of Veterans Affairs Research Career Scientist Award and RR & D Merit Review 1l01IX000420 (to J.C.).	Al-Saktawi K, 2003, J NEUROSCI RES, V72, P12, DOI 10.1002/jnr.10561; Alberdi E, 2002, NEUROBIOL DIS, V9, P234, DOI 10.1006/nbdi.2001.0457; Amaral Ana I, 2013, Front Endocrinol (Lausanne), V4, P54, DOI 10.3389/fendo.2013.00054; An CR, 2014, PROG NEUROBIOL, V115, P6, DOI 10.1016/j.pneurobio.2013.12.002; Babayan AH, 2012, J NEUROSCI, V32, P12854, DOI 10.1523/JNEUROSCI.2024-12.2012; Back SA, 2007, J CEREBR BLOOD F MET, V27, P334, DOI 10.1038/sj.jcbfm.9600344; Bakiri Y, 2008, GLIA, V56, P233, DOI 10.1002/glia.20608; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; Baxter P, 2014, TRANSL STROKE RES, V5, P136, DOI 10.1007/s12975-013-0283-0; Benarroch EE, 2009, NEUROLOGY, V72, P1779, DOI 10.1212/WNL.0b013e3181a6b123; Bendlin BB, 2010, ALZHEIMERS DEMENT, V6, P394, DOI 10.1016/j.jalz.2009.11.003; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Blakemore WF, 1999, J NEUROIMMUNOL, V98, P69, DOI 10.1016/S0165-5728(99)00083-1; Bonora M, 2014, CELL DEATH DIFFER, V21, P1198, DOI 10.1038/cdd.2014.35; Bremer J, 2010, NAT NEUROSCI, V13, P310, DOI 10.1038/nn.2483; Butt AM, 2006, GLIA, V54, P666, DOI 10.1002/glia.20424; Caprariello AV, 2012, ANN NEUROL, V72, P395, DOI 10.1002/ana.23606; Carvalho KS, 2013, SEMIN PEDIATR NEUROL, V20, P194, DOI 10.1016/j.spen.2013.09.001; Cayre M, 2013, DEVELOPMENT, V140, P3107, DOI 10.1242/dev.092999; Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004; Chen DD, 2014, TRANSL STROKE RES, V5, P156, DOI 10.1007/s12975-013-0320-z; Chew LJ, 2005, GLIA, V52, P127, DOI 10.1002/glia.20232; Chu Min, 2012, Front Biosci (Elite Ed), V4, P1926; Corbin JG, 1996, MOL CELL NEUROSCI, V7, P354, DOI 10.1006/mcne.1996.0026; Courtes S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020430; Curatolo L, 1997, CYTOKINE, V9, P734, DOI 10.1006/cyto.1997.0228; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Daneman R, 2012, ANN NEUROL, V72, P648, DOI 10.1002/ana.23648; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Deng YY, 2010, BRAIN PATHOL, V20, P909, DOI 10.1111/j.1750-3639.2010.00387.x; Deng YY, 2008, BRAIN PATHOL, V18, P387, DOI 10.1111/j.1750-3639.2008.00138.x; Deoni SCL, 2011, J NEUROSCI, V31, P784, DOI 10.1523/JNEUROSCI.2106-10.2011; Desmond DW, 2002, CEREBROVASC DIS, V13, P53, DOI 10.1159/000049151; Domercq M, 2005, GLIA, V52, P36, DOI 10.1002/glia.20221; Domercq M, 2013, GLIA, V61, P383, DOI 10.1002/glia.22441; Douaud G, 2011, NEUROIMAGE, V55, P880, DOI 10.1016/j.neuroimage.2010.12.008; Duncan ID, 2009, P NATL ACAD SCI USA, V106, P6832, DOI 10.1073/pnas.0812500106; Edgar JM, 2010, EMBO MOL MED, V2, P42, DOI 10.1002/emmm.200900057; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; El Waly B, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00145; Emery B, 2010, SCIENCE, V330, P779, DOI 10.1126/science.1190927; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Fern RF, 2014, GLIA, V62, P1780, DOI 10.1002/glia.22722; Fischer R, 2014, GLIA, V62, P272, DOI 10.1002/glia.22605; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Funfschilling U, 2012, NATURE, V485, P517, DOI 10.1038/nature11007; Gillum RF, 2011, STROKE, V42, P3294, DOI 10.1161/STROKEAHA.111.625343; Girard C, 2005, J NEUROSCI, V25, P7924, DOI 10.1523/JNEUROSCI.4890-04.2005; Gold BT, 2012, BBA-MOL BASIS DIS, V1822, P416, DOI 10.1016/j.bbadis.2011.07.009; Gold BT, 2010, NEUROIMAGE, V52, P1487, DOI 10.1016/j.neuroimage.2010.05.036; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Ho PW, 2005, STROKE, V36, P2742, DOI 10.1161/01.STR.0000189748.52500.a7; Hovelmeyer N, 2005, J IMMUNOL, V175, P5875, DOI 10.4049/jimmunol.175.9.5875; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2014, PROG NEUROBIOL, V119, P60, DOI 10.1016/j.pneurobio.2014.06.002; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Hu YZ, 2011, HUM BRAIN MAPP, V32, P10, DOI 10.1002/hbm.20996; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; HUSAIN J, 1995, BRAIN RES, V698, P86, DOI 10.1016/0006-8993(95)00832-B; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Jepson S, 2012, J BIOL CHEM, V287, P22184, DOI 10.1074/jbc.M112.366179; Johnstone JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080975; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P151, DOI 10.1016/S0149-7634(96)00005-X; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Karimi-Abdolrezaee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037589; Kassmann CM, 2014, BIOCHIMIE, V98, P111, DOI 10.1016/j.biochi.2013.09.020; Kaur C, 2009, PROG NEUROBIOL, V87, P264, DOI 10.1016/j.pneurobio.2009.01.003; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim S, 2011, J NEUROCHEM, V116, P53, DOI 10.1111/j.1471-4159.2010.07084.x; Kleinsimlinghaus K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00277; Kolodziejczyk Karolina, 2010, F1000 Biol Rep, V2, P57, DOI 10.3410/B2-57; Kong YH, 2014, INTERD T GERONT GERI, V39, P86, DOI 10.1159/000358901; Kostic M, 2013, REV NEUROSCIENCE, V24, P71, DOI 10.1515/revneuro-2012-0062; Kouhsar SS, 2011, BRAIN RES, V1392, P93, DOI 10.1016/j.brainres.2011.03.038; Koutsoudaki PN, 2010, NEUROSCIENCE, V171, P235, DOI 10.1016/j.neuroscience.2010.08.070; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lara-Ramirez R, 2008, NEUROSCIENCE, V152, P601, DOI 10.1016/j.neuroscience.2008.01.014; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Li JR, 2008, J NEUROSCI, V28, P5321, DOI 10.1523/JNEUROSCI.3995-07.2008; Li WW, 2005, J NEUROIMMUNOL, V158, P58, DOI 10.1016/j.jneuroim.2004.08.011; Lin WS, 2005, J CELL BIOL, V169, P603, DOI 10.1083/jcb.200502086; Lisak RP, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-4; Long P, 2014, SCIENCE, V346, P298, DOI 10.1126/science.1261127; Mahad D, 2008, NEUROPATH APPL NEURO, V34, P577, DOI 10.1111/j.1365-2990.2008.00987.x; Maier O, 2013, BIOCHEM BIOPH RES CO, V440, P336, DOI 10.1016/j.bbrc.2013.09.083; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mato S, 2013, GLIA, V61, P750, DOI 10.1002/glia.22470; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Matute C, 2007, J ANAT, V210, P693, DOI 10.1111/j.1469-7580.2007.00733.x; Matute C, 2013, STROKE, V44, P1204, DOI 10.1161/STROKEAHA.112.658328; Matute C, 2011, J ANAT, V219, P53, DOI 10.1111/j.1469-7580.2010.01339.x; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; McKenzie IA, 2014, SCIENCE, V346, P318, DOI 10.1126/science.1254960; McLaughlin B, 2013, TRANSL STROKE RES, V4, P104, DOI 10.1007/s12975-012-0240-3; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; Menichella DM, 2006, J NEUROSCI, V26, P10984, DOI 10.1523/JNEUROSCI.0304-06.2006; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Mi S, 2013, CNS DRUGS, V27, P493, DOI 10.1007/s40263-013-0068-8; Mi S, 2009, ANN NEUROL, V65, P304, DOI 10.1002/ana.21581; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Miron VE, 2011, BBA-MOL BASIS DIS, V1812, P184, DOI 10.1016/j.bbadis.2010.09.010; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Morrison BM, 2013, TRENDS CELL BIOL, V23, P644, DOI 10.1016/j.tcb.2013.07.007; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Murtie JC, 2005, NEUROBIOL DIS, V19, P171, DOI 10.1016/j.nbd.2004.12.006; Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309; Nave KA, 2010, NATURE, V468, P244, DOI 10.1038/nature09614; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Orthmann-Murphy JL, 2007, J NEUROSCI, V27, P13949, DOI 10.1523/JNEUROSCI.3395-07.2007; Owens K, 2013, TRANSL STROKE RES, V4, P618, DOI 10.1007/s12975-013-0278-x; Pang Y, 2005, J NEUROSCI RES, V80, P226, DOI 10.1002/jnr.20450; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Pham LDD, 2012, GLIA, V60, P875, DOI 10.1002/glia.22320; Piaton G, 2011, BRAIN, V134, P1156, DOI 10.1093/brain/awr022; Pizzi M, 2004, MOL CELL NEUROSCI, V25, P301, DOI 10.1016/j.mcn.2003.10.022; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Plemel JR, 2014, PROG NEUROBIOL, V117, P54, DOI 10.1016/j.pneurobio.2014.02.006; Pusic AD, 2014, J NEUROIMMUNOL, V266, P12, DOI 10.1016/j.jneuroim.2013.10.014; Rash JE, 2010, NEUROSCIENCE, V168, P982, DOI 10.1016/j.neuroscience.2009.10.028; Richardson WD, 2011, NEURON, V70, P661, DOI 10.1016/j.neuron.2011.05.013; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Rodgers JM, 2015, GLIA, V63, P768, DOI 10.1002/glia.22783; Rolls A, 2008, PLOS MED, V5, P1262, DOI 10.1371/journal.pmed.0050171; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Ruiz A, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.31; Saab AS, 2013, CURR OPIN NEUROBIOL, V23, P1065, DOI 10.1016/j.conb.2013.09.008; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Scafidi J, 2014, NATURE, V506, P230, DOI 10.1038/nature12880; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; See JM, 2009, J NEUROPATH EXP NEUR, V68, P595, DOI 10.1097/NEN.0b013e3181a66ad9; Segovia KN, 2008, ANN NEUROL, V63, P520, DOI 10.1002/ana.21359; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Shereen A, 2011, J CEREBR BLOOD F MET, V31, P1155, DOI 10.1038/jcbfm.2010.212; Shibata M, 2007, STROKE, V38, P2826, DOI 10.1161/STROKEAHA.107.490151; Siebert JR, 2011, J NEUROCHEM, V119, P176, DOI 10.1111/j.1471-4159.2011.07370.x; Siebert JR, 2011, EXP NEUROL, V231, P19, DOI 10.1016/j.expneurol.2011.05.002; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; Smith CD, 2010, NEUROBIOL AGING, V31, P1122, DOI 10.1016/j.neurobiolaging.2008.08.006; Song MK, 2014, TRANSL STROKE RES, V5, P17, DOI 10.1007/s12975-013-0314-x; Stoffels JMJ, 2013, BRAIN, V136, P116, DOI 10.1093/brain/aws313; Su ZD, 2011, J NEUROTRAUM, V28, P1089, DOI 10.1089/neu.2010.1597; Syed YA, 2011, J NEUROSCI, V31, P3719, DOI 10.1523/JNEUROSCI.4930-10.2011; Takahashi JL, 2003, ANN NEUROL, V53, P588, DOI 10.1002/ana.10519; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Tong XP, 2009, J CELL BIOL, V186, P113, DOI 10.1083/jcb.200811071; Trapp BD, 2009, LANCET NEUROL, V8, P280, DOI 10.1016/S1474-4422(09)70043-2; Tress O, 2012, J NEUROSCI, V32, P7499, DOI 10.1523/JNEUROSCI.0392-12.2012; Valerio A, 2002, MOL CELL NEUROSCI, V21, P602, DOI 10.1006/mcne.2002.1208; van Horssen J, 2012, MULT SCLER J, V18, P1058, DOI 10.1177/1352458512452924; Vela JM, 2002, MOL CELL NEUROSCI, V20, P489, DOI 10.1006/mcne.2002.1127; Volpe JJ, 2011, ANN NEUROL, V70, P525, DOI 10.1002/ana.22533; Wake H, 2011, SCIENCE, V333, P1647, DOI 10.1126/science.1206998; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang LW, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0215-2; Whittaker MT, 2012, GLIA, V60, P281, DOI 10.1002/glia.21262; Windrem MS, 2008, CELL STEM CELL, V2, P553, DOI 10.1016/j.stem.2008.03.020; Windrem MS, 2002, J NEUROSCI RES, V69, P966, DOI 10.1002/jnr.10397; Woodruff RH, 2004, MOL CELL NEUROSCI, V25, P252, DOI 10.1016/j.mcn.2003.10.014; Yang Y, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-108; Yoshizaki K, 2008, EXP NEUROL, V210, P585, DOI 10.1016/j.expneurol.2007.12.005; Young KM, 2013, NEURON, V77, P873, DOI 10.1016/j.neuron.2013.01.006; Zhang RL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00201; Zhang YT, 2006, J NEUROSCI, V26, P12174, DOI 10.1523/JNEUROSCI.2289-06.2006; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	177	65	68	1	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2015	272				SI		17	25		10.1016/j.expneurol.2015.03.017			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	CV6AS	WOS:000364353700004	25819104	Green Accepted			2022-02-06	
J	Combs, HL; Berry, DTR; Pape, T; Babcock-Parziale, J; Smith, B; Schleenbaker, R; Shandera-Ochsner, A; Harp, JP; High, WM				Combs, Hannah L.; Berry, David T. R.; Pape, Theresa; Babcock-Parziale, Judith; Smith, Bridget; Schleenbaker, Randal; Shandera-Ochsner, Anne; Harp, Jordan P.; High, Walter M., Jr.			The Effects of Mild Traumatic Brain Injury, Post-Traumatic Stress Disorder, and Combined Mild Traumatic Brain Injury/Post-Traumatic Stress Disorder on Returning Veterans	JOURNAL OF NEUROTRAUMA			English	Article						assessment; mild TBI; PTSD; veterans	MISERABLE MINORITY; PROCESSING SPEED; BASE RATES; SYMPTOMS; PTSD; PERFORMANCE; DEPLOYMENT; HEALTH; MEMORY; IRAQ	United States veterans of the Iraqi (Operation Iraqi Freedom [OIF]) and Afghanistan (Operation Enduring Freedom [OEF]) conflicts have frequently returned from deployment after sustaining mild traumatic brain injury (mTBI) and enduring stressful events resulting in post-traumatic stress disorder (PTSD). A large number of returning service members have been diagnosed with both a history of mTBI and current PTSD. Substantial literature exists on the neuropsychological factors associated with mTBI and PTSD occurring separately; far less research has explored the combined effects of PTSD and mTBI. The current study employed neuropsychological and psychological measures in a sample of 251 OIF/OEF veterans to determine whether participants with a history of mTBI and current PTSD (mTBI+PTSD) have poorer cognitive and psychological outcomes than participants with mTBI only (mTBI-o), PTSD only (PTSD-o), or veteran controls (VC), when groups are comparable on intelligence quotient, education, and age. The mTBI+PTSD group performed more poorly than VC, mTBI-o, and PTSD-o groups on several neuropsychological measures. Effect size comparisons suggest small deleterious effects for mTBI-o on measures of processing speed and visual attention and small effects for PTSD-o on measures of verbal memory, with moderate effects for mTBI+PTSD on the same variables. Additionally, the mTBI+PTSD group was significantly more psychologically distressed than the PTSD-o group, and PTSD-o group was more distressed than VC and mTBI-o groups. These findings suggest that veterans with mTBI+PTSD perform significantly lower on neuropsychological and psychiatric measures than veterans with mTBI-o or PTSD-o. The results also raise the possibility of mild but persisting cognitive changes following mTBI sustained during deployment.	[Combs, Hannah L.; Berry, David T. R.; Shandera-Ochsner, Anne; Harp, Jordan P.] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; [Schleenbaker, Randal; High, Walter M., Jr.] Univ Kentucky, Dept Phys Med & Rehabil, Lexington, KY USA; [Pape, Theresa; Smith, Bridget] Edward Hines Jr Hosp, Hines, IL USA; [Pape, Theresa; Smith, Bridget] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Babcock-Parziale, Judith] Vet Affairs Hlth Care Syst, Southern Arizona Dept, Tucson, AZ USA; [Schleenbaker, Randal; High, Walter M., Jr.] Lexington Vet Affairs Med Ctr, Lexington, KY USA; [Shandera-Ochsner, Anne] Mayo Clin, Dept Psychiat & Psychol, Jacksonville, FL 32224 USA		High, WM (corresponding author), Lexington VAMC, 1101 Vet Dr, Lexington, KY 40502 USA.	walter.high@va.gov		Bender Pape, Theresa/0000-0001-7738-5963	Department of Veterans Affairs Office of Research and Development, Health Services Research and Development (HSRD) service [VA ORD HSRD SDR 08-377]	This research was supported by grant number VA ORD HSR&D SDR 08-377 from the Department of Veterans Affairs Office of Research and Development, Health Services Research and Development (HSR&D) service. The views expressed in this publication are those of the authors and do not necessarily represent the policies nor views of the U.S. Department of Veterans Affairs or the United States Government. The authors gratefully acknowledge Jordan Harp, M.S., and Shonna Jenkins, for their valuable insight and assistance with this project.. This manuscript is based on a thesis submitted by Hannah L. Combs in partial fulfillment of the requirements for a master's degree in clinical psychology at the University of Kentucky.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Barrett DH, 1996, AM J PSYCHIAT, V153, P1492; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT, 1996, BDI 2 BECK DEPRESSIO; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Ben-Porath YS, 2008, J PERS ASSESS, V90, P119, DOI 10.1080/00223890701845120; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Brady KT, 1997, J CLIN PSYCHIAT, V58, P12; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Conners CK, 2000, CONNERS CONTINUOUS P, V5; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Guiard, 2004, PSYCHOL SCI, V46, P175; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; Mason LH, 2013, J PERS ASSESS, V95, P585, DOI 10.1080/00223891.2013.819512; Miller H.A., 2001, M FAST MILLER FORENS; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Samuelson KW, 2010, CHILD NEUROPSYCHOL, V16, P119, DOI 10.1080/09297040903190782; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shandera-Ochsner AL, 2013, CLIN NEUROPSYCHOL, V27, P881, DOI 10.1080/13854046.2013.802017; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wechsler D., 2008, WECHSLER ADULT INTEL; WechslerD, 2001, WECHSLER TEST ADULT	57	65	65	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2015	32	13					956	966		10.1089/neu.2014.3585			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	CV0SU	WOS:000363964200004	25350012	Green Published			2022-02-06	
J	Eckert, A; Huang, L; Gonzalez, R; Kim, HS; Hamblin, MH; Lee, JP				Eckert, Auston; Huang, Lei; Gonzalez, Rodolfo; Kim, Hye-Sun; Hamblin, Milton H.; Lee, Jean-Pyo			Bystander Effect Fuels Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells to Quickly Attenuate Early Stage Neurological Deficits After Stroke	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Inflammation; Blood-brain barrier; Cellular therapy; Stem cell transplantation; Induced pluripotent stem cells; Stroke; Neural stem cell	BLOOD-BRAIN-BARRIER; CEREBRAL-ARTERY OCCLUSION; ISCHEMIC-STROKE; MATRIX METALLOPROTEINASES; TRAUMATIC BRAIN; RAT MODEL; PROTEIN; INJURY; MICE; MATRIX-METALLOPROTEINASE-9	Present therapies for stroke rest with tissue plasminogen activator (tPA), the sole licensed antithrombotic on the market; however, tPA's effectiveness is limited in that the drug not only must be administered less than 3-5 hours after stroke but often exacerbates blood-brain barrier (BBB) leakage and increases hemorrhagic incidence. A potentially promising therapy for stroke is transplantation of human induced pluripotent stem cell-derived neural stem cells (hiPSC-NSCs). To date, the effects of iPSCs on injuries that take place during early stage ischemic stroke have not been well studied. Consequently, we engrafted iPSC-NSCs into the ipsilesional hippocampus, a natural niche of NSCs, at 24 hours after stroke (prior to secondary BBB opening and when inflammatory signature is abundant). At 48 hours after stroke (24 hours after transplant), hiPSC-NSCs had migrated to the stroke lesion and quickly improved neurological function. Transplanted mice showed reduced expression of proinflammatory factors (tumor necrosis factor-a, interleukin 6 [IL-6], IL-1 beta, monocyte chemotactic protein 1, macrophage inflammatory protein la), microglial activation, and adhesion molecules (intercellular adhesion molecule 1, vascular cell adhesion molecule 1) and attenuated BBB damage. We are the first to report that engrafted hiPSC-NSCs rapidly improved neurological function (less than 24 hours after transplant). Rapid hipSC-NSC therapeutic activity is mainly due to a bystander effect that elicits reduced inflammation and BBB damage.	[Eckert, Auston; Huang, Lei; Hamblin, Milton H.; Lee, Jean-Pyo] Tulane Univ, Sch Med, Dept Neurol, Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70112 USA; [Gonzalez, Rodolfo; Lee, Jean-Pyo] Sanford Burnham Inst Med Res Neurosci Aging & Ste, La Jolla, CA USA; [Kim, Hye-Sun] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul, South Korea		Lee, JP (corresponding author), Tulane Univ, Sch Med, Dept Neurol, Ctr Stem Cell Res & Regenerat Med, 1430 Tulane Ave,SL99, New Orleans, LA 70112 USA.	jeanpyol@tulane.edu			Tulane Center for Stem Cell Research and Regenerative Medicine	We thank Dr. Edward Neuwelt, Oregon Health and Science University, for helpful scientific discussion. We thank Gustavo Vallim and Ryan Park, Tulane University, for technical assistance. This work was supported by startup funds from the Tulane Center for Stem Cell Research and Regenerative Medicine.	Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Castellanos M, 2003, STROKE, V34, P40, DOI 10.1161/01.STR.0000046764.57344.31; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; Chang DI, 2003, J CEREBR BLOOD F MET, V23, P1408, DOI 10.1097/01.WCB.0000091765.61714.30; Chau MJ, 2014, STEM CELLS, V32, P3075, DOI 10.1002/stem.1802; Chen SJ, 2010, STEM CELLS DEV, V19, P1757, DOI 10.1089/scd.2009.0452; Clark WM, 1997, NEUROL RES, V19, P641; Darsalia V, 2011, J CEREBR BLOOD F MET, V31, P235, DOI 10.1038/jcbfm.2010.81; DEFILIPPI P, 1992, J BIOL CHEM, V267, P18303; Emanueli C, 2003, BRIT J PHARMACOL, V140, P614, DOI 10.1038/sj.bjp.0705458; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hu Xueyou, 2010, J Vis Exp, DOI 10.3791/2445; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kang SS, 2013, NEUROBIOL DIS, V49, P68, DOI 10.1016/j.nbd.2012.08.020; Kawai H, 2010, J CEREBR BLOOD F MET, V30, P1487, DOI 10.1038/jcbfm.2010.32; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Knowland D, 2014, NEURON, V82, P603, DOI 10.1016/j.neuron.2014.03.003; Kuntz M, 2014, J CEREBR BLOOD F MET, V34, P95, DOI 10.1038/jcbfm.2013.169; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; Lee JP, 2007, NAT MED, V13, P439, DOI 10.1038/nm1548; Liu SP, 2014, STEM CELLS DEV, V23, P421, DOI 10.1089/scd.2013.0182; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lu YY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3852; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mishiro K, 2012, NEUROSCIENCE, V205, P39, DOI 10.1016/j.neuroscience.2011.12.042; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; O'Neill M J, 2001, Curr Protoc Neurosci, VChapter 9, DOI [10.1002/0471142301.ns0905s12, 10.1002/0471142301.ns0906s12]; Oki K, 2012, STEM CELLS, V30, P1120, DOI 10.1002/stem.1104; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Polentes J, 2012, CELL TRANSPLANT, V21, P2587, DOI 10.3727/096368912X653228; Quinn LP, 2007, J NEUROSCI METH, V164, P43, DOI 10.1016/j.jneumeth.2007.03.021; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Rosell A, 2008, CURR OPIN PHARMACOL, V8, P82, DOI 10.1016/j.coph.2007.12.001; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Rossi B, 2011, J LEUKOCYTE BIOL, V89, P539, DOI 10.1189/jlb.0710432; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Virley D, 2000, J CEREBR BLOOD F MET, V20, P563, DOI 10.1097/00004647-200003000-00015; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Yuan T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt224	51	65	70	2	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	JUL	2015	4	7					841	851		10.5966/sctm.2014-0184			11	Cell & Tissue Engineering	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	CN2ST	WOS:000358272900023	26025980	Green Published, gold			2022-02-06	
J	Haagsma, JA; Scholten, AC; Andriessen, TMJC; Vos, PE; Van Beeck, EF; Polinder, S				Haagsma, Juanita A.; Scholten, Annemieke C.; Andriessen, Teuntje M. J. C.; Vos, Pieter E.; Van Beeck, Ed F.; Polinder, Suzanne			Impact of Depression and Post-Traumatic Stress Disorder on Functional Outcome and Health-Related Quality of Life of Patients with Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; depression; follow-up study; post-traumatic stress disorder; quality of life; trauma	MENTAL-HEALTH; MAJOR DEPRESSION; RISK-FACTORS; HEAD-INJURY; SYMPTOMS; NETHERLANDS; PREVALENCE; MODERATE; SCALE; EPIDEMIOLOGY	The impact of disability following traumatic brain injury (TBI), assessed by functional measurement scales for TBI or by health-related quality of life (HRQoL), may vary because of a number of factors, including presence of depression or post-traumatic stress disorder (PTSD). The aim of this study was to assess prevalence and impact of depression and PTSD on functional outcome and HRQoL six and 12 months following mild TBI. We selected a sample of 1919 TBI patients who presented to the emergency department (ED) followed by either hospital admission or discharge to the home environment. The sample received postal questionnaires six and 12 months after treatment at the ED. The questionnaires included items regarding socio-demographics, the 36-item Short-Form Health Survey (SF-36), the Perceived Quality of Life Scale (PQoL), the Beck Depression Inventory, and the Impact of Event Scale. A total of 797 (42%) TBI patients completed the six-month follow-up survey. Depression and PTSD prevalence rates at both the six- and 12-month follow-up were 7% and 9%, respectively. Living alone was an independent predictor of depression and/or PTSD at six- and 12-month follow-up. Depression and PTSD were associated with a significantly decreased functional outcome (measured with Glasgow Outcome Scale Extended) and HRQoL (measured using the SF-36 and the PQoL). We conclude that depression and/or PTSD are relatively common in our sample of TBI patients and associated with a considerable decrease in functional outcome and HRQoL.	[Haagsma, Juanita A.; Scholten, Annemieke C.; Van Beeck, Ed F.; Polinder, Suzanne] Erasmus Univ, Med Ctr, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands; [Andriessen, Teuntje M. J. C.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands; [Vos, Pieter E.] Slingeland Hosp, Dept Neurol, Doetinchem, Netherlands		Haagsma, JA (corresponding author), Erasmus Univ, Erasmus Med Ctr, POB 1738, NL-3000 DR Rotterdam, Netherlands.	j.haagsma@erasmusmc.nl					*ASS ADV AUT MED, 1998, ABBR INJ SCAL AIS 19; Bijl RV, 1998, SOC PSYCH PSYCH EPID, V33, P587, DOI 10.1007/s001270050098; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bronner MB, 2009, J TRAUMA STRESS, V22, P74, DOI 10.1002/jts.20379; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; de Graaf R, 2010, INT J METH PSYCH RES, V19, P125, DOI 10.1002/mpr.317; de Vries GJ, 2009, J TRAUMA STRESS, V22, P259, DOI 10.1002/jts.20429; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Feise Ronald J, 2002, BMC Med Res Methodol, V2, P8, DOI 10.1186/1471-2288-2-8; Gil S, 2006, CNS SPECTRUMS, V11, P603, DOI 10.1017/S1092852900013651; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Haagsma JA, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-1; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Keane T., 1997, ASSESSING PSYCHOL TR; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; O'Donnell ML, 2013, J CLIN PSYCHIAT, V74, pE137, DOI 10.4088/JCP.12m08011; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Parker SG, 2006, AGE AGEING, V35, P376, DOI 10.1093/ageing/afl003; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Seattle Quality of Life Group, 2008, INF SHEET PERC QUAL; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ware J.E., 1994, SF 36 PHYS MENTAL SU; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wittmann L, 2008, COMPR PSYCHIAT, V49, P430, DOI 10.1016/j.comppsych.2008.02.004; Wohlfarth TD, 2003, PSYCHOL ASSESSMENT, V15, P101, DOI 10.1037/1040-3590.15.1.101; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690, DOI 10.1176/ajp.154.12.1690; Zatzick Douglas, 2003, Semin Clin Neuropsychiatry, V8, P149, DOI 10.1016/S1084-3612(03)00017-0; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	63	65	66	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					853	862		10.1089/neu.2013.3283			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700011	25320845				2022-02-06	
J	Cheng, JS; Craft, R; Yu, GQ; Ho, K; Wang, X; Mohan, G; Mangnitsky, S; Ponnusamy, R; Mucke, L				Cheng, Jason S.; Craft, Ryan; Yu, Gui-Qiu; Ho, Kaitlyn; Wang, Xin; Mohan, Geetha; Mangnitsky, Sergey; Ponnusamy, Ravikumar; Mucke, Lennart			Tau Reduction Diminishes Spatial Learning and Memory Deficits after Mild Repetitive Traumatic Brain Injury in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; MOUSE MODELS; NETWORK	Objective: Because reduction of the microtubule-associated protein Tau has beneficial effects in mouse models of Alzheimer's disease and epilepsy, we wanted to determine whether this strategy can also improve the outcome of mild traumatic brain injury (TBI). Methods: We adapted a mild frontal impact model of TBI for wildtype C57Bl/6J mice and characterized the behavioral deficits it causes in these animals. The Barnes maze, Y maze, contextual and cued fear conditioning, elevated plus maze, open field, balance beam, and forced swim test were used to assess different behavioral functions. Magnetic resonance imaging (MRI, 7 Tesla) and histological analysis of brain sections were used to look for neuropathological alterations. We also compared the functional effects of this TBI model and of controlled cortical impact in mice with two, one or no Tau alleles. Results: Repeated (2-hit), but not single (1-hit), mild frontal impact impaired spatial learning and memory in wildtype mice as determined by testing of mice in the Barnes maze one month after the injury. Locomotor activity, anxiety, depression and fear related behaviors did not differ between injured and sham-injured mice. MRI imaging did not reveal focal injury or mass lesions shortly after the injury. Complete ablation or partial reduction of tau prevented deficits in spatial learning and memory after repeated mild frontal impact. Complete tau ablation also showed a trend towards protection after a single controlled cortical impact. Complete or partial reduction of tau also reduced the level of axonopathy in the corpus callosum after repeated mild frontal impact. Interpretation: Tau promotes or enables the development of learning and memory deficits and of axonopathy after mild TBI, and tau reduction counteracts these adverse effects.	[Cheng, Jason S.; Craft, Ryan; Yu, Gui-Qiu; Ho, Kaitlyn; Wang, Xin; Ponnusamy, Ravikumar; Mucke, Lennart] Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; [Cheng, Jason S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Mucke, Lennart] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Mohan, Geetha; Mangnitsky, Sergey] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA		Mucke, L (corresponding author), Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA.	lmucke@gladstone.ucsf.edu		Mohan, Geetha/0000-0002-4192-5785	National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS041787, NS065780]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041787, P30NS065780] Funding Source: NIH RePORTER	LM received grants NS041787 and NS065780 from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). http://www.ninds.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Crawley JN, 2007, WHATS WRONG MY MOUSE, V2nd; Dawson HN, 2001, J CELL SCI, V114, P1179; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Devos SL, 2013, J NEUROSCI, V33, P12887, DOI 10.1523/JNEUROSCI.2107-13.2013; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Durazzo TC, 2013, J NEUROTRAUM, V30, P1013, DOI 10.1089/neu.2012.2676; Freire MAM, 2012, W INDIAN MED J, V61, P751; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gheyara AL, 2014, ANN NEUROL, V76, P443, DOI 10.1002/ana.24230; Holth JK, 2013, J NEUROSCI, V33, P1651, DOI 10.1523/JNEUROSCI.3191-12.2013; Hylin MJ, 2013, J NEUROTRAUM, V30, P716, DOI 10.1089/neu.2012.2717; Ittner LM, 2010, CELL, V142, P387, DOI 10.1016/j.cell.2010.06.036; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Krainin Benjamin M, 2011, J Spec Oper Med, V11, P38; Lei P, 2012, NAT MED, V18, P291, DOI 10.1038/nm.2613; Li Z, 2014, NEUROBIOL AGING; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mauri M, 2006, FUNCT NEUROL, V21, P223; Morris M, 2013, NEUROBIOL AGING, V34, P1523, DOI 10.1016/j.neurobiolaging.2012.12.003; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Pape TLB, 2013, PM&R, V5, P856, DOI 10.1016/j.pmrj.2013.06.007; Petraglia AL, 2014, J NEUROTRAUMA; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Roberson ED, 2011, J NEUROSCI, V31, P700, DOI 10.1523/JNEUROSCI.4152-10.2011; Sanchez PE, 2012, P NATL ACAD SCI USA, V109, pE2895, DOI 10.1073/pnas.1121081109; Sanders MJ, 2005, NEUROBIOL LEARN MEM, V84, P33, DOI 10.1016/j.nlm.2005.03.001; Turner RC, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00186; Ullmann J.F., 2013, BRAIN STRUCT FUNCT; Vossel KA, 2010, SCIENCE, V330, P198, DOI 10.1126/science.1194653; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zempel H, 2013, EMBO J, V32, P2920, DOI 10.1038/emboj.2013.207	42	65	66	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2014	9	12							e115765	10.1371/journal.pone.0115765			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AX7UC	WOS:000347119100059	25551452	Green Submitted, Green Published, gold			2022-02-06	
J	Schache, AG; Dorn, TW; Williams, GP; Brown, NAT; Pandy, MG				Schache, Anthony G.; Dorn, Tim W.; Williams, Gavin P.; Brown, Nicholas A. T.; Pandy, Marcus G.			Lower-Limb Muscular Strategies for Increasing Running Speed	JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY			English	Article						joint power; sprinting; traumatic brain injury; work	TRAUMATIC BRAIN-INJURY; TO-RUN TRANSITION; HUMAN LOCOMOTION; MUSCLE-ACTIVITY; LOWER-EXTREMITY; JOINT KINETICS; LEG MOVEMENTS; ACCELERATION PHASE; WILD TURKEYS; SWING PHASE	SYNOPSIS: This clinical commentary discusses the mechanisms used by the lower-limb musculature to achieve faster running speeds. A variety of methodological approaches have been taken to evaluate lower-limb muscle function during running, including direct recordings of muscle electromyographic signal, inverse dynamics based analyses, and computational musculoskeletal modeling. Progressing running speed from jogging to sprinting is mostly dependent on ankle and hip muscle performance. For speeds up to approximately 7.0 m/s, the dominant strategy is to push on the ground forcefully to increase stride length, and the major ankle plantar flexors (soleus and gastrocnemius) have a particularly important role in this regard. At speeds beyond approximately 7.0 m/s, the force-generating capacity of these muscles becomes less effective. Therefore, as running speed is progressed toward sprinting, the dominant strategy shifts toward the-goal of increasing stride frequency and pushing on the ground more frequently. This strategy is achieved by generating substantially more power at the hip joint, thereby increasing the biomechanical demand on proximal lower-limb muscles such as the iliopsoas, gluteus maximus, rectus femoris, and hamstrings. Basic science knowledge regarding lower-limb muscle function during running has implications for understanding why sprinting performance declines with age. It is also of great value to the clinician for designing rehabilitation programs to restore running ability in young, previously active adults who have sustained a traumatic brain injury and have severe impairments of muscle function (eg, weakness, spasticity, poor motor control) that limit their capacity to run at any speed.	[Schache, Anthony G.; Pandy, Marcus G.] Univ Melbourne, Dept Mech Engn, Melbourne, Vic 3010, Australia; [Dorn, Tim W.] Stanford Univ, Neuromuscular Biomech Lab, Stanford, CA 94305 USA; [Williams, Gavin P.] Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic, Australia; [Williams, Gavin P.] Univ Melbourne, Dept Physiotherapy, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Brown, Nicholas A. T.] Australian Inst Sport, Belconnen, ACT, Australia		Schache, AG (corresponding author), Univ Melbourne, Dept Mech Engn, Melbourne, Vic 3010, Australia.	anthonys@unimelb.edu.au	Schache, Anthony G/F-4482-2016	Schache, Anthony G/0000-0002-1041-5213; Pandy, Marcus/0000-0001-9234-1782; Brown, Nicholas/0000-0003-2747-6634; Williams, Gavin/0000-0003-2758-7473	Australian Research CouncilAustralian Research Council [LP110100262]; Victorian Neurotrauma Initiative; Australian Physiotherapy Association	Part of the research contained in this clinical commentary was funded by the Australian Research Council (LP110100262), the Victorian Neurotrauma Initiative, and the Australian Physiotherapy Association. The authors certify that they have no affiliations with or financial involvement in any organization or entity with a direct financial interest in the subject matter or materials discussed in the article.	Ae M., 1987, BIOMECHANICS X B, V6B, P895; Alexander RM, 2002, COMP BIOCHEM PHYS A, V133, P1001; ALEXANDER RM, 1992, HUMAN MACHINE, P74; Arampatzis A, 1999, J BIOMECH, V32, P1349, DOI 10.1016/S0021-9290(99)00133-5; Arampatzis A, 2011, EXERC SPORT SCI REV, V39, P18, DOI 10.1097/JES.0b013e318201efe0; Arnold EM, 2013, J EXP BIOL, V216, P2150, DOI 10.1242/jeb.075697; Belli A, 2002, INT J SPORTS MED, V23, P136, DOI 10.1055/s-2002-20136; Bezodis NE, 2014, J SPORT SCI, V32, P738, DOI 10.1080/02640414.2013.849000; Brughelli M, 2011, J STRENGTH COND RES, V25, P933, DOI 10.1519/JSC.0b013e3181c64308; Bus SA, 2003, MED SCI SPORT EXER, V35, P1167, DOI 10.1249/01.MSS.0000074441.55707.D1; CAVAGNA GA, 1971, J PHYSIOL-LONDON, V217, P709, DOI 10.1113/jphysiol.1971.sp009595; Chumanov ES, 2007, J BIOMECH, V40, P3555, DOI 10.1016/j.jbiomech.2007.05.026; Chumanov ES, 2012, BRIT J SPORT MED, V46, P90, DOI 10.1136/bjsports-2011-090176; Chumanov ES, 2011, MED SCI SPORT EXER, V43, P525, DOI 10.1249/MSS.0b013e3181f23fe8; Debaere S, 2013, J SPORT SCI, V31, P137, DOI 10.1080/02640414.2012.722225; Debaere S, 2013, J STRENGTH COND RES, V27, P116, DOI 10.1519/JSC.0b013e31825183ef; Denny MW, 2008, J EXP BIOL, V211, P3836, DOI 10.1242/jeb.024968; Dorn TW, 2012, J EXP BIOL, V215, P1944, DOI 10.1242/jeb.064527; Farley CT, 1998, EXERCISE SPORT SCI R, V26, P253; Farris DJ, 2012, P NATL ACAD SCI USA, V109, P977, DOI 10.1073/pnas.1107972109; Farris DJ, 2012, J R SOC INTERFACE, V9, P110, DOI 10.1098/rsif.2011.0182; Fukuchi R, 2008, J SPORT SCI, V26, P1447, DOI 10.1080/02640410802209018; Fukuchi RK, 2014, CLIN BIOMECH, V29, P304, DOI 10.1016/j.clinbiomech.2013.12.007; HAMILTON N, 1993, J APPL BIOMECH, V9, P15, DOI 10.1123/jab.9.1.15; Hamner SR, 2013, J BIOMECH, V46, P780, DOI 10.1016/j.jbiomech.2012.11.024; Hamner SR, 2010, J BIOMECH, V43, P2709, DOI 10.1016/j.jbiomech.2010.06.025; Hof AL, 2002, ACTA PHYSIOL SCAND, V174, P17, DOI 10.1046/j.1365-201x.2002.00917.x; Hoshikawa T, 1973, BIOMECHANICS 3, V8, P342; HRELJAC A, 1993, MED SCI SPORT EXER, V25, P1158; Hunter JP, 2005, J APPL BIOMECH, V21, P31, DOI 10.1123/jab.21.1.31; Hunter JP, 2004, J BIOMECH, V37, P1439, DOI 10.1016/j.jbiomech.2003.12.018; Ishikawa M, 2007, GAIT POSTURE, V25, P380, DOI 10.1016/j.gaitpost.2006.05.002; JACOBS R, 1992, J BIOMECH, V25, P953, DOI 10.1016/0021-9290(92)90031-U; Johnson MD, 2001, J SPORT SCI, V19, P263; Karamanidis K, 2005, J EXP BIOL, V208, P3907, DOI 10.1242/jeb.01830; KER RF, 1981, J EXP BIOL, V93, P283; KOMI PV, 1990, J BIOMECH, V23, P23, DOI 10.1016/0021-9290(90)90038-5; KOMI PV, 1992, CLIN SPORT MED, V11, P521; Korhonen MT, 2009, MED SCI SPORT EXER, V41, P844, DOI 10.1249/MSS.0b013e3181998366; Korhonen MT, 2003, MED SCI SPORT EXER, V35, P1419, DOI 10.1249/01.MSS.0000079080.15333.CA; Kugler F, 2010, J BIOMECH, V43, P343, DOI 10.1016/j.jbiomech.2009.07.041; Kuitunen S, 2002, MED SCI SPORT EXER, V34, P166, DOI 10.1097/00005768-200201000-00025; Kyrolainen H, 2005, J SPORT SCI, V23, P1101, DOI 10.1080/02640410400021575; Kyrolainen H, 2001, MED SCI SPORT EXER, V33, P1330; Kyrolainen H, 1999, J STRENGTH COND RES, V13, P400; Lai A, 2014, J EXP BIOL, V217, P3159, DOI 10.1242/jeb.100826; Lichtwark GA, 2007, J BIOMECH, V40, P157, DOI 10.1016/j.jbiomech.2005.10.035; MANN RA, 1986, AM J SPORT MED, V14, P501, DOI 10.1177/036354658601400614; Mann RA., 1982, AM AC ORTH SURG S FO, P1; Mero A, 2006, J SPORT SCI, V24, P165, DOI 10.1080/02640410500131753; MERO A, 1992, SPORTS MED, V13, P376, DOI 10.2165/00007256-199213060-00002; MERO A, 1990, EUR J APPL PHYSIOL O, V61, P73, DOI 10.1007/BF00236697; MERO A, 1988, RES Q EXERCISE SPORT, V59, P94, DOI 10.1080/02701367.1988.10605484; Mero A, 1983, SCANDINAVIAN J SPORT, V5, P20; Miller RH, 2012, J BIOMECH, V45, P1092, DOI 10.1016/j.jbiomech.2011.04.040; MOORE DH, 1975, NATURE, V253, P264, DOI 10.1038/253264a0; Morin JB, 2012, EUR J APPL PHYSIOL, V112, P3921, DOI 10.1007/s00421-012-2379-8; Morin JB, 2011, MED SCI SPORT EXER, V43, P1680, DOI 10.1249/MSS.0b013e318216ea37; Nagahara R, 2014, INT J SPORTS MED, V35, P755, DOI 10.1055/s-0033-1363252; Nagahara R, 2014, BIOL OPEN, V3, P689, DOI 10.1242/bio.20148284; Neptune RR, 2005, J EXP BIOL, V208, P799, DOI 10.1242/jeb.01435; NILSSON J, 1985, ACTA PHYSIOL SCAND, V123, P457, DOI 10.1111/j.1748-1716.1985.tb07612.x; NILSSON J, 1987, ACTA PHYSIOL SCAND, V129, P107, DOI 10.1111/j.1748-1716.1987.tb08045.x; Novacheck TF, 1998, GAIT POSTURE, V7, P77, DOI 10.1016/S0966-6362(97)00038-6; Nummela A, 2007, INT J SPORTS MED, V28, P655, DOI 10.1055/s-2007-964896; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pandy MG, 2010, ANNU REV BIOMED ENG, V12, P401, DOI 10.1146/annurev-bioeng-070909-105259; Putnam CA, 1989, BIOMECHANICS SPORT, P1; Roberts TJ, 2004, J EXP BIOL, V207, P4165, DOI 10.1242/jeb.01253; Roberts TJ, 2002, J EXP BIOL, V205, P1485; Rubenson J, 2012, J EXP BIOL, V215, P3539, DOI 10.1242/jeb.070466; Saito M, 1974, BIOMECHANICS 4, P106; Sasaki K, 2006, GAIT POSTURE, V23, P383, DOI 10.1016/j.gaitpost.2005.05.002; Sasaki K, 2006, J BIOMECH, V39, P2005, DOI 10.1016/j.jbiomech.2005.06.019; Schache AG, 2012, MED SCI SPORT EXER, V44, P647, DOI 10.1249/MSS.0b013e318236a3d2; Schache AG, 2011, MED SCI SPORT EXER, V43, P1260, DOI 10.1249/MSS.0b013e3182084929; Segers V, 2013, J EXP BIOL, V216, P3047, DOI 10.1242/jeb.087015; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Swanson SC, 2000, MED SCI SPORT EXER, V32, P1146, DOI 10.1097/00005768-200006000-00018; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; Van Caekenberghe I, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0222; Weyand PG, 2010, J APPL PHYSIOL, V108, P950, DOI 10.1152/japplphysiol.00947.2009; Weyand PG, 2000, J APPL PHYSIOL, V89, P1991, DOI 10.1152/jappl.2000.89.5.1991; Williams G, 2014, AM J PHYS MED REHAB, V93, P511, DOI 10.1097/PHM.0000000000000058; Williams G, 2013, J HEAD TRAUMA REHAB, V28, P379, DOI 10.1097/HTR.0b013e3182575f80; Williams G, 2013, BRAIN INJURY, V27, P434, DOI 10.3109/02699052.2012.750754; Williams GP, 2013, J HEAD TRAUMA REHAB, V28, P371, DOI 10.1097/HTR.0b013e31824a1d40; Williams GP, 2010, J HEAD TRAUMA REHAB, V25, P164, DOI 10.1097/HTR.0b013e3181dc120b; Williams K R, 1985, Exerc Sport Sci Rev, V13, P389; Winter D. A., 2009, BIOMECHANICS MOTOR C, DOI 10.1002/9780470549148	90	65	65	1	55	J O S P T	ALEXANDRIA	1111 NORTH FAIRFAX ST, STE 100, ALEXANDRIA, VA 22314-1436 USA	0190-6011	1938-1344		J ORTHOP SPORT PHYS	J. Orthop. Sports Phys. Ther.	OCT	2014	44	10			SI		813	824		10.2519/jospt.2014.5433			12	Orthopedics; Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rehabilitation; Sport Sciences	AQ0OP	WOS:000342482900013	25103134	Bronze			2022-02-06	
J	Tchantchou, F; Tucker, LB; Fu, AH; Bluett, RJ; McCabe, JT; Patel, S; Zhang, YM				Tchantchou, Flaubert; Tucker, Laura B.; Fu, Amanda H.; Bluett, Rebecca J.; McCabe, Joseph T.; Patel, Sachin; Zhang, Yumin			The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury	NEUROPHARMACOLOGY			English	Article						TBI; FAAH inhibition; AEA; Inflammation; Neuroprotection	ISCHEMIA-REPERFUSION INJURY; AMYLOID PRECURSOR PROTEIN; RAT MODEL; MONOACYLGLYCEROL LIPASE; MOUSE MODEL; EXPRESSION; ANANDAMIDE; ANXIETY; FAAH; NEUROPROTECTION	Traumatic brain injury (TBI) is the leading cause of death in young adults in the United States, but there is still no effective agent for treatment. N-arachidonoylethanolamine (anandamide, AEA) is a major endocannabinoid in the brain. Its increase after brain injury is believed to be protective. However, the compensatory role of AEA is transient due to its rapid hydrolysis by the fatty acid amide hydrolase (FAAH). Thus, inhibition of FAAH can boost the endogenous levels of AEA and prolong its protective effect. Using a TBI mouse model, we found that post-injury chronic treatment with PF3845, a selective and potent FAAH inhibitor, reversed TBI-induced impairments in fine motor movement, hippocampus dependent working memory and anxiety-like behavior. Treatment with PF3845 inactivated FAAH activity and enhanced the AEA levels in the brain. It reduced neurodegeneration in the dentate gyrus, and up-regulated the expression of Bcl-2 and Hsp70/72 in both cortex and hippocampus. PF3845 also suppressed the increased production of amyloid precursor protein, prevented dendritic loss and restored the levels of synaptophysin in the ipsilateral dentate gyrus. Furthermore, PF3845 suppressed the expression of inducible nitric oxide synthase and cyclooxygenase-2 and enhanced the expression of arginase-1 post-TBI, suggesting a shift of microglia/macrophages from M1 to M2 phenotype. The effects of PF3845 on TBI-induced behavioral deficits and neurodegeneration were mediated by activation of cannabinoid type 1 and 2 receptors and might be attributable to the phosphorylation of ERK1/2 and AKT. These results suggest that selective inhibition of FAAH is likely to be beneficial for TBI treatment. Published by Elsevier Ltd.	[Tchantchou, Flaubert; Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Bluett, Rebecca J.; Patel, Sachin] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN 37232 USA; [Bluett, Rebecca J.; Patel, Sachin] Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA		Zhang, YM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	yumin.zhang@usuhs.edu	McCabe, Joseph T/J-6293-2014; Patel, Sachin/E-5608-2012; B, Rebecca/W-4528-2019	McCabe, Joseph T/0000-0002-1159-7442; B, Rebecca/0000-0003-2156-3497; Tucker, Laura/0000-0002-5984-6399	Blast Lethality Injury and Research Program [R600-070-00000-00-106109]; Defense Medical Research and Development Program [0130-10-00003-00002]; Military Center of Excellence Research Award [306514-1.00-63671]; Center for Neuroscience and Regenerative Medicine Surgical and Behavioral Core, Department of DefenseUnited States Department of Defense [300600-7.01-60855]; National Institutes and Health [MH100096, MH090412]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH100096, K08MH090412] Funding Source: NIH RePORTER	This work was supported by grants from the Blast Lethality Injury and Research Program (R600-070-00000-00-106109 to Y.Z.), the Defense Medical Research and Development Program (0130-10-00003-00002 to Y.Z.), the Military Center of Excellence Research Award (306514-1.00-63671 to Y.Z.), the Center for Neuroscience and Regenerative Medicine Surgical and Behavioral Core, Department of Defense (300600-7.01-60855 to J.T.M) and National Institutes and Health (MH100096 and MH090412 to S.P.). The authors wish to thank Dr. Fengshan Yu for his technical assistance. The opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army, Department of Defense, the U.S. government, or the Uniformed Services University of the Health Sciences. The use of trade names does not constitute an official endorsement or approval of the use of such reagents or commercial hardware or software. All the authors declare no conflict of interest.	Ahn K, 2008, CHEM REV, V108, P1687, DOI 10.1021/cr0782067; Ahn K, 2009, CHEM BIOL, V16, P411, DOI 10.1016/j.chembiol.2009.02.013; Amdekar S, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/752015; Bisogno T, 1997, ADV EXP MED BIOL, V433, P201; Booker L, 2012, BRIT J PHARMACOL, V165, P2485, DOI 10.1111/j.1476-5381.2011.01445.x; Busquets-Garcia A, 2011, BIOL PSYCHIAT, V70, P479, DOI 10.1016/j.biopsych.2011.04.022; Chen RQ, 2012, CELL REP, V2, P1329, DOI 10.1016/j.celrep.2012.09.030; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Duggan KC, 2011, NAT CHEM BIOL, V7, P803, DOI 10.1038/nchembio.663; Faul M, 2010, TRAUMATIC BRAIN INJU; Galve-Roperh I, 2008, CURR PHARM DESIGN, V14, P2279, DOI 10.2174/138161208785740117; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Goonawardena AV, 2011, NEUROPHARMACOLOGY, V61, P1016, DOI 10.1016/j.neuropharm.2011.07.003; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Gunduz-Cinar O, 2013, MOL PSYCHIATR, V18, P813, DOI 10.1038/mp.2012.72; Hermanson DJ, 2013, NAT NEUROSCI, V16, P1291, DOI 10.1038/nn.3480; Hwang J, 2010, LIFE SCI, V86, P615, DOI 10.1016/j.lfs.2009.06.003; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kinsey SG, 2009, J PHARMACOL EXP THER, V330, P902, DOI 10.1124/jpet.109.155465; Lehmann ML, 2011, J NEUROSCI, V31, P6159, DOI 10.1523/JNEUROSCI.0577-11.2011; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li Q, 2013, J PHYSIOL SCI, V63, P47, DOI 10.1007/s12576-012-0228-5; Lichtman AH, 2004, J PHARMACOL EXP THER, V311, P441, DOI 10.1124/jpet.104.069401; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lourbopoulos A, 2011, BRAIN RES, V1390, P126, DOI 10.1016/j.brainres.2011.03.020; Marrs WR, 2010, NAT NEUROSCI, V13, P951, DOI 10.1038/nn.2601; Mazzola C, 2009, LEARN MEMORY, V16, P332, DOI 10.1101/lm.1145209; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Molina-Holgado F, 2007, EUR J NEUROSCI, V25, P629, DOI 10.1111/j.1460-9568.2007.05322.x; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Moreira FA, 2008, NEUROPHARMACOLOGY, V54, P141, DOI 10.1016/j.neuropharm.2007.07.005; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Naidoo V, 2012, NEUROTHERAPEUTICS, V9, P801, DOI 10.1007/s13311-011-0100-y; Oddi S, 2012, J MOL MED, V90, P371, DOI 10.1007/s00109-011-0846-z; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Panlilio LV, 2013, PHARMACOL THERAPEUT, V138, P84, DOI 10.1016/j.pharmthera.2013.01.003; Patel S, 2009, NEUROPSYCHOPHARMACOL, V34, P2699, DOI 10.1038/npp.2009.101; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Sagar DR, 2008, BRIT J PHARMACOL, V155, P1297, DOI 10.1038/bjp.2008.335; Savinainen JR, 2012, ACTA PHYSIOL, V204, P267, DOI 10.1111/j.1748-1716.2011.02280.x; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Tanaka K, 2009, NEUROSCI LETT, V462, P235, DOI 10.1016/j.neulet.2009.07.024; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Varvel SA, 2007, NEUROPSYCHOPHARMACOL, V32, P1032, DOI 10.1038/sj.npp.1301224; Vizcaychipi MP, 2011, ANESTHESIOLOGY, V114, P891, DOI 10.1097/ALN.0b013e31820ad3ce; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wise LE, 2009, NEUROBIOL LEARN MEM, V92, P597, DOI 10.1016/j.nlm.2009.06.001; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang D, 2007, NEUROPHARMACOLOGY, V52, P1095, DOI 10.1016/j.neuropharm.2006.11.009	58	65	66	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	OCT	2014	85						427	439		10.1016/j.neuropharm.2014.06.006			13	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	AN8KR	WOS:000340853600045	24937045	Green Accepted			2022-02-06	
J	Louey, AG; Cromer, JA; Schembri, AJ; Darby, DG; Maruff, P; Makdissi, M; Mccrory, P				Louey, Andrea G.; Cromer, Jason A.; Schembri, Adrian J.; Darby, David G.; Maruff, Paul; Makdissi, Michael; Mccrory, Paul			Detecting Cognitive Impairment After Concussion: Sensitivity of Change From Baseline and Normative Data Methods Using the CogSport/Axon Cognitive Test Battery	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Concussion; mTBI; Cognition; Assessment; Injury management; Neuropsychological evaluation	NEUROCOGNITIVE TEST-PERFORMANCE; TEST-RETEST INTERVALS; BIOPSYCHOSOCIAL CHARACTERISTICS; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORTS-MEDICINE; RELIABILITY; SCORES; MANAGEMENT; PLAYERS	Concussion-related cognitive impairments are typically evaluated with repeated neuropsychological assessments where post-injury performances are compared with pre-injury baseline data (baseline method). Many cases of concussions, however, are evaluated in the absence of baseline data by comparing post-injury performances with normative data (normative method). This study aimed to compare the sensitivity and specificity of these two methods using the CogSport/Axon test battery. Normative data and reliable change indices were computed from a non-injured athlete sample (n = 235). Test-retest data from non-injured (n = 260) and recently concussed (n = 29) athlete samples were then used to compare the two methods. The baseline method was found to be more sensitive than the normative method, and both methods had high specificity and overall correct classification rates. This suggests that while the normative method identifies most cases of recent concussions, the baseline method remains a more precise approach to assessing concussion-related cognitive impairments.	[Louey, Andrea G.] Univ Melbourne, Melbourne Sch Psychol Sci, Parkville, Vic 3052, Australia; [Cromer, Jason A.; Schembri, Adrian J.; Maruff, Paul] CogState Ltd, Melbourne, Vic 3000, Australia; [Cromer, Jason A.] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA; [Darby, David G.; Maruff, Paul; Makdissi, Michael; Mccrory, Paul] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Makdissi, Michael] Univ Melbourne, Melbourne Physiotherapy Dept, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia		Maruff, P (corresponding author), CogState Ltd, Melbourne, Vic 3000, Australia.	pmaruff@cogstate.com	McCrory, Paul/Q-8688-2019; Maruff, Paul/ABA-1673-2020; Maruff, Paul/AAD-2454-2021	Maruff, Paul/0000-0002-6947-9537; makdissi, michael/0000-0003-0334-7133; McCrory, Paul/0000-0003-4850-0568	CogStateCogState Limited	Paul McCrory has received consultancy fees from CogState.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brown CN, 2007, J ATHL TRAINING, V42, P515; Bruckner CT, 2006, AM J MENT RETARD, V111, P433, DOI 10.1352/0895-8017(2006)111[433:IKIORB]2.0.CO;2; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Crawford JR, 1998, J CLIN EXP NEUROPSYC, V20, P755, DOI 10.1076/jcen.20.5.755.1132; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Gardner A, 2012, APPL NEUROPSYCH-ADUL, V19, P90, DOI 10.1080/09084282.2011.643945; GLAROS AG, 1988, J CLIN PSYCHOL, V44, P1013, DOI 10.1002/1097-4679(198811)44:6<1013::AID-JCLP2270440627>3.0.CO;2-Z; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hinton-Bayre AD, 2012, CLIN J SPORT MED, V22, P105, DOI 10.1097/JSM.0b013e318248a526; Hinton-Bayre AD, 2010, ARCH CLIN NEUROPSYCH, V25, P244, DOI 10.1093/arclin/acq008; Hopkins WG, 2000, SPORTS MED, V30, P1, DOI 10.2165/00007256-200030010-00001; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2011, APPL NEUROPSYCHOL, V18, P197, DOI 10.1080/09084282.2011.595446; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Salinas CM, 2012, J CLIN SPORT PSYCHOL, V6, P363, DOI 10.1123/jcsp.6.4.363; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Solomon GS, 2013, ARCH CLIN NEUROPSYCH, V28, P9, DOI 10.1093/arclin/acs108; Strauss E., 2006, COMPENDIUM NEUROPSYC	38	65	65	0	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2014	29	5					432	441		10.1093/arclin/acu020			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	AM6AZ	WOS:000339944200004	24813184	Green Published, Bronze			2022-02-06	
J	Lerner, A; Mogensen, MA; Kim, PE; Shiroishi, MS; Hwang, DH; Law, M				Lerner, Alexander; Mogensen, Monique A.; Kim, Paul E.; Shiroishi, Mark S.; Hwang, Darryl H.; Law, Meng			Clinical Applications of Diffusion Tensor Imaging	WORLD NEUROSURGERY			English	Article						Advanced MR imaging; Clinical applications; Diffusion tensor imaging, DTI	NORMAL-APPEARING WHITE; TEMPORAL-LOBE EPILEPSY; MILD COGNITIVE IMPAIRMENT; MULTIPLE-SCLEROSIS LESIONS; TRAUMATIC BRAIN-INJURY; PARTIAL STATUS EPILEPTICUS; MAGNETIC-RESONANCE; WATER DIFFUSION; FIBER TRACTOGRAPHY; SPINAL-CORD	Advancements in diffusion-weighted imaging during the past decade have led to the use of diffusion tensor imaging to further characterize the structural integrity of neural tissue and to noninvasively trace neuronal tracts in the brain and spine. This has led to many clinical applications that have aided in surgical planning for brain and spinal cord tumors and has increased the diagnostic potential of magnetic resonance imaging in disorders such as multiple sclerosis, Alzheimer disease, and traumatic brain injury.	[Lerner, Alexander; Mogensen, Monique A.; Kim, Paul E.; Shiroishi, Mark S.; Hwang, Darryl H.; Law, Meng] Univ So Calif, Keck Sch Med, Dept Radiol, Neuroradiol Div, Los Angeles, CA 90033 USA		Lerner, A (corresponding author), Univ So Calif, Keck Sch Med, Dept Radiol, Neuroradiol Div, Los Angeles, CA 90033 USA.	lernera@med.usc.edu	Mogensen, Monique/Y-1870-2019; Hwang, Darryl/M-7221-2019		Prism Medical Imaging; Seimens Medical Solutions; Bayer HealthcareBayer AGBayer Healthcare Pharmaceuticals	Dr. Meng Law's financial disclosures include Prism Medical Imaging (consultant), Seimens Medical Solutions (Speakers' Bureau), and Bayer Healthcare (Speakers' Bureau). The remaining authors have no conflicts to report.	Andersson JLR, 2002, NEUROIMAGE, V16, P177, DOI 10.1006/nimg.2001.1039; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf BA, 2003, AM J NEURORADIOL, V24, P1857; Bammer R, 2002, MAGNET RESON MED, V48, P128, DOI 10.1002/mrm.10184; Bammer R, 2000, MAGNET RESON MED, V44, P583, DOI 10.1002/1522-2594(200010)44:4<583::AID-MRM12>3.0.CO;2-O; Bammer R, 2001, MAGN RESON MED, V46, P548, DOI 10.1002/mrm.1226; Bammer R, 2009, MAGN RESON IMAGING C, V17, P175, DOI 10.1016/j.mric.2009.01.011; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bello L, 2008, NEUROIMAGE, V39, P369, DOI 10.1016/j.neuroimage.2007.08.031; Bello L, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09240; Berman J, 2009, MAGN RESON IMAGING C, V17, P205, DOI 10.1016/j.mric.2009.02.002; Berman JI, 2007, J NEUROSURG, V107, P488, DOI 10.3171/JNS-07/09/0488; Berman JI, 2004, J NEUROSURG, V101, P66, DOI 10.3171/jns.2004.101.1.0066; Bozzali M, 2002, AM J NEURORADIOL, V23, P985; Bozzali M, 2002, J NEUROL NEUROSUR PS, V72, P742, DOI 10.1136/jnnp.72.6.742; Buchmann N, 2011, ACTA NEUROCHIR, V153, P68, DOI 10.1007/s00701-010-0817-0; Burgel U, 2009, CENT EUR NEUROSURG, V70, P27, DOI 10.1055/s-0028-1087212; Calabrese M, 2011, RADIOLOGY, V261, P891, DOI 10.1148/radiol.11110195; Carlesimo GA, 2010, NEUROLOGY, V74, P194, DOI 10.1212/WNL.0b013e3181cb3e39; Castriota-Scanderbeg A, 2003, AM J NEURORADIOL, V24, P663; Cavazos JE, 2004, NEUROSCIENCE, V126, P677, DOI 10.1016/j.neuroscience.2004.04.014; Cercignani M, 2000, NEUROLOGY, V54, P1139, DOI 10.1212/WNL.54.5.1139; Cercignani M, 2001, J NEUROL NEUROSUR PS, V70, P311, DOI 10.1136/jnnp.70.3.311; CHRISTIANSEN P, 1993, ACTA NEUROL SCAND, V87, P195; Clark CA, 2000, MAGN RESON MED, V43, P133; Coenen VA, 2001, NEUROSURGERY, V49, P86, DOI 10.1097/00006123-200107000-00013; Davie CA, 1997, J NEUROL NEUROSUR PS, V63, P736, DOI 10.1136/jnnp.63.6.736; de la Roque AD, 2005, EUR RADIOL, V15, P279, DOI 10.1007/s00330-004-2578-8; Droogan AG, 1999, MAGN RESON IMAGING, V17, P653, DOI 10.1016/S0730-725X(99)00011-9; Ducreux D, 2007, NEUROIMAG CLIN N AM, V17, P137, DOI 10.1016/j.nic.2006.11.005; El-Koussy M, 2002, EUR RADIOL, V12, P568, DOI 10.1007/s003300100999; Farber RS, 2009, J MAGN RESON IMAGING, V30, P732, DOI 10.1002/jmri.21922; Farina L, 2004, NEURORADIOLOGY, V46, P251, DOI 10.1007/s00234-003-1122-x; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; FARZANEH F, 1990, MAGNET RESON MED, V14, P123, DOI 10.1002/mrm.1910140112; Fellgiebel A, 2004, DEMENT GERIATR COGN, V18, P101, DOI 10.1159/000077817; Field AS, 2004, J MAGN RESON IMAGING, V20, P555, DOI 10.1002/jmri.20169; Filippi M, 2000, ARCH NEUROL-CHICAGO, V57, P1017, DOI 10.1001/archneur.57.7.1017; Filippi M, 1999, NEUROLOGY, V52, P845, DOI 10.1212/WNL.52.4.845; FILIPPI M, 1995, NEUROLOGY, V45, P478, DOI 10.1212/WNL.45.3.478; Filippi M, 2001, NEUROLOGY, V56, P304, DOI 10.1212/WNL.56.3.304; Fischer FU, 2012, J MAGN RESON IMAGING, V36, P84, DOI 10.1002/jmri.23621; Frank LR, 2002, MAGN RESON MED, V47, P1083, DOI 10.1002/mrm.10156; Frank LR, 2001, MAGN RESON MED, V45, P935, DOI 10.1002/mrm.1125; Ge YL, 2005, ANN NY ACAD SCI, V1064, P202, DOI 10.1196/annals.1340.039; Ge YL, 2004, J MAGN RESON IMAGING, V20, P1, DOI 10.1002/jmri.20083; GEANMARTON AD, 1991, RADIOLOGY, V180, P215, DOI 10.1148/radiology.180.1.2052698; Gold BT, 2012, J ALZHEIMERS DIS, V31, pS19, DOI 10.3233/JAD-2012-112165; Guye M, 2007, NEUROIMAGE, V35, P28, DOI 10.1016/j.neuroimage.2006.11.049; Hagmann P, 2010, J NEUROSCI METH, V194, P34, DOI 10.1016/j.jneumeth.2010.01.014; Haselgrove JC, 1996, MAGNET RESON MED, V36, P960, DOI 10.1002/mrm.1910360620; Hendler T, 2003, J NEUROSURG, V99, P1018, DOI 10.3171/jns.2003.99.6.1018; Hesseltine SM, 2006, AM J NEURORADIOL, V27, P1189; Holodny AI, 2001, J NEUROSURG, V95, P1082, DOI 10.3171/jns.2001.95.6.1082; Holodny AI, 2001, AM J NEURORADIOL, V22, P83; Horsfield MA, 1996, MAGN RESON MED, V36, P393, DOI 10.1002/mrm.1910360310; Hosomi A, 2009, NEURORADIOLOGY, V51, P549, DOI 10.1007/s00234-009-0534-7; Huang JB, 2007, ANN NY ACAD SCI, V1097, P259, DOI 10.1196/annals.1379.021; HUSTED CA, 1994, ANN NEUROL, V36, P157, DOI 10.1002/ana.410360207; Hutchinson E, 2010, EPILEPSY RES, V88, P208, DOI 10.1016/j.eplepsyres.2009.11.011; Inoue T, 2005, CLIN NEUROL NEUROSUR, V107, P174, DOI 10.1016/j.clineuro.2004.06.011; Jellison BJ, 2004, AM J NEURORADIOL, V25, P356; Jones JGA, 2013, AM J NEURORADIOL, V34, P471, DOI 10.3174/ajnr.A3199; Kamada K, 2005, J NEUROSURG, V102, P664, DOI 10.3171/jns.2005.102.4.0664; Kantarci K, 2005, NEUROLOGY, V64, P902, DOI 10.1212/01.WNL.0000153076.46126.E9; Kimiwada T, 2006, EPILEPSIA, V47, P167, DOI 10.1111/j.1528-1167.2006.00383.x; Kinoshita M, 2005, NEUROIMAGE, V25, P424, DOI 10.1016/j.neuroimage.2004.07.076; Lansberg MG, 1999, NEUROLOGY, V52, P1021, DOI 10.1212/WNL.52.5.1021; LARSSON HBW, 1992, MAGN RESON IMAGING, V10, P7, DOI 10.1016/0730-725X(92)90367-9; Le Bihan D, 2006, J MAGN RESON IMAGING, V24, P478, DOI 10.1002/jmri.20683; Leclercq D, 2011, NEUROSURG CLIN N AM, V22, P253, DOI 10.1016/j.nec.2010.11.004; Leclercq D, 2010, J NEUROSURG, V112, P503, DOI 10.3171/2009.8.JNS09558; Lehmann TN, 2000, EPILEPSIA, V41, pS190, DOI 10.1111/j.1528-1157.2000.tb01580.x; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Liu CL, 2004, MAGN RESON MED, V51, P924, DOI 10.1002/mrm.20071; Londono A, 2003, AM J NEURORADIOL, V24, P1582; Lu S, 2004, RADIOLOGY, V232, P221, DOI 10.1148/radiol.2321030653; Luat AF, 2008, EPILEPSIA, V49, P15, DOI 10.1111/j.1528-1167.2008.01506.x; Lui YW, NEUROSURGERY, V61, P1199; Maesawa S, 2010, WORLD NEUROSURG, V74, P153, DOI 10.1016/j.wneu.2010.03.022; Maier SE, 2005, ANN NY ACAD SCI, V1064, P50, DOI 10.1196/annals.1340.011; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; Medina David A, 2008, Neuropsychiatr Dis Treat, V4, P737; Mikuni N, J NEUROL NEUROSURG P; Mikuni N, 2007, J NEUROSURG, V106, P128, DOI 10.3171/jns.2007.106.1.128; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Muller MJ, 2007, NEUROBIOL AGING, V28, P398, DOI 10.1016/j.neurobiolaging.2006.01.009; Mukherjee P, 2005, NEUROIMAG CLIN N AM, V15, P655, DOI 10.1016/j.nic.2005.08.010; Mukherjee P, 2000, RADIOLOGY, V215, P211, DOI 10.1148/radiology.215.1.r00ap29211; Nimsky C, 2005, ZBL NEUROCHIR, V66, P133, DOI 10.1055/s-2005-836606; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; NITSCH C, 1983, J NEUROL SCI, V59, P305, DOI 10.1016/0022-510X(83)90016-3; Nusbaum AO, 2000, NEUROLOGY, V54, P1421, DOI 10.1212/WNL.54.7.1421; Ozsunar Y, 2004, AM J NEURORADIOL, V25, P699; Pipe JG, 1999, MAGNET RESON MED, V42, P963, DOI 10.1002/(SICI)1522-2594(199911)42:5<963::AID-MRM17>3.0.CO;2-L; Powell HWR, 2008, J NEUROL NEUROSUR PS, V79, P327, DOI 10.1136/jnnp.2007.126078; Powell HWR, 2007, NEUROIMAGE, V36, P209, DOI 10.1016/j.neuroimage.2007.02.028; Rashid W, 2004, MULT SCLER J, V10, P9, DOI 10.1191/1352458504ms985oa; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; RIGHINI A, 1994, MAGN RESON IMAGING, V12, P865, DOI 10.1016/0730-725X(94)92027-3; Romano A, 2011, NEUROSURGERY, V69, P696, DOI 10.1227/NEU.0b013e31821a8555; Rovaris M, 2009, NEUROIMAG CLIN N AM, V19, P37, DOI 10.1016/j.nic.2008.08.001; Roychowdhury S, 2000, AM J NEURORADIOL, V21, P869; Rugg-Gunn FJ, 2002, LANCET, V359, P1748, DOI 10.1016/S0140-6736(02)08615-4; Rugg-Gunn FJ, 2001, BRAIN, V124, P627, DOI 10.1093/brain/124.3.627; Schonberg T, 2006, NEUROIMAGE, V30, P1100, DOI 10.1016/j.neuroimage.2005.11.015; Sigal T, 2012, J NEUROIMAGING, V22, P33, DOI 10.1111/j.1552-6569.2010.00556.x; Singh M, 2010, MAGN RESON MED, V64, P1676, DOI 10.1002/mrm.22509; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Sinha S, 2002, AM J NEURORADIOL, V23, P520; Sjobeck M, 2010, ARCH GERONTOL GERIAT, V50, P260, DOI 10.1016/j.archger.2009.03.014; Smits M, 2007, AM J NEURORADIOL, V28, P1354, DOI 10.3174/ajnr.A0538; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; Stadlbauer A, 2006, RADIOLOGY, V240, P803, DOI 10.1148/radiol.2403050937; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Takahashi S, 2002, NEUROSCI LETT, V332, P45, DOI 10.1016/S0304-3940(02)00914-X; Takao H, 2012, HUM BRAIN MAPP, V33, P466, DOI 10.1002/hbm.21225; Takao H, 2011, NEUROIMAGE, V54, P1053, DOI 10.1016/j.neuroimage.2010.09.023; TANAKA T, 1992, PROG NEUROBIOL, V38, P317, DOI 10.1016/0301-0082(92)90023-8; Thivard L, 2005, NEUROIMAGE, V28, P682, DOI 10.1016/j.neuroimage.2005.06.045; Thurnher MM, 2009, MAGN RESON IMAGING C, V17, P225, DOI 10.1016/j.mric.2009.02.004; Tuch DS, 2004, MAGN RESON MED, V52, P1358, DOI 10.1002/mrm.20279; Valsasina P, 2005, NEUROIMAGE, V26, P822, DOI 10.1016/j.neuroimage.2005.02.033; Van Petten C, 2004, NEUROPSYCHOLOGIA, V42, P1394, DOI 10.1016/j.neuropsychologia.2004.04.006; von Oertzen J, 2002, J NEUROL NEUROSUR PS, V73, P643, DOI 10.1136/jnnp.73.6.643; Wang FN, 2005, MAGN RESON MED, V54, P1232, DOI 10.1002/mrm.20677; Wang Y, 1996, EPILEPSIA, V37, P1000, DOI 10.1111/j.1528-1157.1996.tb00539.x; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Winston GP, 2011, EPILEPSIA, V52, P1430, DOI 10.1111/j.1528-1167.2011.03088.x; Wortzel HS, 2011, J AM ACAD PSYCHIATRY, V39, P511; Wu JS, 2007, NEUROSURGERY, V61, P935, DOI 10.1227/01.neu.0000303189.80049.ab; Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165	137	65	71	2	31	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUL-AUG	2014	82	1-2					96	109		10.1016/j.wneu.2013.07.083			14	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AQ6HM	WOS:000342911400128	23916498				2022-02-06	
J	McEwen, D; Taillon-Hobson, A; Bilodeau, M; Sveistrup, H; Finestone, H				McEwen, Daniel; Taillon-Hobson, Anne; Bilodeau, Martin; Sveistrup, Heidi; Finestone, Hillel			Virtual Reality Exercise Improves Mobility After Stroke An Inpatient Randomized Controlled Trial	STROKE			English	Article						exercise movement techniques; gait; rehabilitation; virtual reality therapy	FUNCTIONAL BALANCE; ADULTS	Background and Purpose-Exercise using virtual reality (VR) has improved balance in adults with traumatic brain injury and community-dwelling older adults. Rigorous randomized studies regarding its efficacy, safety, and applicability with individuals after stroke are lacking. The purpose of this study was to determine whether an adjunct VR therapy improves balance, mobility, and gait in stroke rehabilitation inpatients. Methods-A blinded randomized controlled trial studying 59 stroke survivors on an inpatient stroke rehabilitation unit was performed. The treatment group (n=30) received standard stroke rehabilitation therapy plus a program of VR exercises that challenged balance (eg, soccer goaltending, snowboarding) performed while standing. The control group (n=29) received standard stroke rehabilitation therapy plus exposure to identical VR environments but whose games did not challenge balance (performed in sitting). VR training consisted of 10 to 12 thirty-minute daily sessions for a 3-week period. Objective outcome measures of balance and mobility were assessed before, immediately after, and 1 month after training. Results-Confidence intervals and effect sizes favored the treatment group on the Timed Up and Go and the Two-Minute Walk Test, with both groups meeting minimal clinical important differences after training. More individuals in the treatment group than in the control group showed reduced impairment in the lower extremity as measured by the Chedoke McMaster Leg domain (P=0.04) immediately after training. Conclusions-This VR exercise intervention for inpatient stroke rehabilitation improved mobility-related outcomes. Future studies could include nonambulatory participants as well as the implementation strategies for the clinical use of VR.	[McEwen, Daniel; Taillon-Hobson, Anne; Bilodeau, Martin; Finestone, Hillel] Bruyere Res Inst, Ottawa, ON K1N 5C8, Canada; [McEwen, Daniel; Bilodeau, Martin; Sveistrup, Heidi] Univ Ottawa, Sch Rehabil Sci, Ottawa, ON, Canada; [Bilodeau, Martin; Sveistrup, Heidi; Finestone, Hillel] Univ Ottawa, Sch Human Kinet, Ottawa, ON, Canada; [Finestone, Hillel] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Finestone, Hillel] Elisabeth Bruyere Hosp, Dept Phys Med & Rehabil, Ottawa, ON, Canada		Finestone, H (corresponding author), Bruyere Res Inst, 43 Bruyere St, Ottawa, ON K1N 5C8, Canada.	hfinestone@bruyere.org			Dr Tony Hakim Innovative Stroke Research Award; Heart and Stroke Foundation Centre for Stroke RecoveryHeart & Stroke Foundation of Canada; Queen Elizabeth II Graduate Scholarship in Science and Technology; University of Ottawa Excellence Scholarship	This study was supported by the Dr Tony Hakim Innovative Stroke Research Award, Heart and Stroke Foundation Centre for Stroke Recovery, and a personal donation from Tony and Elizabeth Graham. D. McEwen holds a Queen Elizabeth II Graduate Scholarship in Science and Technology and a University of Ottawa Excellence Scholarship.	Bisson E, 2007, CYBERPSYCHOL BEHAV, V10, P16, DOI 10.1089/cpb.2006.9997; Brien M, 2011, PEDIATR PHYS THER, V23, P258, DOI 10.1097/PEP.0b013e318227ca0f; Glegg SMN, 2014, DISABIL REHABIL-ASSI, V9, P89, DOI 10.3109/17483107.2013.799236; Hackett ML, 2005, STROKE, V36, P2296, DOI 10.1161/01.STR.0000183622.75135.a4; Hiengkaew V, 2012, ARCH PHYS MED REHAB, V93, P1201, DOI 10.1016/j.apmr.2012.01.014; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4, 10.1002/14651858.CD008349.pub2]; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944	7	65	69	3	55	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JUN	2014	45	6					1853	+		10.1161/STROKEAHA.114.005362			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	AI7QR	WOS:000337090700053	24763929	Bronze			2022-02-06	
J	Eakin, K; Baratz-Goldstein, R; Pick, CG; Zindel, O; Balaban, CD; Hoffer, ME; Lockwood, M; Miller, J; Hoffer, BJ				Eakin, Katharine; Baratz-Goldstein, Renana; Pick, Chiam G.; Zindel, Ofra; Balaban, Carey D.; Hoffer, Michael E.; Lockwood, Megan; Miller, Jonathan; Hoffer, Barry J.			Efficacy of N-Acetyl Cysteine in Traumatic Brain Injury	PLOS ONE			English	Article							INFLAMMATORY RESPONSE; COGNITIVE DEFICITS; ACETYLCYSTEINE; MODEL; STRESS; ACID	In this study, using two different injury models in two different species, we found that early post-injury treatment with N-Acetyl Cysteine (NAC) reversed the behavioral deficits associated with the TBI. These data suggest generalization of a protocol similar to our recent clinical trial with NAC in blast-induced mTBI in a battlefield setting [1], to mild concussion from blunt trauma. This study used both weight drop in mice and fluid percussion injury in rats. These were chosen to simulate either mild or moderate traumatic brain injury (TBI). For mice, we used novel object recognition and the Y maze. For rats, we used the Morris water maze. NAC was administered beginning 30-60 minutes after injury. Behavioral deficits due to injury in both species were significantly reversed by NAC treatment. We thus conclude NAC produces significant behavioral recovery after injury. Future preclinical studies are needed to define the mechanism of action, perhaps leading to more effective therapies in man.	[Eakin, Katharine; Lockwood, Megan; Miller, Jonathan; Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA; [Baratz-Goldstein, Renana; Pick, Chiam G.; Zindel, Ofra] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Balaban, Carey D.] Univ Pittsburgh, Dept Otolaryngol Neurobiol Commun Sci & Disorders, Pittsburgh, PA 15260 USA; [Hoffer, Michael E.] Naval Med Ctr San Diego, Dept Otolaryngol, Spatial Orientat Ctr, San Diego, CA USA; [Hoffer, Barry J.] Taipei Med Univ, Grad Program Neuroregenerat, Taipei, Taiwan		Hoffer, BJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA.	barry.hoffer@case.edu	Balaban, Carey/I-3467-2017; Balaban, Carey/O-6586-2019	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	Lincoln Master Clinician in Neurosurgery Award [USPHS] [NS070825]; National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC98-2314-B-038-011-MY3, NSC101-2321-B-038-005]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS070825] Funding Source: NIH RePORTER	This work was supported in part by the Lincoln Master Clinician in Neurosurgery Award to JM, [USPHS grant #NS070825]; and the National Science Council of Taiwan [#NSC98-2314-B-038-011-MY3], [NSC101-2321-B-038-005]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bergold P, 2012, J NEUROTRAUM, V29, pA109; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cuzzocrea S, 2000, BRIT J PHARMACOL, V130, P1219, DOI 10.1038/sj.bjp.0703421; De Vries H, 1996, PHARMACOL REV, V49, P143; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duarte JMD, 2012, BIOL PSYCHIAT, V71, P1006, DOI 10.1016/j.biopsych.2011.07.035; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Faul M, 2010, TRAUMATIC BRAIN INJU; Franzblau M, 2013, MED HYPOTHESES, V81, P842, DOI 10.1016/j.mehy.2013.09.012; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hart AM, 2004, NEUROSCIENCE, V125, P91, DOI 10.1016/j.neuroscience.2003.12.040; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Lante F, 2008, HIPPOCAMPUS, V18, P602, DOI 10.1002/hipo.20421; Lappas M, 2003, J CLIN ENDOCR METAB, V88, P1723, DOI 10.1210/jc.2002-021677; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Moussawi K, 2009, NAT NEUROSCI, V12, P182, DOI 10.1038/nn.2250; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Prabhu A, 2009, ANN VASC SURG, V23, P645, DOI 10.1016/j.avsg.2008.12.005; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Santangelo F, 2003, CURR MED CHEM, V10, P2599, DOI 10.2174/0929867033456567; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; Stipanuk MH, 2006, J NUTR, V136, p1652S, DOI 10.1093/jn/136.6.1652S; Tang Y, 1997, P NATL ACAD SCI USA, V94, P12667, DOI 10.1073/pnas.94.23.12667; Tsai SY, 2009, P NATL ACAD SCI USA, V106, P22468, DOI 10.1073/pnas.0909089106; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; West CA, 2007, ACTA NEUROCHIR SUPPL, V100, P29; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	40	65	66	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2014	9	4							e90617	10.1371/journal.pone.0090617			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AI4VW	WOS:000336863900004	24740427	gold, Green Published, Green Submitted, Green Accepted			2022-02-06	
J	Yoon, EJ; Kim, YK; Kim, HR; Kim, SE; Lee, Y; Shin, HI				Yoon, Eun Jin; Kim, Yu Kyeong; Kim, Hye-Ri; Kim, Sang Eun; Lee, Youngjo; Shin, Hyung Ik			Transcranial Direct Current Stimulation to Lessen Neuropathic Pain After Spinal Cord Injury: A Mechanistic PET Study	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						neuropathic pain; transcranial direct current stimulation; spinal cord injury; FDG-PET	MOTOR CORTEX STIMULATION; ELECTRICAL-STIMULATION; PREFRONTAL CORTEX; VISUAL ILLUSION; BRAIN ACTIVITY; RESTING-STATE; PERCEPTION; MODULATION; PREVALENCE; HUMANS	Background. It is suggested that transcranial direct current stimulation (tDCS) can produce lasting changes in corticospinal excitability and can potentially be used for the treatment of neuropathic pain. However, the detailed mechanisms underlying the effects of tDCS are unknown. Objective. We investigated the underlying neural mechanisms of tDCS for chronic pain relief using [F-18]-fluorodeoxyglucose positron emission tomography ([F-18] FDG-PET). Methods. Sixteen patients with neuropathic pain (mean age 44.1 +/- 8.6 years, 4 females) due to traumatic spinal cord injury received sham or active anodal stimulation of the motor cortex using tDCS for 10 days (20 minutes, 2 mA, twice a day). The effect of tDCS on regional cerebral glucose metabolism was evaluated by [F-18] FDG-PET before and after tDCS sessions. Results. There was a significant decrease in the numeric rating scale scores for pain, from 7.6 +/- 0.5 at baseline to 5.9 +/- 1.8 after active tDCS (P =.016). We found increased metabolism in the medulla and decreased metabolism in the left dorsolateral prefrontal cortex after active tDCS treatment compared with the changes induced by sham tDCS. Additionally, an increase in metabolism after active tDCS was observed in the subgenual anterior cingulate cortex and insula. Conclusion. The results of this study suggest that anodal stimulation of the motor cortex using tDCS can modulate	[Yoon, Eun Jin; Kim, Yu Kyeong] Seoul Natl Univ, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul, South Korea; [Yoon, Eun Jin; Kim, Yu Kyeong; Kim, Sang Eun] Seoul Natl Univ, Coll Med, Seoul, South Korea; [Yoon, Eun Jin; Kim, Yu Kyeong; Kim, Sang Eun] Seoul Natl Univ, Med Res Ctr, Seoul, South Korea; [Kim, Hye-Ri; Kim, Sang Eun; Shin, Hyung Ik] Seoul Natl Univ, Bundang Hosp, Gyeonggi Do, South Korea; [Lee, Youngjo] Seoul Natl Univ, Seoul, South Korea		Shin, HI (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Rehabil Med, 82,Gumi Ro 173 Beon Gil, Songnam, Gyeonggi Do, South Korea.	hyungik1@snu.ac.kr		Shin, Hyungik/0000-0001-8805-3104	National Research Foundation of Korea (NRF)National Research Foundation of Korea; Korea government (MSIP) [2011-0030815]; SNUBH Research Fund [11-2008-010]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2011-0030815), and Grant 11-2008-010 from SNUBH Research Fund.	Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Baliki MN, 2008, J NEUROSCI, V28, P1398, DOI 10.1523/JNEUROSCI.4123-07.2008; Baliki MN, 2010, NEURON, V66, P149, DOI 10.1016/j.neuron.2010.03.002; Boggio PS, 2008, EUR J NEUROL, V15, P1124, DOI 10.1111/j.1468-1331.2008.02270.x; Burgmer M, 2009, NEUROIMAGE, V44, P502, DOI 10.1016/j.neuroimage.2008.09.008; Cauda F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004542; Coghill RC, 1999, J NEUROPHYSIOL, V82, P1934, DOI 10.1152/jn.1999.82.4.1934; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Soler MD, 2010, BRAIN, V133, P2565, DOI 10.1093/brain/awq184; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Finnerup NB, 2003, BRAIN, V126, P57, DOI 10.1093/brain/awg007; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2007, LANCET NEUROL, V6, P188, DOI 10.1016/S1474-4422(07)70032-7; Fregni F, 2006, PAIN, V122, P197, DOI 10.1016/j.pain.2006.02.023; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Garcia-Larrea L, 2007, NEUROIMAGE, V37, pS71, DOI 10.1016/j.neuroimage.2007.05.062; GEORGE MS, 1995, AM J PSYCHIAT, V152, P341; Ho PT, 2011, J PSYCHOSOM RES, V70, P541, DOI 10.1016/j.jpsychores.2010.10.006; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Kishima H, 2007, J NEUROSURG, V107, P43, DOI 10.3171/JNS-07/07/0043; Kumru H, 2013, EUR J PAIN, V17, P55, DOI 10.1002/j.1532-2149.2012.00167.x; Lefaucheur JP, 2004, J NEUROL NEUROSUR PS, V75, P612, DOI 10.1136/jnnp.2003.022236; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; Mori F, 2010, J PAIN, V11, P436, DOI 10.1016/j.jpain.2009.08.011; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Peyron R, 1999, BRAIN, V122, P1765, DOI 10.1093/brain/122.9.1765; PEYRON R, 1995, PAIN, V62, P275, DOI 10.1016/0304-3959(94)00211-V; Peyron R, 2007, NEUROIMAGE, V34, P310, DOI 10.1016/j.neuroimage.2006.08.037; Phillips ML, 2003, BIOL PSYCHIAT, V54, P515, DOI 10.1016/S0006-3223(03)00171-9; Poreisz C, 2007, BRAIN RES BULL, V72, P208, DOI 10.1016/j.brainresbull.2007.01.004; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Quarantelli M, 2004, J NUCL MED, V45, P192; Rocher AB, 2003, NEUROIMAGE, V20, P1894, DOI 10.1016/j.neuroimage.2003.07.002; Siddall PJ, 2003, PAIN, V103, P249, DOI 10.1016/S0304-3959(02)00452-9; Taylor JJ, 2013, NEUROPSYCHOPHARMACOL, V38, P1189, DOI 10.1038/npp.2013.13; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Vogt BA, 2003, EUR J NEUROSCI, V18, P3134, DOI 10.1111/j.1460-9568.2003.03034.x; Widerstrom-Noga E, 2008, SPINAL CORD, V46, P818, DOI 10.1038/sc.2008.64; Wrigley PJ, 2013, PAIN, V154, P2178, DOI 10.1016/j.pain.2013.06.045	44	65	69	2	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAR	2014	28	3					250	259		10.1177/1545968313507632			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	AA3YF	WOS:000331030400006	24213958				2022-02-06	
J	Purushothuman, S; Johnstone, DM; Nandasena, C; Mitrofanis, J; Stone, J				Purushothuman, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Mitrofanis, John; Stone, Jonathan			Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex - evidence from two transgenic mouse models	ALZHEIMERS RESEARCH & THERAPY			English	Article							LOW-LEVEL LASER; MIDBRAIN DOPAMINERGIC CELLS; TERM NEUROLOGICAL DEFICITS; MESENCHYMAL STEM-CELLS; OXIDATIVE STRESS; BONE-MARROW; RAT-HEART; THERAPY; MICE; PARKINSONISM	Introduction: Previous work has demonstrated the efficacy of irradiating tissue with red to infrared light in mitigating cerebral pathology and degeneration in animal models of stroke, traumatic brain injury, parkinsonism and Alzheimer's disease (AD). Using mouse models, we explored the neuroprotective effect of near infrared light (NIr) treatment, delivered at an age when substantial pathology is already present in the cerebral cortex. Methods: We studied two mouse models with AD-related pathologies: the K369I tau transgenic model (K3), engineered to develop neurofibrillary tangles, and the APPswe/PSEN1dE9 transgenic model (APP/PS1), engineered to develop amyloid plaques. Mice were treated with NIr 20 times over a four-week period and histochemistry was used to quantify AD-related pathological hallmarks and other markers of cell damage in the neocortex and hippocampus. Results: In the K3 mice, NIr treatment was associated with a reduction in hyperphosphorylated tau, neurofibrillary tangles and oxidative stress markers (4-hydroxynonenal and 8-hydroxy-2'-deoxyguanosine) to near wildtype levels in the neocortex and hippocampus, and with a restoration of expression of the mitochondrial marker cytochrome c oxidase in surviving neurons. In the APP/PS1 mice, NIr treatment was associated with a reduction in the size and number of amyloid-beta plaques in the neocortex and hippocampus. Conclusions: Our results, in two transgenic mouse models, suggest that NIr may have potential as an effective, minimally-invasive intervention for mitigating, and even reversing, progressive cerebral degenerations.	[Purushothuman, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Mitrofanis, John; Stone, Jonathan] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Purushothuman, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Stone, Jonathan] Univ Sydney, Discipline Physiol, Sydney, NSW 2006, Australia; [Mitrofanis, John] Univ Sydney, Discipline Anat & Histol, Sydney, NSW 2006, Australia		Johnstone, DM (corresponding author), Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia.	Daniel.Johnstone@sydney.edu.au	Johnstone, Daniel/E-9929-2013	Johnstone, Daniel/0000-0003-2876-3299; Purushothuman, Sivaraman/0000-0002-0880-5060	Tenix Corporation; Sir Zelman Cowen Universities Fund; Bluesand Foundation; National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia	The authors thank Tenix Corporation, Sir Zelman Cowen Universities Fund and Bluesand Foundation for funding. They are grateful to Prof. Lars Ittner for providing the breeding litter for K369I mice, and to Dr Louise Cole and the Bosch Advanced Microscopy facility for the help with MetaMorph. Sharon Spana was splendid for her technical help. DMJ is supported by a National Health and Medical Research Council of Australia (NHMRC) Early Career Fellowship.	Aliev G, 2002, BRAIN PATHOL, V12, P21; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Blanchard V, 2003, EXP NEUROL, V184, P247, DOI 10.1016/S0014-4886(03)00252-8; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Bruck W, 1997, ANN NEUROL, V42, P783, DOI 10.1002/ana.410420515; Calabrese V, 2007, NEUROCHEM RES, V32, P757, DOI 10.1007/s11064-006-9203-y; Cao DF, 2007, J BIOL CHEM, V282, P36275, DOI 10.1074/jbc.M703561200; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017; Grillo SL, 2013, J PHOTOCH PHOTOBIO B, V123, P13, DOI 10.1016/j.jphotobiol.2013.02.015; Hamel E, 2008, EXP PHYSIOL, V93, P116, DOI 10.1113/expphysiol.2007.038729; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709; Ittner LM, 2008, P NATL ACAD SCI USA, V105, P15997, DOI 10.1073/pnas.0808084105; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Karu T, 2010, PHOTOMED LASER SURG, V28, P159, DOI 10.1089/pho.2010.2789; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Moro C, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-40; Natoli R, 2010, MOL VIS, V16, P1801; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; Purushothuman S, 2013, BRAIN RES, V1535, P61, DOI 10.1016/j.brainres.2013.08.047; Purushothuman S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059740; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Stone J, 2008, MED HYPOTHESES, V71, P347, DOI 10.1016/j.mehy.2008.04.007; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Tuby H, 2006, LASER SURG MED, V38, P682, DOI 10.1002/lsm.20377; Tuby H, 2013, PHOTOMED LASER SURG, V31, P269, DOI 10.1089/pho.2012.3395; Tuby H, 2011, LASER SURG MED, V43, P401, DOI 10.1002/lsm.21063; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Wen Y, 2004, J BIOL CHEM, V279, P22684, DOI 10.1074/jbc.M311768200; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; Wilcock DM, 2006, NAT PROTOC, V1, P1591, DOI 10.1038/nprot.2006.277; Wilden L, 1998, J CLIN LASER MED SUR, V16, P159, DOI 10.1089/clm.1998.16.159; Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yan Q, 2003, J NEUROSCI, V23, P7504; Yao J, 2009, P NATL ACAD SCI USA, V106, P14670, DOI 10.1073/pnas.0903563106; Zhang X, 2010, EXP NEUROL, V223, P299, DOI 10.1016/j.expneurol.2009.07.033; Zhu XW, 2006, J ALZHEIMERS DIS, V9, P147	50	65	67	2	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1758-9193			ALZHEIMERS RES THER	Alzheimers Res. Ther.		2014	6	1							2	10.1186/alzrt232			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AM4DB	WOS:000339801600002	24387311	gold, Green Published			2022-02-06	
J	Haber, M; Baki, SGA; Grin'kina, NM; Irizarry, R; Ershova, A; Orsi, S; Grill, RJ; Dash, P; Bergold, PJ				Haber, Margalit; Baki, Samah G. Abdel; Grin'kina, Natalia M.; Irizarry, Rachel; Ershova, Alina; Orsi, Sara; Grill, Raymond J.; Dash, Pramod; Bergold, Peter J.			Minocycline plus N-acetylcysteine synergize to modulate inflammation and prevent cognitive and memory deficits in a rat model of mild traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Animal model; Cognition; Memory; Neuroinflammation; Therapeutics	MICROGLIAL ACTIVATION; SURFACE EXPRESSION; SYSTEM X(C)(-); NEUROINFLAMMATION; HIPPOCAMPUS; MICE; NEUROPROTECTION; MACROSIALIN; MACROPHAGES; IMPAIRMENT	Traumatic brain injury (TBI) differs in severity from severe to mild. This study examined whether a combination of the drugs minocycline (MIND) plus N-acetylcysteine (NAC) produces behavioral and histological improvements in a mild version of the controlled cortical impact model of TBI (mCCI). Following mCCI, rats acquired an active place avoidance task by learning the location of a stationary shock zone on a rotating arena. Rats acquired this task with a training protocol using a 10-minute intertrial interval. Mildly injured rats had an apparent deficit in long-term memory since they did not acquire the task when the intertrial interval was increased to 24 h. Mildly injured rats also had an apparent deficit in set shifting since, after successfully learning one shock zone location they did not learn the location of a second shock zone. MIND plus NAC synergistically limited these behavioral deficits in long-term memory and set shifting. mCCI also produced neuroinflammation at the impact site and at distal white matter tracts including the corpus callosum. At the impact site, MIND plus NAC attenuated CD68-expressing phagocytic microglia without altering neutrophil infiltration or astrocyte activation. The drugs had no effect on astrocyte activation in the corpus callosum or hippocampus. In the corpus callosum, MIND plus NAC decreased CD68 expression yet increased overall microglial activation as measured by Iba-1. MIND plus NAC acted synergistically to increase Iba-1 expression since MIND alone suppressed expression and NAC alone had no effect. Despite the known anti-inflammatory actions of the individual drugs, MINO plus NAC appeared to modulate, rather than suppress neuroinflammation. This modulation of neuroinflammation may underlie the synergistic improvement in memory and set-shifting by the drug combination after mCCI. (C) 2013 Elsevier Inc. All rights reserved.	[Haber, Margalit; Baki, Samah G. Abdel; Grin'kina, Natalia M.; Irizarry, Rachel; Ershova, Alina; Bergold, Peter J.] Robert F Furchgott Ctr Neural & Behav Sci, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; [Haber, Margalit; Baki, Samah G. Abdel; Grin'kina, Natalia M.; Irizarry, Rachel; Ershova, Alina; Bergold, Peter J.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; [Orsi, Sara; Dash, Pramod] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrated Biol & Pharmacol, Houston, TX 77030 USA		Bergold, PJ (corresponding author), Suny Downstate Med Ctr, 450 Clarkson Ave,Box 29, Brooklyn, NY 11203 USA.	Peter.Bergold@downstate.edu		Bergold, Peter/0000-0002-6335-1380; Dash, Pramod/0000-0001-6746-1002	Department of DefenseUnited States Department of Defense [W81XWH-10-2-0171]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076693] Funding Source: NIH RePORTER	This work was supported by an award W81XWH-10-2-0171 from the Department of Defense to P.J.B.	Abdel Bald S.G., 2010, PLOS ONE, V5; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bridges R, 2012, PHARMACOL REV, V64, P780, DOI 10.1124/pr.110.003889; Brune B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai ZY, 2010, NEUROSCI BULL, V26, P28, DOI 10.1007/s12264-010-0818-2; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; De Bundel D, 2011, J NEUROSCI, V31, P5792, DOI 10.1523/JNEUROSCI.5465-10.2011; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faul M, 2002, TRAUMATIC BRAIN INJU; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Inman CF, 2005, J IMMUNOL METHODS, V302, P156, DOI 10.1016/j.jim.2005.05.005; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kupchik YM, 2012, BIOL PSYCHIAT, V71, P978, DOI 10.1016/j.biopsych.2011.10.024; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104, DOI 10.1002/jlb.67.1.104; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lynch MA, 2009, MOL NEUROBIOL, V40, P139, DOI 10.1007/s12035-009-8077-9; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Suma T, 2008, NEUROL RES, V30, P420, DOI 10.1179/016164107X251745; Vassar M. J., 2013, J NEUROTRAUMA; Yong VW, 2009, NEURON, V64, P55, DOI 10.1016/j.neuron.2009.09.035; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang LJ, 2012, NEUROCHEM INT, V61, P1220, DOI 10.1016/j.neuint.2012.09.002	35	65	66	0	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2013	249						169	177		10.1016/j.expneurol.2013.09.002			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	240ZE	WOS:000326135400018	24036416				2022-02-06	
J	Yeoh, S; Bell, ED; Monson, KL				Yeoh, Stewart; Bell, E. David; Monson, Kenneth L.			Distribution of Blood-Brain Barrier Disruption in Primary Blast Injury	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Traumatic brain injury; Vascular dysfunction; Immunohistology; Brain lesion	RATS; PRESSURE; EXPOSURE; MODEL	Traumatic brain injury (TBI) resulting from explosive-related blast overpressure is a topic at the forefront of neurotrauma research. Compromise of the blood-brain barrier (BBB) and other cerebral blood vessel dysfunction is commonly reported in both experimental and clinical studies on blast injury. This study used a rifle primer-driven shock tube to investigate cerebrovascular injury in rats exposed to low-impulse, pure primary blast at three levels of overpressure (145, 232, and 323 kPa) and with three survival times (acute, 24, and 48 h). BBB disruption was quantified immunohistochemically by measuring immunoglobulin G (IgG) extravasation with image analysis techniques. Pure primary blast generated small lesions scattered throughout the brain. The number and size of lesions increased with peak overpressure level, but no significant difference was seen between survival times. Despite laterally directed blast exposure, equal numbers of lesions were found in each hemisphere of the brain. These observations suggest that cerebrovascular injury due to primary blast is distinct from that associated with conventional TBI.	[Yeoh, Stewart; Bell, E. David; Monson, Kenneth L.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA; [Monson, Kenneth L.] Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA		Monson, KL (corresponding author), Univ Utah, Dept Bioengn, 50 S Cent Campus Dr,MEB 2132, Salt Lake City, UT 84112 USA.	ken.monson@utah.edu	Monson, Ken/L-4702-2019; Bell, E David/K-7196-2013	Monson, Ken/0000-0002-8461-6034	Department of DefenseUnited States Department of Defense [W81XWH-08-1-0295]	Funding for this research was provided by the Department of Defense (W81XWH-08-1-0295). The authors would like to acknowledge Jordan Walker and Louise Butler for assistance with tissue processing, imaging, and data analysis.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Courtney MW, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3518970; Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010; Cullis I G, 2001, J R Army Med Corps, V147, P16; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Graham D.I., 1996, NEUROTRAUMA, P43; KLATZO I, 1987, Z KARDIOL, V76, P67; Leonardi AD, 2012, J BIOMECH, V45, P2595, DOI 10.1016/j.jbiomech.2012.08.024; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mouritz A.P., 2001, COMPOSITES B, V32, P431, DOI [DOI 10.1016/S1359-8368(01)00015-4, 10.1016/S1359-8368(01)00015-4]; Ohtake M, 2004, NEUROPATHOLOGY, V24, P219, DOI 10.1111/j.1440-1789.2004.00560.x; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reneer DV, 2012, BLAST INDUCED BRAIN; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; WHITE CS, 1968, ANN NY ACAD SCI, V152, P89, DOI 10.1111/j.1749-6632.1968.tb11969.x	32	65	67	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2013	41	10					2206	2214		10.1007/s10439-013-0805-7			9	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	213QM	WOS:000324073200017	23568152				2022-02-06	
J	Day, NL; Floyd, CL; D'Alessandro, TL; Hubbard, WJ; Chaudry, IH				Day, Nicole L.; Floyd, Candace L.; D'Alessandro, Tracy L.; Hubbard, William J.; Chaudry, Irshad H.			17 beta-Estradiol Confers Protection after Traumatic Brain Injury in the Rat and Involves Activation of G Protein-Coupled Estrogen Receptor 1	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; estrogen; lateral fluid percussion; neuronal degeneration; neuroprotection	SPINAL-CORD-INJURY; SEX STEROID-HORMONES; CORTICAL PERICONTUSIONAL ZONE; FLUID-PERCUSSION MODEL; PROGRAMMED CELL-DEATH; FEMALE RATS; REACTIVE ASTROGLIA; UP-REGULATION; HEMORRHAGE; NEUROPROTECTION	Traumatic brain injury (TBI) is a significant public health problem in the United States. Despite preclinical success of various drugs, to date all clinical trials investigating potential therapeutics have failed. Recently, sex steroid hormones have sparked interest as possible neuroprotective agents after traumatic injury. One of these is 17 beta-estradiol (E2), the most abundant and potent endogenous vertebrate estrogen. The goal of our study was to investigate the acute potential protective effects of E2 or the specific G protein-coupled estrogen receptor 1 (GPER) agonist G-1 when administered in an intravenous bolus dose 1 hour post-injury in the lateral fluid percussion (LFP) rodent model of TBI. The results of this study show that, when assessed at 24 hours post-injury, E2 or G-1 confers protection in adult male rats subjected to LFP brain injury. Specifically, we found that an acute bolus dose of E2 or G-1 administered intravenously 1 hour post-TBI significantly increases neuronal survival in the ipsilateral CA 2/3 region of the hippocampus and decreases neuronal degeneration and apoptotic cell death in both the ipsilateral cortex and CA 2/3 region of the hippocampus. We also report a significant reduction in astrogliosis in the ipsilateral cortex, hilus, and CA 2/3 region of the hippocampus. Finally, these effects were observed to be chiefly dose-dependent for E2, with the 5 mg/kg dose generating a more robust level of protection. Our findings further elucidate estrogenic compounds as a clinically relevant pharmacotherapeutic strategy for treatment of secondary injury following TBI, and intriguingly, reveal a novel potential therapeutic target in GPER.	[Day, Nicole L.; Floyd, Candace L.; D'Alessandro, Tracy L.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Spain Rehabil Ctr, Birmingham, AL 35294 USA; [Hubbard, William J.; Chaudry, Irshad H.] Univ Alabama Birmingham, Dept Surg, Spain Rehabil Ctr, Birmingham, AL 35294 USA		Floyd, CL (corresponding author), Univ Alabama Birmingham, Dept Phys Med & Rehabil, Spain Rehabil Ctr 506, 1717 6th Ave South, Birmingham, AL 35294 USA.	clfloyd@uab.edu		Day, Nicole/0000-0003-3490-4908	Department of Defense Congressionally Directed Medical Research Programs (CDMRP)United States Department of Defense [W81XWH-08-2-0153]	This work was supported by funding from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP), W81XWH-08-2-0153.	Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Ba ZF, 2008, SHOCK, V30, P585, DOI 10.1097/SHK.0b013e31816f1a45; Bao YJ, 2011, MOL CELL NEUROSCI, V48, P185, DOI 10.1016/j.mcn.2011.07.004; Barreto G, 2007, EUR J NEUROSCI, V25, P3039, DOI 10.1111/j.1460-9568.2007.05563.x; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bourque M, 2013, NEUROBIOL AGING, V34, P887, DOI 10.1016/j.neurobiolaging.2012.05.022; Brailoiu E, 2007, J ENDOCRINOL, V193, P311, DOI 10.1677/JOE-07-0017; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Carson FL, 1990, HISTOTECHNOLOGY SELF; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Choudhry MA, 2008, J LEUKOCYTE BIOL, V83, P518, DOI 10.1189/jlb.0607369; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duckles SP, 2007, CLIN EXP PHARMACOL P, V34, P801, DOI 10.1111/j.1440-1681.2007.04683.x; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Faul X. L., 2010, TRAUMATIC BRAIN INJU; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Gingerich S, 2010, NEUROSCIENCE, V170, P54, DOI 10.1016/j.neuroscience.2010.06.076; Hammes SR, 2007, ENDOCR REV, V28, P726, DOI 10.1210/er.2007-0022; Hammond R, 2011, PSYCHONEUROENDOCRINO, V36, P182, DOI 10.1016/j.psyneuen.2010.07.007; Hammond R, 2009, HORM BEHAV, V56, P309, DOI 10.1016/j.yhbeh.2009.06.008; Hazell GGJ, 2009, J ENDOCRINOL, V202, P223, DOI 10.1677/JOE-09-0066; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; Hsieh YC, 2007, CRIT CARE MED, V35, pS621, DOI 10.1097/01.CCM.0000278603.18687.4F; Hsieh YC, 2007, AM J PATHOL, V170, P1210, DOI 10.2353/ajpath.2007.060883; Hsieh YC, 2006, J MOL CELL CARDIOL, V41, P511, DOI 10.1016/j.yjmcc.2006.06.001; Kachadroka S, 2010, J NEUROTRAUM, V27, P611, DOI 10.1089/neu.2009.1069; Lapanantasin S, 2006, SYNAPSE, V60, P406, DOI 10.1002/syn.20308; Lebesgue D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008642; Lebesgue D, 2006, J NEUROTRAUM, V23, P1814, DOI 10.1089/neu.2006.23.1814; Lee E, 2012, J BIOL CHEM, V287, P26817, DOI 10.1074/jbc.M112.341867; Li LZ, 2011, NEUROCHEM INT, V58, P126, DOI 10.1016/j.neuint.2010.11.006; Liu SB, 2012, J NEUROSCI, V32, P4887, DOI 10.1523/JNEUROSCI.5828-11.2012; Liu SB, 2011, CLIN EXP PHARMACOL P, V38, P577, DOI 10.1111/j.1440-1681.2011.05549.x; Liverman CS, 2009, CEPHALALGIA, V29, P520, DOI [10.1111/j.1468-2982.2008.01755.x, 10.1111/j.1468-2982.2008.01789.x]; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Shahrokhi N, 2012, PAK J PHARM SCI, V25, P219; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Simpkins JW, 2010, BBA-GEN SUBJECTS, V1800, P1113, DOI 10.1016/j.bbagen.2009.11.013; Siriphorn A, 2012, J COMP NEUROL, V520, P2630, DOI 10.1002/cne.23056; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xu H, 2009, NEUROSCIENCE, V158, P1599, DOI 10.1016/j.neuroscience.2008.11.028; Yu HP, 2007, ANN SURG, V245, P971, DOI 10.1097/01.sla.0000254417.15591.88; Yu HP, 2009, SHOCK, V31, P227, DOI 10.1097/SHK.0b013e31818347e7; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544	70	65	65	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1531	1541		10.1089/neu.2013.2854			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800009	23659385	Green Published			2022-02-06	
J	Lu, J; Frerich, JM; Turtzo, LC; Li, SQ; Chiang, J; Yang, CZ; Wang, XP; Zhang, C; Wu, CX; Sun, ZC; Niu, G; Zhuang, ZP; Brady, RO; Chen, XY				Lu, Jie; Frerich, Jason M.; Turtzo, L. Christine; Li, Siqi; Chiang, Jeffrey; Yang, Chunzhang; Wang, Xiaoping; Zhang, Chao; Wu, Chenxi; Sun, Zhongchan; Niu, Gang; Zhuang, Zhengping; Brady, Roscoe O.; Chen, Xiaoyuan			Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							NERVE GROWTH-FACTOR; H3 ACETYLATION; UP-REGULATION; HEAD-INJURY; EXPRESSION; RATS; MICE; ASTROCYTES; ACTIVATION; MECHANISMS	Acute traumatic brain injury (TBI) is associated with long-term cognitive and behavioral dysfunction. In vivo studies have shown histone deacetylase inhibitors (HDACis) to be neuroprotective following TBI in rodent models. HDACis are intriguing candidates because they are capable of provoking widespread genetic changes and modulation of protein function. By using known HDACis and a unique small-molecule pan-HDACi (LB-205), we investigated the effects and mechanisms associated with HDACi-induced neuroprotection following CNS injury in an astrocyte scratch assay in vitro and a rat TBI model in vivo. We demonstrate the preservation of sufficient expression of nerve growth factor (NGF) and activation of the neurotrophic tyrosine kinase receptor type 1 (TrkA) pathway following HDACi treatment to be crucial in stimulating the survival of CNS cells after TBI. HDACi treatment up-regulated the expression of NGF, phospho-TrkA, phospho-protein kinase B (p-AKT), NF-kappa B, and B-cell lymphoma 2 (Bcl-2) cell survival factors while down-regulating the expression of p75 neurotrophin receptor (NTR), phospho-JNK, and Bcl-2-associated X protein apoptosis factors. HDACi treatment also increased the expression of the stem cell biomarker nestin, and decreased the expression of reactive astrocyte biomarker GFAP within damaged tissue following TBI. These findings provide further insight into the mechanisms by which HDACi treatment after TBI is neuroprotective and support the continued study of HDACis following acute TBI.	[Lu, Jie; Turtzo, L. Christine; Wu, Chenxi; Sun, Zhongchan; Niu, Gang; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, Bethesda, MD 20892 USA; [Frerich, Jason M.; Li, Siqi; Yang, Chunzhang; Wang, Xiaoping; Zhang, Chao; Zhuang, Zhengping; Brady, Roscoe O.] NINDS, Surg Neurol Branch, Bethesda, MD 20892 USA; [Chiang, Jeffrey] NCI, NIH, Bethesda, MD 20892 USA; [Lu, Jie; Turtzo, L. Christine; Chen, Xiaoyuan] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA		Zhuang, ZP (corresponding author), NINDS, Surg Neurol Branch, Bethesda, MD 20892 USA.	zhuangp@ninds.nih.gov; bradyr@ninds.nih.gov; shawn.chen@nih.gov	Chen, Xiaoyuan/D-1860-2014	Chen, Xiaoyuan/0000-0002-9622-0870; Yang, Chunzhang/0000-0001-6433-0867	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Intramural Research Programs of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NINDS; Imaging Sciences Training Program (sponsored by Radiology and Imaging Sciences in the Clinical Center and Intramural Research Programs of the NIBIB); Howard Hughes Medical Institute-NIH Medical Research Scholars Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003052] Funding Source: NIH RePORTER	We thank Dr. Paul E. Gallant [National Institute of Neurological Disorders and Stroke (NINDS) Light Microscopy Facility] for assistance with confocal microscopy, Dr. Dragan Maric (NINDS Flow Cytometry Core Facility) for assistance with flow cytometry, and Lixte Biotechnology Holdings for providing LB-205. This work was supported by the Department of Defense in the Center for Neuroscience and Regenerative Medicine, Intramural Research Programs of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NINDS, Imaging Sciences Training Program (sponsored by Radiology and Imaging Sciences in the Clinical Center and Intramural Research Programs of the NIBIB) (J.L.), and Howard Hughes Medical Institute-NIH Medical Research Scholars Program (J.M.F.).	Aloe L, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-239; Barr TL, 2011, BIOL RES NURS, V13, P140, DOI 10.1177/1099800410385671; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen LW, 2006, J COMP NEUROL, V497, P898, DOI 10.1002/cne.21014; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Fischer A, 2010, TRENDS PHARMACOL SCI, V31, P605, DOI 10.1016/j.tips.2010.09.003; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; Liu Y, 2011, MOL CANCER RES, V9, P1668, DOI 10.1158/1541-7786.MCR-10-0563; Lu J, 2011, P NATL ACAD SCI USA, V108, P21200, DOI 10.1073/pnas.1119181109; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Peleg S, 2010, SCIENCE, V328, P753, DOI 10.1126/science.1186088; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Rosenberg G, 2007, CELL MOL LIFE SCI, V64, P2090, DOI 10.1007/s00018-007-7079-x; Shein NA, 2011, MOL MED, V17, P448, DOI 10.2119/molmed.2011.00038; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Yang CZ, 2013, CELL REP, V3, P52, DOI 10.1016/j.celrep.2012.12.007; Yang CZ, 2012, P NATL ACAD SCI USA, V109, P6963, DOI 10.1073/pnas.1118754109; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang Y, 2013, J NEUROSURG, V2013, P12	39	65	69	1	15	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUN 25	2013	110	26					10747	10752		10.1073/pnas.1308950110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	179EY	WOS:000321503700067	23754423	Bronze, Green Published			2022-02-06	
J	Tweedie, D; Rachmany, L; Rubovitch, V; Zhang, YQ; Becker, KG; Perez, E; Hoffer, BJ; Pick, CG; Greig, NH				Tweedie, David; Rachmany, Lital; Rubovitch, Vardit; Zhang, Yongqing; Becker, Kevin G.; Perez, Evelyn; Hoffer, Barry J.; Pick, Chaim G.; Greig, Nigel H.			Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Physical-traumatic brain injury; Blast-traumatic brain injury; Cognitive dysfunction; Gene expression; Molecular pathway(s); Neurodegeneration; Stem cells; Alzheimer's disease	IMPAIRED RECOGNITION MEMORY; DIFFUSE AXONAL INJURY; ELEVATED PLUS-MAZE; ALPHA SYNTHESIS INHIBITOR; FLUID-PERCUSSION INJURY; OBJECT-RECOGNITION; HEAD-INJURY; BARRIER PERMEABILITY; SPATIAL MEMORY; CORTEX DAMAGE	Warfare has long been associated with traumatic brain injury (TBI) in militarized zones. Common forms of TBI can be caused by a physical insult to the head brain or by the effects of a high velocity blast shock wave generated by the detonation of an explosive device. While both forms of trauma are distinctly different regarding the mechanism of trauma induction, there are striking similarities in the cognitive and emotional status of survivors. Presently, proven effective therapeutics for the treatment of either form of TBI are unavailable. To be able to develop efficacious therapies, studies involving animal models of physical- and blast-TBI are required to identify possible novel or existing medicines that may be of value in the management of clinical events. We examined indices of cognition and anxiety-like behavior and the hippocampal gene transcriptome of mice subjected to both forms of TBI. We identified common behavioral deficits and gene expression regulations, in addition to unique injury-specific forms of gene regulation. Molecular pathways presented a pattern similar to that seen in gene expression. Interestingly, pathways connected to Alzheimer's disease displayed a markedly different form of regulation depending on the type of TBI. While these data highlight similarities in behavioral outcomes after trauma, the divergence in hippocampal transcriptome observed between models suggests that, at the molecular level, the TBIs are quite different. These models may provide tools to help define therapeutic approaches for the treatment of physical- and blast-TBIs. Based upon observations of increasing numbers of personnel displaying TBI related emotional and behavioral changes in militarized zones, the development of efficacious therapies will become a national if not a global priority. (C) 2013 Elsevier Inc. All rights reserved.	[Tweedie, David; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Zhang, Yongqing; Becker, Kevin G.] NIA, Gene Express & Genom Unit, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Perez, Evelyn] NIA, Lab Expt Gerontol, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA		Tweedie, D (corresponding author), NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program, BRC Room 05B121,251 Bayview Blvd, Baltimore, MD 21224 USA.	tweedieda@grc.nia.nih.gov; litalrac@post.tau.ac.il; rubovitc@post.tau.ac.il; zhangyon@grc.nia.nih.gov; BeckerK@grc.nia.nih.gov; perezev@grc.nia.nih.gov; bjh82@case.edu; pickc@post.tau.ac.il; greign@grc.nia.nih.gov		Becker, Kevin/0000-0002-6794-6656	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute on Drug Abuse, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); Sackler School of Medicine, Tel-Aviv University; Israeli science foundationIsrael Science Foundation [108/09]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZICAG000616, ZIAAG000311, ZIAAG000350, ZIAAG000333] Funding Source: NIH RePORTER	The authors wish to acknowledge Dr. Henriette van Pragg as well as William Wood III and Elin Lehrmann for their help in the preparation of this manuscript. This research was supported in part by the Intramural Research Programs of both the National Institute on Aging and National Institute on Drug Abuse, National Institutes of Health, and by the Sackler School of Medicine, Tel-Aviv University, and in part by a grant from the Israeli science foundation, grant no. 108/09.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Aston C, 2005, MOL PSYCHIATR, V10, P309, DOI 10.1038/sj.mp.4001565; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Bandres E, 2005, J NEURO-ONCOL, V73, P189, DOI 10.1007/s11060-004-5174-5; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Baxter MG, 2001, HIPPOCAMPUS, V11, P61, DOI 10.1002/1098-1063(2001)11:1<61::AID-HIPO1021>3.3.CO;2-Q; Beason-Held LL, 1999, HIPPOCAMPUS, V9, P562, DOI 10.1002/(SICI)1098-1063(1999)9:5<562::AID-HIPO10>3.0.CO;2-X; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bryan C, 2012, J HEAD TRAUMA REHAB, V27, P45, DOI 10.1097/HTR.0b013e318238f146; Burton GR, 2004, GENE, V329, P167, DOI 10.1016/j.gene.2003.12.012; Bye N, 2011, J NEUROSCI RES, V89, P986, DOI 10.1002/jnr.22635; Campdelacreu J., 2012, NEUROLOGIA; Cave C B, 1991, Hippocampus, V1, P329, DOI 10.1002/hipo.450010323; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; Clark RE, 2000, J NEUROSCI, V20, P8853; COLE JC, 1993, BEHAV PHARMACOL, V4, P573; COLE JC, 1995, PHARMACOL BIOCHEM BE, V52, P473, DOI 10.1016/0091-3057(95)00163-Q; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Deacon RMJ, 2002, BEHAV BRAIN RES, V133, P57, DOI 10.1016/S0166-4328(01)00451-X; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Falk A.C., 2012, SCAND J CARING SCI; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gilbert PE, 2003, LEARN MEMORY, V10, P525, DOI 10.1101/lm.64503; Gong DS, 2012, BRAIN INJURY, V26, P291, DOI 10.3109/02699052.2011.648710; Hammond RS, 2004, NEUROBIOL LEARN MEM, V82, P26, DOI 10.1016/j.nlm.2004.03.005; Hattori Y, 1997, MOL BRAIN RES, V47, P139, DOI 10.1016/S0169-328X(97)00044-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hunt MC, 2012, BBA-MOL BASIS DIS, V1822, P1397, DOI 10.1016/j.bbadis.2012.03.009; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang CH, 2001, P NATL ACAD SCI USA, V98, P1930, DOI 10.1073/pnas.98.4.1930; Johnson VE, 2012, EXP NEUROL; Khaldi A, 2002, ANN NY ACAD SCI, V962, P53, DOI 10.1111/j.1749-6632.2002.tb04055.x; Lee WH, 2012, INT J RADIAT ONCOL, V82, P1559, DOI 10.1016/j.ijrobp.2010.12.032; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; Lin Y, 2012, LAB INVEST, V92, P1623, DOI 10.1038/labinvest.2012.118; Lorenzini CGA, 1997, BRAIN RES, V768, P242, DOI 10.1016/S0006-8993(97)00651-3; Luukkainen S., 2012, PSYCHIAT RES; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mody M, 2001, P NATL ACAD SCI USA, V98, P8862, DOI 10.1073/pnas.141244998; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mumby DG, 2001, BEHAV BRAIN RES, V127, P159, DOI 10.1016/S0166-4328(01)00367-9; Mumby DG, 1999, BEHAV BRAIN RES, V106, P97, DOI 10.1016/S0166-4328(99)00097-2; Murray EA, 2000, ANN NY ACAD SCI, V911, P166; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Pittenger C, 2002, NEURON, V34, P447, DOI 10.1016/S0896-6273(02)00684-0; Rachmany L., 2012, AGE DORDR; Rachmany L., 2012, EXP NEUROL; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Reed JM, 1997, BEHAV NEUROSCI, V111, P667, DOI 10.1037/0735-7044.111.4.667; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Russo I, 2012, J NEUROCHEM, V122, P1181, DOI 10.1111/j.1471-4159.2012.07846.x; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Sajja V.S., 2012, NMR BIOMED; Sanders MJ, 2001, BRAIN RES, V904, P141, DOI 10.1016/S0006-8993(01)02424-6; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Seo JH, 2012, CURR PHARM DESIGN, V18, P3645; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Squire LR, 1996, P NATL ACAD SCI USA, V93, P13515, DOI 10.1073/pnas.93.24.13515; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Takahashi N, 2011, PROG NEUROBIOL, V93, P13, DOI 10.1016/j.pneurobio.2010.09.004; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Van Hove I, 2012, MOL NEUROBIOL, V45, P17, DOI 10.1007/s12035-011-8215-z; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Wada K., 1999, J NEUROTRAUM, V16, P203; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Yang CC, 2012, BRAIN INJURY, V26, P1185, DOI 10.3109/02699052.2012.666374; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zola SM, 2001, HIPPOCAMPUS, V11, P92, DOI 10.1002/hipo.1027	99	65	66	0	28	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	JUN	2013	54						1	11		10.1016/j.nbd.2013.02.006			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	132EZ	WOS:000318052000001	23454194	Green Accepted			2022-02-06	
J	Perez-Polo, JR; Rea, HC; Johnson, KM; Parsley, MA; Unabia, GC; Xu, GJ; Infante, SK; DeWitt, DS; Hulsebosch, CE				Perez-Polo, J. Regino; Rea, Harriet C.; Johnson, Kathia M.; Parsley, Margaret A.; Unabia, Geda C.; Xu, GuoJing; Infante, Smitha K.; DeWitt, Douglas S.; Hulsebosch, Claire E.			Inflammatory Consequences in a Rodent Model of Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; blood-brain barrier; cytokines; inflammation; mild traumatic brain injury	SPINAL-CORD-INJURY; NECROSIS-FACTOR-ALPHA; CENTRAL NEUROPATHIC PAIN; INTERLEUKIN-1 RECEPTOR ANTAGONIST; FIBRILLARY ACIDIC PROTEIN; NATIONAL-FOOTBALL-LEAGUE; RAT-BRAIN; CYTOKINE PRODUCTION; MESSENGER-RNA; HEAD-INJURY	Mild traumatic brain injury (mTBI), particularly mild "blast type'' injuries resulting from improvised exploding devices and many sport-caused injuries to the brain, result in long-term impairment of cognition and behavior. Our central hypothesis is that there are inflammatory consequences to mTBI that persist over time and, in part, are responsible for resultant pathogenesis and clinical outcomes. We used an adaptation (1 atmosphere pressure) of a well-characterized moderate-to-severe brain lateral fluid percussion (LFP) brain injury rat model. Our mild LFP injury resulted in acute increases in interleukin-1 alpha/beta and tumor necrosis factor alpha levels, macrophage/microglial and astrocytic activation, evidence of heightened cellular stress, and blood-brain barrier (BBB) dysfunction that were evident as early as 3-6 h postinjury. Both glial activation and BBB dysfunction persisted for 18 days postinjury.	[Perez-Polo, J. Regino; Rea, Harriet C.; Johnson, Kathia M.; Parsley, Margaret A.; Unabia, Geda C.; Xu, GuoJing; Infante, Smitha K.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Parsley, Margaret A.; DeWitt, Douglas S.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Hulsebosch, Claire E.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA		Perez-Polo, JR (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	regino.perez-polo@utmb.edu					Akuzawa S, 2008, J VASC SURG, V48, P694, DOI 10.1016/j.jvs.2008.04.011; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; Banwell V, 2009, J STROKE CEREBROVASC, V18, P269, DOI 10.1016/j.jstrokecerebrovasdis.2008.11.009; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Brambilla R, 2009, J NEUROCHEM, V110, P765, DOI 10.1111/j.1471-4159.2009.06190.x; Brochu ME, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-55; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crown ED, 2008, EXP NEUROL, V213, P257, DOI 10.1016/j.expneurol.2008.05.025; de Leo JA, 2006, PAIN, V122, P17, DOI 10.1016/j.pain.2006.02.034; Department of Veterans Affairs Department of Defense, 2009, CLIN PRACT GUID MAN; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doll H, 2009, J NEUROTRAUM, V26, P235, DOI 10.1089/neu.2008.0741; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Ekmark-Lewen S, 2010, J NEUROTRAUM, V27, P1643, DOI 10.1089/neu.2009.0953; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Fabian RH, 2004, INT J DEV NEUROSCI, V22, P225, DOI 10.1016/j.ijdevneu.2004.03.006; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Genovese T, 2009, J NEUROCHEM, V108, P1360, DOI 10.1111/j.1471-4159.2009.05899.x; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Gwak YS, 2008, PAIN, V138, P410, DOI 10.1016/j.pain.2008.01.021; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hu XM, 2005, J NEUROCHEM, V93, P26, DOI 10.1111/j.1471-4159.2004.02968.x; Hulsebosch CE, 2005, CURR PHARM DESIGN, V11, P1411, DOI 10.2174/1381612053507864; Hulsebosch CE, 2008, EXP NEUROL, V214, P6, DOI 10.1016/j.expneurol.2008.07.016; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; LASEK RJ, 1974, P NATL ACAD SCI USA, V71, P1188, DOI 10.1073/pnas.71.4.1188; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lee SI, 2010, J NEUROSCI RES, V88, P2409, DOI 10.1002/jnr.22411; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Lu HB, 2010, NEUROIMAGE, V50, P7, DOI 10.1016/j.neuroimage.2009.12.053; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; McAdoo DJ, 1999, EXP NEUROL, V159, P538, DOI 10.1006/exnr.1999.7166; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Nesic O, 2005, J NEUROCHEM, V95, P998, DOI 10.1111/j.1471-4159.2005.03462.x; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Nguyen HT, 2009, ANESTHESIOLOGY, V110, P326, DOI 10.1097/ALN.0b013e3181942b5b; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Shafer RA, 1997, GLIA, V21, P370, DOI 10.1002/(SICI)1098-1136(199712)21:4<370::AID-GLIA4>3.0.CO;2-7; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Tai PA, 2010, J NEUROTRAUM, V27, P1121, DOI 10.1089/neu.2009.1162; TANAKA M, 1994, J NEUROCHEM, V63, P266; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3574, DOI 10.2174/138161208786848739; VILLEGAS J, 1972, J PHYSIOL-LONDON, V225, P275, DOI 10.1113/jphysiol.1972.sp009940; Ward JL, 2011, J TRAUMA, V70, P1471, DOI 10.1097/TA.0b013e31821c38bd; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001; Xu GY, 2008, NEUROSCIENCE, V153, P1034, DOI 10.1016/j.neuroscience.2008.02.065; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhou ZG, 2009, EXP NEUROL, V220, P183, DOI 10.1016/j.expneurol.2009.08.018	79	65	67	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		727	740		10.1089/neu.2012.2650			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600005	23360201	Green Published			2022-02-06	
J	Virji-Babul, N; Borich, MR; Makan, N; Moore, T; Frew, K; Emery, CA; Boyd, LA				Virji-Babul, Naznin; Borich, Michael R.; Makan, Nadia; Moore, Tiffany; Frew, Kira; Emery, Carolyn A.; Boyd, Lara A.			Diffusion Tensor Imaging of Sports-Related Concussion in Adolescents	PEDIATRIC NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY; ANISOTROPY; CHILDREN; LESIONS; STROKE	Concussion is among the least understood neurologic injuries. The impact of concussion on the adolescent brain remains largely unknown. This study sought to establish short-term changes in white-matter integrity after sports-related concussion in adolescents, and examine the association between changes in white-matter integrity and a clinical measure of concussion. Twelve adolescents, aged 14-17 years with a sports-related concussion within 2 months, and 10 age-matched adolescents with no history of concussion were evaluated with the Sports Concussion Assessment Tool 2 and diffusion tensor imaging. Two measures compared the two groups: fractional anisotropy and mean diffusivity. Whole-brain fractional anisotropy values significantly increased (F(1,40) = 6.29, P = 0.010), and mean diffusivity values decreased (F(1,40) = 4.75, P = 0.036), in concussed athletes compared with control participants. Total scores on the Sports Concussion Assessment Tool 2 were associated with whole-brain fractional anisotropy. Mean diffusivity values with lower scores were associated with higher fractional anisotropy (R-2 = 0.25, P = 0.017) and lower mean diffusivity (R-2 = 0.20, P = 0.038). We provide evidence of structural changes in the integrity of white matter in adolescent athletes after sports-related concussion. (C) 2013 Elsevier Inc. All rights reserved.	[Virji-Babul, Naznin; Borich, Michael R.; Makan, Nadia; Moore, Tiffany; Frew, Kira; Boyd, Lara A.] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V6T 1Z3, Canada; [Virji-Babul, Naznin] Child & Family Res Inst, Vancouver, BC, Canada; [Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Emery, Carolyn A.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst Child & Maternal, Calgary, AB, Canada		Virji-Babul, N (corresponding author), Univ British Columbia, Dept Phys Therapy, 212-2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	nvb31@mail.ubc.ca	Borich, Michael Robert/E-1683-2011; Emery, Carolyn/AAI-2761-2020	Borich, Michael Robert/0000-0002-0469-6282; Virji-Babul, Naznin/0000-0002-8984-5848	Martha Piper Research Fund; Brain Research Centre at the University of British Columbia; University of British Columbia; British Columbia Hockey; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Canada Research ChairsCanada Research ChairsCGIAR; Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research	This research was supported by the Martha Piper Research Fund, the Brain Research Centre at the University of British Columbia, and the University of British Columbia. The authors thank British Columbia Hockey for their support and all the participants, trainers, and coaches who contributed to this study. M.R.B. received salary support from the Heart and Stroke Foundation of Canada. The Canada Research Chairs and Michael Smith Foundation for Health Research support L.A.B. The authors also thank Alex Rauscher, PhD for his assistance with the magnetic resonance imaging protocol, and Shelina Babul-Wellar, PhD for help with participant recruitment.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Bhagat YA, 2006, J CEREBR BLOOD F MET, V26, P1442, DOI 10.1038/sj.jcbfm.9600294; Billette J- M, INJURIES CANADA INSI; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Green HAL, 2002, STROKE, V33, P1517, DOI 10.1161/01.STR.0000016973.80180.7B; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mazziotta J, 2001, PHILOS T R SOC B, V356, P1293, DOI 10.1098/rstb.2001.0915; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mori S, 2005, MRI ATLAS HUMAN WHIT; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Talairach J., 1988, COPLANAR STEREOTAXIC; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	31	65	69	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	JAN	2013	48	1					24	29		10.1016/j.pediatrneurol.2012.09.005			6	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	079VC	WOS:000314199300005	23290016				2022-02-06	
J	Chandra, N; Ganpule, S; Kleinschmit, NN; Feng, R; Holmberg, AD; Sundaramurthy, A; Selvan, V; Alai, A				Chandra, N.; Ganpule, S.; Kleinschmit, N. N.; Feng, R.; Holmberg, A. D.; Sundaramurthy, A.; Selvan, V.; Alai, A.			Evolution of blast wave profiles in simulated air blasts: experiment and computational modeling	SHOCK WAVES			English	Article						Blast wave; Shock tube; Pressure profiles; Expansion; Jet wind; Experiments; Numerical simulations; TBI	SHOCK-WAVES; INDUCED NEUROTRAUMA; BRAIN-INJURY; OPEN-END; MECHANISMS; RAT; PROPAGATION; PRESSURE	Shock tubes have been extensively used in the study of blast traumatic brain injury due to increased incidence of blast-induced neurotrauma in Iraq and Afghanistan conflicts. One of the important aspects in these studies is how to best replicate the field conditions in the laboratory which relies on reproducing blast wave profiles. Evolution of the blast wave profiles along the length of the compression-driven air shock tube is studied using experiments and numerical simulations with emphasis on the shape and magnitude of pressure time profiles. In order to measure dynamic pressures of the blast, a series of sensors are mounted on a cylindrical specimen normal to the flow direction. Our results indicate that the blast wave loading is significantly different for locations inside and outside of the shock tube. Pressure profiles inside the shock tube follow the Friedlander waveform fairly well. Upon approaching exit of the shock tube, an expansion wave released from the shock tube edges significantly degrades the pressure profiles. For tests outside the shock tube, peak pressure and total impulse reduce drastically as we move away from the exit and majority of loading is in the form of subsonic jet wind. In addition, the planarity of the blast wave degrades as blast wave evolves three dimensionally. Numerical results visually and quantitatively confirm the presence of vortices, jet wind and three-dimensional expansion of the planar blast wave near the exit. Pressure profiles at 90A degrees orientation show flow separation. When cylinder is placed inside, this flow separation is not sustained, but when placed outside the shock tube this flow separation is sustained which causes tensile loading on the sides of the cylinder. Friedlander waves formed due to field explosives in the intermediate-to far-field ranges are replicated in a narrow test region located deep inside the shock tube.	[Chandra, N.; Ganpule, S.; Kleinschmit, N. N.; Feng, R.; Holmberg, A. D.; Sundaramurthy, A.; Selvan, V.; Alai, A.] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA		Chandra, N (corresponding author), Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA.	nchandra2@unl.edu	Sundaramurthy, Aravind/O-2047-2019	Sundaramurthy, Aravind/0000-0002-0359-8680	U.S. Army Research Office [W911NF-08-1-0483]	The authors acknowledge the financial support provided by the U.S. Army Research Office for the project on "Army-UNL Center for Trauma Mechanics," Contract No. W911NF-08-1-0483. Project monitor: Larry Russel, PI: Namas Chandra.	Abdul-Wahab R, 2011, NORTHEAST BIOENGIN C; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Arakeri JH, 2004, PHYS FLUIDS, V16, P1008, DOI 10.1063/1.1649339; Baker W.E., 1973, EXPLOSIONS AIR; BLEAKNEY W, 1949, REV MOD PHYS, V21, P584, DOI 10.1103/RevModPhys.21.584; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Chandra N., 2011, U.S. provisional patent application, Patent No. 61542354; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Courtney AC, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3702803; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; DUFF RE, 1966, REV SCI INSTRUM, V37, P579, DOI 10.1063/1.1720256; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Ganpule S, 2012, COMPUT METHOD BIOMEC, V15, P1233, DOI 10.1080/10255842.2011.597353; Honma H, 2003, SHOCK WAVES, V13, P179, DOI 10.1007/s00193-003-0206-1; Jiang Z, 1999, SHOCK WAVES, V9, P1, DOI 10.1007/s001930050133; Jiang Z, 2003, SHOCK WAVES, V13, P103, DOI 10.1007/s00193-003-0197-y; Jiang Z, 1998, PHYS FLUIDS, V10, P277, DOI 10.1063/1.869566; Kashimura H., 2000, J THERM SCI, V9, P30, DOI [10.1007/s11630-000-0042-x, DOI 10.1007/S11630-000-0042-X]; Kleinschmit N, 2011, SHOCK TUBE TECHNIQUE; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Moss WC, 2011, P NATL ACAD SCI USA, V108, pE82, DOI 10.1073/pnas.1101671108; Onodera O, 1998, JSME INT J B-FLUID T, V41, P408, DOI 10.1299/jsmeb.41.408; Rafaels K., 2010, THESIS U VIRGINIA; Rafaels K.A., 2010, PERS ARM SAF S PASS; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Setoguchi T., 1993, P 1993 ASME WINT M N, V170, P57; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zhu F, 2012, BIOMECH MODEL MECHAN, V11, P341, DOI 10.1007/s10237-011-0314-2	31	65	67	2	53	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-1287	1432-2153		SHOCK WAVES	Shock Waves	SEP	2012	22	5					403	415		10.1007/s00193-012-0399-2			13	Mechanics	Science Citation Index Expanded (SCI-EXPANDED)	Mechanics	996FA	WOS:000308068900002					2022-02-06	
J	Honeybul, S; Ho, KM				Honeybul, Stephen; Ho, Kwok M.			Incidence and Risk Factors for Post-Traumatic Hydrocephalus following Decompressive Craniectomy for Intractable Intracranial Hypertension and Evacuation of Mass Lesions	JOURNAL OF NEUROTRAUMA			English	Article						complications; decompressive craniectomy; neurotrauma	TRAUMATIC BRAIN-INJURY; VENTRICULAR ENLARGEMENT; HEAD-INJURY; COMPLICATIONS; PATHOGENESIS; HYGROMA	There continues to be a considerable interest in decompressive craniectomy in the management of severe traumatic brain injury (TBI). Though technically straightforward, the procedure is not without significant complications. In this study we assessed the incidence and risk factors for the development of subdural hygroma and hydrocephalus after decompressive craniectomy. A total of 195 patients who had had a decompressive craniectomy for severe TBI between 2004 and 2010 at the two major trauma centers in Western Australia were considered. Of the 166 patients who survived after the acute hospital stay, 93 (56%; 95% confidence interval [CI] 48,63%) developed subdural hygroma; 45 patients (48%) had unilateral and 48 patients (52%) had bilateral subdural hygromas. Of the 159 patients who survived more than 6 months after surgery, 72 (45%; 95% CI 38,53%) developed radiological evidence of ventriculomegaly, and 26 of these 72 patients (36%; 95% CI 26,48%) developed clinical evidence of hydrocephalus and required a ventriculoperitoneal (VP) shunt. Maximum intracranial pressure prior to decompression (p = 0.005), subdural hygroma (p = 0.012), and a lower admission Glasgow Coma Scale score (p = 0.009), were significant risk factors for hydrocephalus after decompressive craniectomy. Hydrocephalus requiring a VP shunt was associated with a higher risk of unfavorable neurological outcomes at 18 months (odds ratio 7.46; 95% CI 1.17,47.4; p = 0.033), after adjusting for other factors. Our results showed a clear association between injury severity, subdural hygroma, and hydrocephalus, suggesting that damage to the cerebrospinal fluid drainage pathways contributes to the primary brain injury rather than the margin of the craniectomy as the factor responsible for these complications.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6019, Australia; [Ho, Kwok M.] Univ Western Australia, Royal Perth Hosp, Dept Intens Care Med, Perth, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6019, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Bratton S.L., 2007, J NEUROTRAUMA S1, V24; Choi I, 2008, J KOREAN NEUROSURG S, V43, P227, DOI 10.3340/jkns.2008.43.5.227; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dandy WE, 1932, PRACTICE SURG, P306; De Bonis P, 2010, J NEUROTRAUM, V27, P1965, DOI 10.1089/neu.2010.1425; Evans WA, 1942, ARCH NEURO PSYCHIATR, V47, P931, DOI 10.1001/archneurpsyc.1942.02290060069004; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Jiao Qing-fang, 2007, Chin J Traumatol, V10, P159; Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; KAUFMAN HH, 1984, ACTA NEUROCHIR, V72, P197, DOI 10.1007/BF01406870; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Licata C, 2001, J Neurosurg Sci, V45, P141; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tian HL, 2008, SURG NEUROL, V69, P241, DOI 10.1016/j.surneu.2007.02.032; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	32	65	80	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1872	1878		10.1089/neu.2012.2356			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400391	22583391				2022-02-06	
J	Shultz, SR; MacFabe, DF; Foley, KA; Taylor, R; Cain, DP				Shultz, Sandy R.; MacFabe, Derrick F.; Foley, Kelly A.; Taylor, Roy; Cain, Donald P.			Sub-concussive brain injury in the Long-Evans rat induces acute neuroinflammation in the absence of behavioral impairments	BEHAVIOURAL BRAIN RESEARCH			English	Article						Mild traumatic brain injury; Sub-concussive brain injury; Fluid percussion injury; Animal model; Neuroinflammation; Learning and memory	CHRONIC TRAUMATIC ENCEPHALOPATHY; 3RD INTERNATIONAL-CONFERENCE; FLUID PERCUSSION INJURY; ELEVATED PLUS-MAZE; MILD HEAD-INJURY; ANIMAL-MODEL; AXONAL INJURY; SYNAPTIC PLASTICITY; CONSENSUS STATEMENT; PROPIONIC-ACID	Sub-concussive brain injuries may result in neurophysiological changes, cumulative effects, and neurodegeneration. The current study investigated the effects of a mild lateral fluid percussion injury (0.50-0.99 atm) on rat behavior and neuropathology to address the need to better understand sub-concussive brain injury. Male Long-Evans rats received either a single mild lateral fluid percussion injury or a sham-injury, followed by either a short (24 h) or long (4 weeks) recovery period. After recovery, rats underwent extensive behavioral testing consisting of tasks for rodent cognition, anxiety- and depression-like behaviors, social behavior, and sensorimotor function. At the completion of behavioral testing rats were sacrificed and brains were examined immunohistochemically with markers for neuroinflammation and axonal injury. No significant group differences were found on behavioral and axonal injury measures. However, rats given one mild fluid percussion injury displayed an acute neuroinflammatory response, consisting of increased microglia/macrophages and reactive astrogliosis, at 4 days post-injury. Neuroinflammation is a mechanism with the potential to contribute to the cumulative and neurodegenerative effects of repeated sub-concussive injuries. The current findings are consistent with findings in humans experiencing a sub-concussive blow, and provide support for the use of mild lateral fluid percussion injury in the rat as a model of sub-concussive brain injury. Crown Copyright (C) 2011 Published by Elsevier B.V. All rights reserved.	[Shultz, Sandy R.; Foley, Kelly A.; Cain, Donald P.] Univ Western Ontario, Dept Psychol, Grad Program Neurosci, London, ON, Canada; [MacFabe, Derrick F.; Foley, Kelly A.; Taylor, Roy] Univ Western Ontario, Dept Psychiat, Kilee Patchell Evans Autism Res Grp, London, ON N6A 3K7, Canada; [MacFabe, Derrick F.; Foley, Kelly A.; Taylor, Roy] Univ Western Ontario, Dept Psychol, Kilee Patchell Evans Autism Res Grp, London, ON, Canada		Shultz, SR (corresponding author), Univ Melbourne, Melbourne Brain Ctr, Bldg 144, Melbourne, Vic 3010, Australia.	sshultz@unimelb.edu.au		Shultz, Sandy/0000-0002-2525-8775	Natural Science and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	This research was supported by a grant from the Natural Science and Engineering Research Council (NSERC) to Dr. Donald P. Cain, a scholarship from NSERC to Dr. Sandy R. Shultz, and contributions from Good Life Childrens's Foundation and Round for a Reason Charities to Dr. Derrick F. MacFabe. We thank Drs. Richard Sutton and David Hovda from the UCLA Brain Injury Research Center for their help in LFP training. Additional thanks go to Lisa Tichenoff, Francis Boon, and Acia Blank for their assistance in the research project. Dr. Sandy Shultz now at: Department of Medicine (Royal Melbourne Hospital), Melbourne Brain Centre, University of Melbourne, Parkville, VIC, Australia.	ADAMS FS, 1994, PHYSIOL BEHAV, V55, P947, DOI 10.1016/0031-9384(94)90084-1; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Anderson T, 2006, PRACTICAL NEUROLOGY, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2011, J NEUROTRAUMA; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Cantu RC, 2009, NEUROSURGERY, V64, P786, DOI 10.1227/01.NEU.0000348539.13887.D3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gerber J, 2009, CLIN NEUROPATHOL, V28, P33; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hein AM, 2009, MOL NEUROBIOL, V40, P15, DOI 10.1007/s12035-009-8066-z; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kadhim HJ, 2009, J INTENSIVE CARE MED, V23, P236; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mochizuki A, 1996, EXP NEUROL, V142, P89, DOI 10.1006/exnr.1996.0181; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2008, NEUROPHARMACOLOGY, V54, P901, DOI 10.1016/j.neuropharm.2008.01.013; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Talavage TM, 2010, J NEUROTRAUMA; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318	59	65	66	1	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	APR 1	2012	229	1					145	152		10.1016/j.bbr.2011.12.015			8	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	915SL	WOS:000302047600018	22245525				2022-02-06	
J	Siopi, E; Llufriu-Daben, G; Fanucchi, F; Plotkine, M; Marchand-Leroux, C; Jafarian-Tehrani, M				Siopi, Eleni; Llufriu-Daben, Gemma; Fanucchi, Francesca; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz			Evaluation of late cognitive impairment and anxiety states following traumatic brain injury in mice: The effect of minocycline	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Memory impairment; Anxiety; Minocycline; Neuroprotection	CLINICAL NEUROPSYCHOLOGY; OBJECT RECOGNITION; MEMORY; SEVERITY; DEFICITS; MODEL; MODULATION; RECOVERY; BEHAVIOR; IMPACT	Comorbidity of cognitive and stress disorders is a common clinical sequel of traumatic brain injury (TBI) that is essentially determined by the site and severity of the insult, but also by the extent of the ensuing neuroinflammatory response. The present study sought to examine the late effects of closed-head TBI on memory function and anxiety in mice, in order to further examine the potential efficacy of an acute anti-inflammatory treatment with minocycline. The mouse model of closed-head injury by mechanical percussion was applied on anesthetized Swiss mice. The treatment protocol included three injections of minocycline (i.p.) at 5 min (90 mg/kg), 3 h and 9 h (45 mg/kg) post-TBI. The Novel Object Recognition Test as well as the Elevated Plus Maze (EPM) and Elevated Zero Maze (EZM) tasks were employed to assess post-TBI memory and anxiety respectively. Our results revealed a recognition memory deficit that was significant up to at least 13 weeks post-TBI. However, neither EPM nor EZM revealed any alteration in post-TBI anxiety levels albeit some mild disinhibition. Most importantly, minocycline was able to attenuate the memory impairment in an effective and lasting manner, highlighting its therapeutic potential in TBI. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Siopi, Eleni; Llufriu-Daben, Gemma; Fanucchi, Francesca; Plotkine, Michel; Marchand-Leroux, Catherine; Jafarian-Tehrani, Mehrnaz] Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA 4475, F-75006 Paris, France		Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, Lab Pharmacol Circulat Cerebrale EA 4475, 4 Ave Observ, F-75006 Paris, France.	eleni.siopi@etu.parisdescartes.fr; gemmaldaben@hotmail.com; fanucchifrancesca@yahoo.it; michel.plotkine@parisdescartes.fr; catherine.marchand@parisdescartes.fr; mehrnaz.jafarian@parisdescartes.fr	MARCHAND-LEROUX, Catherine/L-7453-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856	nonprofit organization "Fondation des Gueules Cassees"	This work was supported by the nonprofit organization "Fondation des Gueules Cassees" (Grants to ES and MJT). The authors would like to thank Dr. Florence Noble and Dr. Laurent Naudon for their kind contribution in the project.	Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Cook MN, 2002, BEHAV GENET, V32, P113, DOI 10.1023/A:1015249706579; Emilien G, 1996, ACTA NEUROL BELG, V96, P89; Ennaceur A, 1997, BEHAV BRAIN RES, V88, P181, DOI 10.1016/S0166-4328(97)02297-3; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kondo K, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-147; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Mechan AO, 2009, J NEUROSCI METH, V180, P43, DOI 10.1016/j.jneumeth.2009.02.018; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nicholl J, 2009, SEMIN NEUROL, V29, P247, DOI 10.1055/s-0029-1223878; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	37	65	67	0	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 9	2012	511	2					110	115		10.1016/j.neulet.2012.01.051			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	912AD	WOS:000301764900011	22314279				2022-02-06	
J	Ewert, DL; Lu, JZ; Li, W; Du, XP; Floyd, R; Kopke, R				Ewert, Donald L.; Lu, Jianzhong; Li, Wei; Du, Xiaoping; Floyd, Robert; Kopke, Richard			Antioxidant treatment reduces blast-induced cochlear damage and hearing loss	HEARING RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; IMPULSE NOISE BLAST; OXIDATIVE STRESS; TYMPANIC-MEMBRANE; N-ACETYLCYSTEINE; OVERPRESSURE; NXY-059; MODEL	Exposure to blast overpressure has become one of the hazards of both military and civilian life in many parts of the world due to war and terrorist activity. Auditory damage is one of the primary sequela of blast trauma, affecting immediate situational awareness and causing permanent hearing loss. Protecting against blast exposure is limited by the inability to anticipate the timing of these exposures, particularly those caused by terrorists. Therefore a therapeutic regimen is desirable that is able to ameliorate auditory damage when administered after a blast exposure has occurred. The purpose of this study was to determine if administration of a combination of antioxidants 2,4-disulfonyl alpha-phenyl tertiary butyl nitrone (HPN-07) and N-acetylcysteine (NAC) beginning 1 h after blast exposure could reduce both temporary and permanent hearing loss. To this end, a blast simulator was developed and the operational conditions established for exposing rats to blast overpressures comparable to those encountered in an open-field blast of 14 pounds per square inch (psi). This blast model produced reproducible blast overpressures that resulted in physiological and physical damage to the auditory system that was proportional to the number and amplitude of the blasts. After exposure to 3 consecutive 14 psi blasts 100% of anesthetized rats had permanent hearing loss as determined at 21 days post exposure by auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) testing. Animals treated with HPN-07 and NAC after blast exposure showed a significant reduction in ABR threshold shifts and DPOAE level shifts at 2-16 kHz with significant reduction in inner hair cell (IHC) and outer hair cell (OHC) loss across the 5-36 kHz region of the cochlea compared with control animals. The time course of changes in the auditory system was documented at 3 h, 24 h, 7 day and 21 day after blast exposure. At 3 h after blast exposure the auditory brainstem response (ABR) threshold shifts were elevated by 60 dB in both treated and control groups. A partial recovery of to 35 dB was observed at 24 h in the controls, indicative of a temporary threshold shift (ITS) and there was essentially no further recovery by 21 days representing a permanent threshold shift (PTS) of about 30 dB. Antioxidant treatment increased the amount of both us and PTS recovery relative to controls by 10 and 20 dB respectively. Distortion product otoacoustic emission (DPOAE) reached a maximum level shift of 25-30 dB measured in both control and treated groups at 3 h after blast exposure. These levels did not change by day 21 in the control group but in the treatment group the level shifts began to decline at 24 h until by day 21 they were 10-20 dB below that of the controls. Loss of cochlear hair cells measured at 21 day after blast exposure was mostly in the outer hair cells (OHC) and broadly distributed across the basilar membrane, consistent with the distribution of loss of frequency responses as measured by ABR and DPOAE analysis and typical of blast-induced damage. OHC loss progressively increased after blast exposure reaching an average loss of 32% in the control group and 10% in the treated group at 21 days. These findings provide the first evidence that a combination of antioxidants, HPN-07 and NAC, can both enhance ITS recovery and prevent PTS by reducing damage to the mechanical and neural components of the auditory system when administered shortly after blast exposure. (C) 2012 Elsevier B.V. All rights reserved.	[Ewert, Donald L.; Lu, Jianzhong; Li, Wei; Du, Xiaoping; Kopke, Richard] Hough Ear Inst, Oklahoma City, OK 73112 USA; [Floyd, Robert; Kopke, Richard] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; [Kopke, Richard] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73014 USA; [Kopke, Richard] Univ Oklahoma, Hlth Sci Ctr, Dept Otolaryngol, Oklahoma City, OK 73014 USA		Kopke, R (corresponding author), Hough Ear Inst, 3400 NW 56th St, Oklahoma City, OK 73112 USA.	dewert@houghear.org; jlu@houghear.org; weili@houghear.org; Xiaoping.du@houghear.org; robert-floyd@omrf.org; rkopke@houghear.org			US Department of Navy, Office of Naval Research [N00014-09-1-0999]	The authors appreciate the efforts of Joel Young in the design and construction of the blast simulator and of Dr. Ning Hu and Dr. Charles Stewart and Weihua Cheng for their outstanding technical assistance. This research was supported by grant N00014-09-1-0999 from the US Department of Navy, Office of Naval Research.	Abi-Hachem Ralph N, 2010, Recent Pat CNS Drug Discov, V5, P147; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chait R H, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P9; Chavko M, 2009, SHOCK, V32, P325, DOI 10.1097/SHK.0b013e31819c38f1; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Choi CH, 2008, FREE RADICAL BIO MED, V44, P1772, DOI 10.1016/j.freeradbiomed.2008.02.005; Clausen F, 2008, J NEUROTRAUM, V25, P1449, DOI 10.1089/neu.2008.0585; Elsayed NM, 2003, TOXICOLOGY, V189, P63, DOI 10.1016/S0300-483X(03)00153-7; Elsayed NM, 2000, TOXICOLOGY, V155, P91, DOI 10.1016/S0300-483X(00)00281-X; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Floyd RA, 2008, FREE RADICAL BIO MED, V45, P1361, DOI 10.1016/j.freeradbiomed.2008.08.017; GARTH RJN, 1994, J LARYNGOL OTOL, V108, P925, DOI 10.1017/S0022215100128555; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Haase GM, 2011, AM J OTOLARYNG, V32, P55, DOI 10.1016/j.amjoto.2009.09.002; HAMERNIK RP, 1991, J ACOUST SOC AM, V90, P197, DOI 10.1121/1.402344; HAMERNIK RP, 1987, J ACOUST SOC AM, V81, P1118, DOI 10.1121/1.394632; Henderson D, 2006, EAR HEARING, V27, P1, DOI 10.1097/01.aud.0000191942.36672.f3; HENRY WR, 1995, HEARING RES, V84, P81, DOI 10.1016/0378-5955(95)00014-U; Hoffer M.E., 2010, NEUROTRAUMA LETT; JAFFIN JH, 1987, J TRAUMA, V27, P349, DOI 10.1097/00005373-198704000-00002; JENSEN JH, 1993, ACTA OTO-LARYNGOL, V113, P62, DOI 10.3109/00016489309135768; Kopke R, 2005, ACTA OTO-LARYNGOL, V125, P235, DOI 10.1080/00016480410023038; Kopke RD, 2007, HEARING RES, V226, P114, DOI 10.1016/j.heares.2006.10.008; Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lyden PD, 2007, STROKE, V38, P2262, DOI 10.1161/STROKEAHA.106.472746; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Nilsson D, 2007, J CLIN PHARMACOL, V47, P264, DOI 10.1177/0091270006293752; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P229, DOI 10.1159/000013846; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; PRICE GR, 1989, J ACOUST SOC AM, V85, P1245, DOI 10.1121/1.397455; Richmond D R, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P35; Roberto M, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P23; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; YLIKOSKI J, 1987, ACTA OTO-LARYNGOL, V103, P415	40	65	69	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0378-5955	1878-5891		HEARING RES	Hear. Res.	MAR	2012	285	1-2					29	39		10.1016/j.heares.2012.01.013			11	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	920WN	WOS:000302439600004	22326291				2022-02-06	
J	Gao, TL; Yuan, XT; Yang, D; Dai, HL; Wang, WJ; Peng, X; Shao, HJ; Jin, ZF; Fu, ZJ				Gao, Tie-Lei; Yuan, Xiang-Tian; Yang, Dan; Dai, Hai-Li; Wang, Wen-Jing; Peng, Xue; Shao, Hong-Jiang; Jin, Zhan-Feng; Fu, Zhi-Jun			Expression of HMGB1 and RAGE in rat and human brains after traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						HMGB1; RAGE; traumatic brain injury; brain	MOBILITY GROUP BOX-1; GENE-EXPRESSION; AMPHOTERIN; PROTEIN; CYTOKINE; ISCHEMIA; PATHWAY; CANCER; CELLS	BACKGROUND: Increasing evidence suggests that an inflammatory reaction contributes to the secondary brain injury that plays a critical role in the clinical outcome of patients with traumatic brain injury (TBI). Recently, high-mobility group box 1 (HMGB1) has been identified as a key cytokine in the inflammatory reaction and may represent a new target for the treatment of TBI. However, the expression of HMGB1 during this injury process has not yet been studied. METHODS: In this study, the levels of both HMGB1 and receptor for advanced glycation end products (RAGE) in the rat brain were analyzed by Western blot at different time points after TBI. Immunohistochemistry was also performed to examine the expression pattern of HMGB1 and RAGE in both the rat and the human brain after TBI. RESULTS: In the rat brain, HMGB1 levels significantly declined below the basal level at 6 hours after TBI and then gradually returned to the basal level 2 days later. RAGE expression increased 6 hours after TBI and reached its peak after 1 day; this level then slowly decreased but remained higher than the sham-injury group until 6 days after TBI. In both rat and human brains, HMGB1 either disappeared or was translocated from the nucleus to the cytoplasm at early stages after TBI and then was localized to the cytoplasm of phagocytic microglia at later stages. RAGE expression increased in the region surrounding the contused area after TBI in both rat and human brains. At later stages, RAGE was mainly expressed in microglia. CONCLUSION: HMGB1 is involved in both early and later stages after TBI. Targeting HMGB1 signaling may be a promising therapeutic approach for the treatment of TBI. (J Trauma. 2012; 72: 643-649. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Gao, Tie-Lei; Yang, Dan; Dai, Hai-Li; Wang, Wen-Jing; Peng, Xue; Shao, Hong-Jiang; Jin, Zhan-Feng] Harbin Med Coll, Dept Forens Med, Harbin 150081, Peoples R China; [Yuan, Xiang-Tian] Hulunbeier Municipal Publ Secur Bur, Res Inst Criminal Technol, Hulunbeier, Peoples R China		Jin, ZF (corresponding author), Harbin Med Coll, Dept Forens Med, 157th Bao Jian Rd, Harbin 150081, Peoples R China.	jinzf2003@yahoo.com.cn			211 Foundation at Harbin Medical University	Supported by a grant from the 211 Foundation at Harbin Medical University.	Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Huttunen HJ, 2004, J INTERN MED, V255, P351, DOI 10.1111/j.1365-2796.2003.01301.x; Karlsson S, 2008, INTENS CARE MED, V34, P1046, DOI 10.1007/s00134-008-1032-9; Kawabata H, 2010, SPINE, V35, P1109, DOI 10.1097/BRS.0b013e3181bd14b6; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Luan ZG, 2010, IMMUNOBIOLOGY, V215, P956, DOI 10.1016/j.imbio.2009.11.001; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552; Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005; Park JS, 2003, AM J PHYSIOL-CELL PH, V284, pC870, DOI 10.1152/ajpcell.00322.2002; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Yamada S, 2007, CLIN CHIM ACTA, V375, P36, DOI 10.1016/j.cca.2006.07.019; Yang QW, 2010, J CEREBR BLOOD F MET, V30, P243, DOI 10.1038/jcbfm.2009.202; Zhai DX, 2008, NEUROSCI LETT, V445, P117, DOI 10.1016/j.neulet.2008.08.077	25	65	67	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2012	72	3					643	649		10.1097/TA.0b013e31823c54a6			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	906TR	WOS:000301371100029	22491548				2022-02-06	
J	Chu, XP; Xiong, ZG				Chu, Xiang-Ping; Xiong, Zhi-Gang			Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System	CURRENT DRUG TARGETS			English	Article						Acid-sensing ion channel; acidosis; CNS; neuron; function; neurological disease	BRAIN PHENOBARBITAL UPTAKE; INDUCED NEURONAL DEATH; STATUS EPILEPTICUS; RETINAL FUNCTION; SENSORY NEURONS; EXTRACELLULAR ACIDOSIS; HIPPOCAMPAL-NEURONS; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; ACTIVATED CURRENTS	Protons are important signals for neuronal function. In the central nervous system (CNS), proton concentrations change locally when synaptic vesicles release their acidic contents into the synaptic cleft, and globally in ischemia, seizures, traumatic brain injury, and other neurological disorders due to lactic acid accumulation. The finding that protons gate a distinct family of ion channels, the acid-sensing ion channels (ASICs), has shed new light on the mechanism of acid signaling and acidosis-associated neuronal injury. Accumulating evidence has suggested that ASICs play important roles in physiological processes such as synaptic plasticity, learning/memory, fear conditioning, and retinal integrity, and in pathological conditions such as brain ischemia, multiple sclerosis, epileptic seizures, and malignant glioma. Thus, targeting these channels may lead to novel therapeutic interventions for neurological disorders. The goal of this review is to provide an update on recent advances in our understanding of the functions of ASICs in the CNS.	[Chu, Xiang-Ping] Univ Missouri, Sch Med, Dept Basic Med Sci, Kansas City, MO 64108 USA; [Xiong, Zhi-Gang] Anhui Med Univ, Sch Pharm, Hefei, Peoples R China; [Xiong, Zhi-Gang] Morehouse Sch Med, Dept Neurobiol, Atlanta, GA 30310 USA		Chu, XP (corresponding author), Univ Missouri, Sch Med, Dept Basic Med Sci, 2411 Holmes St, Kansas City, MO 64108 USA.	chux@umkc.edu; zxiong@msm.edu		Chu, Xiang-Ping/0000-0002-6781-0468	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS49470, R01NS47506]; American Heart AssociationAmerican Heart Association [0840132N, 0735092N]; University of Missouri Research Board; University of Missouri-Kansas City School of Medicine Start-up Funding; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047506, R01NS049470, R56NS047506] Funding Source: NIH RePORTER; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [S21MD000101] Funding Source: NIH RePORTER	The work in author's laboratories has been supported by National Institute of Health (R01NS49470 and R01NS47506 to Z-G Xiong), American Heart Association Established Investigator Award (0840132N to Z-G Xiong) and Scientist Development Grant (0735092N to X-P Chu), University of Missouri Research Board and University of Missouri-Kansas City School of Medicine Start-up Funding (X-P Chu).	Ali A, 2004, EPILEPSY BEHAV, V5, P322, DOI 10.1016/j.yebeh.2004.01.005; Ali A, 2006, PHARMACOL REP, V58, P242; Arias RL, 2008, NEUROBIOL DIS, V31, P334, DOI 10.1016/j.nbd.2008.05.008; Back T, 2000, ANN NEUROL, V47, P485, DOI 10.1002/1531-8249(200004)47:4<485::AID-ANA12>3.0.CO;2-8; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Benson CJ, 1999, CIRC RES, V84, P921; Benveniste M, 2005, NEW ENGL J MED, V352, P85, DOI 10.1056/NEJMcibr045010; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; Chang SY, 2007, SOC NEUR ABSTR, V257, P5; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1988, NEUROSCIENCE, V27, P941, DOI 10.1016/0306-4522(88)90197-2; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; Cho JH, 2008, J NEUROPHYSIOL, V99, P426, DOI 10.1152/jn.00940.2007; Coryell MW, 2007, BIOL PSYCHIAT, V62, P1140, DOI 10.1016/j.biopsych.2007.05.008; Coryell MW, 2009, J NEUROSCI, V29, P5381, DOI 10.1523/JNEUROSCI.0360-09.2009; Coryell MW, 2008, J NEUROSCI, V28, P13738, DOI 10.1523/JNEUROSCI.3907-08.2008; CROWELL JW, 1961, AM J PHYSIOL, V200, P743, DOI 10.1152/ajplegacy.1961.200.4.743; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; de la Rosa DA, 2003, J PHYSIOL-LONDON, V546, P77, DOI 10.1113/jphysiol.2002.030692; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Duan B, 2011, J NEUROSCI, V31, P2101, DOI 10.1523/JNEUROSCI.4351-10.2011; Dwyer JM, 2009, PSYCHOPHARMACOLOGY, V203, P41, DOI 10.1007/s00213-008-1373-7; Ettaiche M, 2004, J NEUROSCI, V24, P1005, DOI 10.1523/JNEUROSCI.4698-03.2004; Ettaiche M, 2006, J NEUROSCI, V26, P5800, DOI 10.1523/JNEUROSCI.0344-06.2006; Ettaiche M, 2009, INVEST OPHTH VIS SCI, V50, P2417, DOI 10.1167/iovs.08-3028; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; Gao J, 2005, NEURON, V48, P635, DOI 10.1016/j.neuron.2005.10.011; Gao J, 2004, BRAIN RES, V1017, P197, DOI 10.1016/j.brainres.2004.05.046; Gonzales EB, 2009, NATURE, V460, P599, DOI 10.1038/nature08218; GRANTYN R, 1989, DEV BRAIN RES, V49, P150, DOI 10.1016/0165-3806(89)90070-9; Grunder Stefan, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P73; Gu L, 2010, NEUROSCI LETT, V479, P63, DOI 10.1016/j.neulet.2010.05.029; Herrera Y, 2008, J PHARMACOL EXP THER, V327, P491, DOI 10.1124/jpet.108.143974; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Hu R, 2011, ANN SURG, V254, P353, DOI 10.1097/SLA.0b013e31822645b4; Huang YZ, 2004, CELL, V118, P665, DOI 10.1016/j.cell.2004.09.004; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Jetti SK, 2010, NITRIC OXIDE-BIOL CH, V22, P213, DOI 10.1016/j.niox.2009.12.006; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; Kapoor N, 2009, J BIOL CHEM, V284, P24526, DOI 10.1074/jbc.M109.037390; KOVALCHUK YN, 1990, NEUROSCI LETT, V115, P237, DOI 10.1016/0304-3940(90)90461-H; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; Li MH, 2010, J PHYSIOL-LONDON, V588, P3883, DOI 10.1113/jphysiol.2010.192922; Li MH, 2010, J CEREBR BLOOD F MET, V30, P1247, DOI 10.1038/jcbfm.2010.30; Lin WH, 2002, J NEUROPHYSIOL, V88, P133, DOI 10.1152/jn.2002.88.1.133; LJUNGGREN B, 1974, BRAIN RES, V77, P173, DOI 10.1016/0006-8993(74)90782-3; Mari Y, 2010, CELL CALCIUM, V48, P70, DOI 10.1016/j.ceca.2010.07.002; Maysami S., 2009, SOC NEUR ANN M, P2378; Meng QY, 2009, NEUROSCIENCE, V159, P1126, DOI 10.1016/j.neuroscience.2009.01.069; N'Gouemo P, 2008, BRAIN RES, V1222, P230, DOI 10.1016/j.brainres.2008.05.010; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; Page AJ, 2005, GUT, V54, P1408, DOI 10.1136/gut.2005.071084; PAPP LA, 1993, AM J PSYCHIAT, V150, P1149; Picloplichko VI, 2006, P NATL ACAD SCI USA, V103, P11376, DOI 10.1073/pnas.0600768103; Pignataro G, 2007, BRAIN, V130, P151, DOI 10.1093/brain/awl325; Pignataro Giuseppe, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P1; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; REHNCRONA S, 1985, ANN EMERG MED, V14, P770, DOI 10.1016/S0196-0644(85)80055-X; Render James A, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P69; Revici E., 1949, B I APPL BIOL, V1, P21; Samways DSK, 2009, CELL CALCIUM, V45, P319, DOI 10.1016/j.ceca.2008.12.002; Sherwood TW, 2011, J NEUROSCI, V31, P9723, DOI 10.1523/JNEUROSCI.1665-11.2011; Sherwood TW, 2009, J NEUROSCI, V29, P14371, DOI 10.1523/JNEUROSCI.2186-09.2009; Siesjo BK, 1996, ADV NEUROL, V71, P209; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SIMON RP, 1985, J PHARMACOL EXP THER, V234, P830; SIMON RP, 1987, J CEREBR BLOOD F MET, V7, P783, DOI 10.1038/jcbfm.1987.134; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Sluka KA, 2009, CURR OPIN DRUG DISC, V12, P693; SOMJEN GG, 1984, BRAIN RES, V311, P186, DOI 10.1016/0006-8993(84)91416-1; Stys PK, 1998, NEUROSCIENCE, V82, P21; Sutherland S P, 2000, Prog Brain Res, V129, P21; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TOMBAUGH GC, 1993, J NEUROCHEM, V61, P793, DOI 10.1111/j.1471-4159.1993.tb03589.x; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Ugawa S, 2003, J NEUROSCI, V23, P3616; Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709; Ugawa Shinya, 2003, Anatomical Science International, V78, P205, DOI 10.1046/j.0022-7722.2003.00062.x; URBANICS R, 1978, PFLUG ARCH EUR J PHY, V378, P47, DOI 10.1007/BF00581957; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; Vergo S, 2011, BRAIN, V134, P571, DOI 10.1093/brain/awq337; Vila-Carriles WH, 2006, J BIOL CHEM, V281, P19220, DOI 10.1074/jbc.M603100200; Voilley Nicolas, 2004, Current Drug Targets - Inflammation and Allergy, V3, P71, DOI 10.2174/1568010043483980; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Waxman SG, 2006, NAT REV NEUROSCI, V7, P932, DOI 10.1038/nrn2023; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Weng JY, 2010, J NEUROSCI, V30, P6548, DOI 10.1523/JNEUROSCI.0582-10.2010; Wong HK, 2008, HUM MOL GENET, V17, P3223, DOI 10.1093/hmg/ddn218; Wu LJ, 2004, J BIOL CHEM, V279, P43716, DOI 10.1074/jbc.M403557200; Wu WL, 2010, GENES BRAIN BEHAV, V9, P603, DOI 10.1111/j.1601-183X.2010.00591.x; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xiong ZG, 2007, FRONT BIOSCI-LANDMRK, V12, P1376, DOI 10.2741/2154; Xu TL, 2007, CURR MED CHEM, V14, P1753; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; Zha XM, 2006, P NATL ACAD SCI USA, V103, P16556, DOI 10.1073/pnas.0608018103; Zha XM, 2009, J NEUROSCI, V29, P8438, DOI 10.1523/JNEUROSCI.1284-09.2009; Ziemann AE, 2008, NAT NEUROSCI, V11, P816, DOI 10.1038/nn.2132; Ziemann AE, 2009, CELL, V139, P1012, DOI 10.1016/j.cell.2009.10.029	110	65	67	1	8	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-4501	1873-5592		CURR DRUG TARGETS	Curr. Drug Targets	FEB	2012	13	2					263	271		10.2174/138945012799201685			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	204ND	WOS:000323371100011	22204324	Green Accepted			2022-02-06	
J	Shrey, DW; Griesbach, GS; Giza, CC				Shrey, Daniel W.; Griesbach, Grace S.; Giza, Christopher C.			The Pathophysiology of Concussions in Youth	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Metabolic cascade; Activation; Plasticity; Pediatrics	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; LATERAL FLUID PERCUSSION; NEUROTROPHIC FACTOR EXPRESSION; CEREBRAL GLUCOSE-METABOLISM; CAVUM-SEPTUM-PELLUCIDUM; LONG-TERM ACCUMULATION; FACTOR MESSENGER-RNA; AXONAL INJURY; HEAD-INJURY	Mild traumatic brain injury, especially sport-related concussion, is common among young persons. Consequences of transient pathophysiologic dysfunction must be considered in the context of a developing or immature brain, as must the potential for an accumulation of damage with repeated exposure. This review summarizes the underlying neurometabolic cascade of concussion, with emphasis on the young brain in terms of acute pathophysiology, vulnerability, alterations in plasticity and activation, axonal injury, and cumulative risk from chronic, repetitive damage, and discusses their implications in the context of clinical care for the concussed youth, highlighting areas for future investigation.	[Shrey, Daniel W.; Giza, Christopher C.] Univ Calif Los Angeles, Mattel Childrens Hosp, David Geffen Sch Med, Div Pediat Neurol,Dept Pediat, Los Angeles, CA 90095 USA; [Griesbach, Grace S.; Giza, Christopher C.] Univ Calif Los Angeles, Dept Neurosurg, Brain Injury Res Ctr, Semel Inst,David Geffen Sch Med, Los Angeles, CA 90095 USA		Shrey, DW (corresponding author), Univ Calif Los Angeles, Mattel Childrens Hosp, David Geffen Sch Med, Div Pediat Neurol,Dept Pediat, Room 22-474 MDCC,10833 Le Conte Blvd, Los Angeles, CA 90095 USA.	dshrey@mednet.ucla.edu		Shrey, Daniel/0000-0002-3163-4773	Child Neurology Foundation/Winokur Family Foundation; Today's and Tomorrow's Children Fund; UCLA Brain Injury Research Center;  [NS27544];  [NS057420];  [NS06190]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, R01NS061960, K02NS057420] Funding Source: NIH RePORTER	This work was supported by: NS27544, NS057420, NS06190, the Child Neurology Foundation/Winokur Family Foundation, the Today's and Tomorrow's Children Fund, and the UCLA Brain Injury Research Center.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Appel SH, 2010, MUSCLE NERVE, V42, P851, DOI 10.1002/mus.21939; Armon C, 2011, J NEUROPATH EXP NEUR, V70, P97, DOI 10.1097/01.JNEN.0000392910.86750.32; Ashman TA, 2006, MT SINAI J MED, V73, P999; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Avital A, 2005, INT J NEUROPSYCHOPH, V8, P163, DOI 10.1017/S1461145704004808; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burek MJ, 1996, BRAIN PATHOL, V6, P427, DOI 10.1111/j.1750-3639.1996.tb00874.x; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001; Castelli DM, 2007, J SPORT EXERCISE PSY, V29, P239, DOI 10.1123/jsep.29.2.239; CATSICAS S, 1987, P NATL ACAD SCI USA, V84, P8165, DOI 10.1073/pnas.84.22.8165; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chaddock L, 2011, MED SCI SPORT EXER, V43, P344, DOI 10.1249/MSS.0b013e3181e9af48; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Cribbs DH, 1996, NEUROREPORT, V7, P1773, DOI 10.1097/00001756-199607290-00016; Dalsgaard MK, 2004, J APPL PHYSIOL, V97, P1733, DOI 10.1152/japplphysiol.00450.2004; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Davis CL, 2007, RES Q EXERCISE SPORT, V78, P510, DOI 10.5641/193250307X13082512817660; Desmurget M, 2007, BRAIN, V130, P898, DOI 10.1093/brain/awl300; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; Dinner Dudley S., 1993, P654; Dishman RK, 2000, BRAIN RES BULL, V52, P337, DOI 10.1016/S0361-9230(00)00271-9; Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46; DOBERSTEIN CE, 1993, ANN EMERG MED, V22, P993, DOI 10.1016/S0196-0644(05)82740-4; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; Ekeland E., 2004, COCHRANE DATABASE SY; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Field AS, 2003, AM J NEURORADIOL, V24, P1461; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; GomezPinilla F, 1997, BRAIN RES, V764, P1, DOI 10.1016/S0006-8993(97)00375-2; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hansson AC, 2000, EUR J NEUROSCI, V12, P2918, DOI 10.1046/j.1460-9568.2000.00185.x; Hansson AC, 2006, J NEUROENDOCRINOL, V18, P104, DOI 10.1111/j.1365-2826.2005.01390.x; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hillman CH, 2009, NEUROSCIENCE, V159, P1044, DOI 10.1016/j.neuroscience.2009.01.057; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hovda D.A., 1996, NEUROTRAUMA, P1459; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Ivanco TL, 2000, NEUROPHARMACOLOGY, V39, P765, DOI 10.1016/S0028-3908(00)00004-6; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Johnson KL, 2006, AACN ADV CRIT CARE, V17, P39, DOI 10.1097/00044067-200601000-00006; Johnson MH, 2005, DEV PSYCHOBIOL, V46, P287, DOI 10.1002/dev.20057; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kalimo H, 1981, Acta Neuropathol Suppl, V7, P20; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kesslak JP, 1998, BEHAV NEUROSCI, V112, P1012, DOI 10.1037/0735-7044.112.4.1012; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Koseoglu E, 2003, CEPHALALGIA, V23, P972, DOI 10.1046/j.1468-2982.2003.00624.x; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lein ES, 2000, J NEUROSCI, V20, P1470; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LOCKETT DMC, 1992, HEADACHE, V32, P50, DOI 10.1111/j.1526-4610.1992.hed3201050.x; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161; Merom D, 2008, J ANXIETY DISORD, V22, P959, DOI 10.1016/j.janxdis.2007.09.010; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Pryce CR, 2005, NEUROSCI BIOBEHAV R, V29, P649, DOI 10.1016/j.neubiorev.2005.03.011; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; Salin P, 1995, J NEUROSCI, V15, P8234; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; SCHOUPS AA, 1995, DEV BRAIN RES, V86, P326, DOI 10.1016/0165-3806(95)00043-D; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; SILBERT PL, 1993, J NEUROL NEUROSUR PS, V56, P820, DOI 10.1136/jnnp.56.7.820; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Smits JAJ, 2008, DEPRESS ANXIETY, V25, P689, DOI 10.1002/da.20411; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Takei N, 1997, J NEUROCHEM, V68, P370; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Topolnik L, 2003, EUR J NEUROSCI, V18, P486, DOI 10.1046/j.1460-9568.2003.02742.x; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wipfli BM, 2008, J SPORT EXERCISE PSY, V30, P392, DOI 10.1123/jsep.30.4.392; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; ZAFRA F, 1992, J NEUROSCI, V12, P4793; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399; Zhou JW, 1996, DEV BRAIN RES, V97, P297, DOI 10.1016/S0165-3806(96)00159-9	217	65	69	0	30	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	NOV	2011	22	4					577	+		10.1016/j.pmr.2011.08.002			27	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	858SI	WOS:000297822600003	22050937	Green Accepted			2022-02-06	
J	Dash, PK; Johnson, D; Clark, J; Orsi, SA; Zhang, M; Zhao, J; Grill, RJ; Moore, AN; Pati, S				Dash, Pramod K.; Johnson, Daniel; Clark, Jordan; Orsi, Sara A.; Zhang, Min; Zhao, Jing; Grill, Raymond J.; Moore, Anthony N.; Pati, Shibani			Involvement of the Glycogen Synthase Kinase-3 Signaling Pathway in TBI Pathology and Neurocognitive Outcome	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; SPATIAL MEMORY DEFICITS; N-ACETYL-ASPARTATE; INCREASED PHOSPHORYLATION; CHRONIC LITHIUM; NEURONAL DEATH; VALPROIC ACID; GRANULE CELLS; IN-VIVO	Background: Traumatic brain injury (TBI) sets in motion cascades of biochemical changes that result in delayed cell death and altered neuronal architecture. Studies have demonstrated that inhibition of glycogen synthase kinase-3 (GSK-3) effectively reduces apoptosis following a number of stimuli. The Wnt family of proteins, and growth factors are two major factors that regulate GSK-3 activity. In the absence of stimuli, GSK-3 is constitutively active and is complexed with Axin, adenomatous polyposis coli (APC), and casein kinase I alpha (CK1 alpha) and phosphorylates ss-Catenin leading to its degradation. Binding of Wnt to Frizzled receptors causes the translocation of GSK-3 to the plasma membrane, where it phosphorylates and inactivates the Frizzled co-receptor lipoprotein-related protein 6 (LRP6). Furthermore, the translocation of GSK-3 reduces ss-Catenin phosphorylation and degradation, leading to ss-Catenin accumulation and gene expression. Growth factors activate Akt, which in turn inhibits GSK-3 activity by direct phosphorylation, leading to a reduction in apoptosis. Methodology/Principal Findings: Using a rodent model, we found that TBI caused a rapid, but transient, increase in LRP6 phosphorylation that is followed by a modest decrease in ss-Catenin phosphorylation. Phospho-GSK-3 beta immunoreactivity was found to increase three days post injury, a time point at which increased Akt activity following TBI has been observed. Lithium influences several neurochemical cascades, including inhibiting GSK-3. When the efficacy of daily lithium was assessed, reduced hippocampal neuronal cell loss and learning and memory improvements were observed. These influences were partially mimicked by administration of the GSK-3-selective inhibitor SB-216763, as this drug resulted in improved motor function, but only a modest improvement in memory retention and no overt neuroprotection. Conclusion/Significance: Taken together, our findings suggest that selective inhibition of GSK-3 may offer partial cognitive improvement. As a broad spectrum inhibitor of GSK-3, lithium offers neuroprotection and robust cognitive improvement, supporting its clinical testing as a treatment for TBI.	[Dash, Pramod K.; Johnson, Daniel; Clark, Jordan; Orsi, Sara A.; Zhang, Min; Zhao, Jing; Moore, Anthony N.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrated Biol & Pharmacol, Houston, TX USA; [Pati, Shibani] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX USA		Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX USA.	P.Dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0134, W81XWH-08-2-0150]	This research was made possible by funding support from the Department of Defense (W81XWH-08-2-0134 and W81XWH-08-2-0150). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aghdam SY, 2007, CURR ALZHEIMER RES, V4, P21; ATACK JR, 1992, J NEUROCHEM, V59, P1946, DOI 10.1111/j.1471-4159.1992.tb11031.x; Beurel E, 2006, PROG NEUROBIOL, V79, P173, DOI 10.1016/j.pneurobio.2006.07.006; Castro AA, 2009, PEPTIDES, V30, P1914, DOI 10.1016/j.peptides.2009.07.004; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Davidson G, 2010, TRENDS CELL BIOL, V20, P453, DOI 10.1016/j.tcb.2010.05.002; de Sousa RT, 2011, NEUROSCI LETT, V494, P54, DOI 10.1016/j.neulet.2011.02.054; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Drevets WC, 2001, CURR OPIN NEUROBIOL, V11, P240, DOI 10.1016/S0959-4388(00)00203-8; Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056; Facci L, 2003, NEUROREPORT, V14, P1467, DOI 10.1097/00001756-200308060-00012; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Feng HL, 2008, NEUROSCIENCE, V155, P567, DOI 10.1016/j.neuroscience.2008.06.040; Fukumoto T, 2001, PSYCHOPHARMACOLOGY, V158, P100, DOI 10.1007/s002130100871; Grandjean EM, 2009, CNS DRUGS, V23, P397, DOI 10.2165/00023210-200923050-00004; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Haddad PM, 2009, EXPERT OPIN DRUG MET, V5, P539, DOI [10.1517/17425250902911455 , 10.1517/17425250902911455]; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hashimoto R, 2002, J NEUROCHEM, V80, P589, DOI 10.1046/j.0022-3042.2001.00728.x; Hayes RL, 1998, DRUG NEWS PERSPECT, V11, P215; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Hu SX, 2009, NEUROBIOL DIS, V33, P193, DOI 10.1016/j.nbd.2008.10.007; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Lin D, 2006, CNS DRUGS, V20, P29, DOI 10.2165/00023210-200620010-00003; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Miller JS, 2010, BRAIN RES BULL, V82, P184, DOI 10.1016/j.brainresbull.2010.03.005; Moore GJ, 2000, LANCET, V356, P1241, DOI 10.1016/S0140-6736(00)02793-8; Moore GJ, 2000, BIOL PSYCHIAT, V48, P1, DOI 10.1016/S0006-3223(00)00252-3; Mora A, 2001, J NEUROCHEM, V78, P199, DOI 10.1046/j.1471-4159.2001.00410.x; Neary JT, 2006, J NEUROSCI RES, V84, P515, DOI 10.1002/jnr.20969; Niehrs C, 2010, CELL MOL LIFE SCI, V67, P2551, DOI 10.1007/s00018-010-0329-3; Perez M, 2003, BIOCHEM J, V372, P129, DOI 10.1042/BJ20021596; Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046; Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Silverstone PH, 2003, INT CLIN PSYCHOPHARM, V18, P73, DOI 10.1097/00004850-200303000-00002; Soutar MPM, 2010, J NEUROCHEM, V115, P974, DOI 10.1111/j.1471-4159.2010.06988.x; Spiegelberg BD, 1999, J BIOL CHEM, V274, P13619, DOI 10.1074/jbc.274.19.13619; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Sullivan PG, 1999, J NEUROSCI, V19, P6248; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takadera T, 2004, EUR J PHARMACOL, V499, P239, DOI 10.1016/j.ejphar.2004.07.115; Takadera T, 2004, BRAIN RES, V1020, P196, DOI 10.1016/j.brainres.2004.06.035; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; WRAAE O, 1978, BRIT J PHARMACOL, V64, P273, DOI 10.1111/j.1476-5381.1978.tb17300.x; Wu G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004926; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Zhang F, 2003, J BIOL CHEM, V278, P33067, DOI 10.1074/jbc.M212635200; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	70	65	69	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2011	6	9							e24648	10.1371/journal.pone.0024648			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822JR	WOS:000295041700046	21935433	Green Submitted, Green Published, gold			2022-02-06	
J	Ponsford, J; McLaren, A; Schonberger, M; Burke, R; Rudzki, D; Olver, J; Ponsford, M				Ponsford, Jennie; McLaren, Anna; Schoenberger, Michael; Burke, Richard; Rudzki, Dion; Olver, John; Ponsford, Michael			The Association between Apolipoprotein E and Traumatic Brain Injury Severity and Functional Outcome in a Rehabilitation Sample	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; outcome; traumatic brain injury	AMYLOID BETA-PROTEIN; HEAD-INJURY; APOE GENOTYPE; ALZHEIMERS-DISEASE; E EPSILON-4; E POLYMORPHISM; POSTTRAUMATIC SEIZURES; APOE-EPSILON-4 ALLELE; INFLAMMATORY RESPONSE; EARLY-STAGE	Traumatic brain injury (TBI) can result in significant disability, but outcome is variable. The impact of known predictors accounts for a limited proportion of the variance in outcomes. Apolipoprotein E (ApoE) genotype has been investigated as an additional source of variability in injury severity and outcome, with mixed findings reflecting variable methodology and generally limited sample sizes. This study aimed to examine whether possession of the ApoE epsilon 4 allele was associated with greater acute injury severity and poorer long-term outcome in patients referred for rehabilitation following TBI. ApoE genotype was determined for 648 patients with TBI, who were prospectively followed up a mean of 1.9 years post-injury. Hypotheses that epsilon 4 carriers would have lower Glasgow Coma Scale (GCS) scores and longer post-traumatic amnesia (PTA) duration were not supported. Prediction of worse Glasgow Outcome Scale-Extended (GOSE) scores for epsilon 4 carriers was supported with greater susceptibility seen in females. These results indicate the ApoE epsilon 4 allele may be associated with poorer long-term outcome, but not acute injury severity. Possible mechanisms include differential effects of the epsilon 4 allele on inflammatory and cellular repair processes, and/or amyloid deposition.	[Ponsford, Jennie; McLaren, Anna; Rudzki, Dion] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie; Olver, John; Ponsford, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, Freiburg, Germany; [Burke, Richard] Monash Univ, Sch Biol Sci, Melbourne, Vic 3004, Australia; [Olver, John] Monash Univ, Fac Med, Melbourne, Vic 3004, Australia		Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au		Burke, Richard/0000-0003-0086-0767; Olver, John/0000-0001-7069-1191	Victorian Neurotrauma Initiative; Transport Accident Commission	This study was supported by the Victorian Neurotrauma Initiative and the Transport Accident Commission.	ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Anderson GD, 2009, EPILEPSY BEHAV, V16, P501, DOI 10.1016/j.yebeh.2009.08.025; Aoki K, 2003, STROKE, V34, P875, DOI 10.1161/01.STR.0000064320.73388.C6; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Hiekikanen H, 2007, BRAIN INJURY, V21, P1307, DOI 10.1080/02699050701739549; Hoe HS, 2006, J BIOL CHEM, V281, P3425, DOI 10.1074/jbc.M509380200; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Jiang Y, 2008, ACTA NEUROCHIR SUPPL, V105, P233; Jiang Y, 2007, J NEUROTRAUM, V24, P1802, DOI 10.1089/neu.2007.0299; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Kraus J. F., 1999, REHABILITATION ADULT, P3; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Macfarlane DP, 1999, NEUROREPORT, V10, P3945, DOI 10.1097/00001756-199912160-00040; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Maysinger D, 2008, J NEUROSCI, V28, P7891, DOI 10.1523/JNEUROSCI.1461-08.2008; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Michikawa M, 1999, MECH AGEING DEV, V107, P233, DOI 10.1016/S0047-6374(98)00134-1; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Shea TB, 2002, FREE RADICAL BIO MED, V33, P1115, DOI 10.1016/S0891-5849(02)01001-8; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Willemse-Van Son AHP, 2008, J NEUROL NEUROSUR PS, V79, P426, DOI 10.1136/jnnp.2007.129460; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	78	65	67	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1683	1692		10.1089/neu.2010.1623			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000001	21651315				2022-02-06	
J	Salinsky, M; Spencer, D; Boudreau, E; Ferguson, F				Salinsky, Martin; Spencer, David; Boudreau, Eilis; Ferguson, Felicia			Psychogenic nonepileptic seizures in US veterans	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; EPILEPSY; DIAGNOSIS; DISORDER	Objectives: Psychogenic nonepileptic seizures (PNES) are frequently encountered in epilepsy monitoring units (EMU) and can result in significant long-term disability. We reviewed our experience with veterans undergoing seizure evaluation in the EMU to determine the time delay to diagnosis of PNES, the frequency of PNES, and cumulative antiepileptic drug (AED) treatment. We compared veterans with PNES to civilians with PNES studied in the same EMU. Methods: We reviewed records of all patients admitted to one Veterans Affairs Medical Center (VAMC) EMU over a 10-year interval. These patients included 203 veterans and 726 civilians from the university affiliate. The percentage of patients with PNES was calculated for the veteran and civilian groups. Fifty veterans with only PNES were identified. Each veteran with PNES was matched to the next civilian patient with PNES. The 2 groups were compared for interval from onset of the habitual spells to EMU diagnosis, cumulative AED treatment, and other measures. Results: PNES were identified in 25% of veterans and 26% of civilians admitted to the EMU. The delay from onset of spells to EMU diagnosis averaged 60.5 months for veterans and 12.5 months for civilians (p < 0.001). Cumulative AED treatment was 4 times greater for veterans with PNES as compared to civilians (p < 0.01). Fifty-eight percent of veterans with PNES were thought to have seizures related to traumatic brain injury. Conclusions: The results indicate a substantial delay in the diagnosis of PNES in veterans as compared to civilians. The delay is associated with greater cumulative AED treatment. Neurology (R) 2011;77:945-950	Portland VA Med Ctr, Portland, OR USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA		Salinsky, M (corresponding author), 3181 SW Sam Jackson Pk Rd,CR-120, Portland, OR 97239 USA.	Salinsky@ohsu.edu		Spencer, David/0000-0001-9751-235X	NIH (NIDA, NIAAA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Dr. Salinsky serves on speakers' bureaus for UCB and Pfizer Inc and has served on scientific advisory boards for and received honoraria from Medtronic, Inc., Cyberonics Inc., and Lundbeck Inc. Dr. Spencer has served on the speakers' bureau of and received honoraria from UCB; serves as Patient Page Editor for Neurology (R), Chief Editor for EMedicine, Associate Editor for the Journal of Behavior and Brain Science, and on the Professional Advisory Board for Neurology Now; has received research support from NeuroPace, Inc.; and holds stock in StemCells, Inc. Dr. Boudreau serves on the editorial board of Aviation, Space, and Environmental Medicine; and has received research support from the NIH (NIDA, NIAAA). Dr. Ferguson reports no disclosures.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; Benbadis SR, 1999, EUR NEUROL, V41, P114, DOI 10.1159/000008015; Benbadis SR, 2004, EPILEPSIA, V45, P1150, DOI 10.1111/j.0013-9580.2004.14504.x; Bowman ES, 1996, AM J PSYCHIAT, V153, P57; Buchanan N, 1993, Seizure, V2, P141, DOI 10.1016/S1059-1311(05)80119-0; *COMM GULF WAR HLT, 2009, GULF WAR HLTH, V7, P7; D'Alessio L, 2006, SEIZURE-EUR J EPILEP, V15, P333, DOI 10.1016/j.seizure.2006.04.003; Dworetzky BA, 2005, EPILEPSIA, V46, P1418, DOI 10.1111/j.1528-1167.2005.13004.x; Ettinger AB, 1999, EPILEPSIA, V40, P1292, DOI 10.1111/j.1528-1157.1999.tb00860.x; Goldstein LH, 2010, NEUROLOGY, V74, P1986, DOI 10.1212/WNL.0b013e3181e39658; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Kanner AM, 1999, NEUROLOGY, V53, P933, DOI 10.1212/WNL.53.5.933; LaFrance WC, 2006, EPILEPSY BEHAV, V8, P451, DOI 10.1016/j.yebeh.2006.02.004; LEMPERT T, 1990, J NEUROL, V237, P35, DOI 10.1007/BF00319665; Martin R, 2003, NEUROLOGY, V61, P1791, DOI 10.1212/01.WNL.0000098890.13946.F5; Martin RC, 1998, SEIZURE-EUR J EPILEP, V7, P385, DOI 10.1016/S1059-1311(05)80007-X; McKenzie P, 2010, NEUROLOGY, V74, P64, DOI 10.1212/WNL.0b013e3181c7da6a; PIERELLI F, 1989, EPILEPSIA, V30, P513, DOI 10.1111/j.1528-1157.1989.tb05465.x; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Reuber M, 2003, ANN NEUROL, V53, P305, DOI 10.1002/ana.3000; Rosenberg HJ, 2000, EPILEPSIA, V41, P447, DOI 10.1111/j.1528-1157.2000.tb00187.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Selwa LM, 2000, EPILEPSIA, V41, P1330, DOI 10.1111/j.1528-1157.2000.tb04613.x; vanMerode T, 1997, SEIZURE, V6, P311; WALCZAK TS, 1995, EPILEPSIA, V36, P1131, DOI 10.1111/j.1528-1157.1995.tb00472.x; Westbrook LE, 1998, EPILEPSIA, V39, P978, DOI 10.1111/j.1528-1157.1998.tb01447.x	28	65	65	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP	2011	77	10					945	950		10.1212/WNL.0b013e31822cfc46			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	815PR	WOS:000294538100011	21893668				2022-02-06	
J	Sookplung, P; Siriussawakul, A; Malakouti, A; Sharma, D; Wang, J; Souter, MJ; Chesnut, RM; Vavilala, MS				Sookplung, Pimwan; Siriussawakul, Arunotai; Malakouti, Amin; Sharma, Deepak; Wang, Jin; Souter, Michael J.; Chesnut, Randall M.; Vavilala, Monica S.			Vasopressor Use and Effect on Blood Pressure After Severe Adult Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Vasopressor; Phenylephrine; Norepinephrine; Dopamine; Cerebral perfusion pressure	CEREBRAL PERFUSION-PRESSURE; CORTICAL PERFUSION; TISSUE OXYGENATION; UNITED-STATES; NOREPINEPHRINE; DOPAMINE; MANAGEMENT; AUTOREGULATION; RESUSCITATION; PHENYLEPHRINE	We describe institutional vasopressor usage, and examine the effect of vasopressors on hemodynamics: heart rate (HR), mean arterial blood pressure (MAP), intracranial pressure (ICP), cerebral perfusion pressure (CPP), brain tissue oxygenation (PbtO(2)), and jugular venous oximetry (SjVO(2)) in adults with severe traumatic brain injury (TBI). We performed a retrospective analysis of 114 severely head injured patients who were admitted to the neurocritical care unit of Level 1 trauma center and who received vasopressors (phenylephrine, norepinephrine, dopamine, vasopressin or epinephrine) to increase blood pressure Phenylephrine was the most commonly used vasopressor (43%), followed by norepinephrine (30%), dopamine (22%), and vasopressin (5%). Adjusted for age, gender, injury severity score, vasopressor dose, baseline blood pressure, fluid administration, propofol sedation, and hypertonic saline infusion, phenylephrine use was associated with 8 mmHg higher mean arterial pressure (MAP) than dopamine (P = 0.03), and 12 mmHg higher cerebral perfusion pressure (CPP) than norepinephrine (P = 0.02) during the 3 h after vasopressor start. There was no difference in ICP between the drug groups, either at baseline or after vasopressor treatment. Most severe TBI patients received phenylephrine. Patients who received phenylephrine had higher MAP and CPP than patients who received dopamine and norepinephrine, respectively.	[Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pediat, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Sookplung, Pimwan; Siriussawakul, Arunotai; Malakouti, Amin; Sharma, Deepak; Souter, Michael J.; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA		Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol & Pediat, 325 Ninth Ave,Box 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu	Souter, Michael/ABE-1890-2020	Chesnut, Randall/0000-0001-6377-3666	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS072308-01, R01 NS072308] Funding Source: Medline		Beaumont A, 2001, J NEUROTRAUM, V18, P1359, DOI 10.1089/08977150152725650; BEVAN JA, 1987, FASEB J, V1, P193; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Drummond JC, 1994, ANESTHESIA, P689; Dudkiewicz M, 2008, CRIT CARE MED, V36, P2641, DOI 10.1097/CCM.0b013e3181847af3; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Guimaraes S, 2001, PHARMACOL REV, V53, P319; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; STARKE K, 1981, J CARDIOVASC PHARM, V3, pS14, DOI 10.1097/00005344-198100031-00002; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Stubbe HD, 2006, CRIT CARE MED, V34, P2651, DOI 10.1097/01.CCM.0000239196.17999.B7; Vavilala Monica S, 2002, Anesthesiol Clin North Am, V20, P247, DOI 10.1016/S0889-8537(01)00012-8	28	65	67	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2011	15	1					46	54		10.1007/s12028-010-9448-9			9	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	789XI	WOS:000292552100008	20878264	Green Accepted			2022-02-06	
J	Washington, CW; Schuerer, DJE; Grubb, RL				Washington, Chad W.; Schuerer, Douglas J. E.; Grubb, Robert L., Jr.			Platelet Transfusion: An Unnecessary Risk for Mild Traumatic Brain Injury Patients on Antiplatelet Therapy	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Platelet transfusion; Antiplatelet therapy	INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; ELDERLY-PATIENTS; HEAD-INJURY; CLOPIDOGREL; MORTALITY; IMPACT; CLASSIFICATION; PREDICTORS; OUTCOMES	Introduction: To determine whether there is a benefit to platelet transfusion in mild traumatic brain injury (MTBI) patients with intracranial hemorrhage (ICH), taking antiplatelet therapy before hospitalization. Materials and Methods: The study design retrospectively reviewed patients admitted to a Level I trauma center during a 2-year period with an isolated MTBI (Glasgow Coma Scale score >= 13, ICH seen on a head computed tomographic scan (head computed tomography [HCT]), and taking an antiplatelet agent before hospitalization. HCT's were categorized based on the Marshall Classification, Rotterdam Score, and ICH volume. Hospital records were reviewed noting neurologic, cardiac, respiratory events, and discharge Glasgow Outcome Scale. Results: There were 1,101 patients with TBI hospitalized during the 2-year study period. Three hundred twenty-one of these patients had an MTBI with ICH at the time of admission, and from this group, 113 were taking an antiplatelet agent. Only 4 (1.2%) of the 321 patients suffered a neurologic decline. All were gradual in nature, and none required emergent intervention. An analysis of the 113 patients taking antiplatelet agents, comparing patients who were not given a platelet transfusion with those who received a platelet transfusion, found no significant difference in the rate of HCT progression, neurologic decline, or Glasgow Outcome Scale at hospital discharge between the two groups. There was a trend, which was not significant, toward more medical declines in patients who received a platelet transfusion. A further review, analyzing all 321 patients with ICH showed receiving a transfusion of any type (i.e., platelets, fresh frozen plasma, or blood) was a strong predictor of medical decline (p < 0.0001). The odds ratio of having a medical decline after transfusion was 5.8 (95% confidence interval, 1.2-28.2). Conclusions: Platelet transfusion did not improve short-term outcomes after MTBI. Further randomized controlled trials need to be done to truly assess if there is no benefit in platelet transfusion in patients taking antiplatelet agents suffering an MTBI. Because the overall outcome in MTBI patients is favorable, platelet transfusion in these patients may not be indicated.	[Washington, Chad W.; Grubb, Robert L., Jr.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA; [Schuerer, Douglas J. E.] Washington Univ, Sch Med, Div Gen Surg, Sect Acute & Crit Care Surg, St Louis, MO 63110 USA		Washington, CW (corresponding author), Washington Univ, Sch Med, Dept Neurol Surg, 660 S Euclid Ave,Campus Box 8057, St Louis, MO 63110 USA.	washingtonc@wudosis.wustl.edu					Ajani UA, 2006, AM J PREV MED, V30, P74, DOI 10.1016/j.amepre.2005.08.042; Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Albaladejo P, 2010, BEST PRACT RES-CLIN, V24, P41, DOI 10.1016/j.bpa.2009.09.008; Benson AB, 2009, BRIT J HAEMATOL, V147, P431, DOI 10.1111/j.1365-2141.2009.07840.x; Cesar J, 2009, PLATELETS, V20, P158, DOI 10.1080/09537100902751925; Control NCfIPa, 2003, REP C MILD TRAUM BRA; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; Downey DM, 2009, AM SURGEON, V75, P1100; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Naidech AM, 2009, STROKE, V40, P2398, DOI 10.1161/STROKEAHA.109.550939; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; Spiess BD, 2010, BEST PRACT RES-CLIN, V24, P65, DOI 10.1016/j.bpa.2009.11.001; TEASDALE G, 1974, LANCET, V2, P81; Vilahur G, 2007, J THROMB HAEMOST, V5, P82, DOI 10.1111/j.1538-7836.2006.02245.x; 2010, 10 LEADING CAUSES DE	25	65	65	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2011	71	2					358	363		10.1097/TA.0b013e318220ad7e			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	806XH	WOS:000293850200031	21825939				2022-02-06	
J	Guresir, E; Vatter, H; Schuss, P; Oszvald, A; Raabe, A; Seifert, V; Beck, J				Gueresir, Erdem; Vatter, Hartmut; Schuss, Patrick; Oszvald, Agi; Raabe, Andreas; Seifert, Volker; Beck, Juergen			Rapid closure technique in decompressive craniectomy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; duraplasty; subarachnoid hemorrhage; intracerebral hemorrhage; cerebral infarction; brain swelling	MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; INTRACRANIAL HYPERTENSION; SUBARACHNOID HEMORRHAGE; MALIGNANT INFARCTION; DURAL CLOSURE; HEAD-INJURY; HEMICRANIECTOMY; MULTICENTER; SURGERY	Object. The object of this study was to describe the rapid closure technique in decompressive craniectomy without duraplasty and its use in a large cohort of consecutive patients. Methods. Between 1999 and 2008, supratentorial rapid closure decompressive craniectomy (RCDC) was performed 341 times in 318 patients at the authors' institution. Cases were stratified as 1) traumatic brain injury, 2) subarachnoid hemorrhage, 3) intracerebral hemorrhage, 4) cerebral infarction, and 5) other. A large bone flap was removed and the dura mater was opened in a stellate fashion. Duraplasty was not performed that is, the dura was not sutured, and a dural substitute was neither sutured in nor layed on. The dura and exposed brain tissue were covered with hemostyptic material (Surgicel). Surgical time and complications of this procedure including follow-up (> 6 months) were recorded. After 3-6 months cranioplasty was performed, and, again, surgical time and any complications were recorded. Results. Rapid closure decompressive craniectomy was feasible in all cases. Complications included superficial wound healing disturbance (3.5% of procedures), abscess (2.6%) and CSF fistula (0.6%); the mean surgical time (+/- SD) was 69 +/- 20 minutes. Cranioplasty was performed in 196 cases; the mean interval (+/- SD) from craniectomy to cranioplasty was 118 +/- 40 days. Complications of cranioplasty included epidural hematoma (4.1%), abscess (2.6%), wound healing disturbance (6.1%), and CSF fistula (1%). Compared with the results reported in the literature for decompressive craniectomy with duraplasty followed by cranioplasty, there were no significant differences in the frequency of complications. However, surgical time for RCDC was significantly shorter (69 +/- 20 vs 129 +/- 43 minutes, p < 0.0001). Conclusions. The present analysis of the largest series reported to date reveals that the rapid closure technique is feasible and safe in decompressive craniectomy. The surgical time is significantly shorter without increased complication rates or additional complications. Cranioplasty after a RCDC procedure was also feasible, fast, safe and not impaired by the RCDC technique. (DOI: 10.3171/2009.12.JNS091065)	[Gueresir, Erdem; Vatter, Hartmut; Schuss, Patrick; Oszvald, Agi; Raabe, Andreas; Seifert, Volker; Beck, Juergen] Goethe Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany		Guresir, E (corresponding author), Goethe Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	Gueresir@em.uni-frankfurt.de	Guresir, Erdem/AAL-4484-2020; Schuss, Patrick/ABC-6469-2020; Guresir, Erdem/AAV-7224-2021	Schuss, Patrick/0000-0002-5806-2576; Guresir, Erdem/0000-0001-8319-0847; Guresir, Agi/0000-0003-1492-5461; Beck, Jurgen/0000-0002-7687-6098			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Barth M, 2008, NEUROSURGERY, V63, P352, DOI 10.1227/01.NEU.0000310696.52302.99; Beck J, 2006, J NEUROSURG, V105, P220, DOI 10.3171/jns.2006.105.2.220; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Guresir E, 2008, NEUROSURGERY, V63, P1088, DOI 10.1227/01.NEU.0000335170.76722.B9; Horaczek JA, 2008, NEUROSURGERY, V63, P176, DOI 10.1227/01.NEU.0000312707.25073.CB; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Ko K, 2007, NEUROSURGERY, V60, P255, DOI 10.1227/01.NEU.0000255380.64969.81; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Malliti M, 2004, NEUROSURGERY, V54, P599, DOI 10.1227/01.NEU.0000108640.45371.1A; Marion DW, 2006, NEUROSURGERY, V58, P655; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9	19	65	67	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2011	114	4					954	960		10.3171/2009.12.JNS091065			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	739NW	WOS:000288725900014	20113157				2022-02-06	
J	Khuman, J; Meehan, WP; Zhu, XX; Qiu, JH; Hoffmann, U; Zhang, J; Giovannone, E; Lo, EH; Whalen, MJ				Khuman, Jugta; Meehan, William P., III; Zhu, Xiaoxia; Qiu, Jianhua; Hoffmann, Ulrike; Zhang, Jimmy; Giovannone, Eric; Lo, Eng H.; Whalen, Michael J.			Tumor necrosis factor alpha and Fas receptor contribute to cognitive deficits independent of cell death after concussive traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cognition; concussion; inflammation; mice; traumatic brain injury; tumor necrosis factor	CLOSED-HEAD INJURY; HIPPOCAMPAL SYNAPTIC PLASTICITY; NEURONAL LOSS; TNF-ALPHA; RAT; MEMORY; INVOLVEMENT; IMPAIRMENT; EXPRESSION; MODEL	Tumor necrosis factor alpha (TNF alpha) and Fas receptor contribute to cell death and cognitive dysfunction after focal traumatic brain injury (TBI). We examined the role of TNF alpha/Fas in postinjury functional outcome independent of cell death in a novel closed head injury (CHI) model produced with weight drop and free rotational head movement in the anterior-posterior plane. The CHI produced no cerebral edema or blood-brain barrier damage at 24 to 48 hours, no detectable cell death, occasional axonal injury (24 hours), and no brain atrophy or hippocampal cell loss (day 60). Microglia and astrocytes were activated (48 to 72 hours). Tumor necrosis factor-alpha mRNA, Fas mRNA, and TNF alpha protein were increased in the brain at 3 to 6 hours after injury (P < 0.001 versus sham injured). In wild-type (WT) mice, CHI produced hidden platform (P = 0.009) and probe deficits (P = 0.001) in the Morris water maze versus sham. Surprisingly, injured TNF alpha/Fas knockout (KO) mice performed worse in hidden platform trials (P = 0.036) but better in probe trials than did WT mice (P = 0.0001). Administration of recombinant TNF alpha to injured TNF alpha/Fas KO mice reduced probe trial performance to that of WT. Thus, TNF alpha/Fas influence cognitive deficits independent of cell death after CHI. Therapies targeting TNF alpha/Fas together may be inappropriate for patients with concussive TBI. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 778-789; doi:10.1038/jcbfm.2010.172; published online 13 October 2010	[Khuman, Jugta; Zhang, Jimmy; Giovannone, Eric; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Khuman, Jugta; Meehan, William P., III; Zhu, Xiaoxia; Qiu, Jianhua; Hoffmann, Ulrike; Zhang, Jimmy; Giovannone, Eric; Lo, Eng H.; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Neurosci, Charlestown, MA 02129 USA; [Meehan, William P., III] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med,Dept Med, Boston, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Sports Med,Dept Orthoped,Sports Concuss Clin, Boston, MA USA; [Zhu, Xiaoxia] Fudan Univ, Huashan Hosp, Dept Rheumatol, Shanghai 200433, Peoples R China; [Qiu, Jianhua; Hoffmann, Ulrike; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA		Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA.	mwhalen@partners.org			NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD040128-06]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447]; MGH Center for the Integration of Medicine and Technology (CIMIT); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS064545, R01NS047447] Funding Source: NIH RePORTER	This work was supported by grants from NICHD T32 HD040128-06 (WM), NINDS 5RO1NS047447 (MJW), and MGH Center for the Integration of Medicine and Technology (CIMIT) (MJW).	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Albensi BC, 2000, SYNAPSE, V35, P151; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Corsini NS, 2009, CELL STEM CELL, V5, P178, DOI 10.1016/j.stem.2009.05.004; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Gerlai R, 2001, BEHAV BRAIN RES, V125, P269, DOI 10.1016/S0166-4328(01)00296-0; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Kilbourne M, 2009, J NEUROTRAUM, V26, P2233, DOI 10.1089/neu.2009.0968; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Qiu JH, 2002, J NEUROSCI, V22, P3504; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	37	65	67	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2011	31	2					778	789		10.1038/jcbfm.2010.172			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	715XY	WOS:000286930100038	20940727	Green Published, Bronze			2022-02-06	
J	Eucker, SA; Smith, C; Ralston, J; Friess, SH; Margulies, SS				Eucker, Stephanie A.; Smith, Colin; Ralston, Jill; Friess, Stuart H.; Margulies, Susan S.			Physiological and histopathological responses following closed rotational head injury depend on direction of head motion	EXPERIMENTAL NEUROLOGY			English	Article						Animal models; Brain ischemia; Brain trauma; Cerebral blood flow; Neuropathology; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; AXONAL INJURY; YOUNG-CHILDREN; WHITE-MATTER; BETA-APP; DAMAGE; TIME; AGE; MECHANISMS	Rotational inertial forces are thought to be the underlying mechanism for most severe brain injuries. However, little is known about the effect of head rotation direction on injury outcomes, particularly in the pediatric population. Neonatal piglets were subjected to a single non-impact head rotation in the horizontal, coronal, or sagittal direction, and physiological and histopathological responses were observed. Sagittal rotation produced the longest duration of unconsciousness, highest incidence of apnea, and largest intracranial pressure increase, while coronal rotation produced little change, and horizontal rotation produced intermediate and variable derangements. Significant cerebral blood flow reductions were observed following sagittal but not coronal or horizontal injury compared to sham. Subarachnoid hemorrhage, ischemia, and brainstem pathology were observed in the sagittal and horizontal groups but not in a single coronal animal. Significant axonal injury occurred following both horizontal and sagittal rotations. For both groups, the distribution of injury was greater in the frontal and parietotemporal lobes than in the occipital lobes, frequently occurred in the absence of ischemia, and did not correlate with regional cerebral blood flow reductions. We postulate that these direction-dependent differences in injury outcomes are due to differences in tissue mechanical loading produced during head rotation. (C) 2010 Elsevier Inc. All rights reserved.	[Eucker, Stephanie A.; Ralston, Jill; Margulies, Susan S.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA; [Smith, Colin] Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland; [Friess, Stuart H.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA		Margulies, SS (corresponding author), Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Eucker, Stephanie/AAL-1828-2021	Eucker, Stephanie/0000-0001-9986-5773	American Heart AssociationAmerican Heart Association; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS39679]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER	The authors would like to thank Dr. Nicole Ibrahim, Dr. Brittany Coats, Rahul Natesh, Sarah Casey, and Alison Agres for their valuable technical expertise. This research was funded by the American Heart Association and NIH R01 NS39679.	ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Arbogast KB, 2005, PEDIATRICS, V116, P180, DOI 10.1542/peds.2004-2671; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Baiden-Amissah K, 1998, NEUROPATH APPL NEURO, V24, P346; Bayir H, 2003, CRIT CARE CLIN, V19, P529, DOI 10.1016/S0749-0704(03)00014-9; Chieregato A, 2004, J NEUROTRAUM, V21, P655, DOI 10.1089/0897715041269669; Cotran R. S., 1999, ROBBINS PATHOLOGIC B; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Eucker SA, 2010, BRAIN RES, V1326, P128, DOI 10.1016/j.brainres.2010.02.059; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1987, STAPP CAR CRASH C, P49; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LAPTOOK AR, 1983, BRAIN RES, V276, P51, DOI 10.1016/0006-8993(83)90547-4; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Maxwell WL, 1991, J NEUROTRAUM, V8, P271, DOI 10.1089/neu.1991.8.271; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; Shiina G, 1998, AM J NEURORADIOL, V19, P297; SISSON S, 1975, J NEUROSURG, V93, P315; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; Tanaka Y, 1998, EUR J PHARMACOL, V356, P225, DOI 10.1016/S0014-2999(98)00547-0; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; THIBAULT LE, 1991, STRAIN DEPENDENT ISC, P101; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410	41	65	67	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2011	227	1					79	88		10.1016/j.expneurol.2010.09.015			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	708NF	WOS:000286367800012	20875409	Green Submitted, Green Accepted			2022-02-06	
J	Phillips, LH; Henry, JD; Scott, C; Summers, F; Whyte, M; Cook, M				Phillips, Louise H.; Henry, Julie D.; Scott, Clare; Summers, Fiona; Whyte, Maggie; Cook, Moira			Specific Impairments of Emotion Perception in Multiple Sclerosis	NEUROPSYCHOLOGY			English	Article						multiple sclerosis; emotion perception; quality of life	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; FACIAL EXPRESSIONS; RECOGNITION; DEFICITS; DISABILITY; ATROPHY; MATTER; MEMORY	Objective: Multiple sclerosis (MS) often results in demyelination of a network of frontal-subcortical tracts involved in processing emotional information. We investigated the effect of MS on the ability to identify emotional and nonemotional information from static and dynamic stimuli and determined whether difficulties in emotion perception related to quality of life. Method: 32 MS and 33 control participants, matched for age and education, identified emotions and nonemotional information from static images of faces and dynamic videos of people interacting. They also completed cognitive assessment and quality of life ratings. Results: On the static face perception tasks, participants with MS performed more poorly than healthy controls on emotion perception, t(63) = 3.30, p < .01, d = .83, but not identity perception, t(63) = 1.18, d = .30. For the dynamic tasks, the MS group were impaired on emotion perception, t(63) = 3.41, p = .001, d = .86, but not age/gender perception, t(63) = 0.15, d = .04. Ratings of social and psychological aspects of quality of life in MS were related to emotion perception scores controlling for disease severity and duration, age, depression, and cognitive function, with r(2) ranging from .17 to .24. Conclusions: These results indicate a specific deficit in decoding static and dynamic information about emotion in MS, as compared to nonemotional information. There were specific relationships between emotion perception problems and poor social and psychological quality of life, indicating that emotional skills should be considered when evaluating functioning in MS.	[Phillips, Louise H.] Univ Aberdeen, Sch Psychol, Coll Life Sci & Med, Aberdeen AB24 2UB, Scotland; [Henry, Julie D.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Summers, Fiona; Whyte, Maggie] Aberdeen Royal Infirm, Aberdeen, Scotland		Phillips, LH (corresponding author), Univ Aberdeen, Sch Psychol, Coll Life Sci & Med, Aberdeen AB24 2UB, Scotland.	louise.phillips@abdn.ac.uk	Phillips, Louise H/A-7952-2008	Phillips, Louise H/0000-0003-1005-8567; Phillips, Louise/0000-0002-0988-3028; Henry, Julie/0000-0002-2081-3717	Tenovus, Scotland	This research was funded by Tenovus, Scotland.	Adolphs R, 2000, J NEUROSCI, V20, P2683; Ambadar Z, 2005, PSYCHOL SCI, V16, P403, DOI 10.1111/j.0956-7976.2005.01548.x; BEATTY WW, 1995, NEUROLOGY, V45, P718, DOI 10.1212/WNL.45.4.718; BEATTY WW, 1989, B PSYCHONOMIC SOC, V27, P361; Beatty WW, 2003, MULT SCLER, V9, P148, DOI 10.1191/1352458503ms897oa; Benedict RHB, 2009, J NEUROL NEUROSUR PS, V80, P201, DOI 10.1136/jnnp.2008.148403; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bobholz JA, 2006, NEUROLOGY, V67, P1640, DOI 10.1212/01.wnl.0000242885.71725.76; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Chopra P, 2008, INT J REHABIL RES, V31, P141, DOI 10.1097/MRR.0b013e32830150e6; Clark US, 2008, NEUROPSYCHOLOGIA, V46, P2300, DOI 10.1016/j.neuropsychologia.2008.03.014; Filley CM, 2005, ANN NY ACAD SCI, V1064, P162, DOI 10.1196/annals.1340.028; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1166, DOI 10.1016/j.neuropsychologia.2005.10.006; Henry JD, 2009, J INT NEUROPSYCH SOC, V15, P277, DOI 10.1017/S1355617709090195; HOHOL MJ, 1995, NEUROLOGY, V45, P251, DOI 10.1212/WNL.45.2.251; Kalmar JH, 2008, NEUROPSYCHOLOGY, V22, P442, DOI 10.1037/0894-4105.22.4.442; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Phillips LH, 2010, PSYCHOL AGING, V25, P38, DOI 10.1037/a0017369; Phillips LH, 2009, BRIT J CLIN PSYCHOL, V48, P101, DOI 10.1348/014466508X379566; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Ruffman T, 2008, NEUROSCI BIOBEHAV R, V32, P863, DOI 10.1016/j.neubiorev.2008.01.001; Skevington SM, 2004, QUAL LIFE RES, V13, P299, DOI 10.1023/B:QURE.0000018486.91360.00; Slessor G, 2007, PSYCHOL AGING, V22, P639, DOI 10.1037/0882-7974.22.3.639; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Sullivan S, 2004, BRIT J PSYCHOL, V95, P1, DOI 10.1348/000712604322779424; Tedeschi G, 2005, NEUROLOGY, V65, P280, DOI 10.1212/01.wnl.0000168837.87351.1f; Young A., 2002, FACIAL EXPRESSIONS E; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	29	65	65	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JAN	2011	25	1					131	136		10.1037/a0020752			6	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	711AQ	WOS:000286558500014	21090898				2022-02-06	
J	Reimunde, P; Quintana, A; Castanon, B; Casteleiro, N; Vilarnovo, Z; Otero, A; Devesa, A; Otero-Cepeda, XL; Devesa, J				Reimunde, P.; Quintana, A.; Castanon, B.; Casteleiro, N.; Vilarnovo, Z.; Otero, A.; Devesa, A.; Otero-Cepeda, X. L.; Devesa, J.			Effects of growth hormone (GH) replacement and cognitive rehabilitation in patients with cognitive disorders after traumatic brain injury	BRAIN INJURY			English	Article						Cognitive rehabilitation; frontal lobe; memory; intelligence; traumatic brain injury	POSITRON-EMISSION-TOMOGRAPHY; MOTOR CORTEX PLASTICITY; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; FACTOR-I; RAT-BRAIN; STROKE PATIENTS; IGF-I; INSITU HYBRIDIZATION; DEFICIENT PATIENTS	Objective: To assess the effects of growth hormone (GH) treatment combined with cognitive rehabilitation in patients with adult growth hormone deficiency (GHD) and cognitive disorders occurring after traumatic brain injury (TBI). Participants: Nineteen adult patients with TBI: GHD was found in 11 of them. Intervention: Patients were treated with GH (GHD; sc; 1 mg/day) or vehicle (controls; sc; 1 mg/day); daily cognitive rehabilitation therapy was performed in both groups for 3 months. Main outcome measures: The GHRH arginine test established GHD. The neuropsychological test WAIS was performed before commencing the treatment and 3 months after commencing it. Results: Controls achieved significant improvements in digits and in manipulative intelligence quotient (IQ) (p < 0.05 vs. baseline). GHD achieved significant improvements in more cognitive parameters: understanding, digits, numbers and incomplete figures (p < 0.05 vs. baseline) and similarities, vocabulary, verbal IQ, manipulative IQ and total IQ (p < 0.01). GHD reached significantly greater improvements than controls in similarities (p < 0.01) and in vocabulary, verbal IQ and total IQ (p < 0.05). Conclusion: GH administration significantly improved cognitive rehabilitation in GHD patients. Since at the end of treatment period plasma IGF-I levels were similar in both groups it is likely that exogenous GH administration is responsible for the significant differences found.	[Reimunde, P.; Quintana, A.; Castanon, B.; Casteleiro, N.; Vilarnovo, Z.; Otero, A.; Devesa, A.; Devesa, J.] Med Ctr Proyecto Foltra, La Coruna 15886, Spain; [Reimunde, P.; Devesa, J.] Univ Santiago de Compostela, Dept Physiol, Santiago De Compostela, Spain; [Otero-Cepeda, X. L.] Univ Santiago de Compostela, Dept Biostat, Sch Med, Santiago De Compostela, Spain		Devesa, J (corresponding author), Med Ctr Proyecto Foltra, Cacheiras 64 Teo, La Coruna 15886, Spain.	jesus.devesa@usc.es	Devesa, J./C-4910-2018	Devesa, J./0000-0002-4153-2543; Reimunde, Pedro/0000-0002-9190-2469	Fundacion Foltra (Teo, Spain)	This study was supported by Fundacion Foltra (Teo, Spain).	Aberg MAI, 2003, MOL CELL NEUROSCI, V24, P23, DOI 10.1016/S1044-7431(03)00082-4; Aberg MAI, 2000, J NEUROSCI, V20, P2896; Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Aberg ND, 2009, J ENDOCRINOL, V201, P141, DOI 10.1677/JOE-08-0495; AGUADO F, 1993, J MOL ENDOCRINOL, V11, P231, DOI 10.1677/jme.0.0110231; ARAUJO DM, 1989, BRAIN RES, V484, P130, DOI 10.1016/0006-8993(89)90355-7; Arwert LI, 2006, NEUROENDOCRINOLOGY, V83, P12, DOI 10.1159/000093337; Arwert LI, 2005, NEUROENDOCRINOLOGY, V81, P31, DOI 10.1159/000084872; Arwert LI, 2005, GROWTH HORM IGF RES, V15, P47, DOI 10.1016/j.ghir.2004.11.004; Azcoitia I, 2005, NEUROBIOL AGING, V26, P697, DOI 10.1016/j.neurobiolaging.2004.06.007; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Behrman AL, 2006, PHYS THER, V86, P1406, DOI 10.2522/ptj.20050212; Beilharz EJ, 1998, MOL BRAIN RES, V59, P119, DOI 10.1016/S0169-328X(98)00122-3; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Bulow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; Christophidis LJ, 2009, GROWTH HORM IGF RES, V19, P497, DOI 10.1016/j.ghir.2009.05.001; Chung YH, 2002, BRAIN RES, V946, P307, DOI 10.1016/S0006-8993(02)03041-X; Costoya JA, 1999, ENDOCRINOLOGY, V140, P5937, DOI 10.1210/en.140.12.5937; Daly JJ, 2007, THESCIENTIFICWORLDJO, V7, P2031, DOI 10.1100/tsw.2007.299; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; DEVESA J, 2009, MED CLIN BARC; Drago F, 1996, PSYCHONEUROENDOCRINO, V21, P401, DOI 10.1016/0306-4530(96)00003-0; Dunlop SA, 2008, TRENDS NEUROSCI, V31, P410, DOI 10.1016/j.tins.2008.05.004; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; GOSSARD F, 1987, NEUROSCI LETT, V79, P251, DOI 10.1016/0304-3940(87)90438-1; GUAN J, 1993, J CEREBR BLOOD F MET, V13, P609, DOI 10.1038/jcbfm.1993.79; Guan J, 2001, J CEREBR BLOOD F MET, V21, P493, DOI 10.1097/00004647-200105000-00003; Gustafson K, 1999, PEDIATR RES, V45, P318, DOI 10.1203/00006450-199903000-00005; High WM, 2010, J NEUROTRAUMA; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; Jones TA, 1999, J NEUROSCI, V19, P10153; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kleim JA, 1996, J NEUROSCI, V16, P4529; LAI ZN, 1991, BRAIN RES, V546, P222, DOI 10.1016/0006-8993(91)91485-J; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Liepert J, 2001, J NEUROL, V248, P315, DOI 10.1007/s004150170207; LOBIE PE, 1993, DEV BRAIN RES, V74, P225, DOI 10.1016/0165-3806(93)90008-X; Markowska AL, 1998, NEUROSCIENCE, V87, P559, DOI 10.1016/S0306-4522(98)00143-2; Marshall RS, 2000, STROKE, V31, P656, DOI 10.1161/01.STR.31.3.656; Maruff P, 2005, HORM RES, V64, P100, DOI 10.1159/000089325; Morrison JH, 2002, PROG BRAIN RES, V136, P467; Nelles G, 2001, NEUROIMAGE, V13, P1146, DOI 10.1006/nimg.2001.0757; Nieves-Martinez E, 2010, J ENDOCRINOL, V204, P31, DOI 10.1677/JOE-09-0323; Nudo RJ, 1996, J NEUROSCI, V16, P785; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; PAVLOVIC D, 2009, EUROPEAN J NEUROLOGY; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Rensink M, 2009, J ADV NURS, V65, P737, DOI 10.1111/j.1365-2648.2008.04925.x; Rosa A, 2010, 12 EUR C END PRAG 24, V22; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Sathiavageeswaran M, 2007, EUR J ENDOCRINOL, V156, P439, DOI 10.1530/eje.1.02346; Scheepens A, 2000, J PEDIATR ENDOCR MET, V13, P1483; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; SCHNEIDERRIVAS S, 1995, LIFE SCI, V56, pPL433, DOI 10.1016/0024-3205(95)00171-2; Shetty AK, 1999, EXP NEUROL, V158, P491, DOI 10.1006/exnr.1999.7107; Shin DH, 2004, NEUROSCI LETT, V354, P64, DOI 10.1016/j.neulet.2003.09.070; van Dam P Sylze, 2006, Treat Endocrinol, V5, P159; van Dam PS, 2005, HORM RES, V64, P109, DOI 10.1159/000089326; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; van Nieuwpoort IC, 2008, EUR J ENDOCRINOL, V159, pS53, DOI 10.1530/EJE-08-0279; Vitali P, 2007, NEUROREHAB NEURAL RE, V21, P152, DOI 10.1177/1545968306294735; Vogenthaler D R, 1987, Brain Inj, V1, P113; WECHSLER D, 1990, MANUAL WECHSLER ADUL; WERTHER GA, 1990, MOL ENDOCRINOL, V4, P773, DOI 10.1210/mend-4-5-773; ZIMMERMAN IL, 1989, CLIN INTERPRETATION	74	65	71	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2011	25	1					65	73		10.3109/02699052.2010.536196			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700008	21117918				2022-02-06	
J	Manni, L; Albanesi, M; Guaragna, M; Paparo, SB; Aloe, L				Manni, Luigi; Albanesi, Marcello; Guaragna, Morena; Paparo, Samuele Barbaro; Aloe, Luigi			Neurotrophins and acupuncture	AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL			English	Article						Neurotrophin; Nerve growth factor; Acupuncture	NERVE GROWTH-FACTOR; INDUCED POLYCYSTIC OVARIES; LOW-FREQUENCY ELECTROACUPUNCTURE; DORSAL-ROOT GANGLION; FACTOR MESSENGER-RNA; RAT-BRAIN; DIABETIC POLYNEUROPATHY; SEROTONERGIC NEURONS; CLINICAL-APPLICATION; SIGNAL-TRANSDUCTION	The aim of this review is to report recent findings and ongoing studies on the effects of acupuncture on endogenous biological mediators, in particular on neurotrophins such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). Acupuncture is a therapeutic technique and is a part of Traditional Chinese Medicine (TCM). Western descriptions of the clinical efficacy of acupuncture on pain, inflammation, motor dysfunction, mood disorders, and seizures are based on the stimulation of several classes of sensory afferent fibers and the consequent activation of physiological processes similar to those resulting from physical exercise or deep massage. The established research on the neuro-physiological correlates of acupuncture has pointed towards endogenous opioids as the principal biological mediators of the therapeutic actions of this ancient technique. More recently, several classes of molecules, such as neurotransmitters, cytokines and growth factors, have also been identified as possible mediators for specific acupuncture effects. This review will focus on the links between acupuncture and a class of growth factors known as neurotrophins (NTs), which are the main mediators of neural activity, plasticity and repair following neurodegeneration and/or traumatic injury. A special emphasis will be placed on the work of our laboratory investigating the role of nerve growth factor (NGF), the prototypical member of the neurotrophin family, as a mediator of acupuncture effects in the central nervous system (CNS) and as a modulator of sensory and autonomic activity. (C) 2010 Elsevier B.V. All rights reserved.	[Manni, Luigi; Aloe, Luigi] CNR, Inst Neurobiol & Mol Med, I-00143 Rome, Italy; [Albanesi, Marcello; Guaragna, Morena; Paparo, Samuele Barbaro] Univ Roma La Sapienza, Fac Med & Chirurg 2, Dip Med Interna, UO Allergol Immunol Clin, Rome, Italy		Manni, L (corresponding author), CNR, Inst Neurobiol & Mol Med, Via Fosso di Fiorano 64, I-00143 Rome, Italy.	luigi.manni@inmm.cnr.it	Manni, Luigi/J-5637-2018	Albanesi, Marcello/0000-0001-7608-9572	Regione LazioRegione Lazio	Luigi Manni's contract is supported by Regione Lazio grant "Sviluppo della Ricerca sul Cervello" to INMM-CNR (Regione Lazio, Legge n.9, 17 febbraio 2005, Art. 41 Comma 2).	Aarts MM, 2005, NEUROSCIENTIST, V11, P116, DOI 10.1177/1073858404272966; Allen SJ, 2006, CLIN SCI, V110, P175, DOI 10.1042/CS20050161; Alleva E, 1993, Rev Neurosci, V4, P41; Aloe L, 1999, MICROSC RES TECHNIQ, V45, P285, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<285::AID-JEMT12>3.0.CO;2-3; Aloe L, 2004, PROG BRAIN RES, V146, P515; Aloe L, 2002, PHARMACOL BIOCHEM BE, V73, P159, DOI 10.1016/S0091-3057(02)00757-8; ALOE L, 1994, BRAIN RES BULL, V33, P173, DOI 10.1016/0361-9230(94)90247-X; Aloe L, 1997, ALLERGY, V52, P883, DOI 10.1111/j.1398-9995.1997.tb01247.x; Aloe L, 2001, Arch Physiol Biochem, V109, P354, DOI 10.1076/apab.109.4.354.4235; Aloe L, 2008, PHARMACOL RES, V57, P253, DOI 10.1016/j.phrs.2008.01.010; Aloe L, 2009, NEUROSCI LETT, V449, P173, DOI 10.1016/j.neulet.2008.11.003; ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5; Angelucci F, 2000, J NEUROSCI RES, V60, P783, DOI 10.1002/1097-4547(20000615)60:6<783::AID-JNR11>3.0.CO;2-M; APFEL SC, 1995, BAILLIERE CLIN NEUR, V4, P593; Apfel SC, 2000, JAMA-J AM MED ASSOC, V284, P2215, DOI 10.1001/jama.284.17.2215; Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695; Apfel SC, 2002, INT REV NEUROBIOL, V50, P393; Bai YH, 2004, GYNECOL OBSTET INVES, V57, P80, DOI 10.1159/000075382; BARRIA A, 1993, ENDOCRINOLOGY, V133, P2696, DOI 10.1210/en.133.6.2696; Bartoletti A, 2002, J NEUROSCI, V22, P10072; Bian J T, 1993, Int J Neurosci, V72, P15; Bonini S, 1999, INT ARCH ALLERGY IMM, V118, P159, DOI 10.1159/000024055; Bonini S, 2000, OPHTHALMOLOGY, V107, P1347, DOI 10.1016/S0161-6420(00)00163-9; Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552; Campbell Anthony, 2006, Acupunct Med, V24, P118; CAO XD, 1983, ACUPUNCTURE ELECTRO, V8, P25, DOI 10.3727/036012983816715028; Capsoni S, 2009, J ALZHEIMERS DIS, V16, P371, DOI 10.3233/JAD-2009-0953; Carlsson Christer, 2002, Acupunct Med, V20, P82; Chae Y, 2007, NEUROL RES, V29, pS42, DOI 10.1179/016164107X172284; Chalazonitis A, 2004, PROG BRAIN RES, V146, P243, DOI 10.1016/S0079-6123(03)46016-0; Chao DM, 1999, AM J PHYSIOL-HEART C, V276, pH2127, DOI 10.1152/ajpheart.1999.276.6.H2127; Chao MV, 2006, CLIN SCI, V110, P167, DOI 10.1042/CS20050163; Chen J, 2007, NEUROSCI RES, V59, P399, DOI 10.1016/j.neures.2007.08.006; Chen Xue-Qing, 1998, J Alzheimers Dis, V1, P35; Chen YY, 2008, ACUPUNCTURE ELECTRO, V33, P19, DOI 10.3727/036012908803861212; Chiaretti A, 2005, NEUROL RES, V27, P741, DOI 10.1179/016164105X35611; Colangelo AM, 2004, MOL BRAIN RES, V124, P97, DOI 10.1016/j.molbrainres.2004.01.011; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Cowan WM, 2001, ANNU REV NEUROSCI, V24, P551, DOI 10.1146/annurev.neuro.24.1.551; Culmsee C, 1999, EUR J PHARMACOL, V379, P33, DOI 10.1016/S0014-2999(99)00452-5; DayLollini PA, 1997, EXP NEUROL, V145, P24, DOI 10.1006/exnr.1997.6448; Ding Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-35; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; ERIKSDOTTER JM, 1998, DEMENT GERIATR COGN, V9, P246, DOI DOI 10.1159/000017069; Ernfors P, 2001, CELL MOL LIFE SCI, V58, P1036, DOI 10.1007/PL00000918; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; FRIEDMAN WJ, 1993, EXP NEUROL, V119, P72, DOI 10.1006/exnr.1993.1007; Friedman WJ, 1998, NEUROSCIENCE, V84, P101, DOI 10.1016/S0306-4522(97)00526-5; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; Generini S, 2004, EXP CLIN ENDOCR DIAB, V112, P542, DOI 10.1055/s-2004-821313; Guo HF, 1996, MOL BRAIN RES, V43, P157, DOI 10.1016/S0169-328X(96)00170-2; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HAN JS, 1986, PAIN, V27, P101, DOI 10.1016/0304-3959(86)90227-7; HE LF, 1992, ACUPUNCTURE ELECTRO, V17, P243, DOI 10.3727/036012992816357620; Hefti FF, 2006, TRENDS PHARMACOL SCI, V27, P85, DOI 10.1016/j.tips.2005.12.001; Hochhaus F, 2001, BMC Pediatr, V1, P2, DOI 10.1186/1471-2431-1-2; Holden JE, 2005, AACN ADV CRIT CARE, V16, P291, DOI 10.1097/00044067-200507000-00003; HOLE K, 1981, CEPHALALGIA, V1, P51, DOI 10.1111/j.1468-2982.1981.tb00008.x; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Ibanez CF, 1996, NEUROCHEM RES, V21, P787, DOI 10.1007/BF02532301; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010; KAUFMAN MP, 1984, CARDIOVASC RES, V18, P663, DOI 10.1093/cvr/18.11.663; Kawakita K, 1996, PROG BRAIN RES, V113, P507, DOI 10.1016/S0079-6123(08)61105-X; Kawakita K., 1991, ADV PHYSL SCI, P731; Kawakita K, 2006, J PHARMACOL SCI, V100, P443, DOI 10.1254/jphs.CRJ06004X; Kennedy AJ, 1998, J NEUROL NEUROSUR PS, V65, P393, DOI 10.1136/jnnp.65.3.393; Kim WS, 2009, BRAIN RES, V1248, P176, DOI 10.1016/j.brainres.2008.11.009; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; KNIFFKI KD, 1981, CIRC RES, V48, P25; KOLIATSOS VE, 1991, ANN NEUROL, V30, P831, DOI 10.1002/ana.410300613; Krzan M, 2001, J NEUROSCI RES, V64, P261, DOI 10.1002/jnr.1074; Kwon YB, 2000, AM J CHINESE MED, V28, P435, DOI 10.1142/S0192415X00000519; Lambiase A, 2003, ARCH ITAL BIOL, V141, P141; Lambiase A, 2000, INVEST OPHTH VIS SCI, V41, P1063; Lambiase A, 2007, BRAIN RES, V1127, P45, DOI 10.1016/j.brainres.2006.09.102; Lara HE, 2000, ENDOCRINOLOGY, V141, P1059, DOI 10.1210/en.141.3.1059; Lara HE, 2002, MICROSC RES TECHNIQ, V59, P495, DOI 10.1002/jemt.10229; LARA HE, 1993, ENDOCRINOLOGY, V133, P2690, DOI 10.1210/en.133.6.2690; Lee E, 2009, BMB REP, V42, P239, DOI 10.5483/BMBRep.2009.42.5.239; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Liang XB, 2002, MOL BRAIN RES, V108, P51, DOI 10.1016/S0169-328X(02)00513-2; Lindsay RM, 1996, PHILOS T ROY SOC B, V351, P365, DOI 10.1098/rstb.1996.0030; Liu F, 2009, NEUROSCI LETT, V450, P158, DOI 10.1016/j.neulet.2008.09.066; Lu B, 2000, PROG BRAIN RES, V128, P231; MAESTRIPIERI D, 1990, PHYSIOL BEHAV, V47, P161, DOI 10.1016/0031-9384(90)90056-A; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANNERAS L, 2009, AM J PHYSIOL-REG I, V926, pR1124; Manneras L, 2008, ENDOCRINOLOGY, V149, P3559, DOI 10.1210/en.2008-0053; Manni L, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-21; Manni L, 2006, AM J PHYSIOL-REG I, V290, pR826, DOI 10.1152/ajpregu.00078.2005; Manni L, 2005, J NEUROENDOCRINOL, V17, P846, DOI 10.1111/j.1365-2826.2005.01378.x; Manni L, 2005, AUTON NEUROSCI-BASIC, V118, P79, DOI 10.1016/j.autneu.2005.01.004; Manni L, 2000, BRIT J PHARMACOL, V129, P744, DOI 10.1038/sj.bjp.0703088; Manni L, 2002, RHEUMATOLOGY, V41, P787, DOI 10.1093/rheumatology/41.7.787; Manni L, 2001, NEUROREPORT, V12, P1621, DOI 10.1097/00001756-200106130-00022; McAllister AK, 2001, CELL MOL LIFE SCI, V58, P1054, DOI 10.1007/PL00000920; McArthur JC, 2000, NEUROLOGY, V54, P1080, DOI 10.1212/WNL.54.5.1080; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Mufson EJ, 1999, PROG NEUROBIOL, V57, P451, DOI 10.1016/S0301-0082(98)00059-8; OLSON L, 1993, EXP NEUROL, V124, P5, DOI 10.1006/exnr.1993.1167; OLSON L, 1993, ACTA NEUROCHIR, P3; Pagani L, 2006, BRAIN RES, V1092, P198, DOI 10.1016/j.brainres.2006.03.074; Parkman HP, 2003, AM J GASTROENTEROL, V98, P1338, DOI 10.1016/S0002-9270(03)00252-1; Pezet S, 2004, EXPERT OPIN THER TAR, V8, P391, DOI 10.1517/14728222.8.5.391; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Riaz SS, 2000, MOL BRAIN RES, V85, P179; Rush RA, 1997, CLIN EXP PHARMACOL P, V24, P549, DOI 10.1111/j.1440-1681.1997.tb02089.x; Sahenk Z, 2005, NEUROLOGY, V65, P681, DOI 10.1212/01.WNL.0000171978.70849.c5; Schaaf M J, 2000, Stress, V3, P201, DOI 10.3109/10253890009001124; Schor NF, 2005, PROG NEUROBIOL, V77, P201, DOI 10.1016/j.pneurobio.2005.10.006; Schulte-Herbruggen O, 2007, CURR MED CHEM, V14, P2318, DOI 10.2174/092986707781745578; SEIGER A, 1993, BEHAV BRAIN RES, V57, P255, DOI 10.1016/0166-4328(93)90141-C; Semkova I, 1996, BRAIN RES, V717, P44, DOI 10.1016/0006-8993(95)01567-1; SKUP MH, 1994, ACTA NEUROBIOL EXP, V54, P81; Stener-Victorin E, 2000, BIOL REPROD, V63, P1497, DOI 10.1095/biolreprod63.5.1497; Stener-Victorin Elisabet, 2003, Reprod Biol Endocrinol, V1, P33, DOI 10.1186/1477-7827-1-33; Sun N, 2005, BRAIN RES, V1064, P98, DOI 10.1016/j.brainres.2005.09.060; TAGLIALATELA G, 1991, ENDOCRINOLOGY, V129, P2212, DOI 10.1210/endo-129-4-2212; Takagi J, 1998, JPN J PHARMACOL, V78, P511, DOI 10.1254/jjp.78.511; Terenghi G, 1999, J ANAT, V194, P1, DOI 10.1046/j.1469-7580.1999.19410001.x; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Tirassa P, 1998, BRIT J PHARMACOL, V123, P1230, DOI 10.1038/sj.bjp.0701718; Tirassa P, 1999, P NATL ACAD SCI USA, V96, P6473, DOI 10.1073/pnas.96.11.6473; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Tuveri M, 2000, LANCET, V356, P1739, DOI 10.1016/S0140-6736(00)03212-8; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; Vassilakopoulos T, 2005, CURR OPIN CRIT CARE, V11, P1, DOI 10.1097/00075198-200502000-00002; Vitalis T, 2002, J NEUROSCI, V22, P4987, DOI 10.1523/JNEUROSCI.22-12-04987.2002; Wang TH, 2007, NEUROCHEM RES, V32, P1415, DOI 10.1007/s11064-007-9326-9; Winkler J, 1997, ANN NEUROL, V41, P82, DOI 10.1002/ana.410410114; Wu HG, 2008, DIGEST DIS SCI, V53, P1644, DOI 10.1007/s10620-007-0062-4; Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133; Xing GG, 2007, EXP NEUROL, V208, P323, DOI 10.1016/j.expneurol.2007.09.004; Yamada K, 2002, LIFE SCI, V70, P735, DOI 10.1016/S0024-3205(01)01461-8; Yamada K, 2003, J PHARMACOL SCI, V91, P267; Yasuno H, 2000, BRAIN RES, V887, P53, DOI 10.1016/S0006-8993(00)02966-8; Yun SJ, 2002, NEUROSCI LETT, V318, P85, DOI 10.1016/S0304-3940(01)02492-2; Zhang D, 2008, EXPLORE-NY, V4, P170, DOI 10.1016/j.explore.2008.02.002; Zhang WT, 2004, NEUROSCI LETT, V354, P50, DOI 10.1016/j.neulet.2003.09.080; ZHAO L, 2005, YI XUE YING DE WEN B, V25, P247; Zhao L, 2007, LIFE SCI, V81, P1211, DOI 10.1016/j.lfs.2007.08.034; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; ZHOU XF, 1994, BRAIN RES, V643, P162, DOI 10.1016/0006-8993(94)90022-1; Zijlstra FJ, 2003, MEDIAT INFLAMM, V12, P59, DOI 10.1080/0962935031000114943	148	65	70	1	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1566-0702	1872-7484		AUTON NEUROSCI-BASIC	Auton. Neurosci-Basic Clin.	OCT 28	2010	157	1-2			SI		9	17		10.1016/j.autneu.2010.03.020			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	679SX	WOS:000284182200003	20451467				2022-02-06	
J	Bennet, L; Booth, L; Gunn, AJ				Bennet, L.; Booth, L.; Gunn, A. J.			Potential biomarkers for hypoxic-ischemic encephalopathy	SEMINARS IN FETAL & NEONATAL MEDICINE			English	Article						Asphyxia; Biomarkers; Brain metabolism; Electroencephalogram; Hypoxic-ischemic encephalopathy; Near-infrared spectroscopy	PRETERM FETAL SHEEP; MAGNETIC-RESONANCE-SPECTROSCOPY; NEAR-INFRARED SPECTROSCOPY; UMBILICAL-CORD OCCLUSION; NEURON-SPECIFIC ENOLASE; AMPLITUDE-INTEGRATED ELECTROENCEPHALOGRAPHY; TRAUMATIC BRAIN-INJURY; RAT HIPPOCAMPAL SLICES; TERM NEWBORN-INFANTS; NEONATAL ENCEPHALOPATHY	Cerebral hypothermia reduces brain injury and improves behavioral recovery after hypoxia ischemia (HI) at birth. However, using current enrolment criteria many infants are not helped, and conversely, a significant proportion of control infants survive without disability. In order to further improve treatment we need better biomarkers of injury. A 'true' biomarker for the phase of evolving, 'treatable' injury would allow us to identify not only whether infants are at risk of damage, but also whether they are still able to benefit from intervention. Even a less specific measure that allowed either more precise early identification of infants at risk of adverse neurodevelopmental outcome would reduce the variance of outcome of trials, improving trial power while reducing the number of infants unnecessarily treated. Finally, valid short-term surrogates for long term outcome after treatment would allow more rapid completion of preliminary evaluation and thus allow new strategies to be tested more rapidly. Experimental studies have demonstrated that there is a relatively limited 'window of opportunity' for effective treatment (up to about 6-8 h after HI, the 'latent phase'), before secondary cell death begins. We critically evaluate the utility of proposed biochemical, electronic monitoring, and imaging biomarkers against this framework. This review highlights the two central limitations of most presently available biomarkers: that they are most precise for infants with severe injury who are already easily identified, and that their correlation is strongest at times well after the latent phase, when injury is no longer 'treatable'. This is an important area for further research. (c) 2010 Elsevier Ltd. All rights reserved.	[Bennet, L.; Booth, L.; Gunn, A. J.] Univ Auckland, Dept Physiol, Fetal Physiol & Neurosci Grp, Auckland, New Zealand		Bennet, L (corresponding author), Univ Auckland, Dept Physiol, Fetal Physiol & Neurosci Grp, Private Bag 92019, Auckland, New Zealand.	l.bennet@auckland.ac.nz		Bennet, Laura/0000-0002-4336-7596; Booth, Lindsea/0000-0003-3093-5766; Gunn, Alistair/0000-0003-0656-7035	Health Research Council of New ZealandHealth Research Council of New Zealand; Auckland Medical Research Foundation; Lottery Health New Zealand; March of Dimes USAMarch of Dimes; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS063141] Funding Source: NIH RePORTER	The authors gratefully acknowledge funding support from the Health Research Council of New Zealand, The Auckland Medical Research Foundation, Lottery Health New Zealand, March of Dimes USA, and the US National Institutes of Health.	AZZOPARDI D, 1989, PEDIATR RES, V25, P445, DOI 10.1203/00006450-198905000-00004; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bashir Moataza, 2009, Front Biosci (Elite Ed), V1, P560; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; Bennet L, 2007, J NEUROPHYSIOL, V97, P572, DOI 10.1152/jn.00957.2006; Bennet L, 2006, J PHYSIOL-LONDON, V572, P141, DOI 10.1113/jphysiol.2006.105197; Bennet L, 2009, FETAL NEONATAL NEURO, P472; BENNET L, 2009, FETAL NEONATAL BRAIN, P48; Bennet L, 2007, AM J PHYSIOL-REG I, V292, pR1569, DOI 10.1152/ajpregu.00743.2006; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bokesch PM, 2002, ANESTH ANALG, V95, P889, DOI 10.1097/00000539-200210000-00018; Bruschettini M, 2005, DEV BRAIN RES, V159, P113, DOI 10.1016/j.devbrainres.2005.07.003; Cady EB, 2001, CHILD NERV SYST, V17, P145, DOI 10.1007/s003810000391; Cady EB, 2008, J NEUROCHEM, V107, P1027, DOI 10.1111/j.1471-4159.2008.05662.x; Cooper CE, 1999, J CEREBR BLOOD F MET, V19, P27, DOI 10.1097/00004647-199901000-00003; Cowan F, 2003, LANCET, V361, P736, DOI 10.1016/S0140-6736(03)12658-X; DAWES GS, 1959, J PHYSIOL-LONDON, V146, P516, DOI 10.1113/jphysiol.1959.sp006208; Dean JM, 2006, NEUROSCIENCE, V142, P615, DOI 10.1016/j.neuroscience.2006.06.066; Dean JM, 2006, NEUROPHARMACOLOGY, V50, P491, DOI 10.1016/j.neuropharm.2005.10.017; Dean JM, 2006, EXP PHYSIOL, V91, P423, DOI 10.1113/expphysiol.2005.032375; Dean JM, 2008, NEUROPHARMACOLOGY, V55, P166, DOI 10.1016/j.neuropharm.2008.05.009; DeHaan HH, 1997, PEDIATR RES, V41, P96, DOI 10.1203/00006450-199701000-00015; deHaan HH, 1997, AM J OBSTET GYNECOL, V176, P18, DOI 10.1016/S0002-9378(97)80005-1; DOYLE OM, 2007, C P IEEE ENG MED BIO, P717; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Friel LA, 2007, J PERINAT MED, V35, P385, DOI 10.1515/JPM.2007.101; Fujii EY, 2004, BRAIN RES, V1018, P136, DOI 10.1016/j.brainres.2004.05.061; Garnier Y, 2009, REPROD SCI, V16, P758, DOI 10.1177/1933719109335801; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Gazzolo D, 2000, CLIN CHEM, V46, P998; Gazzolo D, 2009, J MATERN-FETAL NEO M, V22, P57, DOI 10.1080/14767050903181468; Geddes R, 2001, DEV NEUROSCI-BASEL, V23, P180, DOI 10.1159/000046140; George S, 2004, AM J PHYSIOL-REG I, V287, pR925, DOI 10.1152/ajpregu.00263.2004; Giuseppe D, 2009, CURR NEUROVASC RES, V6, P110, DOI 10.2174/156720209788185614; Giussani DA, 2005, PEDIATR RES, V58, P179, DOI 10.1203/01.PDR.0000169999.66157.C0; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Graham EM, 2008, AM J OBSTET GYNECOL, V199, P587, DOI 10.1016/j.ajog.2008.06.094; Greisen G, 2006, SEMIN FETAL NEONAT M, V11, P498, DOI 10.1016/j.siny.2006.07.010; Gunn A J, 2006, NeuroRx, V3, P154, DOI 10.1016/j.nurx.2006.01.007; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Gunn AJ, 2008, CURR OPIN OBSTET GYN, V20, P175, DOI 10.1097/GCO.0b013e3282f4ef9e; Gunn AJ, 2009, CLIN PERINATOL, V36, P579, DOI 10.1016/j.clp.2009.06.007; Hirst JJ, 2008, NEUROCHEM INT, V52, P602, DOI 10.1016/j.neuint.2007.07.018; HOPE PL, 1984, LANCET, V2, P366; HUGHES JR, 1994, CLIN ELECTROENCEPHAL, V25, P127, DOI 10.1177/155005949402500404; Iwata O, 2007, BRAIN RES, V1154, P173, DOI 10.1016/j.brainres.2007.03.083; Jensen EC, 2006, J PHYSIOL-LONDON, V572, P131, DOI 10.1113/jphysiol.2005.100768; Jensen FE, 1998, J NEUROPHYSIOL, V79, P73, DOI 10.1152/jn.1998.79.1.73; JIANG W, 2009, C P IEEE ENG MED BIO, V1, P2192; Laptook AR, 2009, PEDIATRICS, V124, P1619, DOI 10.1542/peds.2009-0934; Loukovaara M, 2009, EUR J OBSTET GYN R B, V142, P115, DOI 10.1016/j.ejogrb.2008.10.008; Low JA, 1997, AM J OBSTET GYNECOL, V177, P1391, DOI 10.1016/S0002-9378(97)70080-2; MacLennan A, 1999, BMJ-BRIT MED J, V319, P1054, DOI 10.1136/bmj.319.7216.1054; Martin E, 1996, PEDIATR RES, V40, P749, DOI 10.1203/00006450-199611000-00015; Martins RO, 2006, ARQ NEURO-PSIQUIAT, V64, P24, DOI 10.1590/S0004-282X2006000100006; Murabayashi M, 2008, PEDIATR INT, V50, P17, DOI 10.1111/j.1442-200X.2007.02506.x; Murray DM, 2009, PEDIATRICS, V124, pE459, DOI 10.1542/peds.2008-2190; Murray DM, 2009, AM J PERINAT, V26, P605, DOI 10.1055/s-0029-1220774; Nagdyman N, 2003, PEDIATR RES, V54, P270, DOI 10.1203/01.PDR.0000072518.98189.A0; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; Nelson KB, 1996, NEW ENGL J MED, V334, P613, DOI 10.1056/NEJM199603073341001; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Okumura A, 2003, J PEDIATR-US, V143, P26, DOI 10.1016/S0022-3476(03)00182-3; PEEBLES DM, 1992, AM J OBSTET GYNECOL, V166, P1369, DOI 10.1016/0002-9378(92)91606-B; Peeters-Scholte C, 2004, EXP BRAIN RES, V156, P20, DOI 10.1007/s00221-003-1761-5; PEZZANI C, 1986, NEUROPEDIATRICS, V17, P11, DOI 10.1055/s-2008-1052492; Ramaswamy V, 2009, PEDIATR NEUROL, V40, P215, DOI 10.1016/j.pediatrneurol.2008.09.026; Robertson NJ, 2007, EARLY HUM DEV, V83, P801, DOI 10.1016/j.earlhumdev.2007.09.015; Roth SC, 1997, DEV MED CHILD NEUROL, V39, P718; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Scher MS, 2002, EPILEPTIC DISORD, V4, P139; SCHER MS, 1994, ELECTROEN CLIN NEURO, V90, P179, DOI 10.1016/0013-4694(94)90089-2; Schulpis KH, 2006, SCAND J CLIN LAB INV, V66, P733, DOI 10.1080/00365510600977737; Selman WR, 2004, BRAIN RES, V999, P167, DOI 10.1016/j.brainres.2003.11.016; Shalak LF, 2003, PEDIATRICS, V111, P351, DOI 10.1542/peds.111.2.351; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHELLEY HJ, 1961, BRIT MED BULL, V17, P137, DOI 10.1093/oxfordjournals.bmb.a069888; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Szeto HH, 2008, ANTIOXID REDOX SIGN, V10, P601, DOI 10.1089/ars.2007.1892; Thayyil S, 2010, PEDIATRICS, V125, pE382, DOI 10.1542/peds.2009-1046; Thorngren-Jerneck K, 2004, PEDIATR RES, V55, P406, DOI 10.1203/01.PDR.0000106806.75086.D3; Tichauer KM, 2009, J APPL PHYSIOL, V106, P1506, DOI 10.1152/japplphysiol.91156.2008; Toet MC, 2009, EARLY HUM DEV, V85, P77, DOI 10.1016/j.earlhumdev.2008.11.007; VANBE, 2008, NEONATOLOGY, V94, P237; Vannucci RC, 2004, J CEREBR BLOOD F MET, V24, P1090, DOI 10.1097/01.WCB.0000133250.03953.63; VecchieriniBlineau MF, 1996, NEUROPHYSIOL CLIN, V26, P350, DOI 10.1016/S0987-7053(97)89149-6; Vicente E, 2007, CLIN EXP PHARMACOL P, V34, P1126, DOI 10.1111/j.1440-1681.2007.04687.x; Wang C, 1996, EPILEPSY RES, V23, P105, DOI 10.1016/0920-1211(95)00086-0; Wassink G, 2007, J APPL PHYSIOL, V103, P1311, DOI 10.1152/japplphysiol.00396.2007; Wayenberg JL, 2005, J MATERN-FETAL NEO M, V18, P381, DOI 10.1080/14767050500249916; WESTGATE JA, 1997, AM J OBSTET GYNECOL, V236, pE1; Wijnberger LDE, 2002, PEDIATR RES, V51, P492, DOI 10.1203/00006450-200204000-00015; Winter JD, 2009, PEDIATR RES, V65, P181, DOI 10.1203/PDR.0b013e31818f06fb; Wong FY, 2007, EARLY HUM DEV, V83, P379, DOI 10.1016/j.earlhumdev.2006.08.002; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839	97	65	67	1	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1744-165X	1878-0946		SEMIN FETAL NEONAT M	Semin. Fetal Neonatal Med.	OCT	2010	15	5					253	260		10.1016/j.siny.2010.05.007			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	653RZ	WOS:000282115700004	20646975	Green Accepted			2022-02-06	
J	Chao, JF; Li, HT; Cheng, KW; Yu, MS; Chang, RCC; Wang, MF				Chao, Jianfei; Li, Haitao; Cheng, Ka-Wing; Yu, Man-Shan; Chang, Raymond Chuen-Chung; Wang, Mingfu			Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells	JOURNAL OF NUTRITIONAL BIOCHEMISTRY			English	Article						Parkinson's disease; 6-Hydroxydopamine; Resveratrol; Pinostilbene; Neuroprotection	AMYLOID PEPTIDE NEUROTOXICITY; TRAUMATIC BRAIN-INJURY; LYCIUM-BARBARUM; PROTEIN-KINASE; PARTIAL NEUROPROTECTION; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; MECHANISM; ANALOGS; ACTIVATION	Resveratrol (3,4',5-trans-trihydroxystilbene) is a phytoalexin with emerging lines of evidence supporting its beneficial effects on cardiovascular systems and inhibition of carcinogenesis. It has also been reported that certain methylated resveratrol derivatives are more effective than resveratrol in the prevention/treatment of cancer. However, little is known about the impact of resveratrol and its derivatives on the development of Parkinson's disease. In this study, we compared the neuroprotective effects of resveratrol with four methylated (fully or partially) resveratrol derivatives against parkinsonian mimetic 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in SH-SY5Y cells. Release of lactate dehydrogenase and activity of caspase-3 triggered by 6-OHDA were significantly reduced by resveratrol and one of the methylated derivatives, pinostilbene (3,4'-dihydroxy-5-methoxystilbene), in a dose-dependent manner. In addition, pinostilbene exerted a potent neuroprotective effect with a wider effective concentration range than resveratrol. By using high-performance liquid chromatography, we found that uptake of pinostilbene into SH-SY5Y cells was significantly higher than that of resveratrol. Enhanced bioavailability may thus be a major factor contributing to the neuroprotective activity of pinostilbene. Moreover. Western blot analysis demonstrated that pinostilbene markedly attenuated the phosphorylation of JNK and c-Jun triggered by 6-OHDA. Besides, mammalian target of rapamycin kinase may be an intracellular target accounting for the neuroprotective effects of pinostilbene. Our findings demonstrate the potential of methylated stilbenes in neuroprotection and provide important information for further research in this field. (C) 2010 Elsevier Inc. All rights reserved.	[Chao, Jianfei; Yu, Man-Shan; Chang, Raymond Chuen-Chung] Univ Hong Kong, Lab Neurodegenerat Dis, Dept Anat, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China; [Wang, Mingfu] Univ Hong Kong, Sch Biol Sci, Fac Sci, Pokfulam, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung] Univ Hong Kong, Res Ctr Heart Brain Hormone & Healthy Aging, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China		Chang, RCC (corresponding author), Univ Hong Kong, Lab Neurodegenerat Dis, Dept Anat, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China.	rccchang@hkucc.hku.hk; mfwang@hkusua.hku.hk	Wang, Mingfu/D-3136-2009; Wang, Mingfu/AAT-3292-2021; Chang, Raymond Chuen-Chung/C-1107-2009; Cheng, Ka Wing/V-9433-2019; Li, Haitao/D-8440-2019	Wang, Mingfu/0000-0003-1469-3963; Chang, Raymond Chuen-Chung/0000-0001-8538-7993; Cheng, Ka Wing/0000-0002-1201-312X; Li, Haitao/0000-0001-9160-8334	HKUUniversity of Hong Kong [200711159028]; University of Hong KongUniversity of Hong Kong	The study is supported by HKU Strategic Theme Research on Drug Discovery, HKU Seed Funding for Basic Research (200711159028) to R. C.-C.C. J.C., HI. and K.-W.C. are supported by a postgraduate studentship, and M.-S.Y. is supported by a postdoctoral fellowship from the University of Hong Kong.	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Auger C, 2005, J AGR FOOD CHEM, V53, P2015, DOI 10.1021/jf048177q; Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567; Borsello T, 2007, CURR PHARM DESIGN, V13, P1875; Burns J, 2002, J AGR FOOD CHEM, V50, P3337, DOI 10.1021/jf0112973; Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x; Chao JF, 2008, FREE RADICAL BIO MED, V45, P1019, DOI 10.1016/j.freeradbiomed.2008.07.002; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.3.CO;2-5; Choi WS, 2004, J BIOL CHEM, V279, P20451, DOI 10.1074/jbc.M311164200; Deng SL, 2006, FOOD CHEM, V98, P112, DOI 10.1016/j.foodchem.2005.05.063; Fang XY, 2005, INT J MOL MED, V16, P1109; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Fujita H, 2006, BRAIN RES, V1113, P10, DOI 10.1016/j.brainres.2006.06.079; Glinka Y, 1997, J NEURAL TRANSM-SUPP, P55; Han YS, 2004, BRIT J PHARMACOL, V141, P997, DOI 10.1038/sj.bjp.0705688; Heynekamp JJ, 2006, J MED CHEM, V49, P7182, DOI 10.1021/jm060630x; Ho YS, 2007, BRAIN RES, V1158, P123, DOI 10.1016/j.brainres.2007.04.075; Kumar A, 2007, PHARMACOLOGY, V79, P17, DOI 10.1159/000097511; Kumar P, 2006, BEHAV PHARMACOL, V17, P485, DOI 10.1097/00008877-200609000-00014; Lai CSW, 2008, BRAIN RES, V1190, P215, DOI 10.1016/j.brainres.2007.10.103; Lai SW, 2006, NEUROPHARMACOLOGY, V50, P641, DOI 10.1016/j.neuropharm.2005.11.009; Lee HH, 2007, J BIOMED SCI, V14, P819, DOI 10.1007/s11373-007-9179-x; Lin KF, 2004, EUR J NEUROSCI, V19, P2047, DOI 10.1111/j.0953-816X.2004.03245.x; Lu KT, 2006, J AGR FOOD CHEM, V54, P3126, DOI [10.1021/jf053011q, 10.1021/JF053011Q]; Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212; Lu ZB, 2006, NEUROCHEM INT, V48, P263, DOI 10.1016/j.neuint.2005.10.010; Ma ZZ, 2006, LIFE SCI, V79, P1307, DOI 10.1016/j.lfs.2006.03.050; Malagelada C, 2006, J NEUROSCI, V26, P9996, DOI 10.1523/JNEUROSCI.3292-06.2006; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Matsuoka A, 2002, MUTAT RES-GEN TOX EN, V521, P29, DOI 10.1016/S1383-5718(02)00211-5; Murias M, 2004, BIOORGAN MED CHEM, V12, P5571, DOI 10.1016/j.bmc.2004.08.008; Orsini F, 2004, J NAT PROD, V67, P421, DOI 10.1021/np0303153; Ramassamy C, 2006, EUR J PHARMACOL, V545, P51, DOI 10.1016/j.ejphar.2006.06.025; Rivera H, 2008, J APPL TOXICOL, V28, P147, DOI 10.1002/jat.1260; Schneider Y, 2003, INT J CANCER, V107, P189, DOI 10.1002/ijc.11344; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Stivala LA, 2001, J BIOL CHEM, V276, P22586, DOI 10.1074/jbc.M101846200; Stojanovic S, 2001, ARCH BIOCHEM BIOPHYS, V391, P79, DOI 10.1006/abbi.2001.2388; Suen KC, 2003, J NEUROCHEM, V87, P1413, DOI 10.1111/j.1471-4159.2003.02259.x; Suen KC, 2003, J BIOL CHEM, V278, P49819, DOI 10.1074/jbc.M306503200; Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885; Wolter F, 2002, J NUTR, V132, P298; Xu BJ, 2007, J FOOD SCI, V72, pS167, DOI 10.1111/j.1750-3841.2006.00261.x; Yu MS, 2007, INT J MOL MED, V20, P261; Yu MS, 2006, INT J MOL MED, V17, P1157; Yu MS, 2006, APOPTOSIS, V11, P687, DOI 10.1007/s10495-006-5540-1; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010; Zheng LF, 2006, FREE RADICAL BIO MED, V41, P1807, DOI 10.1016/j.freeradbiomed.2006.09.007	49	65	68	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0955-2863	1873-4847		J NUTR BIOCHEM	J. Nutr. Biochem.	JUN	2010	21	6					482	489		10.1016/j.jnutbio.2009.02.004			8	Biochemistry & Molecular Biology; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Nutrition & Dietetics	602OT	WOS:000278149400004	19443200				2022-02-06	
J	Bigler, ED; Abildskov, TJ; Wilde, EA; McCauley, SR; Li, XQ; Merkley, TL; Fearing, MA; Newsome, MR; Scheibel, RS; Hunter, JV; Chu, ZL; Levin, HS				Bigler, Erin D.; Abildskov, Tracy J.; Wilde, Elisabeth A.; McCauley, Stephen R.; Li, Xiaoqi; Merkley, Tricia L.; Fearing, Michael A.; Newsome, Mary R.; Scheibel, Randall S.; Hunter, Jill V.; Chu, Zili; Levin, Harvey S.			Diffuse damage in pediatric traumatic brain injury: A comparison of automated versus operator-controlled quantification methods	NEUROIMAGE			English	Article							HUMAN CEREBRAL-CORTEX; GEOMETRICALLY ACCURATE; LONGITUDINAL CHANGES; MRI FINDINGS; SEGMENTATION; MODERATE; HIPPOCAMPAL; CHILDREN; ATROPHY; VOLUME	This investigation had two main objectives: 1) to assess the comparability Of volumes determined by operator-controlled image quantification with automated image analysis in evaluating atrophic brain changes related to traumatic brain injury (TBI) in children, and 2) to assess the extent of diffuse structural changes throughout the brain as determined by reduced volume of a brain Structure or region of interest (ROI). Operator-control led methods used ANALYZE (R) software for segmentation and tracing routines of pre-defined brain structures and Rots. For automated image analyses, the open-access FreeSurfer program was used. Sixteen children with moderate-to-severe TBI were compared to individually matched, typically developing control children and the Volumes of 18 brain structures and/or ROIs were compared between the two methods. Both methods detected atrophic changes but differed in the magnitude of the atrophic effect with the best agreement in subcortical Structures. The volumes of all brain structures/ROIs were smaller in the TBI group regardless of method used; overall effect size differences were minimal for caudate and putamen but moderate to large for all other measures. This is reflective of the diffuse nature of TBI and its widespread impact on structural brain integrity, indicating that both FreeSurfer and operator-control led methods can reliably assess cross-sectional volumetric changes in pediatric TBI. (C) 2010 Elsevier Inc. All rights reserved.	[Bigler, Erin D.; Abildskov, Tracy J.; Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Li, Xiaoqi; Newsome, Mary R.; Scheibel, Randall S.; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Fearing, Michael A.] Hebrew SeniorLife, Dept Med Neuropyschol, Boston, MA USA; [Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Newsome, Mary R.; Scheibel, Randall S.; Levin, Harvey S.] Michael E De Bakey Vet Affairs Med Ctr, Houston, TX USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin-bigler@byu.edu	Merkley, Tricia L./AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-21889]; TIRR Foundation. Erin D. Bigler [1 R01 HD048946-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grant NS-21889 awarded to Harvey S. Levin by the National Institutes of Health. We also acknowledge the generous Support of Mission Connect of the TIRR Foundation. Erin D. Bigler was partially supported by grant 1 R01 HD048946-01A.Z. We acknowledge the contribution of Stacey K. Martin and Jo Ann Petrie for assistance in manuscript preparation. We would also like to thank Paul Swank, PhD, for his helpful advice regarding statistical methodology. Finally, we thank the participants and their farnilies for their interest and involvement in this study.	Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bozzali M, 2008, MAGN RESON IMAGING, V26, P1065, DOI 10.1016/j.mri.2008.01.044; Cherbuin N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005265; Cohen J., 2013, STAT POWER ANAL BEHA; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Diedrichsen J, 2009, NEUROIMAGE, V46, P39, DOI 10.1016/j.neuroimage.2009.01.045; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; FILIPEK PA, 1995, CURR OPIN NEUROL, V8, P134, DOI 10.1097/00019052-199504000-00009; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Ghosh A, 2009, BRAIN INJURY, V23, P228, DOI 10.1080/02699050802672789; Hasan KM, 2009, NEUROIMAGE, V48, P497, DOI 10.1016/j.neuroimage.2009.05.004; Hasan KM, 2009, NEURORADIOLOGY, V51, P201, DOI 10.1007/s00234-008-0492-5; JACK CR, 1995, MAGN RESON IMAGING, V13, P1057, DOI 10.1016/0730-725X(95)02013-J; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; Jovicich J, 2009, NEUROIMAGE, V46, P177, DOI 10.1016/j.neuroimage.2009.02.010; Khan AR, 2008, NEUROIMAGE, V41, P735, DOI 10.1016/j.neuroimage.2008.03.024; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; LEHMANN M, 2009, NEUROIMAGE, DOI DOI 10.1016/J.NEUROIMAGE.200910.056; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Makris N, 2003, J COGNITIVE NEUROSCI, V15, P584, DOI 10.1162/089892903321662967; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; MOREY RA, 2009, NEUROIMAGE, DOI DOI 10.1016/J.NEUROIMAGE.07.013; Morey RA, 2009, NEUROIMAGE, V45, P855, DOI 10.1016/j.neuroimage.2008.12.033; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; ROBB R, 1995, ANAL 3 DIMENSIONAL B; Robb RA, 2001, IEEE T MED IMAGING, V20, P854, DOI 10.1109/42.952724; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Shen L, 2009, HIPPOCAMPUS, V19, P588, DOI 10.1002/hipo.20613; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tae WS, 2008, NEURORADIOLOGY, V50, P569, DOI 10.1007/s00234-008-0383-9; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	56	65	65	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	APR 15	2010	50	3					1017	1026		10.1016/j.neuroimage.2010.01.003			10	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	566YA	WOS:000275408200016	20060915				2022-02-06	
J	Coester, A; Neumann, CR; Schmidt, MI				Coester, Ariane; Neumann, Cristina Rolim; Schmidt, Maria Ines			Intensive Insulin Therapy in Severe Traumatic Brain Injury: A Randomized Trial	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Intensive insulin infusion; Hyperglycemia; Randomized trial	CRITICALLY-ILL PATIENTS; SEVERE HEAD-INJURY; CARE-UNIT; GLUCOSE CONTROL; GLYCEMIC CONTROL; LACTATE/PYRUVATE RATIO; MANAGEMENT PROTOCOL; MORBIDITY REDUCTION; INFUSION PROTOCOL; PRACTICAL SCALE	Background: Intensive insulin therapy (IIT) has been shown to reduce morbidity and mortality in critically ill patients. Little investigation has been done to find out whether it improves the prognosis of patients with severe traumatic brain injury (STBI). Methods: We conducted a prospective controlled study where adult patients with blunt STBI, with Glasgow Coma Scale <= 8, admitted to the intensive care unit (ICU) were randomly assigned to receive either IIT (maintenance of blood glucose between 80 mg/dL and 110 mg/dL with continuous insulin infusion) or conventional glycemic therapy (CGT) (maintenance of blood glucose below 180 mg/dL with subcutaneous insulin and insulin infusion only if blood glucose levels exceeded 220 mg/dL). The main outcome was Glasgow outcome scale 6 months after trauma. Secondary measures were hypoglycemia, incidence of infections, and days in ICU. Results: Of the 88 patients randomized, 42 were assigned to IIT and 46 to CGT. There was no difference (p = 0.63) in neurologic outcomes between the treatment groups: Glasgow outcome scale > 3 was observed in 16 patients (41%) in the IIT and in 13 patients (32.5%) in the CGT group. More patients in the IIT group had hypoglycemia: 32 (82.1%), compared with 7 (17.5%) in the CGT group (p < 0.001). There were no differences in the number of days spent in the ICU (18.2 +/- 27.6 vs. 12.9 +/- 12.7) or in the sepsis rates (84.6% vs. 80%) between the groups. Conclusion: In our study, IIT did not improve the neurologic outcome of patients with STBI but did increase the risk of hypoglycemia compared with CGT.	Univ Fed Rio Grande do Sul, Programa Posgrad Epidemiol, Porto Alegre, RS, Brazil; Hosp Pronto Socorro Porto Alegre, Porto Alegre, RS, Brazil		Coester, A (corresponding author), Rua David Francisco Mauricio 85, BR-91760220 Porto Alegre, RS, Brazil.	arianecoester@yahoo.com.br	Iats, Inct/K-2300-2013; Schmidt, Maria/V-3196-2019; neumann, cristina/K-4692-2012		Brazilian government; CNPq (National Council for Scientific and Technological Development)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	Supported by the Brazilian government and the CNPq (National Council for Scientific and Technological Development).	ALEXANDER EBB, 2002, J PHARM PRACT, V15, P158; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bellomo R, 2009, MAYO CLIN PROC, V84, P400, DOI 10.1016/S0025-6196(11)60557-0; Biffl W, 2007, J TRAUMA, V62, P1375; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta F, 2009, ANESTHESIOLOGY, V110, P611, DOI 10.1097/ALN.0b013e318198004b; Bochicchio GV, 2007, J TRAUMA, V63, P1353, DOI 10.1097/TA.0b013e31815b83c4; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Clayton SB, 2006, CRIT CARE MED, V34, P2974, DOI 10.1097/01.CCM.0000248906.10399.CF; Collier B, 2005, JPEN-PARENTER ENTER, V29, P353, DOI 10.1177/0148607105029005353; de Azevedo JRA, 2007, ARQ NEURO-PSIQUIAT, V65, P733, DOI 10.1590/S0004-282X2007000500001; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Gawryszewski Vilma Pinheiro, 2006, Sao Paulo Med. J., V124, P208, DOI 10.1590/S1516-31802006000400007; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krinsley JS, 2008, CRIT CARE MED, V36, P3008, DOI 10.1097/CCM.0b013e31818b38d2; Krinsley JS, 2007, CRIT CARE MED, V35, P2262, DOI 10.1097/01.CCM.0000282073.98414.4B; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; Lacherade JC, 2007, INTENS CARE MED, V33, P814, DOI 10.1007/s00134-007-0543-0; Langouche L, 2008, CRIT CARE MED, V36, P1475, DOI 10.1097/CCM.0b013e31816f7bae; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Oksanen T, 2007, INTENS CARE MED, V33, P2093, DOI 10.1007/s00134-007-0876-8; *ORG PAN AM SAUD, IND BAS SAUD NO BRAS; Pittas AG, 2004, ARCH INTERN MED, V164, P2005, DOI 10.1001/archinte.164.18.2005; Reed CC, 2007, J AM COLL SURGEONS, V204, P1048, DOI 10.1016/j.jamcollsurg.2006.12.047; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Scalea TM, 2007, ANN SURG, V246, P605, DOI 10.1097/SLA.0b013e318155a789; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Shin S, 2007, AM SURGEON, V73, P769; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; TEASDALE G, 1974, LANCET, V2, P81; Teixeira Paulo José Zimermann, 2004, J. bras. pneumol., V30, P540, DOI 10.1590/S1806-37132004000600009; Toschlog EA, 2007, J TRAUMA, V62, P1370, DOI 10.1097/TA.0b013e318047b7dc; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van den Berghe G, 2006, DIABETES, V55, P3151, DOI 10.2337/db06-0855; Van den Berghe Greet, 2003, Clin Cornerstone, V5, P56, DOI 10.1016/S1098-3597(03)90018-4; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vriesendorp TM, 2008, CURR OPIN CRIT CARE, V14, P397, DOI 10.1097/MCC.0b013e328306c7b1; Vriesendorp TM, 2006, CRIT CARE MED, V34, P2714, DOI 10.1097/01.CCM.0000241155.36689.91; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6	48	65	71	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2010	68	4					904	911		10.1097/TA.0b013e3181c9afc2			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	583GY	WOS:000276663100030	20032790				2022-02-06	
J	Staal, JA; Dickson, TC; Gasperini, R; Liu, Y; Foa, L; Vickers, JC				Staal, Jerome A.; Dickson, Tracey C.; Gasperini, Robert; Liu, Yao; Foa, Lisa; Vickers, James C.			Initial calcium release from intracellular stores followed by calcium dysregulation is linked to secondary axotomy following transient axonal stretch injury	JOURNAL OF NEUROCHEMISTRY			English	Article						calcineurin; diffuse axonal injury; intracellular calcium disruption; neuronal stretch injury; secondary axotomy; traumatic brain injury	TRAUMATIC BRAIN-INJURY; IN-VITRO; CORTICAL-NEURONS; NEURITE OUTGROWTH; SODIUM-CHANNELS; GROWTH CONES; INFLUX; FK506; REORGANIZATION; TETRODOTOXIN	P>Acute axonal shear and stretch in the brain induces an evolving form of axonopathy and is a major cause of ongoing motor, cognitive and emotional dysfunction. We have utilized an in vitro model of mild axon bundle stretch injury, in cultured primary cortical neurons, to determine potential early critical cellular alterations leading to secondary axonal degeneration. We determined that transient axonal stretch injury induced an initial acute increase in intracellular calcium, principally derived from intracellular stores, which was followed by a delayed increase in calcium over 48 h post-injury (PI). This progressive and persistent increase in intracellular calcium was also associated with increased frequency of spontaneous calcium fluxes as well as cytoskeletal abnormalities. Additionally, at 48 h post-injury, stretch-injured axon bundles demonstrated filopodia-like sprout formation that preceded secondary axotomy and degeneration. Pharmacological inhibition of the calcium-activated phosphatase, calcineurin, resulted in reduced secondary axotomy (p < 0.05) and increased filopodial sprout length. In summary, these results demonstrate that stretch injury of axons induced an initial substantial release of calcium from intracellular stores with elevated intracellular calcium persisting over 2 days. These long-lasting calcium alterations may provide new insight into the earliest neuronal abnormalities that follow traumatic brain injury as well as the key cellular changes that lead to the development of diffuse axonal injury and secondary degeneration.	[Staal, Jerome A.] Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas 7001, Australia; Univ Tasmania, Menzies Res Inst, Wicking Dementia Res & Educ Ctr, Hobart, Tas 7001, Australia		Staal, JA (corresponding author), Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Bag 29, Hobart, Tas 7001, Australia.	jerome.staal@utas.edu.au	Vickers, James C/J-7464-2014; Gasperini, Rob/J-7804-2014; Foa, Lisa/J-7781-2014	Vickers, James C/0000-0001-5671-4879; Foa, Lisa/0000-0003-4131-8341; Dickson, Tracey/0000-0002-9196-1661; Gasperini, Rob/0000-0001-6859-1247	Tasmanian Masonic Centenary Medical Research Foundation	The Tasmanian Masonic Centenary Medical Research Foundation supports Dr. Jerome Staal.	Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Blizzard CA, 2007, EUR J NEUROSCI, V26, P1100, DOI 10.1111/j.1460-9568.2007.05750.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Costantini LC, 2000, NEUROSCIENCE, V100, P515, DOI 10.1016/S0306-4522(00)00312-2; Dent EW, 2004, J NEUROSCI, V24, P3002, DOI 10.1523/JNEUROSCI.4963-03.2004; Dent EW, 1999, J NEUROSCI, V19, P8894, DOI 10.1523/JNEUROSCI.19-20-08894.1999; Dent EW, 2001, J NEUROSCI, V21, P9757, DOI 10.1523/JNEUROSCI.21-24-09757.2001; Dickson TC, 2007, NEUROREPORT, V18, P283, DOI 10.1097/WNR.0b013e3280143cdb; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; Erez H, 2008, J COMP NEUROL, V507, P1019, DOI 10.1002/cne.21522; Gallo G, 1998, J NEUROSCI, V18, P5403, DOI 10.1523/JNEUROSCI.18-14-05403.1998; Hutchins BI, 2008, J NEUROSCI, V28, P143, DOI 10.1523/JNEUROSCI.4548-07.2008; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jacobs KM, 1999, J NEUROPHYSIOL, V81, P159, DOI 10.1152/jn.1999.81.1.159; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Kamber D, 2009, EXP NEUROL, V219, P112, DOI 10.1016/j.expneurol.2009.05.004; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1996, LAB INVEST, V74, P315; Meaney DF, 2001, J NEUROSURG, V95, P1108; Prince D A, 1999, Adv Neurol, V79, P665; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Staal JA, 2007, DEV NEUROBIOL, V67, P1831, DOI 10.1002/dneu.20552; Staal JA, 2009, J NEUROTRAUM, V26, P781, DOI 10.1089/neu.2008.0669; Tang FJ, 2005, J NEUROSCI, V25, P6702, DOI 10.1523/JNEUROSCI.0871-05.2005; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; Weber JT, 2002, J NEUROTRAUM, V19, P1433, DOI 10.1089/089771502320914660; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Ziv NE, 1997, J NEUROSCI, V17, P3568	39	65	68	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2010	112	5					1147	1155		10.1111/j.1471-4159.2009.06531.x			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	551VZ	WOS:000274241900005	19968758	Bronze			2022-02-06	
J	Kim, MS; Boone, KB; Victor, T; Marion, SD; Amano, S; Cottingham, ME; Ziegler, EA; Zeller, MA				Kim, Michelle S.; Boone, Kyle B.; Victor, Tara; Marion, Sarah D.; Amano, Stacy; Cottingham, Maria E.; Ziegler, Elizabeth A.; Zeller, Michelle A.			The Warrington Recognition Memory Test for Words as a Measure of Response Bias: Total Score and Response Time Cutoffs Developed on "Real World" Credible and Noncredible Subjects	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; symptom validity testing; Forensic neuropsychology; Head injury; Traumatic brain injury	SENSITIVITY; SPECIFICITY; PERFORMANCE; DYSFUNCTION; IMPAIRMENT; DEFICITS; INJURY; TRIAL	Several studies have examined the usefulness of the Warrington Recognition Memory Test-Words as a measure to detect suspect effort, although samples have generally been small and/or comprised of simulators rather than "real world" credible and noncredible patients. The current study examined the Warrington Recognition Memory Test-Words total score and response time of "real world" noncredible patients (as determined by motive to feign, failure on >= 2 independent measures of response bias, low cognitive scores inconsistent with normal ADLs; n = 190) versus credible patients (as determined by no motive to feign, failure of < 1 measure of response bias; n = 124) derived from an archival database of individuals from the Harbor-UCLA Medical Center, Department of Psychiatry, Outpatient Neuropsychology Service, and the private practice of the second author. Noncredible patients obtained significantly lower total scores and longer times to complete the task. A total correct cutoff of < 42 was found to have excellent specificity (91.9%) and sensitivity (88.9%), whereas a time cutoff of >= 207 ' was associated with 65.5% sensitivity at 90.7% specificity, and when the time cut-score was used in combination with the total score cutoff, an additional 5% of the noncredible participants were captured, raising overall sensitivity to 93.7% (at 87.1% specificity). Thus, the Warrington Recognition Memory Test-Words, although not originally created for the purposes of measuring suspect effort, appears to be an excellent measure for detecting response bias on neuropsychological testing.	[Kim, Michelle S.; Marion, Sarah D.; Amano, Stacy] Fuller Grad Sch Psychol, Pasadena, CA USA; [Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Ctr Forens Studies, Los Angeles, CA USA; [Victor, Tara] Calif State Univ Dominguez Hills, Dept Psychol, Carson, CA USA; [Cottingham, Maria E.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA; [Ziegler, Elizabeth A.] Spokane VA Med Ctr, Spokane, WA USA; [Zeller, Michelle A.] W Los Angeles VA Med Ctr, Dept Psychol, Los Angeles, CA USA		Boone, KB (corresponding author), 24564 Hawthorne Blvd,Suite 208, Torrance, CA 90505 USA.	kboone@labiomed.org	Victor, Tara/K-6581-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Baker R, 2000, Appl Neuropsychol, V7, P111, DOI 10.1207/S15324826AN0702_8; Boone K., 2002, DOT COUNTING TEST; Boone K. B., 2002, B TEST; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; BOONE KB, 2009, CLIN NEUROPSYCHOLOGI; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Egeland J, 2003, J CLIN EXP NEUROPSYC, V25, P79, DOI 10.1076/jcen.25.1.79.13630; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; GOLDBERG HB, 2007, ASSESSMENT FEIGNED C; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; O'Bryant SE, 2003, ARCH CLIN NEUROPSYCH, V18, P135, DOI 10.1016/S0887-6177(01)00189-5; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Ross SR, 2006, J CLIN EXP NEUROPSYC, V28, P111, DOI 10.1080/13803390590929270; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Tardif HP, 2000, INT J PSYCHOPHYSIOL, V36, P1, DOI 10.1016/S0167-8760(00)00083-0; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wogar MA, 1998, BRIT J CLIN PSYCHOL, V37, P327, DOI 10.1111/j.2044-8260.1998.tb01389.x	35	65	65	1	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2010	25	1					60	70		10.1093/arclin/acp088			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	547DI	WOS:000273865400007	19906738	Bronze			2022-02-06	
J	Wilde, EA; Ramos, MA; Yallampalli, R; Bigler, ED; McCauley, SR; Chu, ZL; Wu, TC; Hanten, G; Scheibel, RS; Li, XQ; Vasquez, AC; Hunter, JV; Levin, HS				Wilde, Elisabeth A.; Ramos, Marco A.; Yallampalli, Ragini; Bigler, Erin D.; McCauley, Stephen R.; Chu, Zili; Wu, Trevor C.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Vasquez, Ana C.; Hunter, Jill V.; Levin, Harvey S.			Diffusion Tensor Imaging of the Cingulum Bundle in Children After Traumatic Brain Injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							WHITE-MATTER INJURY; AXONAL INJURY; SPATIAL ATTENTION; COGNITIVE-CONTROL; CORPUS-CALLOSUM; HEAD TRAUMA; CORTEX; MILD; MRI; SEVERITY	Structural damage to the prefrontal-cingulate network has been implicated in cognitive and neurobehavioral deficits associated with traumatic brain injury (TBI). Forty-six children who had sustained moderate-to-severe TBI and 43 children with extracranial injury were imaged using diffusion tensor imaging (DTI). Decreased fractional anisotropy (FA) and increased apparent diffusion coefficient (ADC) values were found in the cingulum bundles bilaterally in the TBI group. Cingulum ADC was related to frontal lesion volume, injury severity, and injury mechanism. Finally, cingulum DTI parameters were related to cognitive control measures. DTI detects TBI-related injury to the cingulum, which may facilitate advances in assessment and treatment.	[Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Yallampalli, Ragini; McCauley, Stephen R.; Hanten, Gerri; Scheibel, Randall S.; Li, Xiaoqi; Vasquez, Ana C.; Levin, Harvey S.] Univ Texas Houston Med Sch, Houston, TX USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Neurol, Hematol Oncol Sect, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Scheibel, Randall S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Ramos, Marco A.; Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA; [Bigler, Erin D.; Wu, Trevor C.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Radiol, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu		Ramos, Marco/0000-0002-1649-7547	National Institute Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS21889]; TIRR Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This work was supported by the National Institute Neurological Disorders and Stroke grant R01-NS21889 ("Neurobehavioral outcome of head injury in children," Levin, PI). The authors also acknowledge the generous contribution of Mission Connect of the TIRR Foundation.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Bunge SA, 2001, BRAIN, V124, P2074, DOI 10.1093/brain/124.10.2074; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; *COMM INJ SCAL, 1990, ABBR INJ SCAL; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GEAN A, 1994, IMAGING HEAD; GENNARELLI TA, 1993, J EMERG MED, V1, P5; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Gong GL, 2005, NEUROREPORT, V16, P1701, DOI 10.1097/01.wnr.0000183327.98370.6a; Gong GL, 2005, HUM BRAIN MAPP, V24, P92, DOI 10.1002/hbm.20072; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; Hoogenraad F., 2002, MULTICENTER EVALUATI; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Huster RJ, 2007, NEUROIMAGE, V34, P888, DOI 10.1016/j.neuroimage.2006.10.023; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kadosh RC, 2008, NEUROPSYCHOLOGIA, V46, P2872, DOI 10.1016/j.neuropsychologia.2008.05.025; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; MacDonald CL, 2008, NEUROLOGY, V71, P1199, DOI 10.1212/01.wnl.0000327521.69520.7f; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Mesulam MM, 2001, NEUROIMAGE, V13, P1065, DOI 10.1006/nimg.2001.0768; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Netsch T, 2001, INT C COMP VIS VANC; Nielson KA, 2005, NEUROBIOL LEARN MEM, V84, P42, DOI 10.1016/j.nlm.2005.03.004; Park HJ, 2004, NEUROIMAGE, V23, P213, DOI 10.1016/j.neuroimage.2004.04.036; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Small DM, 2003, NEUROIMAGE, V18, P633, DOI 10.1016/S1053-8119(02)00012-5; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Stancin T, 2001, J TRAUMA, V51, P69, DOI 10.1097/00005373-200107000-00011; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2009, J CLIN EXP NEUROPSYC, V31, P205, DOI 10.1080/13803390802098118; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Yucel M, 2001, CEREB CORTEX, V11, P17, DOI 10.1093/cercor/11.1.17	77	65	68	0	11	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2010	35	3					333	351	PII 921879186	10.1080/87565641003696940			19	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	594EX	WOS:000277518100007	20446136	Green Accepted			2022-02-06	
J	Mayer, AR; Mannell, MV; Ling, J; Elgie, R; Gasparovic, C; Phillips, JP; Doezema, D; Yeo, RA				Mayer, Andrew R.; Mannell, Maggie V.; Ling, Josef; Elgie, Robert; Gasparovic, Charles; Phillips, John P.; Doezema, David; Yeo, Ronald A.			Auditory Orienting and Inhibition of Return in Mild Traumatic Brain Injury: A FMRI Study	HUMAN BRAIN MAPPING			English	Article						traumatic brain injury; attention; auditory; bottom-up; orienting; FMRI	EVENT-RELATED FMRI; DIFFUSE AXONAL INJURY; VISUOSPATIAL ATTENTION DEFICITS; VISUAL-ATTENTION; FUNCTIONAL MRI; WORKING-MEMORY; SPATIAL ATTENTION; HEAD-INJURY; CONCUSSION; DYSFUNCTION	The semiacute phase of mild traumatic brain injury (mTBI) is associated with deficits in the cognitive domains of attention, memory, and executive function, which previous work suggests may be related to a specific deficit in disengaging attentional focus. However, to date, there have only been a few studies that have employed dynamic imaging techniques to investigate the potential neurological basis of these cognitive deficits during the semiacute stage of injury. Therefore, event-related functional magnetic resonance imaging was used to investigate the neurological correlates of attentional dysfunction in a clinically homogeneous sample of 16 patients with mTBI during the semiacute phase of injury (<3 weeks). Behaviorally, patients with mTBI exhibited deficits in disengaging and reorienting auditory attention following invalid cues as well as a failure to inhibit attentional allocation to a cued spatial location compared to a group of matched controls. Accordingly, patients with mTBI also exhibited hypoactivation within thalamus, striatum, midbrain nuclei, and cerebellum across all trials as well as hypoactivation in the right posterior parietal cortex, presupplementary motor area, bilateral frontal eye fields, and right ventrolateral prefrontal cortex during attentional disengagement. Finally, the hemodynamic response within several regions of the attentional network predicted response times better for controls than for patients with mTBI. These objective neurological findings represent a potential biomarker for the behavioral deficits in spatial attention.that characterize the initial recovery phase of mTBI. Hum Brain Mapp 30:4152-4166, 2009. (C) 2009 Wiley-Liss, Inc.	[Mayer, Andrew R.; Mannell, Maggie V.; Ling, Josef; Gasparovic, Charles; Phillips, John P.; Yeo, Ronald A.] Mind Res Network, Albuquerque, NM 87106 USA; [Mayer, Andrew R.; Phillips, John P.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Elgie, Robert; Doezema, David] Univ New Mexico, Sch Med, Dept Emergency Med, Albuquerque, NM 87131 USA; [Gasparovic, Charles; Yeo, Ronald A.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Gasparovic, Charles/E-7289-2010		Department of EnergyUnited States Department of Energy (DOE) [DE-FG02-99ER62764]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24-HD050836, R21NS064464-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	Contract grant sponsor: Department of Energy; Contract grant number: DE-FG02-99ER62764; Contract grant sponsor: National Institutes of Health; Contract grant number: R24-HD050836, R21NS064464-01A1.	AREND I, 2008, REV NEUROL, V131, P2140; Arrington CM, 2000, J COGNITIVE NEUROSCI, V12, P106, DOI 10.1162/089892900563975; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Belin P, 2002, NEUROPSYCHOLOGIA, V40, P1956, DOI 10.1016/S0028-3932(02)00062-3; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Burock MA, 1998, NEUROREPORT, V9, P3735, DOI 10.1097/00001756-199811160-00030; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278; Corbetta M, 2000, NAT NEUROSCI, V3, P292, DOI 10.1038/73009; Corbetta M, 1998, PHILOS T ROY SOC B, V353, P1353, DOI 10.1098/rstb.1998.0289; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; GASPAROVIC C, 2009, J NEUROTRAU IN PRESS; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Harris NS, 1999, COGNITIVE BRAIN RES, V8, P61, DOI 10.1016/S0926-6410(99)00006-3; Hesselmann V, 2001, HEARING RES, V158, P160, DOI 10.1016/S0378-5955(01)00307-0; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lepsien J, 2002, J COGNITIVE NEUROSCI, V14, P127, DOI 10.1162/089892902317236795; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Mayer AR, 2009, NEUROIMAGE, V44, P182, DOI 10.1016/j.neuroimage.2008.08.025; Mayer AR, 2007, J COGNITIVE NEUROSCI, V19, P455, DOI 10.1162/jocn.2007.19.3.455; Mayer AR, 2004, NEUROIMAGE, V23, P534, DOI 10.1016/j.neuroimage.2004.06.027; Mayer AR, 2004, J COGNITIVE NEUROSCI, V16, P1262, DOI 10.1162/0898929041920531; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; Pavlovskaya M, 2007, BRAIN INJURY, V21, P489, DOI 10.1080/02699050701311117; POSNER MI, 1985, COGNITIVE NEUROPSYCH, V2, P211, DOI 10.1080/02643298508252866; RAFAL RD, 1987, P NATL ACAD SCI USA, V84, P7349, DOI 10.1073/pnas.84.20.7349; Salmi J, 2007, BRAIN STRUCT FUNCT, V212, P181, DOI 10.1007/s00429-007-0152-2; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SMITS M, 2008, HUM BRAIN M IN PRESS; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Talairach J., 1988, COPLANAR STERIOTAXIC; Thiel CM, 2004, NEUROIMAGE, V21, P318, DOI 10.1016/j.neuroimage.2003.08.044; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Ueda Y, 2006, ACTA NEUROPATHOL, V112, P85, DOI 10.1007/s00401-005-0029-5; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Zatorre RJ, 2002, NAT NEUROSCI, V5, P905, DOI 10.1038/nn904	71	65	65	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	DEC	2009	30	12					4152	4166		10.1002/hbm.20836			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	530IW	WOS:000272584000025	19554558	Green Accepted, Green Published			2022-02-06	
J	Mazzeo, AT; Brophy, GM; Gilman, CB; Alves, OL; Robles, JR; Hayes, RL; Povlishock, JT; Bullock, MR				Mazzeo, Anna Teresa; Brophy, Gretchen M.; Gilman, Charlotte B.; Alves, Oscar Luis; Robles, Jaime R.; Hayes, Ronald L.; Povlishock, John T.; Bullock, M. Ross			Safety and Tolerability of Cyclosporin A in Severe Traumatic Brain Injury Patients: Results from a Prospective Randomized Trial	JOURNAL OF NEUROTRAUMA			English	Article						cyclosporin A; neurological outcome; neuroprotection; safety; traumatic brain injury	MITOCHONDRIAL PERMEABILITY TRANSITION; SEVERE HEAD-INJURY; TRANSIENT FOREBRAIN ISCHEMIA; INDUCED AXONAL DAMAGE; CYTOCHROME-C RELEASE; CELL-DEATH; IMMUNOSUPPRESSIVE THERAPY; REPERFUSION INJURY; CASPASE ACTIVATION; OXIDATIVE STRESS	Cyclosporin A (CsA) has recently been proposed for use in the early phase after traumatic brain injury (TBI), for its ability to preserve mitochondrial integrity in experimental brain injury models, and thereby provide improved behavioral outcomes as well as significant histological protection. The aim of this prospective, randomized, double-blind, dual-center, placebo-controlled trial was to evaluate the safety, tolerability, and pharmacokinetics of a single intravenous infusion of CsA in patients with severe TBI. Fifty adult severe TBI patients were enrolled over a 22-month period. Within 12 h of the injury patients received 5mg/kg of CsA infused over 24 h, or placebo. Blood urea nitrogen ( BUN), creatinine, hemoglobin, platelets, white blood cell count (WBC), and a hepatic panel were monitored on admission, and at 12, 24, 36, and 48 h, and on days 4 and 7. Potential adverse events (AEs) were also recorded. Neurological outcome was recorded at 3 and 6 months after injury. This study revealed only transient differences in BUN levels at 24 and 48 h and for WBC counts at 24 h between the CsA and placebo patients. These modest differences were not clinically significant in that they did not negatively impact on patient course. Both BUN and creatinine values, markers of renal function, remained within their normal limits over the entire monitoring period. There were no significant differences in other mean laboratory values, or in the incidence of AEs at any other measured time point. Also, no significant difference was demonstrated for neurological outcome. Based on these results, we report a good safety profile of CsA infusion when given at the chosen dose of 5mg/kg, infused over 24 h, during the early phase after severe head injury in humans, with the aim of neuroprotection.	[Bullock, M. Ross] Univ Miami, Miller Sch Med, Dept Neurosurg, Lois Pope LIFE Ctr, Miami, FL 33136 USA; [Mazzeo, Anna Teresa] Univ Messina, Dept Neurosci, Messina, Italy; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharm & Neurosurg, Richmond, VA USA; [Robles, Jaime R.] Virginia Commonwealth Univ, Dept Pharm, Sch Pharm, Richmond, VA USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Gilman, Charlotte B.] Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; [Alves, Oscar Luis] Univ Porto, Serv Neurocirurgia, Ctr Hosp Vila Nova Gaia, Fac Med, P-4100 Oporto, Portugal; [Hayes, Ronald L.] Univ Florida, Dept Neurosurg, Ctr Innovat Res, Banyan Biomarkers Inc, Alachua, FL USA		Bullock, MR (corresponding author), Univ Miami, Miller Sch Med, Dept Neurosurg, Lois Pope LIFE Ctr, 1095 NW 14th Terrace,Suite 3-20 R-48, Miami, FL 33136 USA.	rbullock@med.miami.edu		Mazzeo, Anna Teresa/0000-0002-8454-7243; Brophy, Gretchen/0000-0002-4749-2693	NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587]; Lind-Lawrence Foundation; Reynolds Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER	This study was funded by the NIH-NINDS as part of project grant no. NS12587 to M.R.B. (the primary investigator), and by the Lind-Lawrence Foundation and the Reynolds Foundation.	Al Aly Z, 2005, CLIN TRANSPLANT, V19, P683, DOI 10.1111/j.1399-0012.2005.00408.x; Aleo MD, 2008, TOXICOL APPL PHARM, V230, P126, DOI 10.1016/j.taap.2008.02.011; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Benigni A, 1999, KIDNEY INT, V55, P674, DOI 10.1046/j.1523-1755.1999.00288.x; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Buki A, 2000, J NEUROSCI, V20, P2825; Cattaneo D, 2004, TRANSPL P, V36, p234S, DOI 10.1016/j.transproceed.2004.01.011; Danovitch GM, 2005, HDB KIDNEY TRANSPLAN, P72; Fellstrom B, 2004, TRANSPLANT P, V36, p220S, DOI 10.1016/j.transproceed.2004.01.028; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Gardiner SM, 2004, BRIT J PHARMACOL, V141, P634, DOI 10.1038/sj.bjp.0705659; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; JENNETT B, 1975, LANCET, V1, P480; Kapturczak MH, 2004, TRANSPL P, V36, p25S, DOI 10.1016/j.transproceed.2004.01.018; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mazzeo AT, 2008, ACTA NEUROCHIR, V150, P1019, DOI 10.1007/s00701-008-0021-7; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Miller LW, 1996, CIRCULATION, V94, P1209, DOI 10.1161/01.CIR.94.6.1209; MIN DI, 1991, PHARMACOTHERAPY, V11, pS119; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Paul LC, 2004, TRANSPL P, V36, p224S, DOI 10.1016/j.transproceed.2004.01.005; Piot C, 2008, NEW ENGL J MED, V359, P473, DOI 10.1056/NEJMoa071142; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; PTACHCINSKI RJ, 1986, CLIN PHARMACOKINET, V11, P107, DOI 10.2165/00003088-198611020-00002; QUATTROCCHI K B, 1991, Neurological Research, V13, P13; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; QUATTROCCHI KB, 1992, J NEUROSURG, V77, P694, DOI 10.3171/jns.1992.77.5.0694; REMUZZI G, 1995, KIDNEY INT, V48, pS70; Rezzani R, 2004, PROG HISTOCHEM CYTO, V39, P85, DOI 10.1016/j.proghi.2004.04.001; ROULLET JB, 1994, J CLIN INVEST, V93, P2244, DOI 10.1172/JCI117222; Schiff J, 2007, CLIN J AM SOC NEPHRO, V2, P374, DOI 10.2215/CJN.03791106; Shaltout HA, 2003, J PHARMACOL EXP THER, V305, P966, DOI 10.1124/jpet.102.048447; Shaw LM, 1996, CLIN CHEM, V42, P1316; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SZABO I, 1991, J BIOL CHEM, V266, P3376; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Wang XD, 2001, GENE DEV, V15, P2922; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	64	65	67	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2195	2206		10.1089/neu.2009.1012			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200007	19621985	Green Published			2022-02-06	
J	Downey, DM; Monson, B; Butler, KL; Fortuna, GR; Saxe, JM; Dolan, JP; Markert, RJ; McCarthy, MC				Downey, Douglas M.; Monson, Benjamin; Butler, Karyn L.; Fortuna, Gerald R., Jr.; Saxe, Jonathan M.; Dolan, James P.; Markert, Ronald J.; McCarthy, Mary C.			Does Platelet Administration Affect Mortality in Elderly Head-Injured Patients Taking Antiplatelet Medications?	AMERICAN SURGEON			English	Article							TRAUMATIC INTRACRANIAL HEMORRHAGE	A significant portion of patients sustaining traumatic brain injury (TBI) take antiplatelet medications (aspirin or clopidogrel), which have been associated with increased morbidity and mortality. In an attempt to alleviate the risk of increased bleeding, platelet transfusion has become standard practice in some institutions. This study was designed to determine if platelet transfusion reduces mortality in patients with TBI on antiplatelet medications. Databases from two Level I trauma centers were reviewed. Patients with TBI 50 years of age or older with documented preinjury use of clopidogrel or aspirin were included in our cohort. Patients who received platelet transfusions were compared with those who did not to assess outcome differences between them. Demographics and other patient characteristics abstracted included Injury Severity Score, Glasgow Coma Scale, hospital length of stay, and warfarin use. Three hundred twenty-eight patients comprised the study group. Of these patients, 166 received platelet transfusion and 162 patients did not. Patients who received platelets had a mortality rate of 17.5 per cent (29 of 166), whereas those who did not receive platelets had a mortality rate of 16.7 per cent (27 of 162) (P = 0.85). Transfusion of platelets in patients with TBI using antiplatelet therapy did not reduce mortality.	[Saxe, Jonathan M.; McCarthy, Mary C.] Wright State Univ, Boonshoft Sch Med, Dept Surg, Div Trauma, Dayton, OH 45409 USA; [Butler, Karyn L.] Hartford Hosp, Dept Surg, Hartford, CT 06115 USA; [Fortuna, Gerald R., Jr.] Univ Cincinnati, Sch Med, Dept Surg, Cincinnati, OH USA; [Dolan, James P.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR USA		Saxe, JM (corresponding author), Wright State Univ, Boonshoft Sch Med, Dept Surg, Weber Ctr Hlth Educ,Miami Valley Hosp, Suite 7000,1 Wyoming St, Dayton, OH 45409 USA.	jonathan.m.saxe@wright.edu					Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Rutledge R, 1997, J TRAUMA, V42, P477, DOI 10.1097/00005373-199703000-00016; Santa-Cruz Richard A, 2004, Curr Cardiol Rep, V6, P264, DOI 10.1007/s11886-004-0074-z; Seegmiller A, 2007, HEMATOL ONCOL CLIN N, V21, P731, DOI 10.1016/j.hoc.2007.06.008; Stuart G, 1998, J CLIN NEUROSCI, V5, P402, DOI 10.1016/S0967-5868(98)90271-5; Vane JR, 2003, THROMB RES, V110, P255, DOI 10.1016/S0049-3848(03)00379-7; Vilahur G, 2007, J THROMB HAEMOST, V5, P82, DOI 10.1111/j.1538-7836.2006.02245.x	12	65	67	0	2	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	NOV	2009	75	11					1100	1103					4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	513PZ	WOS:000271336600015	19927514				2022-02-06	
J	Krajewska, M; Smith, LH; Rong, J; Huang, XS; Hyer, ML; Zeps, N; Iacopetta, B; Linke, SP; Olson, AH; Reed, JC; Krajewski, S				Krajewska, Maryla; Smith, Layton H.; Rong, Juan; Huang, Xianshu; Hyer, Marc L.; Zeps, Nikolajs; Iacopetta, Barry; Linke, Steven P.; Olson, Allen H.; Reed, John C.; Krajewski, Stan			Image Analysis Algorithms for Immunohistochemical Assessment of Cell Death Events and Fibrosis in Tissue Sections	JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY			English	Article						cell death; automated image analysis; algorithm; autoscore; virtual pathology	POLY(ADP-RIBOSE) POLYMERASE; HISTONE H2AX; DNA-DAMAGE; APOPTOSIS; EXPRESSION; HISTOPATHOLOGY; QUANTIFICATION; STRATEGIES; PROTEINS; CLEAVAGE	Cell death is of broad physiological and pathological importance, making quantification of biochemical events associated with cell demise a high priority for experimental pathology. Fibrosis is a common consequence of tissue injury involving necrotic cell death. Using tissue specimens from experimental mouse models of traumatic brain injury, cardiac fibrosis, and cancer, as well as human tumor specimens assembled in tissue microarray (TMA) format, we undertook computer-assisted quantification of specific immunohistochemical and histological parameters that characterize processes associated with cell death. In this study, we demonstrated the utility of image analysis algorithms for color deconvolution, colocalization, and nuclear morphometry to characterize cell death events in tissue specimens: (a) subjected to immunostaining for detecting cleaved caspase-3, cleaved poly(ADP-ribose)polymerase, cleaved lamin-A, phosphorylated histone H2AX, and Bcl-2; (b) analyzed by terminal deoxyribonucleotidyl transferase-mediated dUTP nick end labeling assay to detect DNA fragmentation; and (c) evaluated with Masson's trichrome staining. We developed novel algorithm-based scoring methods and validated them using TMAs as a high-throughput format. The proposed computer-assisted scoring methods for digital images by brightfield microscopy permit linear quantification of immunohistochemical and histochemical stainings. Examples are provided of digital image analysis performed in automated or semiautomated fashion for successful quantification of molecular events associated with cell death in tissue sections. (J Histochem Cytochem 57:649-663, 2009)	[Krajewska, Maryla; Rong, Juan; Huang, Xianshu; Hyer, Marc L.; Reed, John C.; Krajewski, Stan] Burnham Inst Med Res, La Jolla, CA 92037 USA; [Smith, Layton H.] Lake Nona Orlando, Orlando, FL USA; [Zeps, Nikolajs] Bendat Family Comprehens Canc Ctr, Subiaco, WA, Australia; [Iacopetta, Barry] Univ Western Australia, Nedlands, WA 6009, Australia; [Olson, Allen H.] Aperio Technol Inc, Vista, CA USA		Krajewski, S (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stan@burnham.org	Zeps, Nikolajs/C-4180-2013; Zeps, Nikolajs/AAF-3186-2021	Zeps, Nikolajs/0000-0002-6404-6839; Zeps, Nikolajs/0000-0002-6404-6839; Smith, Layton/0000-0003-2621-9740; Linke, Steven/0000-0001-8584-4947	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [036821, U01-CA113318]; California Breast Cancer Research Program [10WB-0194]; Florida Department of Health [06-NIR-09]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R44CA-117001]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [U19CA113318, R44CA117001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036821] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) Grant NS-036821 (to SK), the California Breast Cancer Research Program (grant 10WB-0194) and NIH Grant U01-CA113318 (to JCR) and Florida Department of Health (grant 06-NIR-09 to LS). The TMA project was supported by National Cancer Institute Grant R44CA-117001 (to SPL). We thank Lisa Spalding for high-quality TMA preparation and Jessica Groos and Judy Wade for excellent animal care assistance.	BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Billet S, 2007, J CLIN INVEST, V117, P1914, DOI 10.1172/JCI28764; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Brennan DJ, 2008, CLIN CANCER RES, V14, P2681, DOI 10.1158/1078-0432.CCR-07-1760; Fine JL, 2008, HUM PATHOL, V39, P564, DOI 10.1016/j.humpath.2007.08.007; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Rojo MG, 2006, INT J SURG PATHOL, V14, P285, DOI 10.1177/1066896906292274; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Jonker A, 1997, HISTOCHEM J, V29, P347, DOI 10.1023/A:1026434816947; Kivinen K, 2005, EXP CELL RES, V311, P62, DOI 10.1016/j.yexcr.2005.08.006; Krajewska M, 2005, CLIN CANCER RES, V11, P5451, DOI 10.1158/1078-0432.CCR-05-0094; Krajewska M, 2008, CLIN CANCER RES, V14, P3011, DOI 10.1158/1078-0432.CCR-07-1955; Krajewska M, 2007, PROSTATE, V67, P907, DOI 10.1002/pros.20578; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kumar S, 1997, INT J BIOCHEM CELL B, V29, P393, DOI 10.1016/S1357-2725(96)00146-X; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Meier P, 2007, MOL CELL, V28, P746, DOI 10.1016/j.molcel.2007.11.016; Mulrane L, 2008, EXPERT REV MOL DIAGN, V8, P707, DOI 10.1586/14737159.8.6.707; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Plesca D, 2008, METHOD ENZYMOL, V446, P107, DOI 10.1016/S0076-6879(08)01606-6; Ramires FJA, 1998, J MOL CELL CARDIOL, V30, P475, DOI 10.1006/jmcc.1997.0612; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Reed WP, 2004, SURG ENDOSC, V18, P11, DOI 10.1007/s00464-003-8913-3; Rexhepaj E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2187; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; ROSENTHAL WD, 1990, J PROD AGRIC, V3, P124, DOI 10.2134/jpa1990.0124; Rubin MA, 2004, AM J PATHOL, V164, P831, DOI 10.1016/S0002-9440(10)63171-9; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Takemura G, 2004, PHARMACOL THERAPEUT, V104, P1, DOI 10.1016/j.pharmthera.2004.07.005; Taylor CR, 2006, HISTOPATHOLOGY, V49, P411, DOI 10.1111/j.1365-2559.2006.02513.x; Tewari M, 2008, SURG ONCOL, V17, P301, DOI 10.1016/j.suronc.2008.03.003; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Weber KT, 2004, HYPERTENSION, V43, P716, DOI 10.1161/01.HYP.0000118586.38323.5b; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307	41	65	66	1	11	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0022-1554	1551-5044		J HISTOCHEM CYTOCHEM	J. Histochem. Cytochem.	JUL	2009	57	7					649	663		10.1369/jhc.2009.952812			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	457PZ	WOS:000266945800005	19289554	Bronze, Green Published			2022-02-06	
J	Ryu, WHA; Feinstein, A; Colantonio, A; Streiner, DL; Dawson, DR				Ryu, Won Hyung A.; Feinstein, Anthony; Colantonio, Angela; Streiner, David L.; Dawson, Deirdre R.			Early Identification and Incidence of Mild TBI in Ontario	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							TRAUMATIC BRAIN-INJURY; HEAD-INJURY; MANAGEMENT; EMERGENCY; CARE; EPIDEMIOLOGY; CONCUSSION; AGREEMENT; COMMUNITY	Objectives: (1) To examine the variability in diagnosis of mild traumatic brain injury (mTBI) in primary care relative to that of an expert reviewer; and (2) to determine the incidence rate of mTBI in Ontario, Canada. Method: Potential mTBI cases were identified through reviewing three months of Emergency Department (ED) and Family Physician (FP) health records. Potential cases were selected from ED records using the International Classification of Disease, 9th revision, Clinical Modification and External Cause codes and from all FPS records for the time period. Documented diagnoses of mTBI were compared to expert reviewer diagnosis. Incidence of mTBI was determined using the documented diagnoses and data from hospital catchment areas and population census. Results: 876 potential mTBI cases were identified, 25 from FP records. Key indicators of mTBI were missing on many records (e.g., 308/876 records had Glasgow Coma Scale (GCS) scores). The expert reviewer disagreed with the documented diagnosis in 380/876 cases (kappa=0.19). The expert reviewer was more likely to give a diagnosis if the GCS was 13-14, if there was documented loss of consciousness and/or post-traumatic amnesia, and/or if there was pathology found on an acute brain scan. Calculated incidence rates of hospital-treated mTBI were 426 or 535/100,000 (expert review - hospital diagnosis). Including family physician cases increased the rate to 493 or 653/100,000. Conclusion: Health record documentation of key indicators for mTBI is often lacking. Notwithstanding, some patients with mTBI appear to be missed or misdiagnosed by primary care physicians. A more comprehensive case definition resulted in estimated incidence rates higher than previous reports.	[Ryu, Won Hyung A.; Streiner, David L.; Dawson, Deirdre R.] Baycrest, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; [Ryu, Won Hyung A.; Colantonio, Angela; Streiner, David L.; Dawson, Deirdre R.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Colantonio, Angela; Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Feinstein, Anthony; Streiner, David L.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Feinstein, Anthony] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Ryu, Won Hyung A.; Colantonio, Angela; Dawson, Deirdre R.] Toronto Rehabil Inst, Toronto, ON, Canada		Dawson, DR (corresponding author), Baycrest, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Dawson, Deirdre R/I-8882-2014; Streiner, David/E-6563-2011; Ryu, Won H/AAU-6774-2020	Dawson, Deirdre R/0000-0001-7517-6121; Streiner, David/0000-0003-0610-6271; Colantonio, Angela/0000-0003-2094-4765			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM AC NEUR QUAL S, PRACT PAR MAN CONC S; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; ANDERSON DW, 1980, J NEUROSURG      NOV, pS11; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Hustey FM, 2002, ANN EMERG MED, V39, P248, DOI 10.1067/mem.2002.122057; Jaakkimainen L., 2006, PRIMARY CARE ONTARIO; Kennedy JE, 2006, MIL MED, V171, P516, DOI 10.7205/MILMED.171.6.516; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KURTZKE JF, 1993, CLIN NEUROL; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Medicode (Firm), 1997, ICD 9 CM INT CLASS D; *MILD TRAUM BRAIN, 2003, 1 NAT CTR INJ PREV C; Norman G, 2000, BIOSTATISTICS BARE E; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schootman M, 2000, BRAIN INJURY, V14, P373; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Von Wild K, 2001, BRAIN INJURY, V15, P273	35	65	65	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	JUL	2009	36	4					429	435		10.1017/S0317167100007745			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	481VR	WOS:000268840900005	19650352	Bronze			2022-02-06	
J	Svetlov, SI; Larner, SF; Kirk, DR; Atkinson, J; Hayes, RL; Wang, KKW				Svetlov, Stanislav I.; Larner, Stephen F.; Kirk, Daniel R.; Atkinson, Joseph; Hayes, Ronald L.; Wang, Kevin K. W.			Biomarkers of Blast-Induced Neurotrauma: Profiling Molecular and Cellular Mechanisms of Blast Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; blast; brain injury; molecular pathways; traumatic brain injury	NEURON-SPECIFIC ENOLASE; SPECTRIN BREAKDOWN PRODUCTS; NEUROTROPHIC PROTEIN S100B; NITRIC-OXIDE SYNTHASE; ALPHA-II-SPECTRIN; CEREBROSPINAL-FLUID; NEUROPROTECTIVE ROLE; OXIDATIVE STRESS; SERUM S-100B; TAU CLEAVAGE	The nature of warfare in the 21st century has led to a significant increase in primary blast or over-pressurization injuries to the whole body and head, which manifest as a complex of neuro-somatic damage, including traumatic brain injury (TBI). Identifying relevant pathogenic pathways in reproducible experimental models of primary blast wave exposure is therefore vital to the development of biomarkers for diagnostics of blast brain injury. Comparative analysis of mechanisms and putative biomarkers of blast brain injury is complicated by a deficiency of experimental studies. In this article, we present an overview of current TBI biomarkers, as well as outline experimental strategies to investigate molecular signatures of blast neurotrauma and to develop a pathway network map for novel biomarker discovery. These biomarkers will be effective for triaging and managing both combat and civilian causalities.	[Svetlov, Stanislav I.; Larner, Stephen F.; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL 32615 USA; [Kirk, Daniel R.; Atkinson, Joseph] Florida Inst Technol, Dept Mech & Aerosp Engn, Melbourne, FL 32901 USA; [Svetlov, Stanislav I.] Univ Florida, Dept Physiol Sci, Gainesville, FL 32610 USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA		Svetlov, SI (corresponding author), Banyan Biomarkers Inc, Ctr Innovat Res, 12085 Res Dr, Alachua, FL 32615 USA.	ssvetlov@banyanbio.com		Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [N14-06-1-1029, W81XWH-8-1-0376, X81XWH-07-01-0701]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER	The authors wish to thank Ms. Qiushi Tang for her excellent technical assistance. This work was supported by grants N14-06-1-1029, W81XWH-8-1-0376 and X81XWH-07-01-0701 from Department of Defense.	Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1999, WORLD J SURG, V23, P44, DOI 10.1007/s002689900563; Cernak I, 1991, Vojnosanit Pregl, V48, P515; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1991, Vojnosanit Pregl, V48, P507; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cernak Ibolja, 1995, Magnesium Research, V8, P249; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Elsayed NM, 2003, TOXICOLOGY, V189, P63, DOI 10.1016/S0300-483X(03)00153-7; Elsayed NM, 1997, TOXICOLOGY, V121, P81, DOI 10.1016/S0300-483X(97)03657-3; Elsayed NM, 1996, EXP LUNG RES, V22, P179, DOI 10.3109/01902149609050846; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; GALEA E, 1995, J NEUROSCI RES, V41, P452, DOI 10.1002/jnr.490410404; Gorbunov NV, 1996, BIOCHEM BIOPH RES CO, V219, P835, DOI 10.1006/bbrc.1996.0319; Gorbunov NV, 1997, AM J PHYSIOL-LUNG C, V272, pL320, DOI 10.1152/ajplung.1997.272.2.L320; Guy R J, 2000, J R Nav Med Serv, V86, P125; Guy R J, 2000, J R Nav Med Serv, V86, P27; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; JAFFIN JH, 1987, J TRAUMA, V27, P349, DOI 10.1097/00005373-198704000-00002; Januszkiewicz AJ, 1997, TOXICOLOGY, V121, P51, DOI 10.1016/S0300-483X(97)03655-X; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; Kaur C, 1999, HISTOL HISTOPATHOL, V14, P417, DOI 10.14670/HH-14.417; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Lescuyer P, 2007, J PROTEOME RES, V6, P3371, DOI 10.1021/pr0702060; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Michetti F, 2002, CLIN CHEM, V48, P2097; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Nath R, 1998, J NEUROCHEM, V71, P186; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Park SY, 2007, NEUROSCIENCE, V144, P119, DOI 10.1016/j.neuroscience.2006.09.012; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Savic J, 1991, Vojnosanit Pregl, V48, P499; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Stuhmiller JH, 1996, J BIOMECH, V29, P227, DOI 10.1016/0021-9290(95)00039-9; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Vorst MV, 2007, J TRAUMA, V62, P199, DOI 10.1097/01.ta.0000238665.09611.4b; VINORES SA, 1984, J HISTOCHEM CYTOCHEM, V32, P1295, DOI 10.1177/32.12.6389693; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Yilmaz S, 2007, AM J EMERG MED, V25, P97, DOI 10.1016/j.ajem.2006.04.014; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	89	65	69	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2009	26	6					913	921		10.1089/neu.2008.0609			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	455OV	WOS:000266773600009	19422293	Green Published			2022-02-06	
J	Orrison, WW; Hanson, EH; Alamo, T; Watson, D; Sharma, M; Perkins, TG; Tandy, RD				Orrison, William W., Jr.; Hanson, Eric H.; Alamo, Tony; Watson, David; Sharma, Mythri; Perkins, Thomas G.; Tandy, Richard D.			Traumatic Brain Injury: A Review and High-Field MRI Findings in 100 Unarmed Combatants Using a Literature-Based Checklist Approach	JOURNAL OF NEUROTRAUMA			English	Article						boxing; checklist; magnetic resonance imaging; traumatic brain injury; unarmed combatants	DIFFUSE AXONAL INJURY; VIRCHOW-ROBIN SPACES; CEREBRAL MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; HEAD TRAUMA; HIPPOCAMPAL VOLUME; ARACHNOID CYSTS; FIBER TRACKING; CELL LOSS; MILD	This study reviewed the literature for the extent of neuroimaging findings in boxers, indicative of traumatic brain injury (TBI) as identified in magnetic resonance imaging (MRI). The study then utilized a systematic checklist approach to assess 100 unselected consecutive 1.5- and 3.0-Tesla MRI examinations of professional unarmed combatants to determine the extent of identifiable TBI findings. The percentage of positive findings and the localization of lesions were quantified using the checklist that included the MRI findings previously reported in the medical literature. Seventy-six percent of the unarmed combatants had at least one finding that may be associated with TBI: 59% hippocampal atrophy, 43% cavum septum pellucidum, 32% dilated perivascular spaces, 29% diffuse axonal injury, 24% cerebral atrophy, 19% increased lateral ventricular size, 14% pituitary gland atrophy, 5% arachnoid cysts, and 2% had contusions. Statistical relationships were found between number of bouts and lateral ventricular size (tau-b=0.149, p = 0.0489), with years of fighting correlating with the presence of dilated perivascular spaces (tau-b = 0.167, p = 0.0388) and diffuse axonal injury (tau-b = 0.287, p = 0.0013) findings. The improved resolution and increased signal-to-noise ratio on 1.5- and 3.0-Tesla high-field MRI systems defines the range of pathological variations that may occur in professional unarmed combatants. Additionally, the use of a systematic checklist approach insures evaluation for all possible TBI-related abnormalities. This knowledge can be used to anticipate the regions of potential brain pathology for radiologists and emergency medicine physicians, and provides important information for evaluating unarmed combatants relative to their safety and long-term neurocognitive outcome.	[Orrison, William W., Jr.; Hanson, Eric H.] Amigenics Inc, Las Vegas, NV 89118 USA; [Orrison, William W., Jr.] Nevada Imaging Ctr, Las Vegas, NV USA; [Orrison, William W., Jr.; Hanson, Eric H.; Sharma, Mythri] Touro Univ, Nevada Coll Osteopath Med, Henderson, NV USA; [Alamo, Tony] Alamo Med Clin, Henderson, NV USA; [Watson, David] Nevada State Athlet Commiss, Las Vegas, NV USA; [Perkins, Thomas G.] Philips Healthcare, Cleveland, OH USA; [Tandy, Richard D.] Univ Nevada, Dept Kinesiol, Las Vegas, NV 89154 USA		Hanson, EH (corresponding author), Amigenics Inc, 5495 S Rainbow Blvd,Suite 102, Las Vegas, NV 89118 USA.	eric.hanson@amigenics.com	Hanson, Eric H/B-7367-2009				Adriani M, 2003, NEUROIMAGE, V20, pS66, DOI 10.1016/j.neuroimage.2003.09.007; Allkemper T, 2004, RADIOLOGY, V232, P874, DOI 10.1148/radiol.2323030322; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Bailes JE, 2001, J ATHL TRAINING, V36, P236; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Benvenga Salvatore, 2005, Pituitary, V8, P193, DOI 10.1007/s11102-006-6040-6; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BILANIUK LT, 1984, RADIOLOGY, V153, P409, DOI 10.1148/radiology.153.2.6541355; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; Brandstack N, 2006, BRAIN INJURY, V20, P409, DOI 10.1080/02699050500487951; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Eskandary H, 2005, SURG NEUROL, V63, P550, DOI 10.1016/j.surneu.2004.07.049; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gosalakkal JA, 2002, PEDIATR NEUROL, V26, P93, DOI 10.1016/S0887-8994(01)00329-0; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Groeschel S, 2006, NEURORADIOLOGY, V48, P745, DOI 10.1007/s00234-006-0112-1; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; Hesselink John R, 2006, Top Magn Reson Imaging, V17, P243, DOI 10.1097/01.rmr.0000248666.91834.af; Howell DC., 1997, STAT METHODS PSYCHOL, V4th ed; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2006, BRAIN INJURY, V20, P15, DOI 10.1080/02699050500309593; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2005, AM J NEURORADIOL, V26, P719; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KINARD RE, 1986, AM J ROENTGENOL, V147, P848, DOI 10.2214/ajr.147.4.848; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lidzba K, 2006, NEUROREPORT, V17, P929, DOI 10.1097/01.wnr.0000221841.12632.d6; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P, 2002, BRIT J SPORT MED, V36, P157, DOI 10.1136/bjsm.36.3.157; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; *NAC, 2007, NEV STAT ATHL COMM F; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; ORRISON WW, 1991, RADIOLOGY, V181, P121, DOI 10.1148/radiology.181.1.1887020; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; RODRIGUEZ G, 1983, LANCET, V2, P858; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schneider HJ, 2007, J ENDOCRINOL INVEST, V30, pRC9, DOI 10.1007/BF03346291; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TIMMING R, 1982, ARCH PHYS MED REHAB, V63, P154; Tisserand DJ, 2006, BRAIN COGNITION, V60, P216; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; WESTER K, 1992, NEUROSURGERY, V31, P940, DOI 10.1227/00006123-199211000-00018; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321	79	65	65	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					689	701		10.1089/neu.2008.0636			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500005	19335205				2022-02-06	
J	Aoshiba, K; Onizawa, S; Tsuji, T; Nagai, A				Aoshiba, Kazutetsu; Onizawa, Shigemitsu; Tsuji, Takao; Nagai, Atsushi			Therapeutic effects of erythropoietin in murine models of endotoxin shock	CRITICAL CARE MEDICINE			English	Article						septic shock; erythropoietin; apoptosis; nitric oxide; hypoxia; mouse	NITRIC-OXIDE SYNTHASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; CRITICALLY-ILL PATIENTS; LUNG INJURY; SEPSIS; EFFICACY; RAT; INHIBITION; EXPRESSION; APOPTOSIS	Objective: Erythropoietin has recently emerged as a cytoprotective cytokine, which possesses the ability to protect many tissues, including the brain, heart, and kidneys, against ischemia or traumatic injury. We investigated the therapeutic effects of erythropoietin in a murine model of endotoxin shock. Design. Prospective, randomized study. Setting: University-based research laboratory. Subjects: Male BALB/c mice. Interventions., Mice intraperitoneally received either lipopolysaccharide (LPS) from Escherichia coli or vehicle. Erythropoietin was administered at a dose of 1000 IU/kg subcutaneously at different time points after LPS administration. We also investigated the effect of erythropoietin on the development of septic shock caused by cecal perforation. Measurements and Main Results: Treatment of mice with erythropoietin, within 2 hours after LPS administration, improved the mortality rate. Treatment of cecal perforated mice with erythropoietin extended survival by 12 hours, but all animals died by 72 hours in both groups. Erythropoietin attenuated apoptosis in the lungs, liver, small intestine, thymus, and spleen, as assessed by terminal deoxynucleotidyl transferase-mediated nucleotide nick-end labeling staining, active caspase-3 immunostaining and immunoblotting, and measurements of caspase-3/7 activity. Erythropoietin also reduced inducible nitric oxide synthase expression, nitric oxide production, peroxynitrite formation, and tissue hypoxia. In contrast, erythropoietin did not affect the degree of LPS-induced inflammation, as assessed by measurements of blood levels of interleukin-1 beta, interleukin-6, tumor necrosis factor-a, growth-related oncogene/keratinocyte-derived cytokine, and high mobility group box 1, the phosphorylation levels of nuclear factor kappa B, and the number of neutrophils infiltrating the lungs and the liver. Conclusions: The results of the study demonstrate that administration of a large dose of erythropoietin after induction of experimental endotoxemia improved survival and that the beneficial effects of erythropoietin were associated with inhibition of apoptosis, nitric oxide production, and tissue hypoxia, without alterations in inflammatory responses. (Crit Care Med 2009; 37: 889-898)	[Aoshiba, Kazutetsu; Onizawa, Shigemitsu; Tsuji, Takao; Nagai, Atsushi] Tokyo Womens Med Univ, Dept Med 1, Tokyo, Japan		Aoshiba, K (corresponding author), Tokyo Womens Med Univ, Dept Med 1, Tokyo, Japan.	kaoshiba@chi.twmu.ac.jp					Abdelrahman M, 2004, SHOCK, V22, P63, DOI 10.1097/01.shk.00001276869.21260.9d; Akimoto T, 1999, J HYPERTENS, V17, P1249, DOI 10.1097/00004872-199917090-00003; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Brown K.A., 2006, LANCET, V368, P157, DOI [10.1016/S0140-6736(06)69005-3, DOI 10.1016/S0140-6736(06)69005-3]; Cauwels A, 2007, KIDNEY INT, V72, P557, DOI 10.1038/sj.ki.5002340; Chandra Abhijit, 2006, Clinics, V61, P71, DOI 10.1590/S1807-59322006000100012; Connelly L, 2005, J BIOL CHEM, V280, P10040, DOI 10.1074/jbc.M411991200; Coopersmith CM, 2002, JAMA-J AM MED ASSOC, V287, P1716, DOI 10.1001/jama.287.13.1716; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Cuzzocrea S, 2006, CRIT CARE MED, V34, P1168, DOI 10.1097/01.CCM.0000207346.56477.E8; d'Uscio LV, 2007, HYPERTENSION, V49, P1142, DOI 10.1161/HYPERTENSIONAHA.106.085704; Dellinger R Phillip, 2008, Crit Care Med, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Farrell F, 2004, ONCOLOGIST, V9, P18, DOI 10.1634/theoncologist.9-90005-18; Foster DJ, 2004, AM J PHYSIOL-LUNG C, V287, pL1107, DOI 10.1152/ajplung.00119.2004; Genc K, 2006, PHYSIOL RES, V55, P33; GHEZZL P, 2003, CELL DEATH DIFFER, V11, pS37; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 2003, SCAND J INFECT DIS, V35, P585, DOI 10.1080/00365540310015692; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Kamolz LP, 2002, J RECONSTR MICROSURG, V18, P487, DOI 10.1055/s-2002-33319; Koroglu TF, 2006, PHYSIOL RES, V55, P309; LEERS MP, 1999, J PATHOL, V5, P562; Lehner MD, 2006, J PHARMACOL EXP THER, V317, P181, DOI 10.1124/jpet.105.098673; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Matejovic M, 2004, SHOCK, V21, P458, DOI 10.1097/00024382-200405000-00010; McGown CC, 2007, BRIT J ANAESTH, V98, P163, DOI 10.1093/bja/ael358; Okamoto I, 2000, AM J RESP CRIT CARE, V162, P716, DOI 10.1164/ajrccm.162.2.9907039; PEARCE ML, 1965, CIRC RES, V16, P482, DOI 10.1161/01.RES.16.5.482; Remick DG, 2007, AM J PATHOL, V170, P1435, DOI 10.2353/ajpath.2007.060872; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Savino R, 2004, CELL DEATH DIFFER, V11, pS2, DOI 10.1038/sj.cdd.4401469; Sharples EJ, 2006, NEPHRON EXP NEPHROL, V104, pE83, DOI 10.1159/000094546; Silver M, 2006, CRIT CARE MED, V34, P2310, DOI 10.1097/01.CCM.0000233873.17954.42; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Squadrito F, 1999, BRIT J PHARMACOL, V127, P482, DOI 10.1038/sj.bjp.0702521; Strunk V, 2001, ANESTH ANALG, V92, P681, DOI 10.1213/00000539-200103000-00025; WAND H, 2004, NAT MED, V10, P1216; Wang W, 2004, AM J PHYSIOL-RENAL, V287, pF1044, DOI 10.1152/ajprenal.00136.2004; Wang XQ, 1999, HYPERTENSION, V33, P894, DOI 10.1161/01.HYP.33.3.894; WESHCHESOLDATO DE, 2007, CURR DRUG TARGETS, V8, P493; Westenfelder C, 1999, KIDNEY INT, V55, P808, DOI 10.1046/j.1523-1755.1999.055003808.x; Wu HW, 2006, EUR J CARDIO-THORAC, V29, P902, DOI 10.1016/j.ejcts.2006.02.036; Yang CW, 2003, FASEB J, V17, P1754, DOI 10.1096/fj.02-1191fje; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Yasuda CL, 2006, SEIZURE-EUR J EPILEP, V15, P35, DOI 10.1016/j.seizure.2005.10.005	52	65	68	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2009	37	3					889	898		10.1097/CCM.0b013e31819b8371			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	413FW	WOS:000263779300012	19237893				2022-02-06	
J	Wagner, AK; Drewencki, LL; Chen, X; Santos, FR; Khan, AS; Harun, R; Torres, GE; Michael, AC; Dixon, CE				Wagner, Amy K.; Drewencki, Laura L.; Chen, Xiangbai; Santos, F. Ryan; Khan, Amina S.; Harun, Rashed; Torres, Gonzalo E.; Michael, Adrian C.; Dixon, C. Edward			Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						dopamine; methylphenidate; neurotransmission; striatum; transcription factor; traumatic brain injury; voltammetry	TYROSINE-HYDROXYLASE ACTIVITY; CORTICAL IMPACT INJURY; PROTEIN-KINASE-A; C-FOS; RAT STRIATUM; DYNAMIC REGULATION; GENE-EXPRESSION; TRANSPORTER; RELEASE; TRAFFICKING	Traumatic brain injury (TBI) results in functional deficits that often are effectively treated clinically with the neurostimulant, methylphenidate (MPH). We hypothesized that daily MPH administration would reverse striatal neurotransmission deficits observed in the controlled cortical impact (CCI) model of TBI. CCI or naive rats received daily injections of MPH (5 mg/kg) or saline for 14 days and were assessed on day 15 using fast scan cyclic voltammetry. Dopamine (DA) transporter (DAT) localization, DA-related proteins, and transcription factor (c-fos) expression were also assessed. CCI resulted in reduced electrically evoked overflow of DA and maximal velocity of DA clearance (V-max). In contrast, CCI was associated with a decrease in the apparent K-M of DAT. Daily dose of MPH after CCI resulted in robust increases in evoked DA overflow and V-max as well as increased apparent K-M. Reductions in total striatal DAT expression occurred after CCI and were not further affected by MPH. In contrast, membrane-bound striatal DAT levels were increased in both CCI groups. MPH post-CCI significantly increased striatal c-fos levels compared with saline. These results support the hypothesis that daily MPH improves striatal DA neurotransmission after CCI. DAT expression and transcriptional changes affecting DA protein function may underlie the injury and MPH-induced alterations in neurotransmission observed.	[Wagner, Amy K.; Drewencki, Laura L.; Chen, Xiangbai; Santos, F. Ryan; Khan, Amina S.; Harun, Rashed; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Drewencki, Laura L.; Chen, Xiangbai; Santos, F. Ryan; Harun, Rashed; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Wagner, Amy K.; Harun, Rashed; Torres, Gonzalo E.] Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Torres, Gonzalo E.] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15213 USA; [Michael, Adrian C.] Univ Pittsburgh, Sch Arts & Sci, Dept Chem, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	Wagnerak@upmc.edu		Harun, Rashed/0000-0003-1843-6710	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08HD40833, R01NS40125]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125] Funding Source: NIH RePORTER	This work was supported by NIH K08HD40833 (AKW) and R01NS40125 (CED). Special thanks to Xiecheng Ma and Scott Kunkel for their technical support on this project.	Batchelor M, 1998, J NEUROSCI, V18, P10304; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; Borland LM, 2004, J NEUROCHEM, V91, P220, DOI 10.1111/j.1471-4159.2004.02708.x; Brandon CL, 2003, EUR J NEUROSCI, V18, P1584, DOI 10.1046/j.1460-9568.2003.02892.x; Bungay PM, 2003, J NEUROCHEM, V86, P932, DOI 10.1046/j.1471-4159.2003.01904.x; Canales JJ, 2000, ANN NEUROL, V47, pS53; Chase TD, 2003, NEUROREPORT, V14, P769, DOI 10.1097/00001756-200304150-00022; Crawford CA, 1998, PSYCHOPHARMACOLOGY, V136, P34, DOI 10.1007/s002130050536; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DONNEMILLER E, 2001, EUR J NUCL MED, V27, P1410; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Fleckenstein AE, 2009, NEUROPHARMACOLOGY, V56, P133, DOI 10.1016/j.neuropharm.2008.07.002; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; GARRIS PA, 1994, J NEUROSCI, V14, P442; Garris PA, 1997, BRAIN RES, V753, P225, DOI 10.1016/S0006-8993(97)00003-6; Geerlings A, 2001, J BIOL CHEM, V276, P17584, DOI 10.1074/jbc.M010602200; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Greco PG, 2003, EUR J PHARMACOL, V479, P117, DOI 10.1016/j.ejphar.2003.08.062; Hawken CM, 2004, NEUROREPORT, V15, P1045, DOI 10.1097/00001756-200404290-00022; Hersch SM, 1997, J COMP NEUROL, V388, P211; Hoffman BJ, 1998, FRONT NEUROENDOCRIN, V19, P187, DOI 10.1006/frne.1998.0168; HOPE B, 1992, P NATL ACAD SCI USA, V89, P5764, DOI 10.1073/pnas.89.13.5764; Jones SR, 1999, J NEUROCHEM, V73, P2406, DOI 10.1046/j.1471-4159.1999.0732406.x; Kilbourn MR, 1996, NUCL MED BIOL, V23, P467, DOI 10.1016/0969-8051(96)00023-6; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kulagina NV, 2001, NEUROSCIENCE, V102, P121, DOI 10.1016/S0306-4522(00)00480-2; Kumer SC, 1996, J NEUROCHEM, V67, P443; Lee KH, 2004, NEUROCHEM RES, V29, P1405, DOI 10.1023/B:NERE.0000026404.08779.43; Li LB, 2004, J BIOL CHEM, V279, P21012, DOI 10.1074/jbc.M311972200; Lin JS, 1996, P NATL ACAD SCI USA, V93, P14128, DOI 10.1073/pnas.93.24.14128; Lindgren N, 2001, EUR J NEUROSCI, V13, P773, DOI 10.1046/j.0953-816x.2000.01443.x; Lindgren N, 2000, J NEUROCHEM, V74, P2470, DOI 10.1046/j.1471-4159.2000.0742470.x; MAY LJ, 1989, BRAIN RES, V487, P311, DOI 10.1016/0006-8993(89)90835-4; Michael DJ, 1999, J PHARMACEUT BIOMED, V19, P33, DOI 10.1016/S0731-7085(98)00145-9; Miranda M, 2007, MOL BIOL CELL, V18, P313, DOI 10.1091/mbc.E06-08-0704; Moll GH, 2001, J CHILD ADOL PSYCHOP, V11, P15, DOI 10.1089/104454601750143366; Mortensen OV, 2003, EUR J PHARMACOL, V479, P159, DOI 10.1016/j.ejphar.2003.08.066; Munir M, 2000, NEUROCHEM INT, V37, P147, DOI 10.1016/S0197-0186(00)00018-8; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Quick MW, 2002, P NATL ACAD SCI USA, V99, P5686, DOI 10.1073/pnas.082712899; Robinson DL, 2004, J NEUROCHEM, V90, P894, DOI 10.1111/j.1471-4159.2004.02559.x; Sabeti J, 2002, J NEUROSCI METH, V121, P41, DOI 10.1016/S0165-0270(02)00229-7; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; VanderBorght T, 1995, EUR J PHARMACOL, V294, P577; Venton BJ, 2003, J NEUROCHEM, V87, P1284, DOI 10.1046/j.1471-4159.2003.02109.x; Volz TJ, 2008, J PHARMACOL EXP THER, V327, P161, DOI 10.1124/jpet.108.139386; Volz TJ, 2007, J PHARMACOL EXP THER, V323, P738, DOI 10.1124/jpet.107.126888; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wightman RM, 2007, EUR J NEUROSCI, V26, P2046, DOI 10.1111/j.1460-9568.2007.05772.x; WIGHTMAN RM, 1990, BRAIN RES REV, V15, P135, DOI 10.1016/0165-0173(90)90015-G; Williams JM, 2006, HANDB EXP PHARM, V175, P215; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Wu Q, 2001, J NEUROSCI METH, V112, P119, DOI 10.1016/S0165-0270(01)00459-9; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; Yang H, 1998, J NEUROCHEM, V71, P684; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yatin SM, 2005, J NEUROSCI METH, V143, P69, DOI 10.1016/j.jneumeth.2004.09.016; Yatin SM, 2002, SYNAPSE, V45, P52, DOI 10.1002/syn.10084; Yi JJ, 2005, NEURON, V47, P629, DOI 10.1016/j.neuron.2005.07.008; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zhu J, 2005, J NEUROCHEM, V93, P1434, DOI 10.1111/j.1471-4159.2005.03130.x; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982	70	65	66	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2009	108	4					986	997		10.1111/j.1471-4159.2008.05840.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	395IF	WOS:000262517100013	19077052	Green Accepted			2022-02-06	
J	Catale, C; Marique, P; Closset, A; Meulemans, T				Catale, Corinne; Marique, Patricia; Closset, Annette; Meulemans, Thierry			Attentional and executive functioning following mild traumatic brain injury in children using the Test for Attentional Performance (TAP) battery	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Children; Executive functions; Attentional functions; Test for Attentional Performance	CLOSED-HEAD INJURY; DEFICIT HYPERACTIVITY DISORDER; YOUNG-CHILDREN; ADOLESCENTS; CHILDHOOD	The interpretation of the data regarding cognitive outcome in children who have suffered from mild traumatic brain injury (MTBI) remains currently controversial. The aim of the present study is to explore attentional and executive functioning in 6-12-year-old children who experienced a MTBI. A total of 15 children with MTBI and 15 matched noninjured children participated in the study. Attentional tasks using the Test for Attentional Performance battery were administered one year after the injury. In comparison to the noninjury children, MTBI children performed less accurately on selective attentional and updating tasks. These preliminary findings support the view that MTBI can have an impact on specific attentional functioning in children one year postinjury.	[Catale, Corinne; Closset, Annette; Meulemans, Thierry] Univ Liege, Neuropsychol Unit, B-4000 Liege, Belgium; [Marique, Patricia] Ctr Neurol William Lennox, Ottignies, Belgium; [Closset, Annette] Ctr Hosp Reg Citadelle, Liege, Belgium		Catale, C (corresponding author), Univ Liege, Neuropsychol Unit, Blvd Rectorat B33, B-4000 Liege, Belgium.	corinne.catale@ulg.ac.be					Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Drechsler R, 2005, J CHILD PSYCHOL PSYC, V46, P824, DOI 10.1111/j.1469-7610.2004.00384.x; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; Robin DA, 1999, APHASIOLOGY, V13, P701, DOI 10.1080/026870399401812; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Sattler J. M., 1981, ASSESSMENT CHILDRENS; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; TEASDALE G, 1974, LANCET, V2, P81; Tucha O, 2006, PSYCHOPHARMACOLOGY, V185, P315, DOI 10.1007/s00213-006-0318-2; Wechsler D., 1992, WECHSLER INTELLIGENC, V3rd; Ziminermann P., 1994, TESTS EVALUATION ATT; Zimmermann P, 2004, TESTS EVALUATION ATT; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	26	65	65	1	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	3					331	338	PII 793898307	10.1080/13803390802134616			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	423QF	WOS:000264510100007	18608644				2022-02-06	
J	Flierl, MA; Stahel, PF; Rittirsch, D; Huber-Lang, M; Niederbichler, AD; Hoesel, LM; Touban, BM; Morgan, SJ; Smith, WR; Ward, PA; Ipaktchi, K				Flierl, Michael A.; Stahel, Philip F.; Rittirsch, Daniel; Huber-Lang, Markus; Niederbichler, Andreas D.; Hoesel, L. Marco; Touban, Basel M.; Morgan, Steven J.; Smith, Wade R.; Ward, Peter A.; Ipaktchi, Kyros			Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis	CRITICAL CARE			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; MELANOCYTE-STIMULATING HORMONE; CLOSED-HEAD INJURY; SEPTIC ENCEPHALOPATHY; ANAPHYLATOXIN C5A; RECEPTOR EXPRESSION; ADHESION MOLECULE-1; INNATE IMMUNITY; ANIMAL-MODELS	Introduction Septic encephalopathy secondary to a breakdown of the blood-brain barrier (BBB) is a known complication of sepsis. However, its pathophysiology remains unclear. The present study investigated the effect of complement C5a blockade in preventing BBB damage and pituitary dysfunction during experimental sepsis. Methods Using the standardised caecal ligation and puncture (CLP) model, Sprague-Dawley rats were treated with either neutralising anti-C5a antibody or pre-immune immunoglobulin (Ig) G as a placebo. Sham-operated animals served as internal controls. Results Placebo-treated septic rats showed severe BBB dysfunction within 24 hours, accompanied by a significant upregulation of pituitary C5a receptor and pro-inflammatory cytokine expression, although gene levels of growth hormone were significantly attenuated. The pathophysiological changes in placebo-treated septic rats were restored by administration of neutralising anti-C5a antibody to the normal levels of BBB and pituitary function seen in the sham-operated group. Conclusions Collectively, the neutralisation of C5a greatly ameliorated pathophysiological changes associated with septic encephalopathy, implying a further rationale for the concept of pharmacological C5a inhibition in sepsis.	[Flierl, Michael A.; Stahel, Philip F.; Touban, Basel M.; Morgan, Steven J.; Smith, Wade R.; Ipaktchi, Kyros] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg, Denver, CO 80204 USA; [Rittirsch, Daniel] Univ Zurich Hosp, Dept Trauma Surg, CH-8091 Zurich, Switzerland; [Huber-Lang, Markus] Univ Hosp Ulm, Dept Trauma Hand Plast & Reconstruct Surg, D-89075 Ulm, Germany; [Niederbichler, Andreas D.] Univ Med Ctr Hannover MHH, Dept Plast Hand & Reconstruct Surg, D-30625 Hannover, Germany; [Rittirsch, Daniel; Hoesel, L. Marco; Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA		Stahel, PF (corresponding author), Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg, 777 Bannock St, Denver, CO 80204 USA.	philip.stahel@dhha.org	Huber-Lang, Markus/AAJ-2209-2020	Rittirsch, Daniel/0000-0002-1185-2431			Albrecht EA, 2004, AM J PATHOL, V164, P849, DOI 10.1016/S0002-9440(10)63173-2; Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; BAKER CC, 1983, SURGERY, V94, P331; Boos L, 2004, J IMMUNOL, V173, P4708, DOI 10.4049/jimmunol.173.7.4708; BREDER CD, 1994, P NATL ACAD SCI USA, V91, P11393, DOI 10.1073/pnas.91.24.11393; Brzoska T, 2008, ENDOCR REV, V29, P581, DOI 10.1210/er.2007-0027; Catania A, 2000, CRIT CARE MED, V28, P1403, DOI 10.1097/00003246-200005000-00024; Crane JW, 2007, NEUROSCI LETT, V424, P10, DOI 10.1016/j.neulet.2007.07.012; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Davoust N, 1999, GLIA, V26, P201, DOI 10.1002/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9; ERNST JD, 1984, INFECT IMMUN, V46, P81, DOI 10.1128/IAI.46.1.81-86.1984; Esmon CT, 2004, CRIT CARE MED, V32, pS219, DOI 10.1097/01.CCM.0000127036.27343.48; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; FAUSTUMANN PM, 1995, ACTA NEUROPATHOL, V89, P239; Flierl MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002560; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; Francis K, 2003, FASEB J, V17, P2266, DOI 10.1096/fj.02-1103fje; Francis Karen, 2003, Expert Reviews in Molecular Medicine, V5, P1, DOI 10.1017/S1462399403006252; Gasque P, 1997, AM J PATHOL, V150, P31; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; Gerard C, 2003, NEW ENGL J MED, V348, P167, DOI 10.1056/NEJMcibr022995; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Guo RF, 2000, J CLIN INVEST, V106, P1271, DOI 10.1172/JCI10793; HACK CE, 1989, AM J MED, V86, P20, DOI 10.1016/0002-9343(89)90224-6; Handa O, 2008, AM J PHYSIOL-HEART C, V295, pH1712, DOI 10.1152/ajpheart.00476.2008; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hess DC, 1996, NEUROSCI LETT, V213, P37, DOI 10.1016/0304-3940(96)12837-8; HESS DC, 1994, NEUROSCI LETT, V168, P201, DOI 10.1016/0304-3940(94)90450-2; Hofer S, 2008, J SURG RES, V146, P276, DOI 10.1016/j.jss.2007.07.021; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Huber-Lang MS, 2001, FASEB J, V15, P568; Jacob A, 2007, LAB INVEST, V87, P1186, DOI 10.1038/labinvest.3700686; Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1; Laudes IJ, 2002, J IMMUNOL, V169, P5962, DOI 10.4049/jimmunol.169.10.5962; Laudes IJ, 2002, AM J PATHOL, V160, P1867, DOI 10.1016/S0002-9440(10)61133-9; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; LEWIS BM, 2006, END ABSTR, V11, pP602; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; Maxime V, 2007, CRIT CARE MED, V35, pS596, DOI 10.1097/01.CCM.0000279097.67263.52; Mulligan MS, 1997, J IMMUNOL, V158, P1857; Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818; NAKAE H, 1994, RES COMMUN CHEM PATH, V84, P189; Nakae H, 1996, SURG TODAY, V26, P225, DOI 10.1007/BF00311579; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Niederbichler AD, 2006, J EXP MED, V203, P53, DOI 10.1084/jem.20051207; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; Piazza O, 2007, BRIT J ANAESTH, V99, P518, DOI 10.1093/bja/aem201; Poli-De-Figueiredo LF, 2008, SHOCK, V30, P53, DOI 10.1097/SHK.0b013e318181a343; PORTER JC, 1983, VITAM HORM, V40, P145, DOI 10.1016/S0083-6729(08)60434-3; Raffin-Sanson ML, 2003, EUR J ENDOCRINOL, V149, P79, DOI 10.1530/eje.0.1490079; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Reyes TM, 1999, BRAIN RES, V851, P215, DOI 10.1016/S0006-8993(99)02189-7; RIECKMANN P, 1995, NEUROSCI LETT, V186, P61, DOI 10.1016/0304-3940(95)11282-2; Riedemann NC, 2003, J IMMUNOL, V170, P503, DOI 10.4049/jimmunol.170.1.503; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Rittirsch D, 2007, J LEUKOCYTE BIOL, V81, P137, DOI 10.1189/jlb.0806542; ROSS R, 1991, CLIN ENDOCRINOL, V35, P47, DOI 10.1111/j.1365-2265.1991.tb03495.x; Schmid E, 1997, SHOCK, V8, P119, DOI 10.1097/00024382-199708000-00010; Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38; Sharshar T, 2005, CRIT CARE, V9, P37, DOI 10.1186/cc2951; Sharshar T, 2007, INTENS CARE MED, V33, P798, DOI 10.1007/s00134-007-0598-y; Stahel PF, 1997, J IMMUNOL, V159, P861; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Stove S, 1996, CLIN DIAGN LAB IMMUN, V3, P175; TOKLU HZ, 2008, J SURG RES; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; WILLIAMS CA, 1985, J NEUROIMMUNOL, V9, P29, DOI 10.1016/S0165-5728(85)80004-7; WONG D, 1995, MICROVASC RES, V49, P325, DOI 10.1006/mvre.1995.1028; Wratten ML, 2008, EUR J ANAESTH, V25, P1, DOI 10.1017/S0265021507003444	81	65	71	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	1							R12	10.1186/cc7710			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	421IC	WOS:000264351600012	19196477	gold, Green Accepted, Green Published			2022-02-06	
J	Lange, RT; Iverson, GL; Franzen, MD				Lange, Rael T.; Iverson, Grant L.; Franzen, Michael D.			Neuropsychological functioning following complicated vs. uncomplicated mild traumatic brain injury	BRAIN INJURY			English	Article; Proceedings Paper	27th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 14-17, 2007	Scottsdale, AZ	Natl Acad Neuropsychol		Mild traumatic brain injury; complicated; outcome; neurocognitive	WORD-ASSOCIATION TEST; HEAD-INJURY; COMPUTED-TOMOGRAPHY; CT; MODERATE; TRAIL; ABNORMALITIES; PERFORMANCE; TIME	Objective: It would be logical to assume that patients with intracranial abnormalities (i.e. complicated MTBIs) would have worse outcome than patients without these abnormalities (i.e. uncomplicated MTBIs). However, the literature is limited and somewhat mixed regarding outcome in patients with complicated mild TBIs. The purpose of this study is to employ a carefully controlled research design to compare the acute neuropsychological functioning of patients following complicated and uncomplicated MTBI. Method: Participants were 20 patients with complicated MTBI and 20 patients with uncomplicated MTBI selected from an archival database of 465 patients. Patients were carefully matched on age, education, gender, ethnicity, days assessed post-injury and mechanism of injury. Patients were assessed an average of 3.5 days (SD = 1.9) post-injury with 13 common cognitive variables. Results: There were significant group differences on only three of the 13 cognitive measures (complicated mild TBI worse than uncomplicated mild TBI). There were no significant differences in the proportion of impaired scores between groups on all measures, with the exception of Hopkins Verbal Learning Test Delayed Recall. Conclusion: Patients with complicated MTBIs performed more poorly only on a small number of tests during the acute recovery period.	[Franzen, Michael D.] Allegheny Gen Hosp, Pittsburgh, PA USA; [Lange, Rael T.] BC Mental Hlth & Addict Serv, PHSA Res & Networks, Vancouver, BC V5Z 4C2, Canada; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Franzen, Michael D.] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA		Lange, RT (corresponding author), BC Mental Hlth & Addict Serv, PHSA Res & Networks, Suite 201,601 W Broadway St, Vancouver, BC V5Z 4C2, Canada.	rlange@bcmhs.bc.ca		Iverson, Grant/0000-0001-7348-9570			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BENTON AL, 1994, MANUAL INSTRUCTIONS; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen J., 2013, STAT POWER ANAL BEHA; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; FRENCH BN, 1977, SURG NEUROL, V7, P171; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Heaton R. K., 2004, REVISED COMPREHENSIV; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P1, DOI 10.1016/S0887-6177(01)00176-7; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Meyers JE, 1998, ASSESSMENT, V5, P303, DOI 10.1177/107319119800500309; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; PRIFITERA CA, 1992, NORMATIVE DELA UNPUB; Reitan RM, 1992, TRAIL MAKING TEST MA; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Tellier A, 1999, BRAIN INJURY, V13, P463; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wechsler D, 1987, MEMORY SCALE REVISED; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29	44	65	65	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	2					83	91	PII 908454607	10.1080/02699050802635281			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Rehabilitation	403LD	WOS:000263083200002	19191087				2022-02-06	
J	Vassallo, S; Cooper, SL; Douglas, JM				Vassallo, Suzane; Cooper, Sian L.; Douglas, Jacinta M.			Visual scanning in the recognition of facial affect: Is there an observer sex difference?	JOURNAL OF VISION			English	Article						reaction time; facial expression; eye movements; ocular fixation; nonverbal communication; emotions	TRAUMATIC BRAIN-INJURY; EXPLORATORY EYE-MOVEMENTS; GENDER-DIFFERENCES; EMOTION PERCEPTION; FACE RECOGNITION; LIFE-SPAN; EXPRESSIONS; SCHIZOPHRENIA; IDENTIFICATION; COMMUNICATION	This investigation assessed whether differences exist in the way males and females overtly orient their visual attention to salient facial features while viewing static emotional facial expressions. Eye movements were recorded while fifty healthy participants (23 males, 27 females) viewed a series of six universal facial expressions. Groups were compared with respect to accuracy and reaction time in emotional labeling. The number and duration of foveal fixations to four predefined facial areas of interest (AOIs)-each eye, nose, mouth-were also recorded. There were no significant group differences with respect to accuracy (p = 0.997), though females were significantly faster than males in correctly identifying expressions (p = 0.047). Analysis of the visual scan path revealed that while both groups spent more time and looked more frequently at the eye region, males spent significantly more time viewing the nose and mouth. The duration and number of fixations made to the nose were significantly greater in males (p < 0.05). This study is the first to show reaction time differences between the sexes across a range of universal emotions. Further, this is the first work to suggest the orienting of attention to the lower part of the face, especially the nose, appears to differentiate the sexes.	[Vassallo, Suzane; Cooper, Sian L.] La Trobe Univ, Dept Clin Vis Sci, Bundoora, Vic 3086, Australia; [Douglas, Jacinta M.] La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia		Vassallo, S (corresponding author), La Trobe Univ, Dept Clin Vis Sci, Bundoora, Vic 3086, Australia.	S.Vassallo@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Vassallo, Suzane/0000-0003-1259-5905			Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P516, DOI 10.1037//0894-4105.15.4.516; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Biele C, 2006, EXP BRAIN RES, V171, P1, DOI 10.1007/s00221-005-0254-0; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bourne VJ, 2005, NEUROPSYCHOLOGIA, V43, P953, DOI 10.1016/j.neuropsychologia.2004.08.007; BRYDEN MP, 1977, NEUROPSYCHOLOGIA, V15, P617, DOI 10.1016/0028-3932(77)90067-7; Calder AJ, 2003, NEUROPSYCHOLOGIA, V41, P195, DOI 10.1016/S0028-3932(02)00149-5; Calvo MG, 2008, BEHAV RES METHODS, V40, P109, DOI 10.3758/BRM.40.1.109; Campbell R, 2002, NEUROPSYCHOLOGIA, V40, P575, DOI 10.1016/S0028-3932(01)00164-6; Canli T, 2002, P NATL ACAD SCI USA, V99, P10789, DOI 10.1073/pnas.162356599; Dyer AG, 2006, J FORENSIC SCI, V51, P1397, DOI 10.1111/j.1556-4029.2006.00269.x; Ekman P., 2004, JAPANESE CAUCASIAN F; Goos LM, 2002, J NONVERBAL BEHAV, V26, P27, DOI 10.1023/A:1014418503754; Green MJ, 2005, CURR PSYCHIATRY REV, V1, P11, DOI 10.2174/1573400052953529; Grimshaw GM, 2004, BRAIN COGNITION, V54, P248, DOI 10.1016/j.bandc.2004.02.029; Hall JA, 2004, EMOTION, V4, P201, DOI 10.1037/1528-3542.4.2.201; Hargrave R, 2002, J NEUROPSYCH CLIN N, V14, P64, DOI 10.1176/appi.neuropsych.14.1.64; Henderson JM, 2005, MEM COGNITION, V33, P98, DOI 10.3758/BF03195300; Hooker C, 2002, PSYCHIAT RES, V112, P41, DOI 10.1016/S0165-1781(02)00177-4; Horley K, 2004, PSYCHIAT RES, V127, P43, DOI 10.1016/j.psychres.2004.02.016; KIROUAC G, 1985, J NONVERBAL BEHAV, V9, P3, DOI 10.1007/BF00987555; KIROUAC G, 1984, PERCEPT MOTOR SKILL, V59, P147, DOI 10.2466/pms.1984.59.1.147; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Lee TMC, 2002, NEUROSCI LETT, V333, P13, DOI 10.1016/S0304-3940(02)00965-5; Loughland CM, 2004, SCHIZOPHR RES, V67, P11, DOI 10.1016/S0920-9964(03)00094-X; Loughland CM, 2002, SCHIZOPHR RES, V55, P159, DOI 10.1016/S0920-9964(01)00186-4; Loughland CM, 2002, BIOL PSYCHIAT, V52, P338, DOI 10.1016/S0006-3223(02)01356-2; MANDAL MK, 1985, PERCEPT MOTOR SKILL, V60, P96, DOI 10.2466/pms.1985.60.1.96; Miyahira A, 2000, LIFE SCI, V68, P569, DOI 10.1016/S0024-3205(00)00963-2; Miyahira A, 2000, PSYCHIAT CLIN NEUROS, V54, P31, DOI 10.1046/j.1440-1819.2000.00632.x; Montagne Barbara, 2005, Cogn Process, V6, P136, DOI 10.1007/s10339-005-0050-6; NOTON D, 1971, SCI AM, V224, P34; NOWICKI S, 1988, J SOC PSYCHOL, V128, P363, DOI 10.1080/00224545.1988.9713753; Ogrocki PK, 2000, NEUROPSY NEUROPSY BE, V13, P271; Palermo R, 2004, BEHAV RES METH INS C, V36, P634, DOI 10.3758/BF03206544; Pelphrey KA, 2002, J AUTISM DEV DISORD, V32, P249, DOI 10.1023/A:1016374617369; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Rahman Q, 2004, BRAIN COGNITION, V54, P179, DOI 10.1016/j.bandc.2004.01.002; ROTTER NG, 1988, J NONVERBAL BEHAV, V12, P139, DOI 10.1007/BF00986931; Rutherford MD, 2008, J AUTISM DEV DISORD, V38, P1371, DOI 10.1007/s10803-007-0525-7; Scholten MRM, 2005, SCHIZOPHR RES, V78, P61, DOI 10.1016/j.schres.2005.06.019; Sullivan S, 2007, J GERONTOL B-PSYCHOL, V62, pP53, DOI 10.1093/geronb/62.1.P53; Thayer JF, 2000, SCAND J PSYCHOL, V41, P243, DOI 10.1111/1467-9450.00193; *TOB TECHN, 2006, US MAN TOB EYE TRACK; Wager TD, 2003, NEUROIMAGE, V19, P513, DOI 10.1016/S1053-8119(03)00078-8; WAGNER HL, 1986, J PERS SOC PSYCHOL, V50, P737, DOI 10.1037/0022-3514.50.4.737; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Williams LM, 1999, SCHIZOPHR RES, V40, P189, DOI 10.1016/S0920-9964(99)00056-0; Zee D.S., 1999, NEUROLOGY EYE MOVEME, V3rd	50	65	67	0	24	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	1534-7362			J VISION	J. Vision		2009	9	3							11	10.1167/9.3.11			10	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Ophthalmology	461RJ	WOS:000267287800011	19757950	gold, Green Submitted			2022-02-06	
J	Haxel, BR; Grant, L; Mackay-Sim, A				Haxel, Boris R.; Grant, Leah; Mackay-Sim, Alan			Olfactory Dysfunction After Head Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brief smell identification tests; chemosensory-evoked potentials; head trauma; olfactometry; sense of smell; Sniffin' Sticks; traumatic brain injury	TRAUMATIC BRAIN-INJURY; OF-PENNSYLVANIA SMELL; DISCRIMINATION; IDENTIFICATION; POTENTIALS; ANOSMIA; TASTE	To determine the incidence of olfactory dysfunction after head trauma using clinical and radiologic findings, quantitative assessment, and electro-physiologic methods. Participants: A total of 190 patients with head trauma of different severity (n = 32 with mild traumatic brain injury (TBI), n = 94 with signs of moderate TBI, and n = 64 with severe TBI) 6 to 32 months prior to the study. Design: Patients were selected retrospectively, surveyed by telephone (n = 190), and screened for olfactory function with Brief Smell Identification Test (n = 82). Those with olfactory dysfunction were assessed as outpatients using the Sniffin' Sticks (n = 19) and olfactory-evoked potential recording (n = 16). Results: Twenty-one participants (11%) reported a decreased sense of smell after trauma. The incidence of olfactory dysfunction after head injury was 12.8%. The results of the odor-evoked potentials were heterogeneous. A significant correlation was found between olfactory dysfunction and the appearance of skull base fractures and intracranial hemorrhage or hematoma. Conclusion: The site of trauma may be more relevant to prognosis than a simple probability (of olfactory loss) based on incidence. Odor-evoked potentials indicate that functional anosmia can occur even when there is some evidence of intact olfactory nerve function.	[Haxel, Boris R.] Johannes Gutenberg Univ Mainz, Sch Med, Dept Otolaryngol Head & Neck Surg, Mainz, Germany; [Haxel, Boris R.; Grant, Leah; Mackay-Sim, Alan] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Nathan, Qld 4111, Australia		Haxel, BR (corresponding author), Mainz Med Sch, Dept Otorhinolaryngol, Langenbeckstr 1, D-55101 Mainz, Germany.	haxel@hno.klinik.uni-mainz.de	Mackay-Sim, Alan/C-3431-2008	Mackay-Sim, Alan/0000-0003-4446-5371			Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Costanzo D, 2003, HDB OLFACTION GESTAT, P1038; COSTANZO R, 1991, SMELL TASTE HLTH DIS; COSTANZO RM, 1987, ANN NY ACAD SCI, V510, P242; Doty R.L., 2001, BRIEF SMELL IDENTIFI; Doty RL, 1997, CHEM SENSES, V22, P565, DOI 10.1093/chemse/22.5.565; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DULFANO MJ, 1981, AM REV RESPIR DIS, V123, P139; Geisler MW, 1999, J CLIN NEUROPHYSIOL, V16, P77, DOI 10.1097/00004691-199901000-00008; GRAZIADEI PPC, 1980, BRAIN RES, V201, P39, DOI 10.1016/0006-8993(80)90773-8; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 2001, NEUROREHABILITATION, V16, P237; JAFEK BW, 1989, ARCH NEUROL-CHICAGO, V46, P300, DOI 10.1001/archneur.1989.00520390066018; Kettenmann B, 1997, CHEM SENSES, V22, P493, DOI 10.1093/chemse/22.5.493; KOBAL G, 1988, ELECTROEN CLIN NEURO, V71, P241, DOI 10.1016/0168-5597(88)90023-8; Kobal G, 2000, EUR ARCH OTO-RHINO-L, V257, P205, DOI 10.1007/s004050050223; Kobal G, 1998, LARYNGOSCOPE, V108, P1033, DOI 10.1097/00005537-199807000-00015; Leigh AD, 1943, LANCET, V1, P38; Mackay-Sim A, 2004, J CLIN NEUROSCI, V11, P874, DOI 10.1016/j.jocn.2003.12.001; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; Murrell W, 1996, NEUROREPORT, V7, P1189, DOI 10.1097/00001756-199604260-00019; Ogawa T, 1999, ACTA OTO-LARYNGOL, P50; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; Wolfensberger M, 2000, ACTA OTO-LARYNGOL, V120, P303, DOI 10.1080/000164800750001134; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	26	65	67	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2008	23	6					407	413		10.1097/01.HTR.0000341437.59627.ec			7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	379WZ	WOS:000261428300007	19033834				2022-02-06	
J	McHale, S; Hunt, N				McHale, Sue; Hunt, Nigel			Executive function deficits in short-term abstinent cannabis users	HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL			English	Article						cannabis; marijuana; prospective memory; executive function; visual memory; verbal fluency	TRAUMATIC BRAIN-INJURY; PROSPECTIVE MEMORY; MARIJUANA USERS; DECISION-MAKING; WORKING-MEMORY; VERBAL FLUENCY; PERFORMANCE; EVERYDAY; RECEPTOR; ECSTASY	Objectives Few cognitive tasks are adequately sensitive to show the small decrements in performance in abstinent chronic cannabis users. In this series of three experiments we set out to demonstrate a variety of tasks that are sufficiently sensitive to show differences in visual memory, verbal memory, everyday memory and executive function between controls and cannabis users. Methods A series of three studies explored cognitive function deficits in cannabis users (phonemic verbal fluency, visual recognition and immediate and delayed recall, and prospective memory) in short-term abstinent cannabis users. Participants were selected using snowball sampling, with cannabis users being compared to a standard control group and a tobacco-use control group. Results The cannabis users, compared to both control groups, had deficits on verbal fluency, visual recognition, delayed visual recall, and short- and long-interval prospective memory. There were no differences for immediate visual recall. Conclusions These findings suggest that cannabis use leads to impaired executive function. Further research needs to explore the longer term impact of cannabis use. Copyright (c) 2008 John Wiley & Sons, Ltd.	[McHale, Sue] Sheffield Hallam Univ, Fac Dev & Soc, Brain Behav & Cognit Grp, Sheffield S10 2BP, S Yorkshire, England; [Hunt, Nigel] Univ Nottingham, Inst Work Hlth & Org, Nottingham NG7 2RD, England		McHale, S (corresponding author), Sheffield Hallam Univ, Fac Dev & Soc, Brain Behav & Cognit Grp, Sheffield S10 2BP, S Yorkshire, England.	s.l.mchale@shu.ac.uk	Hunt, Nigel C/B-8755-2009; mchale, sue l/B-8743-2009	Hunt, Nigel C/0000-0002-8492-6577; 			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baddeley A.D., 1994, DOORS PEOPLE TEST; Benton A.L., 1967, CORTEX, V3, P32, DOI [10.1016/s0010-9452(67)80005-4, DOI 10.1016/S0010-9452(67)80005-4]; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Bolla KI, 2002, NEUROLOGY, V59, P1337, DOI 10.1212/01.WNL.0000031422.66442.49; Bolla KI, 2005, NEUROIMAGE, V26, P480, DOI 10.1016/j.neuroimage.2005.02.012; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; Eldreth DA, 2004, NEUROIMAGE, V23, P914, DOI 10.1016/j.neuroimage.2004.07.032; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; Goldman-Rakic PS, 1987, HDB PHYSL NERVOUS SY; Grant I, 2003, J INT NEUROPSYCH SOC, V9, P679, DOI 10.1017/S1355617703950016; Grant S, 2000, NEUROPSYCHOLOGIA, V38, P1180, DOI 10.1016/S0028-3932(99)00158-X; Heffernan TM, 2005, DRUG ALCOHOL DEPEN, V78, P235, DOI 10.1016/j.drugalcdep.2004.11.008; Heffernan TM, 2001, HUM PSYCHOPHARM CLIN, V16, P607, DOI 10.1002/hup.349; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Kanayama G, 2004, PSYCHOPHARMACOLOGY, V176, P239, DOI 10.1007/s00213-004-1885-8; KOPP UA, 2000, 1 INT C PROSP MEM U; LOGIE RH, 1995, CAMBRIDGE HDB VISUOS; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521; Pope HG, 2001, ARCH GEN PSYCHIAT, V58, P909, DOI 10.1001/archpsyc.58.10.909; Rabbitt P., 1997, METHODOLOGY FRONTAL; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; Rodgers J, 2001, HUM PSYCHOPHARM CLIN, V16, P619, DOI 10.1002/hup.345; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; SCHWARTZ RH, 1989, AM J DIS CHILD, V143, P1214, DOI 10.1001/archpedi.1989.02150220110030; SINNOTT J, 1989, EVERYDAY COGNITION A; SMITH SS, 1991, ADDICTIVE DRUG SURVE; SMYTH MM, 1994, MEM COGNITION, V22, P1, DOI 10.3758/BF03202756; SMYTH MM, 1989, Q J EXP PSYCHOL-A, V41, P235, DOI 10.1080/14640748908402363; Solowij N, 2002, JAMA-J AM MED ASSOC, V287, P1123, DOI 10.1001/jama.287.9.1123; Solowij N., 1998, CANNABIS COGNITIVE F; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Whitlow CT, 2004, DRUG ALCOHOL DEPEN, V76, P107, DOI 10.1016/j.drugalcdep.2004.04.009; Wilson BA, 1991, RIVERMEAD BEHAV MEMO	38	65	67	1	16	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	0885-6222			HUM PSYCHOPHARM CLIN	Hum. Psychopharmacol.-Clin. Exp.	JUL	2008	23	5					409	415		10.1002/hup.941			7	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology	328WP	WOS:000257829200005	18421794				2022-02-06	
J	Ayaz, D; Leyssen, M; Koch, M; Yan, JK; Srahna, M; Sheeba, V; Fogle, KJ; Holmes, TC; Hassan, BA				Ayaz, Derya; Leyssen, Maarten; Koch, Marta; Yan, Jiekun; Srahna, Mohammed; Sheeba, Vasu; Fogle, Keri J.; Holmes, Todd C.; Hassan, Bassem A.			Axonal injury and regeneration in the adult brain of Drosophila	JOURNAL OF NEUROSCIENCE			English	Article						Drosophila; explant; injury; regeneration; signal transduction	CIRCADIAN PACEMAKER NEURONS; PROTEIN-KINASE-A; SPINAL-CORD; NEURODEGENERATIVE DISEASE; NEURITE ARBORIZATION; SIGNAL-TRANSDUCTION; BEHAVIORAL RHYTHMS; CYCLIC-AMP; C-JUN; TIMELESS	Drosophila melanogaster is a leading genetic model system in nervous system development and disease research. Using the power of fly genetics in traumatic axonal injury research will significantly speed up the characterization of molecular processes that control axonal regeneration in the CNS. We developed a versatile and physiologically robust preparation for the long-term culture of the whole Drosophila brain. We use this method to develop a novel Drosophila model for CNS axonal injury and regeneration. We first show that, similar to mammalian CNS axons, injured adult wild-type fly CNS axons fail to regenerate, whereas adult-specific enhancement of protein kinase A activity increases the regenerative capacity of lesioned neurons. Combined, these observations suggest conservation of neuronal regeneration mechanisms after injury. We next exploit this model to explore pathways that induce robust regeneration and find that adult-specific activation of c-Jun N-terminal protein kinase signaling is sufficient for de novo CNS axonal regeneration injury, including the growth of new axons past the lesion site and into the normal target area.	[Ayaz, Derya; Leyssen, Maarten; Koch, Marta; Yan, Jiekun; Srahna, Mohammed; Hassan, Bassem A.] Flanders Inst Biotechnol VIB, Dept Mol & Dev Genet, Lab Neurogenet, B-3000 Louvain, Belgium; [Ayaz, Derya; Leyssen, Maarten; Koch, Marta; Yan, Jiekun; Srahna, Mohammed; Holmes, Todd C.; Hassan, Bassem A.] Katholieke Univ Leuven, Sch Med, Dept Human Genet, B-3000 Louvain, Belgium; [Ayaz, Derya; Hassan, Bassem A.] Katholieke Univ Leuven, Grp Biomed, Program Mol & Dev Genet, B-3000 Louvain, Belgium; [Hassan, Bassem A.] Katholieke Univ Leuven, Grp Biomed, Program Mol & Cognit Neurosci, B-3000 Louvain, Belgium; [Sheeba, Vasu; Fogle, Keri J.; Holmes, Todd C.] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA		Hassan, BA (corresponding author), Flanders Inst Biotechnol VIB, Dept Mol & Dev Genet, Lab Neurogenet, B-3000 Louvain, Belgium.	bassem.hassan@med.kuleuven.be	Hassan, Bassem A/D-5221-2012	Hassan, Bassem A/0000-0001-9533-4908; Holmes, Todd/0000-0001-8152-8832; Vasu, Sheeba/0000-0003-2924-7130	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046750] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS046750, R01 NS046750-02, R01 NS046750-01A1, R01 NS046750-04, R01 NS046750, R01 NS046750-03] Funding Source: Medline		Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Belenky M, 1996, NEUROSCIENCE, V70, P127, DOI 10.1016/0306-4522(95)00327-F; Berdnik D, 2006, J NEUROSCI, V26, P3367, DOI 10.1523/JNEUROSCI.4941-05.2006; Bier E, 2005, NAT REV GENET, V6, P9, DOI 10.1038/nrg1503; Bilen J, 2005, ANNU REV GENET, V39, P153, DOI 10.1146/annurev.genet.39.110304.095804; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown HLD, 2006, DEVELOPMENT, V133, P275, DOI 10.1242/dev.02191; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Collin C, 1997, J NEUROPHYSIOL, V77, P1614, DOI 10.1152/jn.1997.77.3.1614; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; Gu HY, 2006, J NEUROSCI, V26, P265, DOI 10.1523/JNEUROSCI.4109-05.2006; Hallem EA, 2004, TRENDS GENET, V20, P453, DOI 10.1016/j.tig.2004.06.015; Hardin PE, 2005, CURR BIOL, V15, pR714, DOI 10.1016/j.cub.2005.08.019; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Hassan BA, 2000, NEURON, V25, P549, DOI 10.1016/S0896-6273(00)81059-4; Hoopfer ED, 2006, NEURON, V50, P883, DOI 10.1016/j.neuron.2006.05.013; Kaneko M, 2000, J COMP NEUROL, V422, P66, DOI 10.1002/(SICI)1096-9861(20000619)422:1<66::AID-CNE5>3.0.CO;2-2; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kiger JA, 2001, GENETICS, V158, P1157; Kiger JA, 1999, GENETICS, V152, P281; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leyssen M, 2005, EMBO J, V24, P2944, DOI 10.1038/sj.emboj.7600757; Leyssen M, 2007, EMBO REP, V8, P46, DOI 10.1038/sj.embor.7400869; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MacDonald JM, 2006, NEURON, V50, P869, DOI 10.1016/j.neuron.2006.04.028; Margulies C, 2005, CURR BIOL, V15, pR700, DOI 10.1016/j.cub.2005.08.024; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; Miesenbock G, 2005, ANNU REV NEUROSCI, V28, P533, DOI 10.1146/annurev.neuro.28.051804.101610; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Nitabach MN, 2002, CELL, V109, P485, DOI 10.1016/S0092-8674(02)00737-7; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Raivich G, 2007, BRAIN RES REV, V53, P287, DOI 10.1016/j.brainresrev.2006.09.005; Reed BH, 2001, CURR BIOL, V11, P1098, DOI 10.1016/S0960-9822(01)00318-9; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Shafer OT, 2002, J NEUROSCI, V22, P5946; Sheeba V, 2008, J NEUROPHYSIOL, V99, P976, DOI 10.1152/jn.00930.2007; Sheeba V, 2008, J NEUROSCI, V28, P217, DOI 10.1523/JNEUROSCI.4087-07.2008; Shulman JM, 2003, CURR OPIN NEUROL, V16, P443, DOI 10.1097/01.wco.0000084220.82329.60; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Srahna M, 2006, PLOS BIOL, V4, P2076, DOI 10.1371/journal.pbio.0040348; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Weissman TA, 2004, NEURON, V43, P647, DOI 10.1016/j.neuron.2004.08.015; Yanik MF, 2004, NATURE, V432, P822, DOI 10.1038/432822a; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956	49	65	65	0	8	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 4	2008	28	23					6010	6021		10.1523/JNEUROSCI.0101-08.2008			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	308QF	WOS:000256404400016	18524906	Bronze, Green Published, Green Accepted			2022-02-06	
J	Taylor, AN; Rahman, SU; Sanders, NC; Tio, DL; Prolo, P; Sutton, RL				Taylor, Anna N.; Rahman, Shayan U.; Sanders, Nicole C.; Tio, Delia L.; Prolo, Paolo; Sutton, Richard L.			Injury severity differentially affects short- and long-term neuroendocrine outcomes of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						allostasis; controlled cortical impact; corticosterone; rat; stress	CONTROLLED CORTICAL IMPACT; CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL AXIS; HIPPOCAMPAL-NEURONS; HEAD-INJURY; CELL-DEATH; RAT-BRAIN; STRESS SENSITIVITY; SPATIAL MEMORY; RECEPTOR	Having reported that traumatic brain injury (TBI), produced by moderate lateral controlled cortical impact (CCI), causes long-term dysregulation of the neuroendocrine stress response, the aim of this study was to assess short- and long-term effects of both moderate and mild CCI on stress-induced hypothalamic-pituitary-adrenal (HPA) function. TBI was induced to the left parietal cortex in adult male rats with a pneumatic piston, at two different impact velocities and compression depths to produce either a moderate or mild CCI. Controls underwent sham surgery without injury. Commencing at one week after recovery from surgery, rats were exposed to stressors: 30-min restraint (days 7, 34, and 70) or 15-min forced swim (days 21 and 54). Tail vein blood was analyzed for corticosterone (CORT) content by radioimmunoassay. On days 7 and 21, the stress-induced HPA responses were significantly attenuated by both mild and moderate CCI. Significant attenuation of the CORT response to stress persisted through day 70 after moderate CCI. In contrast, stress-induced CORT levels on days 34, 54, and 70 were significantly enhanced after mild CCI. Differential effects of injury severity were also observed on motor function in a forelimb test on post-injury day 12 and on cortical lesion volume and hippocampal cell loss at day 70, but not on working memory in a radial maze on day 15. The differing short- and long-term stress-induced HPA responses may be mediated by differential effects of moderate and mild CCI on the efficiency of glucocorticoid negative feedback or signaling among hypothalamic and extrahypothalamic components of the neuroendocrine stress-response system.	[Taylor, Anna N.; Tio, Delia L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Brain Res Inst, Los Angeles, CA 90095 USA; [Taylor, Anna N.; Tio, Delia L.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Rahman, Shayan U.; Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Dept Surg, Los Angeles, CA 90095 USA; [Sanders, Nicole C.] Williams Coll, Williamstown, MA 01267 USA; [Prolo, Paolo] Univ Calif Los Angeles, Sch Dent, Div Oral Biol, Los Angeles, CA 90024 USA		Taylor, AN (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Brain Res Inst, 10833 Conte Ave,Box 951763, Los Angeles, CA 90095 USA.	ataylor@mednet.ucla.edu					Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; Bale TL, 2006, HORM BEHAV, V50, P529, DOI 10.1016/j.yhbeh.2006.06.033; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bhatnagar S, 1998, NEUROSCIENCE, V84, P1025, DOI 10.1016/S0306-4522(97)00577-0; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHILDERS MK, 1998, BRAIN INJURY, V12, P547; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conrad CD, 1999, NEUROBIOL LEARN MEM, V72, P39, DOI 10.1006/nlme.1998.3898; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; DEKOSKY ST, 1984, NEUROENDOCRINOLOGY, V38, P33, DOI 10.1159/000123862; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dinkel K, 2003, J NEUROCHEM, V84, P705, DOI 10.1046/j.1471-4159.2003.01604.x; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Goel N, 2007, ENDOCRINOLOGY, V148, P4585, DOI 10.1210/en.2007-0479; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Grundy PL, 2001, J NEUROTRAUM, V18, P1373, DOI 10.1089/08977150152725669; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1995, J NEUROTRAUM, V12, P307, DOI 10.1089/neu.1995.12.307; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Herman JP, 2003, FRONT NEUROENDOCRIN, V24, P151, DOI 10.1016/j.yfrne.2003.07.001; Houshyar H, 2001, J NEUROENDOCRINOL, V13, P875, DOI 10.1046/j.1365-2826.2001.00714.x; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; LEVIN BE, 1994, RESTOR NEUROL NEUROS, V7, P5, DOI 10.3233/RNN-1994-7102; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; Masera RG, 2002, PSYCHONEUROENDOCRINO, V27, P447, DOI 10.1016/S0306-4530(01)00062-2; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; McEwen BS, 2004, ANN NY ACAD SCI, V1032, P1, DOI 10.1196/annals.1314.001; McIntosh LJ, 1996, EXP NEUROL, V141, P201, DOI 10.1006/exnr.1996.0154; McNay EC, 2001, NEUROBIOL LEARN MEM, V75, P325, DOI 10.1006/nlme.2000.3976; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1228; SCHALLERT T, 2005, BEHAV LAB RATS HDB T, V1, P129; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TAYLOR AN, 2004, 7 INT NEUR S AD AUST; TAYLOR AN, 2007, SOC NEUR ABST, V33; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Wei Q, 2007, J NEUROSCI, V27, P8836, DOI 10.1523/JNEUROSCI.0910-07.2007; Whishaw IQ, 2004, J NEUROTRAUM, V21, P1584, DOI 10.1089/neu.2004.21.1584; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	79	65	66	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2008	25	4					311	323		10.1089/neu.2007.0486			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	282PL	WOS:000254579600004	18373481				2022-02-06	
J	Salim, A; Hadjizacharia, P; Brown, C; Inaba, K; Teixeira, PGR; Chan, L; Rhee, P; Demetriades, D				Salim, Ali; Hadjizacharia, Pantelis; Brown, Carlos; Inaba, Kenji; Teixeira, Pedro G. R.; Chan, Linda; Rhee, Peter; Demetriades, Demetrios			Significance of troponin elevation after severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	66th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 27-29, 2007	Las Vegas, NV	Amer Assoc Surg Trauma		troponin; traumatic head injury; beta blocker; outcome	CRITICALLY-ILL PATIENTS; SUBARACHNOID HEMORRHAGE; MYOCARDIAL INJURY; CATECHOLAMINES; ABNORMALITIES; HYPERGLYCEMIA; DYSFUNCTION; MORTALITY; LEVEL; DEATH	Introduction: Elevation of serum troponin (cTnI) after nontraumatic cerebral insult has been associated with an adverse prognosis. This association has not been well documented in traumatic brain injury (TBI). Objective: To evaluate the association and prognostic significance of cTnI elevation in severe TBI. To evaluate the role of beta-blocker (BB) therapy in TBI patients with elevated cTnI. Methods: Retrospective review of all blunt trauma patients with severe TBI (head Abbreviated Injury Scale score [AIS] >= 3) admitted to the intensive care unit (ICU) with serial TnI measurements at a Level I trauma center from January 1998 to December 2005. Patients with AIS score >= 3 to other body regions were excluded. Univariate and multivariate logistic regression was performed to determine prognostic significance of TnI elevation. Results: There were 420 severe blunt TBI patients who had serial cTnI measurements during the study period. One hundred twenty-five (29.8%) had an elevated admission cTnI. TBI patients with an elevated cTnI had a lower admission Glasgow Coma Scale (GCS) score (7.5 vs. 8.7, p < 0.05), higher Injury Severity Score (27.4 vs. 24.8, p < 0.01), and increased hospital mortality (44% vs. 29%, p < 0.05), compared with TBI patients with a normal cTnI. Increasing severity of head injury was associated with an increasing cTnI (TnI level 0.8 mu g/L for head AIS score = 3 vs. TnI Level 10.3 mu g/L for head AIS score = 4, 5, p = 0.09). After adjusting for injury severity, elevated cTnI was an independent predictor for mortality (Odds ratio [OR[: 8.5; 95% confidence interval [CI]: 3.46, 22.15, p < 0.0001). BB therapy was associated with a significant survival advantage (OR: 0.38; 95% CI: 0.15, 0.87, p = 0.03) in TBI patients with any elevation of cTnI. Conclusion: Elevated TnI is frequently observed after severe TBI. The level of TnI correlates with the severity of head injury and is an independent predictor of adverse outcomes. BB therapy is associated with a survival advantage in TBI patients with elevated cTnI.	[Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Hadjizacharia, Pantelis; Brown, Carlos; Inaba, Kenji; Teixeira, Pedro G. R.; Chan, Linda; Rhee, Peter; Demetriades, Demetrios] Univ So Calif, Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA USA; [Brown, Carlos] Bretonneau Hosp, Austin, TX USA; [Rhee, Peter] Univ Arizona, Tucson, AZ USA		Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	INABA, KENJI/AAC-8532-2020; Teixeira, Pedro/H-2239-2011	Teixeira, Pedro/0000-0002-7258-7977			Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291; Banki NM, 2005, CIRCULATION, V112, P3314, DOI 10.1161/CIRCULATIONAHA.105.558239; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COOPER DKC, 1989, ANN ROY COLL SURG, V71, P261; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Di Angelantonio E, 2005, J NEUROL NEUROSUR PS, V76, P76, DOI 10.1136/jnnp.2004.041491; Dixit S, 2000, ARCH INTERN MED, V160, P3153, DOI 10.1001/archinte.160.20.3153; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P115, DOI 10.1007/BF00571658; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hamm CW, 2002, CIRCULATION, V106, P2871, DOI 10.1161/01.CIR.0000044342.50593.63; Hays A, 2006, NEUROLOGY, V66, P1330, DOI 10.1212/01.wnl.0000210523.22944.9b; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Jeremias A, 2005, ANN INTERN MED, V142, P786, DOI 10.7326/0003-4819-142-9-200505030-00015; King DA, 2005, CRIT CARE, V9, pR390, DOI 10.1186/cc3731; KOLIN A, 1984, STROKE, V15, P990, DOI 10.1161/01.STR.15.6.990; Kollef MH, 1997, CHEST, V111, P1340, DOI 10.1378/chest.111.5.1340; KONO T, 1994, J AM COLL CARDIOL, V24, P636, DOI 10.1016/0735-1097(94)90008-6; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lim W, 2005, CRIT CARE, V9, pR636, DOI 10.1186/cc3816; Lim W, 2006, AM J CRIT CARE, V15, P280; Lindstaedt M, 2002, J TRAUMA, V52, P479, DOI 10.1097/00005373-200203000-00011; Lutz-Dettinger N, 2001, PEDIATR CLIN N AM, V48, P715, DOI 10.1016/S0031-3955(05)70336-9; Maramattom BV, 2006, MAYO CLIN PROC, V81, P192, DOI 10.4065/81.2.192; Martin M, 2005, J TRAUMA, V59, P1086, DOI 10.1097/01.ta.0000190249.19668.37; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; MAYER SA, 1994, NEUROLOGY, V44, P815, DOI 10.1212/WNL.44.5.815; MCLEOD AA, 1982, BRIT HEART J, V47, P221; Naidech AM, 2005, CIRCULATION, V112, P2851, DOI 10.1161/CIRCULATIONAHA.105.533620; NOVITZKY D, 1989, TRANSPLANT P, V21, P2567; NYGAARD CE, 1990, J TRAUMA, V30, P728, DOI 10.1097/00005373-199006000-00013; PILATI CF, 1990, P SOC EXP BIOL MED, V193, P225; Quenot JP, 2005, CHEST, V128, P2758, DOI 10.1378/chest.128.4.2758; Razek T, 2000, SURG CLIN N AM, V80, P1021, DOI 10.1016/S0039-6109(05)70111-0; Roongsritong C, 2004, CHEST, V125, P1877, DOI 10.1378/chest.125.5.1877; Salim A, 2001, J TRAUMA, V50, P237, DOI 10.1097/00005373-200102000-00008; Schuiling WJ, 2005, J NEUROL NEUROSUR PS, V76, P1565, DOI 10.1136/jnnp.2004.060913; Velmahos GC, 2003, J TRAUMA, V54, P45, DOI 10.1097/00005373-200301000-00006; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zaroff JG, 2000, J AM SOC ECHOCARDIOG, V13, P774, DOI 10.1067/mje.2000.105763	41	65	68	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2008	64	1					46	52		10.1097/TA.0b013e31815eb15a			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	250UE	WOS:000252325700012	18188098				2022-02-06	
J	Ziai, WC; Toung, TJK; Bhardwaj, A				Ziai, Wendy C.; Toung, Thomas J. K.; Bhardwaj, Anish			Hypertonic saline: First-line therapy for cerebral edema?	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						cerebral edema; hypertonic saline; intracranial hemorrhage	ELEVATED INTRACRANIAL-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW; SODIUM-CHLORIDE; CELL-VOLUME; RAT-BRAIN; INTRACEREBRAL HEMORRHAGE; FLUID RESUSCITATION; 20-PERCENT MANNITOL; 7.5-PERCENT SALINE	This article highlights the experimental and clinical data, controversies and postulated mechanisms surrounding osmotherapy with hypertonic saline (HS) solutions in the neurocritical care arena and builds on previous reviews on the subject. Special attention is focused on HS therapy on commonly encountered clinical paradigms of acute brain injury including traumatic brain injury (TBI), post-operative "retraction edema", intracranial hemorrhage (ICH), tumor-associated cerebral edema, and ischemia associated with ischemic stroke. (C) 2007 Elsevier B.V. All rights reserved.	Johns Hopkins Univ, Sch Med, Dept Neurol, Neurosci Crit Care Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol Surg, Neurosci Crit Care Div, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Neurosci Crit Care Div, Baltimore, MD USA		Bhardwaj, A (corresponding author), Oregon Hlth & Sci Univ, Neurosci Crit Care Program, 3181 SW Sam Jackson Pk Rd,L-226, Portland, OR 97239 USA.	bhardwaj@ohsu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046379] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS046379] Funding Source: Medline		Angle N, 2000, SHOCK, V14, P503, DOI 10.1097/00024382-200014050-00002; Arbabi S, 1999, J SURG RES, V83, P141, DOI 10.1006/jsre.1999.5583; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bhardwaj, 1999, Curr Treat Options Neurol, V1, P179, DOI 10.1007/s11940-999-0002-z; Bhardwaj A, 2000, STROKE, V31, P1694, DOI 10.1161/01.STR.31.7.1694; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P21; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V6, P449; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; Ciesla DJ, 2000, J TRAUMA, V48, P388, DOI 10.1097/00005373-200003000-00004; COTE CJ, 1979, ANESTHESIOLOGY, V50, P30, DOI 10.1097/00000542-197901000-00007; Cruz J, 2001, NEUROSURGERY, V49, P864; CSERR HF, 1991, J PHYSIOL-LONDON, V442, P277, DOI 10.1113/jphysiol.1991.sp018793; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Fremont-Smith F, 1927, ARCH NEURO PSYCHIATR, V18, P550, DOI 10.1001/archneurpsyc.1927.02210040057002; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; Gemma M, 1996, J NEUROSURG ANESTH, V8, P137, DOI 10.1097/00008506-199604000-00007; Hartl R, 1997, ZBL CHIR, V122, P181; Hartl R, 1997, ACT NEUR S, V70, P126; Harukuni Izumi, 2002, J Anesth, V16, P229, DOI 10.1007/s005400200030; Himmelseher S, 2001, J NEUROSURG ANESTH, V13, P120, DOI 10.1097/00008506-200104000-00009; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; HUDAK ML, 1989, AM J PHYSIOL, V257, pH912, DOI 10.1152/ajpheart.1989.257.3.H912; Hughes J, 1938, ARCH NEURO PSYCHIATR, V39, P1277, DOI 10.1001/archneurpsyc.1938.02270060167009; JAVID M, 1956, JAMA-J AM MED ASSOC, V160, P943, DOI 10.1001/jama.1956.02960460021006; JAVID M, 1961, J NEUROSURG, V18, P51, DOI 10.3171/jns.1961.18.1.0051; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Knapp JM, 2005, AACN ADV CRIT CARE, V16, P199, DOI 10.1097/00044067-200504000-00011; KRAUSZ MM, 1995, SHOCK, V4, P56, DOI 10.1097/00024382-199507000-00009; Krep H, 2004, RESUSCITATION, V63, P73, DOI 10.1016/j.resuscitation.2004.03.023; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; Nau R, 2000, CLIN PHARMACOKINET, V38, P23, DOI 10.2165/00003088-200038010-00002; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Oreopoulos GD, 2000, SHOCK, V14, P409, DOI 10.1097/00024382-200014030-00029; OREOPOULOS GD, 2001, SURGERY, P57; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Phillis JW, 1999, BRAIN RES, V828, P1, DOI 10.1016/S0006-8993(99)01235-4; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 2002, J NEUROSURG ANESTH, V14, P22, DOI 10.1097/00008506-200201000-00005; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; RAICHLE ME, 1983, ACTA NEUROPATHOL, P75; ROPPER AH, 2003, TREATMENT INTRACRANI, P26; Saltarini M, 2002, Eur J Emerg Med, V9, P262, DOI 10.1097/00063110-200209000-00011; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Schrot RJ, 2005, CRIT CARE MED, V33, P257, DOI 10.1097/01.CCM.0000150761.07904.A4; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SCHWARZ S, 1998, STROKE, V29, P1055; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; SHACKFORD SR, 1988, SURGERY, V104, P553; SHENKIN HA, 1962, J NEUROSURG, V19, P897, DOI 10.3171/jns.1962.19.10.0897; Silva MRE, 1998, MEDICINA-BUENOS AIRE, V58, P393; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Soupart A, 1996, J NEUROPATH EXP NEUR, V55, P106, DOI 10.1097/00005072-199601000-00011; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; Suarez JI, 1999, J NEUROSURG ANESTH, V11, P178, DOI 10.1097/00008506-199907000-00004; SUZUKI J, 1985, STROKE, V16, P695, DOI 10.1161/01.STR.16.4.695; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; Toung TJK, 2005, CRIT CARE MED, V33, P203, DOI 10.1097/01.CCM.0000150659.15558.23; Toung TJK, 2002, J NEUROSURG ANESTH, V14, P187, DOI 10.1097/00008506-200207000-00003; Toung TJK, 2002, CRIT CARE MED, V30, P644, DOI 10.1097/00003246-200203000-00025; TRUMBLE ER, 1995, J NEUROSURG, V82, P44, DOI 10.3171/jns.1995.82.1.0044; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V128, P1003; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; WILLERSON JT, 1975, CIRCULATION, V51, P1095, DOI 10.1161/01.CIR.51.6.1095; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; Zausinger S, 2004, NEUROSURGERY, V55, P679, DOI 10.1227/01.NEU.0000134558.28977.EE; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	90	65	70	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	OCT 15	2007	261	1-2					157	166		10.1016/j.jns.2007.04.048			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	216JO	WOS:000249874500019	17585941				2022-02-06	
J	Moro, N; Katayama, Y; Igarashi, T; Mori, T; Kawamata, T; Kojima, J				Moro, Nobuhiro; Katayama, Yoichi; Igarashi, Takahlro; Mori, Tatsuro; Kawamata, Tatsuro; Kojima, Jun			Hyponatremia in patients with traumatic brain injury: incidence, mechanism, and response to sodium supplementation or retention therapy with hydrocortisone	SURGICAL NEUROLOGY			English	Article						cerebral salt wasting syndrome; hydrocortisone; hyponatremia; hypopituitarism; syndrome of inappropriate secretion of antidiuretic hormone; traumatic brain injury	SALT WASTING SYNDROME; ANTERIOR-PITUITARY DYSFUNCTION; CEREBRAL-BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; HEAD-INJURY; INAPPROPRIATE SECRETION; TRANSCRANIAL DOPPLER; ANTIDIURETIC-HORMONE; HYPERVOLEMIC THERAPY; MANAGEMENT	Background: Hyponatremia is a frequently observed electrolyte abnormality in patients with central nervous system disease. Several mechanisms, such as SIADH, hypopituitarism, and CSWS, have been proposed with varied incidences among several studies. We attempted to clarify the incidence and mechanism of hyponatremia for each type of TBI. We also assessed the efficacy of sodium supplementation and retention therapy. For sodium retention therapy, hydrocortisone was administered, expecting its mineralocorticoid effect, when the hyponatremia was associated with excess natriuresis. Methods: Retrospective analysis of 298 patients with TBI between January 2003 and December 2004 was performed. The incidence, background, clinical data, and outcome were evaluated. Results: Of the 298 patients, 50 (16.8%) presented hyponatremia during the time course. Hyponatremia was associated with longer hospital stay (P <.001) and bad outcome (P =.02). Among these 50 patients, 37 recovered from the hyponatremia with simple sodium supplementation. The remaining 13 patients presented massive natriuresis and required additional sodium retention therapy. Hydrocortisone statistically reduced the amount of sodium excretion (P =.002) and returned the serum sodium level to a normal value. Conclusions: A high rate of hyponatremia after TBI was observed. Further studies are required to establish the precise mechanism of hyponatremia after TBI. Clear definition of CSWS is required to avoid confusion of the pathophysiology that causes hyponatremia. Hydrocortisone was useful to prevent excess natriuresis. (C) 2007 Elsevier Inc. All rights reserved.	Nihon Univ, Sch Med, Dept Neurol Surg, Itabashi Ku, Tokyo 1738610, Japan		Moro, N (corresponding author), Nihon Univ, Sch Med, Dept Neurol Surg, Itabashi Ku, Tokyo 1738610, Japan.	moro@med.nihon-u.ac.jp					Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Albanese A, 2001, ARCH DIS CHILD, V85, P246, DOI 10.1136/adc.85.3.246; Berger TM, 2002, CRIT CARE MED, V30, P792, DOI 10.1097/00003246-200204000-00012; Berkenbosch JW, 2002, PEDIATR NEUROSURG, V36, P75, DOI 10.1159/000048356; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Brookes MJ, 2003, J NEUROL NEUROSUR PS, V74, P277, DOI 10.1136/jnnp.74.2.277; Bussmann C, 2001, CHILD NERV SYST, V17, P58; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cole Chad D, 2004, Neurosurg Focus, V16, pE9; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; CORT JH, 1954, LANCET, V1, P752; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Diringer MN, 2006, NEUROLOGIST, V12, P117, DOI 10.1097/01.nrl.0000215741.01699.77; Donati-Genet PCM, 2001, J PEDIATR SURG, V36, P1094, DOI 10.1053/jpsu.2001.24770; ISHIKAWA SE, 1987, ANN INTERN MED, V106, P187, DOI 10.7326/0003-4819-106-2-187; Karovitaki N, 2006, J NEUROL NEUROSUR PS, V77, P276, DOI 10.1136/jnnp.2005.070482; Kinik ST, 2001, PEDIATR NEUROSURG, V35, P216, DOI 10.1159/000050424; Kojima J, 2005, LIFE SCI, V76, P2361, DOI 10.1016/j.lfs.2004.11.010; Kurokawa Y, 1996, SURG NEUROL, V46, P500, DOI 10.1016/S0090-3019(96)00034-1; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; Levine JP, 2001, PLAST RECONSTR SURG, V108, P1501, DOI 10.1097/00006534-200111000-00009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; Miyasaka K, 2004, METHOD FIND EXP CLIN, V26, P287; Mori T, 1999, J NEUROSURG, V91, P947, DOI 10.3171/jns.1999.91.6.0947; Moro N, 2003, STROKE, V34, P2807, DOI 10.1161/01.STR.0000103744.05430.99; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; Oruckaptan HH, 2000, PEDIATR NEUROSURG, V33, P16, DOI 10.1159/000028969; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; Rabinstein AA, 2003, NEUROLOGIST, V9, P290, DOI 10.1097/01.nrl.0000095258.07720.89; SCHWARTZ WB, 1957, AM J MED, V23, P529, DOI 10.1016/0002-9343(57)90224-3; SOLOMON RA, 1984, NEUROSURGERY, V15, P354, DOI 10.1227/00006123-198409000-00010; Sviri GE, 2006, ACTA NEUROCHIR, V148, P529, DOI 10.1007/s00701-005-0666-4; VINGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50, DOI 10.1007/BF01400528; von Bismarck P, 2006, CHILD NERV SYST, V22, P1275, DOI 10.1007/s00381-006-0091-x	47	65	72	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	OCT	2007	68	4					387	393		10.1016/j.surneu.2006.11.052			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	220LO	WOS:000250158400005	17905062				2022-02-06	
J	de la Plata, CM; Ardelean, A; Koovakkattu, D; Srinivasan, P; Miller, A; Phuong, V; Harper, C; Moore, C; Whittemore, A; Madden, C; Diaz-Arrastia, R; Devous, M				de la Plata, Carlos Marquez; Ardelean, Andreea; Della Koovakkattu; Srinivasan, Priya; Miller, Anna; Phuong, Viet; Harper, Caryn; Moore, Carol; Whittemore, Anthony; Madden, Christopher; Diaz-Arrastia, Ramon; Devous, Michael, Sr.			Magnetic resonance imaging of diffuse axonal injury: Quantitative assessment of white matter lesion volume	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury (DAI); FLAIR MRI; functional outcome; TBI	TRAUMATIC BRAIN-INJURY; GLASGOW OUTCOME SCALE; CORPUS-CALLOSUM; HEAD-INJURY; MRI FINDINGS; MORPHOLOGY; ATROPHY; CHILDREN; SEQUELAE; FEATURES	Diffuse axonal injury (DAI) is a common mechanism of traumatic brain injury (TBI) for which there is no well-accepted anatomic measures of injury severity. The present study aims to quantitatively assess DAI by measuring white matter lesion volume visible in fluid-attenuated inversion recovery (FLAIR) weighted images and to determine whether higher lesion volumes are associated with unfavorable functional outcome 6 months after injury. Twenty-four patients who experienced moderate to severe TBI without extra-axial or major cortical contusions were included in this study. Lesion volume was assessed by quantifying areas of hyperintensities in the white matter utilizing digitized FLAIR images. Two independent raters processed the magnetic resonance (MR) images and determined the total DAI volume. Functional outcome was assessed at 6 months after injury using the Glasgow Outcome Scale-Extended (GOSE). Interclass correlation analyses showed very high interrater reliability for each measure between the two raters (Interclass Correlation Coefficient = 0.95,p <= 0.001). Total DAI volume was significantly, although modestly, correlated to GOSE (r = -0.453, p = 0.034). White matter lesion volume resulting from DAI can be quantitatively and reliably assessed from standard FLAIR-weighted MRIs. Patients with greater DAI volume have poorer functional outcomes. These methods may be useful in stratifying injury severity and for the assessment of DAI-directed therapies.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurol Surg, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Radiol, Dallas, TX 75235 USA; Univ Texas, Dept Brain & Behav Sci, Dallas, TX USA		de la Plata, CM (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Carlos.MarquezdelaPlata@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD42652, R01 HD48179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; COTRAN R, 1999, ROBBINS PATHOLOGIC B, P1301; Fu JH, 2005, J NEUROL NEUROSUR PS, V76, P793, DOI 10.1136/jnnp.2003.032771; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 2001, MAGNETIC RESONANCE I, P1069; Gootjes L, 2004, DEMENT GERIATR COGN, V18, P180, DOI 10.1159/000079199; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; LEVIDOW L, 1992, MICROBIAL RELEASES, V1, P55; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; Ouhlous M, 2005, AM J NEURORADIOL, V26, P1044; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Randolph JJ, 2005, J INT NEUROPSYCH SOC, V11, P205, DOI 10.1017/S1355617705050253; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; SANFILIPO M, 2006, NEUROLOGY, V3, P12; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	37	65	66	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2007	24	4					591	598		10.1089/neu.2006.0214			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	159NE	WOS:000245872000002	17439343				2022-02-06	
J	Stuke, L; Diaz-Arrastia, R; Gentilello, LM; Shafi, S				Stuke, Lance; Diaz-Arrastia, Ramon; Gentilello, Larry M.; Shafi, Shahid			Effect of alcohol on Glasgow Coma Scale in head-injured patients	ANNALS OF SURGERY			English	Article; Proceedings Paper	58th Annual Meeting of the Southwestern-Surgical-Congress	APR 03-07, 2006	Kauai, HI	SW Surg Congress			TRAUMA CENTER; INTOXICATION; INTERVENTION; SCORE	Objective: Almost 50% of traumatic brain-injured (TBI) patients are alcohol intoxicated. The Glasgow Coma Scale (GCS) is frequently used to direct diagnostic and therapeutic decisions in these patients. It is commonly assumed that alcohol intoxication reduces GCS, thus limiting its utility in intoxicated patients. The purpose of this study was to test the hypothesis that the presence of blood alcohol has a clinically significant impact on GCS in TBI patients. Methods: The National Trauma Data Bank of the American College of Surgeons was queried (1994-2003). Patients 18 to 45 years of age with blunt injury mechanism, whose GCS in the emergency department, survival status, anatomic severity of TBI (Head Abbreviated Injury Score [AIS]), and blood alcohol testing status were known, were included. GCS of patients who tested positive for alcohol (n = 55,732) was compared with GCS of patients who tested negative (n = 53,197), stratified by head AIS. Results: Groups were similar in age (31 8 vs. 30 8 years), Injury Severity Score (ISS; 12 +/- 11 vs. 12 +/- 11), systolic blood pressure in the ED (131 +/- 25 vs. 134 +/- 25 mm Hg), TRISS (Trauma Injury Severity Score; probability of survival (94% +/- 16% vs. 95% +/- 15%), and actual survival (96% vs. 96%). When stratified by anatomic severity of TBI, the presence of alcohol did not lower GCS by more than I point in any head AIS group (GCS in alcohol-positive vs. alcohol-negative patients; AIS 1 = 13.9 +/- 2.8 vs. 14.3 +/- 2.3; AIS 2 = 13.4 +/- 3.2 vs. 14.1 +/- 2.4; AIS 3 = 11.1 +/- 4.7 vs. 11.6 +/- 4.6; AIS 4 = 9.8 +/- 4.9 vs. 10.4 +/- 4.9; AIS 5 = 5.5 +/- 3.8 vs. 5.9 +/- 4.1, NIS 6: 3.4 +/- 1.1 vs. 3.8 +/- 2.8). Conclusion: Alcohol use does not result in a clinically significant reduction in GCS in trauma patients. Attributing low GCS to alcohol intoxication in TBI patients may delay necessary diagnostic and therapeutic interventions.	Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Surg Crit Care, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA		Shafi, S (corresponding author), Univ Texas, SW Med Ctr, Dept Surg, Div Burns Trauma & Surg Crit Care, 5323 Harry Hines Blvd,Mail Code 9158, Dallas, TX 75390 USA.	shahid.shafi@utsouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594			*AM COLL SURG COMM, 2006, RES OPT CAR INJ PAT; American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; Cherpitel C, 2005, EMERG MED J, V22, P689, DOI 10.1136/emj.2004.016865; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Dunne JR, 2005, J TRAUMA, V58, P959, DOI 10.1097/01.TA.0000158508.84009.49; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; Gentilello LM, 2005, J TRAUMA, V59, P624, DOI 10.1097/01.ta.0000179309.34613.27; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gentilello LM, 1999, J TRAUMA, V47, P1131, DOI 10.1097/00005373-199912000-00027; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; MINION GE, 1989, J TOXICOL-CLIN TOXIC, V27, P375, DOI 10.3109/15563658909000358; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Schermer CR, 2003, J TRAUMA, V55, P849, DOI 10.1097/01.TA.0000091110.83692.38; Soderstrom C A, 1988, Md Med J, V37, P541; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SPERRY J, 2006, J TRAUMA, V60, P252; TEASDALE G, 1974, LANCET, V2, P81; [The American Association of Neurological Surgeons The Brain Trauma Foundation], 2000, J NEUROTRAUM, V17, P463; Valadka A, 2000, TRAUMA, P377; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170	21	65	68	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-4932			ANN SURG	Ann. Surg.	APR	2007	245	4					651	655		10.1097/01.sla.0000250413.41265.d3			5	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	150RB	WOS:000245232900023	17414616	Green Published			2022-02-06	
J	Jacobson, I; Tegner, Y				Jacobson, I.; Tegner, Y.			Injuries among Swedish female elite football players: a prospective population study	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						soccer; sport injuries; women; injury incidence	SOCCER INJURIES; EUROPEAN FOOTBALL; MENSTRUAL-CYCLE; RISK-FACTORS; IMPACT; SYMPTOMS; HISTORY; OUTDOOR; BRAIN; HEAD	Injury occurrence in all 12 female elite senior football teams in premiere league was registered during 1 year. Of 269 players, 129 (48%) sustained 237 injuries. The total injury incidence was 4.6/1000 h of football. The injury incidence during practice was 2.7 and during the game time was 13.9/1000 h. The highest injury incidence during practice was to the knee (0.8/1000 h) and thigh (0.5/1000 h), and during game time was to the knee (4.4/1000 h) and head (2.2/1000 h). In total, the location for the highest injury incidence was the knee with 1.5 injuries/1000 h of football. The majority of injuries (82%) were localized to the lower extremities. Sixty-six injuries (28%) were re-occurring injuries (re-injuries). The incidence of traumatic injuries was 3.3/1000 h of football and for overuse injuries 1.3/1000 h. Overuse injuries occurred mainly during the preseason and at the beginning of the spring season. Thirty-nine percent of the injuries were slight or minor causing absence from practice or game time of less than 1 week, 39% were moderate (absence 7-28 days) and 22% were major (absence more than 28 days). The major injuries occurred often owing to trauma and were mainly to the knee.	Lulea Univ Technol, Inst Hlth Sci, S-96136 Boden, Sweden		Jacobson, I (corresponding author), Lulea Univ Technol, Inst Hlth Sci, S-96136 Boden, Sweden.	inger.jacobson@ltu.se		Tegner, Yelverton/0000-0003-3628-0705			ANDREASEN I, 1992, SCAND J MED SCI SPOR, P62; ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BACKOUS DD, 1988, AM J DIS CHILD, V142, P839, DOI 10.1001/archpedi.1988.02150080045019; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; BENKIBLER W, 1993, MED SCI SPORT EXER, V25, P1330; BRYNHILDSEN J, 1990, INT J SPORTS MED, V11, P489, DOI 10.1055/s-2007-1024843; Brynhildsen J, 1997, ACTA OBSTET GYN SCAN, V76, P873, DOI 10.3109/00016349709024368; Brynhildsen JO, 1997, SCAND J MED SCI SPOR, V7, P348; Chomiak J, 2000, AM J SPORT MED, V28, pS58; Dvorak J, 2000, AM J SPORT MED, V28, pS69; Dvorak J, 2000, AM J SPORT MED, V28, pS3; EKSTRAND J, 1983, AM J SPORT MED, V11, P63, DOI 10.1177/036354658301100203; Ekstrand J, 2004, SCAND J MED SCI SPOR, V14, P34, DOI 10.1111/j.1600-0838.2003.00330.x; Ekstrand J, 2003, SCAND J MED SCI SPOR, V13, P147, DOI 10.1034/j.1600-0838.2003.00129.x; EKSTRAND J, 1983, MED SCI SPORT EXER, V15, P267, DOI 10.1249/00005768-198315030-00014; Ekstrand J, 1982, THESIS LINKOPING U L; ENGSTROM B, 1990, AM J SPORT MED, V18, P101, DOI 10.1177/036354659001800118; ENGSTROM B, 1991, AM J SPORT MED, V19, P372, DOI 10.1177/036354659101900408; Hagglund M, 2003, SCAND J MED SCI SPOR, V13, P364, DOI 10.1046/j.1600-0838.2003.00327.x; HOFF GL, 1986, AM J SPORT MED, V14, P231, DOI 10.1177/036354658601400309; INKLAAR H, 1994, SPORTS MED, V18, P81, DOI 10.2165/00007256-199418020-00002; INKLAAR H, 1994, SPORTS MED, V18, P55, DOI 10.2165/00007256-199418010-00006; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Junge A, 2000, AM J SPORT MED, V28, pS40; Junge A, 2000, AM J SPORT MED, V28, pS16; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; MAEHLUM S, 1986, PHYSICIAN SPORTSMED, V14, P73, DOI 10.1080/00913847.1986.11709124; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MOLLERNIELSEN J, 1989, MED SCI SPORT EXER, V21, P126; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; NIELSEN JM, 1991, SPORTS MED, V12, P152, DOI 10.2165/00007256-199112030-00002; Nilsson S, 1978, Am J Sports Med, V6, P358, DOI 10.1177/036354657800600608; Ostenberg A, 2000, SCAND J MED SCI SPOR, V10, P279, DOI 10.1034/j.1600-0838.2000.010005279.x; Peterson L, 2000, AM J SPORT MED, V28, pS51; Poulsen T D, 1991, Br J Sports Med, V25, P151; ROOS H, 1995, ACTA ORTHOP SCAND, V66, P107, DOI 10.3109/17453679508995501; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Soderman K, 2001, SCAND J MED SCI SPOR, V11, P299, DOI 10.1034/j.1600-0838.2001.110508.x; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	43	65	67	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	FEB	2007	17	1					84	91		10.1111/j.1600-0838.2006.00524.x			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	118SY	WOS:000242963200012	17305943	Bronze, Green Published			2022-02-06	
J	Rivera, P; Elliott, TR; Berry, JW; Grant, JS; Oswald, K				Rivera, Patricia; Elliott, Timothy R.; Berry, Jack W.; Grant, Joan S.; Oswald, Kimberly			Predictors of caregiver depression among community-residing families living with traumatic brain injury	NEUROREHABILITATION			English	Article						caregivers; depression; traumatic brain injury	PROBLEM-SOLVING ABILITIES; PHYSICAL HEALTH; STROKE SURVIVORS; SOCIAL SUPPORT; ADJUSTMENT; DISTRESS; THERAPY; RISK	Objective: To test the hypothesis that ineffective problem-solving abilities would be significantly predictive of risk for depression in caregivers of persons with traumatic brain injury (TBI) after controlling for caregiver burden, caregiver health and demographic characteristics. Design: Correlational and logistic regression analyses of cross-sectional data. Participants: 57 women and 3 men (M age of caregivers=51.4, SD=10.1) caring for a relative with a TBI. Main outcome measure: Centers for Epidemiologic Studies - Depression scale (CES-D). Results: Twenty-nine caregivers (48.3%) had CES-D scores that met the criteria for risk of depression. An ineffective approach to problem solving, characterized by negative, avoidant, and careless/impulsive styles, and self-reported caregiver physical symptoms were significantly predictive of caregiver depression regardless of length of time caregiving, perceived burden, or demographic variables. Conclusions: Caregivers of persons with TBI who report physical health problems and who exhibit ineffective problem solving area at greater risk for depression, regardless of the time they have spent in their role as a caregiver.	Univ Alabama Birmingham, Injury Control Res Ctr, Dept Med Immunol Rheumatol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Nursing, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; Texas A&M Univ, College Stn, TX USA		Rivera, P (corresponding author), Univ Alabama Birmingham, Injury Control Res Ctr, Dept Med Immunol Rheumatol, CH19-401,1530 3rd Ave S, Birmingham, AL 35294 USA.	rivera@uab.edu	Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714; Grant, Joan/0000-0001-6000-4060	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR403641, R49/CCR412718-01] Funding Source: Medline		Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Carey P J, 1991, Oncol Nurs Forum, V18, P1341; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; D'Zurilla T.J., 2002, SOCIAL PROBLEM SOLVI; D'Zurilla TJ., 2004, SOCIAL PROBLEM SOLVI, P11, DOI [10.1037/10805-001, DOI 10.1037/10805-001]; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Elliott TR, 2000, HDB HOPE THEORY MEAS, P373; Elliott TR, 2004, SOCIAL PROBLEM SOLVI, V11, P7, DOI DOI 10.1037/10805-007; ERGH T, PREDICTORS CAREGIVER; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grant JS, 2004, REHABIL PSYCHOL, V49, P172, DOI 10.1037/0090-5550.49.2.172; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HOOKER K, 1992, PSYCHOL AGING, V7, P367, DOI 10.1037/0882-7974.7.3.367; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Livingston MG., 1990, REHABILITATION ADULT, P225; Lui MHL, 2005, STROKE, V36, P2514, DOI 10.1161/01.STR.0000185743.41231.85; Nezu AM, 2004, BEHAV THER, V35, P1, DOI 10.1016/S0005-7894(04)80002-9; Nezu AM, 2003, J CONSULT CLIN PSYCH, V71, P1036, DOI 10.1037/0022-006X.71.6.1036; NEZU AM, 1989, J CONSULT CLIN PSYCH, V57, P408, DOI 10.1037/0022-006X.57.3.408; Pennebaker JW., 1982, PSYCHOL PHYS SYMPTOM; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Shewchuk RM, 1998, HEALTH PSYCHOL, V17, P125, DOI 10.1037/0278-6133.17.2.125; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062	36	65	65	0	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	1					3	8					6	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	150TE	WOS:000245240600002	17379944				2022-02-06	
J	Tomberg, T; Toomela, A; Ennok, M; Tikk, A				Tomberg, T.; Toomela, A.; Ennok, M.; Tikk, A.			Changes in coping strategies, social support, optimism and health-related quality of life following traumatic brain injury: A longitudinal study	BRAIN INJURY			English	Article						coping strategies; social support; optimism; health-related quality of life; longitudinal changes; traumatic brain injury	ADJUSTMENT; DEPRESSION; RECOVERY; STRESS; DISABILITY; FAMILIES; MODERATE; OUTCOMES; STYLE; WORK	Primary objective: To study longitudinal changes in psychological coping strategies, social support, life orientation and health-related quality of life in the late period after traumatic brain injury ( TBI). Subjects: Thirty-one patients with TBI who were first investigated on average 2.3 years after injury and were prospectively followed on average 5.7 years later. Methods: Estonian versions of the COPE-D Test, the Brief Social Support Questionnaire, the Life Orientation Test and the RAND-36 questionnaire. Results: During the late follow-up period health-related quality of life and resuming work did not improve significantly. Persons with TBI reported an increase in seeking social/emotional support ( p < 0.05), frequent use of avoidance-oriented styles and reduced use of task-oriented styles. This was accompanied by low social support and low satisfaction with support, both of which were associated with health-related quality of life and resuming work after TBI. Although the patients had become more optimistic ( p < 0.05), this did not correlate with their health status and social well-being. Conclusions: This prospective study revealed maladaptive changes in the profile of coping strategies and an increase in optimism. As social support, satisfaction with support and health-related quality of life did not improve, then rehabilitation, social and psychological support are continuously needed.	Univ Tartu, Dept Neurol & Neurosurg, EE-51014 Tartu, Estonia; Univ Tartu, Dept Special Educ, EE-51014 Tartu, Estonia		Tomberg, T (corresponding author), Univ Tartu, Dept Neurol & Neurosurg, 2 L Puusepp St, EE-51014 Tartu, Estonia.	tiiu.tomberg@kliinikum.ee	Toomela, Aaro/H-6033-2018	Toomela, Aaro/0000-0002-8520-9676			Bedi G, 2005, BRIT J HEALTH PSYCH, V10, P57, DOI 10.1348/135910704X15266; Carnes S.L., 2005, FAM SYST HEALTH, V23, P186, DOI DOI 10.1037/1091-7527.23.2.186; CARVER CS, 1992, HOSTILITY, COPING & HEALTH, P167, DOI 10.1037/10105-012; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2006, BRAIN COGNITION, V60, P214; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Finset A, 2000, BRAIN INJURY, V14, P887; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Herodes M, 2001, EPILEPSIA, V42, P1061, DOI 10.1046/j.1528-1157.2001.0420081061.x; Herrmann M, 2000, DISABIL REHABIL, V22, P539, DOI 10.1080/096382800416788; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Kallasmaa T, 2000, PERS INDIV DIFFER, V29, P881, DOI 10.1016/S0191-8869(99)00240-8; KAPLAN SP, 1993, REHABIL COUNS BULL, V36, P151; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Power PW, 2003, BRAIN INJURY, V17, P1021, DOI 10.1080/0269905031000110526; RAND Health Sciences Program, 1992, RAND 36 IT HLTH SURV; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; SCHEIER MF, 1986, J PERS SOC PSYCHOL, V51, P1257, DOI 10.1037/0022-3514.51.6.1257; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; Shen BJ, 2004, J BEHAV MED, V27, P39, DOI 10.1023/B:JOBM.0000013643.36767.22; SVELNIKAS K, 1998, THESIS U TARTU TARTU; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; THOITS PA, 1995, J HEALTH SOC BEHAV, V35, P53, DOI 10.2307/2626957; TINA A, 1998, THESIS U TARTU TARTU; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Toomela A, 2004, J REHABIL MED, V36, P63, DOI 10.1080/16501970310017414; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	48	65	65	0	22	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	5					479	488		10.1080/02699050701311737			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	175FI	WOS:000246998000004	17522987				2022-02-06	
J	af Geijerstam, JL; Oredsson, S; Britton, M				af Geijerstam, Jean-Luc; Oredsson, Sven; Britton, Mona		OCTOPUS Study Investigators	Medical outcome after immediate computed tomography or admission for observation in patients with mild head injury: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; RAY TECHNIQUE FACTORS; EMERGENCY-DEPARTMENT; RADIATION; MANAGEMENT; DISCHARGE; MORTALITY; COHORT; SCALE; SIZE	Objective To compare immediate computed tomography during triage for admission with observation in hospital in patients with mild head injury. Design Multicentre, pragmatic, non-inferiority randomised trial. Setting 39 acute hospitals in Sweden. Participants 2602 patients (aged >= 6) with mild head injury. Interventions Immediate computed tomography or admission for observation. Main outcome measure Dichotomised extended Glasgow outcome scale (1-7 v 8). The non-inferiority margin was 5 percentage points. Results At three months, 275 patients (21.4%) in the computed tomography group had not recovered completely compared with 300 (24.2%) admitted for observation. The difference was - 2.8 percentage points, non-significantly in favour of computed tomography (95% confidence interval - 6.1% to 0.6%). The worst outcomes (mortality and more severe loss of function) were similar between the groups. In the patients admitted for observation, there was a considerable delay in time to treatment in those who required surgery. None of the patients with normal findings on immediate computed tomography had complications later. Patients' satisfaction with the two strategies was similar. Conclusions The use of computed tomography in the management of patients with mild head injury is feasible and leads to similar clinical outcomes compared with observation in hospital.	Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, S-17176 Stockholm, Sweden; Helsingborg Hosp, Emergency Dept, Helsingborg, Sweden; Swedish Council Technol Assessement Hlth Care, Stockholm, Sweden		af Geijerstam, JL (corresponding author), Karolinska Univ Hosp, Dept Med, Clin Epidemiol Unit, S-17176 Stockholm, Sweden.	jean-luc.af.geijerstam@ki.se					Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Geijerstam JL, 2005, EMERG MED J, V22, P103; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; GEIJERSTAM JLA, 2004, EMERG MED J, V21, P54; Griffiths PD, 2004, BRIT MED J, V329, P930, DOI 10.1136/bmj.329.7472.930; Hall P, 2004, BMJ-BRIT MED J, V328, P19, DOI 10.1136/bmj.328.7430.19; Huda W, 2004, MED PHYS, V31, P595, DOI 10.1118/1.1646233; Huda W, 2004, MED PHYS, V31, P588, DOI 10.1118/1.1646232; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; *NAT I CLIN EXC, 2003, HEAD INJ TRIAG ASS I; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; *SWED COUNC TECHN, 2000, MILD HEAD INJ OBS CT; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	25	65	65	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2006	333	7566					465	468		10.1136/bmj.38918.669317.4F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	085QP	WOS:000240618900013	16895944	Green Published, Bronze, Green Submitted			2022-02-06	
J	Pappachan, B; Alexander, M				Pappachan, Biju; Alexander, Mohan			Correlating facial fractures and cranial injuries	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							CERVICAL-SPINE INJURY; CLOSED-HEAD INJURIES; MAXILLOFACIAL TRAUMA; SKELETON; PATTERN; IMPACT; FACE	Purpose: This study retrospectively evaluated individuals with traumatic injuries from different mechanisms and tried to determine if there is any relationship between various isolated or combined fractures of facial skeleton and cranial injuries. Materials and Methods: We retrospectively studied hospital charts of all patients who reported to the trauma center at Kasturba Hospital in Manipal with facial fractures and suspected cranial injuries during a 5-year period (January 1, 1995 to December 31, 1999). These patients were admitted to the Department of Neurosurgery or the Maxillofacial Unit of Kasturba Hospital, Manipal. The complete medical record of each patient was reviewed, recording the following in a standard format: age, gender, cause of injury, type of facial fractures, type of cranial bone fracture, concussion, intracranial injury, cerebrospinal fluid (CSF) rhinorrhea, CSF otorrhea, and the Glasgow coma scale. Results: The study data were collected as part of retrospective analysis. A total of 12,329 patients reported to the trauma center of the study hospital during a 5-year period with various injuries. A total of 772 patients had facial fractures (6%). A total of 108 patients with a combination of cranial injuries and facial fractures were identified within this group (14%). Gender predilection was seen to favor males (90%) more than females (10%). The ratio was seen to be nearly 9: 1. The ages of the patients ranged from 7 to 70 years with mean age being 32 years (standard deviation [SD] = +/- 12). Central midfacial bone involvement was found to be more commonly associated with head injury. Conclusions: There is a correlation between midfacial injuries and CNS trauma. A more exhaustive multicentric case-control study with a larger sample and additional parameters will be essential to reach definite conclusions regarding the spectrum of head injuries associated with facial fractures. (C) 2006 American Association of Oral and Maxillofacial Surgeons.	Radhika Meghe Mem Med Trust, Sharad Pawar Dent Coll, Dept Maxillofacial Surg, Wardha, Maharashtra, India; Mahatma Gandhi Dent Coll, Pondicherry, India		Pappachan, B (corresponding author), Care of Kedar S, Snehal Nagar, Wardha, Maharashtra, India.	biju_pappachan@yahoo.com	Pappachan, Biju/AAA-2344-2020				ADEKEYE EO, 1980, ORAL SURG ORAL MED O, V49, P491, DOI 10.1016/0030-4220(80)90068-7; BECK RA, 1989, ARCH OTOLARYNGOL, V115, P826; BERTOLAMI CN, 1982, ORAL SURG ORAL MED O, V53, P122, DOI 10.1016/0030-4220(82)90274-2; BRANDT KE, 1991, J TRAUMA, V31, P15, DOI 10.1097/00005373-199101000-00003; CHANG CJ, 1994, J TRAUMA, V37, P807, DOI 10.1097/00005373-199411000-00017; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; DAWSON RLG, 1953, BRIT J SURG, V41, P254, DOI 10.1002/bjs.18004116707; DAWSON RLG, 1962, BR DENT J, V113, P345; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1994, J ORAL MAXIL SURG, V52, P729, DOI 10.1016/0278-2391(94)90488-X; HAUG RH, 1991, J ORAL MAXIL SURG, V49, P725, DOI 10.1016/S0278-2391(10)80236-8; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; HAYTER JP, 1991, BRIT J ORAL MAX SURG, V29, P370, DOI 10.1016/0266-4356(91)90003-N; HUESTON JT, 1956, MED J AUSTRALIA, V2, P141; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; LUCE EA, 1979, PLAST RECONSTR SURG, V63, P26, DOI 10.1097/00006534-197901000-00005; MCCABE JB, 1984, AM J EMERG MED, V2, P333, DOI 10.1016/0735-6757(84)90130-X; MORGAN B D G, 1972, British Journal of Plastic Surgery, V25, P147, DOI 10.1016/S0007-1226(72)80037-7; Murray J F, 1975, Clin Plast Surg, V2, P131; NORUSIS MJ, 1986, SPSS IBM PC AT VERSI; O'Sullivan ST, 1999, BRIT J PLAST SURG, V52, P519, DOI 10.1054/bjps.1999.3159; ROWE NL, 1968, FRACTURES FACIAL SKE, P857; SCHULTZ RC, 1967, PLAST RECONSTR SURG, V40, P415, DOI 10.1097/00006534-196711000-00001; SINCLAIR D, 1988, Journal of Emergency Medicine, V6, P109, DOI 10.1016/0736-4679(88)90148-5; SLUPCHYNSKYJ OS, 1992, LARYNGOSCOPE, V102, P1247, DOI 10.1288/00005537-199211000-00008; TEASDALE G, 1974, LANCET, V2, P81; Tessier P, 1972, Plast Reconstr Surg, V50, P600; TURVEY TA, 1977, J ORAL SURG, V35, P887; Ugboko VI, 1998, INT J ORAL MAX SURG, V27, P286, DOI 10.1016/S0901-5027(05)80616-2; UNGER JM, 1990, RADIOLOGY, V175, P175, DOI 10.1148/radiology.175.1.2315477; van Beek GJ, 1999, INT J ORAL MAX SURG, V28, P424, DOI 10.1016/S0901-5027(99)80055-1; VANHOOF RF, 1977, INT J ORAL MAXILLOF, V6, P3, DOI 10.1016/S0300-9785(77)80066-5	34	65	66	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JUL	2006	64	7					1023	1029		10.1016/j.joms.2006.03.021			7	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	057OQ	WOS:000238605500006	16781334				2022-02-06	
J	Cameron, JI; Cheung, AM; Streiner, DL; Coyte, PC; Stewart, DE				Cameron, JI; Cheung, AM; Streiner, DL; Coyte, PC; Stewart, DE			Stroke survivors' behavioral and psychologic symptoms are associated with informal caregivers' experiences of depression	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						behavioral symptoms; caregivers; cerebrovascular accident; depression; quality of life; rehabilitation	TRAUMATIC BRAIN INJURY; FAMILY CAREGIVERS; PSYCHOEDUCATIONAL INTERVENTION; ACTIVITY RESTRICTION; SPOUSAL CAREGIVERS; CANCER-PATIENTS; STRESS PROCESS; MENTAL-HEALTH; DEMENTIA; CARE	Objective: To determine the impact of stroke survivors' behavioral and psychologic symptoms (BPS) on informal caregivers' experience of depression in the context of the caregiving situation. Design: Cross-sectional survey using a structured quantitative interview. Setting: Rehabilitation facility outpatient clinic, tertiary care facility outpatient clinic, and community care organizations. Participants: Ninety-four informal caregivers to stroke survivors completed standardized measurement instruments. Interventions: Not applicable. Main Outcome Measures: Measurement instruments included the Center for Epidemiological Studies Depression Scale, Brain Impairment Behavior Inventory-Revised, Caregiver Assistance Scale, Caregiving Impact Scale, and Mastery scale. Results: A substantial percentage (44.7%) of caregivers were at risk of clinical depression. Caregivers experienced more depression symptoms when they cared for stroke survivors exhibiting more BPS of memory and comprehension difficulties, provided less assistance, experienced more lifestyle interference, and had lower mastery (F-5,F-85=26.02, P<.001, adjusted R-2=.58). Conclusions: BPS exhibited by stroke survivors contribute to informal caregivers' experience of depression. These results can assist rehabilitation professionals to identify informal care providers who are at greater risk of experiencing emotional distress and, therefore, may benefit from intervention.	Univ Toronto, Univ Hlth Network, Womens Hlth Program, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Rehabil Inst, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Baycrest Ctr Geriatr Care, Toronto, ON, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada		Cheung, AM (corresponding author), Univ Toronto, Univ Hlth Network, Womens Hlth Program, 200 Elizabeth St,7 Eaton N 221, Toronto, ON M5G 2C4, Canada.	angela.cheung@uhn.on.ca	Streiner, David/E-6563-2011; Stewart, Donna Eileen E/J-2844-2016	Streiner, David/0000-0003-0610-6271; Stewart, Donna Eileen E/0000-0002-8157-7746; Cheung, Angela M./0000-0001-8332-0744; Cameron, Jill/0000-0003-4161-1572			ANDERSON CS, 1995, STROKE, V26, P843, DOI 10.1161/01.STR.26.5.843; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Arai Y, 2001, PSYCHIAT CLIN NEUROS, V55, P379, DOI 10.1046/j.1440-1819.2001.00878.x; BibouNakou I, 1997, SOC PSYCH PSYCH EPID, V32, P104, DOI 10.1007/BF00788928; Bloom JR, 1998, PSYCHO-ONCOLOGY, V7, P89, DOI 10.1002/(SICI)1099-1611(199803/04)7:2<89::AID-PON293>3.0.CO;2-E; Bromberger JT, 2004, AM J PUBLIC HEALTH, V94, P1378, DOI 10.2105/AJPH.94.8.1378; Cameron JI, 2006, CRIT CARE MED, V34, P81, DOI 10.1097/01.CCM.0000190428.71765.31; Cameron JI, 2002, CANCER-AM CANCER SOC, V94, P521, DOI 10.1002/cncr.10212; Devins G M, 1994, Adv Ren Replace Ther, V1, P251; DEVINS GM, 1984, INT J PSYCHIAT MED, V13, P327, DOI 10.2190/5DCP-25BV-U1G9-9G7C; DRAPER BM, 1992, J AM GERIATR SOC, V40, P896, DOI 10.1111/j.1532-5415.1992.tb01986.x; EVANS RL, 1991, ARCH PHYS MED REHAB, V72, P144; Fairclough DL, 2002, DESIGN ANAL QUALITY; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; Folkman S, 1997, SOC SCI MED, V45, P1207, DOI 10.1016/S0277-9536(97)00040-3; Garand L, 2002, ARCH PSYCHIAT NURS, V16, P156, DOI 10.1053/apnu.2002.34392; Gaugler JE, 2000, PSYCHOL AGING, V15, P437, DOI 10.1037/0882-7974.15.3.437; Gerdner LA, 2002, NURS RES, V51, P363, DOI 10.1097/00006199-200211000-00004; Goode KT, 1998, HEALTH PSYCHOL, V17, P190, DOI 10.1037/0278-6133.17.2.190; Gresham GE, 1997, STROKE, V28, P1522, DOI 10.1161/01.STR.28.7.1522; Han B, 1999, STROKE, V30, P1478, DOI 10.1161/01.STR.30.7.1478; KINNEY JM, 1995, J APPL GERONTOL, V14, P3, DOI 10.1177/073346489501400101; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; Li LW, 1999, PSYCHOL AGING, V14, P206, DOI 10.1037/0882-7974.14.2.206; Martire LM, 2000, PSYCHOL AGING, V15, P148, DOI 10.1037/0882-7974.15.1.148; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; Nieboer AP, 1998, SOC SCI MED, V47, P1361, DOI 10.1016/S0277-9536(98)00214-7; Nijboer C, 1999, SOC SCI MED, V48, P1259, DOI 10.1016/S0277-9536(98)00426-2; OBERST MT, 1989, CANCER NURS, V12, P209; Ostwald SK, 1999, GERONTOLOGIST, V39, P299, DOI 10.1093/geront/39.3.299; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; PERIARD ME, 1993, PUBLIC HEALTH NURS, V10, P252, DOI 10.1111/j.1525-1446.1993.tb00061.x; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; Pohjasvaara T, 1998, STROKE, V29, P75, DOI 10.1161/01.STR.29.1.75; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 2004, JAMA-J AM MED ASSOC, V292, P961, DOI 10.1001/jama.292.8.961; SCHULZ R, 1988, PSYCHOL AGING, V3, P131, DOI 10.1037/0882-7974.3.2.131; Stevens JP., 1996, APPL MULTIVARIATE ST; Tabachnick B.G., 2001, USING MULTIVARIATE S; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; Wentzel C, 2001, NEUROLOGY, V57, P714, DOI 10.1212/WNL.57.4.714; Williams A, 1994, J Neurosci Nurs, V26, P155; Williamson GA, 2005, REHABIL PSYCHOL, V50, P215, DOI 10.1037/0090-5550.50.3.215; Williamson GM, 1998, HEALTH PSYCHOL, V17, P152, DOI 10.1037/0278-6133.17.2.152; Yamamoto-Mitani N, 2001, Sch Inq Nurs Pract, V15, P113; Yates ME, 1999, J GERONTOL B-PSYCHOL, V54, pP12, DOI 10.1093/geronb/54B.1.P12; Yee JL, 2000, GERONTOLOGIST, V40, P147, DOI 10.1093/geront/40.2.147; YOUNG RF, 1989, GERONTOLOGIST, V29, P660, DOI 10.1093/geront/29.5.660; [No title captured]; [No title captured]; [No title captured]	54	65	66	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2006	87	2					177	183		10.1016/j.apmr.2005.10.012			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	013CJ	WOS:000235386900005	16442969				2022-02-06	
J	Bayly, PV; Black, EE; Pedersen, RC; Leister, EP; Genin, GM				Bayly, PV; Black, EE; Pedersen, RC; Leister, EP; Genin, GM			In vivo imaging of rapid deformation and strain in an animal model of traumatic brain injury	JOURNAL OF BIOMECHANICS			English	Article						brain injury; concussion; strain; deformation; HARP; MRI	DIFFUSE AXONAL INJURY; SPATIAL MODULATION; MECHANICAL STRETCH; MOTION; RAT; HEART; MRI; MAGNETIZATION; IMPACT	In traumatic brain injury (TBI) rapid deformation of brain tissue leads to axonal injury and cell death. In vivo quantification of such fast deformations is extremely difficult, but important for understanding the mechanisms of degeneration post-trauma and for development of numerical models of injury biomechanics. In this paper, strain fields in the brain of the perinatal rat were estimated from data obtained in vivo during rapid indentation. Tagged magnetic resonance (MR) images were obtained with high spatial (0.2 mm) and temporal (3.9 ms) resolution by gated image acquisition during and after impact. Impacts were repeated either 64 or 128 times to obtain images of horizontal and vertical tag lines in coronal and sagittal planes. Strain fields were estimated by harmonic phase (HARP) analysis of the tagged images. The original MR data was filtered and Fourier-transformed to obtain HARP images, following a method originally developed by Osman et al. (IEEE Trans. Med. Imaging 19(3) (2000) 186). The displacements of material points were estimated from intersections of HARP contours and used to generate estimates of the deformation gradient and Lagrangian strain tensors. Maximum principal Lagrangian strains of > 0.20 at strain rates > 40/s were observed during indentations of 2 mm depth and 21 ms duration. (c) 2005 Elsevier Ltd. All rights reserved.	Washington Univ, St Louis, MO 63130 USA		Bayly, PV (corresponding author), Washington Univ, 1 Brookings Dr,Box 1185, St Louis, MO 63130 USA.	pvb@me.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24-CA83060, R24 CA083060] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45237, R21 NS045237] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24CA083060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS045237] Funding Source: NIH RePORTER		Al-Bsharat AS, 1999, P 43 STAPP CAR CRASH; AXEL L, 1989, RADIOLOGY, V172, P349, DOI 10.1148/radiology.172.2.2748813; AXEL L, 1989, RADIOLOGY, V171, P841, DOI 10.1148/radiology.171.3.2717762; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bayly PV, 2004, J BIOMECH ENG-T ASME, V126, P523, DOI 10.1115/1.1785811; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Black EE, 2004, J NEUROTRAUM, V21, P1276; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy W.N., 1997, ASME PUBLICATION AMD, V225, P241; Holbourn AHS, 1943, LANCET, V2, P438; Kraitchman DL, 2003, CIRCULATION, V107, P2025, DOI 10.1161/01.CIR.0000062684.47526.47; Kuijer JPA, 2001, MAGN RESON MED, V46, P993; Liu W, 2004, MAGN RESON MED, V52, P1282, DOI 10.1002/mrm.20276; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Osman NF, 2000, IEEE T MED IMAGING, V19, P186, DOI 10.1109/42.845177; PRANGE MT, 2001, P 2001 ASME BIOENG C, V50, P833; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Sampath S, 2003, MAGN RESON MED, V50, P154, DOI 10.1002/mrm.10509; Smith DH, 1999, J NEUROSCI, V19, P4263; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; ZERHOUNI EA, 1988, RADIOLOGY, V169, P59, DOI 10.1148/radiology.169.1.3420283; ZHANG L, 2001, P ASME BIOENG C BED, V50, P831; [No title captured], DOI DOI 10.1016/0021-9290(90)90029-3	28	65	66	0	15	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.		2006	39	6					1086	1095		10.1016/j.jbiomech.2005.02.014			10	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	033GL	WOS:000236834900012	16549098	Green Accepted			2022-02-06	
J	Kashluba, S; Casey, JE; Paniak, C				Kashluba, S; Casey, JE; Paniak, C			Evaluating the utility of ICD-10 diagnostic criteria for postconcussion syndrome following mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						longitudinal; control group; symptoms; follow-up; diagnostic criteria; adult	HEAD-INJURY; PATIENT COMPLAINTS; RANDOMIZED-TRIAL; BASE RATES; SYMPTOMS	The present study investigated the utility Of the International Classification of Diseases and Related Health Problems, 10th edition (ICD-10) diagnostic criteria for postconcussion syndrome (PCS) symptoms by comparing symptom endorsement rates in a group of patients with mild traumatic brain injury (MTBT) to those of a noninjured control group at one month and three months post-injury. The 110 MTBI patients and I 18 control participants were group-matched on age, gender, and education level. Seven of the nine self-reported ICD-10 PCS symptoms differentiated the groups at one month post-injury and two symptoms differentiated the groups at three months post-injury: symptom endorsement rates were higher in the MTBI group at both time periods. Fatiguing quickly and dizziness/vertigo best differentiated the groups at both time periods, while depression and anxiety/tension failed to differentiate the groups at either time period. Collectively, the ICD-10 PCS symptoms accurately classified the MTBI patients at one month post-injury, with the optimal positive test threshold of endorsement of five symptoms coinciding with a sensitivity and specificity of 73% and 61%, respectively. The ICD-10 PCS symptoms were unable to accurately classify the MTBI patients at three months post-injury.	Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; Glenrose Rehabil Hosp, Dept Psychol Serv, Edmonton, AB, Canada		Casey, JE (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	jecasey@uwindsor.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CARROLL LJ, 1908, J REHABILITATION MED, V43, pS84; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jagoda A, 2000, EMERG MED CLIN N AM, V18, P355, DOI 10.1016/S0733-8627(05)70130-9; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paniak C, 2000, BRAIN INJURY, V14, P219; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Swets J. A., 1996, SIGNAL DETECTION THE; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 2004, ICD 10 INT STAT CLAS	27	65	66	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2006	12	1					111	118		10.1017/S1355617706060036			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	012BS	WOS:000235313800013	16433950				2022-02-06	
J	Ziino, C; Ponsford, J				Ziino, C; Ponsford, J			Vigilance and fatigue following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						fatigue; attention; brain injury; depression	CLOSED-HEAD-INJURY; DUAL-TASK PERFORMANCE; MULTIPLE-SCLEROSIS; CANCER-PATIENTS; ATTENTION; DEPRESSION; SCALE; MODERATE; REHABILITATION; IMPAIRMENTS	Research, findings have suggested that individuals with traumatic brain injury (TBI) show greater psychophysiological and subjective costs associated with performing vigilance tasks, but have not examined relationships with fatigue. The present study aimed to investigate vigilance and its relationship with subjective and objective fatigue measures. Forty-six TBI participants and 46 controls completed a 45-minute vigilance task. They also completed a subjective fatigue scale (the VAS-F) and a selective attention task before and after the vigilance task, and had their blood pressure (BP) monitored. TBI participants performed at a lower level on the vigilance task, but performed at a similar level across the duration of the task. Higher subjective fatigue ratings,on the VAS-F were associated with more misses on the vigilance task for TBI participants. TBI participants showed greater increases in diastolic BP, and these were associated with greater increases in subjective fatigue ratings on the VAS-F. A subgroup of TBI participants showed a decline in performance on the vigilance task and also showed disproportionate increases in subjective fatigue. Findings provide support for the coping hypothesis, suggesting that TBI individuals expend greater psychophysiological costs in order to maintain stable performance over time, and that these costs are also associated with subjective increases in fatigue.	Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia		Ziino, C (corresponding author), Monash Univ, Dept Psychol, Clayton Campus,POB 17, Clayton, Vic 3800, Australia.	Carlo.Ziino@med.monash.edu.au					Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Annett J, 2002, ERGONOMICS, V45, P966, DOI 10.1080/00140130210166951; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Caci H, 2003, PSYCHIAT RES, V118, P89, DOI 10.1016/S0165-1781(03)00044-1; COHEN RA, 1989, ARCH NEUROL-CHICAGO, V46, P676, DOI 10.1001/archneur.1989.00520420096030; COHEN RA, 1993, NEUROPSYCHOLOGY ATTE, P49; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Ferraccioli G, 1996, J RHEUMATOL, V23, P1539; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Harter M, 2001, DISABIL REHABIL, V23, P737; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Parasuraman R., 1984, SUSTAINED ATTENTION, P61; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; PRIGITANO GP, 1975, AWARENESS DEFICITS B; Ream E, 1996, INT J NURS STUD, V33, P519, DOI 10.1016/0020-7489(96)00004-1; Riccio CA, 2002, ARCH CLIN NEUROPSYCH, V17, P235, DOI 10.1016/S0887-6177(01)00111-1; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMETS EMA, 1993, BRIT J CANCER, V68, P220, DOI 10.1038/bjc.1993.319; Snaith R., 1994, HOSP ANXIETY DEPRESS; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Sturm W, 2001, NEUROIMAGE, V14, pS76, DOI 10.1006/nimg.2001.0839; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Winstead-Fry P, 1998, J Nurs Meas, V6, P111; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	56	65	66	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2006	12	1					100	110		10.1017/S1355617706060139			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	012BS	WOS:000235313800012	16433949				2022-02-06	
J	Borgaro, SR; Baker, J; Wethe, JV; Prigatano, GP; Kwasnica, C				Borgaro, SR; Baker, J; Wethe, JV; Prigatano, GP; Kwasnica, C			Subjective reports of fatigue during early recovery from traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; fatigue; traumatic brain injury	MINOR HEAD-INJURY; MULTIPLE-SCLEROSIS; VITAL EXHAUSTION; MENTAL FATIGUE; DEPRESSION; EXPERIENCE; SEVERITY; SEQUELAE; IMPACT; DISORDERS	Objective: To determine whether patients with traumatic brain injury (TBI) report higher levels of fatigue than do normal controls and to identify demographic and cognitive correlates of self-reported fatigue. Design: Prospective study. Setting: Inpatient neurorehabilitation unit in a medical center and neurological institute. Participants: Forty-seven neurorehabilitation inpatients with TBI. Main Outcome Measures: Barrow Neurological Institute (BNI) Fatigue Scale and BNI Screen for Higher Cerebral Functions. Results: Patients reported significantly greater levels of fatigue compared to the levels reported by normal controls, although fatigue was found to be unrelated to injury severity, number of days from injury to assessment, cognitive impairment, and gender. Inspection of individual items revealed no significant differences between severe versus moderate versus mild TBI groups. However, being able to last the day without taking a nap (ie, item 10) was found to be the most sensitive item associated with fatigue in the TBI group, Conclusions: Results of this study suggest the need to integrate activities and interventions to increase endurance in patients with TBI during early rehabilitation. Accommodating regular rest breaks and increasing restful sleep should be a focus of inpatient neurorehabilitation units.	St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA		Borgaro, SR (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	sborgar@chu.edu					BELZA BL, 1993, NURS RES, V42, P93; BINDER LM, 1987, REHABIL PSYCHOL, P65; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Busek P, 2000, Sb Lek, V101, P233; CARDENAS DD, 1982, NEPHRON, V30, P336, DOI 10.1159/000182512; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chervin R., 2002, CHEST, V118, P372; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FISK JD, 1994, CAN J NEUROL SCI, V21, P9, DOI 10.1017/S0317167100048691; FISK JD, 1994, CLIN INFECT DIS   S1, V18, P79; GROBARMURRAY ME, 1998, J NEUROSCI NURS, V30, P191; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Halstead WC, 1947, BRAIN INTELLIGENCE Q; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; JENNETT B, 1974, MANAGEMENT HEAD INJU; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; Khan AA, 2002, AM J PSYCHIAT, V159, P1427, DOI 10.1176/appi.ajp.159.8.1427; Kop WJ, 1996, J PSYCHOSOM RES, V40, P397, DOI 10.1016/0022-3999(95)00613-3; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; Krupp LB, 1996, CURR OPIN NEUROL, V9, P456, DOI 10.1097/00019052-199612000-00011; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Krupp LB, 2000, NEUROLOGY, V55, P934, DOI 10.1212/WNL.55.7.934; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVITT MA, 1994, AM J EMERG MED, V12, P172, DOI 10.1016/0735-6757(94)90240-2; LJUNGGREN B, 1985, J NEUROSURG, V62, P673, DOI 10.3171/jns.1985.62.5.0673; Lou JS, 2001, MOVEMENT DISORD, V16, P190, DOI 10.1002/mds.1042; Luria A.R., 1948, RESTORATION FUNCTION; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PARAMENTER BA, 2001, MULT SCLER, V9, P111; Pater JL, 1997, SUPPORT CARE CANCER, V5, P410, DOI 10.1007/s005200050100; PAUL R, 2002, MUSCLE NERVE, V23, P1402; Paul RH, 2002, J CLIN NEUROSCI, V9, P243, DOI 10.1054/jocn.2001.1016; Pedersen SS, 2001, J PSYCHOSOM RES, V51, P443, DOI 10.1016/S0022-3999(01)00203-3; Poynard T, 2002, J VIRAL HEPATITIS, V9, P295, DOI 10.1046/j.1365-2893.2002.00364.x; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 1993, BNI Q, V9, P2; Rosenstein LD., 1995, ADM SCORING MANUAL B; Ross S, 2001, Appl Neuropsychol, V8, P4, DOI 10.1207/S15324826AN0801_2; Schenkman M, 2001, PARKINSONISM RELAT D, V8, P41, DOI 10.1016/S1353-8020(00)00079-1; Short K, 2002, J PSYCHOSOM RES, V52, P475, DOI 10.1016/S0022-3999(02)00290-8; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Smets EMA, 1998, BRIT J CANCER, V78, P907, DOI 10.1038/bjc.1998.600; Torres-Harding SR, 2002, J BEHAV MED, V25, P99, DOI 10.1023/A:1014850819995; Uuskula M, 1996, PSYCHOTHER PSYCHOSOM, V65, P327, DOI 10.1159/000289092; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Van Zomeren A. H., 1981, REACTION TIME ATTENT; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469	54	65	65	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					416	425		10.1097/00001199-200509000-00003			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600004	16170250				2022-02-06	
J	Esposito, TJ; Reed, RL; Gamelli, RL; Luchette, FA				Esposito, TJ; Reed, RL; Gamelli, RL; Luchette, FA			Neurosurgical coverage - Essential, desired, or irrelevant for good patient care and trauma center status	ANNALS OF SURGERY			English	Article							MINIMAL HEAD-INJURY; ASSOCIATION; MANAGEMENT; SURGEONS; UTILITY; SCANS; RISK	Summ. and Background Data: As a result of many factors, the availability of neurosurgeons (NS) to care for trauma patients (TP) is increasingly sparse. This has precipitated a crisis in access to neurosurgical support in many trauma systems, often placing undue burden on level I centers. This study examines the profile of head-injured (HI) trauma patients and their actual need for the specific expertise of a neurosurgeon. Methods: The National Trauma Data Bank (NTDB) was queried for specific information relating to the volume, nature, timeliness, and outcome of HI TP. Study patients were identified by reported International Classification of Diseases, 9th Edition (ICD-9) codes denoting open (OHI) or closed head injury (CHI) in isolation or in combination with other injuries. Results: Total number of NTDB patients studied was 731,823, of which 213,357 (29%) had a reported HI. CHI represented 22% of all TP and 74% of HI. OHI was reported in 8% of all TP and was 26% of HI. Craniotomy (crani) was performed in 3.6% of all HI (1% of all TP). This was in 2.8% of OHI and 2.6% of CHI. Mean Glasgow Coma Scale score (GCS) of crani patients was 9, and 13 for the noncrani group. Subdural hematoma occurred in 18% of HI (5% of TP), with 13% undergoing crani. Epidural hematoma occurred in 10% of HI (3% of all TP), with 17% undergoing crani. Median time to OR for all cranis was 195 minutes (195 for CHI; 183 for OHI). Of all crams, 6.5% were performed within 1 hour of hospital admission. intracranial pressure (ICP) monitoring was reportedly used in 0.7% of TP and 2.2% of HI. Conclusions: Care of TP with HI rarely requires the explicit expertise and immediate presence of a neurosurgeon due to volume and nature of care. HI was diagnosed in < 30% of TP reported to the NTDB. Over 95% required nonoperative management alone, with only 1% of all TP and 2%- 4% of HI TP requiring cram and/or ICP monitoring. Immediate availability of NS is not essential if a properly trained and credentialed trauma surgeon or other health care provider can appropriately monitor patients for neurologic demise and effect early transfer to a center capable of, and committed to, operative and postoperative neurosurgical care. A subgroup of patients known to have a high propensity for the specific expertise of a neurosurgeon may be able to be identified for direct transport to these committed centers.	Loyola Univ, Med Ctr, Dept Surg, Div Truma Surg Crit Care & Burns, Maywood, IL 60153 USA; Burn Shock Trauma Inst, Maywood, IL USA		Esposito, TJ (corresponding author), Loyola Univ, Med Ctr, Dept Surg, Div Truma Surg Crit Care & Burns, 2160 S 1st Ave,Bldg 110,Room 4235, Maywood, IL 60153 USA.	tesposi@lumc.edu	Reed, Robert/AAJ-2575-2020; Luchette, Fred/ABF-1710-2020	Luchette, Fred/0000-0002-8857-9111			*AM ASS SURG TRAUM, 1992, J TRAUMA, V33, P491; BIRKMEYER JD, 2003, LEAPFROG GROUPS PATI; BISHOFBERGER TE, 2004, J TRAUMA, V57, P457; Chesnut RM, 1997, J TRAUMA, V42, pS19, DOI 10.1097/00005373-199705001-00004; *COMM TRAUM AM COL, 1999, RES OPT CAR INJ PAT; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Esposito T, 1993, NATL SURVEY SURG TRA; ESPOSITO TJ, 1994, J TRAUMA, V37, P996, DOI 10.1097/00005373-199412000-00022; ESPOSITO TJ, 1991, ARCH SURG-CHICAGO, V126, P292; Ko K, 2003, J TRAUMA, V55, P480, DOI 10.1097/01.TA.0000074111.04885.28; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; *NAT CTR INJ PREV, 2001, INJ FACT BOOK 2001 2; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Rotondo MF, 2005, J TRAUMA, V59, P77, DOI 10.1097/01.TA.0000171848.22633.C0; SANTANIELLO JM, 2003, SURGERY, V134, P4; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEILL IG, 1997, ANN EMERG MED, V30, P14; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Stephan PJ, 2002, J TRAUMA, V53, P895, DOI 10.1097/00005373-200211000-00014; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TRUNKEY DD, 2003, B AM COLL SURG, V88, P9; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004	26	65	66	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	SEP	2005	242	3					364	374		10.1097/01.sla.0000179624.50455.db			11	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	962QV	WOS:000231748200007	16135922	Green Published			2022-02-06	
J	Hutchinson, PJ; O'Connell, MT; Nortje, J; Smith, P; Al-Rawi, PG; Gupta, AK; Menon, DK; Pickard, JD				Hutchinson, PJ; O'Connell, MT; Nortje, J; Smith, P; Al-Rawi, PG; Gupta, AK; Menon, DK; Pickard, JD			Cerebral microdialysis methodology - evaluation of 20 kDa and 100 kDa catheters	PHYSIOLOGICAL MEASUREMENT			English	Article						cerebral metabolism; brain injury; microdialysis; cytokines; lactate/pyruvate ratio	BRAIN; INJURY	Microdialysis monitoring of cerebral metabolism is now performed in several neuro-intensive care units. Conventional microdialysis utilizes CMA70 catheters with 20 kDa molecular weight cut-off membranes enabling the measurement of small molecules such as glucose, lactate, pyruvate and glutamate. The CMA71 100 kDa molecular weight cut-off microdialysis catheter has recently been introduced to allow detection of larger molecules such as cytokines. The objective of this study was to perform in vitro and in vivo testing of the CMA71 microdialysis catheter, comparing its performance with the CMA70. In vitro comparison studies of three of each catheter using reference analyte solutions, demonstrated equivalent recovery for glucose, lactate, pyruvate and glutamate (range 94-97% for CMA70 and 88-103% for CMA71). In vivo comparison involved intracranial placement of paired CMA70 and CMA71 catheters (through the same cranial access device) in six patients with severe traumatic brain injury. Both catheters were perfused with CNS Perfusion Fluid without dextran at 0.3 mu l min(-1) with hourly sampling and bedside analysis on a CMA600 microdialysis analyser. The two catheters yielded equivalent results for glucose, lactate, pyruvate, glutamate and lactate/pyruvate ratio. CMA71 microdialysis catheters can, therefore, be used for routine clinical monitoring of extracellular substances, as well as for their intended research role of larger molecular weight protein sampling.	Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Neurosci Crit Care Unit, Cambridge CB2 2QQ, England		Hutchinson, PJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Hills Rd, Cambridge CB2 2QQ, England.	pjah2@cam.ac.uk		O'Connell, Mark/0000-0001-6272-8767	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Ungerstedt U, 1997, Acta Anaesthesiol Scand Suppl, V110, P123; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039	11	65	66	0	6	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0967-3334	1361-6579		PHYSIOL MEAS	Physiol. Meas.	AUG	2005	26	4					423	428		10.1088/0967-3334/26/4/008			6	Biophysics; Engineering, Biomedical; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering; Physiology	956SC	WOS:000231319100011	15886437				2022-02-06	
J	Pelinka, LE; Hertz, H; Mauritz, W; Harada, N; Jafarmadar, M; Albrecht, M; Redl, H; Bahrami, S				Pelinka, LE; Hertz, H; Mauritz, W; Harada, N; Jafarmadar, M; Albrecht, M; Redl, H; Bahrami, S			Nonspecific increase of systemic neuron-specific enolase after trauma: Clinical and experimental findings	SHOCK			English	Article						cerebral trauma; extra-cranial trauma; ischemia; multiple trauma; neuron-specific enolase; reperfusion	BRAIN-DAMAGE; CEREBROSPINAL-FLUID; SERUM S100B; MARKERS; PROTEIN; INJURY; REPERFUSION; CIRCULATION; PREDICTOR; ISCHEMIA	The aim of this clinical and experimental study was to determine whether systemic neuron-specific enolase (NSE) is a useful early marker of traumatic brain injury (TBI) and whether NSE is affected by ischemia/reperfusion damage of abdominal organs. Our study included patients with and without TBI (verified by computerized tomography) admitted within 6 h after trauma and male Sprague-Dawley rats with ischemia and reperfusion of the abdominal organs liver, gut, or kidney. Thirty-eight study patients included 13 with isolated TBI and 18 patients with multiple trauma and TBI. Seven patients had multiple trauma but no TBI. Fifteen rats were anaesthetized and subjected to isolated ischemia of the liver, gut, or kidney (n = 5 each) for 1 h, followed by reperfusion for 3 h. In patients, NSE increased over 2-fold versus the upper normal limit (10 mu g/L) within 6 h after trauma, regardless of whether TBI had occurred or not. In rats, NSE increased over 3-fold versus laboratory controls during ischemia of the liver and kidney (both P < 0.0005), but not of the gut. NSE increased over 2-fold after onset of reperfusion of the liver and kidney (both P < 0.05), but not of the gut and increased over 3-fold after 3 h of reperfusion of the liver, gut (both P < 0.005), and kidney (P < 0.0005). Our data show that systemic NSE increases to similar degrees with and without TBI. Therefore, NSE is not a useful early marker of TBI in multiple trauma.	Ludwig Boltzmann Inst Expt & Clin Traumatol, Res Ctr, Allgemeine Unfallversicherungsanstalt, A-1200 Vienna, Austria; Lorenz Boehler Trauma Ctr, Allgemeine Unfallversicherungsanstalt, A-1200 Vienna, Austria; Fukuoka Univ, Inst Pharmacol, Jonan Ku, Fukuoka 8140180, Japan		Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Res Ctr, Allgemeine Unfallversicherungsanstalt, Donaueschingenstr 13, A-1200 Vienna, Austria.	lindapel@via.at	Redl, Heinz/AAD-8157-2019	Bahrami, Soheyl/0000-0002-4563-6251; Mauritz, Walter/0000-0001-9043-3712			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arumugam TV, 2004, SHOCK, V21, P401, DOI 10.1097/00024382-200405000-00002; Ashburn JH, 2004, SHOCK, V22, P120, DOI 10.1097/01.shk.0000127683.26493.e4; BOCK E, 1975, SCAND J IMMUNOL, P31; BRADLEY HE, 1994, MONITORING CENTRAL N, P26; CHRISTENSEN EI, 1991, SEMIN NEPHROL, V11, P414; Cooper E. H., 1994, International Journal of Biological Markers, V9, P205; Cucullo L, 2002, BRAIN RES, V951, P243, DOI 10.1016/S0006-8993(02)03167-0; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; FLETCHER L, 1976, BIOCHIM BIOPHYS ACTA, V452, P245, DOI 10.1016/0005-2744(76)90077-2; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; Harada N, 1999, CRIT CARE MED, V27, P1958, DOI 10.1097/00003246-199909000-00040; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; JENNETT B, 1975, LANCET, V1, P480; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Nygaard O, 1998, SCAND J CLIN LAB INV, V58, P183; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Snyder-Ramos SA, 2003, RESTOR NEUROL NEUROS, V21, P123; Sobhian B, 2005, SHOCK, V23, P243, DOI 10.1097/01.shk.0000150775.93741.6f; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378	32	65	68	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	AUG	2005	24	2					119	123		10.1097/01.shk.0000168876.68154.43			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	952SV	WOS:000231026700004	16044081				2022-02-06	
J	Martz, E; Livneh, H; Priebe, M; Wuermser, LA; Ottomanelli, L				Martz, E; Livneh, H; Priebe, M; Wuermser, LA; Ottomanelli, L			Predictors of psychosocial adaptation among people with spinal cord injury or disorder	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						coping behavior; rehabilitation; spinal cord injuries; stress disorders post-traumatic	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; LONG-TERM ADJUSTMENT; COPING STRATEGIES; SOCIAL SUPPORT; PSYCHOLOGICAL DISTRESS; POSTTRAUMATIC-STRESS; PHYSICAL-DISABILITY; EMOTIONAL DISTRESS; DEATH ANXIETY	Objective: To examine the influence of disability-related medical and psychologic variables on psychosocial adaptation to spinal cord injury or disorder (SCI/D). Design: A structural equation modeling design linking 3 sets of predictive variables to an outcome measure of adaptation. Setting: Two outpatient SCI clinics (1 veteran, 1 civilian) in Texas. Participants: Veterans (n = 181) and civilians (n = 132) with SCI/D. Interventions: Not applicable. Main Outcome Measures: The adaptation outcome was measured by 2 subscales (acknowledgment, adjustment) of the Reactions to Impairment and Disability Inventory (RIDI) and by the Quality of Life Scale. The predictive variables were measured by a demographic questionnaire, 3 subscales (intrusion, reexperiencing, hyperarousal) of the Purdue Posttraumatic Stress Disorder-Revised scale, the McMordie-Templer Death Anxiety Scale, and 3 subscales (anxiety, depression, denial) of the RIDI. Results: Goodness-of-fit indices suggested that a revised model of adaptation was a moderately good fit to the data. The revised model of adaptation indicated that there were medium total effects (direct plus indirect) on psychosocial adaptation by 2 latent variables (disability severity and impact, negative affectivity) and small total effects on psychosocial adaptation by disengagement coping. The latent factor of disengagement coping had the strongest direct effect on adaptation (although not statistically significant). Disability severity and impact had medium indirect effects and negative affectivity had small indirect effects on psychosocial adaptation. All of the aforementioned effects had a negative coefficient. Conclusions: Negative emotional responses (eg. depression, anxiety) to SCI/D, disengagement-type coping (eg, disability denial, avoidance), and the severity and impact of disability were related to lower levels of adaptation to SCI/D. Key Words: Coping behavior-, Rehabilitation; Spinal cord injuries; Stress disorders post-traumatic.	Univ Missouri, Sch Educ, Columbia, MO 65211 USA; Univ Missouri, Dept Counseling Psychol, Columbia, MO 65211 USA; Portland State Univ, Portland, OR 97207 USA; Edward Hines Jr VA Hosp, Hines, IL USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; VA N Texas Hlth Care Syst, Dallas, TX USA		Martz, E (corresponding author), Univ Missouri, Sch Educ, 4B Hill Hall, Columbia, MO 65211 USA.	martze@missouri.edu					ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; Bergeman CS, 1999, LIFE-SPAN PERSPECTIVES ON HEALTH AND ILLNESS, P207; BRACKEN MB, 1980, SOC PSYCHIATR, V15, P33, DOI 10.1007/BF00577959; BRACKEN MB, 1981, PARAPLEGIA, V19, P271, DOI 10.1038/sc.1981.53; Breznitz S., 1983, DENIAL STRESS, P257; BROWN DJ, 1992, PARAPLEGIA, V30, P77, DOI 10.1038/sc.1992.28; BUCKELEW SP, 1990, REHABIL PSYCHOL, V35, P101, DOI 10.1037/h0079053; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chase BW, 2000, J REHABIL, V66, P14; CHIBNALL JT, 1990, PSYCHOL, V4, P283, DOI DOI 10.1080/08870449008400397; CLAYTON KS, 1994, ARCH PHYS MED REHAB, V75, P633, DOI 10.1016/0003-9993(94)90184-8; Cook DW, 1979, REHABIL PSYCHOL, V26, P97; COYLE CP, 1994, REHABIL PSYCHOL, V39, P95, DOI 10.1037/0090-5550.39.2.95; CRAIG AR, 1994, PARAPLEGIA, V32, P675, DOI 10.1038/sc.1994.109; CRAIG AR, 1990, AUST NZ J PSYCHIAT, V24, P418, DOI 10.3109/00048679009077711; CRISP R, 1992, AUST PSYCHOL, V27, P43, DOI 10.1080/00050069208257573; DAVIDOFF G, 1990, REHABIL PSYCHOL, V35, P171, DOI 10.1037/0090-5550.35.3.171; de Carvalho SAD, 1998, GEN HOSP PSYCHIAT, V20, P353, DOI 10.1016/S0163-8343(98)00047-4; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; DECKER SD, 1985, AM J OCCUP THER, V39, P740, DOI 10.5014/ajot.39.11.740; Diener E, 1997, SOC INDIC RES, V40, P189, DOI 10.1023/A:1006859511756; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Elliott TR, 1999, J PERS INTERPERS LOS, V4, P361, DOI 10.1080/10811449908409742; Evans R L, 1994, J Am Paraplegia Soc, V17, P60; FABIAN ES, 1991, REHABIL COUNS BULL, V34, P344; FRANK RG, 1987, ARCH PHYS MED REHAB, V68, P344; FUHRER MJ, 1993, ARCH PHYS MED REHAB, V74, P255; Fuhrer MJ, 1996, TOPICS SPINAL CORD I, V4, P56; Go Bette K., 1995, P21; GREEN BC, 1984, ARCH PHYS MED REHAB, V65, P751; HAMMELL KRW, 1992, PARAPLEGIA, V30, P317; HANCOCK KM, 1993, PARAPLEGIA, V31, P349, DOI 10.1038/sc.1993.59; Hansen N, 1994, SCI PSYCHOSOC PROCES, V7, P195; HANSON S, 1993, REHABIL PSYCHOL, V38, P41, DOI 10.1037/h0080289; HEINEMANN AW, 1988, REHABIL PSYCHOL, V33, P195, DOI 10.1037//0090-5550.33.4.195; Hicken BL, 2002, J REHABIL RES DEV, V39, P359; JUDD FK, 1991, PARAPLEGIA, V29, P91, DOI 10.1038/sc.1991.12; Kemp BJ, 1999, DISABIL REHABIL, V21, P241; Kennedy P, 2000, BRIT J HEALTH PSYCH, V5, P157, DOI 10.1348/135910700168838; KENNEDY P, 1995, BRIT J CLIN PSYCHOL, V34, P627, DOI 10.1111/j.2044-8260.1995.tb01496.x; KRAUSE JS, 1990, PARAPLEGIA, V28, P186, DOI 10.1038/sc.1990.24; KRAUSE JS, 1992, REHABIL PSYCHOL, V37, P49, DOI 10.1037/h0079093; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Lauterbach D., 1996, ASSESSMENT, V3, P17, DOI DOI 10.1177/107319119600300102; Livneh H, 2003, INT J REHABIL RES, V26, P191, DOI 10.1097/00004356-200309000-00005; LIVNEH H, 1991, REHABIL COUNS BULL, V34, P298; Livneh H, 2001, REHABIL COUNS BULL, V44, P151, DOI 10.1177/003435520104400305; Livneh H, 1990, J APPLIED REHABILITA, V21, P13; MacLeod L, 1998, DISABIL REHABIL, V20, P448, DOI 10.3109/09638289809166109; MALEC J, 1983, ARCH PHYS MED REHAB, V64, P359; MARINI I, 1995, REHABIL COUNS BULL, V38, P198; McColl MA, 2003, ARCH PHYS MED REHAB, V84, P1137, DOI 10.1016/S0003-9993(03)00138-2; McGrath P, 1999, J REHABIL, V65, P17; McMillen JC, 2003, REHABIL PSYCHOL, V48, P77, DOI 10.1037/0090-5550.48.2.77; MCMORDIE WR, 1979, PSYCHOL REP, V44, P975, DOI 10.2466/pr0.1979.44.3.975; MCNETT SC, 1987, NURS RES, V36, P98; Moore A D, 1994, Int J Rehabil Res, V17, P39, DOI 10.1097/00004356-199403000-00004; Nielsen MS, 2003, REHABIL PSYCHOL, V48, P289, DOI 10.1037/0090-5550.48.4.289; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; OVERHOLSER JC, 1993, REHABIL PSYCHOL, V38, P187, DOI 10.1037/h0080296; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; Radnitz CL, 2000, J ANXIETY DISORD, V14, P313, DOI 10.1016/S0887-6185(00)00025-6; Radnitz CL, 1995, SCI PSYCHOSOCIAL PRO, V8, P145; RICHARDS JS, 1986, ARCH PHYS MED REHAB, V67, P362; Richards JS, 1997, REHABIL PSYCHOL, V42, P115, DOI 10.1037/0090-5550.42.2.115; ROSENSTIEL AK, 1981, J HUM STRESS, V7, P35, DOI 10.1080/0097840X.1981.9934542; SCHLOSSBERG NK, 1981, COUNS PSYCHOL, V9, P2, DOI 10.1177/001100008100900202; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; SHADISH WR, 1981, J CONSULT CLIN PSYCH, V49, P297, DOI 10.1037/0022-006X.49.2.297; TATE D, 1994, AM J PHYS MED REHAB, V73, P175, DOI 10.1097/00002060-199406000-00006; TATE DG, 1990, REHABIL PSYCHOL, V35, P211, DOI 10.1037/h0079062; TEMPLER DI, 1970, J GEN PSYCHOL, V82, P165, DOI 10.1080/00221309.1970.9920634; TOBIN DL, 1989, COGNITIVE THER RES, V13, P343, DOI 10.1007/BF01173478; Whalley Hammell K. R., 1994, Paraplegia, V32, P771; WOODRICH F, 1983, J REHABIL, V49, P26; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	82	65	70	1	13	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2005	86	6					1182	1192		10.1016/j.apmr.2004.11.036			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	934EK	WOS:000229689500017	15954058				2022-02-06	
J	de Boussard, CN; Lundin, A; Karlstedt, D; Edman, G; Bartfai, A; Borg, J				de Boussard, CN; Lundin, A; Karlstedt, D; Edman, G; Bartfai, A; Borg, J			S100 and cognitive impairment after mild traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						MTBI; biochemical markers; S100B; S100A1B; neuropsychology; cognition	MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; PROTEIN; SERUM; S-100B; DYSFUNCTION; MARKERS; ADULTS; DAMAGE	Objective: The aim of this study was to explore the relationship between the proteins S100B and S100A1B and symptoms and signs of cognitive impairment for 3 months after mild traumatic brain injury (MTBI). Methods: Serum concentrations of S100A1B and S100B were examined in a prospective cohort study of patients with MTBI and a Glasgow Coma Scale score of 14 or 15. Cognitive performance was assessed by repeated computerized neuropsychological testing and an extended neuropsychological test. Symptoms were assessed using the Rivermead Post-Concussion Symptoms Questionnaire. Results: Concentrations of S100B and S100A1B were above cut-off in 31% and 48% respectively. Eight percent of the patients had signs of cognitive impairment according to the computerized neuropsychological tests and 30% according to the extended test. Symptoms of cognitive impairment were reported by 44% of the patients on the first day post-injury and by 26% at 3 months. No significant associations between S100B or S100A1B concentrations and symptoms or signs of cognitive impairment were found. Conclusion: Abnormal S100 serum concentrations and symptoms or signs of cognitive impairment were not significantly associated in patients with MTBI and a Glasgow Coma Scale score of 14 or 15.	Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden; Danderyd Hosp, Karolinska Inst, R&D Unit, SE-18288 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Dept Rehabil Med, Stockholm, Sweden; Uppsala Univ, Dept Neurosci, Uppsala, Sweden		de Boussard, CN (corresponding author), Danderyd Hosp, Karolinska Inst, Dept Rehabil Med, SE-18288 Stockholm, Sweden.	catharina.nygren@reh.ds.sll.se		Bartfai, Aniko/0000-0002-0815-2485; Borg, Jorgen/0000-0002-2372-7478			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Biberthaler P, 2002, EUR J MED RES, V7, P164; Bland JM, 1996, BRIT MED J, V313, P744; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GRONWALL D, 1974, LANCET, V2, P605; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEZAK MD, 1991, NEUROPSYCHOLOGICAL A; Marchi N, 2003, RESTOR NEUROL NEUROS, V21, P109; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Spreen O, 1991, COMPENDIUM NEUROPSYC; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Teasdale TW, 1997, BRIT MED J, V315, P569; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Wechsler D., 1981, WAIS R MANUAL; Winer BJ, 1962, STAT PRINCIPLES EXPT; Winocur G, 2001, NEUROBIOL LEARN MEM, V75, P230, DOI 10.1006/nlme.2000.3961; [No title captured]	33	65	67	0	8	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JAN	2005	37	1					53	57		10.1080/16501970410015587			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	893NL	WOS:000226726400009	15788333	gold			2022-02-06	
J	Taub, E				Taub, E			Harnessing brain plasticity through behavioral techniques to produce new treatments in neurorehabilitation	AMERICAN PSYCHOLOGIST			English	Article							INDUCED MOVEMENT THERAPY; CONSTRAINT-INDUCED THERAPY; PHANTOM-LIMB PAIN; CORTICAL REORGANIZATION; SOMATOSENSORY CORTEX; STROKE PATIENTS; MOTOR RECOVERY; LEARNED NONUSE; ADULT; DEAFFERENTATION	Basic behavioral neuroscience research with monkeys has given rise to an efficacious new approach to the rehabilitation of movement after stroke, cerebral palsy, traumatic brain injury, and other types of neurological injury, in humans termed Constraint-Induced Movement therapy or CI therapy. For the upper extremity, the treatment involves intensive training of the more affected arm by "shaping," the application of a number of other behavioral techniques, and prolonged constraint of use of the less affected arm. CI therapy has been shown to produce large changes in the organization and junction of the brain. This result points to the fact that behavior can have a profound effect on the nervous system that is greater than is generally recognized, and harnessing this brain plasticity by behavioral means has promise for the development of new treatments in the field of rehabilitation.	Univ Alabama Birmingham, Vet Affairs Med Ctr, Dept Psychol, Birmingham, AL 35294 USA		Taub, E (corresponding author), Univ Alabama Birmingham, Vet Affairs Med Ctr, Dept Psychol, CPM 712,1530 3rd Ave S, Birmingham, AL 35294 USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD34273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD034273] Funding Source: NIH RePORTER		Azrin N.H., 1966, OPERANT BEHAV AREAS, P380; Bach-y-Rita P, 1992, J NEUROL REHABIL, V6, P191, DOI [10.1177/136140969200600404, DOI 10.1177/136140969200600404]; Bauder H, 1999, PSYCHOPHYSIOLOGY, V36, pS31; Broca PP, 1861, B SOC ANAT PARIS, V6, P398; Candia V, 1999, LANCET, V353, P42, DOI 10.1016/S0140-6736(05)74865-0; CATANIA A. C., 1998, LEARNING; CHAMBERS W W, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P721; DeLuca SC, 2003, PHYS THER, V83, P1003, DOI 10.1093/ptj/83.11.1003; DETTMERS C, IN PRESS ARCH PHYS M; DOSTROVSKY JO, 1976, EXP NEUROL, V52, P480, DOI 10.1016/0014-4886(76)90219-3; Duncan P W, 1997, Top Stroke Rehabil, V3, P1, DOI 10.1080/10749357.1997.11754126; Elbert T., 1995, SCIENCE, V220, P21; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Franz S. I., 1915, JAMA-J AM MED ASSOC, V65, P2150, DOI [10.1001/jama.1915.02580250022007, DOI 10.1001/JAMA.1915.02580250022007]; HALBERSTAM J L, 1971, Archives of Physical Medicine and Rehabilitation, V52, P318; INCE LP, 1969, PSYCHON SCI, V16, P49; JACKSON FL, 1984, BERGEYS MANUAL SYSTE, V1, P591; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; Lashley KS, 1924, ARCH NEURO PSYCHIATR, V12, P249, DOI 10.1001/archneurpsyc.1924.02200030002001; Levy CE, 2001, AM J PHYS MED REHAB, V80, P4, DOI 10.1097/00002060-200101000-00003; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; MARK V, IN PRESS RESTORATIVE; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; MILTNER WHR, 2004, UNPUB CI THERAPY TRE; Mott F.W., 1895, P ROY SOC LOND, V57, P481, DOI DOI 10.1098/RSP1.1894.0179; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Ogden R., 1917, PSYCHOBIOLOGY, V1, P33, DOI [10.1037/h0074814, DOI 10.1037/H0074814]; OSTENDORF CG, 1981, PHYS THER, V61, P1022, DOI 10.1093/ptj/61.7.1022; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Ruch TC, 1960, MED PHYSL BIOPHYSICS, P249; Skinner B.F., 1968, TECHNOLOGY TEACHING; Skinner BF, 1938, BEHAV ORGANISMS; Sterr A, 2002, ARCH PHYS MED REHAB, V83, P1374, DOI 10.1053/apmr.2002.35108; Sterr A, 1998, NATURE, V391, P134, DOI 10.1038/34322; Taub E, 2004, PEDIATRICS, V113, P305, DOI 10.1542/peds.113.2.305; Taub E, 2003, J REHABIL MED, V35, P34, DOI 10.1080/16501960310010124; Taub E, 1998, REHABIL PSYCHOL, V43, P152, DOI 10.1037/0090-5550.43.2.152; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Taub E, 1976, Exerc Sport Sci Rev, V4, P335; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Taub E, 1999, J REHABIL RES DEV, V36, P237; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; TAUB E, 1995, SFI STUDIES SCI COMP, P201; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; Taub E, 1968, NEUROPSYCHOLOGY SPAT, P173; Tower SS, 1940, BRAIN, V63, P36, DOI 10.1093/brain/63.1.36; Uswatte G., 1999, COGN NEUROREHABILIT, P215; Weiss T, 1999, NEUROSCI LETT, V272, P131, DOI 10.1016/S0304-3940(99)00595-9; Wittenberg GF, 2003, NEUROREHAB NEURAL RE, V17, P48, DOI 10.1177/0888439002250456; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; WOLF SL, 1983, PHYS THER, V63, P1448, DOI 10.1093/ptj/63.9.1448; [No title captured]	58	65	70	0	10	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0003-066X	1935-990X		AM PSYCHOL	Am. Psychol.	NOV	2004	59	8					692	704		10.1037/0003-066X.59.8.692			13	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	869XQ	WOS:000225018300006	15554826				2022-02-06	
J	Powell, KB; Voeller, KKS				Powell, KB; Voeller, KKS			Prefrontal executive function syndromes in children	JOURNAL OF CHILD NEUROLOGY			English	Article							SPATIAL WORKING-MEMORY; FRONTAL-LOBE FUNCTIONS; CARD SORTING TEST; HUMAN INFANTS; CORTEX; CEREBELLAR; BRAIN; CONSEQUENCES; PERFORMANCE; DAMAGE	"Executive function" is a term describing the processes required for conscious control of thought, emotion, and action that are central to the management of one's day-to-day life. Executive function is subserved by the prefrontal cortex and related subcortical structures. Disorders affecting the prefrontal cortex-subcortical system are numerous and heterogeneous, but contemporary research has begun to elucidate the mechanisms and consequences of dysfunction in various subsystems with increasing specificity. Prefrontal executive dysfunction results in impaired regulation of cognition, attention, behaviors, arousal, and emotion, all of which have serious and pervasive consequences for functioning across the life span. These executive function deficits are typically difficult to treat, ameliorate, or remediate and require sensitive handling by caretakers. Executive dysfunction can arise as a consequence of many different factors (metabolic, genetic, certain types of epilepsy, cerebral dysgenesis, prematurity, traumatic brain injury, hypoxia, and toxic exposure). The present review delineates the features of prefrontal executive function deficits in children and proposes a roadmap for their diagnosis, treatment, and management. (J Child Neurol 2004; 19:785-797).	Western Inst Neurdev Studies & Intervent, Boulder, CO 80302 USA		Powell, KB (corresponding author), Western Inst Neurdev Studies & Intervent, 2501 Walnut St,Suite 104, Boulder, CO 80302 USA.	kbpow@attglobal.net					Aarsen FK, 2004, NEUROLOGY, V62, P1311, DOI 10.1212/01.WNL.0000120549.77188.36; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Angrilli A, 1999, NEUROREPORT, V10, P1741, DOI 10.1097/00001756-199906030-00021; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5, DOI 10.1080/713755608; Baddeley A.D., 1986, WORKING MEMORY; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BENSON DF, 1990, SCHIZOPHRENIA BULL, V16, P403, DOI 10.1093/schbul/16.3.403; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BERMAN KF, 1995, NEUROPSYCHOLOGIA, V33, P1027, DOI 10.1016/0028-3932(95)00035-2; Blair RJR, 2001, J ABNORM CHILD PSYCH, V29, P499, DOI 10.1023/A:1012277125119; BOONE KB, 1988, NEUROLOGY, V38, P583, DOI 10.1212/WNL.38.4.583; BRADSHAW JL, 2001, DEV DISORDERS FRONTO; Cato MA, 2004, J INT NEUROPSYCH SOC, V10, P453, DOI 10.1017/S1355617704103123; Chang BS, 2003, ANN NEUROL, V53, P596, DOI 10.1002/ana.10520; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; Culhane-Shelburne K, 2002, J INT NEUROPSYCH SOC, V8, P623, DOI 10.1017/S1355617702801308; D'Esposito M., 2002, PRINCIPLES FRONTAL L, P168, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0011; Damasio A., 1994, DESCARTES ERROR EMOT; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; DERIX MMA, 1997, DEPRESSION NEUROBIOL, P109; DIAMOND A, 1985, CHILD DEV, V56, P868, DOI 10.2307/1130099; Diamond A, 2000, CHILD DEV, V71, P44, DOI 10.1111/1467-8624.00117; DIAMOND A, 1989, EXP BRAIN RES, V74, P24; DIAMOND A, 1989, DEV PSYCHOBIOL, V22, P271, DOI 10.1002/dev.420220307; Dimitrov M, 1999, NEUROCASE, V5, P345, DOI 10.1093/neucas/5.4.345; Dum RP, 2003, J NEUROPHYSIOL, V89, P634, DOI 10.1152/jn.00626.2002; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Floel A, 2004, CEREB CORTEX, V14, P404, DOI 10.1093/cercor/bhh002; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Gioia GA IP, 2000, BEHAV RATING INVENTO; GOLDBERG E, 1994, J NEUROPSYCH CLIN N, V6, P371; GOLDMAN PS, 1978, BRAIN RES, V152, P451, DOI 10.1016/0006-8993(78)91103-4; GOLDMAN PS, 1972, BRAIN RES, V43, P53, DOI 10.1016/0006-8993(72)90274-0; GoldmanRakic PS, 1995, ANN NY ACAD SCI, V769, P71, DOI 10.1111/j.1749-6632.1995.tb38132.x; Harlow J.M., 1993, PUBLICATIONS MASSACH, V4, P274, DOI [DOI 10.1177/0957154X9300401407, https://doi.org/10.1177/0957154X9300401407]; Heaton PDRK., 1993, WISCONSIN CARD SORTI; JONESGOTMAN M, 1991, EPILEPSIA, V32, pS41; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Karatekin C, 2000, PEDIATR NEUROL, V22, P106, DOI 10.1016/S0887-8994(99)00128-9; Kerr A, 2004, BRAIN COGNITION, V55, P148, DOI 10.1016/s0278-2626(03)00275-6; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Krasnegor N. A., 1997, DEV PREFRONTAL CORTE; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; Levisohn L, 2000, BRAIN, V123, P1041, DOI 10.1093/brain/123.5.1041; Lichter DC, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P260; Lombardi WJ, 1999, J CLIN EXP NEUROPSYC, V21, P2, DOI 10.1076/jcen.21.1.2.940; Matsuoka T, 2000, IPAP CONFERENCE SER, V1, P11; Mayberg H, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P177; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; Middleton FA, 2001, FRONTAL-SUBCORTICAL CIRCUITS IN PSYCHIATRIC AND NEUROLOGICAL DISORDERS, P44; Middleton FA, 1997, INT REV NEUROBIOL, V41, P61, DOI 10.1016/S0074-7742(08)60347-5; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Moll J, 2003, NEUROREPORT, V14, P299, DOI 10.1097/01.wnr.0000057866.05120.28; Moll J, 2002, J NEUROSCI, V22, P2730, DOI 10.1523/JNEUROSCI.22-07-02730.2002; Moore C., 2001, SELF TIME DEV PERSPE; Nagahama Y, 1996, BRAIN, V119, P1667, DOI 10.1093/brain/119.5.1667; Narushima K, 2003, J NEUROPSYCH CLIN N, V15, P422, DOI 10.1176/appi.neuropsych.15.4.422; OSTERGAARD AL, 1987, NEUROPSYCHOLOGIA, V25, P341, DOI 10.1016/0028-3932(87)90023-6; PENNINGTION BF, 1994, WORKING MEMORY FUNCT; Pennington B. F., 1997, DEV PREFRONTAL CORTE, P265; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Pizzagalli DA, 2002, BIOL PSYCHIAT, V52, P73, DOI 10.1016/S0006-3223(02)01313-6; PODELL K, 2001, FRONTAL LOBES NEUROP, P83; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Riva D, 2000, BRAIN, V123, P1051, DOI 10.1093/brain/123.5.1051; Rogers MA, 1998, BRAIN RES BULL, V47, P297, DOI 10.1016/S0361-9230(98)00126-9; RUFF RM, 1994, ARCH CLIN NEUROPSYCH, V9, P41, DOI 10.1016/0887-6177(94)90013-2; SACKEIM HA, 1982, ARCH NEUROL-CHICAGO, V39, P210, DOI 10.1001/archneur.1982.00510160016003; Saxena S, 1998, BRIT J PSYCHIAT, V173, P26; Schmahmann JD, 1998, TRENDS COGN SCI, V2, P362, DOI 10.1016/S1364-6613(98)01218-2; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Sinclair DB, 2004, PEDIATR NEUROL, V30, P169, DOI 10.1016/j.pediatrneurol.2003.08.005; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; Tranel D, 2000, DEV NEUROPSYCHOL, V18, P273, DOI 10.1207/S1532694201Tranel; WEINBERGER DR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P275; WOOD FB, 1989, BRAIN COGNITION, V10, P76, DOI 10.1016/0278-2626(89)90076-6; ZALD DH, 2001, FRONTAL LOBES NEUROP, P83; Zarahn E, 1999, COGNITIVE BRAIN RES, V7, P255, DOI 10.1016/S0926-6410(98)00029-9; [No title captured]; [No title captured], DOI DOI 10.1016/S0079-7421(08)60452-1; [No title captured]	92	65	70	0	23	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	OCT	2004	19	10					785	797		10.1177/08830738040190100801			13	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	920PT	WOS:000228703300008	15559894				2022-02-06	
J	Zygun, DA; Steiner, LA; Johnston, AJ; Hutchinson, PJ; Al-Rawi, PG; Chatfield, D; Kirkpatrick, PJ; Menon, DK; Gupta, AK				Zygun, DA; Steiner, LA; Johnston, AJ; Hutchinson, PJ; Al-Rawi, PG; Chatfield, D; Kirkpatrick, PJ; Menon, DK; Gupta, AK			Hyperglycemia and brain tissue pH after traumatic brain injury	NEUROSURGERY			English	Article						generalized estimating equation; head injury; hyperglycemia; insulin; neuromonitoring; pH	SEVERE HEAD-INJURY; FOCAL CEREBRAL-ISCHEMIA; BLOOD-GLUCOSE; ADMISSION HYPERGLYCEMIA; DEPRESSIONS; ACIDOSIS; RATS	OBJECTIVE: Hyperglycemia occurring after head injury is associated with poor neurological outcome. We tested the hypothesis that blood glucose levels are associated with brain tissue pH (pH(b)) and that the correction of hyperglycemia would result in an improvement in pH(b). METHODS: This is a retrospective analysis of a prospectively collected database. Thirty-four patients in a tertiary care neuroscience critical care unit with major traumatic brain injury underwent pHb monitoring. RESULTS: A total of 428 glucose measurements were recorded during pHb monitoring. Mean glucose level was 7.1 mmol/L (range, 2.8-21.7 mmol/L) and median (interquartile range) pHb was 7.11 mmol/L (7.00-7.19 mmol/L). To account for the correlated, unbalanced nature of the data, a linear generalized estimating equation model was created. This model predicted that for each 1 mmol/L increase in blood glucose, pHb changed by -0.011 mmol/L (95% confidence interval, -0.016 to -0.005 mmol/L; P < 0.001). This relationship remained significant in a multivariable model that included cerebral perfusion pressure, brain tissue oxygen and carbon dioxide tension, and brain temperature. Twenty-one episodes of significant hyperglycemia (&GE;11.1 mmol/L) treated with intravenous insulin were identified. Insulin therapy significantly reduced blood glucose concentration from a median (interquartile range) of 11.9 mmol/L (range, 11.4-13.6 mmol/L) to 8.8 mmol/L (range, 7.3-9.6 mmol/L; P < 0.001). Baseline pHb was not significantly different from pHb associated with the subsequent glucose reading of less than 11.1 mmol/L (P = 0.29), but there was a suggestion of improvement if the change in blood glucose was large. CONCLUSION: Blood glucose is associated with brain tissue acidosis in patients with major head injury. Prospective studies are required to confirm these results and to determine whether treatment of hyperglycemia improves outcome.	Univ Calgary, Dept Crit Care Med, Foothills Med Ctr, Calgary Hlth Reg, Calgary, AB T2N 2T9, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; Univ Cambridge, Neurosci Crit Care Unit, Cambridge, England; Univ Cambridge, Dept Anaesthesia, Cambridge, England; Addenbrookes Hosp, Cambridge, England; Univ Cambridge, Neurosci Crit Care Unit, Cambridge, England		Zygun, DA (corresponding author), Univ Calgary, Dept Crit Care Med, Foothills Med Ctr, Calgary Hlth Reg, Room EG23,1403 29th St NW, Calgary, AB T2N 2T9, Canada.	david.zygun@calgaryhealthregion.ca	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011				Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Deloof T, 1979, Acta Neurochir Suppl (Wien), V28, P113; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSH WR, 1986, J NEUROSURG, V65, P693, DOI 10.3171/jns.1986.65.5.0693; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; PENTELENYI T, 1977, INJURY, V8, P264, DOI 10.1016/0020-1383(77)90099-7; PENTELENYI T, 1984, INJURY, V15, P397, DOI 10.1016/0020-1383(84)90205-5; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Schurr A, 2002, CRIT CARE, V6, P330; SHIMAZU T, 1966, NATURE, V210, P1178, DOI 10.1038/2101178a0; SMITH ML, 1986, J CEREBR BLOOD F MET, V6, P574, DOI 10.1038/jcbfm.1986.104; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2000, STROKE, V31, P214, DOI 10.1161/01.STR.31.1.214; VOLL CL, 1988, ANN NEUROL, V24, P638, DOI 10.1002/ana.410240508; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Yang SY, 1995, SURG NEUROL, V44, P373, DOI 10.1016/0090-3019(96)80243-6; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	33	65	75	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	OCT	2004	55	4					877	881		10.1227/01.NEU.0000137658.14906.E4			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	860AI	WOS:000224309100031	15458595				2022-02-06	
J	Schachar, R; Levin, HS; Max, JE; Purvis, K; Chen, S				Schachar, R; Levin, HS; Max, JE; Purvis, K; Chen, S			Attention deficit hyperactivity disorder symptoms and response inhibition after closed head injury in children: Do preinjury behavior and injury severity predict outcome?	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CHOICE REACTION-TIME; DEFICIT/HYPERACTIVITY DISORDER; SUSTAINED ATTENTION; DELAY AVERSION; STOP-SIGNAL; ADOLESCENTS; IMPULSIVITY; SEQUELAE; ADHD	We examined the effect of closed head injury (CHI) on the development of symptoms of secondary attention deficit hyperactivity disorder (SADHD), emotional disturbance, and impaired response inhibition. We also investigated the relation of developmental and recovery variables to SADHD symptoms and inhibition. Participants were 200 children aged 5-17 years, 137 children who had CHI, and 63 children with no history of CHI served as controls. We assessed preinjury behavior problems, head injury variables (severity, age at time of injury, time since injury), postinjury SADHD, and anxiety symptoms at least 2 years following the head injury. Response inhibition was measured with the stop-signal task. CHI predicted the development of SADHD symptoms and anxiety with more severe injury predicting more severe outcomes. Only the combination of severe CHI and a high level of SADHD symptoms predicted poor response inhibition. Postinjury anxiety was not associated with poor inhibition. The consequences of CHI did not vary with age at injury or time since injury, but poorer outcome was predicted by preinjury behavior problems. CHI in children leads to SADHD symptoms and anxiety even after taking preinjury disturbance into account. Poor response inhibition is a consequence of CHI but only when the CHI is severe and the child manifests high levels of SADHD symptoms.	Hosp Sick Children, Brain & Behav Program, Res Inst, Toronto, ON M5G 1X8, Canada; Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp & Hlth Ctr, San Diego, CA USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA		Schachar, R (corresponding author), Hosp Sick Children, Brain & Behav Program, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	russell.schachar@sickkids.ca		Schachar, Russell/0000-0002-2015-4395	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH1800-03] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2R01NS 21889-16] Funding Source: Medline		ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Band GPH, 2003, ACTA PSYCHOL, V112, P105, DOI 10.1016/S0001-6918(02)00079-3; BARKHAM J, 1993, GLOBAL ECOL BIOGEOGR, V3, P92, DOI 10.2307/2997552; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Barkley RA, 1996, PEDIATRICS, V98, P1089; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BIJUR PE, 1986, AM J DIS CHILD, V140, P487, DOI 10.1001/archpedi.1986.02140190097036; Boyle MH, 1997, ARCH GEN PSYCHIAT, V54, P793; Boyle MH, 1996, CAN J PSYCHIAT, V41, P549, DOI 10.1177/070674379604100903; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1985, DEV MED CHILD NEUROL, V27, P72; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Crosbie J, 2001, AM J PSYCHIAT, V158, P1884, DOI 10.1176/appi.ajp.158.11.1884; DAUGHERTY TK, 1993, J GENET PSYCHOL, V154, P177, DOI 10.1080/00221325.1993.9914731; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DENNIS M, 1995, TRAUMATIC HEAD INJUR, P1654; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Eaves LJ, 1997, J CHILD PSYCHOL PSYC, V38, P965, DOI 10.1111/j.1469-7610.1997.tb01614.x; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GORDON M, 1988, GORDON DIAGNOSTIC SY; Gordon M, 1983, GORDON DIAGNOSTIC SY; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Jennings JR, 1997, DEV PSYCHOL, V33, P308, DOI 10.1037/0012-1649.33.2.308; JENNINGS JR, 1992, J EXP PSYCHOL HUMAN, V18, P422, DOI 10.1037/0096-1523.18.2.422; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kuntsi J, 2001, J CHILD PSYCHOL PSYC, V42, P199, DOI 10.1017/S0021963001006709; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; LOGAN GD, 1985, J EXP PSYCHOL LEARN, V11, P675, DOI 10.1037/0278-7393.11.1-4.675; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; Logan Gordon D., 1994, P189; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Ollman R. T., 1973, ATTENTION PERFORM, VIV, P571; Oosterlaan J, 1998, J CHILD PSYCHOL PSYC, V39, P411, DOI 10.1111/1469-7610.00336; OSMAN A, 1986, J EXP PSYCHOL HUMAN, V12, P243, DOI 10.1037/0096-1523.12.3.243; Quay HC, 1997, J ABNORM CHILD PSYCH, V25, P7, DOI 10.1023/A:1025799122529; QUAY HC, 1988, ATTENTION DEFICIT DI, P176; Robin DA, 1999, APHASIOLOGY, V13, P701, DOI 10.1080/026870399401812; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; Schachar R, 2000, J ABNORM CHILD PSYCH, V28, P227, DOI 10.1023/A:1005140103162; SCHACHAR R, 1995, J AM ACAD CHILD PSY, V34, P639, DOI 10.1097/00004583-199505000-00016; SCHACHAR R, 1990, DEV PSYCHOL, V26, P710, DOI 10.1037/0012-1649.26.5.710; SCHACHAR RJ, 1993, CLIN PSYCHOL REV, V13, P721, DOI 10.1016/S0272-7358(05)80003-0; SEMRUDCLIKEMAN M, 1994, J AM ACAD CHILD PSY, V33, P875, DOI 10.1097/00004583-199407000-00014; SOLANTO MV, 1990, J CHILD PSYCHOL PSYC, V31, P803, DOI 10.1111/j.1469-7610.1990.tb00819.x; Solanto MV, 2001, J ABNORM CHILD PSYCH, V29, P215, DOI 10.1023/A:1010329714819; TEASDALE G, 1974, LANCET, V2, P81; Thapar A, 1999, BRIT J PSYCHIAT, V174, P105, DOI 10.1192/bjp.174.2.105; Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205	62	65	66	0	7	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2004	25	1-2					179	198		10.1207/s15326942dn2501&2_10			20	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	774CG	WOS:000188961700010	14984334				2022-02-06	
J	Hoane, MR; Akstulewicz, SL; Toppen, J				Hoane, MR; Akstulewicz, SL; Toppen, J			Treatment with vitamin B-3 improves functional recovery and reduces GFAP expression following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						GFAP; niacin; nicotinamide; rat; recovery of function; vitamin B-3	FOCAL CEREBRAL-ISCHEMIA; COGNITIVE DEFICITS; MAGNESIUM THERAPY; WISTAR RATS; FACILITATE RECOVERY; SENSORIMOTOR CORTEX; NMDA ANTAGONISTS; NICOTINAMIDE; LESIONS; INFARCTION	Previous studies have shown that administration of vitamin B-3 (B-3) in animal models of ischemia significantly reduced the size of infarction and improved functional recovery. The present study evaluated the effect of administration of B-3 on recovery of function following traumatic brain injury (TBI), incorporating the bilateral medial frontal cortex contusion injury model. Groups of rats were assigned to B-3 (500 mg/kg) or saline (1.0 ml/kg) treatment conditions and received contusion injuries or sham surgeries. Drug treatment was administered 15 min and 24 h following injury. Rats were examined on a variety of tests to measure sensorimotor performance (bilateral tactile adhesive removal), skilled forelimb use (staircase test), and cognitive ability (reference and working memory) in the Morris Water Maze. Administration of B-3 following injury significantly reduced the behavioral impairments observed on the bilateral tactile removal test, but not on skilled forelimb use. The acquisition of reference and working memory tests were also significantly improved compared to saline-treated rats. Examination of the brains revealed that administration of B-3 significantly reduced the size of the lesion compared to treatment with saline. In addition, examination of glial fibrillary acidic protein (GFAP) expression around the lesion revealed that B-3 significantly reduced the number of GFAP(+) astrocytes. These results indicate that B-3 administration significantly improved behavioral outcome following injury, reduced the size of the lesion, and reduced the expression of GFAP. The current findings suggest that B-3 may have therapeutic potential for the treatment of TBI.	E Carolina Univ, Dept Psychol, Brain Injury Lab, Greenville, NC 27858 USA; E Carolina Univ, Neurosci Program, Greenville, NC 27858 USA; E Carolina Univ, Sch Ind & Technol, Greenville, NC 27858 USA		Hoane, MR (corresponding author), E Carolina Univ, Dept Psychol, Brain Injury Lab, Rawl 218, Greenville, NC 27858 USA.	hoanem@mail.ecu.edu		Hoane, Michael/0000-0001-7779-2657	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 45647] Funding Source: Medline		Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; BARTH TM, 1990, STROKE, V21, P153; BETZ AL, 1994, ACTA NEUROCHIR, P314; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; GREEN RG, 1970, SCHIZOPHRENIA, V2, P70; Hausmann ON, 2002, SPINAL CORD, V40, P449, DOI 10.1038/sj.sc.3101330; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; HOANE MR, 2003, BRAIN RES B, V6586, P1; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; Lindner MD, 1997, NEUROBIOL LEARN MEM, V68, P203, DOI 10.1006/nlme.1997.3782; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lindner MD, 1999, BEHAV BRAIN RES, V102, P1, DOI 10.1016/S0166-4328(98)00160-0; Maynard KI, 2001, ANN NY ACAD SCI, V939, P416; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MODUDAI T, 2000, STROKE, V31, P1679; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; Paxinos G, 1997, RAT BRAIN STEREOTAXI; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; STRATFORD MRL, 1992, RADIOTHER ONCOL, V25, P37, DOI 10.1016/0167-8140(92)90193-X; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vink R, 1990, Magnes Res, V3, P163	38	65	65	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2003	20	11					1189	1199		10.1089/089771503770802871			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	747BE	WOS:000186784600004	14651806				2022-02-06	
J	O'Connor, CA; Cernak, I; Vink, R				O'Connor, CA; Cernak, I; Vink, R			Interaction between anesthesia, gender, and functional outcome task following diffuse traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						anesthesia; female; gender; male; neurotrauma; outcome; TBI	FOREBRAIN ISCHEMIA; ESTROGEN-TREATMENT; AXONAL INJURY; HEAD-INJURY; BLOOD-FLOW; ISOFLURANE; PROGESTERONE; HALOTHANE; FENTANYL; RABBITS	A number of experimental and clinical studies have demonstrated that functional outcome following traumatic brain injury differs between males and females. Some studies report that females have a better outcome than males following trauma while others report the opposite. In experimental studies, some of the contradictory results may be due to the different experimental conditions, including type of anesthesia and the outcome measures employed. In the present study we have used three different anesthetic protocols and four different outcome measures to determine how these parameters interact and affect functional outcome following traumatic brain injury in male and female rats. Diffuse traumatic brain injury was induced in adult male and female animals using the impact-acceleration brain injury model. Mortality in female animals was no different than males when using halothane anesthesia, slightly better than males when using isoflurane anesthesia, but significantly worse than males under pentobarbital anesthesia. Female animals always performed better than males on rotarod tests of motor outcome, with this effect being unrelated to anesthetic effects. Conversely, in cognitive tests using the Barnes Maze, only isoflurane-anesthetized females performed better than their male counterparts. Similarly, in an open field activity task, females always performed better than males after trauma, with isoflurane-anesthetized females also performing significantly better than the halothane-anesthetized female group after injury. Our results suggest that female animals do better than males after diffuse traumatic brain injury, although this observation is dependent upon the type of anesthesia and the functional task employed. Isoflurane is particularly protective in females, pentobarbital is deleterious to female outcome, while halothane anesthesia has the least influence on gender-related outcome.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Georgetown Univ, Dept Neurosci, Washington, DC USA		Vink, R (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.		Vink, Robert/J-7351-2012; Cernak, Ibolja/A-6399-2008; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Alexiou T, 2000, NEUROSCI RES COMMUN, V26, P1, DOI 10.1002/(SICI)1520-6769(200001/02)26:1<1::AID-NRC1>3.0.CO;2-Q; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; EMERSON CS, 1992, NEUROREPORT, V4, P957; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; GIULIAN D, 1975, PHYSIOL BEHAV, V14, P109, DOI 10.1016/0031-9384(75)90150-X; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HATTORI T, 1986, Neurological Research, V8, P33; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Heikkinen T, 2002, HORM BEHAV, V41, P22, DOI 10.1006/hbeh.2001.1738; HOFFMAN A, 1989, PHARM RES-DORDR, V6, P976, DOI 10.1023/A:1015953715346; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P571, DOI 10.1097/00000542-198910000-00016; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCDERMOTT JL, 1994, HORM BEHAV, V28, P16, DOI 10.1006/hbeh.1994.1002; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MURR R, 1993, ANESTH ANALG, V77, P898; Nellgard B, 2000, ANESTHESIOLOGY, V93, P431, DOI 10.1097/00000542-200008000-00022; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Steen P A, 1991, Agressologie, V32, P323; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Tecoult E, 2000, J NEUROSURG ANESTH, V12, P255, DOI 10.1097/00008506-200007000-00010; Torbati D, 1999, CRIT CARE MED, V27, P1878, DOI 10.1097/00003246-199909000-00028; Vallee M, 1997, J NEUROSCI, V17, P2626; VERHAEGEN MJ, 1992, ANESTHESIOLOGY, V76, P743, DOI 10.1097/00000542-199205000-00013; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wise-Faberowski L, 2001, ANESTH ANALG, V93, P1281, DOI 10.1097/00000539-200111000-00051	38	65	65	1	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2003	20	6					533	541		10.1089/089771503767168465			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	697DL	WOS:000183926900002	12906738				2022-02-06	
J	Schick, DM; Meeuwisse, WH				Schick, DM; Meeuwisse, WH			Injury rates and profiles in female ice hockey players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	Canadian-Academy-of-Sport-Medicine Symposium	MAY, 2000	TORONTO, CANADA	Canadian Acad Sport Med				Background: Little data exist on injury rates and profiles in female ice hockey players. Objective: To examine the incidence of injury in female ice hockey players and compare injury rates with those of male players. Study Design: Prospective cohort study. Methods: Six male and six female teams from the Canada West Universities Athletic Association were followed prospectively for one varsity season. Preseason medical history forms were completed by each player. Injury report forms and attendance records for each team session were submitted by team therapists. Results: Male players reported 161 injuries, whereas female players reported 66 injuries. However, the overall injury rates for male (9.19 injuries per 1000 athlete-exposures) and female (7.77 injuries per 1000 athlete-exposures) players did not differ significantly. Ninety-six percent of injuries in female players and 79% in male players were related to contact mechanisms, even though intentional body checking is not allowed in female ice hockey. Women were more likely than men to be injured by contacting the boards or their opponent. Men sustained more severe injuries than women and missed about twice as many sessions (exposures) because of injury. Concussions were the most common injury in female players, followed by ankle sprains, adductor muscle strains, and sacroiliac dysfunction. Conclusion: Although the injury rate in female ice hockey players was expected to be lower than that in male players because of the lack of intentional body checking, the injury rates were found to be similar. (C) 2003 American Orthopaedic Society for Sports Medicine.	Univ Calgary, Fac Kinesiol, Sport Med Ctr, Calgary, AB T2N 1N4, Canada		Meeuwisse, WH (corresponding author), Univ Calgary, Fac Kinesiol, Sport Med Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.						AVERY J, 1997, TOO MANY MEN ICE WOM; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; *CAN HOCK ASS, 2001, ONL STAT; DICK RW, 1994, ASTM STP, V1229; Dryden DM, 2000, MED SCI SPORT EXER, V32, P1378, DOI 10.1097/00005768-200008000-00004; FALCONER T, 1994, EQUINOX          JAN; FINKE R C, 1988, Journal of Orthopaedic and Sports Physical Therapy, V10, P54; LORENTZON R, 1988, AM J SPORT MED, V16, P392, DOI 10.1177/036354658801600415; McKnight Cynthia M., 1992, Journal of Athletic Training, V27, P342; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; MEEUWISSE WH, 1999, J INFORMATICS PR JUN; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; RIELLY MF, 1982, ATHLETIC TRAINING, V17, P88; TATOR C, 1994, ASTM STP, V1229; Tegner Y, 1991, Br J Sports Med, V25, P87	15	65	65	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	2003	31	1					47	52		10.1177/03635465030310011901			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Orthopedics; Sport Sciences	636TP	WOS:000180473300008	12531756				2022-02-06	
J	Jayakumar, AR; Panickar, KS; Norenberg, MD				Jayakumar, AR; Panickar, KS; Norenberg, MD			Effects on free radical generation by ligands of the peripheral benzodiazepine receptor in cultured neural cells	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocytes; free radicals; microglia; mitochondrial permeability transition; neurons; peripheral benzodiazepine receptor	MITOCHONDRIAL PERMEABILITY TRANSITION; GLOBAL FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN INJURY; RAT SCIATIC-NERVE; BINDING-SITES; CYCLOSPORINE-A; OXIDATIVE STRESS; THIAMINE-DEFICIENCY; CONDUCTANCE CHANNEL; LIPID-PEROXIDATION	The effect of peripheral benzodiazepine receptor (PBR) ligands on free radical production was investigated in primary cultures of rat brain astrocytes and neurons as well as in BV-2 microglial cell lines using the fluorescent dye dichlorofluorescein-diacetate. Free radical production was measured at 2, 30, 60 and 120 min of treatment with the PBR ligands 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195), 7-chloro-5-(4-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one (Ro5-4864) and protoporphyrin IX (PpIX) (all at 10 nm). In astrocytes, all ligands showed a significant increase in free radical production at 2 min. The increase was short-lived with PK11195, whereas with Ro5-4864 it persisted for at least 2 h. PpIX caused an increase at 2 and 30 min, but not at 2 h. Similar results were observed in microglial cells. In neurons, PK11195 and PpIX showed an increase in free radical production only at 2 min; Ro5-4864 had no effect. The central-type benzodiazepine receptor ligand, clonazepam, was ineffective in eliciting free radical production in all cell types. As the PBR may be a component of the mitochondrial permeability transition (MPT) pore, and free radical production may occur following induction of the MPT, we further investigated whether cyclosporin A (CsA), an inhibitor of the MPT, could prevent free radical formation by PBR ligands. CsA (1 muM) completely blocked free radical production following treatment with PK11195 and Ro5-4864 in all cell types. CsA was also effective in blocking free radical production in astrocytes following PpIX treatment, but it failed to do so in neurons and microglia. Our results indicate that exposure of neural cells to PBR ligands generates free radicals, and that the MPT may be involved in this process.	Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; Vet Affairs Med Ctr, Miami, FL 33125 USA		Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D33, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034951] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34951] Funding Source: Medline		Afonso S, 1999, FREE RADICAL RES, V31, P161, DOI 10.1080/10715769900300711; ANHOLT RRH, 1986, TRENDS PHARMACOL SCI, V7, P506, DOI 10.1016/0165-6147(86)90438-4; ANHOLT RRH, 1984, J NEUROSCI, V4, P593; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; APRILLE JR, 1977, SCIENCE, V197, P908, DOI 10.1126/science.887930; BASILE AS, 1987, BRAIN RES BULL, V19, P1, DOI 10.1016/0361-9230(87)90158-4; BASILE AS, 1989, J PHARMACOL EXP THER, V248, P463; BENAVIDES J, 1988, ANN NEUROL, V24, P708, DOI 10.1002/ana.410240603; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BERNASSAU JM, 1993, J MOL GRAPHICS, V11, P236, DOI 10.1016/0263-7855(93)80003-A; Berson A, 2001, J PHARMACOL EXP THER, V299, P793; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; BETTENDORFF L, 1995, J NEUROCHEM, V64, P2013; BLACK KL, 1990, CANCER, V65, P93, DOI 10.1002/1097-0142(19900101)65:1<93::AID-CNCR2820650120>3.0.CO;2-1; BLOKHUIS GG, 1970, FEBS LETT, V11, P197, DOI 10.1016/0014-5793(70)80527-0; BOLGER GT, 1984, EUR J PHARMACOL, V105, P143, DOI 10.1016/0014-2999(84)90658-7; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; BROADDUS WC, 1990, BRAIN RES, V518, P199, DOI 10.1016/0006-8993(90)90973-F; Chelli B, 2001, BIOCHEM PHARMACOL, V61, P695, DOI 10.1016/S0006-2952(00)00588-8; COMPORTI M, 1985, LAB INVEST, V53, P599; Conway EL, 1998, NEUROSCIENCE, V82, P805; CROMPTON M, 1988, BIOCHEM J, V255, P357; DAVAL JL, 1989, J NEUROCHEM, V52, P110, DOI 10.1111/j.1471-4159.1989.tb10904.x; Decaudin D, 2002, CANCER RES, V62, P1388; Desjardins P, 1999, NEUROCHEM INT, V35, P363, DOI 10.1016/S0197-0186(99)00082-0; DOBLE A, 1987, BRAIN RES BULL, V18, P49, DOI 10.1016/0361-9230(87)90033-5; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; DUCIS I, 1989, BRAIN RES, V493, P362, DOI 10.1016/0006-8993(89)91171-2; ESHLEMAN AJ, 1989, J NEUROCHEM, V53, P494, DOI 10.1111/j.1471-4159.1989.tb07361.x; Fennell DA, 2001, BRIT J CANCER, V84, P1397, DOI 10.1054/bjoc.2001.1788; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; Gavish M, 1999, PHARMACOL REV, V51, P629; Haber B., 1989, DISSECTION TISSUE CU, P203; HIRSCH JD, 1989, MOL PHARMACOL, V35, P157; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; ITZHAK Y, 1993, GLIA, V9, P211, DOI 10.1002/glia.440090306; Jayakumar AR, 2001, J NEUROCHEM, V78, P25; JAYAKUMAR AR, 2002, IN PRESS SOC NEUR AB; Kinnally KW, 1996, J BIOENERG BIOMEMBR, V28, P115, DOI 10.1007/BF02110641; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; Lacor P, 1999, BRAIN RES, V815, P70, DOI 10.1016/S0006-8993(98)01105-6; Lacor P, 1996, NEUROSCI LETT, V220, P61, DOI 10.1016/S0304-3940(96)13187-6; LEONG DK, 1994, J CEREBR BLOOD F MET, V14, P100, DOI 10.1038/jcbfm.1994.14; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; MARANGOS PJ, 1982, MOL PHARMACOL, V22, P26; Marino F, 2001, PHARMACOLOGY, V63, P42, DOI 10.1159/000056111; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; McGeer E G, 1988, Alzheimer Dis Assoc Disord, V2, P331, DOI 10.1097/00002093-198802040-00001; McKenna MC, 1995, NEUROCHEM RES, V20, P1491, DOI 10.1007/BF00970599; Messmer K, 1998, NEUROSCI LETT, V241, P53, DOI 10.1016/S0304-3940(97)00967-1; MORENOSANCHEZ R, 1991, BIOCHEM PHARMACOL, V41, P1479, DOI 10.1016/0006-2952(91)90564-L; PANICKAR KS, 2001, J NEUROTRAUM, V18, P1160; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; Papadopoulos V, 1998, P SOC EXP BIOL MED, V217, P130; Park CH, 1996, GLIA, V16, P65, DOI 10.1002/(SICI)1098-1136(199601)16:1<65::AID-GLIA7>3.0.CO;2-A; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; RUFF MR, 1985, SCIENCE, V229, P1281, DOI 10.1126/science.2994216; SONNEWALD U, 1993, DEV NEUROSCI-BASEL, V15, P351, DOI 10.1159/000111355; Sonnewald U, 1998, J CEREBR BLOOD F MET, V18, P231, DOI 10.1097/00004647-199803000-00001; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; TRIBBLE DL, 1987, HEPATOLOGY, V7, P377, DOI 10.1002/hep.1840070227; Veenman L, 2000, DRUG DEVELOP RES, V50, P355, DOI 10.1002/1098-2299(200007/08)50:3/4<355::AID-DDR18>3.0.CO;2-W; Veenman L, 2002, J NEUROCHEM, V80, P917, DOI 10.1046/j.0022-3042.2002.00769.x; VERMA A, 1989, ANNU REV PHARMACOL, V29, P307; VILLIGER JW, 1984, NEUROSCI LETT, V46, P267, DOI 10.1016/0304-3940(84)90110-1; Vowinckel E, 1997, J NEUROSCI RES, V50, P345, DOI 10.1002/(SICI)1097-4547(19971015)50:2<345::AID-JNR22>3.0.CO;2-5; Waagepetersen HS, 1999, ANN NY ACAD SCI, V893, P421, DOI 10.1111/j.1749-6632.1999.tb07869.x; WANG JKT, 1984, P NATL ACAD SCI-BIOL, V81, P753, DOI 10.1073/pnas.81.3.753; WEISSMAN BA, 1984, EUR J PHARMACOL, V97, P257; Yokoo H, 1996, J NEUROPATH EXP NEUR, V55, P716, DOI 10.1097/00005072-199606000-00005; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739; Zorov DB, 1996, BBA-BIOENERGETICS, V1275, P10, DOI 10.1016/0005-2728(96)00042-4; [No title captured]	87	65	65	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	DEC	2002	83	5					1226	1234		10.1046/j.1471-4159.2002.01261.x			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	621CR	WOS:000179571400022	12437594				2022-02-06	
J	Schoenberg, MR; Scott, JG; Duff, K; Adams, RL				Schoenberg, MR; Scott, JG; Duff, K; Adams, RL			Estimation of WAIS-III intelligence from combined performance and demographic variables: Development of the OPIE-3	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN INJURY; PREMORBID INTELLIGENCE; INDEX; AGE; VALIDATION; ACCURACY; SCORES; SCALE; IQ	Data from the WAIS-III standardization sample (The Psychological Corporation, 1997) was used to generate several FSIQ estimation formulas that used demographic variables and current WAIS-III subtest performance. The standardization sample (N = 2,450) was randomly divided into two groups, the first was used to develop the formulas and the second group was used to validate the prediction equations. Age, education, ethnicity, gender, region of the country as well as Vocabulary, Information, Matrix Reasoning, and Picture Completion subtests raw scores were used as predictor variables. Regression formulas were generated using four subtest, two subtest, single verbal, two performance subtest, and single performance algorithms. The four-subtest model combined Information, Vocabulary, Matrix Reasoning, and,Picture Completion raw scores with demographic variables. The two-subtest algorithm used Vocabulary and Matrix Reasoning raw scores with demographic variables. Formulas to estimate FSIQ using only verbal or performance subtests were developed for use with lateralized populations. The formulas for estimating premorbid FSIQ were highly significant and accurate in predicting FSIQ scores of participants in the WAIS-III normative sample.	Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Oklahoma City, OK 73190 USA		Schoenberg, MR (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, POB 26901, Oklahoma City, OK 73190 USA.		Schoenberg, Mike R/J-9018-2012	Schoenberg, Mike/0000-0003-1355-3651			ALEKOUMBIDES A, 1987, INT J CLIN NEUROPSYC, V9, P11; Axelrod BN, 1999, ARCH CLIN NEUROPSYCH, V14, P341, DOI 10.1016/S0887-6177(98)00028-6; BAADE LE, 2000, 20 ANN NAT ASS NEUR; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BRYAN J, 1992, J CLIN EXPT NEUROPSY, V14, P64; Cohen J., 2013, STAT POWER ANAL BEHA; CRAWFORD JR, 1989, PERS INDIV DIFFER, V10, P793, DOI 10.1016/0191-8869(89)90126-8; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; EPPINGER MG, 1987, J CONSULT CLIN PSYCH, V55, P86, DOI 10.1037/0022-006X.55.1.86; Ivnik RJ, 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; Kaufman AlanS., 1990, ASSESSING ADOLESCENT; KAUFMAN AS, 1989, INTELLIGENCE, V13, P235, DOI 10.1016/0160-2896(89)90020-2; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; LARRABEE GJ, 1985, J CLIN EXP NEUROPSYC, V7, P497, DOI 10.1080/01688638508401281; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Nelson H.E., 1982, NATL ADULT READING T; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Psychological Corporation, 2001, MAN WECHSL TEST AD R; Ryan J. J., 1990, PSYCHOL ASSESSMENT J, V2, P404; SCHINKA JA, 2000, CLIN GUIDE NEUROPSYC; Schopp LH, 2001, REHABIL PSYCHOL, V46, P279, DOI 10.1037/0090-5550.46.3.279; Scott JG, 1997, CLIN NEUROPSYCHOL, V11, P146, DOI 10.1080/13854049708407043; SILVERSTEIN AB, 1987, J CLIN PSYCHOL, V43, P493, DOI 10.1002/1097-4679(198709)43:5<493::AID-JCLP2270430511>3.0.CO;2-V; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; SWEET JJ, 1990, PSYCHOL ASSESSMENT J, V2, P41; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; VANDERPLOEG RD, 1995, ARCH CLIN NEUROPSYCH, V10, P225, DOI 10.1016/0887-6177(94)00042-O; Vanderploeg RD, 1996, PSYCHOL ASSESSMENT, V8, P404, DOI 10.1037/1040-3590.8.4.404; Vanderploeg RD, 1998, PSYCHOL ASSESSMENT, V10, P277, DOI 10.1037/1040-3590.10.3.277; Veiel HOF, 2001, PSYCHOL ASSESSMENT, V13, P356, DOI 10.1037/1040-3590.13.3.356; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554	37	65	67	0	9	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2002	16	4					426	438		10.1076/clin.16.4.426.13913			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	681AY	WOS:000183015300002	12822052				2022-02-06	
J	Slemmer, JE; Matser, EJT; De Zeeuw, CI; Weber, JT				Slemmer, JE; Matser, EJT; De Zeeuw, CI; Weber, JT			Repeated mild injury causes cumulative damage to hippocampal cells	BRAIN			English	Article						brain trauma; hippocampal neurones; in vitro; neurone-specific enolase; S-100 beta	TRAUMATIC BRAIN INJURY; CONTROLLED CORTICAL IMPACT; NEURON-SPECIFIC ENOLASE; AMATEUR SOCCER PLAYERS; STRETCH-INDUCED INJURY; HEAD-INJURY; S-100 PROTEIN; SERUM LEVELS; RAT; VULNERABILITY	An interesting hypothesis in the study of neurotrauma is that repeated traumatic brain injury may result in cumulative damage to cells of the brain. However, post-injury sequelae are difficult to address at the cellular level in vivo. Therefore, it is necessary to complement these studies with experiments conducted in vitro. In this report, the effects of single and repeated traumatic injury in vitro were investigated in cultured mouse hippocampal cells using a well characterized model of stretch-induced injury. Cell damage was assessed by the level of propidium iodide (PrI) uptake and retention of fluorescein diacetate (FDA). Uninjured control wells displayed minimal PrI uptake and high levels of FDA retention. Mild, moderate and severe levels of stretch caused increasing amounts of PrI uptake, respectively, when measured at 15 min and 24 h post-injury, indicating increased cellular damage with increasing amounts of stretch. For repeated injury studies, cultures received a second injury 1 h after the initial insult. Repeated mild injury caused a slight increase in PrI uptake compared with single injury at 15 min and 24 h post-injury, which was evident primarily in glial cells. However, the neurites of neurones in cultures that received repeated insults showed signs of damage that were not evident after a single mild injury. The release of neurone-specific enolase (NSE) and S-100beta protein, two common clinical markers of CNS damage, was also measured following the repeated injuries paradigm. When measured at 6 h post-injury, both NSE and S-100beta were found to be elevated after repeated mild injuries when compared with the single injury group. These results suggest that cells of the hippocampus may be susceptible to cumulative damage following repeated mild traumatic insults. Both glial cells and neurones appear to exhibit increased signs of damage after repetitive injury. To our knowledge, this study represents the first report on the effects of repeated mechanical insults on specific cells of the brain using an in vitro model system. The biochemical pathways of cellular degradation following repeated mild injuries may differ considerably from those that are activated by a single mild insult. Therefore, we hope to use this model in order to investigate secondary pathways of cellular damage after repeated mild traumatic injury, and as a rapid and economical means of screening possibilities for treatment strategies, including pharmaceutical intervention.	Erasmus Med Ctr, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands; St Anna Hosp, Dept Neuropsychol & Sports Neurol, Geldrop, Netherlands		Weber, JT (corresponding author), Erasmus Med Ctr, Dept Neurosci, Dr Molenwaterplein 50, NL-3000 DR Rotterdam, Netherlands.		DE OLIVEIRA, EDILSON/AAU-5357-2021				Adamchik Y, 2000, BRAIN RES PROTOC, V5, P153, DOI 10.1016/S1385-299X(00)00007-6; Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; Babbs CF, 2000, JAMA-J AM MED ASSOC, V283, P882, DOI 10.1001/jama.283.7.882; BAILES JE, 1998, SPORTS NEUROLOGY, P215; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Mattson MP, 1999, J NEUROSCI RES, V58, P152, DOI 10.1002/(SICI)1097-4547(19991001)58:1<152::AID-JNR15>3.3.CO;2-M; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; OLSSON Y, 1971, ACTA NEUROPATHOL, V19, P225, DOI 10.1007/BF00684599; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHREIBER D, 1995, INT RES COMMITTEE BI, P233; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	50	65	68	0	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	DEC	2002	125		12				2699	2709		10.1093/brain/awf271			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	615MT	WOS:000179250400010	12429597	Bronze			2022-02-06	
J	Zausinger, S; Lumenta, DB; Pruneau, D; Schmid-Elsaesser, R; Plesnila, N; Baethmann, A				Zausinger, S; Lumenta, DB; Pruneau, D; Schmid-Elsaesser, R; Plesnila, N; Baethmann, A			Effects of LF 16-0687 Ms, a bradykinin B-2 receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia	BRAIN RESEARCH			English	Article						cerebral ischemia, focal; bradykinin; bradykinin B-2; receptor antagonization; laser-Doppler flowmetry; neuroprotection; brain edema	ARTERY OCCLUSION; BARRIER PERMEABILITY; SUBARACHNOID HEMORRHAGE; ACETYLCHOLINE-RELEASE; NERVOUS-SYSTEM; BINDING-SITES; SPINAL-CORD; INJURY; REPERFUSION; GLUTAMATE	Bradykinin, an endogenous nonapeptide produced by activation of the kallikrein-kinin system, promotes neuronal tissue damage as well as disturbances in blood-brain barrier function through activation of B-2 receptors. LF 16-0687 Ms, a non-peptide competitive bradykinin B-2 receptor antagonist, was recently found to decrease brain swelling in various models of traumatic brain injury. We have investigated the influence of LF 16-0687 Ms on the edema formation, neurological outcome, and infarct size in temporary focal cerebral ischemia in rats. Sprague-Dawley rats were subjected to MCA occlusion for 90 min by an intraluminal filament. Local CBF was bilaterally recorded by laser Doppler flowmetry. Study I: animals were assigned to one of three treatment arms (n=11 each): (a) vehicle, (b) LF 16-0687 Ms (12.0 mg/kg per day), or (c) LF 16-0687 Ms (36.0 mg/kg per day) given repetitively s.c. over 3 days. The neurological recovery was examined daily. The infarct volume was assessed histologically 7 days after ischemia. Study II: brain swelling and bilateral hemispheric water content were determined at 48 h post ischemia in eight rats, subjected to the low dose regimen as described above, and in eight vehicle-treated control animals. All treated animals showed tendency to exhibit improved neurological recovery throughout the observation period as compared to the vehicle-treated controls, while this improvement was only significant within the low dose group from postischemic days 3 to 4. Low dose LF 16-0687 Ms significantly attenuated the total and cortical infarct volume by 50 and 80%, respectively. Furthermore, postischemic swelling (-62%) and increase in water content of the infarcted brain hemisphere (-60.5%) was significantly inhibited. The present findings provide strong evidence for an involvement of bradykinin-mediated secondary brain damage following from focal cerebral ischemia. Accordingly, specific inhibition of bradykinin B-2 receptors by LF 16-0687 Ms attenuated postischemic brain swelling, improved the functional neurological recovery, and limited ischemic tissue damage, raising its potential for clinical evaluation in patients with acute stroke. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Munich, Klinikum Grosshadern, Dept Neurosurg, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-81377 Munich, Germany; Ctr Rech, Lab Fournier, Daix, France		Zausinger, S (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurosurg, Marchioninistr 15, D-81377 Munich, Germany.		Lumenta, David Benjamin/AAD-5935-2019; Plesnila, Nikolaus/T-7522-2019	Lumenta, David Benjamin/0000-0003-0903-252X; 			Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Ahluwalia A, 1999, TRENDS PHARMACOL SCI, V20, P100, DOI 10.1016/S0165-6147(99)01321-8; Alexandrov AV, 2001, CIRCULATION, V103, P2897, DOI 10.1161/01.CIR.103.24.2897; Araujo RC, 2001, BIOL CHEM, V382, P91, DOI 10.1515/BC.2001.014; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BERTRAND N, 1993, J CEREBR BLOOD F MET, V13, P789, DOI 10.1038/jcbfm.1993.100; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; Firlik AD, 1998, J NEUROSURG, V89, P243, DOI 10.3171/jns.1998.89.2.0243; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; FUJIWARA Y, 1989, LIFE SCI, V44, P1645, DOI 10.1016/0024-3205(89)90481-5; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; GOTOH O, 1985, STROKE, V16, P101, DOI 10.1161/01.STR.16.1.101; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; HOSLI L, 1992, NEUROSCI LETT, V148, P114, DOI 10.1016/0304-3940(92)90817-Q; KAMIYA T, 1993, STROKE, V24, P571, DOI 10.1161/01.STR.24.4.571; KASUYA H, 1988, ACTA NEUROCHIR, V91, P120, DOI 10.1007/BF01424566; Krieger DW, 1999, STROKE, V30, P287, DOI 10.1161/01.STR.30.2.287; Kuroda S, 1997, CLIN NEUROSCI, V4, P199; Li FH, 1999, STROKE, V30, P2464, DOI 10.1161/01.STR.30.11.2464; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MAKEVNINA LG, 1994, BRAZ J MED BIOL RES, V27, P1955; Marceau F, 1998, PHARMACOL REV, V50, P357; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Mayhan WG, 2001, MICROCIRCULATION, V8, P89, DOI 10.1038/sj.mn.7300154; McLean PG, 2000, J EXP MED, V192, P367, DOI 10.1084/jem.192.3.367; Molina CA, 2001, STROKE, V32, P1079, DOI 10.1161/01.STR.32.5.1079; Murone C, 1996, EUR J PHARMACOL, V306, P237, DOI 10.1016/0014-2999(96)00190-2; Murone C, 1997, J COMP NEUROL, V381, P203, DOI 10.1002/(SICI)1096-9861(19970505)381:2<203::AID-CNE7>3.0.CO;2-7; ONOUE H, 1994, AM J PHYSIOL, V267, pH880, DOI 10.1152/ajpheart.1994.267.3.H880; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Phillips LL, 1997, J NEUROSCI RES, V49, P197; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; PRIVITERA PJ, 1992, BRAIN RES, V577, P73, DOI 10.1016/0006-8993(92)90539-L; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V33, P104, DOI 10.1016/0162-3109(96)00021-5; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V32, P39, DOI 10.1016/0162-3109(96)00007-0; Regoli D, 1998, EUR J PHARMACOL, V348, P1, DOI 10.1016/S0014-2999(98)00165-4; Relton JK, 1997, STROKE, V28, P1430, DOI 10.1161/01.STR.28.7.1430; RELTON JK, 1998, INFLAMMATORY CELLS M, P359; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; SIESJO BK, 1995, ANN THORAC SURG, V59, P1316, DOI 10.1016/0003-4975(95)00077-X; SIESJO BK, 1989, J CEREB BLOOD FLOW M, V9, P122; Sobey CG, 1997, STROKE, V28, P2290, DOI 10.1161/01.STR.28.11.2290; STEPHENS GJ, 1993, NEUROSCI LETT, V153, P223, DOI 10.1016/0304-3940(93)90327-H; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; XU J, 1992, J NEUROCHEM, V58, P1930, DOI 10.1111/j.1471-4159.1992.tb10071.x; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zausinger S, 2002, BRAIN RES PROTOC, V9, P112, DOI 10.1016/S1385-299X(02)00138-1; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	62	65	68	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 20	2002	950	1-2					268	278	PII S0006-8993(02)03053-6	10.1016/S0006-8993(02)03053-6			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	601YU	WOS:000178477600031	12231253				2022-02-06	
J	Ip, EYY; Giza, CC; Griesbach, GS; Hovda, DA				Ip, EYY; Giza, CC; Griesbach, GS; Hovda, DA			Effects of enriched environment and fluid percussion injury on dendritic arborization within the cerebral cortex of the developing rat	JOURNAL OF NEUROTRAUMA			English	Article						cortex; dendrite; development; enriched environment; fluid percussion injury; Golgi-Cox; plasticity	TRAUMATIC BRAIN-INJURY; VISUAL-CORTEX; DIFFERENTIAL EXPERIENCE; NEOCORTICAL DAMAGE; COGNITIVE FUNCTION; OCCIPITAL CORTEX; IMMATURE RAT; ADULT-RAT; COMPLEXITY; RECOVERY	We have recently demonstrated that fluid percussion injury (FPI) sustained early in life prevents the neural plasticity response associated with rearing in an enriched environment (EE). In order to determine if this reduction in plasticity capacity is reflected in alterations in dendritic arborization, the present study examined dendritic changes in response to EE, FPI, and FPI followed by EE. Twenty postnatal day 19-20 rat pups were subjected to FPI or sham injury and were subsequently housed in EE (17 days) or standard conditions. Brains were processed according to the Golgi-Cox method and were analyzed using dendritic density (Sholl) and dendritic branching analyses in frontal, parietal, and occipital cortices. Rearing in EE induced an increase in dendritic density, primarily within the occipital cortex. FPI induced an increase in dendritic density, primarily in regions remote from the injury site, namely contralateral parietal cortex and ipsilateral and contralateral occipital cortex. In injured animals subsequently housed in EE, FPI appeared to inhibit the experience-dependent dendritic density effects of EE. However, an unexpected enhancement of dendritic density was seen in the ipsilateral occipital cortex, indicating a unique response of this region based on its distance-specific sensitivity to injury-induced plasticity and its region-specific sensitivity to experience-dependent plasticity. These results suggest that dendritic changes mediate the anatomical and behavioral changes characteristic of impaired developmental plasticity following FPI, and that these changes are dependent on location within the cerebral cortex.	Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Neurosci Interdepartmental PHD Program, Los Angeles, CA USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Med & Mol Pharmacol, Los Angeles, CA USA		Ip, EYY (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA.	eshieh@mednet.ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; BLACK JE, 1987, NEUROSCI LETT, V83, P351, DOI 10.1016/0304-3940(87)90113-3; DIAMOND MC, 1967, J COMP NEUROL, V131, P357, DOI 10.1002/cne.901310305; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; GLOBUS A, 1973, J COMP PHYSIOL PSYCH, V82, P175, DOI 10.1037/h0033910; GREENOUGH WT, 1973, EXP NEUROL, V41, P371, DOI 10.1016/0014-4886(73)90278-1; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; HOLLOWAY RALPH L., 1966, BRAIN RES, V2, P393, DOI 10.1016/0006-8993(66)90009-6; HYMOVITCH B, 1952, J COMP PHYSIOL PSYCH, V45, P313, DOI 10.1037/h0061535; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; JURASKA JM, 1984, DEV PSYCHOBIOL, V17, P209, DOI 10.1002/dev.420170302; JURASKA JM, 1984, BRAIN RES, V295, P27, DOI 10.1016/0006-8993(84)90812-6; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOLB B, 1987, BEHAV BRAIN RES, V26, P47, DOI 10.1016/0166-4328(87)90015-5; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; KRECH D, 1963, ARCH NEUROL-CHICAGO, V8, P403, DOI 10.1001/archneur.1963.00460040073007; Malkasian D R, 1971, Int J Neurosci, V2, P161, DOI 10.3109/00207457109146998; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Narayan RK, 1996, NEUROTRAUMA; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NYMAN AJ, 1967, J GENET PSYCHOL, V110, P31, DOI 10.1080/00221325.1967.10533713; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pascual R, 1996, BIOL NEONATE, V69, P399; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Ramon-Moliner E., 1970, CONT RES METHODS NEU, P32, DOI [10.1007/978-3-642-85986-1_3, DOI 10.1007/978-3-642-85986-1_3]; RAY OS, 1969, DEV PSYCHOL, V1, P311, DOI 10.1037/h0027661; ROSENZWEIG MR, 1962, J COMP PHYSIOL PSYCH, V55, P429, DOI 10.1037/h0041137; ROSENZWEIG MR, 1969, BRAIN RES, V14, P427, DOI 10.1016/0006-8993(69)90120-6; Rosenzweig MR, 1996, ANNU REV PSYCHOL, V47, P1, DOI 10.1146/annurev.psych.47.1.1; SCHWARTZ S, 1964, J COMP PHYSIOL PSYCH, V57, P72, DOI 10.1037/h0045518; SIREVAAG AM, 1988, DEV BRAIN RES, V43, P299, DOI 10.1016/0165-3806(88)90107-1; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VOLKMAR FR, 1972, SCIENCE, V176, P1445, DOI 10.1126/science.176.4042.1445; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; [No title captured]	48	65	68	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					573	585		10.1089/089771502753754055			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900003	12042093				2022-02-06	
J	Gottesfeld, Z; Moore, AN; Dash, PK				Gottesfeld, Z; Moore, AN; Dash, PK			Acute ethanol intake attenuates inflammatory cytokines after brain injury in rats: A possible role for corticosterone	JOURNAL OF NEUROTRAUMA			English	Article						corticosterone; ethanol; interleukin-1 beta; traumatic brain injury; tumor necrosis factor-alpha	TUMOR-NECROSIS-FACTOR; CORTICOTROPIN-RELEASING-FACTOR; BLOOD-ALCOHOL LEVEL; CONTROLLED CORTICAL IMPACT; FACTOR-ALPHA; TNF-ALPHA; HEAD-INJURY; NERVOUS-SYSTEM; INFARCT VOLUME; EXPRESSION	It has been reported that acute ethanol intoxication exerts dose-dependent effects, both beneficial and detrimental, on the outcome of traumatic brain injury (TBI), although the mechanism(s) has not been determined. Given that pro-inflammatory cytokines are either neuroprotective or neurotoxic, depending on their tissue levels, ethanol-induced alterations in brain cytokine production may be involved in determining the recovery after TBI. The present study was undertaken to examine the effect of acute ethanol pretreatments (producing blood alcohol concentrations of 100 +/- 16 mg/dL, and 220 +/- 10 mg/dL, considered low and intoxicating doses, respectively) on interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) levels in discrete brain regions. In addition, serum corticosterone levels were also examined because the hormone is a modulator of cytokine production, its secretion is stimulated by ethanol, and it has been associated with the severity of post-injury neurologic dysfunction. The data presented in this report demonstrate that moderate cortical impact brain injury elicits a marked increase in IL-1beta and TNF-alpha in the injured cortex as well as in the hippocampus ipsilateral to the injury. Ethanol pretreatment lowered cytokine levels in the cortex, hippocampus and hypothalamus in a dose-dependent manner after TBI compared to the untreated injured rats. Serum corticosterone levels were markedly increased in the injured rats, and were further augmented in the ethanol-pretreated injured animals in a dose-dependent manner. Our findings suggest that ethanol-induced decrease in pro,inflarnmatory cytokine production may be linked to increased circulating corticosterone, both of which may contribute to the outcome of brain injury.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457, P50NS23327] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, P50NS023327] Funding Source: NIH RePORTER		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; BRADBURY A, 1991, INJURY, V22, P132, DOI 10.1016/0020-1383(91)90074-O; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Cernak I, 1999, BRAIN INJURY, V13, P1005; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Craighead MW, 2000, BRAIN RES, V881, P139, DOI 10.1016/S0006-8993(00)02759-1; CROSBY WH, 1956, BLOOD, V11, P380, DOI 10.1182/blood.V11.4.380.380; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; DUNN AJ, 1993, CIBA F SYMP, V172, P226; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Hallenbeck JM, 1997, NEUROLOGY, V49, pS5, DOI 10.1212/WNL.49.5_Suppl_4.S5; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kapcala LP, 1995, ANN NY ACAD SCI, V771, P419, DOI 10.1111/j.1749-6632.1995.tb44699.x; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MARWAY JS, 1994, BIOCHEM SOC T, V22, pS351, DOI 10.1042/bst022351s; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIVIER C, 1984, ENDOCRINOLOGY, V115, P882, DOI 10.1210/endo-115-3-882; Rivier C, 1999, ALCOHOL CLIN EXP RES, V23, P673, DOI 10.1111/j.1530-0277.1999.tb04169.x; RIVIER CL, 1986, ANNU REV PHYSIOL, V48, P475, DOI 10.1146/annurev.ph.48.030186.002355; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; STERNBERG EM, 1995, HORM RES, V43, P159, DOI 10.1159/000184268; STRUBELT O, 1974, ARCH TOXICOL, V32, P83, DOI 10.1007/BF00316229; SULLIVAN P, 1997, J NEUROTRAUM, V14, P770; SZABO G, 1994, J CLIN IMMUNOL, V14, P340, DOI 10.1007/BF01546318; Tate PS, 1999, BRAIN INJURY, V13, P767; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Yang GY, 1998, NEUROREPORT, V9, P2131, DOI 10.1097/00001756-199806220-00041; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	67	65	71	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					317	326		10.1089/089771502753594882			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900003	11939499				2022-02-06	
J	Otani, N; Nawashiro, H; Fukui, S; Nomura, N; Yano, A; Miyazawa, T; Shima, K				Otani, N; Nawashiro, H; Fukui, S; Nomura, N; Yano, A; Miyazawa, T; Shima, K			Differential activation of mitogen-activated protein kinase pathways after traumatic brain injury in the rat hippocampus	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						MAPK; traumatic brain injury; ERK; JNK; lateral fluid percussion; hippocampus	TRANSIENT FOREBRAIN ISCHEMIA; SELECTIVE VULNERABILITY; REACTIVE ASTROCYTES; EXPRESSION; RECEPTORS; NEURONS; STRESS; APOPTOSIS; HYPOXIA	Mitogen-activated protein kinases, which play a crucial role in signal transduction, are activated by phosphorylation in response to a variety of mitogenic signals. In the present study, the authors used Western blot analysis and immunohistochemistry to show that phosphorylated extracellular signal-regulated protein kinase (p-ERK) and c-Jun NH(2)terminal kinase (p-JNK), but not p38 mitogen-activated protein kinase, significantly increased in both the neurons and astrocytes after traumatic brain injury in the rat hippocampus. Different immunoreactivities of p-ERK and p-JNK were observed in the pyramidal cell layers and dentate hilar cells immediately after traumatic brain injury. Immunoreactivity for p-JNK was uniformly induced but was only transiently induced throughout all pyramidal cell layers. However, strong immunoreactivity for p-ERK was observed in the dentate hilar cells and the damaged CA3 neurons, along with the appearance of pyknotic morphologic changes. In addition, immunoreactivity for p-ERK was seen in astrocytes surrounding dentate and CA3 pyramidal neurons 6 hours after traumatic brain injury. These findings suggest that ERK and JNK but not p38 cascades may be closely involved in signal transduction in the rat hippocampus after traumatic brain injury.	Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan		Otani, N (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.						Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1089, DOI 10.1097/00004647-200007000-00008; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KURINO M, 1995, J NEUROCHEM, V65, P1282; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; McKeon RJ, 1997, EXP NEUROL, V148, P558, DOI 10.1006/exnr.1997.6698; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Toth Z, 1997, J NEUROSCI, V17, P8106; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	25	65	65	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2002	22	3					327	334		10.1097/00004647-200203000-00010			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	528YG	WOS:000174272800010	11891438	Bronze			2022-02-06	
J	Horsfield, SA; Rosse, RB; Tomasino, V; Schwartz, BL; Mastropaolo, J; Deutsch, SI				Horsfield, SA; Rosse, RB; Tomasino, V; Schwartz, BL; Mastropaolo, J; Deutsch, SI			Fluoxetine's effects on cognitive performance in patients with traumatic brain injury	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article						cognition; fluoxetine; neuronal remodeling; traumatic brain injury; SSRI's	RAT	Objective: There are preclinical data showing that fluoxetine stimulated expression of Brain Derived Neurotrophic Factor (BDNF) and its specific tyrosine kinase receptor, and caused neuritic elongation and increased dendritic branching density of CA3 hippocampal pyramidal cell neurons in rodents. The latter effect of fluoxetine has been referred to as neuronal remodeling. In view of this preclinical data, we wondered if specific cognitive measures could serve as novel therapeutic targets for fluoxetine in head-injured patients. Theoretically, fluoxetine-induced "neuronal remodeling" might improve cognition, independently of a primary effect on mood. Method: In an open-label pilot investigation, fluoxetine hydrochloride (Prozac; 20-60 mg/day) was administered to a heterogeneous group of five head-injured patients with either no or moderate depression for a period of eight months. These patients had no histories of prior treatment with antidepressant medications. They were administered cognitive and memory tests at baseline and after eight months of treatment on fluoxetine. Results: The preliminary results showed that fluoxetine improved mood, in addition to improving performance on the Trail Making Test Part A, an attentional-motor speed task, and the letter-number sequencing subtest of the WAIS-III, a measure reflecting "working memory." Conclusions: Although fluoxetine had beneficial effects on some measures of cognition, more work is needed to connect these improvements with neuronal remodeling.	Mental Hlth Serv Line, Dept Vet Affairs, Ctr Med, Washington, DC 20422 USA; Georgetown Univ, Sch Med, Dept Psychiat, Washington, DC USA		Deutsch, SI (corresponding author), Mental Hlth Serv Line, Dept Vet Affairs, Ctr Med, 116A 50 Irving St,NW, Washington, DC 20422 USA.						*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P171; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Caine ED, 2000, COMPREHENSIVE TXB PS, P854; Detre JA, 2001, ANN NEUROL, V50, P697, DOI 10.1002/ana.10076; Fava M, 1999, J CLIN PSYCHIAT, V60, P21; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GREBB JA, 2000, COMPREHENSIVE TXB PS, P2235; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Lezak MD, 1983, NEUROPSYCHOLOGICAL A, P533; Morinobu S, 1997, SYNAPSE, V25, P313, DOI 10.1002/(SICI)1098-2396(199704)25:4<313::AID-SYN1>3.3.CO;2-J; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Parker ES, 1995, J CLIN EXP NEUROPSYC, V17, P926, DOI 10.1080/01688639508402441; *SCI RES ASS, 1948, ARM GEN CLASS TEST; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Yudofsky SC, 1987, TXB NEUROPSYCHIATRY, P179	15	65	65	0	6	BAYWOOD PUBL CO INC	AMITYVILLE	26 AUSTIN AVE, AMITYVILLE, NY 11701 USA	0091-2174			INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		2002	32	4					337	344		10.2190/KQ48-XT0L-2H14-5UMV			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	680XK	WOS:000183005200002	12779183				2022-02-06	
J	McCrory, PR; Berkovic, SF				McCrory, PR; Berkovic, SF			Concussion - The history of clinical and pathophysiological concepts and misconceptions	NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; HEAD-INJURY; DAMAGE; TRAUMA	Concussion is a well-recognized clinical entity; however, its pathophysiologic basis remains a mystery. One unresolved issue is whether concussion is associated with lesser degrees of diffuse structural change seen in severe traumatic brain injury, or is the mechanism entirely caused by reversible functional changes. This issue is clouded not only by the lack of critical data, but also by confusion in terminology, even in contemporary literature. This confusion began in ancient times when no distinction was made between the transient effects of concussion and severe traumatic brain injury. The first clear separate recognition of concussion was made by the Persian physician, Rhazes, in the 10th century. Lanfrancus subsequently expanded this concept as brain "commotion" in the 13th century, although other Renaissance physicians continued to obscure this concept. By the 18th century, a variety of hypotheses for concussion had emerged. The 19th century discovery of petechial hemorrhagic lesions in severe traumatic brain injury led to these being posited as the basis of concussion, and a similar logic was used later to suggest diffuse axonal injury was responsible. The neuropathology and pathophysiology of concussion has important implications in neurology, sports medicine, medicolegal medicine, and in the understanding of consciousness. Fresh approaches to these questions are needed and modern research tools, including functional imaging and experimental studies of ion-channel function, could help elucidate this puzzle that has evolved over the past 3,000 years.	Univ Melbourne, Austin & Repatriat Med Ctr, Brain Res Inst, Heidelberg, Vic 3084, Australia; Univ Melbourne, Austin & Repatriat Med Ctr, Epilepsy Res Inst, Heidelberg, Vic 3084, Australia; Univ Melbourne, Austin & Repatriat Med Ctr, Ctr Sports Med Res & Educ, Heidelberg, Vic 3084, Australia		McCrory, PR (corresponding author), 31 Grosvenor Parade, Balwyn, Vic 3103, Australia.		McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X			ABBOTT K, 1961, B LA NEUROL SCI, V26, P97; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALBUCASIS, 1532, OCTAVII HORATIANI RU; ALRODHAN NRF, 1986, SURG NEUROL, V26, P92, DOI 10.1016/0090-3019(86)90070-4; AVICENA, 1479, CANON MED; BAUDNES M, 1836, CLIN PLAIES ARMES FE; BELL B, 1786, SYSTEM SURG; BELL J, 1807, DISCOURSES NATURE CU; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Boirel A, 1674, TRITE PLAYES TESTE; Breasted J., 1930, E SMITH SURG PAPYRUS; Bright R., 1831, REPORTS MED CASES SE; Brunschwig H, 1497, IST BUCH CIRURGIE; BRYANT T, 1888, LANCET, V2, P405; BRYANT T, 1888, LANCET, V2, P507; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CELSUS A, 1493, MEDICINA; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; Clevenger S. V., 1889, SPINAL CONCUSSION; COITIER V, 1573, EXTERNARUM INTERNARU; Conrad LI N. M., 1995, W MED TRADITION; COOPER A, 1824, LECT SIR A COOPER PR; Courville C. B., 1967, INJURIES SKULL BRAIN; COURVILLE CB, 1944, B LOS ANGELES NEUROL, V9, P1; DACARPI B, 1535, TRACTATUS PERUTILIS; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DESAULT P, 1830, OEUVRES CHIRURG EXPO; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; Dixon KC, 1940, LANCET, V2, P360; du Chauliac G, 1499, CYRURGIA GUIDONIS CA; DURET H, 1920, REV NEUROL, V27, P888; EBIED R, 1971, BIBLIO MEDIEVAL ARAB; Elsberg Charles A, 1931, Ann Med Hist, V3, P271; Erichsen JE, 1882, CONCUSSION SPINE NER; FABRICIUS H, 1578, OPERE CHIAUGICHE SIG; Fano S., 1853, MEM SOC CHIR PARIS, V3, P163; Flamm E., 1996, HIST NEUROSURGERY, P65; GABRIEL R. A., 1992, HIST MILITARY MED; GALEN C, 1856, OUVRES ANATOMIQUES P; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GOODRICH J, 1996, HIST NEUROSURGERY, P37; Gurdjian ES., 1973, HEAD INJURY ANTIQUIT; HEISSE K, 1929, MONATSCHR UNFALH, V36, P120; HEISTER L, 1739, I CHIRURG; Heister L., 1750, I CHIRURG; HIPPOCRATES, 1525, HIPPOCRATIS COI MEDI; Hippocrates, 1950, HIPPOCRATIC WRITINGS; Hippocrates, 1849, GENUINE WORKS HIPPOC; Hitti Philip Khuri, 1937, HIST ARABS; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; JANE JA, 1985, TRAUMA CENTRAL NERVO, P27; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kontos H.A., 1980, CLIN ASS T, V92, P111; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; KRIKLAND T, 1792, COMMENTARY APOPLECTI; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Littre M., 1705, HIST ACAD ROYALE SCI; Lyons AS, 1987, MED ILLUSTRATED HIST; Majno G., 1975, HEALING HAND MAN WOU; Marchetti P., 1665, OBSERVATIONUM MED CH; MCHENRY LC, 1969, GARRISONS HIST NEURO; METTLER CC, 1947, HIST MED; METTLER FA, 1945, RES PUBL ASSOC RES N, V24, P1; Neuburger M, 1910, HIST MED; Nunn J. F., 1996, ANCIENT EGYPTIAN MED; OPPENHEIMER D, 1968, J EXP NEUROL, V26, P77; Page Herbert, 1883, INJURIES SPINE SPINA; PARE A, 1579, WORKES FAMOUS CHIRUR; PAULUS, 1844, 7 BOOKS PAULUS AEGIN; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Petit J-L, 1774, TRAITE MALADIES CHIR; Polis A, 1894, REV CHIR, V14, P273; Pott P., 1768, OBSERVATIONS NATURE; Quesnay Francois, 1744, RECHERCHES CRITIQUES; QUEYRAT L, 1657, TRACTATUS VULNERABLI; READ A, 1687, CHIRURGORUM COMES WH; RHAZES A, 1548, LUTETIAE EX OFFICINA; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SARMA P, 1931, ANN MED HIST, V3, P320; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; SYME JT, 1856, PRINCIPLES SURG; SYMONDS C, 1962, LANCET, V1, P1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Trotter W, 1924, LANCET, V1, P935; WILKINS RH, 1964, J NEUROSURG, V21, P240, DOI 10.3171/jns.1964.21.3.0240; Witkowski L., 1877, ARCH PATH ANAT, V69, P498	91	65	66	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	DEC 26	2001	57	12					2283	2289		10.1212/WNL.57.12.2283			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	505BP	WOS:000172891500023	11756611				2022-02-06	
J	Adelson, PD; Jenkins, LW; Hamilton, RL; Robichaud, P; Tran, MP; Kochanek, PM				Adelson, PD; Jenkins, LW; Hamilton, RL; Robichaud, P; Tran, MP; Kochanek, PM			Histopathologic response of the immature rat to diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						child abuse; diffuse axonal injury; experimental model; head injury; histopathology; pediatrics; rodent	LONG-TERM POTENTIATION; SEVERE HEAD-INJURY; COMA DATA-BANK; AXONAL INJURY; HIPPOCAMPUS; CHILDREN; MODEL; CA1; SYNAPSES; EDEMA	The purpose of this study was to characterize the histopathologic response of rats at postnatal day (PND) 17 following an impact-acceleration diffuse traumatic brain injury (TBI) using a 150-g/2-meter injury as previously described. This injury produces acute neurologic and physiologic derangements as well as enduring motor and Morris water maze (MWM) functional deficits. Histopathologic studies of perfusion-fixed brains were performed by gross examination and light microscopy using hematoxylin and eosin, Bielschowsky silver stain, and glial fibrillary acidic protein (GFAP) immunohistochemistry at 1, 3, 7, 28, and 90 day after injury. Gross pathologic examination revealed diffuse subarachnoid hemorrhage (SAH) at 1-3 days but minimal supratentorial intraparenchymal hemorrhage. Petechial hemorrhages were noted in ventral brainstem segments and in the cerebellum. After 1-3-day survivals, light microscopy revealed diffuse SAH and intraventricular hemorrhage (IVH), mild edema, significant axonal injury, reactive astrogliosis, and localized midline cerebellar hemorrhage. Axonal injury most commonly occurred in the long ascending and descending fiber tracts of the brainstem and occasionally in the forebrain, and was maximal at 3 days, but present until 7 days after injury. Reactive astrocytes were similarly found both in location and timing, but were also significantly identified in the hippocampus, white matter tracts, and corpus callosum. Typically, TBI produced significant diffuse SAH accompanied by cerebral and brainstem astrogliosis and axonal injury without obvious neuronal loss. Since this injury produces some pathologic changes with sustained functional deficits similar to TBI in infants and children, it should be useful for the further study of the pathophysiology and therapy of diffuse TBI and brainstem injury in the immature brain.	Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Adelson, PD (corresponding author), Childrens Hosp Pittsburgh, Dept Neurosurg, 3705 5th Ave, Pittsburgh, PA 15213 USA.	adelsod@chplink.chp.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, P50NS030318, K08NS001809] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40049, NS30318, KO8 NS01809] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; ADELSON PD, 1997, J NEUROTRAUM, V14, P787; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BARNES CA, 1994, J NEUROSCI, V14, P5793; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BOTHE HW, 1986, STROKE, V17, P1160, DOI 10.1161/01.STR.17.6.1160; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Cimadevilla JM, 1997, MECH AGEING DEV, V99, P49, DOI 10.1016/S0047-6374(97)00090-0; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARCIA JH, 1978, ACTA NEUROPATHOL, V43, P85; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hamm RJ, 1994, NEUROBIOLOGY CENTRAL, P86; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; IZUMI Y, 1995, SYNAPSE, V20, P19, DOI 10.1002/syn.890200104; JACKSON PS, 1993, J NEUROPHYSIOL, V70, P1412, DOI 10.1152/jn.1993.70.4.1412; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LINDENBERG R, 1955, P 2 INT C NEUR LOND, P477; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Printz J, 1998, AGRO FOOD IND HI TEC, V9, P15; STEWARD O, 1986, J NEUROSCI, V6, P412; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEYLER TJ, 1989, NEUROPSYCHOLOGIA, V27, P31, DOI 10.1016/0028-3932(89)90088-2; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9; Zaidel DW, 1999, ANAT REC, V254, P87, DOI 10.1002/(SICI)1097-0185(19990101)254:1<87::AID-AR11>3.0.CO;2-T	38	65	68	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2001	18	10					967	976		10.1089/08977150152693674			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	484NG	WOS:000171696000001	11686497				2022-02-06	
J	Wade, SL; Borawski, EA; Taylor, HG; Drotar, D; Yeates, KO; Stancin, T				Wade, SL; Borawski, EA; Taylor, HG; Drotar, D; Yeates, KO; Stancin, T			The relationship of caregiver coping to family outcomes during the initial year following pediatric traumatic injury	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Developmental-and-Behavioral-Pediatrics	SEP, 1998	CLEVELAND, OHIO	Soc Dev & Behav Pediat			BRAIN INJURY; PSYCHOLOGICAL ADJUSTMENT; STRESSFUL EVENTS; BREAST-CANCER; HEAD-INJURY; CHILDREN; PREDICTORS; ADAPTATION; RESOURCES; STRATEGIES	This study identified coping strategies associated with caregiver outcomes following pediatric injury and examined injury type as a moderator of coping efficacy. Families of 103 children with traumatic brain injury (TBI) and 71 children with orthopedic injuries were followed prospectively during the initial year postinjury. The groups had comparable preinjury characteristics and hospitalization experiences but differed on neurological insult. In hierarchical regression analyses, acceptance was associated with lower burden and denial was associated with greater distress in both groups. Active coping resulted in higher distress following TBI but not orthopedic injuries. Conversely. the use of humor was related to diminishing distress following TBI but unrelated to distress following orthopedic injuries. Results are discussed in terms of the implications for intervention following TBI.	Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; Case Western Reserve Univ, Dept Epidemiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Ohio State Univ, Columbus Childrens Hosp, Columbus, OH 43210 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH 44106 USA		Wade, SL (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Borawski, Elaine/R-9959-2019; Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Borawski, Elaine/0000-0001-7629-6889; Yeates, Keith/0000-0001-7680-2892	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 R01 NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ 390611] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		Aldwin C. M., 1987, J PERS SOC PSYCHOL, V53, P237; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BERESFORD BA, 1994, J CHILD PSYCHOL PSYC, V35, P171, DOI 10.1111/j.1469-7610.1994.tb01136.x; BILLINGS AG, 1984, J PERS SOC PSYCHOL, V46, P877, DOI 10.1037/0022-3514.46.4.877; CARVER CS, 1993, J PERS SOC PSYCHOL, V65, P375, DOI 10.1037/0022-3514.65.2.375; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Compas B.E., 1997, PL S STRESS, P105; Compas BE, 1999, SOOTHING AND STRESS, P229; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR, 1982, BRIEF SYMPTOM INVENT; FELTON BJ, 1984, J CONSULT CLIN PSYCH, V52, P343, DOI 10.1037/0022-006X.52.3.343; FELTON BJ, 1984, SOC SCI MED, V18, P889, DOI 10.1016/0277-9536(84)90158-8; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; Folkman S., 1984, STRESS; FORSYTHE CJ, 1987, COGNITIVE THER RES, V11, P473, DOI 10.1007/BF01175357; HOLAHAN CJ, 1985, J PERS SOC PSYCHOL, V49, P739, DOI 10.1037/0022-3514.49.3.739; JENNETT B, 1975, LANCET, V1, P480; Marks M, 1993, NeuroRehabilitation, V3, P1, DOI 10.3233/NRE-1993-3303; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS RH, 1988, SOC SCI MED, V27, P999, DOI 10.1016/0277-9536(88)90291-2; NEZU AM, 1988, J PERS SOC PSYCHOL, V54, P520, DOI 10.1037/0022-3514.54.3.520; Nezu AM, 1998, HELPING CANC PATIENT; Osowiecki D, 1998, COGNITIVE THER RES, V22, P483, DOI 10.1023/A:1018725716620; Osowiecki DM, 1999, COGNITIVE THER RES, V23, P169, DOI 10.1023/A:1018779228432; PARK C, 1990, J PERS SOC PSYCHOL, V59, P562, DOI 10.1037/0022-3514.59.3.562; PARK CL, 1993, COGNITIVE THER RES, V17, P561, DOI 10.1007/BF01176079; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; ROEMER L, 1994, J ABNORM PSYCHOL, V103, P467, DOI 10.1037/0021-843X.103.3.467; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STEVENSONHINDE J, 1995, FAM PROCESS, V11, P345; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TERRY DJ, 1991, PERS INDIV DIFFER, V12, P1031, DOI 10.1016/0191-8869(91)90033-8; TERRY DJ, 1998, J PERS SOC PSYCHOL, V64, P293; VITALIANO PP, 1990, J PERS SOC PSYCHOL, V59, P582, DOI 10.1037/0022-3514.59.3.582; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Walker LS, 1997, PSYCHOL ASSESSMENT, V9, P392, DOI 10.1037/1040-3590.9.4.392; West S. G., 1991, MULTIPLE REGRESSION; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	51	65	66	0	9	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X			J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	JUN	2001	69	3					406	415		10.1037//0022-006X.69.3.406			10	Psychology, Clinical	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Psychology	470LB	WOS:000170872500006	11495170				2022-02-06	
J	Biberthaler, P; Mussack, T; Wiedemann, E; Kanz, KG; Koelsch, M; Gippner-Steppert, C; Jochum, M				Biberthaler, P; Mussack, T; Wiedemann, E; Kanz, KG; Koelsch, M; Gippner-Steppert, C; Jochum, M			Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma	WORLD JOURNAL OF SURGERY			English	Article; Proceedings Paper	38th World Congress of the International-Society-of-Surgery/Societe-Internationale-de-Chirurgie (ISS/SIC)	AUG 15-20, 1999	VIENNA, AUSTRIA	Int Soc Surg, Soc Int Chirurg			INTRACRANIAL INJURY; SERUM LEVELS; PROTEIN; PREDICTORS; INDICATORS; MANAGEMENT; SCANS; GFAP	Management of patients with minor head trauma (MHT) continues to be debated in the literature. Measurement of S-100b in serum has been introduced into the discussion as an additional screening tool far intracerebral injuries because routine cranial computed tomography (CCT) of a large number of patients causes logistic difficulties, and the neurologic examination is often impaired by a high frequency of coincidental intoxication. The aim of our study was to determine the diagnostic value of measuring S-100b in the serum of MHT patients to identify risk groups. Additional validity should be aquired by a comparison with plasma levels of polymorphonuclear neutrophil (PMN) elastase an established general trauma marker. A series of 52 patients with MHT were included in the prospective study. At admission the patients underwent a routine CCT scan to detect intracerebral lesions, and blood samples were drawn to investigate circulating levels of S-100b and PMN elastase. For comparison, data for a positive control group of 10 severe head trauma patients (initial Glasgow Coma Scale score < 8) and for a negative control group with 20 healthy volunteers were obtained. The interval between MHT and admission to our hospital was 73.4 +/- 47.0 minutes. The initial S-100b serum levels of MHT patients were 0.470 +/- 0.099 ng/ml, those of the positive control group were 7.16 +/- 3.77 ng/ml, and those of the negative control group were 0.05 +/- 0.01 ng/ml. Relevant pathologic CCT scans were detected in 28.8% of MHT patients; one patient of that group was subjected to immediate surgical intervention (1.9%). At a cut-off point of 0.1 ng/ml, the sensitivity of positive S-100b levels reached 100% and the specificity 40.5%. Plasma levels of PMN elastase reached 60.52 +/- 10.75 ng/ml in the MHT group, 66.4 +/- 14.92 ng/ml in the severely head-injured group, and 23.26 +/- 1.53 ng/ml in the negative control group. Serum levels of S-100b seem to be a highly sensitive but not very specific marker for isolated neurotrauma. Measurement of this parameter may be helpful as an additional screening tool to identify high risk groups in the cohort of MHT patients.	Univ Munich, Chirurg Klin & Poliklin Standort Innenstadt, Klin Chem & Klin Biochem Abt, D-80336 Munich, Germany		Biberthaler, P (corresponding author), Univ Munich, Chirurg Klin & Poliklin Standort Innenstadt, Klin Chem & Klin Biochem Abt, Nussbaumstr 20, D-80336 Munich, Germany.						Bianchi R, 1996, BBA-MOL CELL RES, V1313, P258, DOI 10.1016/0167-4889(96)00098-5; BIANCHI R, 1995, BIOCHEM BIOPH RES CO, V208, P910, DOI 10.1006/bbrc.1995.1421; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; HERRMANN M, 1998, ZENTRALBL NEUROCHIR, V59, P208; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Kraus JF, 1987, HEAD INJURY, V2, P1; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; NastKolb D, 1997, J TRAUMA, V42, P446, DOI 10.1097/00005373-199703000-00012; NASTKOLB D, 1997, J TRAUMA, V42, P454; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SACKETT DL, 1995, CLIN EPIDEMIOLOGY, P59; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012	22	65	69	0	4	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0364-2313			WORLD J SURG	World J.Surg.	JAN	2001	25	1					93	97		10.1007/s002680020370			5	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	396KR	WOS:000166636000014	11213162				2022-02-06	
J	Yu, CG; Marcillo, AE; Fairbanks, CA; Wilcox, GL; Yezierski, RP				Yu, CG; Marcillo, AE; Fairbanks, CA; Wilcox, GL; Yezierski, RP			Agmatine improves locomotor function and reduces tissue damage following spinal cord injury	NEUROREPORT			English	Article						agmatine; locomotor function; neuroprotection; nitric oxide; NMDA	NITRIC-OXIDE SYNTHASE; RATS; RECEPTORS; INHIBITION; EXPRESSION; DEFICITS; NEURONS; TRAUMA; BRAIN; NMDA	Clinically effective drug treatments for spinal cord injury (SCI) remain unavailable. Agmatine, an NMDA receptor antagonist and inhibitor of nitric oxide synthase (NOS), is an endogenous neuromodulator found in the brain and spinal cord. Evidence is presented that agmatine significantly improves locomotor function and reduces tissue damage following traumatic SCI in rats. The results suggest the importance of future therapeutic strategies encompassing the use of single drugs with multiple targets for the treatment of acute SCI. The therapeutic targets of agmatine (NMDA receptor and NOS) have been shown to be critically linked to the pathophysiological sequelae of CNS injury and this, combined with the non-toxic profile, lends support to agmatine being considered as a potential candidate for future clinical applications; NeuroReport 11:3203-3207 (C) 2000 Lippincott Williams & Wilkins.	Univ Miami, Sch Med, Miami Project, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL 33136 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA		Yezierski, RP (corresponding author), Univ Miami, Sch Med, Miami Project, 1600 NW 10th Ave,R-48, Miami, FL 33136 USA.		Yu, Chen Guang/C-6176-2011				Agrawal SK, 1997, J NEUROSCI, V17, P1055; AUGUET M, 1995, JPN J PHARMACOL, V69, P285, DOI 10.1254/jjp.69.285; Barinaga M, 1996, SCIENCE, V274, P1466; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Fairbanks CA, 1997, J PHARMACOL EXP THER, V282, P1408; FAIRBANKS CA, 2000, IN PRESS P NATL ACAD; Galea E, 1996, BIOCHEM J, V316, P247, DOI 10.1042/bj3160247; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; GILAD GM, 1996, LIFE SCI, V58, P141; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Horvath G, 1999, EUR J PHARMACOL, V368, P197, DOI 10.1016/S0014-2999(99)00060-6; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; McAdoo DJ, 1997, J NEUROTRAUM, V14, P507, DOI 10.1089/neu.1997.14.507; Olmos G, 1999, BRIT J PHARMACOL, V127, P1317, DOI 10.1038/sj.bjp.0702679; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; Yang XC, 1999, J PHARMACOL EXP THER, V288, P544; Yezierski RP, 1996, J CEREBR BLOOD F MET, V16, P996, DOI 10.1097/00004647-199609000-00025; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085	25	65	68	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	SEP 28	2000	11	14					3203	3207		10.1097/00001756-200009280-00031			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	363JX	WOS:000089833500032	11043549				2022-02-06	
J	Mattson, AJ; Levin, HS; Grafman, J				Mattson, AJ; Levin, HS; Grafman, J			A case of prosopagnosia following moderate closed head injury with left hemisphere focal lesion	CORTEX			English	Article							FACE RECOGNITION; OBJECT; PATHWAYS; DISSOCIATION; AGNOSIA; PET	This study describes a left handed woman with prosopagnosia following traumatic brain injury with a focal lesion confined to the left-posterior hemisphere. Few cases of prosopagnosia following unilateral left hemisphere lesions have previously been reported in the literature. Corrected visual acuity was 20/70 (binocular), color vision was intact on screening, and shape detection was borderline. Impairments in higher order visual perception were evident to varying degrees on nonfacial tasks. Matching of unfamiliar faces was very slow but accurate. A marked impairment in the ability to recognize familiar faces and learn new face-name associations was evident on experimental tasks relative to the performance of healthy control subjects. In contrast, identification of characteristics of faces (gender, age) and identification and matching of facial expressions were relatively preserved. We discuss the cognitive processing stages that appear to be disrupted using Bruce and Young's (1986) model of facial recognition and perception as a framework.	Western State Hosp, Neuropsychol Serv, Steilacoom, WA USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; NIH, Cognit Neurosci Sect, Med Neurol Branch, Bethesda, MD 20892 USA		Levin, HS (corresponding author), PM&R Res Off, 1333 Moursund Ave,Room A205, Houston, TX 77003 USA.			Grafman, Jordan H./0000-0001-8645-4457	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [Z01NS002792, R01NS021889] Funding Source: NIH RePORTER		BENKE T, 1988, EUR NEUROL, V28, P236, DOI 10.1159/000116274; BENTON A, 1990, CORTEX, V26, P491, DOI 10.1016/S0010-9452(13)80299-7; Benton A. L., 1969, EMBEDDED FIGURES TES; BOERI R, 1994, CURR OPIN NEUROL, V7, P61, DOI 10.1097/00019052-199402000-00011; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; BRUYER R, 1986, NEUROPSYCHOLOGY FACE, P63; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CARLESIMO GA, 1995, J CLIN EXP NEUROPSYC, V17, P691, DOI 10.1080/01688639508405159; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DAMASIO AR, 1986, NEUROPSYCHOLOGY FACE, P31; De Renzi E, 1998, CORTEX, V34, P403, DOI 10.1016/S0010-9452(08)70763-9; DERENZI E, 1994, NEUROPSYCHOLOGIA, V32, P893, DOI 10.1016/0028-3932(94)90041-8; DERENZI E, 1986, NEUROPSYCHOLOGIA, V24, P385; DERENZI E, 1991, CORTEX, V27, P213, DOI 10.1016/S0010-9452(13)80125-6; EKMAN P, 1976, CONSULTING PSYCHOL P, V21, P98; FARAH MJ, 1990, VISUAL AGNOSIA; GRADY CL, 1994, J NEUROSCI, V14, P1450, DOI 10.1523/JNEUROSCI.14-03-01450.1994; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; Hooper HE., 1983, HOOPER VISUAL ORG TE; LEVIN HS, 1976, DIS NERV SYST, V37, P68; LEVINE DN, 1989, BRAIN COGNITION, V10, P149, DOI 10.1016/0278-2626(89)90051-1; MATTSON AJ, 1994, J NEUROL NEUROSUR PS, V57, P818, DOI 10.1136/jnnp.57.7.818; MCINTOSH AR, 1994, J NEUROSCI, V14, P655; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; READ DE, 1988, J CLIN EXP NEUROPSYC, V10, P451, DOI 10.1080/01688638808408252; RHODES G, 1985, BRIT J PSYCHOL, V76, P249, DOI 10.1111/j.2044-8295.1985.tb01949.x; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SERGENT J, 1990, BRAIN, V113, P989, DOI 10.1093/brain/113.4.989; TAKAHASHI N, 1995, CORTEX, V31, P317, DOI 10.1016/S0010-9452(13)80365-6; TEASDALE G, 1974, LANCET, V2, P81; Tzavaras A, 1973, Encephale, V62, P382; Van Allen MW, 1968, CORTEX, V93, P38, DOI [10.1016/S0010-9452(68)80018-8, DOI 10.1016/S0010-9452(68)80018, 10.1016/S0010-9452(68)80018]; Warrington E. K., 1991, VISUAL OBJECT SPACE; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson BA, 1997, CORTEX, V33, P529, DOI 10.1016/S0010-9452(08)70234-X; YOUNG AW, 1993, BRAIN, V116, P941, DOI 10.1093/brain/116.4.941	36	65	66	2	8	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	FEB	2000	36	1					125	137		10.1016/S0010-9452(08)70841-4			13	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	291MN	WOS:000085740800010	10728902				2022-02-06	
J	Guyot, LL; Michael, DB				Guyot, LL; Michael, DB			Post-traumatic hydrocephalus	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; post-traumatic hydrocephalus; neurotrauma	NORMAL-PRESSURE HYDROCEPHALUS; SEVERE HEAD-INJURY; POSTTRAUMATIC HYDROCEPHALUS; COMPUTED-TOMOGRAPHY; DIAGNOSIS; DYNAMICS	The syndrome of post-traumatic hydrocephalus (PTH) has been recognized since Dandy's report in 1914. The incidence of symptomatic PTH ranges from 0.7%-29%. If CT criteria of ventriculomegaly are used the incidence has been reported to be from 30%-86%. Differences in diagnostic criteria and classification have contributed to the variation in reported incidence. The diagnosis of PTH is established using a combination of clinical, imaging and physiologic data. Symptomatic PTH is to be distinguished from post-traumatic ventriculomegaly resulting from atrophy. Symptomatic PTH patients are likely to improve when treated by shunting. Ventriculomegaly secondary to atrophy is less likely to respond to shunting. A series of traumatic brain injury patients at Wayne State University has been followed since 1989. The overall incidence of shunt placement in this group is 3.65%. Future studies of PTH should be aimed at refining diagnostic classification and criteria. Analysis of a large PTH population may then identify alterable risk factors in the early post-traumatic brain injury period. Minimizing these factors will help prevent subsequent PTH and obviate the need for shunting.	Wayne State Univ, Dept Anat & Physiol, Detroit, MI USA; Wayne State Univ, Dept Cell Biol, Detroit, MI USA; Wayne State Univ, Dept Neurol Surg, Detroit, MI USA; Detroit Med Ctr, Detroit, MI USA		Michael, DB (corresponding author), Detroit Receiving Hosp, 6E-UHC,4201 St Antoine, Detroit, MI 48201 USA.						CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Dandy WE, 1914, AM J DIS CHILD, V8, P406; FLEISCHER AS, 1988, ANN EMERG MED, V17, P165, DOI 10.1016/S0196-0644(88)80305-6; FOLTZ EL, 1956, J NEUROSURG, V13, P546, DOI 10.3171/jns.1956.13.6.0546; GARDEUR D, 1979, J RADIOL ELEC MED N, V60, P79; GUDEMAN SK, 1981, RADIOLOGY, V141, P397, DOI 10.1148/radiology.141.2.6974874; GURDJIAN E, 1966, HEAD INJURY C P, P550; Hakim S, 1965, J Neurol Sci, V2, P307, DOI 10.1016/0022-510X(65)90016-X; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; KISHORE PRS, 1978, NEURORADIOLOGY, V16, P261, DOI 10.1007/BF00395266; KOSTELJANETZ M, 1985, ACTA NEUROCHIR, V77, P8, DOI 10.1007/BF01402299; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEWIN W, 1965, BIOCH ASPECTS NEUROL, P182; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; OI S, 1987, J PEDIAT NEUROSCI, V3, P133; OJEMANN RG, 1969, J NEUROSURG, V31, P279, DOI 10.3171/jns.1969.31.3.0279; PENDERSON K, 1973, ACTA NEUROL SCAND, V48, P99; Penfield W, 1943, CAN MED ASSOC J, V48, P99; PENN RD, 1978, ANN NEUROL, V3, P216, DOI 10.1002/ana.410030306; PHILIPPON J, 1976, NEUROCHIRURGIE, V22, P111; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; SHEFFLER LR, 1994, ARCH PHYS MED REHAB, V75, P338, DOI 10.1016/0003-9993(94)90039-6; STEIN SC, 1974, J NEUROSURG, V41, P463, DOI 10.3171/jns.1974.41.4.0463; TAGAKI H, 1981, SURG NEUROL, V16, P103; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; WOOD JH, 1974, NEUROLOGY, V24, P517, DOI 10.1212/WNL.24.6.517; ZANDER E, 1976, HDB CLIN NEUROLOGY 2, P231	28	65	73	0	6	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	JAN	2000	22	1					25	28					4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	281HF	WOS:000085152300004	10672577				2022-02-06	
J	Morrison, B; Eberwine, JH; Meaney, DF; McIntosh, TK				Morrison, B; Eberwine, JH; Meaney, DF; McIntosh, TK			Traumatic injury induces differential expression of cell death genes in organotypic brain slice cultures determined by complementary DNA array hybridization	NEUROSCIENCE			English	Article						genomic expression; in vitro model; traumatic brain injury; organotypic culture; stretch injury; cDNA array	NERVE GROWTH-FACTOR; DIFFUSE AXONAL INJURY; PROTEIN-KINASE-C; CORTICAL IMPACT INJURY; TRANSCRIPTION FACTOR CREB; MESSENGER-RNA EXPRESSION; HIPPOCAMPAL CA1 NEURONS; RAT-BRAIN; ENDOTHELIAL-CELLS; HEAD-INJURY	The expression of a large panel of selected genes hypothesized to play a central role in post-traumatic cell death was shown to be differentially altered in response to a precisely controlled, mechanical injury applied to an organotypic slice culture of the rat brain. Within 48 h of injury, the expression of nerve growth factor messenger RNA was significantly increased whereas the levels of bcl-2, alpha-subunit of calcium/calmodulin-dependent protein kinase II, cAMP response element binding protein, 65,000 mel. wt isoform of glutamate decarboxylase, 1 beta isoform of protein kinase C, and ubiquitin messenger RNA were significantly decreased. Because the expression levels of a number of other messenger RNAs such as the neuron-specific amyloid precursor protein, beta(2) microglobulin, bax, bcl(xl), brain-derived neurotrophic factor, cyclooxygenase-2, interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, receptor tyrosine kinase A, and receptor tyrosine kinase B were unaffected, these selective changes may represent components of an active and directed response of the brain initiated by mechanical trauma. Interpretation of these co-ordinated alterations suggests that mechanical injury to the central nervous system may lead to disruption of calcium homeostasis resulting in altered gene expression, an impairment of intracellular cascades responsible for trophic factor signaling, and initiation of apoptosis via multiple pathways. An understanding of these transcriptional changes may contribute to the development of novel therapeutic strategies to enhance beneficial and blunt detrimental, endogenous, post-injury response mechanisms. (C) 2000 IBRO. Published by Elsevier Science Ltd.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), 3320 Smith Walk,Hayden Hall Room 105C, Philadelphia, PA 19104 USA.		Eberwine, James/B-2247-2010; Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Meaney, David/0000-0002-0954-4122	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BAYER SA, 1980, J COMP NEUROL, V190, P115, DOI 10.1002/cne.901900108; Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; CARGILL RS, 1996, J NEUROTRAUM, V13, P396; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chow N, 1998, P NATL ACAD SCI USA, V95, P9620, DOI 10.1073/pnas.95.16.9620; Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FREIDIN M, 1992, P NATL ACAD SCI USA, V89, P10440, DOI 10.1073/pnas.89.21.10440; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HIESTAND DM, 1992, NEUROSCI LETT, V144, P75, DOI 10.1016/0304-3940(92)90719-N; HIESTAND DM, 1992, J NEUROL SCI, V113, P31, DOI 10.1016/0022-510X(92)90261-I; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; HUMPEL C, 1993, NEUROSCIENCE, V57, P913, DOI 10.1016/0306-4522(93)90037-G; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Llanos S, 1998, J NEUROCHEM, V70, P2315; MACKLER SA, 1993, MOL PHARMACOL, V44, P308; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; Morimoto T, 1996, AM J PATHOL, V148, P249; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; OBLINGER MM, 1993, INT J DEV NEUROSCI, V11, P149, DOI 10.1016/0736-5748(93)90075-O; Oh YJ, 1997, MOL BRAIN RES, V51, P133, DOI 10.1016/S0169-328X(97)00229-5; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Pierce JES, 1996, J NEUROSCI, V16, P1083; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; RINK A, 1995, AM J PATHOL, V147, P1575; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Yang SY, 1998, J NEUROSURG, V89, P297, DOI 10.3171/jns.1998.89.2.0297	74	65	69	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	96	1					131	139		10.1016/S0306-4522(99)00537-0			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	283XG	WOS:000085300900016	10683418	Green Published			2022-02-06	
J	Simpson, G; Blaszczynski, A; Hodgkinson, A				Simpson, G; Blaszczynski, A; Hodgkinson, A			Sex offending as a psychosocial sequela of traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article								Objective: To describe the nature and extent of sexual offending after traumatic brain injury (TBI). Design: Retrospective file review. Setting: A brain injury unit providing inpatient and outpatient rehabilitation services. Participants: A review of five years of admissions to the Brain Injury Rehabilitation Unit (N = 477) identified a sample of 29 males who committed 128 incidents of sex offending, Main Outcome Measures: A protocol to record data on demographic, injury, radiological, and psychosocial variables and offending behaviors. Results: Of the total population of 445 clients with TBI, 6.5% (n = 29) were identified as having committed some form of sexual offense. Alcohol was a factor in only three (2.3%) of the incidents, and only two clients had a preinjury history of sexual offending. The most com mon offenses were the "touching" offenses, followed by exhibitionism and overt sexual aggression. Staff members were the most common targets of the offenses, followed by members of the general public, other people with TBI, and family members. Conclusions: Sex offending is a significant clinical problem among a small minority of men after TBI. The absence of alcohol and preinjury histories of sexual offending suggest that the brain injury and contingent sequelae were a significant etiological factor underlying the offenses. A. number of implications for the clinical management of clients with sexually aberrant behaviors is identified and discussed.	Liverpool Hosp, Brain Injury Rehabil Unit, Liverpool BC, NSW 1871, Australia; Univ New S Wales, Sch Psychiat, Kensington, NSW 2033, Australia		Simpson, G (corresponding author), Liverpool Hosp, Brain Injury Rehabil Unit, Locked Bag 7103, Liverpool BC, NSW 1871, Australia.		Simpson, Grahame K/W-1074-2019; Blaszczynski, Alexander/G-2713-2013	Simpson, Grahame K/0000-0001-8156-9060; Blaszczynski, Alexander/0000-0003-1476-0791			American Psychiatric Association, 1995, DIAGN STAT MAN MENT; Arieff AJ, 1942, J NERV MENT DIS, V96, P523, DOI 10.1097/00005053-194211000-00004; BERLIN FS, 1981, AM J PSYCHIAT, V138, P601; BLAIR CD, 1981, PSYCHOL BULL, V89, P439, DOI 10.1037/0033-2909.89.3.439; BLUMER D, 1967, ARCH NEUROL-CHICAGO, V16, P37, DOI 10.1001/archneur.1967.00470190041005; BLUMER D, 1970, AM J PSYCHIAT, V126, P83; DEMETRAL GD, 1994, MENT RETARD, V32, P141; EMORY LE, 1995, J HEAD TRAUMA REHAB, V10, P47; Goldberg R L, 1982, Int J Psychiatry Med, V12, P275; GRABER B, 1982, J FORENSIC SCI, V27, P125; HAWK GL, 1993, HOSP COMMUNITY PSYCH, V44, P784; HENN FA, 1976, AM J PSYCHIAT, V133, P694; HUCKER SJ, 1990, HDB SEXUAL ASSAULT; JENNET WB, 1962, EPILEPSY BLUNT HEAD; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; LEHNE G, 1986, SEX DISABIL, V7, P145; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MILLER BL, 1986, J NEUROL NEUROSUR PS, V49, P867, DOI 10.1136/jnnp.49.8.867; MONEY J, 1990, AM J PSYCHOTHER, V44, P26, DOI 10.1176/appi.psychotherapy.1990.44.1.26; MURREY GJ, 1992, MED SCI LAW, V32, P331, DOI 10.1177/002580249203200408; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; REGESTEIN QR, 1978, J NERV MENT DIS, V166, P794, DOI 10.1097/00005053-197811000-00007; ROSENTHAL M, 1990, REHABILITATION ADULT; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; WEINSTEIN EA, 1961, PSYCHIATR, V24, P69; WESOLOWSKI MD, 1993, BEHAV RESIDENTI 0408, P89; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163	30	65	65	0	9	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					567	580		10.1097/00001199-199912000-00005			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300004	10671702				2022-02-06	
J	Franz, G; Reindl, M; Patel, SC; Beer, R; Unterrichter, I; Berger, T; Schmutzhard, E; Poewe, W; Kampfl, A				Franz, G; Reindl, M; Patel, SC; Beer, R; Unterrichter, I; Berger, T; Schmutzhard, E; Poewe, W; Kampfl, A			Increased expression of apolipoprotein D following experimental traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						apolipoprotein D; traumatic brain injury; neurons; glia; cell death	MICROTUBULE-ASSOCIATED PROTEIN-2; CORTICAL IMPACT INJURY; RNA TISSUE DISTRIBUTION; BREAST-CANCER CELLS; PERIPHERAL-NERVE; MESSENGER-RNA; MOLECULAR CHARACTERIZATION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; TRANSGENIC MICE	Increasing evidence suggests that apolipoprotein D (apoD) could play a major role in mediating neuronal degeneration and regeneration in the CNS and the PNS, To investigate further the temporal pattern of apoD expression after experimental traumatic brain injury in the rat, male Sprague-Dawley rats were subjected to unilateral cortical impact injury. The animals were killed and examined for apoD mRNA and protein expression and for immunohistological analysis at intervals from 15 min to 14 days after injury. Increased apoD mRNA and protein levels were seen in the cortex and hippocampus ipsilateral to the injury site from 48 h to 14 days after the trauma. Immunohistological investigation demonstrated a differential pattern of apoD expression in the cortex and hippocampus, respectively: Increased apoD immunoreactivity in glial cells was detected from 2 to 3 days after the injury in cortex and hippocampus. In contrast, increased expression of apoD was seen in cortical and hippocampal neurons at later time points following impact injury. Concurrent histopathological examination using hematoxylin and eosin demonstrated dark, shrunken neurons in the cortex ipsilateral to the injury site. in contrast, no evidence of cell death was observed in the hippocampus ipsilateral to the injury site up to 14 days after the trauma. No evidence of increased apoD mRNA or protein expression or neuronal pathology by hematoxylin and eosin staining was detected in the contralateral cortex and hippocampus. Our results reveal induction of apoD expression in the cortex and hippocampus following traumatic brain injury in the rat. Our data also suggest that increased apoD expression may play an important role in cortical neuronal degeneration after brain injury in vivo. However, increased expression of apoD in the hippocampus may not necessarily be indicative of neuronal death.	Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria; VA Connecticut Healthcare Syst, Neurobiol Res Lab, Newington, CT USA		Kampfl, A (corresponding author), Univ Innsbruck Hosp, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.		Reindl, Markus/ABE-5880-2020	Berger, Thomas/0000-0001-5626-1144; Schmutzhard, Erich/0000-0003-3295-7491; Reindl, Markus/0000-0003-2817-1402	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-34339] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034339] Funding Source: NIH RePORTER		Bidmon HJ, 1998, NEUROSCIENCE, V82, P377; BOYLES JK, 1990, J LIPID RES, V31, P2243; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CABRAL JHM, 1995, FEBS LETT, V366, P53, DOI 10.1016/0014-5793(95)00484-Q; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chen SF, 1997, PSYCHOL SCI, V8, P80, DOI 10.1111/j.1467-9280.1997.tb00687.x; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Flower DR, 1996, BIOCHEM J, V318, P1; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HIGASHI Y, 1991, INT CONGR SER, V962, P85; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1996, ALZHEIMER RES, V2, P37; Hyman BT, 1996, ANN NY ACAD SCI, V802, P1, DOI 10.1111/j.1749-6632.1996.tb32592.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Keller JN, 1998, J NEUROSCI, V18, P687; LABRIE F, 1990, ANN NY ACAD SCI, V586, P174, DOI 10.1111/j.1749-6632.1990.tb17805.x; Lea O A, 1988, Steroids, V52, P337, DOI 10.1016/0039-128X(88)90135-3; LEBLANC AC, 1990, J NEUROSCI RES, V26, P317, DOI 10.1002/jnr.490260308; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MCCONATH.WJ, 1973, FEBS LETT, V37, P178, DOI 10.1016/0014-5793(73)80453-3; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Navarro A, 1998, NEUROSCI LETT, V254, P17, DOI 10.1016/S0304-3940(98)00639-9; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Ong WY, 1997, NEUROSCIENCE, V79, P359, DOI 10.1016/S0306-4522(96)00608-2; Ong WY, 1999, NEUROSCIENCE, V90, P913, DOI 10.1016/S0306-4522(98)00507-7; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Patel RC, 1997, PROTEIN ENG, V10, P621, DOI 10.1093/protein/10.6.621; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; PATEL SC, 1995, NEUROREPORT, V6, P653, DOI 10.1097/00001756-199503000-00017; Peitsch M C, 1990, New Biol, V2, P197; POIRIER J, 1990, P NATL ACAD SCI USA, V87, P303, DOI 10.1073/pnas.87.1.303; POIRIER J, 1991, MOL BRAIN RES, V9, P191, DOI 10.1016/0169-328X(91)90002-F; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; PROVOST PR, 1990, J LIPID RES, V31, P2057; REBECK GW, 1993, NEURON, V11, P575; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; SEGUIN D, 1995, MOL BRAIN RES, V30, P242, DOI 10.1016/0169-328X(95)00008-G; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; SIMARD J, 1991, CANCER RES, V51, P4336; SIMARD J, 1990, ENDOCRINOLOGY, V126, P3223, DOI 10.1210/endo-126-6-3223; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; SKENE JHP, 1983, P NATL ACAD SCI-BIOL, V80, P4169, DOI 10.1073/pnas.80.13.4169; SPREYER P, 1990, EMBO J, V9, P2479, DOI 10.1002/j.1460-2075.1990.tb07426.x; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Suresh S, 1998, J NEUROCHEM, V70, P242; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Terrisse L, 1998, J NEUROCHEM, V71, P1643; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; Yoshida K, 1996, DNA CELL BIOL, V15, P873, DOI 10.1089/dna.1996.15.873	70	65	66	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	1999	73	4					1615	1625		10.1046/j.1471-4159.1999.0731615.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	236TZ	WOS:000082616200033	10501208	Bronze			2022-02-06	
J	Berge, J; Marque, B; Vital, JM; Senegas, J; Caille, JM				Berge, J; Marque, B; Vital, JM; Senegas, J; Caille, JM			Age-related changes in the cervical spines of front-line rugby players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							DEGENERATIVE DISK DISEASE; MR SIGNAL INTENSITY; MAGNETIC-RESONANCE; INTERVERTEBRAL-DISK; HYPEREXTENSION INJURIES; SPONDYLOTIC MYELOPATHY; FOOTBALL PLAYERS; CORD CONCUSSION; FACET JOINTS; BONE-MARROW	Cervical spine trauma occurs frequently in front-line rugby players. To evaluate the accumulative effects of this trauma, magnetic resonance imaging scans of the cervical spine were performed on 47 rugby players and 40 age-matched control subjects. The aim of this study was to compare the changes in the cervical spine of players at different points in their careers. A study of cervical spine changes, including spinal curve, spinal constituents, posttraumatic deformities, and degenerative modifications, was completed by a study of cervical measurements. Front-line rugby players showed more early degenerative alterations on magnetic resonance imaging scans than did the control subjects of the same age. These changes correlated with age and were probably linked with repetitive cervical trauma throughout the players' careers. Particular attention should be paid to the data confirming cervical spine canal stenosis in front-line players, which may place these athletes at risk for acute neurapraxia while playing this collision sport.	Hop Pellegrin, Dept Neuroradiol, F-33076 Bordeaux, France; Hop Pellegrin, Spine Unit, F-33076 Bordeaux, France		Berge, J (corresponding author), Hop Pellegrin, Dept Neuroradiol, F-33076 Bordeaux, France.						AOKI J, 1987, RADIOLOGY, V164, P411, DOI 10.1148/radiology.164.2.3602378; AUDIGEY I, 1992, THESIS BORDEAUX 2 U; BARNES MP, 1984, J NEUROL NEUROSUR PS, V47, P17, DOI 10.1136/jnnp.47.1.17; BEERS GJ, 1988, J COMPUT ASSIST TOMO, V12, P755, DOI 10.1097/00004728-198809010-00007; BERNADET E, 1984, THESIS BORDEAUX 2 U, V410; BERQUIST T, 1992, IMAGING SPORTS INJUR, P1; BLUMBERG ML, 1991, RADIOLOGY, V179, P584, DOI 10.1148/radiology.179.2.1826566; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P1178, DOI 10.2106/00004623-199072080-00008; BOHRER SP, 1990, SKELETAL RADIOL, V19, P521; BOYE JB, 1975, THESIS BORDEAUX 2 U; CHAKERES DW, 1987, AM J NEURORADIOL, V8, P5; CHIROSSEL JP, 1992, TRAUMATISMES CRANE R, P149; CZERVIONKE LF, 1988, RADIOL CLIN N AM, V26, P921; CZERVIONKE LF, 1988, RADIOLOGY, V169, P753, DOI 10.1148/radiology.169.3.3186997; Daniel M, 1992, J Radiol, V73, P695; DAVIS SJ, 1991, RADIOLOGY, V180, P245, DOI 10.1148/radiology.180.1.2052703; DELBIGIO MR, 1989, SPINE, V14, P37, DOI 10.1097/00007632-198901000-00007; DEROOS A, 1987, AM J ROENTGENOL, V149, P531, DOI 10.2214/ajr.149.3.531; DOOMS GC, 1985, RADIOLOGY, V155, P429, DOI 10.1148/radiology.155.2.3983394; DUSSAULT RG, 1990, RADIOL CLIN N AM, V28, P1033; EDWARDS WC, 1983, SPINE, V8, P20, DOI 10.1097/00007632-198301000-00003; EPSTEIN N, 1980, SPINE, V5, P489, DOI 10.1097/00007632-198011000-00001; FLANNIGAN BD, 1987, AM J ROENTGENOL, V148, P785, DOI 10.2214/ajr.148.4.785; FLETCHER G, 1990, AM J NEURORADIOL, V11, P27; FORSBERG DA, 1990, AM J ROENTGENOL, V154, P751, DOI 10.2214/ajr.154.4.2107670; FUJIWARA K, 1988, SPINE, V13, P1212, DOI 10.1097/00007632-198811000-00002; GERHART KA, 1991, J TRAUMA, V31, P1529, DOI 10.1097/00005373-199111000-00012; GOLDBERG AL, 1989, SKELETAL RADIOL, V18, P283, DOI 10.1007/BF00361208; GRENIER N, 1987, RADIOLOGY, V165, P517, DOI 10.1148/radiology.165.2.3659376; GRENIER N, 1989, RADIOLOGY, V171, P197, DOI 10.1148/radiology.171.1.2928526; GRENIER N, 1990, J COMPUT ASSIST TOMO, V14, P243, DOI 10.1097/00004728-199003000-00016; GRENIER N, 1992, IRM MOELLA RACHIS; HAJEK PC, 1987, RADIOLOGY, V162, P245, DOI 10.1148/radiology.162.1.3786770; HERZOG RJ, 1991, SPINE, V16, pS178, DOI 10.1097/00007632-199106001-00001; HO PSP, 1988, RADIOLOGY, V168, P469, DOI 10.1148/radiology.168.2.3393666; ISU T, 1986, NEURORADIOLOGY, V28, P215, DOI 10.1007/BF00548195; JAHNKE RW, 1991, RADIOL CLIN N AM, V29, P777; KUBINETSKY A, 1969, THESIS PARIS 6 U PAR; KUROSAWA H, 1991, SKELETAL RADIOL, V20, P437; LADD AL, 1986, J BONE JOINT SURG AM, V68A, P1371, DOI 10.2106/00004623-198668090-00009; LAISSY JP, 1990, AM J NEURORADIOL, V11, P394; LOUAIL C, 1992, J NEURORADIOLOGY, V19, P177; MAILLOT C, 1992, RIV NEURORADIOLOG S2, V5, P59; MANELFE C, 1989, REV IMAGERIE MED, V1, P7; Manelfe C., 1989, IMAGERIE RACHIS MOEL; MODIC MT, 1988, RADIOLOGY, V168, P177, DOI 10.1148/radiology.168.1.3289089; MODIC MT, 1988, RADIOLOGY, V166, P193, DOI 10.1148/radiology.166.1.3336678; MODIC MT, 1990, RADIOLOGY, V177, P332, DOI 10.1148/radiology.177.2.2217764; MOMBET J, 1980, MED RUGBY; MURPHEY MD, 1989, RADIOL CLIN N AM, V27, P855; NAKSTAD PH, 1989, NEURORADIOLOGY, V31, P382, DOI 10.1007/BF00343860; NEUHOLD A, 1991, NEURORADIOLOGY, V33, P422, DOI 10.1007/BF00598617; NGUYEN CM, 1989, INVEST RADIOL, V24, P407, DOI 10.1097/00004424-198905000-00014; ODOR JM, 1990, AM J SPORT MED, V18, P507, DOI 10.1177/036354659001800510; OGINO H, 1983, SPINE, V8, P1, DOI 10.1097/00007632-198301000-00001; PAN G, 1988, J NEUROSURG, V68, P798, DOI 10.3171/jns.1988.68.5.0798; PAVLOV H, 1987, RADIOLOGY, V164, P771, DOI 10.1148/radiology.164.3.3615879; PAYOT M, 1977, THESIS BORDEAUX 2 U; PERE JP, 1980, THESIS POITIERS U; PRERE J, 1989, IMAGERIE RACHIS MOEL; RESNICK D, 1978, RADIOLOGY, V126, P57, DOI 10.1148/126.1.57; ROBINSON MD, 1990, SPINE, V15, P1003, DOI 10.1097/00007632-199015100-00004; ROSS JS, 1989, AM J NEURORADIOL, V10, P1243; RUSSELL EJ, 1990, RADIOLOGY, V177, P313, DOI 10.1148/radiology.177.2.2217760; SCHELLINGER D, 1990, RADIOLOGY, V175, P831, DOI 10.1148/radiology.175.3.2343133; SCHER AT, 1991, AM J SPORT MED, V19, P485, DOI 10.1177/036354659101900511; SCOTTI G, 1992, RIV NEURORADIOL, V5, P43; SENEGAS X, 1991, THESIS BORDEAUX 2 U; SETHER LA, 1990, RADIOLOGY, V177, P385, DOI 10.1148/radiology.177.2.2217773; Sortland O, 1982, Br J Sports Med, V16, P80; TERESI LM, 1987, RADIOLOGY, V164, P83, DOI 10.1148/radiology.164.1.3588931; THANGUY A, 1992, RIV NEURORADIOL, V5, P5; TORG JS, 1986, J BONE JOINT SURG AM, V68A, P1354, DOI 10.2106/00004623-198668090-00008; VANDYKE C, 1989, AM J NEURORADIOL, V10, P627; WILLIAMS JPR, 1978, BRIT MED J, V2, P1747, DOI 10.1136/bmj.2.6154.1747; YU SW, 1991, RADIOL CLIN N AM, V29, P691; YU SW, 1989, AM J NEURORADIOL, V10, P1105; YU SW, 1988, RADIOLOGY, V169, P761, DOI 10.1148/radiology.169.3.3186998	78	65	66	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL-AUG	1999	27	4					422	429		10.1177/03635465990270040401			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	218NE	WOS:000081558000004	10424210				2022-02-06	
J	Horsburgh, K; Kelly, S; McCulloch, J; Higgins, GA; Roses, AD; Nicoll, JAR				Horsburgh, K; Kelly, S; McCulloch, J; Higgins, GA; Roses, AD; Nicoll, JAR			Increased neuronal damage in apolipoprotein E-deficient mice following global ischaemia	NEUROREPORT			English	Article						apolipoprotein E; brain; cerebrovascular anatomy; ischaemia; mouse; neuronal damage	TRANSIENT FOREBRAIN ISCHEMIA; CLOSED-HEAD INJURY; CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; E IMMUNOREACTIVITY; SUSCEPTIBILITY; ASSOCIATION; EPSILON-4; STRAIN; CELLS	THERE is accumulating evidence that apolipoprotein E (apoE) plays a role in regulating the response to and outcome following brain injury. The present study compared the histological outcome and recovery following an episode of global ischaemia in apoE-deficient mice and wild-type littermates (12-week-old males, n=8 per group). Transient global ischaemia was induced for ii period of 17 min and the animals were allowed to recover for 72 h, Transient global ischaemia induced selective neuronal degeneration in several brain regions in wild-type mice. There was statistically significant increased ischaemic neuronal damage in apoE-deficient mice compared with wild-type mice in six of the seven regions examined (hippocampal regions CA1, CA3/CA4 and dentate gyrus; thalamus; cortex and caudate nucleus; P < 0.05). The data substantiate a role for apoE in modifying the response of the CNS to acute injury. NeuroReport 10:837-841 (C); 1999 Lippincott Williams & Wilkins.	Univ Glasgow, Hugh Fraser Neurosci Labs, Dept Neuropathol, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Hugh Fraser Neurosci Labs, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland; Glaxo Wellcome Res & Dev Ltd, Res Triangle Pk, NC USA		Horsburgh, K (corresponding author), Univ Glasgow, Hugh Fraser Neurosci Labs, Dept Neuropathol, Garscube Estate,Bearsden Rd, Glasgow G61 1QH, Lanark, Scotland.		Kelly, Stephen/A-8307-2010; Nicoll, James/I-9253-2017	Kelly, Stephen/0000-0001-7618-1328; Horsburgh, Karen/0000-0002-9620-3691; Nicoll, James/0000-0002-9444-7246	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Anderson R, 1998, NEUROSCIENCE, V85, P93, DOI 10.1016/S0306-4522(97)00598-8; BARONE FC, 1993, J CEREBR BLOOD F MET, V13, P683, DOI 10.1038/jcbfm.1993.87; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1996, ALZHEIMER RES, V2, P37; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P570, DOI 10.1097/00004647-199805000-00012; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Masliah E, 1996, APOLIPOPROTEIN E ALZ, P59; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Yang GM, 1997, BRAIN RES, V752, P209, DOI 10.1016/S0006-8993(96)01453-9; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	24	65	69	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	MAR 17	1999	10	4					837	841		10.1097/00001756-199903170-00031			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	180PA	WOS:000079393300033	10208557				2022-02-06	
